TY - JOUR AB - The promise of better health care for rural citizens is becoming a reality in a U.S.A. state (Oklahoma), due to the State Department of Health's mobile health clinic. The clinic is manned by a public health nurse and a home health aide. In some communities, a school nurse also assists in the clinic. Services offered include chest X rays, diabetes screening, blood pressure measurements, various blood tests, tuberculin skin tests, glaucoma screening, family planning conferences, immunizations including diphtheria tetanus pertussis, diphtheria tetanus, rubella, and measles, and oral poliomyelitis vaccine. The glaucoma tests and chest X rays are given in permanent facilities, such as schools, which usually are adjacent to the mobile unit. DB - Embase Classic Medline IS - 12 KW - oral poliomyelitis vaccine ambulatory care blood blood pressure measurement community diabetes mellitus diphtheria family planning glaucoma health health care health care personnel health center health service immunization measles nurse outpatient department pertussis rubella school school health nursing screening tetanus thorax radiography tuberculin test United States LA - English M3 - Article N1 - L293160413 1971-12-01 PY - 1971 SN - 0083-1204 SP - 1064-1065 ST - A mobile health clinic in rural Oklahoma T2 - H.S.M.H.A. health reports TI - A mobile health clinic in rural Oklahoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L293160413&from=export VL - 86 ID - 4125 ER - TY - JOUR C1 - optipranolol DB - Embase IS - 5 KW - antiglaucoma agent beta adrenergic receptor blocking agent metipranolol adult aged allergy beta adrenergic receptor blocking conjunctivitis dermatitis drug cost human intraocular hypertension note open angle glaucoma patient compliance priority journal topical drug administration optipranolol LA - English M3 - Note N1 - L21179348 1991-07-05 PY - 1991 SN - 0016-867X SP - 20 ST - New glaucoma drug may encourage compliance T2 - Geriatrics TI - New glaucoma drug may encourage compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L21179348&from=export VL - 46 ID - 4039 ER - TY - JOUR AB - There are over 1.5 million children blind worldwide. The prevalence of childhood cataract has been reported as 1-4 cases per 10,000 children in the developing world. Aphakic glasses and contact lenses are unsatisfactory for rehabilitation of aphakia because of various problems associated with their use. The development of improved and refined microsurgical techniques, the availability of suitable PMMA and foldable IOL designs, better methods of modern capsular surgery, and a better understanding of the growth and refractive development of eyes in children have all helped make pediatric intraocular lens implantation a most successful technique. There is presently a clear shift in favor of IOL implantation for pediatric cataract. The main advance in treatment of childhood cataract over the past decade has been with the transition from a specific form of surgery, namely varying forms of lensectomy with spectacle or contact lens correction, to a much more modern procedure based on the principles learned in adult cataract surgery. In particular, the use of modern hydrodissection and capsulorhexis techniques, better techniques for removal of lens substance, and placement of modern PC-IOL designs into the capsular bag, have brought this procedure into step with the established techniques applied in adult cataracts. As recently as the early 1990s, there was controversy as to whether or not to place implants in the eyes of children. There is no longer such a controversy; the age limit for receiving lens implants is rapidly decreasing, encroaching on the first week of life. One of the most important factors in the advancement of pediatric surgery has been the recent success in reducing the incidence of secondary cataract (chapter 7). This problem basically occurred in 100% of the cases and had been a major stumbling block in introducing successful pediatric implantation, for a half century. Primary posterior capsulotomy was almost always required. Now, with better cortical removal techniques and introduction of highly biocompatible IOL designs, such as the Alcon AcrySof design, which appears to help to retard PCO, the previously almost unavoidable problem of PCO can now be better contained. Performing primary posterior capsulotomy and anterior vitrectomy is very important in developing countries (Table 9.3). In most cases, it ensures a clear visual axis. This is very important, as follow-up PCO treatment is often limited or not possible. Early use of an IOL may be justified in selected cases in developing countries, where parental compliance and follow up may be particularly difficult to achieve and where regular spectacle or contact lens wear is difficult to maintain. However, of utmost importance, pediatric cataract surgery, as described here, especially in very young children is best performed in a referral center by ophthalmologists with advanced experience in this field. Visually significant cataracts may be successfully operated even in newborns in order to prevent amblyopia. In such cases, careful planning of the surgical procedure, selection of the IOL and use of appropriate IOL power is an obvious must. DB - Embase DO - 10.1016/S0039-6257(00)00182-X IS - 3 SUPPL. 1 KW - aphakia capsulotomy cataract glaucoma human intraocular pressure lens lens implant postoperative complication priority journal review treatment outcome uveitis vitrectomy LA - English M3 - Review N1 - L32175101 2001-03-21 PY - 2000 SN - 0039-6257 SP - S150-S168 ST - Pediatric cataract T2 - Survey of Ophthalmology TI - Pediatric cataract UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32175101&from=export http://dx.doi.org/10.1016/S0039-6257(00)00182-X VL - 45 ID - 3901 ER - TY - JOUR C1 - xalacom(Pharmacia) xalatan C2 - Pharmacia DB - Embase IS - 11 KW - antiglaucoma agent latanoprost latanoprost plus timolol timolol maleate unclassified drug clinical trial drug mechanism drug tolerability glaucoma intraocular pressure monotherapy note patient compliance xalacom xalatan LA - English M3 - Note N1 - L33085915 2001-12-06 PY - 2001 SN - 0262-4230 SP - 6 ST - Pharmacia launches dual glaucomatherapy T2 - Manufacturing Chemist TI - Pharmacia launches dual glaucomatherapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33085915&from=export VL - 72 ID - 3885 ER - TY - JOUR AN - 105492398. Language: English. Entry Date: 20090410. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical DB - ccm DP - EBSCOhost IS - 18 KW - Angiogenesis Inhibitors Cornea -- Surgery Dry Eye Syndromes -- Symptoms Keratitis -- Immunology Keratomileusis, Laser in Situ Appointments and Schedules Equipment Design Lenses Marketing Pharmaceutical Companies Phototherapy Eye Surgery -- Equipment and Supplies N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2002 SN - 8750-3085 SP - 20-21 ST - From the OSNSuperSite.com T2 - Ocular Surgery News TI - From the OSNSuperSite.com UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105492398&site=ehost-live&scope=site VL - 20 ID - 4779 ER - TY - JOUR AB - • First-line drug treatment of chronic open-angle glaucoma or intraocular hypertonia is based on monotherapy with timolol eye drops. Patients in whom several single-agent treatments have failed can use combinations of timolol + dorzolamide (a carbonic anhydrase inhibitor) or a betablocker + pilocarpine (a parasympathomimetic agent). • An eye-drop preparation is now available in which 0.5% timolol is combined with 0.005% latanoprost, a prostaglandin F2α analogue. • A clinical trial indicated that the timolol + latanoprost combination was more effective than the timolol + dorzolamide combination on intraocular pressure, but the report of this study is too scanty to accept these results at face value. Once-a-day dosing with timolol + latanoprost has not been compared with a betablocker + pilocarpine combination. • Patients using the timolol + latanoprost combination are exposed to the adverse effects of both latanoprost (especially ocular irritation and brown iris discoloration) and the betablocker. • It is not known whether the once-a-day dosing of the timolol + latanoprost combination is a significant advantage, especially in terms of adherence to treatment. • In practice, the arrival of the timolol + latanoprost combination changes virtually nothing for patients with chronic open-angle glaucoma, except for those with no other alternative. C1 - xalacom(Pharmacia) C2 - Pharmacia DB - Embase IS - 67 KW - antiglaucoma agent benzalkonium chloride beta adrenergic receptor blocking agent carteolol dorzolamide plus timolol eye drops latanoprost plus timolol pilocarpine unclassified drug article blepharitis chronic disease clinical trial conjunctivitis cornea disease dose response drug efficacy eye color eye irritation eye pain headache human hyperpigmentation intraocular hypertension intraocular pressure iris disease open angle glaucoma patient compliance treatment failure xalacom LA - English M3 - Article N1 - L37185389 2003-10-12 PY - 2003 SN - 1167-7422 SP - 173-174 ST - Last-resort eye drops T2 - Prescrire International TI - Last-resort eye drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37185389&from=export VL - 12 ID - 3793 ER - TY - JOUR DB - Embase IS - 7246 KW - eye drops drug formulation human Internet medical literature note open angle glaucoma patient compliance practice guideline prescription side effect symptomatology LA - English M3 - Note N1 - L36546913 2003-05-20 PY - 2003 SN - 0031-6873 SP - 566 ST - Remind patients with glaucoma of importance of using eye-drops T2 - Pharmaceutical Journal TI - Remind patients with glaucoma of importance of using eye-drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36546913&from=export VL - 270 ID - 3819 ER - TY - JOUR AN - 105529585. Language: English. Entry Date: 20090522. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 9 KW - Patient Compliance Socioeconomic Factors Glaucoma -- Prevention and Control N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2003 SN - 8750-3085 SP - 17-17 ST - Socioeconomic factors affect patient compliance T2 - Ocular Surgery News TI - Socioeconomic factors affect patient compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105529585&site=ehost-live&scope=site VL - 21 ID - 4782 ER - TY - JOUR DB - Embase IS - 1 KW - alpha 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent betaxolol brimonidine carbonate dehydratase inhibitor dorzolamide latanoprost pilocarpine prostaglandin derivative timolol apoptosis clinical practice clinical trial conference paper disease severity follow up glaucoma human intraocular hypertension intraocular pressure optic disk patient compliance perimetry quality of life retina ganglion cell retina nerve cell visual field visual impairment LA - English M3 - Conference Paper N1 - L40069099 2005-01-19 PY - 2004 SN - 1560-2133 SP - 15-17 ST - Management of ocular hypertension and glaucoma T2 - Asian Journal of Ophthalmology TI - Management of ocular hypertension and glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40069099&from=export VL - 6 ID - 3716 ER - TY - JOUR C1 - cymbalta(Lilly) C2 - Lilly DB - Embase IS - 10 KW - duloxetine fluvoxamine monoamine oxidase inhibitor quinoline derived antiinfective agent thioridazine agitation akathisia anxiety appetite closed angle glaucoma coma constipation delirium diabetes mellitus diarrhea disease exacerbation dizziness fatigue heart ventricle arrhythmia hostility hot flush human hyperthermia hypomania impulsiveness insomnia irritability kidney function liver failure major depression mania mental health mydriasis myoclonus nausea neuropathic pain panic patient compliance rigidity short survey somnolence sudden death suicidal behavior sweating xerostomia cymbalta LA - English M3 - Short Survey N1 - L39362300 2004-11-09 PY - 2004 SN - 0016-867X SP - 19 ST - New molecular entity: Cymbalta®, Eli Lilly Duloxetine T2 - Geriatrics TI - New molecular entity: Cymbalta®, Eli Lilly Duloxetine UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39362300&from=export VL - 59 ID - 3725 ER - TY - JOUR C1 - Cop 1 DB - Embase IS - 4 KW - adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bimatoprost carbonate dehydratase inhibitor caspase 3 cyclic GMP dependent protein kinase inhibitor glatiramer latanoprost melanin mitogen activated protein kinase inhibitor phosphatidylinositol 3 kinase inhibitor protein kinase C inhibitor streptozocin timolol travoprost age cataract closed angle glaucoma conference paper dose response drug efficacy drug mechanism drug response ethnology glaucoma human intraocular pressure iridotomy low level laser therapy neuroprotection open angle glaucoma patient compliance retina nerve cell streptozotocin-induced diabetes mellitus trabecular meshwork Cop 1 LA - English M3 - Conference Paper N1 - L39193648 2004-09-20 PY - 2004 SN - 1560-2133 SP - 13-15 ST - Update in glaucoma management. From The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale Florida, USA, 2-7 May 2004 T2 - Asian Journal of Ophthalmology TI - Update in glaucoma management. From The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale Florida, USA, 2-7 May 2004 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39193648&from=export VL - 5 ID - 3731 ER - TY - JOUR DB - Embase IS - 6 KW - analgesic agent antiglaucoma agent backache general practitioner glaucoma government health care access health care delivery human multiple sclerosis national health service note nurse optometry patient care pharmaceutical care pharmacist physiotherapist podiatry prescription professional practice radiologist workload LA - English M3 - Note N1 - L38812163 2004-07-06 PY - 2004 SN - 0029-7917 SP - 7 ST - Health pros get prescribing powers T2 - Occupational Health TI - Health pros get prescribing powers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38812163&from=export VL - 56 ID - 3744 ER - TY - JOUR AB - The 34th annual meeting and exhibition of the American Society of Consultant Pharmacists was held in San Antonio, November 12-14, 2003. The concurrent educational sessions and industry symposia offered participants the chance to gain new clinical knowledge and skills, understand the influence of the marketplace and legislation on the state of health care, and implement new procedures to enhance their practice, all with one goal in mind - improving patient care. DB - Embase IS - 1 KW - adrenergic receptor stimulating agent antidepressant agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor cardiovascular agent cholinergic receptor stimulating agent influenza vaccine neuroleptic agent prostaglandin derivative aged Alzheimer disease cardiovascular disease conference paper daily life activity dementia geriatric care geriatric patient glaucoma health care industry high risk population human influenza influenza vaccination mental disease nursing home organization patient care patient compliance pharmacist prescription residential care United States LA - English M3 - Conference Paper N1 - L38101622 2004-02-04 PY - 2004 SN - 1096-5645 SP - 44-49 ST - American Society of Consultant Pharmacists T2 - Managed Care Interface TI - American Society of Consultant Pharmacists UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38101622&from=export VL - 17 ID - 3765 ER - TY - JOUR DB - Embase IS - 5 KW - beta adrenergic receptor blocking agent eye drops aging asthma diet therapy disease exacerbation drug blood level drug dose regimen drug elimination drug induced disease drug labeling drug metabolism drug safety drug utilization dyspnea editorial glaucoma human kidney function kinesiotherapy liver function patient compliance patient education physiotherapy polypharmacy prescription risk benefit analysis symptom wheezing LA - English M3 - Editorial N1 - L40389564 2005-04-06 PY - 2005 SN - 0564-1470 SP - 1-2 ST - Editor's desk: Multiple medications T2 - Trauma TI - Editor's desk: Multiple medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40389564&from=export VL - 46 ID - 3703 ER - TY - JOUR DB - Embase IS - 37 KW - beta 1 adrenergic receptor blocking agent beta 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bimatoprost cyclic AMP prostaglandin derivative prostaglandin F2 timolol water glaucoma human intraocular hypertension intraocular pressure note patient compliance protein synthesis treatment indication LA - German M3 - Note N1 - L44617217 2006-11-06 PY - 2006 SN - 0011-9857 SP - 32-34 ST - Treatment of glaucoma: A new fixed combination lowers the intraocular pressure T2 - Deutsche Apotheker Zeitung TI - Treatment of glaucoma: A new fixed combination lowers the intraocular pressure UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44617217&from=export VL - 146 ID - 3587 ER - TY - JOUR AN - 106339427. Language: English. Entry Date: 20060929. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost KW - Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Patient Compliance Comparative Studies Disease Progression -- Prevention and Control Drug Administration Drug Combinations Education, Continuing (Credit) Intraocular Pressure -- Drug Effects Medication Compliance Ophthalmic Solutions Timolol -- Administration and Dosage Timolol -- Therapeutic Use N1 - CEU; exam questions; tables/charts. Supplement Title: 2006 Jul 15 Supplement. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 12-15 ST - Compliance issues in glaucoma management T2 - Ocular Surgery News TI - Compliance issues in glaucoma management UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106339427&site=ehost-live&scope=site ID - 4535 ER - TY - JOUR AB - Lupus nephritis is one of the main causes of morbidity and mortality in children with systemic lupus erythematosus. Although the first-line of treatment is corticosteroids, it is important to minimise their dosage because of their extensive adverse event profile. Antimalarials are often added as corticosteroid-sparing agents in patients with mild disease. For patients with more active disease, early cytotoxic therapy with cyclophosphamide is the standard of care for inducing remission. © 2007 Adis Data Information BV. All rights reserved. DB - Embase DO - 10.2165/00042310-200723030-00005 IS - 3 KW - angiotensin receptor antagonist antihistaminic agent antimalarial agent azathioprine blys monoclonal antibody calcium complement component c5b monoclonal antibody corticosteroid cyclophosphamide cyclosporine cytotoxic agent dipeptidyl carboxypeptidase inhibitor diphenhydramine diuretic agent hydroxychloroquine hydroxymethylglutaryl coenzyme A reductase inhibitor interleukin 10 antibody methotrexate methylprednisolone monoclonal antibody mycophenolate mofetil nucleoside derivative prednisolone rituximab tumor necrosis factor antibody unclassified drug vitamin D acne add on therapy alopecia amenorrhea antiinflammatory activity atherosclerosis avascular necrosis cardiovascular disease cataract cause of death clinical trial cognitive defect combination chemotherapy corticosteroid induced osteoporosis corticosteroid therapy Cushing syndrome diabetes mellitus disease classification disease course disease severity drug dose escalation drug dose reduction drug efficacy drug fever drug mechanism face erythema gastrointestinal symptom glaucoma glomerulus filtration rate growth retardation hemorrhagic cystitis hirsutism human hyperlipidemia hypertension immunosuppressive treatment induced hypotension infection infertility kidney disease kidney function kidney transplantation leukopenia long term care low drug dose lupus erythematosus nephritis metastasis monotherapy morbidity nausea nephrotic syndrome nephrotoxicity patient compliance proliferative glomerulonephritis proteinuria pruritus psychosis renovascular hypertension review rigor side effect standard stria systemic lupus erythematosus unspecified side effect vomiting World Health Organization wound healing impairment LA - English M3 - Review N1 - L46255328 2007-04-10 jsessionid=FPCZlQnGMSGhvHpFf05JX7yy4hPxnqhrVTn2NNyczhpJWVmZ0clc!736553971!-949856145!8091!-1 PY - 2007 SN - 1172-0360 SP - 15-19 ST - The treatment of lupus nephritis in children involves corticosteroids and cytotoxic agents T2 - Drugs and Therapy Perspectives TI - The treatment of lupus nephritis in children involves corticosteroids and cytotoxic agents UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46255328&from=export http://dx.doi.org/10.2165/00042310-200723030-00005 http://perspectives.adisonline.com/pt/re/dtp/pdfhandler.00042310-200723030-00005.pdf VL - 23 ID - 3538 ER - TY - JOUR AN - 105398030. Language: English. Entry Date: 20090918. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 3 KW - Contact Lenses Eye Care Contact Lenses -- Utilization Hydrogen Peroxide Keratitis -- Prevention and Control Ophthalmic Solutions Patient Compliance Silicones N1 - questions and answers. Journal Subset: Biomedical; USA. PY - 2008 SN - 1558-0199 SP - 83-86 ST - Expert question and answer session T2 - Johns Hopkins Advanced Studies in Ophthalmology TI - Expert question and answer session UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105398030&site=ehost-live&scope=site VL - 5 ID - 4479 ER - TY - JOUR AN - 105640491. Language: English. Entry Date: 20090327. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 23 KW - Glaucoma -- Therapy Decision Making, Clinical Glaucoma -- Drug Therapy Glaucoma -- Surgery Laser Therapy Patient Compliance Quality of Life Severity of Illness Eye Surgery N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2008 SN - 8750-3085 SP - 13-13 ST - Four factors can help determine best initial glaucoma therapy T2 - Ocular Surgery News TI - Four factors can help determine best initial glaucoma therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105640491&site=ehost-live&scope=site VL - 26 ID - 4610 ER - TY - JOUR AN - 105640495. Language: English. Entry Date: 20090327. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 23 KW - Aging Eye Care -- Utilization Cataract -- Risk Factors Glaucoma -- Risk Factors Health Resource Utilization Health Services Accessibility Macular Degeneration -- Risk Factors Ophthalmology Workforce N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2008 SN - 8750-3085 SP - 14-14 ST - Baby boomers will increase demand for eye care T2 - Ocular Surgery News TI - Baby boomers will increase demand for eye care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105640495&site=ehost-live&scope=site VL - 26 ID - 4699 ER - TY - JOUR C1 - alphagan arteoptic azopt betamann betoptima clonid ophtal glauco stulln isopto carbachol lumigan pilomann taflotan timo ophtal travatan trusopt xalatan DB - Embase IS - 15 KW - betaxolol bimatoprost brimonidine brinzolamide carbachol carteolol clonid ophtal clonidine dorzolamide glauco stulln latanoprost metipranolol pilocarpine pindolol tafluprost timo ophtal timolol travoprost unclassified drug blindness glaucoma human intraocular pressure low level laser therapy pathogenesis patient compliance risk factor short survey visual field alphagan arteoptic azopt betamann betoptima isopto carbachol lumigan pilomann taflotan travatan trusopt xalatan LA - German M3 - Short Survey N1 - L354555469 2009-05-20 PY - 2009 SN - 0011-9857 SP - 67 ST - Glaucoma treatment-Glaucoma: Many affected; high estimated number of unreported cases T2 - Deutsche Apotheker Zeitung TI - Glaucoma treatment-Glaucoma: Many affected; high estimated number of unreported cases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354555469&from=export VL - 149 ID - 3360 ER - TY - JOUR AN - 105268207. Language: English. Entry Date: 20100122. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical DB - ccm DP - EBSCOhost IS - 24 KW - After Care Communication Barriers Glaucoma -- Prognosis Waiting Lists Appointments and Schedules Outcomes (Health Care) N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 18-18 ST - Clinic waiting time, language barrier leading reasons for glaucoma patients' poor follow-up T2 - Ocular Surgery News TI - Clinic waiting time, language barrier leading reasons for glaucoma patients' poor follow-up UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105268207&site=ehost-live&scope=site VL - 27 ID - 4567 ER - TY - JOUR AN - 105248982. Language: English. Entry Date: 20100108. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 22 KW - Communication Barriers Glaucoma -- Therapy Health Services Accessibility Waiting Lists After Care Appointments and Schedules N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 37-37 ST - Glaucoma patients cite long wait times, communication problems as barriers to care T2 - Ocular Surgery News TI - Glaucoma patients cite long wait times, communication problems as barriers to care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105248982&site=ehost-live&scope=site VL - 27 ID - 4568 ER - TY - JOUR AN - 105248997. Language: English. Entry Date: 20100108. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 22 KW - Glaucoma -- Drug Therapy Medication Compliance Office Visits Patient Education Physician-Patient Relations N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 19-19 ST - First patient office visit vital to establishing effective glaucoma medical therapy T2 - Ocular Surgery News TI - First patient office visit vital to establishing effective glaucoma medical therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105248997&site=ehost-live&scope=site VL - 27 ID - 4606 ER - TY - JOUR AN - 105396754. Language: English. Entry Date: 20090918. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 15 KW - Communication Glaucoma -- Drug Therapy Medication Compliance Physician-Patient Relations N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 20-20 ST - Communication key to addressing noncompliance with medication T2 - Ocular Surgery News TI - Communication key to addressing noncompliance with medication UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105396754&site=ehost-live&scope=site VL - 27 ID - 4652 ER - TY - JOUR AN - 105533409. Language: English. Entry Date: 20090710. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 9 KW - Costs and Cost Analysis Drugs, Prescription -- Economics Medication Compliance Counseling Decision Making, Clinical Glaucoma -- Drug Therapy Medical Orders Physician-Patient Relations N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 19-19 ST - Discuss medication costs with patients to reduce adherence issues T2 - Ocular Surgery News TI - Discuss medication costs with patients to reduce adherence issues UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105533409&site=ehost-live&scope=site VL - 27 ID - 4662 ER - TY - JOUR AN - 105544358. Language: English. Entry Date: 20090724. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 11 KW - Community Programs Glaucoma -- Drug Therapy Medication Compliance Patient Education Patient Attitudes N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 14-14 ST - Patients report better understanding of compliance after program T2 - Ocular Surgery News TI - Patients report better understanding of compliance after program UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105544358&site=ehost-live&scope=site VL - 27 ID - 4669 ER - TY - JOUR AB - The proceedings contain 333 papers. The topics discussed include: a case study evaluating Malaysian community pharmacists' professional practices and services; comparison of costing methods: cost to charge ratio and diagnosis related group using Stevens-Johnson syndrome and toxic epidermal necrolysis as a case study; epidemiology and comorbidities of patients with psoriasis in Taiwan; the economic burdens for patients with psoriasis in Taiwan; burden of disease in patients with glaucoma in china: results from 2009 national health and wellness survey; health resource utilization and costs in patients with age-related macular degeneration in Thailand: preliminary findings; economic evaluation on vision screening for preschool children; and cost-effectiveness of brinzolamide/timolol fixed combination (BTFC) versus dorzolamide/timolol fixed combination (DTFC) for patients with open angle glaucoma in Korea and Taiwan. DB - Embase IS - 7 KW - Asia human patient Taiwan case study psoriasis wellbeing health care utilization age related macular degeneration Thailand economic evaluation vision test preschool child cost effectiveness analysis Korea community pharmacist professional practice open angle glaucoma Stevens Johnson syndrome toxic epidermal necrolysis epidemiology glaucoma China public health diagnosis related group LA - English M3 - Conference Review N1 - L70514094 2011-08-30 PY - 2010 SN - 1098-3015 ST - ISPOR 4th Asia-Pacific Conference Research Abstracts T2 - Value in Health TI - ISPOR 4th Asia-Pacific Conference Research Abstracts UR - https://www.embase.com/search/results?subaction=viewrecord&id=L70514094&from=export VL - 13 ID - 3225 ER - TY - JOUR DB - Embase IS - 1082 KW - antiglaucoma agent blindness disease severity doctor patient relationship glaucoma human interview patient attitude patient compliance quality of life short survey L1 - internal-pdf://1713258270/publishing.realviewtechnologies.com.txt LA - English M3 - Short Survey N1 - L359963783 2010-11-24 2010-12-02 PY - 2010 SN - 0311-8002 SP - 83 ST - Attitude influences adherence to anti-glaucoma drugs T2 - Australian Journal of Pharmacy TI - Attitude influences adherence to anti-glaucoma drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359963783&from=export VL - 91 ID - 3243 ER - TY - JOUR C1 - gardasil(Merck) mectizan(Merck) truvada viread zithromax(Pfizer) C2 - Glaxo SmithKline Merck Pfizer DB - Embase DO - 10.1038/nrmicro2345 IS - 4 KW - albendazole antimalarial agent azithromycin emtricitabine plus tenofovir disoproxil generic drug ivermectin tenofovir disoproxil Wart virus vaccine developing country drug cost drug industry drug research editorial eradication therapy filariasis finance funding glaucoma health care access human infection medical device natural disaster onchocerciasis patent priority journal gardasil mectizan truvada viread zithromax LA - English M3 - Editorial N1 - L358475390 2010-03-26 PY - 2010 SN - 1740-1526 SP - 244 ST - Editorial: A step in the right direction T2 - Nature Reviews Microbiology TI - Editorial: A step in the right direction UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358475390&from=export http://dx.doi.org/10.1038/nrmicro2345 VL - 8 ID - 3263 ER - TY - JOUR AB - Diabetic retinopathy (DR), glaucoma, and age-related macular degeneration (ARMD) are major causes of vision loss and blindness. Women have been found to have a higher prevalence of vision loss than men. Early detection and timely treatment by eye-care providers are necessary to delay disease progression and prevent vision loss. To assess the use of professional eye care among women aged >/=40 years, CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) for 19 U.S. states for the period 2006--2008. This report summarizes the results of that analysis, which indicated that 21% of women with self-reported DR, 12% of women with self-reported glaucoma, and 8% of women with self-reported ARMD did not visit an eye-care provider in the recommended follow-up period. Women who did not have insurance coverage for eye care or who did not receive routine medical check-ups were more likely to report not having the recommended follow-up eye care. The two most commonly cited reasons for not having an eye-care visit were cost or not having insurance (range across diseases: 40%--46%) and having no reason to go for follow-up (range: 20%--29%). Compliance with obtaining eye examinations at recommended intervals among women aged >/=40 years with eye diseases might be enhanced by improving access to health care and implementing and expanding existing educational programs to raise awareness regarding the importance of routine follow-up eye examinations. AN - 105020209. Corporate Author: Centers for Disease Control and Prevention (CDC). Language: English. Entry Date: 20100611. Revision Date: 20151015. Publication Type: Journal Article. Journal Subset: Biomedical DB - ccm DP - EBSCOhost IS - 19 KW - Diabetic Retinopathy -- Diagnosis Glaucoma -- Diagnosis Health Services -- Utilization Macular Degeneration -- Diagnosis Vision Screening -- Utilization Adult Aged Female Health Services Accessibility Insurance Coverage Medically Uninsured Middle Age Patient Compliance Risk Assessment United States N1 - Public Health; USA. NLM UID: 7802429. PMID: NLM20489682. PY - 2010 SN - 0149-2195 SP - 588-591 ST - Eye-care utilization among women aged greater than or equal to 40 years with eye diseases -- 19 states, 2006-2008 T2 - MMWR: Morbidity & Mortality Weekly Report TI - Eye-care utilization among women aged greater than or equal to 40 years with eye diseases -- 19 states, 2006-2008 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105020209&site=ehost-live&scope=site VL - 59 ID - 4381 ER - TY - JOUR AB - The article offers information on age-related eye problems, treatment options and preventive measures. It describes how the brain process human vision. A discussion on age-related eye problems like presbyopia and dry eyes is detailed. The methods used for cataract surgery include using an ultrasound probe to break up the lens for removal and making an incision in the eye and removing the lens. Also discussed are the forms of glaucoma, age-related macular degeneration and other tests and procedures during an eye exam. INSETS: When it's an emergency;Nonprescription reading glasses;Eye floaters;When vision improves AN - 53731067. Language: English. Entry Date: 20101001. Revision Date: 20101111. Publication Type: Article DB - ccm DP - EBSCOhost KW - Vision Aging Vision -- Physiology Presbyopia Dry Eye Syndromes Cataract Glaucoma Macular Degeneration Office Visits Diagnosis, Eye Emergencies Eyeglasses Foreign Bodies Ophthalmic Solutions Dietary Supplements Diabetes Mellitus N1 - pictorial. Supplement Title: Oct2010 Supplement. Journal Subset: Consumer Health; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8507508. PY - 2010 SN - 0741-6245 SP - 1-8 ST - Vision T2 - Mayo Clinic Health Letter TI - Vision UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=53731067&site=ehost-live&scope=site ID - 4616 ER - TY - JOUR AN - 105310543. Language: English. Entry Date: 20100319. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy Medication Compliance Communication Patient Attitudes Physician-Patient Relations N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 13-13 ST - Not all medication adherence issues apparent to ophthalmologists T2 - Ocular Surgery News TI - Not all medication adherence issues apparent to ophthalmologists UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105310543&site=ehost-live&scope=site VL - 28 ID - 4653 ER - TY - JOUR AN - 105103020. Language: English. Entry Date: 20101001. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Medication Compliance N1 - brief item. Journal Subset: Core Nursing; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PY - 2010 SN - 1060-135X SP - 27-27 ST - Intervention program improves glaucoma medication adherence T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - Intervention program improves glaucoma medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105103020&site=ehost-live&scope=site VL - 35 ID - 4732 ER - TY - JOUR AN - 104614163. Language: English. Entry Date: 20120104. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 8 KW - Ophthalmology Coding Cornea -- Surgery Eye Foreign Bodies Office Visits Medicare Current Procedural Terminology Corneal Topography Visual Fields Glaucoma Hospitalization Lasers N1 - questions and answers. Journal Subset: Health Services Administration; USA. PY - 2011 SN - 1523-4843 SP - 52-55 ST - Reader Questions T2 - Ophthalmology Coding Alert TI - Reader Questions UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104614163&site=ehost-live&scope=site VL - 14 ID - 4407 ER - TY - JOUR AN - 104844726. Language: English. Entry Date: 20110325. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Health Services Administration DB - ccm DP - EBSCOhost IS - 4 KW - Glaucoma Severity of Illness Coding Physical Examination Current Procedural Terminology Office Visits Medicare Vision Screening N1 - USA. PY - 2011 SN - 1523-4843 SP - 19-20 ST - S0620 or G0117? Let Form and Severity Drive Your Glaucoma Coding Choice T2 - Ophthalmology Coding Alert TI - S0620 or G0117? Let Form and Severity Drive Your Glaucoma Coding Choice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104844726&site=ehost-live&scope=site VL - 14 ID - 4550 ER - TY - JOUR AN - 104614183. Language: English. Entry Date: 20120106. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Health Services Administration DB - ccm DP - EBSCOhost IS - 12 KW - Glaucoma -- Diagnosis Coding Billing and Claims Current Procedural Terminology Visual Fields Office Visits N1 - USA. PY - 2011 SN - 1523-4843 SP - 84-85 ST - 92081-92083 With Modifier 50? Not So Fast T2 - Ophthalmology Coding Alert TI - 92081-92083 With Modifier 50? Not So Fast UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104614183&site=ehost-live&scope=site VL - 14 ID - 4620 ER - TY - JOUR AB - The article offers the insights of physician David S. Friedman during the Richard A. Ellis Lecture which states that enhanced physician-patient discourse is helpful in increasing patients' adherence to glaucoma therapy. AN - 86114932. Language: English. Entry Date: 20130321. Revision Date: 20191101. Publication Type: Article DB - ccm DP - EBSCOhost IS - 8 KW - Medication Compliance Professional-Patient Relations Glaucoma -- Drug Therapy Communication Research Reminder Systems -- Evaluation N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2011 SN - 8750-3085 SP - 16-16 ST - Improved communication may increase patients' adherence to glaucoma medication T2 - Ocular Surgery News TI - Improved communication may increase patients' adherence to glaucoma medication UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=86114932&site=ehost-live&scope=site VL - 29 ID - 4688 ER - TY - JOUR AB - The article reports that reducing the complexity of dosing is deemed beneficial to adherence to a medication regimen which may be problematic for some patients with glaucoma, according to the Automated Dosing Reminder Study. AN - 62546087. Language: English. Entry Date: 20110712. Revision Date: 20150319. Publication Type: Article DB - ccm DP - EBSCOhost IS - 7 KW - Glaucoma -- Drug Therapy Medication Compliance Physician-Patient Relations Communication N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2011 SN - 8750-3085 SP - 17-17 ST - Physician offers simple ways to improve glaucoma regimen adherence T2 - Ocular Surgery News TI - Physician offers simple ways to improve glaucoma regimen adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=62546087&site=ehost-live&scope=site VL - 29 ID - 4689 ER - TY - JOUR AN - 108184267. Language: English. Entry Date: 20120509. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Biomedical DB - ccm DP - EBSCOhost IS - 8 KW - Strabismus -- Surgery Anesthesia, General Child Head Nerve Fibers Corneal Transplantation Eye Surgery Cataract Extraction Meningoencephalitis Recurrence Keratomileusis, Laser in Situ Cornea -- Surgery Visual Fields Patient Compliance Glaucoma -- Drug Therapy Dry Eye Syndromes -- Drug Therapy Growth Substances -- Therapeutic Use Lenses, Intraocular Infant, Premature Tomography Intraocular Pressure Blood Circulation N1 - Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 30-36 ST - IN THE JOURNALS T2 - Ocular Surgery News TI - IN THE JOURNALS UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108184267&site=ehost-live&scope=site VL - 30 ID - 4593 ER - TY - GEN AB - An interview with Mohammed Abdull, the head of the ophthalmology department at Abubakar Tafawa Balewa University Teaching hospital in Bauchim Nigeria, is presented. When asked on the understanding of people about glaucoma, he states that glaucoma was not known. Abdul explains that the lack of symptoms and poor awareness are some of the reasons that prevent early diagnosis of the disease. He also shares the hospital's effort to encourage people to come forward to diagnose the disease early. INSET: Gender and glaucoma. DB - ccm DP - EBSCOhost J2 - Community Eye Health Journal KW - Glaucoma -- Therapy Patient Care -- Methods Health Services Accessibility Help Seeking Behavior Patient Attitudes Health Beliefs N1 - Accession Number: 85836089. Language: English. Entry Date: 20130305. Revision Date: 20190226. Publication Type: Interview; pictorial. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 8912615. PB - International Centre for Eye Health (ICEH), London School of Hygiene & Tropical Medicine PY - 2012 SN - 0953-6833 SP - 44-45 ST - Patients and glaucoma: what are the challenges? TI - Patients and glaucoma: what are the challenges? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=85836089&site=ehost-live&scope=site VL - 25 ID - 4619 ER - TY - JOUR AN - 108098937. Language: English. Entry Date: 20120928. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Biomedical DB - ccm DP - EBSCOhost IS - 16 KW - Glaucoma -- Drug Therapy Medication Compliance -- Evaluation N1 - Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 22-23 ST - Glaucoma treatment adherence difficult to measure, improve T2 - Ocular Surgery News TI - Glaucoma treatment adherence difficult to measure, improve UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108098937&site=ehost-live&scope=site VL - 30 ID - 4635 ER - TY - JOUR AN - 108098040. Language: English. Entry Date: 20121001. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Biomedical DB - ccm DP - EBSCOhost IS - 14 KW - Glaucoma -- Surgery Eye Surgery Patient Compliance Primary Health Care Hypertension -- Surgery N1 - Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 3-4 ST - Glaucoma may transition to surgery-first management T2 - Ocular Surgery News TI - Glaucoma may transition to surgery-first management UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108098040&site=ehost-live&scope=site VL - 30 ID - 4691 ER - TY - JOUR AN - 107933679. Language: English. Entry Date: 20131101. Revision Date: 20150712. Publication Type: Journal Article DA - 2012 Spring DB - ccm DP - EBSCOhost KW - Glaucoma -- Drug Therapy Medication Compliance Adult Aged, 80 and Over Colorado Coping Descriptive Statistics Female Funding Source Human Male Middle Age Motivation Oregon Self Report Self-Efficacy Support, Psychosocial N1 - abstract; research. Journal Subset: Nursing; Peer Reviewed; USA. Grant Information: This study was supported by research contract #2517807.. NLM UID: 7707277. PY - 2012 SN - 0160-1652 SP - 259-259 ST - Glaucoma medication treatment nonadherence: correlates and consequences T2 - Communicating Nursing Research TI - Glaucoma medication treatment nonadherence: correlates and consequences UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107933679&site=ehost-live&scope=site VL - 45 ID - 4702 ER - TY - JOUR AN - 108180329. Language: English. Entry Date: 20120509. Revision Date: 20150712. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 7 KW - Glaucoma -- Drug Therapy Drug Delivery Systems Problem Solving N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 16-16 ST - Obstacles remain for innovative sustained glaucoma drug delivery systems T2 - Ocular Surgery News TI - Obstacles remain for innovative sustained glaucoma drug delivery systems UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108180329&site=ehost-live&scope=site VL - 30 ID - 4704 ER - TY - JOUR AB - Diabetes can lead to visual impairment (VI) and blindness. However, early detection and treatment of many common eye diseases, such as diabetic retinopathy and glaucoma, can reduce the risk for developing VI. Surveillance of VI among persons with diabetes is important for evaluating the effectiveness of efforts to reduce VI and other complications of diabetes. To examine trends in the prevalence of self-reported VI among adults with diagnosed diabetes in the United States and to assess reported access to eye-care providers, Centers for Disease Control and Prevention (CDC) analyzed 1997-2010 data from the National Health Interview Survey (NHIS). This report describes the results of that analysis, which indicated that although the number of adults with diagnosed diabetes reporting VI increased, the age-adjusted percentage of adults with diagnosed diabetes who reported VI declined significantly, from 1997-2010.The percentage of adults with diagnosed diabetes and self-reported VI who reported having consulted an eye-care provider in the past year remained constant at approximately 63%. Continued efforts are needed to sustain and improve the declining trends in self-reported VI and to increase rates of recommended eye examinations in the population with diabetes. The article further talks about the CDC report. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 2012-01407-005 DB - psyh DP - EBSCOhost IS - 1 KW - visual impairment diagnosed diabetes United States eye-care provider access Diabetes Mellitus Epidemiology Health Care Services Health Care Utilization Vision Disorders Medical Diagnosis N1 - Epidemiology; Health Care Services; Health Care Utilization; Vision Disorders. Minor Descriptor: Medical Diagnosis. Classification: Physical & Somatoform & Psychogenic Disorders (3290). Population: Human (10). Location: US. Tests & Measures: National Health Interview Survey. Supplemental Data: Web Sites Internet. References Available: Y. Page Count: 3. Issue Publication Date: Jan 4, 2012. Copyright Statement: All rights reserved. American Medical Association. 2012. PY - 2012 SN - 0098-7484 1538-3598 SP - 25-27 ST - Self-reported visual impairment among persons with diagnosed diabetes—United States, 1997-2010 T2 - JAMA: Journal of the American Medical Association TI - Self-reported visual impairment among persons with diagnosed diabetes—United States, 1997-2010 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-01407-005&site=ehost-live&scope=site VL - 307 ID - 4870 ER - TY - JOUR DB - Embase IS - 1 KW - sorbate potassium timolol timolol maleate vasculotropin inhibitor Ahmed valve clinical practice comorbidity congenital glaucoma correlation analysis editorial eye burning genetic counseling glaucoma glaucoma surgery gonioscopy gravity human in vivo study intraocular hypotension intraocular pressure iridotomy lacrimation lens implantation materials testing molecular biology molecular diagnosis molecular mechanics multicenter study (topic) Nigeria observational study open angle glaucoma ophthalmic argon laser ophthalmic neodymium YAG laser pathogenesis patient compliance phacoemulsification postoperative period prospective study retrospective study risk assessment sclerectomy side effect trabeculoplasty treatment outcome visual acuity LA - English M3 - Editorial N1 - L369024246 2013-06-07 PY - 2013 SN - 0974-0333 0975-1947 SP - V ST - Editorial T2 - Journal of Current Glaucoma Practice TI - Editorial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369024246&from=export VL - 7 ID - 2990 ER - TY - JOUR AB - The article presents views of several eye experts including Stephen C. Pflugfelder, Steven L. Mansberger and Cindy M.L. Hutnik on aging eye problems. According to Pflugfelder, conjunctivochalasis increases with age and it results in pooling and stagnation of the central tear meniscus. Mansberger mentions that disc hemorrhages persist for six months in patients who are poorly adherent to their glaucoma medications and Hutnik discusses ocular surface disease in aged people. AN - 86175499. Language: English. Entry Date: 20130321. Revision Date: 20171010. Publication Type: Article DB - ccm DP - EBSCOhost KW - Aging Diagnosis, Eye Eye Diseases -- Therapy Treatment Outcomes -- Evaluation Eye Diseases -- Classification N1 - forms. Supplement Title: Mar2013 Eye Supplement. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2013 SN - 0193-032X SP - 1-8 ST - Aging Eye T2 - Ophthalmology Times TI - Aging Eye UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=86175499&site=ehost-live&scope=site ID - 4440 ER - TY - JOUR AN - 107805983. Language: English. Entry Date: 20141119. Revision Date: 20150712. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 21 KW - Glaucoma -- Therapy Injections Patient Compliance -- Evaluation Ophthalmology Serial Publications Administration, Topical Patient Care Intraocular Pressure Bimatoprost -- Administration and Dosage N1 - brief item; pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2014 SN - 8750-3085 SP - 18-18 ST - Injectable glaucoma medicine: a possible answer to compliance issues T2 - Ocular Surgery News TI - Injectable glaucoma medicine: a possible answer to compliance issues UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107805983&site=ehost-live&scope=site VL - 32 ID - 4636 ER - TY - JOUR AN - 107869855. Language: English. Entry Date: 20140812. Revision Date: 20150712. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 15 KW - Medication Compliance Glaucoma -- Drug Therapy Communication -- Methods Physicians N1 - brief item; pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2014 SN - 8750-3085 SP - 14-14 ST - Simple communication techniques help physicians address glaucoma medication compliance T2 - Ocular Surgery News TI - Simple communication techniques help physicians address glaucoma medication compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107869855&site=ehost-live&scope=site VL - 32 ID - 4638 ER - TY - JOUR AN - 107807665. Language: English. Entry Date: 20141211. Revision Date: 20150712. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 11 KW - Vision Screening World Wide Web Applications -- Utilization Health Services Accessibility -- Central America Glaucoma Wireless Communications Central America N1 - brief item; pictorial. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2014 SN - 0030-4085 SP - 17-17 ST - Glaucoma Screening App May Benefit Patients Who Lack Access to Eye Care T2 - Optometric Management TI - Glaucoma Screening App May Benefit Patients Who Lack Access to Eye Care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107807665&site=ehost-live&scope=site VL - 49 ID - 4758 ER - TY - JOUR AB - The proceedings contain 411 papers. The topics discussed include: assessment of workflow modifications of the medication synchronization program in a community pharmacy; classifying medication adherence behavior based on beliefs about medicines and illness perceptions: results from a cluster analysis; community pharmacists' interventions: effects on patients' adherence to medicare star rating medications; comparison of medication adherence rates between an appointment-based medication synchronization program and an automatic medication refill process; determinants of glaucoma patients who over-report medication adherence via self-report on a visual analog scale; developing a scoring algorithm for the medication adherence reasons scale; development and implementation of an adherence pharmacy model in community practice; and effects of community pharmacist telephone follow-up on adherence and readmission rates in the heart failure population: a multicenter study. DB - Embase IS - 2 KW - human medication compliance drug therapy pharmacy (shop) multicenter study (topic) pharmacist patient cluster analysis visual analog scale self report glaucoma population medicare heart failure hospital readmission algorithm follow up telephone community model diseases multicenter study workflow LA - English M3 - Conference Review N1 - L71971189 2015-08-08 PY - 2015 SN - 1544-3191 ST - APhA2015 T2 - Journal of the American Pharmacists Association TI - APhA2015 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L71971189&from=export VL - 55 ID - 2821 ER - TY - JOUR AB - Glaucoma is a leading cause of visual morbidity and blindness and the incidence increases with advancing age. Topical therapies that reduce intraocular pressure are commonly used as first-line agents to treat primary open-angle glaucoma, with the choice of treatment based on the need of the individual. Agents that are administered once daily with favourable tolerability profiles may lead to high levels of adherence and good treatment outcomes. AN - 112359907. Language: English. Entry Date: 20170718. Revision Date: 20170718. Publication Type: Article. Journal Subset: Biomedical DB - ccm DO - 10.1007/s40267-015-0270-5 DP - EBSCOhost IS - 2 KW - Glaucoma -- Therapy Intraocular Pressure Administration, Topical Individualized Medicine Medication Compliance Age Factors N1 - Peer Reviewed; USA. NLM UID: 9308798. PY - 2016 SN - 1172-0360 SP - 65-68 ST - Treat primary open-angle glaucoma based on needs of the individual, taking potential adherence problems into account T2 - Drugs & Therapy Perspectives TI - Treat primary open-angle glaucoma based on needs of the individual, taking potential adherence problems into account UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112359907&site=ehost-live&scope=site VL - 32 ID - 4275 ER - TY - JOUR AB - The article talks about three reasons why Minimally Invasive Glaucoma Surgery (MIGS) would replace old standard glaucoma drops as first-line therapy for cataract operation including use of preservatives, compliance and success and fast-learning methods of MIGS. AN - 113412437. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article DB - ccm DP - EBSCOhost IS - 4 KW - Learning Methods Minimally Invasive Procedures Glaucoma Success Cataract N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2016 SN - 8750-3085 SP - 26-26 ST - Three reasons why MIGS may replace glaucoma drops as first-line therapy T2 - Ocular Surgery News TI - Three reasons why MIGS may replace glaucoma drops as first-line therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113412437&site=ehost-live&scope=site VL - 34 ID - 4556 ER - TY - JOUR AB - The article discusses that selective laser trabeculoplasty (SLT) should be considered as a primary therapy for glaucoma patients because it is effective as primary glaucoma medications, less expensive and safer than medications with no patient compliance issues, according to physician L. Jay Katz. He opines that there is a problem with outflow in the trabecular meshwork for Schlemms canal in most patients and all the current drugs, used by physicians, really don't address that problem. AN - 113412424. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article DB - ccm DP - EBSCOhost IS - 4 KW - Glaucoma -- Therapy Patient Compliance Glaucoma Intraocular Pressure Physicians Lasers N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2016 SN - 8750-3085 SP - 21-21 ST - Consider SLT as first-line treatment in management of glaucoma T2 - Ocular Surgery News TI - Consider SLT as first-line treatment in management of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113412424&site=ehost-live&scope=site VL - 34 ID - 4557 ER - TY - JOUR AN - 129676696. Language: English. Entry Date: 20180528. Revision Date: 20190827. Publication Type: Article DB - ccm DP - EBSCOhost IS - 5 KW - Macular Degeneration -- Drug Therapy Dietary Supplementation Nutritional Counseling Diet Life Style Glaucoma -- Therapy Dry Eye Syndromes -- Therapy Patient Compliance Cost Benefit Analysis Health Care Costs Bevacizumab -- Therapeutic Use Dexamethasone -- Therapeutic Use Zeaxanthin -- Therapeutic Use Treatment Outcomes N1 - editorial; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2018 SN - 0030-4085 SP - 29-31 ST - RECOMMEND SUPPLEMENTATION T2 - Optometric Management TI - RECOMMEND SUPPLEMENTATION UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129676696&site=ehost-live&scope=site VL - 53 ID - 4579 ER - TY - JOUR AN - 129061624. Language: English. Entry Date: 20180427. Revision Date: 20180427. Publication Type: Article DB - ccm DP - EBSCOhost IS - 7 KW - Glaucoma -- Therapy Drug Delivery Systems Patient Compliance N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2018 SN - 8750-3085 SP - 11-11 ST - POINT / COUNTER T2 - Ocular Surgery News TI - POINT / COUNTER UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129061624&site=ehost-live&scope=site VL - 36 ID - 4633 ER - TY - JOUR AB - The article reports on new problems that may bring back the same symptoms after cataracts are successfully removed. Topics mentioned include occurrence of changes in vision from secondary cataracts within the first few years after surgery, circumstances that make people more likely to experience the side effect of cataract surgery, and possible complications of YAG laser capsulotomy. AN - 139323919. Language: English. Entry Date: 20191030. Revision Date: 20191031. Publication Type: Article DB - ccm DP - EBSCOhost IS - 3 KW - Cataract Extraction -- Adverse Effects Postoperative Complications -- Risk Factors Recurrence -- Risk Factors Cataract -- Risk Factors Risk Assessment Lenses, Intraocular Office Visits Surgeons Vision Disorders Cataract -- Symptoms Glaucoma -- Complications Uveitis -- Complications Cataract Extraction -- Methods Laser Therapy -- Methods N1 - pictorial; questions and answers. Journal Subset: Biomedical; USA. NLM UID: 9425723. PY - 2019 SN - 1051-5313 SP - 3-3 ST - Are you at risk for a secondary cataract? T2 - Harvard Heart Letter TI - Are you at risk for a secondary cataract? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139323919&site=ehost-live&scope=site VL - 30 ID - 4539 ER - TY - JOUR AB - The proceedings contain 51 papers. The topics discussed include: the human paralaminar nucleus and the HPA axis: salience in major depressive disorder; the association between monocyte subset numbers and significant disease on coronary angiography; the provision of a specialized turner syndrome pediatric clinic in a regional pediatric department; investigating the duration and indications of antimicrobial prescriptions: a clinical audit; efficacy and adverse events with the use of tranexamic acid in the hip fracture population in a university teaching hospital; a virtual HIV clinic at a tertiary referral center: a feasibility study; analyzing the apoptotic signature of activated lamina cribrosa fibroblasts in glaucoma; the relationship between healthcare utilization and mental health in young people; a longitudinal cohort study; and the mental health referral pathway from general practitioners to the emergency department at beaumont hospital. DB - Embase IS - SUPPL 3 KW - antiinfective agent tranexamic acid apoptosis child clinical audit cohort analysis conference review coronary angiography drug therapy emergency ward feasibility study fibroblast general practitioner glaucoma health care utilization hip fracture human Human immunodeficiency virus hypothalamus hypophysis adrenal system major depression mental health monocyte nonhuman pediatric hospital pediatric ward prescription tertiary care center Turner syndrome university hospital LA - English M3 - Conference Review N1 - L633901469 2021-01-18 PY - 2020 SN - 1863-4362 ST - Proceedings of the RAMI Student Section Meeting T2 - Irish Journal of Medical Science TI - Proceedings of the RAMI Student Section Meeting UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633901469&from=export VL - 189 ID - 2405 ER - TY - JOUR AB - BACKGROUND: Glaucoma is an ocular disorder characterized by optic nerve damage which ultimately causes a progressive and an irreversible loss of vision, often characterized by an elevated intraocular pressure. Lowering the intraocular pressure (IOP) is the mainstay for glaucoma treatment but the neuroprotective agents would represent a promising class as the next-generation therapy., EVIDENCE SYNTHESIS: Protein kinases are involved considerably in signal transduction pathways confirmed by various mechanisms giving the evidence of Rho-kinase to be a versatile therapeutic target. Rho associated protein kinases also known as ROCK are serine/threonine kinases, belonging to the Ras superfamily of GTPases. The activation of Rho Kinase results in various actin-myosin arbitrated processes where contraction of actomyosin in the resident trabecular meshwork (TM) cells and extracellular matrix is responsible for the outflow of aqueous humour. Another major drawback of the currently available antiglaucoma drugs is their topical use which poses a problem for patient compliance. The patient intolerability and adherence to the existing therapy therefore call for newer drug delivery systems that would increase the clinical efficacy of the drugs., CONCLUSION: The neuroprotective agents are not considered suitable to be administered through the traditional topical or oral route. This complementary drug therapy requires a delivery system that could release the drug to the optic nerve in a sustained manner and also increase patient compliance and tolerability. This review summarizes the use of ROCK inhibitors that could prevent the damage to the optic nerve along with the reduction in IOP and novel drug delivery systems to increase the efficacy of the drugs. AU - Abbhi, Vasudha AU - Piplani, Poonam IS - 6 KW - Administration, Ophthalmic *Drug Delivery Systems Drugs, Investigational/ad [Administration & Dosage] *Glaucoma/dt [Drug Therapy] Humans *Protein Kinase Inhibitors/ad [Administration & Dosage] *rho-Associated Kinases/ai [Antagonists & Inhibitors] PY - 2016 SE - Piplani, Poonam. University Institute of Pharmaceutical Sciences, UGC-Center of Advanced Study (UGC-CAS), Panjab University, Chandigarh 160014, India. ppvohra28in@yahoo.co.in. SN - 1875-5704 1567-2018 SP - 818-29 ST - Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma T2 - Current drug delivery TI - Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=23855668 VL - 13 ID - 752 ER - TY - JOUR AD - Department of Ophthalmology, Aminu Kano Teaching Hospital, Faculty of Medicine, Bayero University, PMB 3452, Kano, Nigeria AN - 104033846. Language: English. Entry Date: 20140303. Revision Date: 20200708. Publication Type: Journal Article AU - Abdu, Lawan DB - ccm DO - 10.1155/2013/402739 DP - EBSCOhost KW - Glaucoma -- Epidemiology -- Nigeria Nigeria Glaucoma -- Complications Blindness -- Risk Factors Glaucoma -- Physiopathology Glaucoma -- Symptoms Glaucoma -- Prevention and Control Health Screening -- Methods Health Services Accessibility Glaucoma -- Drug Therapy N1 - review. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2013 SN - 2090-004X SP - 1-6 ST - Epidemiological Properties of Primary Open Angle Glaucoma in Nigeria T2 - Journal of Ophthalmology TI - Epidemiological Properties of Primary Open Angle Glaucoma in Nigeria UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104033846&site=ehost-live&scope=site ID - 4694 ER - TY - JOUR AB - Purpose: To describe a case of intraocular lens (IOL) dystrophic calcification as a complication of trans-scleral diode laser successfully used to treat a post-trabeculectomy cyclodialysis cleft. Observations: A 76-year-old male with primary open angle glaucoma and pseudophakia (+19.0D Akreos M160L, Bausch & Lomb) was evaluated for vision impairment 4 months post-trabeculectomy complicated by a cyclodialysis cleft of his right eye. The patient was successfully treated with trans-scleral diode laser. After this treatment IOL opacification developed. Slit lamp examination and color photography of the anterior segment was performed prior to exchange of the opacified IOL. The explanted IOL underwent star testing, macroscopic imaging, phase contrast and scanning electron microscopy in addition to energy dispersive x-ray spectroscopy. Confluent IOL deposits developed 4 months after trans-scleral diode laser treatment requiring IOL exchange. Star optical testing of the explanted IOL showed disruption of the diffraction image. An asymmetric pattern of deposition was congruent with the laser treatment quadrant. The subsurface location and discrete nature of the deposits were seen on phase contrast and electron microscopy. Energy dispersive x-ray spectroscopy demonstrated a predominance of calcium/phosphate in the deposits. We are unaware of previous reports in the literature of IOL dystrophic calcification occurring as a complication of trans-scleral diode laser treatment for a post-trabeculectomy cyclodialysis cleft. Conclusion and importance: Delayed postoperative IOL dystrophic calcification in our case may have been from a combination of IOL biomaterial susceptibility to diode laser energy; damaged IOL material providing a nidus for calcific nucleation; and blood ocular barrier breakdown altering aqueous composition. We suggest that pseudophakia should influence the consideration of diode laser as treatment of a cyclodialysis cleft. © 2018 The Authors AD - Department of Ophthalmology, Counties Manukau DHB, Auckland, New Zealand Center for Ophthalmology and Visual Science, Lions Eye Institute, The University of Western Australia, Verdun St, Nedlands, Western Australia 6009, Australia Royal Perth Hospital, 197 Wellington St, Perth, Western Australia 6000, Australia AU - Abdul-Rahman, A. AU - House, P. AU - Richards, J. DB - Scopus DO - 10.1016/j.ajoc.2018.06.012 KW - Calcium phosphates Glaucoma Lasers Pseudophakia Trabeculectomy M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2018 SP - 78-83 ST - Intraocular lens dystrophic calcification after trans-scleral diode laser treatment for a cyclodialysis cleft T2 - American Journal of Ophthalmology Case Reports TI - Intraocular lens dystrophic calcification after trans-scleral diode laser treatment for a cyclodialysis cleft UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048892308&doi=10.1016%2fj.ajoc.2018.06.012&partnerID=40&md5=98e5c88ed10de984887a0fadc29a1d39 VL - 11 ID - 5449 ER - TY - JOUR AB - IMPORTANCE: To investigate the safety, effectiveness and follow-up rates after transscleral diode laser cyclophotocoagulation as primary treatment for seeing eyes with primary open angle glaucoma in Bauchi, Nigeria., BACKGROUND: There is a high prevalence of primary open angle glaucoma in Africa where adherence to medical treatment and acceptance of surgery are poor., DESIGN: Prospective case series., PARTICIPANTS: New glaucoma patients where surgical intervention was recommended., METHODS: A diode 810 nm laser G-probe was used under retrobulbar anaesthesia to deliver approximately 20 shots for 2000 ms, titrating the power. If both eyes were treated the first was the study eye. Repeat treatment offered if the intraocular pressure (IOP) was >21 mmHg on two consecutive visits., MAIN OUTCOME MEASURES: IOP < 22 mmHg, change in >=2 lines of Snellen visual acuity (VA), and complications., RESULTS: 201 out of 204 eyes with complete data analysed. Mean age 52 years, 17 (8.3%) eyes were re-treated. Mean pre-treatment IOP was 39 (SD 11) mmHg. 106 (53%) attended at 12 months when the mean IOP was 19 (7-45) mmHg; 77 (73%) had IOP < 22 mmHg. VAs were better in 13 (12.3%) and worse in 23 (21.7%) eyes. Postoperative complications included mild uveitis (5.5%), corneal oedema (2.5%), severe uveitis (0.5%) and transient hypotony (2.0%). No hypotony at 12 months., CONCLUSIONS AND RELEVANCE: Transscleral diode laser cyclophotocoagulation controlled IOP in almost three quarters of eyes at 12 months with short-term preservation of vision and minimal complications. Poor follow-up in this setting highlights the need for an effective, safe and acceptable treatment where regular follow-up is less critical. Copyright © 2018 The Authors Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologists. AU - Abdull, Mohammed M. AU - Broadway, David C. AU - Evans, Jennifer AU - Kyari, Fatima AU - Muazu, Fatima AU - Gilbert, Clare DO - https://dx.doi.org/10.1111/ceo.13328 IS - 9 KW - Adolescent Adult Aged Aged, 80 and over Child *Ciliary Body/su [Surgery] Female Follow-Up Studies Glaucoma, Open-Angle/ep [Epidemiology] Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] Humans *Intraocular Pressure/ph [Physiology] *Laser Coagulation/mt [Methods] *Lasers, Semiconductor/tu [Therapeutic Use] Male Middle Aged Nigeria/ep [Epidemiology] Prevalence Prospective Studies *Sclera/su [Surgery] Treatment Outcome Visual Acuity *Visual Fields/ph [Physiology] Young Adult PY - 2018 SE - Abdull, Mohammed M. Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria. Abdull, Mohammed M. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK. Broadway, David C. Directorate of Ophthalmology, Norwich and Norfolk University Hospital NHS Foundation Trust, Norwich, UK. Evans, Jennifer. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK. Kyari, Fatima. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK. Kyari, Fatima. Baze University, Abuja, Nigeria. Muazu, Fatima. Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria. Gilbert, Clare. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK. SN - 1442-9071 1442-6404 SP - 1041-1047 ST - Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria T2 - Clinical & experimental ophthalmology TI - Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29808573 VL - 46 Y2 - 20180617// ID - 426 ER - TY - JOUR AB - BACKGROUND: In Nigeria, glaucoma has a high prevalence and is the second cause of blindness among adults after cataract. People with glaucoma frequently present very late with advanced disease, and acceptance of and adherence to treatment is low. The purpose of the study was to explore how patients' understand and respond to glaucoma in order develop an intervention to improve adherence to treatment., METHOD: Hospital based qualitative study. Six focus group discussions were held with patients with advanced disease and who had either undergone glaucoma surgery, were receiving medical treatment, or had neither surgery nor medical treatment. Two traditional healers who treat eye conditions were interviewed. Audio files were transcribed, translated into English and recurring themes coded and categorized as the impact of vision loss, and understandings of the disease and its management., RESULTS: Visual loss impacted significantly on the lives of people with glaucoma in many ways. Many heard the term "glaucoma" for the first time during the study. Local terms to describe the symptoms included Hawan jinin ido ("hypertension of the eye"). Patients sought treatment in pharmacies, or with traditional healers who had different interpretations of glaucoma and its treatment to biomedical understandings. Cost and forgetfulness were the main reasons for low adherence to treatment while fear was a reason for not accepting surgery. Lack of money and negative staff attitudes were reasons for low follow up., CONCLUSION: Halting the progression of glaucoma is possible with treatment but the condition will remain a "silent thief of sight" in West Africa unless awareness, uptake of services and adherence to treatment improve. Understanding how glaucoma is locally conceptualised, lived with and responded to by patients is essential to aid the design of interventions to prevent glaucoma blindness in Africa. Findings have been used to adapt a motivational interviewing intervention, which is being evaluated in a clinical trial. AU - Abdull, Mohammed Mahdi AU - Chandler, Clare AU - Gilbert, Clare DO - https://dx.doi.org/10.1186/s12886-016-0220-6 KW - Antihypertensive Agents/tu [Therapeutic Use] Female Filtering Surgery Glaucoma/ep [Epidemiology] *Glaucoma/px [Psychology] *Glaucoma/th [Therapy] *Health Behavior *Health Knowledge, Attitudes, Practice Health Services Accessibility Humans Intraocular Pressure Male Nigeria/ep [Epidemiology] *Patient Acceptance of Health Care/px [Psychology] Patient Compliance *Patients/px [Psychology] Rural Population Visual Acuity PY - 2016 SE - Abdull, Mohammed Mahdi. Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, PMB 0117, Bauchi, Bauchi State, Nigeria. mohammed.abdull@lshtm.ac.uk. Abdull, Mohammed Mahdi. International Centre for Eye Health, Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. mohammed.abdull@lshtm.ac.uk. Chandler, Clare. Department of Global Health and Development London School of Hygiene & Tropical Medicine, London, UK. Gilbert, Clare. International Centre for Eye Health, Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. SN - 1471-2415 SP - 44 ST - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria T2 - BMC ophthalmology TI - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27102524 VL - 16 Y2 - 20160421// ID - 639 ER - TY - JOUR AB - BACKGROUND: Glaucoma is a chronic eye disease associated with irreversible visual loss. In Africa, glaucoma patients often present late, with very advanced disease. One-off procedures, such as laser or surgery, are recommended in Africa because of lack of or poor adherence to medical treatment. However, acceptance of surgery is usually extremely low. To prevent blindness, adherence to treatment needs to improve, using acceptable, replicable and cost-effective interventions. After reviewing the literature and interviewing patients in Bauchi (Nigeria) motivational interviewing (MI) was selected as the intervention for this trial, with adaptation for glaucoma (MIG). MI is designed to strengthen personal motivation for, and commitment to a specific goal by eliciting and exploring a person's reasons for change within an atmosphere of acceptance and compassion. The aim of this study is to assess whether MIG increases the uptake of laser or surgery amongst glaucoma patients where this is the recommended treatment. The hypothesis is that MIG increases the uptake of treatment. This will be the first trial of MI in Africa., METHODS: This is a hospital based, single centre, randomized controlled trial of MIG plus an information sheet on glaucoma and its treatment (the latter being "standard care") compared with standard care alone for glaucoma patients where the treatment recommended is surgery or laser.Those eligible for the trial are adults aged 17 years and above who live within 200 km of Bauchi with advanced glaucoma where the examining ophthalmologist recommends surgery or laser. After obtaining written informed consent, participants will be randomly allocated to MIG plus standard care, or standard care alone. Motivational interviewing will be delivered in Hausa or English by one of two MIG trained personnel. One hundred and fifty participants will be recruited to each arm. The primary outcome is the proportion of participants undergoing laser or surgery within two months of the date given to re attend for the procedure. MIG quality will be assessed using the validated MI treatment integrity scale., DISCUSSION: Motivational interviewing may be an important tool to increase the acceptance of treatment for glaucoma. The approach is potentially scalable and may be useful for other chronic conditions in Africa., TRIAL REGISTRATION: ISRCTN79330571 (Controlled-Trials.com). AU - Abdull, Mohammed M. AU - Gilbert, Clare AU - McCambridge, Jim AU - Evans, Jennifer DO - https://dx.doi.org/10.1186/1745-6215-15-149 KW - Clinical Protocols Glaucoma/di [Diagnosis] Glaucoma/px [Psychology] *Glaucoma/su [Surgery] Health Knowledge, Attitudes, Practice Humans *Motivational Interviewing Nigeria *Ophthalmologic Surgical Procedures *Patient Acceptance of Health Care/px [Psychology] Patient Education as Topic *Research Design Time Factors Treatment Outcome PY - 2014 SE - Abdull, Mohammed M. Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Hospital Road, PMB 0117 Bauchi, Bauchi State, Nigeria. mohammed.abdull@lshtm.ac.uk. SN - 1745-6215 SP - 149 ST - Adapted motivational interviewing to improve the uptake of treatment for glaucoma in Nigeria: study protocol for a randomized controlled trial T2 - Trials TI - Adapted motivational interviewing to improve the uptake of treatment for glaucoma in Nigeria: study protocol for a randomized controlled trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24773760 VL - 15 Y2 - 20140429// ID - 889 ER - TY - JOUR AB - BACKGROUND: To determine the stage of primary open angle glaucoma at presentation at a tertiary eye unit, to assess patient's knowledge of glaucoma and acceptance and subsequent adherence to treatment., METHOD: Information collected prospectively on new glaucoma patients aged 30 or more years included distance from residence and what they knew about glaucoma and its treatment. Treatment offered took account of disease severity and socioeconomic factors. Reasons for not accepting surgery were recorded. At follow up intraocular pressure (IOP) was measured and adherence to medication assessed verbally. Four categories of severity were defined based on visual acuity and visual fields defects in the worse eye., RESULTS: 131 patients were recruited (mean age 52.8 years; 62% male). Most attended because of symptoms (70%). Mean IOP in affected eyes was 31.9+/-SD 12.4 and mean vertical cup:disc ratio was 0.8. 99 eyes (47%) had a visual acuity of light perception or worse. Risk factors for advanced/end-stage disease were age >50 years, living >10 km from the hospital, some awareness of glaucoma, not being literate, being unemployed and presenting with symptoms. In multivariable analysis older age and poor knowledge of glaucoma remained independent risk factors. 75 were offered trabeculectomy: five agreed but only one underwent surgery. Reasons for rejecting surgery were fear (37%), preferred medical treatment (27 %) and cost (15 %). 32/85 (24 %) participants started on topical medication attended follow up. 72% reported excellent compliance but only 56% of glaucomatous eyes had IOPs less than 21 mmHg., CONCLUSIONS: To prevent glaucoma blindness strategies are required which promote earlier detection, with counselling to promote acceptance of and adherence to treatment. AU - Abdull, Mohammed M. AU - Gilbert, Clare C. AU - Evans, Jennifer DO - https://dx.doi.org/10.1186/s12886-015-0097-9 KW - Adult Aged Aged, 80 and over Female *Glaucoma, Open-Angle/di [Diagnosis] Glaucoma, Open-Angle/ep [Epidemiology] *Glaucoma, Open-Angle/su [Surgery] Health Knowledge, Attitudes, Practice Humans Intraocular Pressure/ph [Physiology] Male Middle Aged Nigeria/ep [Epidemiology] *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] *Patient Compliance/sn [Statistics & Numerical Data] Prospective Studies Risk Factors Trabeculectomy Visual Acuity/ph [Physiology] Visual Field Tests Visual Fields/ph [Physiology] PY - 2015 SE - Abdull, Mohammed M. Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Bauchi State, Nigeria. mohammed.abdull@lshtm.ac.uk. Abdull, Mohammed M. International Centre for Eye Health, Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. mohammed.abdull@lshtm.ac.uk. Gilbert, Clare C. International Centre for Eye Health, Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. clare.gilbert@lshtm.ac.uk. Evans, Jennifer. International Centre for Eye Health, Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. jennifer.evans@lshtm.ac.uk. SN - 1471-2415 SP - 111 ST - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment T2 - BMC ophthalmology TI - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26296993 VL - 15 Y2 - 20150822// ID - 779 ER - TY - JOUR AB - PURPOSE: To assess whether adapted motivational interviewing (MI) has any impact on the proportion of participants who subsequently underwent surgery or laser treatment for glaucoma., MATERIALS AND METHODS: A single site randomized controlled trial in Bauchi, Nigeria. Participants were new patients with a confirmed diagnosis of primary open-angle glaucoma in 1 or both eyes, where surgery or laser was recommended. Intervention was a session of MI adapted for glaucoma and the local context, using an interview guide based on local qualitative research. Participants were randomly allocated to intervention or usual care. Usual care was routine explanation by an ophthalmologist and an educational pamphlet. After the interview, a 12-item Working Alliance Inventory questionnaire was administered to patient-interviewer pairs to assess the collaborative relationship., RESULTS: Two hundred seventy-six glaucoma patients participated; 70% males. One hundred thirty-five (49%) were assigned to adapted MI and 141 to usual care. All received the intervention as allocated. Uptake (ie, the proportion who underwent treatment) of laser or surgery in the MI group was 52% compared with 45% in the usual care group (risk difference 7.2%; 95% confidence interval, -4.5% to 18.9%). Mean Working Alliance Inventory scores were 68.0 for interviewers and 68.5 for participants with a combined reliability coefficient of 93.9% (ie, high internal consistency and reliability)., CONCLUSIONS: We observed only a small increase in the uptake of surgery or laser with MI compared with usual care which was not statistically significant. Although only 1 in 2 patients accepted surgery or laser in this trial, this is a much higher proportion than in other studies. AU - Abdull, Mohammed M. AU - McCambridge, Jim AU - Evans, Jennifer AU - Muazu, Fatima AU - Gilbert, Clare DO - https://dx.doi.org/10.1097/IJG.0000000000000729 IS - 9 KW - Adolescent Adult Aged Counseling Female *Glaucoma, Open-Angle/su [Surgery] Humans Intraocular Pressure Laser Therapy/sn [Statistics & Numerical Data] *Laser Therapy Male Middle Aged *Motivational Interviewing Nigeria *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Reproducibility of Results Surveys and Questionnaires *Trabeculectomy/sn [Statistics & Numerical Data] Young Adult PY - 2017 SE - Abdull, Mohammed M. *Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi State, Nigeria Department of Clinical Research, London School of Hygiene & Tropical Medicine, London ++Department of Health Sciences, University of York, York, UK. SN - 1536-481X 1057-0829 SP - 822-828 ST - Can Adapted Motivational Interviewing Improve Uptake of Surgical or Laser Treatment for Glaucoma in Nigeria: Randomized Controlled Trial T2 - Journal of glaucoma TI - Can Adapted Motivational Interviewing Improve Uptake of Surgical or Laser Treatment for Glaucoma in Nigeria: Randomized Controlled Trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28857945 VL - 26 ID - 494 ER - TY - JOUR AB - PURPOSE: To determine the psychometric properties of a reduced version of the Glaucoma Treatment Compliance Assessment Tool (GTCAT), which was translated to Brazilian Portuguese., PATIENTS AND METHODS: We translated into Portuguese the GTCAT using validated techniques and administered it to a group of glaucoma patients using at least 1 ocular hypotensive eye drop medication. We used principal components analysis to determine construct validity, Rasch analysis, and Cronbach alpha for internal consistency reliability, frequency analysis for floor and ceiling effects, and Spearman rho for test-retest reliability., RESULTS: We included 76 glaucoma patients. Principal component analysis loaded 14 questions into 7 components that were consistent with the Health Belief Model. The components were related to "barriers due to lack of drops," "self-efficacy," "experience of negative effects of the disease," "well-being," "general glaucoma knowledge," "glaucoma symptoms," and "cues-to-action." No statements had floor or ceiling effects, and all statements had acceptable test-retest reliability. Components had internal consistency Cronbach alpha reliability between 0.125 and 0.794. and average Spearman rho reliability was 0.73, ranging from 0.44 to 1.00. According to Rasch analysis, the mean (+/-SD) of the person measures was 0.24+/-0.15 logits, person separation index was 0.58, and person reliability 0.25., CONCLUSIONS: The Portuguese-translated version of the GTCAT showed acceptable psychometric properties. With further refinement, clinicians and researchers could use it to better investigate glaucoma adherence issues in the Brazilian population. AU - Abe, Ricardo Y. AU - Wen, Lorena de Campos AU - Barker, Gordon T. AU - Mansberger, Steven L. DO - https://dx.doi.org/10.1097/IJG.0000000000000876 IS - 3 KW - Administration, Ophthalmic Adult Aged *Antihypertensive Agents/ad [Administration & Dosage] Brazil Female *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Humans Intraocular Pressure/de [Drug Effects] Intraocular Pressure/ph [Physiology] Language Male Middle Aged Ophthalmic Solutions *Patient Compliance Principal Component Analysis *Psychometrics/mt [Methods] Reproducibility of Results Surveys and Questionnaires PY - 2018 SE - Abe, Ricardo Y. Hospital Oftalmologico de Brasilia, Brasilia, Distrito Federal, Brazil. Wen, Lorena de Campos. Hospital Oftalmologico de Brasilia, Brasilia, Distrito Federal, Brazil. Barker, Gordon T. Devers Eye Institute at Legacy Health, Portland, OR. Mansberger, Steven L. Devers Eye Institute at Legacy Health, Portland, OR. SN - 1536-481X 1057-0829 SP - 257-265 ST - Psychometric Properties of the Glaucoma Treatment Compliance Assessment Tool (GTCAT) in a Brazilian Population T2 - Journal of glaucoma TI - Psychometric Properties of the Glaucoma Treatment Compliance Assessment Tool (GTCAT) in a Brazilian Population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29369851 VL - 27 ID - 456 ER - TY - JOUR AB - Objective: To develop and validate a comprehensive patient-reported outcomes instrument focusing on the impact of dry eye on everyday life (IDEEL). Methods: Development and validation of the IDEEL occurred in four phases: 1) focus groups with 45 dry eye patients to develop a draft instrument, 2) item generation, 3) pilot study to assess content validity in 16 patients and 4) psychometric validation in 210 subjects: 130 with non-Sjögren’s keratoconjunctivitis sicca, 32 with Sjögren’s syndrome and 48 controls, and subsequent item reduction. Results: Focus groups identified symptoms and the associated bother, the impact of dry eye on daily life and the patients’ satisfaction with their treatment as the central concepts in patients’ experience of dry eye. Qualitative analysis indicated that saturation was achieved for these concepts and yielded an initial 112-item draft instrument. Patients understood the questionnaire and found the items to be relevant indicating content validity. Patient input, item descriptive statistics and factor analysis identified 55 items that could be deleted. The final 57-item IDEEL assesses dry eye impact constituting 3 modules: dry eye symptom-bother, dry eye impact on daily life comprising impact on daily activities, emotional impact, impact on work, and dry eye treatment satisfaction comprising satisfaction with treatment effectiveness and treatment-related bother/inconvenience. The psychometric analysis results indicated that the IDEEL met the criteria for item discriminant validity, internal consistency reliability, testretest reliability and floor/ceiling effects. As expected, the correlations between IDEEL and the Dry Eye Questionnaire (a habitual symptom questionnaire) were higher than between IDEEL and Short-Form-36 and EuroQoL-5D, indicating concurrent validity. Conclusion: The IDEEL is a reliable, valid and comprehensive questionnaire relevant to issues that are specific to dry eye patients, and meets current FDA patient-reported outcomes guidelines. The use of this questionnaire will provide assessment of the impact of dry eye on patient dry eye-related quality of life, impact of treatment on patient outcomes in clinical trials, and may aid in treatment effectiveness evaluation. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Abetz, Linda, Mapi Values, Adelphi Mill, Grimshaw Lane, Cheshire, Bollington, United Kingdom, SK10 5JB AN - 2017-28448-001 AU - Abetz, Linda AU - Rajagopalan, Krithika AU - Mertzanis, Polyxane AU - Begley, Carolyn AU - Barnes, Rod AU - Chalmers, Robin DB - psyh DO - 10.1186/1477-7525-9-111 DP - EBSCOhost KW - Dry eye Sjögren’s Syndrome non-Sjögren’s keratoconjunctivitis sicca health-related quality of life treatment satisfaction symptoms impact patient-reported outcome questionnaire Adult Aged Aged, 80 and over Case-Control Studies Dry Eye Syndromes Female Focus Groups Humans Male Middle Aged Pilot Projects Principal Component Analysis Psychometrics Quality of Life Reproducibility of Results Self Disclosure Surveys and Questionnaires Eye Disorders Questionnaires Test Construction Treatment Compliance Test Reliability Test Validity Treatment Outcomes N1 - Mapi Values, Bollington, United Kingdom. Institutional Authors: Impact of Dry Eye on Everyday Life (IDEEL) Study Group. Release Date: 20170713. Correction Date: 20180517. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Eye Disorders; Quality of Life; Questionnaires; Test Construction; Treatment Compliance. Minor Descriptor: Test Reliability; Test Validity; Treatment Outcomes. Classification: Health Psychology Testing (2226); Vision & Hearing & Sensory Disorders (3299). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Impact of Dry Eye on Everyday Life Questionnaire DOI: 10.1037/t66096-000. Methodology: Empirical Study; Interview; Focus Group; Qualitative Study; Quantitative Study. References Available: Y. ArtID: 111. Issue Publication Date: Dec 8, 2011. Publication History: First Posted Date: Dec 8, 2011; Accepted Date: Dec 8, 2011; First Submitted Date: Aug 17, 2011. Copyright Statement: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abetz et al; licensee BioMed Central Ltd. 2011. PY - 2011 SN - 1477-7525 ST - Development and validation of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients T2 - Health and Quality of Life Outcomes TI - Development and validation of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-28448-001&site=ehost-live&scope=site Linda.Abetz@mapivalues.com VL - 9 ID - 4882 ER - TY - JOUR AB - Artificial Intelligence (AI) has long promised to increase healthcare affordability, quality and accessibility but FDA, until recently, had never authorized an autonomous AI diagnostic system. This pivotal trial of an AI system to detect diabetic retinopathy (DR) in people with diabetes enrolled 900 subjects, with no history of DR at primary care clinics, by comparing to Wisconsin Fundus Photograph Reading Center (FPRC) widefield stereoscopic photography and macular Optical Coherence Tomography (OCT), by FPRC certified photographers, and FPRC grading of Early Treatment Diabetic Retinopathy Study Severity Scale (ETDRS) and Diabetic Macular Edema (DME). More than mild DR (mtmDR) was defined as ETDRS level 35 or higher, and/or DME, in at least one eye. AI system operators underwent a standardized training protocol before study start. Median age was 59 years (range, 22-84 years); among participants, 47.5% of participants were male; 16.1% were Hispanic, 83.3% not Hispanic; 28.6% African American and 63.4% were not; 198 (23.8%) had mtmDR. The AI system exceeded all pre-specified superiority endpoints at sensitivity of 87.2% (95% CI, 81.8-91.2%) (> 85%), specificity of 90.7% (95% CI, 88.3-92.7%) (> 82.5%), and imageability rate of 96.1% (95% CI, 94.6-97.3%), demonstrating AI's ability to bring specialty-level diagnostics to primary care settings. Based on these results, FDA authorized the system for use by health care providers to detect more than mild DR and diabetic macular edema, making it, the first FDA authorized autonomous AI diagnostic system in any field of medicine, with the potential to help prevent vision loss in thousands of people with diabetes annually. AN - WOS:000444195100001 AU - Abramoff, M. D. AU - Lavin, P. T. AU - Birch, M. AU - Shah, N. AU - Folk, J. C. DA - AUG 28 DO - 10.1038/s41746-018-0040-6 PY - 2018 SN - 2398-6352 ST - Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices T2 - NPJ DIGITAL MEDICINE TI - Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices VL - 1 ID - 6323 ER - TY - JOUR AB - Atopic dermatitis is a common, chronic, relapsing inflammatory skin disease frequently affecting infants and children. The worldwide prevalence of atopic dermatitis is estimated to be 5-20% of the paediatric population. First-line therapy has generally consisted of dry skin care, avoidance of triggers, application of topical corticosteroids, and administration of antihistamines and oral antibacterials. Topical corticosteroids improve the lesions of atopic dermatitis; however, concern on the part of physicians and patients regarding adverse effects has led to reluctance to utilise topical corticosteroids early and especially for prolonged periods. Topical immunomodulators (TIMs), including tacrolimus ointment and pimecrolimus cream, were recently introduced for the treatment of atopic dermatitis. Clinical data show that TIMs are effective in atopic dermatitis, yet do not cause the significant adverse effects associated with topical corticosteroids. Questions remain regarding the place of TIMs as a treatment for atopic dermatitis and how to use them most effectively, from both therapeutic and pharmacoeconomic standpoints. Specifically, two major issues remain unresolved: (i) how TIMs measure up to other therapies, especially topical corticosteroids; and (ii) how members of the TIM drug class compare against each other. Previous research has established that atopic dermatitis has a significant impact on quality of life (QOL) and carries a substantial economic burden. Some studies have also measured the utility of various atopic dermatitis disease states. While there is a need for further research, early economic studies provide evidence that TIMs positively affect the QOL of patients and families. In certain patients, TIMs may be cost effective and have an acceptable incremental cost utility compared with topical corticosteroids. Making cost-effectiveness comparisons between tacrolimus and pimecrolimus is challenging because there are limited head-to-head comparative data. Given currently available efficacy data, the results of one study suggest that tacrolimus may be more cost effective than pimecrolimus in paediatric patients with moderate atopic dermatitis. The full economic and QOL benefits of both agents are yet to be completely understood. The studies reviewed herein are the first to delineate the pharmacoeconomic benefits of TIMs in atopic dermatitis, and lay the foundation for future analyses. TIMs represent an exciting advance in the treatment of atopic dermatitis. Additional research will help determine the proper place of TIMs among the current array of therapeutic options for atopic dermatitis. © 2005 Adis Data Information BV. All rights reserved. AD - K.B. Tong, Quorum Consulting, Inc., 222 Kearny Street, San Francisco, CA 94108, United States AU - Abramovits, W. AU - Boguniewicz, M. AU - Paller, A. S. AU - Whitaker-Worth, D. L. AU - Prendergast, M. M. AU - Tokar, M. AU - Tong, K. B. DB - Embase Medline DO - 10.2165/00019053-200523060-00003 IS - 6 KW - antibiotic agent antihistaminic agent corticosteroid cyclosporine cytokine hydrocortisone acetate hydrocortisone butyrate immunomodulating agent immunosuppressive agent pimecrolimus tacrolimus acne adolescence adrenal suppression antibiotic therapy atopic dermatitis Australia bacterial infection body surface carcinogenicity cataract clinical feature clinical practice clinical trial comorbidity comparative study corticosteroid therapy cost benefit analysis cost effectiveness analysis cost utility analysis cream Denmark disease severity drug absorption drug blood level drug cost drug dose regimen drug effect drug efficacy drug mechanism drug potency drug safety drug tolerability epidemiological data face folliculitis Germany gingiva hyperplasia glaucoma growth retardation health care cost health care utilization human hypertension hypopigmentation Italy long term care meta analysis monotherapy mycosis nephrotoxicity Netherlands New Zealand nonhuman ointment perioral dermatitis prevalence priority journal pruritus quality of life rating scale review rosacea scoring system side effect skin atrophy skin burning sensation skin infection skin manifestation stria Sweden systemic disease telangiectasia topical treatment treatment indication treatment outcome tremor United Kingdom United States virus infection LA - English M3 - Review N1 - L40994124 2005-08-24 PY - 2005 SN - 1170-7690 SP - 543-566 ST - The economics of topical immunomodulators for the treatment of atopic dermatitis T2 - PharmacoEconomics TI - The economics of topical immunomodulators for the treatment of atopic dermatitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40994124&from=export http://dx.doi.org/10.2165/00019053-200523060-00003 http://saturn.bids.ac.uk/cgi-bin/ds_deliver/1/u/d/ISIS/19808983.1/adis/pec/2005/00000023/00000006/art00003/D714807354DCA5101121168388DF101F11BBE750B1.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf VL - 23 ID - 3672 ER - TY - JOUR AB - OBJECTIVE: To study the adherence to the Mediterranean diet in patients affected by primary open angle glaucoma (POAG)., MATERIALS AND METHODS: An observational study was conducted to assess the adherence to the Mediterranean diet in patients affected by POAG, and who attended the Ophthalmology Department of the Canary Islands University Hospital. The study included completing a 14-item questionnaire validated by the PREDIMED Study, in person or by telephone., RESULTS: A total of 100 questionnaires were completed successfully by 50 males and 50 females. The mean age was 69.58 years for the males and 67.42 years for women. The men had more comorbidities than women (tobacco 14 vs. 3%), arterial hypertension, and diabetes (30 vs. 28%, and 16 vs. 6%, respectively). Adherence to the Mediterranean diet in males, was low in 9 patients (18%), moderate in 37 (74%), and high in 4 (8%) cases. In women adherence was low in 14 patients (28%), moderate in 34 (68%), and high in 2 (6%) cases. The overall adhesion to the Mediterranean diet is low in 23%, moderate in 71% and high in 6% of the cases., CONCLUSION: Patients who are affected by POAG have moderate adherence to the Mediterranean diet. Copyright © 2017 Sociedad Espanola de Oftalmologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. AU - Abreu-Reyes, J. A. AU - Alvarez-Luis, D. AU - Arteaga-Hernandez, V. AU - Sanchez-Mendez, M. AU - Abreu-Gonzalez, R. DO - https://dx.doi.org/10.1016/j.oftal.2016.12.002 IS - 8 KW - Aged *Diet, Mediterranean Female *Glaucoma, Open-Angle/dh [Diet Therapy] Humans Male *Patient Compliance/sn [Statistics & Numerical Data] Self Report PY - 2017 SE - Abreu-Reyes, J A. Servicio de Oftalmologia, Hospital Universitario de Canarias, Tenerife, Espana. Electronic address: jaabreureyes@gmail.com. Alvarez-Luis, D. Facultad de Medicina, Universidad de La Laguna, Tenerife, Espana. Arteaga-Hernandez, V. Servicio de Oftalmologia, Hospital Universitario de Canarias, Tenerife, Espana. Sanchez-Mendez, M. Servicio de Oftalmologia, Hospital Universitario de Canarias, Tenerife, Espana. Abreu-Gonzalez, R. Servicio de Oftalmologia, Hospital Universitario de La Candelaria, Tenerife, Espana. SN - 1989-7286 0365-6691 SP - 353-358 ST - Mediterranean diet adherence by patients with primary open angle glaucoma T2 - Adherencia a la dieta mediterranea en pacientes afectos de glaucoma primario de angulo abierto. TI - Mediterranean diet adherence by patients with primary open angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28185696 VL - 92 Y2 - 20170206// ID - 537 ER - TY - JOUR AU - Abreu-Reyes, J. A. AU - Álvarez-Luis, D. AU - Arteaga-Hernández, V. AU - Sánchez-Mendez, M. AU - Abreu-González, R. DB - Medline DO - 10.1016/j.oftal.2016.12.002 IS - 8 KW - aged diet therapy female human male Mediterranean diet open angle glaucoma patient compliance self report statistics and numerical data LA - English Spanish M3 - Article N1 - L622732409 2018-07-02 PY - 2017 SN - 1989-7286 SP - 353-358 ST - Adherencia a la dieta mediterránea en pacientes afectos de glaucoma primario de ángulo abierto T2 - Archivos de la Sociedad Espanola de Oftalmologia TI - Adherencia a la dieta mediterránea en pacientes afectos de glaucoma primario de ángulo abierto UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622732409&from=export http://dx.doi.org/10.1016/j.oftal.2016.12.002 VL - 92 ID - 2640 ER - TY - JOUR AB - Purpose . To study factors affecting patients' compliance to antiglaucoma medications in Egypt where there are unique factors as a developing country. Patients and Methods. A cross-sectional descriptive study on 440 Egyptian patients with open angle glaucoma (OAG) recruited for over two years. The patients were thoroughly interviewed about their age, education level, duration of glaucoma, difficulty in instilling the drops, medication regimens, a family history of glaucoma, knowledge of the disease, and the presence of medical insurance. Results . 236 (53.6%) were noncompliant compared to 204 (46.4%) who were compliant. Females had a tendency for higher compliance (p=0.061). Patient age above 50 years and low level of education and negative family history of glaucoma were factors significantly associated with poor compliance (p < 0.0001). Polytherapy and lack of medical insurance could be contributing factors. Conclusion . Egyptian patients have a high rate of noncompliance compared to the average in literature. Great effort is needed in educating patients about the importance of medications and the risk and the prognosis of this disease. Economic factors must also be taken into consideration in developing countries with large number of poor patients. We recommend simplifying drug regimens, incorporating electronic dose monitors, and creating reminders for follow-up visits of glaucoma patients. AU - Abu Hussein, Nahla B. AU - Eissa, Iman M. AU - Abdel-Kader, Ahmed A. DO - https://dx.doi.org/10.1155/2015/234157 PY - 2015 SE - Abu Hussein, Nahla B. Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo 11562, Egypt. Eissa, Iman M. Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo 11562, Egypt. Abdel-Kader, Ahmed A. Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo 11562, Egypt. SN - 2090-004X SP - 234157 ST - Analysis of Factors Affecting Patients' Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model T2 - Journal of ophthalmology TI - Analysis of Factors Affecting Patients' Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26167292 VL - 2015 Y2 - 20150617// ID - 1062 ER - TY - JOUR AB - Purpose: To describe clinical manifestations, diagnostic approaches, therapy, and outcomes of biopsy-proven intraocular lymphoma. Methods: Review of tertiary referral center records between 2005 and 2015. Results: A total of 51 eyes of 26 patients were included; mean age of onset was 60.42 years. Common ocular complaints included floaters (42%) and blurred vision (35%); 62% of patients had ocular and central nervous system involvement; 11% had systemic lymphoma; and 27% had only ocular involvement. Vitreous analysis was positive for malignant cells in 77% of patients on initial biopsy, and in 100% of patients on repeat biopsy. In total, 20/26 patients received systemic and topical treatment before IOL diagnosis was made; 25 patients received intravitreal methotrexate and/or rituximab; one patient received intracameral rituximab. All patients achieved remission by their final visit. Conclusions: Intraocular lymphoma often masquerades as intraocular inflammation, resulting in delayed or misdiagnosis with subsequent inappropriate management. Optimal therapy is a challenge for oncologists and ophthalmologists. AD - C.S. Foster, Massachusetts Eye Research and Surgery Institution, 1440 Main Street, Suite 201, Waltham, MA, United States AU - Abu Samra, K. AU - Oray, M. AU - Ebrahimiadib, N. AU - Lee, S. AU - Anesi, S. AU - Foster, C. S. DB - Embase Medline DO - 10.1080/09273948.2016.1193206 IS - 3 KW - slit lamp cyclophosphamide doxorubicin immunoglobulin interleukin 10 interleukin 6 methotrexate prednisone rituximab steroid vincristine adult aged anterior eye chamber article best corrected visual acuity blurred vision brain biopsy brain radiation branch retinal vein occlusion cancer combination chemotherapy cancer diagnosis cancer mortality cancer radiotherapy cancer recurrence cancer regression cancer survival cataract clinical article clinical feature descriptive research diffuse large B cell lymphoma epiretinal membrane female gene rearrangement glaucoma histopathology Hodgkin disease human hyphema hypopyon intraocular lymphoma large cell lymphoma lymphocytic lymphoma lymphoma cell male mantle cell lymphoma medical record review medication compliance nonhodgkin lymphoma onset age optic disk optic nerve atrophy paracentesis pars plana vitrectomy patient compliance primary central nervous system lymphoma retina detachment retina macula cystoid edema retinal pigment epithelium retrospective study slit lamp microscopy stem cell transplantation survival rate systemic disease systemic therapy tertiary care center topical treatment treatment outcome treatment response tumor biopsy uveitis vitreous biopsy vitreous body vitreous floaters LA - English M3 - Article N1 - L611348303 2016-07-28 2018-07-25 PY - 2018 SN - 1744-5078 0927-3948 SP - 347-352 ST - Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes T2 - Ocular Immunology and Inflammation TI - Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611348303&from=export http://dx.doi.org/10.1080/09273948.2016.1193206 VL - 26 ID - 2594 ER - TY - JOUR AB - PURPOSE: To determine cataract surgical coverage, and barriers to modern cataract surgery in Nigeria., METHODS: Multistage stratified cluster random sampling was used to identify a nationally representative sample of 15,027 persons aged 40+ years. All underwent visual acuity testing, frequency doubling technology visual field testing, autorefraction, and measurement of best corrected vision if <6/12 in one or both eyes. An ophthalmologist examined the anterior segment and fundus through an undilated pupil for all participants. Participants were examined by a second ophthalmologist using a slit lamp and dilated fundus examination using a 90 diopter condensing lens if vision was <6/12 in one or both eyes, there were optic disc changes suggestive of glaucoma, and 1 in 7 participants regardless of findings. All those who had undergone cataract surgery were asked where and when this had taken place. Individuals who were severely visually impaired or blind from unoperated cataract were asked to explain why they had not undergone surgery., RESULTS: A total of 13,591 participants were examined (response rate 89.9%). Prevalence of cataract surgery was 1.6% (95% confidence interval 1.4-1.8), significantly higher among those aged >=70 years. Cataract surgical coverage (persons) in Nigeria was 38.3%. Coverage was 1.7 times higher among males than females. Coverage was only 9.1% among women in the South-South geopolitical zone. Over one third of those who were cataract blind said they could not afford surgery (36%)., CONCLUSIONS: Cataract surgical coverage in Nigeria was among the lowest in the world. Urgent initiatives are necessary to improve surgical output and access to surgery. AU - Abubakar, Tafida AU - Gudlavalleti, Murthy V. S. AU - Sivasubramaniam, Selvaraj AU - Gilbert, Clare E. AU - Abdull, Mohammed M. AU - Imam, Abdullahi U. DO - https://dx.doi.org/10.3109/09286586.2011.643271 IS - 2 KW - Adult Aged *Blindness/ep [Epidemiology] *Cataract/ep [Epidemiology] *Cataract Extraction/sn [Statistics & Numerical Data] Cross-Sectional Studies Female *Health Services Accessibility/sn [Statistics & Numerical Data] Health Surveys Humans Male Middle Aged Nigeria/ep [Epidemiology] Prevalence Rural Population/sn [Statistics & Numerical Data] Urban Population/sn [Statistics & Numerical Data] Visual Acuity/ph [Physiology] Visual Fields/ph [Physiology] *Visually Impaired Persons/sn [Statistics & Numerical Data] PY - 2012 SE - Abubakar, Tafida. Ministry of Health, Dutse, Jigawa state, Nigeria. SN - 1744-5086 0928-6586 SP - 58-66 ST - Coverage of hospital-based cataract surgery and barriers to the uptake of surgery among cataract blind persons in nigeria: the Nigeria National Blindness and Visual Impairment Survey T2 - Ophthalmic epidemiology TI - Coverage of hospital-based cataract surgery and barriers to the uptake of surgery among cataract blind persons in nigeria: the Nigeria National Blindness and Visual Impairment Survey UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22360449 VL - 19 Y2 - 20120224// ID - 1148 ER - TY - JOUR AB - Impairment in hearing and vision are common for persons age 65 and older, and severe impairments may result in dependencies in daily activities. Hearing loss with age often results in diminished ability to communicate with others and may lead to isolation, depression, and cognitive changes. A hearing evaluation involving simple screening tools in important for early recognition and treatment of otologic conditions. Cataracts, macular degeneration, diabetic retinopathy, and glaucoma are the most sight-threatening ocular diseases of aging. Visual loss usually occurs gradually and may go unrecognised for some time. Primary care screening is important to preserve sight and prevent disability and loss of function. AU - Abyad, A. IS - 6 KW - Aged *Blindness/di [Diagnosis] Blindness/et [Etiology] *Diabetic Retinopathy/di [Diagnosis] Female *Geriatric Assessment *Glaucoma/di [Diagnosis] Glaucoma/su [Surgery] *Hearing Loss, Sensorineural/di [Diagnosis] Hearing Tests Humans Macular Degeneration/co [Complications] Male *Office Visits PY - 1997 SE - Abyad, A. Abyad Medical Center (AMC), Tripoli, Lebanon. SN - 0016-867X SP - 45-57 ST - In-office screening for age-related hearing and vision loss T2 - Geriatrics TI - In-office screening for age-related hearing and vision loss UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9194790 VL - 52 ID - 2019 ER - TY - JOUR AB - In the present study, we examined the causes and the prevalence of avoidable blindness and visual impairment, as well as the prevalence of diabetic retinopathy in individuals aged >=50 years in Costa Rica, in order to provide baseline data for the initial planning and monitoring of ongoing blindness intervention programs. The assessment was based on the standardized methodology of the Rapid Assessment of Avoidable Blindness and Diabetic Retinopathy, a population-based survey for blindness and visual impairment. From 3,255 eligible subjects, 76.6% were examined. The adjusted prevalence of bilateral blindness [presenting visual acuity (VA) in the better eye of less than 3/60] was 1.7% (95% confidence interval, 1.2%-2.2%), with avoidable causes (treatable and preventable) accounting for 68.8% of cases. The main causes of blindness were cataract (52.1%), glaucoma (6.3%), and diabetic retinopathy (6.3%); these data were similar to those for other neighboring countries. Cataract surgical coverage (CSC) in the survey area was estimated as 88.9% for individuals with blindness (VA, <3/60), 76.6% for those with a VA of <6/60, and 60.3% for those with a VA of <6/18. The most common barriers against cataract surgery in individuals with a best-corrected VA of <=6/60 included "need not felt" (48.8%) and "fear" (14.6%). Among individuals with a past history of cataract surgery, only 57.1% showed a "good" or "very good" outcome (VA, >=6/18). Finally, 23.5% individuals with known or newly diagnosed diabetes showed retinopathy and/or maculopathy, with 6.2% exhibiting sight-threatening diabetic retinopathy (proliferative retinopathy, referable maculopathy, or both). Our findings indicate the need to overcome barriers against surgery for cataract, which is the main cause of avoidable blindness, to increase CSC, and to improve surgical outcomes. Moreover, improved methods for diabetic retinopathy screening can ensure prompt identification of patients with a risk of blindness. Glaucoma screening is also necessary for areas with a high prevalence. AU - Acevedo Castellon, Roger Ivan AU - Carranza Vargas, Esteban AU - Cortes Chavarria, Ritzi Elena AU - Rodriguez Vargas, Gabriel Andres DO - https://dx.doi.org/10.1371/journal.pone.0212660 IS - 2 KW - Age Factors Aged Aged, 80 and over *Blindness/ep [Epidemiology] Costa Rica/ep [Epidemiology] *Diabetic Retinopathy/ep [Epidemiology] Female Humans Male Middle Aged Prevalence Risk Factors PY - 2019 SE - Acevedo Castellon, Roger Ivan. Ophthalmology Service, Surgery Department, Mexico Hospital, Caja Costarricense de Seguro Social, Uruca, San Jose, Costa Rica. Carranza Vargas, Esteban. Ophthalmology Service, Surgery Department, Mexico Hospital, Caja Costarricense de Seguro Social, Uruca, San Jose, Costa Rica. Cortes Chavarria, Ritzi Elena. Ophthalmology Service, Surgery Department, Mexico Hospital, Caja Costarricense de Seguro Social, Uruca, San Jose, Costa Rica. Rodriguez Vargas, Gabriel Andres. Ophthalmology Service, Surgery Department, Mexico Hospital, Caja Costarricense de Seguro Social, Uruca, San Jose, Costa Rica. SN - 1932-6203 SP - e0212660 ST - Rapid assessment of avoidable blindness and diabetic retinopathy in individuals aged 50 years or older in Costa Rica T2 - PloS one TI - Rapid assessment of avoidable blindness and diabetic retinopathy in individuals aged 50 years or older in Costa Rica UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30789973 VL - 14 Y2 - 20190221// ID - 354 ER - TY - JOUR AB - INTRODUCTION: As the world population ages, glaucoma is becoming an increasingly significant cause of blindness. A key component in the management of glaucoma is the use of prescribed medications and the adherence to treatment. However, there is evidence of low adherence to prescribed medication in chronic diseases, such as glaucoma. This study aims to explore the level of medication adherence, self-efficacy, social support and health literacy among the patients with glaucoma and to determine if there are any correlations between them. The ultimate aim is to use the information to develop an educational programme for patients with glaucoma at a later stage., METHODS AND ANALYSIS: This is a mixed-methods study which includes two stages: a descriptive study (stage 1) and focus group discussions (stage 2)., SAMPLE: Patients with glaucoma or ocular hypertension, using at least one kind of drops, from two ophthalmology clinics. Selected measures include: The Glaucoma Treatment Compliance Assessment Tool, The European Health Literacy Survey Questionnaire, The Glaucoma Medication Self-Efficacy Questionnaire and The Multidimensional Scale of Perceived Social Support. Two focus groups will be used for the collection of qualitative data, aiming to enrich the study with the patients' experiences. The data will be analysed with SPSS, using descriptive and inferential statistics for stage 1 whereas content analysis will be used for the data from the focus group discussions (stage 2)., ETHICS AND DISSEMINATION: Permission to conduct the study was received from the National Bioethics Committee and the board of management of the two ophthalmology clinics. All participants will be informed fully on the purpose and methods of the study. Consent forms will be signed and at any time participants will have the right to withdraw. Confidentiality and the protection of data will be respected at all times. Copyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. AU - Achilleos, Maria AU - Merkouris, Anastasios AU - Charalambous, Andreas AU - Papastavrou, Evridiki DO - https://dx.doi.org/10.1136/bmjopen-2020-039788 IS - 1 KW - Glaucoma/dt [Drug Therapy] *Glaucoma *Health Literacy Humans Medication Adherence *Ocular Hypertension Self Efficacy PY - 2021 SE - Achilleos, Maria. Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus maria_ach_@hotmail.com. Merkouris, Anastasios. Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus. Charalambous, Andreas. Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus. Charalambous, Andreas. Nursing, Turun Yliopisto, Turku, Finland. Papastavrou, Evridiki. Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus. SN - 2044-6055 SP - e039788 ST - Medication adherence, self-efficacy and health literacy among patients with glaucoma: a mixed-methods study protocol T2 - BMJ open TI - Medication adherence, self-efficacy and health literacy among patients with glaucoma: a mixed-methods study protocol UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33472775 VL - 11 Y2 - 20210120// ID - 184 ER - TY - JOUR AB - Background: Teriparatide (parathyroid hormone [1-34] [ribosomal DNA origin]) stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity. It has been found to significantly reduce vertebral fractures by 65%, and nonvertebral fragility fractures by 53% in treatment-naive postmenopausal women who have previously suffered a vertebral fracture. Objective: This study examined the compliance, acceptance, and adherance of SC teriparatide 20 pg QD. Methods: In this 18-month, multicenter, openlabel, prospective study, women with postmenopausal osteoporosis, and men >30 years of age with either idiopathic or hypogonadal osteoporosis (with low bone mass [T-score of -1 or worse] and ≥1 fragility fracture), who had experienced a treatment-related adverse event (AE) or an inadequate response while receiving antiresorptive treatment, and who were willing to receive open-label teriparatide for ≥18 months were eligible. Compliance was defined as self-reported use of ≥80% of study medication. Acceptance of the injection pen was determined by scores obtained from questionnaires and rating scales measuring patients' perception. Patients self-reported on injection discomfort, ease of use, and the overall injection administration. Acceptance was assessed at baseline, and 3, 6, and 18 months. AEs were recorded at each clinical visit from the patients' self-reports. At the 3-month visit, a serum calcium level was drawn ≥16 hours after the previous teriparatide dose. Results: In this study, 116 patients-102 women with postmenopausal osteoporosis and 14 men (12 with idiopathic osteoporosis and 2 with hypogonadal osteoporosis)-were assessed for inclusion in the study. The mean (SD) age was 68.8 (11.1) years (range, 40-89 years) and the mean (SD) weight was 60.5 (11.7) kg (range, 37-87 kg). Seventy-three percent of the patients in this study had baseline spinal T-scores ≤-2.5, and 72% had fractured during treatment with an osteoporosis medication. Reported compliance was 89% at 6 months and 82% at 18 months. At baseline, 42% of patients were concerned about injection discomfort, and 43% were somewhat concerned with daily injections, while 7% were quite concerned. At 6 months, most patients reported much less concern (49%) or no concern (42%). Patient perceptions associated with learning how to use the pen injection, attaching the needle, holding the pen, and injecting the dose, improved during the first 6 months of the study. The most commonly reported AEs were dizziness, 12 (10.3%); nausea, 12 (10.3%); back pain, 9 (7.8%); and muscle cramps, 9 (7.8%). No AEs were believed to be associated with the use of the pen injection or teriparatide. Five patients had mildly elevated serum calcium concentrations (maximum value 2.8 mmol/L) at 3 months. However, all were normal on repeat testing ~4 weeks thereafter. Conclusions: This study found that teriparatide pen injection was well accepted in these patients, and acceptance rates improved during the first 6 months of treatment and, thereafter, improved slightly for ~18 months. Reported compliance remained high throughout the study (82%-89%). Teriparatide pen injection was a viable treatment in these osteopenic or osteoporotic patients with fragility fractures. © 2007 Excerpta Medica, Inc. AD - J.D. Adachi, Department of Medicine, McMaster University, Hamilton, Ont., Canada AU - Adachi, J. D. AU - Hanley, D. A. AU - Lorraine, J. K. AU - Yu, M. C2 - Lilly(Canada) DB - Embase Medline DO - 10.1016/j.clinthera.2007.09.024 IS - 9 KW - bisphosphonic acid derivative calcitonin parathyroid hormone[1-34] raloxifene selective estrogen receptor modulator vitamin D abdominal distension acute coronary syndrome acute heart infarction adult aged Alzheimer disease arthralgia article backache bone pain breast carcinoma clinical trial congestive heart failure controlled study contusion coughing dizziness drug efficacy drug safety falling fatigue female glaucoma headache heart arrhythmia atrial fibrillation human hypogonadism injection site contusion limb pain lung disease major clinical study male multicenter study muscle cramp musculoskeletal disease nausea neck pain open study osteoporosis pain patient compliance patient satisfaction pneumonia postmenopause osteoporosis prosthesis infection rhinopharyngitis rib fracture self injection self report shoulder dislocation side effect sigmoid carcinoma cerebrovascular accident subdural hematoma upper respiratory tract infection weakness LA - English M3 - Article N1 - L350218118 2007-12-17 PY - 2007 SN - 0149-2918 1879-114X SP - 2055-2067 ST - Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study T2 - Clinical Therapeutics TI - Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350218118&from=export http://dx.doi.org/10.1016/j.clinthera.2007.09.024 VL - 29 ID - 3505 ER - TY - JOUR AB - The future of next generation therapeutics for glaucoma is strong. The recent approval of two novel intraocular pressure (IOP)-lowering drugs with distinct mechanisms of action is the first in over 20 years. However, these are still being administered as topical drops. Efforts are underway to increase patient compliance and greater therapeutic benefits with the development of sustained delivery technologies. Furthermore, innovations from biologics- and gene therapy-based therapeutics are being developed in the context of disease modification, which are expected to lead to more permanent therapies for patients. Neuroprotection, including the preservation of retinal ganglion cells (RGCs) and optic nerve is another area that is actively being explored for therapeutic options. With improvements in imaging technologies and determination of new surrogate clinical endpoints, the therapeutic potential for translation of neuroprotectants is coming close to clinical realization. This review summarizes the aforementioned topics and other related aspects. AU - Adams, Christopher M. AU - Stacy, Rebecca AU - Rangaswamy, Nalini AU - Bigelow, Chad AU - Grosskreutz, Cynthia L. AU - Prasanna, Ganesh DO - https://dx.doi.org/10.1007/s11095-018-2557-4 IS - 2 KW - Animals *Antihypertensive Agents/ad [Administration & Dosage] Delayed-Action Preparations *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Ocular Hypertension/dt [Drug Therapy] PY - 2018 SE - Adams, Christopher M. Global Discovery Chemistry, Novartis Institutes for Biomedical Research (NIBR),, Cambridge, Massachusetts, USA. Stacy, Rebecca. Translational Medicine, Ophthalmology, NIBR, Cambridge, Massachusetts, USA. Rangaswamy, Nalini. Ophthalmology Research, Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts, 02139, USA. Bigelow, Chad. Ophthalmology Research, Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts, 02139, USA. Grosskreutz, Cynthia L. Ophthalmology Research, Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts, 02139, USA. Prasanna, Ganesh. Ophthalmology Research, Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts, 02139, USA. ganesh.prasanna@novartis.com. SN - 1573-904X 0724-8741 SP - 25 ST - Glaucoma - Next Generation Therapeutics: Impossible to Possible T2 - Pharmaceutical research TI - Glaucoma - Next Generation Therapeutics: Impossible to Possible UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30547244 VL - 36 Y2 - 20181213// ID - 395 ER - TY - JOUR AB - Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveoscleral pathway) with nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal. Nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal leads to increased outflow through the trabecular meshwork and thus lowering of IOP. LBN has now been shown in multiple clinical studies to be effective and safe. In this article, we summarize the clinical trials that led to LBN’s approval as well as the comparative studies that have been done to evaluate the efficacy of this drug as compared to other US Food and Drug Administration (FDA)-approved therapies for OAG and OHT. We then review the side effects of treatment that were seen in each of these studies. Finally, we will attempt to discuss the place of this drug in therapy for patients with OAG. AD - V.M. Addis, Division of Glaucoma, Scheie Eye Institute, University of Pennsylvania, 51 N. 39th St, Philadelphia, PA, United States AU - Addis, V. M. AU - Miller-Ellis, E. C1 - vyzulta(Valeant,United States) C2 - Valeant(United States) DB - Embase DO - 10.2147/OPTH.S156038 KW - eye drops latanoprostene bunod nitric oxide prostaglandin derivative abnormal sensation application site erythema application site hyperpigmentation application site pain asthenopia blepharitis blurred vision cataract clinical outcome conjunctiva disease conjunctival hemorrhage conjunctival hyperemia drug efficacy drug mechanism drug safety drug screening drug tolerability dry eye eye irritation eye pain eyelash foreign body hair growth human intraocular hypertension intraocular pressure nonhuman ocular pruritus open angle glaucoma outcome assessment patient compliance phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) photophobia punctate keratitis randomized controlled trial (topic) review side effect trichiasis visual acuity visual impairment vitreous floaters vyzulta LA - English M3 - Review N1 - L2001839881 2019-05-14 PY - 2018 SN - 1177-5483 1177-5467 SP - 2649-2657 ST - Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: Design, development, and place in therapy T2 - Clinical Ophthalmology TI - Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: Design, development, and place in therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001839881&from=export http://dx.doi.org/10.2147/OPTH.S156038 VL - 12 ID - 2607 ER - TY - JOUR AB - OBJECTIVES: To determine ocular outcomes and factors associated with adherence to ophthalmic follow-up in a medically underserved population at a single health centre in Philadelphia., DESIGN: Retrospective chart review., PARTICIPANTS: Patients from a community glaucoma screening program., METHODS: Chart review was conducted for participants who received a complete eye examination at the Philadelphia District Health Center 5 between January 1, 2012 and May 31, 2014 within the Philadelphia Glaucoma Detection and Treatment Project. Multivariate logistic regression was used to determine factors related to ophthalmic follow-up adherence., RESULTS: A total of 249 participants completed an eye examination (mean age=57.7 +/- 6.9 years). Most were African American (n=220; 88.4%); female (n=129; 51.8%). Forty-seven participants (18.9%) received glaucoma-related diagnoses, 20 (8.0%) were prescribed ocular medication, and 26 (10.4%) underwent laser therapy. Ninety (36.1%) attended their recommended follow-up eye examination at the health centre. Glaucoma-related diagnosis (p <= 0.001), recommendation of a 4- to 6-week follow-up period (p < 0.001), prescribed eye drops (p < 0.001), or received laser therapy (p=0.047) were factors most predictive of ophthalmic follow-up adherence., CONCLUSIONS: The collaborative effort of eye care providers and health centres offers an important opportunity to detect, treat, and manage glaucoma and other ocular pathology in medically underserved communities. Having a glaucoma-related diagnosis, initiating treatment, and scheduling regular follow-up visits are the most important factors influencing adherence to follow-up eye appointments. Copyright © 2019 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. AU - Adeghate, Jennifer O. AU - Hark, Lisa A. AU - Brown, Helayna AU - Henderer, Jeffrey D. AU - Waisbourd, Michael AU - Molineaux, Jeanne AU - Malik, Kunal AU - Maity, Alisha AU - Chuang, Danielle AU - Donches, Katherine AU - Heres, Caroline AU - Eburuoh, Rita AU - Schardt, Martin AU - Yu, Daohai AU - Ramsey, Frederick AU - Myers, Jonathan S. AU - Katz, L. Jay DO - https://dx.doi.org/10.1016/j.jcjo.2019.03.003 IS - 6 KW - Adult Aftercare Aged Antihypertensive Agents/tu [Therapeutic Use] Community Health Services/mt [Methods] *Community Health Services Female Follow-Up Studies *Glaucoma, Open-Angle/di [Diagnosis] Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/th [Therapy] Humans Intraocular Pressure/ph [Physiology] Laser Coagulation Male Medically Underserved Area Middle Aged *Patient Compliance/sn [Statistics & Numerical Data] Philadelphia Retrospective Studies Tonometry, Ocular Trabeculectomy Visual Acuity PY - 2019 SE - Adeghate, Jennifer O. Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA; Department of Ophthalmology, Weill Cornell Medical College, New York, N.Y. Hark, Lisa A. Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA; Department of Ophthalmology, Columbia University Irving Medical Center, New York, N.Y. Brown, Helayna. Department of Ophthalmology, Temple University Hospital, Philadelphia, PA. Henderer, Jeffrey D. Department of Ophthalmology, Columbia University Irving Medical Center, New York, N.Y.; Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Waisbourd, Michael. Department of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Molineaux, Jeanne. Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA. Malik, Kunal. Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Maity, Alisha. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. Chuang, Danielle. Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Donches, Katherine. Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Heres, Caroline. Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Eburuoh, Rita. Health District #5 Health Center, Philadelphia Department of Health, Philadelphia, PA. Schardt, Martin. Philadelphia College of Osteopathic Medicine, Philadelphia, PA. Yu, Daohai. Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Ramsey, Frederick. Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Myers, Jonathan S. Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. Katz, L Jay. Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. SN - 1715-3360 0008-4182 SP - 717-722 ST - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31836105 VL - 54 Y2 - 20190919// ID - 223 ER - TY - JOUR AB - BACKGROUND: Glaucoma management is challenging to patients as well as to the eye care providers. The study is aimed at describing the challenges faced by providers using qualitative methods., METHODS: In-depth interviews were conducted with selected Ophthalmologists and resident doctors in ophthalmology at centres offering medical and surgical glaucoma services in Lagos state, Nigeria, according to established qualitative methods. This was done using semi-structured, open ended questions to explore the providers' perspective on glaucoma burden, challenges in the management, surgery for glaucoma, acceptance of glaucoma surgery by patients, and recommendations for improving glaucoma services. The discussions were recorded with the aid of a micro-cassette recorder. Familiarisation was done to identify key ideas in the data, then, the main themes and sub-themes were identified. Quotes that reflect the themes and sub-themes were then identified in the data., RESULTS: In-depth interviews were conducted with a total of 11 ophthalmologists and resident doctors in training. Majority were of the opinion that glaucoma is a significant burden constituting about 35% of outpatient visits. Identified patient related challenges include; late presentation, lack of glaucoma awareness, delay in referral from optometrists, and poor compliance with medications. Shortages in needed equipment were also identified. Availability, affordability and counterfeiting of drugs were the major challenges related to medical treatment. Majority of the participants agreed that surgery should be offered to the patients as soon as the diagnosis of glaucoma is made. However, continuous monitoring of the patient on medical treatment is another line of option for them in early cases; if they are convinced the patients will be compliant. Some respondents considered the current number of glaucoma surgeries as adequate, while some think otherwise. Reasons put forward for reluctance to offer glaucoma surgery include; late presentation, lack of patient satisfaction, complications of surgery, and negative publicity., CONCLUSION: Even though the challenges in the management of glaucoma in developing countries are many, they are not insurmountable. There is need for concerted and integrated efforts involving all cadres of eye care practitioners, patients, institutions and governments to address this important eye disease. Improved awareness, provision of adequate equipment, availability and affordability of medications, need for training and retraining of eye care providers are all important measures that can lead to better management of the glaucoma patient. AU - Adekoya, B. J. AU - Adepoju, F. G. AU - Moshood, K. F. AU - Balarabe, A. H. IS - 4 KW - Adult *Attitude of Health Personnel Developing Countries Disease Management Female *Glaucoma/di [Diagnosis] *Glaucoma/th [Therapy] *Health Personnel/sn [Statistics & Numerical Data] *Health Services Needs and Demand/sn [Statistics & Numerical Data] Humans Male Middle Aged Nigeria Ophthalmology/st [Standards] Patient Satisfaction Qualitative Research Referral and Consultation/sn [Statistics & Numerical Data] PY - 2015 SN - 1115-2613 SP - 315-22 ST - CHALLENGES IN THE MANAGEMENT OF GLAUCOMA IN A DEVELOPING COUNTRY; A QUALITATIVE STUDY OF PROVIDERS' PERSPECTIVES T2 - Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria TI - CHALLENGES IN THE MANAGEMENT OF GLAUCOMA IN A DEVELOPING COUNTRY; A QUALITATIVE STUDY OF PROVIDERS' PERSPECTIVES UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=27487608 VL - 24 ID - 753 ER - TY - JOUR AB - PURPOSE: To determine the prevalence of patient refusal of glaucoma surgery (GSR) and the associated factors in Lagos, Nigeria., MATERIALS AND METHODS: A multicenter cross-sectional survey was conducted in Lagos state, Nigeria. Twelve centres were invited to participate, but data collection was completed in 10. Newly diagnosed glaucoma patients were recruited and interviewed from these sites over a four week period on prior awareness of glaucoma, surgery refusal, and reason(s) for the refusal. Presenting visual acuity was recorded from the patient files. The odds ratio and 95% confidence intervals (CI) were calculated., RESULTS: A total of 208 newly diagnosed glaucoma patients were recruited. Sixty-five (31.2%) patients refused surgery. Fear of surgery (31 (47.7%) patients), and fear of going blind (19 (29.2%) patients) were the most common reasons. The odds ratio of surgery refusal were marital status - not married versus married (2.0; 95% CI, 1.02-3.94), use of traditional medication - users versus non users (2.4; 95% CI, 1.1-5.2), perception of glaucoma causing blindness - no versus yes (3.7; 95% CI, 1.3-10.5), type of institution - government versus private (5.7; 95% CI, 1.3-25.1), and visual acuity in the better eye - normal vision versus visual impairment (2.3; 95% CI, 1.1-4.9). Age, gender, level of education, family history of glaucoma, and prior awareness of the diagnosis of glaucoma, were not significantly associated with surgery refusal. Perception of patients concerning glaucoma blindness was the strongest factor on multivariate analysis., CONCLUSION: GSR was relatively low in this study. Unmarried status, use of traditional medications, perception that glaucoma cannot cause blindness, government hospital patients, and good vision in the better eye were associated with GSR. These factors might help in the clinical setting in identifying appropriate individuals for targeted counseling, as well as the need for increased public awareness about glaucoma. AU - Adekoya, Bola Josephine AU - Akinsola, Feyisayo B. AU - Balogun, Bola Grace AU - Balogun, Modupe Medinat AU - Ibidapo, Olajumoke O. DO - https://dx.doi.org/10.4103/0974-9233.110612 IS - 2 KW - Adult Aged Female *Filtering Surgery/sn [Statistics & Numerical Data] Glaucoma/di [Diagnosis] *Glaucoma/su [Surgery] Health Surveys Humans Intraocular Pressure Male Middle Aged Nigeria/ep [Epidemiology] Patient Acceptance of Health Care/sn [Statistics & Numerical Data] *Patients/px [Psychology] Surveys and Questionnaires Treatment Refusal/px [Psychology] *Treatment Refusal/sn [Statistics & Numerical Data] Vision Disorders/et [Etiology] Visual Acuity Visually Impaired Persons Young Adult PY - 2013 SE - Adekoya, Bola Josephine. Department of Ophthalmology, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria. SN - 0975-1599 0974-9233 SP - 168-73 ST - Patient refusal of glaucoma surgery and associated factors in Lagos, Nigeria T2 - Middle East African journal of ophthalmology TI - Patient refusal of glaucoma surgery and associated factors in Lagos, Nigeria UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23741137 VL - 20 ID - 966 ER - TY - JOUR AB - AIMS AND OBJECTIVES: There is a paucity of data onthe human resourcesand ophthalmic equipmentavailable for the diagnosis and management of glaucoma in Nigeria. This study is aimed at describing the ophthalmic human resources, as well as available and functioning equipment used in diagnosing and managing glaucoma in Lagos State, Nigeria., MATERIALS AND METHODS: This was a prospective multicentre cross sectional study.Data on human resources and equipmentavailable were collected from all government tertiaryand secondary health institutions in the state. One large-practice private eye hospital in the state was included for comparative purposes., RESULTS: The average number of ophthalmologists per hospital was 1.3 and 4.5 in the secondary and tertiary centres respectively, with overall ophthalmologists to population ratio of 1:400,000, and ophthalmic nurses to population ratio of 1:150,000. There were only 2 full time low vision therapists and 3 equipment technicians. Only the private hospital had a dedicated patient counsellor and an eye unit manager. 64% of ophthalmic equipment in the government sector were functioning compared with 100% in the private centre. Overall, equipment to population ratios were; slit lamp=1:517,000, 78/90D lens=1:1,487,000, tonometer=1:660,000, visual field analyser=1:2,380,000, and pachymeter=1:5,950,000., CONCLUSIONS: Current population ratios for ophthalmologists and ophthalmic nurses in the state meets vision 2020 recommendations, but there are shortages of other key human resources such as equipment technicians, low vision therapists and patient counsellors. In addition, equipment required for the management of glaucoma wereinadequate, not available or not functioning. Findings from this study suggest that there is an urgent need for increased government funding to glaucoma services in Lagos State. AU - Adekoya, B. J. AU - Shah, S. P. AU - Adepoju, F. G. IS - 2 KW - Cross-Sectional Studies *Diagnostic Equipment/sn [Statistics & Numerical Data] *Diagnostic Techniques, Ophthalmological/is [Instrumentation] Glaucoma/di [Diagnosis] Glaucoma/ec [Economics] *Glaucoma *Health Care Rationing/sn [Statistics & Numerical Data] Health Services Needs and Demand *Health Workforce/sn [Statistics & Numerical Data] Humans Nigeria Ophthalmology/og [Organization & Administration] *Ophthalmology Prospective Studies Staff Development/og [Organization & Administration] PY - 2013 SE - Adekoya, B J. Department of Ophthalmology, Lagos State University Teaching Hospital, Lagos, Nigeria. bjadekoya2007@yahoo.com SN - 1117-1936 SP - 111-5 ST - Managing glaucoma in Lagos State, Nigeria - availability of Human resources and equipment T2 - The Nigerian postgraduate medical journal TI - Managing glaucoma in Lagos State, Nigeria - availability of Human resources and equipment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23959351 VL - 20 ID - 944 ER - TY - JOUR AB - Ophthalmologists are among those healers facing a higher risk of acquiring novel coronavirus disease 2019, called COVID-19, during their professional duties since they have close physical contact with their patients. Some patients with COVID-19 may present with or may develop conjunctivitis during the course of the illness. The ocular secretions and tears have been identified to have positive results to COVID-19 tests and as such could be a source of spread. This review aims at providing the useful guidelines to ophthalmic professionals for their own safety, and safety of their patients based on the available current literature, and also based on personal experience and observations. Literature search was made on PubMed for COVID-19 in relation to ophthalmology in the limited period of the last quarter of 2019 and first quarter of 2020. Research also included access to current guidelines published by various ophthalmic societies. Accordingly, present and future ophthalmic practice patterns need to be modified. © 2020 Pakistan Medical Association. All rights reserved. AD - Division Ophthalmologist, Department of Surgery, King Abdul Aziz Medical Centre, King Abdullah Specialized Children Hospital, National Guard Health Affairs, Riyadh, Saudi Arabia AU - Adhi, M. I. DB - Scopus DO - 10.5455/JPMA.18 IS - 5 KW - Conjunctivitis COVID-19 Ophthalmologist Pandemic SARS-CoV-2 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - S95-S97 ST - Novel coronavirus disease pandemic and ophthalmologist's perspectives T2 - Journal of the Pakistan Medical Association TI - Novel coronavirus disease pandemic and ophthalmologist's perspectives UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086297935&doi=10.5455%2fJPMA.18&partnerID=40&md5=49a28379560be3fe312b4578f3a68598 VL - 70 ID - 5605 ER - TY - JOUR AB - BACKGROUND: Primary open angle glaucoma is reported to blind 150,000 people in the Nigerian population and over 7000 in Rivers State, and requires constant follow-up. Compliance is a challenge, given that most inhabitants live below the poverty line. This study was performed to determine how Nigerian patients are affected economically by the disease., METHODS: Consecutive adult patients attending the eye clinic of the University of Port Harcourt Teaching Hospital, Rivers State, Nigeria, with a diagnosis of primary open angle glaucoma and on outpatient antiglaucoma treatment in the first 6 months of 2006, were recruited for the study. The lowest paid government worker was on USD50 (N7500.00) per month and the gross domestic product per capita was USD1150 for the period under review., RESULTS: We enrolled 120 consecutive patients of mean age 52.7 +/- 10.4 years, with a male to female ratio of 2:3. The most common occupations were in the civil service (n = 56, 46.7%). All participants were on topical antiglaucoma treatment. The average cost of medical antiglaucoma medication was N6000 (USD40) per month. Computed to include indirect costs, including medical laboratory tests, transportation, and care by patient escorts, an average sum of USD105.4 (N15,810) was spent by each patient per month. Most of the patients (73.3%) were responsible for their own treatment costs. No patient accepted the cheaper option of surgery (USD275.4, N41,310). Eighty of the patients (66.7%) visited our eye clinic monthly. Direct and indirect loss to the economy was USD3,064587 per annum from those already blind. This was in addition to the USD 4.1 million being spent yearly on medical treatment by those who were visually impaired by glaucoma., CONCLUSION: Middle-income earners spent over 50% of their monthly income and low-income earners spend all their monthly earnings on treatment for glaucoma. This situation often resulted in noncompliance with treatment and hospital follow-up visits. To reduce the economic burden of glaucoma, trabeculectomy performed by experienced surgeons should be offered as first-line treatment for glaucoma in this country, rather than medical therapy. AU - Adio, Adedayo O. AU - Onua, Alfred A. DO - https://dx.doi.org/10.2147/OPTH.S37145 PY - 2012 SE - Adio, Adedayo O. University Of Port Harcourt Teaching Hospital, Rivers State, Nigeria. SN - 1177-5483 1177-5467 SP - 2023-31 ST - Economic burden of glaucoma in Rivers State, Nigeria T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Economic burden of glaucoma in Rivers State, Nigeria UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=23271881 VL - 6 Y2 - 20121205// ID - 1185 ER - TY - JOUR AB - Colored lenses were first designed for patients with eye pathologies, such as aniridia or corneal opacity. However, in recent years they have become readily available over-the-counter as cosmetic accessories. Widespread use of these lenses has been noted among young adults. Acanthamoeba keratitis is a rare cause of corneal infection, which is associated with poor visual prognosis. Over the past ten years, improvements in the management of this infection have been documented, yet the best treatment is still primary prevention. Hence, contact lens wearers must be provided with proper instructions regarding contact lens hygiene. We present a case of unilateral Acanthamoeba keratitis in a cosmetic contact lens wearer who presented with a month history of right eye pain, photophobia, redness and blurred vision. The contact lenses were obtained over the counter, and a history of poor contact lens hygiene was found. The patient was started on empirical treatment initially. The treatment was modified once the diagnosis was confirmed via Giemsa Stain of corneal scrapings, which showed Acanthamoeba cysts. The patient improved markedly and was discharged from the hospital. The disease classically has a slowly progressive, chronic course, with frequent remission periods. Our patient was lost to follow-up due to poor compliance and failure to adhere to guidelines. © 2017, Bahrain Medical Bulletin. All rights reserved. AD - Eye and Laser Centre, Bahrain Defense Force Hospital, Royal Medical Services, Bahrain AU - Agab, A. W. AU - Albuainain, A. R. AU - Al Bin Ali, G. DB - Scopus DO - 10.12816/0047447 IS - 1 M3 - Article N1 - Export Date: 19 July 2021 PY - 2017 SP - 69-71 ST - Unilateral acanthamoeba keratitis following the use of cosmetic contact lens T2 - Bahrain Medical Bulletin TI - Unilateral acanthamoeba keratitis following the use of cosmetic contact lens UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014662591&doi=10.12816%2f0047447&partnerID=40&md5=5d5903f633cebc8bfabc856ff38d1af1 VL - 39 ID - 5738 ER - TY - JOUR AB - CONTEXT: Risk factors for failure of trabeculectomy may have a cumulative effect on the outcome., AIMS: To study the effect of preoperative ocular risk factors on the surgical outcome of trabeculectomy augmented with 2 commonly used doses of Mitomycin C., SETTINGS AND DESIGN: In a prospective cohort study, cases were recruited over an 18 month period. 92 eyes of 83 patients with one to three known risk factors for failure of trabeculectomy underwent Mitomycin-C (MMC) augmented trabeculectomy., METHODS AND MATERIAL: Trabeculectomy was done with a randomly chosen MMC dose of 0.2 mg/ml or 0.4 mg/ml. All cases were followed up for a period of at least 3 months. Surgical success was defined as the lowering of intraocular pressure (IOP) below 21 mmHg during the follow up period., STATISTICAL ANALYSIS USED: Chi square test, paired t test, odds ratio, effect size., RESULTS: Eyes with two or three risk factors (out of aphakic glaucoma, failed trabeculectomy, neovascular glaucoma, post uveitic glaucoma, traumatic glaucoma, adherent leucoma, juvenile glaucoma, prolonged medical therapy, steroid induced glaucoma, post penetrating keratoplasty glaucoma and developmental glaucoma) had a significantly poorer surgical success rate (88% and 78%) than eyes with one risk factor (100%). 0.4 mg/ml MMC used sub-sclerally had a statistically similar effect on lowering the IOP as 0.2 mg/ml in all groups. The rate of complications was significantly higher in the 0.4 mg/ml subgroup., CONCLUSIONS: The presence of more than one preoperative ocular risk factor, affects the surgical success of MMC augmented trabeculectomy in high-risk cases. Because of the significantly higher rate of complications with the higher dose of MMC, this should be used sparingly, only in cases with more than two risk factors. AU - Agarwal, H. C. AU - Sharma, T. K. AU - Sihota, R. AU - Gulati, V. IS - 2 KW - Adult Chemotherapy, Adjuvant Cohort Studies Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies *Glaucoma/dt [Drug Therapy] *Glaucoma/su [Surgery] Humans Intraocular Pressure Male Middle Aged *Mitomycin/ad [Administration & Dosage] Odds Ratio Postoperative Complications Preoperative Care Probability Prospective Studies Risk Factors *Trabeculectomy/mt [Methods] Treatment Outcome PY - 2002 SE - Agarwal, H C. RP Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi - 110 029, India. SN - 0022-3859 SP - 92-6 ST - Cumulative effect of risk factors on short-term surgical success of mitomycin augmented trabeculectomy T2 - Journal of postgraduate medicine TI - Cumulative effect of risk factors on short-term surgical success of mitomycin augmented trabeculectomy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=12215687 VL - 48 ID - 1872 ER - TY - JOUR AB - PURPOSE: Subtenon triamcinolone acetonide injection (STAI) is a safe drug delivery method for various ocular conditions. We report two cases of necrotic scleral melt, a rare complication of STAI., METHODS: The first patient received STAI for post-operative inflammation control and developed necrotic scleral melt at the site of STAI with superadded fungal keratitis. The second patient received three STAI for non-necrotizing, non-infectious anterior scleritis and developed scleral necrosis at the site of her last STAI. Noncompliance with medications resulted in the progression of scleral necrosis to a new area., RESULTS: In the first patient, surgical removal of triamcinolone deposit resulted in healing of the scleral melt while the second patient was managed conservatively with corticosteroids and immunosuppressants., CONCLUSION: Scleral melt is a rare complication of STAI; however, an early diagnosis and management of any predisposing factor along with surgical debridement should be considered as a potential critical treatment option to salvage the eye. AU - Agarwal, Manisha AU - Ranjan, Richa AU - Mathur, Umang DO - https://dx.doi.org/10.1186/s12348-020-0197-4 IS - 1 PY - 2020 SE - Agarwal, Manisha. Dr. Shroff's Charity Eye Hospital, 5027-Kedar Nath Road, Daryaganj, New Delhi, 110002, India. agarwalmannii@yahoo.co.in. Ranjan, Richa. Dr. Shroff's Charity Eye Hospital, 5027-Kedar Nath Road, Daryaganj, New Delhi, 110002, India. Mathur, Umang. Dr. Shroff's Charity Eye Hospital, 5027-Kedar Nath Road, Daryaganj, New Delhi, 110002, India. SN - 1869-5760 SP - 3 ST - Necrotic scleral melt and fungal keratitis-a complication of subtenon triamcinolone acetonide injection T2 - Journal of ophthalmic inflammation and infection TI - Necrotic scleral melt and fungal keratitis-a complication of subtenon triamcinolone acetonide injection UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=31984430 VL - 10 Y2 - 20200127// ID - 146 ER - TY - JOUR AB - PURPOSE: The aim of this study was to evaluate the effect of clinical and biochemical effects of subconjunctival bevacizumab injection in eyes with corneal neovascularization (CNV) due to varied etiologies., METHODS: This prospective interventional case series included 12 eyes of 12 patients with CNV after failed therapeutic penetrating keratoplasty (4 eyes), viral keratitis (4 eyes), adherent leucoma (2 eyes), and pseudophakic bullous keratopathy (2 eyes). Each eye received 3 doses of 1.25 mg (0.05 mL) of bevacizumab at 1-month intervals. Morphological changes in neovascularization were evaluated at each visit by slit-lamp examination and corneal digital photography. Corneal buttons of 4 eyes that underwent optical penetrating keratoplasty after bevacizumab injections were analyzed for vascular endothelial growth factor (VEGF) expression and were compared with untreated vascularized and normal cadaveric donor corneas., RESULTS: Of the 12 patients, 10 were males and 2 were females. Four eyes received injections in the early phase of vascularization (<12 weeks of onset) of which 3 showed regression of vessels. Eight eyes received bevacizumab in the mature phase (>12 weeks) of which 5 showed regression. The follow-up ranged from 1 to 16 months. Five eyes underwent optical penetrating keratoplasty after receiving the last dose of bevacizumab and maintained graft clarity with no episodes of rejection over a mean follow-up of 9.8 months. Four of these 5 corneal buttons analyzed for VEGF expression revealed clinically significant lower levels of expression as compared with the vascular untreated corneas. No local or systemic adverse effects were noted in any patient., CONCLUSIONS: Subconjunctival bevacizumab helps to regress CNV due to a decrease in corneal VEGF levels and might prove beneficial for use in clinical conditions leading to CNV. AU - Agarwal, Shweta AU - Angayarkanni, Narayanasamy AU - Iyer, Geetha AU - Srinivasan, Bhaskar AU - Natarajan, Radhika AU - Charola, Sanket AU - Arumugam, Sumathi AU - Padmanabhan, Prema DO - https://dx.doi.org/10.1097/ICO.0000000000000198 IS - 10 KW - Adolescent Adult Aged *Angiogenesis Inhibitors/tu [Therapeutic Use] *Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] Bevacizumab Conjunctiva/de [Drug Effects] *Corneal Neovascularization/dt [Drug Therapy] Corneal Neovascularization/pa [Pathology] Corneal Neovascularization/su [Surgery] Female Follow-Up Studies Humans Injections, Intraocular Keratoplasty, Penetrating Male Middle Aged Prospective Studies RNA, Messenger/ge [Genetics] Real-Time Polymerase Chain Reaction Vascular Endothelial Growth Factor A/ai [Antagonists & Inhibitors] Vascular Endothelial Growth Factor A/ge [Genetics] Young Adult PY - 2014 SE - Agarwal, Shweta. *C. J. Shah Department of Cornea and Refractive Surgery, Medical Research Foundation, Sankara Nethralaya, Chennai, India; and R. S. Mehta Jain Department of Biochemistry and Cell Biology, Vision Research Foundation, Chennai, India. SN - 1536-4798 0277-3740 SP - 1016-21 ST - Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization T2 - Cornea TI - Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25090164 VL - 33 ID - 869 ER - TY - JOUR AB - INTRODUCTION: Intravitreal injections of medication are designed to obtain a high concentration in the posterior segment. We conducted a retrospective study of our practice of intravitreal injections to assess safety of the technique and short- and medium-term tolerability, and to analyze indications and the complications., PATIENTS AND METHODS: This analytic retrospective study focused on consecutive patients treated with intravitreal injections for the period of January 2015 to June 2016 in the "Lumiere" ohthalmology clinic in Cotonou, with incidents or accidents during the injection procedure as a measure of safety. Included were all patients undergoing one or more intravitreal injections regardless of the type of product injected, who had undergone a complete ophthalmologic work-up prior to injection and who had been followed at one week (W1) and 1 month (M1) after treatment., RESULTS: During the study period, we safely performed 124 intravitreal injections on 49 patients. The indications were diabetic macular edema in 53.06% and macular edema due to vein occlusions in 26.53%. The main complication observed was ocular hypertension in 60%, mainly related to triamcinolone injection. In 51.02%, the drug used was Ranibizumab, followed by Bevacizumab in 28.54% and Triamcinolone in 20.40%., DISCUSSION: The main goal of intravitreal injection is to achieve instantly effective concentrations in the center of the globe. Intravitreal injection is a safe, feasible practice in our context. The male predominance observed in our series is explained by the low socio-economic status of women in our context as well as the economically difficult accessibility of important drugs such as anti-VEGF. Significant improvements in D7 and D30 visual acuity in our patients highlights the beneficial effects of the presence of the active molecule in the vitreous cavity for these indications., CONCLUSION: Intravitreal injection is a common practice in our context, which is being performed safely. The indications are many, and ocular hypertension is a significant complication. The difficulties in terms of supply and preservation of the main drugs used (anti-VEGF) remains to be resolved. Copyright © 2018 Elsevier Masson SAS. All rights reserved. AU - Agbahoungba, L. AU - Alamou, S. AU - Abouki, C. AU - Djossou-Doutetien, A. AU - Lawani, R. AU - Tchabi, S. DO - https://dx.doi.org/10.1016/j.jfo.2018.02.027 IS - 10 KW - Adult Aged Angiogenesis Inhibitors/ad [Administration & Dosage] Angiogenesis Inhibitors/ae [Adverse Effects] Antibodies, Monoclonal, Humanized/ad [Administration & Dosage] Antibodies, Monoclonal, Humanized/ae [Adverse Effects] Benin/ep [Epidemiology] *Diabetic Retinopathy/dt [Drug Therapy] Diabetic Retinopathy/ep [Epidemiology] Female Glucocorticoids/ad [Administration & Dosage] Glucocorticoids/ae [Adverse Effects] Humans *Intravitreal Injections/ae [Adverse Effects] *Intravitreal Injections/sn [Statistics & Numerical Data] *Macular Edema/dt [Drug Therapy] Macular Edema/ep [Epidemiology] Male Middle Aged Ocular Hypertension/ep [Epidemiology] Ocular Hypertension/et [Etiology] Postoperative Complications/ep [Epidemiology] Practice Patterns, Physicians'/st [Standards] *Practice Patterns, Physicians'/sn [Statistics & Numerical Data] Retinal Vein Occlusion/co [Complications] Retinal Vein Occlusion/dt [Drug Therapy] Retinal Vein Occlusion/ep [Epidemiology] Retrospective Studies Young Adult PY - 2018 SE - Agbahoungba, L. Clinique Ophtalmologique la Lumiere, Cotonou, Benin; Centre d'Exploration de la Retine, Cotonou, Benin. Electronic address: aagleonard@gmail.com. Alamou, S. Centre National Hospitalier Universitaire Hubert Koutoukou Maga, Cotonou, Benin. Abouki, C. Centre Hospitalier Departemental Oueme-Plateau, Porto-Novo, Benin. Djossou-Doutetien, A. Clinique Ophtalmologique la Lumiere, Cotonou, Benin; Centre d'Exploration de la Retine, Cotonou, Benin. Lawani, R. Centre d'Exploration de la Retine, Cotonou, Benin. Tchabi, S. Centre National Hospitalier Universitaire Hubert Koutoukou Maga, Cotonou, Benin. SN - 1773-0597 0181-5512 SP - 963-967 ST - [Evaluation of intravitreal injection practice patterns in Cotonou] T2 - Evaluation de la pratique de l'injection intravitreenne a Cotonou. TI - [Evaluation of intravitreal injection practice patterns in Cotonou] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30470487 VL - 41 Y2 - 20181122// ID - 398 ER - TY - JOUR AB - Glaucoma is a common progressive eye disorder which remains the second leading cause of blindness worldwide. Current therapy involves frequent administration of eye drops which often results in poor patient adherence and therapeutic outcomes. The aim of this study was to overcome these limitations by developing a novel nanoparticle cross-linked collagen shield for sustained delivery of pilocarpine hydrochloride (PHCl). Three metal oxide nanoparticles (NPs); titanium dioxide (TiO2), zinc oxide (ZnO) and polyvinylpyrrolidone (PVP) capped zinc oxide (ZnO/PVP), were evaluated for their cytotoxicity as well as shield transparency before selecting ZnO/PVP NPs as the ideal candidate. Cross-linked collagen shields were then characterized for their mechanical strength, swelling capacity and bioadhesive properties, with ZnO/PVP NP cross-linked shields showing the most favorable characteristics compared to plain films. The shield with the best properties was then loaded with PHCl and in vitro release of zinc ions as well as PHCl was measured without and with further cross-linking by ultraviolet irradiation. The concentration of zinc ions released was well below the IC50 rendering them safe for ocular use. Moreover, collagen shields cross-linked with ZnO/PVP NPs released PHCl over a period of 14 days offering a promising sustained release treatment option for glaucoma. Copyright © 2016 Elsevier B.V. All rights reserved. AU - Agban, Yosra AU - Lian, Jiaxin AU - Prabakar, Sujay AU - Seyfoddin, Ali AU - Rupenthal, Ilva D. DO - https://dx.doi.org/10.1016/j.ijpharm.2016.01.069 IS - 1-2 KW - Adhesiveness Animals Cattle Cell Line Cell Survival/de [Drug Effects] *Collagen/ad [Administration & Dosage] Collagen/ch [Chemistry] Cornea/ch [Chemistry] Delayed-Action Preparations/ad [Administration & Dosage] Delayed-Action Preparations/ch [Chemistry] Humans *Metal Nanoparticles/ad [Administration & Dosage] Metal Nanoparticles/ch [Chemistry] Miotics/ad [Administration & Dosage] Miotics/ch [Chemistry] *Pilocarpine/ad [Administration & Dosage] Pilocarpine/ch [Chemistry] *Povidone/ad [Administration & Dosage] Povidone/ch [Chemistry] *Titanium/ad [Administration & Dosage] Titanium/ch [Chemistry] *Zinc Oxide/ad [Administration & Dosage] Zinc Oxide/ch [Chemistry] PY - 2016 SE - Agban, Yosra. Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand; School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. Lian, Jiaxin. Leather and Shoe Research Association of New Zealand, P.O. Box 8094, Palmerston North 4446, New Zealand. Prabakar, Sujay. Leather and Shoe Research Association of New Zealand, P.O. Box 8094, Palmerston North 4446, New Zealand. Seyfoddin, Ali. School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. Rupenthal, Ilva D. Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. Electronic address: i.rupenthal@auckland.ac.nz. SN - 1873-3476 0378-5173 SP - 96-101 ST - Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride T2 - International journal of pharmaceutics TI - Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26828672 VL - 501 Y2 - 20160129// ID - 723 ER - TY - JOUR AB - Cannabis (marijuana) has been used for medicinal purposes for millennia, said to be first noted by the Chinese in c. 2737 BCE. Medicinal cannabis arrived in the United States much later, burdened with a remarkably checkered, yet colorful, history. Despite early robust use, after the advent of opioids and aspirin, medicinal cannabis use faded. Cannabis was criminalized in the United States in 1937, against the advice of the American Medical Association submitted on record to Congress. The past few decades have seen renewed interest in medicinal cannabis, with the National Institutes of Health, the Institute of Medicine, and the American College of Physicians, all issuing statements of support for further research and development. The recently discovered endocannabinoid system has greatly increased our understanding of the actions of exogenous cannabis. Endocannabinoids appear to control pain, muscle tone, mood state, appetite, and inflammation, among other effects. Cannabis contains more than 100 different cannabinoids and has the capacity for analgesia through neuromodulation in ascending and descending pain pathways, neuroprotection, and anti-inflammatory mechanisms. This article reviews the current and emerging research on the physiological mechanisms of cannabinoids and their applications in managing chronic pain, muscle spasticity, cachexia, and other debilitating problems. AD - S. K. Aggarwal, Medical Scientist Training Program, University of Washington, Seattle, WA, United States AU - Aggarwal, S. K. AU - Carter, G. T. AU - Sullivan, M. D. AU - ZumBrunnen, C. AU - Morrill, R. AU - Mayer, J. D. C1 - aspirin DB - Embase Medline DO - 10.5055/jom.2009.0016 IS - 3 KW - acetylsalicylic acid ajumelic acid alizapride cannabinoid derivative cannabis domperidone dronabinol endocannabinoid levonantradol nabilone nabiximol opiate placebo prochlorperazine unclassified drug anorexia antiemetic activity antiinflammatory activity antioxidant activity cachexia cancer pain chronic pain clinical trial depersonalization disease association drowsiness drug industry drug overdose dysphoria dyspnea epilepsy Food and Drug Administration Gilles de la Tourette syndrome glaucoma health care access health care delivery health care personnel human intractable pain intraocular pressure abnormality medical information medical practice medical society migraine multiple sclerosis myofascial pain nausea neuropathic pain neuroprotection pain pain threshold panic patient counseling psychosis review spasticity spinal cord injury tachycardia tranquilizing activity United States vomiting aspirin LA - English M3 - Review N1 - L355070572 2009-09-07 PY - 2009 SN - 1551-7489 SP - 153-168 ST - Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions T2 - Journal of Opioid Management TI - Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355070572&from=export http://dx.doi.org/10.5055/jom.2009.0016 VL - 5 ID - 3394 ER - TY - JOUR AB - Background: Glaucoma remains one of the leading causes of blindness in South Africa. Early detection, effective treatment and strict compliance with treatment are instrumental to prevent further damage to the optic nerve and thus preserve vision. Aim: The purpose of this study was to assess the knowledge, attitude and self-care practices of patients with glaucoma in KwaZulu-Natal. Setting: The study was conducted in the ophthalmology outpatient department of a public hospital and a private ophthalmology practice in the uThungulu district. Methods: This was an observational, analytic, cross-sectional study. Structured questionnaires assessing knowledge, attitudes and self-care practices were administered to patients presenting for follow-up glaucoma management. Results: The median age of the 384 patients in this study was 60 (interquartile range [IQR] 48.5-69.5) and 59 years (IQR 49.0-66.5) for males and females, respectively (p > 0.05). Two hundred and thirty-eight (62.0%) patients had good knowledge of glaucoma. Age, gender and duration of glaucoma diagnosis were significantly associated with good knowledge of glaucoma. Three hundred and forty-four (89.6%) patients reported having good self-care practices. Patients over the age of 65 years were significantly less likely to have good self-care practices compared to patients aged 26-45 years (odds ratio [OR]: 0.2, confidence interval [CI]: 0.1-0.6, p = 0.01). Good knowledge of glaucoma was significantly associated with good selfcare practices of glaucoma (p < 0.001). Conclusion: Elderly patients do not have sufficient knowledge of glaucoma and have poor self-care glaucoma practices. It is important to involve family members of these patients in the education and counselling of glaucoma to facilitate improved disease management. © 2018. The Author(s). AD - School of Nursing and Public Health, University of KwaZulu-Natal, South Africa School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, South Africa AU - Aghedo, A. V. AU - Tlou, B. AU - Mahomed, S. C7 - a442 DB - Scopus DO - 10.4102/aveh.v77i1.442 IS - 1 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2018 ST - Knowledge, attitudes and self-care practices of patients with glaucoma in uThungulu in KwaZulu-Natal T2 - African Vision and Eye Health TI - Knowledge, attitudes and self-care practices of patients with glaucoma in uThungulu in KwaZulu-Natal UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057283988&doi=10.4102%2faveh.v77i1.442&partnerID=40&md5=e0889942b9b6dbc4d0fb95b208e9bb32 VL - 77 ID - 5558 ER - TY - JOUR AB - Glaucoma, the leading cause of irreversible blindness, affects >70 million people worldwide. Lowering intraocular pressure via topical administration of eye drops is the most common first-line therapy for glaucoma. This treatment paradigm has notoriously high non-adherence rates: ranging from 30% to 80%. The advent of smart phone enabled technologies creates promise for improving eyedrop adherence. However, previous eyedrop electronic monitoring solutions had awkward medication bottle adjuncts and crude software for monitoring the administration of a drop that adversely affected their ability to foster sustainable improvements in adherence. The current work begins to address this unmet need for wireless technology by creating a "smart drop" bottle. This medication bottle is instrumented with sensing electronics that enable detection of each eyedrop administered while maintaining the shape and size of the bottle. This is achieved by a thin electronic force sensor wrapped around the bottle and underneath the label, interfaced with a thin electronic circuit underneath the bottle that allows for detection and wireless transmission to a smart-phone application. We demonstrate 100% success rate of wireless communication over 75 feet with <1% false positive and false negative rates of single drop deliveries, thus providing a viable solution for eyedrop monitoring for glaucoma patients. AU - Aguilar-Rivera, Marcelo AU - Erudaitius, Dieanira T. AU - Wu, Vincent M. AU - Tantiongloc, Justin C. AU - Kang, Dae Y. AU - Coleman, Todd P. AU - Baxter, Sally L. AU - Weinreb, Robert N. DO - https://dx.doi.org/10.3390/s20092570 IS - 9 KW - Electronics Glaucoma/dt [Drug Therapy] *Glaucoma Humans Intraocular Pressure *Medication Adherence Ophthalmic Solutions PY - 2020 SE - Aguilar-Rivera, Marcelo. Department of Bioengineering, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Erudaitius, Dieanira T. Department of Bioengineering, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Wu, Vincent M. Department of Bioengineering, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Tantiongloc, Justin C. Department of Computer Science and Engineering, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Kang, Dae Y. Department of Bioengineering, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Coleman, Todd P. Department of Bioengineering, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Coleman, Todd P. Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Baxter, Sally L. Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Baxter, Sally L. Health Department of Biomedical Informatics, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Weinreb, Robert N. Department of Bioengineering, University of California San Diego, La Jolla, San Diego, CA 92093, USA. Weinreb, Robert N. Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, San Diego, CA 92093, USA. SN - 1424-8220 ST - Smart Electronic Eyedrop Bottle for Unobtrusive Monitoring of Glaucoma Medication Adherence T2 - Sensors (Basel, Switzerland) TI - Smart Electronic Eyedrop Bottle for Unobtrusive Monitoring of Glaucoma Medication Adherence UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32366013 VL - 20 Y2 - 20200430// ID - 201 ER - TY - JOUR AB - Asthma in older populations is characterized by frequent comorbid conditions, which increase the risk of side effects and of detrimental interactions between respiratory and non-respiratory drugs. These observations lead to the need to manage asthma in older populations by applying a multidimensional assessment and a multidisciplinary treatment; therefore, we favor the use of the ‘geriatric’ term to define asthma in the elderly. Geriatric asthma is a complex disease, which may not necessarily imply that it is also complicated, although the two conditions may often coexist. On this basis, the switch from an organ-driven management to the holistic approach may be the key factor to attain optimal control of the disease in this age range. The current review discusses the age-related factors affecting asthma treatment in the oldest individuals, such as the comorbid conditions, and age-related changes of metabolism and excretion that can impair the efficacy and safety of drugs. AD - N. Scichilone, Dipartimento della salute delle popolazioni, nutraceutica e biomarkers, Istituto Euro-Mediterraneo della Scienza e Tecnologia, via Trabucco 180, Palermo, Italy AU - Agusta, F. AU - Battaglia, S. AU - Benfante, A. AU - Spatafora, M. AU - Scichilone, N. DB - Embase Medline DO - 10.1586/17512433.2016.1167596 IS - 7 KW - allergen antiasthmatic agent beta 2 adrenergic receptor stimulating agent bronchodilating agent calcium channel blocking agent cholinergic receptor blocking agent clarithromycin corticosteroid creatinine cytochrome P450 immunoglobulin E itraconazole Staphylococcus enterotoxin theophylline aged aging airway obstruction anosmia asthma cataract chronic obstructive lung disease chronic rhinosinusitis closed angle glaucoma cognitive defect comorbidity creatinine blood level diabetes mellitus disease control drug efficacy drug safety dry powder inhaler electrolyte disturbance fracture gastroesophageal reflux geriatric asthma geriatric disorder glaucoma headache heart arrhythmia heart failure human hyperglycemia hypokalemia inhalation inhaler kidney failure liver disease lung tuberculosis medication compliance metered dose inhaler mydriasis nausea and vomiting nose allergy nose polyp obesity osteoporosis patient compliance peak inspiratory flow physical inactivity pneumonia QT prolongation review sensitization skin contusion smoking stomach acid secretion stomach disease supraventricular tachycardia tachycardia thrush tremor xerostomia LA - English M3 - Review N1 - L611061878 2016-07-08 2016-07-19 PY - 2016 SN - 1751-2441 1751-2433 SP - 917-926 ST - Challenges in the pharmacological treatment of geriatric asthma T2 - Expert Review of Clinical Pharmacology TI - Challenges in the pharmacological treatment of geriatric asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611061878&from=export http://dx.doi.org/10.1586/17512433.2016.1167596 VL - 9 ID - 2726 ER - TY - JOUR AB - Introduction: COVID-19 led to rapid policy changes to expand telemedicine adoption. We examined rates of early telemedicine adoption among surgical departments at a large academic institution and compared provider characteristics associated with teleophthalmology. Methods: With data from departmental and electronic medical records across surgical departments at Johns Hopkins Medicine, we performed a retrospective analysis using the Fisher test and binomial logistic regression. Results: Telemedicine adoption in ophthalmology was disproportionately lower than other surgical departments. Providers who were female [odds ratio, OR, 2.42 (95% confidence interval, CI, 1.03-5.67)], clinical assistants, clinical associates, or instructors [OR 12.5 (95% CI 2.63-59.47)], associate professors [OR 4.38 (95% CI 1.42-13.52)], practiced for >=36 years [OR 0.20 (95% CI 0.06-0.66)], cornea [OR 0.13 (95% CI 0.04-0.47)], glaucoma [OR 0.18 (95% CI 0.04-0.93)] or retina [OR 0.04 (95% CI 0.01-0.17)] specialists, or had a MD/MBBCh/MBBS [OR 0.30 (95% CI 0.10-0.94)] or second degree [OR 0.28 (95% CI 0.08-0.99)] were significantly more or less likely to adopt. When adjusted, cornea [adjusted OR 0.10 (95% CI 0.02-0.57)] or retina [adjusted OR 0.01 (95% CI 0.002-0.12)] specialists or providers who practiced for 12-18 years [adjusted OR 0.22 (95% CI 0.05-0.91)] or >=36 years [adjusted OR 0.13 (95% CI 0.03-0.68)] were significantly more or less likely to adopt. Discussion: Subspecialty among other provider characteristics influences the likelihood of teleophthalmology adoption. As the pandemic continues, strategies to reduce adoption barriers are needed to ensure the provision of health care services. AU - Aguwa, Ugochi T. AU - Aguwa, Chibuzo J. AU - Repka, Michael AU - Srikumaran, Uma AU - Woreta, Fasika AU - Singman, Eric L. AU - Jenkins, Sabrina G. AU - Srikumaran, Divya DO - https://dx.doi.org/10.1089/tmj.2020.0372 IS - 7 PY - 2021 SE - Aguwa, Ugochi T. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Aguwa, Chibuzo J. Meharry Medical College School of Medicine, Nashville, Tennessee, USA. Repka, Michael. Department of Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, USA. Srikumaran, Uma. Department of Orthopedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA. Woreta, Fasika. Department of Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, USA. Singman, Eric L. Department of Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, USA. Jenkins, Sabrina G. Department of Orthopedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA. Srikumaran, Divya. Department of Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, USA. SN - 1556-3669 1530-5627 SP - 739-746 ST - Teleophthalmology in the Era of COVID-19: Characteristics of Early Adopters at a Large Academic Institution T2 - Telemedicine journal and e-health : the official journal of the American Telemedicine Association TI - Teleophthalmology in the Era of COVID-19: Characteristics of Early Adopters at a Large Academic Institution UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=33074795 VL - 27 Y2 - 20201016// ID - 46 ER - TY - JOUR AD - F. Woreta, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD, United States AU - Aguwa, U. T. AU - Srikumaran, D. AU - Brown, N. AU - Woreta, F. DB - Embase Medline DO - 10.1016/j.ajo.2020.10.007 KW - African American Black person coronavirus disease 2019 editorial ethnic difference glaucoma health care access health care disparity health care need health workforce human maternal mortality minority group minority health ophthalmology patient satisfaction priority journal race difference racism workforce LA - English M3 - Editorial N1 - L2010467713 2021-01-08 2021-04-28 PY - 2021 SN - 1879-1891 0002-9394 SP - 306-307 ST - Improving Racial Diversity in the Ophthalmology Workforce: A Call to Action for Leaders in Ophthalmology T2 - American Journal of Ophthalmology TI - Improving Racial Diversity in the Ophthalmology Workforce: A Call to Action for Leaders in Ophthalmology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010467713&from=export http://dx.doi.org/10.1016/j.ajo.2020.10.007 VL - 223 ID - 2319 ER - TY - JOUR AB - Purpose: To compare the efficacy of different microinvasive glaucoma surgery (MIGS) devices for reducing intraocular pressure (IOP) and medications in open-angle glaucoma (OAG). Design: Prospective, multicenter, randomized clinical trial. Participants: One hundred fifty-two eyes from 152 patients aged 45 to 84 years with OAG, Shaffer angle grade best-corrected visual acuity (BCVA) 20/30 or better, and IOP 23 to 39 mmHg after washout of all hypotensive medications. Eyes with secondary glaucoma other than pseudoexfoliative or pigmentary glaucoma, angle closure, previous incisional glaucoma surgery, or any significant ocular pathology other than glaucoma were excluded. Intervention: Study eyes were randomized 1:1 to standalone MIGS consisting of either 1 Hydrus Microstent (Ivantis, Inc, Irvine, CA) or 2 iStent Trabecular Micro Bypass devices (Glaukos Inc, San Clemente, CA). Follow-up was performed 1 day, 1 week, and 1, 3, 6, and 12 months postoperatively. Main Outcome Measures: Within-group and between-group differences in IOP and medications at 12 months and complete surgical success defined as freedom from repeat glaucoma surgery, IOP 18 mmHg or less, and no glaucoma medications. Safety measures included the frequency of surgical complications, changes in visual acuity, slit-lamp findings, and adverse events. Results: Study groups were well matched for baseline demographics, glaucoma status, medication use, and baseline IOP. Twelve-month follow-up was completed in 148 of 152 randomized subjects (97.3%). At 12 months, the Hydrus had a greater rate of complete surgical success (P < 0.001) and reduced medication use (difference = -0.6 medications, P = 0.004). More Hydrus subjects were medication free at 12 months (difference = 22.6% P = 0.0057). Secondary glaucoma surgery was performed in 2 eyes in the 2-iStent group (3.9%) and in none of the Hydrus eyes. Two eyes in the Hydrus group and 1 in the 2-iStent group had BCVA loss of >= 2 lines. Conclusion: Standalone MIGS in OAG with the Hydrus resulted in a higher surgical success rate and fewer medications compared with the 2-iStent procedure. The 2 MIGS devices have similar safety profiles. (C) 2019 by the American Academy of Ophthalmology AN - WOS:000503224300019 AU - Ahmed, I. I. K. AU - Fea, A. AU - Au, L. AU - Ang, R. E. AU - Harasymowycz, P. AU - Jampel, H. AU - Samuelson, T. W. AU - Chang, D. F. AU - Rhee, D. J. AU - Investigators, Compare DA - JAN DO - 10.1016/j.ophtha.2019.04.034 IS - 1 PY - 2020 SN - 0161-6420 1549-4713 SP - 52-61 ST - A Prospective Randomized Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone Treatment of Open-Angle Glaucoma The COMPARE Study T2 - OPHTHALMOLOGY TI - A Prospective Randomized Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone Treatment of Open-Angle Glaucoma The COMPARE Study VL - 127 ID - 6133 ER - TY - JOUR AB - PURPOSE: To evaluate the intraocular pressure (IOP) lowering effect of 2 trabecular microbypass stents and postoperative travoprost in patients with open-angle glaucoma (OAG) not controlled on 2 medications preoperatively. SETTING: S.V. Malayan Ophthalmology Centre, Yerevan, Armenia. DESIGN: Prospective open-label nonrandomized study. METHODS: This prospective pilot study involved 39 qualified phakic patients with OAG, medicated IOP between 18 mm Hg and 30 mm Hg, and unmedicated baseline (after washout) IOP between 22 mm Hg and 38 mm Hg. Patients received 2 stents (iStent) through a clear corneal incision and were prescribed travoprost starting the night of postoperative day 1. Intraocular pressure, complications, and various safety measures were assessed at examinations through 18 months and planned for every 6 months thereafter until month 60. A washout of medications was performed 13 months postoperatively. RESULTS: All patients achieved an IOP reduction of 20% or more from baseline to 12 months with reduction of 1 medication and with IOP 18 mm Hg or less. Follow-up through 18 months showed that medicated IOP decreased from 22.2 mm Hg +/- 2.0 (SD) on 2 medications preoperatively to 14 mm Hg or less on 1 medication at the postoperative visits. The mean unmedicated IOP decreased from 25.3 +/- 1.8 mm Hg preoperatively to 17.1 +/- 2.2 mm Hg 13 months postoperatively. No intraoperative or serious device-related adverse events occurred. CONCLUSIONS: Patients with OAG treated with 2 trabecular microbypass stents and 1 presumptive postoperative medication achieved a significant and sustained reduction in IOP and medication through 18 months. AN - WOS:000340442800008 AU - Ahmed, I. I. K. AU - Katz, L. J. AU - Chang, D. F. AU - Dormenfeld, E. D. AU - Solomon, K. D. AU - Voskanyan, L. AU - Samuelson, T. W. DA - AUG DO - 10.1016/j.jcrs.2014.07.004 IS - 8 PY - 2014 SN - 0886-3350 1873-4502 SP - 1295-1300 ST - Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma VL - 40 ID - 6166 ER - TY - JOUR AB - Purpose: To assess, from the Canadian public payer perspective, the cost-utility of implanting iStent Inject trabecular bypass stent (TBS) devices in conjunction with cataract surgery versus cataract surgery alone in patients with open-angle glaucoma (OAG) and visually significant cataract. Design: Cost-utility analysis using efficacy and safety results of pivotal randomized clinical trial. Participants: Modeled cohort of patients with OAG (83.1% with mild disease, 16.9% with moderate disease) and visually significant cataract. Methods: Open-angle glaucoma treatment costs and effects were projected over a 15-year time horizon using a Markov model with Hodapp-Parrish-Anderson glaucoma stages (mild, moderate, advanced, severe or blind) and death as health states. Patients in the mild or moderate OAG health states received implantation of iStent Inject during cataract surgery versus cataract surgery alone. On worsening of visual field defect and optic disc damage, patients could receive selective laser trabeculoplasty and trabeculectomy. We measured treatment effect as reduction in intraocular pressure (IOP) and mean medication use and estimated transition probabilities based on efficacy-adjusted visual field mean deviation decline per month. Healthcare resource utilization and utility scores were obtained from the literature. Cost inputs (2017 Canadian dollars [C$]) were derived using the Ontario Health Insurance Plan, expert opinion, medication claims datasets, and Ontario Drug Benefit Formulary medication consumption costs. We conducted deterministic and probabilistic sensitivity analyses to examine the impact of alternative model input values on results. Main Outcome Measures: Incremental cost per quality-adjusted life year (QALY) gained. Results: Compared with cataract surgery alone, TBS plus cataract surgery showed a 99% probability of being more effective (+0.023 QALYs; 95% confidence interval [CI], 0.004 to 0.044) and a 73.7% probability of being cost-saving (net cost, –C$389.00; 95% CI, –C$1712.00 to C$850.70). In 95% of all simulations, TBS plus cataract surgery showed a cost per QALY of C$62 366 or less. Results were robust in additional sensitivity and scenario analyses. Conclusions: iStent Inject TBS implantation during cataract surgery seems to be cost effective for reducing IOP in patients with mild to moderate OAG versus cataract surgery alone. AD - M. Botteman, Pharmerit International, LP, 4350 East West Highway, No. 1100, Bethesda, MD, United States AU - Ahmed, I. I. K. AU - Podbielski, D. W. AU - Patel, V. AU - Falvey, H. AU - Murray, J. AU - Botteman, M. AU - Goeree, R. C1 - alphagan azarga azopt betagan combigan cosopt duotrav lumigan simbrinza trusopt vistitan xalacom xalatan C2 - Teva DB - Embase Medline DO - 10.1016/j.ogla.2019.11.009 IS - 2 KW - glaucoma drainage implant bimatoprost brimonidine brimonidine plus brinzolamide brimonidine plus timolol brinzolamide brinzolamide plus timolol dorzolamide dorzolamide plus timolol latanoprost latanoprost plus timolol levobunolol timolol timolol plus travoprost travoprost vistitan aged Canada cataract cataract extraction clinical effectiveness cohort analysis conference paper cost control cost utility analysis cross-sectional study death device safety disease exacerbation disease severity drug use eye injury health care utilization health insurance human implantation medical expert open angle glaucoma optic disk priority journal probability quality adjusted life year scoring system sensitivity analysis simulation trabeculectomy trabeculoplasty visual field defect alphagan azarga azopt betagan combigan cosopt duotrav lumigan simbrinza trusopt xalacom xalatan iStent LA - English M3 - Conference Paper N1 - L2004705302 2020-01-31 2020-03-24 PY - 2020 SN - 2589-4196 2589-4234 SP - 103-113 ST - A Canadian Cost-Utility Analysis of 2 Trabecular Microbypass Stents at Time of Cataract Surgery in Patients with Mild to Moderate Open-Angle Glaucoma T2 - Ophthalmology Glaucoma TI - A Canadian Cost-Utility Analysis of 2 Trabecular Microbypass Stents at Time of Cataract Surgery in Patients with Mild to Moderate Open-Angle Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004705302&from=export http://dx.doi.org/10.1016/j.ogla.2019.11.009 VL - 3 ID - 2429 ER - TY - JOUR AB - Purpose: To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS) with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone. Design: Multicenter randomized clinical trial. Participants: Five hundred fifty-six eyes from 556 patients with cataract and primary open-angle glaucoma (POAG) treated with 1 or more glaucoma medication, washed out diurnal intraocular pressure (IOP) of 22 to 34 mmHg, and no prior incisional glaucoma surgery. Methods: After phacoemulsification, eyes were randomized 2:1 to receive a Hydrus Microstent or no stent. Follow-up included comprehensive eye examinations through 3 years. Main Outcome Measures: Outcome measures included IOP, medical therapy, reoperation rates, visual acuity, adverse events, and changes in corneal endothelial cell counts. Results: Three hundred sixty-nine eyes were randomized to microstent treatment and 187 to CS only. Preoperative IOP, medication use, washed-out diurnal IOP, and glaucoma severity did not differ between the two treatment groups. At 3 years, IOP was 16.7 +/- 3.1 mmHg in the microstent group and 17.0 +/- .4 mmHg in the CS group (P = 0.85). The number of glaucoma medications was 0.4 +/- 0.8 in the microstent group and 0.8 +/- 1.0 in the CS group (P < 0.001), and 73% of microstent group eyes were medication free compared with 48% in the CS group (P < 0.001). The microstent group included a higher proportion of eyes with IOP of 18 mmHg or less without medications compared with the CS group (56.2% vs. 34.6%; P < 0.001), as well as IOP reduction of at least 20%, 30%, or 40% compared with CS alone. The cumulative probability of incisional glaucoma surgery was lower in the microstent group (0.6% vs. 3.9%; hazard ratio, 0.156; 95% confidence interval, 0.031-0.773; P = 0.020). No difference was found in postoperative corneal endothelial cell loss between groups. No procedureor device-related serious adverse events resulting in vision loss occurred in either group. Conclusions: Combined CS and microstent placement for mild to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to result in further incisional glaucoma filtration surgery than CS alone at 3 years. (C) 2020 by the American Academy of Ophthalmology AN - WOS:000654913100018 AU - Ahmed, I. I. K. AU - Rhee, D. J. AU - Jones, J. AU - Singh, I. P. AU - Radcliffe, N. AU - Gazzard, G. AU - Samuelson, T. W. AU - Ong, J. AU - Singh, K. AU - Investigators, Horizon DA - JUN DO - 10.1016/j.ophtha.2020.11.004 IS - 6 PY - 2021 SN - 0161-6420 1549-4713 SP - 857-865 ST - Three-Year Findings of the HORIZON Trial A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract T2 - OPHTHALMOLOGY TI - Three-Year Findings of the HORIZON Trial A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract VL - 128 ID - 6232 ER - TY - JOUR AB - PURPOSE: There is a disparity between the number of people who need healthcare and availability of medical services in rural areas. This paper describes the experience of using telemedicine technologies for ophthalmologic evaluation in diabetic and hypertensive patients presenting to a community health center in rural West Virginia., METHODS: A registered nurse at a community health center in McDowell County, WV was trained to use a retinal camera to capture high-resolution digital images of the retina. Patients with diabetes or hypertension were screened during their routine primary care visits. Retinal photos were transmitted to an ophthalmologist for review and reports from the screenings were returned with instruction for follow-up care or specialist referral when indicated., FINDINGS: A retrospective chart review of 643 patients with diabetes or hypertension who were screened for ocular problems from October 2003 to December 2009 was completed. 44.8% of patients who were screened in the primary care center were identified as having 1 of 34 types of eye pathology that were previously unknown, of which 33% of patients were recommended to seek prompt attention by a retina consultant or glaucoma specialist for suspected ocular pathology., CONCLUSIONS: Our review demonstrates the actual benefits of telemedicine in the effective screening of diabetic and hypertensive patients for eye pathology, and our experience suggests that using distance medicine and telemedicine technologies is valuable for screening rural populations. AU - Ahmed, Rezwan AU - Petrany, Stephen AU - Fry, Russell AU - Krasnow, Michael IS - 1 KW - Adult Aged *Diabetes Complications/di [Diagnosis] *Eye Diseases/di [Diagnosis] Eye Diseases/et [Etiology] Female Health Services Accessibility Healthcare Disparities Humans *Hypertension/co [Complications] Male Middle Aged Retrospective Studies *Rural Health Services *Telemedicine/mt [Methods] PY - 2013 SE - Ahmed, Rezwan. Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, Huntington, USA. SN - 0043-3284 SP - 6-10 ST - Screening diabetic and hypertensive patients for ocular pathology using telemedicine technology in rural West Virginia: a retrospective chart review T2 - The West Virginia medical journal TI - Screening diabetic and hypertensive patients for ocular pathology using telemedicine technology in rural West Virginia: a retrospective chart review UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23413540 VL - 109 ID - 989 ER - TY - JOUR AB - Ocular surface chemical injury (OSCI) is a common type of ocular emergency that can potentially cause significant and permanent visual impairment. However, the global prevalence, demographic factors, socioeconomic burden, and psychological impact of OSCI have not been well investigated or reported. This review aims to provide a comprehensive overview of these aspects, highlight gaps in the literature, and advocate key strategies in reducing the incidence of OSCI. OSCI was responsible for 0.1–15% of all ocular emergency presentations, with an estimated incidence of 5.1–50 per 100,000 population-year. Young working adult men were the most at-risk group, though high rates of OSCI were also observed in young children in developed countries, especially from detergent pods. Low- and middle-income countries were noted to have higher proportions of assault-related and pediatric OSCI cases, often with more severe presentations. Direct and indirect costs for some hospitalized patients led to loss of all personal and household income after the injury. Emergency department costs in the United States were estimated at $106.7 million over four years and costs of treating long term complications such as glaucoma were estimated to be as high as $93,003 over five years. Significant negative impacts on visual and health-related quality of life and psychological well-being have been reported after injury, with higher rates of anxiety, depression, and psychological distress compared to the general population. AD - F.C. Figueiredo, Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom AU - Ahmmed, A. A. AU - Ting, D. S. J. AU - Figueiredo, F. C. DB - Embase Medline DO - 10.1016/j.jtos.2021.02.006 KW - Baerveldt glaucoma implant keratoprosthesis osteoodonto keratoprosthesis protective equipment punctal plug acid alkali ammonia calcium hydroxide cement cyclosporine detergent domestic chemical formic acid holoclar hydrofluoric acid hypochlorite sodium lubricating agent mitomycin mustard gas nitric acid nutrition supplement petroleum derivative potassium hydroxide sodium hydroxide sulfuric acid adult aged anxiety disorder assault chemical burn chemical injury child comparative study cornea disease corneal scarring daily life activity depression developed country disease burden distress syndrome dry eye economic development emergency care emergency ward epidemiological data ethnic group eye injury female glaucoma health care cost health economics health insurance high risk population hospital patient household income human humanism incidence injury severity limbal stem cell deficiency low income country major clinical study male middle income country narrative occupational accident ocular surface chemical injury ocular surface disease patient compliance pediatrics penetrating keratoplasty population prevalence psychological aspect psychological well-being quality of life retrospective study review school child social psychology social status socioeconomics systematic review tertiary health care trabeculectomy young adult LA - English M3 - Review N1 - L2011423630 2021-03-29 2021-04-01 PY - 2021 SN - 1937-5913 1542-0124 SP - 199-211 ST - Epidemiology, economic and humanistic burdens of Ocular Surface Chemical Injury: A narrative review T2 - Ocular Surface TI - Epidemiology, economic and humanistic burdens of Ocular Surface Chemical Injury: A narrative review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2011423630&from=export http://dx.doi.org/10.1016/j.jtos.2021.02.006 VL - 20 ID - 2305 ER - TY - JOUR AB - Purpose: To assess the efficacy and safety of switching from timolol 0.5% to brimonidine 0.1% in patients with glaucoma treated with a prostaglandin analog (PGA) and timolol combination. Methods: This prospective, open-label multicenter study enrolled patients with open-angle glaucoma or ocular hypertension who were being treated with a PGA and timolol. After baseline measurements, timolol was switched to brimonidine 0.1%, and patients were followed for 12 weeks. Patients visited at 4 and 12 weeks after switching. The main outcome measure was the change in intraocular pressure (IOP). For safety evaluations, hyperemia, formation of conjunctival follicles, superficial punctate keratopathy as a local side effect, blood pressure (BP), and heart rate (HR) were evaluated. Results: One hundred seven patients participated in this study. Among them, 103 patients completed the study. The IOP values at baseline, 4 weeks, and 12 weeks after the transition were 15.7±2.7, 14.3±2.8, and 14.0±2.8mmHg, respectively. IOP was significantly reduced at 4 and 12 weeks compared with baseline (p<0.001). There were no significant changes in hyperemia or follicle formation. The superficial punctate keratopathy score was significantly reduced at 12 weeks compared with baseline (p<0.05). Systolic and diastolic BP values were significantly reduced and HR significantly increased after switching (p<0.05). Conclusion: Switching from timolol 0.5% to brimonidine 0.1% may not change IOP in the combination use of timolol 0.5% and a PGA and was well tolerated by patients without severe ocular or systemic side effects. AD - M. Aihara, Shirato Eye Clinic, 1-1-2 Yotsuya, Shinjuku, Tokyo, Japan AU - Aihara, M. AU - Adachi, M. AU - Hamada, N. AU - Honda, N. AU - Koseki, N. AU - Matsuo, H. AU - Miyata, K. AU - Otani, S. I. AU - Unoki, K. DB - Embase DO - 10.1089/jop.2014.0174 IS - 8 KW - brimonidine eye drops prostaglandin derivative timolol aged article blood pressure conjunctival hyperemia drug efficacy drug safety drug substitution female glaucoma Goldmann applanation tonometer heart rate human hyperemia intraocular hypertension intraocular pressure Japanese (people) keratopathy major clinical study male multicenter study open angle glaucoma open study patient compliance prospective study punctate keratitis LA - English M3 - Article N1 - L606372146 2015-10-15 2015-10-27 PY - 2015 SN - 1557-7732 1080-7683 SP - 482-486 ST - Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy T2 - Journal of Ocular Pharmacology and Therapeutics TI - Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606372146&from=export http://dx.doi.org/10.1089/jop.2014.0174 VL - 31 ID - 2863 ER - TY - JOUR AB - AIMS AND PURPOSE: To identify patterns and rates of adherence with travoprost eye drops using the Travatan dosing aid (TDA) and to present a method for graphically presenting adherence data., METHODS: A prospective observational cohort study of patients on travoprost (prostaglandin) monotherapy. Patients were dispensed a TDA and followed up after approximately 3 months of usage. Data were downloaded from the TDA into a computer for analysis. Analysis used inter-dose intervals (the time between each dosing) to look at adherence between days 4 and 75., RESULTS: In all, 100 patients were invited to participate, 53 agreed and complete TDA data sets were obtained from 37. In total 23 of the complete data sets showed good adherence (dosing within +/-4 h of the agreed dosing time on >80% of occasions), 3 patients discontinued usage before 75 days, 4 showed frequent drug holidays (no dosing for > or =8 days) and 7 frequently missed doses with adherence rates of <60%. Of the 16 patients for whom no TDA data was obtained, 5 were lost to follow-up, 4 had faulty/damaged TDAs, 3 changed medication, 3 preferred not to use the TDA, and 1 was hospitalized., CONCLUSIONS: There were four easily defined patterns of adherence; (1) good adherence; (2) discontinued usage; (3) frequent drug holidays; and (4) frequent missed doses with low adherence rates. A new method for graphically presenting adherence data helps clinicians identify the pattern of usage and is a valuable aid to the overall management of patients on travoprost therapy. AU - Ajit, R. R. AU - Fenerty, C. H. AU - Henson, D. B. DO - https://dx.doi.org/10.1038/eye.2010.27 IS - 8 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Cloprostenol/ad [Administration & Dosage] *Cloprostenol/aa [Analogs & Derivatives] Cohort Studies *Drug Monitoring/is [Instrumentation] Female *Glaucoma/dt [Drug Therapy] Humans Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ophthalmic Solutions/ad [Administration & Dosage] Prospective Studies Travoprost N1 - Comment in (CIN) PY - 2010 SE - Ajit, R R. Manchester Royal Eye Hospital, Manchester, UK. SN - 1476-5454 0950-222X SP - 1338-43 ST - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid T2 - Eye (London, England) T3 - Comment in: Eye (Lond). 2011 Sep;25(9):1238; author reply 1238-9; PMID: 21597482 [https://www.ncbi.nlm.nih.gov/pubmed/21597482] TI - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20339390 VL - 24 Y2 - 20100326// ID - 1365 ER - TY - JOUR AD - R.R. Ajit, Manchester Royal Eye Hospital, Manchester, United Kingdom AU - Ajit, R. R. AU - Fenerty, C. H. AU - Henson, D. B. DB - Embase DO - 10.1038/eye.2011.113 IS - 9 KW - antiglaucoma agent prostaglandin follow up glaucoma human hyperemia hypotension intraocular pressure letter monitor patient compliance treatment outcome LA - English M3 - Letter N1 - L362528847 2011-09-19 PY - 2011 SN - 0950-222X 1476-5454 SP - 1238-1239 ST - Response to Cate and Broadway T2 - Eye TI - Response to Cate and Broadway UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362528847&from=export http://dx.doi.org/10.1038/eye.2011.113 VL - 25 ID - 3152 ER - TY - JOUR AB - The intraocular pressure (IOP) lowering efficacy of once-daily levobunolol 0.5% was compared with timolol 0.5% twice-daily and timolol 0.5% once-daily in 20 chronic open angle glaucoma and 5 ocular hypertensive patients. The design used was a randomised double blind cross-over trial with three periods each of 8 weeks separated by 2 weeks of no treatment. We found that following levobunolol a two week washout was not sufficient for the IOP to return to its original baseline level suggesting that levobunolol is a longer acting drug than timolol. Adjusting for this carryover effect, we found on significant difference in the IOP lowering effect among the three regimes (p = 0.53). Reduced cost, less ocular discomfort and better compliance are the main potential advantages of the once daily treatments. AU - Akafo, S. K. AU - Thompson, J. R. AU - Rosenthal, A. R. IS - 3 KW - Adrenergic beta-Antagonists/ad [Administration & Dosage] *Adrenergic beta-Antagonists/tu [Therapeutic Use] Adult Aged Aged, 80 and over Cross-Over Studies Double-Blind Method Drug Administration Schedule Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Levobunolol/ad [Administration & Dosage] *Levobunolol/tu [Therapeutic Use] Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions Timolol/ad [Administration & Dosage] *Timolol/tu [Therapeutic Use] PY - 1995 SE - Akafo, S K. University of Leicester School of Medicine, Department of Ophthalmology, Leicester Royal Infirmary, England. SN - 1120-6721 SP - 172-6 ST - A cross-over trial comparing once daily levobunolol with once and twice daily timolol T2 - European journal of ophthalmology TI - A cross-over trial comparing once daily levobunolol with once and twice daily timolol UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8845685 VL - 5 ID - 2053 ER - TY - JOUR AB - Aim: To determine the effect of the menstrual cycle on white-on-white perimetry (WWP) tests of diabetic women. Subjects and Methods: Left eyes of 129 normally menstruating women (81 type 1 diabetes mellitus (DM) with mild (n = 43) and severe (n = 38) non-proliferative diabetic retinopathy (NPDR), and 48 healthy control females) were included in the study. All subjects underwent complete ocular examination and WWP tests both in the follicular (7-10th day of the cycle) and luteal phases (days 3-7 before the bleeding) of two consecutive menstrual cycles. WWP was performed using Humphrey Field Analyzer II with SITA Standard, central 30-2 program. Mean sensitivity (MS) of points located at central 3, 9, 15, 21 and 27 degrees retinal locations (4, 12, 18, 24 and 16 points, respectively) were calculated in all menstrual phases. Results: The mean age of diabetic patients with mild and severe NPDR and control subjects were 28.8 +/- 4.7, 30.1 +/- 5.9 and 29.4 +/- 5.1 years, respectively (p > 0.05). Their mean MS values were 30.7 +/- 1.0, 30.4 +/- 1.0 and 30.8 +/- 0.8 dB, respectively (p > 0.05). Diabetic patients with severe NPDR demonstrated significant decreases in mean MS values of peripheral 21 and 27 degrees visual field locations in the luteal phase (p < 0.05). However, changes in that of the locations within central 15 degrees visual field were non-significant (p > 0.05). Diabetic patients with mild NPDR and control subjects demonstrated no significant changes in mean MS values of any of the visual field locations (p > 0.05). Conclusion: Peripheral, rather than central, locations of central visual field of diabetic women with severe NPDR demonstrated a significant retinal sensitivity loss in the luteal phase. These findings should be taken into consideration during the clinical follow-up of diabetic women at risk of glaucoma and ocular hypertension. Copyright (C) 2005 S. Karger AG, Basel. AN - WOS:000231389700006 AU - Akar, M. E. AU - Apaydin, K. C. AU - Taskin, O. AU - Akar, Y. AU - Trak, B. DO - 10.1159/000085327 IS - 2 PY - 2005 SN - 0378-7346 1423-002X SP - 92-97 ST - Menstrual cycle-dependent changes in white-on-white visual field analysis of diabetic women T2 - GYNECOLOGIC AND OBSTETRIC INVESTIGATION TI - Menstrual cycle-dependent changes in white-on-white visual field analysis of diabetic women VL - 60 ID - 6255 ER - TY - JOUR AB - The suitability of treatment with Ocusert-P-40, a lamellar system inserted in the eye and allowing the constant release of pilocarpine, was studied in a group of patients (age range 43-83 years) with wide-angle glaucoma. Those patients completing a 3-week trial were included in an 8 month follow-up study in which the long-term efficacy and tolerance of Ocusert were studied. Treatment was discontinued in 13 of the 42 patients in the 3-week trial owing to initial irritation and retention problems (n = 11) or unsatisfactory control of the intraocular pressure (I.O.P.) (n = 2). Of the 29 patients entering the long-term study, two were withdrawn because of tolerance problems and two as a result of unsatisfactory control of I.O.P. The 25 patients completing the study considered the Ocusert system more convenient and less liable to produce troublesome side-effects than their previous therapy. Ocusert was best tolerated by the younger patients. AU - Akerblom, T. AU - Aurell, E. AU - Cristiansson, J. AU - Kriisa-Kunnos, V. AU - Wiebert, O. IS - 4 KW - Adult Aged Clinical Trials as Topic Drug Implants Follow-Up Studies *Glaucoma/dt [Drug Therapy] Humans Interinstitutional Relations *Intraocular Pressure/de [Drug Effects] Middle Aged Patient Dropouts *Pilocarpine/ad [Administration & Dosage] Pilocarpine/ae [Adverse Effects] Sweden Time Factors PY - 1980 SN - 0001-639X SP - 617-23 ST - A multicentre study of the effect and tolerance of Ocusert-P-40 T2 - Acta ophthalmologica TI - A multicentre study of the effect and tolerance of Ocusert-P-40 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=7010885 VL - 58 ID - 2263 ER - TY - JOUR AB - QUESTION: Is hydroxyzine safe and effective for generalized anxiety disorder in adult outpatients?DesignRandomised trial. Investigators and participants were blind to treatment allocation.Setting89 French general practices (supervised by psychiatrists); January 1998-March 1999.Participants334 outpatients diagnosed with generalised anxiety disorder (DSM-IV criteria) and a Hamilton Rating Scale for Anxiety (HAM-A) total score of at least 20. All were aged 18-65 years (mean 45 years); 68% women. Exclusion criteria were alcohol or drug dependence; major depressive episode within 6 months; score of 7 or above on the Raskin Severity of Depression and Mania scale; psychotic or delusional disorders within 3 years; chronic disease; prostate cancer; closed angle glaucoma; antidepressants, neuroleptics, mood regulators, morphine or derivatives, hydroxyzine, or bromazepam within 4 weeks; benzodiazepines more than 2 days per week during the past 30 days; benzodiazepines during the previous 2 weeks; need for psychotherapy; contraindication to study medication; and women who were pregnant, breastfeeding or not using contraception.InterventionAfter a 2 week placebo run in phase, participants received 12 weeks of 50 mg hydroxyzine per day, 6 mg bromazepam per day or placebo. Treatment was divided into three daily doses. Treatment was followed by 4 weeks of run out placebo. 83% of participants completed treatment. Adherence to medication was 85%.Main outcome measuresResponse (mean change in HAM-A total score); remission; adverse effects.Main resultsCompared with placebo, after 3 months of treatment the hydroxyzine group had superior response rates (P=0.003); remission rates (P=0.028); changes in Clinical Impressions Severity score (P=0.001); maintenance of efficacy (P=0.022), and Hospital Anxiety and Depression scale score on day 84 (P=0.008). There was no significant difference in efficacy between hydroxyzine and bromazepam. Safety was comparable between groups. Drowsiness was the most commonly reported adverse effect in the hydroxyzine group, although drowsiness was twice as common with bromazepam (see table).ConclusionsHydroxyzine appears to be safe and effective in adults with generalised anxiety disorder. AD - Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran AN - 106878754. Language: English. Entry Date: 20031024. Revision Date: 20150711. Publication Type: Journal Article AU - Akhondzadeh, S. DB - ccm DP - EBSCOhost IS - 3 KW - Anxiety Disorders -- Drug Therapy Hydroxyzine -- Therapeutic Use Treatment Outcomes Clinical Trials N1 - abstract; commentary. Original Study: Llorca PM, Spadone C, Sol O et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002 Nov; 63: 1020-7. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 100883413. PMID: NLM12893802. PY - 2003 SN - 1362-0347 SP - 91-91 ST - Hydroxyzine may be safe and effective in generalised anxiety disorder T2 - Evidence Based Mental Health TI - Hydroxyzine may be safe and effective in generalised anxiety disorder UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106878754&site=ehost-live&scope=site VL - 6 ID - 4780 ER - TY - JOUR AB - Purpose : Panuveitis is defined by inflammation of the uveal tract in both the anterior and posterior segment. Panuveitis generally accounts for less than 25% of all uveitis presenting to tertiary care facilities. Successful treatment relies on consistent follow up and good compliance with treatment. The inner city population presents a unique cohort in which both follow up and treatment compliance are inconsistent. We undertook this study to evaluate the etiology and long term visual outcomes in this cohort to further understand how best to treat panuveitis patients when socioeconomic factors limits management options. Methods : A retrospective chart review was conducted on patients with a diagnosis of panuveitis from January 2012 to January 2017. Factors analyzed included demographics, visual acuity, etiology, degree of posterior involvement, treatment, including steroids, immunomodulatory therapy or intraocular therapy, loss of follow up and sequelae. IRB approval was obtained from the Wayne State University School of Medicine. All subjects were treated in accordance to the Declaration of Helsinki. Results : 101 patients were analyzed: 79% were African-American, 13% were Caucasian and 4% were other. The average age was 50. 68% of the patients were female and 32% were male. 39% of patients had systemic disease, of which sarcoidosis was the most common (49%). 30% of patients were idiopathic and 27% were infectious, of which syphilis was the most common (41%). 78% of patients were on steroids and and 54% were on immunomodulatory medication, of which methotrexate was the most common (43%). There was no significant change in vision after treatment. 25% of patients developed uveitic glaucoma. At least 18% of the patients in our study were lost to follow up two or more times. Conclusions : The etiology of panuveitis seen in our study, most notably the predominance of sarcoidosis and syphilis, is unique to our inner city population when compared to other studies. This knowledge may help guide treatment in this challenging patient population. AD - M. Akhter, Kresge Eye Institute, Detroit, MI, United States AU - Akhter, M. AU - Lin, X. DB - Embase IS - 9 KW - methotrexate steroid adult African American Caucasian cohort analysis complication conference abstract controlled study drug therapy female follow up glaucoma human major clinical study male medical record review middle aged retrospective study sarcoidosis socioeconomics syphilis systemic disease urban population uveitis visual acuity LA - English M3 - Conference Abstract N1 - L628472090 2019-07-16 PY - 2018 SN - 1552-5783 ST - Etiology and longitudinal outcomes of panuveitis in an inner city underserved population T2 - Investigative Ophthalmology and Visual Science TI - Etiology and longitudinal outcomes of panuveitis in an inner city underserved population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628472090&from=export VL - 59 ID - 2578 ER - TY - JOUR AB - Treatment for several major age-related ocular diseases has undergone a paradigm shift in recent years. Advances in basic science and clinical research have led to a more thorough understanding of the complex pathophysiology underlying common ocular diseases of aging, and to the development of highly effective new therapies for these conditions. The use of intraocular anti-angiogenic drugs, for example, has transformed the management of neovascular age-related macular degeneration and diabetic retinopathy. Many patients achieve impressive and durable gains in vision with these agents that were unattainable with older treatments. For glaucoma and dry eye disease, clinicians have a variety of pharmacologic and surgical options to choose from. However, significant challenges remain: not all patients respond to treatment, many older patients have difficulty complying with complex drug regimens, frequent office visits put a substantial strain on patients and caregivers, and therapies may cause unpleasant side effects. This article reviews the current treatment landscape for 4 major age-related ocular diseases: age-related macular degeneration, glaucoma, diabetic retinopathy, and dry eye. AU - Akpek, Esen K. AU - Smith, Roderick A. IS - 5 Suppl KW - Aged Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] Bevacizumab Clinical Trials as Topic Cyclosporine/tu [Therapeutic Use] Diabetes Mellitus/bl [Blood] Diabetes Mellitus/dt [Drug Therapy] *Diabetic Retinopathy/dt [Drug Therapy] *Diabetic Retinopathy/pc [Prevention & Control] Disease Progression Dry Eye Syndromes/et [Etiology] *Dry Eye Syndromes/th [Therapy] *Glaucoma/th [Therapy] Glycated Hemoglobin A/an [Analysis] Humans *Macular Degeneration/dt [Drug Therapy] Medication Adherence Ophthalmic Solutions/tu [Therapeutic Use] Ophthalmologic Surgical Procedures Ranibizumab Receptors, Vascular Endothelial Growth Factor/tu [Therapeutic Use] Recombinant Fusion Proteins/tu [Therapeutic Use] Vascular Endothelial Growth Factor A/ai [Antagonists & Inhibitors] PY - 2013 SE - Akpek, Esen K. Ocular Surface Disease & Dry Eye Clinic and Division of Cornea, Cataract, & External Diseases, The Wilmer Eye Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA. Esakpek@jhmi.edu SN - 1936-2692 1088-0224 SP - S76-84 ST - Current treatment strategies for age-related ocular conditions T2 - The American journal of managed care TI - Current treatment strategies for age-related ocular conditions UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23725499 VL - 19 ID - 970 ER - TY - JOUR AB - Renal transplantation is the surgical implantation of a human kidney from a compatible donor into a recipient. Renal transplantation is a means of restoring renal function to normal in most patients, thus allowing a return to a healthy lifestyle. Patients and their families often ask nurses for health information. Professional nurses must ensure that patients and families understand the transplantation and therapeutic regimen and provide health education. It should be remembered that certain physiological, psychosocial and pathological conditions might inhibit the education process. Before renal transplantation the patient's understanding of the procedure and follow-up regimen and also the patient's ability to cope with a complex medication regimen are assessed. The nurse and the patient and family should work together to set realistic, achievable goals, the aims of which are mutually agreed. The agreed goals of health education should be documented in a care plan, which will also provide reinforcement for both the nurse and patient. AD - N. Akyolcu, Istanbul Univ. Hemsirel. Yuksekokulu, Abide-i Hurriyet Cad. 80270, Istanbul, Turkey AU - Akyolcu, N. DB - Embase Medline DO - 10.1111/j.1755-6686.2002.tb00240.x IS - 4 KW - immunosuppressive agent article cooperation coping behavior Cushing disease diabetes mellitus family counseling follow up gastrointestinal hemorrhage glaucoma health education hemorrhagic shock home care human kidney artery stenosis kidney function kidney transplantation learning lifestyle lung disease nurse patient relationship nursing paralytic ileus patient compliance patient education quality of life side effect social psychology treatment planning urethra fistula urinary tract infection wound infection LA - English M3 - Article N1 - L36245037 2003-03-08 PY - 2002 SN - 1019-083X SP - 176-179 ST - Patient education in renal transplantation T2 - EDTNA-ERCA Journal TI - Patient education in renal transplantation UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36245037&from=export http://dx.doi.org/10.1111/j.1755-6686.2002.tb00240.x VL - 28 ID - 3851 ER - TY - JOUR AB - Background: Oral corticosteroids (OCSs) are often used to achieve asthma control. OCS-related comorbidities increase the burden of disease for patients and healthcare providers. Most studies characterizing OCS use and risk of adverse events (AEs) are in non-asthma patients. We sought to systematically review the literature on the burden of OCS use among adults with asthma. Methods: We systematically reviewed the literature including MEDLINE (1946–May 2017), EMBASE (1974–May 2017), and the Cochrane Library (2005–May 2017) to identify studies that considered AEs due to OCS treatment of adults with asthma, their burden on healthcare utilization, and costs. Results: We retrieved 9,589 citations; and 15 studies were included. AEs were significantly higher among OCS-users compared with non-OCS users with pooled adjusted odds ratio (OR) 1.68 (95% CI 1.15–2.46) for diabetes mellitus and 1.34 (95% CI 1.23–1.46) for hypertension. Among high dose OCS-users (>10 mg) compared with non-OCS users, the pooled adjusted ORs for development of any complication was 3.35 (95% CI 2.94–3.82), and bone and muscle complications 2.30 (95% CI 2.18–2.42). The risk of any complication increased with higher doses of OCS, with pooled adjusted OR from 2 studies of 2.26 (95% CI 1.37–3.72), 2.94 (95% CI 2.62–3.29) and 3.35 (95% CI 2.94–3.82) for low dose (<6 mg), medium dose (5–12 mg) and high dose (>10 mg) respectively compared with no OCS use. Conclusions: The use of OCS in the management of asthma is associated with a higher risk of complications. This risk is higher as the OCS dose increases. AD - J.M. FitzGerald, Gordon and Leslie Diamond Healthcare Centre, The Lung Centre, 7th Floor, 2775 Laurel Street, Vancouver, BC, Canada AU - Al Efraij, K. AU - Johnson, K. M. AU - Wiebe, D. AU - Sadatsafavi, M. AU - FitzGerald, J. M. DB - Embase Medline DO - 10.1080/02770903.2018.1539100 IS - 12 KW - corticosteroid adverse drug reaction article asthma bone disease cardiovascular disease cataract corticosteroid therapy diabetes mellitus drug dose comparison drug megadose fracture gastrointestinal disease glaucoma health care cost health care utilization human hypertension infection low drug dose obesity osteoporosis peptic ulcer systematic review LA - English M3 - Article N1 - L625353043 2018-12-11 2019-12-03 PY - 2019 SN - 1532-4303 0277-0903 SP - 1334-1346 ST - A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma T2 - Journal of Asthma TI - A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625353043&from=export http://dx.doi.org/10.1080/02770903.2018.1539100 VL - 56 ID - 2467 ER - TY - JOUR AB - BACKGROUND: Rapid Assessment for the Avoidable Blindness (RAAB) was conducted in Qatar during 2009. We present the prevalence and determinants of visual disabilities and status of cataract among citizens aged 50 years and older., METHODS: Residents of randomly selected houses and clusters participated in the survey. Opticians noted the presenting and the best corrected vision of participants from 49 clusters. Ophthalmologists examined participants with additional instruments like bio-microscope, digital camera, auto-perimeter and auto-refractor in a mobile van. World Health Organization recommended principal cause of blindness (Visual acuity [VA] < 3/60 in better eye), Severe visual impairment (SVI) (<6/60), low vision (VA < 6/18) and unilateral blindness (VA < 3/60) were designated. Persons with VA < 6/18 and cataract were interviewed to calculate coverage and barriers for cataract surgeries. Age sex adjusted prevalence of visual disabilities and their 95% Confidence Intervals (CI) were estimated., RESULTS: We examined 2,433 (97.3%) participants. The age sex adjusted prevalence of bilateral blindness was 1.28% [95% CI 1.22-1.35], SVI (1.67%), low vision (3.66%) and unilateral blindness (3.61%) in 50 years and older population. Female and older age groups were significant risk factors of visual disabilities. Cataract and glaucoma were the main causes of visual disabilities. The coverage of cataract services was 68.2%. Believing that cataract as an aging process (25) and adequate vision in the fellow eye (15) were the reasons for delay in surgery., CONCLUSIONS: To reduce avoidable blindness, un-operated cataract should be addressed. Primary and secondary eye care systems should be strengthened to improve the care of blinding eye diseases in Qatar. AU - Al Gamra, Hamad AU - Al Mansouri, Fatima AU - Khandekar, Rajiv AU - Elshafei, Maha AU - Al Qahtani, Omar AU - Singh, Rajvir AU - Hashim, Shakeel P. AU - Mujahed, Amjad AU - Makled, Alaa AU - Pai, Anant DO - https://dx.doi.org/10.3109/09286586.2010.508350 IS - 5 KW - Aged Aged, 80 and over *Blindness/ep [Epidemiology] Blindness/et [Etiology] *Cataract/ep [Epidemiology] Disability Evaluation Female Health Surveys Humans Male Middle Aged Prevalence Qatar/ep [Epidemiology] Risk Factors *Vision, Low/ep [Epidemiology] Vision, Low/et [Etiology] Visual Acuity/ph [Physiology] *Visually Impaired Persons/sn [Statistics & Numerical Data] PY - 2010 SE - Al Gamra, Hamad. Department of Ophthalmology, Hamad Medical Corporation, Doha, Qatar. halnabit@hmc.org.qa SN - 1744-5086 0928-6586 SP - 292-300 ST - Prevalence and causes of blindness, low vision and status of cataract in 50 years and older citizen of Qatar-a community based survey T2 - Ophthalmic epidemiology TI - Prevalence and causes of blindness, low vision and status of cataract in 50 years and older citizen of Qatar-a community based survey UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20868255 VL - 17 ID - 1331 ER - TY - JOUR AB - Purpose: To assess the effectiveness and safety of a single iStent trabecular micro-bypass stent implantation in combination with cataract surgery in lowering the intra ocular pressure (IOP) and number of anti-glaucoma medications in Saudi patients with open-angle glaucoma (OAG)., Setting: King Fahad Hospital of the University, Al Khobar, Saudi Arabia., Design: Prospective, non-comparative, uncontrolled, non-randomized interventional case series., Methods: One iStent was implanted during phacoemulsification cataract surgery for adult patients with OAG by a single surgeon over a period of 3 years. Main outcome measures include number of anti-glaucoma medications, IOP, corrected distance visual acuity (CDVA) and complications., Results: Thirty-six eyes of 33 patients with OAG underwent the surgery. The pre-operative mean IOP and mean anti-glaucoma medications were 17.47 +/- 5.44 mmHg and 2.69 +/- 0.92, respectively. At 1 year of follow-up mean, IOP decreased to 13.44 +/- 1.99 (23.1% reduction) (P<0.001) and mean anti-glaucoma medications decreased to 1.47+/-1.13 (45.4% reduction) (P<0.001)., Conclusion: After 12-month follow-up, phacoemulsification with the implantation of a single iStent seems to be an effective and safe procedure to lower IOP and the number of anti-glaucoma medications, and to overcome the problems associated with medication nonadherence in OAG patients with cataracts. Copyright © 2020 Al Habash and Khan. AU - Al Habash, Ahmed AU - Khan, Omar DO - https://dx.doi.org/10.2147/OPTH.S249261 PY - 2020 SE - Al Habash, Ahmed. Department of Ophthalmology, College of Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. Khan, Omar. Ministry of Health, Madinah, Saudi Arabia. SN - 1177-5467 SP - 1573-1580 ST - Outcomes of Combined iStent Trabecular Micro-Bypass and Cataract Surgery for the Treatment of Open-Angle Glaucoma in a Saudi Population T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Outcomes of Combined iStent Trabecular Micro-Bypass and Cataract Surgery for the Treatment of Open-Angle Glaucoma in a Saudi Population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=32606572 VL - 14 Y2 - 20200611// ID - 134 ER - TY - JOUR AB - Purpose: To describe the pattern of both types of primary glaucoma in Qatari adult patients and to outline the main problem related to its management. Material and Methods: A random sample of Qatari patients with primary glaucoma either open angle or angle closure glaucoma in whom the diagnosis was made after the age of 30 years was studied over the last 2 years (1997-1998) by standard questionnaire as regards their personal and medical profile, and assessed ophthalmologically both subjectively and objectively. Results: 195 patients were studied, of whom 29.7% had angle closure glaucoma. Early presentation was clearly shown in both type of glaucoma. Legal blindness was present in significant proportion of patients. Comment: Glaucoma in Qatari patients presents at an early age, with substantial loss of visual function at presentation. Poor compliance is an obstacle for management in both types of glaucomas. The need for an educational campaign and a program for early detection is highly advised. AD - F. Al Mansouri, Ophthalmology Section, Surgery Department, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar AU - Al Mansouri, F. DB - Embase IS - 1 KW - adult aged article blindness closed angle glaucoma controlled study disease severity early diagnosis female health education health program health status human major clinical study male onset age open angle glaucoma patient care patient compliance primary glaucoma Qatar questionnaire randomization visual system examination LA - English M3 - Article N1 - L35071770 2002-10-09 PY - 2002 SN - 0253-8253 SP - 31-35 ST - The pattern and severity of primary glaucoma in Qatar T2 - Qatar Medical Journal TI - The pattern and severity of primary glaucoma in Qatar UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35071770&from=export VL - 11 ID - 3881 ER - TY - GEN AB - Fungal keratitis is one of the major causes of ophthalmic mycosis and is difficult to treat. The range of common antifungal agents available for fungal keratitis remains inadequate and is generally associated with poor clinical outcomes. Voriconazole is a new generation triazole antifungal agent. Only marketed in systemic formulation and, with broad-spectrum activity and high intraocular penetration, voriconazole has demonstrated effectiveness against fungal keratitis. Systemic voriconazole, however, is not without side effects and is costly. Voriconazole eye drops have been prepared extemporaneously and used for the treatment of ophthalmic fungal keratitis. The current article sought to review the literature for evidence related to the effectiveness and safety of topical voriconazole and its corneal penetration into the aqueous humor of the eye. The voriconazole eye drops used are typically of 1% concentration, well tolerated by the eye, and are stable. Despite existing evidence to suggest that the eye drops are effective in the treatment of fungal keratitis, more studies are needed, especially in relation to using the eye drops as first-line and stand-alone treatment, preparation of higher concentrations, and optimal dosing frequency. © 2010 Al-Badriyeh et al, publisher and licensee Dove Medical Press Ltd. AD - D. C. M. Kong, Centre for Medicine Use and Safety, Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia AU - Al-Badriyeh, D. AU - Neoh, C. F. AU - Stewart, K. AU - Kong, D. C. M. C1 - vfend(Pfizer) C2 - Pfizer DB - Embase J2 - Clin. Ophthalmol. KW - allylamine derivative amphotericin B antifungal agent beta cyclodextrin derivative caspofungin echinocandin eye drops fluconazole immunosuppressive agent itraconazole ketoconazole miconazole natamycin nystatin polyene posaconazole pyrrole derivative steroid terbinafine voriconazole alopecia aqueous humor clinical feature clinical trial disease predisposition drug absorption drug bioavailability drug blood level drug cost drug delivery system drug distribution drug efficacy drug megadose drug metabolism drug penetration drug protein binding drug safety drug stability drug substitution drug tissue level drug tolerability drug withdrawal eye toxicity fungal strain gastrointestinal toxicity gynecomastia human impotence incidence keratomycosis liver toxicity low drug dose minimum inhibitory concentration nephrotoxicity nonhuman optimal drug dose patient compliance review risk factor vfend L1 - internal-pdf://3520709988/3251-Clinical utility of voriconazole eye-2010.pdf LA - English M1 - (Al-Badriyeh D.; Neoh C.F.; Stewart K.; Kong D.C.M., david.kong@pharm.monash.edu.au) Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, VIC, Australia M3 - Review N1 - L358837731 2010-05-26 2010-06-02 PY - 2010 SN - 1177-5467 1177-5483 SP - 391-405 ST - Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis TI - Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358837731&from=export VL - 4 ID - 3251 ER - TY - JOUR AB - INTRODUCTION: Endoscopic diode cycloablation (ECP) has shown modest efficacy for the management of pediatric glaucomas. Eyes with pediatric glaucoma and corneal opacities pose obstacles to intraocular surgery. We examined the role of ECP in lowering intraocular pressure (IOP) as well as that of endoscopy in facilitating tube shunt placement in these eyes., METHODS: Retrospective chart review of 12 eyes (11 patients) with glaucoma and corneal opacities from 12/99 to 9/05. ECP was performed for IOP control with success defined as postoperative IOP < or =21 mm Hg, with or without medications and without procedure-related complications. Success of ECP, repeat ECP, and endoscopically guided tube shunt placement was studied., RESULTS: Diagnoses included the following: Peters/anterior segment dysgenesis in nine eyes and corneal scar/failed corneal graft in three. Patients included eight females and three males with median age 3 years (0.5 to 10.3) at treatment. Median number of prior surgeries was three; median time to failure was 7.8 months (0.3 to 38). Ten eyes had prior external cycloablation(s). Success of first ECP (mean 6.1 clock hours) was 2/12 (17%), with Kaplan-Meier median survival 12 months. Two treatment failures had repeat ECP, and both failed. Four treatment failures had subsequent tube shunt surgery (three with endoscopic assistance), and all were successful at median follow-up of 33 months (11 to 63). Baseline IOP was 36.8 +/- 11 mm Hg before ECP versus 28.2 +/- 16 mm Hg after first treatment (p = 0.07). Procedure-related complications included chorioretinal detachment in one eye., CONCLUSIONS: ECP had limited success in children with refractory glaucoma. However, with anatomic limitations, endoscopy itself was valuable in facilitating subsequent successful tube shunt surgery. AU - Al-Haddad, Christiane E. AU - Freedman, Sharon F. IS - 1 KW - Adolescent Child Child, Preschool *Ciliary Body/su [Surgery] *Corneal Opacity/co [Complications] *Endoscopy Female Follow-Up Studies Glaucoma/co [Complications] *Glaucoma/su [Surgery] Humans Infant Intraocular Pressure *Laser Coagulation/mt [Methods] Male Retrospective Studies Treatment Outcome N1 - Erratum in (EIN), Comment in (CIN) PY - 2007 SE - Al-Haddad, Christiane E. Duke University Eye Center, Durham, NC 27710, USA. SN - 1091-8531 SP - 23-8 ST - Endoscopic laser cyclophotocoagulation in pediatric glaucoma with corneal opacities T2 - Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus T3 - Erratum in: J AAPOS. 2007 Jun;11(3):319Comment in: J AAPOS. 2007 Feb;11(1):10-1; PMID: 17307677 [https://www.ncbi.nlm.nih.gov/pubmed/17307677] TI - Endoscopic laser cyclophotocoagulation in pediatric glaucoma with corneal opacities UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17307679 VL - 11 ID - 1614 ER - TY - JOUR AB - UNLABELLED: Aggressive administration of hepatitis B immune globulin (HBIg) has been shown to prevent hepatitis B viral (HBV) infection of the allograft; however, the clinical sequela of such therapy has not been previously described. We reviewed our experience with high dose, intravenous infusion of an intramuscular HBIg preparation to assess the effectiveness and complications of such therapy. Thirty three orthotopic liver transplants (OLTx) were performed in 32 patients with chronic HBV cirrhosis at the University of Virginia between March 1990 and June 1995. Twenty-nine of 32 (91%) patients remain free of HBV recurrence (defined by undetectable serum HBsAg and HBV-DNA) after a mean of 21 months (2-54 months), with one patient requiring retransplantation. Three (10%) patients died of non-HBV causes (two vascular events, one infectious event). Twenty episodes of acute cellular rejection were treated in 18 patients (two had two episodes). Sixteen rejections occurred within 18 d of transplant, 19 by day 120, and one late rejection occurred at 18 months owing to medication non-compliance. Eighteen patients had at least one documented infection. Six patients were treated for CMV infection (five empirically). Eight patients were treated for HSV infections (seven mild herpetic labialis and one herpetic keratitis). Four patients had documented fungal infection (one mucormycosis pneumonia and three minor superficial mucosal infections). With the exception of one necrotizing pneumonia, 11 bacterial infections were successfully treated with conventional antimicrobial agents. No patient developed post-transplant lymphoproliferative disorder. Symptoms associated with HBIg infusion were intermittent but frequent and consisted of myalgias, predominantly back pain (90%), headache (20%) and flushing (5%). No patient experienced anaphylaxis, fever, rash, arthritis or hypotension. Despite the potential for mercury toxicity and HCV transmission in the HBIg formulations currently available in the United States, serum mercury levels remained below standards for industrial exposure (60 micrograms/ml), and only one individual developed post-transplant HCV infection after receiving multiple units of unscreened blood prior to 1991., SUMMARY: High-dose HBIg prevented HBV infection of the allograft in 29 of 32 patients transplanted for HBV cirrhosis with three non-HBV associated deaths. The intravenous infusion of HBIg was frequently associated with minor side effects that were safely tolerated by patients. The risk of HCV transmission and mercury toxicity are minimal, but support the need for a new intravenous formulation of HBIg. HBIg therapy successfully decreased post-OLTx HBV recurrence with no clinical events associated with immunosuppression. Patients did non experience allergic or infusion-related complications that altered or terminated therapy. Manufacturing modifications of HBIg may allow for improved patient tolerance and decreased risks. AU - al-Hemsi, B. AU - McGory, R. W. AU - Shepard, B. AU - Ishitani, M. B. AU - Stevenson, W. C. AU - McCullough, C. AU - Pruett, T. L. IS - 6 Pt 2 KW - Adult Aged Chronic Disease Disease-Free Survival Female Graft Rejection/et [Etiology] *Hepatitis B/co [Complications] Humans *Immunization, Passive Immunoglobulins/ae [Adverse Effects] Infections/et [Etiology] *Liver Cirrhosis/su [Surgery] *Liver Cirrhosis/vi [Virology] Liver Transplantation/ae [Adverse Effects] *Liver Transplantation/im [Immunology] Male Middle Aged Recurrence PY - 1996 SE - al-Hemsi, B. Department of Surgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA. SN - 0902-0063 SP - 668-75 ST - Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization T2 - Clinical transplantation TI - Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=8996763 VL - 10 ID - 2028 ER - TY - JOUR AB - WHAT IS KNOWN AND OBJECTIVE: Physical bottle characteristics differ of brand name topical glaucoma medications and local generic equivalents. This study compares the bottle characteristics of international topical glaucoma brands versus local brands from the Kingdom of Saudi Arabia., METHODS: Data were collected on bottle drum volume, drop volume, bottle squeezability, bottle tip diameter, labels and instructions, cap color coding, and clarity of the drug label. Density-based calculations of drops in bottle volume were assessed using an analytic balance. Bottle tip diameter was measured using 0.05 mm Vernier calipers. A Likert scale-based questionnaire was used to evaluate the subjective opinions of patients on bottle squeezability, clarity of usage and storage instructions, and the consistency of the cap color coding., RESULTS: The volumes of international brands were statistically significantly higher than the local brands (P < 0.001). A number of drops per bottle and tip diameter were comparable between the international local brands. Cap color coding was inconsistent for international and local brands. Patients were dissatisfied with the label font size. Patients reported that the international and local brands were similar in terms of the ease of opening the bottle, instilling a drop, and the clarity of the instructions; but the local brands were subjectively easier to squeeze than international brands., WHAT IS NEW AND CONCLUSIONS: This is the first study to compare bottle characteristics of local Saudi Arabia brands with international brands. The bottle characteristics and patient feedback were similar between the local and international topical glaucoma medications. However, there were differences between the local and international brands in drug volume, bottle squeezability. Hence, patient compliance and drop dosage may differ based on the origin of manufacture. AU - Al-Jumaian, Nasser AU - Malik, Rizwan AU - Khandekar, Rajiv AU - Al-Humaidan, Abdullah AU - Al-Madany, Rana AU - Al-Qahtani, Reham AU - Altowairqi, Ahmed AU - Al-Theeb, Abdulwahab AU - Zaman, Babar AU - Al-Djasim, Leyla AU - Craven, E. Randy AU - Edward, Deepak P. IS - 4 KW - Administration, Topical Adolescent Adult Antihypertensive Agents/ad [Administration & Dosage] *Antihypertensive Agents/ch [Chemistry] *Drug Packaging/st [Standards] *Drugs, Generic/ch [Chemistry] Female *Glaucoma/dt [Drug Therapy] Humans Male Middle Aged Ophthalmic Solutions/ad [Administration & Dosage] *Ophthalmic Solutions/ch [Chemistry] *Prescription Drugs/ch [Chemistry] Prospective Studies Saudi Arabia Surveys and Questionnaires PY - 2016 SE - Al-Jumaian, Nasser. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Malik, Rizwan. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Khandekar, Rajiv. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Al-Humaidan, Abdullah. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Al-Madany, Rana. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Al-Qahtani, Reham. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Altowairqi, Ahmed. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Al-Theeb, Abdulwahab. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Zaman, Babar. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Al-Djasim, Leyla. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Craven, E Randy. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; Wilmer Eye Institute, Baltimore, Maryland, USA. Edward, Deepak P. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; Wilmer Eye Institute, Baltimore, Maryland, USA. SN - 0975-1599 0974-9233 SP - 296-301 ST - Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia T2 - Middle East African journal of ophthalmology TI - Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27994392 VL - 23 ID - 650 ER - TY - JOUR AB - Aqueous gels formulated using hydrophilic polymers (hydrogels) along with those based on stimuli responsive polymers (in situ gelling or gel forming systems) continue to attract increasing interest for various eye health-related applications. They allow the incorporation of a variety of ophthalmic pharmaceuticals to achieve therapeutic levels of drugs and bioactives at target ocular sites. The integration of sophisticated drug delivery technologies such as nanotechnology-based ones with intelligent and environment responsive systems can extend current treatment duration to provide more clinically relevant time courses (weeks and months instead of hours and days) which will inevitably reduce dose frequency, increase patient compliance and improve clinical outcomes. Novel applications and design of contact lenses and intracanalicular delivery devices along with the move towards integrating gels into various drug delivery devices like intraocular pumps, injections and implants has the potential to reduce comorbidities caused by glaucoma, corneal keratopathy, cataract, diabetic retinopathies and age-related macular degeneration. This review describes ophthalmic gelling systems with emphasis on mechanism of gel formation and application in ophthalmology. It provides a critical appraisal of the techniques and methods used in the characterization of ophthalmic preformed gels and in situ gelling systems along with a thorough insight into the safety and biocompatibility of these systems. Newly developed ophthalmic gels, hydrogels, preformed gels and in situ gelling systems including the latest in the area of stimuli responsive gels, molecularly imprinted gels, nanogels, 3D printed hydrogels; 3D printed devices comprising ophthalmic gels are covered. Finally, new applications of gels in the production of artificial corneas, corneal wound healing and hydrogel contact lenses are described. Copyright © 2017 Elsevier B.V. All rights reserved. AU - Al-Kinani, Ali A. AU - Zidan, Ghada AU - Elsaid, Naba AU - Seyfoddin, Ali AU - Alani, Adam W. G. AU - Alany, Raid G. DO - https://dx.doi.org/10.1016/j.addr.2017.12.017 KW - Drug Delivery Systems Gels/pd [Pharmacology] Humans *Ophthalmic Solutions/pd [Pharmacology] Polymers/pd [Pharmacology] Printing, Three-Dimensional *Wound Healing/de [Drug Effects] PY - 2018 SE - Al-Kinani, Ali A. Drug Discovery, Delivery and Patient Care (DDDPC) Research Theme, Kingston University London, School of Life Sciences, Pharmacy and Chemistry, Kingston Upon Thames KT1 2EE, UK. Zidan, Ghada. Drug Delivery Research Group, School of Science, Auckland University of Technology, Auckland, New Zealand. Elsaid, Naba. Anglia Ruskin University, Bishop Hall Lane, Chelmsford CM1 1SQ, UK. Seyfoddin, Ali. Drug Delivery Research Group, School of Science, Auckland University of Technology, Auckland, New Zealand; School of Interprofessional Health Studies, Auckland University of Technology, Auckland, New Zealand. Alani, Adam W G. Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR, United States; Department of Biomedical Engineering, School of Medicine, Oregon Health & Sciences University, Portland, OR, United States. Alany, Raid G. Drug Discovery, Delivery and Patient Care (DDDPC) Research Theme, Kingston University London, School of Life Sciences, Pharmacy and Chemistry, Kingston Upon Thames KT1 2EE, UK; School of Pharmacy, The University of Auckland, Auckland, New Zealand. Electronic address: r.alany@kingston.ac.uk. SN - 1872-8294 0169-409X SP - 113-126 ST - Ophthalmic gels: Past, present and future T2 - Advanced drug delivery reviews TI - Ophthalmic gels: Past, present and future UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29288733 VL - 126 Y2 - 20171227// ID - 463 ER - TY - JOUR AB - The Saudi Initiative for Asthma (SINA) provides up-to-date guidelines for healthcare workers managing patients with asthma. SINA was developed by a panel of Saudi experts with respectable academic backgrounds and long-standing experience in the field. SINA is founded on the latest available evidence, local literature, and knowledge of the current setting in Saudi Arabia. Emphasis is placed on understanding the epidemiology, pathophysiology, medications, and clinical presentation. SINA elaborates on the development of patient-doctor partnership, self-management, and control of precipitating factors. Approaches to asthma treatment in SINA are based on disease control by the utilization of Asthma Control Test for the initiation and adjustment of asthma treatment. This guideline is established for the treatment of asthma in both children and adults, with special attention to children 5 years and younger. It is expected that the implementation of these guidelines for treating asthma will lead to better asthma control and decrease patient utilization of the health care system. AD - M. Al-Moamary, P. O. Box 106911, Riyadh 11676, Saudi Arabia AU - Al-Moamary, M. AU - Al-Hajjaj, M. AU - Idrees, M. AU - Zeitouni, M. AU - Alanezi, M. AU - Al-Jahdal, H. AU - Al Dabbagh, M. C1 - seretide symbicort DB - Embase DO - 10.4103/1817-1737.56001 IS - 4 KW - acetylsalicylic acid allergen antihistaminic agent beclometasone beta 2 adrenergic receptor stimulating agent budesonide budesonide plus formoterol cholinergic receptor blocking agent ciclesonide corticosteroid fluticasone propionate fluticasone propionate plus salmeterol formoterol glucocorticoid hydrocortisone ipratropium bromide leukotriene receptor blocking agent long acting drug magnesium sulfate methylprednisolone montelukast nonsteroid antiinflammatory agent omalizumab prednisolone prednisone salbutamol salmeterol short acting drug theophylline unindexed drug add on therapy adrenal insufficiency desensitization allergic asthma allergic reaction anaphylaxis asthma bitter taste cataract clinical feature clinical protocol continuous infusion diabetes mellitus disease control disease exacerbation doctor patient relationship drug dose reduction drug dose regimen drug efficacy drug fatality drug hypersensitivity drug indication drug safety drug tolerability dysphonia evidence based practice exercise induced asthma fetus disease gastrointestinal symptom glaucoma headache health care organization health care personnel health care utilization heart arrhythmia human hypertension hypokalemia immunotherapy influenza vaccination injection site contusion injection site pain low drug dose medical literature muscle cramp muscle weakness nausea obesity oropharynx candidiasis osteoporosis pathophysiology patient education practice guideline review risk factor risk reduction Saudi Arabia Saudi Initiative for Asthma seizure self care side effect single drug dose skin disease skin thinning tachycardia thrush treatment outcome tremor unspecified side effect vomiting xerostomia seretide symbicort LA - English M3 - Review N1 - L355416084 2009-12-09 PY - 2009 SN - 1817-1737 1998-3557 SP - 216-233 ST - The Saudi initiative for asthma T2 - Annals of Thoracic Medicine TI - The Saudi initiative for asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355416084&from=export http://dx.doi.org/10.4103/1817-1737.56001 VL - 4 ID - 3329 ER - TY - JOUR AB - This an updated guidelines for the diagnosis and management of asthma, developed by the Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi Thoracic Society. The main objective of SINA is to have updated guidelines, which are simple to understand and easy to use by non-asthma specialists, including primary care and general practice physicians. This new version includes updates of acute and chronic asthma management, with more emphasis on the use of Asthma Control Test in the management of asthma, and a new section on "difficult-to-treat asthma." Further, the section on asthma in children was re-written to cover different aspects in this age group. The SINA panel is a group of Saudi experts with well-respected academic backgrounds and experience in the field of asthma. The guidelines are formatted based on the available evidence, local literature, and the current situation in Saudi Arabia. There was an emphasis on patient-doctor partnership in the management that also includes a self-management plan. The approach adopted by the SINA group is mainly based on disease control as it is the ultimate goal of treatment. AD - M.S. Al-Moamary, Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia AU - Al-Moamary, M. S. AU - Alhaider, S. A. AU - Al-Hajjaj, M. S. AU - Al-Ghobain, M. O. AU - Idrees, M. M. AU - Zeitouni, M. O. AU - Al-Harbi, A. S. AU - Al Dabbagh, M. M. AU - Al-Matar, H. AU - Alorainy, H. S. C1 - aspirin seretide symbicort DB - Embase DO - 10.4103/1817-1737.102166 IS - 4 KW - acetylsalicylic acid alkane allergen beclomethasone dipropionate beta 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bronchodilating agent budesonide budesonide plus formoterol chlorofluorocarbon cholinergic receptor blocking agent ciclesonide corticosteroid fluticasone propionate fluticasone propionate plus salmeterol xinafoate formoterol hydrocortisone hydrofluroalkane ipratropium bromide leukotriene receptor blocking agent methylprednisolone nonsteroid antiinflammatory agent omalizumab prednisolone salbutamol salmeterol steroid theophylline tiotropium bromide unclassified drug unindexed drug add on therapy adrenal insufficiency adult aerosol air pollutant air pollution allergic asthma ambient air anamnesis anaphylaxis article aspirin exacerbated respiratory disease asthma Asthma Control Test bitter taste breath-actuated inhaler cataract child Childhood Asthma Control Test corticosteroid induced osteoporosis cost effectiveness analysis cough variant asthma coughing device safety diabetes mellitus diagnostic test disease exacerbation disease severity drug delivery system drug efficacy drug fatality drug formulation drug intermittent therapy drug megadose dysphonia dyspnea education program evidence based practice exercise induced asthma gastroesophageal reflux gastrointestinal symptom glaucoma heart arrhythmia hospital care human hypertension immunotherapy influenza vaccination inhalation spacer inhalation test inhaler injection site contusion injection site pain intensive care low drug dose maintenance therapy medical nebulizer metered dose inhaler muscle weakness nausea and vomiting obesity occupational asthma occupational exposure oropharynx candidiasis outpatient care oxygen therapy patient compliance patient education phenotype physical examination powder inhaler practice guideline predictive value pregnancy pressurized metered dose inhaler questionnaire randomized controlled trial (topic) recommended drug dose Respiratory and Asthma Control in Kids Test risk assessment risk reduction scoring system seizure side effect skin manifestation skin thinning spirometry thorax radiography treatment planning treatment response wheezing xerostomia aspirin seretide symbicort LA - English M3 - Article N1 - L366139546 2012-12-05 2012-12-12 PY - 2012 SN - 1817-1737 1998-3557 SP - 175-204 ST - The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and children T2 - Annals of Thoracic Medicine TI - The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and children UR - https://www.embase.com/search/results?subaction=viewrecord&id=L366139546&from=export http://dx.doi.org/10.4103/1817-1737.102166 VL - 7 ID - 3063 ER - TY - JOUR AB - Purpose: To evaluate learning effects with respect to outcomes of a microinvasive glaucoma stent (MIGS) inserted during cataract surgery in glaucoma patients. Patients and Methods: Single surgeon, observational cohort study of 25 consecutive Ivantis Hydrus microstent insertions, with a minimum follow-up of 12 months. A learning curve analysis was performed by assessing hypotensive effect, adverse effects, and surgical procedure duration, with respect to consecutive case number. Success was defined with respect to various intraocular pressure (IOP) targets (21, 18, 15mmHg) and reduction in required antiglaucoma medications. Complete success was defined as achieving target IOP without antiglaucoma therapy. Results: No clinically significant adverse events or learning effects were identified, although surgical time reduced with consecutive case number. Mean follow-up was 16.8 months. At final follow-up the mean IOP for all eyes was reduced from 18.1 (+/- 3.6) mm Hg [and a simulated untreated value of 25.9 (+/- 5.2) mm Hg] to 15.3 (+/- 2.2) mm Hg (P = 0.007; < 0.0001) and the mean number of topical antiglaucoma medications was reduced from 1.96 (+/- 0.96) to 0.04 (+/- 0.20) (P < 0.0001). Complete success (IOP < 21 mm Hg, no medications) was 96% at final follow- up. Complete success (IOP < 18 mm Hg, no medications) was 80% at final follow-up, but only 32% with a target IOP of < 15 mm Hg (no medications). Conclusions: No significant learning curve effects were observed for a trained surgeon with respect to MIGS microstent insertion performed at the time of cataract surgery. Adjunctive MIGS surgery was successful in lowering IOP to <18 mm Hg and reducing/abolishing the requirement for antiglaucoma medication in eyes with open-angle glaucoma, but less successful at achieving low IOP levels (< 15 mm Hg). AN - WOS:000404661900008 AU - Al-Mugheiry, T. S. AU - Cate, H. AU - Clark, A. AU - Broadway, D. C. DA - JUL DO - 10.1097/IJG.0000000000000691 IS - 7 PY - 2017 SN - 1057-0829 1536-481X SP - 646-651 ST - Microinvasive Glaucoma Stent (MIGS) Surgery With Concomitant Phakoemulsification Cataract Extraction: Outcomes and the Learning Curve T2 - JOURNAL OF GLAUCOMA TI - Microinvasive Glaucoma Stent (MIGS) Surgery With Concomitant Phakoemulsification Cataract Extraction: Outcomes and the Learning Curve VL - 26 ID - 6010 ER - TY - JOUR AB - PURPOSE: The current study aims to know the glaucoma diagnoses and legal blindness from glaucoma among a tertiary referral center in Riyadh (King Abdulaziz Medical City [KAMC]-Riyadh patients). METHODS: This is a retrospective cohort study on chart review, where all eligible glaucoma patients attending the ophthalmology clinic at KAMC-Riyadh, between 2018 and 2019; were included. RESULTS: A total of 248 patients were included in the study; 142 patients (57.3%) were females and 106 (42.7%) were males. The mean age of the patients was 62.2 +/- 18 years and most of them (93.5%) did not have a family history of glaucoma. Nearly one-quarter (26.6%; n = 66) of the included patients were legally blind, out of those, 36.4% had their right eye affected, 34.8% had their left eye affected, and 28.8% had both eyes affected. Legally, blind patients (LBGs) did not show a statistically significant reduction in the intraocular pressure (IOP) in the right eye (P = 0.103), on comparing the IOP in both visits. Nevertheless, there was a statistically significant reduction in the IOP of the left eye among the LBGs in both visits (P = 0.016). Regarding the nonblind group of patients, there were highly statistically significant reductions in both eyes (P < 0.001). CONCLUSION: The present findings show a high prevalence rate of legal blindness among glaucoma patients, with IOP reduction, age, and glaucoma diagnoses being the most important predictors among the study population. AN - WOS:000647105300006 AU - Al-Najmi, Y. AU - Kirat, O. AU - Elsayed, M. A. AU - Albeedh, M. AU - Al-Rashed, D. AU - Al-Mohammed, A. DA - JAN-MAR DO - 10.4103/meajo.MEAJO_77_21 IS - 1 PY - 2021 SN - 0974-9233 0975-1599 SP - 29-35 ST - Glaucoma Diagnoses and Legal Blindness from Glaucoma among Bedouin Patients of Central Saudi Arabia: A Hospital-Based Study T2 - MIDDLE EAST AFRICAN JOURNAL OF OPHTHALMOLOGY TI - Glaucoma Diagnoses and Legal Blindness from Glaucoma among Bedouin Patients of Central Saudi Arabia: A Hospital-Based Study VL - 28 ID - 6048 ER - TY - JOUR AB - Purpose: To study clinical and histopathological findings of corneal opacification caused by thickened epithelium leading to reduced vision and topographical changes and to evaluate the outcome of its removal., Methods: Twelve patients (17 eyes) with central, paracentral or peripheral corneal opacification were reviewed to obtain their visual acuity, describe their slit lamp (SL) appearance (depth, extent and density) and document their topographic changes before and after peeling of the epithelium under SL or surgical removal under the microscope. Specimens of six cases were available for histopathological examination and immunohistochemical staining., Results: Most of the eye opacifications were secondary to corneal procedures in 10 [Penetrating keratoplasty (PKP) in 7 for congenital glaucoma, keratoconus or adherent leukoma - usually over graft-host junction -, Photorefractive keratectomy (PRK) in 2 and Phototherapeutic keratectomy in one], chronic inflammation following trachoma or non-specific causes (3), and herpetic scar (1). Three cases were considered to be idiopathic. All cases presented with decreased vision, astigmatism or changes in topography or refraction. Their vision, clinical symptoms and topography improved after treatment. Histopathologically, all six cases shared findings that are similar to what have been described as peripheral hypertrophic subepithelial corneal degeneration (PHSCD) rather than Salzmann's nodular degeneration. None of the cases showed inflammation or subepithelial pannus formation in the excised tissue. However, our cases did not fit into the diagnosis of PHSCD because of the location of the corneal opacification (being peripheral in 41% of the corneas, the presence of underlying primary etiologic factors in 82% of the eyes and the bilateral occurrence in 5 patients., Conclusions: Meticulous SL examination aided by corneal imaging may accurately diagnose and determine the depth of corneal opacification as a cause for reduced vision. Histopathologically, the removed tissue is similar to PHSCD, but cases differ in their clinical profile. Peeling the thickened epithelial/subepithelial tissue is curative in most patients, improves visual and clinical outcome and avoids unnecessary corneal grafting. Copyright © 2019 Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University. AU - Al-Rajhi, A. A. AU - Helmi, H. A. AU - Alkatan, H. M. AU - Al-Obailan, M. AU - Al-Rajhi, A. DO - https://dx.doi.org/10.1016/j.sjopt.2019.02.002 IS - 3 PY - 2019 SE - Al-Rajhi, A A. Ophthalmology Resident, PSMMC, Riyadh, Saudi Arabia. Helmi, H A. Alfaisal University, Riyadh, Saudi Arabia. Alkatan, H M. Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Alkatan, H M. Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Al-Obailan, M. Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Al-Rajhi, A. Specialized Experts Center, Riyadh, Saudi Arabia. Al-Rajhi, A. College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. SN - 1319-4534 SP - 203-208 ST - Successful Treatment of Corneal Opacification with Associated Thickened Epithelium by Simple Peeling: Acquired Corneal Subepithelial Hypertrophy (ACSH) T2 - Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society TI - Successful Treatment of Corneal Opacification with Associated Thickened Epithelium by Simple Peeling: Acquired Corneal Subepithelial Hypertrophy (ACSH) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=31686959 VL - 33 Y2 - 20190213// ID - 577 ER - TY - JOUR AB - To determine the most common causes of blindness and the age of onset of these conditions among Jordanians of Irbid, a study of all registered members in two societies for the care of the blind was carried out. Of all registered members, 185 individuals were blind according to the World Health Organization definition and satisfied our inclusion criteria. It was found that genetically determined causes made up 41% of the total causes. In 57% of the subjects, blindness occurred in the first two decades of life. The specific leading causes of blindness, in the order of their frequencies, were tapetoretinal degenerations as different variants of retinitis pigmentosa (17.6%), glaucomas (16%), diabetic retinopathy (13%), post-infection corneal scarring (11.5%), congenital cataract (8.8%) and uveitis (8%). The results reflect the satisfactory achievements in primary health care levels and the challenge to make specialized tertiary health care more accessible. AD - M. Al-Salem, Yarmouk University, PO Box 4955, 211-63 Irbid, Jordan AU - Al-Salem, M. AU - Arafat, A. F. AU - Ismail, L. AU - Jaradat, M. DB - Embase DO - 10.5144/0256-4947.1996.420 IS - 4 KW - adolescent adult aged article blindness congenital cataract diabetic retinopathy female genetic disorder glaucoma health care access health care quality human Jordan major clinical study male onset age primary health care priority journal retinitis pigmentosa scar formation school child uveitis LA - English M3 - Article N1 - L26293617 1996-09-24 PY - 1996 SN - 0256-4947 SP - 420-423 ST - Causes of blindness in Irbid, Jordan T2 - Annals of Saudi Medicine TI - Causes of blindness in Irbid, Jordan UR - https://www.embase.com/search/results?subaction=viewrecord&id=L26293617&from=export http://dx.doi.org/10.5144/0256-4947.1996.420 VL - 16 ID - 3972 ER - TY - JOUR AB - PURPOSE: To define the main causes of blindness, demographic characteristics and barriers to care of blind patients attending a teaching eye hospital in Iraq., MATERIAL AND METHOD: Successive new patients, 6 years of age and older, who attended three outpatients clinics at Ibn Al-Haetham Teaching Eye Hospital (IAHTEH), Baghdad, Iraq, from September 1 to November 30, 2007, were included in this study. Inclusion criterion was fulfillment of the World Health Organization's definition of blindness. The cause of blindness was identified and subjects were interviewed for collection of data on demographic characteristics and barriers to treatment., RESULTS: Of 18612 consecutive patients who attended the outpatient clinics, 497 (2.7%) patients were blind. Cataract (76.1%), diabetic retinopathy (12.9%), and glaucoma (5%) were the leading causes of blindness. The majority of blind patients had low socioeconomic status and poor educational level. In cases of cataract, the most important barrier to treatment was the waiting list at the hospital (53.7%). A lack of awareness was the most important barrier to treatment for patients with diabetic retinopathy (54.7%) and glaucoma (56%)., CONCLUSIONS: The preliminary data from our study will aid in the development of blindness prevention programs in Iraq. Priorities include decreasing waiting lists for cataract surgeries at governmental hospitals. Active health promotion programs for early detection and treatment of diabetic retinopathy and glaucoma are also warranted. AU - Al-Shakarchi, Faiz I. DO - https://dx.doi.org/10.4103/0974-9233.84044 IS - 3 PY - 2011 SE - Al-Shakarchi, Faiz I. Department of Ophthalmology Medical College, Research Unit, Ibn Al-Haetham Teaching Eye Hospital, Al-Mustanserya University, Baghdad, Iraq. SN - 0975-1599 0974-9233 SP - 199-203 ST - Blindness in iraq: leading causes, target patients, and barriers to treatment T2 - Middle East African journal of ophthalmology TI - Blindness in iraq: leading causes, target patients, and barriers to treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=21887073 VL - 18 ID - 1199 ER - TY - JOUR AB - The ophthalmic rod (OR) is a new ophthalmic drug-delivery system. The rod is made of nontoxic plastic. The active substance is deposited as a thin film on the end of the rod. To deliver the drug, the tip of the rod is introduced into the conjunctival sac and rubbed against the palpebral conjunctiva of the lower lid. The OR is a single-dose sterile applicator. By using the OR the problems of preservation and sterility of eyedrops are eliminated, and the risk of cross-infection is avoided. This was an open uncontrolled study. Clonidine ORs were used by 15 patients with glaucoma for 12 days. Fluorescein ORs were used for tonometry and to check the safetness of using the ORs. Patients with dry eyes or scotoma were excluded from the study. The clonidine film remaining on the ORs after delivery was quantitatively analyzed. A dose of 20 micrograms clonidine rod, three ORs/day, was sufficient to keep the ocular pressure under control. The fluorescin ORs, 30 micrograms/rod, were satisfactory for coloring the cornea. On the last day (12th) no clinically apparent side effects were observed. Subjectively, the patients were satisfied with the OR method of application, as an alternative to eyedrops. AU - Alani, S. D. AU - Hammerstein, W. IS - 4 KW - Adult Aged Aged, 80 and over Clinical Trials as Topic *Clonidine/ad [Administration & Dosage] Clonidine/tu [Therapeutic Use] Conjunctiva/de [Drug Effects] Female Fluorescein Fluoresceins/ad [Administration & Dosage] *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Male Middle Aged Patient Acceptance of Health Care Plastics Safety Tonometry, Ocular PY - 1990 SE - Alani, S D. Universitats-Augenklinik, Dusseldorf, Federal Republic of Germany. SN - 0721-832X SP - 302-4 ST - The ophthalmic rod--a new drug-delivery system II T2 - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie TI - The ophthalmic rod--a new drug-delivery system II UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2205545 VL - 228 ID - 2148 ER - TY - JOUR AU - Alany, R. DB - Embase Medline DO - 10.1080/10837450.2018.1427530 IS - 3 KW - eye bandage aceclofenac agents acting on the eye antifungal agent antiinfective agent brimonidine dexamethasone metoclopramide microbicide nanocarrier nose spray silver steroid sucrose tenofovir aerosol aqueous humor bioavailability cataract choroid clinical evaluation conjunctiva cornea cornea disease drug absorption drug administration route drug delivery system drug exposure drug formulation dry powder editorial endoscopic sinus surgery gastrointestinal tract gel glaucoma human Human immunodeficiency virus infection in vivo study inflammation intranasal drug administration intraocular drug administration intravaginal drug administration lens life threat macular degeneration ointment optic nerve otic drug administration otitis media patient compliance pharmacokinetic parameters priority journal rectal drug administration retina macula lutea sclera sexually transmitted disease suppository uvea World Health Organization LA - English M3 - Editorial N1 - L620390724 2018-02-02 2018-08-20 PY - 2018 SN - 1097-9867 1083-7450 SP - 217 ST - Ocular, otic, nasal, rectal and vaginal formulation innovations and regulatory considerations T2 - Pharmaceutical Development and Technology TI - Ocular, otic, nasal, rectal and vaginal formulation innovations and regulatory considerations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620390724&from=export http://dx.doi.org/10.1080/10837450.2018.1427530 VL - 23 ID - 2601 ER - TY - JOUR AD - R.G. Alany, Dept. of Pharmaceutics, School of Pharmacy and Chemistry, Kingston University London, Kingston upon Thames, United Kingdom AU - Alany, R. G. DB - Embase Medline DO - 10.1185/03007995.2013.818968 IS - 9 KW - bimatoprost closed angle glaucoma comparative study conjunctival hyperemia drug cost drug formulation geriatric patient human intraocular pressure medication compliance non insulin dependent diabetes mellitus nursing home open angle glaucoma optic nerve lesion patient compliance prescription pruritus randomized controlled trial (topic) review sleep disorder visual field LA - English M3 - Review N1 - L369629903 2013-08-30 2013-09-04 PY - 2013 SN - 0300-7995 1473-4877 SP - 1187-1189 ST - Adherence, persistence and cost-consequence comparison of bimatoprost topical ocular formulations T2 - Current Medical Research and Opinion TI - Adherence, persistence and cost-consequence comparison of bimatoprost topical ocular formulations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369629903&from=export http://dx.doi.org/10.1185/03007995.2013.818968 VL - 29 ID - 2972 ER - TY - JOUR AB - BACKGROUND: Current visual field screening machines are bulky and expensive, limiting their accessibility, affordability and use. We report the design and evaluation of a novel, portable, cost-effective system for glaucoma screening using smartphone-based visual field screening using frequency doubling technology (FDT) and a head-mounted display., METHODS: Nineteen eyes of 10 subjects with new-onset or chronic primary open angle glaucoma were tested and compared with the Humphrey Zeiss FDT and the newly developed Mobile Virtual Perimetry (MVP) FDT with the C-20 testing pattern. Mann-Whitney, Bland-Altman and linear regression analyses were performed to assess statistical difference, agreement and correlation, respectively, between the two devices., RESULTS: The average age of the participants was 58+/-15 years. No statistically significant difference was found between the MVP FDT and the Humphrey Zeiss FDT (p>0.05). Bland-Altman and linear regression analyses demonstrated good agreement and correlation between the two devices., CONCLUSION: The MVP FDT is a low-cost, portable visual field screening device that produces comparable results to the Humphrey Zeiss FDT and may be used as an easily accessible screening tool for glaucoma. Copyright © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. AU - Alawa, Karam AlRahman AU - Nolan, Ryan P. AU - Han, Elaine AU - Arboleda, Alejandro AU - Durkee, Heather AU - Sayed, Mohamed S. AU - Aguilar, Mariela C. AU - Lee, Richard K. DO - https://dx.doi.org/10.1136/bjophthalmol-2019-314031 IS - 3 KW - Equipment Design Female *Glaucoma, Open-Angle/di [Diagnosis] Glaucoma, Open-Angle/pp [Physiopathology] Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged *Smartphone *Visual Field Tests/is [Instrumentation] *Visual Fields/ph [Physiology] PY - 2021 SE - Alawa, Karam AlRahman. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Nolan, Ryan P. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Han, Elaine. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Arboleda, Alejandro. Ophthalmic Biophysics Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Durkee, Heather. Ophthalmic Biophysics Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Sayed, Mohamed S. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Aguilar, Mariela C. Ophthalmic Biophysics Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Lee, Richard K. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA RLee@med.miami.edu. SN - 1468-2079 0007-1161 SP - 440-444 ST - Low-cost, smartphone-based frequency doubling technology visual field testing using a head-mounted display T2 - The British journal of ophthalmology TI - Low-cost, smartphone-based frequency doubling technology visual field testing using a head-mounted display UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31530566 VL - 105 Y2 - 20190917// ID - 169 ER - TY - JOUR AB - Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options. AD - T.A. Albini, 111 Huntington Avenue, 14th Floor, Boston, MA, United States AU - Albini, T. A. AU - Rice, J. B. AU - White, A. G. AU - Johnson, M. AU - Reiff, J. AU - Lima, A. F. AU - Bartels-Peculis, L. AU - Ciepielewska, G. AU - Nelson, W. W. DB - Embase Medline DO - 10.1080/09273948.2018.1560476 IS - 1 KW - adult article blindness cataract cohort analysis controlled study economic aspect eye disease eye inflammation female glaucoma health care cost health care utilization human macular degeneration major clinical study male medically uninsured middle aged non infectious inflammatory eye disease retina detachment unemployment United States visual disorder LA - English M3 - Article N1 - L626601572 2019-03-08 PY - 2020 SN - 1744-5078 0927-3948 SP - 164-174 ST - Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States T2 - Ocular Immunology and Inflammation TI - Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626601572&from=export http://dx.doi.org/10.1080/09273948.2018.1560476 VL - 28 ID - 2435 ER - TY - JOUR AB - AIMS: To investigate changes in the mechanical compliance of ex vivo human lamina cribrosa with age., METHODS: A laser scanning confocal microscope was used to image the surface of the fluorescently labelled lamina cribrosa in cadaver eyes. A method was developed to determine changes in the volume and strain of the lamina cribrosa created by increases in pressure. The ability of the lamina cribrosa to reverse its deformation on removal of pressure was also measured., RESULTS: Volume and strain measurements both demonstrated that the lamina cribrosa increased in stiffness with age and the level of pressure applied. The ability of the lamina cribrosa to regain its original shape and size on removal of pressure appeared to decrease with age, demonstrating an age related decrease in resilience of the lamina cribrosa., CONCLUSIONS: The mechanical compliance of the human lamina cribrosa decreased with age. Misalignment of compliant cribriform plates in a young eye may exert a lesser stress on nerve axons, than that exerted by the rigid plates of an elderly lamina cribrosa. The resilience of the lamina cribrosa also decreased with age, suggesting an increased susceptibility to plastic flow and permanent deformation. Such changes may be of importance in the explanation of age related optic neuropathy in primary open angle glaucoma. AU - Albon, J. AU - Purslow, P. P. AU - Karwatowski, W. S. AU - Easty, D. L. IS - 3 KW - Adolescent Adult Aged Aged, 80 and over *Aging/ph [Physiology] Child Compliance Glaucoma, Open-Angle/pp [Physiopathology] Humans Microscopy, Confocal Middle Aged *Optic Disk/ph [Physiology] Optic Disk/pp [Physiopathology] Pressure Rheology PY - 2000 SE - Albon, J. Department of Optometry and Vision Science, Cardiff University, Cardiff, UK. SN - 0007-1161 SP - 318-23 ST - Age related compliance of the lamina cribrosa in human eyes T2 - The British journal of ophthalmology TI - Age related compliance of the lamina cribrosa in human eyes UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10684845 VL - 84 ID - 1952 ER - TY - JOUR AB - Orbital lymphoma can result in rapid loss of vision if not diagnosed and treated in a timely manner. This patient presented with rapid visual loss and on examination had a rubeosis iridis with a hyphema as well as neovascular glaucoma with vitreous hemorrhage. His medical history included systemic diffuse large B-cell lymphoma and a workup ultimately revealed an orbital mass in the body of the optic nerve. Optic nerve biopsy demonstrated diffuse large B-cell lymphoma. To the authors' knowledge, neovascular glaucoma as the presentation of an extraocular diffuse large B-cell lymphoma has not been reported previously. Lymphomas of the orbit and its adnexa constitute roughly 1% of all non-Hodgkin lymphoma. Most cases are marginal-zone B-cell lymphomas, with the second most common being diffuse large B-cell lymphomas. Orbital lymphomas can rapidly progress to complete visual loss when not diagnosed early. The authors report a patient who presented with rapid visual loss due to hyphema, rubeosis iridis, neovascular glaucoma and vitreous hemorrhage secondary to orbital diffuse large B-cell lymphoma. Research methods were adherent to the ethical principles outlined in the Declaration of Helsinki as amended in 2013. The collection and evaluation of protected patient health information was Health Insurance Portability and Accountability Act compliant. The authors report a case of lymphoma metastatic to the optic nerve masquerading as neovascular glaucoma with vitreous hemorrhage. AU - Aldaas, Khalid M. AU - Randall, Cara AU - Eftekhari, Kian AU - Zhang, Alice Y. DO - https://dx.doi.org/10.1097/IOP.0000000000001498 IS - 1 KW - Glaucoma, Neovascular/di [Diagnosis] Glaucoma, Neovascular/et [Etiology] *Glaucoma, Neovascular Humans *Lymphoma, B-Cell, Marginal Zone Lymphoma, Large B-Cell, Diffuse/di [Diagnosis] *Lymphoma, Large B-Cell, Diffuse Orbit Orbital Neoplasms/di [Diagnosis] *Orbital Neoplasms PY - 2020 SE - Aldaas, Khalid M. Department of Ophthalmology. Randall, Cara. Department of Pathology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, U.S.A. Eftekhari, Kian. Department of Ophthalmology. Zhang, Alice Y. Department of Ophthalmology. SN - 1537-2677 0740-9303 SP - e12-e13 ST - Orbital Diffuse Large B-Cell Lymphoma Initially Presenting as Neovascular Glaucoma T2 - Ophthalmic plastic and reconstructive surgery TI - Orbital Diffuse Large B-Cell Lymphoma Initially Presenting as Neovascular Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31593042 VL - 36 ID - 219 ER - TY - JOUR AB - PURPOSE: To describe the variations in intraoperative technique, postoperative complications, and visual outcomes associated with Descemet stripping endothelial keratoplasty (DSEK) after Ophtec iris reconstruction lens implantation., DESIGN: Retrospective, interventional, consecutive case series., PARTICIPANTS: Patients who underwent DSEK after Ophtec 311 iris reconstruction lens implantation at the Jules Stein Eye Institute, University of California, Los Angeles., METHODS: Medical records were reviewed for demographic information, ophthalmic history, DSEK surgical technique, and postoperative clinical course., MAIN OUTCOME MEASURES: Intraoperative and postoperative complications and visual outcomes., RESULTS: Four patients were identified (1 man and 3 women, age: 43-78). Three of the eyes had undergone prior penetrating keratoplasty (PKP), and each of the eyes had a history of glaucoma, with previous glaucoma surgery having been performed in 2 of the eyes. No intraoperative complications were encountered during the procedures, although an unplanned anterior vitrectomy was required in a previously vitrectomized eye. In each case, a complete air fill of the globe was obtained to ensure adherence of the donor button, and in 3 of the 4 cases, the donor button was sutured to the recipient cornea to prevent potential posterior dislocation. None of the cases developed donor button dislocation or primary graft failure. Corrected distance visual acuities improved to 20/40-20/160, corresponding to a mean improvement of 0.25 (range, 0.12-0.40), limited by irregular corneal astigmatism and advanced glaucomatous optic neuropathy. During a mean follow-up period of 15.6 months (range, 4.9-24.8 months), graft rejection developed in 2 of the 3 eyes with a history of endothelial rejection after PKP (0.42 episode per eye-year). Both of these eyes developed secondary graft failure, which also developed 14 months after DSEK in the other eye with a history of PKP failure before DSEK., CONCLUSIONS: DSEK can be successfully performed in eyes with partial or complete aniridia, such as those after Ophtec iris reconstruction lens implantation. Modifications to the standard DSEK technique increase the probability of successful donor adherence and decrease the risk of posterior dislocation of the donor corneal button. However, endothelial rejection may occur at an increased frequency, resulting in secondary graft failure. AU - Aldave, Anthony J. AU - Baghdasaryan, Elmira AU - Miller, Kevin M. DO - https://dx.doi.org/10.1097/ICO.0b013e3181f237c4 IS - 4 KW - Adult Aged Corneal Edema/su [Surgery] *Descemet Stripping Endothelial Keratoplasty Female Graft Rejection/su [Surgery] Humans Intraoperative Complications *Iris Diseases/rh [Rehabilitation] *Lens Implantation, Intraocular Male Middle Aged Postoperative Care Postoperative Complications Prosthesis Design Retrospective Studies Sclerostomy Surgical Flaps Visual Acuity/ph [Physiology] PY - 2011 SE - Aldave, Anthony J. Jules Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA. aldave@jsei.ucla.edu SN - 1536-4798 0277-3740 SP - 405-8 ST - Descemet stripping endothelial keratoplasty after Ophtec 311 iris reconstruction lens implantation T2 - Cornea TI - Descemet stripping endothelial keratoplasty after Ophtec 311 iris reconstruction lens implantation UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21045643 VL - 30 ID - 1307 ER - TY - JOUR AB - OBJECTIVES: Geriatric patients can be non-adherent to ophthalmic glaucoma medications because of complex eye drops instillation techniques and forgetfulness, so pharmacists can play their part in improving the clinical outcomes of patients by acting as care providers. The purpose of the current study was to implement various pharmacist-led interventions to improve adherence to glaucoma medications and to evaluate the outcomes of interventions in the geriatric population., METHODS: The Morisky Green Levine (MGL) adherence scale was used for analysis because it measures the extent of non-adherence and analyses the reasons for it. The interview-based sessions were conducted with control and interventional groups followed by educational interventions, including techniques for eye drop instillation, graphical images, precautionary measures, and individual patient counselling for the interventional group. Patients were asked to complete the adherence scale after the conclusion of every follow-up session for a duration of 6 months., RESULTS: After 6 months of pharmacist-led interventions, a significant shift was found in the interventional group from low to high adherence according to MGL scale evaluation. Moreover, the number of patients in the interventional group whose intraocular pressure was in the safe range significantly increased and follow-up sessions significantly improved the patient's knowledge about glaucoma., CONCLUSION: The results of this pharmacist-led educational interventional study showed it was effective in improving adherence to glaucoma medications in the geriatric patients, who showed better adherence scores and improved intraocular pressure. Copyright © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ. AU - Aleem, Ayesha AU - Amin, Fatima AU - Asim, Mulazim Hussain AU - Farooq, Nayab AU - Arshad, Shumaila AU - Raziq, Mairah DO - https://dx.doi.org/10.1136/ejhpharm-2021-002788 PY - 2021 SE - Aleem, Ayesha. Lahore College for Women University, Lahore, Pakistan. Amin, Fatima. Lahore College for Women University, Lahore, Pakistan. Asim, Mulazim Hussain. Department of Pharmaceutics, University of Sargodha, Sargodha, Pakistan mulazim.hussain@uos.edu.pk. Farooq, Nayab. Lahore College for Women University, Lahore, Pakistan. Arshad, Shumaila. The University of Lahore, Lahore, Pakistan. Raziq, Mairah. Department of Pharmacy, District Head Quarter Hospital, Chiniot, Pakistan. SN - 2047-9956 ST - Impact of pharmacist-led interventions in improving adherence to glaucoma medications in the geriatric population T2 - European journal of hospital pharmacy : science and practice TI - Impact of pharmacist-led interventions in improving adherence to glaucoma medications in the geriatric population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=34233905 Y2 - 20210707// ID - 7 ER - TY - JOUR AB - PURPOSE: To determine the incidence of progression of primary open-angle glaucoma at individual levels of mean intraocular pressure (IOP) in patients in Ethiopia., METHODS: A retrospective, multicenter, cohort analysis of patient records with at least 5 years of potential follow-up were evaluated for risk factors associated with progressive optic disc and visual field loss., RESULTS: There were 300 patients with the potential of 5 years of follow-up. In total, 166 patients progressed before 5 years and 134 remained stable for the full 5-year follow-up period. Of the total sample, 84% of patients with IOPs or =25 mmHg (n=0/79) remained stable over at least 5 years. The mean IOP was 17.4+/-2.1 in the stable group and 25.0+/-5.9 mmHg in the progressed group (p<0.0001). The highest average peak IOP was 24.5+/-4.5 in the stable group and 29.0+/-6.1 mmHg in the progressed group (p<0.0001). A multivariant regression analysis to determine risk factors for progression was positive for mean IOP (p=0.0097)., CONCLUSIONS: This study suggests that IOP reduction in a developing country, despite potential limitations in diagnostic techniques, follow-up, and compliance, can be effective in reducing the risk of glaucomatous progression over long-term follow-up. AU - Alemu, Abiye M. AU - Kristoffersen, Caroline J. AU - Kristoffersen, Michael S. AU - Stewart, Jeanette A. AU - Stewart, William C. IS - 2 KW - Aged Antihypertensive Agents/tu [Therapeutic Use] Disease Progression Ethiopia/ep [Epidemiology] Female Follow-Up Studies Glaucoma, Open-Angle/ep [Epidemiology] *Glaucoma, Open-Angle/pp [Physiopathology] Glaucoma, Open-Angle/th [Therapy] Gonioscopy Humans Incidence *Intraocular Pressure/ph [Physiology] Male Middle Aged Prognosis Retinoscopy Retrospective Studies Risk Factors Time Factors Trabeculectomy/mt [Methods] PY - 2010 SE - Alemu, Abiye M. Ras Desta Hospital, Addis Ababa, Ethiopia. SN - 1120-6721 SP - 310-5 ST - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia T2 - European journal of ophthalmology TI - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=19882542 VL - 20 ID - 1391 ER - TY - JOUR AB - • Aim: To evaluate the prevalence of glaucoma, treatment patterns and patient attitudes in Ethiopia. • Methods: A survey was administered to glaucoma patients in hospitals in Addis Ababa, Ethiopia. • Results: Of the 415 qualified patients, exfoliative glaucoma (17%) was most commonly found in the Gurage population (33%), whereas chronic angle-closure glaucoma (5%) was found in the Amhara/Tigre (6%) population (P = 0.006). Patients were treated with an average of 1.4 ± 0.8 medications: 52% admitted recent noncompliance and 36% had undergone filtering surgery. Patients believed their physician was trying to help them (93%). God wanted them to receive treatment (89%) and their spouse was sympathetic to their disease (82%). Patients noted their community was unaware of their condition (87%) with Muslims [most common in the Gurage population (31%, P < 0.0001)] reporting this the most (25%, P = 0.01). Amhara/Tigre patients strongly believed their doctors were concerned about them (94%, P = 0.04). • Conclusion: The prevalence of glaucoma type varies among ethnic groups in Ethiopia with exfoliation more common in the Gurage population and chronic angle-closure glaucoma more frequent in the Amhara/Tigre population. AD - W.C. Stewart, PRN Pharmaceutical Research Network, LLC, Dallas, TX, United States AU - Alemu, A. M. AU - Nelson, L. A. AU - Kruft, B. AU - Stewart, J. A. AU - Stewart, W. C. DB - Embase IS - 9 KW - antiglaucoma agent adult article attitude to illness closed angle glaucoma controlled study disease classification Ethiopia ethnic difference female filtering operation glaucoma health survey human major clinical study male Muslim patient attitude patient compliance prevalence religion LA - English M3 - Article N1 - L352543506 2008-10-31 PY - 2008 SN - 1672-5123 SP - 1729-1733 ST - Epidemiology of glaucoma in central Ethiopia T2 - International Journal of Ophthalmology TI - Epidemiology of glaucoma in central Ethiopia UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352543506&from=export VL - 8 ID - 3428 ER - TY - JOUR AB - Objectives: Patient contracts are increasingly utilized in medical practice and have the potential to improve health outcomes in high-risk populations. However, as a relatively new tool, there has been limited research regarding the efficacy of patient contracts. Diabetic retinopathy (DR) is one of the leading causes of vision impairment in adults in the US and only 50–60% of adults with diabetes adhere to annual dilated fundus exam recommendations. This study aimed to evaluate the impact of patient contracts on follow-up adherence in diabetic patients with ocular abnormalities after a free, pharmacy-based eye screening. Study design: This prospective study implemented a non-invasive, non-mydriatic fundus camera in an urban, community-based pharmacy setting to screen for ocular diseases in patients with diabetes. Patients were assigned to the contract or non-contract group. Patients who signed a contract agreed to: 1) review their results with their primary care doctor, 2) follow-up with an ophthalmologist if their results were abnormal, and 3) inform research staff if/when they completed an eye care appointment. All study participants and their primary care doctors were notified of their results via mail. Follow-up questionnaires were administered to all patients by telephone three months after the screening results. Results: 500 patients were screened and 113 (22.6%) had abnormal results. Of the patients who had abnormal results, 83 (74.3%) were able to be contacted. Of the 83 patients who were able to be contacted, the majority of patients were African American (73.5%) and female (56.6%). The mean age was 54.7 years. Of those, 34 (41.0%) adhered to follow-up recommendations. There was no significant difference in follow-up adherence between the contract (38.1%) and non-contract group (43.9%) (P = 0.59). In addition, 70.4% of patients did not comply with at least one measure of the contract agreement. Conclusion: Contracts did not increase follow-up adherence to eye appointments in diabetic patients with ocular abnormalities. The majority of patients did not comply with their contract and follow-up adherence was low in both groups. Most research has yielded mixed results regarding the efficacy of contracts in improving health outcomes. Therefore, different types of contracts or other patient-centered tools should be evaluated in order to increase follow-up adherence in patients at high risk for DR. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Aleo, C. L., Wills Eye Hospital, 840 Walnut Street, Suite 802, Philadelphia, PA, US, 19107 AN - 2015-42074-028 AU - Aleo, C. L. AU - Murchison, A. P. AU - Dai, Y. AU - Hark, L. A. AU - Mayro, E. L. AU - Collymore, B. AU - Haller, J. A. DB - psyh DO - 10.1016/j.puhe.2015.05.012 DP - EBSCOhost IS - 7 KW - diabetic retinopathy contract appointment adherence screening Adult African Americans Community Pharmacy Services Female Follow-Up Studies Humans Male Mass Screening Middle Aged Patient Compliance Prospective Studies Referral and Consultation Surveys and Questionnaires Telephone Urban Population Diabetes Eye Disorders Treatment Compliance N1 - Wills Eye Hospital, Philadelphia, PA, US. Release Date: 20151019. Correction Date: 20200921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Diabetes; Eye Disorders; Screening; Treatment Compliance. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Longitudinal Study; Prospective Study; Quantitative Study. References Available: Y. Page Count: 4. Issue Publication Date: Jul, 2015. Publication History: First Posted Date: Jun 25, 2015; Accepted Date: May 13, 2015; Revised Date: Mar 4, 2015; First Submitted Date: May 16, 2014. Copyright Statement: Published by Elsevier Ltd. All rights reserved. The Royal Society for Public Health. 2015. Sponsor: Centers for Disease Control and Prevention, US. Grant: 5U58DP002655-02. Recipients: No recipient indicated PY - 2015 SN - 0033-3506 1476-5616 SP - 996-999 ST - Improving eye care follow-up adherence in diabetic patients with ocular abnormalities: The effectiveness of patient contracts in a free, pharmacy-based eye screening T2 - Public Health T3 - Governance for health TI - Improving eye care follow-up adherence in diabetic patients with ocular abnormalities: The effectiveness of patient contracts in a free, pharmacy-based eye screening UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-42074-028&site=ehost-live&scope=site caleo@willseye.org VL - 129 ID - 4847 ER - TY - JOUR AB - Primary open-angle glaucoma offers a significant diagnostic and management challenge for primary care providers. Uncertainty clouds the definition of the disease, its prevalence, the sensitivity and accuracy of the clinical tests used for its diagnosis, the efficacy of antiglaucoma medications, the compliance of patients with these drug regimens, the appropriate use of follow-up examinations, and the use of surgical techniques in lieu of medical management. This discussion addresses these many vexing issues for the purpose of assisting primary care providers to better diagnose and manage glaucoma patients. AU - Alexander, L. J. IS - 1 KW - Fundus Oculi *Glaucoma, Open-Angle/di [Diagnosis] Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/et [Etiology] Humans Optic Atrophy/pa [Pathology] Optic Disk/pa [Pathology] Optometry United States/ep [Epidemiology] Visual Field Tests Visual Fields PY - 1991 SN - 1050-6918 SP - 19-102 ST - Diagnosis and management of primary open-angle glaucoma T2 - Optometry clinics : the official publication of the Prentice Society TI - Diagnosis and management of primary open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1799817 VL - 1 ID - 2134 ER - TY - JOUR AB - INTRODUCTION: Fixed-combination glaucoma medications are commonly used to achieve target intraocular pressure (IOP) reduction in patients uncontrolled with monotherapy; however, ocular discomfort associated with eye drops can decrease adherence. This study assessed the efficacy and tolerability of twice-daily fixed-combination brinzolamide 1%/timolol 0.5% (BRINZ/TIM-FC) in Latin American patients transitioned from fixed-combination brimonidine 0.2%/timolol 0.5% (BRIM/TIM-FC) because of insufficient IOP control or treatment intolerance., METHODS: This 8-week, open-label, prospective study was conducted at six sites in Argentina, Chile, and Mexico. Enrolled patients were aged >=18 years with open-angle glaucoma (including primary, exfoliative, or pigment-dispersion glaucoma) or ocular hypertension with IOP of 19-35 mmHg in >=1 eye at baseline (on BRIM/TIM-FC). Patients self-administered BRINZ/TIM-FC to both eyes at 8 a.m. and 8 p.m. daily for 8 weeks. The primary and secondary efficacy endpoints were mean IOP change from baseline at week 8 and percentage of patients achieving target IOP (<=18 mmHg) at week 8, respectively. Exploratory endpoints included patient and investigator preference for treatment at week 8. Adverse events (AEs) were assessed as the safety endpoint., RESULTS: Fifty patients (mean +/- SD age, 66.7 +/- 11.5 years) received BRINZ/TIM-FC, and 49 were included in the intent-to-treat population. Mean +/- SD IOP was significantly reduced from baseline after 8 weeks of treatment with BRINZ/TIM-FC (-3.6 +/- 3.0 mmHg; P < 0.0001, Wilcoxon signed-rank test; 17.1% reduction). Overall, 55.3% of patients achieved IOP <=18 mmHg at week 8. Significantly more patients (89.4%) and investigators (95.7%) preferred BRINZ/TIM-FC to BRIM/TIM-FC (both P < 0.0001, exact binomial test). Of the 13 AEs observed, 8 were related to BRINZ/TIM-FC; the most common treatment-related AEs were eye irritation (n = 4) and abnormal sensation in the eye (n = 2)., CONCLUSION: BRINZ/TIM-FC provides an effective and well-tolerated treatment option for patients transitioned from BRIM/TIM-FC. AU - Alezzandrini, Arturo AU - Hubatsch, Douglas AU - Alfaro, Rene DO - https://dx.doi.org/10.1007/s12325-014-0145-5 IS - 9 KW - Adult Aged Aged, 80 and over Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Brimonidine Tartrate/ad [Administration & Dosage] Brimonidine Tartrate/ae [Adverse Effects] *Brimonidine Tartrate/tu [Therapeutic Use] Drug Combinations Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure Latin America Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Prospective Studies Research Design Sulfonamides/ad [Administration & Dosage] Sulfonamides/ae [Adverse Effects] *Sulfonamides/tu [Therapeutic Use] Thiazines/ad [Administration & Dosage] Thiazines/ae [Adverse Effects] *Thiazines/tu [Therapeutic Use] Timolol/ad [Administration & Dosage] Timolol/ae [Adverse Effects] *Timolol/tu [Therapeutic Use] United States PY - 2014 SE - Alezzandrini, Arturo. University of Buenos Aires, Buenos Aires, Argentina, aalezzandrini@oftalmos.com. SN - 1865-8652 0741-238X SP - 975-85 ST - Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination T2 - Advances in therapy TI - Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25138224 VL - 31 Y2 - 20140820// ID - 864 ER - TY - JOUR AB - Vision significantly affects quality of life and the treatment of ocular disease poses a number of unique challenges. This review presents the major challenges faced during topical ocular drug administration and highlights strategies used to overcome the natural transport barriers of the eye. The circulation of tear fluid and aqueous humor decrease the residence time of topically delivered drugs, while ocular barriers in the corneal and conjuctival epithelia and the retinal pigment epithelium limit transport. Successful treatment strategies increase the residence time of drugs in the eye and/or enhance the ability of the drug to penetrate the ocular barriers and reach the target tissue. In this review, we discuss several drug-delivery strategies that have achieved clinical success or demonstrate high potential. We also draw attention to a number of excellent reviews that explore various ocular drug-delivery techniques in depth. Finally, we highlight cutting-edge drug-delivery technologies that improve the efficacy of current drug-delivery methods or use proven techniques to deliver novel therapeutics. © 2008 Future Drugs Ltd. AD - M. Ali, Auburn University, Biomedical Devices and Drug Delivery Laboratories, Department of Chemical Engineering, Auburn, AL 36849, United States AU - Ali, M. AU - Byrne, M. E. C1 - lacrisert(Merck) medidur(Alimera) ocusert(Alza) retisert(Bausch and Lomb) vitrasert C2 - Alimera Alza Bausch and Lomb Merck DB - Embase DO - 10.1586/17512433.1.1.145 IS - 1 KW - agents acting on the eye antibiotic agent carbomer chitosan ciprofloxacin cisplatin cyclodextrin cyclosporine dexamethasone eye drops fluocinolone acetonide ganciclovir gellan gentamicin glucocorticoid hydroxypropylcellulose ketotifen fumarate liposome nanoparticle ofloxacin pegaptanib pilocarpine poloxamer polyglactin ranibizumab tacrolimus timolol timolol maleate unclassified drug unindexed drug vancomycin aqueous humor blood eye barrier cataract clinical trial conjunctiva epithelium contact lens controlled release formulation cornea epithelium diabetic macular edema drug absorption drug bioavailability drug delivery system drug efficacy drug formulation drug penetration drug solubility drug transport dry eye esterification eye disease glaucoma human hydrogel hydrophilicity intraocular hypertension iontophoresis lacrimal fluid lipophilicity microemulsion nonhuman particle size patient compliance pigment epithelium age related macular degeneration retinitis review unspecified side effect uveitis lacrisert medidur ocusert retisert vitrasert LA - English M3 - Review N1 - L351120786 2008-02-14 PY - 2008 SN - 1751-2433 SP - 145-161 ST - Challenges and solutions in topical ocular drug-delivery systems T2 - Expert Review of Clinical Pharmacology TI - Challenges and solutions in topical ocular drug-delivery systems UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351120786&from=export http://dx.doi.org/10.1586/17512433.1.1.145 VL - 1 ID - 3472 ER - TY - JOUR AB - BACKGROUND: The pterygopalatine fossa (PPF) and inferomedial orbital apex are difficult regions for open neurosurgical access. The traditional extensive anterior approach (transfacial or transmandibular) and lateral/posterolateral (transcranial) approach were used to access the PPF. The combined endonasal and sublabial transmaxillary approach is a less invasive access route for these lesions. In this study, we present the technical and clinical details of our experience with the combined endoscopic endonasal and transmaxillary approach., METHODS: A retrospective analysis of our patients operated on using a combined endoscopic endonasal and transmaxillary approach was done. The preoperative, intraoperative and postoperative images and all the clinical data were evaluated. The accessibility to the area and extent of surgical resection were reviewed. The surgery-related complications and postoperative morbidities were analyzed. The main items of interest were the exposure of the target area and possibility for safe removal., RESULTS: Five patients with pathologies located in the area of the PPF and orbital apex were operated on using the combined endoscopic sublabial and endonasal transmaxillary approach. The technique provided sufficient exposure of the area and allowed for safe removal of the preoperatively determined target in all of the patients. One patient developed dry eye and a neurotrophic corneal ulcer, and another patient developed temporary postoperative facial numbness. In the follow-up, only one patient with skull base chordoma had an asymptomatic tumor regrowth. The other patients had no recurrence or regrowth., CONCLUSIONS: The combined endoscopic sublabial and endonasal transmaxillary approach is a safe and effective method for resection of lesions in the PPF and inferomedial orbital apex. AU - Alimohamadi, Maysam AU - Hajiabadi, Mohamadreza AU - Gerganov, Venelin AU - Fahlbusch, Rudolf AU - Samii, Madjid DO - https://dx.doi.org/10.1007/s00701-015-2402-z IS - 6 KW - Adolescent Adult Chordoma/su [Surgery] *Endoscopy/mt [Methods] Female Humans Intraoperative Neurophysiological Monitoring Male Middle Aged *Mouth Floor/su [Surgery] *Nasal Cavity/su [Surgery] Neuronavigation *Neurosurgical Procedures/mt [Methods] *Orbit/su [Surgery] *Pterygopalatine Fossa/su [Surgery] Retrospective Studies Skull Base Neoplasms/su [Surgery] Treatment Outcome N1 - Erratum in (EIN) PY - 2015 SE - Alimohamadi, Maysam. International Neuroscience Institute, Rudolf Pichlmayr Street, No. 4, 30625, Hannover, Germany, alimohamadi59@gmail.com. SN - 0942-0940 0001-6268 SP - 919-929 ST - Combined endonasal and sublabial endoscopic transmaxillary approach to the pterygopalatine fossa and orbital apex T2 - Acta neurochirurgica T3 - Erratum in: Acta Neurochir (Wien). 2016 Jun;158(6):1229; PMID: 27086347 [https://www.ncbi.nlm.nih.gov/pubmed/27086347] TI - Combined endonasal and sublabial endoscopic transmaxillary approach to the pterygopalatine fossa and orbital apex UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25845548 VL - 157 Y2 - 20150407// ID - 804 ER - TY - JOUR AB - Objective: To provide the frequency and potential determinants of eye care utilization over the last 12 months among Canadians between the ages of 45 and 85 years old. Design: Cross-sectional population-based study. Participants: 30,097 people in the Comprehensive Cohort of the Canadian Longitudinal Study on Aging. Methods: Inclusion criteria included being between the ages of 45 and 85 years old, community-dwelling and living near one of the 11 data collection sites across 7 Canadian provinces. Eye care utilization was defined as the self-report of a visit to an optometrist or ophthalmologist in the past 12 months. Results: In the last year, 57% of 28 728 adults visited an eye care provider although there was heterogeneity between provinces. The highest eye care utilization was found in Ontario at 62%, whereas the lowest was in Newfoundland and Labrador at 50%. Of concern, 25.3% of people with diabetes above the age of 60 years had not seen an eye care provider in the last year. Our novel finding was that current smokers were less likely to use eye care compared to never smokers (odds ratio [OR] = 0.76, 95% confidence interval [CI] 0.67–0.87). Confirming previous research, men compared to women (OR = 0.67, 95% CI 0.62–0.71), people with less than a bachelor's degree compared to more than a bachelor's degree (OR = 0.87, 95% CI 0.79–0.95), and people making less income (linear trend p < 0.05) were less likely to use eye care. Conclusions: Disparities exist in eye care utilization in Canada. Efforts should be made to reduce these disparities to reduce avoidable vision loss. AD - E.E. Freeman, 600 Peter Morand Crescent, Office 301H, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ont., Canada AU - Aljied, R. AU - Aubin, M. J. AU - Buhrmann, R. AU - Sabeti, S. AU - Freeman, E. E. DB - Embase Medline DO - 10.1016/j.jcjo.2018.01.021 IS - 3 KW - adult age aged article Canada Canadian cataract cross-sectional study eye care female glaucoma health care personnel health care utilization household income human insulin dependent diabetes mellitus longitudinal study macular degeneration major clinical study male non insulin dependent diabetes mellitus ophthalmologist optometrist population research smoking very elderly visual impairment LA - English M3 - Article N1 - L621118579 2018-03-13 2018-05-31 PY - 2018 SN - 1715-3360 0008-4182 SP - 298-304 ST - Eye care utilization and its determinants in Canada T2 - Canadian Journal of Ophthalmology TI - Eye care utilization and its determinants in Canada UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621118579&from=export http://dx.doi.org/10.1016/j.jcjo.2018.01.021 VL - 53 ID - 2583 ER - TY - JOUR AB - PURPOSE: Herpes simplex is a common cause of visual disability, and there are published evidence-based guidelines for therapy. This survey aims to determine the preferred practice patterns of ophthalmologists in Gulf Coast Countries regarding herpetic eye disease, as well as identify areas of controversy or barriers to acceptance of evidence-based protocols., METHODS: Anonymous web-based survey of ophthalmologists in Saudi Arabia, Bahrain, the United Arab Emirates, and Oman., RESULTS: There were 48 responses to the survey. For a first episode of epithelial dendritic keratitis, 28.2% reported "observation" rather than specific therapy. The majority of respondents utilize oral or topical antiviral for epithelial keratitis, with oral antiviral being the most popular (43.6%). The majority also included a corticosteroid with antiviral for stromal keratitis (83.9%) or iritis (70.3%). Over 90% prescribe a prophylactic antiviral after keratoplasty for herpetic eye disease, although the length of therapy ranged widely from <6 months to indefinite. The perceived risk of recurrent disease was ranked as the most important factor when considering antiviral prophylaxis, followed by risk of adverse effects. Topical cyclosporine was utilized "never or almost never" by 76.9% of respondents., CONCLUSIONS: Most respondents report following evidence-based guidelines. There was less consensus in areas where there are remaining knowledge gaps, such as the length of antiviral prophylaxis after keratoplasty and the potential role for topical cyclosporine. AU - Alkhayyal, Mashael A. AU - Stone, Donald U. DO - https://dx.doi.org/10.1016/j.sjopt.2017.03.007 IS - 2 PY - 2017 SE - Alkhayyal, Mashael A. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Stone, Donald U. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Stone, Donald U. Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States. SN - 1319-4534 SP - 61-64 ST - Practice patterns for herpes simplex keratitis: A survey of ophthalmologists in Gulf Coast countries T2 - Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society TI - Practice patterns for herpes simplex keratitis: A survey of ophthalmologists in Gulf Coast countries UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=28559714 VL - 31 Y2 - 20170406// ID - 626 ER - TY - GEN AB - Curcumin has been successfully applied to treat inflammatory conditions in experimental research and in clinical trials. The purpose of our study is to evaluate the efficacy of an adjunctive-to-traditional treatment with Norflo tablets (curcumin-phosphatidylcholine complex; Meriva) administered twice a day in recurrent anterior uveitis of different etiologies. The study group consisted of 106 patients who completed a 12-month follow-up therapeutic period. We divided the patients into three main groups of different uveitis origin: group 1 (autoimmune uveitis), group 2 (herpetic uveitis), and group 3 (different etiologies of uveitis). The primary end point of our work was the evaluation of relapse frequency in all treated patients, before and after Norflo treatment, followed by the number of relapses in the three etiological groups. Wilcoxon signed-rank test showed a P < 0.001 in all groups. The secondary end points were the evaluation of relapse severity and of the overall quality of life. The results showed that Norflo was well tolerated and could reduce eye discomfort symptoms and signs after a few weeks of treatment in more than 80% of patients. In conclusion, our study is the first to report the potential therapeutic role of curcumin and its efficacy in eye relapsing diseases, such as anterior uveitis, and points out other promising curcumin-related benefits in eye inflammatory and degenerative conditions, such as dry eye, maculopathy, glaucoma, and diabetic retinopathy. © 2010 Allegri et al. AD - P. Allegri, Uveitis Center Head, Ophthalmological Department of Lavagna Hospital, Corso Valparaiso 96/3, Chiavari 16043, Genova, Italy AU - Allegri, P. AU - Mastromarino, A. AU - Neri, P. C1 - meriva(Indena,Italy) norflo(Eye Pharma,Italy) C2 - Eye Pharma(Italy) Indena(Italy) DB - Embase DO - 10.2147/OPTH.S13271 J2 - Clin. Ophthalmol. KW - curcumin curcumin phosphatidylcholine cycloplegic agent immunosuppressive agent meriva mydriatic agent nonsteroid antiinflammatory agent norflo steroid unclassified drug adjuvant therapy adult aged article autoimmune disease chronic disease controlled study disease severity drug efficacy drug response drug tolerability drug withdrawal eye discomfort female follow up gastrointestinal symptom herpes simplex human iridocyclitis long term care major clinical study male patient compliance quality of life recurrence risk recurrent disease risk reduction L1 - internal-pdf://2511712092/3217-Management of chronic anterior uveit-2010.pdf LA - English M1 - (Allegri P., pallegri@asl4.liguria.it; Mastromarino A.) Uveitis Center Head, Ophthalmological Department of Lavagna Hospital, Corso Valparaiso 96/3, Chiavari 16043, Genova, Italy M3 - Article N1 - L361011373 2011-01-11 PY - 2010 SN - 1177-5467 1177-5483 SP - 1201-1206 ST - Management of chronic anterior uveitis relapses: Efficacy of oral phospholipidic curcumin treatment. Long-term follow-up TI - Management of chronic anterior uveitis relapses: Efficacy of oral phospholipidic curcumin treatment. Long-term follow-up UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361011373&from=export http://dx.doi.org/10.2147/OPTH.S13271 VL - 4 ID - 3217 ER - TY - JOUR AB - Inhaled corticosteroids play a pivotal role in the treatment of asthma. Inhalation permits effective delivery of the corticosteroid in high concentration to target sites within the lung while minimizing systemic exposure. Consequently, the safety profile of inhaled corticosteroids is markedly better than that of oral corticosteroid therapy. However, although it was first thought that direct delivery might eliminate systemic adverse effects, this has not been confirmed by clinical trials and experience. Inhaled corticosteroids are absorbed from the lungs into the systemic circulation, in which they can acutely decrease growth velocity in children, an effect that fortunately appears to be temporary and might have no effect on final adult height. In sufficient dosages, they also produce bone mineral loss leading to osteoporosis and might increase the risk of cataracts, glaucoma, skin atrophy, and vascular changes that increase the risk of ecchymoses. Effective evaluation of the severity and significance of these complications is challenging because highly sensitive tests do not reliably predict clinically significant events, and short-term observations do not predict long-term consequences. Also, compliance wanes with long-term treatment, and susceptibility to a particular adverse event can vary over time, even in the same individual, because of developmental or hormonal changes. This journal supplement will review what has been learned about the safety of inhaled cortico-steroids during the past decade, discussing some of the questions that remain and considering the characteristics of an "ideal" inhaled corticosteroid: one with high local activity in the lung and minimal or no adverse systemic effects. AU - Allen, David B. AU - Bielory, Leonard AU - Derendorf, Hartmut AU - Dluhy, Robert AU - Colice, Gene L. AU - Szefler, Stanley J. IS - 3 Suppl KW - Administration, Inhalation Adolescent Adult *Anti-Asthmatic Agents/ae [Adverse Effects] Anti-Asthmatic Agents/tu [Therapeutic Use] *Asthma/dt [Drug Therapy] Bone Density/de [Drug Effects] Cataract/ci [Chemically Induced] Child Child, Preschool Ecchymosis/ci [Chemically Induced] Female Glaucoma/ci [Chemically Induced] *Glucocorticoids/ae [Adverse Effects] Glucocorticoids/tu [Therapeutic Use] Growth/de [Drug Effects] Humans Male Middle Aged Osteoporosis/ci [Chemically Induced] PY - 2003 SE - Allen, David B. Division of Endocrinology, University of Wisconsin Children's Hospital, Madison 53792-4108, USA. SN - 0091-6749 SP - S1-40 ST - Inhaled corticosteroids: past lessons and future issues T2 - The Journal of allergy and clinical immunology TI - Inhaled corticosteroids: past lessons and future issues UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=14515117 VL - 112 ID - 1826 ER - TY - JOUR AB - Relatively little is known in terms of patient demographics, indications, previous cannabis use, or the forms and dosages of medical marijuana (MM) dispensed for patients at MM dispensaries. Even less is known in terms of how male and female patients may differ in each of these aspects. The goal of the current study was to examine each of these variables using a retrospective analysis of deidentified patient data from MM dispensaries in Louisiana. Deidentified data were analyzed from web-based pharmacist–patient consultations at MM dispensaries throughout Louisiana. Data were collected during the first 6 months following the initiation of the MM dispensing program in Louisiana. A total of 1195 MM patients (598 male/597 female) were included in the analyses. The average age of the sample was 51.9 years (±14.8) and it was composed primarily of white patients (86.7%). Males and females were nearly identical in terms of average age, race, previous cannabis use, indication profile, and MM recommendations. Differences between males and females were observed in terms of opioid use, history of psychosis, presence of more than one indication, and the duration of previous cannabis use. Our data indicate that, in MM dispensaries of the Deep South state, there are numerous similarities—and some potentially important differences—between male and female MM patients. The importance of these differences, and the importance of continued data collection/analysis, for improving MM dispensing are discussed. AD - J.N. Keller, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, United States J.N. Keller, Keller-Lamar Health Foundation, 5321 Corporate Boulevard, Baton Rouge, LA, United States AU - Allen, H. R. AU - Boudreaux, D. AU - Keller, J. N. DB - Embase DO - 10.3390/jcm9061865 IS - 6 KW - cannabidiol cannabis opiate tetrahydrocannabinol derivative vegetable oil adult ambulatory care article autism cannabis use comparative study consultation diseases drug cost epilepsy female glaucoma human Human immunodeficiency virus infection intractable pain Louisiana major clinical study male middle aged multiple sclerosis muscle spasm muscular dystrophy Parkinson disease pharmacist pharmacy (shop) psychosis retrospective study seizure self report LA - English M3 - Article N1 - L2004558189 2020-07-24 2020-08-25 PY - 2020 SN - 2077-0383 SP - 1-9 ST - Comparison of male and female patients in Louisiana medical Marijuana dispensaries T2 - Journal of Clinical Medicine TI - Comparison of male and female patients in Louisiana medical Marijuana dispensaries UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004558189&from=export http://dx.doi.org/10.3390/jcm9061865 VL - 9 ID - 2403 ER - TY - JOUR AB - BACKGROUND: Congenital cataract significantly impairs visual development. Although treatable, a good visual outcome is difficult to achieve, requiring prompt lensectomy and prolonged visual rehabilitation., PURPOSE: The aim of this study was to investigate whether useable visual acuity (VA) is a realistic goal in these patients., METHODS: A retrospective case review from a tertiary referral centre was performed. This study included children with unilateral congenital cataract who underwent cataract surgery with posterior capsulectomy and anterior vitrectomy., RESULTS: A total of 62 patients were identified. Of them, 32% of aphakic eyes had a final VA of 0.6 LogMAR or better (average 0.34+/-0.17). The average age at the time of surgery was 5.0+/-4.1 weeks. The remaining 68% had vision that was less than 0.6, with 27% having vision of <1.00. The group with vision less than 0.6 (68%) had an average age of 9.7+/-6.5 weeks at the time of surgery. One case (1.6%) achieved a VA of 0.0 and also had demonstrable stereoacuity (110 arc s). Manifest strabismus was present in 85% of cases. Glaucoma developed in 19% of patients and 31% discontinued the occlusion regime before the age of 4 years. In most of these cases, occlusion was ceased by the age of 2 years when testing revealed dense amblyopia in the aphakic eye even if good compliance had previously been achieved. In many cases, this coincided with the child becoming noncompliant with occlusion., CONCLUSIONS: More than two-thirds of children in our cohort did not develop acuity better than 0.6 LogMAR in their aphakic eye. AU - Allen, R. J. AU - Speedwell, L. AU - Russell-Eggitt, I. DO - https://dx.doi.org/10.1038/eye.2009.295 IS - 7 KW - Anterior Chamber/su [Surgery] *Cataract/cn [Congenital] Cataract/pp [Physiopathology] *Cataract Extraction Child Child, Preschool Cohort Studies Female Humans Lens Capsule, Crystalline/su [Surgery] Male Refraction, Ocular Retrospective Studies *Visual Acuity Vitrectomy PY - 2010 SE - Allen, R J. Department of Ophthalmology, Great Ormond Street Hospital for Children, Essex, UK. Richard.allen@colchesterhospital.nhs.uk SN - 1476-5454 0950-222X SP - 1263-7 ST - Long-term visual outcome after extraction of unilateral congenital cataracts T2 - Eye (London, England) TI - Long-term visual outcome after extraction of unilateral congenital cataracts UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20019767 VL - 24 Y2 - 20091218// ID - 1388 ER - TY - JOUR AD - Visiting scholar at UC Berkeley Adjunct professor at the University of Houston AN - 131246326. Language: English. Entry Date: 20180827. Revision Date: 20191106. Publication Type: Article AU - Aller, Thomas DB - ccm DP - EBSCOhost IS - 8 KW - Myopia -- Therapy Disease Management Medical Practice, Evidence-Based Cataract -- Risk Factors Glaucoma -- Risk Factors Retinal Detachment -- Risk Factors Medical Practice Myopia -- Diagnosis Patient Compliance Atropine -- Administration and Dosage Atropine -- Therapeutic Use Marketing Contact Lenses -- Economics Corneal Topography Decision Making Social Media Optometrists Myopia -- Complications Professional Knowledge N1 - statistics. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2018 SN - 0030-4085 SP - 16-18 ST - NO BETTER TIME FOR MYOPIA MANAGEMENT T2 - Optometric Management TI - NO BETTER TIME FOR MYOPIA MANAGEMENT UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131246326&site=ehost-live&scope=site VL - 53 ID - 4561 ER - TY - JOUR AB - Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of prostaglandin (PG) F2alpha, which was the first of the currently available topical PGF2alpha analogs to be launched for glaucoma or ocular hypertension and which still accounts for the majority of prescriptions. It is better absorbed than the parent compound through the cornea, and peak concentration of the active drug is in the aqueous humor 1-2 hours after topical dosing (15-30 ng/mL). Metabolism occurs mainly in the liver. Latanoprost (0.005%) has been very well studied in clinical trials and meta-analyses that show it to be generally as effective as the other PG analogs (bimatoprost, travoprost, and tafluprost) and more effective than timolol, dorzolamide, and brimonidine. Latanoprost has good short- and long-term safety and tolerability profiles. In common with other prostaglandins, it lacks systemic effects, but can cause ocular adverse events such as conjunctival hyperemia, pigmentation of the iris, periocular skin or eyelashes, hypertrichosis, and ocular surface effects or irritation. Latanoprost is significantly better tolerated than either bimatoprost or travoprost. Patients treated with latanoprost have better compliance and persist with therapy longer than those that are given other drugs. An improved formulation of latanoprost without the preservative benzalkonium chloride has recently been developed. It is as effective as conventional latanoprost, has a lower incidence of hyperemia, and can be stored at room temperature. In conclusion, latanoprost has the best efficacy-tolerability ratio of the PG analogs available for glaucoma treatment, and has good compliance and persistence. These factors should be improved further by the recent development of preservative-free latanoprost. AU - Alm, Albert DO - https://dx.doi.org/10.2147/OPTH.S59162 PY - 2014 SE - Alm, Albert. Department of Neuroscience, Ophthalmology, University Hospital, Uppsala, Sweden. SN - 1177-5467 SP - 1967-85 ST - Latanoprost in the treatment of glaucoma T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Latanoprost in the treatment of glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=25328381 VL - 8 Y2 - 20140926// ID - 1077 ER - TY - JOUR AB - Microbial keratitis is a major risk for corneal blindness worldwide. We aimed to study the clinical presentation and outcome of hospitalized patients having infective corneal ulcers.All patients who were diagnosed as microbial keratitis and were admitted to Al-Ain Hospital during the period July 2011-Dec 2016 were retrospectively studied. Patients' demography, predisposing factors, symptoms and signs at presentation, time to presentation after onset of symptoms, microbial isolates, hospital stay, and visual acuity (VA) outcome were studied.74 patients with corneal ulcers were hospitalized. 79.7% were males. The median (range) age was 44 years (1-91). 36.5% had trauma as a risk factor. The main presenting symptoms were pain (90.5%), red eye (79.7%), and decreased vision (63.5%). All patients had stromal infiltrate while 39.2% had hypopyon at presentation. The average time from the start of the symptoms to hospital presentation was 11 (1-90) days. The mean (range) hospital stay was 10.6 (1-60) days. Forty eyes were culture positive. Bacteria were identified in 27 eyes and fungus in 16. Pseudomonas aeruginosa (9 eyes) and Staphylococcus epidermis (5 eyes) were the most common bacterial islolates. Aspergillus (6 eyes) was the most common fungus species. 95.2% of the bacterial isolates were susceptible to the quinolone antibiotics group. Twenty eight (51.9%) patients had a vision worse than 6/60 in the affected eye.Corneal ulcer poses a significant threat to the sight of an affected eye. Trauma was the most common risk factor for corneal ulcers. Usage of eyes personal protective equipment for high risk occupations and earlier accessibility to health care may reduce the impact of corneal ulcers in our community. AU - AlMahmoud, Tahra AU - Elhanan, Mohamed AU - Elshamsy, Mohamed H. AU - Alshamsi, Hanan N. AU - Abu-Zidan, Fikri M. DO - https://dx.doi.org/10.1097/MD.0000000000018243 IS - 51 KW - Adolescent Adult Aged Aged, 80 and over Child Child, Preschool Corneal Ulcer/di [Diagnosis] Corneal Ulcer/ep [Epidemiology] *Corneal Ulcer/th [Therapy] Developing Countries Female Humans Infant Male Middle Aged Retrospective Studies Risk Factors United Arab Emirates/ep [Epidemiology] Young Adult PY - 2019 SE - AlMahmoud, Tahra. Department of Surgery, College of Medicine and Health Sciences, Khalifa Bin Zayed Street, United Arab Emirates University. AlMahmoud, Tahra. Department of Ophthalmology, Al-Ain Hospital, Al Jimi District, Al-Ain, UAE. Elhanan, Mohamed. Department of Ophthalmology, Al-Ain Hospital, Al Jimi District, Al-Ain, UAE. Elshamsy, Mohamed H. Department of Ophthalmology, Al-Ain Hospital, Al Jimi District, Al-Ain, UAE. Alshamsi, Hanan N. Department of Ophthalmology, Al-Ain Hospital, Al Jimi District, Al-Ain, UAE. Abu-Zidan, Fikri M. Department of Surgery, College of Medicine and Health Sciences, Khalifa Bin Zayed Street, United Arab Emirates University. SN - 1536-5964 0025-7974 SP - e18243 ST - Management of infective corneal ulcers in a high-income developing country T2 - Medicine TI - Management of infective corneal ulcers in a high-income developing country UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31860971 VL - 98 ID - 303 ER - TY - JOUR AB - PURPOSE: To compare Goldmann manual perimetry and Humphrey automated perimetry for sensitivity in detecting visual field loss, efficiency, and patient preference., METHODS: This prospective study compared Goldmann manual perimetry and Humphrey automated perimetry testing techniques in 20 consecutive preoperative blepharoptosis patients with unilateral or bilateral blepharoptosis with a marginal reflex distance of <=+2.5 mm, no dermatochalasis overhanging the eyelid margin, and no superior visual field defects due to glaucoma, neurologic disease, or other causes. Main outcome measures included efficiency, patient preference, and sensitivity in detecting visual field loss. Institutional review board approval was obtained prior to the start of the study., RESULTS: Goldmann perimetry had significantly shorter examination times (-DELTA6.4 minutes, 95% confidence interval: 4.5-8.3, p < 0.001) and was preferred by most patients (70%). There was no statistically significant difference between the 2 techniques in detecting superior visual field loss at 90degree meridian., CONCLUSIONS: Goldmann manual perimetry for assessing visual field loss in blepharoptosis patients is more efficient than Humphrey automated perimetry and is preferred by patients. Both techniques are sensitive in detecting ptosis-related visual field loss. AU - Alniemi, Saba T. AU - Pang, Noelene K. AU - Woog, John J. AU - Bradley, Elizabeth A. DO - https://dx.doi.org/10.1097/IOP.0b013e31829a7288 IS - 5 KW - Adult Aged Aged, 80 and over *Blepharoptosis/co [Complications] Female Humans Male Middle Aged Patient Preference Prospective Studies Sensitivity and Specificity *Vision Disorders/di [Diagnosis] Vision Disorders/et [Etiology] *Visual Field Tests/mt [Methods] *Visual Fields Young Adult PY - 2013 SE - Alniemi, Saba T. *Mayo Clinic Department of Ophthalmology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota; and Department of Ophthalmology, University of Oklahoma, Dean McGee Eye Institute Foundation, Oklahoma City, Oklahoma, U.S.A. SN - 1537-2677 0740-9303 SP - 361-3 ST - Comparison of automated and manual perimetry in patients with blepharoptosis T2 - Ophthalmic plastic and reconstructive surgery TI - Comparison of automated and manual perimetry in patients with blepharoptosis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23924985 VL - 29 ID - 949 ER - TY - JOUR AB - Purpose: To describe the results of selective laser trabeculoplasty (SLT) in eyes with angle recession glaucoma (ARG). To our knowledge, this is the first report of SLT being used as treatment modality for angle recession glaucoma. Argon laser trabeculoplasty (ALT) was used for ARG but showed a little therapeutic effect. Observations: Retrospective case series of 4 eyes of 4 patients with history of non-penetrating injury to the eye resulted in angle recession glaucoma. All eyes underwent SLT. Post-treatment, the best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of glaucoma medications, additional need for intervention, and complications were recorded. Success of treatment was defined as an IOP reduction of 20% or reduction in medications and maintaining target IOP without further intervention during follow up period of more than 3 months. Mean patient age was 44 years (SD = 9) and 2 out of 4 were females. SLT treatment resulted in decreased IOP from 21 to 12 mmHg in one patient and from 26 to 20 mmHg with reduced medication burden in another patient and reduced medication burden in the third patient who stopped glaucoma medication with no significant change in IOP (from 10 to 14 mmHg) at last follow up visit at 45 months. Two SLT sessions failed in one patient who underwent tube surgery. In the 3 patients with successful treatment, IOP remained controlled for the duration of follow up ranging from 4 to 45 months. Conclusions and Importance: Predicting IOP outcomes after SLT is difficult in patients with ARG. Success was noted early in the post-treatment period and was maintained for years. Repeating SLT in a case of early failure didn't change the result and is not recommended. A larger study is required to confirm the safety and effectiveness of SLT for ARG. AD - I. AlObaida, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia AU - AlObaida, I. AU - Aljasim, L. A. DB - Embase DO - 10.1016/j.ajoc.2020.100835 KW - ophthalmic argon laser posterior chamber lens betaxolol brinzolamide plus timolol latanoprost pilocarpine adult angle recession glaucoma article blunt trauma brain concussion case report case study clinical article disease burden epithelium lesion extracapsular cataract extraction eye injury female follow up glaucoma gonioscopy human hyphema intraocular pressure laser surgery male medical record review medication compliance middle aged patient compliance reduction (chemistry) retina hemorrhage retrospective study selective laser trabeculoplasty trabeculectomy trabeculoplasty treatment failure treatment refusal visual field defect LA - English M3 - Article N1 - L2007306447 2020-08-06 2020-08-14 PY - 2020 SN - 2451-9936 ST - Selective laser trabeculoplasty in patients with angle recession glaucoma: A small case series T2 - American Journal of Ophthalmology Case Reports TI - Selective laser trabeculoplasty in patients with angle recession glaucoma: A small case series UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2007306447&from=export http://dx.doi.org/10.1016/j.ajoc.2020.100835 VL - 19 ID - 2388 ER - TY - SER AB - Glaucoma is the second leading cause of blindness globally and the second most common cause of avoidable visual impairment. It also holds a record in noncompliance to therapy from the patients in up to 50% of the subjects treated with anti-glaucoma eye drops. LiveCity e-Health is a European research program, which aims to provide better treatment and follow up of glaucoma patients at their home, through telemonitoring with high definition video-to-video (v2v) communication from the University Hospital. Secondly, it aims to reduce the cost of health and improve the city environment by decreasing the number of visits to the Hospital. For this purpose, a software application has been developed; the latter is easy to use for elderly people at home, and capable of keeping the medical history and digital records of every patient in the Glaucoma Department. In addition, a specific web camera with snapshot ability of high quality photo of the eye has utilised. Two patients have been initially enrolled in the study and the preliminary results are so presented. © IFIP International Federation for Information Processing 2014. AD - 2nd Department of Ophthalmology, University of Athens,“Attikon” Hospital, 1, Rimini Street, Haidari, Athens, GR-124 62, Greece Department of Informatics and Telecommunications National and Kapodistrian University of Athens, 6, Panepistimiopolis, Ilissia, Athens, GR-15784, Greece Research Programs Section, Fixed Hellenic Telecommunications Organization (OTE) S.A, 99, Kifissias Avenue, Athens, GR-151 24, Greece AU - Alonistiotis, D. AU - Kontou, E. AU - Karachalios, N. AU - Patouni, E. AU - Diamantopoulos, P. AU - Bompetsis, N. AU - Alonistioti, N. AU - Chochliouros, I. P. DB - Scopus DO - 10.1007/978-3-662-44722-2_6 KW - E-Health Glaucoma Telemonitoring Video-to-video (v2v) communication M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2014 SP - 48-55 ST - Remote video-to-video eye telemonitoring use case for glaucoma patients T2 - IFIP Advances in Information and Communication Technology TI - Remote video-to-video eye telemonitoring use case for glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84921500002&doi=10.1007%2f978-3-662-44722-2_6&partnerID=40&md5=9727c4263bbd821c927ee41411ce4477 VL - 437 ID - 5571 ER - TY - JOUR AB - Over the past decade the application of gene therapy of retinal diseases such as glaucoma has produced promising results. However, optic nerve regeneration and restoration of vision in patients with glaucoma is still far from reality. Neuroprotective approaches in the form of gene therapy may provide significant advantages, but are still limited by many factors both at the organ and cellular levels. In general, gene delivery systems for eye diseases range from simple eye drops and ointments to more advanced bio- and nanotechnology-based systems such as muco-adhesive systems, polymers, liposomes and ocular inserts. Most of these technologies were developed for front-of-the-eye ophthalmic therapies and are not applicable as back-of-the-eye delivery systems. Currently, only the invasive intravitreal injections are capable of successfully delivering genes to the retina. Here we review the challenges and possible strategies for the noninvasive gene therapy of glaucoma including the barriers in the eye and in neural cells, and present a cross-sectional view of gene delivery as it pertains to the prevention and treatment of glaucoma. AU - Alqawlaq, Samih AU - Huzil, J. Torin AU - Ivanova, Marina V. AU - Foldvari, Marianna DO - https://dx.doi.org/10.2217/nnm.12.69 IS - 7 KW - Animals Drug Delivery Systems/mt [Methods] Eye/me [Metabolism] Eye/pa [Pathology] *Gene Transfer Techniques *Genetic Therapy/mt [Methods] *Glaucoma/ge [Genetics] Glaucoma/pa [Pathology] *Glaucoma/th [Therapy] Humans PY - 2012 SE - Alqawlaq, Samih. School of Pharmacy, University of Waterloo, 200 University Avenue West, Waterloo, ON, Canada. SN - 1748-6963 1743-5889 SP - 1067-83 ST - Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma T2 - Nanomedicine (London, England) TI - Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22846092 VL - 7 ID - 1119 ER - TY - JOUR AB - AIM: Primary open angle glaucoma (POAG) is a leading cause of permanent visual loss affecting significant numbers in Saudi Arabia. There is no cure for glaucoma but there is mounting evidence to guide ophthalmologists in diagnosing and managing this disease. The aim of this pilot project was to assess the compliance with evidence-based criteria and to implement an adapted clinical practice guideline (CPG) for the management of patients with POAG at a tertiary eye care center in Riyadh, Saudi Arabia that will lead to improving quality, consistency and optimizing patients' care., METHODS: The project consisted of three phases using audit and feedback strategy. It has utilized the Joanna Briggs Institute Practical Application of Clinical Evidence System and Getting Research into Practice audit and feedback tool. Eleven evidence-based audit criteria were developed. A baseline audit was then conducted. Barriers behind areas of noncompliance were identified and a number of strategies were implemented to overcome them. A follow-up postimplementation audit was then conducted., RESULTS: Twenty electronic medical files were randomly selected for baseline audit. The results of the audit have identified a number of possible areas to improve in the diagnosis and management of POAG in compliance with the adapted CPG with compliance rate as low as 20% (4/20) in some criteria. Multifaceted interventions were implemented targeting mainly attitude and lack of knowledge and time and resource barriers. Significant improvement occurred in most criteria audited postimplementation., CONCLUSION: The project demonstrates that audit and feedback is a feasible and effective tool to change glaucoma practice in a teaching hospital in Saudi Arabia. The success was due to multifaceted interventions including clear communication to promote awareness, an easily accessible CPG, and regular reminders to improve knowledge and change behavior. We propose our pilot implementation to be generalized to promote implementing evidence-based ophthalmology. Copyright © 2020 University of Adelaide, Joanna Briggs Institute. AU - Alshowaeir, Daniah AU - Almasoud, Nouf AU - Aldossari, Sheikhah AU - Alsirhy, Ehab Y. AU - Osman, Essam AU - Turjoman, Abdulsalam AU - Amer, Yasser AU - Munn, Zachary AU - McArthur, Alexa DO - https://dx.doi.org/10.1097/XEB.0000000000000257 IS - 2 PY - 2020 SE - Alshowaeir, Daniah. Ophthalmology Department, College of Medicine. Almasoud, Nouf. Ophthalmology Department, College of Medicine. Aldossari, Sheikhah. Ophthalmology Department, College of Medicine. Alsirhy, Ehab Y. Ophthalmology Department, King Abdul-Aziz University Hospital, King Saud University. Osman, Essam. Ophthalmology Department, College of Medicine. Turjoman, Abdulsalam. Ophthalmology Department, King Abdul-Aziz University Hospital, King Saud University. Amer, Yasser. Clinical Practice Guidelines Unit, Quality Management Department, King Khalid University Hospital, King Saud University Medical City. Amer, Yasser. Research Chair for Evidence-Based Health Care and Knowledge Translation, King Saud University. Amer, Yasser. Pediatrics Department, King Khalid University Hospital, King Saud University Medical city, Riyadh, Saudi Arabia. Munn, Zachary. Faculty of health and medical science, Joanna Briggs Institute, University of Adelaide. South Australia, Australia. McArthur, Alexa. Faculty of health and medical science, Joanna Briggs Institute, University of Adelaide. South Australia, Australia. SN - 2691-3321 SP - 208-216 ST - Primary open angle glaucoma management in a tertiary eye care center in Saudi Arabia: a best practice implementation pilot project T2 - JBI evidence implementation TI - Primary open angle glaucoma management in a tertiary eye care center in Saudi Arabia: a best practice implementation pilot project UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=34061052 VL - 19 Y2 - 20201205// ID - 63 ER - TY - JOUR AB - PURPOSE: The objective of this study was to assess preference for fixed-combination brinzolamide 1%/timolol 0.5% (BTFC) versus fixed-combination dorzolamide 2%/timolol 0.5% (DTFC) in patients with open-angle glaucoma or ocular hypertension., METHODS: In this prospective, single-masked crossover study, patients were randomized 1:1 to BTFC-DTFC or DTFC-BTFC treatment sequences. Patients self-administered each medication for 7 days, with a 48-hour washout period between treatments, and rated ocular discomfort after each treatment period. Medication preferences based on ocular comfort (primary endpoint) and anticipated adherence were assessed. Safety outcomes included adverse events and intraocular pressure. Between-group differences in treatment preference and ocular discomfort scores were analyzed using chi-square and Wilcoxon-Mann-Whitney tests, respectively. Adherence, intraocular pressure, and adverse events were summarized descriptively., RESULTS: In total, 112 patients were enrolled (mean +/- SD age, 66+/-11 years), and 109 patients completed the study. Numerically, more patients in the intent-to-treat dataset preferred BTFC versus DTFC (59.3% versus 40.7%); however, this result was not statistically significant (treatment difference, 18.6%; P=0.0670). Mean ocular discomfort scores (range, 0-9) were statistically significantly lower with BTFC versus DTFC (2.6 versus 3.7; P=0.0002, Wilcoxon- Mann-Whitney test). More patients who preferred BTFC over DTFC were confident that they would adhere to their preferred medication. Treatment-related adverse events included blurred vision with BTFC and eye irritation or eye pain with DTFC., CONCLUSION: BTFC and DTFC were preferred by approximately 60% and 40% of patients, respectively, and BTFC was associated with less patient-reported ocular discomfort. Greater ocular comfort of glaucoma medications may improve treatment adherence. AU - Altafini, Romeo AU - Scherzer, Maria-Luise AU - Hubatsch, Douglas A. AU - Frezzotti, Paolo DO - https://dx.doi.org/10.2147/OPTH.S88891 PY - 2015 SE - Altafini, Romeo. Glaucoma Segment Unit, "San Bortolo" Hospital, Vicenza, Italy. Scherzer, Maria-Luise. Private Practice, Regenstauf, Germany. Hubatsch, Douglas A. Alcon Laboratories, Inc., Fort Worth, TX, USA. Frezzotti, Paolo. Ophthalmic Unit, University of Siena, Siena, Italy. SN - 1177-5467 SP - 2263-70 ST - Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26664041 VL - 9 Y2 - 20151201// ID - 1055 ER - TY - JOUR AD - C. Altamura, Department of Psychiatry, University of Milan, Via G.B. Grassi 74, 20127 Milan, Italy AU - Altamura, C. AU - Elliott, T. C1 - metamucil DB - Embase DO - 10.1016/S0924-9338(03)80005-6 IS - SUPPL. 2 KW - amisulpride antacid agent atypical antipsychotic agent cholinergic receptor blocking agent clozapine gastrointestinal agent haloperidol ispagula neuroleptic agent olanzapine phenothiazine placebo quetiapine risperidone ziprasidone adverse drug reaction aging agranulocytosis akathisia article body weight cardiovascular disease cognitive defect comorbidity confusion constipation delirium delusional disorder depression diabetes mellitus disease exacerbation disease predisposition drug metabolism drug tissue level dystonia elderly care extrapyramidal symptom falling glaucoma human hyperlipidemia memory disorder onset age orthostatic hypotension parkinsonism patient compliance polypharmacy priority journal prostatism schizophrenia sedation side effect tardive dyskinesia tremor urine retention xerostomia metamucil LA - English M3 - Article N1 - L40848721 2005-08-02 PY - 2003 SN - 0924-9338 SP - 46s-53s ST - Schizophrenia in the elderly: A special case requiring special management? T2 - European Psychiatry TI - Schizophrenia in the elderly: A special case requiring special management? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40848721&from=export http://dx.doi.org/10.1016/S0924-9338(03)80005-6 VL - 18 ID - 3786 ER - TY - JOUR AB - OBJECTIVE: To assess perceived barriers to glaucoma follow-up care, including the lack of glaucoma knowledge and the lack of health care access, among participants in a community glaucoma screening program., DESIGN: Community survey., PARTICIPANTS: Two hundred forty-three consecutive participants in a series of free glaucoma screenings between November 2002 and August 2003., METHODS: The survey consisted of 20 questions designed to elicit knowledge of glaucoma and perception of potential barriers to follow-up care. Our aim was to find correlations between patient demographics and knowledge of glaucoma as well as perceived potential barriers to follow-up care. The data were analyzed using SPSS, v. 10.1., RESULTS: The average age of the respondents was 70 years, and females predominated (66%). About half of the respondents knew of an eye doctor in their neighborhood, and 60% had had an eye examination in the past year. Two hundred twenty-two (91%) indicated they could get to an eye doctor if the screening examination indicated they needed a follow-up examination. Two hundred twenty (90.5%) had medical insurance. One hundred seventy-eight (73%) of the participants had heard of glaucoma; 71 (29%) identified an accurate definition of glaucoma. The level of education and the language spoken at home were correlated with both glaucoma awareness (p < 0.001; p < 0.001) and knowledge of an accurate definition of glaucoma (p < 0.001; p < 0.025)., CONCLUSIONS: In this population, a lack of adequate education about glaucoma may be more significantly associated with poor follow-up rates than a lack of access to care in those identified as glaucoma suspects. AU - Altangerel, Undraa AU - Nallamshetty, Hema S. AU - Uhler, Tara AU - Fontanarosa, Joann AU - Steinmann, William C. AU - Almodin, Juliana M. AU - Chen, Brian H. AU - Henderer, Jeffrey D. DO - https://dx.doi.org/10.3129/i08-175 IS - 1 KW - Adolescent Adult Aged Aged, 80 and over Attitude to Health Child *Diagnostic Techniques, Ophthalmological Female Follow-Up Studies *Glaucoma/di [Diagnosis] *Health Knowledge, Attitudes, Practice *Health Services Accessibility Health Services Research Health Surveys Humans Male Middle Aged Surveys and Questionnaires PY - 2009 SE - Altangerel, Undraa. Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA. SN - 0008-4182 SP - 66-9 ST - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19169316 VL - 44 ID - 1480 ER - TY - JOUR AB - Purpose: The first line of treatment for open-angle glaucoma is the use of daily hypotensive eye drops to control intra-ocular pressure. Adherence to this treatment is known to be challenging for patients, and has been reported to be worse in patients of African descent (AD), a segment of the population that is disproportionately affected by the disease. Motivational interviewing (MI) can improve adherence and has been shown to be more effective in minority populations. The purpose of this prospective, longitudinal and interventional pilot study was to determine whether MI might improve adherence in glaucoma patients of AD. Methods: Thirteen patients of African descent (AD) who received a clinical diagnosis of open-angle glaucoma within the past five years were included in this study. All patients used once-daily prostaglandin analog eye drops and administered their medication. Adherence was measured using Medical Event Monitoring System (MEMS) bottles. The cap of these bottles electronically records the date and time at which the bottle is opened. At visit 1, patients were instructed to place their eye drop bottle in the MEMS bottle and to otherwise use their eye drops as usual. At the 4-weeks visit, baseline adherence was assessed. Patients with adherence levels below 75% (n=9) received an approximately 20-minutes MI intervention and those with adherence levels over 75% served as controls (n=4). At the 12-weeks visit, patients returned and the final adherence was assessed. The difference between baseline and final adherence was compared between the groups using one-tailed paired t-tests. Results: In the group who received MI, final adherence (67.9% ± 7.68) was significantly higher than baseline adherence (55.95% ± 22.16) (p=0.03). Adherence improved in all but one of these patients (the adherence of one patient decreased by 0.2%). In controls, no significant difference between baseline adherence (81.38% ± 5.52) and final adherence (82% ± 17.33) (p=0.46) was observed. In this group, adherence improved in two patients (by 11.3% and 10.7%) and decreased in two patients (by 3.6% and 15.9%). Conclusions: These preliminary results obtained in a small sample suggest that MI may be effective in improving adherence in glaucoma in patients of African descent. AD - I. Altaras, Ophthalmology, Indiana University Glick Eye Institute, Indianapolis, IN, United States AU - Altaras, I. AU - Bigatti, S. AU - Sirk, E. AU - Hosty, E. AU - Payton, C. AU - Grow, S. AU - Sutton, B. AU - Torbit, J. AU - Idowu, E. AU - Racette, L. DB - Embase IS - 7 KW - antihypertensive agent eye drops prostaglandin derivative clinical article clinical trial controlled study diagnosis drug therapy female human human tissue information processing male monitoring motivational interviewing open angle glaucoma pilot study Student t test LA - English M3 - Conference Abstract N1 - L615920756 2017-05-15 PY - 2015 SN - 0146-0404 SP - 5021 ST - A pilot study of the effectiveness of motivational interviewing to improve adherence to glaucoma treatment in patients of African descent T2 - Investigative Ophthalmology and Visual Science TI - A pilot study of the effectiveness of motivational interviewing to improve adherence to glaucoma treatment in patients of African descent UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615920756&from=export VL - 56 ID - 2813 ER - TY - JOUR AB - Glaucoma experts continue to look for reasons for noncompliance and ways to increase patient cooperation. AN - 106471502. Language: English. Entry Date: 20060714. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Altersitz, K. DB - ccm DP - EBSCOhost IS - 11 KW - Glaucoma -- Therapy Patient Compliance Drug Delivery Systems Glaucoma -- Complications Medication Compliance Ophthalmic Solutions Patient Attitudes N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 82-85 ST - Compliance an ongoing issue in glaucoma T2 - Ocular Surgery News TI - Compliance an ongoing issue in glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106471502&site=ehost-live&scope=site VL - 24 ID - 4542 ER - TY - JOUR AB - Glaucoma medication persistence in Medicare-aged patients was comparable to persistence in all other age groups. AN - 106337030. Language: English. Entry Date: 20060922. Revision Date: 20150711. Publication Type: Journal Article AU - Altersitz, K. DB - ccm DP - EBSCOhost IS - 16 KW - Glaucoma -- Drug Therapy Patient Compliance -- Evaluation Aged Medicare Medication Compliance Patient Attitudes N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 25-26 ST - Glaucoma medication persistence low in all age groups, study finds T2 - Ocular Surgery News TI - Glaucoma medication persistence low in all age groups, study finds UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106337030&site=ehost-live&scope=site VL - 24 ID - 4708 ER - TY - JOUR AB - Physicians can use patients to reach family members, who are at high risk of glaucoma. AN - 106455933. Language: English. Entry Date: 20060616. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Altersitz, K. DB - ccm DP - EBSCOhost IS - 9 KW - Glaucoma -- Familial and Genetic Risk Assessment Glaucoma -- Prevention and Control Glaucoma -- Risk Factors Health Knowledge Health Services Accessibility Intraocular Pressure Patient Education Race Factors Surveys Vision Screening -- Methods N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 30-30 ST - Glaucoma patient can serve as conduit to reach out to family members at risk T2 - Ocular Surgery News TI - Glaucoma patient can serve as conduit to reach out to family members at risk UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106455933&site=ehost-live&scope=site VL - 24 ID - 4742 ER - TY - JOUR AB - PURPOSE: To facilitate future glaucoma model development and to provide guidance for decision-makers evaluating them, we provide an overview of an innovative glaucoma model and highlight important modeling considerations., CONSIDERATIONS: The considerations that were addressed include: disease outcome that is both relevant and meaningful to current clinical practice; diversity in treatment options and practices; incorporation of therapy discontinuation; and consideration of the variability in patient response to treatment., MODEL SCOPE: A state-transition, Monte Carlo simulation model was developed to simulate the management and treatment of patients with glaucoma and/or ocular hypertension. The model examines strategies involving sequential use of up to 6 pharmacologic interventions. Transitions are based on the monthly probability that a patient is no longer "successfully maintained" on therapy, which can be a consequence of lack of intraocular pressure control, adverse events, lack of compliance, or lack of persistence. Outputs of the model include months on each treatment, frequency of therapy switches, days of intraocular pressure control, frequency of ophthalmologist visits, frequency of surgery, and glaucoma-related costs. The model allows the user to specify country-specific treatment strategies, survival on therapy, surgical rates, practice patterns, and costs., CONCEPT APPLICATION: The model presented offers insights into accommodating patient and clinician variability through the use of persistence distributions. It will facilitate future glaucoma model development and provide insight for decision-makers who must evaluate model-based analyses of the economic value of glaucoma interventions. AU - Althin, Rikard AU - Grima, Daniel T. AU - Dhawan, Ravinder AU - Bernard, Lisa M. IS - 6 KW - Antihypertensive Agents/ec [Economics] Antihypertensive Agents/tu [Therapeutic Use] Cost-Benefit Analysis Delivery of Health Care/ec [Economics] Drug Costs Filtering Surgery/ec [Economics] *Glaucoma/ec [Economics] *Glaucoma/th [Therapy] Health Care Costs Health Services Research/ec [Economics] Humans Intraocular Pressure *Models, Economic Monte Carlo Method Ocular Hypertension/ec [Economics] Ocular Hypertension/th [Therapy] Treatment Outcome PY - 2006 SE - Althin, Rikard. Pfizer Global Pharmaceuticals, Sandwich, UK. rikard.althin@pfizer.com SN - 1057-0829 SP - 541-7 ST - Considerations in developing model-based economic evaluations of glaucoma treatment T2 - Journal of glaucoma TI - Considerations in developing model-based economic evaluations of glaucoma treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17106369 VL - 15 ID - 1634 ER - TY - JOUR AB - OBJECTIVES: To determine the prevalence of blindness and visual impairment in Honduras, its causes and the response by the health services to growing demand., METHODS: A cross-sectional population study was conducted between June and December 2013 using the standard methodology of the Rapid Assessment of Avoidable Blindness. A random sample survey was done in 63 clusters of 50 individuals aged >= 50, representative of the country as a whole. Visual acuity (VA) was assessed using a Snellen eye chart, and the condition of the lens and posterior pole was examined by direct ophthalmoscopy. Cataract surgical coverage was calculated and an assessment made of its quality, the causes of VA < 20/60 and the barriers to accessing surgical treatment., RESULTS: A total of 2 999 people were examined (95.2% of the forecast total). Blindness prevalence was 1.9% (confidence interval of 95%: 1.4-2.4%) and 82.2% of these cases were avoidable. The main causes of blindness were unoperated cataracts (59.2%) and glaucoma (21.1%). Uncorrected refraction error was the main cause of severe (19.7%) and moderate (58.6%) visual impairment. Cataract surgical coverage was 75.2%. 62.5% of the eyes operated for cataracts achieved a VA > 20/60 with available correction. The main barriers against cataract surgery were cost (27.7%) and the lack of availability or difficulty of geographical access to the treatment (24.6%)., CONCLUSIONS: The prevalence of blindness and visual impairment in Honduras is similar to that of other Latin American countries. 67% of cases of blindness could be resolved by improving the response capacity of the ophthalmological services, especially of cataract surgery, improving optician services and incorporating eye care in primary health care. AU - Alvarado, Doris AU - Rivera, Belinda AU - Lagos, Luis AU - Ochoa, Mayra AU - Starkman, Ivette AU - Castillo, Mariela AU - Flores, Eduardo AU - Lansingh, Van C. AU - Limburg, Hans AU - Silva, Juan Carlos IS - 5 KW - Aged Aged, 80 and over *Blindness/ep [Epidemiology] Blindness/et [Etiology] Blindness/pc [Prevention & Control] Cataract/co [Complications] Cataract/ep [Epidemiology] Cataract Extraction Cross-Sectional Studies Female Glaucoma/co [Complications] Glaucoma/ep [Epidemiology] Health Services Needs and Demand Health Surveys Honduras/ep [Epidemiology] Humans Male Middle Aged Prevalence Sampling Studies Vision Disorders/ep [Epidemiology] Vision Disorders/th [Therapy] PY - 2014 SE - Alvarado, Doris. Hospital San Felipe, Tegucigalpa, Honduras. Rivera, Belinda. Hospital San Felipe, Tegucigalpa, Honduras. Lagos, Luis. Hospital San Felipe, Tegucigalpa, Honduras. Ochoa, Mayra. Instituto Hondureno de la Seguridad Social, Tegucigalpa, Honduras. Starkman, Ivette. Instituto Hondureno de la Seguridad Social, Tegucigalpa, Honduras. Castillo, Mariela. Centro de Salud Integral ZOE, Tegucigalpa, Honduras. Flores, Eduardo. Centro de Salud Integral ZOE, Tegucigalpa, Honduras. Lansingh, Van C. Agencia Internacional para la Prevencion de la Ceguera, Mexico, Mexico. Limburg, Hans. Health Information Services, Grootebroek, Paises Bajos. Silva, Juan Carlos. Organizacion Panamericana de la Salud, Bogota, Colombia, silvajuan@paho.org. SN - 1680-5348 1020-4989 SP - 300-5 ST - [National survey of blindness and avoidable visual impairment in Honduras] T2 - Encuesta nacional de ceguera y deficiencia visual evitables en Honduras. TI - [National survey of blindness and avoidable visual impairment in Honduras] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25604099 VL - 36 ID - 847 ER - TY - JOUR AB - Objectives. To determine the prevalence of blindness and visual impairment in Honduras, its causes and the response by the health services to growing demand. Methods. A cross-sectional population study was conducted between June and December 2013 using the standard methodology of the Rapid Assessment of Avoidable Blindness. A random sample survey was done in 63 clusters of 50 individuals aged ≥ 50, representative of the country as a whole. Visual acuity (VA) was assessed using a Snellen eye chart, and the condition of the lens and posterior pole was examined by direct ophthalmoscopy. Cataract surgical coverage was calculated and an assessment made of its quality, the causes of VA < 20/60 and the barriers to accessing surgical treatment. Results. A total of 2 999 people were examined (95.2% of the forecast total). Blindness prevalence was 1.9% (confidence interval of 95%: 1.4-2.4%) and 82.2% of these cases were avoidable. The main causes of blindness were unoperated cataracts (59.2%) and glaucoma (21.1%). Uncorrected refraction error was the main cause of severe (19.7%) and moderate (58.6%) visual impairment. Cataract surgical coverage was 75.2%. 62.5% of the eyes operated for cataracts achieved a VA > 20/60 with available correction. The main barriers against cataract surgery were cost (27.7%) and the lack of availability or difficulty of geographical access to the treatment (24.6%). Conclusions. The prevalence of blindness and visual impairment in Honduras is similar to that of other Latin American countries. 67% of cases of blindness could be resolved by improving the response capacity of the ophthalmological services, especially of cataract surgery, improving optician services and incorporating eye care in primary health care. Objetivo. Determinar la prevalencia de ceguera y deficiencia visual en Honduras, sus causas y la respuesta que los servicios de salud están dando a la creciente demanda. Métodos. Estudio poblacional transversal realizado entre junio y diciembre de 2013 mediante la metodología estándar de evaluación rápida de ceguera evitable. Se realizó un muestreo aleatorio en 63 conglomerados de 50 personas de 50 años o más, representativo de todo el país. Se evaluó la agudeza visual (AV) mediante una cartilla de Snellen y el estado del cristalino y del polo posterior por oftalmoscopía directa. Se calculó la cobertura de cirugía de catarata y se evaluó su calidad, las causas de tener AV < 20/60 y las barreras para acceder al tratamiento quirúrgico. Resultados. Se examinaron 2 999 personas (95,2% del total previsto). La prevalencia de ceguera fue de 1,9% (intervalo de confianza de 95%: 1,4-2,4%) y 82,2% de esos casos era evitable. La catarata no operada fue la causa principal de ceguera (59,2%), seguida del glaucoma (21,1%). Los errores de refracción no corregidos fueron la principal causa de deficiencia visual, tanto severa (19,7%) como moderada (58,6%). La cobertura de cirugía de catarata fue de 75,2%. De los ojos operados de catarata, 62,5% alcanzó una AV ≥ 20/60 con la corrección disponible. Las principales barreras para someterse a la cirugía de catarata fueron el costo (27,7%) y la falta de disponibilidad o de acceso geográfico al tratamiento (24,6%). Conclusiones. La prevalencia de ceguera y deficiencia visual en Honduras es similar a la de otros países latinoamericanos. Mejorar la capacidad resolutiva de los servicios oftalmológicos, especialmente de cirugía de catarata, desarrollar los servicios ópticos y la atención ocular incorporada en la atención primaria en salud, podrían resolver el 67% de los casos de ceguera. AD - Hospital San Felipe, Tegucigalpa, Honduras Instituto Hondureño de la Seguridad Social, Tegucigalpa, Honduras Centro de Salud Integral ZOE, Tegucigalpa, Honduras Visión 2000, Agencia Internacional para la Prevención de la Ceguera, México, D.F., México Health Information Services, Grootebroek, Países Bajos Organizacion Panamericana de la Salud, Bogotá, Colombia AN - 100666017. Language: Spanish. Entry Date: 20150128. Revision Date: 20190308. Publication Type: Article AU - Alvarado, Doris AU - Rivera, Belinda AU - Lagos, Luis AU - Ochoa, Mayra AU - Starkman, Ivette AU - Castillo, Mariela AU - Flores, Eduardo AU - Lansingh, Van C. AU - Limburg, Hans AU - Silva, Juan Carlos DB - ccm DP - EBSCOhost IS - 5 KW - Blindness -- Epidemiology -- Honduras Vision Disorders -- Epidemiology -- Honduras Prevalence Human Honduras Descriptive Statistics Cross Sectional Studies Random Sample Visual Acuity Blindness -- Etiology -- Honduras Cataract -- Complications -- Honduras Glaucoma -- Complications -- Honduras Cataract Extraction -- Economics -- Honduras Health Services Accessibility Male Female N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. NLM UID: 9705400. PY - 2014 SN - 1020-4989 SP - 300-305 ST - Investigación original. Encuesta nacional de ceguera y deficiencia visual evitables en Honduras T2 - Revista Panamericana de Salud Pública TI - Investigación original. Encuesta nacional de ceguera y deficiencia visual evitables en Honduras UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=100666017&site=ehost-live&scope=site VL - 36 ID - 4456 ER - TY - JOUR AB - In an objective test to determine compliance with acetazolamide regimens by patients with glaucoma, treated inpatients had lower carbon dioxide levels (less than or equal to mEq/L) than untreated patients (greater than or equal to 25 mEq/L). The test results may be inaccurate in some obese diabetic patients with hyperglycemia and in some patients with obstructive lung disease, such as asthma and emphysema. In an outpatient clinic population, the test showed that 35% (30/87) of the patients did not seem to be taking acetazolamide and 22% (19/87) seemed to be taking it less frequently. AU - Alward, P. D. AU - Wilensky, J. T. IS - 11 KW - Acetazolamide/ad [Administration & Dosage] *Acetazolamide/tu [Therapeutic Use] *Carbon Dioxide/bl [Blood] Glaucoma/bl [Blood] *Glaucoma/dt [Drug Therapy] Humans *Patient Compliance PY - 1981 SN - 0003-9950 SP - 1973-6 ST - Determination of acetazolamide compliance in patients with glaucoma T2 - Archives of ophthalmology (Chicago, Ill. : 1960) TI - Determination of acetazolamide compliance in patients with glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=6794553 VL - 99 ID - 2260 ER - TY - JOUR AB - Adherence to medical treatment in primary open angle glaucoma is key to the success of the treatment. Most of the work show that glaucoma patients are poor observant. Poor adherence is multifactorial. The analysis of these factors is crucial. That is why the author wanted to expose, through a literature review, the main determinants of adherence in glaucoma. AU - Amara, Fatma AU - Ben Amor, Hager AU - Kaibi, Imene AU - Taktak, Mariem AU - Taktak, Jalel IS - 6 KW - *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Medication Adherence Risk Factors Treatment Outcome PY - 2018 SN - 0041-4131 SP - 335-338 ST - The determinants of therapeutic observance in open-angle glaucoma T2 - La Tunisie medicale TI - The determinants of therapeutic observance in open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30430469 VL - 96 ID - 400 ER - TY - JOUR AB - Introduction: The International Classification of Headache Disorders classifies ophthalmoplegic migraine (OM) under 'cranial neuralgias and central causes of facial pain.' OM is diagnosed when all the following criteria are satisfied: At least two attacks fulfilling criterion B. Migraine-like headache accompanied or followed within four days of its onset by paresis of one or more of the III, IV and/or VI cranial nerves. Parasellar orbital fissure and posterior fossa lesions ruled out by appropriate investigations. In children the syndrome is rare and magnetic resonance (MR) shows strongly enhancing thickened nerve at the root entry zone (REZ). Method: The authors review the literature focusing on pathogenesis theories. Results: The authors suggest that ischemic reversible breakdown of the blood-nerve barrier is the most probable cause of OM and to include MR findings in the hallmarks of the disease. Conclusion: OM is the same disease in adulthood and childhood, even if in adults the MR imaging findings are negative. In the authors’ opinion, OM should be classified as migraine. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Nicolini, Francesca, Department of Neurosurgery, IRCCS Istituto delle Scienze Neurologiche, Via Altura 3, 40138, Bologna, Italy AN - 2014-42746-007 AU - Ambrosetto, Paolo AU - Nicolini, Francesca AU - Zoli, Matteo AU - Cirillo, Luigi AU - Feraco, Paola AU - Bacci, Antonella DB - psyh DO - 10.1177/0333102414523843 DP - EBSCOhost IS - 11 KW - Ophthalmoplegic migraine neuroradiology headache cranial nerve palsy pediatric Cerebral Palsy Migraine Headache Eye Disorders Magnetic Resonance Imaging Neuralgia Pediatrics N1 - Department of Diagnostic Imaging, Villalba Hospital, GVM, Care and Research, Italy. Other Publishers: Wiley-Blackwell Publishing Ltd. Release Date: 20150622. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Cerebral Palsy; Migraine Headache. Minor Descriptor: Eye Disorders; Magnetic Resonance Imaging; Neuralgia; Pediatrics. Classification: Physical & Somatoform & Psychogenic Disorders (3290). Population: Human (10). References Available: Y. Page Count: 6. Issue Publication Date: Oct, 2014. Publication History: Accepted Date: Jan 11, 2014; Revised Date: Jan 10, 2014; Nov 18, 2013; Sep 29, 2013; Jul 26, 2013; May 29, 2013; First Submitted Date: Mar 7, 2013. Copyright Statement: International Headache Society. 2014. PY - 2014 SN - 0333-1024 1468-2982 SP - 914-919 ST - Ophthalmoplegic migraine: From questions to answers T2 - Cephalalgia TI - Ophthalmoplegic migraine: From questions to answers UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-42746-007&site=ehost-live&scope=site francescanicolini@hotmail.it VL - 34 ID - 4857 ER - TY - JOUR AD - Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles St, Boston, MA 02114-4724, United States Menelick II Hospital, Addis Ababa University, Addis Ababa, Ethiopia Makkah Eye Complex, Makkah Ophthalmic Technical College, Al-Rayad, Khartoum, Sudan AU - Ament, J. D. AU - Tilahun, Y. AU - Mudawi, E. AU - Pineda, R. DB - Scopus DO - 10.1001/archophthalmol.2010.79 IS - 6 M3 - Letter N1 - Cited By :14 Export Date: 19 July 2021 PY - 2010 SP - 795-797 ST - Role for ipsilateral autologous corneas as a carrier for the Boston keratoprosthesis: The Africa experience T2 - Archives of Ophthalmology TI - Role for ipsilateral autologous corneas as a carrier for the Boston keratoprosthesis: The Africa experience UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953628471&doi=10.1001%2farchophthalmol.2010.79&partnerID=40&md5=044d339770af470f1723a3fa7c5100d8 VL - 128 ID - 5204 ER - TY - JOUR AB - BACKGROUND: To support patient-centred care, healthcare organisations increasingly offer patients access to data stored in the institutional electronic health record (EHR)., OBJECTIVES: Primary objective 1. To assess the effects of providing adult patients with access to electronic health records (EHRs) alone or with additional functionalities on a range of patient, patient-provider, and health resource consumption outcomes, including patient knowledge and understanding, patient empowerment, patient adherence, patient satisfaction with care, adverse events, health-related quality of life, health-related outcomes, psychosocial health outcomes, health resource consumption, and patient-provider communication. Secondary objective 1. To assess whether effects of providing adult patients with EHR access alone versus EHR access with additional functionalities differ among patient groups according to age, educational level, or different status of disease (chronic or acute)., SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and Scopus in June 2017 and in April 2020., SELECTION CRITERIA: Randomised controlled trials and cluster-randomised trials of EHR access with or without additional functionalities for adults with any medical condition., DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures., MAIN RESULTS: We included 10 studies with 78 to 4500 participants and follow-up from 3 to 24 months. Nine studies assessed the effects of EHR with additional functionalities, each addressing a subset of outcomes sought by this review. Five studies focused on patients with diabetes mellitus, four on patients with specific diseases, and one on all patients. All studies compared EHR access alone or with additional functionalities plus usual care versus usual care only. No studies assessing the effects of EHR access alone versus EHR access with additional functionalities were identified. Interventions required a variety of data within the EHR, such as patient history, problem list, medication, allergies, and lab results. In addition to EHR access, eight studies allowed patients to share self-documented data, seven offered individualised disease management functions, seven offered educational disease-related information, six supported secure communication, and one offered preventive reminders. Only two studies were at low or unclear risk of bias across domains. Meta-analysis could not be performed, as participants, interventions, and outcomes were too heterogeneous, and most studies presented results based on different adjustment methods or variables. The quality of evidence was rated as low or very low across outcomes. Overall differences between intervention and control groups, if any, were small. The relevance of any small effects remains unclear for most outcomes because in most cases, trial authors did not define a minimal clinically important difference. Overall, results suggest that the effects of EHR access alone and with additional functionalities are mostly uncertain when compared with usual care. Patient knowledge and understanding: very low-quality evidence is available from one study, so we are uncertain about effects of the intervention on patient knowledge about diabetes and blood glucose testing. Patient empowerment: low-quality evidence from three studies suggests that the intervention may have little or no effect on patient empowerment measures. Patient adherence: low-quality evidence from two studies suggests that the intervention may slightly improve adherence to the process of monitoring risk factors and preventive services. Effects on medication adherence are conflicting in two studies; this may or may not improve to a clinically relevant degree. Patient satisfaction with care: low-quality evidence from three studies suggests that the intervention may have little or no effect on patient satisfaction, with conflicting results. Adverse events: two small studies reported on mortality; one of these also reported on serious and other adverse events, but sample sizes were oo small for small differences to be detected. Therefore, low-quality evidence suggests that the intervention may have little to no effect on mortality and other adverse events. Health-related quality of life: only very low-quality evidence from one study is available. We are uncertain whether the intervention improves disease-specific quality of life of patients with asthma. Health-related outcomes: low-quality evidence from eight studies suggests that the intervention may have little to no effect on asthma control, glycosylated haemoglobin (HbA1c) levels, blood pressure, low-density lipoprotein or total cholesterol levels, body mass index or weight, or 10-year Framingham risk scores. Low-quality evidence from one study suggests that the composite scores of risk factors for diabetes mellitus may improve slightly with the intervention, but there is uncertainty about effects on ophthalmic medications or intraocular pressure. Psychosocial health outcomes: no study investigated psychosocial health outcomes in a more than anecdotal way. Health resource consumption: low-quality evidence for adult patients in three studies suggests that there may be little to no effect of the intervention on different measures of healthcare use. Patient-provider communication: very low-quality evidence is available from a single small study, and we are uncertain whether the intervention improves communication measures, such as the number of messages sent., AUTHORS' CONCLUSIONS: The effects of EHR access with additional functionalities in comparison with usual care for the most part are uncertain. Only adherence to the process of monitoring risk factors and providing preventive services as well as a composite score of risk factors for diabetes mellitus may improve slightly with EHR access with additional functionalities. Due to inconsistent terminology in this area, our search may have missed relevant studies. As the overall quality of evidence is very low to low, future research is likely to change these results. Further trials should investigate the impact of EHR access in a broader range of countries and clinical settings, including more patients over a longer period of follow-up, as this may increase the likelihood of detecting effects of the intervention, should these exist. More studies should focus on assessing outcomes such as patient empowerment and behavioural outcomes, rather than concentrating on health-related outcomes alone. Future studies should distinguish between effects of EHR access only and effects of additional functionalities, and investigate the impact of mobile EHR tools. Future studies should include information on usage patterns, and consider the potential for widening health inequalities with implementation of EHR access. A taxonomy for EHR access and additional functionalities should be developed to promote consistency and comparability of outcome measures, and facilitate future reviews by better enabling cross-study comparisons. Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. AU - Ammenwerth, Elske AU - Neyer, Stefanie AU - Horbst, Alexander AU - Mueller, Gerhard AU - Siebert, Uwe AU - Schnell-Inderst, Petra DO - https://dx.doi.org/10.1002/14651858.CD012707.pub2 KW - Adult Asthma/th [Therapy] Bias Blood Glucose/an [Analysis] Comprehension Diabetes Mellitus/bl [Blood] Diabetes Mellitus/di [Diagnosis] Electronic Health Records/sn [Statistics & Numerical Data] *Electronic Health Records Glaucoma/dt [Drug Therapy] Health Knowledge, Attitudes, Practice Health Services Needs and Demand/sn [Statistics & Numerical Data] Heart Failure/th [Therapy] Humans Hypertension/th [Therapy] Middle Aged Patient Access to Records/sn [Statistics & Numerical Data] *Patient Access to Records Patient Compliance Patient Participation Patient Satisfaction Quality of Life Randomized Controlled Trials as Topic Treatment Outcome PY - 2021 SE - Ammenwerth, Elske. Department of Biomedical Informatics and Mechatronics, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. Neyer, Stefanie. Department of Nursing Science and Gerontology, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. Horbst, Alexander. Department of Biomedical Informatics and Mechatronics, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. Mueller, Gerhard. Department of Nursing Science and Gerontology, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. Siebert, Uwe. Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. Schnell-Inderst, Petra. Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. SN - 1469-493X 1361-6137 SP - CD012707 ST - Adult patient access to electronic health records T2 - The Cochrane database of systematic reviews TI - Adult patient access to electronic health records UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33634854 VL - 2 Y2 - 20210226// ID - 221 ER - TY - JOUR AD - Universitats-Augenklinik, Spitalgasse 2, A-1090 Wien AU - Amon, A. AU - Menapace, R. AU - Wedrich, A. AU - Radax, U. DB - Embase IS - 1 KW - article clinical article education glaucoma human methodology patient care patient compliance patient education psychological aspect LA - German M3 - Article N1 - L20133605 1990-05-27 PY - 1990 SN - 0930-4282 SP - 5-8 ST - Aspects of glaucoma patient care and its impact on compliance T2 - Spektrum der Augenheilkunde TI - Aspects of glaucoma patient care and its impact on compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L20133605&from=export VL - 4 ID - 4043 ER - TY - JOUR AB - Purpose: To analyze the knowledge level shown by glaucomatous patients about their disease. Methods: Seventy glaucomatous patients, cared for at the Glaucoma Department - Altino Ventura Foundation, Recife-PE-Brasil, were interviewed from August to October, 2001. Results: Thirty-one patients (44.3%) did not know they had glaucoma, whereas 52 (74.3%) did not know what glaucoma meant and 26 (52.0%) did not know the purpose of the medication. Comments: The results suggest that the patients were not well informed about their disease and this may affect the treatment compliance. AD - C. Amorim Barretto, Fundacao Altino Ventura, Rua da Soledade, 170 - Boa Vista, Recife - PE - CEP: 50070-040, Brazil AU - Amorim Barretto, C. AU - De Melo Ventura, A. G. G. AU - Dantas, H. DB - Embase IS - 3 KW - adult aged article Brazil female glaucoma human major clinical study male patient attitude patient compliance patient education LA - Portuguese M3 - Article N1 - L36740920 2003-07-08 PY - 2003 SN - 0034-7280 SP - 187-189 ST - Glaucomatous knowledge level about their disease T2 - Revista Brasileira de Oftalmologia TI - Glaucomatous knowledge level about their disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36740920&from=export VL - 62 ID - 3829 ER - TY - JOUR AB - Rigid gas permeable (RGP) contact lenses were prescribed and worn with little difficulty by 10 consecutive aphakic infants. Fluoroperm 92 lenses were used instead of silicone lenses (Bausch & Lomb) because of their lower cost, ease in handling, flexibility in design, and better neutralization of astigmatism. Lenses were worn on a daily wear basis (with occasional overnight wear) to reduce the risk of keratitis. Keratometry readings were taken at the time of surgery with the patient in a supine position. Trial lens fitting was performed 1 to 7 days later using a Burton Lamp. None of the patients developed keratitis, corneal neovascularization, or the sucked-on-lens syndrome. The lenses were well tolerated and the parents soon became adept at handling them. We now use RGP lenses as our lens of choice when treating aphakic infants. AU - Amos, C. F. AU - Lambert, S. R. AU - Ward, M. A. IS - 4 KW - *Aphakia, Postcataract/th [Therapy] *Cataract/cn [Congenital] *Cataract Extraction Child, Preschool *Contact Lenses Follow-Up Studies Humans Infant Patient Satisfaction PY - 1992 SE - Amos, C F. Department of Ophthalmology, Emory University School of Medicine, Atlanta, Ga. SN - 0191-3913 SP - 243-5 ST - Rigid gas permeable contact lens correction of aphakia following congenital cataract removal during infancy T2 - Journal of pediatric ophthalmology and strabismus TI - Rigid gas permeable contact lens correction of aphakia following congenital cataract removal during infancy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1512667 VL - 29 ID - 2110 ER - TY - JOUR AB - Expert patient programmes (EPPs) are becoming an increasingly important aspect of chronic disease management, resulting in improved health outcomes for patients. Patients with chronic open angle glaucoma (COAG) require lifelong therapy. However, to date, no EPPs have been designed specifically for patients with chronic eye conditions like COAG. This article describes the development and implementation of the Glaucoma Expert Patient Programme (GEPP), a glaucoma-specific educational self-management programme which aims to improve glaucoma patients' knowledge, self-management skills, expectations and adherence to treatment. A review of theoretical frameworks and models which underpin the design, use and conduct of EPPs was undertaken, and the GEPP was designed based on the model by Kate Lorig (2003). The result is an educational programme which offers COAG patients a different perspective on their condition and supports them with knowledge, skills and strategies to better manage their condition on a daily basis. AU - Amro, Raed AU - Cox, Carol L. AU - Waddington, Kathryn AU - Siriwardena, Dilani IS - 20 KW - Chronic Disease Disease Management *Glaucoma, Open-Angle/pc [Prevention & Control] Glaucoma, Open-Angle/px [Psychology] Health Behavior Humans Models, Educational Models, Organizational Motivation Patient Compliance *Patient Education as Topic/og [Organization & Administration] Patient Participation Peer Group Program Development Self Care/mt [Methods] Self Care/px [Psychology] *Self-Help Groups/og [Organization & Administration] PY - 2010 SE - Amro, Raed. Accident and Emergency Department, Moorfields Eye Hospital NHS Foundation Trust, London. SN - 0966-0461 SP - 1287-92 ST - Glaucoma expert patient programme and ocular hypotensive treatment T2 - British journal of nursing (Mark Allen Publishing) TI - Glaucoma expert patient programme and ocular hypotensive treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21072015 VL - 19 ID - 1324 ER - TY - JOUR AB - BACKGROUND: The lack of prospective data comparing early surgery and medical management in primary open-angle glaucoma (POAG) in the developing world led us to conduct a small randomised controlled clinical trial to evaluate acceptance and effectiveness of early trabeculectomy in these patients., METHODS: A total of 60 patients with moderately advanced POAG were randomised into three groups (Group I-Conventional medical management, Group II-Option for early trabeculectomy, Group III-Received an educational package about their disease before an option for early trabeculectomy). The patients were followed up for a period of 6 months for visual acuity, intraocular pressures (IOP), and subjective satisfaction., RESULTS: The three study groups were statistically similar with respect to mean IOP, demographic, and socio-economic profile. 35% of the patients accepted early surgery when offered a choice between early surgery and medical management in one of the groups. 65% of patients in another group expressed willingness for an early surgery after receiving health education on glaucoma. The mean IOP in the operated eyes was lower than the medically treated eyes at 2 weeks (16.6 vs 23.0 mmHg), 6 months (18.5 vs 22.8 mmHg), and 1-year review (17.9 vs 22.3 mmHg) (P<0.001). No significant difference was seen among the groups with regard to visual acuity and subjective satisfaction., CONCLUSION: There is a reasonable acceptance of early surgery in POAG patients in the developing world and increases on educating patients about their disease. Early surgery offers better IOP control with no long-term subjective adverse effects. AU - Anand, A. AU - Negi, S. AU - Khokhar, S. AU - Kumar, H. AU - Gupta, S. K. AU - Murthy, G. V. S. AU - Sharma, T. K. IS - 1 KW - Adult Aged Antihypertensive Agents/tu [Therapeutic Use] *Developing Countries Female Follow-Up Studies Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] Humans India Intraocular Pressure Male Middle Aged Patient Education as Topic/mt [Methods] Patient Satisfaction Prospective Studies *Trabeculectomy Treatment Outcome Treatment Refusal Visual Acuity PY - 2007 SE - Anand, A. Dr RP Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. aasshishanand@hotmail.com SN - 0950-222X SP - 40-5 ST - Role of early trabeculectomy in primary open-angle glaucoma in the developing world T2 - Eye (London, England) TI - Role of early trabeculectomy in primary open-angle glaucoma in the developing world UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16200053 VL - 21 Y2 - 20050930// ID - 1625 ER - TY - JOUR AB - PURPOSE:: The purpose of the study was to determine proportion of adherence to topical glaucoma medications and associated factors among glaucoma patients in Gondar University Hospital Tertiary Eye Care and Training Center, northwest Ethiopia., METHODS:: This cross-sectional design study was conducted on 360 participants from April-May 2017. Structured questionnaire was completed and adherence was assessed by patients' self-report survey. The data were analyzed by SPSS version 20. Multivariate logistic regression was used to identify the determinant factors. The significance was considered at p value less than 0.05., RESULT:: More than half, 221 (61.4%) (95% confidence interval: 56.1-66.7), of the study participants were found to adhere well to glaucoma medications. Male sex (adjusted odds ratio = 1.86 (95% confidence interval: 1.13-3.06)), urban residence (adjusted odds ratio = 2.33 (95% confidence interval: 1.46-3.72)), normal visual acuity (adjusted odds ratio = 2.23 (95% confidence interval: 1.13-4.42)), low visual acuity (adjusted odds ratio = 1.74 (95% confidence interval: 1.05-2.88)), and self-sponsor for medications (adjusted odds ratio = 0.21 (95% confidence interval: 0.12-0.38)) were significantly associated with good adherence., CONCLUSION:: The level of medication adherence to topical glaucoma medications is not good enough as compared to other studies done in Ethiopia. Male sex, urban residence, normal, and low visual acuity were positive predictors, whereas self-sponsored for medications was negative predictors for good adherence to glaucoma medications. AU - Anbesse, Dereje Hayilu AU - Yibekal, Betelhem Temesgen AU - Assefa, Natnael Lakachew DO - https://dx.doi.org/10.1177/1120672118772517 IS - 2 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] Cross-Sectional Studies Ethiopia/ep [Epidemiology] Female *Glaucoma/dt [Drug Therapy] Glaucoma/ep [Epidemiology] Glaucoma/pp [Physiopathology] *Hospitals, University Humans Incidence Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Odds Ratio Surveys and Questionnaires *Tertiary Care Centers Young Adult PY - 2019 SE - Anbesse, Dereje Hayilu. 1 Department of Ophthalmology, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. Yibekal, Betelhem Temesgen. 2 Department of Optometry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia. Assefa, Natnael Lakachew. 2 Department of Optometry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia. SN - 1724-6016 1120-6721 SP - 189-195 ST - Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia T2 - European journal of ophthalmology TI - Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=29747522 VL - 29 Y2 - 20180510// ID - 382 ER - TY - JOUR AB - The article describes establishment of a glaucoma course for patients with recently developed or long-term glaucoma. The course is being run in cooperation between the opthalmology unit at Vejle Hospital and Vejle Municipality, The aim of the course is to improve compliance and enhance exchange of experience between participants. The training includes anatomy, disease pathology and instruction in correct instillation of eye drops, based on the unit's concept: 'Self-administration of eye drops: Getting it right.' In the long term the aim is to evaluate the efficacy of the course by using a questionnaire. AN - 105122162. Language: Danish. Entry Date: 20100319. Revision Date: 20150818. Publication Type: Journal Article AU - Andersen, C. AU - Sloth, L. AU - Solbæk, U. AU - Spøer, K. DB - ccm DP - EBSCOhost IS - 3 KW - Glaucoma -- Prevention and Control Patient Education -- Methods Ophthalmic Solutions -- Administration and Dosage Seminars and Workshops N1 - pictorial. Journal Subset: Continental Europe; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Nursing; Peer Reviewed. NLM UID: 0421366. PY - 2010 SN - 0106-8350 SP - 58-61 ST - Glaucoma course for beginners and experienced T2 - Sygeplejersken / Danish Journal of Nursing TI - Glaucoma course for beginners and experienced UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105122162&site=ehost-live&scope=site VL - 110 ID - 4286 ER - TY - JOUR AB - PURPOSE: Recent developments in electronic technology are making it possible to home monitor the sensitivity of the central visual field using portable devices. We used simulations to investigate whether the higher test frequency afforded by home monitoring improves the early detection of rapid visual field loss in glaucoma and how any benefits might be affected by imperfect compliance or increased variability in the home-monitoring test., DESIGN: Computer simulation, with parameter selection confirmed with a cohort study., PARTICIPANTS: A total of 43 patients with treated glaucoma (both open-angle and closed-angle), ocular hypertension or glaucoma suspects (mean age, 71 years; range, 37-89 years), were followed in the cohort study., METHODS: We simulated series (n = 100 000) of visual fields for patients with stable glaucoma and patients with progressing glaucoma for 2 in-clinic (yearly and 6-monthly) and 3 home-monitoring (monthly, fortnightly, and weekly) schedules, each running over a 5-year period. Various percentages of home-monitored fields were omitted at random to simulate reduced compliance, and the variability of the home monitored fields also was manipulated. We used previously published variability characteristics for perimetry and confirmed their appropriateness for a home-monitoring device by measuring the device's retest variability at 2 months in a cohort of 43 patients. The criterion for flagging progression in our simulation was a significant slope of the ordinary least squares regression of a simulated patient's mean deviation (MD) data., MAIN OUTCOME MEASURES: The sensitivity for identifying rapid visual field loss (-2 decibels [dB]/year loss of MD)., RESULTS: Although a sensitivity of 0.8 for rapid field loss was achieved after 2.5 years of 6-monthly testing in the clinic, weekly home monitoring achieved this by 0.9 years despite moderate test compliance of 63%. The improved performance of weekly home monitoring over 6-monthly clinical testing was retained even when home monitoring was assumed to produce more variable test results or be associated with low patient compliance., CONCLUSIONS: Detecting rapid visual field progression may be improved using a home-monitoring strategy, even when compliance is imperfect. The cost-benefit of such an approach is yet to be demonstrated, however. Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AU - Anderson, Andrew J. AU - Bedggood, Phillip A. AU - George Kong, Yu Xiang AU - Martin, Keith R. AU - Vingrys, Algis J. DO - https://dx.doi.org/10.1016/j.ophtha.2017.06.028 IS - 12 KW - Adult Aged Aged, 80 and over Cohort Studies Computer Simulation Disease Progression Early Diagnosis Female Follow-Up Studies *Glaucoma, Angle-Closure/di [Diagnosis] *Glaucoma, Open-Angle/di [Diagnosis] Humans Intraocular Pressure/ph [Physiology] Male Middle Aged Monitoring, Physiologic Ocular Hypertension/di [Diagnosis] Sensitivity and Specificity *Vision Disorders/di [Diagnosis] Visual Field Tests/mt [Methods] *Visual Fields PY - 2017 SE - Anderson, Andrew J. Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Australia. Electronic address: aaj@unimelb.edu.au. Bedggood, Phillip A. Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Australia. George Kong, Yu Xiang. Clinical Research Department, Centre for Eye Research Australia, East Melbourne, Australia. Martin, Keith R. Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom. Vingrys, Algis J. Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Australia. SN - 1549-4713 0161-6420 SP - 1735-1742 ST - Can Home Monitoring Allow Earlier Detection of Rapid Visual Field Progression in Glaucoma? T2 - Ophthalmology TI - Can Home Monitoring Allow Earlier Detection of Rapid Visual Field Progression in Glaucoma? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28764889 VL - 124 Y2 - 20170729// ID - 500 ER - TY - JOUR AB - BACKGROUND AND OBJECTIVES: A topical-subconjunctival anesthesia technique named circumferential perilimbal anesthesia was tested in a consecutive series of 34 combined cataract and glaucoma cases to determine effectiveness in long duration anterior segment surgery., PATIENTS AND METHODS: The circumferential perilimbal technique for combined surgery involved administration of 4% topical Xylocaine drops and injection of 0.25 cc of 4% Xylocaine subconjunctivally 3-4 mm inferior to the limbus. The inferior subconjunctival anesthesia was then spread 360 degrees around the limbus circumferentially with a smooth forceps. The topical and local anesthetic was supplemented by intravenous preoperative and intraoperative sedative and analgesic medications., RESULTS: All patients had successful phacoemulsification cataract extraction with intraocular lens combined with trabeculectomy. Medical records and postoperative interviews of the combined cataract-glaucoma cases revealed an average surgery time of 46 minutes (range 35 minutes-60 minutes) and only one incident of patient intraoperative pain., CONCLUSION: The circumferential perilimbal technique was an effective anesthesia technique for long duration combined cataract and glaucoma surgery. AU - Anderson, C. J. IS - 3 KW - Aged *Anesthesia, Local/mt [Methods] Anesthetics, Local/ad [Administration & Dosage] Conjunctiva/de [Drug Effects] Female Follow-Up Studies Glaucoma/co [Complications] *Glaucoma/su [Surgery] Humans Injections Lidocaine/ad [Administration & Dosage] Male Orbit/de [Drug Effects] Patient Satisfaction *Phacoemulsification Retrospective Studies Surveys and Questionnaires *Trabeculectomy PY - 1999 SE - Anderson, C J. Department of Ophthalmology and Visual Sciences, University of Wisconsin at Madison. SN - 1082-3069 SP - 205-7 ST - Circumferential perilimbal anesthesia for combined cataract glaucoma surgery T2 - Ophthalmic surgery and lasers TI - Circumferential perilimbal anesthesia for combined cataract glaucoma surgery UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10100254 VL - 30 ID - 1975 ER - TY - JOUR AB - PURPOSE: To investigate the usefulness of daily-wear opaque contact lens treatment for older children with amblyopia., METHODS: A retrospective chart review of all children undergoing opaque contact lens therapy for amblyopia between 2000 and 2003 was performed. All patients were included except for those younger than 5 years of age, those undergoing maintenance treatment only, those lost to follow-up, or those unable to cooperate with Snellen visual acuity testing., RESULTS: Thirteen children were identified, and seven met the inclusion criteria. The seven patients had a mean age of 7.5 years (range, 5.7-8.7 years). The causes of amblyopia were anisometropia (five patients), cataract (one patient), and strabismus (one patient). For all seven patients, the mean logMAR improvement in visual acuity was 0.52 (range, 0.26-1.22). The average duration of opaque contact lens use was 9.3 months (range, 2-21 months). Compliance problems were encountered in three patients. No major complications occurred, but one patient had an episode of mild superficial punctate keratitis., CONCLUSIONS: Daily-wear opaque contact lens treatment is a useful occlusion method for amblyopia treatment in older children with various practical and social impediments to skin patching. Meaningful improvement in visual acuity can be obtained, even in children older than 8 years of age. AU - Anderson, Justin E. AU - Brown, Sandra M. AU - Mathews, Taryn A. AU - Mathews, Steven M. IS - 2 KW - *Amblyopia/th [Therapy] Child *Contact Lenses, Hydrophilic Humans Patient Compliance Prosthesis Design Retrospective Studies *Sensory Deprivation Visual Acuity PY - 2006 SE - Anderson, Justin E. Department of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, 79430, USA. steven.mathews@ttuhsc.edu SN - 1542-2321 SP - 84-7 ST - Opaque contact lens treatment for older children with amblyopia T2 - Eye & contact lens TI - Opaque contact lens treatment for older children with amblyopia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16538129 VL - 32 ID - 1675 ER - TY - JOUR AB - PURPOSE: To compare the utility of Pascal dynamic contour tonometry with Goldmann applanation tonometry in routine practice, METHODS: In a prospective study, 10 clinicians recruited 97 patients attending outpatient ophthalmology appointments. Intraocular pressure was measured with both Pascal and Goldmann tonometry in a randomized order. The time taken with each instrument, the number of measurements required to obtain a satisfactory Pascal reading (Q1 to Q3) and the quality value of this reading were recorded. Both the difficulty experienced by the clinician and patient experience for each instrument were assessed., RESULTS: Satisfactory Pascal measurements were obtained for 181 of 194 eyes (93%). For these eyes there was no significant difference in mean measured intraocular pressure between Pascal (15.95+/-3.20) and Goldmann (16.37+/-3.51) (mean difference 0.43 mm Hg, P=0.26) tonometry. The median number of attempts required to obtain a satisfactory Pascal measurement was 2 (range, 1 to 10). The time taken to obtain bilateral satisfactory Pascal readings was 2.76+/-1.53 minutes (range, 0.5 to 7 min), compared with 0.82+/-0.43 minutes (range, 0.5 to 3 min) for Goldmann tonometry (P<0.001). For these patients, clinicians scored the difficulty of tonometry as 3.24+/-1.97 for Pascal (1=very easy, 10=very difficult) and 1.28+/-0.85 for Goldmann (P<0.0001). The mean score (1=no discomfort, 10=extremely unpleasant) given by patients was 1.31+/-0.64 for Goldmann and 2.11+/-1.83 for Pascal tonometry (P<0.0001)., CONCLUSIONS: Clinicians found Pascal tonometry significantly more time consuming and difficult than Goldmann tonometry in routine practice. Most eyes required repeated Pascal measurements, and for some an acceptable result was not obtained. Both types of tonometry were well tolerated by patients. AU - Anderson, Matthew Frederick AU - Agius-Fernandez, Adriana AU - Kaye, Stephen B. DO - https://dx.doi.org/10.1097/IJG.0b013e31824cb10c IS - 5 KW - Adult Aged Aged, 80 and over Female Glaucoma/di [Diagnosis] Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged Ophthalmology Patient Satisfaction Practice Patterns, Physicians' Prospective Studies Reproducibility of Results Sensitivity and Specificity Time Factors *Tonometry, Ocular/is [Instrumentation] PY - 2013 SE - Anderson, Matthew Frederick. University Hospital Aintree, Liverpool, UK. matthewanderson2@nhs.net SN - 1536-481X 1057-0829 SP - 422-6 ST - Comparison of the utility of Pascal dynamic contour tonometry with Goldmann applanation tonometry in routine clinical practice T2 - Journal of glaucoma TI - Comparison of the utility of Pascal dynamic contour tonometry with Goldmann applanation tonometry in routine clinical practice UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=22407393 VL - 22 ID - 1020 ER - TY - JOUR AB - How do the tolerability and adverse-effect profiles of newer psychotropic drugs for bipolar disorder balance against their enhanced therapeutic benefits? The growing range of pharmacotherapy options across all phases of bipolar illness should, ideally, enhance the ability of clinicians to provide optimal treatments while considering differential adverse effects and drug tolerability. Such approaches help to increase medication adherence in patients who might otherwise discontinue treatment due to adverse effects. Clinically diverse, often significant adverse effects are evident with both older and newer drug therapies for bipolar illness. Most notably, problems related to gastrointestinal upset, weight gain, glucose dysregulation, sexual dysfunction, cognitive impairment, dermatologic reactions, and central nervous system effects are a potential liability with numerous compounds. Strategies exist for either minimizing or counteracting the adverse effects of most psychotropic agents. These include slow-dose escalations, preferential use of delayed-release formulations, and adjunctive treatments with additional agents. Clinical decisions to switch primary medications due to adverse effects-rather than treat through adverse effects-must reflect careful balancing of drug efficacy (benefits) versus side-effect liability (costs). AD - J.F. Goldberg, Zucker Hillside Hospital, 75-59 263rd St, Glen Oaks, NY 11004, United States AU - Anderson, T. R. AU - Goldberg, J. F. AU - Harrow, M. DB - Embase IS - 9 KW - amantadine amfebutamone anticonvulsive agent aripiprazole atypical antipsychotic agent buspirone carbamazepine clozapine Ginkgo biloba extract granisetron lamotrigine lithium methylphenidate mirtazapine nefazodone olanzapine oral contraceptive agent placebo propranolol psychotropic agent quetiapine risperidone serotonin uptake inhibitor sildenafil topiramate unindexed drug valproate semisodium valproic acid yohimbine ziprasidone anorgasmia bipolar disorder clinical trial closed angle glaucoma cognitive defect cost benefit analysis delayed release formulation diarrhea dose response drowsiness drug choice drug dose reduction drug efficacy drug formulation drug safety drug tolerability dyslipidemia enteric coated tablet erectile dysfunction gastrointestinal symptom glucose intolerance human hyperandrogenism hyperglycemia hyperlipoproteinemia hypertriglyceridemia intraocular hypertension libido disorder mania medical decision making menstruation disorder metabolic disorder nausea nephrolithiasis neurotoxicity non insulin dependent diabetes mellitus obesity ovary polycystic disease paresthesia patient compliance patient counseling psychopharmacotherapy rash review schizophrenia sedation sexual dysfunction side effect skin manifestation Stevens Johnson syndrome teratogenesis tremor vomiting body weight gain LA - English M3 - Review N1 - L39332332 2004-10-20 PY - 2004 SN - 1082-6319 SP - 48-54 ST - A review of medication side effects and treatment adherence in bipolar disorder T2 - Primary Psychiatry TI - A review of medication side effects and treatment adherence in bipolar disorder UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39332332&from=export VL - 11 ID - 3732 ER - TY - JOUR AB - PURPOSE: To compare the anesthetic effectiveness of topical proparacaine drops, subconjunctival lidocaine, and 2% lidocaine gel., METHODS: Ninety-two patients undergoing intravitreal injections were randomized to 1 of 3 groups: proparacaine 0.5% drops (Group Drops), proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC), or 2% lidocaine gel (Group Gel). Patients were asked to score their pain experience using a visual analog scale of 0 to 10 immediately following the injections and 10 min, 1 h, 6 h, and 24 h after the injections. Patients also graded the overall injection experience as Excellent, Very Good, Fair, Poor, or Awful. The physician evaluated the patients' eye movement during intravitreal injection on 3 levels: (0) none or minimal, (1) not compromising the injection, and (2) compromising the injection., RESULTS: The patients in Group Drops had the worst mean pain scores during the injection and 10 min after, with the highest occurrence of movements compromising the procedure (Grade 2; 38.7%). The patients in Group SC had a higher percentage of good experiences (37.9%) but a higher incidence of chemosis (16.7%). The patients in Group Gel had similar overall pain scores to Group Drops patients but a higher incidence of keratitis (19.4%). There was no statistically significant correlation between the use of aspirin or anticoagulants and the occurrence of hyperemia or hyposphagma., CONCLUSION: Subconjunctival lidocaine was most effective in preventing pain and eye movements during intravitreal injections. Although 2% lidocaine gel produced a good overall experience for the patients, the incidence of keratitis was very high (19.4%). Therefore, we do not recommend 2% lidocaine gel as the first anesthetic choice for intravitreal injections. There is no evidence to suspend the use of aspirin or other anticoagulants drugs prior to intravitreal injections. AU - Andrade, Gabriel Costa de AU - Carvalho, Andre Correa Maia de DO - https://dx.doi.org/10.5935/0004-2749.20150008 IS - 1 KW - Adult Aged Aged, 80 and over *Anesthesia, Local/mt [Methods] *Anesthetics, Local/ad [Administration & Dosage] Eye Movements Female Humans Intravitreal Injections/ae [Adverse Effects] *Intravitreal Injections/mt [Methods] Keratitis/ci [Chemically Induced] *Lidocaine/ad [Administration & Dosage] Macular Degeneration/dt [Drug Therapy] Macular Edema/dt [Drug Therapy] Male Middle Aged Pain Measurement Patient Satisfaction *Propoxycaine/ad [Administration & Dosage] Prospective Studies PY - 2015 SE - Andrade, Gabriel Costa de. Retina Clinic, Sao Paulo, SP, Brazil. Carvalho, Andre Correa Maia de. Retina Clinic, Sao Paulo, SP, Brazil. SN - 1678-2925 0004-2749 SP - 27-31 ST - Comparison of 3 different anesthetic approaches for intravitreal injections: a prospective randomized trial T2 - Arquivos brasileiros de oftalmologia TI - Comparison of 3 different anesthetic approaches for intravitreal injections: a prospective randomized trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25714534 VL - 78 ID - 810 ER - TY - JOUR AB - PURPOSE: To assess the in vitro tolerance and in vivo efficacy of new unpreserved formulations of timolol maleate (TM) in aqueous solutions of bioadhesive polymers used for dry eye treatment and to compare them with three traditional TM formulations: unpreserved Timabak (Thea, Madrid, Spain), benzalkonium chloride (BAK)-preserved Timoftol (Frosst Laboratories, Madrid, Spain), and BAK-preserved Timolol Sandoz (Frosst Laboratories)., METHODS: New formulations were composed of TM (0.5%) and carboxymethyl cellulose (0.5%), hyaluronic acid (0.2%), or hydroxypropylmethyl cellulose (0.3% or 0.5%). In vitro tolerance was determined in human corneal-limbal epithelial cells and normal human conjunctival cells. The ocular hypotensive effect was evaluated measuring IOP in rabbit eyes for 8 hours., RESULTS: In all cases, cell survival after exposure to the formulations was greater in the new unpreserved TM formulations than in the traditional TM solutions (BAK-preserved and unpreserved). In addition, the new formulations were demonstrated to maintain the hypotensive effect of TM in different magnitudes. The maximum hypotensive effect was reached by TM 0.5% in carboxymethyl cellulose 0.5% (32.37%)., CONCLUSIONS: The results demonstrated that new unpreserved formulations of TM with bioadhesive polymers decreased IOP in rabbits and reached values closer to those reached by traditional solutions. Furthermore, new formulations presented a significantly higher in vitro tolerance than the same compound in traditional formulations. Although unpreserved formulations are usually more expensive, preservative-free antiglaucoma eye drops should improve compliance and adherence in the medical treatment of glaucoma. Bioadhesive polymers could be part of antiglaucoma formulations to reduce ocular toxicity, improve drug efficacy, and protect the ocular surface in long-term therapies. AU - Andres-Guerrero, Vanessa AU - Vicario-de-la-Torre, Marta AU - Molina-Martinez, Irene T. AU - Benitez-del-Castillo, Jose Manuel AU - Garcia-Feijoo, Julian AU - Herrero-Vanrell, Rocio DO - https://dx.doi.org/10.1167/iovs.10-6338 IS - 6 KW - Animals Carboxymethylcellulose Sodium/pd [Pharmacology] Cell Survival Cells, Cultured Chemistry, Pharmaceutical *Conjunctiva/de [Drug Effects] Conjunctiva/pa [Pathology] *Epithelium, Corneal/de [Drug Effects] Epithelium, Corneal/pa [Pathology] Humans Hyaluronic Acid/pd [Pharmacology] Hydrogen-Ion Concentration Hypromellose Derivatives *Intraocular Pressure/de [Drug Effects] Male Methylcellulose/aa [Analogs & Derivatives] Methylcellulose/pd [Pharmacology] Ophthalmic Solutions/ch [Chemistry] *Ophthalmic Solutions/pd [Pharmacology] Osmolar Concentration Pharmaceutical Preparations Preservatives, Pharmaceutical/pd [Pharmacology] Rabbits Rheology Timolol/ch [Chemistry] *Timolol/pd [Pharmacology] Tonometry, Ocular PY - 2011 SE - Andres-Guerrero, Vanessa. Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Complutense University, Madrid, Spain. SN - 1552-5783 0146-0404 SP - 3548-56 ST - Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers T2 - Investigative ophthalmology & visual science TI - Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21296826 VL - 52 Y2 - 20110601// ID - 1289 ER - TY - JOUR AN - WOS:000651872000013 AU - Andrews, C. AU - Yoganathan, P. AU - Pereira, J. A. DA - JUN DO - 10.1016/j.jcjd.2020.10.001 IS - 4 PY - 2021 SN - 1499-2671 SP - 375-378 ST - Blind Spots: Gaps in Disease Knowledge and the Role of Patient Education for Canadians With Diabetic Macular Edema T2 - CANADIAN JOURNAL OF DIABETES TI - Blind Spots: Gaps in Disease Knowledge and the Role of Patient Education for Canadians With Diabetic Macular Edema VL - 45 ID - 5909 ER - TY - JOUR AB - Background: Juvenile idiopathic arthritis-associated uveitis (JIA-U) can lead to poor visual outcomes and impact a child's quality of life (QOL) and function. Our aim is to identify risk markers of JIA-U and examine differences in the QOL of children with JIA and JIA-U. Methods: Rheumatology and ophthalmology record reviews and questionnaires were completed every 4-6 months on 287 children with JIA. We collected arthritis, uveitis, and QOL data. We examined data through last study visit. Results: There were 52/287 (18 %) children with JIA-U who were younger at arthritis diagnosis, had oligoarticular persistent JIA, and ANA positive. Confirmed uveitis predictors were age at JIA diagnosis (OR=0.86) and oligoarticular subtype (OR=5.92). They had worse vision specific QOL and function, but similar general QOL. Blindness occurred in 17.5 % of children but was more common in African American children compared to non-Hispanic Caucasian children ((5/7 (71 %) vs. 2/29 (7 %), p <0.001) despite a similar uveitis prevalence (22 % vs. 16 %). Both races had similar complications, although band keratopathy was more frequent in African Americans (75 % vs. 15.6 %, p=0.003). Conclusions: We confirm young age at JIA diagnosis and the oligoarticular JIA subtype as predictors of uveitis development. Although we were unable to identify predictors of ocular complications or blindness, AA children appeared to have a more severe disease course manifested by increased ocular complications, vision loss and blindness. Potential causes that warrant additional study include underlying disease severity, access to medical care and referral bias. Further investigation of the risk factors for vision-compromising uveitis and its' long-term effects should be conducted in a large racially diverse population. AD - S.T. Angeles-Han, Emory University School of Medicine, Department of Ophthalmology, 1365-B Clifton Rd, Atlanta, GA, United States AU - Angeles-Han, S. T. AU - McCracken, C. AU - Yeh, S. AU - Jenkins, K. AU - Stryker, D. AU - Rouster-Stevens, K. AU - Vogler, L. B. AU - Lambert, S. R. AU - Drews-Botsch, C. AU - Prahalad, S. DB - Embase Medline DO - 10.1186/s12969-015-0018-8 IS - 1 KW - abatacept adalimumab antinuclear antibody cyclic citrullinated peptide antibody etanercept eye drops infliximab methotrexate nonsteroid antiinflammatory agent rheumatoid factor steroid adolescent adult African American age article blindness cataract cataract extraction Caucasian child childhood disease cohort analysis controlled study disease association disease duration disease severity eye disease female follow up glaucoma health care access human juvenile idiopathic arthritis associated uveitis juvenile rheumatoid arthritis keratopathy major clinical study male oligoarticular juvenile rheumatoid arthritis patient referral preschool child prevalence priority journal quality of life race difference retina macula cystoid edema risk assessment school child synechiae systemic juvenile idiopathic arthritis uveitis visual impairment young adult LA - English M3 - Article N1 - L604589305 2015-06-08 2015-06-11 PY - 2015 SN - 1546-0096 ST - Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis T2 - Pediatric Rheumatology TI - Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604589305&from=export http://dx.doi.org/10.1186/s12969-015-0018-8 VL - 13 ID - 2804 ER - TY - JOUR AU - Anonymous IS - 1 KW - *Gelatin *Glaucoma/su [Surgery] Humans *Retinal Detachment/su [Surgery] *Surgical Equipment PY - 1967 SN - 0016-4488 SP - 63-9 ST - [Round table conference. Study on non-adherent material, gelfilm] T2 - Ganka. Ophthalmology TI - [Round table conference. Study on non-adherent material, gelfilm] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=6068156 VL - 9 ID - 2290 ER - TY - JOUR AB - The Glaucoma Laser Trial (GLT) was an investigator-initiated, grant-supported, multicenter, randomized, controlled clinical trial designed to investigate the efficacy and safety of argon laser trabeculoplasty (ALT) as an alternative to medical treatment for newly diagnosed primary open-angle glaucoma (POAG). One eye of each patient was randomly assigned to ALT followed by medical treatment if needed to control intraocular pressure (IOP). The patient's other eye was assigned to medical treatment. Medical treatment for either eye was prescribed according to a stepped sequence. Patients were followed for a minimum of 2 years. Monitoring for control of IOP and for adherence to the protocol continued throughout the followup period. This article describes the design and methods of the trial and provides a discussion of the underlying rationale for key design decisions. AU - Anonymous IS - 4 KW - Double-Blind Method Female *Glaucoma, Open-Angle/su [Surgery] Humans Intraocular Pressure *Laser Therapy Male *Multicenter Studies as Topic/mt [Methods] *Randomized Controlled Trials as Topic/mt [Methods] *Trabeculectomy PY - 1991 SN - 0197-2456 SP - 504-24 ST - The Glaucoma Laser Trial (GLT): 3. Design and methods. Glaucoma Laser Trial Research Group T2 - Controlled clinical trials TI - The Glaucoma Laser Trial (GLT): 3. Design and methods. Glaucoma Laser Trial Research Group UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1657527 VL - 12 ID - 2142 ER - TY - JOUR AB - Data collected at enrollment on the 271 patients (542 eyes) who participated in the Glaucoma Laser Trial (GLT) were analyzed for subgroup differences. The subgrouping variables included four patient characteristics (race, sex, age, and history of a vascular disease) and one ocular characteristic (myopia). The strongest differences observed were between blacks and whites. As compared with the eyes of the white patients, those of the black patients had lower mean decibels per test location in the visual field (P < .001), greater mean defect (P < .001), number of abnormal test locations (P < .001), and corrected loss variance (P = .009), as well as greater cup depth (P < .001), and larger mean horizontal (P = .002) and vertical (P < .001) cup/disc ratios. AU - Anonymous IS - 4 KW - Adult African Continental Ancestry Group Aged Aged, 80 and over European Continental Ancestry Group Female Glaucoma, Open-Angle/eh [Ethnology] *Glaucoma, Open-Angle/pa [Pathology] Glaucoma, Open-Angle/su [Surgery] Humans Intraocular Pressure *Laser Therapy Male Middle Aged Myopia/pa [Pathology] Optic Nerve/pa [Pathology] Patient Participation Trabeculectomy Vision Disorders/pa [Pathology] Visual Acuity Visual Fields PY - 1993 SN - 0022-023X SP - 232-40 ST - The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Glaucoma Laser Trial Research Group T2 - Ophthalmic surgery TI - The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Glaucoma Laser Trial Research Group UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8321504 VL - 24 ID - 2095 ER - TY - JOUR AB - This paper is the complete protocol (Manual of Operations) used in the Central Vein Occlusion Study (CVOS). The CVOS is a randomized clinical trial and natural history study of central retinal vein occlusion supported by the National Eye Institute. The administrative structure includes a Data and Safety Monitoring Board, 9 clinical centers, a coordinating center, and a photograph reading center. The Manual of Operations describes study design, organization, policies, and procedures. Procedures described in detail include measurement of visual acuity, fundus and iris photography, fluorescein angiography, and quality control. AU - Anonymous KW - Adult *Clinical Protocols Glaucoma, Neovascular/et [Etiology] Glaucoma, Neovascular/pc [Prevention & Control] Humans *Iris/bs [Blood Supply] Ischemia Laser Coagulation/mt [Methods] *Laser Coagulation Macular Edema/et [Etiology] *Macular Edema/su [Surgery] Multicenter Studies as Topic Neovascularization, Pathologic/et [Etiology] *Neovascularization, Pathologic/pc [Prevention & Control] Patient Compliance Prospective Studies *Randomized Controlled Trials as Topic *Research Design Retinal Artery Occlusion/co [Complications] *Retinal Artery Occlusion/su [Surgery] Visual Acuity PY - 1993 SN - 1059-2725 ST - Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group T2 - The Online journal of current clinical trials TI - Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7508321 VL - Doc No 92 ID - 2101 ER - TY - JOUR AB - OBJECTIVE: To assess the benefit of adding oral acyclovir to a regimen of topical prednisolone phosphate and trifluridine for the treatment of iridocyclitis caused by herpes simplex virus (HSV)., METHODS: Patients with HSV iridocyclitis were enrolled in a multicenter controlled clinical trial supported by the National Eye Institute, Bethesda, Md, and randomly assigned to receive a 10-week course of either oral acyclovir, 400 mg, 5 times daily, or oral placebo in conjunction with regimens of topical trifluridine and a topical corticosteroid. Follow-up examinations were performed weekly during the 10-week treatment period, every 2 weeks for an additional 6 weeks, and at 26 weeks after enrollment in the trial. Treatment failure was defined as a persistence or worsening of ocular inflammation, withdrawal of medication because of toxicity, or a request by the patient to withdraw from the trial for any reason. The trial was stopped because of slow recruitment after only 50 of the originally planned 104 patients were enrolled in more than 4 years., RESULTS: A treatment failure occurred in 11 (50%) of the 22 patients in the acyclovir-treated group and in 19 (68%) of the 28 patients in the placebo group. Compared with the placebo group, the adjusted rate ratio for a treatment failure in the acyclovir-treated group during the 10-week treatment period was 0.43 (90% confidence interval, 0.18-1.02; P = .06, 1-tailed) and during the 16-week follow-up period (10-week treatment period plus 6-week observation period) was 0.60 (90% confidence interval, 0.29-1.25; P = .13, 1-tailed in a proportional hazards model). The treatment effect seemed slightly greater when only the patients with a persistence or worsening of ocular HSV disease were considered as treatment failures (ie, excludes terminations because of toxic effects of the drug and patients who requested to withdraw from the trial). By life-table analysis, similar results were obtained; the possible benefit of acyclovir became apparent after the first 3 weeks of follow-up., CONCLUSION: While the number of patients recruited in this trial was too small to achieve statistically conclusive results, the trend in the results suggests a benefit of oral acyclovir in the treatment of HSV iridocyclitis in patients receiving topical corticosteroids and trifluridine prophylaxis. AU - Anonymous IS - 9 KW - Acyclovir/ad [Administration & Dosage] *Acyclovir/tu [Therapeutic Use] Administration, Oral Administration, Topical Anti-Inflammatory Agents/ad [Administration & Dosage] Anti-Inflammatory Agents/tu [Therapeutic Use] Antiviral Agents/ad [Administration & Dosage] *Antiviral Agents/tu [Therapeutic Use] Corneal Stroma/vi [Virology] Female Follow-Up Studies Herpes Simplex/co [Complications] *Herpes Simplex/dt [Drug Therapy] Herpesvirus 1, Human/ip [Isolation & Purification] Humans *Iridocyclitis/dt [Drug Therapy] *Iridocyclitis/vi [Virology] Keratitis, Herpetic/co [Complications] Keratitis, Herpetic/dt [Drug Therapy] Male Middle Aged Ophthalmic Solutions Patient Compliance Prednisolone/ad [Administration & Dosage] Prednisolone/tu [Therapeutic Use] Treatment Failure Treatment Outcome Trifluridine/ad [Administration & Dosage] Trifluridine/tu [Therapeutic Use] PY - 1996 SN - 0003-9950 SP - 1065-72 ST - A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group T2 - Archives of ophthalmology (Chicago, Ill. : 1960) TI - A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=8790090 VL - 114 ID - 2037 ER - TY - JOUR AB - For a number of years there has been a trend towards the sharing of skills, with their transfer from one group with which they have been traditionally associated to another within the health care professions. Examples in medicine include nurses delivering care to patients with diabetes mellitus, carrying out gastrointestinal endoscopy, administering intravenous chemotherapy to patients with cancer, and contributing to the management of patients with myocardial infarction and with asthma; opticians are employed in the screening of patients for glaucoma and diabetic retinopathy; and physiotherapy and radiography grew out of nursing. This movement is seen to be advantageous for patient care in that it extends the range and numbers of personnel. If this development is to be fostered and to continue to represent an advance in the delivery of health care, it is necessary to lay down guidelines to ensure that standards are maintained with safety and efficacy safeguarded. It was for this reason that representatives of the Royal Colleges of Nursing and of Physicians of London met to agree a set of principles that, while constructed for medicine and nursing, should be of general application to all the professions involved in providing health care. AU - Anonymous IS - 1 KW - Delivery of Health Care *Education, Medical/st [Standards] Humans Patient Satisfaction *Professional Competence United Kingdom PY - 1996 SN - 0035-8819 SP - 57 ST - Skillsharing. Joint statement from the Royal College of Physicians of London and the Royal College of Nursing T2 - Journal of the Royal College of Physicians of London TI - Skillsharing. Joint statement from the Royal College of Physicians of London and the Royal College of Nursing UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=8745365 VL - 30 ID - 2038 ER - TY - JOUR AB - Physicians who treat patients with glaucoma say there is a serious lack of attention to screening, a deficiency that can lead to blindness for many patients with asthma, diabetes, and heart disease. Here's what your DM program can do about it. AU - Anonymous IS - 4 KW - *Diagnostic Tests, Routine *Disease Management Glaucoma/dt [Drug Therapy] *Glaucoma/pc [Prevention & Control] Humans Patient Compliance Physical Examination Risk Factors United States PY - 1998 SN - 1094-2521 SP - 59-61 ST - Make glaucoma screening a routine part of DM programs T2 - Healthcare demand & disease management TI - Make glaucoma screening a routine part of DM programs UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10178986 VL - 4 ID - 1981 ER - TY - JOUR AB - (1) First-line drug treatment of chronic open-angle glaucoma or intraocular hypertonia is based on monotherapy with timolol eye drops. Patients in whom several single-agent treatments have failed can use combinations of timolol + dorzolamide (a carbonic anhydrase inhibitor) or a betablocker + pilocarpine (a parasympathomimetic agent). (2) An eye-drop preparation is now available in which 0.5% timolol is combined with 0.005% latanoprost, a prostaglandin F2alpha analogue. (3) A clinical trial indicated that the timolol + latanoprost combination was more effective than the timolol + dorzolamide combination on intraocular pressure, but the report of this study is too scanty to accept these results at face value. Once-a-day dosing with timolol + latanoprost has not been compared with a betablocker + pilocarpine combination. (4) Patients using the timolol + latanoprost combination are exposed to the adverse effects of both latanoprost (especially ocular irritation and brown iris discoloration) and the betablocker. (5) It is not known whether the once-a-day dosing of the timolol + latanoprost combination is a significant advantage, especially in terms of adherence to treatment. (6) In practice, the arrival of the timolol + latanoprost combination changes virtually nothing for patients with chronic open-angle glaucoma, except for those with no other alternative. AU - Anonymous IS - 67 KW - Antihypertensive Agents/ae [Adverse Effects] Antihypertensive Agents/tu [Therapeutic Use] Clinical Trials as Topic *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Ophthalmic Solutions/tu [Therapeutic Use] Prostaglandins F, Synthetic/ae [Adverse Effects] *Prostaglandins F, Synthetic/tu [Therapeutic Use] Timolol/ae [Adverse Effects] *Timolol/tu [Therapeutic Use] Treatment Outcome PY - 2003 SN - 1167-7422 SP - 173-4 ST - Timolol + latanoprost: new preparation. Last-resort eye drops T2 - Prescrire international TI - Timolol + latanoprost: new preparation. Last-resort eye drops UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=14619889 VL - 12 ID - 1815 ER - TY - JOUR AU - Anonymous IS - 2 KW - *Glaucoma/dt [Drug Therapy] Humans Ophthalmic Solutions/tu [Therapeutic Use] Patient Compliance/sn [Statistics & Numerical Data] *Patient Compliance Polypharmacy PY - 2006 SN - 1042-1882 SP - 6-7 ST - Keeping an eye on glaucoma treatment T2 - The Johns Hopkins medical letter health after 50 TI - Keeping an eye on glaucoma treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16544434 VL - 18 ID - 1673 ER - TY - JOUR AU - Anonymous IS - 53 KW - Adrenergic alpha-Agonists/tu [Therapeutic Use] Adrenergic beta-Antagonists/tu [Therapeutic Use] Angiogenesis Inhibitors/tu [Therapeutic Use] Anti-Bacterial Agents/tu [Therapeutic Use] Antioxidants/tu [Therapeutic Use] Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] Cholinergic Agonists/tu [Therapeutic Use] *Conjunctivitis, Allergic/dt [Drug Therapy] *Conjunctivitis, Bacterial/dt [Drug Therapy] Cyclosporine/tu [Therapeutic Use] Diuretics, Osmotic/tu [Therapeutic Use] *Dry Eye Syndromes/dt [Drug Therapy] Eye Diseases/dt [Drug Therapy] *Glaucoma/dt [Drug Therapy] Glucocorticoids/tu [Therapeutic Use] Humans Immunosuppressive Agents/tu [Therapeutic Use] *Macular Degeneration/dt [Drug Therapy] Macular Degeneration/th [Therapy] Ophthalmic Solutions/ae [Adverse Effects] *Ophthalmic Solutions/tu [Therapeutic Use] Patient Compliance Patient Selection Photochemotherapy Prostaglandins/tu [Therapeutic Use] Treatment Outcome Triamcinolone Acetonide/tu [Therapeutic Use] Vascular Endothelial Growth Factor A/ai [Antagonists & Inhibitors] Zinc/tu [Therapeutic Use] PY - 2007 SN - 1541-2784 SP - 1-8 ST - Drugs for some common eye disorders T2 - Treatment guidelines from the Medical Letter TI - Drugs for some common eye disorders UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17179899 VL - 5 ID - 1620 ER - TY - JOUR AU - Anonymous IS - 7 KW - *Diagnostic Equipment/ec [Economics] *Glaucoma/di [Diagnosis] Humans *Leasing, Property/og [Organization & Administration] *Office Visits *Optometry/ec [Economics] *Optometry/is [Instrumentation] PY - 2009 SN - 1558-1527 SP - 402-3 ST - In-office diagnostic equipment rental T2 - Optometry (St. Louis, Mo.) TI - In-office diagnostic equipment rental UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19554754 VL - 80 ID - 1440 ER - TY - JOUR AB - Lowering intraocular pressure (IOP) is the only clinically established method of treating glaucoma, and the Canadian Ophthalmological Society's clinical practice guidelines for glaucoma recommend an initial target IOP based on the severity of glaucoma, to be modified based on patients' age, life expectancy, quality of life, and risk factors for progression. Pharmacologic therapy is the most common method of lowering IOP, and the most common first-line therapy in Canada is topical prostaglandin analogues (PGAs), including latanoprost. Since patients with open-angle glaucoma (OAG) require lifetime therapy, they are at greater risk of ocular surface disease (OSD), which is associated with the long-term use of topical ophthalmic antiglaucoma medications. Patients with OSD may experience dry eye or sensations of burning, stinging, itching, or discomfort in the eye. Preservatives in topical ophthalmic solutions, of which the most common is benzalkonium chloride (BAK), have been implicated in OSD. Glaucoma medical therapy is often characterized by nonadherence, and the availability of preservative-free PGAs would address an unmet need for patients who do not tolerate preserved PGAs well. The objective of this report is to perform a systematic review of the beneficial and harmful effects of preservative-free latanoprost 50 mug/mL ophthalmic solution (Monoprost) for the reduction of IOP in patients with OAG or ocular hypertension. Copyright © 2018 Canadian Agency for Drugs and Technologies in Health. AU - Anonymous PY - 2018 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=30475546 ID - 38 ER - TY - JOUR AB - INTRODUCTION: Singapore's ageing population is likely to see an increase in chronic eye conditions in the future. This study aimed to estimate the burden of eye diseases among resident Singaporeans stratified for age and ethnicity by 2040., MATERIALS AND METHODS: Prevalence data on myopia, epiretinal membrane (ERM), retinal vein occlusion (RVO), age macular degeneration (AMD), diabetic retinopathy (DR), cataract, glaucoma and refractive error (RE) by age cohorts and educational attainment from the Singapore Epidemiology of Eye Diseases (SEED) study were applied to population estimates from the Singapore population model., RESULTS: All eye conditions are projected to increase by 2040. Myopia and RE will remain the most prevalent condition, at 2.393 million (2.32 to 2.41 million) cases, representing a 58% increase from 2015. It is followed by cataract and ERM, with 1.33 million (1.31 to 1.35 million), representing an 81% increase, and 0.54 million (0.53 to 0.549 million) cases representing a 97% increase, respectively. Eye conditions that will see the greatest increase from 2015 to 2040 in the Chinese are: DR (112%), glaucoma (100%) and ERM (91.4%). For Malays, DR (154%), ERM (136%), and cataract (122%) cases are expected to increase the most while for Indians, ERM (112%), AMD (101%), and cataract (87%) are estimated to increase the most in the same period., CONCLUSION: Results indicate that the burden for all eye diseases is expected to increase significantly into the future, but at different rates. These projections can facilitate the planning efforts of both policymakers and healthcare providers in the development and provision of infrastructure and resources to adequately meet the eye care needs of the population. By stratifying for age and ethnicity, high risk groups may be identified and targeted interventions may be implemented. AU - Ansah, John P. AU - Koh, Victoria AU - de Korne, Dirk F. AU - Bayer, Steffen AU - Pan, Chong AU - Thiyagarajan, Jayabaskar AU - Matchar, David B. AU - Lamoureux, Ecosse AU - Quek, Desmond IS - 1 KW - Adult Age Factors Aged Chronic Disease *Cost of Illness Ethnic Groups Eye Diseases/di [Diagnosis] Eye Diseases/ec [Economics] Eye Diseases/eh [Ethnology] *Eye Diseases Female *Health Care Rationing *Health Planning/og [Organization & Administration] Humans Male Middle Aged Needs Assessment Prevalence Risk Factors Singapore/ep [Epidemiology] PY - 2018 SE - Ansah, John P. Health Services and Systems Research, Duke-NUS Medical School, Singapore. SN - 0304-4602 SP - 13-28 ST - Projection of Eye Disease Burden in Singapore T2 - Annals of the Academy of Medicine, Singapore TI - Projection of Eye Disease Burden in Singapore UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29493707 VL - 47 ID - 447 ER - TY - JOUR AB - Purpose: To investigate whether implantation of a glaucoma shunt device leads to inappropriate accumulation of plasma derived proteins in the aqueous humor. Methods: Aqueous humor samples were collected from 11 patients (study group) with a glaucoma shunt device undergoing either cataract surgery or a corneal transplant and 11 patients (control) with senile cataract undergoing routine cataract extraction. Of the study group, 9 had an Ahmed valve implant and 2 eyes had a Baerveldt implant. Tryptic digests of the mixture of proteins in aqueous humor (AH) were analyzed using Liquid Chromatography/Mass Spectrometry (LC-MS/MS). Proteins were identified with high confidence using stringent criteria and compared quantitatively using a label-free platform (IdentiQuantXL (TM)). Results: We identified 135 proteins in the albumin-depleted fraction in both the study and control group AH. Using stringent criteria, 13 proteins were detected at a significantly higher level compared to controls. These proteins are known to play a role in oxidative stress, apoptosis, inflammation and/or immunity and include gelsolin (p=0.00005), plasminogen (p=0.00009), angiotensinogen (p=0.0001), apolipoprotein A-II (p=0.0002), beta-2-microglobulin (p=0.0002), dickkopf-3 (DKK-3; p=0.0002), pigment epithelium-derived factor (p=0.0002), RIG-like 7-1 (p=0.0002), afamin (p=0.0003), fibronectin 1 (FN1; p=0.0003), apolipoprotein A-I (p=0.0004), activated complement C4 protein (C4a; p=0.0004) and prothrombin (p=0.0004). Many of the identified proteins were novel proteins that have not been associated with glaucoma in prior studies. All but C4a (complement C4 is a plasma protein but not in an activated form) are known plasma proteins and the elevated levels of these proteins in the aqueous humor suggests a breach in the blood-aqueous barrier with passive influx into the anterior chamber of the eye. Conclusions: The presence of these proteins in the aqueous humor suggests that glaucoma shunt device causes either a breach in blood-aqueous barrier or chronic trauma, increasing influx of oxidative, apoptotic and inflammatory proteins that could potentially cause corneal endothelial damage. AN - WOS:000292724500002 AU - Anshu, A. AU - Price, M. O. AU - Richardson, M. R. AU - Segu, Z. M. AU - Lai, X. Y. AU - Yoder, M. C. AU - Price, F. W. DA - JUL 14 IS - 205-07 PY - 2011 SN - 1090-0535 SP - 1891-1900 ST - Alterations in the aqueous humor proteome in patients with a glaucoma shunt device T2 - MOLECULAR VISION TI - Alterations in the aqueous humor proteome in patients with a glaucoma shunt device VL - 17 ID - 6253 ER - TY - JOUR AB - Inhaled corticosteroids (ICS) are currently the mainstay of therapy in persistent childhood asthma. However, systemic adverse effects of various available agents - particularly on growth, bone metabolism, and the hypothalamic-pituitary-adrenal (HPA) axis - continue to concern the families of asthmatic children, and are debated within the medical community. Although there is short- and medium-term suppressive effect of usual doses of ICS on linear growth, the findings of long term studies are reassuring, suggesting attainment of the full potential of adult height. ICS do not appear to exert significant untoward effects on bone mineral density. Measurable systemic effect of ICS by sensitive measurements of function of the HPA axis does not necessarily translate into clinically significant side effects. However, use of higher than recommended doses of ICS may on occasion lead to symptomatic adrenal insufficiency and should be of concern; there may be important differences among available compounds regarding such potential. Variation in adverse effects of ICS is explained by differences in their pharmacokinetic and pharmacodynamic properties, formulation and delivery devices, and patient factors such as degree of airway obstruction, suppressive effect of airway inflammation per se on the HPA axis, genetic factors, patient training in the use of delivery devices, and compliance. © 2008 Bentham Science Publishers Ltd. AD - M.B. Anthracopoulos, Respiratory Unit, Department of Pediatrics, University Hospital of Patras, 265 04 Rio, Patras, Greece AU - Anthracopoulos, M. B. AU - Priftis, K. N. AU - Russell, G. DB - Embase DO - 10.2174/157339608785856018 IS - 3 KW - beclomethasone dipropionate beta 2 adrenergic receptor stimulating agent betamethasone valerate budesonide ciclesonide corticosteroid corticotropin corticotropin releasing factor cortisone cortisone acetate dexamethasone flunisolide fluticasone propionate glucocorticoid insulin leukotriene receptor blocking agent metyrapone mometasone furoate nedocromil omalizumab placebo prednisolone salmeterol tetracosactide theophylline triamcinolone acetonide adrenal cortex insufficiency adrenal suppression asthma bone density bone metabolism bone mineral bronchospasm calcium deficiency child growth clinical trial corticosteroid induced osteoporosis coughing Cushing syndrome volume of distribution drug bioavailability drug clearance drug dose comparison drug dose reduction drug efficacy drug intermittent therapy drug mechanism drug megadose drug protein binding drug receptor binding drug safety dysphonia endocrine function test forced expiratory volume fracture glaucoma growth disorder growth rate growth retardation half life time human hypothalamus hypophysis adrenal system long term care low drug dose mean residence time metered dose inhaler mild persistent asthma oropharynx candidiasis particle size patient compliance patient education pharmacodynamics powder inhaler priority journal recommended drug dose respiratory tract inflammation review rheumatoid arthritis secondary hyperparathyroidism side effect single drug dose skin contusion sore throat subcapsular cataract systemic disease treatment duration Diskhaler Turbuhaler LA - English M3 - Review N1 - L352564475 2008-11-18 PY - 2008 SN - 1573-3963 SP - 198-215 ST - Safety of inhaled corticosteroids. Why the variation in systemic adverse effects? T2 - Current Pediatric Reviews TI - Safety of inhaled corticosteroids. Why the variation in systemic adverse effects? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352564475&from=export http://dx.doi.org/10.2174/157339608785856018 http://www.ingentaconnect.com/content/ben/cpr/2008/00000004/00000003/art00011 VL - 4 ID - 3435 ER - TY - JOUR AB - Streptococcus pneumoniae (pneumococcus) displays broad tissue tropism and infects multiple body sites in the human host. However, infections of the conjunctiva are limited to strains within a distinct phyletic group with multilocus sequence types ST448, ST344, ST1186, ST1270, and ST2315. In this study, we sequenced the genomes of six pneumococcal strains isolated from eye infections. The conjunctivitis isolates are grouped in a distinct phyletic group together with a subset of nasopharyngeal isolates. The keratitis (infection of the cornea) and endophthalmitis (infection of the vitreous body) isolates are grouped with the remainder of pneumococcal strains. Phenotypic characterization is consistent with morphological differences associated with the distinct phyletic group. Specifically, isolates from the distinct phyletic group form aggregates in planktonic cultures and chain-like structures in biofilms grown on abiotic surfaces. To begin to investigate the association between genotype and epidemiology, we focused on a predicted surface-exposed adhesin (SspB) encoded exclusively by this distinct phyletic group. Phylogenetic analysis of the gene encoding SspB in the context of a streptococcal species tree suggests that sspB was acquired by lateral gene transfer from Streptococcus suis. Furthermore, an sspB deletion mutant displays decreased adherence to cultured cells from the ocular epithelium compared to the isogenic wild-type and complemented strains. Together these findings suggest that acquisition of genes from outside the species has contributed to pneumococcal tissue tropism by enhancing the ability of a subset of strains to infect the ocular epithelium causing conjunctivitis. IMPORTANCE Changes in the gene content of pathogens can modify their ability to colonize and/or survive in different body sites in the human host. In this study, we investigate a gene acquisition event and its role in the pathogenesis of Streptococccus pneumoniae (pneumococcus). Our findings suggest that the gene encoding the predicted surface protein SspB has been transferred from Streptococcus suis (a distantly related streptococcal species) into a distinct set of pneumococcal strains. This group of strains distinguishes itself from the remainder of pneumococcal strains by extensive differences in genomic composition and by the ability to cause conjunctivitis. We find that the presence of sspB increases adherence of pneumococcus to the ocular epithelium. Thus, our data support the hypothesis that a subset of pneumococcal strains has gained genes from neighboring species that enhance their ability to colonize the epithelium of the eye, thus expanding into a new niche. AU - Antic, Irena AU - Brothers, Kimberly M. AU - Stolzer, Maureen AU - Lai, Han AU - Powell, Evan AU - Eutsey, Rory AU - Cuevas, Rolando A. AU - Miao, Xinyu AU - Kowalski, Regis P. AU - Shanks, Robert M. Q. AU - Durand, Dannie AU - Hiller, N. Luisa DO - https://dx.doi.org/10.1128/mSphere.00213-17 IS - 5 PY - 2017 SE - Antic, Irena. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Brothers, Kimberly M. Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Stolzer, Maureen. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Lai, Han. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Powell, Evan. Center of Excellence in Biofilm Research, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Eutsey, Rory. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Cuevas, Rolando A. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Miao, Xinyu. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Kowalski, Regis P. Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Shanks, Robert M Q. Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Durand, Dannie. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Hiller, N Luisa. Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. Hiller, N Luisa. Center of Excellence in Biofilm Research, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. SN - 2379-5042 ST - Gene Acquisition by a Distinct Phyletic Group within Streptococcus pneumoniae Promotes Adhesion to the Ocular Epithelium T2 - mSphere TI - Gene Acquisition by a Distinct Phyletic Group within Streptococcus pneumoniae Promotes Adhesion to the Ocular Epithelium UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=29085912 VL - 2 Y2 - 20171025// ID - 620 ER - TY - JOUR AB - PURPOSE: To investigate the feasibility of Trabeculectomy on outpatients. METHODS: Postspectively compared and discussed the surgery effect and complications of trabeculectomy on 38 eyes of 27 outpatients with those on 38 eyes of 30 inpatients. All the surgeries were performed by the same surgeon in the same period. RESULT: The IOP of outpatients' group after one week, one month, three months or more are respectively 1.4800 +/- 0.5977 kPa, 1.8379 +/- 0.5517 kPa, 1.9650 +/- 0.4879 kPa, while the inpatients' group are 1.3468 +/- 0.5994 kPa, 1.7737 +/- 0.5177 kPa, 2.0144 +/- 0.5447 kPa. t-test has shown that the differences of the IOP after the surgery, the surgery effect and complications of trabeculectomy between the outpatients and the inpatients had no significance. CONCLUSION: Trabeculectomy on outpatients in hospital with satisfied facility would be effective, safe and feasible. AD - J. Ao, Zhongshan Ophthalmic Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China. AU - Ao, J. AU - Liu, X. DB - Medline IS - 4 KW - adolescent adult aged ambulatory care article closed angle glaucoma female glaucoma human intraocular pressure male middle aged prospective study trabeculectomy treatment outcome visual acuity LA - Chinese M3 - Article N1 - L137601178 2004-07-26 PY - 1998 SN - 1000-4432 SP - 245-248 ST - Clinical research of trabeculectomy on outpatients T2 - Yan ke xue bao = Eye science / "Yan ke xue bao" bian ji bu TI - Clinical research of trabeculectomy on outpatients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L137601178&from=export VL - 14 ID - 3933 ER - TY - JOUR AB - Lens implantation is now a highly successful operation. Although follow-up over 5 to 10 years with posterior chamber lenses is incomplete, the complication rate appears to be as low or lower than other lens styles. We present an exception: a clinicopathologic analysis of a globe, enucleated 4 years postoperatively, which in spite of uneventful implantation of a posterior chamber lens, developed neovascular glaucoma. Microscopic studies suggest several mechanisms for this rare complication including deep erosion of a prolene loop into the ciliary body, anterior segment ischemia, and breakdown of the blood-aqueous barrier. Scanning microscopy showed cracking of this deeply embedded loop, a finding we interpret as possible stress cracking and/or oxidation. The more flexible loops now used in modern lenses may decrease the chance of deep erosion. Implantation of a loop in the capsular bag may minimize the danger of both erosion and loop degradation. Patients should be followed long-term in order to recognize and treat these rare, but potentially disastrous complications. © 1984, American Academy of Ophthalmology, Inc. All rights reserved. AD - Departments of Ophthalmology and Pathology, University of Utah School of Medicine, Salt Lake City, United States Las Vegas, Nevada, United States Eugene, Oregon, United States AU - Apple, D. J. AU - Craythorn, J. M. AU - Olson, R. J. AU - Little, L. E. AU - Lyman, J. B. AU - Reidy, J. J. AU - Loftfield, K. DB - Scopus DO - 10.1016/S0161-6420(84)34290-7 IS - 4 KW - anterior segment ischemia blood aqueous barrier intraocular lens loop stress cracking posterior chamber lens prolene oxidation M3 - Article N1 - Cited By :50 Export Date: 19 July 2021 PY - 1984 SP - 403-419 ST - Anterior Segment Complications and Neovascular Glaucoma Following Implantation of a Posterior Chamber Intraocular Lens T2 - Ophthalmology TI - Anterior Segment Complications and Neovascular Glaucoma Following Implantation of a Posterior Chamber Intraocular Lens UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021257022&doi=10.1016%2fS0161-6420%2884%2934290-7&partnerID=40&md5=058174f61ec7971e053fd56ffbbc35a7 VL - 91 ID - 4998 ER - TY - JOUR AN - 126475336. Language: English. Entry Date: 20171206. Revision Date: 20190715. Publication Type: Article AU - Appold, Karen DB - ccm DP - EBSCOhost IS - 11 KW - Glaucoma -- Drug Therapy Intraocular Pressure Patient Compliance Vision Disorders -- Risk Factors Economic Aspects of Illness Financial Support Patient Education After Care Mindfulness Physician-Patient Relations N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2017 SN - 0030-4085 SP - 16-19 ST - MANAGE NON-COMPLIANCE T2 - Optometric Management TI - MANAGE NON-COMPLIANCE UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126475336&site=ehost-live&scope=site VL - 52 ID - 4462 ER - TY - JOUR AB - Intraocular pressure (IOP) reduction is currently the only therapeutic approach demonstrated to preserve visual function in patients with glaucoma. The first line of glaucoma treatment consists of topical IOP-lowering medications, usually initiated as monotherapy. A significant proportion of patients require more than one medication to reach a target IOP at which optic nerve damage will not progress. As prostaglandin analogues (PGAs) are the most effective class for reducing IOP, one of the other commonly used classes (beta-adrenoceptor antagonist [beta-blocker], carbonic anhydrase inhibitor or alpha(2)-adrenoceptor agonist) is frequently combined with a PGA. In the last decade, the use of fixed combinations containing two medications in a single bottle has steadily increased. Fixed combinations have the potential to simplify the dosing regimen, increase patient adherence, avoid the washout effect of the second drop on the first medication instilled, decrease exposure to preservatives and, sometimes, reduce the cost of treatment. Clinical trials have evaluated PGA-based fixed combinations versus unfixed combinations (individual components administered concomitantly) or versus individual monotherapies; however, any advantage that the fixed combinations may have in terms of IOP-lowering efficacy is still debated. For these reasons, the PGA-based fixed combinations are not approved by regulatory authorities in some countries, such as the US. We review the published studies evaluating the efficacy and tolerability of the IOP-lowering unfixed and fixed combination therapies with PGAs. Regarding unfixed combinations, the review shows that alpha(2)-adrenergic agonists-PGA and carbonic anhydrase inhibitor-PGA combinations seem to be at least as effective at reducing IOP as the beta-blocker-PGA combinations. As for the fixed combinations, the review shows that the three PGA-timolol fixed combinations are more effective than their component medications used separately as monotherapy and are better tolerated than the three respective prostaglandins. The three PGA-timolol fixed combinations are less effective at reducing IOP than the unfixed combinations but are better tolerated. The advantage of the fixed combinations in terms of patient adherence and persistence is supported by a very small number of studies and remains to be more accurately determined. Most studies, but not all, seem to show that PGA-timolol fixed combinations are more effective than other available beta-blocker fixed combinations (dorzolamide-timolol fixed combinations) at reducing IOP and are similarly tolerated. AU - Aptel, Florent AU - Chiquet, Christophe AU - Romanet, Jean-Paul DO - https://dx.doi.org/10.2165/11634460-000000000-00000 IS - 10 KW - Adrenergic alpha-2 Receptor Agonists/ad [Administration & Dosage] Adrenergic alpha-2 Receptor Agonists/tu [Therapeutic Use] Adrenergic beta-Antagonists/ad [Administration & Dosage] Adrenergic beta-Antagonists/tu [Therapeutic Use] Carbonic Anhydrase Inhibitors/ad [Administration & Dosage] Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] Clinical Trials as Topic Drug Combinations Drug Therapy, Combination *Glaucoma/dt [Drug Therapy] Glaucoma/me [Metabolism] Glaucoma/pp [Physiopathology] Humans *Intraocular Pressure/de [Drug Effects] Prostaglandins/ad [Administration & Dosage] *Prostaglandins/tu [Therapeutic Use] Treatment Outcome PY - 2012 SE - Aptel, Florent. Universit Joseph Fourier (UJF), Grenoble, France. faptel@chu-grenoble.fr SN - 1179-1950 0012-6667 SP - 1355-71 ST - Intraocular pressure-lowering combination therapies with prostaglandin analogues T2 - Drugs TI - Intraocular pressure-lowering combination therapies with prostaglandin analogues UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22686588 VL - 72 ID - 1127 ER - TY - JOUR AB - Purpose. To evaluate the intraocular pressure (IOP)-lowering effects and tolerability of the 3 prosta-glandin-timolol fixed combinations (PG-timolol FCs). methods. Clinical trials comparing directly the PG-timolol FCs or comparing the PG-timolol FCs to their individual components were thoroughly searched. The main outcome measures were efficacy assessed by IOP (taken at 9 am, noon, 4 pm, and over the mean diurnal curve) change at 3 months (or after 1 to 6 months of treatment if no data were available at month 3) from baseline and tolerability assessed by the incidence of conjunctival hyperemia. results. Twenty trials were identified (n=4684 patients). Intraocular pressure reduction was usually greater with the 3 PG-timolol FCs than the individual PG (mean difference [MD] 0.00 mmHg to 2.59 mmHg; p>0.1 to p<0.001). The incidence of hyperemia was significantly less with latanoprost- and bi-matoprost-timolol FCs than with the individual PG (relative risk = 0.66 and 0.61; p=0.05 and p<0.001). From direct comparisons, IOP reduction was significantly greatest with bimatoprost-timolol FC, at 9 am, 4 pm, and over the mean diurnal curve compared to latanoprost-timolol FC (MD = 0.90 mmHg to 1.48 mmHg; p<0.001) and at all time points compared to travoprost-timolol FC (MD = 0.66 mmHg to 0.90 mmHg; p<0.001). The incidence of hyperemia was not significantly less with latanoprost-timolol FC than with bimatoprost-timolol FC (relative risk = 1.32; p>0.1). ConClusions. The 3 PG-timolol FCs provide a greater IOP reduction and lower incidence of hyperemia than the 3 PGs alone. The direct comparisons suggest a greater efficacy of the bimatoprost-timolol FC compared with latanoprost- and travoprost-timolol FCs. © 2011 Wichtig Editore. AD - F. Aptel, Department of Ophthalmology, Edouard Herriot Hospital, 5, place d'Arsonval, 69437 Lyon, France AU - Aptel, F. AU - Cucherat, M. AU - Denis, P. C2 - Alcon(United States) Allergan(United States) Pfizer(United States) DB - Embase Medline DO - 10.5301/ejo.5000009 IS - 1 KW - antiglaucoma agent bimatoprost bimatoprost plus timolol latanoprost latanoprost plus timolol prostaglandin prostaglandin plus timolol timolol plus travoprost travoprost unclassified drug adult article conjunctival hyperemia controlled study dosage schedule comparison drug activity drug efficacy drug tolerability evening dosage female follow up glaucoma human intraocular hypertension intraocular pressure intraocular pressure lowering effect major clinical study male meta analysis monotherapy morning dosage patient compliance priority journal randomized controlled trial (topic) systematic review LA - English M3 - Article N1 - L362978639 2011-11-30 2011-12-06 PY - 2011 SN - 1120-6721 SP - 5-18 ST - Efficacy and tolerability of prostaglandin-timolol fixed combinations: A meta-analysis of randomized clinical trials T2 - European Journal of Ophthalmology TI - Efficacy and tolerability of prostaglandin-timolol fixed combinations: A meta-analysis of randomized clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362978639&from=export http://dx.doi.org/10.5301/ejo.5000009 http://www.eur-j-ophthalmol.com/public/EJO/issue/Article.action?cmd=navigate&urlkey=Public_Details&uid=CD24A391-D8DD-479E-88CF-E6E92ECC1F8F&t=EJO VL - 22 ID - 3207 ER - TY - JOUR AB - BACKGROUND: Lowering intraocular pressure (IOP) is currently the only therapeutic approach that preserves visual function in primary open-angle glaucoma. In making treatment decisions for first- and second-line therapy, the clinician needs to provide an appropriate balance of efficacy and tolerability. Prostaglandin analogues (PGAs) are frequently used as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Similarly, PGA-based fixed combinations are frequently used in patients who progress or fail to achieve the target IOP., SCOPE: We have reviewed the literature on the management of primary open-angle glaucoma with PGAs, both as monotherapies and in fixed combinations., FINDINGS: In the clinical trial and meta-analysis data identified, bimatoprost 0.03% seems to be associated with a greater overall ability to lower IOP compared with latanoprost, travoprost or tafluprost, at the cost of a slightly higher incidence of conjunctival hyperaemia. Studies indicate that patients' adherence to treatment is generally better with PGAs than with many other monotherapies. In patients requiring more than one IOP-lowering agent, fixed combination treatments may provide improved adherence and tolerability benefits compared with concomitant use of individual treatments. Bimatoprost/timolol fixed combination appears to be slightly more efficacious than latanoprost/timolol or travoprost/timolol, and tolerability differences between the fixed combinations appear to be slight, probably because the addition of timolol to the PGA component lessens the associated hyperaemia. Surveys on EU physician attitudes appear largely in line with these clinical data., CONCLUSION: An appropriate balance between efficacy and tolerability ensures optimum IOP lowering and reduces the risk of non-adherence. PGAs largely fulfil this need as monotherapies and as components of combinations. AU - Aptel, F. AU - Denis, P. DO - https://dx.doi.org/10.1185/03007995.2011.613923 IS - 10 KW - Adrenergic beta-Antagonists/ae [Adverse Effects] Adrenergic beta-Antagonists/ec [Economics] *Adrenergic beta-Antagonists/tu [Therapeutic Use] Conjunctival Diseases/ci [Chemically Induced] Conjunctival Diseases/ec [Economics] Conjunctival Diseases/pp [Physiopathology] Drug Therapy, Combination/mt [Methods] *Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/ec [Economics] Glaucoma, Open-Angle/pp [Physiopathology] Humans Hyperemia/ci [Chemically Induced] Hyperemia/ec [Economics] Hyperemia/pp [Physiopathology] Patient Compliance Prostaglandins F, Synthetic/ae [Adverse Effects] *Prostaglandins F, Synthetic/tu [Therapeutic Use] Timolol/ae [Adverse Effects] Timolol/ec [Economics] *Timolol/tu [Therapeutic Use] PY - 2011 SE - Aptel, F. Department of Ophthalmology, Edouard Herriot Hospital, Lyon 1 University, France. aptel_florent@hotmail.com SN - 1473-4877 0300-7995 SP - 1949-58 ST - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma T2 - Current medical research and opinion TI - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21878000 VL - 27 Y2 - 20110831// ID - 1250 ER - TY - JOUR AB - Background:Lowering intraocular pressure (IOP) is currently the only therapeutic approach that preserves visual function in primary open-angle glaucoma. In making treatment decisions for first- and second-line therapy, the clinician needs to provide an appropriate balance of efficacy and tolerability. Prostaglandin analogues (PGAs) are frequently used as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Similarly, PGA-based fixed combinations are frequently used in patients who progress or fail to achieve the target IOP.Scope:We have reviewed the literature on the management of primary open-angle glaucoma with PGAs, both as monotherapies and in fixed combinations.Findings:In the clinical trial and meta-analysis data identified, bimatoprost 0.03% seems to be associated with a greater overall ability to lower IOP compared with latanoprost, travoprost or tafluprost, at the cost of a slightly higher incidence of conjunctival hyperaemia. Studies indicate that patients’ adherence to treatment is generally better with PGAs than with many other monotherapies. In patients requiring more than one IOP-lowering agent, fixed combination treatments may provide improved adherence and tolerability benefits compared with concomitant use of individual treatments. Bimatoprost/timolol fixed combination appears to be slightly more efficacious than latanoprost/timolol or travoprost/timolol, and tolerability differences between the fixed combinations appear to be slight, probably because the addition of timolol to the PGA component lessens the associated hyperaemia. Surveys on EU physician attitudes appear largely in line with these clinical data.Conclusion:An appropriate balance between efficacy and tolerability ensures optimum IOP lowering and reduces the risk of non-adherence. PGAs largely fulfil this need as monotherapies and as components of combinations. AN - 104691148. Language: English. Entry Date: 20111020. Revision Date: 20150711. Publication Type: Journal Article AU - Aptel, F. AU - Denis, P. DB - ccm DO - 10.1185/03007995.2011.613923 DP - EBSCOhost IS - 10 KW - Intraocular Pressure Glaucoma -- Drug Therapy Prostaglandins -- Administration and Dosage Human Timolol Bimatoprost Drug Therapy, Combination Meta Analysis N1 - meta analysis; research; systematic review. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 0351014. PMID: NLM21878000. PY - 2011 SN - 0300-7995 SP - 1949-1958 ST - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin–timolol fixed combinations in primary open-angle glaucoma T2 - Current Medical Research & Opinion TI - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin–timolol fixed combinations in primary open-angle glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104691148&site=ehost-live&scope=site VL - 27 ID - 4390 ER - TY - JOUR AB - The side effects of glaucoma hypotensive treatments usually remain moderate and limited to local side effects - conjunctival hyperemia, itching, discomfort after instillation - but are very often a leading source of poor compliance to treatment and thereby may decrease its efficacy. Moreover, these symptoms usually reflect progressive and irreversible major ocular surface changes. These ocular surface changes induced by glaucoma eyedrops may include subconjunctival fibrosis, increasing the risk of failure of a further glaucoma surgery. All the components of the hypotensive eye drops, including the active ingredient, the preservatives, and the excipients, may be involved in the occurrence of these side effects. It is therefore important to identify the agents involved and the mechanisms of these side effects, in order to choose a treatment minimizing their risk and the discomfort felt by patients, and therefore increasing the likelihood of good compliance. When available, preservative-free solutions should be considered. Copyright © 2011 Elsevier Masson SAS. All rights reserved. AU - Aptel, F. AU - Denis, P. AU - Baudouin, C. DO - https://dx.doi.org/10.1016/j.jfo.2010.12.005 IS - 6 KW - Benzalkonium Compounds/ae [Adverse Effects] Conjunctival Diseases/ci [Chemically Induced] Dry Eye Syndromes/ci [Chemically Induced] Excipients/ae [Adverse Effects] Fibrosis *Glaucoma/dt [Drug Therapy] Humans Hyperemia/ci [Chemically Induced] Medication Adherence *Ophthalmic Solutions/ae [Adverse Effects] *Preservatives, Pharmaceutical/ae [Adverse Effects] Prostaglandins/ae [Adverse Effects] Pruritus/ci [Chemically Induced] PY - 2011 SE - Aptel, F. Service d'ophtalmologie, hospices civils de Lyon, hopital Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France. aptel_florent@hotmail.com SN - 1773-0597 0181-5512 SP - 409-12 ST - [Managing treatment side effects: the respective roles of the active ingredient and the preservative] T2 - Gerer les effets secondaires des traitements : les roles respectifs de la molecule et du conservateur. TI - [Managing treatment side effects: the respective roles of the active ingredient and the preservative] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21511364 VL - 34 Y2 - 20110420// ID - 1273 ER - TY - JOUR AB - Therapeutic ultrasound, although less well known than ultrasound for diagnostic imaging, has become a topic of growing interest in ophthalmology. High intensity focused ultrasound (HIFU) for the treatment of glaucoma and ultrasonic drug delivery are the two main areas of research and potential clinical applications. For the treatment of glaucoma, the specific advantage of HIFU, particularly when compared to the laser, is that the energy can be focused through optically opaque media, especially through the sclera which is a strongly light-scattering medium. HIFU is therefore a possible method for partial coagulation of the ciliary body (an anatomical structure responsible for the production of the liquid filling the eye) and, hence, reducing intraocular pressure and the risk of glaucoma. Ocular drug bioavailability also remains a challenge, being limited by multiple barriers to drug entry and lacrimal drainage, and making it difficult to achieve a sufficient drug concentration for numerous diseases of the front and back of the eye. As the front wall of the eye (cornea and anterior sclera) is a pathway for topically applied drugs, locally applied ultrasound has been proposed as a way of enhancing the delivery and activity of drugs and genes. Despite the fact that experimental studies seem to confirm the potential benefit of ultrasound ocular drug delivery, there is still a lack of clinical evidence. The aim of this contribution is to provide an update on recent advances in the field of therapeutic ultrasound in ophthalmology. AU - Aptel, Florent AU - Lafon, Cyril DO - https://dx.doi.org/10.3109/02656736.2012.665566 IS - 4 KW - Animals *Drug Delivery Systems/mt [Methods] Eye/me [Metabolism] Eye Diseases/me [Metabolism] *Eye Diseases/th [Therapy] Humans Ophthalmology/mt [Methods] Sound *Ultrasonic Therapy PY - 2012 SE - Aptel, Florent. Inserm, U1032, Lyon, F-69003, France. SN - 1464-5157 0265-6736 SP - 405-18 ST - Therapeutic applications of ultrasound in ophthalmology T2 - International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group TI - Therapeutic applications of ultrasound in ophthalmology UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22621741 VL - 28 ID - 1134 ER - TY - JOUR AU - Aptel, Florent AU - Toren, Andrew DO - https://dx.doi.org/10.1016/j.ophtha.2020.02.015 IS - 5 KW - Antihypertensive Agents Cost-Benefit Analysis *Glaucoma Humans *Medication Adherence N1 - Comment on (CON) PY - 2020 SN - 1549-4713 0161-6420 SP - 599-600 ST - Societal and Economic Impact of Poor Glaucoma Medication Adherence T2 - Ophthalmology T3 - Comment on: Ophthalmology. 2020 May;127(5):589-598; PMID: 31767436 [https://www.ncbi.nlm.nih.gov/pubmed/31767436] TI - Societal and Economic Impact of Poor Glaucoma Medication Adherence UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med17&NEWS=N&AN=32327131 VL - 127 Y2 - 20200219// ID - 275 ER - TY - JOUR AD - Glaucoma Service, Department of Ophthalmology, University of Campinas, Campinas, Sao Paulo, Brazil. rsaran@triang.com.br AN - 105809167. Language: English. Entry Date: 20080905. Revision Date: 20200708. Publication Type: Journal Article AU - Arcieri, E. S. AU - Pierre Filho, P. T. AU - Wakamatsu, T. H. AU - Costa, V. P. DB - ccm DO - 10.1038/sj.eye.6702542 DP - EBSCOhost IS - 2 KW - Antihypertensive Agents -- Pharmacodynamics Ocular Hypertension -- Physiopathology Prostaglandins, Synthetic -- Pharmacodynamics Uvea -- Drug Effects Adult Aged Amides -- Adverse Effects Amides -- Pharmacodynamics Antihypertensive Agents -- Adverse Effects Aqueous Humor -- Drug Effects Clinical Trials Epidemiological Research Female Glaucoma -- Drug Therapy Glaucoma -- Pathology Glaucoma -- Physiopathology Intraocular Pressure -- Drug Effects Male Middle Age Ocular Hypertension -- Drug Therapy Ocular Hypertension -- Pathology Prostaglandins, Synthetic -- Adverse Effects Prostaglandins, Synthetic -- Analogs and Derivatives Human N1 - clinical trial; research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM16936646. PY - 2008 SN - 0950-222X SP - 179-183 ST - The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension T2 - Eye TI - The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105809167&site=ehost-live&scope=site VL - 22 ID - 4471 ER - TY - JOUR AB - Objectives: To investigate the effects of prostaglandin analogues on the blood-aqueous barrier and to evaluate the occurrence of cystoid macular edema in aphakic or pseudophakic patients with glaucoma. Methods: In this randomized, masked-observer, 6-month clinical trial, patients with primary open-angle, pseudophakic, or aphakic glaucoma were treated once daily with bimatoprost (n=16), latanoprost (n = 15), or travoprost (n = 17) or twice daily with unoprostone (n = 16) or lubricant drops (control group) (n=16). Blood-aqueous barrier status, which was assessed using a laser flare meter; intraocular pressure; the occurrence of angiographic cystoid macular edema; and conjunctival hyperemia were evaluated. Results: Mean flare values were significantly higher in the bimatoprost, latanoprost, and travoprost groups throughout follow-up (P < .02). Four latanoprost-treated eyes, 1 bimatoprost-treated eye, and 1 travoprost-treated eye developed cystoid macular edema; all cases resolved after discontinuation of the prostaglandin analogue and treatment with topical diclofenac sodium. Mean intraocular pressure reductions after 6 months were higher for the latanoprost (26%), bimatoprost (28%), and travoprost (29%) groups than for the control (3%) and unoprostone (14%) groups (P < .05). Bimatoprost induced significantly higher hyperemia scores than latanoprost, unoprostone, and placebo (P < .01). Conclusion: Bimatoprost, latanoprost, and travoprost use may lead to disruption of the blood-aqueous barrier in patients with pseudophakia and aphakia. AD - Glaucoma Service, Department of Ophthalmology, University of Campinas, Campinas, São Paulo, Brazil Department of Ophthalmology, School of Medicine, Fed. University of Uberlândia, Uberlândia, Minas Gerais, Brazil Department of Ophthalmology, University of São Paulo, Brazil Department of Ophthalmology, School of Medicine, Fed. University of Uberlândia, Rua Corcovado, No. 155, Uberlândia, MG, 38411-092, Brazil AU - Arcieri, E. S. AU - Santana, A. AU - Rocha, F. N. AU - Guapo, G. L. AU - Costa, V. P. DB - Scopus DO - 10.1001/archopht.123.2.186 IS - 2 M3 - Article N1 - Cited By :91 Export Date: 19 July 2021 PY - 2005 SP - 186-192 ST - Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: A 6-month randomized trial T2 - Archives of Ophthalmology TI - Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: A 6-month randomized trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-13244292239&doi=10.1001%2farchopht.123.2.186&partnerID=40&md5=d68ac189b2928a6a9ef26e36536eff5b VL - 123 ID - 4937 ER - TY - JOUR AB - Millions of people have low vision, a disability condition caused by uncorrectable or partially correctable disorders of the eye. The primary goal of low vision rehabilitation is increasing access to printed material. This paper describes how adjustable typography, a computer graphic approach to enhancing text accessibility, can play a role in this process, by allowing visually-impaired users to customize fonts to maximize legibility according to their own visual needs. Prototype software and initial testing of the concept is described. The results show that visually-impaired users tend to produce a variety of very distinct fonts, and that the adjustment process results in greatly enhanced legibility. But this initial testing has not yet demonstrated increases in legibility over and above the legibility of highly legible standard fonts such as Times New Roman. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Arditi, Aries, Arlene R Gordon Research Institute, Lighthouse International, 111 East 59th Street, New York, NY, US, 10022-1202 AN - 2004-12205-002 AU - Arditi, Aries DB - psyh DO - 10.1080/0014013031000085680 DP - EBSCOhost IS - 5 KW - adjustable typography computer graphic approach low vision eye disorders text accessibility Adult Aged Aged, 80 and over Communication Aids for Disabled Computer Graphics Humans Middle Aged Reading Software User-Computer Interface Vision, Low Visual Acuity Visually Impaired Persons Computer Software Graphical Displays Optical Aids Vision Disorders Medical Therapeutic Devices N1 - Lighthouse International, New York, NY, US. Release Date: 20050214. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Computer Software; Eye Disorders; Graphical Displays; Optical Aids; Vision Disorders. Minor Descriptor: Medical Therapeutic Devices. Classification: Human Factors Engineering (4010). Population: Human (10). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 14. Issue Publication Date: Apr, 2004. PY - 2004 SN - 0014-0139 1366-5847 SP - 469-482 ST - Adjustable typography: An approach to enhancing low vision text accessibility T2 - Ergonomics TI - Adjustable typography: An approach to enhancing low vision text accessibility UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2004-12205-002&site=ehost-live&scope=site VL - 47 ID - 4879 ER - TY - JOUR AB - Introduction: Netarsudil and latanoprost ophthalmic solution (0.02%/0.005%) is indicated for intraocular pressure (IOP) lowering in open-angle glaucoma (OAG) or ocular hypertension (OHTN). The once-daily agent combines the mechanism of action for each of the individual components and provides a new avenue for long-term intraocular pressure control. This review aims to cover the agent's current efficacy and safety data and opine as to its role in glaucoma management. Areas covered: This article will cover Phase II-III clinical efficacy and safety data as well as basic science literature pertaining to the agent's mechanism of action and pharmacodynamics. In selecting articles for inclusion in this review, a literature search using the PubMed database was carried out. Cross-referencing was carried out where applicable. We did not use any date or language restrictions in electronic searches. Expert opinion: Netarsudil and latanoprost ophthalmic solution plays a pivotal role in management of individuals with OAG and OHTN. The agent may be used as first-line therapy to provide substantial IOP-lowering or when additional lowering is indicated and prostaglandins have provided insufficient IOP lowering. The once-daily dosing regimen decreases the risk of inadequate treatment due to nonadherence. AU - Aref, Ahmad A. AU - Geyman, Lawrence S. AU - Zakieh, Abdel-Rahman AU - Alotaibi, Humoud M. DO - https://dx.doi.org/10.1080/17512433.2019.1701435 IS - 12 KW - Animals Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/ae [Adverse Effects] *Benzoates/ad [Administration & Dosage] Benzoates/ae [Adverse Effects] Drug Combinations *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure *Latanoprost/ad [Administration & Dosage] Latanoprost/ae [Adverse Effects] *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions beta-Alanine/ad [Administration & Dosage] beta-Alanine/ae [Adverse Effects] *beta-Alanine/aa [Analogs & Derivatives] PY - 2019 SE - Aref, Ahmad A. Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA. Geyman, Lawrence S. Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA. Zakieh, Abdel-Rahman. Chicago Medical School, Rosalind Franklin University, Chicago, IL, USA. Alotaibi, Humoud M. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. SN - 1751-2441 1751-2433 SP - 1073-1079 ST - Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension T2 - Expert review of clinical pharmacology TI - Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31842637 VL - 12 ID - 304 ER - TY - JOUR AB - Uveitis in children has been reported at a much lower incidence than in adults, although with worse prognosis because at the time of diagnosis a substantial number of patients have complications that represent an important cause of ocular morbidity and visual loss. Children may be at special risk of complications, because inflammation is frequently chronic, and diagnosis is often delayed because of lack of symptoms or failure to report changes in vision. In addition, children are more difficult to examine and to treat. The evaluation and management of children with uveitis require special considerations. Medical and surgical management can be challenging owing to the unique features of clinical presentation. Therefore, early and aggressive anti-inflammatory therapy is the best means to improved long-term outcomes in children. Surgical intervention for diagnostic or therapeutic reasons may be necessary, and generally is required to address complications that are unresponsive to or not amenable to medical therapy. In addition, surgical procedures must be appropriately planned keeping in mind the risks and benefits and always under an appropriate and strict immunosuppressive (preoperative, intraoperative, and postoperative) therapy. Surgical treatment should be considered only when uveitis is controlled medically. Multistage surgery may be necessary to address each complication of uveitis using diverse strategies. Finally, a close relation should be fostered among pediatricians, pediatric rheumatologist, and ophthalmologist to more effectively diagnose and manage children with uveitis. © 2008, Lippincott Williams & Wilkins.SRSR. AU - Arevalo, J. F. AU - Garcia-Amaris, R. A. C1 - posurdex(Allergan,United States) retisert(Bausch and Lomb,United States) C2 - Allergan(United States) Bausch and Lomb(United States) DB - Embase Medline DO - 10.1097/IIO.0b013e31817d7fc1 IS - 3 KW - azathioprine chlorambucil corticosteroid cyclophosphamide cyclosporine dexamethasone fluocinolone acetonide fluorocarbon methotrexate nonsteroid antiinflammatory agent steroid triamcinolone acetonide amblyopia cataract cataract extraction childhood disease clinical trial cryotherapy disease exacerbation drug delivery system epiretinal membrane eye surgery follow up glaucoma human immunosuppressive treatment intermediate uveitis intraocular hypotension iridocyclitis keratopathy laser coagulation laser surgery lens implantation lensectomy patient compliance polymerase chain reaction priority journal retina retina detachment retina injury review sarcoidosis strabismus surgical technique toxocariasis treatment indication uveitis vitrectomy vitreoretinopathy vitreous biopsy posurdex retisert LA - English M3 - Review N1 - L354171771 2009-02-26 PY - 2008 SN - 0020-8167 SP - 153-172 ST - The role of vitreo-retinal surgery in children with uveitis T2 - International Ophthalmology Clinics TI - The role of vitreo-retinal surgery in children with uveitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354171771&from=export http://dx.doi.org/10.1097/IIO.0b013e31817d7fc1 VL - 48 ID - 3449 ER - TY - JOUR AB - PURPOSE: To determine the work time used for out-patients seen in the ophthalmology out-patient clinic according to treatment for each diagnosis and examination guidelines. Another objective was to discover the diagnostic related outpatient demand as well as the time spent on each technique., METHOD: We have designed a computer database system that includes examinations, treatments and medical services. Their duration was measured in a random sample of 127 ophthalmology outpatients in the General Hospital of Castellon. Sixty five of the patients had come to their first visit and 62 to the follow-up visits., RESULTS: A new patient spends a mean of 42 minutes and a follow-up patient spends a mean of 27 minutes. The most frequent diagnoses are retinal diseases (30%), cataract (18.6%), glaucoma (11.8%) and ocular motility disorders (11.8%). We present the mean times used by the physician in the ophthalmic techniques used in outpatients., CONCLUSIONS: We have modified the standard times of 30 minutes for the first visit and 15 minutes for the follow-up visit. Data on the work time used for all the ophthalmics techniques in our outpatient clinic are presented. This ophthalmology survey can be used for health care managers to establish the <> and health care plan administration to adapt the resources to the demand. AU - Arias Lopez, M. C. AU - Lanuza Garcia, A. AU - Garcia Garcia, N. AU - Ramos Marti, F. IS - 3 KW - *Ambulatory Care Facilities/sn [Statistics & Numerical Data] Eye Diseases/di [Diagnosis] Eye Diseases/th [Therapy] Humans *Office Visits/sn [Statistics & Numerical Data] *Ophthalmology/sn [Statistics & Numerical Data] Time Factors PY - 2001 SE - Arias Lopez, M C. Servicio de Oftalmologia, Hospital General de Castellon, Castellon, Espana. SN - 0365-6691 SP - 159-63 ST - [Evaluation of the work time used in outpatient ophthalmology techniques] T2 - Estimacion de tiempos medicos para tecnicas oftalmologicas ambulatorias. TI - [Evaluation of the work time used in outpatient ophthalmology techniques] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11283781 VL - 76 ID - 1924 ER - TY - JOUR AB - The authors present the case of a young woman with the diagnosis of late juvenile glaucoma. The treatment began in the very moment of the diagnosis but the lack of compliance, as well as the associated risk factors, led to a evolution difficult to control only through medical therapy, which is why we also used laser and surgical treatment. At present, the anatomical and functional status is stable but the long-term prognosis is reserved. AU - Armegioiu, Monica AU - Craiu, Andreea AU - Beraru, Vlad AU - Constantin, Camelia AU - Malcea, Cristina IS - 2 KW - Adult Diagnosis, Differential Female *Glaucoma, Angle-Closure/di [Diagnosis] Glaucoma, Angle-Closure/pp [Physiopathology] Glaucoma, Angle-Closure/su [Surgery] *Glaucoma, Angle-Closure/th [Therapy] Humans *Intraocular Pressure Laser Therapy Microscopy, Acoustic Prognosis Refraction, Ocular Risk Factors Trabeculectomy Treatment Outcome Visual Acuity PY - 2008 SE - Armegioiu, Monica. Clinica de Oftalmologie, SCUMC - Bucuresti. SN - 1220-0875 SP - 52-8 ST - [Tardive juvenile glaucoma] T2 - Glaucom juvenil tardiv. TI - [Tardive juvenile glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19065915 VL - 52 ID - 1501 ER - TY - JOUR AU - Armstrong, G. W. AU - Lorch, A. C. DB - Embase Medline DO - 10.1097/IIO.0000000000000298 IS - 1 KW - artificial intelligence cataract clinical practice computer assisted diagnosis congenital cataract diabetic patient diagnostic accuracy glaucoma health care access health care cost health care utilization human keratoconus machine learning multimodal imaging ophthalmologist ophthalmology optical coherence tomography patient counseling review screening test systemic disease telemedicine LA - English M3 - Review N1 - L630713619 2020-01-31 2020-07-20 PY - 2020 SN - 1536-9617 0020-8167 SP - 57-71 ST - A(eye): A Review of Current Applications of Artificial Intelligence and Machine Learning in Ophthalmology T2 - International Ophthalmology Clinics TI - A(eye): A Review of Current Applications of Artificial Intelligence and Machine Learning in Ophthalmology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630713619&from=export http://dx.doi.org/10.1097/IIO.0000000000000298 VL - 60 ID - 2363 ER - TY - JOUR AD - Ophthalmic Associates, PC, Anchorage, AK, United States University of Illinois College of Medicine, Peoria, IL, United States AU - Arnold, R. W. AU - Lichtenstein, S. J. AU - Nelson, L. B. DB - Scopus DO - 10.3928/01913913-20100505-01 IS - 3 M3 - Conference Paper N1 - Export Date: 19 July 2021 PY - 2010 SP - 134-138 ST - Treatment options for dense amblyopia in uncooperative children T2 - Journal of Pediatric Ophthalmology and Strabismus TI - Treatment options for dense amblyopia in uncooperative children UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952809443&doi=10.3928%2f01913913-20100505-01&partnerID=40&md5=94458406fd700d4152a3be7a569e31dc VL - 47 ID - 5764 ER - TY - JOUR AB - Data on the elderly population with inflammatory bowel disease (IBD) are scarce, as this population is normally excluded from clinical trials. With an ageing population and an overall increasing prevalence of IBD; the incidence of IBD in elderly is rising. Comorbidities, wide differential diagnosis and polypharmacy make the diagnosis and management of the disease in elderly more challenging compared to that in younger adults. The knowledge of specific requirements for the management and treatment of IBD in advanced age may help in the framing of the definition of the appropriate care of this patient group. This manuscript reviews the most recent knowledge in the epidemiology, diagnosis and management of IBD in this population. AU - Arnott, I. AU - Rogler, G. AU - Halfvarson, J. DB - Embase DO - 10.1159/000490053 IS - 4 KW - acetylsalicylic acid allopurinol anticonvulsive agent antidiabetic agent azathioprine C reactive protein calcium channel blocking agent calgranulin clotrimazole corticosteroid digoxin dipeptidyl carboxypeptidase inhibitor diuretic agent hydralazine loop diuretic agent mercaptopurine mesalazine methotrexate nonsteroid antiinflammatory agent penicillin derivative tetracycline derivative tuberculostatic agent tumor necrosis factor inhibitor warfarin aged bone marrow toxicity cataract colitis comorbidity Crohn disease differential diagnosis disease exacerbation drug antagonism drug blood level drug dose reduction drug potentiation fatigue gastrointestinal hemorrhage glaucoma hospital admission human hypokalemia ileal pouch-anal anastomosis incidence infection inflammatory bowel disease infusion related reaction leukopenia lymphoma malabsorption malnutrition mycosis nausea neurologic disease nonhodgkin lymphoma patient compliance patient-reported outcome polypharmacy prevalence priority journal proctocolectomy rash remission review rheumatic disease skin manifestation stomatitis surgical mortality toxic megacolon ulcerative colitis LA - English M3 - Review N1 - L622924644 2018-07-11 2018-08-14 PY - 2018 SN - 2296-9365 2296-9403 SP - 189-199 ST - The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives T2 - Inflammatory Intestinal Diseases TI - The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622924644&from=export http://dx.doi.org/10.1159/000490053 VL - 2 ID - 2576 ER - TY - JOUR AD - S. Arora AU - Arora, S. DB - Embase Medline DO - 10.1109/MPULS.2020.3022143 IS - 5 KW - medical device carbon dioxide article coronavirus disease 2019 electroencephalogram glaucoma health care utilization heart rate hospital readmission hospital waste hospitalization human Internet Internet of medical things intraocular pressure medical technology patient care patient monitoring physician quality of life quarantine resuscitation social network telemedicine telemonitoring videorecording waste management LA - English M3 - Article N1 - L633133249 2020-11-02 2020-11-24 PY - 2020 SN - 2154-2317 2154-2287 SP - 24-27 ST - IoMT (Internet of Medical Things): Reducing Cost while Improving Patient Care T2 - IEEE Pulse TI - IoMT (Internet of Medical Things): Reducing Cost while Improving Patient Care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633133249&from=export http://dx.doi.org/10.1109/MPULS.2020.3022143 VL - 11 ID - 2391 ER - TY - JOUR AB - Viruses have the property to replicate very fast in host cell. It can attack any part of host cell. Therefore, the clinical efficacy of antiviral drugs and its bioavailability is more important concern taken into account to treat viral infections. The oral and parenteral routes of drug administration have several shortcomings, however, which could lead to the search for formulating better delivery systems. Now, a day′s novel drug delivery systems (NDDS) proved to be a better approach to enhance the effectiveness of the antivirals and improve the patient compliance and decrease the adverse effect. The NDDS have reduced the dosing frequency and shorten the duration of treatment, thus, which could lead the treatment more cost-effective. The development of NDDS for antiviral and antiretroviral therapy aims to deliver the drug devoid of toxicity, with high compatibility and biodegradability, targeting the drug to specific sites for viral infection and in some instances it also avoid the first pass metabolism effect. This article aims to discuss the usefulness of novel delivery approaches of antiviral agents such as niosomes, microspheres, microemulsions, nanoparticles that are used in the treatment of various Herpes viruses and in human immunodeficiency virus (HIV) infections. AD - P. Pawar, Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Rajpura, Rajpura, Patiala, Punjab-140401, India AU - Arora, S. AU - Chawla, A. AU - Pawar, P. AU - Sharma, P. C1 - cervarix cymevene(Hoffmann La Roche) cytovene(Hoffmann La Roche) gardasil varivax virgan virusan vitrasert(Bausch and Lomb) zostavax C2 - Bausch and Lomb Hoffmann La Roche DB - Embase DO - 10.4103/2231-4040.101007 IS - 3 KW - aciclovir antiretrovirus agent antivirus agent atazanavir beta cyclodextrin chickenpox vaccine cidofovir drug carrier ethosome famciclovir foscarnet ganciclovir glycyrrhizic acid idoxuridine indinavir liposome macrogol nanoparticle nevirapine niosome nonnucleoside reverse transcriptase inhibitor penciclovir polymer RNA directed DNA polymerase inhibitor solid lipid nanoparticle unclassified drug unindexed drug valaciclovir valganciclovir varicella zoster vaccine Wart virus vaccine adenovirus infection adverse drug reaction anus cancer biocompatibility biodegradability bone marrow toxicity chickenpox conference paper cost effectiveness analysis cytomegalovirus infection DNA virus drug delivery system drug dosage form comparison drug efficacy drug formulation drug safety drug synthesis first pass effect genital herpes herpes labialis herpes simplex herpes simplex keratitis herpes zoster human Human immunodeficiency virus infection human T cell leukemia virus Kaposi varicelliform eruption keratoconjunctivitis microemulsion nanopharmaceutics nephrotoxicity nonhuman novel drug delivery system papillomavirus infection patient compliance physical chemistry priority journal RNA virus treatment duration uterine cervix cancer viral skin disease cervarix cymevene cytovene gardasil varivax virgan virusan vitrasert zostavax LA - English M3 - Conference Paper N1 - L365661258 2012-09-27 2012-10-02 PY - 2012 SN - 0110-5558 0976-2094 SP - 147-159 ST - Novel drug delivery approaches on antiviral and antiretroviral agents T2 - Journal of Advanced Pharmaceutical Technology and Research TI - Novel drug delivery approaches on antiviral and antiretroviral agents UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365661258&from=export http://dx.doi.org/10.4103/2231-4040.101007 VL - 3 ID - 3076 ER - TY - JOUR AB - BACKGROUND: To compare access time and cycle time between an "in-house" teleglaucoma program and in-person glaucoma consultation., PATIENTS AND METHODS: This was a prospective comparative study of 71 patients seen through the teleglaucoma program (eligible patients were glaucoma suspects or early-stage open-angle glaucoma) and 63 patients seen via a traditional in-person exam with a physician present. Access time was calculated as the time from the patient being referred to the date of a booked visit for either a teleglaucoma or in-person exam. Cycle time was defined as the time from registration until departure during the visit to the hospital; it was calculated for the subset of patients from each study group who completed activity logs on the day of their visit., RESULTS: The mean access time was significantly shorter for patients seen through teleglaucoma compared with in-person exam: 45+/-22 days (range, 13-121 days) (n=68) versus 88+/-47 days (range, 27-214 days) (n=63), respectively (p<0.0001). The cycle time was also reduced for patients seen through teleglaucoma, compared with in-person assessment: 78+/-20 min (range, 40-130 min) (n=39) versus 115+/-44 min (range, 51-216 min) (n=39), respectively (p<0.001). The mean percentage time spent in the waiting room was also significantly reduced for patients seen through teleglaucoma versus in-person assessments: 19+/-13% versus 41+/-24% (n=39), respectively (p<0.01)., CONCLUSIONS: Teleglaucoma improves access to care and is a more efficient way of managing glaucoma suspects and patients with early-stage glaucoma compared with in-person assessment. AU - Arora, Sourabh AU - Rudnisky, Chris J. AU - Damji, Karim F. DO - https://dx.doi.org/10.1089/tmj.2013.0241 IS - 5 KW - Adult Aged Aged, 80 and over Alberta *Appointments and Schedules Cohort Studies Female *Glaucoma/di [Diagnosis] Glaucoma/th [Therapy] Health Services Accessibility/og [Organization & Administration] Humans Inpatients/sn [Statistics & Numerical Data] Male Middle Aged Ophthalmology/mt [Methods] *Patient-Centered Care/og [Organization & Administration] *Physical Examination/mt [Methods] Program Evaluation Prospective Studies Quality Improvement *Referral and Consultation/og [Organization & Administration] Statistics, Nonparametric *Telemedicine/og [Organization & Administration] Time Factors PY - 2014 SE - Arora, Sourabh. Department of Ophthalmology, University of Alberta, Edmonton, Alberta, Canada . SN - 1556-3669 1530-5627 SP - 439-45 ST - Improved access and cycle time with an "in-house" patient-centered teleglaucoma program versus traditional in-person assessment T2 - Telemedicine journal and e-health : the official journal of the American Telemedicine Association TI - Improved access and cycle time with an "in-house" patient-centered teleglaucoma program versus traditional in-person assessment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24568152 VL - 20 Y2 - 20140225// ID - 898 ER - TY - JOUR AB - Background: Prostanoids are the newest pharmacologic group of ocular hypotensive drugs for clinical management of glaucoma. The group includes four chemical compounds structurally derived from naturally-occurring prostaglandin (PG) F2α. Prostanoids have been divided into PG analogues (unoprostone, latanoprost and travoprost) and prostamides (bimatoprost) because of differences in molecular structures. The drugs share a novel mechanism of action that produces a potent ocular hypotensive effect and a novel local adverse effect of increased iridial pigmentation. Objective: To summarise the pharmacologic and clinical data regarding the effectiveness and safety of prostanoids in clinical glaucoma management. Methods: The review was supported by a literature search of peer-reviewed publications, based on medical information available in databases such as PubMed. Results/conclusion: The prostanoids began a treatment revolution not only because of their novel mechanism of action but also as a result of a new local side effect. © 2008 Informa UK Ltd. AD - E. Arranz-Marquez, Vissum Madrid, C/Santa Hortensia 58, 28002 Madrid, Spain AU - Arranz-Marquez, E. AU - Teus, M. A. DB - Embase Medline DO - 10.1517/14740330802465474 IS - 6 KW - benzalkonium chloride bimatoprost collagen type 1 collagen type 3 collagen type 4 collagen type 6 fibronectin gelatinase A gelatinase B hyaluronic acid interstitial collagenase laminin latanoprost prostaglandin receptor stromelysin timolol travoprost unoprostone isopropyl ester angina pectoris aqueous humor flow article asthma bronchospasm ciliary muscle conjunctival hyperemia cornea erosion dizziness dosage schedule comparison drug absorption drug blood level drug efficacy drug elimination drug half life drug mechanism drug metabolism drug safety drug structure evening dosage extracellular matrix glaucoma herpes simplex keratitis human intraocular pressure iris disease medical information medical literature Medline muscle relaxation patient compliance peer review receptor upregulation LA - English M3 - Article N1 - L352760947 2008-12-22 PY - 2008 SN - 1474-0338 SP - 801-808 ST - Prostanoids for the management of glaucoma T2 - Expert Opinion on Drug Safety TI - Prostanoids for the management of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352760947&from=export http://dx.doi.org/10.1517/14740330802465474 VL - 7 ID - 3420 ER - TY - JOUR AB - Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes of irreversible blindness globally and for which intraocular pressure is the only modifiable risk factor. Although neuroprotective therapies have been suggested to have therapeutic potential, drug delivery for the treatment of ocular disorders such as glaucoma remains an unmet clinical need, further complicated by poor patient compliance with topically applied treatments. In the present study we describe the development of multi-loaded PLGA-microspheres (MSs) incorporating three recognised neuroprotective agents (dexamethasone (DX), melatonin (MEL) and coenzyme Q10 (CoQ10)) in a single formulation (DMQ-MSs) to create a novel sustained-release intraocular drug delivery system (IODDS) for the treatment of glaucoma. MSs were spherical, with a mean particle size of 29.04+/-1.89mum rendering them suitable for intravitreal injection using conventional 25G-32G needles. >62% incorporation efficiency was achieved for the three drug cargo and MSs were able to co-deliver the encapsulated active compounds in a sustained manner over 30-days with low burst release. In vitro studies showed DMQ-MSs to be neuroprotective in a glutamate-induced cytotoxicity model (IC50 10.00+/-0.94mM versus 6.89+/-0.82mM in absence of DMQ-MSs) in R28 cell line. In vivo efficacy studies were performed using a well-established rodent model of chronic ocular hypertension (OHT), comparing single intravitreal injections of microspheres of DMQ-MSs to their equivalent individual single-drug loaded MSs mixture (MSsmix), empty MSs, no-treatment OHT only and naive groups. Twenty one days after OHT induction, DMQ-MSs showed a significantly neuroprotective effect on RGCs compared to OHT only controls. No such protective effect was observed in empty MSs and single-drug MSs treated groups. This work suggests that multi-loaded PLGA MSs present a novel therapeutic approach in the management of retinal neurodegeneration conditions such as glaucoma. Copyright © 2019. Published by Elsevier B.V. AU - Arranz-Romera, A. AU - Davis, B. M. AU - Bravo-Osuna, I. AU - Esteban-Perez, S. AU - Molina-Martinez, I. T. AU - Shamsher, E. AU - Ravindran, N. AU - Guo, L. AU - Cordeiro, M. F. AU - Herrero-Vanrell, R. DO - https://dx.doi.org/10.1016/j.jconrel.2019.01.012 KW - Animals Dexamethasone/ad [Administration & Dosage] Dexamethasone/ch [Chemistry] Disease Models, Animal *Drug Carriers/ch [Chemistry] Drug Compounding Drug Liberation Drug Therapy, Combination/mt [Methods] *Glaucoma/dt [Drug Therapy] Humans Injections, Intraocular Male Melatonin/ad [Administration & Dosage] Melatonin/ch [Chemistry] *Microspheres Neuroprotective Agents/ad [Administration & Dosage] *Neuroprotective Agents/ch [Chemistry] *Polylactic Acid-Polyglycolic Acid Copolymer/ch [Chemistry] Rats Retina/de [Drug Effects] Transcription Factor Brn-3B/me [Metabolism] Treatment Outcome Ubiquinone/ad [Administration & Dosage] Ubiquinone/aa [Analogs & Derivatives] Ubiquinone/ch [Chemistry] PY - 2019 SE - Arranz-Romera, A. Pharmaceutical Innovation in Ophthalmology (InnOftal), Research Group (UCM 920415), Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain; Red Tematica de Investigacion Cooperativa Sanitaria en Enfermedades Oculares (Oftared) e Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), United Kingdom. Davis, B M. Glaucoma and Retinal Neurodegeneration Research, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom; Imperial College Ophthalmology Research Group (ICORG), Western Eye Hospital, Imperial College London, United Kingdom. Bravo-Osuna, I. Pharmaceutical Innovation in Ophthalmology (InnOftal), Research Group (UCM 920415), Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain; Red Tematica de Investigacion Cooperativa Sanitaria en Enfermedades Oculares (Oftared) e Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), United Kingdom. Esteban-Perez, S. Pharmaceutical Innovation in Ophthalmology (InnOftal), Research Group (UCM 920415), Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain; Red Tematica de Investigacion Cooperativa Sanitaria en Enfermedades Oculares (Oftared) e Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), United Kingdom. Molina-Martinez, I T. Pharmaceutical Innovation in Ophthalmology (InnOftal), Research Group (UCM 920415), Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain; Red Tematica de Investigacion Cooperativa Sanitaria en Enfermedades Oculares (Oftared) e Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), United Kingdom. Shamsher, E. Glaucoma and Retinal Neurodegeneration Research, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom. Ravindran, N. Glaucoma and Retinal Neurodegeneration Research, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom. Guo, L. Glaucoma and Retinal Neurodegeneration Research, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom. Cordeiro, M F. Glaucoma and Retinal Neurodegeneration Research, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom; Imperial College Ophthalmology Research Group (ICORG), Western Eye Hospital, Imperial College London, United Kingdom. Electronic address: m.cordeiro@ucl.ac.uk. Herrero-Vanrell, R. Pharmaceutical Innovation in Ophthalmology (InnOftal), Research Group (UCM 920415), Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain; Red Tematica de Investigacion Cooperativa Sanitaria en Enfermedades Oculares (Oftared) e Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), United Kingdom. Electronic address: rociohv@farm.ucm.es. SN - 1873-4995 0168-3659 SP - 26-38 ST - Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma T2 - Journal of controlled release : official journal of the Controlled Release Society TI - Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30664980 VL - 297 Y2 - 20190118// ID - 359 ER - TY - JOUR AB - PURPOSE: To describe the association of water exposure with contact lens (CL)-related disease and explore the guidelines regarding water exposure to CL wearers, provided by CL manufacturing industry, global public health, and CL-related professional associations., METHODS: A review of the literature was conducted by searching PubMed, MEDLINE, and Web of Science databases up to September 2017 for articles published or translated in English using keywords: contact lens* AND tap water OR swimming OR showering OR water exposure AND microbial keratitis OR Acanthamoeba keratitis OR corneal infiltrate* OR ocular adverse event*. References in all relevant publications were also reviewed., RESULTS: Water exposure during CL wear is associated with complications ranging from sterile corneal infiltrative events to sight-threatening infections. Despite the documented risks due to water exposure, water-related habits are common among CL wearers. This suggests a lack of awareness and understanding regarding the risks among CL wearers and potentially CL practitioners. Discrepancies exist in guidelines for CL hygiene and compliance provided by the CL manufacturing industry, global public health, and CL-related professional associations. There is also widespread use of water imagery within CL marketing and packaging materials. These factors may give rise to confusion among wearers and may contribute toward risk-taking behaviors., CONCLUSIONS: Consensus among stakeholders about water and CL care is needed. Guidelines should unequivocally advocate for the avoidance of any water exposure including handling CLs with wet hands, rinsing CLs or storage cases in tap water, showering while wearing CLs and swimming with CLs without wearing goggles. AU - Arshad, Memoona AU - Carnt, Nicole AU - Tan, Jacqueline AU - Ekkeshis, Irenie AU - Stapleton, Fiona DO - https://dx.doi.org/10.1097/ICO.0000000000001898 IS - 6 KW - *Contact Lenses *Corneal Diseases/et [Etiology] Corneal Diseases/mi [Microbiology] *Eye Infections/et [Etiology] Eye Infections/mi [Microbiology] Humans *Hygiene Keratitis/et [Etiology] Keratitis/mi [Microbiology] *Water/ae [Adverse Effects] PY - 2019 SE - Arshad, Memoona. School of Optometry and Vision Science, UNSW-Sydney, NSW, Australia. Carnt, Nicole. School of Optometry and Vision Science, UNSW-Sydney, NSW, Australia. Tan, Jacqueline. School of Optometry and Vision Science, UNSW-Sydney, NSW, Australia. Ekkeshis, Irenie. New Citizenship Project, London, UK. Stapleton, Fiona. School of Optometry and Vision Science, UNSW-Sydney, NSW, Australia. SN - 1536-4798 0277-3740 SP - 791-797 ST - Water Exposure and the Risk of Contact Lens-Related Disease T2 - Cornea TI - Water Exposure and the Risk of Contact Lens-Related Disease UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30789440 VL - 38 ID - 355 ER - TY - JOUR AB - BACKGROUND: Water exposure during contact lens wear has been associated with contact lens disease including microbial keratitis and sterile corneal infiltrates. Despite the documented risks, water exposure is common amongst lens wearers. This study aimed to determine the effect of water education in the form of "no-water" lens case stickers on water-contact behaviours and storage case contamination., METHODS: In a prospective, masked, randomised controlled trial, 200 daily lens wearers were randomised to either receive a storage case with a "no-water" sticker (test) or without a "no-water" sticker (control). Both groups received written compliance information. Participants completed a self-administered lens hygiene questionnaire at baseline and after 6 weeks. Microbial analysis of used storage cases, collected at both study visits, was conducted using ATP and limulus amebocyte lysate (LAL) assays for overall microbial contamination and endotoxin levels, respectively. A one-way ANCOVA and multiple logistic regression determined the change in water-contact behaviours and storage case contamination over time., RESULTS: A total of 188 lens wearers completed both study visits; 128 females and 60 males; average age 29 +/- 13 (range 18-78 years); 95 test and 93 control participants. After 6 weeks, the overall water exposure score and endotoxin levels reduced significantly in the test group compared with the control group (p < 0.05). There were no significant changes in individual water-contact behaviours or overall storage case contamination., CONCLUSION: A no-water infographic on the contact lens case improved overall water-contact behaviours and reduced storage case endotoxin. Refining the messaging may be beneficial in future to improve other aspects of compliance. AU - Arshad, Memoona AU - Carnt, Nicole AU - Tan, Jacqueline AU - Stapleton, Fiona DO - https://dx.doi.org/10.1038/s41433-020-1015-9 IS - 3 KW - Adolescent Adult Aged *Contact Lens Solutions *Contact Lenses Female Humans Hygiene Male Middle Aged Prospective Studies Surveys and Questionnaires Young Adult PY - 2021 SE - Arshad, Memoona. School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia. m.arshad@unsw.edu.au. Carnt, Nicole. School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia. Tan, Jacqueline. School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia. Stapleton, Fiona. School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia. SN - 1476-5454 0950-222X SP - 988-995 ST - Compliance behaviour change in contact lens wearers: a randomised controlled trial T2 - Eye (London, England) TI - Compliance behaviour change in contact lens wearers: a randomised controlled trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=mesx&NEWS=N&AN=32546749 VL - 35 Y2 - 20200616// ID - 152 ER - TY - JOUR AB - Glaucoma is the second most common cause of world blindness (following cataract) with estimated cases reaching 79.6 million by 2020. Although the etiology of glaucoma is multi-factorial, intraocular pressure (IOP) is the only modifiable factor in glaucoma management proven to alter the natural course of the disease. Among various classes of IOP-lowering medications currently available, alpha-adrenergic receptor agonists are used either as monotherapy, as second-line therapy, or in fixed combination with beta-blockers. Non-selective adrenergic agonists such as epinephrine and dipivefrin are infrequently used today for the treatment of glaucoma or ocular hypertension, and have been replaced by the alpha-2-selective agonists. The use of apraclonidine for IOP reduction in glaucoma or OHT is limited due to a high rate of follicular conjunctivitis. The alpha-2-selective agonist in use today is brimonidine. The brimonidine-purite formulations are preferred to brimonidine-benzalkonium chloride (BAC) formulations due better tolerability while maintaining similar efficacy. Brimonidine is also effective when used in combination with a beta-blocker. Using brimonidine-timolol fixed combination (BTFC) as first-line therapy has an added potential for neuroprotection. This would be a valuable strategy for glaucoma treatment, for patients who are intolerant of prostaglandin analogs, or for patients where prostaglandin analogues are contraindicated as first-line therapy, such as in patients with inflammatory glaucoma. © 2011 Elsevier Ltd. AD - L.B. Cantor, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Department of Ophthalmology, 702 Rotary Circle, Indianapolis, IN 46202, United States AU - Arthur, S. AU - Cantor, L. B. C1 - alphagan(Allergan,United States) combigan(Allergan,United States) C2 - Allergan(United States) DB - Embase Medline DO - 10.1016/j.exer.2011.04.002 IS - 3 KW - epinephrine alpha adrenergic receptor stimulating agent apraclonidine brimonidine brimonidine plus timolol dipivefrine dorzolamide plus timolol latanoprost allergic reaction aphakia apnea article ataxia bradycardia conjunctivitis contact dermatitis dizziness drowsiness drug blood level drug cost drug efficacy drug elimination drug half life drug mechanism drug safety drug tolerability drug withdrawal eye burning eye discomfort eye irritation fatigue glaucoma headache heart arrhythmia human hyperemia hypertension hypotension hypothermia intraocular hypertension intraocular pressure irritability lethargy miosis monotherapy muscle hypotonia neuroprotection nonhuman ocular pruritus pallor patient compliance priority journal pseudophakia randomized controlled trial (topic) respiration depression side effect somnolence tachyphylaxis unspecified side effect xerostomia alphagan combigan LA - English M3 - Article N1 - L51397264 2011-05-04 2011-11-07 PY - 2011 SN - 0014-4835 1096-0007 SP - 271-283 ST - Update on the role of alpha-agonists in glaucoma management T2 - Experimental Eye Research TI - Update on the role of alpha-agonists in glaucoma management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51397264&from=export http://dx.doi.org/10.1016/j.exer.2011.04.002 VL - 93 ID - 3155 ER - TY - JOUR AB - Purpose: To describe the care seeking journey and causes of delay among patients with Microbial Keratitis in Uganda. Methods: A prospective cohort of patients presenting with microbial keratitis at the two main eye units in Southern Uganda (2016-2018). We collected information on demographics, home address, clinical history, and presentation pathway including, order of facilities where patients went to seek care, treatment advice, cost of care, and use of Traditional Eye Medicine. Presentation time was noted. We compared "direct" presenters versus "indirect" presenters and analysed predictors of delay. Results: About 313 patients were enrolled. All were self-referred. Only 19% of the patients presented directly to the eye hospital. Majority (52%) visited one facility before presenting, 19% visited two facilities, 9% visited three facilities, and 2% visited four facilities. The cost of care increased with increase in the number of facilities visited. People in a large household, further distance from the eye hospital and those who used Traditional Eye Medicine were less likely to come directly to the eye hospital. Visiting another facility prior to the eye hospital and use of Traditional Eye Medicine aOR 1.58 (95%CI 1.03-2.43), p = .038 were associated with delayed presentation to the eye hospital. Conclusion: This study provided information on patient journeys to seek care. Delay was largely attributable to having visited another health facility: a referral mechanism for microbial keratitis was non-existent. There is need to explore how these health system gaps can be strengthened. AU - Arunga, Simon AU - Kintoki, Guyguy M. AU - Gichuhi, Stephen AU - Onyango, John AU - Newton, Rob AU - Leck, Astrid AU - Macleod, David AU - Hu, Victor H. AU - Burton, Matthew J. DO - https://dx.doi.org/10.1080/09286586.2019.1616775 IS - 5 KW - Adult Eye Infections, Fungal/ec [Economics] *Eye Infections, Fungal/th [Therapy] Female Health Care Costs *Health Services Accessibility/sn [Statistics & Numerical Data] Humans Keratitis/ec [Economics] *Keratitis/th [Therapy] Male Middle Aged *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Prospective Studies Referral and Consultation/st [Standards] Regression Analysis Uganda PY - 2019 SE - Arunga, Simon. International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. Arunga, Simon. Department of Ophthalmology, Mbarara University of Science and Technology, Mbarara, Uganda. Kintoki, Guyguy M. Department of Ophthalmology, Mbarara University of Science and Technology, Mbarara, Uganda. Gichuhi, Stephen. Department of Ophthalmology, University of Nairobi, Nairobi, Kenya. Onyango, John. Department of Ophthalmology, Mbarara University of Science and Technology, Mbarara, Uganda. Newton, Rob. Department of Ophthalmology, Uganda Virus Research Institute, Entebbe, Uganda. Leck, Astrid. International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. Macleod, David. Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK. Hu, Victor H. International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. Burton, Matthew J. International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. SN - 1744-5086 0928-6586 SP - 311-320 ST - Delay Along the Care Seeking Journey of Patients with Microbial Keratitis in Uganda T2 - Ophthalmic epidemiology TI - Delay Along the Care Seeking Journey of Patients with Microbial Keratitis in Uganda UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31088316 VL - 26 Y2 - 20190515// ID - 290 ER - TY - JOUR AB - PURPOSE: To study the indications and variables correlating with graft survival in optical penetrating keratoplasty in a tertiary care hospital in north India., PARTICIPANTS: All patients who underwent optical keratoplasty, except those undergoing lamellar grafts, tectonic grafts transplants and penetrating keratoplasty done for therapeutic purposes were included in the study. Patients with follow-up less than 2 years were excluded from the study., MATERIALS AND METHODS: Data were obtained by reviewing the records of 101 patients who underwent optical penetrating keratoplasty from 2008 to 2013 for various indications., RESULTS: Out of 101 patients who underwent optical penetrating keratoplasty, 71 were males and 30 were females. The mean age of the recipient was 48.53 years with range 1-82 years. The main indications were previous failed graft (29.7%), healed keratitis except HSV (15.8%), pseudophakic or aphakic bullous keratopathy (14.8%), corneal dystrophies/degenerations (12.9%), adherent leucoma (9.9%), post-HSV scars (8.9%), and others like anterior staphyloma, congenital corneal opacities, buphthalmos and keratoconus (7.9%). The graft survival rate was 67.33% at 1-year follow-up and 59.4% at 2-year follow-up. The mean survival time of the grafts was 22.42 months. The mean time for graft failure was 7.12 (+/-0.9) months., CONCLUSION: One- and 2-year survival of grafts at our center is lower as compared to western studies, probably due to higher percentage of poor prognosis indications for surgery and a relative scarcity of excellent-quality donor corneas. AU - Arya, Sudesh Kumar AU - Raj, Amit AU - Bamotra, Ravi Kant AU - Bhatti, Anubha AU - Deswal, Jyoti AU - Sindhu, Meenakshi DO - https://dx.doi.org/10.1007/s10792-017-0641-0 IS - 4 KW - Adolescent Adult Aged Aged, 80 and over Child Child, Preschool *Corneal Diseases/su [Surgery] Endothelial Cells/cy [Cytology] Female *Graft Survival Humans India Infant Kaplan-Meier Estimate Keratoplasty, Penetrating/mt [Methods] *Keratoplasty, Penetrating Male Middle Aged Retrospective Studies Suture Techniques Tertiary Care Centers Visual Acuity Young Adult PY - 2018 SE - Arya, Sudesh Kumar. Department of Ophthalmology, D Block, Level 3, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India. Raj, Amit. Department of Ophthalmology, D Block, Level 3, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India. rajdoc78@yahoo.com. Bamotra, Ravi Kant. Department of Ophthalmology, D Block, Level 3, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India. Bhatti, Anubha. Department of Ophthalmology, D Block, Level 3, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India. Deswal, Jyoti. Department of Ophthalmology, D Block, Level 3, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India. Sindhu, Meenakshi. Department of Ophthalmology, D Block, Level 3, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India. SN - 1573-2630 0165-5701 SP - 1669-1679 ST - Indications and graft survival analysis in optical penetrating keratoplasty in a tertiary care center in North India: a 5-year study T2 - International ophthalmology TI - Indications and graft survival analysis in optical penetrating keratoplasty in a tertiary care center in North India: a 5-year study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=28688026 VL - 38 Y2 - 20170707// ID - 475 ER - TY - JOUR AB - The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects. AU - Asbell, Penny A. AU - Potapova, Natalia IS - 1 PY - 2005 SE - Asbell, Penny A. Department of Ophthalmology, Mount Sinai Medical Center, New York, New York 10029, USA. Penny.Asbell@mssm.edu SN - 1542-0124 SP - 27-40 ST - Effects of topical antiglaucoma medications on the ocular surface T2 - The ocular surface TI - Effects of topical antiglaucoma medications on the ocular surface UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=17131003 VL - 3 ID - 1229 ER - TY - JOUR AB - Each subspecialty has its own guidelines that must be followed. AN - 105910960. Language: English. Entry Date: 20080509. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Asbell, R. L. DB - ccm DP - EBSCOhost IS - 7 KW - Insurance, Health, Reimbursement Medicare Ophthalmology -- Standards Audit Cataract Extraction Coding Corneal Diseases -- Surgery Current Procedural Terminology Diagnosis, Eye Documentation Fees and Charges Glaucoma International Classification of Diseases Office Visits -- Economics Retinal Diseases -- Surgery Surgery, Plastic N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2008 SN - 8750-3085 SP - 33-36 ST - Expert: knowing guidelines will help avoid audit trap T2 - Ocular Surgery News TI - Expert: knowing guidelines will help avoid audit trap UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105910960&site=ehost-live&scope=site VL - 26 ID - 4643 ER - TY - JOUR AB - BACKGROUND: The aim of this study was to characterize veterans' adherence to glaucoma medications and follow-up eye care, and to examine the influence of coexisting chronic conditions such as posttraumatic stress disorder (PTSD)/anxiety., PATIENTS AND METHODS: A retrospective review of computerized medical records was performed for 161 veterans taking topical glaucoma medications. Medication possession ratio (MPR) was calculated using pharmacy data. Mean follow-up ratio (FUR) was calculated using the number of days between visits., RESULTS: Among the health conditions examined, the most prevalent was hearing loss (0.34), followed by arthritis (0.29), PTSD, or other anxiety disorder (0.27), and dementia or other memory disorder (0.09). The average rates of MPR and FUR were 0.69+/-0.20 and 0.84+/-0.19, respectively.Group comparisons found that patients with hearing loss had higher MPR compared with patients without hearing loss, and patients who were white had higher FUR than African American patients. When demographic and health characteristics were examined simultaneously in multiple linear regressions, hearing loss emerged as a significant predictor of MPR, and being older was significantly related to FUR. Younger age was also associated with MPR and being white (vs. African American) or having a PTSD/other anxiety disorder was related to FUR, although these findings did not reach statistical significance., CONCLUSIONS: FUR was better than MPR in a veteran population being treated for glaucoma.Hearing loss was significantly related to higher MPR, whereas being older was significantly associated with higher FUR. These characteristics should be taken into consideration in future programs to improve adherence to glaucoma care. AU - Asefzadeh, Baharak AU - Rett, Douglas AU - Pogoda, Terri K. AU - Selvin, Gerald AU - Cavallerano, Anthony DO - https://dx.doi.org/10.1097/IJG.0000000000000044 IS - 4 KW - Administration, Topical Adult Aged Aged, 80 and over Ambulatory Care/sn [Statistics & Numerical Data] *Antihypertensive Agents/tu [Therapeutic Use] Anxiety Disorders/co [Complications] Arthritis/co [Complications] *Chronic Disease Dementia/co [Complications] Drug Prescriptions/sn [Statistics & Numerical Data] *Exfoliation Syndrome/dt [Drug Therapy] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Hearing Loss/co [Complications] Humans *Low Tension Glaucoma/dt [Drug Therapy] Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ophthalmic Solutions Retrospective Studies Stress Disorders, Post-Traumatic/co [Complications] United States Veterans *Veterans Health/sn [Statistics & Numerical Data] PY - 2014 SE - Asefzadeh, Baharak. VA Boston Health Care System, Eye Clinic, Jamaica Plain Campus, Jamaica Plain, MA. SN - 1536-481X 1057-0829 SP - 240-5 ST - Glaucoma medication adherence in veterans and influence of coexisting chronic disease T2 - Journal of glaucoma TI - Glaucoma medication adherence in veterans and influence of coexisting chronic disease UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24522105 VL - 23 ID - 902 ER - TY - JOUR AB - PURPOSE: To find the dropout rate and identify the clinical characteristics of patients who drop out in the first year of follow-up from a glaucoma clinic., DESIGN: Descriptive hospital-based study at a tertiary hospital eye department., METHODS: Clinical characteristics of consecutive patients newly diagnosed with glaucoma who dropped out (n=452) were compared with patients who did not drop out (n=295) within 12 months., RESULTS: The rate of dropout from follow-up was 60.5% within 1 year; 43.1% of the study group dropped out after their first follow-up visit. The dropout rate was high in all age groups, but higher in the age groups 21 to 30 years, 41 to 50 years, and over 70 years. Males had a higher dropout rate than females (78.6% vs. 34.5%). Dropout rate was higher among those with mild/moderate glaucoma than those with severe disease (88.2% vs. 37.2%); those who lived further away from the hospital than those who lived nearer to the hospital (72.5% vs. 40.8%), those who were referred from screening clinics for nonblinding eye disease compared with those referred because of a blinding eye disease (72.2% vs. 58.9%). More patients (63.8%) unsure of their family eye disease history dropped out, compared with 34.3% of those with positive family history of glaucoma and other potentially blinding diseases. More patients who had no systemic disease dropped out, than those with systemic disease (54.6% vs. 39.6%); whereas patients on 2 medications or more had a higher dropout rate than those on less than 2 medications (68.1% vs. 52.1%). Of the study factors, those that were statistically significantly associated with dropping out of follow-up from the glaucoma clinic were age, sex, place of domicile, diagnosis at referral, severity of disease, family history, and polydrug use., CONCLUSIONS: The dropout rate from this glaucoma clinic in the first year was high (60.5%). Patients who were more likely to dropout were younger patients, male, those who travelled far distances to the clinic, those with mild to moderate glaucoma, those with no family history of blinding eye diseases, and patients taking 2 or more eyedrops. Patients who seem to perceive their problems as not serious dropped out of follow-up. These findings have great implications in planning future studies and intervention to improve the follow-up of glaucoma patients in the study area. AU - Ashaye, Adeyinka O. AU - Adeoye, Adenike O. DO - https://dx.doi.org/10.1097/IJG.0b013e31815768b3 IS - 3 KW - Adult Age Distribution Aged Aged, 80 and over Female Follow-Up Studies *Glaucoma, Angle-Closure/ep [Epidemiology] Glaucoma, Angle-Closure/px [Psychology] *Glaucoma, Open-Angle/ep [Epidemiology] Glaucoma, Open-Angle/px [Psychology] Humans Male Middle Aged Nigeria/ep [Epidemiology] *Outpatient Clinics, Hospital/sn [Statistics & Numerical Data] Patient Dropouts/px [Psychology] *Patient Dropouts/sn [Statistics & Numerical Data] Retrospective Studies Sex Distribution Treatment Refusal PY - 2008 SE - Ashaye, Adeyinka O. Department of Ophthalmology, College of Medicine, University of Ibadan, Nigeria. adeyinkaashaye@yahoo.com SN - 1057-0829 SP - 227-32 ST - Characteristics of patients who dropout from a glaucoma clinic T2 - Journal of glaucoma TI - Characteristics of patients who dropout from a glaucoma clinic UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18414110 VL - 17 ID - 1533 ER - TY - JOUR AB - BACKGROUND: The degree to which ocular morbidity affects workers productivity in the developing countries has not been studied adequately. A federal government research institute based in Lagos introduced an annual health screen for all its workers, which included eye tests. This provided an opportunity to study the pattern of ocular conditions among workers who were 30 years and above, and to determine the effect of eye diseases on the workers productivity., STUDY DESIGN: Detailed eye examination including refraction, was done on every respondent at the institution's clinic by an ophthalmologist. A questionnaire on ocular health status and occupational history was administered independently by an ophthalmic nurse. Sickness absenteeism, use of the clinic were obtained from clinic records, and the results were analysed., RESULTS: The common ocular conditions were uncorrected or poorly corrected refractive error, uncorrected or poorly corrected presbyopia and allergic. conjunctivitis. Glaucoma, maculopathy and optic atrophy were causes of severe visual impairment or blindness in 1.9 % of the subjects. Absenteeism and clinic use were more common in subjects with ocular morbidity than those with non-ocular morbidity. Subjects with ocular morbidity had more illnesses, absenteeism and used the clinic more., CONCLUSION: Ocular problems which reduce worker's productivity are prevalent among the staff of the institution studied. They are mostly unrecognised. AU - Ashaye, A. O. AU - Asuzu, M. C. IS - 2 KW - *Absenteeism Academies and Institutes Adult Aged Developing Countries *Efficiency Eye Diseases/cl [Classification] Eye Diseases/di [Diagnosis] *Eye Diseases/ep [Epidemiology] Female Humans Male Mass Screening Middle Aged Nigeria/ep [Epidemiology] Occupational Diseases/di [Diagnosis] *Occupational Diseases/ep [Epidemiology] Surveys and Questionnaires Urban Health Workplace PY - 2005 SE - Ashaye, A O. Department of Ophthalmology, College of Medicine, University of lbadan, Nigeria. aashaye@skannet.com SN - 0189-160X SP - 96-9 ST - Ocular findings seen among the staff of an institution in Lagos, Nigeria T2 - West African journal of medicine TI - Ocular findings seen among the staff of an institution in Lagos, Nigeria UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16092306 VL - 24 ID - 1728 ER - TY - JOUR AB - Patient noncompliance with the physician's prescribed therapeutic regimen can present serious obstacles both to individual patient care and to the obtaining of information necessary for controlled drug trials. Unfortunately, the physician often is unable to determine whether and to what extent a patient is not complying with therapy. This article reviews the problem of patient noncomplicance with particular emphasis on how and why noncompliance occurs, and methods of predicting, detecting and coping with the defaulting patient. AD - Glaucoma Cent., Dept. Ophthalmol., Washington Univ. Sch. Med., St Louis, Mo. AU - Ashburn Jr, F. S. AU - Goldberg, I. AU - Kass, M. A. DB - Embase Medline DO - 10.1016/0039-6257(80)90045-4 IS - 4 KW - eye drops pilocarpine drug therapy glaucoma patient compliance psychological aspect review therapy topical drug administration visual system LA - English M3 - Review N1 - L10161239 1980-03-20 PY - 1980 SN - 0039-6257 SP - 237-248 ST - Compliance with ocular therapy T2 - Survey of Ophthalmology TI - Compliance with ocular therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L10161239&from=export http://dx.doi.org/10.1016/0039-6257(80)90045-4 VL - 24 ID - 4104 ER - TY - JOUR AB - INTRODUCTION: New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibitor approved by the US Food and Drug Administration, reduces intraocular pressure (IOP) by increasing trabecular outflow. Two phase 3 superiority studies compared a fixed-dose combination (FDC) of netarsudil and the prostaglandin latanoprost with each active component for IOP-lowering efficacy., METHODS: Pooled efficacy and safety data were analyzed from MERCURY-1 and -2 studies in patients with OAG or OHT. Patients instilled one drop of netarsudil (0.02%)/latanoprost (0.005%) FDC (n = 483), netarsudil (0.02%, n = 499), or latanoprost (0.005%, n = 486) into each eye once-daily between 20:00 and 22:00. IOP was measured at 08:00, 10:00, and 16:00 at weeks 2, 6, and the primary endpoint at month 3., RESULTS: Baseline mean diurnal IOP was 23.6, 23.6, and 23.5 mmHg in netarsudil/latanoprost FDC, netarsudil, and latanoprost groups, respectively. Mean diurnal IOP in each group was 15.3, 18.1, and 17.5 mmHg at week 2, 15.7, 18.4, and 17.4 mmHg at week 6, and 15.8, 18.4, and 17.3 mmHg at week 12. The netarsudil/latanoprost FDC met criteria for superiority compared with each active component (p < 0.0001 for all nine time points). At month 3, among patients randomized to netarsudil/latanoprost FDC or latanoprost, 58.4% vs 37.3% (p < 0.0001) achieved IOP <= 16 mmHg. Among patients randomized to netarsudil/latanoprost FDC or netarsudil or latanoprost, 30.9% vs 5.9% (p < 0.0001) vs 8.5% (p < 0.0001) achieved at least a 40% reduction from baseline in mean diurnal IOP. Pooled safety results were consistent with individual MERCURY studies., CONCLUSION: Once-daily netarsudil/latanoprost FDC produced statistically significant and clinically relevant reductions in mean IOP that were statistically superior to IOP reductions achieved by netarsudil and latanoprost monotherapy. Results of the pooled efficacy and safety analyses were consistent with the individual studies., TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT02558400 and NCT02674854. AU - Asrani, Sanjay AU - Bacharach, Jason AU - Holland, Edward AU - McKee, Hayley AU - Sheng, Huan AU - Lewis, Richard A. AU - Kopczynski, Casey C. AU - Heah, Theresa DO - https://dx.doi.org/10.1007/s12325-020-01277-2 IS - 4 KW - Aged Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Benzoates/ae [Adverse Effects] *Benzoates/tu [Therapeutic Use] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Latanoprost/ae [Adverse Effects] *Latanoprost/tu [Therapeutic Use] Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions/ae [Adverse Effects] *Ophthalmic Solutions/tu [Therapeutic Use] Tonometry, Ocular United States United States Food and Drug Administration beta-Alanine/ae [Adverse Effects] *beta-Alanine/aa [Analogs & Derivatives] beta-Alanine/tu [Therapeutic Use] PY - 2020 SE - Asrani, Sanjay. Duke University School of Medicine, Durham, NC, USA. sanjay.asrani@duke.edu. Bacharach, Jason. North Bay Eye Associates, Petaluma, CA, USA. Holland, Edward. Cincinnati Eye Institute, Cincinnati, OH, USA. McKee, Hayley. Aerie Pharmaceuticals, Inc, Durham, NC, USA. Sheng, Huan. Aerie Pharmaceuticals, Inc, Durham, NC, USA. Lewis, Richard A. Aerie Pharmaceuticals, Inc, Durham, NC, USA. Lewis, Richard A. Sacramento Eye Consultants, Sacramento, CA, USA. Kopczynski, Casey C. Aerie Pharmaceuticals, Inc, Durham, NC, USA. Heah, Theresa. Aerie Pharmaceuticals, Inc, Durham, NC, USA. SN - 1865-8652 0741-238X SP - 1620-1631 ST - Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2 T2 - Advances in therapy TI - Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32166538 VL - 37 Y2 - 20200312// ID - 247 ER - TY - JOUR AB - PURPOSE: The authors have further developed their method of retinal thickness analysis to rapidly generate multiple optical cross sections of the retina and provide thickness maps at the posterior pole. The potential use of this method was evaluated in a number of macular disorders., METHODS: A commercial prototype of the scanning retinal thickness analyzer was used to examine patients with a variety of macular diseases. A laser slit beam was projected on the retina and scanned across a 2- X 2-mm retinal area in 200 to 400 msec. The images of the intersection of the laser slit beam with the retina were recorded digitally and used for visualization of disease. Nine scans were combined, and an operator-free algorithm generated a three-dimensional thickness map at the posterior pole., RESULTS: Cysts could be visualized in macular edema associated with diabetes mellitus and with retinal vein occlusion. The retinal thickness map quantitated the location, extent, and height of the edema. In serous detachment, the extent and the height of the retinal pigment epithelial elevation could be documented. In cases of suspected macular holes and pseudoholes, the diagnosis was considered more reliable than with conventional biomicroscopy. The extent of epiretinal membranes, the sites of adherence, and associated intraretinal cystic changes were identified. In glaucoma, the anatomic course of localized loss of neuronal retinal tissue could be traced., CONCLUSIONS: Scanning retinal thickness analysis provided multiple optical cross sections of the retina and yielded information useful in the diagnosis and monitoring of macular diseases. The three-dimensional thickness map provided quantitative information that may be useful for clinical management. AU - Asrani, S. AU - Zeimer, R. AU - Goldberg, M. F. AU - Zou, S. IS - 7 KW - *Anatomy, Cross-Sectional/mt [Methods] Diabetic Retinopathy/di [Diagnosis] Female Fovea Centralis/pa [Pathology] Glaucoma/di [Diagnosis] Humans *Lasers Macular Edema/di [Diagnosis] Male Reference Values *Retina/pa [Pathology] *Retinal Diseases/di [Diagnosis] Retinal Perforations/di [Diagnosis] PY - 1997 SE - Asrani, S. Johns Hopkins University School of Medicine, Wilmer Ophthalmological Institute, Baltimore, Maryland 21287-9131, USA. SN - 0161-6420 SP - 1145-51 ST - Application of rapid scanning retinal thickness analysis in retinal diseases T2 - Ophthalmology TI - Application of rapid scanning retinal thickness analysis in retinal diseases UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9224468 VL - 104 ID - 2018 ER - TY - JOUR AB - BACKGROUND: The direct costs associated with menopausal and postmenopausal symptoms (hereafter “menopausal symptoms”) may include the costs of physician and emergency department visits, medications, laboratory testing, and the management of side effects. However, much remains unknown about the costs related to menopausal symptoms, including how they compare with the costs of other diseases that are common among menopausal women. OBJECTIVE: To compare the economic burden of menopausal symptoms with other select prevalent chronic conditions among a nationally representative sample of US menopausal women aged 45 to 65 years. METHODS: Women aged 45 to 65 years who have not had a hysterectomy and who participated in the 2010-2012 Medical Expenditure Panel Survey Household Component were included in the analysis. We estimated the direct costs of care associated with the management of menopausal symptoms and compared them with the direct costs of care for other indications, including osteoporosis, influenza, disorders of lipid metabolism, essential hypertension, mood disorders, esophageal disorders, headache, osteoarthritis, urinary tract infections, asthma, glaucoma, anxiety disorder, diabetes, chronic obstructive pulmonary disease/bronchiectasis, and cataract. Regression analyses were used to estimate the differences in direct costs, which included total expenditures and charges for inpatient, outpatient, and emergency department visits. RESULTS: The annual per-patient direct cost of menopausal symptoms was $248 in 2010-2012 dollars. Based on the modeled costs, menopausal symptoms were associated with significantly higher annual costs than osteoporosis, disorders of lipid metabolism, and esophageal disorders; and these annual costs were comparable to those of influenza, asthma, anxiety disorder, essential hypertension, and headache. The direct costs associated with the management of menopausal symptoms were significantly lower than the direct costs associated with osteoarthritis, mood disorders, chronic obstructive pulmonary disease/ bronchiectasis, urinary tract infections, diabetes, glaucoma, and cataract. CONCLUSION: The direct costs of care for menopausal symptoms are substantial and are similar to or greater than the direct healthcare costs associated with a number of medical conditions often requiring medical attention in menopausal women. AU - Assaf, A. R. AU - Bushmakin, A. G. AU - Joyce, N. AU - Louie, M. J. AU - Flores, M. AU - Moffatt, M. DB - Embase IS - 6 KW - adult anxiety disorder article asthma bronchiectasis chronic obstructive lung disease drug cost emergency ward essential hypertension female headache health care cost health care utilization human hysterectomy menopausal syndrome middle aged mood disorder osteoarthritis osteoporosis sensitivity analysis urinary tract disease LA - English M3 - Article N1 - L619157085 2017-11-14 2017-11-28 PY - 2017 SN - 1942-2970 1942-2962 SP - 311-320 ST - The relative burden of menopausal and postmenopausal symptoms versus other major conditions: A retrospective analysis of the medical expenditure panel survey data T2 - American Health and Drug Benefits TI - The relative burden of menopausal and postmenopausal symptoms versus other major conditions: A retrospective analysis of the medical expenditure panel survey data UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619157085&from=export VL - 10 ID - 2634 ER - TY - JOUR AB - Background: Glaucoma is a chronic optic nerve disease, often asymptomatic in an early stage, which is usually associated with elevated intraocular pressure. Good adherence to ocular hypotensive agents is essential to control the intraocular pressure and optic nerve damage. There is limited information on glaucoma drug adherence and associated factors in Ethiopia, particularly in the study area., Objective: To determine the level of glaucoma drug adherence and associated factors among adult glaucoma patients attending Felege Hiwot Specialized Hospital, Northwest Ethiopia, 2019., Materials and Methods: A hospital-based cross-sectional study was conducted at Felege Hiwot specialized Hospital from March 2019 to May 2019. A systematic random sampling method was used to select 402 study participants. A structured questionnaire was prepared, and adherence was assessed by using self-report questions. The collected data were entered into Epi data version 4.2.2.1 and exported into Statistical Package for Social Science version 23 for analysis. Tables, graphs, frequency, mean, and standard deviation were used for descriptive statistics. Variables with a p-value of <0.2 in the bivariable logistic regression were entered in the multivariable logistic regression, and variables with a p-value of <0.05 under multivariable analysis were taken as statistically significant factors for glaucoma drug adherence., Results: Among a total of 390 study participants, 212 (56.2%) were adherent to their topical medication. Early glaucoma (AOR=2.8: 95% CI =1.29-5.91), normal vision (AOR=1.9: 95% CI=1.15-3.09), urban residence (AOR=1.6: 95% CI=1.03-2.51), family support (AOR=1.7: 95% CI=1.06-2.76) and information from pharmacist (AOR=1.8: 95% CI=1.11-2.99) were significantly associated with adherence., Conclusion: The level of glaucoma drug adherence was 56.2% among patients attending Felege Hiwot Specialized Hospital. Early glaucoma, normal visual acuity, family support, information on medication from the pharmacist, and urban residence were positively associated with adherence. Copyright © 2020 Assem et al. AU - Assem, Abel Sinshaw AU - Fekadu, Sofonias Addis AU - Yigzaw, Amsal Ambaw AU - Nigussie, Zelalem Mehari AU - Achamyeleh, Anemaw Asrat DO - https://dx.doi.org/10.2147/OPTO.S274850 PY - 2020 SE - Assem, Abel Sinshaw. Department of Optometry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. Fekadu, Sofonias Addis. Department of Optometry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. Yigzaw, Amsal Ambaw. Department of Ophthalmology, Felege Hiwot Specialized Hospital, Bahir Dar, Ethiopia. Nigussie, Zelalem Mehari. Department of Epidemiology and Biostatics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia. Achamyeleh, Anemaw Asrat. Department of Epidemiology and Biostatics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia. SN - 1179-2752 SP - 189-197 ST - Level of Glaucoma Drug Adherence and Its Associated Factors Among Adult Glaucoma Patients Attending Felege Hiwot Specialized Hospital, Bahir Dar City, Northwest Ethiopia T2 - Clinical optometry TI - Level of Glaucoma Drug Adherence and Its Associated Factors Among Adult Glaucoma Patients Attending Felege Hiwot Specialized Hospital, Bahir Dar City, Northwest Ethiopia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33149714 VL - 12 Y2 - 20201027// ID - 125 ER - TY - JOUR AB - PURPOSE: To report the visual, refractive, and functional outcomes of photorefractive keratectomy (PRK) and of laser-assisted subepithelial keratectomy in a group of children with significant refractive error and underlying medical conditions or ocular pathology who were noncompliant with traditional management., SETTING: Nonhospital surgical facility and a hospital clinic., METHODS: This case series comprised 5 individual cases of anisometropic amblyopia and/or high myopia. Underlying medical and ocular conditions were as follows: upper eyelid hemangioma with oblique myopic astigmatism, Pelizaeus-Merzbacher leukodystrophy with nystagmus, Klippel-Trenaunay-Weber syndrome with glaucoma, incontinentia pigmenti with unilateral optic nerve atrophy, and Goldenhar syndrome with unilateral optic nerve hypoplasia. Photorefractive keratectomy or LASEK was performed in 6 eyes of 5 patients. Age range at the time of surgery was 1.0 to 7.0 years. All procedures were performed under general anesthesia., RESULTS: Best corrected visual acuity improved by 2 lines in 2 patients and 1 line in 2 patients by 6 months after surgery. Stereopsis and/or fusional status improved in 3 patients. Amblyopia treatment compliance improved in 1 patient. Alignment improved without strabismus surgery in 2 cases. A functional vision survey demonstrated a positive effect on the ability of all 5 children to function in their environment., CONCLUSION: During the period of visual cortical plasticity, refractive surgery, by eliminating the refractive component of amblyopia and by promoting fusional ability, provides considerable improvement in children, even those with underlying medical conditions associated with ocular pathology. AU - Astle, William F. AU - Papp, Andrea AU - Huang, Peter T. AU - Ingram, April IS - 1 KW - Abnormalities, Multiple Amblyopia/co [Complications] *Amblyopia/th [Therapy] Anisometropia/co [Complications] *Anisometropia/su [Surgery] Child Child, Preschool Comorbidity Eye Diseases/co [Complications] Female Humans Infant *Keratectomy, Subepithelial, Laser-Assisted Lasers, Excimer Male Myopia/co [Complications] *Myopia/su [Surgery] Patient Compliance *Photorefractive Keratectomy Visual Acuity/ph [Physiology] PY - 2006 SE - Astle, William F. Alberta Children's Hospital, University of Calgary, Division of Ophthalmology, Canada. SN - 0886-3350 SP - 103-8 ST - Refractive laser surgery in children with coexisting medical and ocular pathology T2 - Journal of cataract and refractive surgery TI - Refractive laser surgery in children with coexisting medical and ocular pathology UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16516787 VL - 32 ID - 1679 ER - TY - JOUR AB - The authors studied the adherence of Pseudomonas aeruginosa and Staphylococcus aureus to extended wear soft contact lenses (EWSCLs) with and without focal deposits using both a radiolabeling technique and electron microscopy. P. aeruginosa showed significant adherence to contact lenses in vitro. In contrast, S. aureus failed to show significant adherence to contact lenses in vitro (i.e., the radioactive uptake was not significantly above background). The extent of adherence of Pseudomonas was proportional to the number of focal deposits on the lenses. Results of electron microscopic examination showed the bacteria to be adherent primarily to large focal deposits (greater than or equal to 150 microns). There was no pseudomonal adherence to the small focal deposits (less than or equal to 50 microns) and little adherence to the areas in between the focal deposits. The authors hypothesize that worn lenses, especially those with large focal deposits, serve as a vehicle for the transport of P. aeruginosa to the cornea. This hypothesis could be a partial explanation for the high incidence of keratitis caused by P. aeruginosa in EWSCL patients. AU - Aswad, M. I. AU - John, T. AU - Barza, M. AU - Kenyon, K. AU - Baum, J. IS - 3 KW - *Bacterial Adhesion Colony Count, Microbial *Contact Lenses, Extended-Wear Humans Microscopy, Electron, Scanning *Pseudomonas aeruginosa/gd [Growth & Development] Pseudomonas aeruginosa/ul [Ultrastructure] *Staphylococcus aureus/gd [Growth & Development] Staphylococcus aureus/ul [Ultrastructure] Thymidine Tritium PY - 1990 SE - Aswad, M I. Department of Ophthalmology, New England Medical Center, Boston, MA 02111. SN - 0161-6420 SP - 296-302 ST - Bacterial adherence to extended wear soft contact lenses T2 - Ophthalmology TI - Bacterial adherence to extended wear soft contact lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2110642 VL - 97 ID - 2150 ER - TY - JOUR AB - Background: The possible sequel of poorly controlled intraocular pressure (IOP) includes treatment failure, unnecessary medication use, and economic burden on patients with glaucoma., Objective: To assess the impact of adherence and instillation technique on IOP control., Methods: A cross-sectional study was conducted on 359 glaucoma patients in Menelik II Hospital from June 1 to July 31, 2015. After conducting a Q-Q analysis, multiple binary logistic analyses, linear regression analyses, and two-tailed paired t-test were conducted to compare IOP in the baseline versus current measurements., Results: Intraocular pressure was controlled in 59.6% of the patients and was relatively well controlled during the study period (mean (M) = 17.911 mmHg, standard deviation (S) = 0.323) compared to the baseline (M = 20.866 mmHg, S = 0.383, t (358) = -6.70, p < 0.0001). A unit increase in the administration technique score resulted in a 0.272 mmHg decrease in IOP (p = 0.03). Moreover, primary angle-closure glaucoma (adjusted odds ratio (AOR) = 0.347, 95% confidence interval (CI): 0.144-0.836) and two medications (AOR = 1.869, 95% CI: 1.259-9.379) were factors affecting IOP., Conclusion: Good instillation technique of the medications was correlated with a reduction in IOP. Consequently, regular assessment of the instillation technique and IOP should be done for better management of the disease. AU - Atey, Tesfay Mehari AU - Shibeshi, Workineh AU - T Giorgis, Abeba AU - Asgedom, Solomon Weldegebreal DO - https://dx.doi.org/10.1155/2017/1683430 PY - 2017 SE - Atey, Tesfay Mehari. Clinical Pharmacy Unit, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Tigray, Ethiopia. Shibeshi, Workineh. Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. T Giorgis, Abeba. Department of Ophthalmology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. Asgedom, Solomon Weldegebreal. Clinical Pharmacy Unit, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Tigray, Ethiopia. SN - 2090-004X SP - 1683430 ST - The Impact of Adherence and Instillation Proficiency of Topical Glaucoma Medications on Intraocular Pressure T2 - Journal of ophthalmology TI - The Impact of Adherence and Instillation Proficiency of Topical Glaucoma Medications on Intraocular Pressure UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=29104803 VL - 2017 Y2 - 20170914// ID - 619 ER - TY - JOUR AB - PURPOSE: To validate the treatment-specific Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP)., METHODS: Item content was developed by 4 heterogeneous patient focus groups (n = 32). Instrument validation involved 250 patients on ocular hypotensive medications recruited from ophthalmology practices in the Southern USA. Participants responded to demographic and test questions during a clinic visit. Standard psychometric analyses were performed on the resulting data., SAMPLE: Of the 412 patients screened, 253 consented to participate, and 250 provided complete datasets. The sample included 44% male (n = 109), 44% Black (n = 109) and 57% brown eyed (n = 142) participants, with a mean age of 64.6 years (SD 13.1) and a history of elevated IOP for an average of 8.4 yrs (SD 7.8). A majority was receiving monotherapy (60%, n = 151)., RESULTS: A PC Factor analysis (w/ varimax rotation) of the 31 items yielded 5 factors (Eigenvalues > 1.0) explaining 70% of the total variance. Weaker and conceptually redundant items were removed and the remaining 15 items reanalyzed. The satisfaction factors were; Eye Irritation (EI; 4 items), Convenience of Use (CofU; 3 items), Ease of Use (EofU; 3 items), Hyperemia (HYP; 3 items), and Medication Effectiveness (EFF; 2 items). Chronbach's Alphas ranged from.80 to.86. Greater distributional skew was found for less common experiences (i.e., HYP & EI with 65% & 48.4% ceilings) than for more common experiences (i.e., EofU, CofU, EFF with 10.8%, 20.8% & 15.9% ceilings). TSS-IOP scales converged with conceptually related scales on a previously validated measure of treatment satisfaction, the TSQM (r =.36 to.77). Evidence of concurrent criterion-related validity was found. Patients' symptomatic ratings of eye irritation, hyperemia and difficulties using the medication correlated with satisfaction on these dimensions (r =.30-.56, all p <.001). Clinicians' ratings of IOP control, severity of side effects and problematic medication use correlated with patients' satisfaction scores on these dimensions (r =.13-.26, all p <.01)., CONCLUSIONS: This study provides initial evidence that the TSS-IOP is a reliable and valid measure, assessing patients' satisfaction with ocular hypotensive medications. AU - Atkinson, Mark J. AU - Stewart, William C. AU - Fain, Joel M. AU - Stewart, Jeanette A. AU - Dhawan, Ravinder AU - Mozaffari, Essy AU - Lohs, Jan KW - Adult Aged Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Factor Analysis, Statistical Focus Groups *Glaucoma/dt [Drug Therapy] Health Care Surveys Humans Intraocular Pressure Middle Aged *Ocular Hypertension/dt [Drug Therapy] Patient Compliance/px [Psychology] Patient Compliance/sn [Statistics & Numerical Data] Patient Satisfaction/sn [Statistics & Numerical Data] *Patient Satisfaction *Psychometrics/is [Instrumentation] Qualitative Research *Self Administration/px [Psychology] *Surveys and Questionnaires United States PY - 2003 SE - Atkinson, Mark J. Worldwide Outcomes Research, Pfizer, La Jolla, California, USA. mark.j.atkinson@pfizer.com SN - 1477-7525 SP - 67 ST - A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) T2 - Health and quality of life outcomes TI - A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=14617372 VL - 1 Y2 - 20031115// ID - 1816 ER - TY - JOUR AB - Aims To improve diabetes management in Indigenous Australians using an integrated nurse‐led model of diabetes education and eye screening in indigenous primary care and specialist diabetes clinics. Design A pre–post study. Methods This study will be implemented in indigenous primary care and specialist diabetes clinics in Victoria, Australia. Participants recruited to the study will be existing adult patient with diagnosed diabetes attending study sites. A nurse‐credentialled diabetes educator and certified retinal imager will deliver three study components: (a) retinal photography as a diabetic retinopathy screening and patient engagement tool; (b) lifestyle and behaviour surveys, administered at baseline and at the final visit, in 12 months. Findings from the surveys and participants’ retinal images will be used to guide; and (c) personalized diabetes education. The primary outcomes are participant adherence to diabetic eye screening recommendations and health service diabetic retinopathy screening coverage. Secondary outcomes are baseline DR prevalence and changes in clinical and lifestyle risk factor levels, diabetes knowledge and satisfaction with diabetes care. Discussion Compared with non‐indigenous Australians, Indigenous Australians have a high prevalence of diabetic retinopathy and blindness, low adherence to eye screening recommendations and suboptimal health literacy. Nurse‐credentialled diabetes educators can be trained to incorporate retinal imaging and eye screening into their clinical practice to give image‐based diabetes education to facilitate diabetic retinopathy management. Impact Credentialled nurse diabetes educators who integrate eye screening and diabetes education can facilitate timelier diabetic retinopathy screening, referral pathways and treatment of sight‐threatening retinopathy. We believe that this model of integrated diabetes education and eye screening will also improve adherence to eye screening recommendations, population screening coverage, health literacy, risk factor levels and diabetes self‐care. Clinical Trial Registration: ANZCTRN1261800120435. (PsycInfo Database Record (c) 2021 APA, all rights reserved) AD - Atkinson‐Briggs, Sharon, Department of Medicine, University of Melbourne (St Vincent's Hospital), Level 4 Clinical Sciences Building, 29 Regent Street (corner of Princes and Regent Streets), Fitzroy, Melbourne, Australia, 3065 AN - 2021-17512-041 AU - Atkinson‐Briggs, Sharon AU - Jenkins, Alicia AU - Keech, Anthony AU - Ryan, Christopher AU - Brazionis, Laima DB - psyh DO - 10.1111/jan.14734 DP - EBSCOhost IS - 3 KW - advanced nursing diabetes management diabetes education diabetic retinopathy screening eye care indigenous specialist diabetes clinics Diabetes Disease Management Health Screening Primary Health Care Clinics Education Eye Disorders Health Education Indigenous Populations Integrated Services Nursing Screening Tests N1 - Department of Medicine, University of Melbourne, Melbourne, VIC, Australia. Institutional Authors: Centre of Research Excellence in Diabetic Retinopathy Study Group. Other Publishers: Blackwell Publishing. Release Date: 20210315. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishGrant Information: Jenkins, Alicia. Major Descriptor: Diabetes; Disease Management; Health Screening; Primary Health Care. Minor Descriptor: Clinics; Education; Eye Disorders; Health Education; Indigenous Populations; Integrated Services; Nursing; Screening Tests. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10). Location: Australia. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. Supplemental Data: Tables and Figures Internet. Page Count: 13. Issue Publication Date: Mar, 2021. Publication History: Accepted Date: Dec 10, 2020; First Submitted Date: Nov 24, 2020. Copyright Statement: John Wiley & Sons Ltd. 2021. Sponsor: University of Melbourne, Australia. Grant: 780535. Recipients: No recipient indicated Sponsor: Sydney Medical School Foundation, Australia. Other Details: Fellow. Recipients: Jenkins, Alicia Sponsor: National Health and Medical Research Council, Australia. Other Details: Practitioner Fellowship. Recipients: Jenkins, Alicia PY - 2021 SN - 0309-2402 1365-2648 SP - 1578-1590 ST - A model of culturally‐informed integrated diabetes education and eye screening in indigenous primary care services and specialist diabetes clinics: Study protocol T2 - Journal of Advanced Nursing TI - A model of culturally‐informed integrated diabetes education and eye screening in indigenous primary care services and specialist diabetes clinics: Study protocol UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2021-17512-041&site=ehost-live&scope=site satkinson1@student.unimelb.edu.au VL - 77 ID - 4801 ER - TY - JOUR AB - Ophthalmic drugs typically achieve < 10% ocular bioavailability. A drug applied to the surface of the eye may cross ocular-blood barriers where it may encounter metabolising enzymes and cellular transporters before it distributes to the site of action. Characterisation of ocular enzyme systems and cellular transporters and their respective substrate selectivity have provided new insight into the roles these proteins may play in ocular drug delivery and distribution. Altered metabolism and transport have been proposed to contribute to a number of ocular disease processes including inflammation, glaucoma, cataract, dry eye and neurodegeneration. As ocular enzyme and transport systems are better characterised, their properties become an integral consideration in drug design and development. AU - Attar, Mayssa AU - Shen, Jie AU - Ling, Kah-Hiing John AU - Tang-Liu, Diane IS - 5 KW - Animals Carrier Proteins/ge [Genetics] Carrier Proteins/me [Metabolism] *Drug Delivery Systems *Eye/cy [Cytology] Eye/en [Enzymology] *Eye/me [Metabolism] Eye Diseases/dt [Drug Therapy] Humans *Ophthalmic Solutions Structure-Activity Relationship PY - 2005 SE - Attar, Mayssa. Allergan, Inc., Department of Pharmacokinetics and Drug Metabolism, Irvine, CA 92612, USA. SN - 1742-5247 SP - 891-908 ST - Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters T2 - Expert opinion on drug delivery TI - Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16296785 VL - 2 ID - 1707 ER - TY - JOUR AB - BACKGROUND: This study aimed to determine the impact of switching patients requiring multiple drug treatment from the dorzolamide-timolol fixed combination to the brinzolamide-timolol fixed combination and potential effects on tolerability and compliance., METHODS: Patients were switched from dorzolamide-timolol to brinzolamide-timolol and questioned within a period of 4-26 weeks. Questions were asked to confirm if a specific side effect had been experienced, and then a numerical comparison between the two types of eye drop was made., RESULTS: Thirty-one consecutive patients (12 males and 19 females aged 41-89 years) successfully completed the questionnaire. Comparison of the severity and chronicity of the side effects of the two types of fixed-combination eye drops showed that brinzolamide-timolol caused significantly less stinging for a shorter amount of time than dorzolamide-timolol; it also produced less eye redness for a significantly shorter amount of time. Brinzolamide-timolol produced more blurring, although the length of time this was present was similar to that for dorzolamide-timolol. No differences between the two eye drops were found for taste, overall impression, and likelihood of compliance., CONCLUSION: Our study confirms the findings of other researchers pertaining to the side effect profile of brinzolamide-timolol after switching from dorzolamide-timolol, which is a reduction in stinging but an increase in blurred vision. The advantage of one eye drop over the other then becomes patient-specific, depending on which side effect they find most tolerable. We suggest that both eye drops are acceptable choices in treating patients with glaucoma, and are interchangeable if compliance becomes an issue because of a specific side effect of one eye drop or the other. AU - Auger, Graham Anthony AU - Raynor, Mathew AU - Longstaff, Simon DO - https://dx.doi.org/10.2147/OPTH.S33254 PY - 2012 SE - Auger, Graham Anthony. Ophthalmology Department, Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom. SN - 1177-5483 1177-5467 SP - 2059-62 ST - Patient perspectives when switching from Cosopt( R) (dorzolamide-timolol) to Azarga TM (brinzolamide-timolol) for glaucoma requiring multiple drug therapy T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Patient perspectives when switching from Cosopt( R) (dorzolamide-timolol) to Azarga TM (brinzolamide-timolol) for glaucoma requiring multiple drug therapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=23271886 VL - 6 Y2 - 20121211// ID - 1184 ER - TY - JOUR AD - T. Aung, Singapore Eye Research Institute, Singapore National Eye Center, Singapore; and Yong Loo Lin School of Medicine, Singapore AU - Aung, T. DB - Embase Medline DO - 10.1016/j.ajo.2010.03.003 IS - 5 KW - blindness cataract diabetic retinopathy disease course editorial ethnic group eye disease follow up glaucoma health care access health insurance Hispanic human minority group prevalence priority journal risk assessment risk factor visual impairment LA - English M3 - Editorial N1 - L358620255 2010-04-21 2010-05-31 PY - 2010 SN - 0002-9394 SP - 697-698 ST - Eye Disease in Latinos: Insights From the Los Angeles Latino Eye Study T2 - American Journal of Ophthalmology TI - Eye Disease in Latinos: Insights From the Los Angeles Latino Eye Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358620255&from=export http://dx.doi.org/10.1016/j.ajo.2010.03.003 VL - 149 ID - 3257 ER - TY - JOUR AU - Awobem, J. F. AU - Cassels-Brown, A. AU - Buchan, J. C. AU - Hughes, K. A. DO - https://dx.doi.org/10.1038/eye.2008.42 IS - 1 KW - *African Continental Ancestry Group Aged Caribbean Region/eh [Ethnology] England/ep [Epidemiology] *Glaucoma/th [Therapy] Health Knowledge, Attitudes, Practice Humans *Patient Acceptance of Health Care/eh [Ethnology] N1 - Comment on (CON) PY - 2009 SN - 1476-5454 0950-222X SP - 243-243 ST - Exploring glaucoma awareness and the utilization of primary eye care services: community perceived barriers among elderly African Caribbeans in Chapeltown, Leeds T2 - Eye (London, England) T3 - Comment on: Eye (Lond). 2007 Jul;21(7):912-20; PMID: 16902494 [https://www.ncbi.nlm.nih.gov/pubmed/16902494] TI - Exploring glaucoma awareness and the utilization of primary eye care services: community perceived barriers among elderly African Caribbeans in Chapeltown, Leeds UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18344962 VL - 23 Y2 - 20080314// ID - 1492 ER - TY - JOUR AB - We evaluated the cytotoxicity of antiglaucoma ophthalmic solutions preserved with the same concentration of benzalkonium chloride (BAK) in four cultured corneal and conjunctival cell lines. The viability of cell cultures was determined following the exposure of cells to timolol maleate, dorzolamide, and their fixed combination, Kosoputo( R) (MSD, a Japanese formulation of Cosopt( R) (Merck)), and two commercially available eyedrop solutions, 0.5% Timpotol( R) (containing 0.5% timolol maleate, MSD) and 1% Trusopt( R) (containing 1% dorzolamide, MSD) for varying exposure times and at various dilutions using the MTT and neutral red assays. All the three commercially available eyedrop solutions tested in this study were preserved with 0.005% BAK. The toxicity of each solution was compared using the % cell viability score (CVS) . Cell viability was also subjected to statistical analysis using ANOVA, Dunnett's multiple comparison tests and a chi-square test. %CVS50/%CVS40/80s for the tested solutions were 53/-13 for 0.5% Timoptol( R), 100/88 for preservative-free 0.5% timolol maleate, 50/ -10 for 1% Trusopt( R), 72/100 for preservative-free 1% dorzolamide, and 44/-17 for Kosoputo( R). The results of statistical analysis were consistent to them. In conclusion, Kosoputo( R) had greater cytotoxicity than each component; however, in actual use it may have the advantages of reduced toxicity (side effect) due to reduced instillation frequency, and better patient adherence to the treatment regimen as well as a comparable pressure reduction effect. AU - Ayaki, Masahiko AU - Iwasawa, Atsuo AU - Niwano, Yoshimi IS - 3 KW - Animals *Benzalkonium Compounds/to [Toxicity] Cattle Cell Line Cell Survival/de [Drug Effects] Conjunctiva/cy [Cytology] *Conjunctiva/de [Drug Effects] Cornea/cy [Cytology] *Cornea/de [Drug Effects] Drug Combinations *Glaucoma/dt [Drug Therapy] Humans Ophthalmic Solutions/an [Analysis] *Ophthalmic Solutions/tu [Therapeutic Use] *Preservatives, Pharmaceutical/to [Toxicity] Rabbits Sulfonamides/an [Analysis] *Sulfonamides/tu [Therapeutic Use] Thiophenes/an [Analysis] *Thiophenes/tu [Therapeutic Use] Timolol/an [Analysis] *Timolol/tu [Therapeutic Use] PY - 2012 SE - Ayaki, Masahiko. Department of Ophthalmology, Mita Hospital, International University of Health and Welfare, Tokyo Institute of Technology, Japan. mayaki@olive.ocn.ne.jp SN - 1884-0205 1342-4815 SP - 115-20 ST - Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride T2 - Biocontrol science TI - Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=23007102 VL - 17 ID - 1106 ER - TY - JOUR AB - PURPOSE: To describe the indications, visual acuity outcomes, and graft survival after penetrating keratoplasty (PKP) in Addis Ababa, Ethiopia., METHODS: The medical records of patients who underwent PKP at Menelik II Hospital between September 2000 and September 2013 were retrospectively reviewed. The prespecified outcomes were graft survival, visual acuity, and complication rates., RESULTS: A total of 321 patients underwent PKP during the study period and were included in the analysis. Indications for surgery were trachoma or leukoma in 141 (44%), keratoconus in 45 (14%), corneal dystrophy in 46 (14%), pseudophakic or aphakic bullous keratopathy in 28 (9%), trauma in 27 (8%), previous graft failure in 18 (6%), active ulcer, burn, or perforation in 9 (3%), and others in 7 (2%). The graft survival rate was 80% overall at 2 years but varied considerably depending on the indication for surgery. Uncorrected visual acuity improved from baseline mean logarithm of the minimum angle of resolution 2.09 (SD 0.67) to mean logarithm of the minimum angle of resolution of 1.53 (SD 1.03) at 2 years. A number of factors affected the visual acuity outcomes. Patients were not routinely refracted, and only 18% (N = 60) of patients had access to corrective spectacles or contact lenses postoperatively. Complication rates were high with infectious keratitis being the most common., CONCLUSIONS: PKP is becoming a viable treatment for corneal opacity in developing countries. However, the high burden of disease and lack of corrective lenses remain significant obstacles to overcome. AU - Ayalew, Menen AU - Tilahun, Yonas AU - Holsclaw, Doug AU - Indaram, Maanasa AU - Stoller, Nicole E. AU - Keenan, Jeremy D. AU - Rose-Nussbaumer, Jennifer DO - https://dx.doi.org/10.1097/ICO.0000000000001190 IS - 6 KW - Adolescent Adult Aged Corneal Opacity/pp [Physiopathology] *Corneal Opacity/su [Surgery] Developing Countries Ethiopia Eye Banks/sn [Statistics & Numerical Data] Female Graft Survival/ph [Physiology] Humans Intraoperative Complications *Keratoplasty, Penetrating Male Middle Aged Postoperative Complications Referral and Consultation Retrospective Studies Tertiary Care Centers/sn [Statistics & Numerical Data] Tissue Donors Visual Acuity/ph [Physiology] Young Adult N1 - Comment in (CIN) PY - 2017 SE - Ayalew, Menen. *Department of Ophthalmology, Addis Ababa University, Addis Ababa, Ethiopia; Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA; and ++Department of Ophthalmology, University of California, San Francisco, San Francisco, CA. SN - 1536-4798 0277-3740 SP - 665-668 ST - Penetrating Keratoplasty at a Tertiary Referral Center in Ethiopia: Indications and Outcomes T2 - Cornea T3 - Comment in: Cornea. 2018 Jan;37(1):e1; PMID: 28990997 [https://www.ncbi.nlm.nih.gov/pubmed/28990997] TI - Penetrating Keratoplasty at a Tertiary Referral Center in Ethiopia: Indications and Outcomes UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28368993 VL - 36 ID - 521 ER - TY - GEN AD - H. Ayshford AU - Ayshford, H. DB - Embase J2 - Manuf. Chem. KW - lisinopril birth control congestive heart failure consultation diabetes mellitus disease course education glaucoma human information outcome assessment packaging patient compliance pharmacist pharmacy (shop) safety short survey LA - English M1 - (Ayshford H.) M3 - Short Survey N1 - L358971017 2010-06-16 PY - 2010 SN - 0262-4230 SP - 41-43 ST - Compliance conundrum TI - Compliance conundrum UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358971017&from=export VL - 81 ID - 3259 ER - TY - JOUR AB - BACKGROUND: Eye care is an essential component in the management of critically ill patients. Standardized eye care can prevent corneal complications in ventilated patients., OBJECTIVE: This study was designed to compare old and new practices of corneal care for reduction in corneal complications in ventilated patients., METHODS: This study was done in three phases each of six month duration. Phase 1 was the ongoing practice of eye care in the unit. Before the start of phase 2, a new protocol was made for eye care. Corneal complications were observed in terms of haziness, dryness, and ulceration. All nursing staffs were educated and made compliant with the new protocol. In phase 2, a follow-up audit was done to check the effectiveness and compliance to protocol. In phase 3, a follow-up audit was started 3 months after phase 2., RESULTS: In phase 1, total ventilated patients were 40 with 240 ventilator days. The corneal dryness rate was 40 per 1000 ventilator days while the haziness and ulceration rate was 16 per 1000 ventilator days each. In the second phase 2, total ventilated patients were 53 making 561 ventilator days. The rate of corneal haziness and dryness was 3.52 and 1.78 per 1000 ventilator days, respectively, with no case of corneal ulceration. In phase 3, the number of ventilated patients was 91 with 1114 ventilator days. The corneal dryness rate was 2.69 while the haziness and ulceration rate was 1.79 each., CONCLUSION: Protocolized eye care can reduce the risk of corneal complications in ventilated patients. AU - Azfar, Mohammad Feroz AU - Khan, Muhammad Faisal AU - Alzeer, Abdulaziz H. DO - https://dx.doi.org/10.4103/1658-354X.109805 IS - 1 PY - 2013 SE - Azfar, Mohammad Feroz. Department of Critical Care, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia. SN - 1658-354X SP - 33-6 ST - Protocolized eye care prevents corneal complications in ventilated patients in a medical intensive care unit T2 - Saudi journal of anaesthesia TI - Protocolized eye care prevents corneal complications in ventilated patients in a medical intensive care unit UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=23717229 VL - 7 ID - 1093 ER - TY - JOUR AB - Herpes simplex virus is responsible for numerous ocular diseases, the most common of which is herpetic stromal keratitis. This is a recurrent infection of the cornea that typically begins with a subclinical infection of the cornea that establishes a latent infection of sensory gan-glia, most often the trigeminal ganglia. Recurring infections occur when the virus is reactivated from latency and travels back to the cornea, where it restimulates an inflammatory response. This inflammatory response can lead to decreased corneal sensation, scarring, and blindness. The diagnosis of these lesions as the result of a recurrent herpes simplex virus infection can at times be problematic. Currently, herpetic stromal keratitis is diagnosed by its clinical presentation on the slit-lamp examination, but the literature does not always support the accuracy of these clinical findings. Other diagnostic tests such as polymerase chain reaction assay, enzyme-linked immunosorbent assay, immunofluorescent antibody, and viral cultures have provided more definitive diagnosis, but also have some limitations. That said, accurate diagnosis is necessary for proper treatment, in order to prevent serious consequences. Current treatment reduces the severity of lesions and controls further viral spread, but does not provide a cure. AD - P.M. Stuart, Department of Ophthalmology, Saint Louis University, 1402 South Grand Boulevard, St Louis, MO, United States AU - Azher, T. N. AU - Yin, X. T. AU - Tajfirouz, D. AU - Huang, A. J. AU - Stuart, P. M. DB - Embase DO - 10.2147/OPTH.S80475 KW - aciclovir antivirus agent CD4 antigen cidofovir corticosteroid DNA polymerase foscarnet ganciclovir idoxuridine immunoglobulin A antibody oxybuprocaine placebo rose bengal secretory immunoglobulin steroid trifluridine valaciclovir vidarabine virus antigen virus DNA amebic infection anterior eye segment antibody detection antiviral activity astigmatism asymptomatic infection blindness blurred vision CD4+ T lymphocyte clinical examination clinical feature cornea disease cornea edema cornea epithelium cornea necrosis cornea opacity cornea thickness cornea transplantation cornea ulcer corneal hypoesthesia corneal scarring corneal scraping cost dendritiform epithelial lesion diagnostic accuracy diagnostic error diarrhea differential diagnosis disciform keratitis disease classification disease severity drug bioavailability drug choice drug megadose drug specificity dry eye endothelial keratitis enzyme linked immunosorbent assay epiphora eye discharge eye examination eye irritation eye pain eye redness eyelid reflex false negative result false positive result fungal eye infection gastrointestinal symptom gene amplification geographic epithelial keratitis graft rejection herpes simplex herpes simplex keratitis Herpes simplex virus herpes zoster ophthalmicus human immune response immunocompromised patient immunofluorescence assay immunomediated simplex keratitis infection prevention inflammation intermethod comparison iritis lacrimal fluid latent period multidrug resistance mycosis nausea necrotizing keratitis neovascularization (pathology) neurotrophic keratopathy nonhuman ocular fibrosis ocular pruritus pathophysiology patient compliance photophobia physical examination posterior eye segment punctate keratitis real time polymerase chain reaction recurrent infection relapse review scar formation sensitivity and specificity sensory ganglion slit lamp microscopy staining treatment indication trigeminus ganglion unspecified side effect viral clearance virus culture virus detection virus isolation virus latency virus load virus reactivation virus replication virus transcription vomiting LA - English M3 - Review N1 - L614196671 2017-02-03 2017-02-27 PY - 2017 SN - 1177-5483 1177-5467 SP - 185-191 ST - Herpes simplex keratitis: Challenges in diagnosis and clinical management T2 - Clinical Ophthalmology TI - Herpes simplex keratitis: Challenges in diagnosis and clinical management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614196671&from=export http://dx.doi.org/10.2147/OPTH.S80475 VL - 11 ID - 2676 ER - TY - JOUR AD - A. Azuara-Blanco, Eye Clinic, Aberdeen AB25 2ZN, United Kingdom AU - Azuara-Blanco, A. AU - Burr, J. DB - Embase Medline DO - 10.1136/bjo.2005.079996 IS - 2 KW - alpha 2 adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor prostaglandin derivative cost benefit analysis drug cost drug efficacy drug indication drug safety drug tolerability editorial glaucoma glaucoma surgery health care utilization human prescription prevalence priority journal trabeculoplasty treatment indication visual field LA - English M3 - Editorial N1 - L43163836 2006-02-20 PY - 2006 SN - 0007-1161 SP - 130-131 ST - The rising cost of glaucoma drugs T2 - British Journal of Ophthalmology TI - The rising cost of glaucoma drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43163836&from=export http://dx.doi.org/10.1136/bjo.2005.079996 VL - 90 ID - 3629 ER - TY - JOUR AB - Purpose: This study evaluates the influence of intraocular silicone oil on iris diabetic microangiopathy in diabetic vitrectomized eyes. Methods: The authors examined 20 eyes of 20 patients with diabetes undergoing primary vitrectomy for tractional diabetic retinal detachment, endophotocoagulation, and 1000 centistokes silicone oil tamponade. The vascular status of the iris in these eyes was examined by iris fluorescein angiography once before silicone oil injection and again when it was removed (mean follow-up, 8.3 months). Results: Iris diabetic microangiopathy, including breakdown of the blood-iris barrier and iris neovascularization, improved or remained stable in 40% of eyes. It worsened in 60% of eyes, including all aphakic eyes. Neovascular glaucoma developed in one of them. A significant correlation was found between worsening of iris diabetic microangiopathy and both aphakia (P = 0.01) and severe immediate postvitrectomy inflammation (P = 0.02). Eyes with recurrent retinal detachment (n = 4) showed worsening of iris diabetic microangiopathy, but this was not significantly correlated. Conclusions: Aphakic vitrectomized eyes have a higher risk of iris diabetic microangiopathy developing, even after silicone oil tamponade. Immediate postoperative intraocular inflammation also is a risk factor for worsening of iris diabetic microangiopathy in phakic eyes. Recurrence of retinal detachment was not significantly correlated with worsening of iris status. © 1993, American Academy of Ophthalmology, Inc. All rights reserved. AD - Department of Ophthalmology and Visual Sciences, University of Milano, Milano, Italy AU - Azzolini, C. AU - Brancato, R. AU - Camesasca, F. I. AU - Codenotti, M. DB - Scopus DO - 10.1016/S0161-6420(93)31521-6 IS - 8 M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 1993 SP - 1152-1159 ST - Influence of Scone Oil on Iris Microangiopathy in Diabetic Vitrectomized Eyes T2 - Ophthalmology TI - Influence of Scone Oil on Iris Microangiopathy in Diabetic Vitrectomized Eyes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027323144&doi=10.1016%2fS0161-6420%2893%2931521-6&partnerID=40&md5=6452322cf661f663085dd71d89c0a990 VL - 100 ID - 5294 ER - TY - JOUR AB - AIM: To describe the challenges peculiar to Nigeria in the implementation of vision 2020: the right to sight and to proffer solutions as to the way forward, METHOD: A review of the recently completed national blindness survey, current literature, and the advocacy experience of the Ophthalmological Society of Nigeria., FINDINGS: The prevalence of blindness in Nigeria is 0.78%. Over 43% of these are blind from cataracts and a further 9% from uncorrected aphakia or complications of couching. 50% of all cataract interventions are carried out by itinerant couchers. Other major causes of blindness are glaucoma (16%) corneal opacities (12%), trachoma (4%), optic atrophy (3%) onchocerciasis (1%) and macular disease (1%). 70% of these are either preventable or reversible. Nigeria has a relatively favourable ophthalmologist/population ratio of about 2.8 per million, but has a low Cataract surgical rate of 300 per million per year. The reasons for this include a lack of ownership of blindness prevention programs, a lack of political will and parlous state of funding for vision 2020. There is an abdication of responsibility for both training and services on the part of government to the International NonGovernmental organisations. Teaching hospitals no longer generate enough patient surgical load to support training. We estimate it would cost N8.5 billion ($56.8 million) to sustain the WHO recommended Cataract Surgical Rate of 3000 per million per year in Nigeria., CONCLUSIONS: Nigeria is not headed in the direction of meeting Vision 2020 targets. Advocacy involving funding through the MDGs, needs to be intensified. AU - Babalola, O. E. IS - 4 KW - Blindness/ep [Epidemiology] *Blindness/et [Etiology] *Blindness/pc [Prevention & Control] Cataract/di [Diagnosis] Cataract/ep [Epidemiology] Cataract Extraction/sn [Statistics & Numerical Data] Consumer Advocacy Financing, Government Health Services Accessibility Health Surveys Health Workforce/sn [Statistics & Numerical Data] Humans Nigeria/ep [Epidemiology] Ophthalmology Physicians Prevalence Societies, Medical Vision, Low/ep [Epidemiology] *Vision, Low/et [Etiology] *Vision, Low/pc [Prevention & Control] PY - 2011 SE - Babalola, O E. Bingham University, New Karu, Abuja. bablo57@yahoo.com SN - 0309-3913 SP - 309-19 ST - The peculiar challenges of blindness prevention in Nigeria: a review article T2 - African journal of medicine and medical sciences TI - The peculiar challenges of blindness prevention in Nigeria: a review article UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=22783680 VL - 40 ID - 1233 ER - TY - JOUR AB - Aim: To assess the efficacy of Intracameral (bevacizumab) in combination with and without pan retinal photocoagulation (PRP) in regressing anterior chamber iris and angle neovascularization and stabilizing IOP and improving outcome of secondary neovascular glaucoma in patients with proliferative retinal ischemic disorders in our population. Methods: A Prospective, consecutive, interventional case series study was conducted at AFIO RWP and CMH Khuzdar on a series of patients 25 to 70 years of age. Thirty patients (30 eyes) with NVG secondary to ischemic retinal disorders were enrolled in the study design. The study group included 18(60%) males and 12 (40%) females. Cases were divided into two groups (A, B) and written informed consent was taken prior to procedure. Group A (15 patients) were managed with Intracameral bevacizumab alone While group B (15 patients) received laser pan retinal photocoagulation in addition to Intracameral bevacizumab. Majority had proliferative diabetic retinopathy (21 cases) and remaining nine cases were secondary to ischemic central retinal vein occlusion (CRVO). Baseline records were documented after carrying out complete ophthalmic evaluation in all patients. Follow up was carried out for 03 to 06 months depending on patient compliance. Results: Significantly better reduction of Iris (rubeosis) and anterior chamber angle neovascularization and stabilizing of IOP was observed in Group B who received PRP in addition to Intracameral bevacizumab as compared to group A who were managed with Intracameral bevacizumab alone. Moreover early remission of neovascularization was observed in group A receiving bevacizumab only. Conclusions: Combined procedures seems to be more effective in regressing and stabilizing iris/angle neovascularization, and lowering IOP in patients with NVG particularly in advanced cases. AD - T.P. Khan, AFIO RWP, Pakistan AU - Babar, Z. U. D. AU - Khan, T. P. C1 - avastin DB - Embase IS - 1 KW - bevacizumab adult aged anterior eye chamber anterior eye chamber angle article case study central retina vein occlusion clinical article controlled study diabetes mellitus diabetic retinopathy drug efficacy female fluorescence angiography follow up gonioscopy human intervention study iris rubeosis laser coagulation male neovascular glaucoma oculoplethysmography ophthalmoscopy outcome assessment panretinal photocoagulation paracentesis patient compliance prospective study remission retina ischemia retina neovascularization slit lamp visual acuity visual acuity chart avastin LA - English M3 - Article N1 - L373018199 2014-05-15 2014-05-23 PY - 2014 SN - 1996-7195 SP - 75-78 ST - Role of intracameral bevacizumab in combination with and without Panretinal Photocoagulation (PRP) in neovascular glaucoma patients in our population T2 - Pakistan Journal of Medical and Health Sciences TI - Role of intracameral bevacizumab in combination with and without Panretinal Photocoagulation (PRP) in neovascular glaucoma patients in our population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373018199&from=export VL - 8 ID - 2906 ER - TY - JOUR AB - INTRODUCTION: Combining two medications in one bottle may improve compliance by reducing the time required to administer drops and the frequency of the total number of medication bottles., OBJECTIVE: To compare the efficacy of reduced intraocular pressure (IOP) and safety of fixed combination travoprost 0.004%/timolol 0.5% vs. fixed combination dorzolamide 2%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension., METHODS: Prospective randomized clinical study included 60 patients divided into 2 groups. Follow-up was done at day 14 and 45 and month 3. IOP measurements were taken at each follow-up examination at 8 am, 10 am and 4 pm., RESULTS: Both fixed combinations reduced IOP significantly compared to initial values at all follow-ups (p < 0.001). Mean pooled IOP at all visits and time points was slightly lower in the travoprost/timolol group compared with the dorzolamide/timolol group (16.13 mmHg vs. 16.15 mmHg). Mean IOP reduction from baseline ranged from -7.46 mmHg to -9.92 mmHg in the travoprost/timolol group and from -6.93 mmHg to -8.93 mmHg for the dorzolamide/timolol group. Mean (+/- standard error of the mean) reduction in diurnal LOP from baseline to 3rd month was 8.96 +/- 2.79 in the travoprost/timolol group versus 8.07 +/- 2.91 in patients receiving dorzolamide/timolol fixed combination (p = 0.196). The most frequent treatment-related adverse events were conjunctival hyperemia in the travoprost/timolol group, and dry eye and foreign body sensation in the dorzolamide/timolol group., CONCLUSION: Travoprost/timolol fixed combination was slightly more effective than dorzolamide/timolol fixed combination in reducing mean diurnal IOP. Travoprost/timolol group resulted in an IOP reduction for up to 1.07 mmHg higher than dorzolamide/timolol group. Both fixed combinations were well tolerated and safe. AU - Babic, Nikola AU - Andreic, Veljko AU - Miljkovic, Aleksandar AU - Grkovic, Desanka AU - Jovanovic, Predrag IS - 7-8 KW - Antihypertensive Agents/ae [Adverse Effects] Antihypertensive Agents/tu [Therapeutic Use] *Antihypertensive Agents Cloprostenol/ae [Adverse Effects] *Cloprostenol/aa [Analogs & Derivatives] Cloprostenol/tu [Therapeutic Use] Drug Combinations Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/ep [Epidemiology] *Glaucoma, Open-Angle Humans Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/ep [Epidemiology] *Ocular Hypertension Patient Compliance Prospective Studies Sulfonamides/ae [Adverse Effects] Sulfonamides/tu [Therapeutic Use] *Sulfonamides Thiophenes/ae [Adverse Effects] Thiophenes/tu [Therapeutic Use] *Thiophenes Timolol/ae [Adverse Effects] Timolol/tu [Therapeutic Use] *Timolol Travoprost PY - 2013 SE - Babic, Nikola. Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia. nikobab@sbb.rs SN - 0370-8179 SP - 441-6 ST - Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension T2 - Srpski arhiv za celokupno lekarstvo TI - Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=24073548 VL - 141 ID - 936 ER - TY - JOUR AB - BACKGROUND: Innovative Vision Products, Inc. (IVP)'s scientists developed the lubricant eye drops (Can-C) designed as 1% N-acetylcarnosine (NAC) prodrug of L-carnosine containing a mucoadhesive cellulose-based compound combined with corneal absorption promoters in a sustained drug delivery system. Only the natural L-isomeric form of NAC raw material was specifically synthesized at the cGMP facility and employed for the manufacturing of Can-C eye drops., OBJECTIVE AND STUDY DESIGN: In the present clinical study the authors assessed vision before and after 9 month term of topical ocular administration of NAC lubricant eye drops or placebo in 75 symptomatic patients with age-related uncomplicated cataracts in one or both eyes, with acuity in one eye of 20/40 or worse (best-corrected distance), and no previous cataract surgery in either eye and no other ocular abnormality and 72 noncataract subjects ranged in age from 54 to 78 years., SETTING: Subjects in these subsample groups have reported complaints of glare and wanted to administer eye drops to get quick eye relief and quality of vision for their daily activities including driving and computer works. Following 9 months of treatment with NAC lubricant eye drops, most patients' glare scores were improved or returned to normal in disability glare tests with Halometer DG. Improvement in disability glare was accompanied with independent improvement in acuity. Furthermore, patients with the poorest pretreatment vision were as likely to regain certain better visual function after 9 months of treatment with N-acetylcarnosine lubricant eye drops as those with the worth pretreatment vision., PATIENTS OR OTHER PARTICIPANTS: The authors made a reference to electronic records of the product sales to patients who have been made the repurchase of the Can-C eye drops since December 2001., INTERVENTION: Based on this analysis of recorded adjustments to inventory, various parameters were analyzed during the continued repurchase behavior program, including testimonials from buyers. With these figures, researchers judged on the patients' compliance rate to self-administer NAC eye-drops., MAIN OUTCOME MEASURE AND RESULTS: The ophthalmic drug showed potential for the non-surgical treatment of age-related cataracts for participants after controlling for age, gender and daily activities and on a combined basis of repurchases behavior reports in more than 50,000 various cohort survivors, has been demonstrated to have a high efficacy and good tolerability for prevention and treatment of visual impairment determined for the older population with relative stable pattern of causes for blindness and visual impairment. The mechanisms of prevention and reversal of cataracts with NAC ophthalmic drug are considered which include prevention by the intraocular released carnosine of free-radical-induced inactivation of proprietary lens antioxidant enzymes (superoxide dismutase); prevention of carbohydrate and metal-catalyzed autooxidation of ascorbic acid-induced cross-linking glycation reactions to the lens proteins; transglycation properties of carnosine, allowing it to compete for the glycating agent, protecting proteins (lens crystallins) against modification; universal antioxidant and scavenging activity towards lipid hydroperoxides, aldehydes and oxygen radicals; activation with l-carnosine ingredient of proteasome activity in the lens; chaperone-like disaggregating to lens crystallins activity of NAC and of its bioactivated principal carnosine. Blindness incidence increased with advancing age, such as cataract and glaucoma, which are by far the commonest causes of blindness in our sample and in all age groups, glaucomatous neurodegeneration can be treated with developed NAC autoinduction prodrug eye drops equipped with corneal absorption promoters. The common blinding affections presenting in developed countries such as, senile macular degeneration, hereditary chorioretinal dystrophies, diabetic retinopathy are poorly represented in our current summary of vital-statistics and will be reported i herent in next N-acetylcarnosine ophthalmic drug studies., CONCLUSION: The authors present evidence, about why only a certain kind of NAC is safe, and why only certain formulas designed by IVP for drug discovery are efficacious in the prevention and treatment of senile cataract for long-term use. Overall cumulated studies demonstrate that the designed by IVP new vision-saving drug NAC eye drops help the aging eye to recover by improving its clarity, glare sensitivity, color perception and overall vision. AU - Babizhayev, Mark A. AU - Burke, Leslie AU - Micans, Philip AU - Richer, Stuart P. KW - Aged Aged, 80 and over Carnosine/ad [Administration & Dosage] *Carnosine/aa [Analogs & Derivatives] Carnosine/pd [Pharmacology] *Cataract/dt [Drug Therapy] Delayed-Action Preparations Female *Glare Humans Macular Degeneration/dt [Drug Therapy] Male Middle Aged *Ophthalmic Solutions/ad [Administration & Dosage] *Vision, Ocular/de [Drug Effects] PY - 2009 SE - Babizhayev, Mark A. Innovative Vision Products, Inc., County of New Castle, Delaware, USA. markbabizhayev@mail.ru SN - 1178-1998 1176-9092 SP - 31-50 ST - N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population T2 - Clinical interventions in aging TI - N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19503764 VL - 4 Y2 - 20090514// ID - 1452 ER - TY - JOUR AB - The antioxidant activity of L-carnosine (β-alanyl-L-histidine, bioactivated in ocular tissues) versus N-acetylcarnosine (N-acetyl-β- alanyl-L-histidine, ocular-targeted small dipeptide molecules) was studied in aqueous solution and in a lipid environment, employing liposomes as a model of lipid membranes. Reactive oxygen species (ROS) were generated by an iron/ascorbate promoter system for induction of lipid peroxidation (LPO). L-carnosine, which is stabilized from enzymatic hydrolysis, operates as a universal aldehyde and ROS scavenger in both aqueous and lipid environments and is effective at preventing ROS-induced damage to biomolecules. Second-generation carnosine analogs bearing the histidyl-hydrazide moiety were synthesized and tested versus L-carnosine for their ability to reverse the glycation process, also known as the Maillard reaction, and reverse the stable intermolecular cross-links, monitored in the glucose-ethylamine Schiff base model, ultimately resulting in the formation of the advanced glycation end products (AGEs) from nonenzymatic glycation, accumulating in numerous body tissues and fluids. The obtained data demonstrate the transglycation properties of the ophthalmically stabilized L-carnosine and L-carnosine histidyl-hydrazide derivatives tested and can be used to decrease or predict the occurrence of long-term complications of AGE formation and improve therapeutically the quality of vision and length of life for diabetes mellitus patients and survivors with early aging. Scientists at Innovative Vision Products, Inc. (IVP), developed lubricant eyedrops designed as a sustained-release 1% N-acetylcarnosine prodrug of L-carnosine. The eyedrops contain a mucoadhesive cellulose-based compound combined with corneal absorption promoters and glycerine in a drug-delivery system. Anti-aging therapeutics with the ophthalmic drug eyedrop formula including N-acetylcarnosine showed efficacy in the nonsurgical treatment of age-related cataracts for enrolled participants in the prospective, randomized, double-masked, placebo-controlled crossover clinical trial after controlling for age, gender, and daily activities. In a cohort in excess of 50,500 various patients seeking cutting-edge medical care, the N-acetylcarnosine topical eyedrops target therapy was demonstrated to have significant efficacy, safety, and good tolerability for the prevention and treatment of visual impairment in this older population with relatively stable patterns of causes for blindness and visual impairment. Overall, accumulated study data demonstrate that the IVP-designed new vision-saving drugs, including N-acetylcarnosine eyedrops, promote health vision and prevent vision disability from senile cataracts, primary open-angle glaucoma, age-related macular degeneration, diabetic retinopathy, and aging. N-acetylcarnosine eyedrop therapy is the crown jewel of the anti-aging medical movement and revolutionizes early detection, treatment, and rejuvenation of aging-related eye-disabling disorders. N-acetylcarnosine, as an innovative medical science tool and component of the home medicine and alternative medicine approaches, has the potential to alleviate visual impairment and its associated social, economic, and political woes for an aging population.new landscapes but in having new eyes.-Marcel Proust. © 2009 Lippincott Williams & Wilkins. AD - M. A. Babizhayev, Innovative Vision Products, Inc., Moscow Division, Ivanovskaya 20, Moscow 127434, Russian Federation AU - Babizhayev, M. A. AU - Micans, P. AU - Guiotto, A. AU - Kasus-Jacobi, A. C2 - Hamari(Japan) Innovative Vision Products DB - Embase Medline DO - 10.1097/MJT.0b013e318195e327 IS - 6 KW - advanced glycation end product aldehyde ascorbic acid benzyl alcohol carboxymethylcellulose carnosine ethylamine eye drops glucose glycerol iron lubricating agent malonaldehyde n acetylcarnosine penetration enhancing agent placebo potassium bicarbonate potassium borate reactive oxygen metabolite Schiff base unclassified drug adult aged aging antioxidant activity aqueous solution article blindness cataract chemical model clinical trial controlled clinical trial controlled study cross linking diabetes mellitus disability double blind procedure drug efficacy drug safety drug stability drug synthesis female glycation health care cost human lipid membrane lipid peroxidation major clinical study male mucoadhesion patient compliance priority journal randomized controlled trial survivor sustained release formulation vision visual acuity visual impairment LA - English M3 - Article N1 - L358136386 2010-02-15 PY - 2009 SN - 1075-2765 SP - 517-533 ST - N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: A clinical study of the new vision-saving drug n-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients T2 - American Journal of Therapeutics TI - N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: A clinical study of the new vision-saving drug n-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358136386&from=export http://dx.doi.org/10.1097/MJT.0b013e318195e327 VL - 16 ID - 3319 ER - TY - JOUR AB - IOP was lowered 10% in the fellow eye of SLT-treated eyes, even if the treated eye was nonresponsive to SLT. AD - North Bay Eye Associates, 104 Lynch Creek Way, Petalmua, CA AN - 106356317. Language: English. Entry Date: 20061103. Revision Date: 20150711. Publication Type: Journal Article AU - Bacharach, J. DB - ccm DP - EBSCOhost IS - 19 KW - Glaucoma -- Surgery Intraocular Pressure -- Drug Effects Laser Therapy -- Methods Circadian Rhythm Glaucoma -- Complications Glaucoma -- Diagnosis Patient Compliance Patient Satisfaction Surgeons Time Factors Treatment Outcomes N1 - tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 29-30 ST - Study: SLT has contralateral eye effect T2 - Ocular Surgery News TI - Study: SLT has contralateral eye effect UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106356317&site=ehost-live&scope=site VL - 24 ID - 4772 ER - TY - JOUR AB - The article focuses on the advantages and disadvantages of brand-name and generic medications for glaucoma. It discusses the safety, efficacy, and cost of medications that need to be considered when prescribing glaucoma medications. Comments from Jason Bacharach of North Bay Eye Associates are provided. AN - 110023347. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Bacharach, Jason DB - ccm DP - EBSCOhost IS - 17 KW - Glaucoma Safety Physicians Eye Office Visits N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2015 SN - 8750-3085 SP - 19-19 ST - Safety, efficacy and cost fac to r into physicians' decisions regarding glaucoma medication T2 - Ocular Surgery News TI - Safety, efficacy and cost fac to r into physicians' decisions regarding glaucoma medication UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110023347&site=ehost-live&scope=site VL - 33 ID - 4581 ER - TY - JOUR AB - Objective AR-13324 is a small-molecule inhibitor of Rho kinase and a norepinephrine transporter. The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design Double-masked, randomized study in 22 private practice ophthalmology clinics. Participants Participants were required to be adults with a diagnosis of OAG or OHT with unmedicated intraocular pressure (IOP) in the range of 22 to 36 mmHg. Methods Patients were randomized to receive AR-13324 ophthalmic solution 0.01%, daily (pm), AR-13324 ophthalmic solution 0.02% daily (pm), or latanoprost 0.005% daily (pm) for 28 days. Main Outcome Measures The primary efficacy endpoint was the mean diurnal IOP across subjects within the treatment group at day 28. Results Randomized and treated were 224 patients, 213 (95.1%) of whom completed the study. On day 28, mean diurnal IOP was 20.1, 20.0, and 18.7 mmHg in the AR-13324 0.01%, 0.02%, and latanoprost groups, respectively, representing a decrease from unmedicated baseline of 5.5, 5.7, and 6.8 mmHg (P<0.001). The 5.7-mmHg reduction in IOP by AR-13324 0.02% did not meet the criterion for noninferiority to latanoprost. The most frequently reported adverse event was conjunctival/ocular hyperemia, with a combined incidence of 52%, 57%, and 16%, respectively. On day 28 at 08:00 hours, the incidence of mild to moderate hyperemia by biomicroscopy was 18%, 24%, and 11%, respectively. Conclusions AR-13324 0.02% was less effective than latanoprost by approximately 1 mmHg in patients with unmedicated IOPs of 22 to 35 mmHg. The major safety finding was ocular hyperemia, which was more common for both concentrations of AR-13324 than for latanoprost. AD - G.D. Novack, PharmaLogic Development, Inc, 17 Bridgegate Drive, San Rafael, CA, United States AU - Bacharach, J. AU - Dubiner, H. B. AU - Levy, B. AU - Kopczynski, C. C. AU - Novack, G. D. C1 - ar 13324 DB - Embase Medline DO - 10.1016/j.ophtha.2014.08.022 IS - 2 KW - NCT01528787 NCT01731002 netarsudil eye drops latanoprost Rho kinase inhibitor unclassified drug abnormal sensation adult aged article biomicroscopy clinical article conjunctival hemorrhage conjunctival hyperemia controlled study disease severity dose response double blind procedure drug efficacy drug safety drug withdrawal female foreign body sensation human incidence intraocular hypertension intraocular pressure lacrimation disorder male open angle glaucoma patient compliance priority journal randomized controlled trial ar 13324 LA - English M3 - Article N1 - L600200629 2014-10-28 2015-02-03 PY - 2015 SN - 1549-4713 0161-6420 SP - 302-307 ST - Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure T2 - Ophthalmology TI - Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600200629&from=export http://dx.doi.org/10.1016/j.ophtha.2014.08.022 VL - 122 ID - 2827 ER - TY - JOUR AB - PURPOSE: To evaluate consistency in documentation of glaucoma medications in the electronic medical record and identify which regimen patients adhere to when inconsistencies exist. Factors contributing to medication nonadherence are also explored., METHODS: Retrospective chart review of medication adherence encompassing 200 patients from three glaucoma physicians at a tertiary referral center over a 1-month period. Adherence was determined by the consistency between a patients stated medication regimen and either the active medication list in the electronic medical record, or the physicians planned medication regimen in the preceding clinic visit. Patient charts were also reviewed for patient sex, age, primary language, race, and total number of medications., RESULTS: A total of 160 charts showed consistency in documentation between the physician note and electronic medication reconciliation. Of those patients, 83.1% reported adherence with their glaucoma medication schedule. When there was a discrepancy in documentation (40 charts), 72.5% patients followed the physician-stated regimen vs 20% who followed neither vs 7.5% who followed the medical record (P<0.01). No difference in adherence was observed based on sex (P=0.912) or total number of medications taken (P=0.242). Language, both English- (P=0.075) and Haitian (P=0.10) -speaking populations, as well as race, Caucasian (P=0.31), African-American (P=0.54), and Hispanic (P=0.58), had no impact on medication adherence. Patients over 80 years of age were more nonadherent as compared to other decades (P=0.04)., CONCLUSION: Inconsistent documentation between the electronic medical record physician note and medication regimen may contribute to patient medication nonadherence. Patients over 80 years of age were associated with higher rates of nonadherence, while sex, total number of medications, race, and language had no interaction with medication adherence. AU - Bacon, Thomas S. AU - Fan, Kenneth C. AU - Desai, Manishi A. DO - https://dx.doi.org/10.2147/OPTH.S92785 PY - 2016 SE - Bacon, Thomas S. Department of Ophthalmology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA. Fan, Kenneth C. Department of Ophthalmology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA. Desai, Manishi A. Department of Ophthalmology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA. SN - 1177-5467 SP - 221-5 ST - Electronic medical record and glaucoma medications: connecting the medication reconciliation with adherence T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Electronic medical record and glaucoma medications: connecting the medication reconciliation with adherence UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26869756 VL - 10 Y2 - 20160128// ID - 1047 ER - TY - JOUR AB - BACKGROUND: Cataract is a leading cause of childhood blindness in eastern Africa and other resource-constrained regions around the world, and high-quality surgical centers are increasingly responding to this challenge. Despite evidence concerning the ongoing risk of postoperative glaucoma after lensectomy, little is known of the incidence of glaucoma after pediatric cataract surgery in Africa. We sought to evaluate the frequency and predictors of postoperative glaucoma in this setting., METHODS: The medical records of all children who underwent surgery for congenital or developmental cataract between 2003 and 2005 at the Kilimanjaro Christian Medical Centre were retrospectively reviewed to determine the incidence of postoperative glaucoma. Potential risk factors were evaluated by means of logistic regression., RESULTS: Cumulative incidence of glaucoma at 3 years was 6.5% (95% CI, 2.5-16.0), and the annual incidence rate was 2.0 cases per 100 operated eyes (95% confidence interval, 0.74-4.37). Total time of follow-up and absence of primary intraocular lens implantation correlated with risk for postoperative glaucoma, but multivariate analysis could not confirm independent associations., CONCLUSIONS: As cataract surgical rates continue to increase and pediatric ophthalmology centers in Africa progress toward the goals of Vision 2020: The Right to Sight, renewed efforts must be directed toward the long-term postoperative care of all children undergoing operation for pediatric cataract. Copyright © 2013 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved. AU - Baden, Craig AU - Shija, Fortunate AU - Lewallen, Susan AU - Courtright, Paul AU - Hall, Anthony DO - https://dx.doi.org/10.1016/j.jaapos.2012.11.009 IS - 2 KW - Adolescent Africa/ep [Epidemiology] *Cataract Extraction Child Child, Preschool Female *Glaucoma/ep [Epidemiology] Glaucoma/et [Etiology] Health Services Accessibility Humans Incidence Infant Logistic Models Male Postoperative Complications Retrospective Studies Risk Factors Tanzania/ep [Epidemiology] PY - 2013 SE - Baden, Craig. University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. craigbaden@gmail.com SN - 1528-3933 1091-8531 SP - 158-62 ST - Glaucoma after pediatric cataract surgery in a population with limited access to care T2 - Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus TI - Glaucoma after pediatric cataract surgery in a population with limited access to care UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23528376 VL - 17 Y2 - 20130322// ID - 980 ER - TY - JOUR AB - Purpose: Self-care in chronic disease is increasingly important. In glaucoma services, there is an unmet need for a self-care tool such as a patient passport. This study aims to evaluate adoption of a new self-care tool, the Glaucoma Patient Passport (GPP) within a tertiary hospital glaucoma service., Patients and methods: The GPP was designed following consultation exercises between patients and clinicians at the first and second UK National Glaucoma Think Tanks. A patient questionnaire, comprising a mixed methods quantitative and qualitative research approach was used to explore the utility of GPP, patient attitude to GPP and barriers to adoption, 6 months after GPP receipt., Results: GPP feedback was received from 62 patients. On-going utilization of the GPP after receipt was high, at 84%, with patients most commonly using the GPP at home, to "look for information." Seventy-three percent reported improved knowledge of glaucoma care since using the GPP, with two-thirds (63%) reporting that the GPP had improved their glaucoma care. Three main themes were identified in exploring barriers to GPP adoption; clinician involvement in GPP use, GPP size, and GPP use in visual impairment., Conclusion: Implementation and adoption of the world's first GPP were a success. GPP utility was high and patient attitudes were predominantly positive, with improved self-care. However, several areas were identified for future GPP improvement. The GPP has the potential to improve patient self-care in glaucoma, bridging the care gap created by the increased workload in glaucoma services. AU - Badran, Imad AU - Bruynseels, Alice AU - Khan, Salim AU - Sii, Freda AU - Shah, Peter DO - https://dx.doi.org/10.2147/OPTH.S208377 PY - 2019 SE - Badran, Imad. Ophthalmology Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK. Badran, Imad. Department for Therapies and Public Health, Birmingham City University, Birmingham, UK. Bruynseels, Alice. Ophthalmology Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK. Bruynseels, Alice. Birmingham Institute for Glaucoma Research, Institute for Translational Medicine, Birmingham, UK. Khan, Salim. Department for Therapies and Public Health, Birmingham City University, Birmingham, UK. Sii, Freda. Ophthalmology Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK. Sii, Freda. Birmingham Institute for Glaucoma Research, Institute for Translational Medicine, Birmingham, UK. Shah, Peter. Ophthalmology Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK. Shah, Peter. Birmingham Institute for Glaucoma Research, Institute for Translational Medicine, Birmingham, UK. Shah, Peter. Institute of Ophthalmology, University College London, London, UK. Shah, Peter. Centre for Health and Social Care Improvement, School of Health and Wellbeing, University of Wolverhampton, Wolverhampton, UK. SN - 1177-5467 SP - 1369-1375 ST - Barriers to adoption of a personal health record in an ophthalmic setting: lessons from implementation of a Glaucoma Patient Passport T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Barriers to adoption of a personal health record in an ophthalmic setting: lessons from implementation of a Glaucoma Patient Passport UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=31440025 VL - 13 Y2 - 20190725// ID - 581 ER - TY - JOUR AB - Hypersensitive reactions to eyedrops are a common finding in clinical practice and represent a frequent cause of discontinuation of the therapy. Moreover, experimental and clinical studies show that long term use of topical drugs may induce ocular surface changes causing discomfort and potentially negatively affecting the compliance to the treatment as well as the success rate of filtering procedures. The exact mechanism involved and the roles of the active compound and the preservatives in inducing such detrimental effects of ophthalmic solutions are unclear. During the last years several antiglaucoma agents have been marketed as either preservative-free or benzalkonium chloride-free formulations in an attempt to reduce the adverse effects related to preservatives. This paper summarizes the body of evidence from existing studies about preservatives in antiglaucoma eyedrops, focusing on the latest compounds commercially available. A systematic review of the literature was performed. Current research is focusing not only on the efficacy of the drugs but also on their tolerability. Based on the existing data, there is a rationale to support the use of benzalkonium-free solutions whenever possible, especially in patients suffering from concomitant ocular surface diseases, experiencing local side effects and in those expected to need multiple and prolonged topical treatments. © 2011. AD - C.E. Traverso, Clinica Oculistica, Università di Genova, Viale benedetto XV, 16132 Genova, Italy AU - Bagnis, A. AU - Papadia, M. AU - Scotto, R. AU - Traverso, C. E. DB - Embase DO - 10.1016/j.sjopt.2011.08.004 IS - 4 KW - antiglaucoma agent benzalkonium chloride betaxolol brimonidine brimonidine plus timolol carteolol dorzolamide dorzolamide plus timolol levobunolol pilocarpine tafluprost timolol travoprost allergic reaction dermatitis drug efficacy drug formulation drug tolerability dry eye epiphora eye burning eye pain glaucoma human intraocular pressure Medline monotherapy ocular pruritus open angle glaucoma patient compliance periocular dermatitis priority journal quality of life review single drug dose systematic review treatment response vision LA - English M3 - Review N1 - L51635951 2011-10-07 2011-11-14 PY - 2011 SN - 1319-4534 SP - 389-394 ST - Antiglaucoma drugs: The role of preservative-free formulations T2 - Saudi Journal of Ophthalmology TI - Antiglaucoma drugs: The role of preservative-free formulations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51635951&from=export http://dx.doi.org/10.1016/j.sjopt.2011.08.004 VL - 25 ID - 3146 ER - TY - JOUR AB - Background: To report rates of recurrence and complications of localized ocular surface squamous neoplasia treated with 5-fluorouracil or mitomycin C as adjunctive treatment to surgical excision. Design: Long-term follow up of two prospective, non-comparative interventional case series. Participants: One hundred fifty-three eyes with histologically confirmed localized, non-invasive ocular surface squamous neoplasia. 89 eyes were treated with adjuvant 5-fluorouracil and 64 eyes were treated with adjuvant mitomycin C. Methods: Following surgical excision±cryotherapy patients received topical 5-fluorouracil 1% four times daily for two weeks or topical mitomycin C 0.04% four times daily for two to three 1-week cycles. Main Outcome Measures: Ocular surface squamous neoplasia recurrence, complications of therapy and compliance. Results: Median follow up was 33.6 (range 12-84) months and 57.9 (range 12-160) months in 5-fluorouracil and mitomycin C groups, respectively. There was one recurrence in the 5-fluorouracil group and no recurrences in the mitomycin C group. Side-effects occurred in 69% of 5-fluorouracil patients and 41% of mitomycin C patients. Five patients (6%) required intervention for treatment-related side-effects in the 5-fluorouracil group versus 11 (17%) in the mitomycin C group. No vision-threatening complications were noted. Conclusions: Long-term recurrence of localised ocular surface squamous neoplasia is rare when topical 5-fluorouracil or mitomycin C are used as adjunctive treatment to surgical excision. While side-effects are common, the majority are transient and rarely limit compliance. © 2013 Royal Australian and New Zealand College of Ophthalmologists. AD - South Australian Institute of Ophthalmology, Adelaide, Australia Discipline of Ophthalmology and Visual Sciences, University of Adelaide, North Terrace, SA, Australia AU - Bahrami, B. AU - Greenwell, T. AU - Muecke, J. S. DB - Scopus DO - 10.1111/ceo.12184 IS - 4 KW - Chemotherapy Ocular oncology Ocular surface tumours OSSN M3 - Article N1 - Cited By :28 Export Date: 19 July 2021 PY - 2014 SP - 317-322 ST - Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia T2 - Clinical and Experimental Ophthalmology TI - Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901648819&doi=10.1111%2fceo.12184&partnerID=40&md5=24819439125d4fedfdfecb7ed5f28e63 VL - 42 ID - 5070 ER - TY - JOUR AB - UNLABELLED: The high risk of complications and long period of recovery associated with glaucoma filtration procedures have been significant deterrents to surgery for both clinicians and patients. With the advent of microinvasive glaucoma procedures and the persistence of glaucoma medical compliance issues, clinicians have demonstrated a renewed interest in earlier glaucoma surgical intervention. This article reviews the indications, technique, and surgical results for trabecular ablation to lower intraocular pressure., FINANCIAL DISCLOSURE: Dr. Vold has received research support and is on the speakers bureau for Neomedix Corp. No author has a financial or proprietary interest in any material or method mentioned. Copyright © 2014 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved. AU - Bailey, Andrew K. AU - Vold, Steven D. AU - Sarkisian, Steven R., Jr. DO - https://dx.doi.org/10.1016/j.jcrs.2014.06.014 IS - 8 KW - Glaucoma/pp [Physiopathology] *Glaucoma/su [Surgery] Humans Intraocular Pressure/ph [Physiology] Limbus Corneae/su [Surgery] *Trabecular Meshwork/su [Surgery] *Trabeculectomy/mt [Methods] PY - 2014 SE - Bailey, Andrew K. From the Dean McGee Eye Institute (Bailey, Sarkisian), University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, and Vold Vision, PLLC (Vold), Fayetteville, Arkansas, USA. Vold, Steven D. From the Dean McGee Eye Institute (Bailey, Sarkisian), University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, and Vold Vision, PLLC (Vold), Fayetteville, Arkansas, USA. Sarkisian, Steven R Jr. From the Dean McGee Eye Institute (Bailey, Sarkisian), University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, and Vold Vision, PLLC (Vold), Fayetteville, Arkansas, USA. Electronic address: steven-sarkisian@dmei.org. SN - 1873-4502 0886-3350 SP - 1281-4 ST - Ab interno approach to Schlemm canal: ab interno trabecular ablative procedures T2 - Journal of cataract and refractive surgery TI - Ab interno approach to Schlemm canal: ab interno trabecular ablative procedures UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25088625 VL - 40 ID - 870 ER - TY - JOUR AB - OBJECTIVES: To explore views of all stakeholders (patients, optometrists, general practitioners (GPs), commissioners and ophthalmologists) regarding the operation of community-based enhanced optometric services., DESIGN: Qualitative study using mixed methods (patient satisfaction surveys, semi-structured telephone interviews and optometrist focus groups)., SETTING: A minor eye conditions scheme (MECS) and glaucoma referral refinement scheme (GRRS) provided by accredited community optometrists., PARTICIPANTS: 189 patients, 25 community optometrists, 4 glaucoma specialist hospital optometrists (GRRS), 5 ophthalmologists, 6 GPs (MECS), 4 commissioners., RESULTS: Overall, 99% (GRRS) and 100% (MECS) patients were satisfied with their optometrists' examination. The vast majority rated the following as 'very good'; examination duration, optometrists' listening skills, explanations of tests and management, patient involvement in decision-making, treating the patient with care and concern. 99% of MECS patients would recommend the service. Manchester optometrists were enthusiastic about GRRS, feeling fortunate to practise in a 'pro-optometry' area. No major negatives were reported, although both schemes were limited to patients resident within certain postcode areas, and some inappropriate GP referrals occurred (MECS). Communication with hospitals was praised in GRRS but was variable, depending on hospital (MECS). Training for both schemes was valuable and appropriate but should be ongoing. MECS GPs were very supportive, reporting the scheme would reduce secondary care referral numbers, although some MECS patients were referred back to GPs for medication. Ophthalmologists (MECS and GRRS) expressed very positive views and widely acknowledged that these new care pathways would reduce unnecessary referrals and shorten patient waiting times. Commissioners felt both schemes met or exceeded expectations in terms of quality of care, allowing patients to be seen quicker and more efficiently., CONCLUSIONS: Locally commissioned schemes can be a positive experience for all involved. With appropriate training, clear referral pathways and good communication, community optometrists can offer high-quality services that are highly acceptable to patients, health professionals and commissioners. Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. AU - Baker, H. AU - Harper, R. A. AU - Edgar, D. F. AU - Lawrenson, J. G. DO - https://dx.doi.org/10.1136/bmjopen-2016-011934 IS - 10 KW - *Attitude of Health Personnel *Community Health Services *Delivery of Health Care/mt [Methods] England Eye Diseases/di [Diagnosis] *Eye Diseases General Practitioners Glaucoma Humans Ophthalmologists Optometrists *Optometry *Patient Satisfaction *Professional Role Referral and Consultation PY - 2016 SE - Baker, H. Division of Optometry and Visual Science, City, University of London, London, UK. Baker, H. UCL (University College London), Institute of Ophthalmology, London, UK. Harper, R A. Manchester Academic Health Sciences Centre, Manchester Royal Eye Hospital, Manchester, UK. Edgar, D F. Division of Optometry and Visual Science, City, University of London, London, UK. Lawrenson, J G. Division of Optometry and Visual Science, City, University of London, London, UK. SN - 2044-6055 SP - e011934 ST - Multi-stakeholder perspectives of locally commissioned enhanced optometric services T2 - BMJ open TI - Multi-stakeholder perspectives of locally commissioned enhanced optometric services UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27798000 VL - 6 Y2 - 20161025// ID - 655 ER - TY - JOUR AB - AIM: To investigate whether a public education campaign can increase awareness and change help-seeking behaviour with respect to ocular health in an Indian population., METHODS: A health knowledge questionnaire was used investigating and assessing the health campaign. The health campaign comprised four components: (1) television, (2) local press, (3) local radio and (4) places of worship. The target population were Indian residents in Southall, Ealing aged 60+. The aim was to get people to go and have their eyes tested at their local optometric practice. Optometric practices within the borough of Ealing collected sight-test data for the study over 6 months before and after the advertising campaign., RESULTS: The repeat in-depth glaucoma knowledge questionnaire showed a significant increase in the number of people who had heard of glaucoma rising from 22% to 53%. Before intervention, most people had heard about glaucoma from their GP, friend or relative. After intervention, the majority (69%) had heard of glaucoma from the radio., CONCLUSION: This study has shown a significant increase in awareness from using different kinds of media and has shown radio to be the most effective in our target community. Although the campaign has raised awareness, this study has not shown a change in health-seeking behaviour. AU - Baker, H. AU - Murdoch, I. E. DO - https://dx.doi.org/10.1136/bjo.2008.143537 IS - 12 KW - Adult Aged Aged, 80 and over Female *Glaucoma/di [Diagnosis] Glaucoma/eh [Ethnology] Health Behavior/eh [Ethnology] Health Knowledge, Attitudes, Practice *Health Promotion/mt [Methods] Humans Male Middle Aged Patient Acceptance of Health Care/eh [Ethnology] Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Persuasive Communication Program Evaluation Surveys and Questionnaires PY - 2008 SE - Baker, H. Department of Epidemiology and International Eye Health, Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK. h.baker@ucl.ac.uk SN - 1468-2079 0007-1161 SP - 1671-5 ST - Can a public health intervention improve awareness and health-seeking behaviour for glaucoma? T2 - The British journal of ophthalmology TI - Can a public health intervention improve awareness and health-seeking behaviour for glaucoma? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18838409 VL - 92 Y2 - 20081006// ID - 1513 ER - TY - JOUR AB - PURPOSE: UK demographic and legislative changes combined with increasing burdens on National Health Service manpower and budgets have led to extended roles for community optometrists providing locally-commissioned enhanced optometric services (EOS). This realist review's objectives were to develop programme theories that implicitly or explicitly explain quality outcomes for eye care provided by optometrists via EOS and to test these theories by investigating the effectiveness of services for cataract, glaucoma, and primary eye care., METHODS: The review protocol was published on PROSPERO, and RAMESES publication standards were followed. Programme theories were formulated via scoping literature searches and expert consultation. The searching process involved all relevant electronic databases and grey literature, without restrictions on study design. Data synthesis focussed on questioning the integrity of each theory by considering supportive and refuting evidence from the source literature., RESULTS: Good evidence exists for cataract, glaucoma and primary eye care EOS that: with appropriate training, accredited optometrists manage patients commensurate with usual care standards; genuine partnerships can exist between community and hospital providers for cataract and glaucoma EOS; patient satisfaction with all three types of service is high; cost-effectiveness of services is unproven for cataract and primary eye care, while glaucoma EOS cost-effectiveness depends on service type; contextual factors may influence service success., CONCLUSIONS: The EOS reviewed are clinically effective and provide patient satisfaction but limited data is available on cost-effectiveness. Copyright © 2016 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists. AU - Baker, Helen AU - Ratnarajan, Gokulan AU - Harper, Robert A. AU - Edgar, David F. AU - Lawrenson, John G. DO - https://dx.doi.org/10.1111/opo.12312 IS - 5 KW - Cataract/di [Diagnosis] Community Health Services/ec [Economics] Community Health Services/og [Organization & Administration] Community Health Services/st [Standards] Cost-Benefit Analysis *Eye Diseases/di [Diagnosis] Glaucoma/di [Diagnosis] Humans Optometry/ec [Economics] Optometry/og [Organization & Administration] *Optometry/st [Standards] Patient Satisfaction United Kingdom N1 - Comment in (CIN), Comment in (CIN) PY - 2016 SE - Baker, Helen. Division of Optometry and Visual Science, City University London, London, UK. Baker, Helen. UCL Institute of Ophthalmology, London, UK. Ratnarajan, Gokulan. UCL Institute of Ophthalmology, London, UK. Ratnarajan, Gokulan. Corneo-Plastic Unit, Queen Victoria Hospital, East Grinstead, UK. Ratnarajan, Gokulan. Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, UK. Harper, Robert A. Manchester Academic Health Sciences Centre, Manchester Royal Eye Hospital, Manchester, UK. Edgar, David F. Division of Optometry and Visual Science, City University London, London, UK. Lawrenson, John G. Division of Optometry and Visual Science, City University London, London, UK. SN - 1475-1313 0275-5408 SP - 545-57 ST - Effectiveness of UK optometric enhanced eye care services: a realist review of the literature T2 - Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) T3 - Comment in: Ophthalmic Physiol Opt. 2017 Jan;37(1):113; PMID: 28030878 [https://www.ncbi.nlm.nih.gov/pubmed/28030878]Comment in: Ophthalmic Physiol Opt. 2017 Jan;37(1):113-114; PMID: 28030879 [https://www.ncbi.nlm.nih.gov/pubmed/28030879] TI - Effectiveness of UK optometric enhanced eye care services: a realist review of the literature UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27580754 VL - 36 ID - 662 ER - TY - JOUR AD - M. Baker, Centre for Eye Research Australia, University of Melbourne, Parkville, VIC, Australia AU - Baker, M. AU - Le Mesurier, R. AU - Szetu, J. AU - Painter, G. AU - Hue, J. AU - McLellan, S. AU - Aluta, W. DB - Embase Medline DO - 10.1111/j.1442-9071.2006.01362.x IS - 8 KW - antibiotic agent chloramphenicol antibiotic therapy blindness cornea injury cornea opacity cornea ulcer eye burn eye care eye injury eye surgery health belief health care access health care delivery health care financing health care personnel health promotion human keratitis letter medical education monocular vision penetrating trauma preventive medicine public health service resource allocation resource management scar formation self medication Solomon Islands traditional medicine visual acuity LA - English M3 - Letter N1 - L44650163 2006-11-29 PY - 2006 SN - 1442-9071 1442-6404 SP - 813-814 ST - Ocular trauma in the Solomon Islands [6] T2 - Clinical and Experimental Ophthalmology TI - Ocular trauma in the Solomon Islands [6] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44650163&from=export http://dx.doi.org/10.1111/j.1442-9071.2006.01362.x VL - 34 ID - 3644 ER - TY - JOUR AB - Purpose: this survey aimed to assess levels of compliance with contact lens wear and care among university student ?s population in Jordan. Methods: An interviewer -administered questionnaire was used to assess the extent of compliance among contact lens wearers toward contact lens care in a university population. The questionnaire included 12 questions re- garding compliance with contact lens care, lens case/solution replacement, general hygiene procedures related to contact lens and adherence to aftercare visits. Results: 210 contact lens wearers were interviewed. Of the study population 187 (89 %) were females and 23 (11 %) were males. The average age of the study group was 22.35 ( ? 3.77) years and all the study population were students (undergraduate or postgraduate).The average compliance rate of the study population was 75 %. High level of compliance was noticeable in the following aspects; not sharing lenses with others, not sleeping while wearing lenses, hand washing before lens use and not using water to clean lenses. Moderate level of compliance was reported in the following aspects; showering/swimming with lenses, using lenses longer than recommended replacement schedule and all behaviours related to contact lens care solution. However, low levels of compliance were reported in relation to cleaning and rinsing lens case and adherence to aftercare visits. Conclusion: High to moderate levels of compliance were reported generally by participants. However, better strategies are recommended to further increase levels of compliance among contact lens wearers in Jordan related to adherence to aftercare visits. While this study is targeted contact lens wearers from a university student ?s population, a future study is recommended to include larger sample of contact lens wearers from the general lay population. AN - WOS:000545344000014 AU - Bakkar, M. M. AU - Alzghoul, E. A. DA - AUG DO - 10.1016/j.clae.2020.02.020 IS - 4 PY - 2020 SN - 1367-0484 1476-5411 SP - 395-401 ST - Assessment of compliance with contact lens wear and care among university -based population in Jordan T2 - CONTACT LENS & ANTERIOR EYE TI - Assessment of compliance with contact lens wear and care among university -based population in Jordan VL - 43 ID - 6077 ER - TY - JOUR AB - On the basis of a prolonged dispensary observation (from 14 to 27 years) over 107 patients, the authors have studied timeliness of therapeutic and surgical treatment, dynamics of glaucomatous process after 3, 6, 9, 12, 15, 18, 21-27 years. In the beginning of the observation, initial and advanced stages (88.5%) with a moderate rise of intraocular pressure (69%) prevailed. With prolongation of observation, initial stages regularly turn into subsequent ones, sometimes in the presence of normal values of intraocular pressure. Stabilization of glaucomatous process was most frequently observed in patients who had underwent regular complex medicamentous therapy and timely surgical treatment. Glaucoma of stage I most frequently turns into more advanced stages with decreased visual functions within first three years. Therefore, it is in this period when patients should be subjected to thorough dispensary observation, timely refer to in-patient's treatment, and the question about surgical treatment be decided in early terms. AD - V.I. Bakurskaia AU - Bakurskaia, V. I. AU - Kunin, V. D. DB - Medline IS - 1 KW - aged ambulatory care article female glaucoma human male middle aged pathology time LA - Russian M3 - Article N1 - L19437849 1989-07-17 PY - 1989 SN - 0030-0675 SP - 20-23 ST - The dynamics of the glaucoma process based on data from prolonged ambulatory care of patients T2 - Oftalmologicheskiǐ zhurnal TI - The dynamics of the glaucoma process based on data from prolonged ambulatory care of patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L19437849&from=export ID - 4050 ER - TY - JOUR AB - INTRODUCTION: The frequency of eye diseases has been suggested to start increasing around 40 years of age, with an even steeper increase beginning around 60 years of age. Health promotions and curative and rehabilitative services for the visually impaired elderly population should therefore be a priority in the coming years especially in low and middle income countries., AIM: To examine the changing pattern of ocular morbidity in the elderly population of Northern India and to determine the socioeconomic status in relation to ocular morbidities., MATERIALS AND METHODS: A team from the Department of Ophthalmology and Department of Community Medicine, conducted house visits and did a complete eye examination of 450 elderly subjects. They were selected by systematic random sampling from the data base available in the Department of Community Medicine., RESULTS: A total of 900 eyes were examined. Visual impairment and blindness was seen in 135 (30%) and 36 (8%) individuals respectively. The most common cause of blindness was cataract, followed by corneal opacity, glaucoma, refractive error, diabetic retinopathy, macular scar, age related macular degeneration, retinal detachment, retinitis pigmentosa. Visual impairment was more in individuals with low socioeconomic status., CONCLUSION: The results of this study suggest that though cataract remains the main cause of blindness, there is an increase in blindness and visual impairment due to corneal diseases and glaucoma which was not seen earlier. The availability and accessibility to eye care facilities particularly for corneal diseases and glaucoma should be increased to reduce blindness in Northern India. AU - Baldev, Vibha Florence AU - Chopra, Rupali AU - Batra, Nitin AU - Singh, Shavinder DO - https://dx.doi.org/10.7860/JCDR/2017/27056.10496 IS - 8 PY - 2017 SE - Baldev, Vibha Florence. Assistant Professor, Department of Ophthalmology, Christian Medical College and Hospital, Ludhiana, Punjab, India. Chopra, Rupali. Professor, Department of Ophthalmology, Christian Medical College and Hospital, Ludhiana, Punjab, India. Batra, Nitin. Professor, Department of Ophthalmology, Christian Medical College and Hospital, Ludhiana, Punjab, India. Singh, Shavinder. Professor, Department of Community Medicine, Christian Medical College and Hospital, Ludhiana, Punjab, India. SN - 2249-782X 0973-709X SP - NC20-NC23 ST - Pattern of Ocular Morbidity in the Elderly Population of Northern India T2 - Journal of clinical and diagnostic research : JCDR TI - Pattern of Ocular Morbidity in the Elderly Population of Northern India UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=28969173 VL - 11 Y2 - 20170801// ID - 622 ER - TY - JOUR AB - BACKGROUND: Glaucoma comprises a group of neurodegenerative diseases resulting in retinal ganglion cell death within the optic nerve head. It is projected to affect almost 80 million people worldwide by 2020. The condition's asymptomatic nature translates to over half of glaucoma sufferers being unaware of their condition. By the time of diagnosis, irreversible blindness is likely to have occurred. Prime areas of glaucoma research therefore include identification and optimization of risk factors for the disease, accurate and early diagnostic tools and novel therapeutic methods., METHODS: The goal of this review was to summarize main areas of latest glaucoma research into risk factors of glaucoma, diagnostic tools and treatments. PubMed was used to search for terms including glaucoma risk factors, glaucoma diagnostics, glaucoma treatment, glaucoma drug delivery and glaucoma IOP., RESULTS: The evidence for risk factors of low CSF pressure, IOP, smoking, vascular risk factors and light toxicity is described. Latest diagnostic and monitoring techniques for glaucoma include SD-OCT, DARC and IOP telemetry. Current and emerging medical and surgical treatments in glaucoma are discussed. Rho kinase inhibitors have the potential to both lower IOP and also provide neuroprotection, several of which are in clinical trials. Several other new medical treatments such as calcium channel blockers and neurotrophic agents also have the capacity to provide neuroprotection. Minimally Invasive Glaucoma Surgery (MIGS) devices provide an improved safety profile compared to traditional trabeculectomy; the latest ab interno and ab externo devices are described. Novel drug delivery methods, including punctual plugs and contact lenses, help overcome the challenges with patient adherence., CONCLUSION: The ultimate goals are to reduce the individual patient risk factors associated with glaucoma, diagnose the condition early and to find treatments that not only reduce IOP but also reverse neurodegeneration of RGCs. The usage of combinations of novel medical and surgical treatments may help maximize IOP reduction and neuroprotection. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org. AU - Balendra, Shiama I. AU - Shah, Parth Arvind AU - Jain, Mishank AU - Grzybowski, Andrzej AU - Cordeiro, Maria F. DO - https://dx.doi.org/10.2174/1381612822666161129151308 IS - 4 KW - *Calcium Channel Blockers/tu [Therapeutic Use] Glaucoma/di [Diagnosis] *Glaucoma/dt [Drug Therapy] Glaucoma/su [Surgery] Humans *Neuroprotective Agents/tu [Therapeutic Use] Risk Factors PY - 2017 SE - Balendra, Shiama I. Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology, London. United Kingdom. Shah, Parth Arvind. Department of Ophthalmology, The Princess Alexandra Eye Pavilion, Chalmers St, Edinburgh EH3 9HA. United Kingdom. Jain, Mishank. Department of Ophthalmology, Central Middlesex Hospital, Acton Lane, Park Royal, London, NE10 7NS. United Kingdom. Grzybowski, Andrzej. University of Warmia and Mazury, Olsztyn. Poland. Cordeiro, Maria F. Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology, London. United Kingdom. SN - 1873-4286 1381-6128 SP - 596-607 ST - Glaucoma: Hot Topics in Pharmacology T2 - Current pharmaceutical design TI - Glaucoma: Hot Topics in Pharmacology UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=27897119 VL - 23 ID - 554 ER - TY - JOUR AB - Introduction: Personalized medicine is the future goal across all specialties. Accurate prediction of optimal treatment beneficial and adverse effects could transform patient management. This is of particular importance in chronic conditions, where a ‘trial and error’ approach over months and years can contribute to significant morbidity. Glaucoma is a chronic irreversible progressive optic neuropathy, a leading cause of blindness worldwide. An ideal personalized approach in glaucoma clinic would be to answer the inevitable question in a patient’s first visit: ‘Which treatment option will work best for me so that I won’t go blind?’ Areas covered: This review will give an overview of the knowledge we have acquired to achieve this goal, particularly discussing using patient’s individual risk factors, their genetic profile, and different treatment modalities, including therapy compliance, to personalize care. Expert opinion: Pharmacogenomics and genetic profiling are the most tangible ways in which glaucoma management can be personalized. Future challenges will include developing realistic animal models to reflect the underlying genetic patterns in glaucoma to investigate their interaction with different treatments. AD - M.F. Cordeiro, UCL - UCL Institute of Ophthalmology, UCL Institute of Ophthalmology, Bath Street, London, United Kingdom AU - Balendra, S. I. AU - Zollet, P. AU - Cisa Asinari Di Gresy E Casasca, G. AU - Cordeiro, M. F. DB - Embase DO - 10.1080/23808993.2020.1756770 IS - 3 KW - glaucoma drainage implant beta adrenergic receptor blocking agent neurotrophin prostaglandin steroid Alzheimer disease apoptosis drug response endoplasmic reticulum stress Flammer syndrome genetic predisposition genetic profile glaucoma glaucoma surgery glaucomatous optic neuropathy human hypotension intraocular hypertension intraocular pressure migraine morbidity neuroprotection open angle glaucoma patient care patient compliance patient counseling personalized medicine pharmacogenetics pharmacogenomics prediction prognosis pseudoexfoliation review risk factor topical treatment trabecular meshwork trabeculectomy vasospasm LA - English M3 - Review N1 - L2004968376 2020-05-26 2020-07-10 PY - 2020 SN - 2380-8993 SP - 145-164 ST - Personalized approaches for the management of glaucoma T2 - Expert Review of Precision Medicine and Drug Development TI - Personalized approaches for the management of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004968376&from=export http://dx.doi.org/10.1080/23808993.2020.1756770 VL - 5 ID - 2407 ER - TY - JOUR AB - BACKGROUND: Glaucoma is an important public health concern in the United States, particularly among older adults (aged >or=65 years). Pharmacologic therapy for glaucoma consists mainly of topical eye drops containing beta-blockers or prostaglandin analogs., OBJECTIVE: The goal of this study was to assess the associations between factors of topical medication use (self reported medication compliance, belief in benefit of medication use, usage difficulty, usage assistance, and complexity of medication regimen) and health-related quality of life (HRQOL) in a cross-sectional population of older patients with glaucoma., METHODS: A self-administered, 48-question survey soliciting information on medication-taking behaviors, treatmen-trelated factors, and HRQOL was mailed to members of a Medicare health maintenance organization who were aged >or=65 years and had primary open-angle glaucoma. Two mailings were conducted 4 months apart; the second was sent to members whose responses to the first mailing had not yet been received. The 12-Item Short-Form Health Survey (SF-12) and the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) were used to assess HRQOL. Other questions addressed perceptions of eye drop use in these patients. Multiple regression techniques were used to analyze associations between medication-related factors and HRQOL in this population., RESULTS: The questionnaire was mailed to 589 patients; 375 responded (218 in the first mailing and 157 in the second mailing). A total of 358 responses were complete and analyzable (effective response rate, 62%). After controlling for the effects of other confounders, we found that self reported difficulty in using eye drops was strongly associated with decreased HRQOL (11.5% in VFQ-25 total score and 8.4% in SF-12 mental health score, P<0.05). Other medication-related factors that were examined were not significantly associated with changes in HRQOL., CONCLUSION: Based on our findings, patients aged >or=65 years with glaucoma were likely to have significant comorbidity, which affected both visual and general health and well-being perception. Additionally, a significant proportion of these patients reported difficulty with use of topical medication, which was independently associated with a significant decrease in HRQOL. Care of older patients with glaucoma should incorporate strategies to minimize the difficulty associated with medication use. AU - Balkrishnan, Rajesh AU - Bond, J. Brent AU - Byerly, Wesley G. AU - Camacho, Fabian T. AU - Anderson, Roger T. IS - 2 KW - Administration, Topical Aged Aged, 80 and over Cross-Sectional Studies Female *Glaucoma/dt [Drug Therapy] Glaucoma/px [Psychology] *Health Maintenance Organizations/sn [Statistics & Numerical Data] Humans Male *Medicare/sn [Statistics & Numerical Data] Ophthalmic Solutions Patient Compliance *Quality of Life Regression Analysis Surveys and Questionnaires Treatment Outcome United States PY - 2003 SE - Balkrishnan, Rajesh. Division of Management and Policy Sciences, University of Texas School of Public Health, Houston, Texas 77030, USA. Rajesh.Balkrishnan@uth.tmc.edu SN - 1543-5946 1876-7761 SP - 75-81 ST - Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization T2 - The American journal of geriatric pharmacotherapy TI - Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15555469 VL - 1 ID - 1802 ER - TY - JOUR AB - The objective of this study was to evaluate systemic immunosuppression regimens used for patients undergoing ocular surface stem cell transplantation, including their benefits and adverse effects in the adjunctive management of limbal stem cell deficiency (LSCD). A systematic literature review was conducted using the MEDLINE and EMBASE databases (1980–2015). Data were collected on surgical intervention(s), type of immunosuppressive agent(s), duration of immunosuppression, percentage with stable ocular surface at last follow-up, mean follow-up time, and demographics. Data were also collected on adverse ocular and systemic outcomes. Sixteen reports met the inclusion criteria. There were no randomized controlled studies. Three studies were noncomparative prospective case series, whereas the majority were retrospective case series. Bilateral severe LSCD was the most common disease (50%), and keratolimbal allograft was the most common intervention (80%). Immunosuppressive regimens showed a progression from early studies using oral cyclosporine to later studies using combinations of mycophenolate mofetil and tacrolimus. Most studies included a course of high-dose systemic corticosteroids. For patients adherent to long-term systemic immunosuppression, stable ocular surface rates of 70%–80% at last follow-up were reported. Adverse effects included hypertension, diabetes mellitus, and biochemical abnormalities managed with pharmacotherapy or discontinuation of offending agents. There were no cases of mortality related to immunosuppression. However, the current literature does not elucidate which immunosuppressive regimen is most efficacious for different categories of LSCD or graft types. Evidence-based guidelines for systemic immunosuppression in limbal allograft therapy would benefit from randomized controlled and/or additional prospective studies. Long-term immunosuppression would benefit from close collaboration between ophthalmologists and transplant specialists to individualize treatments. © 2018 AD - Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont, Canada Department of Family and Community Medicine, University of Toronto, Toronto, Ont, Canada Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Toronto, Ont, Canada Toronto Transplant Institute, University Health Network, Toronto, Ont, Canada Department of Medicine (Nephrology), Toronto General Hospital, University of Toronto, Toronto, Ont, Canada University Health Network, Toronto General Hospital, Toronto, Ont, Canada AU - Ballios, B. G. AU - Weisbrod, M. AU - Chan, C. C. AU - Borovik, A. AU - Schiff, J. R. AU - Tinckam, K. J. AU - Humar, A. AU - Kim, S. J. AU - Cole, E. H. AU - Slomovic, A. R. DB - Scopus DO - 10.1016/j.jcjo.2017.10.040 IS - 4 M3 - Review N1 - Cited By :5 Export Date: 19 July 2021 PY - 2018 SP - 314-323 ST - Systemic immunosuppression in limbal stem cell transplantation: best practices and future challenges T2 - Canadian Journal of Ophthalmology TI - Systemic immunosuppression in limbal stem cell transplantation: best practices and future challenges UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040655479&doi=10.1016%2fj.jcjo.2017.10.040&partnerID=40&md5=166dfac3702b6b8a46b1193bc2076c3c VL - 53 ID - 5409 ER - TY - JOUR AB - PRCIS: Community-engaged research (CER) enables researchers to identify community-specific barriers and facilitators to program implementation. Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust, and community-specific barriers, such as Language and Convenience/Access, were identified., PURPOSE: The aim was to identify the facilitators and barriers to implementing glaucoma screening programs in 2 community clinics., METHODS: A concurrent mixed-methods process analysis using CER. Key stakeholders-including patients, providers, and staff members-from 2 community clinics were interviewed using a semistructured interview guide. Interviews had 2 parts: (1) asking patients about community-based facilitators and barriers to implementing glaucoma screening and care and (2) eliciting feedback about a personalized coaching program. The transcripts were coded using Grounded Theory. Number of participants and number of representative citations were counted per theme. The qualitative analysis was coded using Dedoose 8.3.17 (Los Angeles, CA)., RESULTS: Thematic saturation was reached after coding 12 interviews. 30 participants were interviewed, 13 from Hamilton Clinic (Flint, MI; 8 patients, 5 providers and staff members) and 17 from Hope Clinic (Ypsilanti, MI; 6 patients, 11 providers and staff members). The most commonly cited themes were: Priorities (98 citations, 30 participants), Knowledge (73, 26) Transportation (63, 26), Cost (60, 23), and Convenience/Access (63, 22). Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust were identified alongside community-specific barriers such as Language and Convenience/Access. Participants rated their likelihood to follow up with an ophthalmologist after participating in the personalized coaching program at a mean of 8.83 (on a scale of 1 to 10 with 10 being the most confident)., CONCLUSIONS: CER enables researchers to identify community-specific barriers and facilitators, allowing more effective program implementation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. AU - Ballouz, Dena AU - Cho, Juno AU - Woodward, Maria A. AU - Elam, Angela R. AU - Musch, David C. AU - Zhang, Jason AU - Moroi, Sayoko E. AU - Johnson, Leroy AU - Cederna, Jean AU - Newman-Casey, Paula A. DO - https://dx.doi.org/10.1097/IJG.0000000000001756 IS - 5 PY - 2021 SE - Ballouz, Dena. Department of Ophthalmology and Visual Sciences. Cho, Juno. Department of Ophthalmology and Visual Sciences. Woodward, Maria A. Department of Ophthalmology and Visual Sciences. Woodward, Maria A. Institute for Healthcare Policy and Innovation, University of Michigan. Elam, Angela R. Department of Ophthalmology and Visual Sciences. Musch, David C. Department of Ophthalmology and Visual Sciences. Musch, David C. Institute for Healthcare Policy and Innovation, University of Michigan. Musch, David C. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor. Zhang, Jason. Department of Ophthalmology and Visual Sciences. Moroi, Sayoko E. Department of Ophthalmology, Ohio State University, Columbus, OH. Johnson, Leroy. Hamilton Community Health Network, Flint. Cederna, Jean. Hope Clinic, Ypsilanti, MI. Newman-Casey, Paula A. Department of Ophthalmology and Visual Sciences. Newman-Casey, Paula A. Institute for Healthcare Policy and Innovation, University of Michigan. SN - 1536-481X 1057-0829 SP - 402-409 ST - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach T2 - Journal of glaucoma TI - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=33273279 VL - 30 ID - 68 ER - TY - JOUR AB - PURPOSE: To understand medication use and patient burden for treatment of bacterial keratitis (BK)., METHODS: A retrospective study was conducted examining medical records of adult patients with BK in an academic cornea practice. Data collected included medications used in the treatment of BK, dosing of medications, and the number and total duration of clinical encounters. Costs of medications were estimated using the average wholesale pharmacy price. Linear regression analysis was used to investigate associations of medication use with patient demographics and corneal culture results and reported with beta estimates (beta) and 95% confidence intervals (95% CIs)., RESULTS: Forty-eight patients with BK (56% female) were studied. Patients were treated for a median of 54 days with 10 visits, 5 unique medications, 587 drops, and 7 prescriptions. The estimated median medication cost was $933 (interquartile range: $457-$1422) US dollars. Positive bacterial growth was significantly associated with more visits (beta: 6.16, 95% CI: 1.75-10.6, P = 0.007), more days of treatment (beta: 86.8, 95% CI: 10.8-163, P = 0.026), more prescribed medications (beta: 2.86, 95% CI: 1.04-4.67, P = 0.003), and more doses of medications (beta: 796, 95% CI: 818-1412, P = 0.012) compared with patients who did not undergo corneal scraping. Patients were prescribed 132 more drops of medication for every 10 years of older age (beta: 132, 95% CI: 18.2-246, P = 0.024). Sex and income were not associated with medication burden or treatment length., CONCLUSIONS: Older patients and those with positive cultures incur the most medication burden in treatment of BK. Providers should be aware of medication usage and cost burden as it may affect compliance with treatment. AU - Ballouz, Dena AU - Maganti, Nenita AU - Tuohy, Megan AU - Errickson, Josh AU - Woodward, Maria A. DO - https://dx.doi.org/10.1097/ICO.0000000000001942 IS - 8 KW - Administration, Ophthalmic *Anti-Bacterial Agents/ec [Economics] *Anti-Bacterial Agents/tu [Therapeutic Use] Bacteria/ip [Isolation & Purification] *Corneal Ulcer/dt [Drug Therapy] Corneal Ulcer/mi [Microbiology] *Costs and Cost Analysis *Drug Costs Drug Prescriptions/sn [Statistics & Numerical Data] *Drug Utilization/sn [Statistics & Numerical Data] *Eye Infections, Bacterial/dt [Drug Therapy] Eye Infections, Bacterial/mi [Microbiology] Female Glucocorticoids/ec [Economics] Glucocorticoids/tu [Therapeutic Use] Humans Male Middle Aged Mydriatics/ec [Economics] Mydriatics/tu [Therapeutic Use] Ophthalmic Solutions Retrospective Studies PY - 2019 SE - Ballouz, Dena. Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI. Maganti, Nenita. Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI. Maganti, Nenita. Feinberg School of Medicine, Northwestern University, Chicago, IL. Tuohy, Megan. Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI. Errickson, Josh. Consulting for Statistics, Computing and Analytics Research (CSCAR), University of Michigan, Ann Arbor, MI. Woodward, Maria A. Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI. Woodward, Maria A. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI. SN - 1536-4798 0277-3740 SP - 933-937 ST - Medication Burden for Patients With Bacterial Keratitis T2 - Cornea TI - Medication Burden for Patients With Bacterial Keratitis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31276456 VL - 38 ID - 324 ER - TY - JOUR AB - Purpose: To compare the visual outcomes of patients with acute retinal necrosis (ARN) treated initially with intravenous acyclovir vs oral valacyclovir therapy. Design: Retrospective, comparative, interventional case series. Methods: Sixty-two patients (68 eyes) with ARN, treated at Moorfields Eye Hospital (United Kingdom) between 1992 and 2016, were identified through the hospital's electronic database. Exclusion criteria included insufficient patient records or follow-up (<150 days). Fifty-six patients had unilateral ARN, while 6 had bilateral ARN. Patients who received intravenous acyclovir on diagnosis (n = 33) were compared with patients treated with oral valacyclovir (n = 29) across outcomes including best-corrected visual acuity, retinal detachment, severe vision loss, and other complications. The impact of adjunctive intravitreal antiviral and prophylactic barrier laser treatment was also assessed. Results: Change in best-corrected visual acuity was not significantly different for eyes treated initially with intravenous therapy vs oral therapy over 5 years of follow-up data (P =.16). There was no difference in the rates of severe vision loss between the 2 groups (46% and 59%, respectively, P =.18), or of those eyes retaining good vision (28% vs 31%, respectively, P =.80). Retinal detachment occurred in 63% of cases and did not differ across treatment groups (62% vs 66%, respectively, P =.67). Barrier laser and intravitreal therapy had no effect on retinal detachment rate in either group. Conclusion: Oral valacyclovir is clinically equivalent to intravenous therapy in the management of ARN. Oral valacyclovir as an outpatient therapy—with or without intravitreal foscarnet—can therefore be considered as an acceptable alternative to inpatient therapy required for intravenous treatment. © 2018 Elsevier Inc. AD - Moorfields Eye Hospital, London, United Kingdom UCL Institute of Ophthalmology, London, United Kingdom Technion – Israel Institute of Technology, Bnai Zion Medical Center, Haifa, Israel AU - Baltinas, J. AU - Lightman, S. AU - Tomkins-Netzer, O. DB - Scopus DO - 10.1016/j.ajo.2018.02.001 M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2018 SP - 173-180 ST - Comparing Treatment of Acute Retinal Necrosis With Either Oral Valacyclovir or Intravenous Acyclovir T2 - American Journal of Ophthalmology TI - Comparing Treatment of Acute Retinal Necrosis With Either Oral Valacyclovir or Intravenous Acyclovir UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042634259&doi=10.1016%2fj.ajo.2018.02.001&partnerID=40&md5=b411148454262e7bc9bc5b5a17eb7e82 VL - 188 ID - 5177 ER - TY - JOUR AB - PURPOSE: To evaluate the treatment compliance level of glaucoma patients and the correlation between the compliance level and a series of patient's demographic characteristics., METHODS: We conducted an observational study in which we studied 100 glaucoma patients who answered the questions we included into a questionnaire. We defined and calculated a broad compliance score and a narrow score, and we investigated the connection between the first score and age, gender, demographic location (urban versus rural), education level, current occupation and duration of disease respectively., RESULTS: The mean of the broad compliance score was 9.64 +/- 1.72, which represents 80% of the maximum value of the score, and the mean of the narrow compliance score was 4.73 +/- 1.12, (78% of the maximum value). The correlation coefficient between score and age was z = -0.09 (p value = 0.19), the Z value for the evaluation of the connection between score and gender was -1.16 (p value = 0.24), and for the connection between compliance score and demographic location Z value = -2.42 (p value = 0.01). Chi-square value for the evaluation of the relation between the score and education level was 14.66 (p value = 0.001), and for the current occupation Chi-square value = 3.47 (p value = 0.06). The correlation coefficient between score and disease duration was tau = 0.09 (p value = 0.23)., DISCUSSIONS: According to the answers the patients gave, we identified the parameters that require more attention in the ophthalmologist - glaucoma patient communication: genetic transmission of glaucoma, treatment's side effects, number of visits to the ophthalmologist, awareness of the life-long gradului period of treatment., CONCLUSIONS: In this study, the compliance level of glaucoma patients is relatively high and we observe a correlation between the compliance level and demographic location, and between the compliance level and patient's education level respectively. AU - Banc, Ana AU - Stan, Cristina IS - 2 KW - Adult Aged Aged, 80 and over Cross-Sectional Studies Educational Status Female *Glaucoma/dt [Drug Therapy] *Health Knowledge, Attitudes, Practice Humans Male *Medication Adherence Middle Aged Risk Factors Surveys and Questionnaires PY - 2013 SE - Banc, Ana. Clinica de Oftalmologie Cluj-Napoca. Stan, Cristina. Clinica de Oftalmologie Cluj-Napoca. SN - 1220-0875 SP - 51-9 ST - [Compliance of treatment in glaucoma patients] T2 - Complianta la tratament a pacientilor cu glaucom. TI - [Compliance of treatment in glaucoma patients] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=24386793 VL - 57 ID - 927 ER - TY - JOUR AB - To evaluate the treatment compliance level of glaucoma patients and the correlation between the compliance level and a series of patient's demographic characteristics. We conducted an observational study in which we studied 100 glaucoma patients who answered the questions we included into a questionnaire. We defined and calculated a broad compliance score and a narrow score, and we investigated the connection between the first score and age, gender, demographic location (urban versus rural), education level, current occupation and duration of disease respectively. The mean of the broad compliance score was 9.64 +/- 1.72, which represents 80% of the maximum value of the score, and the mean of the narrow compliance score was 4.73 +/- 1.12, (78% of the maximum value). The correlation coefficient between score and age was z = -0.09 (p value = 0.19), the Z value for the evaluation of the connection between score and gender was -1.16 (p value = 0.24), and for the connection between compliance score and demographic location Z value = -2.42 (p value = 0.01). Chi-square value for the evaluation of the relation between the score and education level was 14.66 (p value = 0.001), and for the current occupation Chi-square value = 3.47 (p value = 0.06). The correlation coefficient between score and disease duration was tau = 0.09 (p value = 0.23). According to the answers the patients gave, we identified the parameters that require more attention in the ophthalmologist - glaucoma patient communication: genetic transmission of glaucoma, treatment's side effects, number of visits to the ophthalmologist, awareness of the life-long gradului period of treatment. In this study, the compliance level of glaucoma patients is relatively high and we observe a correlation between the compliance level and demographic location, and between the compliance level and patient's education level respectively. AD - Clinica de Oftalmologie Cluj-Napoca AU - Banc, A. AU - Stan, C. DB - Scopus IS - 2 M3 - Article N1 - Export Date: 19 July 2021 PY - 2013 SP - 51-59 ST - Complianţa la tratament a pacienţilor cu glaucom. T2 - Oftalmologia (Bucharest, Romania : 1990) TI - [Compliance of treatment in glaucoma patients] UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897019751&partnerID=40&md5=61e603cfa1142638e941318df72a8e64 VL - 57 ID - 5755 ER - TY - JOUR AB - AIM: This study was undertaken to compare the measurement of intraocular pressure (IOP) in a population-based glaucoma survey by the Goldmann Applanation Tonometer (GAT) and the Tonopen with respect to IOP readings, the time required to measure IOP and subjects' preference for the two instruments. The purpose of the study was to see which of the two instruments could be more suitable in a rural survey, particularly house-to-house, in trying to find cases of advanced glaucoma., METHOD: The study was conducted on a total of 203 subjects as a part of a population-based glaucoma survey. The IOP of one randomly selected eye of each subject was measured, first with the GAT and subsequently with the Tonopen. The time taken for each procedure was noted and subjects' preference was ascertained., RESULTS: The mean of the paired differences between the readings of the two instruments (Tonopen minus GAT) was 1 mm Hg with a standard deviation of 2.28. The Tonopen readings were within +/-3 mm Hg of the GAT readings in 86.2% of eyes. In 7.4% of the eyes the paired differences were > or =+/-5 mm Hg. Measurement of IOP by the Tonopen was much quicker, the mean time difference being 38.7 sec. Subjects' preference for the Tonopen was higher., CONCLUSION: The overall agreement between the measurements of the two instruments was good but a small percentage of large difference (> or = +/-5 mm Hg in 7.4%) may be of concern in a population-based survey. The time to measure IOP and the subjects' preference were strongly in favour of the Tonopen. AU - Bandyopadhyay, Manas AU - Raychaudhuri, Amitabha AU - Lahiri, Saibendu K. AU - Schwartz, Ellen C. AU - Myatt, Mark AU - Johnson, Gordon J. IS - 3 KW - Aged Aged, 80 and over Female *Glaucoma/di [Diagnosis] *Glaucoma/ep [Epidemiology] Humans India/ep [Epidemiology] *Intraocular Pressure Male Middle Aged Patient Satisfaction Random Allocation Reproducibility of Results *Rural Population/sn [Statistics & Numerical Data] Time Factors Tonometry, Ocular/is [Instrumentation] *Tonometry, Ocular/mt [Methods] PY - 2002 SE - Bandyopadhyay, Manas. Regional Institute of Ophthalmology, Medical College, Calcutta, India. manasban@hotmail.com SN - 0928-6586 SP - 215-24 ST - Comparison of Goldmann applanation tonometry with the Tonopen for measuring intraocular pressure in a population-based glaucoma survey in rural West Bengal T2 - Ophthalmic epidemiology TI - Comparison of Goldmann applanation tonometry with the Tonopen for measuring intraocular pressure in a population-based glaucoma survey in rural West Bengal UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=12045888 VL - 9 ID - 1889 ER - TY - JOUR AB - Essential iris atrophy is a rare disease of abnormal proliferative corneal endothelium which usually presents with iris atrophy, corectopia, pseudopolycoria, corneal oedema and glaucoma. The disease occurs typically in one eye of a young to middle aged woman. The unusual feature in this case was that, the patient was a 36-year-old male presenting with iris atrophy, corneal oedema and uniocular glaucoma. AU - Bandyopadhyay, Sabyasachi AU - Biswas, Gautam AU - Biswas, Jaya AU - Das, Debabrata IS - 9 KW - Acetazolamide/tu [Therapeutic Use] Adult Brimonidine Tartrate Humans *Iridocorneal Endothelial Syndrome/dt [Drug Therapy] Iridocorneal Endothelial Syndrome/pa [Pathology] *Iridocorneal Endothelial Syndrome/pp [Physiopathology] Male Quinoxalines/tu [Therapeutic Use] Timolol/tu [Therapeutic Use] Treatment Refusal Visual Acuity PY - 2010 SE - Bandyopadhyay, Sabyasachi. Department of Ophthalmology, RG Kar Medical College and Hospital, Kolkata 700004. SN - 0019-5847 SP - 609-10 ST - A case of essential iris atrophy in a male patient T2 - Journal of the Indian Medical Association TI - A case of essential iris atrophy in a male patient UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21510538 VL - 108 ID - 1315 ER - TY - JOUR AB - Background: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Abiraterone (CORAL) trial was designed to evaluate the clinical activity of abiraterone in EOC. Patients & Methods: CORAL was a multi-centre, open-label, non-randomised, 2-stage phase II clinical trial. Eligible patients had progression within 12 months of last systemic therapy and no prior hormonal anti-cancer agents. Patients received abiraterone 1000 mg daily plus 5 mg prednisone until progression. The primary endpoint was objective response rate (ORR) according to combined Response Evaluation Criteria in Solid Tumours/Gynaecological Cancer Intergroup (RECIST/GCIG) criteria at 12 weeks. Secondary endpoints included clinical benefit rate (CBR) at 12 weeks. Results: A total of 42 patients were recruited; median age 65 (range 34–85) years; 37 (88.1%) had high-grade serous tumours; 20 (48%) had at least three prior lines of therapy; 29/40 (72.5%) were AR+. In stage 1, 1/26 response was observed (in an AR+, low-grade serous EOC); response lasted 47 weeks. Overall, 12 week ORR was 1/42 (2%), CBR was 11/42 (26%) (8/29 (28%) in AR+ patients). Disease control was ⩾6 months for 4/29 (14%). One patient (AR+, low-grade serous) had a RECIST response at 82 weeks. Four (10%) had grade ⩾3 hypokalaemia; 11 (26%) had dose delays. Conclusions: CORAL represents the first trial of an AR targeted agent in ovarian cancer. While responses were rare, a subset of patients achieved sustained clinical benefit. Targeting AR in EOC including low-grade serous cancer warrants further investigation. Trial registration: CORAL is registered on the ISRCTN registry: ISRCTN63407050; http://www.isrctn.com/ISRCTN63407050. AD - S. Banerjee, Gynaecology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, United Kingdom AU - Banerjee, S. AU - Tovey, H. AU - Bowen, R. AU - Folkerd, E. AU - Kilburn, L. AU - McLachlan, J. AU - Hall, M. AU - Tunariu, N. AU - Attygalle, A. AU - Lima, J. P. D. S. N. AU - Perry, S. AU - Chatfield, P. AU - Hills, M. AU - Kaye, S. AU - Attard, G. AU - Dowsett, M. AU - Bliss, J. M. DB - Embase DO - 10.1177/1758835920975352 KW - ISRCTN63407050 abiraterone androstenedione doxorubicin estradiol prasterone sulfate prednisolone prednisone testosterone abdominal discomfort abdominal pain adult aged anemia article atrial fibrillation backache cancer recurrence clinical article computer assisted tomography constipation controlled clinical trial controlled study coughing decreased appetite diarrhea drug withdrawal dyspepsia dyspnea fatigue female glaucoma headache hematuria histology hot flush human hypertension hypertransaminasemia hypokalemia lower respiratory tract infection middle aged muscle spasm muscle weakness nausea nuclear magnetic resonance imaging ovary carcinoma overall survival patient compliance peripheral edema peripheral neuropathy phase 2 clinical trial progression free survival prospective study rash tachycardia treatment duration treatment response urinary tract infection very elderly vomiting LA - English M3 - Article N1 - L2007695774 2021-01-04 2021-01-21 PY - 2020 SN - 1758-8359 1758-8340 ST - Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037) T2 - Therapeutic Advances in Medical Oncology TI - Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2007695774&from=export http://dx.doi.org/10.1177/1758835920975352 VL - 12 ID - 2457 ER - TY - JOUR AB - BACKGROUND/AIMS: Although optometrists have become an accepted part of the team in many hospital glaucoma clinics, their decision making ability has not been assessed formally. This study aims to document the accuracy and safety of clinical work undertaken by optometrists in the hospital setting by investigating their management decisions on follow up of patients with glaucoma., METHODS: Four optometrists and three medical clinicians examined 50 patients each. Clinical findings were recorded as usual in the hospital records but management decisions were documented separately on a specially designed data collection form. Subsequently, the patient records and clinical findings were reviewed retrospectively and independently by two consultant ophthalmologists, who were masked to the management decisions of the optometrists and medical clinicians. The consultants' management decisions were then compared with those made by the optometrists and medical clinicians. Percentage agreements were computed together with kappa (kappa), or weighted kappa, statistics where appropriate., RESULTS: Agreement between consultants and optometrists was 55% (kappa = 0.33) for evaluation of visual field status, 79% (kappa = 0.67) for medical management, 72-98% for other aspects of patient management, and 78% (weighted kappa = 0.35) for scheduling of next clinic appointment. Very similar levels of agreement were found between consultants and medical clinicians., CONCLUSION: Agreement between optometrists and consultants, in glaucoma clinical decision making, was at least as good as that between medical clinicians and consultants. Within an appropriate environment, optometrists can safely work as part of the hospital glaucoma team in outpatient clinics. AU - Banes, M. J. AU - Culham, L. E. AU - Bunce, C. AU - Xing, W. AU - Viswanathan, A. AU - Garway-Heath, D. IS - 5 KW - Appointments and Schedules Clinical Competence Glaucoma/di [Diagnosis] Glaucoma/pa [Pathology] *Glaucoma/th [Therapy] Humans Interprofessional Relations *Ophthalmology Optic Disk/pa [Pathology] *Optometry Outpatient Clinics, Hospital Physical Examination/mt [Methods] *Physician's Role Sensitivity and Specificity Visual Fields PY - 2006 SE - Banes, M J. Moorfields Eye Hospital, London, UK. banes@clara.co.uk SN - 0007-1161 SP - 579-85 ST - Agreement between optometrists and ophthalmologists on clinical management decisions for patients with glaucoma T2 - The British journal of ophthalmology TI - Agreement between optometrists and ophthalmologists on clinical management decisions for patients with glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16622087 VL - 90 ID - 1669 ER - TY - JOUR AB - PURPOSE: To report the magnitude and causes of unilateral absolute blindness (no light perception) and barriers faced by persons with unilateral blindness in the South Batinah region of Oman., METHODS: Between January and June 2002, 12,000 patients were evaluated for visual acuity, ocular pressure, anterior ocular biomicroscopic examination, and posterior segment indirect ophthalmoscopy examination by ophthalmologists at Al Rustaq hospital in Oman. Patients having no perception of light in at least one eye were included in the cohort. A closed-ended questionnaire was used to collect data on the personal profile, history of blindness, barriers perceived as the cause of blindness, and participants' attitude towards eye care and quality of life following visual disability., RESULTS: In the 12,000 patients studied, absolute unilateral blindness (no perception of light) was present in 122 persons, a rate of 1.0% in our series. The onset of blindness was gradual in 78 (63.9%) persons and 64 (54.9%) persons had unilateral blindness for more than 10 years. The main causes of blindness e phthisis/absent/disorganized blind eye, which was present in 64 (52.5%) persons; glaucoma, seen in 49 (40.2%) participants; and corneal opacity, seen in 8 (6.5%) persons. Eighty 4.8%) persons had <3/60 vision in the fellow eye. Thirty (24.6%) persons had cataract and 19 (15.6%) persons glaucoma in the fellow eye. Forty-eight (39.3%) persons had undergone cataract surgeries while 2 (1.6%) persons were operated for glaucoma in the fellow eye. Lack of access to ophthalmic services and use of traditional medicines during the onset of blindness were reported by nearly half of the cohort. The attitude towards blindness was negative in two thirds of subjects., CONCLUSIONS: Cataract and glaucoma were important determinants of visual impairment in the fellow eyes of this cohort. These patients are at higher risk of developing bilateral impairment and need special care to prevent/treat visual disabilities in the fellow eyes. Using appropriate services, one can attempt attitudinal changes, rehabilitate them, and create a positive attitude towards life. AU - Bansal, R. K. AU - Khandekar, R. AU - Nagendra, P. AU - Kurup, P. IS - 3 KW - Adolescent Adult Attitude to Health *Blindness/ep [Epidemiology] Blindness/et [Etiology] Eye Diseases/co [Complications] Female Hospitals, Special Humans Intraocular Pressure Male Middle Aged Oman/ep [Epidemiology] Ophthalmology Ophthalmoscopy Prevalence Visual Acuity *Visually Impaired Persons/sn [Statistics & Numerical Data] PY - 2007 SE - Bansal, R K. Ophthalmology Department, Rustaq Hospital, Ministry of Health, Rustaq, Oman. SN - 1120-6721 SP - 418-23 ST - Magnitude and causes of unilateral absolute blindness in a region of Oman: a hospital-based study T2 - European journal of ophthalmology TI - Magnitude and causes of unilateral absolute blindness in a region of Oman: a hospital-based study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17534827 VL - 17 ID - 1604 ER - TY - JOUR AB - Purpose To evaluate use of medical, laser, or incisional surgical interventions for glaucoma after laser peripheral iridotomy (LPI). Design Retrospective longitudinal cohort study. Methods All enrollees aged ≥21 years in a US managed-care network who underwent bilateral LPIs in 2001-2011 were identified. The mean numbers of pre- and post-LPI glaucoma medication classes prescribed and the proportion of enrollees requiring cataract or glaucoma surgery within 2 years after the LPIs were determined. Multivariable logistic regression assessed factors associated with enrollees' prescription of ≥1 glaucoma medication class after bilateral LPIs. Results Of the 1660 patients undergoing bilateral LPIs, 1280 (77.1%) had no pre- or post-LPI prescriptions for any glaucoma medication class. Of the remaining patients, 251 (66.1%) required more glaucoma medication classes after than before the procedures, whereas 44 (11.6%) used fewer after the procedures; 85 (22.4%) were prescribed the same number before and after the LPIs. A total of 167 patients (10.1%) underwent cataract surgery and 79 (4.8%) received glaucoma surgery over the 2-year follow-up. Black patients had a 130% increased odds for glaucoma medication-class prescriptions after bilateral LPIs, compared with white patients (P =.02). The odds of post-LPI glaucoma medication use increased by 21% for every additional 5 years of age (P <.0001). Conclusion Most patients undergoing bilateral LPIs received no pre- or post-LPI glaucoma medication-class prescriptions and had no cataract or additional glaucoma surgery within 2 years after LPIs. Clinicians should alert black or older patients and those already taking glaucoma medications before the procedure of their higher odds of requiring medications afterward. AD - J.D. Stein, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Center for Eye Policy and Innovation, W.K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI, United States AU - Bansal, S. AU - Balakrishnan, S. A. AU - Blachley, T. AU - Weizer, J. S. AU - Lee, P. P. AU - Stein, J. D. C1 - alphagan alphagan p azopt betagan betimol betoptic betoptic s combigan cosopt diamox diamox sequels epifrin iopidine isopto carbachol isopto carpine istalol lumigan neptazane ocupress ocusert pilo 20 ocusert pilo 40 optipranolol phospholine iodide pilocar pilopine hs piloptic 1 piloptic 2 piloptic 4 piloptic 6 propine rescula timoptic timoptic xe travatan travatan z trusopt xalatan DB - Embase Medline DO - 10.1016/j.ajo.2015.04.031 IS - 2 KW - acetazolamide adrenergic receptor stimulating agent alpha adrenergic receptor stimulating agent antiglaucoma agent apraclonidine beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brimonidine plus timolol brinzolamide carbachol carbonate dehydratase inhibitor carteolol dipivefrine dorzolamide dorzolamide plus timolol ecothiopate iodide latanoprost levobunolol methazolamide metipranolol miotic agent pilocarpine propranolol prostaglandin derivative timolol timolol maleate travoprost unoprostone isopropyl ester adult article Black person cataract cataract extraction Caucasian cohort analysis female follow up glaucoma glaucoma surgery health care utilization human iridotomy laser peripheral iridotomy laser surgery longitudinal study major clinical study male postoperative care preoperative treatment prescription priority journal retrospective study alphagan alphagan p azopt betagan betimol betoptic betoptic s combigan cosopt diamox diamox sequels epifrin iopidine isopto carbachol isopto carpine istalol lumigan neptazane ocupress ocusert pilo 20 ocusert pilo 40 optipranolol phospholine iodide pilocar pilopine hs piloptic 1 piloptic 2 piloptic 4 piloptic 6 propine rescula timoptic timoptic xe travatan travatan z trusopt xalatan LA - English M3 - Article N1 - L604512814 2015-06-01 2015-07-30 PY - 2015 SN - 1879-1891 0002-9394 SP - 275-282.e4 ST - Subsequent Receipt of Interventions for Glaucoma among a Nationwide Sample of Patients Who Underwent Laser Peripheral Iridotomy T2 - American Journal of Ophthalmology TI - Subsequent Receipt of Interventions for Glaucoma among a Nationwide Sample of Patients Who Underwent Laser Peripheral Iridotomy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604512814&from=export http://dx.doi.org/10.1016/j.ajo.2015.04.031 VL - 160 ID - 2847 ER - TY - JOUR AD - A.P. Baptist, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106, United States AU - Baptist, A. P. AU - Hamad, A. AU - Patel, M. R. DB - Embase Medline DO - 10.1016/j.anai.2014.05.013 IS - 2 KW - acetylsalicylic acid antiasthmatic agent antiinflammatory agent beta adrenergic receptor blocking agent beta adrenergic receptor stimulating agent corticosteroid estrogen progesterone adrenal cortex insufficiency aged asthma bone density caregiver cataract comorbidity corticosteroid induced osteoporosis depression disease exacerbation dyspnea elderly care eosinophilia female fracture Geriatric Depression Scale glaucoma health care access health care cost health care utilization health insurance heart arrhythmia hormone substitution human income lung function test medicaid medical assessment medical decision making menopause nausea obesity onset age patient attitude patient referral phenotype poverty priority journal respiratory flowmeter review risk benefit analysis self care self monitoring side effect tremor LA - English M3 - Review N1 - L373641974 2014-08-07 2014-08-11 PY - 2014 SN - 1534-4436 1081-1206 SP - 125-130 ST - Special challenges in treatment and self-management of older women with asthma T2 - Annals of Allergy, Asthma and Immunology TI - Special challenges in treatment and self-management of older women with asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373641974&from=export http://dx.doi.org/10.1016/j.anai.2014.05.013 VL - 113 ID - 2915 ER - TY - JOUR AB - Excessive bodyweight gain was reported during the 1950s as an adverse effect of typical antipsychotic drug treatment, but the magnitude of bodyweight gain was found to be higher with the atypical antipsychotic drugs that were introduced after 1990. Clozapine and olanzapine produce the greatest bodyweight gain, ziprasidone and aripiprazole have a neutral influence, and quetiapine and risperidone cause an intermediate effect. In the CATIE study, the percentage of patients with bodyweight gain of >7% compared with baseline differed significantly between the antipsychotic drugs, i.e. 30%, 16%, 14%, 12% and 7% for olanzapine, quetiapine, risperidone, perphenazine (a typical antipsychotic) and ziprasidone, respectively (p < 0.001). Appetite stimulation is probably a key cause of bodyweight gain, but genetic polymorphisms modify the bodyweight response during treatment with atypical antipsychotics. In addition to nutritional advice, programmed physical activity, cognitive-behavioural training and atypical antipsychotic switching, pharmacological adjunctive treatments have been assessed to counteract excessive bodyweight gain. In some clinical trials, nizatidine, amantadine, reboxetine, topiramate, sibutramine and metformin proved effective in preventing or reversing atypical antipsychotic-induced bodyweight gain; however, the results are inconclusive since few randomized, placebo-controlled clinical trials have been conducted. Indeed, most studies were short-term trials without adequate statistical power and, in the case of metformin, nizatidine and sibutramine, the results are contradictory. The tolerability profile of these agents is adequate. More studies are needed before formal recommendations on the use of these drugs can be made. Meanwhile, clinicians are advised to use any of these adjunctive treatments according to their individual pharmacological and tolerability profiles, and the patient's personal and family history of bodyweight gain and metabolic dysfunction. © 2008 Adis Data Information BV. All rights reserved. AD - T. Baptista, Department of Physiology, Los Andes University Medical School, PO Box 93, Mérida 5101-A, Venezuela AU - Baptista, T. AU - ElFakih, Y. AU - Uzcátegui, E. AU - Sandia, I. AU - Tálamo, E. AU - Araujo De Baptista, E. AU - Beaulieu, S. DB - Embase Medline DO - 10.2165/00023210-200822060-00003 IS - 6 KW - amantadine amisulpride aripiprazole atypical antipsychotic agent betahistine chlorpromazine clozapine famotidine fluoxetine fluphenazine fluvoxamine haloperidol mesoridazine metformin molindone nizatidine olanzapine perphenazine quetiapine ranitidine reboxetine risperidone sertindole sibutramine tetrahydrolipstatin thioridazine topiramate unindexed drug ziprasidone zotepine abdominal discomfort agitation anorgasmia anxiety disorder appetite arthralgia blurred vision clinical trial closed angle glaucoma cognitive therapy constipation defecation diarrhea dizziness drug efficacy drug tolerability drug withdrawal dysmenorrhea dysphoria dyspnea edema ejaculation disorder family history fatigue feces incontinence flatulence gastrointestinal hemorrhage gastrointestinal pain gastrointestinal symptom genetic polymorphism headache heart arrhythmia heart rate hematuria hot flush human hypertension hypotension insomnia jaundice lactic acidosis leukopenia livedo reticularis liver toxicity loose feces memory disorder mental concentration mental disease metabolic acidosis metabolic disorder mood change myalgia myopia nausea nephrolithiasis nutrition obesity paresthesia patient compliance physical activity priority journal psychomotor disorder pulmonary hypertension rash review schizophrenia sedation seizure serotonin syndrome sexual dysfunction side effect sleep disorder somnolence suicidal ideation taste taste disorder thorax pain thrombocytopenia treatment indication treatment outcome treatment response urinary hesitancy urine retention body weight gain xerostomia LA - English M3 - Review N1 - L351693690 2008-06-16 PY - 2008 SN - 1172-7047 SP - 477-495 ST - Pharmacological management of atypical antipsychotic-induced weight gain T2 - CNS Drugs TI - Pharmacological management of atypical antipsychotic-induced weight gain UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351693690&from=export http://dx.doi.org/10.2165/00023210-200822060-00003 VL - 22 ID - 3444 ER - TY - JOUR AB - Glaucoma is a chronic neurodegenerative optic nerve disease. Treatment is intended to prevent the development and progression of optic nerve damage by lowering intraocular pressure (IOP). Current therapy options include topical/systemic drugs that increase aqueous humor outflow or decrease its production, laser therapy that targets the trabecular meshwork and ciliary body, and incisional surgery. Trabeculectomy as well as glaucoma drainage devices are often performed, given their high efficacy in lowering IOP. However, the significant risk profile with potential sight-threatening complications has motivated glaucoma experts to create alternative surgeries to treat glaucoma. Minimally invasive glaucoma surgery (MIGS) is defined by: micro-invasive approach, minimal tissue trauma, high safety profile, and rapid recovery. The new devices might promote an earlier transition from medical/laser therapy to surgery, and therefore decrease the side effects associated with long-term use of topical medications as well as deal with the limited adherence of patients to their regimens. This review presents the surgical options available for glaucoma patients and their evolution over the past 25 years. AU - Bar-David, Laura AU - Blumenthal, Eytan Z. DO - https://dx.doi.org/10.5041/RMMJ.10345 IS - 3 PY - 2018 SE - Bar-David, Laura. Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel. Blumenthal, Eytan Z. Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel. Blumenthal, Eytan Z. The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. SN - 2076-9172 ST - Evolution of Glaucoma Surgery in the Last 25 Years T2 - Rambam Maimonides medical journal TI - Evolution of Glaucoma Surgery in the Last 25 Years UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=30089089 VL - 9 Y2 - 20180730// ID - 599 ER - TY - JOUR AB - PURPOSE: The purpose of this study was to describe the management of a keratoplasty lenticule adhering to the retina after intraoperative dislocation., METHODS: We describe the posterior dislocation of the donor lenticule during endothelial keratoplasty in a 72-year-old woman with a transscleraly sutured intraocular lens, previous pars plana vitrectomy, and a posteriorly positioned Ahmed glaucoma tube shunt. The lenticule was retrieved through a pars plana approach 2 weeks later, at which time it was tightly adherent to the extramacular retina. Concurrent keratoplasty was performed., RESULTS: Six months after retrieval of the dislocated lenticule with repeat keratoplasty, the retinal examination is stable and the new graft remains attached., CONCLUSION: An iris defect, the absence of capsular support, and a history of previous vitrectomy are all potential risk factors for the intraoperative migration of a keratoplasty lenticule. The surgical view 2 weeks after dislocation was not a limiting factor in the retrieval of the lenticule. However, the tight adherence of the lenticule to the retina required extensive peeling. To avoid a more difficult surgical repair and the potential for scar formation, earlier surgical repair would be preferable, especially if dealing with a macular location. AU - Barakat, Mark R. AU - Sachdeva, Reecha AU - Sepulveda, Ricardo N. AU - Schoenfield, Lynn AU - Dupps, William J., Jr. AU - Sears, Jonathan E. DO - https://dx.doi.org/10.1097/ICB.0b013e3181d4272d IS - 2 PY - 2011 SE - Barakat, Mark R. From the *Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio; ++Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio; and Department of Transplant, Cleveland Clinic, Cleveland, Ohio. SN - 1935-1089 SP - 163-4 ST - Management of posteriorly dislocated endothelial keratoplasty donor lenticule T2 - Retinal cases & brief reports TI - Management of posteriorly dislocated endothelial keratoplasty donor lenticule UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=25389891 VL - 5 ID - 1177 ER - TY - JOUR AB - PURPOSE: To determine prevalence, primary causes, and risk indicators of visual impairment in cataract-operated eyes., DESIGN: Population-based cross-sectional study of adult Latinos., PARTICIPANTS: Two hundred sixty-one participants with cataract extraction., METHODS: Participants underwent an in-home interview and a comprehensive ophthalmologic examination. Visual impairment in the cataract-operated eye was defined by presenting visual acuity (PVA) of 20/40 or less or best-corrected visual acuity (BCVA) of 20/40 or less. The association of cataract extraction status (aphakic, pseudophakic) and severity of visual impairment was evaluated. Risk indicators associated with visual impairment by BCVA in the worse-seeing cataract-operated eye were evaluated., MAIN OUTCOME MEASURES: Visual acuity, causes of visual impairment, and risk indicators associated with visual impairment., RESULTS: Of the 261 participants with at least one cataract extraction and a complete clinical examination, 100 (38%) participants had undergone a unilateral extraction and 161 (62%) had undergone bilateral extractions. The prevalence of visual impairment was 41% (n = 107) defined by BCVA and 60.5% (n = 158) defined by PVA in the worse-seeing cataract-operated eye, and 32.2% (n = 136) defined by BCVA versus 48.1% (n = 203) defined by PVA in all cataract-operated eyes. Uncorrected refractive error, age-related macular degeneration, and diabetic retinopathy were the primary causes of visual impairment, accounting for 49% in worse-seeing cataract-operated eyes and 57% in all cataract-operated eyes. Self-reported history of glaucoma, barriers to eye care, and unmarried participants were independent risk indicators associated with visual impairment (P<0.05)., CONCLUSIONS: Despite cataract surgery, a significant proportion of participants had residual visual impairment. Refractive correction eliminated visual impairment in 15% to 20% of the participants, demonstrating the need for regular ophthalmologic examinations in cataract-operated patients. AU - Baranano, Anne E. AU - Wu, Joanne AU - Mazhar, Kashif AU - Azen, Stanley P. AU - Varma, Rohit AU - Los Angeles Latino Eye Study, Group IS - 5 KW - Activities of Daily Living Adult Aphakia, Postcataract/eh [Ethnology] *Cataract Extraction Cross-Sectional Studies Female Health Surveys *Hispanic Americans/eh [Ethnology] Humans Los Angeles/ep [Epidemiology] Male Outcome and Process Assessment, Health Care Prevalence Pseudophakia/eh [Ethnology] Risk Factors Sickness Impact Profile Surveys and Questionnaires *Vision Disorders/eh [Ethnology] Vision Disorders/et [Etiology] *Visual Acuity/ph [Physiology] *Visually Impaired Persons/sn [Statistics & Numerical Data] PY - 2008 SE - Baranano, Anne E. Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. SN - 1549-4713 0161-6420 SP - 815-21 ST - Visual acuity outcomes after cataract extraction in adult latinos. The Los Angeles Latino Eye Study T2 - Ophthalmology TI - Visual acuity outcomes after cataract extraction in adult latinos. The Los Angeles Latino Eye Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=17826836 VL - 115 Y2 - 20070912// ID - 1557 ER - TY - JOUR AB - INTRODUCTION: Ocular targeted therapy has enormously been advanced by implementation of new methods of drug delivery and targeting using implantable drug delivery systems (DDSs) or devices (DDDs), stimuli-responsive advanced biomaterials, multimodal nanomedicines, cell therapy modalities and medical bioMEMs. These technologies tackle several ocular diseases such as inflammation-based diseases (e.g., scleritis, keratitis, uveitis, iritis, conjunctivitis, chorioretinitis, choroiditis, retinitis, retinochoroiditis), ocular hypertension and neuropathy, age-related macular degeneration and mucopolysaccharidosis (MPS) due to accumulation of glycosaminoglycans (GAGs). Such therapies appear to provide ultimate treatments, even though much more effective, yet biocompatible, noninvasive therapies are needed to control some disabling ocular diseases/disorders., METHODS: In the current study, we have reviewed and discussed recent advancements on ocular targeted therapies., RESULTS: On the ground that the pharmacokinetic and pharmacodynamic analyses of ophthalmic drugs need special techniques, most of ocular DDSs/devices developments have been designed to localized therapy within the eye. Application of advanced DDSs such as Subconjunctival insert/implants (e.g., latanoprost implant, Gamunex-C), episcleral implant (e.g., LX201), cationic emulsions (e.g., Cationorm TM, Vekacia TM, Cyclokat TM), intac/punctal plug DDSs (latanoprost punctal plug delivery system, L-PPDS), and intravitreal implants (I-vitaion TM, NT-501, NT- 503, MicroPump, Thethadur, IB-20089 Verisome TM, Cortiject, DE-102, Retisert TM, Iluvein TM and Ozurdex TM) have significantly improved the treatment of ocular diseases. However, most of these DDSs/devices are applied invasively and even need surgical procedures. Of these, use of de novo technologies such as advanced stimuli-responsive nanomaterials, multimodal nanosystems (NSs)/nanoconjugates (NCs), biomacromolecualr scaffolds, and bioengineered cell therapies need to be further advanced to get better compliance and higher clinical impacts., CONCLUSION: Despite mankind successful battle on ocular diseases, our challenge will continue to battle the ocular disease that happen with aging. Yet, we need to understand the molecular aspects of eye diseases in a holistic way and develop ultimate treatment protocols preferably as non-invasive systems. AU - Barar, Jaleh AU - Aghanejad, Ayuob AU - Fathi, Marziyeh AU - Omidi, Yadollah DO - https://dx.doi.org/10.15171/bi.2016.07 IS - 1 PY - 2016 SE - Barar, Jaleh. Research Centre for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Aghanejad, Ayuob. Research Centre for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Fathi, Marziyeh. Research Centre for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Omidi, Yadollah. Research Centre for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. SN - 2228-5652 SP - 49-67 ST - Advanced drug delivery and targeting technologies for the ocular diseases T2 - BioImpacts : BI TI - Advanced drug delivery and targeting technologies for the ocular diseases UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=27340624 VL - 6 Y2 - 20160330// ID - 1040 ER - TY - JOUR AB - Background: Ocular drug delivery is an extremely challenging area due to its restrictive barrier functionalities. Objective: Drug transport via corneal/non-corneal routes involves several intricate biological processes such as drug penetration across the ocular barriers and transfer to the anterior or posterior chambers, thus the influence of these processes on the pharmacotherapy of the eye should be fully addressed. Methods: To pursue the impacts of such impediments in novel drug therapy, recent publications were reviewed regarding advanced strategies such as nanomedicines. Conclusion: The ocular barriers are highly specialized and selectively control the inward/outward traverse of compounds, hence a better understanding of these biological obstacles would provide a platform to advance ophthalmic drug therapy towards specified delivery/targeting with minimal adverse consequences. © 2008 Informa UK Ltd. AD - Y. Omidi, Tabriz University of Medical Sciences, Research Centre for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz, Iran AU - Barar, J. AU - Javadzadeh, A. R. AU - Omidi, Y. C1 - avastin lucentis macugen ocusert piloplex retisert timoptol visudyne vitrasert DB - Embase Medline DO - 10.1517/17425247.5.5.567 IS - 5 KW - acetazolamide adenovirus vector agents acting on the eye albumin bevacizumab chitosan clathrin eudragit eye drops fluocinolone acetonide foscarnet sodium ganciclovir gentamicin ABC transporter subfamily B lentivirus vector liposome macrogol methylprednisolone acetate mifepristone nucleic acid pegaptanib pilocarpine piloplex piroxicam polyglactin polylactic acid prostaglandin F2 alpha ranibizumab timolol maleate unindexed drug verteporfin aqueous humor flow astigmatism blood eye barrier blood retina barrier cataract cell membrane transport ciliary body clinical trial conjunctiva epithelium cornea endothelium cornea epithelium drug absorption drug activity drug bioavailability drug delivery system drug implantation drug penetration drug targeting drug transport endocytosis endophthalmitis eye disease gene therapy glaucoma human intraocular pressure abnormality lacrimal fluid liposomal gene delivery system long term care nanomedicine nonhuman nonviral gene therapy patient compliance permeability barrier photodynamic therapy retina degeneration macular degeneration retinitis review subretinal neovascularization sustained drug release tear film uveitis viral gene delivery system vitreous body vitreous hemorrhage avastin lucentis macugen ocusert retisert timoptol visudyne vitrasert LA - English M3 - Review N1 - L351877434 2008-07-04 PY - 2008 SN - 1742-5247 SP - 567-581 ST - Ocular novel drug delivery: Impacts of membranes and barriers T2 - Expert Opinion on Drug Delivery TI - Ocular novel drug delivery: Impacts of membranes and barriers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351877434&from=export http://dx.doi.org/10.1517/17425247.5.5.567 VL - 5 ID - 3456 ER - TY - JOUR AD - K.H. Baratz, Department of Ophthalmology, Mayo Clinic, 200 First St NW, Rochester, MN 55902, United States AU - Baratz, K. H. DB - Embase Medline DO - 10.1001/archophthalmol.2011.379 IS - 1 KW - aciclovir corticosteroid famciclovir placebo trifluridine valaciclovir virus DNA add on therapy antiviral resistance antiviral therapy clinical decision making cornea neovascularization cost effectiveness analysis disease duration disease free interval disease severity dose response drug cost drug efficacy drug megadose drug potency editorial health care cost herpes simplex keratitis herpes zoster ophthalmicus human immunocompetence keratopathy patient compliance priority journal prophylaxis recurrent disease retrospective study treatment duration uveitis virus strain visual impairment LA - English M3 - Editorial N1 - L364061552 2012-01-17 2012-01-19 PY - 2012 SN - 0003-9950 1538-3601 SP - 108-110 ST - The role of antiviral therapy after the resolution of acute herpes simplex keratitis or acute herpes zoster ophthalmicus T2 - Archives of Ophthalmology TI - The role of antiviral therapy after the resolution of acute herpes simplex keratitis or acute herpes zoster ophthalmicus UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364061552&from=export http://dx.doi.org/10.1001/archophthalmol.2011.379 http://archopht.ama-assn.org/cgi/reprint/130/1/108 VL - 130 ID - 3114 ER - TY - JOUR AB - In this study, we examined the relation between spontaneously reported adverse experiences and responses given on the comparison of ophthalmic medications for tolerability (COMTOL) checklist questionnaire which queries the frequency and bother of specific side-effects known to be associated with topical ophthalmic agents used to treat ocular hypertension or open-angle glaucoma, and the impact that the side-effects have on health-related quality of life. The study was a 4-week, randomized, open-label, two-period cross-over clinical trial comparing dorzolamide and pilocarpine in 92 patients who were also receiving timolol for the treatment of ocular hypertension or open-angle glaucoma. Patients completed the COMTOL questionnaire at baseline and at the end of each period and spontaneous reports of adverse experiences (AEs) were collected throughout the study by the investigator. Since there were only 3 spontaneously reported AEs related to drug treatment while patients received dorzolamide and since COMTOL scores indicated a low level of side-effects, the analyses were limited to pilocarpine treatment periods. We discovered that during the pilocarpine treatment periods, a large percentage (94%) of the 47 patients, who failed to spontaneously report any adverse experiences, indicated on the COMTOL that they had experienced side-effects. These discrepancies between the methods of spontaneous reports and a checklist questionnaire are similar to those previously reported in the literature for other drugs. Unlike previous literature, we went beyond identifying discrepancies with the two reporting methods and we looked for possible explanations for why the discrepancies existed. We discovered that patients who spontaneously reported AEs expressed more bother from these specific side-effects on the questionnaire than patients who did not spontaneously report AEs. As well, patients who spontaneously reported AEs and discontinued drug as a result of the AEs expressed on the COMTOL the greatest bother from side-effects. This trend of increasing negative impact (as patients reported AEs and discontinued) was also observed with COMTOL global question scores on the impact of side-effects on health-related quality of life, the impact of activity limitations on quality of life, satisfaction with medication and compliance with medication. Therefore, spontaneous reporting of side-effects appears to be detecting the most clinically meaningful side-effects. AU - Barber, B. L. AU - Santanello, N. C. IS - 11 KW - Adult *Adverse Drug Reaction Reporting Systems Aged Aged, 80 and over Antihypertensive Agents/ae [Adverse Effects] Cross-Over Studies Female Glaucoma, Open-Angle/dt [Drug Therapy] Humans Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] *Ophthalmic Solutions/ae [Adverse Effects] Sulfonamides/ae [Adverse Effects] *Surveys and Questionnaires Thiophenes/ae [Adverse Effects] Timolol/ae [Adverse Effects] PY - 1995 SE - Barber, B L. Department of Health Economic Statistics, Merck Research Laboratories, West Point, PA, USA. SN - 0946-1965 SP - 598-604 ST - Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability T2 - International journal of clinical pharmacology and therapeutics TI - Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8688984 VL - 33 ID - 2054 ER - TY - JOUR AB - PURPOSE: The Comparison of Ophthalmic Medications for Tolerability (COMTOL) questionnaire was developed for use in clinical trials to compare the tolerability of topical ophthalmic medications used in the treatment of glaucoma. The questionnaire captures the frequency and bother of common side effects (i.e., ocular and other local effects, and effects on visual function) of topical therapy for lowering intraocular pressure. In addition, the questionnaire measures the extent to which these side effects and any associated limitations in routine living activities interfere with health-related quality of life, medication compliance, and patient satisfaction with the medication. This study was designed to assess the measurement characteristics of the COMTOL questionnaire., METHODS: The internal consistency, reliability, reproducibility, construct validity, discriminant validity, and responsiveness of the questionnaire were assessed in 70 adult patients with glaucoma in a clinical trial comparing timolol and pilocarpine., RESULTS: The questionnaire showed good-to-excellent internal consistency (0.73 to 0.98), reliability (0.76 to 0.94), and reproducibility (0.75 to 0.93). In general, there was a strong correlation in the expected direction between the frequency and bother of side effects and patient-perceived global measures. The questionnaire discriminated between patients receiving timolol and patients receiving pilocarpine. The questionnaire demonstrated significant responsiveness to change., CONCLUSIONS: The COMTOL questionnaire showed acceptable measurement characteristics for inclusion as a tolerability measure to supplement spontaneous adverse event reporting in clinical trials of topical ophthalmic therapy. AU - Barber, B. L. AU - Strahlman, E. R. AU - Laibovitz, R. AU - Guess, H. A. AU - Reines, S. A. IS - 2 KW - *Adrenergic beta-Antagonists/ae [Adverse Effects] Adrenergic beta-Antagonists/tu [Therapeutic Use] Adult Aged Aged, 80 and over Eye Diseases/ci [Chemically Induced] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Health Status Indicators Humans Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions *Parasympathomimetics/ae [Adverse Effects] Parasympathomimetics/tu [Therapeutic Use] *Pilocarpine/ae [Adverse Effects] Pilocarpine/tu [Therapeutic Use] Reproducibility of Results *Surveys and Questionnaires/st [Standards] *Timolol/ae [Adverse Effects] Timolol/tu [Therapeutic Use] N1 - Erratum in (EIN) PY - 1997 SE - Barber, B L. Department of Outcomes and Performance Assessment, Merck-Medco Managed Care, Montvale, New Jersey 07645-1753, USA. SN - 0161-6420 SP - 334-42 ST - Validation of a questionnaire for comparing the tolerability of ophthalmic medications T2 - Ophthalmology T3 - Erratum in: Ophthalmology 1997 May;104(5):736, 890-3 TI - Validation of a questionnaire for comparing the tolerability of ophthalmic medications UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9052642 VL - 104 ID - 2026 ER - TY - JOUR AB - Purpose: To explore the published evidence on the link between treatment satisfaction and patients' compliance, adherence, and/or persistence. Methods: Articles published from January 2005 to November 2010 assessing compliance, adherence, or persistence and treatment satisfaction were identified through literature searches in Medline, Embase, and PsycInfo. Abstracts were reviewed by two independent researchers who selected articles for inclusion. The main attributes of each study examining the link between satisfaction and adherence, compliance, or persistence were summarized. Results: The database searches yielded 1278 references. Of the 281 abstracts that met the inclusion criteria, 20 articles were retained. In the articles, adherence and compliance were often used interchangeably and various methods were used to measure these concepts. All showed a positive association between treatment satisfaction and adherence, compliance, or persistence. Sixteen studies demonstrated a statistically significant link between satisfaction and compliance or persistence. Of these, ten demonstrated a significant link between satisfaction and compliance, two showed a significant link between satisfaction and persistence, and eight demonstrated a link between either a related aspect or a component of satisfaction (eg, treatment convenience) or adherence (eg, intention to persist). An equal number of studies aimed at explaining compliance or persistence according to treatment satisfaction (n = 8) and treatment satisfaction explained by compliance or persistence (n = 8). Four studies only reported correlation coefficients, with no hypothesis about the direction of the link. The methods used to evaluate the link were varied: two studies reported the link using descriptive statistics, such as percentages, and 18 used statistical tests, such as Spearman's correlation or logistic regressions. Conclusion: This review identified few studies that evaluate the statistical association between satisfaction and adherence, compliance, or persistence. The available data suggested that greater treatment satisfaction was associated with better compliance and improved persistence, and with lower regimen complexity or treatment burden. © 2012 Dias Barbosa et al, publisher and licensee Dove Medical Press Ltd. AD - C. D. Barbosa, Mapi Consultancy, 27 rue de la Villette, Lyon 69003, France AU - Barbosa, C. D. AU - Balp, M. M. AU - Kulich, K. AU - Germain, N. AU - Rofail, D. DB - Embase DO - 10.2147/PPA.S24752 KW - article clinical practice correlational study data analysis diabetes mellitus evidence based medicine glaucoma human medical research osteoporosis patient attitude patient compliance patient satisfaction publication schizophrenia systematic review validation study L1 - internal-pdf://1374344043/3102-A literature review to explore the l-2012.pdf LA - English M3 - Article N1 - L364269149 2012-02-23 2012-03-06 PY - 2012 SN - 1177-889X SP - 39-48 ST - A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence T2 - Patient Preference and Adherence TI - A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364269149&from=export http://dx.doi.org/10.2147/PPA.S24752 VL - 6 ID - 3102 ER - TY - JOUR AB - PURPOSE: To assess the psychometric properties of a new version of the Glaucoma Treatment Compliance Assessment Tool, a survey evaluating health behavior and glaucoma adherence using constructs from the Health Belief Model., DESIGN: Psychometric analysis., METHODS: We administered the 47-statement Glaucoma Treatment Compliance Assessment Tool to 201 participants who were using a single bottle of an ocular hypotensive agent, and objectively measured adherence with medication event monitoring system devices over 60 days. Adherence was the percentage of days with correctly timed bottle openings. We used principal components analysis to determine construct validity, Cronbach's alpha for internal consistency reliability, frequency analysis for floor and ceiling effects, and Spearman rho for test-retest reliability. We determined predictive validity using univariate and multiple regression., RESULTS: The mean (+/-SD, range) adherence percentage was 79.9% (+/-18.5%, 20.3%-100.0%). Principal component analysis loaded 24 questions into 6 components that were consistent with the Health Belief Model. All 6 components had Cronbach's alpha reliability between 0.601 and 0.797. No statements had floor or ceiling effects, and all statements had acceptable test-retest reliability. Multiple regression analysis showed 4 Health Belief Model statements, white race, older age, and married marital status to be associated with higher adherence (adjusted R(2) = 0.27, P < .001)., CONCLUSIONS: The newest version of the Glaucoma Treatment Compliance Assessment Tool showed acceptable psychometric properties. With further refinement, clinicians and researchers could use it to examine factors related to adherence and measure improvement in adherence with a change in health behavior attitudes. Copyright © 2015 Elsevier Inc. All rights reserved. AU - Barker, Gordon T. AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Kahook, Malik Y. AU - Kammer, Jeffrey A. AU - Mansberger, Steven L. DO - https://dx.doi.org/10.1016/j.ajo.2015.03.006 IS - 6 KW - Aged *Antihypertensive Agents/ad [Administration & Dosage] Attitude to Health False Positive Reactions Female *Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/px [Psychology] *Health Behavior Humans Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged *Models, Psychological Models, Statistical Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/px [Psychology] Ophthalmic Solutions Patient Acceptance of Health Care Predictive Value of Tests *Psychometrics Reproducibility of Results *Surveys and Questionnaires PY - 2015 SE - Barker, Gordon T. Devers Eye Institute at Legacy Health, Portland, Oregon. Cook, Paul F. University of Colorado College of Nursing, Aurora, Colorado. Schmiege, Sarah J. University of Colorado College of Nursing, Aurora, Colorado. Kahook, Malik Y. University of Colorado School of Medicine, Aurora, Colorado. Kammer, Jeffrey A. Vanderbilt University, Nashville, Tennessee. Mansberger, Steven L. Devers Eye Institute at Legacy Health, Portland, Oregon. Electronic address: smansberger@deverseye.org. SN - 1879-1891 0002-9394 SP - 1092-1099.e2 ST - Psychometric properties of the Glaucoma Treatment Compliance Assessment Tool in a multicenter trial T2 - American journal of ophthalmology TI - Psychometric properties of the Glaucoma Treatment Compliance Assessment Tool in a multicenter trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25794793 VL - 159 Y2 - 20150317// ID - 805 ER - TY - JOUR AB - PURPOSE: To measure the psychometric properties of a reduced, 27-statement version of the Glaucoma Treatment Compliance Assessment Tool (GTCAT)., METHODS: We administered the GTCAT to 183 participants who were using a single bottle of an ocular hypotensive agent, and objectively measured adherence with Medication Event Monitoring System devices over 60 days. Adherence was the number of days with correctly timed bottle openings divided by the total number of study days. Using the 47-statement GTCAT, we created a reduced GTCAT by removing statements that: (1) did not load using Principal Components Analysis (PCA); (2) did not have a univariable association with adherence; or (3) were highly correlated (.75 or higher) with another statement. We assessed the construct validity of the remaining statements using PCA and assessed the predictive validity using multiple logistic regression analysis., RESULTS: We removed 20 statements because they did not appear in the PCA analysis; were not predictive of adherence; and/or had high correlation. PCA of the reduced GTCAT (27 statements) extracted 5 components of the Health Belief Model (knowledge, susceptibility, cues-to-action, self-efficacy, and barriers). Multiple regression showed that the 27 statements predicted adherence (Rsq = .11, p = .03)., CONCLUSIONS: The reduced version of the GTCAT is associated with adherence, which suggests that after external validation, future glaucoma medication adherence studies could use the reduced version to efficiently measure health behaviors and determine the benefit of the GTCAT to develop personalized interventions in glaucoma adherence. AU - Barker, Gordon T. AU - Mansberger, Steven L. DO - https://dx.doi.org/10.1080/09286586.2018.1516785 IS - 1 KW - Aged *Antihypertensive Agents/ad [Administration & Dosage] *Attitude to Health Female *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Glaucoma/px [Psychology] Humans *Intraocular Pressure/ph [Physiology] Male *Medication Adherence Ophthalmic Solutions/ad [Administration & Dosage] *Psychometrics/mt [Methods] *Surveys and Questionnaires PY - 2019 SE - Barker, Gordon T. a Devers Eye Institute at Legacy Health, Portland, OR, USA. Mansberger, Steven L. a Devers Eye Institute at Legacy Health, Portland, OR, USA. SN - 1744-5086 0928-6586 SP - 55-62 ST - Psychometric Properties of the Reduced Version of the Glaucoma Treatment Compliance Assessment Tool (GTCAT) T2 - Ophthalmic epidemiology TI - Psychometric Properties of the Reduced Version of the Glaucoma Treatment Compliance Assessment Tool (GTCAT) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30204034 VL - 26 Y2 - 20180911// ID - 376 ER - TY - JOUR AB - Chronic pain is among the most common conditions to initiate medical care; 40% of patients victimized by chronic pain are not under the supervision of a physician, and about 70% of patients with severe pain are receiving pain medical care. About $100 billion is an annual estimated cost representing loss of productivity, increased medical costs, and income loss. Major depressive disorder is not infrequently encountered in daily clinical practice often presenting with somatic complaints that include varieties of pain, and these may be so prominent as to direct the treatment to the somatic complaint evaluation to the exclusion of underlying psychopathology. Anxiety disorders and other psychiatric disorders may also present with such a somatization evaluation focus. Serotonin noradrenergic reuptake inhibitors (SNRIs), ie, venlafaxine and duloxetine, offer benefits over tricyclic antidepressants and serotonin reuptake inhibitors. Years of experience with venlafaxine representing a first-line pharmacotherapy for depression and anxiety have benefited patients presenting with somatic symptoms with a robust onset. A more rapid achievement by venlafaxine of remission and a high-quality pharmacokinetic and pharmacodynamic profile lead to patient compliance and facilitate both fewer relapses and recurrences. Duloxetine is broadly discussed, revealing pharmacokinetic, pharmacodynamic, adverse/side effects, cautions with requisite patient-specific selection, and laboratory monitoring. The management of somatic pain complaints of physical and psychiatric origin is discussed. © 2005 Lippincott Williams & Wilkins. AD - R.L. Barkin, Department of Anesthesiology, Rush University Medical Center, 1653 W. Congress Parkway, Chicago, IL 60012, United States AU - Barkin, R. L. AU - Barkin, S. C2 - Wyeth(United States) DB - Embase Medline DO - 10.1097/01.mjt.0000162011.58990.94 IS - 5 KW - anticonvulsive agent antidepressant agent anxiolytic agent carbamazepine celecoxib duloxetine fluoxetine fluvoxamine methadone muscle relaxant agent nonsteroid antiinflammatory agent paroxetine pethidine serotonin serotonin noradrenergic reuptake inhibitors serotonin uptake inhibitor tramadol tricyclic antidepressant agent unclassified drug valdecoxib venlafaxine anxiety disorder appetite disorder area under the curve asthenia behavior therapy chronic pain clinical practice clinical trial closed angle glaucoma constipation diaphoresis diarrhea dizziness dose response drug binding drug half life ejaculation disorder erectile dysfunction fatigue health care cost human hypertension income insomnia liver toxicity major depression medical care mental disease mydriasis nausea neuropathic pain pain assessment patient compliance patient selection physician pollakisuria priority journal productivity quality of life recurrent disease relapse review side effect somatization somnolence symptomatology urinary dysfunction vomiting withdrawal syndrome xerostomia LA - English M3 - Review N1 - L41445141 2005-12-19 PY - 2005 SN - 1075-2765 SP - 431-438 ST - The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy T2 - American Journal of Therapeutics TI - The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41445141&from=export http://dx.doi.org/10.1097/01.mjt.0000162011.58990.94 VL - 12 ID - 3669 ER - TY - JOUR AB - BACKGROUND: The first topically active carbonic anhydrase inhibitor, dorzolamide, was developed to circumvent the adverse systemic effects of oral carbonic anhydrase inhibitors. However, its use has been associated with ocular discomfort., OBJECTIVE: The present study examined the acceptability of brinzolamide, as measured by patients' ratings and stated preferences, in patients with glaucoma previously treated with dorzolamide in the clinical practice setting., METHODS: This was a prospective, open-label, noncomparative study conducted shortly after the approval of brinzolamide. Ophthalmologists in private practice in the continental United States were asked to select patients currently using dorzolamide as their sole or combination therapy for glaucoma. Patients underwent a screening assessment in which they were asked to rate their ocular comfort with dorzolamide on a scale from 1 to 6. Brinzolamide was then substituted for dorzolamide, and patients returned for a follow-up visit approximately 1 to 3 months later. At this visit, patients were asked about ocular comfort, their preferred medication, and whether they thought ocular comfort influenced their adherence to treatment. Intraocular pressure (IOP) was measured at both visits., RESULTS: Valid visit dates (ie, both baseline and follow-up dates) were available for 447 of 501 patients from 68 of 73 sites (range, 1-40 patients per site). Because not all measurements were available for all patients at each visit, the sample size varied for each measurement. Demographic data were not available. The switch to brinzolamide resulted in a mean decrease in IOP of approximately 0.8 mm Hg (P < 0.001, paired t test). Sixty-nine percent of patients (274/397) reported an improvement of > or =1 grade in their comfort rating with brinzolamide versus dorzolamide. The mean (+/- SD) improvement in comfort rating was 1.43 +/- 1.48 grades (P < 0.001, Wilcoxon rank sum test). When patients were asked whether their adherence to treatment was affected by the occurrence of burning and stinging, 43% (173/399) answered affirmatively. Fifty-nine percent (251/424) preferred brinzolamide to dorzolamide. At the end of the study, based on patient preference, physician judgment, and other factors, 73% of responding patients (301/410) continued with brinzolamide therapy., CONCLUSIONS: In this study, the switch from dorzolamide to brinzolamide resulted in overall improvements in comfort and ocular hypotensive efficacy. However, studies using a more rigorous randomized, controlled, crossover design are needed to support these observations. AU - Barnebey, H. AU - Kwok, S. Y. IS - 10 KW - Carbonic Anhydrase Inhibitors/ae [Adverse Effects] *Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] *Patient Satisfaction Prospective Studies Sulfonamides/ae [Adverse Effects] *Sulfonamides/tu [Therapeutic Use] Thiazines/ae [Adverse Effects] *Thiazines/tu [Therapeutic Use] Thiophenes/ae [Adverse Effects] *Thiophenes/tu [Therapeutic Use] PY - 2000 SE - Barnebey, H. Department of Ophthalmology, University of Washington, Seattle, USA. barnebey@u.washington.edu SN - 0149-2918 SP - 1204-12 ST - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting T2 - Clinical therapeutics TI - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11110231 VL - 22 ID - 1942 ER - TY - JOUR AB - PURPOSE: To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids., DESIGN: Randomized, controlled, observer-masked clinical trial., METHODS: setting: Two US clinical sites., PATIENT POPULATION: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension. Patients (n = 81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12 months., INTERVENTION: TTFC was administered once daily in the morning or evening with a single dosing aid. Patients randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids., MAIN OUTCOME MEASURE: Adherence with administered medication, as recorded by the dosing aids., RESULTS: Mean +/- SD patient age was 60 +/- 10 years; most patients were male and white. Compared with TRAV+TIM (n = 40), patients receiving TTFC (n = 41) were consistently adherent on a greater percentage of days through month 12 (60% vs 43%). At months 1, 3, 6, and 12, 80% adherence was achieved by 71% vs 38%, 53% vs 30%, 45% vs 16%, and 32% vs 11% of patients receiving TTFC vs TRAV+TIM, respectively. Significantly more patients were adherent on >=80% of days with TTFC compared with TRAV+TIM (P < .001 to P = .041). Both treatments reduced IOP from baseline, and no safety issues were identified in either group. Ocular hyperemia was the most common treatment-related adverse event (n = 3/group)., CONCLUSIONS: Patients receiving TTFC maintained better treatment adherence compared with patients receiving TRAV+TIM through 12 months of on-therapy evaluation. This suggests that, for patients requiring multiple IOP-lowering medications, a fixed combination may provide improved long-term adherence compared with unfixed therapy. Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved. AU - Barnebey, Howard S. AU - Robin, Alan L. DO - https://dx.doi.org/10.1016/j.ajo.2016.12.002 KW - Adrenergic beta-Antagonists/ad [Administration & Dosage] Adult Aged Aged, 80 and over Antihypertensive Agents/ad [Administration & Dosage] Dose-Response Relationship, Drug Drug Therapy, Combination Female Follow-Up Studies Humans Instillation, Drug *Intraocular Pressure/de [Drug Effects] Male Middle Aged Ocular Hypertension/di [Diagnosis] *Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/pp [Physiopathology] *Patient Compliance Single-Blind Method Time Factors *Timolol/ad [Administration & Dosage] Tonometry, Ocular *Travoprost/ad [Administration & Dosage] Treatment Outcome PY - 2017 SE - Barnebey, Howard S. Specialty Eyecare Centre, Bellevue, Washington. Electronic address: hbarnebey@specialtyeyecarecentre.com. Robin, Alan L. Department of Ophthalmology, Johns Hopkins University, Baltimore, Maryland; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; University of Maryland, Baltimore, Maryland; University of Michigan, Ann Arbor, Michigan. SN - 1879-1891 0002-9394 SP - 61-69 ST - Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial T2 - American journal of ophthalmology TI - Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=27993589 VL - 176 Y2 - 20161218// ID - 547 ER - TY - JOUR AB - PURPOSE: To examine the clinical outcomes of scleral lenses for visual rehabilitation after penetrating keratoplasty (PK)., METHODS: A retrospective review was conducted for 34 patients (48 eyes) who had a history of prior PK and were fit with scleral lenses between October 2009 and December 2013 at the UC Davis Eye Center., RESULTS: The most common initial indication for PK was keratoconus in 27 eyes (56%). Thirty-three eyes (69%) had previously been fit with other types of contact lenses, with small-diameter rigid gas-permeable lenses being the most common. The improvement in best-corrected visual acuity with a scleral lens compared with prior spectacle refraction or other contact lens was a mean of two best-corrected visual acuity lines. Forty-four eyes (91.7%) achieved functional vision with best scleral lens-corrected visual acuities of 20/40 or better. Patients who continued wearing scleral lenses were significantly more likely to report "good" subjective vision compared with patients who abandoned scleral lens wear (P=0.009), although change in objective best-corrected visual acuity did not differ significantly. There were no cases of infectious keratitis. Six eyes (12.5%) developed graft rejection; 3 were able to resume scleral lens wear. Nineteen eyes (39.5%) discontinued scleral lens wear for various reasons, the most common reason for discontinuation of lens wear was difficulty with scleral lens insertion or removal (8 eyes, 42.1%)., CONCLUSION: Scleral lenses are effective and safe in patients who have had PK. There was a mean gain in visual acuity, with the majority of patients achieving 20/40 vision or better. The patient's subjective perception of vision was a significant factor in determining whether scleral lens wear was continued or abandoned. AU - Barnett, Melissa AU - Lien, Vivian AU - Li, Jennifer Y. AU - Durbin-Johnson, Blythe AU - Mannis, Mark J. DO - https://dx.doi.org/10.1097/ICL.0000000000000163 IS - 3 KW - Adult Aged Aged, 80 and over *Contact Lenses *Corneal Diseases/su [Surgery] Female Humans *Keratoplasty, Penetrating Male Middle Aged Patient Satisfaction Prosthesis Fitting Retrospective Studies *Sclera Vision Disorders/pp [Physiopathology] *Vision Disorders/rh [Rehabilitation] Visual Acuity/ph [Physiology] PY - 2016 SE - Barnett, Melissa. UC Davis Health System Eye Center, Sacramento, CA. SN - 1542-233X 1542-2321 SP - 185-9 ST - Use of Scleral Lenses and Miniscleral Lenses After Penetrating Keratoplasty T2 - Eye & contact lens TI - Use of Scleral Lenses and Miniscleral Lenses After Penetrating Keratoplasty UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26214530 VL - 42 ID - 747 ER - TY - JOUR AB - PURPOSE: This evaluation was conducted as part of a protocol entitled Evaluation of the Menicon Z Rigid Gas Permeable Contact Lens for up to 30 Days Extended Wear. The purpose of the protocol was to compare corneal endothelial morphology changes after wearing rigid gas-permeable (RGP) Menicon Z contact lenses, continuously for up to 30 days, with ACUVUE (Johnson & Johnson Vision Care) hydrogel contact lenses, worn for up to 6 nights of extended wear., METHODS: Sixty patients, who were adapted to RGP daily wear and soft contact lens daily wear, were recruited at two study sites. The thirty subjects who wore RGP daily wear lenses were fitted with the Menicon Z (tisilfocon A, oxygen permeablility [Dk] = 163) RGP contact lens comprised the test group. The control group subjects (n = 30 former users of daily wear soft contact lenses) were fitted with ACUVUE (etafilcon A, Dk = 28) hydrogel contact lenses. After a 2-week adaptation period of daily wear, subjects began extended wear. Endothelial imaging was performed at the two study sites in this multicenter study (University Hospitals of Cleveland/Case Western Reserve University Department of Ophthalmology [CWRU] and The Ohio State University [OSU]). The hydrogel lens group was instructed to wear their lenses for 7 days and 6 nights before discarding the lenses and to sleep with no lenses on the seventh night. The RGP group was permitted to wear the lenses for up to 30 days and 29 consecutive nights before removing the lenses for cleaning and overnight soaking., RESULTS: CWRU had 24 patients (12 soft contact lens and 12 rigid contact lens) and OSU had 21 patients (12 soft contact lens and 9 rigid contact lens) who completed the study and were included in the analyses. Patients who were withdrawn from the study at CWRU included one RGP patient dropped out because of pregnancy; one RGP patient developed vascularized limbal keratitis and discomfort; one could not be fitted with a bitoric RGP; two soft lens patients moved from the area, and one dropped out because of dry eyes. At OSU, four patients dropped out due to discomfort (two in each lens type);one moved from the study area; one decided not to participate soon after the consent visit; one had worries of reduced vision at 6 months; one subject's attitude changed prior to the 6 month visit; and one subject was withdrawn for reasons of poor study schedule compliance., CONCLUSION: The Menicon Z lens wearers in this study did not show significant endothelial cell morphology changes after 1 year of nearly continuous contact lens wear. This finding is particularly important considering the RGP wearers in this study were older by a average of 10 years (mean age approximately 40) and had worn their contact lenses an average of almost 10 years longer than the soft contact lens wearers. AU - Barr, Joseph T. AU - Pall, Brian AU - Szczotka, Loretta B. AU - Mitchell, G. Lynn AU - Gleason, William IS - 1 KW - Adult Cell Count *Contact Lenses, Extended-Wear/sn [Statistics & Numerical Data] *Endothelium, Corneal/pa [Pathology] Humans Patient Satisfaction Prospective Studies Refraction, Ocular Safety Treatment Outcome Visual Acuity PY - 2003 SE - Barr, Joseph T. The Ohio State University, College of Optometry, Columbus, OH 43218-2342, USA. barr.2@osu.edu SN - 1542-2321 SP - 14-6 ST - Corneal endothelial morphology results in the Menicon Z 30-day continuous-wear contact lens clinical trial T2 - Eye & contact lens TI - Corneal endothelial morphology results in the Menicon Z 30-day continuous-wear contact lens clinical trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=12769149 VL - 29 ID - 1843 ER - TY - JOUR AB - BACKGROUND: This research was designed to provide an in-depth exploration of the perceptions of optometrists relating to the challenges of glaucoma case finding in the Irish health-care system., METHODS: A survey was developed, piloted and distributed for anonymous completion by optometrists registered to practise in Ireland. The survey included 10 five-level Likert items exploring potential barriers to glaucoma detection and a free-text box for participants to comment more broadly., RESULTS: One hundred and ninety-nine optometrists (27 per cent of registrants) responded to the survey. Among the barriers identified, there was notable agreement (71 per cent) with the need for extra training on glaucoma detection. Logistic regression showed that optometrists without postgraduate qualifications were more likely to agree with the need for extra training (OR 3.2, 95 per cent CI 1.3-8.1). Respondents largely agreed (61 per cent) that patient unwillingness to pay additional fees for supplementary glaucoma-specific tests was also a barrier. Appointment times of less than 30 minutes were significantly associated with six of the 10 proposed barriers to glaucoma detection. A logistic regression analysis (n = 179) confirmed that the time allotted per appointment was a significant predictor of the agreement time of optometrists as a barrier (chi2 [1] = 13.52, p < 0.001). Multiple linear regression showed that optometrists with less experience, charging lower fees, and working in large multiples or franchised practices have the shortest appointment times., CONCLUSION: The strong link found between postgraduate education and the confidence of optometrists in detecting glaucoma indicates that optometrists wishing to increase their scope of practice in the new legislative environment in Ireland may more actively seek training in areas of interest. The responses also indicate a lack of funding for the level of diagnostic testing required for accurate glaucoma diagnosis. Recent increases in the state's eye examination fees look likely to address the identified time and financial barriers to glaucoma detection in Ireland. Future work should look to analyse the effects of increased funding on optometric case finding for glaucoma. Copyright © 2017 Optometry Australia. AU - Barrett, Catriona AU - O'Brien, Colm AU - Butler, John S. AU - Loughman, James DO - https://dx.doi.org/10.1111/cxo.12573 IS - 1 KW - *Delivery of Health Care/og [Organization & Administration] *Diagnostic Techniques, Ophthalmological/sn [Statistics & Numerical Data] *Glaucoma/di [Diagnosis] Glaucoma/ep [Epidemiology] *Glaucoma, Open-Angle/di [Diagnosis] Glaucoma, Open-Angle/ep [Epidemiology] *Health Knowledge, Attitudes, Practice Humans Ireland/ep [Epidemiology] Morbidity/td [Trends] *Optometrists/st [Standards] *Optometry Retrospective Studies Surveys and Questionnaires Workforce PY - 2018 SE - Barrett, Catriona. School of Physics and Clinical and Optometric Sciences, Dublin Institute of Technology, Dublin, Ireland. O'Brien, Colm. Mater Misericordiae University Hospital, Dublin, Ireland. Butler, John S. School of Mathematical Sciences, Dublin Institute of Technology, Dublin, Ireland. Loughman, James. School of Physics and Clinical and Optometric Sciences, Dublin Institute of Technology, Dublin, Ireland. Loughman, James. African Vision Research Institute, University of KwaZulu Natal, Durban, South Africa. SN - 1444-0938 0816-4622 SP - 90-99 ST - Barriers to glaucoma case finding as perceived by optometrists in Ireland T2 - Clinical & experimental optometry TI - Barriers to glaucoma case finding as perceived by optometrists in Ireland UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=28718219 VL - 101 Y2 - 20170717// ID - 473 ER - TY - JOUR AB - Aims: To determine the degree of adherence to treatment for glaucoma and/or ocular hypertension and describe the medication used for glaucoma in patients at a community pharmacy. Methods: A descriptive study carried out over 4 months (January-April 2012) at a community pharmacy in Benalmádena (Málaga) with the patients who came in for their glaucoma and/or ocular hypertension medication. Those who agreed to take part in the study were given a survey which included: patient details, details of medicines and indirect methods to assess compliance (self-reporting of compliance according to Haynes-Sackett and the Morisky-Green test). Results: Thirty six patients were included. Adherence to the treatment was 66.7% self-reported compliance and 50% according to the Morisky-Green test. The most-dispensed pharmacological group was that of prostaglandin analogues at 36.1% as monotherapy and 27.8% as part of polytherapy. 27.8% of the patients used more than one medication, while 72.2% used monotherapy for glaucoma and/or ocular hypertension. No association was observed between therapeutic adherence and the clinical and demographic variables analysed. Conclusions: Adherence to treatment for glaucoma could be improved. Prostaglandin analogues are the most-prescribed medicines, followed by beta blockers. As well as assessing compliance there is a need to analyse the administration techniques for medication of these types with a view to future health education measures. © 2012 Ediciones Mayo. AD - D. Barris Blundell, Licenciado en Farmacia, Farmacéutico Comunitario, Ciudad de Melilla-Plaza Mayor, 20-21, 29630 Benalmádena (Málaga), Spain AU - Barris Blundell, D. DB - Embase IS - 5 KW - beta adrenergic receptor blocking agent prostaglandin derivative article clinical article demography glaucoma human intraocular hypertension patient compliance pharmacy (shop) self report LA - Spanish M3 - Article N1 - L365991997 2012-11-14 2012-11-19 PY - 2012 SN - 1139-6202 SP - 202-209 ST - Adherence to treatment for glaucoma in patients at a community pharmacy T2 - Pharmaceutical Care Espana TI - Adherence to treatment for glaucoma in patients at a community pharmacy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365991997&from=export http://www.pharmcareesp.com/index.php/PharmaCARE/article/view/90/84 VL - 14 ID - 3057 ER - TY - JOUR AB - PURPOSE: To evaluate the efficacy of oral acyclovir in treating stromal keratitis caused by herpes simplex virus (HSV) in patients receiving concomitant topical corticosteroids and trifluridine., METHODS: The authors performed a randomized, double-masked, placebo-controlled, multicenter trial in 104 patients with HSV stromal keratitis without accompanying HSV epithelial keratitis. Sample size was chosen so that a 5%, one-tailed test would have an 80% chance of detecting a doubling of the median time to treatment failure. Patients were randomized to receive a 10-week course of either oral acyclovir (400 mg 5 times daily, n = 51) or placebo (n = 53). All patients also received a standard regimen of topical prednisolone phosphate and trifluridine. Ophthalmologic examinations were performed weekly during the 10-week treatment period, every 2 weeks for an additional 6 weeks, and at 6 months after entry into the trial., RESULTS: The median time to treatment failure (defined as worsening or no improvement of stromal keratitis or an adverse event) was 84 days (95% confidence interval, 69-93 days) for the acyclovir group and 62 days (95% confidence interval, 57-90 days) for the placebo group. By 16 weeks, 38 patients (75%) in the acyclovir group and 39 patients (74%) in the placebo group had failed treatment. Also by that time, the keratitis had resolved with trial medications, and there was no subsequent worsening in nine patients (18%) in the acyclovir group and ten (19%) in the placebo group. None of these results were significantly different between the two groups. However, visual acuity improved over 6 months in significantly more patients in the acyclovir group than in the placebo group., CONCLUSION: There was no statistically or clinically significant beneficial effect of oral acyclovir in treating HSV stromal keratitis in patients receiving concomitant topical corticosteroids and trifluridine with regard to time to treatment failure, proportion of patients who failed treatment, proportion of patients whose keratitis resolved, time to resolution, or 6-month best-corrected visual acuity. Visual acuity improved over 6 months in more patients in the acyclovir group than in the placebo group. AU - Barron, B. A. AU - Gee, L. AU - Hauck, W. W. AU - Kurinij, N. AU - Dawson, C. R. AU - Jones, D. B. AU - Wilhelmus, K. R. AU - Kaufman, H. E. AU - Sugar, J. AU - Hyndiuk, R. A. IS - 12 KW - Acyclovir/ad [Administration & Dosage] Acyclovir/ae [Adverse Effects] *Acyclovir/tu [Therapeutic Use] Administration, Oral Administration, Topical Adolescent Adult Aged Double-Blind Method Drug Therapy, Combination Female Follow-Up Studies Humans *Keratitis, Herpetic/dt [Drug Therapy] Keratitis, Herpetic/pp [Physiopathology] Male Middle Aged Patient Compliance Prednisolone/ad [Administration & Dosage] Prednisolone/tu [Therapeutic Use] Prospective Studies Regression Analysis Treatment Outcome Trifluridine/ad [Administration & Dosage] Trifluridine/tu [Therapeutic Use] United States Visual Acuity PY - 1994 SE - Barron, B A. Francis I. Proctor Foundation, University of California, San Francisco 94143-0412. SN - 0161-6420 SP - 1871-82 ST - Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis T2 - Ophthalmology TI - Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7997323 VL - 101 ID - 2081 ER - TY - JOUR AB - Objective: To describe the characteristics, treatment patterns, health care resource utilization (HCRU), and cost of care for members of a large United States (US) health insurance plan with lupus nephritis (LN). Methods: A retrospective observational study was conducted using a health insurance plan database to identify adult members with a diagnosis of LN. Medical and pharmacy claims were used to describe demographics, comorbidities, HCRU, and cost patterns over a 12-month follow-up period for each patient, between January 1, 2014, and December 31, 2016. All study variables were examined descriptively. Results: A total of 1039 patients were available for analysis (median age, 47 years; 83% female). The median Charlson Comorbidity Index (CCI) was 3.3. Less than half (41%) of patients received immunosuppressive therapies commonly used to treat LN. Evidence indi-cated that 58% of the study population were prescribed corticosteroid therapy, in most cases (73%) for more than 60 days. Adverse events known to be associated with corticosteroid therapy were recorded in 58% of patients. Guideline-recommended preventive therapy with hydroxychloroquine was prescribed for 54% of members with LN. Nearly half (47%) of members with LN did not see a nephrologist and more than one-third (36%) did not see a rheumatologist over 1 year of follow-up. Rates of all-cause hospitalization and emergency department (ED) use were 25% and 35%, respectively. The mean all-cause per-member-per-month (PMPM) medical cost for the study population was $2801, with LN-specific costs accounting for $1147 PMPM. Conclusion: Patients with LN who are insured through a large US health plan appeared to underutilize outpatient specialist services and guideline-recommended hydroxychloroquine therapy. Corticosteroid use and adverse events known to be associated with corticosteroids were common in this cohort. AD - L. Bartels-Peculis, Mallinckrodt Pharmaceuticals, Inc., Bedminster, NJ, United States AU - Bartels-Peculis, L. AU - Sharma, A. AU - Edwards, A. M. AU - Sanyal, A. AU - Connolly-Strong, E. AU - Nelson, W. W. DB - Embase DO - 10.2147/OARRR.S248750 KW - antilipemic agent azathioprine corticosteroid cyclophosphamide cyclosporine hydroxychloroquine hydroxymethylglutaryl coenzyme A reductase inhibitor methylprednisolone mycophenolate mofetil mycophenolic acid prednisone rituximab tacrolimus adult article avascular necrosis Charlson Comorbidity Index controlled study diabetes mellitus digestive system ulcer drug efficacy drug safety emergency ward female follow up fracture gastrointestinal hemorrhage glaucoma health care cost health care planning health care utilization health insurance heart infarction hospitalization human immunosuppressive treatment lupus erythematosus nephritis major clinical study male middle aged observational study osteoporosis patient compliance population research retrospective study treatment planning United States LA - English M3 - Article N1 - L2004587106 2020-07-28 2020-08-04 PY - 2020 SN - 1179-156X SP - 117-124 ST - Treatment patterns and health care costs of lupus nephritis in a united states payer population T2 - Open Access Rheumatology: Research and Reviews TI - Treatment patterns and health care costs of lupus nephritis in a united states payer population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004587106&from=export http://dx.doi.org/10.2147/OARRR.S248750 VL - 12 ID - 2441 ER - TY - JOUR AB - PURPOSE: To assess the comparative efficacy and the long-term cost-utility of alternative minimally invasive glaucoma surgeries (MIGSs) when combined with cataract surgery in patients with primary open-angle glaucoma (POAG)., METHODS: Treatment effects, as measured by the 1-year reduction in intraocular pressure (IOP), were estimated with an adjusted indirect treatment comparison. Evidence from randomized clinical trials was identified for four different MIGS methods. A disease-transition model was developed by capturing clinically relevant POAG stages and the expected natural disease evolution. Outcomes of the disease-transition model were the comparative utility [quality-adjusted life years (QALYs)], cost and cost-utility of included strategies in a lifetime horizon., RESULTS: Estimated 1-year IOP reductions were: cataract surgery - 2.05 mmHg (95% CI - 3.38; - 0.72), one trabecular micro-bypass stent - 3.15 mmHg (95% CI - 5.66; - 0.64), two trabecular micro-bypass stents - 4.85 mmHg (95% CI - 7.71; - 1.99) and intracanalicular scaffold - 2.25 mmHg (95% CI - 4.87; 0.37). Discounted outcomes from the disease-transition model appraised the strategy of two trabecular micro-bypass stents with cataract surgery in the moderate POAG stage as the one providing the greatest added value, with 10,955 per additional QALY. Improved outcomes were seen when assessing MIGS in the moderate POAG stage., CONCLUSIONS: When indirectly comparing alternative MIGS methods combined with cataract surgery, the option of two trabecular micro-bypass stents showed both a superior efficacy and long-term cost-utility from a German perspective. Moreover, outcomes of the disease-transition model suggest POAG patients to beneficiate the most from an earlier intervention in the moderate stage contrary to waiting until an advanced disease is present. AU - Bartelt-Hofer, Jose AU - Flessa, Steffen DO - https://dx.doi.org/10.1007/s10792-020-01314-7 IS - 6 KW - *Cataract/co [Complications] Cataract/ec [Economics] *Cataract Extraction/mt [Methods] Cost-Benefit Analysis Glaucoma, Open-Angle/co [Complications] Glaucoma, Open-Angle/ec [Economics] *Glaucoma, Open-Angle/su [Surgery] Humans Minimally Invasive Surgical Procedures/ec [Economics] *Minimally Invasive Surgical Procedures/mt [Methods] *Patient Acceptance of Health Care Trabeculectomy/ec [Economics] *Trabeculectomy/mt [Methods] *Visual Acuity PY - 2020 SE - Bartelt-Hofer, Jose. University of Greifswald, Greifswald, Germany. joselo.bartelt@gmail.com. Flessa, Steffen. University of Greifswald, Greifswald, Germany. SN - 1573-2630 0165-5701 SP - 1469-1479 ST - Comparative efficacy and cost-utility of combined cataract and minimally invasive glaucoma surgery in primary open-angle glaucoma T2 - International ophthalmology TI - Comparative efficacy and cost-utility of combined cataract and minimally invasive glaucoma surgery in primary open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32185590 VL - 40 Y2 - 20200317// ID - 208 ER - TY - JOUR AB - PURPOSE: To analyze intraocular pressure (IOP) response after 20-mg decanted intravitreal triamcinolone acetonide followed by early prophylactic IOP-lowering therapy., METHODS: Overall, IOP results of 120 high-dose decanted intravitreal triamcinolone acetonide injections from 58 nonglaucomatous patients with macular edema, with antiglaucoma therapy prescribed from Week 1 regardless of baseline IOP were retrospectively reviewed., RESULTS: In cases of consistent compliance with IOP-lowering drugs (79.2%), IOP increased by 2 mmHg at 4 months (P = 0.300) and returned to baseline at 6 months. In cases of noncompliance (20.8%), IOP increased by 7 mmHg at 1 month (P < 0.001) and returned to baseline after starting treatment. Multivariate regression analysis showed that nonvitrectomized eyes and noncompliance with IOP-lowering drugs were independent predictors of increase in IOP greater than 21 mmHg (P = 0.0098 and P = 0.0019, respectively). Nonvitrectomized eyes had a 46% greater chance to experience increase in IOP compared with vitrectomized ones. Poor compliance with IOP-lowering drugs lead to a 45% greater likelihood of experiencing increase in IOP compared with compliant patients. Multiple injections were not associated with the increased risk for increase in IOP greater than 21 mmHg (P = 0.273). Of 120 cases, 2 eyes (1.7%) developed uncontrolled IOP and required glaucoma surgery by 4 months, with good final IOP outcome., CONCLUSION: Twenty milligram decanted intravitreal triamcinolone acetonide can be safely used to treat macular edema in nonglaucomatous patients; IOP elevation can be adequately controlled with prophylactic antiglaucoma drugs. Noncompliance with prophylactic therapy creates an early spike in IOP, and vitreous status can significantly impact increase in IOP. Compliance with IOP-lowering drugs should be stressed to patients receiving high-dose intravitreal triamcinolone acetonide especially in cases of nonvitrectomized eyes. AU - Barteselli, Giulio AU - Amini, Payam AU - Ezon, Isaac C. AU - Nezgoda, Joseph T. AU - Cheng, Lingyun AU - Freeman, William R. DO - https://dx.doi.org/10.1097/IAE.0000000000000268 IS - 1 KW - Adult Aged Aged, 80 and over Female *Glaucoma/pc [Prevention & Control] *Glucocorticoids/ad [Administration & Dosage] Humans *Intraocular Pressure/de [Drug Effects] Intravitreal Injections *Macular Edema/dt [Drug Therapy] Male Middle Aged Retrospective Studies Tonometry, Ocular *Triamcinolone Acetonide/ad [Administration & Dosage] Triamcinolone Acetonide/ch [Chemistry] PY - 2015 SE - Barteselli, Giulio. Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla CA. Barteselli, Giulio. Ophthalmological Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. Amini, Payam. Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla CA. Ezon, Isaac C. Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla CA. Nezgoda, Joseph T. Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla CA. Cheng, Lingyun. Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla CA. Freeman, William R. Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla CA. SN - 1539-2864 0275-004X SP - 75-81 ST - Impact on intraocular pressure after 20-mg decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy T2 - Retina (Philadelphia, Pa.) TI - Impact on intraocular pressure after 20-mg decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25077534 VL - 35 ID - 834 ER - TY - JOUR AB - Purpose: The aim of this study was to assess the clinical features and outcome of paediatric retinal detachment (RD). Methods: Ninety-five eyes of 87 children under 18 years of age with RD were assessed. The risk factors, morphology of RD, therapeutic approach and functional results were evaluated. Results: Sixty-seven boys and 20 girls with a mean age of 10.4 years (standard deviation 5.5) presented with RD. The following risk factors were identified: myopia (23%), congenital or developmental ocular abnormalities (37%), history of ocular trauma (40%) and previous ocular surgery (27%). Seventy-seven (81%) eyes underwent surgery. The primary reattachment rate was 44%. In 18%, reattachment was achieved after several surgeries. The overall recurrence rate after surgical reattachment was 39%. Conclusions: Paediatric RD is a sight-threatening condition. Often, aggravating factors, such as delayed diagnosis, hereditary ocular abnormalities or strong vitreous adherence, are present. Hopefully, modern surgical techniques may contribute to a better outcome of RD in the future. © 2017 S. Karger AG, Basel. AD - Department of Ophthalmology, University Medical Centre Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, DE-93053, Germany Centre for Clinical Studies (ZKS), University Medical Centre Regensburg, Regensburg, Germany AU - Barth, T. AU - Zeman, F. AU - Helbig, H. AU - Oberacher-Velten, I. DB - Scopus DO - 10.1159/000455355 IS - 2 KW - Clinical characteristics Paediatric retinal detachment Risk factors Surgical outcome M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2017 SP - 63-72 ST - Clinical Features and Outcome of Paediatric Retinal Detachment T2 - Ophthalmologica TI - Clinical Features and Outcome of Paediatric Retinal Detachment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013124319&doi=10.1159%2f000455355&partnerID=40&md5=6d6eead5b09f2f0b5ae390377c076432 VL - 237 ID - 5455 ER - TY - JOUR AU - Bartlett, J. D. IS - 9 KW - Blindness/et [Etiology] Blindness/pc [Prevention & Control] Costs and Cost Analysis Glaucoma/co [Complications] *Glaucoma/th [Therapy] Health Services Accessibility Humans Optometry/ec [Economics] *Optometry/mt [Methods] Social Security PY - 1987 SN - 0003-0244 SP - 694-5 ST - Why optometrists should treat glaucoma T2 - Journal of the American Optometric Association TI - Why optometrists should treat glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=3446696 VL - 58 ID - 2197 ER - TY - JOUR AB - BACKGROUND: Lions Outback Vision has run a state-wide teleophthalmology service since 2011. In September 2015 the Australian federal government introduced a Medicare reimbursement for optometry-facilitated teleophthalmology consultations under specific circumstances. This audit demonstrates the first 12 months experience with this scheme. We aim to provide practical insights for others looking to embed a telemedicine program as part of delivering outreach clinical services., METHODS: A 12-month retrospective audit was performed between September 2015 and August 2016, inclusive. A research officer used a specifically designed data extraction tool to record information from all teleophthalmology consultations performed in the time period. The primary outcome was the diagnosis at the end of the teleophthalmology consultation. Secondary outcome measures included the number of teleconsultations, cataract surgery rate, remoteness area of patients referred and imaging accompanying the referral., RESULTS: In the 12-month period, 709 patients were referred resulting in 683 teleophthalmology teleconsultations. Cataract was the most frequent diagnosis (n = 287, 42.7 per cent), followed by glaucoma (n = 77, 11 per cent), age-related macular degeneration (n = 30, 4.4 per cent) and diabetic retinopathy (n = 26, 3.8 per cent). Of those who had teleconsultations, 98.6 per cent were from Outer Regional, Remote or Very Remote Australia. One or more accompanying images or investigations were part of 349 (49 per cent) teleconsultations, most commonly optical coherence tomography (215, 30 per cent) and fundus photography (148, 21 per cent). Face-to-face consultations were undertaken at an outreach clinic in 23 (3.4 per cent) cases, to determine the diagnosis. There were no statistically significant factors associated with attendance at teleophthalmology consultation, or for successfully undergoing cataract surgery., CONCLUSION: Teleophthalmology is a valuable adjunct to regional outreach ophthalmology services, providing patients with increased access to specialist care for a wide range of ophthalmic conditions, and more efficient access to surgical care. Copyright © 2018 Optometry Australia. AU - Bartnik, Stephen E. AU - Copeland, Stephen P. AU - Aicken, Angela J. AU - Turner, Angus W. DO - https://dx.doi.org/10.1111/cxo.12658 IS - 5 KW - Adolescent Adult Aged Aged, 80 and over Child Child, Preschool *Delivery of Health Care/sn [Statistics & Numerical Data] *Eye Diseases/di [Diagnosis] Eye Diseases/th [Therapy] Female *Health Services Accessibility Humans Male *Medical Audit Middle Aged *Ophthalmology/sn [Statistics & Numerical Data] *Optometry/sn [Statistics & Numerical Data] Referral and Consultation Retrospective Studies Rural Population *Telemedicine/sn [Statistics & Numerical Data] Western Australia PY - 2018 SE - Bartnik, Stephen E. Lions Outback Vision, Lions Eye Institute, Perth, Western Australia, Australia. Copeland, Stephen P. Lions Outback Vision, Lions Eye Institute, Perth, Western Australia, Australia. Aicken, Angela J. Lions Outback Vision, Lions Eye Institute, Perth, Western Australia, Australia. Turner, Angus W. Lions Outback Vision, Lions Eye Institute, Perth, Western Australia, Australia. Turner, Angus W. The Centre for Vision and Ophthalmic Science, The University of Western Australia, Perth, Western Australia, Australia. SN - 1444-0938 0816-4622 SP - 700-703 ST - Optometry-facilitated teleophthalmology: an audit of the first year in Western Australia T2 - Clinical & experimental optometry TI - Optometry-facilitated teleophthalmology: an audit of the first year in Western Australia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29444552 VL - 101 Y2 - 20180214// ID - 450 ER - TY - JOUR AB - The aqueous shunts that are currently available are based on the principles of the Molteno implant, i.e., a permanent sclerostomy, routing of aqueous to the equatorial subconjunctival space, and an end plate to prevent obstruction, and also to determine the surface area for absorption. While the Ahmed Glaucoma Valve appears to have improved the predictability of early intraocular pressure (IOP) control, the Baerveldt Glaucoma Implant has a tendency towards a lower rate of long-term excessive encapsulation. As a result of improvements in predictability, shunts are used more widely. Because of these positive factors, and ongoing concerns regarding the bleb-related problems associated with mitomycin C trabeculectomy, there is an increasing interest in the use of shunts as primary surgical management for primary glaucoma. At present, the main barrier to wider use of shunts in less-complicated glaucomas will probably be the unknown long-term effect on corneal endothelium, an issue that has not yet been properly addressed. AN - WOS:000280604100020 AU - Barton, K. AU - Heuer, D. K. DO - 10.1016/S0079-6123(08)01119-9 PY - 2008 SN - 0079-6123 978-0-444-53256-5 SP - 263-276 ST - Modern aqueous shunt implantation: future challenges T2 - GLAUCOMA: AN OPEN WINDOW TO NEURODEGENERATION AND NEUROPROTECTION TI - Modern aqueous shunt implantation: future challenges VL - 173 ID - 6087 ER - TY - JOUR AB - PURPOSE: We sought to illustrate the difficulty in managing uncommon, pigmented mold-related corneal ulceration and to highlight the role of itraconazole in treating these patients., METHOD: We describe the management and clinical course of a patient with a recurring corneal infection caused by Fonsecaea pedrosoi and discuss this experience in the light of existing literature on management of cutaneous chromoblastomycosis., RESULTS: A corneal ulcer caused by this organism healed initially on treatment with topical and systemic antifungal medication, but infection recurred in the deep stroma 4 months after cessation of therapy. After failure to respond to a further period of medical therapy, a small therapeutic penetrating keratoplasty was performed. Culture of a fibrinous membrane from the anterior iris surface demonstrated intraocular fungal infection, and postoperatively, an episode of marked fibrinous uveitis developed, suggesting the presence of viable intraocular fungal elements. A large penetrating keratoplasty was therefore performed with excision of involved iris in combination with extracapsular cataract extraction. F. pedrosoi was again cultured from the fibrinous membrane adherent to the iris and from the anterior lens capsule. Postoperatively the patient received a 5-month course of systemic itraconazole, and no further recurrences have been encountered after a further 2 months., CONCLUSION: F. pedrosoi is the organism most commonly isolated from the chronic cutaneous mycosis, chromoblastomycosis, and is relatively resistant to medical therapy. As has been reported for cutaneous disease, surgery in combination with systemic itraconazole may provide the best chance of cure in corneal chromoblastomycosis. AU - Barton, K. AU - Miller, D. AU - Pflugfelder, S. C. IS - 2 KW - *Antifungal Agents/tu [Therapeutic Use] Cataract Extraction Combined Modality Therapy Cornea/mi [Microbiology] Cornea/pa [Pathology] Cornea/su [Surgery] Corneal Ulcer/mi [Microbiology] Corneal Ulcer/pa [Pathology] *Corneal Ulcer/th [Therapy] Eye Infections, Fungal/et [Etiology] Eye Infections, Fungal/pa [Pathology] *Eye Infections, Fungal/th [Therapy] Follow-Up Studies Humans *Itraconazole/tu [Therapeutic Use] *Keratoplasty, Penetrating Male Middle Aged Mitosporic Fungi/ip [Isolation & Purification] Mycoses/et [Etiology] Mycoses/pa [Pathology] *Mycoses/th [Therapy] Recurrence PY - 1997 SE - Barton, K. Corneal and External Disease Service, Bascom Palmer Eye Institute, University of Miami School of Medicine, Florida, USA. SN - 0277-3740 SP - 235-9 ST - Corneal chromoblastomycosis T2 - Cornea TI - Corneal chromoblastomycosis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9071540 VL - 16 ID - 2025 ER - TY - JOUR AB - In 1987, it was estimated that over 13 million people in the world were visually impaired, and more than 27 to 35 million were classified as blind. Greater than 6 million visually impaired people live in the United States. There are many causes of visual impairment, including age-related macular degeneration, cataracts, glaucoma, diabetic retinopathy, autoimmune deficiency syndrome, and trauma. Some patients may be helped or visual loss delayed with surgery. Many may have dramatic visual improvement with optical devices, large-print publications, and improved lighting. The ophthalmic nurse may assist in accurately assessing the patient's vision and identifying his or her lifestyle and ability to function independently. Assisting the patient to overcome psychosocial and economic barriers and helping to obtain assistance is critical to enable patients to function independently. Ophthalmic nurses may be instrumental in increasing patients' awareness of community resources and services available to those who are visually impaired. AU - Barton, W. IS - 1 KW - Activities of Daily Living Humans *Job Description Nursing Assessment *Ophthalmology Patient Education as Topic *Specialties, Nursing Vision Disorders/cl [Classification] Vision Disorders/ep [Epidemiology] Vision Disorders/et [Etiology] *Vision Disorders/nu [Nursing] PY - 1998 SE - Barton, W. Department of Ophthalmology, Veteran Administration Puget Sound Health Care System, Seattle, WA 98108, USA. SN - 1060-135X SP - 5-10 ST - Role of ophthalmic nurses with visually impaired patients T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Role of ophthalmic nurses with visually impaired patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9866521 VL - 23 ID - 1984 ER - TY - JOUR AB - There are a number of barriers to the ocular transport of poorly lipid-soluble antibiotics such as beta-lactams and aminoglycosides. Knowledge of these barriers can help the physician in the choice of agent and the route of administration for specific ocular infections. Because of the corneal epithelial barrier, topically applied drugs should be administered frequently; "fortified" drops afford higher corneal concentrations than commercially available drops. Periocular injections may occasionally be of benefit in the treatment of refractory corneal ulcers. The mainstay of treatment of bacterial endophthalmitis should be intravitreal injection of antimicrobial agents; ancillary treatments include the periocular and systemic administration of antimicrobial agents, the systemic administration of probenecid, the administration of corticosteroids, and the use of vitrectomy. AU - Barza, M. IS - 3 KW - Animals Anti-Bacterial Agents/ad [Administration & Dosage] Anti-Bacterial Agents/pk [Pharmacokinetics] *Anti-Bacterial Agents/tu [Therapeutic Use] *Bacterial Infections/dt [Drug Therapy] Bacterial Infections/mi [Microbiology] Biological Transport Eye Diseases/dt [Drug Therapy] *Eye Diseases/et [Etiology] Half-Life Humans Rabbits PY - 1989 SE - Barza, M. Tufts University School of Medicine, Boston, Massachusetts. SN - 0891-5520 SP - 533-51 ST - Antibacterial agents in the treatment of ocular infections T2 - Infectious disease clinics of North America TI - Antibacterial agents in the treatment of ocular infections UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2671138 VL - 3 ID - 2165 ER - TY - JOUR AD - D. Bass, Department of Health, Provincial Govt. of the Western Cape, PO Box 2060, Cape Town 8000, South Africa AU - Bass, D. DB - Embase Medline IS - 7303 KW - aged case report female glaucoma health care access human letter male physician attitude priority journal social isolation LA - English M3 - Letter N1 - L32682009 2001-08-08 PY - 2001 SN - 0959-8146 SP - 47 ST - Doctors must learn to let others treat them and their families [1] T2 - British Medical Journal TI - Doctors must learn to let others treat them and their families [1] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32682009&from=export VL - 323 ID - 3893 ER - TY - JOUR AB - A non-communicative patient with vascular dementia who was admitted to hospital with non-specific symptoms. Ophthalmic emergencies are rare, however they should be considered as part of a systemic work-up in unexplained non-specific presentations, particularly in patients who are not able to communicate as in the case we present here. AU - Bastawrous, Andrew AU - Southward, Suzanne AU - Horner, Michael AU - Noonan, Carmel DO - https://dx.doi.org/10.1093/ageing/afs011 IS - 3 KW - *Communication *Dementia, Vascular/co [Complications] Dementia, Vascular/px [Psychology] Diagnostic Techniques, Ophthalmological Female Glaucoma, Angle-Closure/co [Complications] *Glaucoma, Angle-Closure/di [Diagnosis] Glaucoma, Angle-Closure/pp [Physiopathology] Glaucoma, Angle-Closure/px [Psychology] Glaucoma, Angle-Closure/th [Therapy] Humans *Intraocular Pressure Ophthalmologic Surgical Procedures *Patient Compliance Physician-Patient Relations Predictive Value of Tests Treatment Outcome *Vision Disorders/di [Diagnosis] Vision Disorders/et [Etiology] Vision Disorders/pp [Physiopathology] Vision Disorders/px [Psychology] Vision Disorders/th [Therapy] Visual Acuity PY - 2012 SE - Bastawrous, Andrew. Department of Ophthalmology, Aintree University Teaching Hospitals, Longmoor Lane, Liverpool, UK. andrew.bastawrous@gmail.com SN - 1468-2834 0002-0729 SP - 422-3 ST - Losing sight under pressure T2 - Age and ageing TI - Losing sight under pressure UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22311894 VL - 41 Y2 - 20120205// ID - 1150 ER - TY - JOUR AB - Propensity for increased postoperative inflammation and capsular opacification, a refractive state that is constantly in a state of flux due to growth of the eye, difficulty in documenting anatomic and refractive changes due to poor compliance, and a tendency to develop amblyopia, makes management of cataract in the child different from that in the adult. The recent past has unraveled several caveats of pediatric cataract management-the importance of atraumatic surgery and complete removal of lens matter, benefits of in-the-bag intraocular lens (IOL) implantation, role of titrating IOL power to counter refractive changes due to growth of the eye, prudery of continuously following these eyes for early detection of aphakic glaucoma and benefits of some surgical innovations. Although these promise to significantly improve our management of pediatric cataract, their long-term benefits are yet to be determined. We will also have to harness newer techniques, especially in the areas of wound construction and capsule management, and will have to develop effective strategies for the refractive management of infantile aphakia. AU - Basti, S. AU - Greenwald, M. J. IS - 4 KW - Adult *Cataract/cn [Congenital] *Cataract Extraction/mt [Methods] Child Humans Infant Intraocular Pressure/ph [Physiology] Lenses, Intraocular Refraction, Ocular Treatment Outcome Visual Acuity/ph [Physiology] PY - 1995 SE - Basti, S. Cornea and Anterior Segment Service, L.V. Prasad Eye Institute, Hyderabad, India. SN - 0301-4738 SP - 159-76 ST - Principles and paradigms of pediatric cataract management T2 - Indian journal of ophthalmology TI - Principles and paradigms of pediatric cataract management UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8655194 VL - 43 ID - 2055 ER - TY - JOUR AB - This study reports the short-term functional and anatomical outcome of Boston Type 1 keratoprosthesis (Boston Kpro) implantation for bilateral limbal stem cell deficiency (LCSD). Retrospective analysis was done on eight eyes of eight patients who underwent Boston Kpro implantation between July 2009 and October 2009. The best corrected visual acuity (BCVA) and slit-lamp biomicroscopy findings were assessed at 1, 3 and 6 months postoperatively. All eight eyes retained the prosthesis. BCVA of 20/40 or better was achieved in 8, 6, and 5 eyes at 1, 3, and 6 months, respectively, postoperatively. One patient each developed epithelial defect, sterile stromal melt and fungal keratitis in the late postoperative period associated with antecedent loss of the soft contact lens from the eye. Boston Kpro has good short-term visual and anatomical outcome in patients with bilateral LSCD, provided compliance with postoperative care can be ensured. AU - Basu, Sayan AU - Taneja, Mukesh AU - Narayanan, Raja AU - Senthil, Sirisha AU - Sangwan, Virender S. DO - https://dx.doi.org/10.4103/0301-4738.94060 IS - 2 KW - Adolescent Adult Blindness/et [Etiology] *Blindness/su [Surgery] Corneal Diseases/co [Complications] Corneal Diseases/pa [Pathology] *Corneal Diseases/su [Surgery] Follow-Up Studies Humans *Limbus Corneae/pa [Pathology] Middle Aged *Prostheses and Implants Retrospective Studies *Stem Cells/pa [Pathology] Treatment Outcome Young Adult PY - 2012 SE - Basu, Sayan. Cornea & Anterior Segment Service, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad, India. SN - 1998-3689 0301-4738 SP - 151-3 ST - Short-term outcome of Boston Type 1 keratoprosthesis for bilateral limbal stem cell deficiency T2 - Indian journal of ophthalmology TI - Short-term outcome of Boston Type 1 keratoprosthesis for bilateral limbal stem cell deficiency UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22446917 VL - 60 ID - 1144 ER - TY - JOUR AB - BACKGROUND: The National Patient Safety Agency (2009) publication advising timely follow-up of patients with established glaucoma followed several reported instances of visual loss due to postponed appointments and patients lost to follow-up. The Royal College of Ophthalmologists Quality Standards Development Group stated that all hospital appointments should occur within 15% of the intended follow-up period., AIM: To determine whether: 1. Glaucoma follow-up appointments at a teaching hospital occur within the requested time 2. Appointments are requested at appropriate intervals based on the NICE Guidelines 3. The capacity of the glaucoma service is adequate Methods: A two-part audit was undertaken of 98 and 99 consecutive patients respectively attending specialist glaucoma clinics. In the first part, the reasons for delayed appointments were recorded. In the second part the requested follow-up was compared with NICE guidelines where applicable. Based on the findings, changes were implemented and a re-audit of 100 patients was carried out., RESULTS: The initial audit found that although clinical decisions regarding follow-up intervals were 100% compliant with NICE guidelines where applicable, 24% of appointments were delayed beyond 15% of the requested period, due to administrative errors and inadequate capacity, leading to significant clinical deterioration in two patients. Following the introduction of an electronic appointment tracker and increased clinical capacity created by extra clinics and clinicians, the re-audit found a marked decrease in the percentage of appointments being delayed (9%)., CONCLUSIONS: This audit is a useful tool to evaluate glaucoma service provision, assist in resource planning for the service and bring about change in a non-confrontational way. It can be widely applied and adapted for use in other medical specialities. AU - Batra, Ruchika AU - Sharma, Hannah E. AU - Elaraoud, Ibrahim AU - Mohamed, Shabbir DO - https://dx.doi.org/10.1080/08820538.2017.1418012 IS - 6 KW - *Appointments and Schedules *Benchmarking/mt [Methods] Female *Glaucoma, Open-Angle/th [Therapy] *Hospitals, University/og [Organization & Administration] Humans Intraocular Pressure Male *Management Audit/mt [Methods] *Ophthalmology/st [Standards] Patient Compliance *Referral and Consultation/st [Standards] PY - 2018 SE - Batra, Ruchika. a Department of Ophthalmology, University Hospitals Birmingham, United Kingdom. Sharma, Hannah E. a Department of Ophthalmology, University Hospitals Birmingham, United Kingdom. Elaraoud, Ibrahim. a Department of Ophthalmology, University Hospitals Birmingham, United Kingdom. Mohamed, Shabbir. a Department of Ophthalmology, University Hospitals Birmingham, United Kingdom. SN - 1744-5205 0882-0538 SP - 733-738 ST - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity T2 - Seminars in ophthalmology TI - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29283293 VL - 33 Y2 - 20171228// ID - 464 ER - TY - JOUR AB - Purpose: To describe a series of 4 patients with inadequately controlled primary open angle glaucoma and ocular surface disease (OSD) in whom a combination approach was used to manage the OSD resulting in improved intraocular pressure (IOP) control. PAtients and methods: A retrospective review of the clinical notes of 4 patients referred to a tertiary surgical glaucoma service was performed. At the initial visit, measures to control the OSD were employed in all patients; twice-daily lid hygiene measures, a 3-month course of 50 mg daily oral doxycycline, topical carmellose sodium (celluvisc) 0.5% 4 to 6 times daily, and preservative-free equivalents of topical antiglaucoma medications as deemed appropriate, depending on the perceived severity of the OSD. Results: Patients were reviewed for a maximum of 24 months after intervention. In all patients treatment resulted in a marked symptomatic and clinical improvement in the ocular surface with a reduction in hyperemia, meibomian gland dysfunction and superficial keratopathy. A reduction in the IOP also occurred in all patients, obviating the need for glaucoma drainage surgery during the study period. Conclusions: Patients with severe OSD often have glaucoma that is refractive to medical therapy. Furthermore, the surgical success of glaucoma filtering surgery is compromised in patients with scarring and inflammation of the conjunctiva. The term we postulate is "OSD exacerbated glaucoma." This is the first study to suggest that the use of a combination approach comprising medical treatment to manage the OSD in patients with primary open angle glaucoma may lead to an improvement in the IOP control and the management of glaucoma. Copyright © 2013 by Lippincott Williams & Wilkins. AD - University Hospitals Birmingham, Birmingham, United Kingdom Birmingham and Midland Eye Centre, Birmingham City Hospital, Dudley Road, Birmingham B18 7QH, United Kingdom AU - Batra, R. AU - Tailor, R. AU - Mohamed, S. DB - Scopus DO - 10.1097/IJG.0b013e318264cd68 IS - 1 KW - Glaucoma ocular surface disease ocular surface inflammation preservative M3 - Article N1 - Cited By :30 Export Date: 19 July 2021 PY - 2014 SP - 56-60 ST - Ocular surface disease exacerbated glaucoma: Optimizing the ocular surface improves intraocular pressure control T2 - Journal of Glaucoma TI - Ocular surface disease exacerbated glaucoma: Optimizing the ocular surface improves intraocular pressure control UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891863054&doi=10.1097%2fIJG.0b013e318264cd68&partnerID=40&md5=df86f62675dd77177a5e965afd7309aa VL - 23 ID - 5060 ER - TY - JOUR AB - PURPOSE: To report an unusual case of contact lens-associated pseudomonal keratitis in a compliant daily disposable contact lens wearer., METHODS: A case report is presented of a compliant daily disposable contact lens wearer who developed culture-positive pseudomonal keratitis., RESULTS: A 38-year-old woman who reported compliant and infrequent use of daily disposable contact lenses presented with rapid-onset, severe keratitis consistent with pseudomonal infection. Corneal cultures were positive for Pseudomonas aeruginosa. She had no identifiable risk factors, although notably had a remote history of contact lens-associated keratitis in the fellow eye., CONCLUSIONS: Although extremely rare, pseudomonal keratitis should still be considered in the differential diagnosis of severe keratitis in daily disposable contact lens wearers. Given the history of a previous contact lens-related bacterial keratitis in this compliant patient, it is possible that host susceptibility factors played a role in the case of pseudomonal keratitis described here. AU - Batta, Priti AU - Goldstein, Michael H. DO - https://dx.doi.org/10.1097/ICL.0b013e3181da2339 IS - 3 KW - Adult *Contact Lenses, Hydrophilic/ae [Adverse Effects] Diagnosis, Differential Disposable Equipment Female Humans *Keratitis/mi [Microbiology] Keratitis/pa [Pathology] Medical Records Pseudomonas Infections/di [Diagnosis] *Pseudomonas Infections/et [Etiology] *Pseudomonas aeruginosa Severity of Illness Index PY - 2010 SE - Batta, Priti. Tufts Medical Center-New England Eye Center, Boston, MA 02116, USA. pbatta@tuftsmedicalcenter.org SN - 1542-233X 1542-2321 SP - 181-2 ST - Severe pseudomonal keratitis in an infrequent daily disposable contact lens wearer T2 - Eye & contact lens TI - Severe pseudomonal keratitis in an infrequent daily disposable contact lens wearer UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20386315 VL - 36 ID - 1361 ER - TY - JOUR AB - Introduction: Although eye drops are widely used as drug delivery systems for the anterior segment of the eye, they are also associated with poor drug bioavailability due to transient contact time and rapid washout by tearing. Moreover, effective drug delivery to the posterior segment of the eye is challenging, and alternative routes of administration (periocular and intravitreal) are generally needed, the blood–retinal barrier being the major obstacle to systemic drug delivery. Areas covered: Nanotechnology, and especially lipid nanoparticles, can improve the therapeutic efficiency, compliance and safety of ocular drugs, administered via different routes, to both the anterior and posterior segment of the eye. This review highlights the main ocular barriers to drug delivery, as well as the most common eye diseases suitable for pharmacological treatment in which lipid nanoparticles have proved efficacious as alternative delivery systems. Expert opinion: Lipid-based nanocarriers are among the most biocompatible and versatile means for ocular delivery. Mucoadhesion with consequent increase in pre-corneal retention time, and enhanced permeation due to cellular uptake by corneal epithelial cells, are the essential goals for topical lipid nanoparticle delivery. Gene delivery to the retina has shown very promising results after intravitreal administration of lipid nanoparticles as non-viral vectors. AD - L. Battaglia, Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Torino, Italy AU - Battaglia, L. AU - Serpe, L. AU - Foglietta, F. AU - Muntoni, E. AU - Gallarate, M. AU - Del Pozo Rodriguez, A. AU - Solinis, M. A. DB - Embase Medline DO - 10.1080/17425247.2016.1201059 IS - 12 KW - aciclovir antibiotic agent antifungal agent antivirus agent chloramphenicol gatifloxacin itraconazole ketoconazole levofloxacin lipid nanoparticle tobramycin anatomy anterior eye segment antibiotic therapy conjunctivitis cornea disease cornea injury drug delivery system eye eye disease eye infection eye inflammation glaucoma human nanotechnology nonhuman oxidative stress patient compliance physiology posterior eye segment retina disease review safety visual disorder wound healing LA - English M3 - Review N1 - L613363628 2016-11-30 2017-01-09 PY - 2016 SN - 1744-7593 1742-5247 SP - 1743-1757 ST - Application of lipid nanoparticles to ocular drug delivery T2 - Expert Opinion on Drug Delivery TI - Application of lipid nanoparticles to ocular drug delivery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613363628&from=export http://dx.doi.org/10.1080/17425247.2016.1201059 VL - 13 ID - 2689 ER - TY - JOUR AB - The medical treatment of primary open angle glaucoma has progressively become more and more efficient and safe, and surgery is therefore mostly restricted to failure of and intolerance to antiglaucoma eyedrops. Glaucoma surgery may thus cause severe complications and a high risk of failure has tempered its prognostic. Nevertheless, when efficacious, glaucoma surgery definitively resolves two major pitfalls of medical treatment: patient compliance and eyedrops tolerance. Moreover, new surgical developments of surgery have come from the new technique of non-penetrating deep sclerectomy, which is actually an external trabeculectomy involving removal of the area of maximal resistance to aqueous outflow. This procedure has a very low risk of complications, much lower than that of standard trabeculectomy, but its efficacy is still controversial. Whatever the technique chosen for filtering surgery, antimetabolites may be used in order to limit the risk of postoperative fibrosis, but they also expose to specific, sometimes sight-threatening, complications. Therefore, the most important--and also the most difficult--choice for treating glaucoma patients still remains the best timing for surgery, either excessive, useless, and aggressive medical treatment, or systematic primary surgery. AU - Baudouin, C. IS - 10 KW - *Glaucoma/su [Surgery] Humans Trabeculectomy/mt [Methods] PY - 2001 SE - Baudouin, C. CHNO des Quinze-Vingts, Hopital Ambroise Pare, AP-HP, Universite Paris V. SN - 0181-5512 SP - 1103-9 ST - [When should glaucoma be surgically treated?] T2 - Quand operer un glaucome? TI - [When should glaucoma be surgically treated?] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11913244 VL - 24 ID - 1906 ER - TY - JOUR AB - Antiglaucoma medications are often associated with ocular adverse reactions such as dry eye, and burning or stinging sensations. These undesirable effects may lead to treatment discontinuation and reduced quality of life in patients with glaucoma. Antiglaucoma medications usually contain benzalkonium chloride (BAK) as a preservative. Animal studies, in vitro studies and in vivo experiments have demonstrated various adverse effects of BAK. Clinical studies have also shown an increased incidence of adverse events with BAK and have demonstrated that the withdrawal of preservatives reduces these effects. Collectively, these data suggest that preservative-free antiglaucoma treatments have clinically relevant benefits for patients. AU - Baudouin, Christophe DO - https://dx.doi.org/10.1111/j.1755-3768.2008.01250.x IS - 7 KW - Animals Benzalkonium Compounds/ad [Administration & Dosage] *Benzalkonium Compounds/ae [Adverse Effects] *Eye/de [Drug Effects] *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Humans *Ophthalmic Solutions/ae [Adverse Effects] *Ophthalmic Solutions/ch [Chemistry] Ophthalmic Solutions/tu [Therapeutic Use] Patient Compliance *Preservatives, Pharmaceutical/ae [Adverse Effects] Quality of Life PY - 2008 SE - Baudouin, Christophe. Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, Paris, France. baudouin@quinze-vingts.fr SN - 1755-3768 1755-375X SP - 716-26 ST - Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma T2 - Acta ophthalmologica TI - Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18537937 VL - 86 Y2 - 20080603// ID - 1526 ER - TY - JOUR AB - Purpose: To review the effects of preservatives on the ocular surface and assess how preserved eyedrops can affect clinical outcome in patients with glaucoma. Rationale: Dry eye and other symptoms of ocular surface disease are frequently encountered in patients with glaucoma and ocular hypertension and associated with the use of preserved topical antiglaucoma medications. The most commonly used preservative in ophthalmic solutions is benzalkonium chloride, which has adverse effects on the production and quality of tears and can cause damage to the corneal surface and conjunctival epithelia. Findings: Evidence from in vitro human cell culture and animal and clinical studies suggests that benzalkonium chloride is toxic to ocular tissues, even at very low concentrations. Use of benzalkonium chloride can result in clinical symptoms that disrupt treatment and reduce patients' quality of life. Conclusions: Switching patients to preservative-free antiglaucoma treatments greatly improves tolerability, reducing the incidence of adverse events such as burning, stinging, and dry eye. Preservative-free antiglaucoma formulations therefore offer clinical benefits to patients in terms of improved safety and increased likelihood of adherence to treatment. © 2009 by Lippincott Williams & Wilkins. AD - C. Baudouin, Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, 28 rue de Charenton, 75012 Paris, France AU - Baudouin, C. DB - Embase DO - 10.1097/ICO.0b013e3181ae8402 IS - SUPPL. 1 KW - antiglaucoma agent benzalkonium chloride drug preservative eye drops timolol blurred vision burning sensation cataract conference paper conjunctiva epithelium cornea epithelium drug formulation drug hypersensitivity drug safety dry eye epiphora filtering operation glaucoma glaucoma drainage implant human human cell immunohistochemistry inflammation intraocular hypertension intraocular pressure nonhuman patient compliance priority journal quality of life macular edema treatment failure treatment outcome LA - English M3 - Conference Paper N1 - L358275509 2010-02-19 2010-03-23 PY - 2009 SN - 0277-3740 SP - S14-S19 ST - The ocular surface in glaucoma T2 - Cornea TI - The ocular surface in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358275509&from=export http://dx.doi.org/10.1097/ICO.0b013e3181ae8402 VL - 28 ID - 3304 ER - TY - JOUR AB - Chronic glaucoma is a severe disease that can induce blindness.Early diagnosis and symptomatic treatment reduce the risk of blindness. Treatment that will be started before the onset of clinical signs and will remain lifelong thereafter is troublesome, and therapeutic compliance is usually poor. Thus, quality of life (QOL) measurement in patients with chronic glaucoma has a particular purpose: to measure patients' perception of the disease and treatment in order to maintain good treatment compliance to ensure therapeutic management efficacy and to preserve visual function. No glaucoma-specific instrument is available in the medical and QOL literature. Various generic(SF-36, SF-20 and SIP) and specific(VAQ, VF-14, NEI-VFQ) QOL questionnaires,one glaucoma-specific symptomatic scale (GSS),and one treatment preference scale (COMTol) have been used to measure QOL in glaucoma patients. These instruments do not sufficiently measure the psychosocial dimension of the disease and the QOL impact of treatment. An instrument able to measure all dimensions needs to be developed in order to help ophthalmologists in the therapeutic management of their patients and to measure QOLin patients in the successive stages of the disease. AU - Baudouin, C. AU - Bechetoille, A. AU - Bron, A. AU - Denis, P. AU - Nordmann, J. P. AU - Renard, J. P. AU - Rouland, J. F. AU - Sellem, E. AU - Rigeade, M. C. AU - Arnould, B. IS - 10 KW - Attitude to Health Chronic Disease *Glaucoma, Open-Angle/px [Psychology] Glaucoma, Open-Angle/rh [Rehabilitation] *Glaucoma, Open-Angle/th [Therapy] Humans *Patient Compliance *Quality of Life Reproducibility of Results Social Adjustment Surveys and Questionnaires PY - 2000 SE - Baudouin, C. C.H.N.O des XV-XX, Paris. SN - 0181-5512 SP - 1057-64 ST - [Relevance of quality of life and treatment compliance measurement in patients with chronic open-angle glaucoma] T2 - Interet de la mesurede la qualite de vie (QDV) et de l'observance therapeutiquechez les patients atteints de glaucome chronique a angleouvert. Groupe d'etude Glaucome et Qualite de Vie. TI - [Relevance of quality of life and treatment compliance measurement in patients with chronic open-angle glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11139707 VL - 23 ID - 1938 ER - TY - JOUR AB - Second leading cause of blindness worldwide, glaucoma is an optic neuropathy related mainly but not exclusively to an increase of intraocular pressure. Angle closure glaucoma is related to a blockade of aqueous humor to the trabecular meshwork, whereas open-angle glaucoma is a degeneration of the trabecular meshwork, the filter that allows aqueous outflow from the eye. Many improvements have been made in terms of diagnosis, follow-up and treatments, although the treatment of glaucoma is restricted to control intraocular pressure, in order to prevent optic nerve degeneration or to stop the progression of the disease toward blindness. The first line therapy is based on topical medications that are administered for the whole life span. Although globally efficient, these treatments, and most likely the preservative included in the excipient to prevent bottle contamination, induce side effects in the long-term that may impair the quality of life, patient compliance or directly induce ocular surface changes like inflammatory cytokine release, or tear film destruction, with further dry eye disease and chronic inflammation. A large body of evidence has been accumulated, showing that benzalkonium chloride, the preservative mainly used, is toxic over the long run and plays a role in such ocular surface impairment. Therefore efforts have been made in the last decade to eliminate or replace this compound, providing safer therapies to the patients. Furthermore, the identification of chemokines as playing a role in the trabecular degeneration has open new directions for treating glaucoma. The blockade of one receptor of CXCL12 has been experimentally shown not only to decrease intraocular pressure but also to prevent trabecular cell degeneration. This is an innovative concept that could allow development of new treatments, more specifically targeting the disease at its onset, rather than attempting to reduce its progression in its later stages. Copyright © Societe de Biologie, 2013. AU - Baudouin, Christophe AU - Denoyer, Alexandre AU - Rostene, William DO - https://dx.doi.org/10.1051/jbio/2013009 IS - 2 KW - Chemokines/tu [Therapeutic Use] Diagnostic Techniques, Ophthalmological/td [Trends] Drug Stability *Glaucoma/di [Diagnosis] *Glaucoma/th [Therapy] Humans Mass Screening Monitoring, Physiologic/mt [Methods] Ophthalmic Solutions/st [Standards] Ophthalmic Solutions/tu [Therapeutic Use] Ophthalmologic Surgical Procedures/td [Trends] Preservatives, Pharmaceutical/st [Standards] Preservatives, Pharmaceutical/to [Toxicity] PY - 2013 SE - Baudouin, Christophe. Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, 28 rue de Charenton, 75012 Paris, France - Institut de la Vision, Universite Pierre et Marie Curie, INSERM UMR S968, CNRS UMR 7210, 17 rue Moreau, 75012 Paris, France. SN - 2105-0686 2105-0678 SP - 87-95 ST - [Glaucoma today: detection and therapeutic progress] T2 - Le glaucome aujourd'hui : depistage et avancees therapeutiques. TI - [Glaucoma today: detection and therapeutic progress] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=24103339 VL - 207 Y2 - 20131010// ID - 935 ER - TY - JOUR AB - Second leading cause of blindness worldwide, glaucoma is an optic neuropathy related mainly but not exclusively to an increase of intraocular pressure. Angle closure glaucoma is related to a blockade of aqueous humor to the trabecular meshwork, whereas open-angle glaucoma is a degeneration of the trabecular meshwork, the filter that allows aqueous outflow from the eye. Many improvements have been made in terms of diagnosis, follow-up and treatments, although the treatment of glaucoma is restricted to control intraocular pressure, in order to prevent optic nerve degeneration or to stop the progression of the disease toward blindness. The first line therapy is based on topical medications that are administered for the whole life span. Although globally efficient, these treatments, and most likely the preservative included in the excipient to prevent bottle contamination, induce side effects in the long-term that may impair the quality of life, patient compliance or directly induce ocular surface changes like inflammatory cytokine release, or tear film destruction, with further dry eye disease and chronic inflammation. A large body of evidence has been accumulated, showing that benzalkonium chloride, the preservative mainly used, is toxic over the long run and plays a role in such ocular surface impairment. Therefore efforts have been made in the last decade to eliminate or replace this compound, providing safer therapies to the patients. Furthermore, the identification of chemokines as playing a role in the trabecular degeneration has open new directions for treating glaucoma. The blockade of one receptor of CXCL12 has been experimentally shown not only to decrease intraocular pressure but also to prevent trabecular cell degeneration. This is an innovative concept that could allow development of new treatments, more specifically targeting the disease at its onset, rather than attempting to reduce its progression in its later stages. © 2013 Société de Biologie. AD - Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, 28 rue de Charenton, 75012 Paris, France Institut de la Vision, Université Pierre et Marie Curie, INSERM UMR S968, CNRS UMR 7210, 17 rue Moreau, 75012 Paris, France AU - Baudouin, C. AU - Denoyer, A. AU - Rostène, W. DB - Scopus DO - 10.1051/jbio/2013009 IS - 2 KW - Benzalkonium Chemokines CXCL12 Glaucoma Imaging M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2013 SP - 87-95 ST - Le glaucome aujourd'hui: Dépistage et avancées thérapeutiques T2 - Biologie Aujourd'hui TI - Glaucoma today: Detection and therapeutic progress UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886532148&doi=10.1051%2fjbio%2f2013009&partnerID=40&md5=def3d926f75e8fc2615cfc4f4b60a4be VL - 207 ID - 5472 ER - TY - JOUR AB - Purpose: The SICCANOVE study aimed to compare the efficacy and safety of 0.1% cyclosporine A cationic emulsion (CsA CE) versus vehicle in patients with moderate to severe dry eye disease (DED). Methods: In this multicenter, double-masked, parallel-group, controlled study, patients were randomized (1:1) to receive CsA CE (Ikervis®) or vehicle for 6 months. The co-primary efficacy endpoints at month 6 were mean change from baseline in corneal fluorescein staining (CFS; modified Oxford scale) and in global ocular discomfort (visual analogue scale [VAS]). Results: The mean change in CFS from baseline to month 6 (CsA CE: n = 241; vehicle: n = 248) was significantly greater with CsA CE than with vehicle (-1.05 ± 0.98 and -0.82 ± 0.94, respectively; p = 0.009). Ocular discomfort improved similarly in both groups; however, the percentage of patients with ≥25% improvement in VAS was significantly higher with CsA CE (50.2%) than with vehicle (41.9%; p = 0.048). In a post hoc analysis of patients with severe ocular surface damage (CFS score 4) at baseline (CsA CE: n = 43; vehicle: n = 42), the percentage of patients with improvements of ≥2 grades in CFS score and ≥30% in Ocular Surface Disease Index score was significantly greater with CsA CE (p = 0.003). Treatment compliance and ocular tolerability were satisfactory and as expected for CsA use. Conclusion: Cyclosporine A CE was well-tolerated and effectively improved signs and symptoms in patients with moderate to severe DED over 6 months, especially in patients with severe disease, who are at risk of irreversible corneal damage. © 2017 Wichtig Publishing. AD - Quinze-Vingts National Ophthalmology Hospital, Paris, France Pierre et Marie Curie University, Paris 6, Vision Institute, INSERM UMR968, CNRS UMR7210, Paris, France University of Versailles Saint-Quentin en Yvelines, Versailles, France Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, United Kingdom Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany Santen SAS, Evry, France Campus Bio Medico, Università di Roma, Rome, Italy Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy AU - Baudouin, C. AU - Figueiredo, F. C. AU - Messmer, E. M. AU - Ismail, D. AU - Amrane, M. AU - Garrigue, J. S. AU - Bonini, S. AU - Leonardi, A. DB - Scopus DO - 10.5301/EJO.5000952 IS - 5 KW - Cationic emulsion CsA Cyclosporine Dry eye disease Severe keratitis M3 - Article N1 - Cited By :33 Export Date: 19 July 2021 PY - 2017 SP - 520-530 ST - A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye T2 - European Journal of Ophthalmology TI - A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028698795&doi=10.5301%2fEJO.5000952&partnerID=40&md5=cf795b6059791b577d3e1f79517979fd VL - 27 ID - 5042 ER - TY - JOUR AB - Purpose . To determine the prevalence of ocular surface diseases and identify risk factors in a population of patients receiving antiglaucomatous eyedrops over the long term. Methods. An observational cross-sectional study was designed to investigate ocular surface signs and symptoms using simple clinical tools. An ocular surface disease intensity score was calculated based on 10 questions regarding ocular surface symptoms and signs with a 4-grade scale. Patients were classified into 3 groups (A, B, and C) according to this total score. A multinomial logistic regression was performed in order to identify risk factors for surface disease. Results . In an overall population of 516 patients, 49% belonged to group A, 30% to group B, and 21% to group C. The multivariate analysis showed that the following factors were correlated with the severity of ocular surface disease: patient age, number of daily eyedrops, past topical treatment changes for ocular intolerance (found in the history of 40% of the patients), intraocular pressure (found to be significantly higher in patients with more severe ocular surface disease), and glaucoma severity. Conclusions . Patients treated for primary open-angle glaucoma or ocular hypertension often have ocular surface diseases, more often and more severely in older patients receiving more drugs and presenting with more severe glaucoma. These high prevalence values might therefore have consequences on the burden of the disease in terms of adherence to treatment and quality of life. AU - Baudouin, Christophe AU - Renard, Jean-Paul AU - Nordmann, Jean-Philippe AU - Denis, Philippe AU - Lachkar, Yves AU - Sellem, Eric AU - Rouland, Jean-Francois AU - Jeanbat, Viviane AU - Bouee, Stephane DO - https://dx.doi.org/10.5301/ejo.5000181 PY - 2012 SE - Baudouin, Christophe. Quinze-Vingts National Ophthalmology Hospital, Paris - France; and UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris - France; and University of Versailles St Quentin en Yvelines - France. SN - 1724-6016 1120-6721 SP - 0 ST - Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension T2 - European journal of ophthalmology TI - Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=22729444 Y2 - 20120611// ID - 42 ER - TY - JOUR AB - OBJECTIVES: The aim of this study was to assess the changes in intraocular pressure (IOP) and ophthalmic symptoms with the Glaucoma Symptom Scale in patients suffering from open-angle glaucoma (OAG) or ocular hypertension (OHT) after 3 months of treatment with latanoprost., MATERIALS AND METHODS: This multicentric open study was carried out in adult patients suffering from OAG or simple OHT (naive or previously treated with monotherapy) and needing a change or initiation of anti-glaucomatous treatment. One drop of latanoprost 0.005% was instilled every evening for 12 weeks in each affected eye. Efficacy was assessed by the variation in IOP and ophthalmic symptomatology at the end of treatment. Prognosis factors associated with a relative IOP reduction of at least 30% were sought (using a logistic regression model)., RESULTS: A total of 920 patients suffering from OAG (54%) or OHT (44%), either previously treated (69%) or naive (31%), were included. The male:female ratio was 0.78 and the mean age was 63+/-13 years. At inclusion, the mean IOP was 22.1+/-3.8 mmHg. After treatment, IOP was significantly decreased by 5.1+/-4 mmHg, corresponding to a 22% reduction. IOP reduction was 7.1+/-4 mmHg, corresponding to 29% in naive patients and 4.2+/-4 mmHg, corresponding to 19% in previously treated patients. A relative IOP reduction of at least 30% was reached by 47% of naive patients and 21% of previously treated patients. In previously treated patients, a relative IOP reduction of at least 30% had a greater chance of being reached in men with previous ophthalmic history and high IOP at inclusion (above 21 mmHg). IOP reduction was similar in patients with OAG and OHT. A significant improvement in ophthalmic symptoms was observed after treatment in previously treated patients. A total of 7% of the patients presented an adverse event affecting the visual system: eye irritation (2%), eye pain (2%), or eye hyperemia (1%). Compliance was good for 94% of the patients., CONCLUSION: Latanoprost given as first or second-line treatment at the recommended dose effectively decreases IOP in patients with OAG or OHT. This treatment also improves visual and nonvisual symptoms in previously treated patients and presents a good safety profile. AU - Baudouin, C. AU - Rouland, J. F. AU - Nordmann, J. P. AU - Bron, A. AU - Pelen, F. IS - 6 KW - *Antihypertensive Agents/ad [Administration & Dosage] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Latanoprost Male Middle Aged Ocular Hypertension/dt [Drug Therapy] *Prostaglandins F, Synthetic/ad [Administration & Dosage] Time Factors PY - 2006 SE - Baudouin, C. Service d'Ophtalmologie III, CHNO des XV-XX, Paris. SN - 1773-0597 0181-5512 SP - 615-24 ST - [Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension] T2 - Efficacite du latanoprost, donne en premiere ou deuxieme intention, sur la pression intra-oculaire et la symptomatologie oculaire chez des patients presentant un glaucome a angle ouvert ou une hypertension oculaire simple. TI - [Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16885890 VL - 29 ID - 1652 ER - TY - JOUR AB - PURPOSE: To describe the clinical outcome and complications of repeat Descemet membrane endothelial keratoplasty (re-DMEK)., DESIGN: Retrospective case series study at a tertiary referral center., PARTICIPANTS: From a series of 550 consecutive DMEK surgeries with >= 6 months follow-up, 17 eyes underwent re-DMEK for graft detachment after initial DMEK (n = 14) and/or endothelial graft failure (n = 3). The outcomes were compared with an age-matched control group of uncomplicated primary DMEK surgeries., METHODS: The re-DMEK eyes were evaluated for best-corrected visual acuity (BCVA), densitometry, endothelial cell density (ECD), pachymetry, and intraoperative and postoperative complications., MAIN OUTCOME MEASURES: Feasibility and clinical outcome of re-DMEK., RESULTS: In all eyes, re-DMEK was uneventful. At 12 months, 12 of 14 eyes (86%) achieved a BCVA of >= 20/40 (>= 0.5); 8 of 14 eyes (57%) achieved >= 20/25 (>= 0.8), 3 of 14 eyes (21%) achieved >= 20/20 (>= 1.0), and 1 eye (7%) achieved 20/17 (1.2); 5 eyes were fitted with a contact lens. Average donor ECD decreased from 2580 +/- 173 cells/mm(2) before to 1390 +/- 466 cells/mm(2) at 6 months after surgery, and pachymetry from 703 +/- 126 mum to 515 +/- 39 mum, respectively. No difference in densitometry could be detected between re-DMEK and control eyes (P = 0.99). Complications after re-DMEK included primary graft failure (n = 1), secondary graft failure (n = 2), graft detachment requiring rebubbling (n = 1), secondary glaucoma (n = 2), cataract (n = 1), and corneal ulcer (n = 1). One eye received tertiary DMEK., CONCLUSIONS: In the management of persistent graft detachment and graft failure after primary DMEK, re-DMEK proved a feasible procedure. Acceptable BCVA may be achieved, albeit lower than after DMEK in virgin eyes, and some cases may benefit from contact lens fitting. Complications after re-DMEK may be better anticipated than after primary DMEK because graft detachment and graft failure tended to recur, suggesting that intrinsic properties of the host eye play a role in graft adherence and graft failure. Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AU - Baydoun, Lamis AU - van Dijk, Korine AU - Dapena, Isabel AU - Musa, Fayyaz U. AU - Liarakos, Vasilis S. AU - Ham, Lisanne AU - Melles, Gerrit R. J. DO - https://dx.doi.org/10.1016/j.ophtha.2014.07.024 IS - 1 KW - Adult Aged Aged, 80 and over Cell Count *Corneal Diseases/su [Surgery] Corneal Pachymetry *Descemet Stripping Endothelial Keratoplasty/ae [Adverse Effects] *Descemet Stripping Endothelial Keratoplasty/mt [Methods] Endothelium, Corneal/pa [Pathology] Feasibility Studies Female Graft Rejection/et [Etiology] Humans Intraoperative Complications Male Middle Aged Postoperative Complications Reoperation Retrospective Studies Tissue Donors Visual Acuity/ph [Physiology] N1 - Comment in (CIN) PY - 2015 SE - Baydoun, Lamis. Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands; Amnitrans EyeBank, Rotterdam, The Netherlands. van Dijk, Korine. Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands. Dapena, Isabel. Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands. Musa, Fayyaz U. Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands; Calderdale and Huddersfield NHS Trust, Huddersfield, West Yorkshire, UK. Liarakos, Vasilis S. Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands. Ham, Lisanne. Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands; Amnitrans EyeBank, Rotterdam, The Netherlands. Melles, Gerrit R J. Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands; Amnitrans EyeBank, Rotterdam, The Netherlands. Electronic address: research@niios.com. SN - 1549-4713 0161-6420 SP - 8-16 ST - Repeat Descemet membrane endothelial keratoplasty after complicated primary Descemet membrane endothelial keratoplasty T2 - Ophthalmology T3 - Comment in: Ophthalmology. 2015 Jan;122(1):6-7; PMID: 25542538 [https://www.ncbi.nlm.nih.gov/pubmed/25542538] TI - Repeat Descemet membrane endothelial keratoplasty after complicated primary Descemet membrane endothelial keratoplasty UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25200401 VL - 122 Y2 - 20140905// ID - 833 ER - TY - JOUR AB - Aim: The aim of this study was to evaluate the long-term follow-up of patients who were changed to latanoprost from previous glaucoma therapies. Methods: Primary open-angle, exfoliative or chronic angle-closure glaucoma, or ocular hypertensive patients who switched to latanoprost therapy with a 2-year follow-up, were evaluated for efficacy, safety, and continuance of therapy. Results: In 1,571 patients, the intraocular pressure (IOP) across all treatment groups of 21.3 ± 4.1 was reduced to 17.6 ± 3.2 mm Hg after switching to latanoprost. Latanoprost reduced the IOP from previous monotherapies, including nonselective beta-adrenergic blockers, topical carbonic anhydrase inhibitors, alpha-adrenergic agonists and pilocarpine (p < 0.0001) and adjunctive therapies, including the fixed combinations of dorzolamide and timolol, pilocarpine and timolol, and pilocarpine and metipranolol, and the unfixed combination of dorzolamide and timolol and dorzolamide and clonidine (p < 0.0028). Latanoprost further reduced the IOP across all diagnostic groups (p < 0.0001). The most common ocular adverse event was ocular irritation (n = 25; 1.6%), which was also the most common reason given for patients who discontinued latanoprost because of an adverse event (n = 20; 1.3%). Conclusions: The mean IOP was maintained at an acceptable level throughout the 2-year follow-up period on latanoprost. Latanoprost generally provides further reduction of IOP when switched from previous mono- and adjunctive therapies, with a low rate of side effects and discontinuations. AD - W.C. Stewart, Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC 29412-2464, United States AU - Bayer, A. AU - Weiler, W. AU - Oeverhaus, U. AU - Skrotzki, F. E. AU - Stewart, W. C. C1 - xalatan(Pfizer,United States) C2 - Pfizer(United States) DB - Embase Medline DO - 10.1089/jop.2004.20.470 IS - 6 KW - epinephrine alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent betaxolol brimonidine carbonate dehydratase inhibitor carteolol cholinergic receptor stimulating agent clonidine dipivefrine dorzolamide latanoprost levobunolol metipranolol pilocarpine timolol adult aged article closed angle glaucoma conjunctival hyperemia controlled study drug efficacy drug safety pseudoexfoliation eye inflammation eye irritation female follow up glaucoma human intraocular hypertension intraocular pressure intraocular pressure abnormality major clinical study male monotherapy open angle glaucoma patient compliance treatment outcome treatment withdrawal visual impairment xalatan LA - English M3 - Article N1 - L39628493 2004-12-31 PY - 2004 SN - 1080-7683 SP - 470-478 ST - Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies T2 - Journal of Ocular Pharmacology and Therapeutics TI - Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39628493&from=export http://dx.doi.org/10.1089/jop.2004.20.470 VL - 20 ID - 3715 ER - TY - JOUR AD - T.K. Beattie, Department of Vision Sciences, Glasgow Caledonian University, Cowcaddens Road, Glasgow G4 OBA, United Kingdom AU - Beattie, T. K. AU - Tomlinson, A. AU - Seal, D. V. DB - Embase Medline DO - 10.1136/bjo.86.11.1319 IS - 11 KW - catalase hydrogen peroxide poly(hexamethylenebiguanide) Acanthamoeba Acanthamoeba keratitis contact lens disinfection keratitis letter microbial sensitivity test minimum inhibitory concentration patient compliance priority journal LA - English M3 - Letter N1 - L35238631 2002-11-12 PY - 2002 SN - 0007-1161 SP - 1319-1320 ST - Anti-acanthamoeba efficacy in contact lens disinfecting systems [11] T2 - British Journal of Ophthalmology TI - Anti-acanthamoeba efficacy in contact lens disinfecting systems [11] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35238631&from=export http://dx.doi.org/10.1136/bjo.86.11.1319 VL - 86 ID - 3847 ER - TY - JOUR AB - The use of trabeculectomy in advanced pediatric glaucoma is reviewed. Intraocular pressure was controlled in only 50% of the patients, and the best visual results was 20/200. Complications of vitreous loss, scleral collapse, ectasia, retinal detachment, and endophthalmitis were encountered. No evidence was found to support the claim that in the seriously compromised buphthalmic eyes, trabeculectomy is safer than other filtering operations since it filters under a scleral flap. AU - Beauchamp, G. R. AU - Parks, M. M. IS - 1 KW - Adolescent Adult Child Child, Preschool Endophthalmitis/co [Complications] Female *Glaucoma/su [Surgery] Humans Infant *Intraocular Pressure Intraoperative Complications Male Postoperative Complications Retinal Detachment/co [Complications] *Trabecular Meshwork/su [Surgery] Visual Acuity PY - 1979 SN - 0161-6420 SP - 170-80 ST - Filtering surgery in children: barriers to success T2 - Ophthalmology TI - Filtering surgery in children: barriers to success UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=316885 VL - 86 ID - 2270 ER - TY - JOUR AN - 105533385. Language: English. Entry Date: 20090710. Revision Date: 20150711. Publication Type: Journal Article AU - Bechtel, B. AU - Boyle, E. L. AU - Hasson, M. AU - Mullin, D. W. DB - ccm DP - EBSCOhost IS - 9 KW - Contact Lenses -- Adverse Effects Keratitis -- Risk Factors Environment Keratitis -- Physiopathology Keratitis -- Symptoms Patient Compliance Time Factors N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 27-27 ST - Several factors increase risk of severe keratitis due to contact lens use T2 - Ocular Surgery News TI - Several factors increase risk of severe keratitis due to contact lens use UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105533385&site=ehost-live&scope=site VL - 27 ID - 4656 ER - TY - JOUR AB - BACKGROUND: To compare the tolerability of commonly prescribed topical glaucoma medications by determining frequency and bother of side effects, patient satisfaction with their medication, and the chance of discontinuation of eye drops., METHODS: The tolerability of topical glaucoma medication was studied in glaucoma patients from nine hospitals. The frequency and severity of side effects was investigated together with patient satisfaction with the medication and the probability to change medication due to reported side effects. To register side effects of topical glaucoma medication, patients were requested to fill in a questionnaire based on "the Comparison of Ophthalmic Medications for Tolerability" (COMTOL) questionnaire supplemented with items based on the most frequently observed and severe side effects., RESULTS: The number of patients responding was 3,333 (87%). Most patients (79%) were satisfied with their eye medication. The median score for ocular side effects was 58 on a scale ranging from 0 to 320. The probability that medication would be changed by the ophthalmologist at the next visit due to reported side effects occurring since the patients' last or last but one visit to the ophthalmologist was 9%. The most frequently prescribed drugs were timolol, latanoprost, and the fixed combinations of dorzolamide/timolol (Cosopt) and latanoprost/timolol (Xalcom). Only small differences in tolerability were found between these drugs., CONCLUSIONS: The tolerability of timolol, latanoprost, and the fixed combinations of latanoprost/timolol (Xalcom) and dorzolamide/timolol (Cosopt) seem to be comparable. Patients are satisfied with their glaucoma medication and have a low chance of discontinuation of eye drops due to side effects. AU - Beckers, Henny J. M. AU - Schouten, Jan S. A. G. AU - Webers, Carroll A. B. AU - van der Valk, Rikkert AU - Hendrikse, Fred DO - https://dx.doi.org/10.1007/s00417-008-0875-7 IS - 10 KW - Administration, Topical Adult Aged Aged, 80 and over Antihypertensive Agents/ad [Administration & Dosage] *Antihypertensive Agents/ae [Adverse Effects] Drug Combinations Female *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Latanoprost Male Middle Aged Ophthalmic Solutions/ad [Administration & Dosage] *Ophthalmic Solutions/ae [Adverse Effects] *Patient Compliance *Patient Satisfaction Prostaglandins F, Synthetic/ad [Administration & Dosage] Prostaglandins F, Synthetic/ae [Adverse Effects] Sulfonamides/ad [Administration & Dosage] Sulfonamides/ae [Adverse Effects] Surveys and Questionnaires Thiophenes/ad [Administration & Dosage] Thiophenes/ae [Adverse Effects] Timolol/ad [Administration & Dosage] Timolol/ae [Adverse Effects] PY - 2008 SE - Beckers, Henny J M. Department of Ophthalmology, Maastricht University Hospital, Maastricht, The Netherlands. hbec@soog.azm.nl SN - 0721-832X SP - 1485-90 ST - Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction T2 - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie TI - Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18575878 VL - 246 Y2 - 20080625// ID - 1525 ER - TY - JOUR AB - PURPOSE: To study the effect of patient education and the TravAlert( R) -Eyot( R) drop guider on intraocular pressure (IOP) and adherence in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) monitored with the TravAlert( R) dosing aid., METHODS: Multicentre, randomized, controlled clinical trial among 18 Dutch hospitals. Patients were randomized to one of the four study arms: (1) use of the dosing aid, (2) use of the dosing aid with the drop guider, (3) use of the dosing aid together with patient education or (4) use of the dosing aid and drop guider together with patient education. IOP was recorded at baseline and after 3 and 6 months. Data on adherence generated by the dosing aid were collected and studied at the end of the study., RESULTS: Mean IOP dropped from 20.3 +/- 5.7 mmHg at baseline to 16.3 +/- 4.0 mmHg (right eye) after 6 months and from 20.2 +/- 5.9 mmHg to 16.4 +/- 4.1 mmHg (left eye). The mean adherence rate was 0.91 +/- 0.1. IOP and adherence rate were not statistically different between the study arms. Patients with 'drug holidays' had a significantly higher mean IOP after 6 months. Patients who used the drop guider were less adherent. A lower adherence level was also associated with new patients with glaucoma and patients with a lower level of knowledge on glaucoma., CONCLUSION: Patient education is especially useful for new patients with glaucoma. The use of a drop guider does not improve adherence. Especially patients with 'drug holidays' are at risk for developing uncontrolled IOP levels. Copyright © 2012 Acta Ophthalmologica Scandinavica Foundation. AU - Beckers, Henny J. M. AU - Webers, Carroll A. B. AU - Busch, Michiel J. W. M. AU - Brink, Hendrik M. A. AU - Colen, Thomas P. AU - Schouten, Jan S. A. G. AU - Dutch Adherence Study, Group DO - https://dx.doi.org/10.1111/j.1755-3768.2012.02571.x IS - 7 KW - Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Cloprostenol/aa [Analogs & Derivatives] Drug Combinations *Drug Monitoring/is [Instrumentation] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Netherlands *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions *Patient Compliance/sn [Statistics & Numerical Data] *Patient Education as Topic Surveys and Questionnaires Timolol Tonometry, Ocular Travoprost PY - 2013 SE - Beckers, Henny J M. University Eye Clinic, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Ophthalmology, Catharina Hospital, Eindhoven, The NetherlandsDepartment of Ophthalmology, Jeroen Bosch Hospital, 's Hertogenbosch, The NetherlandsDepartment of Ophthalmology, Amphia Hospital Langendijk, Breda, The Netherlands. SN - 1755-3768 1755-375X SP - 610-8 ST - Adherence improvement in Dutch glaucoma patients: a randomized controlled trial T2 - Acta ophthalmologica TI - Adherence improvement in Dutch glaucoma patients: a randomized controlled trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23025424 VL - 91 Y2 - 20121001// ID - 1014 ER - TY - JOUR AB - PURPOSE: Currently, the most feared complication by ophthalmologists of contact lens (CL) wear is microbial keratitis (MK), even though its incidence remains low. It is also a significant financial burden for society. This study aimed to identify the risk factors for CL-related MK especially with regard to hygiene and pattern of use, in a large, prospective, multicenter, case-control study., METHODS: A multicenter retrospective case-control study was designed. The CL-related MK subpopulation (case) was compared with healthy CL wearers (control) using a 52-item anonymous questionnaire designed to determine subject demographics, lens wear history, lens type and disinfection solution, fitting, patient education, hygiene and maintenance of contact lenses, and patient history. Univariate logistic regression analysis was performed to compare both groups., RESULTS: The study included 497 cases and 364 controls. The risk factors associated with the greatest increased odds of CL-related MK were as follows: extended wear (OR=2.96 [1.65-5.33], P<0.001), occasional overnight lens use (OR=6.37 [4,55-8.90], P<0.001), fitting by an optician (OR=1.97 [1.38-2.83], P<0.001), absence of ophthalmologic exam (OR=6.56 [2-22], P<0.01) or no training in handling the contact lens (OR=4.47 [2.27-8.77], P<0.01), use of optician's disinfection solution (OR=5.55 [3.12-9.85], P<0.001), mixing solutions ("topping off") (OR=4.68 [2.73-8.04], P<0.001), no case replacement (OR=3.95 [2.28-6.82] P<0.01), no compliance with hygiene rules and smoking (OR=2.29 [1.67-3.14], P<0.01). The protective factors associated with the greatest reduction in OR were female gender (OR=0.49 [0.36-0.66], P<0.01), hypermetropia (OR=0.28 [0.16-0.48], P=0.01), rigid contact lens wear, fitting by an ophthalmologist, written and verbal instruction, and daily case maintenance., CONCLUSION: The knowledge of these risks factors incentivizes action at all levels to reduce the incidence of MK, from the prescriber to the patient, including the type of CL, case and contact lens solution. Copyright © 2017 Elsevier Masson SAS. All rights reserved. AU - Becmeur, P. H. AU - Abry, F. AU - Bourcier, T. AU - Meyer, N. AU - Sauer, A. DO - https://dx.doi.org/10.1016/j.jfo.2016.10.008 IS - 3 KW - Adolescent Adult Aged Aged, 80 and over Case-Control Studies Child *Contact Lenses/ae [Adverse Effects] Contact Lenses/mi [Microbiology] Contact Lenses/sn [Statistics & Numerical Data] *Eye Infections, Bacterial/ep [Epidemiology] *Eye Infections, Bacterial/et [Etiology] Eye Infections, Bacterial/mi [Microbiology] Female France/ep [Epidemiology] Humans *Keratitis/ep [Epidemiology] *Keratitis/et [Etiology] Keratitis/mi [Microbiology] Male Middle Aged Retrospective Studies Risk Factors Young Adult N1 - <> PY - 2017 SE - Becmeur, P H. Ophtalmologie, NHC, CHU de Strasbourg, 1, place de l'Hopital, 67000 Strasbourg, France. Electronic address: pierrehenri.becmeur@gmail.com. Abry, F. Centre hospitalier d'Epinal, 3, avenue Robert-Schuman, 88021 Epinal, France. Bourcier, T. Ophtalmologie, NHC, CHU de Strasbourg, 1, place de l'Hopital, 67000 Strasbourg, France. Meyer, N. Ophtalmologie, NHC, CHU de Strasbourg, 1, place de l'Hopital, 67000 Strasbourg, France. Sauer, A. Ophtalmologie, NHC, CHU de Strasbourg, 1, place de l'Hopital, 67000 Strasbourg, France. SN - 1773-0597 0181-5512 SP - 224-231 ST - [Risk factors for contact lens-related microbial keratitis: A multicenter case-control study] T2 - Facteurs de risque de keratites infectieuses chez les porteurs de lentilles de contact, une etude cas-temoins. TI - [Risk factors for contact lens-related microbial keratitis: A multicenter case-control study] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28325674 VL - 40 Y2 - 20170318// ID - 524 ER - TY - JOUR AB - It has been suggested (Block, 2007) that the core neural bases for visual phenomenal consciousness and for access consciousness are located in anatomically separate regions. If this is correct, and if, as Block suggests, the core neural substrate of visual phenomenality is located early in the visual cortex where detailed chromatic information is available, then it would be reasonable to infer that our intuitions of chromatically rich visual phenomenality are plausible. It is furthermore suggested that during perception cognitive access to this chromatic cornucopia is mediated through mereologically superordinate (MS) concepts that regionally characterize both semantic and quantitative integrated properties within complex visual percepts. Such concepts contain much less information than do the particulars that they characterize, implying that the information represented in phenomenal consciousness greatly exceeds the information in the accompanying access consciousness. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Beeckmans, John, University of Western Ontario, Faculty of Engineering, 1393 Western Road, London, ON, Canada, N6G 1G9 AN - 2009-21982-005 AU - Beeckmans, John DB - psyh DO - 10.1016/j.concog.2009.08.007 DP - EBSCOhost IS - 4 KW - chromatic phenomenality cognitive accessibility visual phenomenal consciousness visual cortex chromatic cornucopia visual percepts Attention Awareness Color Perception Consciousness Discrimination (Psychology) Field Dependence-Independence Frontal Lobe Humans Judgment Memory, Short-Term Orientation Pattern Recognition, Visual Prefrontal Cortex Psychophysics Retention (Psychology) Semantics Size Perception Social Environment Unconscious (Psychology) Visual Perception Chromaticity Consciousness States Cornea N1 - Faculty of Engineering, University of Western Ontario, London, ON, Canada. Release Date: 20100125. Correction Date: 20180927. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Chromaticity; Consciousness States; Visual Cortex; Visual Perception. Minor Descriptor: Cornea. Classification: Visual Perception (2323). Population: Human (10). References Available: Y. Page Count: 12. Issue Publication Date: Dec, 2009. Publication History: First Posted Date: Sep 24, 2009; First Submitted Date: Jan 22, 2009. Copyright Statement: All rights reserved. Elsevier Inc. 2009. PY - 2009 SN - 1053-8100 1090-2376 SP - 917-928 ST - How chromatic phenomenality largely overflow its cognitive accessibility T2 - Consciousness and Cognition: An International Journal TI - How chromatic phenomenality largely overflow its cognitive accessibility UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-21982-005&site=ehost-live&scope=site jbeeckmans@eng.uwo.ca VL - 18 ID - 4881 ER - TY - JOUR AB - Prevention and early management of post-burn cicatricial ectropion is the best strategy to avoid ocular complications, with poor visual prognosis in extreme cases. A 51-year old man presented with diminution of vision and absolute inability to close both eyes, three months after thermal burn injuries to face, upper limbs and trunk. His best corrected visual acuity (BCVA) was 1/60 in BE. He had bilateral extremely severe ectropion involving both upper and lower lids with complete inability to close the eyes. The ensuing exposure keratitis developed secondary infection by Methicillin resistant Staphylococcus aureus (MRSA) in the right eye and multi-drug resistant Pseudomonas aeruginosa in the left eye. His extreme ectropion prevented infection healing, so its release and full-thickness skin grafting was done when partial resolution of infection was noted. After three months, he had moderate residual ectropion in BE; vascularised corneal scar in the inferior part of the right eye (BCVA:20/40) and adherent leucoma in left eye (BCVA:HM). Prioritising ectropion surgery in our extreme case for infection control, facilitated corneal healing. Our case highlights the extreme consequences of not taking preventive measures or of managing incident ectropion following thermal injury to the face. Copyright © The Author(s) 2021. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. AU - Behera, Geeta AU - Sangaraju, Suneel AU - Thiruvoth, Friji M. AU - Kasturi, Nirupama AU - Babu, Krishna Ramesh DO - https://dx.doi.org/10.1093/jbcr/irab027 PY - 2021 SE - Behera, Geeta. Department of Ophthalmology, Department of Plastic Surgery. Sangaraju, Suneel. Department of Ophthalmology, Department of Plastic Surgery. Thiruvoth, Friji M. Jawaharlal Institute of Post-Graduate Medical Education and Research (JIPMER), Puducherry, India. Kasturi, Nirupama. Department of Ophthalmology, Department of Plastic Surgery. Babu, Krishna Ramesh. Department of Ophthalmology, Department of Plastic Surgery. SN - 1559-0488 1559-047X ST - Vision and Ocular Surface Salvage in Extreme Post-Burn Cicatricial Ectropion with Infectious Exposure Keratitis T2 - Journal of burn care & research : official publication of the American Burn Association TI - Vision and Ocular Surface Salvage in Extreme Post-Burn Cicatricial Ectropion with Infectious Exposure Keratitis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=33528555 Y2 - 20210202// ID - 26 ER - TY - JOUR AB - PurposeTo determine the cumulative worldwide incidence of infectious endophthalmitis and associated vision loss after Boston keratoprosthesis (B-KPro) Type I/II implantation and to propose both safe and inexpensive prophylactic antibiotic regimens. MethodsTwo retrospective methods were used to determine the incidence, visual outcomes and aetiologies of infectious endophthalmitis associated with the B-KPro divided per decade: (i) systematic review of the literature from 1990 through January 2013 and (ii) a surveillance survey sent to all surgeons who implanted B-KPros through 2010 with 1-year minimum follow-up. In addition, a single-Boston surgeon 20-year experience was examined. ResultsFrom 1990 through 2010, there were 4729 B-KPros implanted worldwide by 209 U.S. surgeons and 159 international surgeons. The endophthalmitis cumulative mean incidence declined from 12% during its first decade of use to about 3% during its second decade in the Unites States and about 5% internationally during the second decade. There remains a large incidence range both in the United States (1-12.5%) and internationally (up to 17%). Poor compliance with daily topical antibiotics is an important risk factor. While Gram-positive organisms remained dominant, fungal infections emerged during the second decade. ConclusionsDaily prophylactic topical antibiotics have dramatically reduced the endophthalmitis incidence. Although Gram-positive organisms are the most common aetiology, antimicrobials must be inclusive of Gram-negative organisms. Selection of prophylactic regimens should be tailored to local antibiotic susceptibility patterns, be cost-effective, and should not promote the emergence of antimicrobial resistance. An example of a broad-spectrum, low-cost prophylactic option for non-autoimmune patients includes trimethoprim/polymyxinB once daily. AN - WOS:000344162700007 AU - Behlau, I. AU - Martin, K. V. AU - Martin, J. N. AU - Naumova, E. N. AU - Cadorette, J. J. AU - Sforza, J. T. AU - Pineda, R. AU - Dohlman, C. H. DA - NOV DO - 10.1111/aos.12309 IS - 7 PY - 2014 SN - 1755-375X 1755-3768 SP - e546-e555 ST - Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention T2 - ACTA OPHTHALMOLOGICA TI - Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention VL - 92 ID - 6327 ER - TY - JOUR AD - K.R. Belen'kii AU - Belen'kii, K. R. DB - Medline IS - 4 KW - ambulatory care article follow up glaucoma human intraocular pressure oculoplethysmography prospective study LA - Russian M3 - Article N1 - L5525421 1975-10-02 PY - 1975 SN - 0030-0675 SP - 275-277 ST - Pre-glaucoma T2 - Oftalmologicheskii zhurnal TI - Pre-glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L5525421&from=export VL - 30 ID - 4118 ER - TY - JOUR AB - OBJECTIVES: Glaucoma is a major cause of blindness, preventable by a regular therapy. Thus, a good knowledge of patients' adherence to preventive therapy is critical to improve disease management. Early persistence to first-line glaucoma therapy is poorly documented in France. We verified to what extent first-line glaucoma therapy was interrupted within the 12 months following initiation and how this interruption varied with patients' characteristics and drug classes., METHODS: Patients newly-treated with chronic glaucoma therapy (prostaglandins, beta-blockers alone or combined with another therapy, and topical carbonic anhydrase inhibitors) between 2005 and 2008 were identified in the French National Claims data (1/97th random sample). Twelve-month persistence was defined by the presence of the first-line drug class (>=1dispensation) between the 12th and 24th months following initiation. Twelve-month persistence was compared between patients according to the first-line drug classes and baseline characteristics. Proportion of days covered (12 months) and number of quarters with initiated drug class (24 months) were also studied., RESULTS: Among 5331 patients initiated with chronic glaucoma therapy in monotherapy (63% aged >=60 years old, 57% females), initiated therapy mainly consisted of prostaglandins (43%) and beta-blockers alone (32%). Only 45% of the patients were persistent to first-line therapy 12 months after initiation. Salient differences in persistence rates appeared between drug classes (P<0.0001): from 59% with prostaglandins to 26% for topical carbonic anhydrase inhibitors. Better results also appeared for prostaglandins with other dimensions of adherence. Non-persistent patients were more likely younger than 40, or conversely aged>=80 (P<0.0001). They were also more likely to necessitate social assistance for therapy (P=0.0007). No salient difference appeared as to gender., CONCLUSIONS: Our findings confirm the low early persistence of first-line therapy, despite better results for prostaglandins. Education of patients and identification of barriers to adherence could contribute to improve quality of care. Copyright © 2016 Societe francaise de pharmacologie et de therapeutique. Published by Elsevier Masson SAS. All rights reserved. AU - Belhassen, Manon AU - Laforest, Laurent AU - Licaj, Idlir AU - Van Ganse, Eric DO - https://dx.doi.org/10.1016/j.therap.2016.02.033 IS - 5 KW - Adrenergic beta-Antagonists/tu [Therapeutic Use] Adult Aged Aged, 80 and over Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] Female France *Glaucoma/dt [Drug Therapy] Humans Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Prostaglandins/tu [Therapeutic Use] PY - 2016 SE - Belhassen, Manon. HESPER 7425, Health Services and Performance Research, universite Claude-Bernard Lyon-1, Lyon, France; PELyon, Lyon, France. Laforest, Laurent. HESPER 7425, Health Services and Performance Research, universite Claude-Bernard Lyon-1, Lyon, France; PELyon, Lyon, France. Licaj, Idlir. HESPER 7425, Health Services and Performance Research, universite Claude-Bernard Lyon-1, Lyon, France; PELyon, Lyon, France. Van Ganse, Eric. HESPER 7425, Health Services and Performance Research, universite Claude-Bernard Lyon-1, Lyon, France; PELyon, Lyon, France; Service de pneumologie, hopital universitaire de la Croix-Rousse, Lyon, France. Electronic address: eric.van-ganse@univ-lyon1.fr. SN - 0040-5957 SP - 491-499 ST - [Early adherence to anti-glaucoma therapy: An observational study] T2 - Etude observationnelle sur l'adhesion precoce aux traitements hypotonisants anti-glaucomateux. TI - [Early adherence to anti-glaucoma therapy: An observational study] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27203158 VL - 71 Y2 - 20160411// ID - 679 ER - TY - JOUR AB - The main treatment for angle-closure glaucoma is laser iridectomy. Somatic comorbidity (autoimmune, allergic, chronic infectious diseases) affects the results of laser iridectomy. Purpose: to evaluate in practice the algorithm for applying the method of laser iridectomy in compliance with preventive measures, including medical support before and after surgery, both in patients with concomitant somatic pathology and without it. Patients and methods. The analysis of combined laser iridectomy's results in 61 patients (94 eyes) was carried out. A method was used to determine the tactics of management the patients with latent stage of angle-closure glaucoma and pigment dispersion syndrome (Patent RU N 2726404), including an assessment of the general immune status based on information about somatic diseases and medications taken. Combined laser iridectomy was performed in two stages in one visit. The first stage is coagulation in the projection of the lacunae at the periphery of the iris; at the second stage, two through holes were formed. All patients received medication in accordance with the algorithm. The level of reactive hypertension was assessed in 1 hour after surgery, on the first and seventh days after the intervention. Results. In case of standard medical support for laser iridectomy, the level of reactive hypertension is higher in the group of patients with concomitant somatic pathology than without it. Adding additions to the standard drug regimen in a group of patients with impaired general immune status ensures that the target intraocular pressure is achieved. The use of an algorithm for performing laser iridectomy in patients with angle-closure glaucoma and concomitant somatic pathology makes it possible to achieve the target intraocular pressure early after surgery and to avoid complications. © 2020 Ophthalmology Publishing Group. All rights reserved. AD - Federal Institute of the Professional Development, Gamalei str., 15, Moscow, 123098, Russian Federation Ophthalmology Clinic of Dr. Belikova, Budenny ave., 26/2, Moscow, 105118, Russian Federation AU - Belikova, E. I. AU - Sharova, G. A. DB - Scopus DO - 10.18008/1816-5095-2020-4-705-710 IS - 4 KW - Algorithm Angle-closure glaucoma Combined laser iridectomy Laser iridectomy Reactive hypertension M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 ST - Алгоритм выполнения лазерной иридэктомии у пациентов с закрытоугольной глаукомой и сопутствующей соматической патологией T2 - Oftalmologiya TI - Algorithm for performing laser iridectomy in patients with angle-closure glaucoma and concomitant somatic pathology UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099715824&doi=10.18008%2f1816-5095-2020-4-705-710&partnerID=40&md5=2e7b2984e874804956e7136279379d45 VL - 17 ID - 5680 ER - TY - JOUR AB - PURPOSE: To present a case of repeated graft dislocation after Descemet stripping automated endothelial keratoplasty (DSAEK) in a post-trabeculectomy eye and to suggest a simple postoperative maneuver to minimize this occurrence., METHODS: A 61-year-old woman presented to our cornea clinic with pseudophakic bullous keratopathy in her left eye 13 years after a trabeculectomy had been performed. After the DSAEK was performed, repeated graft dislocations were observed. When air was seen in the filtering bleb in the immediate postoperative period, it was assumed that it had escaped from the air bubble remaining in the anterior chamber at the end of the surgery. The patient was thus placed in the Trendelenburg position immediately after performing a rebubbling procedure to retain the air bubble in the anterior chamber and away from the filtering bleb., RESULTS: The corneal graft remained centered and clear at postoperative day 1 and remained so at the last follow-up visit 8 months after the surgery had taken place. The patient's intraocular pressure was well controlled with a functional filtering bleb., CONCLUSIONS: Postoperative Trendelenburg positioning is an easily applied maneuver that may promote graft adherence after performing a DSAEK in eyes that have undergone glaucoma surgery. AU - Belkin, Avner AU - Nesher, Ronit AU - Segev, Fani DO - https://dx.doi.org/10.1097/ICO.0b013e31829eeafb IS - 11 KW - *Descemet Stripping Endothelial Keratoplasty/mt [Methods] Female *Glaucoma/su [Surgery] *Graft Rejection/pc [Prevention & Control] *Head-Down Tilt Humans Middle Aged Patient Positioning/mt [Methods] Postoperative Period Treatment Outcome PY - 2013 SE - Belkin, Avner. *Department of Ophthalmology, Meir Medical Center, Kfar Saba, Israel; and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. SN - 1536-4798 0277-3740 SP - 1509-11 ST - Postoperative trendelenburg position for graft adherence after descemet stripping automated endothelial keratoplasty T2 - Cornea TI - Postoperative trendelenburg position for graft adherence after descemet stripping automated endothelial keratoplasty UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23974891 VL - 32 ID - 942 ER - TY - JOUR AB - Glaucoma is a collection of diseases characterized by multifactorial progressive changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocular pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic nerve damage. Treatment usually begins with topical pharmacological agents as monotherapy, progresses to combination therapy with agents from up to 4 different classes of IOP-lowering medications, and then proceeds to laser or incisional surgical modalities for refractory cases. The fixed combination therapy with the carbonic anhydrase inhibitor dorzolamide hydrochloride 2% and the beta blocker timolol maleate 0.5% is now available in a generic formulation for the treatment of patients who have not responded sufficiently to monotherapy with beta adrenergic blockers. In pre- and postmarketing clinical studies, the fixed combination dorzolamide-timolol has been shown to be safe and efficacious, and well tolerated by patients. The fixed combination dorzolamide-timolol is convenient for patients, reduces their dosing regimen with the goal of increasing their compliance, reduces the effects of "washout" when instilling multiple drops, and reduces the preservative burden by reducing the number of drops administered per day. AU - Bell, Nicholas P. AU - Ramos, Jose L. AU - Feldman, Robert M. DO - https://dx.doi.org/10.2147/OPTH.S14054 PY - 2010 SE - Bell, Nicholas P. Robert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, Houston, Texas 77030, USA. SN - 1177-5483 1177-5467 SP - 1331-46 ST - Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=21139674 VL - 4 Y2 - 20101122// ID - 1208 ER - TY - JOUR AB - Low patient compliance and poor bioavailability of ophthalmic medications are the main limitations of topical eye drops. A potential solution to these disadvantages could be provided by thermoresponsive hydrogels, which could be used as the basis for a gelling eye drop for long-term release of therapeutics. We previously reported such a system capable of being retained in the lower fornix of rabbits, continuously releasing an anti-glaucoma drug for one month. Here, we sought to improve the properties of the existing gels as most relevant to patient use without altering the drug release profile. Specifically, we optimized the sol-to-gel transition temperature and de-swelling kinetics of pNIPAAm gels to avoid risk of the gelled drop reverting to liquid during cold or windy weather, and ensure quick gelation upon administration. A reduction of the gel LCST, faster gelation kinetics, and suitable viscosity for the administration as an eye drop were successfully achieved through modification of the poly(ethylene glycol) content in the water phase and its molecular weight. Our data suggest that drug release is not affected by these changes, with representative drug concentration profiles of the previous and new formulations demonstrating comparable anti-glaucoma release kinetics. AU - Bellotti, Elena AU - Fedorchak, Morgan V. AU - Velankar, Sachin AU - Little, Steven R. DO - https://dx.doi.org/10.1039/C8TB02976H IS - 8 KW - *Acrylic Resins/ch [Chemistry] Administration, Topical Cell Survival/de [Drug Effects] Conjunctiva/cy [Cytology] *Drug Carriers/ch [Chemistry] Drug Liberation Elastic Modulus Epithelial Cells/cy [Cytology] Epithelial Cells/de [Drug Effects] Epithelial Cells/me [Metabolism] *Hydrogels/ch [Chemistry] Hydrogels/pd [Pharmacology] Kinetics Ophthalmic Solutions/ch [Chemistry] Ophthalmic Solutions/me [Metabolism] Transition Temperature Viscosity PY - 2019 SE - Bellotti, Elena. Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA, 15261, USA. Fedorchak, Morgan V. Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA, 15261, USA. Fedorchak, Morgan V. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15261, USA. Fedorchak, Morgan V. Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. Fedorchak, Morgan V. Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, 15213, USA. Fedorchak, Morgan V. McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, 15219, USA. Velankar, Sachin. Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA, 15261, USA. Little, Steven R. Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA, 15261, USA. Little, Steven R. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15261, USA. Little, Steven R. Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. Little, Steven R. McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, 15219, USA. Little, Steven R. Department of Immunology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. Little, Steven R. Department of Pharmaceutical Science, University of Pittsburgh, Pittsburgh, PA, 15213, USA. SN - 2050-750X SP - 1276-1283 ST - Tuning of thermoresponsive pNIPAAm hydrogels for the topical retention of controlled release ocular therapeutics T2 - Journal of materials chemistry. B TI - Tuning of thermoresponsive pNIPAAm hydrogels for the topical retention of controlled release ocular therapeutics UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30931126 VL - 7 Y2 - 20190125// ID - 345 ER - TY - JOUR AB - CCT is a simple, noninvasive, short, ablative surgical procedure that has been effectively used to treat advanced uncontrolled glaucoma. A specific protocol is recommended and the rationale for strict adherence is presented. The long-term benefits of CCT in patients with open-angle glaucoma following cataract extraction have been well established. However, although patients with neovascular glaucoma may have adequate pressure control following CCT, the serious complications of progression to no light perception and phthisis bulbi have discouraged its use. CCT can be effective for neovascular glaucoma when other methods of surgical management prove unsuccessful and visual prognosis is very poor. The loss of functional vision occurred in fewer than 10 percent of eyes treated with CCT, and it is important to emphasize that only eyes with greatest risk and poorest prognosis were treated with this modality. CCT has become an important addition to the surgical armamentarium for the treatment of some specific types of glaucoma. AU - Bellows, A. R. IS - 1 KW - *Ciliary Body/su [Surgery] Cryosurgery/ae [Adverse Effects] *Cryosurgery/mt [Methods] *Glaucoma/su [Surgery] Humans PY - 1981 SN - 0020-8167 SP - 99-111 ST - Cyclocryotherapy for glaucoma T2 - International ophthalmology clinics TI - Cyclocryotherapy for glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=7216652 VL - 21 ID - 2257 ER - TY - JOUR AB - Two cases of delayed bacterial keratitis with serious acute corneal ulceration, previously operated by radical keratotomy in another institution one and three years ago and later referred to our Hospital to be operated by penetrating keratoplasty are reported. Ulcerative bacterial keratitis evolved slowly requiring vigorous local and systemic antibiotic therapy but gradually the infiltrate resolved, the cornea thickened and the ulcer epitheliazed leaving a dense paracentral leucoma. Penetrating keratoplasty was suggested. The main surgical problem was the tendency of the radial incisions to unfold when cut by the corneal trephine and during the graft suture, causing poor wound edge apposition. In the first case, transverse 10/0 nylon interrupted stitches, across each opened radial incision, about 1 mm external to the graft wound were used. In the second case, a preplaced 10/0 nylon single purse-string suture, 1 mm from the limbus was used before trephination, in order to stabilize the peripheral cornea. In the last case dehiscence of the radical incision did not occur during surgical handling. The graft was secured with a single 10/0 nylon running suture placed in each peripheral corneal pillar, between radial keratotomy incisions. Postoperative follow-up was uneventful. One year after penetrating keratoplasty both cases showed a clear graft and visual acuity of 20/20 under correction. Histopathologic examination of the corneal buttons at the level of the leucoma disclosed a thickened epithelium associated with a defective stromal structure. More characteristically, round prominent epithelial retention cysts or long epithelial plugs within some radial incision, that by chance extended deeply through the corneal stroma, were observed. These pathological changes demonstrate abnormal would healing after radial keratotomy. The violation of the epithelial barrier explains the vulnerability of the cornea after this refractive procedure with respect to infection or trauma. This gives rise to an increased risk of postoperative bacterial ulcerative keratitis even several years after surgery or radical incision dehiscence during the subsequent penetrating keratoplasty. AD - Hospital General, Servicio de Oftalmologia, C/. Maestro Alonso, 109, 03010 Alicante, Spain AU - Belmonte Martinez, J. AU - Vidal Candela, T. AU - Munoz Gil, B. AU - Baeza Diaz, M. AU - Hernandez Artola, F. AU - Trigueros Mateos, M. DB - Scopus IS - 3 KW - keratitis penetrating keratoplasty radical keratotomy M3 - Conference Paper N1 - Export Date: 19 July 2021 PY - 1996 SP - 293-302 ST - Queratoplastia penetrante en queratitis bacteriana tras queratotomia radial T2 - Archivos de la Sociedad Espanola de Oftalmologia TI - Penetrating keratoplasty in bacterial keratitis after radial keratotomy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029780560&partnerID=40&md5=0d8bd10d9a074b1240afb03cff1f365d VL - 71 ID - 5798 ER - TY - JOUR AB - Penetrating keratoplasty in children is a high risk transplantation. Indications increased with improvement of surgical techniques and therapies. Our purpose is to study anatomic and functional results of penetrating keratoplasty in children. We report the results of a retrospective study including 23 penetrating keratoplasties (22 eyes) performed in 20 patients younger than 16 years old, between 1991 and 2000 at the department of ophthalmology at Charles Nicolle University Hospital -Tunis. Penetrating keratoplasty was performed for congenital dystrophies in 6 cases (17.3%), for acquired traumatic opacities in 4 cases (26%) and for non traumatic acquired opacities in 13 cases (56.7%). Non traumatic acquired opacities were keratoconus in 8 cases (61.5%), keratitis in 3 cases (23%) and graft rejection in 2 cases (15.5%). The mean follow-up was 41.8 months. Grafts remained clear in 20 cases (83.3%). Graft rejection occurred in 4 cases. Graft failure occurred in 3 cases (16.6%). Mean postoperative visual acuity was 3/10 (ranging from 1/20 to 7/10). Penetrating keratoplasty in children allows a satisfying anatomic success but a moderate visual improvement. Amblyopia is the major obstacle to success in children corneal grafting. AD - Service Ophtalmologie, E.P. S Charles Nicolle, Tunis, Tunisia Service Ophtalmologie, Hôpital Mongi Slim, La Marsa, Tunisia AU - Beltaief, O. AU - Farah, H. AU - Kamoun, R. AU - Ben Said, A. AU - Ouertani, A. DB - Scopus IS - 7 KW - Children Complications Graft failure Penetrating keratoplasty Visual outcome M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2003 SP - 477-481 ST - La greffe de cornee chez l'enfant T2 - Tunisie Medicale TI - Penetrating keratoplasty in children UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141522596&partnerID=40&md5=faf89ffd52c3131e52de4af86a68676b VL - 81 ID - 5487 ER - TY - JOUR AB - PReCIS:: A 15-year analysis of 198,843 visual field (VF) tests revealed a growing trend for their performance for nonglaucoma indications. Adherence to glaucoma management guidelines was suboptimal. Guidelines for referral to VF assessments should be established., PURPOSE: The purpose of this study was to identify trends in VF assessments over 15 years among patients with and without suspected or confirmed glaucoma, in a large healthcare maintenance organization., METHODS: This was a population-based retrospective cohort study, conducted by means of electronic medical database analyses., STUDY POPULATION: Maccabi Healthcare Services is an healthcare maintenance organization that insures 2 million members constituting 25% of the population. All members who underwent at least 1 VF test between January 2000 and December 2014 were included. In addition, all members with glaucoma or suspected glaucoma diagnosis or who were prescribed with antiglaucoma medications were evaluated., MAIN OUTCOME MEASURES: VF performance rates., RESULTS: A total of 93,617 Maccabi Healthcare Services members underwent 198,843 VF tests; of whom 47.9% involved patients without any glaucoma-related conditions. There was a growing trend over time toward more of those members to undergo VF tests and, by 2014, non-glaucoma-related members comprised 74.0% of new VF assessments. In contrast, 32.3% of glaucoma-related patients did not perform even 1 VF test throughout the entire study period. Although over 2 years (25.95+/-6.33 mo) passed between the first glaucoma-related diagnosis and first VF test, once a patient underwent the first VF test, an average once-a-year VF follow-up (0.95+/-0.37 annual tests) began., CONCLUSION: There is a growing trend for VF tests being apparently overused for indications other than glaucoma. Concurrently, adherence to glaucoma management guidelines on VF tests is suboptimal, leading to discernible underuse. Guidelines for VF assessments in nonglaucoma patients should be established. Adherence to existing glaucoma management guidelines should be improved. AU - Ben-Artsi, Elad AU - Goldenfeld, Modi AU - Zehavi-Dorin, Tzukit AU - Cohen, Asaf AU - Porath, Avi AU - Levkovitch-Verbin, Hani DO - https://dx.doi.org/10.1097/IJG.0000000000001262 IS - 7 KW - Aged Aged, 80 and over Cohort Studies Electronic Health Records/sn [Statistics & Numerical Data] Female Follow-Up Studies *Glaucoma/di [Diagnosis] *Glaucoma/ep [Epidemiology] Health Maintenance Organizations Humans Intraocular Pressure Israel/ep [Epidemiology] Male Middle Aged Procedures and Techniques Utilization/st [Standards] *Procedures and Techniques Utilization/sn [Statistics & Numerical Data] Retrospective Studies Visual Field Tests/st [Standards] *Visual Field Tests/sn [Statistics & Numerical Data] *Visual Fields/ph [Physiology] PY - 2019 SE - Ben-Artsi, Elad. Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Affiliated to the Sackler School of Medicine, Tel Aviv University. Goldenfeld, Modi. Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Affiliated to the Sackler School of Medicine, Tel Aviv University. Goldenfeld, Modi. Maccabi Healthcare Services, Tel Aviv, Israel. Zehavi-Dorin, Tzukit. Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Affiliated to the Sackler School of Medicine, Tel Aviv University. Cohen, Asaf. Maccabi Healthcare Services, Tel Aviv, Israel. Porath, Avi. Maccabi Healthcare Services, Tel Aviv, Israel. Levkovitch-Verbin, Hani. Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Affiliated to the Sackler School of Medicine, Tel Aviv University. Levkovitch-Verbin, Hani. Maccabi Healthcare Services, Tel Aviv, Israel. SN - 1536-481X 1057-0829 SP - 660-665 ST - Overuse and Underuse of Visual Field Testing Over 15 Years T2 - Journal of glaucoma TI - Overuse and Underuse of Visual Field Testing Over 15 Years UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30973423 VL - 28 ID - 341 ER - TY - JOUR AN - 141717178. Language: English. Entry Date: 20200224. Revision Date: 20200224. Publication Type: Article AU - Bence, Brett G. DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Diagnosis Diagnosis, Eye Optometrists Glaucoma -- Therapy Optometry -- Equipment and Supplies Intraocular Pressure Health Services Accessibility Primary Health Care Tomography, Optical -- Methods Optometry -- Education N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2020 SN - 0030-4085 SP - 17-18 ST - GLAUCOMA 2020: A CALL TO ARMS: The three reasons glaucoma should be on our radar T2 - Optometric Management TI - GLAUCOMA 2020: A CALL TO ARMS: The three reasons glaucoma should be on our radar UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141717178&site=ehost-live&scope=site VL - 55 ID - 4448 ER - TY - JOUR AB - Ocular inflammation is one of the leading causes of blindness worldwide, and steroids in topical ophthalmic solutions (e.g. dexamethasone eye drops) are the mainstay of therapy for ocular inflammation. For many non-infectious ocular inflammatory diseases, such as uveitis, eye drops are administered as often as once every hour. The high frequency of administration coupled with the side effects of eye drops leads to poor adherence for patients. Drug-eluting contact lenses have long been sought as a potentially superior alternative for sustained ocular drug delivery; but loading sufficient drug into contact lenses and control the release of the drug is still a challenge. A dexamethasone releasing contact lens (Dex-Lens) was previously developed by encapsulating a dexamethasone-polymer film within the periphery of a hydrogel-based contact lens. Here, we demonstrate safety and efficacy of the Dex-Lens in rabbit models in the treatment of anterior ocular inflammation. The Dex-Lens delivered drug for 7 days in vivo (rabbit model). In an ocular irritation study (Draize test) with Dex-Lens extracts, no adverse events were observed in normal rabbit eyes. Dex-Lenses effectively inhibited suture-induced corneal neovascularization and inflammation for 7 days and lipopolysaccharide-induced anterior uveitis for 5 days. The efficacy of Dex-Lenses was similar to that of hourly-administered dexamethasone eye drops. In the corneal neovascularization study, substantial corneal edema was observed in rabbit eyes that received no treatment and those that wore a vehicle lens as compared to rabbit eyes that wore the Dex-Lens. Throughout these studies, Dex-Lenses were well tolerated and did not exhibit signs of toxicity. Dexamethasone-eluting contact lenses may be an option for the treatment of ocular inflammation and a platform for ocular drug delivery. STATEMENT OF SIGNIFICANCE: Inflammation of the eye can happen either on the ocular surface (i.e. the cornea) or inside the eye, both of which can result in loss of vision or even blindness. Ocular inflammation is normally treated by steroid eye drops. Depending on the type and severity of inflammation, patients may have to take drops every hour for days at a time. Such severe dosing regimen can lead to patients missing doses. Also, more than 95% drug in an eye drop never goes inside the eye. Here we present a contact lens that release a steroid (dexamethasone) for seven days at a time. It is much more efficient than eye drops and a significant improvement since once worn, the patient will avoid missing doses. Copyright © 2020. Published by Elsevier Ltd. AU - Bengani, Lokendrakumar C. AU - Kobashi, Hidenaga AU - Ross, Amy E. AU - Zhai, Hualei AU - Salvador-Culla, Borja AU - Tulsan, Rekha AU - Kolovou, Paraskevi E. AU - Mittal, Sharad K. AU - Chauhan, Sunil K. AU - Kohane, Daniel S. AU - Ciolino, Joseph B. DO - https://dx.doi.org/10.1016/j.actbio.2020.08.013 KW - Animals *Contact Lenses Cornea Humans Inflammation/dt [Drug Therapy] Rabbits Steroids Uveitis/dt [Drug Therapy] *Uveitis PY - 2020 SE - Bengani, Lokendrakumar C. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States. Kobashi, Hidenaga. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States. Ross, Amy E. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States. Zhai, Hualei. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States. Salvador-Culla, Borja. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States; Department of Anesthesiology, Boston Children's Hospital, Boston, MA, United States. Tulsan, Rekha. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States; Department of Anesthesiology, Boston Children's Hospital, Boston, MA, United States. Kolovou, Paraskevi E. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States; Department of Anesthesiology, Boston Children's Hospital, Boston, MA, United States. Mittal, Sharad K. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States. Chauhan, Sunil K. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States. Kohane, Daniel S. Department of Anesthesiology, Boston Children's Hospital, Boston, MA, United States. Electronic address: daniel.kohane@childrens.harvard.edu. Ciolino, Joseph B. Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute at Massachusetts Eye & Ear, 325 Charles Street, Boston 02114, MA, United States. Electronic address: Joseph_Ciolino@meei.harvard.edu. SN - 1878-7568 1742-7061 SP - 149-161 ST - Steroid-eluting contact lenses for corneal and intraocular inflammation T2 - Acta biomaterialia TI - Steroid-eluting contact lenses for corneal and intraocular inflammation UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32814140 VL - 116 Y2 - 20200816// ID - 189 ER - TY - JOUR AB - PURPOSE: The primary objective of the ongoing Glaucoma Intensive Treatment Study (GITS) is to evaluate the effectiveness of immediate intensive treatment in comparison with the commonly recommended stepped regimen on the predicted visual field. The two treatment arms are also being compared regarding quality of life (QoL), intraocular pressure (IOP) reduction, frequency of reported side-effects, adverse events and adherence to prescribed treatment., DESIGN: A randomized, two-centre, prospective open-labelled treatment trial for open-angle glaucoma., PARTICIPANTS: Individuals aged 40-78 years with previously untreated and newly diagnosed glaucoma with early to moderate visual field loss were eligible., METHODS: Patients were randomized to initial treatment either using drug monotherapy in accordance with common glaucoma guidelines or using a more intensive approach including eyedrops containing drugs from three different classes combined with 360degree laser trabeculoplasty. The patients are to be followed for 5 years at visits including standard automated perimetry, optical coherence tomography (OPT) and tonometry. Change of treatment is allowed and decided upon jointly with the patient as in conventional glaucoma management., MAIN OUTCOME: The estimated predicted preserved visual field and QoL at end of expected lifetime., RESULTS: A total of 242 patients, 45% females, mean age 68 years, were randomized. The median untreated IOP was 24 mm Hg, and the median visual field index (VFI), indicating the percentage of a full field, was 92%., CONCLUSION: Glaucoma Intensive Treatment Study is a clinical trial in which two groups of patients randomized to different initial intensities of IOP-reducing treatment are being compared with regard to rate of visual field progression and prediction of serious glaucomatous visual field loss at estimated at end of life. Copyright © 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. AU - Bengtsson, Boel AU - Heijl, Anders AU - Johannesson, Gauti AU - Andersson-Geimer, Sabina AU - Aspberg, Johan AU - Linden, Christina DO - https://dx.doi.org/10.1111/aos.13791 IS - 6 KW - Adult Aged *Antihypertensive Agents/tu [Therapeutic Use] Female Follow-Up Studies Glaucoma/pp [Physiopathology] *Glaucoma/th [Therapy] Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged Prospective Studies Quality of Life *Trabeculectomy/mt [Methods] Treatment Outcome Visual Acuity *Visual Fields PY - 2018 SE - Bengtsson, Boel. Department of Clinical Sciences in Malmo, Ophthalmology, Lund University, Malmo, Sweden. Heijl, Anders. Department of Clinical Sciences in Malmo, Ophthalmology, Lund University, Malmo, Sweden. Johannesson, Gauti. Department of Clinical Sciences, Ophthalmology, Umea University, Umea, Sweden. Andersson-Geimer, Sabina. Department of Clinical Sciences in Malmo, Ophthalmology, Lund University, Malmo, Sweden. Aspberg, Johan. Department of Clinical Sciences in Malmo, Ophthalmology, Lund University, Malmo, Sweden. Linden, Christina. Department of Clinical Sciences, Ophthalmology, Umea University, Umea, Sweden. SN - 1755-3768 1755-375X SP - 557-566 ST - The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data T2 - Acta ophthalmologica TI - The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30171664 VL - 96 Y2 - 20180831// ID - 409 ER - TY - JOUR AB - PURPOSE: To report the outcome of epiretinal membrane (ERM) surgery in young patients., DESIGN: Interventional case series study., METHOD: A retrospective review of 20 young patients who had undergone vitrectomy and epiretinal membrane removal. All patients had a preoperative examination, including fundus biomicroscopy, red free photographs, and fluorescein angiography., RESULTS: Nine patients were males and 11 females (age: 7-26 years; mean: 16.3 years). Follow up ranged from 4-96 months (mean: 21.2 months). The 20 patients comprised 13 cases of idiopathic ERM, six cases in which ERM was associated with ocular inflammation and one case of combined hamartoma of the retina and retinal pigment epithelium (RPE). In 13 cases, the ERM was especially white, thick, and opaque, with localized constriction and severe retinal distortion. Final best-corrected visual acuity (VA) was significantly better than preoperatively (20/50 vs. 20/112), (P = 0.0002). Mean improvement in VA was 4.25 lines and 17 patients gained two or more lines. This improvement was better in secondary than idiopathic ERM (6 lines vs. 3.3). During follow up, five cases of recurrence were observed (25%). In another case, postoperative persistent ocular hypertension required filtering surgery., CONCLUSION: The characteristics of ERM in young patients are quite different in many cases from those in adults in terms of thickness and adherence. Removal of ERM in young patients is feasible and safe although the membrane may focally adhere strongly to retinal vessels. VA usually improves significantly after surgery, but recurrences are more frequent than in adults. AU - Benhamou, Nathanael AU - Massin, Pascale AU - Spolaore, R. AU - Paques, Michel AU - Gaudric, Alain IS - 3 KW - Adolescent Adult Child Epiretinal Membrane/pa [Pathology] *Epiretinal Membrane/su [Surgery] Female Fluorescein Angiography Follow-Up Studies Humans Male Postoperative Complications Recurrence Retrospective Studies Safety Treatment Outcome Visual Acuity *Vitrectomy PY - 2002 SE - Benhamou, Nathanael. Department of Ophthalmology, Hopital Lariboisiere, Assistance Publique-Hopitaux de Paris, Universite Paris 7, Paris, France. SN - 0002-9394 SP - 358-64 ST - Surgical management of epiretinal membrane in young patients T2 - American journal of ophthalmology TI - Surgical management of epiretinal membrane in young patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11860973 VL - 133 ID - 1898 ER - TY - JOUR AB - Understanding of ocular diseases and the search for their cure have been based on the common assumption that the eye is an immune privileged site, and the consequent conclusion that entry of immune cells to this organ is forbidden. Accordingly, it was assumed that when immune cell entry does occur, this reflects an undesired outcome of breached barriers. However, studies spanning more than a decade have demonstrated that acute insults to the retina, or chronic conditions resulting in retinal ganglion cell loss, such as in glaucoma, result in an inferior outcome in immunocompromised mice; likewise, steroidal treatment was found to be detrimental under these conditions. Moreover, even conditions that are associated with inflammation, such as age-related macular degeneration, are not currently believed to require immune suppression for treatment, but rather, are thought to benefit from immune modulation. Here, we propose that the immune privilege of the eye is its ability to enable, upon need, the entry of selected immune cells for its repair and healing, rather than to altogether prevent immune cell entry. The implications for acute and chronic degenerative diseases, as well as for infection and inflammatory diseases, are discussed. AU - Benhar, Inbal AU - London, Anat AU - Schwartz, Michal DO - https://dx.doi.org/10.3389/fimmu.2012.00296 PY - 2012 SE - Benhar, Inbal. Department of Neurobiology, Weizmann Institute of Science Rehovot, Israel. SN - 1664-3224 SP - 296 ST - The privileged immunity of immune privileged organs: the case of the eye T2 - Frontiers in immunology TI - The privileged immunity of immune privileged organs: the case of the eye UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=23049533 VL - 3 Y2 - 20120921// ID - 1186 ER - TY - JOUR AB - PURPOSE: To assess the impact of intrastromal corneal ring segments (ICRS) as a surgical alternative to corneal grafting in patients with keratoconus who were scheduled for a corneal transplant., METHODS: This single-surgeon, single-center, retrospective, observational case series study included 19 eyes of 18 patients (mean age, 23.36 +/- 6.22 years) with a confirmed diagnosis of keratoconus. These patients were enrolled from the State of Goias, Brazil corneal graft waiting list. Following extensive pre-operative testing, including the measurement of best-corrected visual acuity (BCVA), applanation tonometry, biomicroscopy, funduscopy, pachymetry, and corneal topography, patients were implanted with Keraring R ICRS. Patients underwent clinical examination at postoperative days 1, 7, 30, 90, and 180 and were examined again 2 years following surgery., RESULTS: At the 2-year cut-off following ICRS implantation (mean follow-up, 28.72 +/- 4.71 months), there was a statistically significant improvement in BCVA (logMAR) from 0.59 +/- 0.35 preoperatively to 0.35 +/- 0.45 postoperatively ( p <0.01). Three of 19 eyes (15.8%) still required keratoplasty. In the remaining patients (84.2%), BCVA was managed with spectacles (52.6%) or contact lenses (31.6%). One patient developed infectious keratitis, requiring removal of ICR at the first postoperative visit., CONCLUSION: ICRS implantation may be a surgical alternative to keratoplasty in patients with keratoconus. This procedure may delay or even eliminate the need for keratoplasty in such patients. AU - Beniz, Luiz Arthur F. AU - Queiroz, Gustavo H. AU - Queiroz, Carlos F. AU - Lopes, Wanessa L. AU - Moraes, Leiser F. AU - Beniz, Jose DO - https://dx.doi.org/10.5935/0004-2749.20160009 IS - 1 KW - Adolescent Adult *Corneal Stroma/su [Surgery] Corneal Topography *Corneal Transplantation Female Humans *Keratoconus/su [Surgery] Male Postoperative Period *Prostheses and Implants *Prosthesis Implantation Reproducibility of Results Retrospective Studies Time Factors Treatment Outcome Visual Acuity Waiting Lists Young Adult PY - 2016 SE - Beniz, Luiz Arthur F. Centro de Referencia em Oftalmologia, Universidade Federal de Goias, Goiania, GO, Brazil. Queiroz, Gustavo H. Centro de Referencia em Oftalmologia, Universidade Federal de Goias, Goiania, GO, Brazil. Queiroz, Carlos F. Centro de Referencia em Oftalmologia, Universidade Federal de Goias, Goiania, GO, Brazil. Lopes, Wanessa L. Centro de Referencia em Oftalmologia, Universidade Federal de Goias, Goiania, GO, Brazil. Moraes, Leiser F. Centro de Referencia em Oftalmologia, Universidade Federal de Goias, Goiania, GO, Brazil. Beniz, Jose. Centro de Referencia em Oftalmologia, Universidade Federal de Goias, Goiania, GO, Brazil. SN - 1678-2925 0004-2749 SP - 30-2 ST - Intrastromal corneal ring segments delay corneal grafting in patients with keratoconus T2 - Arquivos brasileiros de oftalmologia TI - Intrastromal corneal ring segments delay corneal grafting in patients with keratoconus UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26840163 VL - 79 ID - 720 ER - TY - JOUR AB - The article announces the appointments of Doctor Ron Kurtz, president of PrimaPharma, to the board of directors of Allegro Ophthalmics and Clayton Edwards as senior vice president for operations and Eric Rice as vice president for client relations at Imprimis Pharmaceuticals. AN - 118418045. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Bennett, Talitha DB - ccm DP - EBSCOhost IS - 18 KW - Dry Eye Syndromes -- Drug Therapy Intraocular Pressure Glaucoma -- Drug Therapy Governing Board Appointments and Schedules ERIC Database Rice Physicians N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2016 SN - 8750-3085 SP - 32-33 ST - MOVERS & SHAKERS T2 - Ocular Surgery News TI - MOVERS & SHAKERS UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118418045&site=ehost-live&scope=site VL - 34 ID - 4612 ER - TY - JOUR AB - Streptococcus pneumoniae is a gram-positive, facultatively anaerobic pathogen that can cause severe infections such as pneumonia, meningitis, septicemia, and middle ear infections. It is also one of the top pathogens contributing to bacterial keratitis and conjunctivitis. Though two pneumococcal vaccines exist for the prevention of nonocular diseases, they do little to fully prevent ocular infections. This pathogen has several virulence factors that wreak havoc on the conjunctiva, cornea, and intraocular system. Polysaccharide capsule aids in the evasion of host complement system. Pneumolysin (PLY) is a cholesterol-dependent cytolysin that acts as pore-forming toxin. Neuraminidases assist in adherence and colonization by exposing cell surface receptors to the pneumococcus. Zinc metalloproteinases contribute to evasion of the immune system and disease severity. The main purpose of this review is to consolidate the multiple studies that have been conducted on several pneumococcal virulence factors and the role each plays in conjunctivitis, keratitis, and endophthalmitis. AU - Benton, Angela H. AU - Marquart, Mary E. DO - https://dx.doi.org/10.1155/2018/2525173 PY - 2018 SE - Benton, Angela H. Department of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216, USA. Marquart, Mary E. Department of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216, USA. SN - 1687-708X SP - 2525173 ST - The Role of Pneumococcal Virulence Factors in Ocular Infectious Diseases T2 - Interdisciplinary perspectives on infectious diseases TI - The Role of Pneumococcal Virulence Factors in Ocular Infectious Diseases UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=30538741 VL - 2018 Y2 - 20181113// ID - 590 ER - TY - JOUR AB - ImportanceAdditional data are sought regarding treatment options for glaucoma, a major cause of global blindness. BackgroundThe study assessed outcomes following standalone implantation of two second-generation trabecular micro-bypass stents and postoperative topical prostaglandin in eyes with open-angle glaucoma not controlled on two preoperative medications. DesignThe study design is a prospective, nonrandomized, open-label study at a tertiary-care ophthalmology centre. ParticipantsSubjects had open-angle glaucoma with preoperative intraocular pressure of 18-30mmHg on two medications, a medication washout phase, and post-washout intraocular pressure of 22-38mmHg. All subjects (N=53) have been followed for 18months. MethodsOne day following implantation of two second-generation trabecular micro-bypass stents, subjects started topical travoprost. Medication washout was repeated at month 12. Main Outcome MeasuresThe main outcome measure was the proportion of eyes with intraocular pressure reduction 20% versus medicated baseline intraocular pressure with reduction of one medication at 12months. ResultsAt 12months, 91% of eyes achieved intraocular pressure reduction 20% with reduction of one medication. All eyes had intraocular pressure 18mmHg with reduction of one medication, and 87% had intraocular pressure 15mmHg. Mean intraocular pressure on one medication was 13.0mmHg (34% reduction) through 18months. Mean post-washout intraocular pressure at month 13 was 33% lower than preoperative unmedicated intraocular pressure. No adverse events occurred through 18months. Conclusions and RelevanceIn open-angle glaucoma eyes on two preoperative medications, treatment with two second-generation trabecular stents and one postoperative prostaglandin resulted in mean intraocular pressure 13mmHg with reduction of one medication, with favourable safety. These findings show the utility of second-generation trabecular bypass with postoperative prostaglandin in patients with open-angle glaucoma. AN - WOS:000415722400006 AU - Berdahl, J. AU - Voskanyan, L. AU - Myers, J. S. AU - Hornbeak, D. M. AU - Giamporcaro, J. E. AU - Katz, L. J. AU - Samuelson, T. W. DA - NOV DO - 10.1111/ceo.12958 IS - 8 PY - 2017 SN - 1442-6404 1442-9071 SP - 797-802 ST - Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up VL - 45 ID - 6185 ER - TY - JOUR AB - Importance Long-term data are needed regarding effective and safe glaucoma treatment modalities. Background This study evaluated 4-year outcomes of second-generation trabecular micro-bypass stent implantation (iStent inject) combined with topical travoprost in open-angle glaucoma (OAG). Design Prospective, non-randomized, multi-surgeon study at a tertiary care ophthalmology centre. Participants OAG subjects with preoperative intraocular pressure (IOP) 18 to 30 mmHg on two medications and 22 to 38 mmHg post-washout. Methods Subjects (n = 53) underwent standalone iStent inject implantation and started travoprost on postoperative Day 1. Measures included IOP, medications, comprehensive ophthalmic examinations and testing, and adverse events (AEs). Annual medication washouts were performed. Main Outcome Measures Mean medicated and unmedicated IOP; and proportions of eyes with IOP <= 18mmHg, <= 15 mmHg, or >= 20% reduced while on travoprost vs screening IOP on two medications. Results At 48 months postoperative, 85% of eyes reduced IOP >= 20% on travoprost vs screening IOP on 2 medications; 92% of eyes had IOP <= 18 mmHg on travoprost; and 83% had IOP <= 15 mmHg on travoprost. At Month 49 (post-washout), 90% of eyes reduced IOP >= 20% vs preoperative washout IOP. Throughout follow-up, mean IOP on travoprost was 11.9 to 13.0 mmHg (34%-40% reduced vs 19.7 mmHg on 2 medications preoperatively; P < .0001 throughout), and post-washout IOP was 16.5 to 17.7 mmHg (28%-34% reduced vs 24.9 mmHg preoperatively; P < .0001 throughout). Favourable safety included minimal AEs; stable visual acuity, cup-to-disc ratio and visual fields; and no secondary surgeries. Conclusions and Relevance Combining iStent inject implantation with topical prostaglandin produced significant and safe 4-year IOP and medication reductions in OAG. AN - WOS:000531823700001 AU - Berdahl, J. AU - Voskanyan, L. AU - Myers, J. S. AU - Katz, L. J. AU - Samuelson, T. W. DA - AUG DO - 10.1111/ceo.13763 IS - 6 PY - 2020 SN - 1442-6404 1442-9071 SP - 767-774 ST - iStent inject trabecular micro-bypass stents with topical prostaglandin as standalone treatment for open-angle glaucoma: 4-year outcomes T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - iStent inject trabecular micro-bypass stents with topical prostaglandin as standalone treatment for open-angle glaucoma: 4-year outcomes VL - 48 ID - 6248 ER - TY - JOUR AB - BACKGROUND:Glaucoma is a slowly progressive disease that can lead to blindness. Multiple, prospective, randomized clinical trials have demonstrated that bimatoprost achieves greater intraocular pressure (IOP) lowering compared with other prostaglandin analogues (PGA). However, few studies have evaluated the associated cost savings of lower IOP and its impact on glaucomatous progression. OBJECTIVE: To develop a cost benefit model from a payer's perspective to compare glaucomatous progression and costs among POAG patients treated with bimatoprost, latanoprost, or travoprost in the United States. METHODS: A health economic model was used to estimate glaucomatous progression for a cohort of POAG patients (baseline IOP 26 mm Hg) over 7 years. The absolute reduction in IOP from baseline secondary to treatment with a PGA was based on a systematic review of the literature; the base case model assumed a 1 mm Hg advantage of bimatoprost over latanoprost or travoprost. IOP was used to estimate the baseline mean deviation (MD) score in the worst eye and to determine the proportion of patients with MD score progression each year. Patients who progressed were assumed to progress at a mean rate of 0.6 decibels (dB) per year. Medical, pharmacy, and indirect costs associated with categories of MD scores from the published literature were applied to each treatment cohort to calculate the expected 7-year costs of treating patients with the different PGAs. Visual impairment costs were applied solely to severe disease patients. Costs were discounted at 3% per year. RESULTS: The results of the base case in this analysis showed that for a managed care plan of 1,000,000 members with 19,000 glaucoma patients, treatment with bimatoprost would prevent progression in 130 more patients compared with treatment with travoprost or latanoprost. The preservation of vision with bimatoprost resulted in cost savings of office visits, medication use, and surgeries, estimated at $796 per patient.There was an additional cost savings of $28 and $171 per treated patient in direct bimatoprost pharmacy costs compared with latanoprost and travoprost, respectively. The total cost savings with bimatoprost for a plan with 1,000,000 members, due to delayed/avoided progression, were estimated to be $103,480. CONCLUSIONS: Results from this model demonstrate that greater reduction in IOP from treatment with bimatoprost is associated with lower rates of glaucomatous progression and increased cost savings compared with latanoprost or travoprost. SPONSORSHIP: This research was funded by Allergan, Inc., Irvine, CA. AD - C. Burk, Allergan, Inc., 2525 Dupont Dr., Irvine, CA, United States AU - Berenson, K. AU - Arora, S. AU - Kymes, S. AU - Hollander, D. A. AU - Fiscella, R. AU - Burk, C. AU - Patel, V. DB - Embase IS - 2 KW - bimatoprost prostaglandin travoprost latanoprost adrenalin hydrogen tartrate promethazine open angle glaucoma patient pharmacy (shop) cost benefit analysis United States managed care cost control model glaucoma statistical model health intraocular pressure clinical trial blindness systematic review eye visual impairment preservation ambulatory care drug therapy surgery LA - English M3 - Conference Abstract N1 - L70148984 2010-05-27 PY - 2010 SN - 1083-4087 SP - 146 ST - Cost benefit analysis of bimatoprost compared with other prostaglandin analogues in patients with primary open angle glaucoma (POAG) in the United States: A payer's perspective T2 - Journal of Managed Care Pharmacy TI - Cost benefit analysis of bimatoprost compared with other prostaglandin analogues in patients with primary open angle glaucoma (POAG) in the United States: A payer's perspective UR - https://www.embase.com/search/results?subaction=viewrecord&id=L70148984&from=export VL - 16 ID - 3275 ER - TY - JOUR AB - Purpose: To determine the relationship between mean deviation (MD) scores and resource utilization among glaucoma patients in the United States and Europe. Methods: A retrospective analysis of patient in the United States (June 1990 to January 2003, N = 151) and Europe (June 1994 to July 2003, N = 194) was conducted. Office visits, pressure-lowering medications, visual field examinations, and glaucoma surgeries were recorded with age, intraocular pressure (IOP), and MD. Patients with missing MD and IOP were excluded; final sample sizes were 130 in the United States and 161 in Europe. Fixed effects and logistic regression models assessed the associations between MD and visits, medication, examinations, and surgery. Results: Number of office visits and visual field examinations significantly increased but the number of glaucoma medications decreased as MD worsened and IOP increased. Odds of trabeculoplasty within 2 years decreased by 8.1% in the United States and 9.9% in Europe with every 1.0 dB improvement in MD. Odds of trabeculectomy within 2 years increased by 13.9% in the United States and by 18.6% in Europe with every 1 mm Hg increase in IOP. In the United States, odds of trabeculectomy within 5 years increased by 12.2% with each 1.0 dB worsening in MD. Conclusions: MD is associated with resource utilization in glaucoma patients. Evidence supporting use of MD to predict surgery is less conclusive, possibly due to the relative low frequency of surgeries. Therapies aimed at stabilizing visual field deterioration may reduce resource use and costs associated with glaucoma; however, more research is necessary to establish whether such treatments meet common standards of cost-effectiveness. Copyright © 2009 by Lippincott Williams & Wilkins. AD - J. G. Walt, 2525 Dupont Drive, Irvine, CA 92623-9534, United States AU - Berenson, K. AU - Kymes, S. AU - Walt, J. G. AU - Siegartel, L. R. DB - Embase Medline DO - 10.1097/IJG.0b013e3181879ea0 IS - 5 KW - adult age distribution aged ambulatory care article Europe female glaucoma glaucoma surgery health care utilization human intraocular pressure logistic regression analysis major clinical study male mean deviation medical record review priority journal retrospective study sample size scoring system trabeculectomy trabeculoplasty United States visual field LA - English M3 - Article N1 - L355052278 2009-09-22 PY - 2009 SN - 1057-0829 SP - 390-394 ST - The relationship of mean deviation scores and resource utilization among patients with glaucoma: A retrospective United States and European chart review analysis T2 - Journal of Glaucoma TI - The relationship of mean deviation scores and resource utilization among patients with glaucoma: A retrospective United States and European chart review analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355052278&from=export http://dx.doi.org/10.1097/IJG.0b013e3181879ea0 VL - 18 ID - 3352 ER - TY - JOUR AU - Berggren, L. IS - 5 KW - Administration, Topical Adrenergic Agonists/pd [Pharmacology] Adrenergic beta-Antagonists/pd [Pharmacology] Animals Biological Availability Carbonic Anhydrase Inhibitors/pd [Pharmacology] *Glaucoma/dt [Drug Therapy] Humans Parasympathomimetics/pd [Pharmacology] Patient Compliance PY - 1990 SE - Berggren, L. Department of Ophthalmology, University of Uppsala, Sweden. SN - 0001-639X SP - 497-507 ST - Pharmacological and clinical aspects of glaucoma therapy T2 - Acta ophthalmologica TI - Pharmacological and clinical aspects of glaucoma therapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1980392 VL - 68 ID - 2154 ER - TY - JOUR AB - The systemic mucopolysaccharidoses are complex syndromes, which may include corneal clouding as a mechanism leading to decreased vision and hence decreased quality of life. This study presents three young adult patients with mucopolysaccharidoses in order to compare their visual status through retrospective chart review, including patient and guardian interview, history, and examination, including a modified form of the VF-14 questionnaire (visual function with 14 questions). When the visual acuity and VF-14 results of the three patients were compared, the results of the VF-14 correlated with the patients" visual acuity status. The two patients who retained clear corneas or underwent penetrating keratoplasty had a wider range of social and physical activities, and an overall better quality of life than did the patient with decreased vision due to opacified corneas. We conclude that close monitoring of the ocular health of patients with storage syndromes that may compromise visual acuity must be stressed, and intervention to insure good vision is of the utmost importance to maintaining a good quality of life for these patients, especially as new therapies assist these patients to achieve increased longevity with better health. AU - Bergwerk, Katherine L. AU - Rabinowitz, Yaron S. AU - Falk, Rena E. KW - Adult Corneal Opacity/di [Diagnosis] *Corneal Opacity/et [Etiology] Corneal Opacity/su [Surgery] Female Glaucoma/di [Diagnosis] *Glaucoma/et [Etiology] Humans Intellectual Disability/et [Etiology] Male *Mucopolysaccharidoses/co [Complications] Mucopolysaccharidoses/pp [Physiopathology] *Quality of Life Retrospective Studies Surveys and Questionnaires Treatment Refusal Visual Acuity PY - 2003 SE - Bergwerk, Katherine L. Cornea-Genetic Eye Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. bergwerk@juno.com SN - 1537-744X SP - 922-9 ST - Quality of life related to visual function in three young adults with mucopolysaccharidoses T2 - TheScientificWorldJournal TI - Quality of life related to visual function in three young adults with mucopolysaccharidoses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15241497 VL - 3 Y2 - 20031005// ID - 1804 ER - TY - JOUR AB - IMPORTANCE: Familial amyloid polyneuropathy, a lethal genetic disease caused by aggregation of variant transthyretin, induces progressive peripheral nerve deficits and disability. Diflunisal, a nonsteroidal anti-inflammatory agent, stabilizes transthyretin tetramers and prevents amyloid fibril formation in vitro. OBJECTIVE: To determine the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy. DESIGN, SETTING, AND PARTICIPANTS: International randomized, double-blind, placebo-controlled study conducted among 130 patients with familial amyloid polyneuropathy exhibiting clinically detectable peripheral or autonomic neuropathy at amyloid centers in Sweden (Umeå), Italy (Pavia), Japan (Matsumoto and Kumamoto), England (London), and the United States (Boston, Massachusetts; New York, New York; and Rochester, Minnesota) from 2006 through 2012. INTERVENTION: Participants were randomly assigned to receive diflunisal, 250 mg (n=64), or placebo (n=66) twice daily for 2 years. MAIN OUTCOMES AND MEASURES: The primary end point, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurological deficits) to 270 points (no detectable peripheral nerve function). Secondary outcomes included a quality-of-life questionnaire (36-Item Short-Form Health Survey [SF-36]) and modified body mass index. Because of attrition, we used likelihood-based modeling and multiple imputation analysis of baseline to 2-year data. RESULTS: By multiple imputation, the NIS+7 score increased by 25.0 (95% CI, 18.4-31.6) points in the placebo group and by 8.7 (95% CI, 3.3-14.1) points in the diflunisal group, a difference of 16.3 points (95% CI, 8.1-24.5 points; P < .001). Mean SF-36 physical scores decreased by 4.9 (95% CI, -7.6 to -2.2) points in the placebo group and increased by 1.5 (95% CI, -0.8 to 3.7) points in the diflunisal group (P < .001). Mean SF-36 mental scores declined by 1.1 (95% CI, -4.3 to 2.0) points in the placebo group while increasing by 3.7 (95% CI, 1.0-6.4) points in the diflunisal group (P = .02). By responder analysis, 29.7% of the diflunisal group and 9.4% of the placebo group exhibited neurological stability at 2 years (<2-point increase in NIS+7 score; P = .007). CONCLUSIONS AND RELEVANCE: Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life. Although longer-term follow-up studies are needed, these findings suggest benefit of this treatment for familial amyloid polyneuropathy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00294671. Copyright 2013 American Medical Association. All rights reserved. AD - J.L. Berk, Amyloidosis Center, Departments of Medicine and Neurology, Boston University School of Medicine, Boston, MA, United States AU - Berk, J. L. AU - Suhr, O. B. AU - Obici, L. AU - Sekijima, Y. AU - Zeldenrust, S. R. AU - Yamashita, T. AU - Heneghan, M. A. AU - Gorevic, P. D. AU - Litchy, W. J. AU - Wiesman, J. F. AU - Nordh, E. AU - Corato, M. AU - Lozza, A. AU - Cortese, A. AU - Robinson-Papp, J. AU - Colton, T. AU - Rybin, D. V. AU - Bisbee, A. B. AU - Ando, Y. AU - Ikeda, S. I. AU - Seldin, D. C. AU - Merlini, G. AU - Skinner, M. AU - Kelly, J. W. AU - Dyck, P. J. DB - Embase Medline DO - 10.1001/jama.2013.283815 IS - 24 KW - NCT00294671 diflunisal placebo adult article body mass clinical effectiveness congestive heart failure controlled clinical trial controlled study disease association disease course double blind procedure drug efficacy drug hypersensitivity drug safety drug tolerability familial amyloid polyneuropathy female functional assessment gastrointestinal hemorrhage gastrointestinal symptom glaucoma headache heart disease human kidney disease kidney failure major clinical study male middle aged multicenter study musculoskeletal disease nausea outcome assessment patient assessment patient compliance priority journal quality of life randomized controlled trial scoring system sensitivity analysis survival rate survival time treatment duration LA - English M3 - Article N1 - L370550938 2014-01-02 2014-01-20 2021-07-13 PY - 2013 SN - 1538-3598 0098-7484 SP - 2658-2667 ST - Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial T2 - JAMA - Journal of the American Medical Association TI - Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370550938&from=export http://dx.doi.org/10.1001/jama.2013.283815 VL - 310 ID - 2942 ER - TY - GEN AB - This article describes how a team of senior UCSF researchers, including Daniel Bernards, PhD, Robert Bhisitkul, MD, PhD, and Tejal Desai, PhD, are developing a nanoporous membrane-based implant which can significantly improve drug delivery to the back of the eye. Zordera, Inc, is the company set up to take the device through commercial development. © 2014 Frederick Furness Publishing Ltd. AU - Bernards, D. A. AU - Bhisitkul, R. B. AU - Desai, T. DB - Embase J2 - ONdrugDelivery KW - antibody biosimilar agent nanowire polymer ranibizumab cataract cost drug delivery system drug release glaucoma human instrument sterilization membrane nanopore nanotechnology nonhuman note patient compliance retina retina detachment safety syringe technology uveitis LA - English M1 - (Bernards D.A.) Department of Bioengineering and Therapeutic Sciences, UCSF, United States M3 - Note N1 - L372819904 2014-04-22 2014-05-01 PY - 2014 SN - 2049-1468 2049-145X SP - 20-21 ST - Zero order sustained drug delivery to the retina from a nanoporous film device TI - Zero order sustained drug delivery to the retina from a nanoporous film device UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372819904&from=export ID - 2903 ER - TY - JOUR AB - For the treatment and prevention of ocular diseases, most patients are treated with conventional drug delivery formulations such as eye drops or ointments. However, eye drops and ointments suffer from low patient compliance and low effective drug concentration at the target site. Therefore, new medical devices are being explored to improve drug delivery to the eye. Over the years, various delivery devices have been developed including resorbable devices, oval- and ring-shaped devices, rod-shaped devices, punctum plugs, contact lenses and corneal shields. Only a few devices (eg. Mydriasert®, Ozurdex®, Surodex®, Iluvien®, Lacrisert® and Retisert®) have made it to the market while others are being investigated in clinical trials. Altogether, there is a need for enhanced topical drug delivery. Only by working together (academia, industry and authorities) and by exploring parallel strategies (new drug delivery devices, enhanced drug formulations, better understanding of the pharmacokinetic properties), the therapeutic effect of drug treatments can be improved. AD - C.J.F. Bertens, Department of Ophthalmology, University Eye Clinic Maastricht, University Medical Center +, P. Debyelaan 25, P.O. box 5800, Maastricht, AZ, Netherlands AU - Bertens, C. J. F. AU - Gijs, M. AU - van den Biggelaar, F. J. H. M. AU - Nuijts, R. M. M. A. C1 - gelfoam iluvien(Alimera,United States) lacrisert(Aton) ocusert(Alza) ozurdex(Allergan,United States) C2 - Alimera(United States) Allergan(United States) Alza Aton forsight vision5 DB - Embase Medline DO - 10.1016/j.exer.2018.01.010 KW - contact lens dexamethasone drug delivery device Evolute eye shield gelfoam spine plate fluocinolone acetonide hydroxypropylcellulose lens implant ophthalmic drug insert Ocufi SR pilocarpine punctal plug Surodex topical drug delivery device Topical Ophthalmic Drug Delivery Device amphotericin B atropine brimonidine chloramphenicol ciprofloxacin clonidine eye drops idoxuridine insulin latanoprost neomycin ofloxacin oxybuprocaine phenylephrine pradofloxacin sodium sulfamethoxypyridazine tetracaine tropicamide clinical trial (topic) drug delivery system drug formulation dry eye eye eye disease glaucoma human keratomycosis mydriasis nonhuman ointment patient compliance priority journal review iluvien lacrisert ocusert ozurdex Dextenza Helios Mydriasert Retisert LA - English M3 - Review N1 - L620554886 2018-02-13 2018-02-16 PY - 2018 SN - 1096-0007 0014-4835 SP - 149-160 ST - Topical drug delivery devices: A review T2 - Experimental Eye Research TI - Topical drug delivery devices: A review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620554886&from=export http://dx.doi.org/10.1016/j.exer.2018.01.010 VL - 168 ID - 2602 ER - TY - JOUR AB - BACKGROUND: The importance of the four most commonly occurring vision-threatening diseases, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and cataract in ophthalmological practices has changed due to demographic developments, medical progress and transference of inpatient treatment to the outpatient area of private practice., METHODS: In the fourth quarter year of 2010 a survey of 15,125 patients (approximately 10%) from 96 private ophthalmology practices (mean 149 patients per ophthalmologist, range 45-376) was carried out. The results for the four most commonly occurring vision-threatening diseases were compared with the result from a previous survey carried out for the fourth quarter year of 1997., RESULTS: Compared to 1997 there was an increase in the age-adjusted proportion of examinations in 2010 for cataracts by 29 %, for glaucoma by 21 %, for diabetic retinopathy by 39 % and for vitreoretinal diseases by 19 %. The number of AMD examinations in the age group over 70 years old showed a particularly high increase., CONCLUSIONS: The number of patients examined for the four most commonly occurring vision-threatening diseases increased from 1997 to 2010 not only in absolute numbers but also in relation to age. In the future financial and personnel resources must be made available for the early and guidelines-conform detection, diagnostics and therapy by ophthalmologists. AU - Bertram, B. AU - Gante, C. AU - Hilgers, R. D. DO - https://dx.doi.org/10.1007/s00347-013-2966-z IS - 8 KW - Adult Aged Aged, 80 and over *Cataract/di [Diagnosis] Cataract/ep [Epidemiology] Comorbidity Cross-Sectional Studies *Diabetic Retinopathy/di [Diagnosis] Diabetic Retinopathy/ep [Epidemiology] *Diagnostic Techniques, Ophthalmological/sn [Statistics & Numerical Data] Diagnostic Techniques, Ophthalmological/td [Trends] Female Germany/ep [Epidemiology] *Glaucoma/di [Diagnosis] Glaucoma/ep [Epidemiology] Health Care Surveys Humans *Macular Degeneration/di [Diagnosis] Macular Degeneration/ep [Epidemiology] Male Middle Aged Office Visits/sn [Statistics & Numerical Data] Office Visits/td [Trends] *Ophthalmology/sn [Statistics & Numerical Data] *Practice Patterns, Physicians'/sn [Statistics & Numerical Data] Prevalence Utilization Review PY - 2014 SE - Bertram, B. Augenarztpraxis, Lohergraben 30, 52064, Aachen, Deutschland, BerndBertram@t-online.de. SN - 1433-0423 0941-293X SP - 757-64 ST - [Increase in examinations for cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration : Comparative cross-sectional study between 2010 and 1997 in ophthalmological practices] T2 - Zunahme der Untersuchungen wegen Katarakt, Glaukom, diabetischer Retinopathie und Makuladegeneration : Vergleichende Querschnittstudie der Jahre 2010 und 1997 in Augenarztpraxen. TI - [Increase in examinations for cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration : Comparative cross-sectional study between 2010 and 1997 in ophthalmological practices] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24343245 VL - 111 ID - 911 ER - TY - JOUR AB - It is estimated that 2.2 million people have glaucoma in the US and 67 million people worldwide. The majority of cases are associated with elevated intraocular pressure (IOP) and decreasing IOP eliminates or greatly reduces degeneration in most cases, including cases in which the IOP is in the normal range but optic neuropathy occurs. Timolol maleate has the longest record of safety and efficacy to lower IOP and is administered via eye drops one or more times per day. Unfortunately, compliance is poor across patient populations leading to degeneration. Patients typically see their ophthalmologist once every 3-4 months. If one could administer a long-acting treatment while in the doctor's office, one might overcome the compliance issue and effectively preserve sight. The critical step is to develop a formulation for timolol maleate that leads to sustained delivery for greater than 90 days and would permit a different treatment paradigm, namely subconjunctival administration once every 3-4 months. By using a 50 : 50 blend of PLGA 502H and PLA, this study was able to fabricate microspheres that delivered timolol maleate continually over 107 days, well within the time frame needed to make subconjunctival administration feasible and permit a new approach to treating glaucoma and diseases of the eye more broadly. AU - Bertram, James P. AU - Saluja, Sandeep S. AU - McKain, Jodi AU - Lavik, Erin B. DO - https://dx.doi.org/10.1080/02652040802095250 IS - 1 KW - *Delayed-Action Preparations/ch [Chemistry] Eye Diseases/dt [Drug Therapy] Humans *Lactic Acid *Microspheres Polyesters *Polyglycolic Acid Polylactic Acid-Polyglycolic Acid Copolymer *Polymers *Timolol/ad [Administration & Dosage] N1 - Erratum in (EIN) PY - 2009 SE - Bertram, James P. Department of Biomedical Engineering, Yale University, New Haven, CT, USA. SN - 1464-5246 0265-2048 SP - 18-26 ST - Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months T2 - Journal of microencapsulation T3 - Erratum in: J Microencapsul. 2009 Feb;26(1):26 TI - Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18465288 VL - 26 ID - 1490 ER - TY - JOUR AB - Health fairs provide multiphasic screening to more than 2 million Americans each year, and the number is growing rapidly. Nearly 40 different tests are in use, commonly including the measurement of up to 30 different blood chemistry levels. This report reviews the activities in a sample of 940 health fair sites and examines the experience regarding six specific screening procedures (blood pressure, anemia, blood chemistries, glaucoma, hearing, and fecal occult blood testing). Widespread use of these and other tests raises complex issues of cost, risk, and benefit. Rates of false alarm of healthy people and false reassurance of those at risk may be high for some tests, and the benefits of detecting new disease are easily overestimated. Detailed data collection and evaluation could help health fair sponsors to identify more rational screening strategies. AU - Berwick, D. M. IS - 11 KW - Anemia/ep [Epidemiology] Blood Chemical Analysis Cost-Benefit Analysis Diagnostic Errors Glaucoma/ep [Epidemiology] Health Education/ec [Economics] *Health Education Health Fairs/ec [Economics] *Health Fairs Hearing Disorders/ep [Epidemiology] Humans Hypertension/ep [Epidemiology] Mass Screening/ec [Economics] *Mass Screening/mt [Methods] Occult Blood Patient Compliance Risk PY - 1985 SN - 0098-7484 SP - 1492-8 ST - Screening in health fairs. A critical review of benefits, risks, and costs T2 - JAMA TI - Screening in health fairs. A critical review of benefits, risks, and costs UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=3928913 VL - 254 ID - 2219 ER - TY - JOUR AB - PURPOSE: In response to recent calls for clearer specification of behavior change interventions, the purpose of this study was to apply a system of taxonomy for behavior change techniques (BCTs) to two educational interventions to improve adherence to glaucoma eye drops. Clarification of constituent BCTs will promote easy and reliable application of the interventions in clinical settings and research., METHODS: A published taxonomy of BCTs was used to code two interventions (group and individual) to increase adherence to eye drops. Intervention materials were coded by assigning a BCT label to each text unit. We noted the frequency with which each BCT occurred, compared the interventions in terms of the BCTs that were delivered, and identified whether the taxonomy was sufficient to describe the intervention components., RESULTS: The individual intervention consisted of 94 text units. Fifty-seven were identified as targeting behavior change and coded using 18 BCTs, many coded more than once. In the group intervention, 165 units of text were identified, and 125 were coded using 22 BCTs. The most frequently coded BCT was "provide information about behavior-health link" in the group intervention and "prompt barrier identification" in the individual intervention. The interventions included similar BCTs. All text units targeting behavior change were codable into BCTs., CONCLUSION: The similarity of the two interventions may have implications for the cost-effectiveness of the interventions. The taxonomy was found sufficient to describe both interventions. This level of specification can be used to ensure that precisely the same intervention that has been pilot tested is reproducible in the clinical setting and in any further research. AU - Berzins, Kathryn M. AU - Gray, Trish A. AU - Waterman, Heather AU - Francis, Jill J. DO - https://dx.doi.org/10.2147/PRBM.S74664 PY - 2015 SE - Berzins, Kathryn M. School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK. Gray, Trish A. School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK. Waterman, Heather. School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK. Francis, Jill J. School of Health Sciences, City University London, London, UK. SN - 1179-1578 SP - 201-9 ST - Specifying active components of educational interventions to promote adherence to treatment in glaucoma patients: application of a taxonomy of behavior change techniques T2 - Psychology research and behavior management TI - Specifying active components of educational interventions to promote adherence to treatment in glaucoma patients: application of a taxonomy of behavior change techniques UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26185475 VL - 8 Y2 - 20150709// ID - 1060 ER - TY - JOUR AB - PURPOSE.: We document a presumptive case of unilateral post-streptococcal uveitis. The affected eye manifested a granulomatous anterior uveitis with elevated intra-ocular pressure (IOP) compared with the contra-lateral eye. This presentation was preceded by a recent streptococcal pharyngitis. CASE REPORT.: An asymptomatic, otherwise healthy 13-year-old black female presented with anterior chamber cells, mutton fat resembling keratic precipitates, and elevated IOP in the left eye relative to the right eye. The patient had been diagnosed with streptococcal pharyngitis approximately 1 week before her eye examination. A blood chemistry analysis, rheumatoid profile panel and antistreptolysin antibody titer were requested. The patient was prescribed predinisolone acetate 1% ophthalmic suspension in the left eye. RESULTS.: Anti-streptolysin antibody titers were significantly elevated (291 IU/ml). The patient responded favorably to topical ophthalmic steroid treatment with a reduction of IOP and inflammation. CONCLUSIONS.: Unilateral, granulomatous anterior uveitis may be a variant manifestation of post-streptococcal uveitis. The IOP elevation in these cases may result secondary to concurrent trabeculitis. © 2008 American Academy of Optometry. AD - E. Besada, College of Optometry, Nova Southeastern University, Fort Lauderdale, FL AU - Besada, E. AU - Frauens, B. J. DB - Embase Medline DO - 10.1097/OPX.0b013e31818b9622 IS - 11 KW - amoxicillin prednisolone acetate rheumatoid factor steroid adolescent anterior eye chamber antibody titer article blood analysis case report clinical feature diagnostic imaging disease association disease duration eye eye examination eye inflammation female human intraocular hypertension iridocyclitis keratitis patient compliance photophobia priority journal slit lamp streptococcal pharyngitis Streptococcus streptolysin titer symptom tonometry treatment duration treatment outcome unilateral granulomatous anterior uveitis uveitis visual acuity LA - English M3 - Article N1 - L354902963 2009-08-14 PY - 2008 SN - 1040-5488 SP - 1110-1115 ST - Unilateral granulomatous post-streptococcal uveitis with elevated tension T2 - Optometry and Vision Science TI - Unilateral granulomatous post-streptococcal uveitis with elevated tension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354902963&from=export http://dx.doi.org/10.1097/OPX.0b013e31818b9622 VL - 85 ID - 3421 ER - TY - JOUR AU - Best, Stephen J. IS - 7 KW - *Glaucoma/dt [Drug Therapy] Humans *Ophthalmic Solutions/tu [Therapeutic Use] *Patient Compliance N1 - Comment on (CON) PY - 2007 SN - 1442-6404 SP - 593 ST - Does persistency truly equate to compliance? T2 - Clinical & experimental ophthalmology T3 - Comment on: Clin Exp Ophthalmol. 2007 Sep-Oct;35(7):602-11; PMID: 17894679 [https://www.ncbi.nlm.nih.gov/pubmed/17894679] TI - Does persistency truly equate to compliance? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17894676 VL - 35 ID - 1576 ER - TY - JOUR AB - The authors indicate four key issues which, in their opinion, represent the most stimulating challenges in the field of glaucoma today, and describe the present approaches and the developments that can be expected or advised in the near future: (1) Glaucoma is often undiagnosed or diagnosed too late. Accurate detection is crucial to correctly recognize and treat affected subjects, thus reducing the disability and the social burden of the disease. Is glaucoma screening advisable and cost-effective? What strategies can be implemented to achieve an earlier diagnosis? (2) What role can genetics play in glaucoma clinics? (3) What are the fundamentals and the limits of medical hypotensive and nonhypotensive treatment of glaucoma today, and what novelties could be introduced in the next few years? (4) What are the current and future options for glaucoma surgery? Should we aim at reducing aqueous production or at enhancing aqueous outflow? What are the success figures and the pros and cons of ab externo procedures with external filtration (trabeculectomy, nonpenetrating techniques and glaucoma drainage devices) and of ab externo techniques with internal filtration (viscocanalostomy and canaloplasty)? Will microinvasive procedures ever play a role in the treatment of the disease? These questions and the possible future developments in the management of glaucoma are discussed critically, based on the current clinical state of the art, on a review of the literature, and on an everyday experience in a busy university hospital glaucoma service. Copyright © 2013 S. Karger AG, Basel. AD - Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Via Olgettina 60, IT-20132 Milan, Italy AU - Bettin, P. AU - Di Matteo, F. DB - Embase Medline DO - 10.1159/000348736 IS - 4 KW - acetylsalicylic acid adenosine receptor stimulating agent alpha adrenergic receptor stimulating agent antihypertensive agent apraclonidine beta adrenergic receptor blocking agent brimonidine calcium channel blocking agent cannabinoid 1 receptor carbonate dehydratase inhibitor cholinergic receptor stimulating agent cyanocobalamin cyclin dependent kinase inhibitor 2B dapiprazole fatty acid latrunculin B melatonin memantine metalloproteinase miotic agent mitomycin myocilin n methyl dextro aspartic acid receptor blocking agent optineurin palmidrol pilocarpine prostaglandin derivative Rho kinase inhibitor timolol aqueous humor formation aqueous humor outflow cataract extraction cataractogenesis closed angle glaucoma conjunctival hemorrhage contact lens cost effectiveness analysis disease predisposition drug dose regimen drug efficacy drug induced headache drug tolerability early diagnosis eye blood flow filtering operation genetic association geniculate body glaucoma glaucoma drainage implant glaucoma surgery human hyperemia hypersensitivity hypertrichosis intraocular pressure iridotomy iris disease lethargy long term care loss of appetite mass screening medication compliance meta analysis (topic) metal stent miosis myopia nephrolithiasis neuroprotection nonhuman nuclear magnetic resonance imaging oculoplethysmography open angle glaucoma ophthalmic diode laser ophthalmoscopy optical coherence tomography paresthesia patient compliance patient education phacoemulsification phase 1 clinical trial (topic) phase 3 clinical trial (topic) pigment disorder postoperative complication priority journal pseudoexfoliation punctal plug quality of life randomized controlled trial (topic) retina maculopathy review scanning laser ophthalmoscopy scanning laser polarimetry side effect stereoscopic vision trabeculectomy trabeculoplasty unspecified side effect vision test visual acuity visual cortex visual impairment CyPass iStent LA - English M3 - Review N1 - L370333735 2013-12-03 2013-12-05 PY - 2013 SN - 0030-3747 1423-0259 SP - 197-208 ST - Glaucoma: Present challenges and future trends T2 - Ophthalmic Research TI - Glaucoma: Present challenges and future trends UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370333735&from=export http://dx.doi.org/10.1159/000348736 VL - 50 ID - 2955 ER - TY - JOUR AB - Autoinflammatory diseases (AIDs) are heterogeneous disorders characterized by dysregulation in the inflammasome, a large intracellular multiprotein platform, leading to overproduction of interleukin-1(IL-1)β that plays a predominant pathogenic role in such diseases. Appropriate treatment is crucial, also considering that AIDs may persist into adulthood with negative consequences on patients’ quality of life. IL-1β blockade results in a sustained reduction of disease severity in most AIDs. Agrowing experience with the human IL-1 receptor antagonist, Anakinra (ANA), and the monoclonal anti IL-1β antibody, Canakinumab (CANA), has also been engendered, highlighting their efficacy upon protean clinical manifestations of AIDs. Safety and tolerability have been confirmed by several clinical trials and observational studies on both large and small cohorts of AID patients. The same treatment has been proposed in refractory Kawasaki disease, an acute inflammatory vasculitis occurring in children before 5 years, which has been postulated to be autoinflammatory for its phenotypical and immunological similarity with systemic juvenile idiopathic arthritis. Nevertheless, minor concerns about IL-1 antagonists have been raised regarding their employment in children, and the development of novel pharmacological formulations is aimed at minimizing side effects that may affect adherence to treatment. The present review summarizes current findings on the efficacy, safety, and tolerability of ANA and CANA for treatment of AIDs and Kawasaki vasculitis with a specific focus on the pediatric setting. AD - G. Lopalco, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy AU - Bettiol, A. AU - Lopalco, G. AU - Emmi, G. AU - Cantarini, L. AU - Urban, M. L. AU - Vitale, A. AU - Denora, N. AU - Lopalco, A. AU - Cutrignelli, A. AU - Lopedota, A. AU - Venerito, V. AU - Fornaro, M. AU - Vannacci, A. AU - Rigante, D. AU - Cimaz, R. AU - Iannone, F. DB - Embase Medline DO - 10.3390/ijms20081898 IS - 8 KW - acetylsalicylic acid anakinra C reactive protein canakinumab colchicine corticosteroid cryopyrin cyclooxygenase 2 immunoglobulin inflammasome interleukin 1 antibody interleukin 1alpha interleukin 1beta interleukin 23 interleukin 6 methotrexate mevalonic acid multiprotein complex nitric oxide phospholipase A procalcitonin prostaglandin E2 ribavirin thrombocyte activating factor tocilizumab toll like receptor adaptor molecule 1 tumor necrosis factor unindexed drug ustekinumab abdominal abscess abdominal pain anemia anxiety disorder appendectomy appendicitis arthralgia article asthma autoinflammatory disease bacteremia bronchitis CINCA syndrome computer assisted tomography connective tissue disease creatinine clearance dehydration diarrhea disease activity disease severity drug efficacy drug safety drug tolerability erythema gastroenteritis gastrointestinal disease gastrointestinal hemorrhage glaucoma headache heart sinoatrial block hepatitis hidradenitis hospitalization human hyperkalemia hypertriglyceridemia immune response immunophenotyping influenza injection site reaction intestine obstruction intracranial pressure kidney transplantation knee meniscus rupture coinfection monogenic disorder mucocutaneous lymph node syndrome multifactorial genetic disorder nausea nuclear magnetic resonance imaging patient compliance pericarditis peritonitis pharyngitis phase 2 clinical trial (topic) phase 3 clinical trial (topic) pneumonia pruritus quality of life rash rhinitis rhinopharyngitis rhinorrhea skin manifestation Streptococcus infection tonsillitis tooth infection unilateral blindness upper respiratory tract infection urinalysis urinary tract infection vaginitis vasculitis vertigo volume of distribution vomiting LA - English M3 - Article N1 - L2001802690 2019-05-15 2019-09-02 PY - 2019 SN - 1422-0067 1661-6596 ST - Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases T2 - International Journal of Molecular Sciences TI - Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001802690&from=export http://dx.doi.org/10.3390/ijms20081898 VL - 20 ID - 2509 ER - TY - JOUR AD - E. Beyzarov, NJ, United States AU - Beyzarov, E. C1 - avalide(Bristol Myers Squibb) bystolic(Forest) diovan(Novartis) tekturna(Novartis) C2 - Bristol Myers Squibb Forest Novartis DB - Embase IS - 2 KW - aldosterone antagonist aliskiren amlodipine angiotensin receptor antagonist antihypertensive agent atenolol hydrochlorothiazide plus irbesartan beta adrenergic receptor blocking agent bisoprolol nebivolol calcium channel blocking agent carvedilol dipeptidyl carboxypeptidase inhibitor diuretic agent losartan metoprolol perindopril placebo thiazide diuretic agent unclassified drug valsartan angina pectoris atherosclerosis blood pressure regulation child care clinical practice clinical trial combination chemotherapy congestive heart failure coronary artery disease diabetes mellitus disease severity drug approval drug dose titration drug efficacy drug mechanism Food and Drug Administration glaucoma health survey atrial fibrillation heart left ventricle failure heart muscle ischemia human hypertension hypotension ischemic heart disease lifestyle modification medical society meta analysis metabolic syndrome X monotherapy morbidity mortality patient compliance practice guideline prevalence recurrent disease renin angiotensin aldosterone system risk assessment short survey staging cerebrovascular accident systematic review systolic blood pressure treatment indication avalide bystolic diovan tekturna LA - English M3 - Short Survey N1 - L351346592 2008-04-02 PY - 2008 SN - 0012-6616 ST - Hypertension: So many treatments, yet so undermanaged T2 - Drug Topics TI - Hypertension: So many treatments, yet so undermanaged UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351346592&from=export http://drugtopics.modernmedicine.com/drugtopics/Pharmacy/Hypertension-So-many-treatments-yet-so-undermanage/ArticleStandard/Article/detail/484451 VL - 152 ID - 3475 ER - TY - JOUR AB - BACKGROUND: Benzalkonium chloride (BAK) is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes. This study compared the intraocular pressure (IOP)-lowering efficacy and safety of a novel once-daily, BAK-free, fixed-dose combination of latanoprost plus timolol with latanoprost or timolol administered as monotherapy or concomitantly., METHODS: This was a 6-week, randomized, open-label, parallel-group, active-controlled study in patients aged >=18 years with open-angle glaucoma or ocular hypertension. A total of 227 patients were randomized to either a once-daily, BAK-free, fixed-dose combination of latanoprost 0.005%/timolol 0.5% ophthalmic solution or concomitant administration of once-daily latanoprost 0.005% plus twice-daily timolol 0.5% or once-daily latanoprost 0.005% monotherapy, or twice-daily timolol 0.5% monotherapy. Efficacy end points were assessed at three time points on visits at weeks 1, 2, 4, and 6 versus baseline., RESULTS: The IOP-lowering efficacy of the fixed-dose combination of latanoprost/timolol was similar to that of latanoprost plus timolol administered concomitantly at all time points (mean IOP difference and 95% confidence interval within +/-1.5 mmHg; P=0.4223 to P=0.9981). The fixed-dose combination of latanoprost/timolol demonstrated significantly better IOP-lowering efficacy than timolol monotherapy at all time points (P=0.001 to P<0.0001) and significantly better IOP-lowering efficacy than latanoprost monotherapy at all time points. Responder rates on at least one time point and on at least two time points with fixed-dose combination latanoprost/timolol were similar to those with concomitant latanoprost plus timolol (85.5% versus 82.1%, P=0.6360; 78.2% versus 75%, P=0.6923), but significantly better than either latanoprost or timolol monotherapy (68.5%, P=0.0355; 55.4%, P=0.0005; 57.4%, P=0.0202; and 46.4%, P=0.0006, respectively). No significant differences in ocular and nonocular treatment-emergent adverse events were found between the treatment groups., CONCLUSION: A BAK-free, fixed-dose combination of latanoprost 0.005%/timolol 0.5% was as effective and well tolerated as concomitant latanoprost and timolol for treatment of elevated IOP in patients with open-angle glaucoma or ocular hypertension. AU - Bhagat, Purvi AU - Sodimalla, Kalyani AU - Paul, Chandrima AU - Pandav, Surinder S. AU - Raman, Ganesh V. AU - Ramakrishnan, Rengappa AU - Joshi, Abhijeet AU - Raut, Atul DO - https://dx.doi.org/10.2147/OPTH.S64584 PY - 2014 SE - Bhagat, Purvi. Glaucoma Clinic, M & J Western Regional Institute of Ophthalmology, Civil Hospital, Ahmedabad, Gujarat, India. Sodimalla, Kalyani. Glaucoma Department, PBMA's H.V. Desai Eye Hospital, Maharashtra, India. Paul, Chandrima. Glaucoma Service, B B Eye Foundation, Kolkata, India. Pandav, Surinder S. Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Raman, Ganesh V. Glaucoma Clinic, Aravind Eye Hospital, Coimbatore, Tamilnadu, India. Ramakrishnan, Rengappa. Glaucoma Clinic, Aravind Eye Hospital, Tirunelveli, Tamilnadu, India. Joshi, Abhijeet. Clinical Research Department, Sun Pharma Advanced Research Company Ltd, Mumbai, Maharashtra, India. Raut, Atul. Clinical Research Department, Sun Pharma Advanced Research Company Ltd, Mumbai, Maharashtra, India. SN - 1177-5467 SP - 1241-52 ST - Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=25061271 VL - 8 Y2 - 20140628// ID - 1078 ER - TY - JOUR AB - Pathology of eye, especially in the case of glaucoma, requires optimal therapeutically effective concentration of the drug in the ocular tissues for prolonged period of time with decreased dosing frequency and improved patient compliance. In the present study, brimonidine tartrate (BRT) ocular inserts were designed based on hydrophilic and/or inert/zwitterionic polymer matrix to design mucoadhesive and extended release ocular inserts. Designed inserts were evaluated for their physicochemical properties such as crushing strength/hardness, friability, drug content and mucoadhesion, and erosion and in vitro drug release characteristics. The selected optimised formulations were compared with marketed preparation for in vivo ocular irritation in healthy rabbits and for in vivo pharmacodynamic efficacy on alpha-chymotrypsin-induced glaucomatous rabbits. The developed formulations showed good physicochemical properties and mucoadhesive strength, and a good correlation was seen between rate of erosion or swelling with drug release rate in case of formulations with higher proportion of polyethylene oxide (PEO). Modulation of drug release was achieved by incorporating Eudragit in PEO matrix. Addition of Eudragit resulted in shifting of drug release mechanism from erosion-controlled to diffusion-controlled mechanism. In vivo ocular irritation studies confirmed the absence of any irritation upon administration in rabbits. Intraocular pressure (IOP) measurement studies showed an improved IOP-lowering ability of ocular insert of BRT in comparison to eye drops. AU - Bhagav, Prakash AU - Trivedi, Vaibhav AU - Shah, Darshan AU - Chandran, Sajeev DO - https://dx.doi.org/10.1007/s13346-011-0018-2 IS - 2 PY - 2011 SE - Bhagav, Prakash. Formulation Development and Pharmacokinetics Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, India. SN - 2190-393X SP - 161-74 ST - Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma T2 - Drug delivery and translational research TI - Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=25788114 VL - 1 ID - 1176 ER - TY - JOUR AB - An 11-year-old boy underwent simple limbal epithelial transplantation (SLET) from the healthy right eye to his left eye for total limbal stem cell deficiency. One month later, corneal surface epithelialised and whitish plaques overlying the transplants were seen inferiorly. Those plaques were adherent to the surface of the contact lens and underlying corneal surface had smooth elevations. Similar findings were noted in a 23-year man following cyanoacrylate glue application for corneal perforation. On histological and immunohistochemical analysis, cells lining the contact lenses were identified as corneal epithelial cells. These cases illustrate epithelial cell growth on the contact lens and epithelial hyperplasia on corresponding surface of the cornea. Exorbitant proliferation of the epithelial cells may be owing to young age; therefore, early contact lens removal after SLET in young age, can possibly avoid epithelial hyperplasia. This also reiterates the possibility of using contact lens as a scaffold to grow epithelial cells. AU - Bhalekar, Swapnil AU - Sangwan, Virender S. AU - Basu, Sayan DO - https://dx.doi.org/10.1136/bcr-2013-009113 KW - Burns, Chemical/su [Surgery] Cell Proliferation Child *Cornea/cy [Cytology] *Corneal Transplantation/mt [Methods] *Epithelial Cells/cy [Cytology] Eye Burns/ci [Chemically Induced] Eye Burns/su [Surgery] Humans Keratitis, Herpetic/su [Surgery] Lens Implantation, Intraocular/mt [Methods] Lenses, Intraocular *Limbus Corneae/cy [Cytology] Male Tissue Scaffolds Young Adult PY - 2013 SE - Bhalekar, Swapnil. Cornea and Anterior Segment Services, L V Prasad Eye Institute, Hyderabad, Andhra Pradesh, India. SN - 1757-790X ST - Growth of corneal epithelial cells over in situ therapeutic contact lens after simple limbal epithelial transplantation (SLET) T2 - BMJ case reports TI - Growth of corneal epithelial cells over in situ therapeutic contact lens after simple limbal epithelial transplantation (SLET) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23814196 VL - 2013 Y2 - 20130627// ID - 961 ER - TY - JOUR AB - The present research work summarises the development of an in situ gelling ophthalmic nanoemulsion of brinzolamide providing sustained release and prolonged therapeutic effect for the treatment of glaucoma. Nanoemulsions were prepared using castor oil, polyoxyl 35 castor oil and polysorbate 80 and with gellan gum as the in situ gelling agent. Formulations were screened based on globule size, Zeta potential, in vitro drug release and stability towards phase separation and sol to gel conversion upon storage. Selected formulations exhibiting a low mean globule diameter (< 160 nm), narrow size distribution (polydispersity index < 0.3), quick in vitro gelling time (< 15 s) and stability for at least 6 months at 25 degreeC/40% RH and 40 degreeC/25% RH were evaluated for intraocular pressure (IOP)-lowering efficacy studies using glaucomatous rabbits. Tested nanoemulsion formulations were well tolerated and significantly decreased IOP relative to saline and placebo controls (p < 0.005). Furthermore, an appreciable increase in the area under change in IOP from baseline (DELTAIOP) vs. time curve and a longer mean residence time (MRT) was also observed for the test formulations compared with commercially available suspension of brinzolamide (Azopt, Alcon Laboratories, USA). Thus, nanoemulsion formulations containing in situ gelling polymer may serve as improved drug delivery system providing superior therapeutic efficacy and better patient compliance for the treatment of glaucoma. . Graphical abstract. AU - Bhalerao, Hemant AU - Koteshwara, K. B. AU - Chandran, Sajeev DO - https://dx.doi.org/10.1007/s13346-019-00697-0 IS - 2 KW - Administration, Ophthalmic Animals *Castor Oil/ch [Chemistry] Delayed-Action Preparations Disease Models, Animal Drug Compounding Emulsions *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Nanoparticles *Polysaccharides, Bacterial/ch [Chemistry] *Polysorbates/ch [Chemistry] Rabbits *Sulfonamides/ad [Administration & Dosage] Sulfonamides/ch [Chemistry] Sulfonamides/pd [Pharmacology] *Thiazines/ad [Administration & Dosage] Thiazines/ch [Chemistry] Thiazines/pd [Pharmacology] PY - 2020 SE - Bhalerao, Hemant. Advanced Drug Delivery Systems, Pharma Research, Lupin Research Park, 46/47A, Nande Village, Mulshi Taluka, Pune, 412115, India. Koteshwara, K B. Department of Pharmaceutics Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. Chandran, Sajeev. Advanced Drug Delivery Systems, Pharma Research, Lupin Research Park, 46/47A, Nande Village, Mulshi Taluka, Pune, 412115, India. sajeevchandran@lupin.com. SN - 2190-3948 2190-393X SP - 529-547 ST - Design, optimisation and evaluation of in situ gelling nanoemulsion formulations of brinzolamide T2 - Drug delivery and translational research TI - Design, optimisation and evaluation of in situ gelling nanoemulsion formulations of brinzolamide UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med17&NEWS=N&AN=31820300 VL - 10 ID - 283 ER - TY - JOUR AB - The purpose to do this research was to find out the habits of contact lens wearers towards lens care in this country, and to evaluate the compliance of contact lens wearers. Methods: All respondents underwent an interview regarding questionnaire which was carried out at the Klang Valley and Sabah, Malaysia by trained bilingual optometrists. The questionnaire was obtained from a study by Yvonne Wu et al., 2010. The questionnaire included information about respondents' demographics, contact lens hygiene behaviors and attitudes toward lens care. Comparison between groups and certain factors of lens care were analyzed. Results: Within the 100 respondents, 74% were female. The majority used monthly disposable lens (53%, 53/100), 35% (35/100) wore daily lens, 3% (3/100) wore biweekly disposable lens, 8% (8/100) wore quarter-yearly (3 months) lens, and only a participant (1%) used conventional lenses. The major non-compliance aspect that found out from this research were poor lens case (46%), inadequate cleaning of lens before storing (38%) and wearers not remembering how often they were advised to return for an aftercare (24%). Conclusion: The poor lens care hygiene, inadequate cleaning of lens before storing may due to lack of proper advice to the contact lens wearers during examination or lack of awareness of aftercare visit. AD - Twintech International University College of Technology, Faculty of Optometry, Wishma Twintech, Persiaran Dagang, Bandar Sri Damansara, Kuala Lumpur, Malaysia AU - Bhandari, M. AU - Rou, H. P. DB - Scopus IS - 3 KW - Aftercare Contact lens Disinfecting solution Microbial keratitis Questionnaire M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2012 SP - 274-277 ST - Habits of contact lens wearers toward lens care in Malaysia T2 - Medical Journal of Malaysia TI - Habits of contact lens wearers toward lens care in Malaysia UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864429668&partnerID=40&md5=30088a522ef9052754f904ba622be3cb VL - 67 ID - 5257 ER - TY - JOUR AB - AIMS: To determine patients' preferences for provision of glaucoma follow-up services examining preferences for location, access and personnel for delivery of this care., METHODS: 100 patient patients attending the glaucoma outpatient clinic for follow-up review underwent an interview-based assessment during which they completed the visual function questionnaire 25 and ranking of scenario options for provision of follow-up care for their glaucoma. Percentage preferences for aspects of care offered in the conjoint analysis scenario packages and generation of utility values for each of the factor levels included in the scenario design were calculated., RESULTS: Travel time and training of health professional were the most important factors for patients (accounting for over 60%) of their preference. Utility scores were generated for each factor, with shorter travel time and examination by a doctor being the most important features to the patients. Patients who lived furthest from the hospital and had severe visual disability considered the number of visits to complete an episode to be an important feature., CONCLUSION: Patients ideally would like to travel a short distance and be seen by a doctor when being followed up for their glaucoma. AU - Bhargava, J. S. AU - Bhan-Bhargava, A. AU - Foss, A. J. E. AU - King, A. J. DO - https://dx.doi.org/10.1136/bjo.2008.140483 IS - 12 KW - Adult Aged Aged, 80 and over Continuity of Patient Care Delivery of Health Care/og [Organization & Administration] *Delivery of Health Care/st [Standards] Female *Glaucoma/th [Therapy] Health Care Surveys Health Services Accessibility Humans Male Middle Aged *Patient Satisfaction Regression Analysis Time Factors N1 - Comment in (CIN) PY - 2008 SE - Bhargava, J S. Department of Ophthalmology, Nottingham University NHS Trust, Queen's Medical Centre Campus, Derby Road, Nottingham NG7 2UH, UK. SN - 1468-2079 0007-1161 SP - 1601-5 ST - Views of glaucoma patients on provision of follow-up care; an assessment of patient preferences by conjoint analysis T2 - The British journal of ophthalmology T3 - Comment in: Br J Ophthalmol. 2008 Dec;92(12):1571-2; PMID: 19029156 [https://www.ncbi.nlm.nih.gov/pubmed/19029156] TI - Views of glaucoma patients on provision of follow-up care; an assessment of patient preferences by conjoint analysis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18664502 VL - 92 Y2 - 20080729// ID - 1520 ER - TY - JOUR AB - PURPOSE: To determine by conjoint analysis which factors in the management and treatment of glaucoma were of most importance to patients and to relate these factors to the patient's clinical glaucoma condition., METHODS: An interview-based study was performed. Demographic and visual function data are recorded. Participants completed the Visual Function Questionnaire-25 and ranked 10 hypothetical patient scenarios that contained different risks of moderate visual loss, postoperative complications, long-term blindness, use of topical medication, and glaucoma surgery. Conjoint analysis was performed to determine the relative importance of these factors for individuals and the group as a whole., RESULTS: Eighty-two patients were interviewed from two consultants' outpatient clinics. Forty-five were male and 37 female. Seventy-nine were white. The most important factors to patients with glaucoma were the risk of moderate visual impairment and the risk of blindness, with an importance of 38% and 27%, respectively. The use of topical medication had an importance of 11%. Proceeding to surgical intervention (trabeculectomy) had an importance of 15%, and the small risk of visual deterioration after surgery (trabeculectomy) had an importance of 9%., CONCLUSIONS: To patients, the most important factors regarding glaucoma and its treatment are the risks of moderate visual loss (the ability to continue to drive) and long-term blindness. The treatment methods used are of much less importance. AU - Bhargava, Jonathan S. AU - Patel, Bakula AU - Foss, Alexander J. E. AU - Avery, Anthony J. AU - King, Anthony J. IS - 7 KW - Adult Aged Aged, 80 and over Antihypertensive Agents/tu [Therapeutic Use] Blindness/et [Etiology] Female *Glaucoma, Open-Angle/th [Therapy] Health Care Surveys Humans Intraocular Pressure Male Middle Aged *Patient Satisfaction/sn [Statistics & Numerical Data] *Patients/px [Psychology] Risk Assessment Surveys and Questionnaires Trabeculectomy/mt [Methods] Vision, Low/et [Etiology] PY - 2006 SE - Bhargava, Jonathan S. Department of Ophthalmology, Queen's Medical Centre, Division of Primary Care, University of Nottingham, United Kingdom. SN - 0146-0404 SP - 2885-8 ST - Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis T2 - Investigative ophthalmology & visual science TI - Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16799029 VL - 47 ID - 1659 ER - TY - SER AD - Kapil Bharti National Institutes of Health NEI, Bethesda, MD, United States AU - Bharti, K. DB - Scopus M3 - Editorial N1 - Export Date: 19 July 2021 PY - 2019 SP - v-vi ST - Preface T2 - Advances in Experimental Medicine and Biology TI - Preface UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074641900&partnerID=40&md5=9ff4f9be8a7ac899433e61fe38083bd6 VL - 1186 ID - 5726 ER - TY - JOUR AB - The ultimate goal of glaucoma therapy, as of any other therapeutic intervention, is to achieve superior clinical outcomes, patient satisfaction, and patient adherence to treatment. In a chronic asymptomatic disease, such as, glaucoma, where diagnostic and therapeutic algorithms may have multiple acceptable treatment arms, patient centricity becomes increasingly important. Shared decision-making, patient participation, quality of life (QoL) concerns, and risk-benefit analyzes further complicate this decision-making. In addition, the ethics of research in glaucoma and also that of glaucoma screening may often be in conflict with the ethics of patient care. This article aims to highlight the ethical dilemmas that confound decision-making in current glaucoma practice, and the doctors' fiduciary duties to the patient. How to cite this article: Bhartiya S. Patient Centricity and the Ethics of Glaucoma Care. J Curr Glaucoma Pract 2020;14(2):68-71. Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. AU - Bhartiya, Shibal DO - https://dx.doi.org/10.5005/jp-journals-10078-1281 IS - 2 PY - 2020 SE - Bhartiya, Shibal. Department of Ophthalmology, Glaucoma Services, Fortis Memorial Research Institute, Gurugram, Haryana, India. SN - 0974-0333 SP - 68-71 ST - Patient Centricity and the Ethics of Glaucoma Care T2 - Journal of current glaucoma practice TI - Patient Centricity and the Ethics of Glaucoma Care UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33304063 VL - 14 ID - 119 ER - TY - JOUR AB - There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the market with a patent, whereas branded generic drugs are produced by a different company once the patent of innovator company expires. Given that glaucoma is a chronic, largely asymptomatic disease, the choice of drugs is extremely important: the duration of medication is often lifelong, and the cost of drugs, side effects and efficacy affect compliance and adherence to therapy. This review is a brief overview of the available brand name and branded generic drugs for the management of glaucoma, in terms of efficacy and side effect profiles. It also aimed to guide rational and pragmatic drug choices in different clinical scenarios. Copyright ©Romanian Society of Ophthalmology. AU - Bhartiya, Shibal AU - Dhingra, Deepika IS - 3 PY - 2020 SE - Bhartiya, Shibal. Glaucoma Services, Fortis Memorial Research Institute, Gurugram, Haryana, India. Dhingra, Deepika. Shah Satnam Ji Speciality Hospitals, Sirsa, Haryana, India. SN - 2501-2533 2457-4325 SP - 239-244 ST - Generics versus brand-named drugs for glaucoma: the debate continues T2 - Romanian journal of ophthalmology TI - Generics versus brand-named drugs for glaucoma: the debate continues UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=33367157 VL - 64 ID - 88 ER - TY - JOUR AB - Glaucoma is a chronic disease which requires a lifelong therapeutic regimen, without any apparent subjective improvement. In fact, the quality of life of patients is known to deteriorate on institution of therapy. It is, therefore, imperative that the risks and benefits of glaucoma therapy be explained to the patient in great detail in order to increase compliance and adherence to the prescribed regimen. Since good communication is a precondition for optimal care and treatment in care of glaucoma patients, this review attempts to offer a solution to the serious communication problems still experienced by patients as well as by health care professionals. AD - S. Bhartiya, Glaucoma Services, Department of Ophthalmology, Fortis Memorial Research Institute, Gurgaon, Haryana, India AU - Bhartiya, S. AU - Ichhpujani, P. DB - Embase DO - 10.5005/jp-journals-10008-1122 IS - 1 KW - article attitude blindness caregiver communication disorder doctor patient relationship glaucoma health care personnel human intelligence interpersonal communication intraocular hypertension intraocular pressure iridotomy low level laser therapy patient care patient compliance quality of life risk assessment therapeutic misconception trabeculoplasty visual impairment LA - English M3 - Article N1 - L622118647 2018-05-18 2018-05-22 PY - 2011 SN - 0975-1947 0974-0333 SP - 1-7 ST - Patient communication and the glaucoma surgeon T2 - Journal of Current Glaucoma Practice TI - Patient communication and the glaucoma surgeon UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622118647&from=export http://dx.doi.org/10.5005/jp-journals-10008-1122 VL - 5 ID - 3211 ER - TY - JOUR AB - This study aims to evaluate the efficacy and safety of post-trabeculectomy topical bevacizumab, in preventing bleb failure. A total of 11 females and 12 males were enrolled for the study. After a complete ophthalmic evaluation, the patients underwent trabeculectomy. Full ophthalmic examination was done the next day, which included visual acuity, intraocular pressure (IOP), and bleb morphology. Next, two drops of bevacizumab [0.25 mg (0.01 ml)] were instilled over the wound area with a tuberculin (1 ml) syringe. Pressure was applied at the medial canthus to prevent it from going into the lacrimal passage. Similar postoperative procedures were repeated at 1, 2, 3, and 4 weeks. So in all, five instillations of bevacizumab were completed. Later, the patients were followed at 1-month interval for 6 months. Target IOP was achieved in all eyes and was maintained during the study period of 6 months without any anti-glaucoma medication. Average IOP before trabeculectomy was 27.27±8.92 mmHg, which decreased postoperatively to 8.77±0.97 mmHg at 3 months and 9.27±1.16 mmHg at 6 months. This drop in IOP was statistically significant on both occasions (p=0.00). A nice low filtering bleb was formed after the surgery, and it remained the same during the study period. The other parameters like cup-to-disc ratio and visual field did not change during the 6 months of study as expected because glaucoma is a slow progressive disease. Modulating the wound at multiple sites by bevacizumab (inflammation, proliferative, and remodeling stages) can lead to success of trabeculectomy. © Springer Science+Business Media New York 2013. AD - S.K. Bhasker, King George's Medical University, Lucknow, Uttar Pradesh, India AU - Bhasker, S. K. AU - Saxena, S. AU - Singh, K. C1 - avastin(Genentech,United States) C2 - Genentech(United States) DB - Embase DO - 10.1007/s12177-013-9108-3 IS - 3-4 KW - antiglaucoma agent bevacizumab absence of side effects adult aged article bleb failure clinical article conjunctiva disease drug efficacy drug safety female follow up human intraocular pressure male middle aged open angle glaucoma optic disk cup patient compliance postoperative period preoperative evaluation priority journal trabeculectomy treatment outcome visual acuity visual field visual system examination wound healing avastin LA - English M3 - Article N1 - L52652307 2013-07-01 2014-02-13 PY - 2012 SN - 1936-8437 1936-8445 SP - 89-95 ST - Post-trabeculectomy topical bevacizumab preventing bleb failure: A preliminary study T2 - Journal of Ocular Biology, Diseases, and Informatics TI - Post-trabeculectomy topical bevacizumab preventing bleb failure: A preliminary study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52652307&from=export http://dx.doi.org/10.1007/s12177-013-9108-3 VL - 5 ID - 3055 ER - TY - JOUR AB - Background: Narcolepsy is a rare chronic sleep disorder classically characterized by excessive daytime sleepiness. Other symptoms of the disease, including cataplexy, sleep paralysis, hypnagogic hallucinations and disturbed nocturnal sleep, may follow later. The disease can be incapacitating and frequently results in impaired psychosocial interaction. In the absence of a cure for narcolepsy, medical therapy is directed at symptom control. Objectives: The aim of this study was to review the current approach to the treatment of narcolepsy. Methods: A search of three bibliographic databases (MEDLINE/PubMed, EMBASE and the Cochrane Library Database) was conducted from 1966 to January 2008 using the National Library of Medicine MeSH search terms narcolepsy and cataplexy. Relevant studies, case reports, review articles, editorials, short communications and chapters from selected textbooks were then extracted and manually cross-referenced. Results/conclusions: Traditionally, stimulants have been used to improve the symptoms of excessive daytime sleepiness. However, the treatment of narcolepsy has evolved recently with the widespread use of newer drugs, including modafinil for daytime sleepiness, newer antidepressants for cataplexy and γ-hydroxybutyrate (sodium oxybate) for both excessive daytime sleepiness and cataplexy. © 2008 Informa UK Ltd. AD - A.A. El Solh, State University of New York at Buffalo, Western New York Respiratory Research Center, Department of Medicine, Buffalo, NY, United States AU - Bhat, A. AU - El Solh, A. A. DB - Embase Medline DO - 10.1517/14656566.9.10.1721 IS - 10 KW - amphetamine amphetamine derivative antidepressant agent armodafinil central stimulant agent clomipramine desipramine dexamphetamine diazepam ethinylestradiol fluoxetine imipramine mazindol methamphetamine methylphenidate modafinil oxybate sodium pemoline pethidine phenytoin placebo propranolol protriptyline reboxetine selegiline serotonin uptake inhibitor tricyclic antidepressant agent unindexed drug venlafaxine viloxazine aggression agitation anorexia anxiety bedtime dosage blood pressure body temperature catalepsy cataplexy clinical trial Cochrane Library combination chemotherapy confusion constipation coping behavior daytime somnolence depression diaphoresis diarrhea dizziness dosage schedule comparison dose response drug bioavailability drug blood level drug choice drug dose escalation drug dose increase drug effect drug efficacy drug elimination drug half life drug induced headache drug mechanism drug megadose drug metabolism drug potentiation drug safety drug substitution drug tolerability drug withdrawal ejaculation disorder Embase erectile dysfunction exercise gait disorder glaucoma hallucination heart arrhythmia heart palpitation human hyperreflexia hypotension impotence insomnia irritability libido disorder liver toxicity low drug dose Medline mental health monotherapy mood change morning dosage muscle rigidity myoclonus narcolepsy nausea nervousness neuroleptic malignant syndrome night sleep nocturnal enuresis nonhuman paranoia parkinsonism patient compliance patient safety psychopathy psychosis quality of life recommended drug dose REM sleep review sedation serotonin syndrome shivering side effect single drug dose sleep disordered breathing sleep deprivation sleep pattern smoking cessation somnolence stupor suicide sweating symptom tachycardia taste disorder tremor unspecified side effect urine retention valvular heart disease vomiting wakefulness body weight gain body weight loss xerostomia LA - English M3 - Review N1 - L352055018 2008-08-05 PY - 2008 SN - 1465-6566 SP - 1721-1733 ST - Management of narcolepsy T2 - Expert Opinion on Pharmacotherapy TI - Management of narcolepsy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352055018&from=export http://dx.doi.org/10.1517/14656566.9.10.1721 VL - 9 ID - 3439 ER - TY - JOUR AD - L. Bhat, Department of Ophthalmic Surgeon, Maidstone and Pembury Hospitals, Kent, United Kingdom AU - Bhat, L. DB - Embase IS - 2 KW - cataract extraction community care doctor patient relationship eye disease glaucoma health care access human India letter ophthalmology prognosis age related macular degeneration screening test United Kingdom visual acuity LA - English M3 - Letter N1 - L43526939 2006-04-18 PY - 2005 SN - 0253-8253 SP - 64 ST - Two memorable patients T2 - Qatar Medical Journal TI - Two memorable patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43526939&from=export VL - 14 ID - 3711 ER - TY - JOUR AB - AIM: To identify the relative incidence and profile of adverse drug reaction (ADR) to various topical ocular hypotensives in a hospital setting., METHODS: All the patients presenting in outpatients clinic and accident and emergency with an ADR to topical hypotensive agent from August 2000 to January 2001 were included in the study. Details regarding the type date of commencing the treatment, the date of developing ADR, time to resolution of the ADR were noted., RESULTS: Over the period of 6 months, 66 patients presented with 73 ADRs. Brimonidine was the most frequent offending agent. In total, 23 (34.8%) presented with ADR after being commenced on treatment for more than 12 months. In all, 16 (24%) patients had IOP > 21 on presentation, eight (12%) patients underwent filtration surgery following the development of ADR., CONCLUSION: Adverse drug reaction to ocular hypotensive agents is not uncommon and can have a major impact on glaucoma management. Delayed presentation and association with raised intraocular pressure presentation emphasise the need for effective patient education to encourage prompt reporting of ADR. AU - Bhatt, R. AU - Whittaker, K. W. AU - Appaswamy, S. AU - Desai, A. AU - Fitt, A. AU - Sandramouli, S. IS - 4 KW - Adrenergic alpha-Agonists/ae [Adverse Effects] Aged Aged, 80 and over *Antihypertensive Agents/ae [Adverse Effects] Brimonidine Tartrate Female Filtering Surgery *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Glaucoma/su [Surgery] Humans Intraocular Pressure Male Middle Aged Ophthalmic Solutions/ae [Adverse Effects] Outpatient Clinics, Hospital Patient Acceptance of Health Care Prospective Studies Quinoxalines/ae [Adverse Effects] Time Factors PY - 2005 SE - Bhatt, R. Wolverhampton & Midland Counties Eye Infirmary, Wolverhampton WV3 9QR, UK. SN - 0950-222X SP - 392-5 ST - Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population T2 - Eye (London, England) TI - Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=15297863 VL - 19 ID - 1753 ER - TY - JOUR AB - Childhood blindness due to corneal ulceration has historically been prevalent among poor Indian children. To tackle this situation the National Institute of Nutrition (NIN), Hyderabad, India, launched (after field-testing) massive dose based national vitamin A (Vit-A) prophylaxis program. Over a period of time reduction in childhood mortality was also hailed as a beneficial effect of the program. Data from the Indian Council for Medical Research (ICMR) indicate that in most Indian states there has been a gradual reduction in the prevalence of Bitot's spots. However, it was not attributed to the prophylaxis program because of its low and patchy coverage. It was, rather, attributed to the control of malnutrition, along with measles vaccination and improvement in healthcare access. Various studies have concluded that massive dose vitamin A prophylaxis does not reduce childhood mortality; this may have been due to the Hawthorne effect; whereby beneficial effects arose from frequent contact of health workers with community members. Paradoxically, harmful effects of massive doses of Vit-A are documented, e.g. acute toxicity in certain groups of children, ranging from increased intracranial pressure, mental retardation (postnatal period), and even death. Vit-A also intensifies bone demineralization, and increased levels can lead to calcium deficiency and, hence, growth retardation in vulnerable children. According to the present authors, for children who have Bitot's spots or who have just recovered from an attack of measles, the best approach is to give Vit-A in therapeutic doses along with adequate daily intake of vegetables and fruits. Public-spirited citizens, along with the scientific community, must ensure the scrapping of the universal massive dose Vit-A prophylaxis approach, to avoid Vit-A toxicity and reduce economic burden to the health system. AD - S. Bhattacharya, School of Public Health, Department of Community Medicine, Postgraduate Institute of Medical Education & Research, India AU - Bhattacharya, S. AU - Singh, A. DB - Embase Medline DO - 10.1016/j.clnesp.2017.07.001 KW - measles vaccine retinol acute toxicity article blindness bone demineralization bone density calcium deficiency childhood blindness childhood mortality growth retardation health care health care access health insurance human intracranial pressure measles vaccination mental deficiency public health respiratory tract infection systematic review vitamin supplementation LA - English M3 - Article N1 - L617421033 2017-07-25 2017-08-29 PY - 2017 SN - 2405-4577 SP - 26-30 ST - Time to revisit the strategy of massive vitamin A prophylaxis dose administration to the under five children in India – An analysis of available evidence T2 - Clinical Nutrition ESPEN TI - Time to revisit the strategy of massive vitamin A prophylaxis dose administration to the under five children in India – An analysis of available evidence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617421033&from=export http://dx.doi.org/10.1016/j.clnesp.2017.07.001 VL - 21 ID - 2629 ER - TY - JOUR AB - Overactive bladder is a common condition that significantly impacts overall quality of life. Antimuscarinics are the current main pharmacological option for treatment; however, many patients fail to adhere to therapy due to troublesome side effects. Mirabegron is a new beta-3 adrenoreceptor agonist which causes detrusor smooth muscle relaxation and has been proposed to be effective for treating overactive bladder symptoms. Mirabegron has been shown to be superior to placebo for reducing the mean number of incontinence episodes per 24 hours and the mean number of micturitions per 24 hours. Side effects such as dry mouth were observed at similar or lower rates than those seen for placebo and antimuscarinics. Higher doses of mirabegron were associated with minor increases in pulse rate and mean blood pressure. Mirabegron offers a new alternative for treating overactive bladder in patients for which antimuscarinics are either not tolerated or not appropriate. © 2012 Bhide et al, publisher and licensee Dove Medical Press Ltd. AD - G. Alessandro Digesu, Department of Urogynaecology, St Mary's Hospital, London, W2 1NY, United Kingdom AU - Bhide, A. A. AU - Alessandro Digesu, G. AU - Fernando, R. AU - Khullar, V. DB - Embase IS - 1 KW - NCT01340027 beta 3 adrenergic receptor stimulating agent cytochrome P450 2D6 cytochrome P450 3A4 darifenacin desipramine metformin mirabegron muscarinic receptor muscarinic receptor blocking agent oxybutynin placebo solifenacin tolterodine trospium chloride absence of side effects bladder training blurred vision closed angle glaucoma constipation detrusor muscle disorientation dizziness drowsiness drug dose comparison drug efficacy drug fatality drug half life drug metabolism drug safety drug selectivity drug tolerability drug urine level drug withdrawal dry eye fatigue flatulence gastrointestinal disease gastrointestinal symptom hallucination headache heart rate human hypertension infection infestation intraocular pressure maximum plasma concentration mean arterial pressure multicenter study (topic) nonhuman overactive bladder patient compliance patient satisfaction phase 2 clinical trial (topic) phase 3 clinical trial (topic) pulse rate quality of life randomized controlled trial (topic) receptor blocking restlessness review rhinopharyngitis side effect single drug dose smooth muscle relaxation taste disorder treatment outcome urinary frequency urinary tract infection urine incontinence xerostomia L1 - internal-pdf://1129566413/3074-Mirabegron - a selective β3-adrenore-2012.pdf LA - English M3 - Review N1 - L365412448 2012-08-17 2012-08-21 PY - 2012 SN - 1179-1551 SP - 41-45 ST - Mirabegron - a selective β3-adrenoreceptor agonist for the treatment of overactive bladder T2 - Open Access Journal of Urology TI - Mirabegron - a selective β3-adrenoreceptor agonist for the treatment of overactive bladder UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365412448&from=export VL - 4 ID - 3074 ER - TY - JOUR AB - The effective use of aqueous and oily pilocarpine was studied in 19 glaucomatous eyes. The aqueous drops were used 4 times a day while the oily drops were used only twice. It was found that the oily drops were better than the aqueous drops in lowering the mean intraocular pressure and the maximum pressure reached during the day. no statistically significant difference was found between the 2 pilocarpine treatments in the reduction of daily variation of intraocular pressure. It is felt that oily drops used only twice a day would lead to better patient compliance and better control of chronic simple glaucoma. AU - Bhojwani, S. C. AU - Jones, D. K. IS - 8 KW - Aged Drug Administration Schedule *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Middle Aged Ophthalmic Solutions *Pilocarpine/ad [Administration & Dosage] Pilocarpine/pd [Pharmacology] PY - 1981 SN - 0007-1161 SP - 530-2 ST - Comparative study of aqueous and oily pilocarpine in the production of ocular hypotension T2 - The British journal of ophthalmology TI - Comparative study of aqueous and oily pilocarpine in the production of ocular hypotension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=7295614 VL - 65 ID - 2254 ER - TY - JOUR AB - Purpose of review The utility of the monocular trial to determine the response to topical ocular hypotensive medications has been recently debated. This review provides a critical evaluation of recent studies and discusses factors that affect the accurate determination of medication response. Recent findings Recent concerns about the validity of the monocular trial arise from studies reporting a low-to-moderate correlation of intraocular pressure (IOP) response between the first and second eyes to the same topical ocular hypotensive medication. Few studies, however, have addressed the classic monocular trial that adjusts IOP in the trial eye based on IOP change in the fellow eye. Conflicting results from prior studies are due to differences in study question, study design, and method of analysis. Factors such as variability of IOP, diurnal variation, and regression to the mean further complicate the understanding of whether monocular trials or binocular simultaneous trials (i.e. testing each eye separately) are better for determining medication effect. Summary The issue of whether or not to use the monocular trial remains controversial. A more clear understanding of factors such as nontherapeutic variability of IOP within the same eye and between eyes may elucidate the answer to this question. Further studies of monocular and binocular trials are needed to clarify which method better estimates medication response. © 2009 Wolters Kluwer Health|Lippincott Williams & Wilkins. AD - A.M. Bhorade, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8096, St Louis, MO 63110, United States AU - Bhorade, A. M. DB - Embase Medline DO - 10.1097/ICU.0b013e3283249c67 IS - 2 KW - adrenergic receptor stimulating agent alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor latanoprost prostaglandin derivative accuracy circadian rhythm clinical trial glaucoma human intraocular hypertension intraocular pressure open angle glaucoma patient compliance priority journal review treatment response LA - English M3 - Review N1 - L354355310 2009-04-07 PY - 2009 SN - 1040-8738 SP - 104-109 ST - The monocular trial controversy: A critical review T2 - Current Opinion in Ophthalmology TI - The monocular trial controversy: A critical review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354355310&from=export http://dx.doi.org/10.1097/ICU.0b013e3283249c67 VL - 20 ID - 3374 ER - TY - JOUR AB - PURPOSE: To describe variability of intraocular pressure (IOP) measurements within the same eye and between right and left eyes over a 60-month period in participants in the Ocular Hypertension Treatment Study., DESIGN: Analysis of data from a prospective, randomized clinical trial., PARTICIPANTS: Eight hundred ten participants randomized to the observation group., METHODS: Intraocular pressure measurements were obtained at the baseline visit and every 6 months thereafter. Pearson correlation coefficients were calculated for IOP measurements in the same eye between visits and for IOP measurements between right and left eyes of participants at each visit. Differences in IOP measurements between visits are reported in percent change (>15%, >20%, and >30%) and in millimeters of mercury (<3 mmHg, 3-5 mmHg, and >5 mmHg). The effects of regression to the mean, consistency in time of day, and sequence of IOP measurement of right and left eyes were examined., MAIN OUTCOME MEASURES: Correlation of IOP measurements between consecutive 6-month visits., RESULTS: The correlation of IOP measurements within the same eye between consecutive visits was r = 0.62, whereas the correlation of IOP measurements between right and left eyes at the same visit was r = 0.72. Thirteen percent of eyes had >20% change in IOP between consecutive visits. Sixty-six percent of eyes had a change in IOP within 3 mmHg, and 10% of eyes had a change in IOP >5 mmHg between visits. Eyes with a higher baseline IOP had a lower IOP at 6 months. There was a stronger correlation of IOP measured within 2 hours of the time of day between visits (r = 0.56) than >2 hours apart (r = 0.39). IOP of the right eye, which was measured first, was 0.3+/-2.8 mmHg higher than the left eye., CONCLUSIONS: The variability of IOP measurements in the same eye between consecutive visits is moderate and is greater than the variability of IOP measurements between right and left eyes at the same visit. Factors affecting the variability of IOP measurement include regression to the mean, time of day, and measurement order. Knowledge of variability in IOP and its measurements may help clinicians establish a more accurate baseline IOP, target IOP, and assessment of medication effect. AU - Bhorade, Anjali M. AU - Gordon, Mae O. AU - Wilson, Brad AU - Weinreb, Robert N. AU - Kass, Michael A. AU - Ocular Hypertension Treatment Study, Group DO - https://dx.doi.org/10.1016/j.ophtha.2008.12.036 IS - 4 KW - Adult Aged Aged, 80 and over Antihypertensive Agents/tu [Therapeutic Use] Circadian Rhythm/ph [Physiology] Female Follow-Up Studies *Functional Laterality/ph [Physiology] Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged Observation Ocular Hypertension/dt [Drug Therapy] *Ocular Hypertension/pp [Physiopathology] Office Visits Prospective Studies Tonometry, Ocular N1 - Erratum in (EIN) PY - 2009 SE - Bhorade, Anjali M. Washington University School of Medicine, St. Louis, Missouri 63110, USA. SN - 1549-4713 0161-6420 SP - 717-24 ST - Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study T2 - Ophthalmology T3 - Erratum in: Ophthalmology. 2009 May;116(5):822 Note: Weinrab, Robert N [corrected to Weinreb, Robert N] TI - Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19243824 VL - 116 Y2 - 20090225// ID - 1468 ER - TY - JOUR AB - BACKGROUND: Latanoprost, a prostaglandin inhibitor, is increasingly being used in the therapeutic management of glaucoma. However, there is scant literature examining the cost and outcome ramifications of latanoprost., OBJECTIVES: This study examined the medication use behavior (medication-related persistence and adherence rates) and costs associated with the introduction of latanoprost therapy in a treatment-naive older population (aged >or=65 years) enrolled in Medicare., METHODS: The study employed a retrospective observational cohort design and used administrative claims data from a Medicare health maintenance organization (HMO), which offered complete coverage to enrollees, including prescription benefits. The case group consisted of patients with glaucoma who began latanoprost therapy. The control group consisted of enrollees with glaucoma who started any therapy other than latanoprost. Both groups were followed up for 1 year before and after initiation of therapy. Bivariate and multivariate techniques incorporating health care utilization in the year before the start of new therapy were used to determine the study outcomes., RESULTS: The case group comprised 101 patients (mean age, 77.60 years), while the control group included 168 patients (mean age, 77.59 years). There were no significant differences across the 2 groups with respect to age, sex, general health scores on the 12 item Short-Form Health Survey, severity of comorbidity, or the proportion of respondents with perception of worsened health. Introduction of latanoprost therapy was associated with higher medication persistence (hazard ratio, 0.90; 95% CI, 0.68-0.98) and adherence rates (mean [SD], 0.51 [0.26] vs 0.40 [0.25]; P < 0.001) compared with patients starting other glaucoma medication. Furthermore, there were no additional increases in total health care costs in the entire population associated with the introduction of latanoprost therapy, after adjusting for group and time effects, as well as other confounders (mean [SD], $4718.24 [$8982.92] vs $4046.55 [$6505.39])., CONCLUSIONS: Latanoprost therapy offered improved medication use behavior in these older adults enrolled in a Medicare HMO. There were no significant additional increases in overall health care costs as a result of introduction of latanoprost therapy, after adjusting for group and time effects, as well as other baseline confounders in this study cohort. AU - Bhosle, Monali J. AU - Reardon, Gregory AU - Camacho, Fabian T. AU - Anderson, Roger T. AU - Balkrishnan, Rajesh IS - 2 KW - Aged Cohort Studies Costs and Cost Analysis Drug Therapy, Combination Female *Glaucoma/dt [Drug Therapy] *Health Care Costs Humans Intraocular Pressure/de [Drug Effects] Latanoprost Male *Managed Care Programs/ec [Economics] *Medicare/ec [Economics] Ocular Hypertension/dt [Drug Therapy] *Patient Compliance Proportional Hazards Models *Prostaglandins F, Synthetic/tu [Therapeutic Use] Retrospective Studies Survival Analysis Terminology as Topic Treatment Outcome PY - 2007 SE - Bhosle, Monali J. Department of Pharmacy Practice and Administration, The Ohio State University, Columbus, Ohio 43210, USA. SN - 1543-5946 1876-7761 SP - 100-11 ST - Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population T2 - The American journal of geriatric pharmacotherapy TI - Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17719512 VL - 5 ID - 1580 ER - TY - JOUR AB - The aim of this review is to report the updates in the medical literature on the outcomes associated with inhaled corticosteroid use. This update finds that inhaled corticosteroids remain a frontline choice as controller therapy in the treatment of asthma. Adherence to medications, especially inhaled corticosteroids used as controller medications, is responsible for a decrease in hospital, emergency room and physician visits. All of these translate to reduced asthma-related healthcare costs and an increase in health-related quality of life. There is a need for further research on the role of inhaled corticosteroids in chronic obstructive pulmonary disease outcomes. © 2004 Future Drugs Ltd. AD - R. Balkrishnan, The University of Texas, Health Science Center, School of Public Health, 1200 Hermann Pressler, Houston, TX 77030, United States AU - Bhosle, M. J. AU - Shenolikar, R. A. AU - Kulkarni, A. S. AU - Balkrishnan, R. C1 - aerobid azmacort beclovent vanceril DB - Embase DO - 10.1586/14737167.4.6.645 IS - 6 KW - beclometasone beclomethasone dipropionate beta 2 adrenergic receptor stimulating agent budesonide ciclesonide corticosteroid cortisone cromoglycate disodium flunisolide fluticasone propionate fluticasone propionate plus salmeterol formoterol leukotriene receptor blocking agent long acting drug montelukast nedocromil nonsteroid antiinflammatory agent placebo salbutamol short acting drug triamcinolone acetonide zafirlukast adrenal cortex disease asthma bone metabolism cataract chronic obstructive lung disease clinical trial concentration response congenital malformation cost effectiveness analysis diabetes mellitus drug choice drug cost fracture glaucoma growth retardation health care cost health economics hoarseness hospital admission human hypertension long term care low drug dose monotherapy myopathy osteoporosis patient compliance quality of life review side effect skin contusion systematic review throat disease thrush treatment outcome aerobid azmacort beclovent vanceril LA - English M3 - Review N1 - L39591899 2004-12-17 PY - 2004 SN - 1473-7167 SP - 645-656 ST - Outcomes associated with inhaled corticosteroid use in asthma and COPD: An update T2 - Expert Review of Pharmacoeconomics and Outcomes Research TI - Outcomes associated with inhaled corticosteroid use in asthma and COPD: An update UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39591899&from=export http://dx.doi.org/10.1586/14737167.4.6.645 VL - 4 ID - 3713 ER - TY - JOUR AB - BACKGROUND: The patient's wish for permanent refractive solution and optimal comfort must be weighed against the risk of infections. In order to meet these wishes and the demand for minimising associated risks, hyperoxygen-transmissible silicone hydrogel contact lenses have been developed., METHODS: Colonisation and sensitivity to antibiotics of bacteria in vitro, expression of bacterial ligands of the corneal epithelium (rabbit model), and the morphology of complications in patients have been reported to characterise HOTL., RESULTS: Bacterial adherence to hydrophobic silicone elastomers is low. The reduction of sensitivity towards antibiotics is higher for PMMA-adherent bacteria with respect to the conventional antibiotics compared to the silicone-elastomer adherent bacteria. Colonising bacteria are not significantly different in asymptomatic CL wearers concerning CFU and species: asymptomatic: CNS (54 vs. 47 %), propioni- (43 vs. 48 %), coryne- (6 vs. 10 %) and gram-negative bacteria (2 vs. 3 %), S. aureus (2 vs. 1 %), and in patients with keratitis are not significantly different concerning species: CLARE (H. influenzae, S. pneumoniae), CLPU (S. aureus, S. pneumoniae), IK (P. aeruginosa), however, concerning the CFU (gram-negative) 23.7 % (keratitis) vs. 3.8 %, (asymptomatic), S. pneumoniae 7.6 % vs. 0.6 %. The epithelial expression of bacterial ligands like WGA is lower for HOTL (3230 p/750 micro) than for low oxygen-transmissible (4611 p/750 micro) consistent with a decreased adherence of pseudomonas of 5.31 - 5.98 vs. 5.9 - 7.81 bacteria/cell. Asymptomatic morphological anomalies and keratitis are less frequent in HOTL. Apoptosis-induced desquamation and the central epithelial thickness decreased. In a one-year study of 504 patients wearing continuous wear HOTL for 30 days, corneal staining was seen in 10.6 vs. 10.5 % 30-day 7 day extended wear, infiltrates in 2.3 vs. 4.6 %, epithelial oedema in 3.6 vs. 2.0 % und tarsal conjunctival anomalies in 3.0 vs. 1.6 %. Individual reports on infectious keratitis in HOTL wearers have been published., CONCLUSIONS: Fewer morphological anomalies and a decreased incidence of infections (on the basis of duration of wear) can be associated with the higher oxygen transmission of HOTL. From the clinical point of view, colonisation of HOTL with the same bacterial species as in conventional biomaterials, and the extended wear demand clear patient counseling and vigilant follow-up by an ophthalmologist. AU - Bialasiewicz, Alexander A. IS - 7 KW - Animals Bacterial Adhesion/de [Drug Effects] Bacterial Adhesion/im [Immunology] Bacterial Infections/dt [Drug Therapy] *Bacterial Infections/im [Immunology] Bacterial Infections/mi [Microbiology] *Contact Lenses, Extended-Wear/mi [Microbiology] Epithelium, Corneal/im [Immunology] Epithelium, Corneal/mi [Microbiology] Humans *Hydrogel, Polyethylene Glycol Dimethacrylate Microbial Sensitivity Tests Polymethyl Methacrylate Prosthesis Design Prosthesis-Related Infections/dt [Drug Therapy] *Prosthesis-Related Infections/im [Immunology] Prosthesis-Related Infections/mi [Microbiology] Rabbits *Silicone Elastomers PY - 2003 SE - Bialasiewicz, Alexander A. Dept. of Ophthalmology & School of Ophthalmic Technicians, Sultan Qaboos University Hospital, University of Oman. SN - 0023-2165 SP - 453-8 ST - [Infection immunology in silicone hydrogel contact lenses for continuous wear--a review] T2 - Infektionsimmunologie bei Silikonhydrogelkontaktlinsen mit verlangerter Tragezeit--- eine Ubersicht. TI - [Infection immunology in silicone hydrogel contact lenses for continuous wear--a review] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=12886503 VL - 220 ID - 1833 ER - TY - JOUR AB - Background: The patient's wish for permanent refractive solution and optimal comfort must be weighed against the risk of infections. In order to meet these wishes and the demand for minimising associated risks, hyperoxygen-transmissible silicone hydrogel contact lenses have been developed. Methods: Colonisation and sensitivity to antibiotics of bacteria in vitro, expression of bacterial ligands of the corneal epithelium (rabbit model), and the morphology of complications in patients have been reported to characterise HOTL. Results: Bacterial adherence to hydrophobic silicone elastomers is low. The reduction of sensitivity towards antibiotics is higher for PMMA-adherent bacteria with respect to the conventional antibiotics compared to the silicone-elastomer adherent bacteria. Colonising bacteria are not significantly different in asymptomatic CL wearers concerning CFU and species: asymptomatic: CNS (54 vs. 47%), propioni- (43 vs. 48%), coryne- (6 vs. 10%) and gram-negative bacteria (2 vs. 3%), S. aureus (2 vs. 1%), and in patients with keratitis are not significantly different concerning species: CLARE (H. influenzae, S. pneumoniae), CLPU (S. aureus, S. pneumoniae), IK (P. aeruginosa), however, concerning the CFU (gram-negative) 23.7% (keratitis) vs. 3.8%, (asymptomatic), S. pneumoniae 7.6% vs. 0.6%. The epithelial expression of bacterial ligands like WGA is lower for HOTL (3230 p/750 μ) than for low oxygen-transmissible (4611 p/750 μ) consistent with a decreased adherence of pseudomonas of 5.31 - 5.98 vs. 5.9 - 7.81 bacteria/cell. Asymptomatic morphological anomalies and keratitis are less frequent in HOTL. Apoptosis-induced desquamation and the central epithelial thickness decreased. In a one-year study of 504 patients wearing continuous wear HOTL for 30 days, corneal staining was seen in 10.6 vs. 10.5% 30-day 7 day extended wear, infiltrates in 2.3 vs. 4.6%, epithelial oedema in 3.6 vs. 2.0% und tarsal conjunctival anomalies in 3.0 vs. 1.6%. Individual reports on infectious keratitis in HOTL wearers have been published. Conclusions: Fewer morphological anomalies and a decreased incidence of infections (on the basis of duration of wear) can be associated with the higher oxygen transmission of HOTL. From the clinical point of view, colonisation of HOTL with the same bacterial species as in conventional biomaterials, and the extended wear demand clear patient counseling and vigilant follow-up by an ophthalmologist. AD - Dept. of Ophthalmology and School of Ophthalmic Technicians, Sultan Qaboos University Hospital, University of Oman, 123 Al Khod, Muscat, Oman AU - Bialasiewicz, A. A. DB - Scopus DO - 10.1055/s-2003-40940 IS - 7 KW - Contact lenses HOTL Infections Silicone hydrogel M3 - Review N1 - Cited By :4 Export Date: 19 July 2021 PY - 2003 SP - 453-458 ST - Infektionsimmunologie bei silikonhydrogelkontaktlinsen mit verlängerter tragezeit - Eine übersicht T2 - Klinische Monatsblatter fur Augenheilkunde TI - Infection immunology in silicone hydrogel contact lenses for continuous wear - A review UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042827780&doi=10.1055%2fs-2003-40940&partnerID=40&md5=1cdc6a7db0a83df403ef358c0569b7ec VL - 220 ID - 5488 ER - TY - JOUR AB - Background: The patient's wish for permanent refractive solution and optimal comfort must be weighed against the risk of infections. In order to meet these wishes and the demand for minimising associated risks, hyperoxygen-transmissible silicone hydrogel contact lenses have been developed. Methods: Colonisation and sensitivity to antibiotics of bacteria in vitro, expression of bacterial ligands of the corneal epithelium (rabbit model), and the morphology of complications in patients have been reported to characterise HOTL. Results: Bacterial adherence to hydrophobic silicone elastomers is low. The reduction of sensitivity towards antibiotics is higher for PMMA-adherent bacteria with respect to the conventional antibiotics compared to the silicone-elastomer adherent bacteria. Colonising bacteria are not significantly different in asymptomatic CL wearers concerning CFU and species: asymptomatic: CNS (54 vs. 47%), propioni- (43 vs. 48%), coryne- (6 vs. 10%) and gram-negative bacteria (2 vs. 3%), S. aureus (2 vs. 1%), and in patients with keratitis are not significantly different concerning species: CLARE (H. influenzae, S. pneumoniae), CLPU (S. aureus, S. pneumoniae), IK (P. aeruginosa), however, concerning the CFU (gram-negative) 23.7% (keratitis) vs. 3.8%, (asymptomatic), S. pneumoniae 7.6% vs. 0.6%. The epithelial expression of bacterial ligands like WGA is lower for HOTL (3230 p/750 mu) than for low oxygen-transmissible (4611 p/750 mu) consistent with a decreased adherence of pseudomonas of 5.31-5.98 vs. 5.9-7.81 bacteria/cell. Asymptomatic morphological anomalies and keratitis are less frequent in HOTL. Apoptosis-induced desquamation and the central epithelial thickness decreased. In a one-year study of 504 patients wearing continuous wear HOTL for 30 days, corneal staining was seen in 10.6 vs. 10.5% 30-day 7 day extended wear, infiltrates in 2.3 vs. 4.6%, epithelial oedema in 3.6 vs. 2.0% und tarsal conjunctival anomalies in 3.0 vs. 1.6%. Individual reports on infectious keratitis in HOTL wearers have been published. Conclusions: Fewer morphological anomalies and a decreased incidence of infections (on the basis of duration of wear) can be associated with the higher oxygen transmission of HOTL. From the clinical point of view, colonisation of HOTL with the same bacterial species as in conventional biomaterials, and the extended wear demand clear patient counseling and vigilant follow-up by an ophthalmologist. AN - WOS:000184753900001 AU - Bialasiewicz, A. A. DA - JUL IS - 7 PY - 2003 SN - 0023-2165 1439-3999 SP - 453-458 ST - Infection immunology in silicone hydrogel contact lenses for continuous wear - A review T2 - KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE TI - Infection immunology in silicone hydrogel contact lenses for continuous wear - A review VL - 220 ID - 6278 ER - TY - JOUR AB - BACKGROUND: The potential benefits of anterior segment surgery to achieve visual rehabilitation in severely compromised eyes subsequent to infectious complications in the anterior segment remain a subject of controversy., PATIENTS AND METHODS: Anterior segment reconstructive surgery was performed on twelve patients (12 eyes) with infectious adherent leukoma and extensively damaged intraocular structures. Nine patients (nine eyes) were followed up over a period of two years (20-26 months) and three over a period of nine months (8-11 months)., RESULTS: Simultaneous and consecutive surgical interventions including corneal grafting, anterior chamber reconstruction and posterior chamber lens implantation combined with antimicrobial and antiviral prophylaxis as well as corticosteroid treatment resulted in visual recovery in nine eyes, and in four in a visual acuity of 0.4 or better (reading VA)., CONCLUSIONS: Surgery for optic reasons due to infectious adherent leukoma does not seem to be completely unsuccessful with respect to the low complication rate despite proven retrocorneal membranes in this study. AU - Bialasiewicz, A. A. AU - Forster, W. AU - Busse, H. IS - 4 KW - Adult Aged Anterior Eye Segment/pp [Physiopathology] *Anterior Eye Segment/su [Surgery] Combined Modality Therapy Corneal Opacity/pp [Physiopathology] Corneal Opacity/su [Surgery] Female Follow-Up Studies Humans Keratitis/pp [Physiopathology] Keratitis/su [Surgery] Keratitis, Herpetic/pp [Physiopathology] Keratitis, Herpetic/su [Surgery] Keratoplasty, Penetrating/mt [Methods] Lenses, Intraocular Male Middle Aged Postoperative Complications/pp [Physiopathology] *Postoperative Complications/su [Surgery] Refraction, Ocular Reoperation *Visual Acuity/ph [Physiology] PY - 1993 SE - Bialasiewicz, A A. Augenklinik, Friedrich Wilhelms-Universitat Munster. SN - 0023-2165 SP - 240-6 ST - [Optical rehabilitation by tectonic anterior segment reconstruction] T2 - Optische Rehabilitation durch tektonische Vorderabschnitts-Rekonstruktion. TI - [Optical rehabilitation by tectonic anterior segment reconstruction] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8114465 VL - 203 ID - 2099 ER - TY - JOUR AB - Background: The potential benefits of anterior segment surgery to achieve visual rehabilitation in severely compromised eyes subsequent to infectious complications in the anterior segment remain a subject of controversy. Patients and Methods: Anterior segment reconstructive surgery was performed on twelve patients (12 eyes) with infectious adherent leukoma and extensively damaged intraocular structures. Nine patients (nine eyes) were followed up over a period of two years (20-26 months) and three over a period of nine months (8-11 months). Results: Simultaneous and consecutive surgical interventions including corneal grafting, anterior chamber reconstruction and posterior chamber lens implantation combined with antimicrobial and antiviral prophylaxis as well as corticosteroid treatment resulted in visual recovery in nine eyes, and in four in a visual acuity of 0.4 or better (reading VA). Conclusions: Surgery for optic reasons due to infectious adherent leukoma does not seem to be completely unsuccessful with respect to the low complication rate despite proven retrocorneal membranes in this study. AD - Universitats-Augenklinik, Martinistr. 52, D-30251 Hamburg, Germany AU - Bialasiewicz, A. A. AU - Forster, W. AU - Busse, H. DB - Scopus DO - 10.1055/s-2008-1045675 IS - 4 KW - adherent leukoma allogeneic keratoplasty bacterial keratitis herpetic keratitis transscleral fixation of posterior chamber lens M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 1993 SP - 240-246 ST - OPTISCHE REHABILITATION DURCH TEKTONISCHE VORDERABSCHNITTS-REKONSTRUKTION T2 - Klinische Monatsblatter fur Augenheilkunde TI - Visual rehabilitation achieved by reconstructive surgery of the anterior segment of the eye UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027329997&doi=10.1055%2fs-2008-1045675&partnerID=40&md5=8fa82ea63cb3b9722e63ba7ffeb45945 VL - 203 ID - 5594 ER - TY - JOUR AB - Background The potential benefits of anterior segment surgery to achieve visual rehabilitation in severely compromised eyes subsequent to infectious complications in the anterior segment remain a subject of controversy. Patients and Methods Anterior segment reconstructive surgery was performed on twelve patients (12 eyes) with infectious adherent leukoma and extensively damaged intraocular structures. Nine patients (nine eyes) were followed up over a period of two years (20-26 months) and three over a period of nine months (8-11 months). Results Simultaneous and consecutive surgical interventions including corneal grafting, anterior chamber reconstruction and posterior chamber lens implantation combined with antimicrobial and antiviral prophylaxis as well as corticosteroid treatment resulted in visual recovery in nine eyes, and in four in a visual acuity of 0.4 or better (reading VA). Conclusions Surgery for optic reasons due to infectious adherent leukoma does not seem to be completely unsuccessful with respect to the low complication rate despite proven retrocorneal membranes in this study. AN - WOS:A1993ML78900002 AU - Bialasiewicz, A. A. AU - Forster, W. AU - Busse, H. DA - OCT DO - 10.1055/s-2008-1045675 IS - 4 PY - 1993 SN - 0023-2165 SP - 240-246 ST - VISUAL REHABILITATION ACHIEVED BY RECONSTRUCTIVE SURGERY OF THE ANTERIOR SEGMENT OF THE EYE T2 - KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE TI - VISUAL REHABILITATION ACHIEVED BY RECONSTRUCTIVE SURGERY OF THE ANTERIOR SEGMENT OF THE EYE VL - 203 ID - 6227 ER - TY - JOUR AB - The inner blood-retinal barrier is a gliovascular unit in which glial cells surround capillary endothelial cells and regulate retinal capillaries by paracrine interactions. During chronic ocular inflammation, microvascular complications can give rise to vascular proliferative lesions, which compromise visual acuity. This pathologic remodelling caused by proliferating Müller cells determines occlusion of retinal capillaries. The aim of the present study was to identify qualitative and quantitative alterations in the retinal capillaries in patients with post-traumatic chronic ocular inflammation or post-thrombotic vascular glaucoma. Moreover, we investigated the potential role of vascular endothelial growth factor (VEGF) and pro-inflammatory cytokines in retinal inflammation. Our electron microscopy findings demonstrated that during chronic ocular inflammation, thickening of the basement membrane, loss of pericytes and endothelial cells and proliferation of Müller cells occur with irreversible occlusion of retinal capillaries. Angiogenesis takes place as part of a regenerative reaction that results in fibrosis. We believe that VEGF and pro-inflammatory cytokines may be potential therapeutic targets in the treatment of this disease although further studies are required to confirm these findings. AN - 109712845. Language: English. Entry Date: 20150923. Revision Date: 20180628. Publication Type: journal article. Journal Subset: Biomedical AU - Bianchi, E. AU - Ripandelli, G. AU - Feher, J. AU - Plateroti, A. M. AU - Plateroti, R. AU - Kovacs, I. AU - Plateroti, P. AU - Taurone, S. AU - Artico, M. DB - ccm DO - 10.5603/FM.2015.0006 DP - EBSCOhost IS - 1 N1 - Continental Europe; Europe. NLM UID: 0374620. PMID: NLM25792393. PY - 2015 SN - 0015-5659 SP - 33-41 ST - Occlusion of retinal capillaries caused by glial cell proliferation in chronic ocular inflammation T2 - Folia Morphologica TI - Occlusion of retinal capillaries caused by glial cell proliferation in chronic ocular inflammation UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109712845&site=ehost-live&scope=site VL - 74 ID - 4425 ER - TY - JOUR AB - Monocular (right eye) visual fields were recorded with the Humphrey Visual Field Analyzer (30-2 Program) at baseline as well as 6 and 12 months later in 120 patients with established ocular hypertension. Indices of field reliability (fixation loss, <20%; false-positives and false-negatives, <33%) and field sensitivity (mean deviation [MD] and pattern standard deviation [PSD]) were examined. At baseline, 35% of patients exhibited low reliability (LR) fields, a figure which decreased to approximately 25% at 6 and 12 months, respectively. During this period, over 50% of patients produced at least one LR field, whereas 8.3% were unable to produce even one reliable field. Exhibition of a LR field appeared to be independent of patient age. Fixation errors, the major cause of LR fields, decreased by approximately 10% over the 12-month period; most patients had between 20 and 32% fixation errors. The incidence of significant defects indentified by PSD was greater than that for MD; this was true for both reliable and LR fields. It is suggested that increasing the fixation loss criteria for assessing patient reliability to a 33% cutoff might substantially increase the percentage of fields graded reliable with minimal effect on the sensitivity or specificity of the test. AD - Department of Ophthalmology, Washington University School of Medicine, St. Louis, MO 63110 AU - Bickler-Bluth, M. AU - Trick, G. L. AU - Kolker, A. E. AU - Cooper, D. G. DB - Embase Medline IS - 5 KW - computer analysis computer assisted perimetry human intraocular hypertension major clinical study methodology patient compliance priority journal reliability visual field LA - English M3 - Article N1 - L19119465 1989-05-29 PY - 1989 SN - 0161-6420 SP - 616-619 ST - Assessing the utility of reliability indices for automated visual fields. Testing ocular hypertensives T2 - Ophthalmology TI - Assessing the utility of reliability indices for automated visual fields. Testing ocular hypertensives UR - https://www.embase.com/search/results?subaction=viewrecord&id=L19119465&from=export VL - 96 ID - 4052 ER - TY - JOUR AB - Objectives: This paper describes research findings that try to understand some of the reasons that prevent older people in deprived communities in South Wales from accessing NHS funded sight tests and leads to a discussion of suitable interventions that seek to improve access to primary eye care services and prevent avoidable sight loss. Study design: Data were collected from eight focus groups (n = 63) of mixed gender and ages (60-80+ years), of white origin living in deprived communities in South Wales. Individuals were recruited for the focus groups by extensively publicizing the project, with a range of health and older people's community services and groups such as sheltered housing complexes, stroke support groups and coffee morning groups. The study included people who attended optometry services and people not engaged with services. A purposive sampling technique summarizes the sampling approach taken, an approach which the team utilized to recruit 'information rich' cases, namely individuals, groups and organizations that provided the greatest insight into the research question. Methods: Focus groups were recorded and transcribed verbatim. Data underwent thematic content analysis and subsequent interpretations were corroborated by expert advisors and a project steering group. Results: Cost was perceived as a significant barrier to accessing sight tests, particularly in relation to purchasing glasses. Other barriers included the perceived pressure to buy glasses associated with visits to the optometrists; poor understanding of the purpose of a sight test in a health prevention context and acceptance of deteriorating sight loss due to the ageing process. Conclusion: Areas of improvement for the delivery of preventative eye health services to older people are identified, as are areas for reflection on the part of those who work within the eye health industry. (C) 2014 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. AN - WOS:000351300500005 AU - Biddyr, S. AU - Jones, A. DA - FEB DO - 10.1016/j.puhe.2014.10.013 IS - 2 PY - 2015 SN - 0033-3506 1476-5616 SP - 110-116 ST - Preventing sight loss in older people. A qualitative study exploring barriers to the uptake of regular sight tests of older people living in socially deprived communities in South Wales T2 - PUBLIC HEALTH TI - Preventing sight loss in older people. A qualitative study exploring barriers to the uptake of regular sight tests of older people living in socially deprived communities in South Wales VL - 129 ID - 6345 ER - TY - JOUR AB - Context: Allergy symptoms that affect the eyes are common in adults and children worldwide, and are often associated with nasal allergy symptoms, prompting the term 'rhinoconjunctivitis' to describe the condition. However, this condition has not always been recognized, and earlier literature reported allergic conjunctivitis only within a subset of nasal allergy patients. Evidence Acquisition: To assess the current state of ocular allergy epidemiology, pathophysiology, and currently available treatment options, we performed a MEDLINE search for articles regarding ocular allergy, rhinoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). Evidence Synthesis: The more severe forms of ocular allergy are not only distressing, but can also threaten a patient's vision. Each type of ocular allergy is associated with ocular redness, itching, and tearing; however, AKC and VKC can threaten the cornea, and research has revealed that involvement of different immune cell populations (mast cells, eosinophils, and lymphocytes) may cause these more severe symptoms. A variety of treatment options exist to control ocular allergy symptoms. Nonpharmacologic options include allergen avoidance and lubrication with saline, and if these fail to be sufficiently effective, symptom relief may be provided by medicinal agents that are either applied topically to the eye or taken orally. Recent evidence suggests that nasal allergy treatments applied topically to the nose may also positively affect ocular allergy symptoms, which raises the interesting possibility that a parasympathetic nasal-ocular neural reflex pathway may be involved in the stimulation of allergic responses in the eye. Conclusions: Ocular allergy is underdiagnosed and has a significant impact on the life of the patient. It is vital to reach a better understanding of ocular allergic mechanisms and inflammation, which may lead to improved treatment. © 2007 Medscape. AD - L. Bielory, Department of of Medicine, Pediatrics, Ophthalmology and Visual Sciences, UMDNJ, New Jersey Medical School, Newark, NJ, United States AU - Bielory, L. AU - Katelaris, C. H. AU - Lightman, S. AU - Naclerio, R. M. C1 - acular alocril alomide alrex lotemax optivar patanol zaditor DB - Embase Medline IS - 3 KW - allergen antihistaminic agent azelastine cetirizine corticosteroid cromoglycate disodium decongestive agent desloratadine dexamethasone eye drops fexofenadine fluticasone propionate ketorolac trometamol ketotifen fumarate levocabastine lodoxamide trometamol loratadine loteprednol etabonate nedocromil nonsteroid antiinflammatory agent olopatadine oxymetazoline pemirolast placebo prednisolone pseudoephedrine rimexolone tetryzoline triamcinolone acetonide unindexed drug air pollution allergic disease allergy anamnesis article atopic keratoconjunctivitis bitter taste burning sensation cataract clinical trial closed angle glaucoma competitive inhibition conjunctivitis disease association disease severity drug bioavailability drug contraindication drug efficacy drug induced headache drug potency drug tolerability eosinophil erythema evidence based medicine eye allergy eye burning eye discomfort eye irritation first pass effect geographic distribution giant papillary conjunctivitis health care cost human hyperemia immunotherapy industrialization intraocular pressure lacrimation lubrication lymphocyte mast cell Medline mydriasis nose allergy nose obstruction ocular pruritus pathophysiology patient compliance pharyngitis prevalence primary medical care pruritus rhinitis rhinoconjunctivitis risk factor seasonal variation side effect symptom systematic review vernal conjunctivitis acular alocril alomide alrex lotemax optivar patanol zaditor LA - English M3 - Article N1 - L47263998 2007-10-03 PY - 2007 SN - 1531-0132 ST - Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders T2 - MedGenMed Medscape General Medicine TI - Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47263998&from=export http://medgenmed.medscape.com/viewarticle/560750_print VL - 9 ID - 3502 ER - TY - JOUR AB - Eighty-nine patients with newly diagnosed asymptomatic elevations of intraocular pressure were followed up over a 12- to 20-month interval. During this period 33 (37%) of the patients were lost to ophthalmic follow-up evaluation. The majority of these patients dropped out within one month following the initial diagnosis. While institution of medical therapy for the elevated ocular pressure improved patient compliance when compared to the nontreated group, the rates of noncompliance in both groups were unacceptably high in view of the disease risk. Management of the noncompliant patient requires good physician-patient communication, emphasis on patient education activities, and the use of selective reminder and recall systems within the ophthalmologist's office. AU - Bigger, J. F. IS - 2 KW - Adult Aged Female Follow-Up Studies *Glaucoma/th [Therapy] Humans *Intraocular Pressure Male Middle Aged *Patient Compliance PY - 1976 SN - 0161-6978 SP - 277-85 ST - A comparison of patient compliance in treated vs untreated ocular hypertension T2 - Transactions. Section on Ophthalmology. American Academy of Ophthalmology and Otolaryngology TI - A comparison of patient compliance in treated vs untreated ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=936400 VL - 81 ID - 2280 ER - TY - JOUR AU - Biggerstaff, Kristin Schmid AU - Lin, Albert DO - https://dx.doi.org/10.1097/IIO.0000000000000230 IS - 3 KW - Activities of Daily Living/px [Psychology] *Glaucoma/px [Psychology] Glaucoma/th [Therapy] Humans Outcome Assessment, Health Care/mt [Methods] Patient Satisfaction *Quality of Life *Sickness Impact Profile PY - 2018 SN - 1536-9617 0020-8167 SP - 11-22 ST - Glaucoma and Quality of Life T2 - International ophthalmology clinics TI - Glaucoma and Quality of Life UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29870407 VL - 58 ID - 423 ER - TY - JOUR AB - BACKGROUND: Many glaucoma patients do not adhere to their medication regimens because they fail to internalize the (health) costs of non-adherence, which may not occur until years or decades later. Behavioural economic theory suggests that adherence rates can be improved by offering patients a near-term benefit. Our proposed strategy is to offer adherence-contingent rebates on medication and check-up costs. This form of value pricing (VP) ensures that rebates are granted only to those most likely to benefit. Moreover, by leveraging loss aversion, rebates are expected to generate a stronger behavioural response than equivalent financial rewards., METHODS/DESIGN: The main objective of the Study on Incentives for Glaucoma Medication Adherence (SIGMA) is to test the VP approach relative to usual care (UC) in improving medication adherence. SIGMA is a randomized, controlled, open-label, single-centre superiority trial with two parallel arms. A total of 100 non-adherent (Morisky Medication Adherence Scale <=6) glaucoma patients from the Singapore National Eye Centre are block-randomized (blocking factor: single versus multiple medications users) into the VP and UC arms in a 1:1 ratio. The treatment received by VP patients will be strictly identical to that received by UC patients, with the only exception being that VP patients can earn either a 50 % or 25 % rebate on their glaucoma-related healthcare costs conditional on being adherent on at least 90 % or 75 % of days as measured by a medication event monitoring system. Masking the arm allocation will be precluded by the behavioural nature of the intervention but blocking size will not be disclosed to protect concealment. The primary outcome is the mean change from baseline in percentage of adherent days at month 6. A day will be counted as adherent when the patients take all their medication(s) within the appropriate dosing windows., DISCUSSION: This trial will provide evidence on whether adherence-contingent rebates can improve medication adherence among non-adherent glaucoma patients, and more generally whether this approach represents a promising strategy to cost-effectively improve chronic disease management., TRIAL REGISTRATION: NCT02271269 . Registered on 19 October 2014. AU - Bilger, Marcel AU - Wong, Tina T. AU - Howard, Kaye L. AU - Lee, Jia Yi AU - Toh, Ai Nee AU - John, Geraldine AU - Lamoureux, Ecosse L. AU - Finkelstein, Eric A. DO - https://dx.doi.org/10.1186/s13063-016-1459-1 IS - 1 KW - Adult Aged Aged, 80 and over *Drug Costs Female Glaucoma/di [Diagnosis] *Glaucoma/dt [Drug Therapy] *Glaucoma/ec [Economics] Glaucoma/px [Psychology] Health Knowledge, Attitudes, Practice Humans *Insurance, Health, Reimbursement Male *Medication Adherence Middle Aged *Motivation *Office Visits/ec [Economics] Research Design Risk Assessment Risk Factors Singapore Time Factors Treatment Outcome *Value-Based Health Insurance/ec [Economics] Young Adult PY - 2016 SE - Bilger, Marcel. Health Services & Systems Research, Duke-NUS Graduate Medical School, 8 College Road, 169857, Singapore, Singapore. marcel.bilger@duke-nus.edu.sg. Wong, Tina T. Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, 168751, Singapore, Singapore. Howard, Kaye L. Health Services & Systems Research, Duke-NUS Graduate Medical School, 8 College Road, 169857, Singapore, Singapore. Lee, Jia Yi. Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, 168751, Singapore, Singapore. Toh, Ai Nee. Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, 168751, Singapore, Singapore. John, Geraldine. Health Services & Systems Research, Duke-NUS Graduate Medical School, 8 College Road, 169857, Singapore, Singapore. Lamoureux, Ecosse L. Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, 168751, Singapore, Singapore. Finkelstein, Eric A. Health Services & Systems Research, Duke-NUS Graduate Medical School, 8 College Road, 169857, Singapore, Singapore. Finkelstein, Eric A. Duke Global Health Institute, Duke University, 310 Trent Drive, Durham, NC, 27710, USA. SN - 1745-6215 SP - 316 ST - Study on Incentives for Glaucoma Medication Adherence (SIGMA): study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing T2 - Trials TI - Study on Incentives for Glaucoma Medication Adherence (SIGMA): study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27422389 VL - 17 Y2 - 20160715// ID - 670 ER - TY - JOUR AB - BACKGROUND: Poor adherence to medications is a global public health concern with substantial health and cost implications, especially for chronic conditions. In the USA, poor adherence is estimated to cause 125,000 deaths and cost $US100 billion annually. The most successful adherence-promoting strategies that have been identified so far have moderate effect, are relatively costly, and raise availability, feasibility, and/or scalability issues., OBJECTIVE: The main objective of SIGMA (Study on Incentives for Glaucoma Medication Adherence) was to measure the effectiveness on medication adherence of a novel incentive strategy based on behavioral economics that we refer to as adherence-contingent rebates. These rebates offered patients a near-term benefit while leveraging loss aversion and regret and increasing the salience of adherence., METHODS: SIGMA is a 6-month randomized, controlled, open-label, single-center superiority trial with two parallel arms. A total of 100 non-adherent glaucoma patients from the Singapore National Eye Centre were randomized into intervention (adherence-contingent rebates) and usual care (no rebates) arms in a 1:1 ratio. The primary outcome was the mean change from baseline in percentage of adherent days at Month 6. The trial registration number is NCT02271269 and a detailed study protocol has been published elsewhere., FINDINGS: We found that participants who were offered adherence-contingent rebates were adherent to all their medications on 73.1% of the days after 6 months, which is 12.2 percentage points (p = 0.027) higher than in those not receiving the rebates after controlling for baseline differences. This better behavioral outcome was achieved by rebates averaging 8.07 Singapore dollars ($US5.94 as of 2 November 2017) per month during the intervention period., CONCLUSION: This study shows that simultaneously leveraging several insights from behavioral economics can significantly improve medication adherence rates. The relatively low cost of the rebates and significant health and cost implications of medication non-adherence suggest that this strategy has the potential to cost-effectively improve health outcomes for many conditions. AU - Bilger, Marcel AU - Wong, Tina T. AU - Lee, Jia Yi AU - Howard, Kaye L. AU - Bundoc, Filipinas G. AU - Lamoureux, Ecosse L. AU - Finkelstein, Eric A. DO - https://dx.doi.org/10.1007/s40258-019-00497-0 IS - 6 KW - Adult Aged Aged, 80 and over *Chronic Disease/dt [Drug Therapy] *Drug Therapy/ec [Economics] Female *Glaucoma/dt [Drug Therapy] Humans Male *Medication Adherence Middle Aged *Reimbursement, Incentive Young Adult PY - 2019 SE - Bilger, Marcel. Health Economics and Policy, Vienna University of Business and Economics, Welthandelsplatz 1, Building D4, 1020, Vienna, Austria. marcel.bilger@wu.ac.at. Bilger, Marcel. Health Services & Systems Research Program, Duke-NUS Medical School, Singapore, Singapore. marcel.bilger@wu.ac.at. Wong, Tina T. Singapore National Eye Centre, Singapore Eye Research Institute, Singapore, Singapore. Lee, Jia Yi. Singapore National Eye Centre, Singapore Eye Research Institute, Singapore, Singapore. Howard, Kaye L. Health Services & Systems Research Program, Duke-NUS Medical School, Singapore, Singapore. Bundoc, Filipinas G. Health Services & Systems Research Program, Duke-NUS Medical School, Singapore, Singapore. Lamoureux, Ecosse L. Health Services & Systems Research Program, Duke-NUS Medical School, Singapore, Singapore. Lamoureux, Ecosse L. Singapore National Eye Centre, Singapore Eye Research Institute, Singapore, Singapore. Finkelstein, Eric A. Health Services & Systems Research Program, Duke-NUS Medical School, Singapore, Singapore. Finkelstein, Eric A. Duke Global Health Institute, Duke University, Durham, NC, USA. SN - 1179-1896 1175-5652 SP - 841-855 ST - Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial T2 - Applied health economics and health policy TI - Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31317511 VL - 17 ID - 323 ER - TY - JOUR AB - We aimed to determine true and false positives of glaucoma screening, relying solely on photos of the retina, taken with a smartphone. We performed a descriptive and analytical study on patients with type 2 diabetes at the National Obesity Centre, Yaounde, Cameroon. Participating patients had retinal photography sessions using an iPhone 5s (iOS 10.3.3; Apple, Cupertino, CA) coupled to the Make in India Retinal Camera (MIIRetCam; MIIRetCam Inc., Coimbatore, TN, India). Obtained pictures of the retina were stored and transferred via the internet to an ophthalmologist to assess glaucoma. Selected patients were then invited to undergo a conventional ophthalmological examination to confirm the diagnosis. A total of 395 patients were screened, 39 (including 20 women) were diagnosed with suspicion of glaucoma based on retinal photos, a prevalence rate of 9.87%. The following signs were found; Cup/Disc ratio (C/D) >=0.5 in 64.1% (25/39), asymmetric C/D >0.2 in 35.9% (14/39), papillary haemorrhage in 10.2% (4/39) and retinal nerve fibre deficiency in 2.5% (1/39). Only 14 of 39 patients with suspicion of glaucoma were examined, giving a lost-to-follow-up rate of 64.1%. Chronic open-angle glaucoma was confirmed in 8 patients (true positives) and absent in 6 patients (false positives). The prevalence of smartphone-detected glaucoma and lost-to-follow-up rates were high. So we need to improve this type of screening, with additional tests like transpalpebral applanation tonometer and the smartphone Frequency Doubling Technique visual field combined with better education of patients to increase their adherence to follow-up. Copyright © 2020, Author(s). AU - Bilong, Yannick AU - Domngang, Christelle Noche AU - Nwanlih Gimma, Gebding AU - Katte, Jean-Claude AU - Afetane, Ted Evina AU - Kagmeni, Gilles AU - Mbanya, Jean Claude AU - Kumar, Nilesh AU - Sharma, Ashish AU - Sobngwi, Eugene IS - 1 PY - 2020 SE - Bilong, Yannick. Department of Ophthalmology, Faculty of Medicine and Biomedical Sciences, The University of Yaounde 1, Yaounde, Cameroon. Domngang, Christelle Noche. Department of Clinical Sciences, Faculty of Health Sciences, Universite des Montagnes, Bangangte, Cameroon. Nwanlih Gimma, Gebding. Department of Clinical Sciences, Faculty of Health Sciences, Universite des Montagnes, Bangangte, Cameroon. Katte, Jean-Claude. Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaounde 1, Yaounde, Cameroon. Afetane, Ted Evina. Ophthalmo-Pediatric Unit, Magrabi ICO Cameroon Eye Institute, Okala, Cameroon. Kagmeni, Gilles. Department of Ophthalmology, Faculty of Medicine and Biomedical Sciences, The University of Yaounde 1, Yaounde, Cameroon. Mbanya, Jean Claude. Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon. Kumar, Nilesh. Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, TN, India. Sharma, Ashish. Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, TN, India. Sobngwi, Eugene. Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon. SN - 2322-4436 2322-3219 SP - 61-65 ST - Smartphone-Assisted Glaucoma Screening in Patients With Type 2 Diabetes: a Pilot Study T2 - Medical hypothesis, discovery & innovation ophthalmology journal TI - Smartphone-Assisted Glaucoma Screening in Patients With Type 2 Diabetes: a Pilot Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=31976345 VL - 9 Y2 - 20200101// ID - 147 ER - TY - JOUR AB - Objective: To assess the prevalence of visual impairment and unmet eye care needs of the Syrian adult refugee population in Canada. Design: Cross-sectional descriptive study. Participants: Enrolment was offered to all Syrian refugees 18 years or older, with 248 patients enrolled. Methods: Five clinics were organized from July 2016 to November 2017 in Toronto, Ontario. A vision screening and dilated retinal examination was performed on all participants. Prevalence of visual impairment and nonrefractive pathologies as well as information on sociodemographics and subjective visual acuity were obtained. Results: The mean age of participants was 36 years (interquartile range, 30–35) and 53% were females. The prevalence of reported uncorrected vision problems was 22.2% for distance vision, 6.5% for near vision, and 5.6% for both distance and near vision, including loss of vision. Compared with the Canadian population, Syrian adult refugees were 19.04 times more likely to report uncorrected vision problems (34.4% vs 1.8%, p < 0.01). The presenting visual acuity in the better-seeing eye was 20/50 or worse in 19.4%. Pinhole improved this to 12.5% (95% confidence interval [CI], 8.7%–17.3%). Compared with the Canadian population (0.95%), Syrian adult refugees were 13 times more likely to have 20/50 vision or worse (p < 0.01). The most common finding was refractive error in 46.0% (95% CI, 39.6%–52.4%) followed by nonrefractive error in 30.2% (95% CI, 24.9%–36.2%). Conclusions: This is the first study to assess ocular health in a refugee population in Canada. Syrian adult refugees have a high prevalence of visual impairment, even when living within a system of universal health care. AD - M. Lichter, Department of Ophthalmology, St Michael's Hospital, Health Centre, 61 Queen St E, 8th Floor, Toronto, Ont, Canada AU - Bin Yameen, T. A. AU - Abadeh, A. AU - Slomovic, J. AU - Lichter, M. DB - Embase Medline DO - 10.1016/j.jcjo.2019.07.023 IS - 2 KW - spectacles adult age related macular degeneration article Canada Canadian cataract cross-sectional study descriptive research diabetic retinopathy eye care eye examination eye injury female glaucoma health care access health care need human hypermetropia major clinical study male myopia presbyopia refraction error refugee retinitis pigmentosa Syrian vision test visual acuity visual impairment young adult LA - English M3 - Article N1 - L2003445524 2019-11-12 PY - 2020 SN - 1715-3360 0008-4182 SP - 137-142 ST - Visual impairment and unmet eye care needs among a Syrian adult refugee population in a Canadian city T2 - Canadian Journal of Ophthalmology TI - Visual impairment and unmet eye care needs among a Syrian adult refugee population in a Canadian city UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003445524&from=export http://dx.doi.org/10.1016/j.jcjo.2019.07.023 VL - 55 ID - 2415 ER - TY - JOUR AB - Infection of newborns and immunocompromised hosts with herpes simplex virus appears to be no more common than in the normal adult. However, the disease tends to be more difficult to treat in the newborn because of poor patient compliance, delay in the diagnosis, and the tendency for retinal disease to occur. The disease is more difficult to treat in the immunocompromised host because of the necessity for maintenance of immunosuppression. Initial treatment is usually the same as used for adults unless intraocular infection occurs. Early diagnosis and treatment in the newborn can prevent corneal opacification and amblyopia, whereas ocular disease in the immunocompromised host may be an insignificant problem compared with infection elsewhere in the host's body. AU - Binder, P. S. IS - 3 KW - Antiviral Agents/tu [Therapeutic Use] Combined Modality Therapy Humans Immunologic Deficiency Syndromes/di [Diagnosis] *Immunologic Deficiency Syndromes/th [Therapy] Infant, Newborn Keratitis, Dendritic/di [Diagnosis] *Keratitis, Dendritic/th [Therapy] Prognosis Recurrence Uveitis/th [Therapy] PY - 1984 SN - 0277-3740 SP - 178-82 ST - A review of the treatment of ocular herpes simplex infections in the neonate and immunocompromised host T2 - Cornea TI - A review of the treatment of ocular herpes simplex infections in the neonate and immunocompromised host UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=6544193 VL - 3 ID - 2212 ER - TY - JOUR AB - Purpose: Intraocular lenses (IOLs) are now being implanted in infants and children with unilateral cataracts. However, there are no prospective data on the development of visual acuity after implantation. The aim of the present study was to prospectively assess the development of acuity in infants and preschool children who received IOLs or aphakic contacts lenses (CLs) after the extraction of a unilateral cataract. Methods: Visual acuity was assessed using Teller Acuity Cards and/or crowded HOTV tests at target ages of 6 months, 1, 2, 3, and 4 years. Results: Infants who received a primary IOL after extraction of dense congenital unilateral cataract (n = 5) showed improvement from an initially low mean visual acuity of 20/170 at 6 months to 20/85 at 12 months and 20/54 at 4 years. Visual acuity in the IOL group was similar to that of children who had good-to-excellent compliance with CL wear (n = 36; 4-year visual acuity 20/50) and better than that of children who had moderate-to-poor compliance (n = 11; 4-year visual acuity 20/135). Children who received IOLs after extraction of developmental unilateral cataracts by 6 months (n = 4; 4-year visual acuity 20/55) had visual acuity development similar to those treated with CLs (n = 5; 4-year visual acuity 20/55). Children who received IOLs after extraction of developmental unilateral cataracts after 1 year of age (n = 18) had better visual acuity than children those treated with CLs (n = 4) at 4 years of age (20/40 vs. 20/135). Conclusion: IOLs and aphakic CLs support similar visual acuity development after surgery for a unilateral cataract. IOLs may support better visual acuity development when compliance with CL wear is moderate to poor or when a cataract is extracted after 1 year of age. Copyright © 2005 by the American Association for Pediatric Ophthalmology and Strabismus. AD - E.E. Birch, Retina Foundation of the Southwest, 9900 N. Central Expressway, Dallas, TX 75231, United States AU - Birch, E. E. AU - Cheng, C. AU - Stager Jr, D. R. AU - Felius, J. DB - Embase Medline DO - 10.1016/j.jaapos.2005.07.008 IS - 6 KW - aphakia article cataract cataract extraction clinical trial contact lens controlled clinical trial controlled study endophthalmitis glaucoma human infant lens implant major clinical study patient compliance preschool child priority journal visual acuity LA - English M3 - Article N1 - L43097378 2006-01-31 PY - 2005 SN - 1091-8531 SP - 527-532 ST - Visual acuity development after the implantation of unilateral intraocular lenses in infants and young children T2 - Journal of AAPOS TI - Visual acuity development after the implantation of unilateral intraocular lenses in infants and young children UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43097378&from=export http://dx.doi.org/10.1016/j.jaapos.2005.07.008 VL - 9 ID - 3651 ER - TY - JOUR AB - Giant papillary conjunctivitis is an inflammation of the conjunctiva, which is associated with immunological-allergic disorders, but is difficult to integrate as a defined type of illness. The deposits of contact lenses are responsible in predisposed wearers. They induce a special immune answer to their biochemical ingredients. In addition, roughness of the superficial corneal layers and the conjunctiva, even without any contact lenses after filtrating glaucoma surgery, leads to mechanically induced papillary formations. In former days these symptoms of building giant papillae were seen mostly in wearers of soft hydrogel contact lenses. Nowadays manufacturers have developed contact lens systems with a variety of material components, with an increase of protein and lipid deposits. In combination with the observed non-compliance of wearers regarding lens exchange and contact lens hygiene, GPC is an issue which should be taken into consideration again. Copyright Georg Thieme Verlag KG Stuttgart . New York. AU - Bischoff, G. DO - https://dx.doi.org/10.1055/s-0034-1368334 IS - 5 KW - Conjunctivitis, Allergic/di [Diagnosis] *Conjunctivitis, Allergic/et [Etiology] *Conjunctivitis, Allergic/pc [Prevention & Control] *Contact Lenses/ae [Adverse Effects] Eyelid Diseases/di [Diagnosis] *Eyelid Diseases/et [Etiology] *Eyelid Diseases/pc [Prevention & Control] Humans *Immunosuppressive Agents/tu [Therapeutic Use] *Ophthalmic Solutions/ad [Administration & Dosage] PY - 2014 SE - Bischoff, G. Praxis & Klinik, Medical Eye-Care Center, Hamburg. SN - 1439-3999 0023-2165 SP - 518-21 ST - [Giant papillary conjunctivitis] T2 - Gigantopapillare Konjunktivitis. TI - [Giant papillary conjunctivitis] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24799171 VL - 231 Y2 - 20140505// ID - 887 ER - TY - JOUR AB - Keratitis is a rare but important and possibly sight threatening complication of Contact Lens wearing. Despite of the number of only about 1.7 keratitis cases per ophthalmolgist per year, this serious side effect needs knowledge and special diagnosis and treatment. Global changes of infectious agents and increase of previously unsuspicious pathogens in combination with a high degress of non-compliance indicate that Contact Lens wearing must be accompanied careful ophthalmologist's medical care and after-care. Copyright © Georg Thieme Verlag KG Stuttgart . New York. AU - Bischoff, G. AU - Brocks, U. DO - https://dx.doi.org/10.1055/s-0031-1299535 IS - 5 KW - *Contact Lenses/ae [Adverse Effects] Humans Keratitis/di [Diagnosis] *Keratitis/et [Etiology] *Keratitis/pc [Prevention & Control] PY - 2012 SE - Bischoff, G. Praxis & Klinik, Medical Eye-Care Center, Hamburg. gudrunbischoff@gmx.de SN - 1439-3999 0023-2165 SP - 514-20 ST - [Contact lenses and keratitis] T2 - Kontaktlinsen und Keratitis. TI - [Contact lenses and keratitis] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22592342 VL - 229 Y2 - 20120516// ID - 1135 ER - TY - JOUR AB - Purpose: To evaluate the safety and efficacy of transscleral diode laser cyclophotocoagulation (TSDLC) in advanced glaucoma refractory to medical or surgical treatment. Material and Method: The data of subjects who were treated with TSDLC between 2009 and 2011 were retrospectively reviewed. Intraocular pressure before and after treatment, visual acuity, the number of medications and complications were analysed. Success was defined as final IOP of 6-22 mmHg with or without antiglaucomatous medications. Results: Thirty seven eyes of 37 patients were included in the study. Mean age of patients and mean follow-up time were 61.73±17.13 years (range: 19-80 years) and 8.06±5.81 months (range: 3-22 months), respectively. Mean pretreatment IOP was 38.68±8.94 mmHg and IOP was 26.46±11.34 mmHg (p <0.01) at the second week, whereas it was 24.97±10.84 mmHg (p<0.01) at the last visit. IOP of less than 22 mmHg was achieved in 40.5% of eyes at the last visit. Mean treatment number per eye was 1.48±0.73, and more than one treatment was required in 13 (35.1%) eyes. Preoperative and postoperative mean total antiglaucomatous medications were 3.14±1.18 and 2.76±1.23, respectively. No phthisis bulbi or persistent hypotonia developed during the follow-up period. Discussion: TSDLC is an effective and safe method for the treatment of refractory glaucoma. It also served to reduce the number of antiglaucoma medications, thus improving both the quality of life of the patients and their compliance to therapy. © Galenos Yayinevi. AD - Necmettin Erbakan Üniversitesi Meram Tip Fakültesi, Göz Hastaliklari Anabilim Dali, Konya, Turkey Selçuk Üniversitesi Selçuklu Tip Fakültesi, Göz Hastaliklari Anabilim Dali, Konya, Turkey AU - Bitirgen, G. AU - Okka, M. AU - Bozkurt, B. AU - Doǧru, I. AU - Kerimoǧlu, H. AU - Öztürk, B. T. AU - Kamiş, U. DB - Scopus DO - 10.4274/tjo.42.04127 IS - 6 KW - Diode laser cyclophotocoagulation Intraocular pressure Refractory glaucoma M3 - Review N1 - Cited By :1 Export Date: 19 July 2021 PY - 2013 SP - 434-437 ST - Dirençli glokom olgularında transskleral diod lazer siklofotokoagülasyon T2 - Turk Oftalmoloiji Dergisi TI - Transscleral diode laser cyclophotocoagulation in refractory glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872764268&doi=10.4274%2ftjo.42.04127&partnerID=40&md5=9ac36a3535a9ba1846dd748b46f23376 VL - 42 ID - 5634 ER - TY - JOUR AB - Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population. © the author(s), publisher and licensee Libertas Academica Ltd. AD - D. J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC, 27710, United States AU - Bitting, R. L. AU - Armstrong, A. J. AU - George, D. J. C1 - jevtana provenge zytiga DB - Embase DO - 10.4137/CMO.S5977 KW - abiraterone acetate cabazitaxel corticosteroid denosumab docetaxel estramustine ipilimumab mitoxantrone placebo prednisone prostate specific antigen sipuleucel T zibotentan zoledronic acid advanced cancer antineoplastic activity cancer combination chemotherapy cancer grading cancer immunization cancer immunotherapy cancer screening cancer survival castration resistant prostate cancer chill dose response drug approval drug dependence drug dose sequence drug efficacy drug protein binding drug safety drug tolerability fever glaucoma glucose intolerance headache health care access human hypertension low drug dose melanoma metastasis myalgia overall survival peptic ulcer progression free survival prostate cancer review side effect treatment indication body weight gain jevtana provenge zytiga LA - English M3 - Review N1 - L362874294 2011-11-11 2011-11-18 PY - 2011 SN - 1179-5549 SP - 325-332 ST - Management options in advanced prostate cancer: What is the role for sipuleucel-T? T2 - Clinical Medicine Insights: Oncology TI - Management options in advanced prostate cancer: What is the role for sipuleucel-T? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362874294&from=export http://dx.doi.org/10.4137/CMO.S5977 VL - 5 ID - 3204 ER - TY - JOUR AD - M. Bitzer, Tübingen, Germany AU - Bitzer, M. DB - Embase IS - 5 KW - competence disease course glaucoma health status human note patient compliance LA - German M3 - Note N1 - L352670763 2008-11-28 PY - 2008 SN - 1432-2625 SP - 309-310 ST - Glaucoma: Good health competence is positive for the course of the disease T2 - Gesundheitsokonomie und Qualitatsmanagement TI - Glaucoma: Good health competence is positive for the course of the disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352670763&from=export VL - 13 ID - 3426 ER - TY - JOUR AB - Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality globally, and its prevalence is projected to continue to increase owing to trends in smoking. Treatment of COPD has evolved from the initial adaptations of drugs and treatment strategies successfully used in asthma into more specific pharmacological strategies following global guidelines. Bronchodilating anticholinergic and beta-2-stimulating agents and anti-inflammatory corticosteroid drugs delivered by inhalators are the mainstay of COPD treatment. Despite significant progress, current pharmacotherapies neither fully alleviate the airway obstruction in COPD, nor reverse the progressive nature of the disease. This review discusses inhalation therapies which have recently become clinically available or are being developed, with focus on combination therapies. There is accumulating evidence that the combination of two or all three drug classes, triple therapy, is superior to single drug therapy. Several fixed combinations of both currently available and novel molecules will be launched for clinical use within the next few years. Also, improved understanding of subgroups within the clinical spectrum of COPD, is likely to offer new potentials to improve COPD care. © 2012 Elsevier Ltd. All rights reserved. AD - A. Bjerg, Department of Internal Medicine, Krefting Research Centre, University of Gothenburg, S-40530 Göteborg, Sweden AU - Bjerg, A. AU - Lundbäck, B. AU - Lötvall, J. C1 - gsk 961081(Glaxo SmithKline) pf 3429281(Pfizer) seretide(Glaxo SmithKline) symbicort(Astra Zeneca) C2 - Astra Zeneca Glaxo SmithKline Pfizer DB - Embase Medline DO - 10.1016/j.coph.2012.03.004 IS - 3 KW - beclometasone beclometasone dipropionate plus formoterol fumarate beta 2 adrenergic receptor stimulating agent bronchodilating agent budesonide budesonide plus formoterol carmoterol cholinergic receptor blocking agent ciclesonide corticosteroid flunisolide fluticasone furoate fluticasone propionate fluticasone propionate plus salmeterol fluticasone propionate plus salmeterol xinafoate formoterol formoterol fumarate plus mometasone furoate glycopyrronium gsk 961081 indacaterol ipratropium bromide mometasone furoate olodaterol pf 3429281 placebo salmeterol tiotropium bromide triamcinolone unclassified drug unindexed drug vilanterol trifenatate article asthma bronchus obstruction cardiovascular risk chronic obstructive lung disease combination chemotherapy constipation drug efficacy drug mechanism drug safety drug tolerability hoarseness human intraocular hypertension nonhuman patient compliance priority journal risk assessment systemic disease thrush tremor urine retention xerostomia seretide symbicort LA - English M3 - Article N1 - L51938406 2012-04-03 2012-07-11 PY - 2012 SN - 1471-4892 1471-4973 SP - 252-255 ST - The future of combining inhaled drugs for COPD T2 - Current Opinion in Pharmacology TI - The future of combining inhaled drugs for COPD UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51938406&from=export http://dx.doi.org/10.1016/j.coph.2012.03.004 VL - 12 ID - 3083 ER - TY - JOUR AB - PURPOSE. To investigate the prevalence of vitreomacular interface abnormalities (VMIAs) in a French elderly glaucomatous population. METHODS. Using a population-based study, the MONTRACHET (Maculopathy Optic Nerve nuTRition neurovAsCular and HEarT diseases) study conducted in Dijon from 2009 to 2013 in individuals older than 75 years, the prevalence of VMIAs was estimated on glaucoma patients. RESULTS. A total of 1130 participants (2225 eyes) were included in the study. The mean age of participants was 82.3 ± 3.8 years, and 62.74% were women. Regarding the frequency of all VMIAs, there was no statistical difference between glaucoma patients and nonglaucoma participants (51.85% vs. 53.92%, respectively, P = 0.372). In univariate analysis, vitreomacular adherences were more frequent in nonglaucoma participants (18.39% vs. 10.78%, P = 0.036). Epiretinal membranes were more frequent in the glaucomatous population (47.06% vs. 38.13%, P = 0.018). The prevalence of macular cysts was comparable in the two groups (7.84% vs. 5.64%, P = 0.262). Macular cysts were more frequent in eyes treated with preservative-free, IOP-lowering eye drops when compared with the eyes of nonglaucomatous participants treated with IOP-lowering eye drops containing a preservative (26.67% vs. 3.37% and 5.76%, respectively, P < 0.001). In multivariate analysis, these results were no longer significant. CONCLUSIONS. The prevalence of VMIAs was high in this elderly population and similar in both glaucomatous and nonglaucomatous participants. The information provided by macular optical coherence tomography scans should be considered with caution when used for glaucoma management in elderly patients. © 2019 The Authors. AD - University Hospital, Department of Ophthalmology, Dijon, France Institut National de la Santé et de la Recherche Médicale (INSERM), Clinical Center Investigation, Clinical Epidemiology/Clinical Trials Unit, Universal Hospital, Dijon, France Centre des Sciences du Goût et de l’Alimentation, Centre National pour la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique (INRA), University Bourgogne Franche-Comté, Dijon, France AU - Blanc, J. AU - Seydou, A. AU - Ben Ghezala, I. AU - Deschasse, C. AU - Meillon, C. AU - Bron, A. M. AU - Binquet, C. AU - Creuzot-Garcher, C. DB - Scopus DO - 10.1167/iovs.18-26510 IS - 6 KW - Glaucoma Population-based study Spectral-domain optical coherence tomography Vitreomacular interface M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2019 SP - 1996-2002 ST - Vitreomacular interface abnormalities and glaucoma in an elderly population (The MONTRACHET study) T2 - Investigative Ophthalmology and Visual Science TI - Vitreomacular interface abnormalities and glaucoma in an elderly population (The MONTRACHET study) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065790085&doi=10.1167%2fiovs.18-26510&partnerID=40&md5=01bd5bef45ef87f843b30477472ad6b2 VL - 60 ID - 5404 ER - TY - JOUR AB - Of a randomly selected sample of 40 patients with chronic simple glaucoma 11 were identified as having failed to comply adequately with medical advice. Noncompliers were more likely: to be men, to have had no other medical disorder but glaucoma, not to rank glaucoma as most troubling if they had another illness, to have experienced side effects from the treatment, and not to have appreciated the association between glaucoma and blindness. Detailed clinical study revealed that several interrelated psychosocial factors contributed to noncompliance. AU - Bloch, S. AU - Rosenthal, A. R. AU - Friedman, L. AU - Caldarolla, P. IS - 8 KW - Adult Aged Blindness/et [Etiology] Drug-Related Side Effects and Adverse Reactions Female Glaucoma/co [Complications] *Glaucoma/dt [Drug Therapy] Humans Male Middle Aged *Patient Compliance PY - 1977 SN - 0007-1161 SP - 531-4 ST - Patient compliance in glaucoma T2 - The British journal of ophthalmology TI - Patient compliance in glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=911733 VL - 61 ID - 2275 ER - TY - JOUR AB - PURPOSE: To study the impact of a 2-hour information session and 3 patients' phone calls on patient persistence with glaucoma medication., PATIENTS AND METHODS: All patients with glaucoma treatment, part of a 27-year old solo glaucoma practice, were invited to attend the information session. Patients who attended the session (n=342) were contacted by phone 1, 4, 10 months later and regular use of drops was stressed. Patients were unaware of the study. We compared the persistence of the patients before and after attending the session, and their persistence to that of patients who did not attend (n=1187). Persistence with glaucoma medication was assessed by examination of data (2002 to 2007) from a provincial medical and drug insurance database., RESULTS: Patients attending the session had glaucoma for 10 years. They had a better persistence than those who did not attend (P<0.05). Their persistence remained the same 1 year after attending the session but tended to be improved in the first 180 days (P<0.076). During the study period, there was a 4% increase in overall persistence (P<0.05). This could be due to an increase in prostaglandins prescriptions and changes in beta-blockers formulation., CONCLUSIONS: The information session and patient's recalls had a limited impact on patient persistence. This could be due to the selection of a population already persistent (78.9%). The results could have been different in less persistent patients and new patients. It could be different in another practice setting. AU - Blondeau, Pierre AU - Carbonneau, Marjorie AU - Esper, Philip AU - Turcotte, Pierre-Christophe DO - https://dx.doi.org/10.1097/IJG.0b013e3182127a9b IS - 6 KW - Adrenergic beta-Antagonists/ad [Administration & Dosage] Aged *Antihypertensive Agents/ad [Administration & Dosage] Databases, Factual Drug Prescriptions/sn [Statistics & Numerical Data] *Drug Utilization/sn [Statistics & Numerical Data] *Glaucoma/dt [Drug Therapy] Humans *Mental Recall *Patient Compliance *Patient Education as Topic Prostaglandins F, Synthetic/ad [Administration & Dosage] Time Factors PY - 2012 SE - Blondeau, Pierre. Division of Ophthalmology, Faculty of Medicine and Health Sciences, Universite de Sherbrooke, Quebec, Canada. pierre.blondeau@videotron.ca SN - 1536-481X 1057-0829 SP - 379-82 ST - A 2-hour information session and patient recall has minimal impact on glaucoma-treatment persistence in a mature practice T2 - Journal of glaucoma TI - A 2-hour information session and patient recall has minimal impact on glaucoma-treatment persistence in a mature practice UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=21430550 VL - 21 ID - 1169 ER - TY - JOUR AB - BACKGROUND: A 2-hour information session to improve understanding and compliance was offered to glaucoma patients. Three studies are presented regarding the participants, their satisfaction with the presentation, and their retention of information., METHODS: One hundred consecutive patients were invited to participate. Age, sex, race, travelling distance, type of glaucoma, number of medications, duration of glaucoma, laser trabeculoplasty, trabeculectomy, medical conditions, visual acuity, visual field mean deviation, and pattern standard deviation (PSD) were documented. At the conclusion of the session, patient satisfaction was determined using a questionnaire. Responses to 6 glaucoma-related questions were requested prior to the session and again at 1, 4, and 10 months afterwards. The effects of age, sex, duration of glaucoma, drops applied, and compliance were analysed., RESULTS: The invitation was accepted by 65.2% of all subjects, including 93.4% of those who had been undergoing therapy for less than 1 year. Factors identified in nonparticipation were advanced age, a longer duration of glaucoma, coronary heart disease, and worse PSD in the worse eye. Transportation was the main reason for nonparticipation. Patient satisfaction was excellent, and 99% indicated that they would recommend the clinic to friends with glaucoma. Patient knowledge increased and persisted throughout the 10 months. Older participants had lower scores., INTERPRETATION: Most patients wanted to participate in the information session. Participants subjectively felt that the session was useful. It improved their knowledge of glaucoma, and has the potential to increase patient compliance. AU - Blondeau, Pierre AU - Esper, Philip AU - Mazerolle, Eric IS - 6 KW - Aged Antihypertensive Agents/ad [Administration & Dosage] Female *Glaucoma/dt [Drug Therapy] *Health Knowledge, Attitudes, Practice Humans Intraocular Pressure/de [Drug Effects] Male Middle Aged *Patient Compliance *Patient Education as Topic/og [Organization & Administration] Patient Participation Patient Satisfaction Surveys and Questionnaires PY - 2007 SE - Blondeau, Pierre. Universite de Sherbrooke, department de l'opthalmologie, Sherbrooke, Quebec. pierre.blondeau@videotron.ca SN - 0008-4182 SP - 816-20 ST - An information session for glaucoma patients T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - An information session for glaucoma patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=18033325 VL - 42 ID - 1567 ER - TY - JOUR AB - Background Guidelines recommend stepping down asthma treatment to the minimum effective dose to achieve symptom control, prevent adverse side effects, and reduce costs. Limited data exist on asthma prescription patterns in a real-world setting. We aimed to evaluate the appropriateness of doses prescribed to a UK general asthma population and assess whether stepping down medication increased exacerbations or reliever use, as well as its impact on costs. Methods and findings We used nationwide UK primary care medical records, 2001–2017, to identify 508,459 adult asthma patients managed with preventer medication. Prescriptions of higher-level medication: medium/high-dose inhaled corticosteroids (ICSs) or ICSs + add-on medication (long-acting β2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline, or long-acting muscarinic antagonist [LAMA]) steadily increased over time (2001 = 49.8%, 2017 = 68.3%). Of those prescribed their first preventer, one-third were prescribed a higher-level medication, of whom half had no reliever prescription or exacerbation in the year prior. Of patients first prescribed ICSs + 1 add-on, 70.4% remained on the same medication during a mean follow-up of 6.6 years. Of those prescribed medium/high-dose ICSs as their first preventer, 13.0% already had documented diabetes, cataracts, glaucoma, or osteopenia/osteoporosis. A cohort of 125,341 patients were drawn to assess the impact of stepping down medication: mean age 50.4 years, 39.4% males, 39,881 stepped down. Exposed patients were stepped down by dropping their LABAs or another add-on or by halving their ICS dose (halving their mean-daily dose or their inhaler dose). The primary and secondary outcomes were, respectively, exacerbations and an increase in reliever prescriptions. Multivariable regression was used to assess outcomes and determine the prognostic factors for initiating stepdown. There was no increased exacerbation risk for each possible medication stepdown (adjusted hazard ratio, 95% CI, p-value: ICS inhaler dose = 0.86, 0.77–0.93, p < 0.001; ICS mean daily = 0.80, 0.74–0.87, p < 0.001; LABA = 1.01, 0.92–1.11, p = 0.87, other add-on = 1.00, 0.91–1.09, p = 0.79) and no increase in reliever prescriptions (adjusted odds ratio, 95% CI, p-value: ICS inhaler dose = 0.99, 0.98–1.00, p = 0.59; ICS mean daily = 0.78, 0.76–0.79, p < 0.001; LABA = 0.83, 0.82–0.85, p < 0.001; other add-on = 0.86, 0.85–0.87, p < 0.001). Prognostic factors to initiate stepdown included medication burden, but not medication side effects. National Health Service (NHS) indicative prices were used for cost estimates. Stepping down medication, either LABAs or ICSs, could save annually around £17,000,000 or £8,600,000, respectively. Study limitations include the possibility that prescribed medication may not have been dispensed or adhered to and the reason for stepdown was not documented. Conclusion In this UK study, we observed that asthma patients were increasingly prescribed higher levels of treatment, often without clear clinical indication for such high doses. Stepping down medication did not adversely affect outcomes and was associated with substantial cost savings. © 2020 Bloom et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. AD - National Heart and Lung Institute, Imperial College London, London, United Kingdom Imperial College Business School, Imperial College London, London, United Kingdom Asthma UK Centre for Applied Research, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom AU - Bloom, C. I. AU - de Preux, L. AU - Sheikh, A. AU - Quint, J. K. C7 - e1003145 DB - Scopus DO - 10.1371/journal.pmed.1003145 IS - 7 M3 - Review N1 - Cited By :4 Export Date: 19 July 2021 PY - 2020 ST - Health and cost impact of stepping down asthma medication for UK patients, 2001–2017: A population-based observational study T2 - PLoS Medicine TI - Health and cost impact of stepping down asthma medication for UK patients, 2001–2017: A population-based observational study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088518046&doi=10.1371%2fjournal.pmed.1003145&partnerID=40&md5=eefc44c12cb8faa660bbb64c60012daf VL - 17 ID - 5440 ER - TY - JOUR AD - D.M. Blumberg, Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, 635W165th St, New York, NY, United States AU - Blumberg, D. M. DB - Embase Medline DO - 10.1001/jamaophthalmol.2018.3670 IS - 11 KW - glaucoma health care access human low income country middle income country note priority journal World Health Organization LA - English M3 - Note N1 - L623831186 2018-09-14 2019-10-02 PY - 2018 SN - 2168-6165 SP - 1279-1280 ST - Affordability of Glaucoma Treatment Around the Globe: An Initial Step Toward Improving Universal Access to Glaucoma Treatment T2 - JAMA Ophthalmology TI - Affordability of Glaucoma Treatment Around the Globe: An Initial Step Toward Improving Universal Access to Glaucoma Treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623831186&from=export http://dx.doi.org/10.1001/jamaophthalmol.2018.3670 VL - 136 ID - 2564 ER - TY - JOUR AB - IMPORTANCE: Understanding factors that lead to nonadherence to glaucoma treatment is important to diminish glaucoma-related disability., OBJECTIVES: To determine whether the implementation of the Medicare Part D prescription drug benefit affected rates of cost-related nonadherence and cost-reduction strategies in Medicare beneficiaries with and without glaucoma and to evaluate associated risk factors for such nonadherence., DESIGN, SETTING, AND PARTICIPANTS: Serial cross-sectional study using 2004 to 2009 Medicare Current Beneficiary Survey data linked with Medicare claims. Coding to extract data started in January 2014 and analyses were performed between September and November of 2014. Participants were all Medicare beneficiaries, including those with a glaucoma-related diagnosis in the year prior to the collection of the survey data, those with a nonglaucomatous ophthalmic diagnosis in the year prior to the collection of the survey data, and those without a recent eye care professional claim., INTERVENTION: Effect of the implementation of the Medicare Part D drug benefit., MAIN OUTCOMES AND MEASURES: The change in cost-related nonadherence and the change in cost-reduction strategies., RESULTS: Between 2004 and 2009, the number of Medicare beneficiaries with glaucoma who reported taking smaller doses and skipping doses owing to cost dropped from 9.4% and 8.2% to 2.7% (P < .001) and 2.8%, respectively (P = .001). However, reports of failure to obtain prescriptions owing to cost did not improve in the same period (3.4% in 2004 and 2.1% in 2009; P = .12). After Part D, patients with glaucoma had a decrease in several cost-reduction strategies, namely price shopping (26.2%-15.2%; P < .001), purchasing outside the United States (6.9%-1.3%; P < .001), and spending less money to save for medications (8.0% to 3.5%; P < .001). Using a multivariate analysis, the main independent risk factors common to all cost-related nonadherence measures were female sex, younger age, lower income (<$30000), self-reported visual disability, and a smaller Lawton index., CONCLUSIONS AND RELEVANCE: After the implementation of Part D, there was a decrease in the rate that beneficiaries with glaucoma reported engaging in cost-saving measures. Although there was a decline in the rate of several cost-related nonadherence behaviors, patients reporting failure to fill prescriptions owing to cost remained stable. This suggests that efforts to improve cost-related nonadherence should focus both on financial hardship and medical therapy prioritization, particularly in certain high-risk sociodemographic groups. AU - Blumberg, Dana M. AU - Prager, Alisa J. AU - Liebmann, Jeffrey M. AU - Cioffi, George A. AU - De Moraes, C. Gustavo DO - https://dx.doi.org/10.1001/jamaophthalmol.2015.1671 IS - 9 KW - Aged Antihypertensive Agents/ec [Economics] Consumer Behavior/ec [Economics] *Consumer Behavior/sn [Statistics & Numerical Data] *Cost Savings/ec [Economics] Cross-Sectional Studies *Drug Costs Drug Utilization/ec [Economics] Female Glaucoma/dt [Drug Therapy] Glaucoma/ec [Economics] *Glaucoma/px [Psychology] Health Plan Implementation Humans Male *Medicare Part D/ec [Economics] *Medication Adherence/px [Psychology] United States PY - 2015 SE - Blumberg, Dana M. Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. Prager, Alisa J. Columbia University Medical Center, College of Physicians and Surgeons, New York, New York. Liebmann, Jeffrey M. Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. Cioffi, George A. Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. De Moraes, C Gustavo. Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. SN - 2168-6173 2168-6165 SP - 985-96 ST - Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D T2 - JAMA ophthalmology TI - Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26042393 VL - 133 ID - 794 ER - TY - JOUR AB - PURPOSE: To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT)., METHODS: Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs., RESULTS: Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program ("screen only") cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program ("screen and treat") had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813., CONCLUSIONS: Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc. AU - Blumberg, Dana M. AU - Vaswani, Reena AU - Nong, Eva AU - Al-Aswad, Lama AU - Cioffi, George A. DO - https://dx.doi.org/10.1167/iovs.14-14014 IS - 6 KW - *African Americans Female Follow-Up Studies *Glaucoma/di [Diagnosis] Glaucoma/eh [Ethnology] Humans Male *Mass Screening/mt [Methods] Middle Aged Monte Carlo Method Prevalence Quality-Adjusted Life Years *Scotoma/di [Diagnosis] Scotoma/eh [Ethnology] Scotoma/et [Etiology] Time Factors *Tomography, Optical Coherence/mt [Methods] United States/ep [Epidemiology] *Visual Fields PY - 2014 SE - Blumberg, Dana M. Department of Ophthalmology, Harkness Eye Institute, Columbia University, New York, New York, United States. Vaswani, Reena. Department of Ophthalmology, Harkness Eye Institute, Columbia University, New York, New York, United States. Nong, Eva. Columbia University College of Physicians and Surgeons, New York, New York, United States. Al-Aswad, Lama. Department of Ophthalmology, Harkness Eye Institute, Columbia University, New York, New York, United States. Cioffi, George A. Department of Ophthalmology, Harkness Eye Institute, Columbia University, New York, New York, United States. SN - 1552-5783 0146-0404 SP - 3491-500 ST - A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SD-OCT in African American communities T2 - Investigative ophthalmology & visual science TI - A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SD-OCT in African American communities UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24787570 VL - 55 Y2 - 20140501// ID - 888 ER - TY - JOUR AB - Purpose. To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT). Methods. Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs. Results. Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program ("screen only") cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program ("screen and treat") had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813. Conclusions. Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program. © 2014 The Association for Research in Vision and Ophthalmology, Inc. AD - D. M. Blumberg, Columbia University Medical Center, Department of Ophthalmology, 635 West 165th Street, New York, NY, United States AU - Blumberg, D. M. AU - Vaswani, R. AU - Nong, E. AU - Al-Aswad, L. AU - Cioffi, G. A. DB - Embase Medline DO - 10.1167/iovs.14-14014 IS - 6 KW - adult aged article cost benefit analysis eye examination follow up glaucoma health care cost human major clinical study medication compliance optical coherence tomography outcome assessment prevalence priority journal quality adjusted life year retinal nerve fiber layer thickness screening sensitivity and specificity spectral domain optical coherence tomography very elderly visual field visual system function LA - English M3 - Article N1 - L373292766 2014-06-23 2014-07-01 PY - 2014 SN - 1552-5783 0146-0404 SP - 3491-3500 ST - A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SDOCT in African American communities T2 - Investigative Ophthalmology and Visual Science TI - A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SDOCT in African American communities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373292766&from=export http://dx.doi.org/10.1167/iovs.14-14014 VL - 55 ID - 2885 ER - TY - JOUR AB - Glaucomas treatment. Glaucoma is the first cause of blindness in Europe. The purposes of its treatment are lowering intraocular pressure (IOP), but also getting a good patient compliance with a good tolerance and a good ratio cost/effectiveness. Glaucoma treatment should stop optic nerve fiber layer loss and stabilize visual field defects. Medical topic treatment is the first line of treatment, with possible association of drops and absence of benzalkonium chloride for some of them. Four therapeutic classes are available: beta blockers, prostaglandins , alpha-2 agonists and carbonic anhydrase inhibitors. Laser peripheral iridotomy (LPI) can treat occludable angles or angle closure when there is no or only localized peripheral anterior synechia. Laser iridoplasty is indicated in plateau iris when remains an appositional angle closure after LPI. Selective laser trabeculoplasty is an effective tool in lowering IOP and decrease IOP fluctuation. It can be successfully used as primary or adjunctive therapy for the management of both early and advanced glaucoma in primary open angle glaucoma or in angle closure glaucoma after LPI. Surgical approach should be considered after medical and/or laser treatment when glaucomatous visual field defects still progress. Filtering surgeries (non penetrating deep sclerectomy or trabeculectomy) or glaucoma valve implantation are well known for their effectiveness but bleb complications lead to develop blebless procedures called MIGS (mini invasive glaucoma surgery) or, in refractory glaucoma, non invasive surgery devices such as High-intensity focused ultrasound which consist in ultrasonic circular cyclo-coagulation of ciliary body, leading to less long term complication than diode transscleral cyclocoagulation. AU - Bluwol, Elisa IS - 5 KW - Europe Glaucoma/th [Therapy] *Glaucoma Glaucoma, Angle-Closure/th [Therapy] *Glaucoma, Angle-Closure Humans Intraocular Pressure Iris Treatment Outcome PY - 2016 SE - Bluwol, Elisa. Institut du glaucome, hopital Saint-Joseph, Paris, France. SN - 2101-017X 0035-2640 SP - 508-513 ST - [Glaucoma treatment] T2 - Traitement des glaucomes. TI - [Glaucoma treatment] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=30512573 VL - 66 ID - 642 ER - TY - JOUR AB - The biomechanical properties of the cornea and sclera are important in the onset and progression of multiple ocular pathologies and vary substantially between individuals, yet the source of this variation remains unknown. Here we identify genes putatively regulating corneoscleral biomechanical tissue properties by conducting high-fidelity ocular compliance measurements across the BXD recombinant inbred mouse set and performing quantitative trait analysis. We find seven cis-eQTLs and non-synonymous SNPs associating with ocular compliance, and show by RT-qPCR and immunolabeling that only two of the candidate genes, Smarce1 and Tns4, showed significant expression in corneal and scleral tissues. Both have mechanistic potential to influence the development and/or regulation of tissue material properties. This work motivates further study of Smarce1 and Tns4 for their role(s) in ocular pathology involving the corneoscleral envelope as well as the development of novel mouse models of ocular pathophysiology, such as myopia and glaucoma. Copyright © 2021 Boazak, King, Wang, Chu, Toporek, Sherwood, Overby, Geisert and Ethier. AU - Boazak, Elizabeth M. AU - King, Rebecca AU - Wang, Jiaxing AU - Chu, Cassandra M. AU - Toporek, Aaron M. AU - Sherwood, Joseph M. AU - Overby, Darryl R. AU - Geisert, Eldon E. AU - Ethier, C. Ross DO - https://dx.doi.org/10.3389/fbioe.2021.596154 PY - 2021 SE - Boazak, Elizabeth M. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Emory University, Atlanta, GA, United States. King, Rebecca. Department of Ophthalmology, Emory University, Atlanta, GA, United States. Wang, Jiaxing. Department of Ophthalmology, Emory University, Atlanta, GA, United States. Chu, Cassandra M. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Emory University, Atlanta, GA, United States. Toporek, Aaron M. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Emory University, Atlanta, GA, United States. Sherwood, Joseph M. Department of Bioengineering, Imperial College London, London, United Kingdom. Overby, Darryl R. Department of Bioengineering, Imperial College London, London, United Kingdom. Geisert, Eldon E. Department of Ophthalmology, Emory University, Atlanta, GA, United States. Ethier, C Ross. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Emory University, Atlanta, GA, United States. Ethier, C Ross. George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, United States. SN - 2296-4185 SP - 596154 ST - Smarce1 and Tensin 4 Are Putative Modulators of Corneoscleral Stiffness T2 - Frontiers in bioengineering and biotechnology TI - Smarce1 and Tensin 4 Are Putative Modulators of Corneoscleral Stiffness UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33634081 VL - 9 Y2 - 20210205// ID - 98 ER - TY - JOUR AB - PURPOSE: To evaluate the accuracy of a prototype electronic device for recording eye drop usage., PARTICIPANTS AND METHODS: Ten volunteers were randomly assigned to one of five usage patterns designed to mimic common patterns of use in glaucoma patients from 100% compliant to 50% compliant. All participants agreed to adhere to a pre-determined "dosing" schedule for 15 days using the monitoring/reminder device to instill artificial tears. Participants also recorded drop usage in a diary. The main outcome measures were device accuracy and reproducibility. Device accuracy was defined as the magnitude of the difference between the diary and device output for three variables: date, number of drops, and instillation time., RESULTS: Date stamping by the device was 100% accurate. The mean +/- SD time difference between the device and the diary was -2.0 +/- 19.7 minutes when data from all participants was pooled. In seven of the ten participants, the device did not record at least one drop. The mean +/- SD difference in the number of drops recorded by the device minus the diary was 0.16 +/- 0.97 when data from all participants was pooled., CONCLUSIONS: The prototype compliance reminder/monitoring device may underestimate compliance in some patients. The date and time stamping mechanisms were generally accurate and reproducible. AU - Boden, Catherine AU - Sit, Arthur AU - Weinreb, Robert N. IS - 1 KW - *Antihypertensive Agents/ad [Administration & Dosage] Cloprostenol/ad [Administration & Dosage] *Cloprostenol/aa [Analogs & Derivatives] Drug Utilization *Glaucoma/dt [Drug Therapy] Humans *Monitoring, Ambulatory/is [Instrumentation] Monitoring, Ambulatory/mt [Methods] *Ophthalmic Solutions/ad [Administration & Dosage] *Patient Compliance Reproducibility of Results Travoprost PY - 2006 SE - Boden, Catherine. Hamilton Glaucoma Center, Department of Ophthalmology, University of California at San Diego, La Jolla, USA. cboden@eyecenter.ucsd.edu SN - 1057-0829 SP - 30-4 ST - Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops T2 - Journal of glaucoma TI - Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16378015 VL - 15 ID - 1691 ER - TY - JOUR AB - Background: Purpose of this retrospective study was to analyze outcome and complications after penetrating keratoplasty (PK) in patients with Down's syndrome. Patients and methods: The medical records of all patients with Down's syndrome and PK from 1985 were reviewed retrospectively. Age, sex, systemic diseases, communication, indication for surgery and surgical technique, age at first PK, complications, visual acuity and best corrected visual acuity and findings at last follow-up were noted. Age matched mentally non-retarded patients with keratoconus and PK served as a control group. Results: All eyes of 9 patients had keratoconus, 16 were operated. Indication for surgery was spontaneous perforation in 3 and refractive in the remaining 13 eyes. Five grafts were clear at last follow-up. In 7 eyes, at least 1 re-PK had to be performed. Seven eyes developed graft rejection and 4 eyes needed conjunctival grafting because of non-healing epithelial defects. Ten eyes developed cataracts, 3 secondary glaucoma. In the control group 22 out of 25 operated corneas were clear at last follow-up. Conclusions: Prognosis of PK in patients with Down's syndrome is worse than in other patients with keratoconus. Poor results are not only explained due to the lack of cooperation of patients, but also because of: 1) high rate of emergency procedures (3/16), 2) presence of lid anomalies and 3) very advanced keratoconus, necessitating bigger sized grafts, leading to frequent immunological reactions, suture loosening and secondary glaucoma. Indication for PK in Down's syndrome patients with keratoconus and floppy eyelids should be very restrictive. Postoperative complications and the high rejection rate might be decreased by performing deep lamellar keratoplasty as this would not be an intraocular procedure. AD - M. Bodenmueller, Department of Ophthalmology, University of Bern, Inselspital, 3010 Bern, Switzerland AU - Bodenmueller, M. AU - Goldblum, D. AU - Frueh, B. E. DB - Embase Medline DO - 10.1055/s-2003-38178 IS - 3 KW - adolescent cataract child clinical article conference paper controlled study disease course disease severity doctor patient relationship Down syndrome emergency treatment eyelid disease female follow up graft rejection human keratoconus male medical record patient compliance penetrating keratoplasty postoperative complication prognosis refraction error reoperation retrospective study secondary glaucoma surgical technique treatment indication treatment outcome visual acuity LA - German M3 - Conference Paper N1 - L36402456 2003-04-23 PY - 2003 SN - 0023-2165 SP - 99-102 ST - Penetrating keratoplasty in Down's syndrome T2 - Klinische Monatsblatter fur Augenheilkunde TI - Penetrating keratoplasty in Down's syndrome UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36402456&from=export http://dx.doi.org/10.1055/s-2003-38178 VL - 220 ID - 3828 ER - TY - JOUR AB - Background: Purpose of this retrospective study was to analyze outcome and complications after penetrating keratoplasty (PK) in patients with Down's syndrome. Patients and methods: The medical records of all patients with Down's syndrome and PK from 1985 were reviewed retrospectively. Age, sex, systemic diseases, communication, indication for surgery and surgical technique, age at first PK, complications, visual acuity and best corrected visual acuity and findings at last follow-up were noted. Age matched mentally non-retarded patients with keratoconus and PK served as a control group. Results: All eyes of 9 patients had keratoconus, 16 were operated. Indication for surgery was spontaneous perforation in 3 and refractive in the remaining 13 eyes. Five grafts were clear at last follow-up. In 7 eyes, at least 1 re-PK had to be performed. Seven eyes developed graft rejection and 4 eyes needed conjunctival grafting because of non-healing epithelial defects. Ten eyes developed cataracts, 3 secondary glaucoma. In the control group 22 out of 25 operated corneas were clear at last follow-up. Conclusions: Prognosis of PK in patients with Down's syndrome is worse than in other patients with keratoconus. Poor results are not only explained due to the lack of cooperation of patients, but also because of: 1) high rate of emergency procedures (3/16), 2) presence of lid anomalies and 3) very advanced keratoconus, necessitating bigger sized grafts, leading to frequent immunological reactions, suture loosening and secondary glaucoma. Indication for PK in Down's syndrome patients with keratoconus and floppy eyelids should be very restrictive. Postoperative complications and the high rejection rate might be decreased by performing deep lamellar keratoplasty as this would not be an intraocular procedure. AD - Department of Ophthalmology, University of Bern, Inselspital, 3010 Bern, Switzerland AU - Bodenmueller, M. AU - Goldblum, D. AU - Frueh, B. E. DB - Scopus DO - 10.1055/s-2003-38178 IS - 3 KW - Complications Down's syndrome Floppy eyelid Keratoconus Lamellar keratoplasty Penetrating keratoplasty M3 - Conference Paper N1 - Cited By :11 Export Date: 19 July 2021 PY - 2003 SP - 99-102 ST - Perforierende keratoplastik bei trisomie 21 T2 - Klinische Monatsblatter fur Augenheilkunde TI - Penetrating keratoplasty in Down's syndrome UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037356958&doi=10.1055%2fs-2003-38178&partnerID=40&md5=581d6ed320f874abf0d2b9373ec883cd VL - 220 ID - 5268 ER - TY - JOUR AB - Purpose: Long-term treatment compliance to a chronic asymptomatic condition is a demanding task for many patients. Treating progressive glaucoma can also be confounding for physicians, particularly when management relies on assumption of compliance. This study aims to investigate the relationship between self-reported compliance and frequency of medication changes due to glaucoma progression. Methods: 128 participants with primary open angle glaucoma were recruited from glaucoma clinics in Flinders Eye Centre, South Australia and completed confidential questionnaires. Information was obtained regarding beliefs about glaucoma and their treatment. Compliance was assessed using Morisky Medication Adherence Scale (MARS). Medical records were analyzed for the number of medication changes, due to glaucoma progression. Results: Compliance to topical glaucoma medication was found in 41.4% (MARS = 0). Data were analyzed for behaviors affecting compliance, history of compliance and reasons for changing compliance. Qualitative data and detailed responses were collated from all participants. There was no significant relationship between compliance and changes in medication regime (Chi-squared test for independence), however a significantly lower compliance was detected if participants had difficulties with their drop regime (p = 0.001) and participants who had help with drop insertion at home. (p = 0.015). Conclusion: Using a questionnaire and sympathetic questioning, confidential from their treating physician, higher non-compliance was revealed than in previous studies. Qualitative data indicated availability of ongoing glaucoma education and counselling would be a valuable adjunctive resource alongside medical treatment. Development of a simple validated questionnaire is also needed for assessing glaucoma medication compliance, so an individual tailored approach to non-compliance can be developed. AD - L. Bodle, Flinders Centre for Ophthalmology and Eye Vision Research, Australia AU - Bodle, L. AU - Craig, J. AU - Little, J. A. DB - Embase DO - 10.1111/ceo.12451 KW - drug therapy human Australian New Zealand college ophthalmologist glaucoma questionnaire medication compliance physician astronomy hospital open angle glaucoma patient compliance independence medical record patient asymptomatic disease Australia eye education counseling therapy long term care LA - English M3 - Conference Abstract N1 - L71939751 2015-07-10 PY - 2014 SN - 1442-6404 SP - 97 ST - Compliance to glaucoma medication and its effect on treatment regime T2 - Clinical and Experimental Ophthalmology TI - Compliance to glaucoma medication and its effect on treatment regime UR - https://www.embase.com/search/results?subaction=viewrecord&id=L71939751&from=export http://dx.doi.org/10.1111/ceo.12451 VL - 42 ID - 2871 ER - TY - JOUR AB - Compliance with glaucoma treatment and treatment plans have been difficult to obtain since the initiation of the medical management of glaucoma. There have been many definitions of noncompliance put forth and multiple reasons for this noncompliance isolated. If doctors hope to improve compliance in their patients, they must take a more active role in educating their patients and modifying treatment plans to inspire greater compliance. AU - Boeyink, S. J. DB - Embase DO - 10.1016/S0953-4431(97)10002-9 IS - 3 KW - dipivefrine pilocarpine timolol eye disease glaucoma human medical decision making patient compliance patient education short survey treatment planning LA - English M3 - Short Survey N1 - L27528515 1998-01-09 PY - 1997 SN - 0953-4431 SP - 169-172 ST - Patient compliance: The doctor's duty T2 - Clinical Eye and Vision Care TI - Patient compliance: The doctor's duty UR - https://www.embase.com/search/results?subaction=viewrecord&id=L27528515&from=export http://dx.doi.org/10.1016/S0953-4431(97)10002-9 VL - 9 ID - 3956 ER - TY - JOUR AB - BACKGROUND: The correct self-administration of topical antiglaucomatous eye drops is important for the success of glaucoma treatment. Individual impairment, like increased age, decreased visual acuity, impaired visual-field perception or the frequency of drug appliance may influence a correct application technique and the patients compliance and therewith intraocular pressure (IOP). The aim of this study was to explore alterations of IOP due to self versus external administration (by trained medical personnel) of topical antiglaucomatous eye drops due to impairing factors., MATERIAL AND METHODS: A prospective analysis was undertaken of 123 patients with primary chronic open-angle glaucoma receiving a diurnal intraocular pressure (DIP) measurement over 72 hours at our department. During the first 24 hours, the application of topical eye drops was self-administered by patients (SA), while the application of eye drops within the following 48 hours was performed by trained medical personnel (EA). Alterations of mean intraocular pressure (MIP) and diurnal fluctuations (DF) between EA and SA were analysed with regard to initial IOP, restrictions of visual field perception, visual acuity, age, general health status and frequency of daily eye drop administration., RESULTS: Overall comparable MIP in SA and EA was seen. 19.2-43.9 % of the patients with an initial IOP >= 11 mmHg showed beneficial effects of EA with lowering of IOP under 15.5 mmHg. 27.6 % of the patients showed lowering of DF < 5 mmHg due to EA. EA influenced DF beneficially in cases of poor visual acuity (<= 0.1, - 0.8 mmHg) and frequent drop administration (- 0.75 mmHg)., CONCLUSIONS: Subpopulations of investigated patients showed lowering of MIP due to EA, although EA showed no MIP lowering effects in comparison with SA in general. Glaucoma-impaired patients show decreased DF by EA. Particularly beneficial influences to DF by EA were observed due to impaired visual acuity and frequent drop administration. We recommend a 72-hour DIP to evaluate individual parameters influencing the success of topical glaucomatous treatment. The benefit of EA in patients with certain impairments should be the subject of further investigations. Copyright Georg Thieme Verlag KG Stuttgart . New York. AU - Bohm, M. R. R. AU - Lill, T. M. AU - Eter, N. AU - Prokosch-Willing, V. DO - https://dx.doi.org/10.1055/s-0034-1368639 IS - 8 KW - Administration, Ophthalmic Adult Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Circadian Rhythm/de [Drug Effects] *Clinical Competence Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Male Middle Aged *Ophthalmic Solutions/ad [Administration & Dosage] Prospective Studies Self Administration Young Adult PY - 2014 SE - Bohm, M R R. Klinik fur Augenheilkunde, Universitatsklinikum Munster. Lill, T M. Klinik fur Augenheilkunde, Universitatsklinikum Munster. Eter, N. Klinik fur Augenheilkunde, Universitatsklinikum Munster. Prokosch-Willing, V. Klinik fur Augenheilkunde, Universitatsklinikum Munster. SN - 1439-3999 0023-2165 SP - 810-7 ST - [Alterations of intraocular pressure in comparison of self- and external-administered topical antiglaucomatosa during diurnal intraocular pressure measurements] T2 - Vergleichende Analyse intraokularer Druckwerte zwischen Fremd- und Eigenapplikation topischer Antiglaukomatosa bei stationarem Tagestensioprofil. TI - [Alterations of intraocular pressure in comparison of self- and external-administered topical antiglaucomatosa during diurnal intraocular pressure measurements] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25133559 VL - 231 Y2 - 20140818// ID - 866 ER - TY - JOUR AB - Purpose: To evaluate surgical outcomes and to describe a strategy for pediatric uveitic glaucoma. Design: Retrospective case series. Methods: The clinical practice of a single surgeon identified 36 patients with juvenile uveitic glaucoma (diagnosed before 18 years of age) who underwent 1 or more intraocular pressure (IOP)-lowering surgical procedures. The first eye operated on was included in the analysis. The main indication for success was IOP of less than 21 mm Hg with controlled inflammation, without further IOP-lowering surgery or devastating complication. Results: Patients with uveitic glaucoma associated with juvenile idiopathic arthritis (n = 20), idiopathic uveitis (n = 9), other (n = 6) were included. Mean age ± standard deviation at initial glaucoma surgery was 11.1 ± 4.4 years with a follow-up of 5.6 ± 4.8 years (range, 0.2 to 16.4 years). Goniotomy was the initial surgical procedure in 31 (86%) eyes. Fifteen eyes did not require further IOP-lowering surgery. Sixteen eyes had additional IOP-lowering surgery: second goniotomy (n = 9), glaucoma drainage device (n = 6), and trabeculectomy (n = 1). By Kaplan-Meier survival analysis, the first versus the first or second goniotomy were successful at 10 years in 48% (95% confidence interval, 28% to 65%) versus 69% (95% confidence interval, 47% to 84%). Goniotomy failure was noncorrelative with phakic status or presence of preoperative synechiae. Five eyes (14%) had initial glaucoma drainage device implantation because of closed angles. Visual acuity was similar between initial and final examinations (0.37 ± 0.48 logarithm of the minimal angle of resolution units [Snellen 20/47] vs 0.28 ± 0.34 logarithm of the minimal angle of resolution units [Snellen 20/38]). IOP was reduced (33.0 ± 8.0 mm Hg vs 12.6 ± 4.5 mm Hg; P <.0001), as was number of glaucoma medications (3.2 ± 1.1 vs 1.2 ± 1.3; P <.0001). Eyes undergoing cataract removal after successful glaucoma surgery maintained IOP control. Glaucoma was controlled and vision was preserved in 33 (92%) eyes. Conclusions: Refractory juvenile uveitic glaucoma was managed successfully by goniosurgery and glaucoma drainage device implantation. Cataract removal can be accomplished successfully, provided IOP and uveitis are well controlled before surgery. © 2013 Elsevier Inc. AD - S.F. Freedman, Department of Ophthalmology, Duke University, School of Medicine, 2351 Erwin Road, Durham, NC 27710, United States AU - Bohnsack, B. L. AU - Freedman, S. F. DB - Embase Medline DO - 10.1016/j.ajo.2012.07.008 IS - 1 KW - adolescent adult article cataract extraction child clinical article clinical practice controlled study disease association eye injury eye surgery female follow up glaucoma glaucoma surgery goniotomy human infant intermediate uveitis interstitial nephritis intraocular pressure juvenile rheumatoid arthritis male outcome assessment patient compliance phakic intraocular lens preschool child priority journal retina detachment retrospective study sarcoidosis school child surgeon survival time trabeculectomy treatment failure treatment indication treatment outcome uveitic glaucoma uveitis vision LA - English M3 - Article N1 - L52238657 2012-10-04 2013-01-02 PY - 2013 SN - 0002-9394 1879-1891 SP - 134-142 ST - Surgical outcomes in childhood uveitic glaucoma T2 - American Journal of Ophthalmology TI - Surgical outcomes in childhood uveitic glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52238657&from=export http://dx.doi.org/10.1016/j.ajo.2012.07.008 VL - 155 ID - 3044 ER - TY - JOUR AB - OBJECTIVES AND SETTING: To determine the cost effectiveness of screening for glaucoma., METHODS: Information on treatment efficacy, diagnostic methods, epidemiological characteristics of glaucoma, and costs were determined from the literature, from administrative databases, and from experts. Scenarios with different screening frequency, age, participation in screening, compliance with treatment, treatment efficacy, and diagnostic tests were examined., RESULTS: The initial scenario comprised three-yearly screening of subjects aged 40-79 by funduscopy and tonometry, followed by perimetry when abnormalities were discovered. The assumption of levels of participation in screening and of compliance with treatment of 75%, and treatment efficacy of 50% resulted in a cost of $C100,000 per year of blindness prevented. A scenario in which screening was restricted to subjects aged 65-79, with the same input variables, would prevent 81% of the cases of blindness prevented with scenario 1, at a cost of $C42,000 per year of blindness prevented. Screening with tonometry only as the initial diagnostic test in subjects aged 65-79 would result in a cost of $C36,000 per year of blindness prevented, but would only prevent 59% of the cases prevented with scenario 1., CONCLUSIONS: There is as yet no proof that treatment of glaucoma or of high intraocular pressure will arrest the progression of glaucoma to blindness. Even when treatment efficacy is assumed to be as high as 50%, however, the cost effectiveness of most glaucoma screening programmes considered would not be competitive. AU - Boivin, J. F. AU - McGregor, M. AU - Archer, C. IS - 3 KW - Adult Aged *Cost-Benefit Analysis Fluorescein Angiography/ec [Economics] *Glaucoma, Open-Angle/di [Diagnosis] Glaucoma, Open-Angle/ec [Economics] Glaucoma, Open-Angle/th [Therapy] Humans Middle Aged Outcome Assessment, Health Care Tonometry, Ocular/ec [Economics] Treatment Outcome Visual Field Tests/ec [Economics] PY - 1996 SE - Boivin, J F. Department of Epidemiology and Biostatistics, Faculty of Medicine, McGill University, Montreal, Canada. SN - 0969-1413 SP - 154-63 ST - Cost effectiveness of screening for primary open angle glaucoma T2 - Journal of medical screening TI - Cost effectiveness of screening for primary open angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=8946311 VL - 3 ID - 2030 ER - TY - JOUR AB - Background/Aims: To evaluate intraocular pressure (IOP) after phacoemulsification in open-angle glaucoma (OAG) patients with uncontrolled or marginally controlled glaucoma and/or severe visual field (VF) loss. Patients and Methods: Retrospective case series of OAG patients without prior glaucoma surgery undergoing phacoemulsification. Uncontrolled or marginally controlled glaucoma was defined as IOP>21 mm Hg despite maximally tolerated medications or requiring >3 topical drugs for IOP control. Severe VF loss was defined as VF mean deviation ≤-12 dB. Eyes with postoperative IOP elevation were identified using 4 different definitions. Results: Of 56 eyes (56 patients), 10 eyes (17.8%) had IOP elevation ≥10 mm Hg at postoperative day 1. At 1 year (N=45), the average preoperative IOP of 14.3±3.5 mm Hg decreased to 13.8±3.6 mm Hg (P=0.312), and number of medications of 3.2±1.1 decreased to 2.8±1.2 (P=0.165). Eleven eyes (24.4%) had increase in IOP of ≥3 mm Hg, whereas 14 eyes (31.1%) had decrease of ≥3 mm Hg. Nine eyes (20.0%) had higher IOP without medication changes and 9 eyes (20.0%) required additional medications or surgery for IOP control; 3 eyes (6.7%) required trabeculectomy. Higher IOP at 1 year was associated with IOP elevation ≥10 mm Hg at postoperative week 1 (P=0.020). Conclusions: Phacoemulsification resulted in nonsignificant 1-year IOP change in OAG patients with uncontrolled or marginally controlled glaucoma and/or with severe VF loss. Although 40% of eyes had higher IOP after phacoemulsification at 1-year postoperatively, only 6.7% required trabeculectomy. AD - K.D. Bojikian, Department of Ophthalmology, University of Washington, 325 Ninth Ave., Seattle, WA, United States AU - Bojikian, K. D. AU - Chen, P. P. DB - Embase Medline DO - 10.1097/IJG.0000000000000854 IS - 2 KW - acetazolamide adult aged article case study cataract disease severity female glaucoma human intraocular pressure iridotomy low tension glaucoma major clinical study male open angle glaucoma outcome assessment patient compliance phacoemulsification postoperative period preoperative evaluation priority journal retrospective study trabeculectomy treatment outcome very elderly visual field defect LA - English M3 - Article N1 - L620281043 2018-01-24 2018-04-26 PY - 2018 SN - 1536-481X 1057-0829 SP - 108-114 ST - Intraocular Pressure after Phacoemulsification in Open-angle Glaucoma Patients with Uncontrolled or Marginally Controlled Glaucoma and/or with Severe Visual Field Loss T2 - Journal of Glaucoma TI - Intraocular Pressure after Phacoemulsification in Open-angle Glaucoma Patients with Uncontrolled or Marginally Controlled Glaucoma and/or with Severe Visual Field Loss UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620281043&from=export http://dx.doi.org/10.1097/IJG.0000000000000854 VL - 27 ID - 2611 ER - TY - JOUR AD - M. V. Boland, Baltimore, MD, United States AU - Boland, M. V. DB - Embase Medline DO - 10.1016/j.ophtha.2010.08.051 IS - 12 KW - editorial electronic medical record glaucoma health care organization health care utilization health service medicaid medicare ophthalmology priority journal LA - English M3 - Editorial N1 - L360105301 2010-12-15 2010-12-20 PY - 2010 SN - 0161-6420 SP - 2239-2240 ST - Meaningful use of electronic health records in ophthalmology T2 - Ophthalmology TI - Meaningful use of electronic health records in ophthalmology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L360105301&from=export http://dx.doi.org/10.1016/j.ophtha.2010.08.051 VL - 117 ID - 3214 ER - TY - JOUR AB - IMPORTANCE: Adherence with topical glaucoma medications is low in some patients. To identify these patients, we need more information on risk factors for nonadherence., OBJECTIVE: To assess adherence with once-daily glaucoma medication., DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study involving patients who were recruited from a university-based glaucoma clinic and treated with once-daily prostaglandin eyedrops. Baseline characteristics were recorded, and each patient was provided a medication bottle to hold his or her eyedrop bottle throughout the study. An electronic cap recorded each time the larger bottle holding the eyedrops was opened. Participants were administered standardized tests of depression and mental status and answered questions about their health and their attitudes toward medication adherence. They used the electronic monitors for 3 months, during which their adherence with medications was assessed., MAIN OUTCOMES AND MEASURES: Adherence with daily glaucoma medication and factors associated with poor adherence., RESULTS: Of the 491 participants enrolled, 407 (82.9%) successfully completed the 3-month adherence assessment. Of this group, 337 (82.8%) took their medication correctly on at least 75% of days and were deemed adherent. Compared with this adherent group, the 70 participants (17.2%) who were nonadherent were slightly younger, were more likely to be of African descent, took medications for a shorter time, had a lower level of educational attainment, and had worse scores on mental status and depression scales (P < .05 for all). Nonadherent participants were less likely to be able to name their glaucoma medications, reported a lower estimate of adherence, and were more likely to admit some missed doses over the past 2 weeks or in general (P < .05 for all). Those who were nonadherent were also less likely to agree that remembering their eyedrops is easy, more likely to strongly agree with the statement that eyedrops can cause problems, and less likely to agree that they followed physicians' orders., CONCLUSIONS AND RELEVANCE: Electronic monitoring of patient adherence documented that a sizable number of patients with glaucoma do not take their medications as prescribed. Factors were identified that may prove useful in targeting those nonadherent patients for interventions. AU - Boland, Michael V. AU - Chang, Dolly S. AU - Frazier, Travis AU - Plyler, Ryan AU - Friedman, David S. DO - https://dx.doi.org/10.1001/jamaophthalmol.2014.856 IS - 7 KW - Aged *Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/tu [Therapeutic Use] Cohort Studies Drug Monitoring/is [Instrumentation] *Drug Monitoring/mt [Methods] Female *Glaucoma/dt [Drug Therapy] Health Behavior Health Knowledge, Attitudes, Practice Humans Intraocular Pressure/de [Drug Effects] Male *Medication Adherence/sn [Statistics & Numerical Data] Ophthalmic Solutions Prospective Studies *Prostaglandins F, Synthetic/ad [Administration & Dosage] Prostaglandins F, Synthetic/tu [Therapeutic Use] *Reminder Systems/is [Instrumentation] Risk Factors Surveys and Questionnaires PY - 2014 SE - Boland, Michael V. Glaucoma Center of Excellence, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland2Division of Health Sciences Informatics, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Chang, Dolly S. Glaucoma Center of Excellence, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland3Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University, Baltimore, Maryland. Frazier, Travis. Madigan Army Medical Center, Fort Lewis, Washington. Plyler, Ryan. Georgetown University School of Medicine, Washington, DC. Friedman, David S. Glaucoma Center of Excellence, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland3Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University, Baltimore, Maryland. SN - 2168-6173 2168-6165 SP - 838-44 ST - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study T2 - JAMA ophthalmology TI - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24830878 VL - 132 ID - 885 ER - TY - JOUR AB - IMPORTANCE: Topical glaucoma medications lower intraocular pressure and alter the course of the disease. Because adherence with glaucoma medications is a known problem, interventions are needed to help those patients who do not take their medications as prescribed., OBJECTIVE: To assess the ability of an automated telecommunication-based intervention to improve adherence with glaucoma medications., DESIGN, SETTING, AND PARTICIPANTS: We performed a prospective cohort study of medication adherence, followed by a randomized intervention for those found to be nonadherent, of individuals recruited from a university-based glaucoma subspecialty clinic. A total of 491 participants were enrolled in the initial assessment of adherence. Of those, 70 were nonadherent with their medications after 3 months of electronic monitoring and randomized to intervention and control groups., INTERVENTIONS: A personal health record was used to store the list of patient medications and reminder preferences. On the basis of those data, participants randomized to the intervention received daily messages, either text or voice, reminding them to take their medication. Participants randomized to the control group received usual care., MAIN OUTCOMES AND MEASURES: Difference in adherence before and after initiation of the intervention., RESULTS: Using an intent-to-treat analysis, we found that the median adherence rate in the 38 participants randomized to the intervention increased from 53% to 64% (P < .05). There was no statistical change in 32 participants in the control group. To assess the real efficacy of the intervention, the same comparison was performed for the participants who successfully completed the study after randomization. Analyzed this way, the adherence rate in the 20 participants in the intervention group increased from 54% to 73% (P < .05), whereas there was again no statistical change in the 19 participants in the control group. Eighty-four percent of the participants who received reminders agreed they were helpful and would continue using them outside the study., CONCLUSIONS AND RELEVANCE: Automated telecommunication-based reminders linked to data in a personal health record improved adherence with once-daily glaucoma medications. This is an effective method to improve adherence that could realistically be implemented in ophthalmology practices with a minimum amount of effort on the part of the practice or the patient. AU - Boland, Michael V. AU - Chang, Dolly S. AU - Frazier, Travis AU - Plyler, Ryan AU - Jefferys, Joan L. AU - Friedman, David S. DO - https://dx.doi.org/10.1001/jamaophthalmol.2014.857 IS - 7 KW - Administration, Topical Aged *Antihypertensive Agents/ad [Administration & Dosage] Cohort Studies *Drug Monitoring Female *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Male Medical Record Linkage *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ophthalmic Solutions Prospective Studies *Reminder Systems/is [Instrumentation] *Telecommunications/is [Instrumentation] PY - 2014 SE - Boland, Michael V. Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland2Division of Health Sciences Informatics, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Chang, Dolly S. Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland3Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Frazier, Travis. Madigan Army Medical Center, Fort Lewis, Washington. Plyler, Ryan. Georgetown University School of Medicine, Washington, DC. Jefferys, Joan L. Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Friedman, David S. Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland3Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. SN - 2168-6173 2168-6165 SP - 845-50 ST - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the automated dosing reminder study T2 - JAMA ophthalmology TI - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the automated dosing reminder study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24831037 VL - 132 ID - 884 ER - TY - JOUR AB - Decades of epidemiologic research into open-angle glaucoma have elucidated several risk factors related in some way to the disease. As more and more risk factors are identified, however, assessing their individual and collective contributions in a particular patient is becoming increasingly complicated. To help organize our knowledge of risk in glaucoma we first review some concepts of risk and then propose a scheme that places known risk factors into categories (state of the individual, ocular anatomy and physiology, signs of disease, nonglaucoma medications, and personal behaviors) and also indicates how each factor interacts with disease (incidence, prevalence, progression, therapy.) We also describe methods for using risk factors in clinical practice and describe ways that a large and complex body of knowledge can be applied to individual patients. © 2007 Lippincott Williams & Wilkins, Inc. AD - M.V. Boland, Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Wilmer 119, Baltimore, MD 21287, United States AU - Boland, M. V. AU - Quigley, H. A. DB - Embase Medline DO - 10.1097/IJG.0b013e31806540a1 IS - 4 KW - epinephrine alcohol antiglaucoma agent antilipemic agent beta adrenergic receptor blocking agent betaxolol caffeine calcium channel blocking agent corticosteroid fat fluorouracil pilocarpine prostaglandin age alcohol consumption anatomy behavior bleeding body mass cardiovascular disease causal attribution choroid cigarette smoking classification clinical practice cornea thickness diabetes mellitus dietary intake disease course disease severity epidemiological data ethnicity exercise pseudoexfoliation eye surgery family history fat intake human hypertension incidence intraocular pressure laser surgery migraine myopia open angle glaucoma optic disk patient compliance physician attitude physiology pigmentation priority journal Raynaud phenomenon review risk assessment risk factor sex difference side effect sleep disordered breathing symptomatology systemic disease therapy effect thickness thyroid disease trabeculectomy treatment response venous pressure LA - English M3 - Review N1 - L46945541 2007-06-01 PY - 2007 SN - 1057-0829 SP - 406-418 ST - Risk factors and open-angle glaucoma: Classification and application T2 - Journal of Glaucoma TI - Risk factors and open-angle glaucoma: Classification and application UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46945541&from=export http://dx.doi.org/10.1097/IJG.0b013e31806540a1 VL - 16 ID - 3522 ER - TY - JOUR AB - Importance: During the coronavirus disease 2019 (COVID-19) pandemic, eye care professionals caring for patients with sight-threatening diseases, such as glaucoma, have had to determine whether some patient appointments could safely get postponed, weighing the risk that the patient's glaucoma could worsen during the interim vs the morbidity risk of acquiring COVID-19 while seeking ophthalmic care. They also need to prioritize appointment rescheduling during the ramp-up phase (when pandemic-associated service reductions are eased)., Objective: To describe a flexible and scalable scoring algorithm for patients with glaucoma that considers glaucoma severity and progression risk vs the presence of high-risk features for morbidity from COVID-19, using information from a large data repository., Design, Setting, and Participants: In this cross-sectional study, patients with upcoming clinic appointments for glaucoma from March 16, 2020, to April 16, 2020, at an academic institution enrolled in the Sight Outcomes Research Collaborative (SOURCE) Ophthalmology Electronic Health Record Data Repository were identified. A risk stratification tool was developed that calculated a glaucoma severity and progression risk score and a COVID-19 morbidity risk score. These scores were summed to determine a total score for each patient., Main Outcomes and Measures: Total scores and percentages of clinic appointments recommended for rescheduling., Results: Among the 1034 patients with upcoming clinic appointments for glaucoma, the mean (SD) age was 66.7 (14.6) years. There were 575 women (55.6%), 733 White individuals (71%), and 160 Black individuals (15.5%). The mean (SD) glaucoma severity and progression risk score was 4.0 (14.4) points, the mean (SD) COVID-19 morbidity risk score was 27.2 (16.1) points, and the mean (SD) total score was 31.2 (21.4) points. During pandemic-associated reductions in services, using total score thresholds of 0, 25, and 50 points would identify 970 appointments (93.8%), 668 appointments (64.6%), and 275 appointments (26.6%), respectively, for postponement and rescheduling. The algorithm-generated total scores also helped prioritize appointment rescheduling during the ramp-up phase., Conclusions and Relevance: A tool that considers the risk of underlying ophthalmic disease progression from delayed care receipt and the morbidity risk from COVID-19 exposure was developed and implemented, facilitating the triage of upcoming ophthalmic appointments. Comparable approaches for other ophthalmic and nonophthalmic care during the COVID-19 pandemic and similar crises may be created using this methodology. AU - Bommakanti, Nikhil K. AU - Zhou, Yunshu AU - Ehrlich, Joshua R. AU - Elam, Angela R. AU - John, Denise AU - Kamat, Shivani S. AU - Kelstrom, Jared AU - Newman-Casey, Paula Anne AU - Shah, Manjool M. AU - Weizer, Jennifer S. AU - Wood, Sarah D. AU - Zhang, Amy D. AU - Zhang, Jason AU - Lee, Paul P. AU - Stein, Joshua D. AU - Consortium, Source DO - https://dx.doi.org/10.1001/jamaophthalmol.2020.2974 IS - 9 KW - Aged Aged, 80 and over Ambulatory Care Facilities *Appointments and Schedules *Betacoronavirus COVID-19 *Coronavirus Infections/ep [Epidemiology] Cross-Sectional Studies Female *Glaucoma/th [Therapy] Humans Male Middle Aged Ophthalmology *Outcome Assessment, Health Care Pandemics *Pneumonia, Viral/ep [Epidemiology] SARS-CoV-2 *Triage PY - 2020 SE - Bommakanti, Nikhil K. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Bommakanti, Nikhil K. Center for Eye Policy and Innovation, University of Michigan, Ann Arbor. Zhou, Yunshu. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Zhou, Yunshu. Center for Eye Policy and Innovation, University of Michigan, Ann Arbor. Ehrlich, Joshua R. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Ehrlich, Joshua R. Center for Eye Policy and Innovation, University of Michigan, Ann Arbor. Elam, Angela R. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Elam, Angela R. Center for Eye Policy and Innovation, University of Michigan, Ann Arbor. John, Denise. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Kamat, Shivani S. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Kelstrom, Jared. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Newman-Casey, Paula Anne. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Newman-Casey, Paula Anne. Center for Eye Policy and Innovation, University of Michigan, Ann Arbor. Shah, Manjool M. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Weizer, Jennifer S. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Wood, Sarah D. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Zhang, Amy D. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Zhang, Jason. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Lee, Paul P. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Lee, Paul P. Center for Eye Policy and Innovation, University of Michigan, Ann Arbor. Stein, Joshua D. W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor. Stein, Joshua D. Center for Eye Policy and Innovation, University of Michigan, Ann Arbor. Stein, Joshua D. Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor. SN - 2168-6173 2168-6165 SP - 974-980 ST - Application of the Sight Outcomes Research Collaborative Ophthalmology Data Repository for Triaging Patients With Glaucoma and Clinic Appointments During Pandemics Such as COVID-19 T2 - JAMA ophthalmology TI - Application of the Sight Outcomes Research Collaborative Ophthalmology Data Repository for Triaging Patients With Glaucoma and Clinic Appointments During Pandemics Such as COVID-19 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med17&NEWS=N&AN=32678424 VL - 138 ID - 266 ER - TY - JOUR AB - PRECIS: Targeted educational interventions for physicians may be useful in increasing adoption of selective laser trabeculoplasty (SLT) as first line therapy for the treatment of glaucoma., PURPOSE: SLT is a safe and effective first line treatment for glaucoma, however, it is underutilized. To evaluate barriers for the widespread adoption of this procedure, we assessed the beliefs and attitudes of ophthalmologists. We developed an educational intervention directed to physicians to increase the consideration of SLT earlier in the glaucoma treatment paradigm., SUBJECTS AND METHODS: In this prospective study, an online survey and educational slide presentation was sent to a group of comprehensive ophthalmologists, ophthalmology residents, and glaucoma specialists. Subjects were asked to respond to questions regarding their beliefs and attitudes towards SLT before and after watching the educational slide presentation., RESULTS: A total of 53 subjects were enrolled. Before watching the slide presentation, 85% of subjects stated they offer SLT to newly diagnosed patients, although only 28% preferred it over medications. While 52% of physicians reported between 0% and 10% of their newly diagnosed patients receive laser therapy, 47% said they would use it as a first line therapy for all or most newly diagnosed glaucoma patients. Most subjects (94%) stated the educational slide presentation convinced them that SLT is appropriate as a first line therapy for treatment of open angle glaucoma., CONCLUSIONS: A better understanding of the barriers for utilizing SLT as a first line therapy provides valuable information to help increase the adoption of this safe and effective procedure. A targeted educational intervention may improve acceptance of SLT as first line therapy for open angle glaucoma. AU - Bonafede, Lucas AU - Sanvicente, Carina T. AU - Hark, Lisa A. AU - Tran, Judie AU - Tran, Evelyn AU - Zhang, Qiang AU - Costello, Rose AU - Myers, Jonathan S. AU - Katz, L. Jay DO - https://dx.doi.org/10.1097/IJG.0000000000001615 IS - 10 KW - Attitude of Health Personnel Female Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] *Health Knowledge, Attitudes, Practice Health Surveys Humans Intraocular Pressure/ph [Physiology] *Laser Therapy/mt [Methods] *Lasers, Solid-State/tu [Therapeutic Use] Male Middle Aged *Ophthalmologists/px [Psychology] Prospective Studies Surveys and Questionnaires *Trabeculectomy/mt [Methods] Treatment Outcome PY - 2020 SE - Bonafede, Lucas. Glaucoma Research Center. Sanvicente, Carina T. Glaucoma Research Center. Hark, Lisa A. Glaucoma Research Center. Hark, Lisa A. Department of Ophthalmology, Columbia University Irving Medical Center, New York City, NY. Tran, Judie. Glaucoma Research Center. Tran, Evelyn. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. Zhang, Qiang. Biostatistics Consulting Core, Vickie and Jack Farber Vision Research Center, Wills Eye Hospital. Zhang, Qiang. Thomas Jefferson University. Costello, Rose. Biostatistics Consulting Core, Vickie and Jack Farber Vision Research Center, Wills Eye Hospital. Myers, Jonathan S. Glaucoma Research Center. Katz, L Jay. Glaucoma Research Center. SN - 1536-481X 1057-0829 SP - 851-856 ST - Beliefs and Attitudes of Ophthalmologists Regarding SLT as First Line Therapy for Glaucoma T2 - Journal of glaucoma TI - Beliefs and Attitudes of Ophthalmologists Regarding SLT as First Line Therapy for Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32740509 VL - 29 ID - 238 ER - TY - JOUR AB - PURPOSE: To evaluate the lowering of intraocular pressure (IOP) one year after SLT and to assess if differences are related to number of pre-SLT topical treatments in ocular hypertension (OHT) and primary open angle glaucoma (POAG) patients., METHODS: Retrospective review of 106 eyes of 13 OHT and 93 POAG patients treated by SLT for insufficient IOP control, allergy, discomfort or non-compliance to glaucoma medications, excluding patients with less than 1 year of follow-up after SLT. IOP was measured by applanation before and at 1, 6 and 12 months after SLT., RESULTS: Hundred and six eyes untreated (n=13), or treated with one (n=25), two (n=40) or three or more (n=28) glaucoma medications were included. Mean IOP decreased from 19.4+/-3.6mmHg preoperatively to 15.7+/-3.1mmHg at 12 months, which corresponds to an average decrease of 18.8%. At 1 year, 62.2% (n=66) were responders (IOP reduction>=3mmHg): 92.3% without medications (n=12), 68% with one (n=17), 57.5% with two (n=23) and 50% with three or more medications (n=14). Their average IOP decreased from 20.7+/-3.4 to 15.2+/-2.9mmHg (26.6%), respectively from 20.8+/-2.6 to 15.8+/-3.2 (25%) without medications, 20.6+/-3.2 to 14.9+/-3.7 (27.3%) with one, 20.8+/-4.1 to 15.5+/-3.3 (25.1%) with two and 20.7+/-3.2 to 14.4+/-2.4mmHg (29.7%) with three medications., CONCLUSIONS: The number of responders seems to be greater in OHT and POAG patients without or with few glaucoma medications, but the IOP reduction seems to be similar regardless of the number of glaucoma medications. Copyright © 2016 Elsevier Masson SAS. All rights reserved. AU - Bonnel, S. AU - Fenolland, J. R. AU - Marill, A. F. AU - Gaillard, R. AU - Rosenberg, R. AU - Theillac, V. AU - Mazharian, A. AU - Giraud, J. M. AU - Renard, J. P. DO - https://dx.doi.org/10.1016/j.jfo.2016.11.003 IS - 1 KW - Administration, Topical *Antihypertensive Agents/ad [Administration & Dosage] Combined Modality Therapy *Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] Humans *Intraocular Pressure/de [Drug Effects] *Laser Therapy/mt [Methods] *Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/pp [Physiopathology] *Ocular Hypertension/su [Surgery] Preoperative Care/mt [Methods] Preoperative Period Retrospective Studies *Trabeculectomy/mt [Methods] Treatment Outcome PY - 2017 SE - Bonnel, S. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Electronic address: sambonnelbasely@hotmail.com. Fenolland, J-R. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Marill, A-F. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Gaillard, R. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Rosenberg, R. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Theillac, V. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Mazharian, A. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Giraud, J-M. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. Renard, J-P. Hopital d'instruction des armees du Val-de-Grace, 75005 Paris, France. SN - 1773-0597 0181-5512 SP - 22-28 ST - [Selective laser trabeculoplasty: Effect of number of preoperative topical glaucoma medications on pressure lowering and success rate] T2 - Trabeculoplastie selective au laser : effet du nombre de traitements antiglaucomateux topiques preoperatoires sur la baisse pressionnelle et le taux de succes. TI - [Selective laser trabeculoplasty: Effect of number of preoperative topical glaucoma medications on pressure lowering and success rate] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28081918 VL - 40 Y2 - 20170109// ID - 544 ER - TY - JOUR AB - Purpose To evaluate the lowering of intraocular pressure (IOP) one year after SLT and to assess if differences are related to number of pre-SLT topical treatments in ocular hypertension (OHT) and primary open angle glaucoma (POAG) patients. Methods Retrospective review of 106 eyes of 13 OHT and 93 POAG patients treated by SLT for insufficient IOP control, allergy, discomfort or non-compliance to glaucoma medications, excluding patients with less than 1 year of follow-up after SLT. IOP was measured by applanation before and at 1, 6 and 12 months after SLT. Results Hundred and six eyes untreated (n = 13), or treated with one (n = 25), two (n = 40) or three or more (n = 28) glaucoma medications were included. Mean IOP decreased from 19.4 ± 3.6 mmHg preoperatively to 15.7 ± 3.1 mmHg at 12 months, which corresponds to an average decrease of 18.8%. At 1 year, 62.2% (n = 66) were responders (IOP reduction ≥ 3 mmHg): 92.3% without medications (n = 12), 68% with one (n = 17), 57.5% with two (n = 23) and 50% with three or more medications (n = 14). Their average IOP decreased from 20.7 ± 3.4 to 15.2 ± 2.9 mmHg (26.6%), respectively from 20.8 ± 2.6 to 15.8 ± 3.2 (25%) without medications, 20.6 ± 3.2 to 14.9 ± 3.7 (27.3%) with one, 20.8 ± 4.1 to 15.5 ± 3.3 (25.1%) with two and 20.7 ± 3.2 to 14.4 ± 2.4 mmHg (29.7%) with three medications. Conclusions The number of responders seems to be greater in OHT and POAG patients without or with few glaucoma medications, but the IOP reduction seems to be similar regardless of the number of glaucoma medications. © 2016 Elsevier Masson SAS AD - Hôpital d'instruction des armées du Val-de-Grâce, Paris, 75005, France AU - Bonnel, S. AU - Fenolland, J. R. AU - Marill, A. F. AU - Gaillard, R. AU - Rosenberg, R. AU - Theillac, V. AU - Mazharian, A. AU - Giraud, J. M. AU - Renard, J. P. DB - Scopus DO - 10.1016/j.jfo.2016.11.003 IS - 1 KW - Intraocular pressure Ocular hypertension Primary open angle glaucoma Trabeculoplasty M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2017 SP - 22-28 ST - Trabéculoplastie sélective au laser : effet du nombre de traitements antiglaucomateux topiques préopératoires sur la baisse pressionnelle et le taux de succès T2 - Journal Francais d'Ophtalmologie TI - Selective laser trabeculoplasty: Effect of number of preoperative topical glaucoma medications on pressure lowering and success rate UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009289995&doi=10.1016%2fj.jfo.2016.11.003&partnerID=40&md5=1f5861bc7abb6c204555d04cb48207c5 VL - 40 ID - 5625 ER - TY - JOUR AB - Latanoprost is a PGF2α analogue able to reduce intraocular pressure (IOP) in glaucomatous eyes. We valued many multicentric randomized, double- blind placebo studies in which latanoprost 0.005% was administered once a day while timolol 0.5% was administered twice a day. Both these drugs reduced effectively IOP but latanoprost 0.005% administered at 8 P.M. seems to be more effective than timolol 0.5%. At ocular level latanoprost caused a slight increase in conjunctival hyperemia well tolerable, and an iris increased pigmentation in mixed colour iris without clinical diseases. Consequently latanoprost can be considered a useful drug in the glaucoma therapy so as timolol, but with no contraindications and a better compliance of patients. AD - D. Bonsanto, Clinica Oculistica II, Policlinico S. Orsola, Bologna, Italy AU - Bonsanto, D. DB - Embase IS - 3-4 KW - latanoprost timolol article clinical trial conjunctivitis controlled study double blind procedure drug efficacy drug safety drug tolerability glaucoma human intraocular pressure major clinical study multicenter study patient compliance randomized controlled trial LA - Italian M3 - Article N1 - L30007030 2000-01-08 PY - 1999 SN - 0003-4665 SP - 89-94 ST - Glaucoma medical therapy: A comparison of timolol and latanoprost T2 - Annali di Ottalmologia e Clinica Oculistica TI - Glaucoma medical therapy: A comparison of timolol and latanoprost UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30007030&from=export VL - 125 ID - 3917 ER - TY - JOUR AB - (ortho-k) patients, and the levels of contamination of their lenses and lens accessories, and to correlate compliance with levels of contamination. Method Normal ocular flora of 41 subjects was determined twice before commencing ortho-k lens wear by culture of the lower conjunctiva. Further specimens were collected on six follow-up visits after beginning lens wear, as were samples from their lenses, cases, and suction holders. A questionnaire on lens care was administered after the fifth visit. Results. Three subjects provided conjunctival samples yielding Staphylococcus aureus on one occasion before lens wear, one being positive for this organism after beginning lens wear. Of 38 subjects yielding no growth or only normal eye flora before use, 28 remained free of ocular pathogens after beginning lens wear. Only four subjects had positive cultures on more than one occasion after lens wear. There was no significant difference in isolation levels of pathogens with lens wear (p = 0.423). Lens culture of 54% of subjects yielded no growth or normal flora only; lenses of 16 subjects yielded potential pathogens, including three subjects contaminated on more than one occasion. Lens isolates did not match the organisms transiently colonizing the eye. Lens case, the most frequently contaminated item, was associated with lens contamination (p < 0.001), the same organism being isolated from both items in 11 subjects. Lens suction holder was less frequently contaminated. Neither lens case nor suction holder contamination was associated with isolates from the eye. Reported good compliance correlated with lack of contamination in all but one subject. The most frequent breaches in the lens care protocol were failure to clean, disinfect, and replace the lens case. Conclusion. Ocular flora was not altered by ortho-k lens wear over an extended period, and patients remained free of infection. Contaminants identified were generally of a transient nature. Most patients had significant contamination of at least one item, most frequently the lens case. Lens case isolates were significantly associated with those from the lens. The majority of patients reporting good compliance had low or no contamination of their lenses and accessories. AN - WOS:000230320800003 AU - Boost, M. V. AU - Cho, P. DA - JUN DO - 10.1097/01.opx.0000168587.72893.ec IS - 6 PY - 2005 SN - 1040-5488 1538-9235 SP - 451-458 ST - Microbial flora of tears of orthokeratology patients, and microbial contamination of contact lenses and contact lens accessories T2 - OPTOMETRY AND VISION SCIENCE TI - Microbial flora of tears of orthokeratology patients, and microbial contamination of contact lenses and contact lens accessories VL - 82 ID - 5879 ER - TY - JOUR AB - PURPOSE: To evaluate to what extent contemporary glaucoma abstracts offer complete information and to suggest a new manner of pressure results reporting., MATERIALS, METHODS, AND RESULTS: Most of the 36 relevant surgical glaucoma abstracts found in one issue of International Glaucoma Review contain insufficient data-supported statements. Such abstracts cannot offer a clear picture of the study essence if economic, linguistic, or political barriers prevent access to the full text. In order to enrich abstract content and to avoid typographic space waste, a formula is suggested to provide, in one single line of symbols and figures, all the necessary data for statistical interpretation at two evolution moments: the first significative control (6 months) and the final one., CONCLUSION: The current manner of results reporting in surgical glaucoma abstracts is subject to too little standardization, allowing insufficiently data-supported statements. Abstracts, especially those printed in small-circulation language journals, should be conceived and standardized in such a manner that any abstract review reader is capable of grasping the essence of the study at first glance. The suggested manner of reporting results would bring satisfaction to all areas of the process. Publishers would save typographic space, readers would find all the necessary data for statistical analysis and comparison with other studies, and authors would be convinced that the essence of their work would penetrate in spite of any economic, linguistic, or political barriers. AU - Bordeianu, Constantin-Dan AU - Ticu, Cristina-Eugenia DO - https://dx.doi.org/10.2147/OPTH.S13674 PY - 2012 SE - Bordeianu, Constantin-Dan. Department of Ophthalmology, Emergency Hospital, Ploiesti, Romania. SN - 1177-5483 1177-5467 SP - 23-31 ST - A new manner of reporting pressure results after glaucoma surgery T2 - Clinical ophthalmology (Auckland, N.Z.) TI - A new manner of reporting pressure results after glaucoma surgery UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=22259232 VL - 6 Y2 - 20111230// ID - 1193 ER - TY - JOUR AB - Gene therapy of the eye has a high potential of becoming the preferred treatment of a number of eye diseases. Because of its easy accessibility, all the tissues of the eye can be reached and genetically manipulated with nowadays standard gene delivery technologies. Gene therapy offers the possibility to do both, correct a genetic defect by replacing the mutated or missing gene and that of using genes as drugs. Gene drugs would be more specific and would have a longer duration of action and less toxicity than conventional drugs. Examples of both applications are beginning to emerge. Using gene replacement, vision has been restored in several patients of Leber congenital amaurosis (Maguire et al., 2009). Some gene drugs, such as siRNA, are currently in clinical trials to silence angiogenic factors in macular degeneration (Campa and Harding, 2011). In this manuscript we first give a short overview of the basics of gene therapy in the eye and then review the ongoing preclinical studies in our laboratory for the gene-drug treatment of steroid-induced ocular hypertension. AU - Borras, Teresa DO - https://dx.doi.org/10.1016/j.sjopt.2011.07.005 IS - 4 PY - 2011 SE - Borras, Teresa. Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. SN - 1319-4534 SP - 353-62 ST - Gene therapy strategies in glaucoma and application for steroid-induced hypertension T2 - Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society TI - Gene therapy strategies in glaucoma and application for steroid-induced hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=23960949 VL - 25 Y2 - 20110508// ID - 1194 ER - TY - JOUR AB - Treatment of diseases with gene therapy is advancing rapidly. The use of gene therapy has expanded from the original concept of re-placing the mutated gene causing the disease to the use of genes to con-trol nonphysiological levels of expression or to modify pathways known to affect the disease. Genes offer numerous advantages over conventional drugs. They have longer duration of action and are more specific. Genes can be delivered to the target site by naked DNA, cells, nonviral, and viral vectors. The enormous progress of the past decade in molecular bi-ology and delivery systems has provided ways for targeting genes to the intended cell/tissue and safe, long-term vectors. The eye is an ideal organ for gene therapy. It is easily accessible and it is an immune-privileged site. Currently, there are clinical trials for diseases affecting practically every tissue of the eye, including those to restore vision in patients with Leber congenital amaurosis. However, the number of eye trials compared with those for systemic diseases is quite low (1.8%). Nevertheless, judg-ing by the vast amount of ongoing preclinical studies, it is expected that such number will increase considerably in the near future. One area of great need for eye gene therapy is glaucoma, where a long-term gene drug would eliminate daily applications and compliance issues. Here, we review the current state of gene therapy for glaucoma and the possibilities for treating the trabecular meshwork to lower intraocular pressure and the retinal ganglion cells to protect them from neurodegeneration. Copyright© 2017 Asia-Pacific Academy of Ophthalmology. AU - Borras, Teresa DO - https://dx.doi.org/10.22608/APO.2016126 IS - 1 KW - Clinical Trials as Topic Gene Expression Regulation Gene Transfer Techniques *Genetic Therapy/mt [Methods] Glaucoma/ge [Genetics] *Glaucoma/th [Therapy] Humans Neurodegenerative Diseases/th [Therapy] Ocular Hypertension/th [Therapy] Retinal Degeneration/th [Therapy] PY - 2017 SE - Borras, Teresa. Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. SN - 2162-0989 SP - 80-93 ST - The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs T2 - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) TI - The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28161916 VL - 6 ID - 539 ER - TY - JOUR AU - Borrero, Patricia AU - Techer-Arbez, Danielle AU - Revol, Carole AU - Camp, Charlene AU - Rademacher, Catherine IS - 8 KW - Glaucoma/di [Diagnosis] *Glaucoma/nu [Nursing] Glaucoma/th [Therapy] Humans Nursing Diagnosis Patient Compliance Patient Education as Topic *Referral and Consultation Switzerland PY - 2016 SN - 0253-0465 SP - 60-63 ST - La consultation d'enseignement therapeutique T2 - Krankenpflege. Soins infirmiers TI - La consultation d'enseignement therapeutique UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=30398748 VL - 109 ID - 643 ER - TY - JOUR AB - Urticaria is a common disorder with diverse clinical presentations. Correct recognition of the different clinical patterns promotes more effective treatment. Management involves treatment of any identifiable external causes, including infection, avoidance drug, food and physical triggers and the appropriate use of pharmacological therapies. These can be divided into first-, second- and third-line approaches. The-choice of treatment will be influenced by many factors, including drug licensing, safety, pattern of disease, disease severity, pharmacoeconomic considerations and patient preference. H1 antihistamines are the mainstay of treatment of most patterns of urticaria and are effective in the majority of patients with mast cell-mediated disease. Second-generation antihistamines have a better therapeutic index and improved pharmacodynamic properties compared with older' classic' antihistamines and should be prescribed preferentially for chronic urticaria. Patients who are unresponsive to H1 antihistamines at full dose may require short-term treatment with oral corticosteroids but their long-term use for urticaria should be avoided whenever possible on account of the risk of serious adverse effects. Antileukotrienes and alternative second-line agents, prescribed off licence, can be helpful for patients who respond poorly to antihistamines when taken in conjunction but a better evidence base is needed to guide prescribing. Third-line immunosuppressive therapies can be considered for debilitating urticaria, especially for patients with corticosteroid-dependent chronic disease, and may have some potential to modify the natural course of the illness. Possible new therapeutic approaches on the horizon include new H1 antihistamines, H4 receptor antagonists, a histidine decarboxylase inhibitor under development and biological agents that target histamine-releasing autoantibody production and function. © 2007 Future Drugs Ltd. AD - E. Borzova, Norfolk and Norwich University Hospital, Dermatology Department, Norwich, Norfolk NR4 7UY, United Kingdom AU - Borzova, E. AU - Grattan, C. C1 - aspirin DB - Embase DO - 10.1586/17469872.2.3.317 IS - 3 KW - acetylsalicylic acid acrivastine antihistaminic agent antithyroid agent autoantibody biological product cetirizine chlorpheniramine codeine corticosteroid cyclosporine decarboxylase inhibitor desloratadine dipeptidyl carboxypeptidase inhibitor diphenhydramine ebastine fexofenadine histamine H1 receptor antagonist histamine H4 receptor histidine decarboxylase hydroxyzine leukotriene receptor blocking agent levocetirizine levothyroxine loratadine menthol mizolastine nonsteroid antiinflammatory agent penicillin G placebo unindexed drug add on therapy agitation angioneurotic edema antibody production anticholinergic effect aseptic necrosis blood brain barrier blurred vision car driving clinical feature clinical trial cognitive defect convulsion Cushingoid syndrome diabetes mellitus diagnostic accuracy disease association disease course disease severity drug absorption drug blood level drug dependence drug distribution drug dose comparison drug dose increase drug dose reduction drug efficacy drug half life drug megadose drug metabolism drug penetration drug protein binding drug safety drug use evidence based medicine heart palpitation histamine release human hyperactivity hypertension hypothyroidism increased appetite infection intraocular hypertension irritability licensing long term care mast cell medical decision making monotherapy mydriasis nervousness optimal drug dose patient compliance performance pharmacoeconomics prescription priority journal protein function psychomotor performance recommended drug dose respiration depression review sedation short course therapy side effect sleep disordered breathing thyrotoxicosis time to maximum plasma concentration urine retention urticaria body weight gain xerostomia aspirin LA - English M3 - Review N1 - L46916275 2007-06-01 PY - 2007 SN - 1746-9872 SP - 317-334 ST - Urticaria: Current and future treatments T2 - Expert Review of Dermatology TI - Urticaria: Current and future treatments UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46916275&from=export http://dx.doi.org/10.1586/17469872.2.3.317 http://www.future-drugs.com/doi/pdf/10.1586/17469872.2.3.317 VL - 2 ID - 3521 ER - TY - JOUR AB - Presents an outline of a local pilot project on disease management in Ollerton, Nottinghamshire, UK. Disease management has been a staff college exercise at a national level: the alliance for health in Ollerton involved a purchaser, an acute trust and a practice. Secondary care expertise was used earlier in the disease process to identify patients and to treat them with a more continuous care programme. Disease management began with gastric illness--in examination, review and treatment for H Pylori eradication; extensions are planned to glaucoma and epilepsy. The project involved co-ordinated investment in building extensions, staff skills and records. AU - Bosanquet, N. IS - 2-3 KW - Asthma/th [Therapy] Diabetes Mellitus/th [Therapy] *Disease Management Glaucoma/th [Therapy] Health Care Coalitions/og [Organization & Administration] Health Care Rationing Humans Medical Audit Medical Records/st [Standards] Patient Selection Pilot Projects State Medicine Stomach Diseases/th [Therapy] United Kingdom PY - 1997 SE - Bosanquet, N. Imperial College, University of London, UK. SN - 1366-0756 SP - 73-5 ST - Disease management: from sand table exercise to local achievement T2 - International journal of health care quality assurance incorporating Leadership in health services TI - Disease management: from sand table exercise to local achievement UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10169237 VL - 10 ID - 2003 ER - TY - JOUR AB - We encountered a patient with Acanthamoeba keratitis whose contact lens care solution contained numerous trophozoites and cysts admixed with Xanthomonas maltophilia organisms, many of which were adherent to the trophozoite surface and internalized within endocytic vacuoles. Because of this finding, we investigated the role of bacterial cocontaminants in contact lens care systems as substrates for the growth of Acanthamoeba spp. Individual cocultivation of Acanthamoeba castellanii and A. polyphaga with X. maltophilia, Flavobacterium breve, and Pseudomonas paucimobilis showed better enhancement (1.5x) of ameba growth after 96 h than that obtained in the presence of Staphylococcus aureus, S. epidermidis, and Escherichia coli, the standard cocultivation species used for isolation of amebae from clinical specimens. Our data suggest that contamination of contact lens care systems with Acanthamoeba spp. and a bacterial species capable of supporting amebic growth may be the first step in the pathogenesis of ameba-induced keratitis by the provision of large inocula of amebae. AU - Bottone, E. J. AU - Madayag, R. M. AU - Qureshi, M. N. IS - 9 KW - *Acanthamoeba/gd [Growth & Development] *Acanthamoeba Keratitis/et [Etiology] Animals Bacteria *Contact Lenses/ae [Adverse Effects] Culture Media Humans PY - 1992 SE - Bottone, E J. Clinical Microbiology Laboratories, Mount Sinai Hospital, New York, New York 10029. SN - 0095-1137 SP - 2447-50 ST - Acanthamoeba keratitis: synergy between amebic and bacterial cocontaminants in contact lens care systems as a prelude to infection T2 - Journal of clinical microbiology TI - Acanthamoeba keratitis: synergy between amebic and bacterial cocontaminants in contact lens care systems as a prelude to infection UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1401013 VL - 30 ID - 2051 ER - TY - JOUR AB - Objective: To assess real-world results and the impact on a hospital service corridor for screening for DR through an urban community teleophthalmology service. Methods: Retrospective analysis at the hospital service corridor of 148 diabetics referred to it following DR teleophthalmology screening of 1185 type II diabetics. Results: Of the screened diabetics, 87.4% (n = 1036) were exempted from face-to-face clinical examination (FFCE) in a traditional hospital eye care pathway and continued monitoring through teleophthalmology under a watch-and-wait attitude, while 12.5% (n = 148) were recommended for an FFCE. The FFCEs revealed that significant DR was present in 48.2% or in 5.6% of this screened diabetic population. Reasons for referral were findings of significant DR in 40.5%, of which diabetic macular edema (DME) represented 86.6%, other incidental significant sight-threatening findings represented 32.4% (4% of the screened diabetics), and insufficient image quality was obtained for the other 27.0%. Optical coherence tomography (OCT) imaging at FFCE confirmed DME in 26.4% and led to treatment. Patients referred for insufficient image quality showed significant pathology in 90.2%, of whom 63.4% underwent further monitoring or treatment. The readers requested the FFCEs for 148 patients within 1 month of the reading in 19.6%, 3 months in 26.3%, 4–12 months in 47.3%, and 12 months in 6.7% over the 34 months of the study. Compliance with FFCEs was 91.9%, absolute in 78.4% and relative in 21.5%. The availability of OCT at the imaging site would have impacted 4.5% of the screened diabetics by enabling teleophthalmology monitoring of 91.6%, identifying just-in-time interventions for DME treatments in 26.4% and reducing by 25% the need for referral of OCT-negative reader-identified DME. Conclusion: The FFCEs generated at the hospital service corridor by an urban community DR screening teleophthalmology project did not impact negatively on its services; moreover, the service corridor was exempted from providing FFCEs to 87.4% of the diabetic population it serves. This study may help provide cost-efficiency indications for a screening protocol that would include OCT availability at the imaging site and measure its positive effects. While DR of which DME was the main cause of referral for FFCE, incidental significant sight-threatening findings were significant and approached DR as a cause of referral; this supports the recommendation of continued human intervention in DR teleophthalmology screening at this time and for this population, until automatic computer-aided diagnosis systems can recognise biomarkers associated with other significant fundus diseases. As a secondary gain this project benefited individuals in need of care who were lost to the traditional eye care pathway. Good compliance with the follow-up FFCE further supports teleophthalmology in its effort to provide better access to DR screening. AD - M.C. Boucher, CUO Maisonneuve-Rosemont, 5415 Boulevard de l'Assomption, Montréal, Québec, Canada AU - Boucher, M. C. AU - El Yamani, M. E. M. DB - Embase Medline DO - 10.1016/j.jcjo.2018.06.008 IS - 3 KW - vasculotropin inhibitor adult age related macular degeneration article capsulotomy cataract clinical examination diabetic macular edema diabetic patient diabetic retinopathy epiretinal membrane eye care eye examination glaucoma hospital service human hypertension retinopathy image enhancement image quality insulin dependent diabetes mellitus iridotomy macular degeneration major clinical study microaneurysm non insulin dependent diabetes mellitus nonproliferative diabetic retinopathy ophthalmology optical coherence tomography population research proliferative diabetic retinopathy pseudophakia retina maculopathy retrospective study screening test telemedicine urban population visual acuity young adult LA - English M3 - Article N1 - L2001067624 2018-10-05 2019-05-29 PY - 2019 SN - 1715-3360 0008-4182 SP - 359-366 ST - Urban diabetic retinopathy teleophthalmology screening: results and impact at the service corridor T2 - Canadian Journal of Ophthalmology TI - Urban diabetic retinopathy teleophthalmology screening: results and impact at the service corridor UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001067624&from=export http://dx.doi.org/10.1016/j.jcjo.2018.06.008 VL - 54 ID - 2503 ER - TY - JOUR AB - Background: Although many diabetic retinopathy (DR) tele-screening projects have shown effectiveness for DR, timely follow-up care after screening is essential to achieve the expected visual benefits of screening. Objective: To better understand the possible factors of non-compliance to follow-up care in diabetics after tele-screening for DR. Method: This cross-sectional retrospective descriptive study analyses the data of 148 diabetics referred to follow-up care following screening of 1185 diabetics through an urban community-based DR Teleophthalmology Project aimed at Type 2 diabetes. A telephone survey was conducted to assess the screening program appreciation and the sociodemographic characteristics of that population. Results: This study achieved a 91,9% (n=136) compliance rate to follow-up care. Female sex, type 2 diabetes, lower general and DR education, telephone unreachability, age less than 60 years, knowledge of a visually impaired acquaintance and more severe DR were more prevalent in non-compliant patients. Age, ethnicity, economic status, level of precariousness, distance from home to the screening/examination sites, and previous adherence to the DR screening guidelines were similar in both compliants and noncompliants. A high satisfaction score (4,8/5, n=96) to the tele-screening program was measured. Conclusion: This study is applicable to other screening programs and suggests that an increase in the number of recall letters and a greater flexibility in the organization of follow-up care appointments as well as the addition of multilingual members to the recalling team may have further improved compliance to follow-up care. It measures a high level of satisfaction provided by this model of urban teleophthalmology screening. AD - M.C. Boucher, Department of Ophthalmology, Université de Montréal, 5415 Assumption Blvd, Montreal, Que., Canada AU - Boucher, M. C. AU - Ouazani Chahdi, H. AU - El Yamani, M. E. M. DB - Embase Medline DO - 10.1016/j.jcjo.2019.01.001 IS - 1 KW - adult article blood vessel occlusion cross-sectional study demography diabetic retinopathy disease duration economic status ethnicity female follow up glaucoma human insulin dependent diabetes mellitus macular edema major clinical study male non insulin dependent diabetes mellitus nonproliferative diabetic retinopathy patient education practice guideline retrospective study screening telephone interview urban area urban population visual acuity LA - English M3 - Article N1 - L2001603059 2019-02-26 PY - 2020 SN - 1715-3360 0008-4182 SP - 2-7 ST - Compliance to follow-up care after urban diabetic retinopathy tele-screening T2 - Canadian Journal of Ophthalmology TI - Compliance to follow-up care after urban diabetic retinopathy tele-screening UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001603059&from=export http://dx.doi.org/10.1016/j.jcjo.2019.01.001 VL - 55 ID - 2432 ER - TY - JOUR AB - PURPOSE: To evaluate the efficacy of functional amblyopia treatment in children having undergone surgery for primary infantile glaucoma., PATIENTS AND METHOD: Parameters studied included: age at surgery, current age, visual acuity (VA) (initial and most recent acuity), refraction, alignment, adherence to amblyopia treatment, condition of the cornea (Haab striae, stromal scarring, pachymetry, cell count), condition of the optic disc (cupping, RNFL OCT) and intraocular pressure. Pearson's p-value was fixed at 5%., RESULTS: Retrospective study of 29 eyes; average age at surgery was four months, mean follow-up was 11.2 years. Initial VA averaged 4.5 over 10, most recent VA 7 over 10, i.e. a gain of 2.3 over 10. Refraction revealed 37.9% myopia, 10.3% emmetropia, 48.2% hyperopia and an average astigmatism of 2.14 D. A negative correlation was found between astigmatism and most recent VA (rho=-0.7; P<0.001). A positive correlation was found between the quality of the occlusion therapy and the recovery of VA with a gain of 3.2 over 10 (P=0.001). A strong positive correlation was found between the cylinder power and the number of Haab striae [rho 0.702, P<0.0001]; final VA is best when the striae show no organized scar formation (P=0.04)., CONCLUSION: This study underlines the necessity of prolonged treatment of functional amblyopia in primary infantile glaucoma for the best possible visual rehabilitation. Copyright A© 2012 Elsevier Masson SAS. All rights reserved. AU - Boulze-Pankert, M. AU - Zanin, E. AU - Matonti, F. AU - Benso, C. AU - Toesca, E. AU - Denis, D. DO - https://dx.doi.org/10.1016/j.jfo.2011.08.008 IS - 3 KW - Age of Onset Amblyopia/ep [Epidemiology] Amblyopia/et [Etiology] Amblyopia/pp [Physiopathology] *Amblyopia/rh [Rehabilitation] Child Child, Preschool Female Follow-Up Studies Glaucoma/ep [Epidemiology] Glaucoma/pp [Physiopathology] Glaucoma/rh [Rehabilitation] *Glaucoma/su [Surgery] Humans Infant Male *Ophthalmologic Surgical Procedures/rh [Rehabilitation] Postoperative Period Recovery of Function/ph [Physiology] Retrospective Studies Time Factors Visual Acuity/ph [Physiology] PY - 2012 SE - Boulze-Pankert, M. Service d'ophtalmologie, hopital Nord, CHU, chemin des Bourrely, 13015 Marseille, France. SN - 1773-0597 0181-5512 SP - 181-6 ST - [Post-operative rehabilitation of functional amblyopia in primary infantile glaucoma: 11 year-follow-up] T2 - Reeducation de la part fonctionnelle de l'amblyopie dans le glaucome primitif infantile opere, recul de 11ans. TI - [Post-operative rehabilitation of functional amblyopia in primary infantile glaucoma: 11 year-follow-up] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22284858 VL - 35 Y2 - 20120128// ID - 1151 ER - TY - JOUR AB - Purpose: To evaluate the efficacy of functional amblyopia treatment in children having undergone surgery for primary infantile glaucoma. Patients and method: Parameters studied included: age at surgery, current age, visual acuity (VA) (initial and most recent acuity), refraction, alignment, adherence to amblyopia treatment, condition of the cornea (Haab striae, stromal scarring, pachymetry, cell count), condition of the optic disc (cupping, RNFL OCT) and intraocular pressure. Pearson's p-value was fixed at 5%. Results: Retrospective study of 29 eyes; average age at surgery was four months, mean follow-up was 11.2 years. Initial VA averaged 4.5 over 10, most recent VA 7 over 10, i.e. a gain of 2.3 over 10. Refraction revealed 37.9% myopia, 10.3% emmetropia, 48.2% hyperopia and an average astigmatism of 2.14 D. A negative correlation was found between astigmatism and most recent VA (rho = -0.7; P < 0.001). A positive correlation was found between the quality of the occlusion therapy and the recovery of VA with a gain of 3.2 over 10 (P = 0.001). A strong positive correlation was found between the cylinder power and the number of Haab striae [rho 0.702, P <0.0001]; final VA is best when the striae show no organized scar formation (P = 0.04). Conclusion: This study underlines the necessity of prolonged treatment of functional amblyopia in primary infantile glaucoma for the best possible visual rehabilitation. © 2011 Elsevier Masson SAS. Tous droits réserv́s. AD - Service D'ophtalmologie, Hôpital Nord, CHU, chemin des Bourrely, 13015 Marseille, France AU - Boulze-Pankert, M. AU - Zanin, É AU - Matonti, F. AU - Benso, C. AU - Toesca, É AU - Denis, D. DB - Scopus DO - 10.1016/j.jfo.2011.08.008 IS - 3 KW - Amblyopia Haab Primary infantile glaucoma M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2012 SP - 181-186 ST - Rééducation de la part fonctionnelle de l'amblyopie dans le glaucome primitif infantile opéré, recul de 11 ans T2 - Journal Francais d'Ophtalmologie TI - Post-operative rehabilitation of functional amblyopia in primary infantile glaucoma: 11 year-follow-up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858702500&doi=10.1016%2fj.jfo.2011.08.008&partnerID=40&md5=d3fde6a3300a3fe8a7670f6bbaf8c02d VL - 35 ID - 5636 ER - TY - JOUR AB - Patient compliance with treatment is an important factor in chronic diseases such as primary open-angle glaucoma (POAG). Among the 404 glaucoma patients included in our study in the department of Marne (France), 341 patients responded by completing an anonymous questionnaire at home in which the psychological effect of the illness, their knowledge about it, compliance with treatment and their relationships with the physician were explored. Sixty-eight per cent of these patients confirmed strict compliance with the treatment prescribed; this rate does not vary with respect to either the ophthalmologist (p = 0.57), or the duration of treatment (p = 0.42). Half of the remaining patients only alter the hours of their treatment and 6% forget to instill the eyedrops on certain days. According to our survey, the principal causes of poor compliance are forgetfulness, time constraints with other duties, poor doctor-patient relationship and lack of sufficient knowledge about the disease and its treatment. The majority of patients (59%) are minimally disturbed by the treatment; 2/3 of the subjects do not feel any change in their moral whereas 15% are more depressed or weakened since the time the illness was discovered. Fifty-six per cent of them observed little or no change in their vision; 32% believe to have a moderate or considerable repercussion and 6% claim a very severe visual deterioration. Generally, patients appear to have a positive attitude towards their illness and do not try to deny it. Thirty-eight per cent of them consider it as a handicap which they can overcome and 42% have either no particular opinion or take it as a minor event. AU - Bour, T. AU - Blanchard, F. AU - Segal, A. IS - 6-7 KW - Activities of Daily Living France Glaucoma, Open-Angle/ep [Epidemiology] Glaucoma, Open-Angle/px [Psychology] *Glaucoma, Open-Angle/th [Therapy] Humans *Patient Compliance Physician-Patient Relations Surveys and Questionnaires PY - 1993 SE - Bour, T. Service d'ophthalmologie, Hopital N.-D.-de-Bon-Secours, C.H.R. de Metz-Thionville. SN - 0181-5512 SP - 380-91 ST - [Therapeutic observance and life of patients with primary open-angle glaucoma. Apropos of 341 cases in the department of Marne] T2 - Observance therapeutique et vecu du glaucome primitif a angle ouvert. A propos de 341 cas dans la Marne. TI - [Therapeutic observance and life of patients with primary open-angle glaucoma. Apropos of 341 cases in the department of Marne] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8360421 VL - 16 ID - 2092 ER - TY - JOUR AB - Patient compliance with treatment is an important factor in chronic diseases such as primary open-angle glaucoma (POAG). Among the 404 glaucoma patients included in our study in the department of Marne (France), 341 patients responded by completing an anonymous questionnaire at home in which the psychological effect of the illness, their knowledge about it, compliance with treatment and their relationships with the physician were explored. Sixty-eight per cent of these patients confirmed strict compliance with the treatment prescribed; this rate does not vary with respect to either the ophthalmologist (p = 0.57), or the duration of treatment (p = 0.42). Half of the remaining patients only alter the hours of their treatment and 6% forget to instil the eyedrops on certain days. According to our survey, the principal causes of poor compliance are forgetfulness, time constraints with other duties, poor doctor-patient relationship and lack of sufficient knowledge about the disease and its treatment. The majority of patients (59%) are minimally disturbed by the treatment; 2/3 of the subjects do not feel any change in their morale whereas 15% are more depressed or weakened since the time the illness was discovered. Fifty-six per cent of them observed little or no change in their vision; 32% believe to have a moderate or considerable repercussion and 6% claim a very severe visual deterioration. Generally, patients appear to have a positive attitude towards their illness and do not try to deny it. Thirty-eight per cent of them consider it as a handicap which they can overcome and 42% have either no particular opinion or take it as a minor event. AD - T. Bour, Service d'Ophtalmologie, Hopital N.-D.-de Bon-Secours, C.H.R. de Metz-Thionville, B.P. 1065, F-57038 Metz Cedex 1, France AU - Bour, T. AU - Blanchard, F. AU - Segal, A. C1 - carteol diamox timoptol DB - Embase Medline IS - 6-7 KW - acetazolamide adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carteolol pilocarpine timolol timolol maleate adult aged article controlled study doctor patient relationship France human major clinical study open angle glaucoma patient compliance questionnaire carteol diamox timoptol LA - French M3 - Article N1 - L23251115 1993-09-09 PY - 1993 SN - 0181-5512 SP - 380-391 ST - Primary open-angle glaucoma: Compliance with treatment and repercussion of glaucoma on the patient's life. Concerning 341 cases in the department of Marne, France T2 - Journal Francais d'Ophtalmologie TI - Primary open-angle glaucoma: Compliance with treatment and repercussion of glaucoma on the patient's life. Concerning 341 cases in the department of Marne, France UR - https://www.embase.com/search/results?subaction=viewrecord&id=L23251115&from=export VL - 16 ID - 4017 ER - TY - JOUR AB - BACKGROUND: Within a surveillance of the prevalence and causes of vision impairment in high-income regions and Central/Eastern Europe, we update figures through 2015 and forecast expected values in 2020., METHODS: Based on a systematic review of medical literature, prevalence of blindness, moderate and severe vision impairment (MSVI), mild vision impairment and presbyopia was estimated for 1990, 2010, 2015, and 2020., RESULTS: Age-standardised prevalence of blindness and MSVI for all ages decreased from 1990 to 2015 from 0.26% (0.10-0.46) to 0.15% (0.06-0.26) and from 1.74% (0.76-2.94) to 1.27% (0.55-2.17), respectively. In 2015, the number of individuals affected by blindness, MSVI and mild vision impairment ranged from 70 000, 630 000 and 610 000, respectively, in Australasia to 980 000, 7.46 million and 7.25 million, respectively, in North America and 1.16 million, 9.61 million and 9.47 million, respectively, in Western Europe. In 2015, cataract was the most common cause for blindness, followed by age-related macular degeneration (AMD), glaucoma, uncorrected refractive error, diabetic retinopathy and cornea-related disorders, with declining burden from cataract and AMD over time. Uncorrected refractive error was the leading cause of MSVI., CONCLUSIONS: While continuing to advance control of cataract and AMD as the leading causes of blindness remains a high priority, overcoming barriers to uptake of refractive error services would address approximately half of the MSVI burden. New data on burden of presbyopia identify this entity as an important public health problem in this population. Additional research on better treatments, better implementation with existing tools and ongoing surveillance of the problem is needed. Copyright © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. AU - Bourne, Rupert R. A. AU - Jonas, Jost B. AU - Bron, Alain M. AU - Cicinelli, Maria Vittoria AU - Das, Aditi AU - Flaxman, Seth R. AU - Friedman, David S. AU - Keeffe, Jill E. AU - Kempen, John H. AU - Leasher, Janet AU - Limburg, Hans AU - Naidoo, Kovin AU - Pesudovs, Konrad AU - Peto, Tunde AU - Saadine, Jinan AU - Silvester, Alexander J. AU - Tahhan, Nina AU - Taylor, Hugh R. AU - Varma, Rohit AU - Wong, Tien Y. AU - Resnikoff, Serge AU - Vision Loss Expert Group of the Global Burden of Disease, Study DO - https://dx.doi.org/10.1136/bjophthalmol-2017-311258 IS - 5 KW - *Blindness/ep [Epidemiology] Cataract/co [Complications] Developed Countries Diabetic Retinopathy/co [Complications] Europe/ep [Epidemiology] Female Glaucoma/co [Complications] Humans Macular Degeneration/co [Complications] Refractive Errors/co [Complications] PY - 2018 SE - Bourne, Rupert R A. Vision & Eye Research Unit, Anglia Ruskin University, Cambridge, UK. Jonas, Jost B. Department of Ophthalmology, Universitatsmedizin, Mannheim, Germany. Jonas, Jost B. Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Bron, Alain M. INRA, UMR1324 Centre des Sciences du Gout et de l'Alimentation, Dijon, France. Bron, Alain M. CNRS, UMR6265 Centre des Sciences du Gout et de l'Alimentation, Dijon, France. Bron, Alain M. Centre des Sciences du Gout et de l'Alimentation, Universite Bourgogne Franche-Comte, Dijon, France. Bron, Alain M. Ophthalmology Department, Dijon University Hospital, Dijon, France. Cicinelli, Maria Vittoria. San Raffaele Scientific Institute, Milan, Italy. Das, Aditi. Health Education Yorkshire and the Humber, Leeds, UK. Flaxman, Seth R. Department of Mathematics and Data Science Institute, Imperial College London, London, UK. Flaxman, Seth R. Department of Statistics, University of Oxford, Oxford, UK. Friedman, David S. Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Keeffe, Jill E. LV Prasad Eye Institute, Hyderabad, India. Kempen, John H. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA. Kempen, John H. Discovery Eye Center, Addis Ababa, Ethiopia. Kempen, John H. Myungsung Christian Medical Center and Medical School, Addis Ababa, Ethiopia. Leasher, Janet. Nova Southeastern University, Davie, Florida, USA. Limburg, Hans. Health Information Services, Grootebroek, The Netherlands. Naidoo, Kovin. African Vision Research Institute, University of Kwazulu-Natal, Brien Holden Vision Institute, Durban, South Africa. Pesudovs, Konrad. NHMRC Centre for Clinical Eye Research, Flinders University, Adelaide, South Australia, Australia. Peto, Tunde. School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. Saadine, Jinan. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Silvester, Alexander J. St Pauls Eye Unit, Royal Liverpool University Hospital, Liverpool, UK. Tahhan, Nina. Brien Holden Vision Institute, Sydney, New South Wales, Australia. Tahhan, Nina. School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia. Taylor, Hugh R. Melbourne School of Population Health, University of Melbourne, Melbourne, Victoria, Australia. Varma, Rohit. Department of Ophthalmology, Keck School of Medicine of USC, Los Angeles, California, USA. Wong, Tien Y. Singapore Eye Research Institute, Duke-NUS Graduate Medical School, National University of Singapore, Singapore. Resnikoff, Serge. Brien Holden Vision Institute, Sydney, New South Wales, Australia. Resnikoff, Serge. School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia. SN - 1468-2079 0007-1161 SP - 575-585 ST - Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections T2 - The British journal of ophthalmology TI - Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29545417 VL - 102 Y2 - 20180315// ID - 444 ER - TY - JOUR AB - PURPOSE: Our goal is to investigate the opinion and practice pattern of Canadian ophthalmologists regarding the use of and recommendations for complementary and alternative medicine (CAM) for their glaucoma patients., METHODS: Institutional review board approval for this prospective, cross-sectional survey was obtained from the Research Ethics Board of Sunnybrook Health Sciences Centre. The survey was sent to all ophthalmologists in Canada electronically through the e-mail lists of 4 ophthalmology associations., RESULTS: A total of 241 ophthalmologists representing all provinces in Canada responded to the questionnaire. Twenty-two percent felt that CAM does have a role in glaucoma therapy with specialists being more likely to believe there is a role (P<0.05). Of the total respondents, 26% ask their patients if they use CAM with those in practice for <20 years more likely to encourage use (P<0.05). Of the respondents, 9% recommend CAM and if an ophthalmologist was in practice for <20 years he/she was significantly more likely to recommend CAM (P<0.01). Respondents (62%) in general do not discourage CAM with younger ophthalmologists (younger than 50 y, P<0.02) and ophthalmologists in practice for <20 years (P<0.05) being less likely to discourage CAM use. Respondents (41%) believe that CAM rarely ever affects compliance with ophthalmologists from an urban practice (P<0.01) and academic practice (P<0.05) more likely to deny effect on compliance. Respondents believe that CAM sometimes (46%) results in patient morbidity with ophthalmologists being in practice for <20 years believing that morbidity is less likely (P<0.05)., CONCLUSION: A substantial minority of respondents believe that CAM has a role in glaucoma therapy, recommend its use, and ask their patients if they use CAM. Younger doctors are more likely to encourage alternatives; those in practice for <20 years are more likely to ask about alternative medicine use, recommend its use, and believe that morbidity usually does not result from the use of alternative treatments. AU - Bower, Tenley N. AU - Muhsen, Sana AU - Overbury, Olga AU - Birt, Catherine AU - Kasner, Oscar DO - https://dx.doi.org/10.1097/IJG.0b013e31827b139d IS - 7 KW - Aged *Attitude of Health Personnel Canada Complementary Therapies/mt [Methods] *Complementary Therapies/sn [Statistics & Numerical Data] Cross-Sectional Studies Female *Glaucoma/th [Therapy] Health Surveys Humans Male *Ophthalmology Patient Compliance *Practice Patterns, Physicians' Prospective Studies Surveys and Questionnaires Workforce PY - 2014 SE - Bower, Tenley N. *Department of Ophthalmology, Jewish General Hospital, McGill University, Montreal, QC Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada. SN - 1536-481X 1057-0829 SP - 430-4 ST - Canadian ophthalmologists' opinions concerning complementary and alternative medicine (CAM) use in glaucoma T2 - Journal of glaucoma TI - Canadian ophthalmologists' opinions concerning complementary and alternative medicine (CAM) use in glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=23429615 VL - 23 ID - 920 ER - TY - JOUR AB - Regardless of lifestyle and patient-dependent factors, glaucoma specialists must monitor patients for disease progression. AN - 106210185. Language: English. Entry Date: 20070112. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Boyle, E. DB - ccm DP - EBSCOhost IS - 22 KW - Disease Progression Glaucoma Patient Compliance Accidental Falls -- Risk Factors Adrenergic Beta-Antagonists -- Adverse Effects Clinical Competence Diagnosis, Eye -- Methods Education, Medical Glaucoma -- Complications Glaucoma -- Therapy Intraocular Pressure Life Style Medication Compliance Monitoring, Physiologic Ophthalmology -- Education Patient Education Physician-Patient Relations N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 48-48 ST - Improving compliance with glaucoma treatment requires patient-focused approach T2 - Ocular Surgery News TI - Improving compliance with glaucoma treatment requires patient-focused approach UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106210185&site=ehost-live&scope=site VL - 24 ID - 4724 ER - TY - JOUR AB - Economics and patient education can play a role in patients' adherence to glaucoma treatment regimes. AN - 106210182. Language: English. Entry Date: 20070112. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 22 KW - Glaucoma -- Therapy Patient Compliance Communication Comorbidity Glaucoma -- Drug Therapy Glaucoma -- Economics Glaucoma -- Surgery Medication Compliance Patient Education Physician's Role Physician-Patient Relations Surgeons N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 42-43 ST - Compliance still often a missing link in glaucoma therapy T2 - Ocular Surgery News TI - Compliance still often a missing link in glaucoma therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106210182&site=ehost-live&scope=site VL - 24 ID - 4674 ER - TY - JOUR AB - Making selective laser trabeculoplasty the initial treatment for glaucoma allows patients to return to their every day lives without requiring drop compliancy. AN - 106206672. Language: English. Entry Date: 20070105. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 21 KW - Glaucoma -- Surgery Laser Therapy -- Methods Patient Compliance Antihypertensive Agents -- Therapeutic Use Clinical Trials Intraocular Pressure -- Drug Effects Ophthalmic Solutions Surgeons Treatment Outcomes N1 - pictorial; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 65-66 ST - SLT as initial glaucoma treatment addresses compliance issues, eye drop sensitivity T2 - Ocular Surgery News TI - SLT as initial glaucoma treatment addresses compliance issues, eye drop sensitivity UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106206672&site=ehost-live&scope=site VL - 24 ID - 4690 ER - TY - JOUR AB - Glaucoma patients understand dosages more easily with grid that is color-coded to correspond to medications' caps. AN - 106428714. Language: English. Entry Date: 20060421. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 6 KW - Assistive Technology Devices -- Utilization Glaucoma -- Drug Therapy Medication Compliance Aged Assistive Technology Devices -- Education Color Equipment Design Health Personnel -- Education Patient Compliance Product Evaluation N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 32-32 ST - Color-coded grid helps glaucoma patient compliance, doctor says T2 - Ocular Surgery News TI - Color-coded grid helps glaucoma patient compliance, doctor says UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106428714&site=ehost-live&scope=site VL - 24 ID - 4725 ER - TY - JOUR AB - Coordination with primary caregivers and others is essential for a good prognosis, one specialist noted. AN - 106397437. Language: English. Entry Date: 20060217. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 1 KW - Glaucoma -- Therapy -- In Infancy and Childhood Multidisciplinary Care Team Child Diagnosis, Eye Glaucoma -- Diagnosis Glaucoma -- Education Glaucoma -- Physiopathology Glaucoma -- Prevention and Control -- In Infancy and Childhood Glaucoma -- Surgery Health Screening Patient Compliance Risk Assessment Students, Medical N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 4-5 ST - Multidisciplinary approach needed for childhood glaucoma T2 - Ocular Surgery News TI - Multidisciplinary approach needed for childhood glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106397437&site=ehost-live&scope=site VL - 24 ID - 4731 ER - TY - JOUR AB - A study of Medicare beneficiaries found that blacks were 78% more likely to undergo surgical procedures for glaucoma than whites. AN - 106422622. Language: English. Entry Date: 20060407. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 5 KW - Glaucoma -- Surgery Race Factors Eye Surgery -- Utilization Age Factors Black Persons Glaucoma -- Diagnosis Glaucoma -- Ethnology Health Services Accessibility Health Services -- Utilization Medicare Prospective Studies Severity of Illness White Persons Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 64-64 ST - Glaucoma surgery rates higher in blacks than whites, study finds T2 - Ocular Surgery News TI - Glaucoma surgery rates higher in blacks than whites, study finds UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106422622&site=ehost-live&scope=site VL - 24 ID - 4743 ER - TY - JOUR AB - More evidence of efficacy is needed to garner support for screening programs, one expert says. AN - 106414012. Language: English. Entry Date: 20060324. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 4 KW - Glaucoma -- Prevention and Control Students, Medical Vision Screening -- Education Curriculum Disease Progression -- Prevention and Control Eye Care Health Services Accessibility Intraocular Pressure Patient Education Socioeconomic Factors N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 40-40 ST - Effective glaucoma screening strategies should include involvement of medical students T2 - Ocular Surgery News TI - Effective glaucoma screening strategies should include involvement of medical students UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106414012&site=ehost-live&scope=site VL - 24 ID - 4760 ER - TY - JOUR AB - Electronic monitoring devices may soon provide ophthalmologists with more accurate information about patient compliance. AN - 106449547. Language: English. Entry Date: 20060602. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 8 KW - Patient Compliance -- Evaluation Patient Education Physician-Patient Relations Electronics Glaucoma -- Therapy Intraocular Pressure Medication Compliance -- Evaluation Monitoring, Physiologic -- Equipment and Supplies N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 32-32 ST - Strategies to improve compliance include patient education T2 - Ocular Surgery News TI - Strategies to improve compliance include patient education UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106449547&site=ehost-live&scope=site VL - 24 ID - 4777 ER - TY - JOUR AB - The laser procedure also reduced the mean number of medications needed and assisted in patient compliance and tolerance. AN - 106330711. Language: English. Entry Date: 20060908. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 15 KW - Glaucoma -- Surgery Intraocular Pressure Laser Therapy -- Methods Patient Compliance Record Review Retrospective Design Surgeons T-Tests Treatment Outcomes Human N1 - pictorial; research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 32-32 ST - Study: SLT procedures lowered IOP T2 - Ocular Surgery News TI - Study: SLT procedures lowered IOP UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106330711&site=ehost-live&scope=site VL - 24 ID - 4783 ER - TY - JOUR AB - Response included suggestions for memory aids, closer doctor-patient relationships. AN - 105969837. Language: English. Entry Date: 20080215. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 23 KW - Ophthalmology Alternative Therapies Antioxidants -- Therapeutic Use Biological Markers Blood Pressure -- Physiology Congresses and Conferences Glaucoma -- Drug Therapy Glaucoma -- Familial and Genetic Glaucoma -- Prevention and Control Glaucoma -- Rehabilitation Glaucoma -- Surgery Glaucoma -- Therapy Health Screening -- Methods Intraocular Pressure -- Physiology Louisiana Medication Compliance Organizations Phacoemulsification -- Methods Plants, Medicinal -- Therapeutic Use Posture -- Physiology Quality of Life Rehabilitation -- Methods Sleep -- Physiology Stents -- Equipment and Supplies Eye Surgery -- Methods N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2007 SN - 8750-3085 SP - 27-30 ST - Survey: identifying factors to improve compliance among glaucoma patients T2 - Ocular Surgery News TI - Survey: identifying factors to improve compliance among glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105969837&site=ehost-live&scope=site VL - 25 ID - 4592 ER - TY - JOUR AB - The American Glaucoma Society surveyed physicians, staff nd patients for suggestions on how to improve drug adherence. AN - 105878217. Language: English. Entry Date: 20080404. Revision Date: 20171109. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 5 KW - Glaucoma -- Drug Therapy Medication Compliance Glaucoma -- Psychosocial Factors Memory Patient Attitudes Patient Education Questionnaires Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2008 SN - 8750-3085 SP - 26-26 ST - Survey gathers innovative ideas to improve glaucoma compliance T2 - Ocular Surgery News TI - Survey gathers innovative ideas to improve glaucoma compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105878217&site=ehost-live&scope=site VL - 26 ID - 4520 ER - TY - JOUR AB - More than half noncomplaint, with one-third having an improper eye drop instillation technique. AN - 105712681. Language: English. Entry Date: 20081212. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 19 KW - Glaucoma -- Rehabilitation Ophthalmic Solutions -- Administration and Dosage Ophthalmic Solutions -- Therapeutic Use Glaucoma -- Drug Therapy Ophthalmic Solutions -- Adverse Effects Ophthalmology -- Methods Patient Compliance Treatment Outcomes N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2008 SN - 8750-3085 SP - 28-28 ST - Glaucoma patients need guidance when using eye drops T2 - Ocular Surgery News TI - Glaucoma patients need guidance when using eye drops UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105712681&site=ehost-live&scope=site VL - 26 ID - 4611 ER - TY - JOUR AB - Nonprofit organization seeks to address need in Africa for congenital cataract surgery in children and glaucoma and cataract treatment in adults AN - 105990186. Language: English. Entry Date: 20080222. Revision Date: 20171109. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 2 KW - Health Services Accessibility Eye Surgery -- Methods -- Zambia Cataract Extraction Drugs, Prescription -- Economics Glaucoma -- Drug Therapy Glaucoma -- Surgery Health Facilities Medication Compliance Organizations Poverty Volunteer Workers Zambia N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2008 SN - 8750-3085 SP - 93-93 ST - Group offers services to Zambians with little access to eye care T2 - Ocular Surgery News TI - Group offers services to Zambians with little access to eye care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105990186&site=ehost-live&scope=site VL - 26 ID - 4670 ER - TY - JOUR AB - Glaucoma support groups play an important role in the community, assisting in diagnosis and patient adherence. AN - 105329030. Language: English. Entry Date: 20091120. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Psychosocial Factors Goals and Objectives Support Groups Health Knowledge Patient Education Support, Psychosocial N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2009 SN - 8750-3085 SP - 62-63 ST - Setting goals effective way to start glaucoma support organizations T2 - Ocular Surgery News TI - Setting goals effective way to start glaucoma support organizations UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105329030&site=ehost-live&scope=site VL - 27 ID - 4475 ER - TY - JOUR AB - From drop amount permitted by insurance companies to glaucoma patients' difficulty, glaucoma medical therapy adherence is a challenge to maintain. AN - 105068679. Language: English. Entry Date: 20100910. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 15 KW - Glaucoma -- Drug Therapy Medication Compliance Insurance Coverage Insurance, Health, Reimbursement Ophthalmic Solutions -- Administration and Dosage N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 16-17 ST - Glaucoma compliance a complex issue with many contributing factors T2 - Ocular Surgery News TI - Glaucoma compliance a complex issue with many contributing factors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105068679&site=ehost-live&scope=site VL - 28 ID - 4386 ER - TY - JOUR AB - Clinicians should educate patients about possible implications of missing follow-up appointments. AN - 105045474. Language: English. Entry Date: 20100820. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. DB - ccm DP - EBSCOhost IS - 13 KW - After Care Glaucoma -- Surgery Outcomes (Health Care) Patient Compliance Patient Education Physician-Patient Relations N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 35-35 ST - Poor office visit follow-up compliance could affect glaucoma surgical success T2 - Ocular Surgery News TI - Poor office visit follow-up compliance could affect glaucoma surgical success UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105045474&site=ehost-live&scope=site VL - 28 ID - 4564 ER - TY - JOUR AN - 105015981. Language: English. Entry Date: 20101110. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. AU - Bechtel, B. AU - Hasson, M. AU - Master, J. AU - Mullin, D. W. DB - ccm DP - EBSCOhost IS - 22 KW - Glaucoma -- Therapy -- United States Geographic Factors Health Services Accessibility United States Health Care Costs N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 24-24 ST - Study: Regional differences appear to be costliest disparity in US glaucoma care T2 - Ocular Surgery News TI - Study: Regional differences appear to be costliest disparity in US glaucoma care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105015981&site=ehost-live&scope=site VL - 28 ID - 4583 ER - TY - JOUR AB - The article reports on the challenges posed by glaucoma medication cost and compliance in India, which was discussed by physician G. Chandra Sekhar during the Asia-Pacific Academy of Ophthalmology Congress held in Beijing, China on September 16-20, 2010. AN - 54395104. Language: English. Entry Date: 20101015. Revision Date: 20101111. Publication Type: Article AU - Boyle, Erin L. AU - Mullin, David W. DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Drug Therapy -- India Prostaglandins -- Economics Costs and Cost Analysis Medication Compliance Patient Attitudes India N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 17-17 ST - Glaucoma medication cost, compliance pose challenges in India T2 - Ocular Surgery News TI - Glaucoma medication cost, compliance pose challenges in India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=54395104&site=ehost-live&scope=site VL - 28 ID - 4482 ER - TY - JOUR AB - The article reports on the importance of the establishment of target pressure, selection of the appropriate medication or combination of medications and addressing compliance issues in treating open angle glaucoma patients with medical therapy, which was discussed by physician Douglas J. Rhee at the Asia-Pacific Academy of Ophthalmology Congress held in Beijing, China on September 16-20, 2010. AN - 54395151. Language: English. Entry Date: 20101015. Revision Date: 20191029. Publication Type: Article AU - Boyle, Erin L. AU - Mullin, David W. DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Drug Therapy Prostaglandins -- Therapeutic Use Decision Making, Clinical Medication Compliance Goals and Objectives Physician-Patient Relations Counseling N1 - brief item; pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 18-18 ST - Stepwise approach useful for medical treatment of open-angle glaucoma T2 - Ocular Surgery News TI - Stepwise approach useful for medical treatment of open-angle glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=54395151&site=ehost-live&scope=site VL - 28 ID - 4528 ER - TY - JOUR AB - The article reports on the claim of physician Paul Healey that laser trabeculoplasty provides a viable treatment option for effective lowering of intraocular pressure (IOP) with improved compliance in early to moderate glaucoma. AN - 54395015. Language: English. Entry Date: 20101015. Revision Date: 20101111. Publication Type: Article AU - Boyle, Erin L. AU - Mullin, David W. DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Surgery Eye Surgery -- Methods Decision Making, Clinical Intraocular Pressure Patient Compliance N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 16-16 ST - Physician shares pearls, indications for laser trabeculoplasty T2 - Ocular Surgery News TI - Physician shares pearls, indications for laser trabeculoplasty UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=54395015&site=ehost-live&scope=site VL - 28 ID - 4614 ER - TY - JOUR AB - Current therapy to slow disease progression in patients with neovascular age-related macular degeneration (AMD) entails regular intravitreal anti-vascular endothelial growth factor (VEGF) injections, often indefinitely. Little is known about the burden imposed on patients by this repetitive treatment schedule and how this can be best managed. The aim of this study was to explore the psychosocial impact of repeated intravitreal injections on patients with neovascular AMD. Forty patients (16 males, 24 females) with neovascular AMD undergoing anti-VEGF treatment were recruited using purposive sampling from a private ophthalmology practice and public hospital in Melbourne. Patients were surveyed using the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ; Bradley, Health Psychology Research Unit, Surrey, England) and underwent semi-structured, one-on-one interviews. Interview topics were: treatment burden and satisfaction; tolerability; barriers to adherence; treatment motivation; and patient education. Interviews were audio recorded and thematic analysis performed using NVivo 10 (QSR International, Doncaster, Australia). Patients recognised the importance of treatment to preserve eyesight, yet experienced significant psychosocial and practical burden from the treatment schedule. Important issues included treatment-related anxiety, financial considerations and transport burden placed on relatives or carers. Many patients were restricted to sedentary activities post-injection owing to treatment side effects. Patients prioritised treatment, often sacrificing family, travel and social commitments owing to a fear of losing eyesight if treatment was not received. Whilst anti-VEGF injections represent the current mainstay of treatment for neovascular AMD, the ongoing treatment protocol imposes significant burden on patients. An understanding of the factors that contribute to the burden of treatment may help inform strategies to lessen its impact and assist patients to better manage the challenges of treatment. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Boyle, Jessica AN - 2017-56632-001 AU - Boyle, Jessica AU - Vukicevic, Meri AU - Koklanis, Konstandina AU - Itsiopoulos, Catherine AU - Rees, Gwyneth DB - psyh DO - 10.1080/13548506.2016.1274040 DP - EBSCOhost IS - 2 KW - Age-related macular degeneration exudative maculopathies neovascular intravitreal injection anti-VEGF treatment patient experience burden Disease Course Drug Therapy Eye Disorders Injections N1 - Department of Community & Clinical Allied Health, La Trobe University, Melbourne, VIC, Australia. Release Date: 20180122. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Disease Course; Drug Therapy; Eye Disorders; Injections; Treatment. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: Australia. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Macular Disease Treatment Satisfaction Questionnaire; Retinopathy Treatment Satisfaction Questionnaire; Focus Groups. Methodology: Empirical Study; Interview; Focus Group; Qualitative Study. References Available: Y. Page Count: 14. Issue Publication Date: Feb, 2018. Publication History: Accepted Date: Dec 14, 2016; First Submitted Date: Jul 21, 2016. Copyright Statement: Informa UK Limited, trading as Taylor & Francis Group. 2017. Sponsor: Bayer Australia Ltd, Australia. Other Details: Investigator-initiated research grant. Recipients: No recipient indicated Sponsor: Orthoptics Australia, Victorian Branch, Australia. Other Details: Small Project Research Grant. Recipients: No recipient indicated Sponsor: La Trobe University, Australia. Other Details: Postgraduate Support Grant. Recipients: No recipient indicated PY - 2018 SN - 1354-8506 1465-3966 SP - 127-140 ST - Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration T2 - Psychology, Health & Medicine TI - Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-56632-001&site=ehost-live&scope=site ORCID: 0000-0002-6740-9586 jess.boyle@latrobe.edu.au VL - 23 ID - 4832 ER - TY - JOUR AB - A 27-year-old male patient with a corneal scar secondary to herpetic keraritis in the right eye underwent penetrating keraroplasty (PK). At the 14th month of follow-up, latanoprost was started to treat high intraocular pressure which was refracrory to trearment. On the 15th day of latanoprost use, allograft reaction (AR) developed. Insufficient clinical response despite incensive immunosuppressive therapy made us consider the possibility of recurrent herpetic kerarouveitis secondary co steroid trearment. The dramatic reduction in the number of keratic precipitates with oral valacydovir trearment confirmed this diagnosis. The graft remained dear 3 monchs after the AR trearment. Inflammation in eyes that had undergone PK jeopardizes the graft success by disrupting the immune privilege of anrerior chamber. Considering the effects of prostaglandin analogues on blood-aqueous barrier, laranoprost use might have been related co allograft reaction in this case. Another remarkable characteristics of this case was the herpes simplex virus (HSV) reactivation secondary co AR therapy. For this reason, oral acyclovir prophylaxis together with AR rherapy would improve grafi: success in cases with HSV history. AN - 104472192. Language: English. Entry Date: 20120817. Revision Date: 20150711. Publication Type: Journal Article AU - Bozkurt, Tahir Kansu AU - Bahadir, Ayse Ebru AU - Kutan, Selda Aktay AU - Acar, Suphi DB - ccm DP - EBSCOhost IS - 2 KW - Corneal Diseases -- Surgery Corneal Transplantation -- Methods Glaucoma -- Prevention and Control Graft Rejection Keratitis, Herpetic -- Complications Latanoprost -- Adverse Effects Adult Male N1 - case study; pictorial. Journal Subset: Biomedical; Double Blind Peer Reviewed; Middle East; Peer Reviewed. NLM UID: 9513588. PY - 2012 SN - 1300-0365 SP - 150-153 ST - Allograft reaction after latanoprost use following penetrating keratoplasty for corneal scarring due to herpatic keratitis T2 - Turkish Journal of Ophthalmology / Turk Oftalmoloji Dergisi TI - Allograft reaction after latanoprost use following penetrating keratoplasty for corneal scarring due to herpatic keratitis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104472192&site=ehost-live&scope=site VL - 42 ID - 4486 ER - TY - JOUR AB - A 27-year-old male patient with a corneal scar secondary to herpetic keratitis in the right eye underwent penetrating keratoplasty (PK). At the 14th month of follow-up, latanoprost was started to treat high intraocular pressure which was refractory to treatment. On the 15th day of latanoprost use, allograft reaction (AR) developed. Insufficient clinical response despite intensive immunosuppressive therapy made us consider the possibility of recurrent herpetic keratouveitis secondary to steroid treatment. The dramatic reduction in the number of keratic precipitates with oral valacyclovir treatment confirmed this diagnosis. The graft remained clear 3 months after the AR treatment. Inflammation in eyes that had undergone PK jeopardizes the graft success by disrupting the immune privilege of anterior chamber. Considering the effects of prostaglandin analogues on blood-aqueous barrier, latanoprost use might have been related to allograft reaction in this case. Another remarkable characteristics of this case was the herpes simplex virus (HSV) reactivation secondary to AR therapy. For this reason, oral acyclovir prophylaxis together with AR therapy would improve graft success in cases with HSV history. AD - Gümüşsuyu Asker Hastanesi, Göz Kliniǧi, Istanbul, Turkey Sakarya Hendek Devlet Hastanesi, Göz Kliniǧi, Sakarya, Turkey Karadeniz Ereǧli Devlet Hastanesi, Göz Kliniǧi, Zonguldak, Turkey Haydarpaşa Numune Eǧitim ve Araştirma Hastanesi, 2. Göz Kliniǧi, Istanbul, Turkey AU - Bozkurt, T. K. AU - Bahadïr, A. E. AU - Kutan, S. A. AU - Acar, S. DB - Scopus DO - 10.4274/tjo.42.462200 IS - 2 KW - Allograft reaction Herpes simplex virus Latanoprost Oral acylovir prophylaxis Penetrating keratoplasty M3 - Article N1 - Export Date: 19 July 2021 PY - 2012 SP - 150-153 ST - Herpetik keratit skarı nedeniyle penetran keratoplasti yapılan olguda latanoprost kullanımı sonrası görülen allograft reaksiyonu T2 - Turk Oftalmoloiji Dergisi TI - Allograft reaction after latanoprost use following penetrating keratoplasty for corneal scarring due to herpetic keratitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862002411&doi=10.4274%2ftjo.42.462200&partnerID=40&md5=e6dfc94cfd75dc95071d912c3c873ea8 VL - 42 ID - 5760 ER - TY - JOUR AB - Asthma is underdiagnosed and undertreated in older adults. The classic symptoms, including episodic wheezing, shortness of breath, and chest tightness, are nonspecific in this age group. Older patients may underrate symptoms, and other diseases, such as chronic obstructive pulmonary disease, congestive heart failure, and angina, may have similar presentations. Objective measurements of lung function always should complement the history taking and physical examination. Management of asthma in older adults should include careful monitoring, controlling triggers, optimizing and monitoring pharmacotherapy, and providing appropriate asthma education. Adverse effects to commonly used asthma medications are more common in older adults, and careful monitoring of their use and adverse effects is important. © 2007 Elsevier Inc. All rights reserved. AD - S.S. Braman, The Warren Alpert Medical School, Brown University, Division of Pulmonary and Critical Care Medicine, 593 Eddy Street, Providence, RI 02903, United States AU - Braman, S. S. AU - Hanania, N. A. C1 - aspirin DB - Embase Medline DO - 10.1016/j.ccm.2007.08.007 IS - 4 KW - acetylsalicylic acid antiasthmatic agent antiinflammatory agent beclometasone beta 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent betaxolol bronchodilating agent budesonide cholinergic receptor blocking agent corticosteroid dipeptidyl carboxypeptidase inhibitor flunisolide fluticasone formoterol ibuprofen indometacin ipratropium bromide leukotriene receptor blocking agent lipoxygenase inhibitor methylprednisolone mometasone furoate naproxen prednisone salbutamol salmeterol steroid theophylline triamcinolone unindexed drug add on therapy adrenal suppression aging airway obstruction allergic asthma anamnesis angina pectoris asthma asthmatic state backache blood pressure bronchospasm bronchus hyperreactivity cardiotoxicity cataract chest tightness chronic obstructive lung disease Churg Strauss syndrome clinical feature congestive heart failure contusion corticosteroid induced myopathy corticosteroid induced osteoporosis coughing diabetes mellitus disease association dosage schedule comparison drug efficacy drug fatality dysphonia dyspnea fracture geriatric patient glaucoma heart arrhythmia atrial fibrillation heart palpitation heart ventricle extrasystole heart ventricle tachycardia histopathology hoarseness human hypertension hypokalemia insomnia ischemic heart disease lung function test mucosal dryness muscle weakness nausea and vomiting pathophysiology patient assessment patient compliance patient education patient monitoring physical examination potassium blood level priority journal prognosis QT prolongation review seizure senescence side effect skin atrophy supraventricular tachycardia symptom tachycardia thrush treatment outcome tremor unspecified side effect urine retention wheezing aspirin LA - English M3 - Review N1 - L47625701 2007-12-01 PY - 2007 SN - 0272-5231 SP - 685-702 ST - Asthma in Older Adults T2 - Clinics in Chest Medicine TI - Asthma in Older Adults UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47625701&from=export http://dx.doi.org/10.1016/j.ccm.2007.08.007 VL - 28 ID - 3496 ER - TY - JOUR AB - Background: Switches between anti-tumor necrosis factor agents in the treatment of Crohn's disease (CD) occur in case of treatment failure, intolerance, or patient preference. No data are currently available on the usefulness of a second infliximab treatment after earlier discontinuation and previous switch to an alternative anti-tumor necrosis factor agent. In this study, we evaluated the clinical benefit of infliximab retreatment in patients with CD after sequential use of both infliximab and adalimumab. Methods: Twenty-nine patients with CD who had received earlier treatments with sequential infliximab and adalimumab and were then restarted on infliximab were retrieved from a multicenter registry designed for the follow-up of adalimumab treatment for CD. Short-term and sustained effects of infliximab retreatment were evaluated retrospectively by reviewing clinical records. Follow-up was 18 months for all patients. Results: In 13/29 (45%) patients, infliximab was reintroduced at intensified dosing schedule (>5 mg/kg or <8 wk) for 23/29 (79%) of patients similar to the schedule who were on at time of previous discontinuation. During the second infliximab treatment course, dosing was further intensified in 11 out of 29 (38%) patients. After 18 months 18/29 (62%), patients were still on continued therapy of their second infliximab treatment. Infliximab was discontinued (after a median of 7 mo) in 11 out of 29 patients for loss of response (n = 7 [24%]), intolerance (n = 3 [10%]), or non-compliance (n = 1 [3%]). Use of induction schedule or concomitant immunomodulators were not significantly associated with treatment benefit. Conclusions: The majority of patients with CD benefit from a second treatment with infliximab after previous treatment with infliximab and adalimumab, which offer a meaningful therapeutic option in often highly refractory patients. Copyright © 2013 Crohn's & Colitis Foundation of America, Inc. AD - Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands Department of Gastroenterology and Hepatology, Medisch Centrum Alkmaar, North-Holland, Netherlands AU - Brandse, J. F. AU - Peters, C. P. AU - Gecse, K. B. AU - Eshuis, E. J. AU - Jansen, J. M. AU - Tuynman, H. A. AU - Löwenberg, M. AU - Ponsioen, C. Y. AU - Van Den Brink, G. R. AU - D'Haens, G. R. DB - Scopus DO - 10.1097/01.MIB.0000438248.14218.1d IS - 2 KW - Adalimumab Clinical response Crohn's disease Infliximab Retreatment M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2014 SP - 251-258 ST - Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease T2 - Inflammatory Bowel Diseases TI - Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893809447&doi=10.1097%2f01.MIB.0000438248.14218.1d&partnerID=40&md5=c339c327202a85815fcbf371464431a2 VL - 20 ID - 5161 ER - TY - JOUR AB - Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) has been in clinical use for more than three decades. Its value has, however, been questioned recently for several reasons, e.g., the occurrence of newer AEDs, for which the use of TDM has to be evaluated, but also because of financial strains on health systems. The current review aims at assessing the use of TDM in newer AEDs, i.e., those that entered the market since the beginning of the 1990s. As some have been licensed only recently and others are only in very limited use, either because of orphan drug status or because of limited efficacy or potentially severe adverse events, only limited data exist for some of the newer AEDs. General considerations are made in the review, and each new AED is discussed, and, in some cases preliminary, assessment of the use of TDM is given. © 2011 by Walter de Gruyter Berlin Boston. AD - C. Brandt, Bethel Epilepsy Centre, Mara Hospital, Maraweg 21, 33617 Bielefeld, Germany AU - Brandt, C. AU - May, T. W. DB - Embase DO - 10.1515/JLM.2011.022 IS - 3 KW - anticonvulsive agent carbamazepine clobazam eslicarbazepine acetate etiracetam felbamate gabapentin lacosamide lamotrigine mesuximide oxcarbazepine phenytoin pregabalin rufinamide stiripentol tiagabine topiramate valproic acid vigabatrin zonisamide abdominal pain abnormal thinking add on therapy aggressiveness anorexia aplastic anemia ataxia bipolar depression blurred vision body weight brain disease cerebellar symptom closed angle glaucoma cognitive defect concentration loss coordination disorder decreased appetite depression diarrhea differential diagnosis diplopia dizziness drowsiness drug absorption drug clearance drug dose increase drug dose reduction drug dose titration drug elimination drug excretion drug formulation drug half life drug intoxication drug marketing drug metabolism drug monitoring drug protein binding drug tolerability drug use drug withdrawal ecchymosis epilepsy epileptic state fatigue focal epilepsy generalized anxiety disorder generalized epilepsy headache hematologic disease human hyperthermia hyponatremia in vitro study infantile spasm lactation Lennox Gastaut syndrome leukocyte count liver failure liver toxicity mental disease mental health metabolic acidosis migraine monotherapy myoclonus epilepsy nasuea nausea nephrolithiasis neuropathic pain oligohidrosis paresthesia patient compliance peripheral edema pregnancy psychosis psychotic symptom puerperium review sedation seizure severe myoclonic epilepsy in infancy side effect single drug dose skin manifestation sleep disorder somnolence speech disorder tonic clonic seizure visual field defect vomiting body weight gain body weight loss LA - English M3 - Review N1 - L362692119 2011-10-13 2011-10-21 PY - 2011 SN - 0342-3026 1439-0477 SP - 161-169 ST - Therapeutic drug monitoring of newer antiepileptic drugs T2 - LaboratoriumsMedizin TI - Therapeutic drug monitoring of newer antiepileptic drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362692119&from=export http://dx.doi.org/10.1515/JLM.2011.022 VL - 35 ID - 3171 ER - TY - JOUR AU - Brandt, James D. DO - https://dx.doi.org/10.1016/j.ophtha.2015.08.035 IS - 12 KW - *Antihypertensive Agents/ad [Administration & Dosage] *Communication *Drug Packaging/st [Standards] Female *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Male *Medication Adherence *Physician-Patient Relations N1 - Comment on (CON), Comment on (CON), Comment in (CIN) PY - 2015 SE - Brandt, James D. Sacramento, California. Electronic address: jdbrandt@ucdavis.edu. SN - 1549-4713 0161-6420 SP - 2368-70 ST - Human Factors and Ophthalmic Drug Packaging: Time for a Global Standard T2 - Ophthalmology T3 - Comment on: Ophthalmology. 2015 Dec;122(12):2577-8; PMID: 26077575 [https://www.ncbi.nlm.nih.gov/pubmed/26077575]Comment on: Ophthalmology. 2015 Dec;122(12):2373-9; PMID: 26260280 [https://www.ncbi.nlm.nih.gov/pubmed/26260280]Comment in: Ophthalmology. 2017 Jan;124(1):e6-e7; PMID: 27993279 [https://www.ncbi.nlm.nih.gov/pubmed/27993279] TI - Human Factors and Ophthalmic Drug Packaging: Time for a Global Standard UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26592669 VL - 122 ID - 762 ER - TY - JOUR AB - PURPOSE: Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need. A topical bimatoprost ocular insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) treated for 6 months., DESIGN: Parallel-arm, multicenter, double-masked, randomized, controlled trial., PARTICIPANTS: One hundred thirty adult OAG or OHT patients., METHODS: Eligible patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus timolol (0.5% solution) twice daily for 6 months after a screening washout period. Diurnal IOP measurements (at 0, 2, and 8 hours) were obtained at baseline; weeks 2, 6, and 12; and months 4, 5, and 6. Key eligibility included washout IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or less at all time points; no prior incisional surgery for OAG or OHT; and no known nonresponders to prostaglandins., MAIN OUTCOME MEASURES: The primary efficacy end point examined the difference in mean change from baseline in diurnal IOPs (point estimate, 95% confidence interval) across 9 coprimary end points at weeks 2, 6, and 12 comparing the bimatoprost arm with the timolol arm using a noninferiority margin of 1.5 mmHg. Secondary end points were diurnal IOP measurements at months 4, 5, and 6 and adverse events (AEs)., RESULTS: A mean reduction from baseline IOP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared with -4.2 to -6.4 mmHg for the timolol group over 6 months. The study met the noninferiority definition at 2 of 9 time points but was underpowered for the observed treatment effect. Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AEs were observed. Primary retention rate of the insert was 88.5% of patients at 6 months., CONCLUSIONS: Clinically relevant reduction in mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well tolerated. The topically applied bimatoprost insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery, and reduction of elevated IOP. Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AU - Brandt, James D. AU - Sall, Kenneth AU - DuBiner, Harvey AU - Benza, Robert AU - Alster, Yair AU - Walker, Gary AU - Semba, Charles P. AU - Collaborators DO - https://dx.doi.org/10.1016/j.ophtha.2016.04.026 IS - 8 KW - Administration, Topical Adult Aged Aged, 80 and over Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Bimatoprost/ae [Adverse Effects] *Bimatoprost/tu [Therapeutic Use] Delayed-Action Preparations Double-Blind Method Female Follow-Up Studies *Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/pp [Physiopathology] Humans *Intraocular Pressure/de [Drug Effects] Intraocular Pressure/ph [Physiology] Male Middle Aged Prospective Studies Timolol/ae [Adverse Effects] Timolol/tu [Therapeutic Use] Tonometry, Ocular PY - 2016 SE - Brandt, James D. Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, California. Electronic address: jdbrandt@ucdavis.edu. Sall, Kenneth. Sall Research Medical Center, Artesia, California. DuBiner, Harvey. Clayton Eye Center, Morrow, Georgia. Benza, Robert. Apex Eye, Cincinnati, Ohio. Alster, Yair. ForSight VISION5, Inc., Menlo Park, California. Walker, Gary. ForSight VISION5, Inc., Menlo Park, California. Semba, Charles P. ForSight VISION5, Inc., Menlo Park, California. SN - 1549-4713 0161-6420 SP - 1685-1694 ST - Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study T2 - Ophthalmology TI - Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27157843 VL - 123 Y2 - 20160505// ID - 684 ER - TY - JOUR AB - OBJECTIVE: To better understand the course of glaucoma during pregnancy in women with preexisting disease., METHODS: Retrospective case series of 28 eyes of 15 women with glaucoma followed up during pregnancy. Data were analyzed for age, race/ethnicity, medications, glaucoma type, intraocular pressure (IOP), and visual fields before, during, and after pregnancy., RESULTS: In 16 (57.1%) of 28 eyes, IOP was stable during pregnancy, with no progression of visual field loss. In 5 eyes (17.9%), visual field loss progressed during pregnancy, while IOP remained stable or increased. In 5 eyes (17.9%), IOP increased during pregnancy, but there was no progression of visual field loss. In 2 eyes (7.1%), data were inconclusive because of medication noncompliance and preexisting severe visual field loss. Glaucoma medications were used by 13 of 15 patients to control glaucoma during pregnancy. The classes of medications used most frequently were beta-blockers, alpha2-adrenergic agents, cholinergic agents, and topical carbonic anhydrase inhibitors., CONCLUSIONS: The course of glaucoma during pregnancy is variable, and women must be monitored closely during pregnancy. Medications may be necessary to control IOP and to prevent vision loss during pregnancy. AU - Brauner, Stacey C. AU - Chen, Teresa C. AU - Hutchinson, B. Thomas AU - Chang, Michael A. AU - Pasquale, Louis R. AU - Grosskreutz, Cynthia L. IS - 8 KW - Adult Disease Progression Female *Glaucoma/pp [Physiopathology] Humans Intraocular Pressure/ph [Physiology] Pregnancy *Pregnancy Complications/pp [Physiopathology] Retrospective Studies Visual Fields/ph [Physiology] PY - 2006 SE - Brauner, Stacey C. Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA. SN - 0003-9950 SP - 1089-94 ST - The course of glaucoma during pregnancy: a retrospective case series T2 - Archives of ophthalmology (Chicago, Ill. : 1960) TI - The course of glaucoma during pregnancy: a retrospective case series UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16908810 VL - 124 ID - 1649 ER - TY - JOUR AB - Objective: To better understand the course of glaucoma during pregnancy in women with preexisting disease. Methods: Retrospective case series of 28 eyes of 15 women with glaucoma followed up during pregnancy. Data were analyzed for age, race/ethnicity, medications, glaucoma type, intraocular pressure (IOP), and visual fields before, during, and after pregnancy. Results: In 16 (57.1%) of 28 eyes, IOP was stable during pregnancy, with no progression of visual field loss. In 5 eyes (17.9%), visual field loss progressed during pregnancy, while IOP remained stable or increased. In 5 eyes (17.9%), IOP increased during pregnancy, but there was no progression of visual field loss. In 2 eyes (7.1%), data were inconclusive because of medication noncompliance and preexisting severe visual field loss. Glaucoma medications were used by 13 of 15 patients to control glaucoma during pregnancy. The classes of medications used most frequently were beta-blockers, alpha(2)-adrenergic agents, cholinergic agents, and topical carbonic anhydrase inhibitors. Conclusions: The course of glaucoma during pregnancy is variable, and women must be monitored closely during pregnancy. Medications may be necessary to control IOP and to prevent vision loss during pregnancy. AN - WOS:000239758100001 AU - Brauner, S. C. AU - Chen, T. C. AU - Hutchinson, T. AU - Chang, M. A. AU - Pasquale, L. R. AU - Grosskreutz, C. L. DA - AUG DO - 10.1001/archopht.124.8.1089 IS - 8 PY - 2006 SN - 0003-9950 1538-3601 SP - 1089-1094 ST - The course of glaucoma during pregnancy - A retrospective case series T2 - ARCHIVES OF OPHTHALMOLOGY TI - The course of glaucoma during pregnancy - A retrospective case series VL - 124 ID - 6089 ER - TY - JOUR AB - Currently, topical glucocorticosteroids are the most frequently used drugs in dermatologic practice. Over the years, research has focused on strategies to optimize potency and, in particular, the anti-inflammatory and immunosuppressive capacity of these drugs, while minimizing adverse effects. However, 'ideal' topical corticosteroids have not yet been synthesized. They should be able to permeate the stratum corneum and reach adequate concentrations in the skin without reaching high serum concentrations. Such characteristics can be obtained by increasing the natural lipophilicity of corticosteroids, e.g. by esterification. In the past, many structural modifications have been made to improve the efficacy of topical corticosteroids to produce drugs with greater potency, although this has often been associated with a higher likelihood of adverse effects. Betamethasone dipropionate and clobetasol propionate, known as fifth-generation corticosteroids, are a typical example of potent molecules that can control specific dermatoses very rapidly, but which are associated with a high risk of topical and systemic adverse effects. Recently, steroid components have been synthesized that aim to have adequate anti-inflammatory effects and minimal adverse effects. The newest topical corticosteroids used for the treatment of different dermatoses and allergic reactions of the respiratory tract (in particular asthma) are budesonide, mometasone furoate, prednicarbate, the di-esters 17,21-hydrocortisone aceponate and hydrocortisone-17-butyrate-21-propionate, methylprednisolone aceponate, alclometasone dipropionate, and carbothioates such as fluticasone propionate. These new topical corticosteroids are evaluated in the current review, which compares the risk/benefit ratio of each molecule with established agents. The new molecules, compared with the well known and established corticosteroids, generally have a higher anti-inflammatory effect, good compliance among patients (only a once-daily application is needed), rarely induce cross-sensitivity reactions and have weak atrophogenicity. AU - Brazzini, Benedetta AU - Pimpinelli, Nicola IS - 1 KW - Administration, Topical Anti-Inflammatory Agents/ae [Adverse Effects] *Anti-Inflammatory Agents/pd [Pharmacology] Anti-Inflammatory Agents/tu [Therapeutic Use] Budesonide/tu [Therapeutic Use] Drug Compounding Glaucoma/et [Etiology] Humans Hydrocortisone/tu [Therapeutic Use] Hypertrichosis/et [Etiology] Risk Assessment Rosacea/et [Etiology] *Skin Diseases/dt [Drug Therapy] PY - 2002 SE - Brazzini, Benedetta. Department of Dermatology, University of Florence, Florence, Italy. SN - 1175-0561 SP - 47-58 ST - New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use T2 - American journal of clinical dermatology TI - New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11817968 VL - 3 ID - 1899 ER - TY - JOUR AB - THE IMPORTANCE OF VISUAL FUNCTION IN THE ASSESSMENT OF QUALITY OF LIFE: The notion of visual function is related to visual acuity but also to many other parameters such as the visual field, perception of colour, contrasts, and the resistance to blinding. These factors are difficult to measure during routine ophthalmic examination but can be assessed during questionnaires on quality of life. MARKERS OF QUALITY OF LIFE IN OPHTHALMOLOGY: Various quality of life questionnaires have been developed in ophthalmology because the non-specific generic instruments appear inadequate. The SF 36 and SF 20 scales, which are generic instruments widely used in many fields, do not adequately explore the problems related to vision. The first efficient instrument is the VF 14, which is a questionnaire specific to ophthalmic diseases, developed by C. Mangione in 1992. This self-administered questionnaire permits calculation of a 0 to 100 score exploring 5 dimensions (long-sight acuity, near-sight acuity, unclear sight, and driving during the day and at night) during 14 activities with 18 questions. It was translated and adapted into French by Gresset in 1997. Today it is the most commonly used questionnaire in ophthalmology, particularly in the assessment of efficacy and impact in surgery. Along the other specific questionnaires developed, there is the NEI-VQF which was created in 1995 to assess vision and the impact of visual problems on the quality of life of patients, independently of an ophthalmic pathology. Many studies have been conducted on various diseases that affect vision, such as diabetes or hypertension. THE LIMITS OF EXISTING INSTRUMENTS: The specific scales appear far more sensitive and specific than generic scales with regard to ophthalmic problems, but they provide less information on the general status of the patient, except for the NEI-VQF. They are limited in some parameters and do not, unfortunately, take into account the patient's age. No specific scale has been developed for children or adolescents, although the impact of vision on daily life is fundamental. The complexity of vision means that the elaboration of an ideal instrument is difficult. However, in the meantime, it is essential that the practitioners continue to use and to test the instruments available in order to improve with regard to pathologies, or in particular sub-groups of the population. AU - Bremond-Gignac, D. AU - Tixier, J. AU - Missotten, T. AU - Laroche, L. AU - Beresniak, A. IS - 34 KW - Activities of Daily Living Adolescent Adult Aged Automobile Driving Blepharoptosis/su [Surgery] Cataract Cataract Extraction Child Eye Diseases/px [Psychology] Eye Diseases/th [Therapy] *Eye Diseases Glaucoma Humans Middle Aged Patient Satisfaction *Quality of Life *Surveys and Questionnaires Time Factors Vision Disorders/px [Psychology] Vision Disorders/th [Therapy] *Vision Disorders Vision, Ocular Visual Acuity Visual Fields PY - 2002 SE - Bremond-Gignac, D. Service d'ophtalmologie Hopital Robert Debre 48, bd Serurier 75019 Paris. dominique.bremond@rdb.ap-hop-paris.fr SN - 0755-4982 SP - 1607-12 ST - [Evaluation of the quality of life in ophthalmology] T2 - Evaluation de la qualite de vie en ophtalmologie. TI - [Evaluation of the quality of life in ophthalmology] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=12426979 VL - 31 ID - 1866 ER - TY - JOUR AB - BACKGROUND: Convenience and safety are major motivating factors in the choice of a mode of correction for refractive errors. Extended wear of contact lenses is associated with greater convenience than daily wear, but questions remain concerning the safety and risks associated with this modality. This paper investigates the hurdles that have rendered extended wear an unfavorable option thus far and seeks to identify strategies to overcome these obstacles., METHOD: We review the history of extended contact lens wear, focusing on soft extended wear for cosmetic use. Results of incidence and relative risk studies for the major complications are scrutinized. The factors that are associated with increased risk together with mechanisms which have been proposed on based on scientific research are analyzed to derive strategies for preventing adverse reactions in extended wear., RESULT: Infectious keratitis associated with extended wear of contact lenses has been identified by the community as a major issue, although the degree of concern may be disproportionate. Current perceptions of the relative risk of extended wear versus daily wear in the context of the risk for nonwearers may be misplaced, and the role of eye closure versus consistency and duration of wear remains open to debate. In the minds of practitioners and patients, other adverse reactions may be of greater significance in rejecting extended wear. Nonetheless, the potential extent of injury from infection demands attention. Studies collectively attest that corneal hypoxia during extended wear is a potential causative mechanism in infectious keratitis, suggesting that the provision of higher oxygen levels to the cornea will reduce morbidity rates from this unwanted complication. However, the issues of stagnation of the post-lens tear film during eye closure, mechanical properties of the lens, and lens movement remain unresolved and may prove to be contributing factors to adverse responses., CONCLUSIONS: Attention to oxygen permeability and mechanical properties of soft contact lenses should solve the remaining problems with extended wear. Materials currently under development promise to meet at least some of the desired properties and may lead to the long-awaited advent of safe extended wear. AU - Brennan, N. A. AU - Coles, M. L. IS - 8 KW - Animals Contact Lenses, Extended-Wear/ae [Adverse Effects] *Contact Lenses, Extended-Wear Cornea/ph [Physiology] Eye Infections, Bacterial/et [Etiology] Humans Keratitis/mi [Microbiology] Oxygen/me [Metabolism] *Refractive Errors/th [Therapy] Risk Factors Safety PY - 1997 SE - Brennan, N A. Brennan Consultants Pty. Ltd., Medical Centre, Melbourne, Australia. SN - 1040-5488 SP - 609-23 ST - Extended wear in perspective T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Extended wear in perspective UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9323732 VL - 74 ID - 2011 ER - TY - JOUR AB - Intraocular pressure (IOP) measurement in children is often difficult to perform because younger children are non-compliant and resisting the examination. Normal IOP in children is not well established yet because in the studies reporting about IOP, the instruments used and clinical conditions have varied. Non contact tonometer often overestimates IOP in blinking children and is not always reliable. But all the others measurement techniques use contact (GAT, Perkins, Tono-Pen, ORA, RBT), and are not always suitable and easy-touse. Under general anaesthesia, mean IOP measured with Perkins applanation tonometer is under 8 mmHg before age of 3 months and under 12 mmHg between ages of 6 and 9 months. After, IOP shows an increasing trend with age of 1 mmHg per year up to 12 years. Some studies have proposed as normal pediatric IOP: To=0.71 x age (years) +10, up to age 10. Then, IOP tends to approach adult levels by 12 years of age. However pediatric glaucoma is rare: congenital glaucoma, before age of 3 years, autosomal dominant juvenile glaucoma, with family history of glaucoma and elevated IOP, or secondary glaucoma with special context. Thus, hypertony has to be confirmed by another measurement technique, correlated to central corneal thickness, and clinical examination (optic nerve head and visual field). AU - Bresson-Dumont, H. DO - https://dx.doi.org/10.1016/j.jfo.2009.03.008 IS - 3 KW - Child *Glaucoma/di [Diagnosis] *Glaucoma/pp [Physiopathology] Humans *Intraocular Pressure *Tonometry, Ocular PY - 2009 SE - Bresson-Dumont, H. Departement Glaucome, Clinique Sourdille, 3, place Anatole France, 44000 Nantes, France. hbressondumont@free.fr SN - 1773-0597 0181-5512 SP - 176-81 ST - [Intraocular pressure measurement in children] T2 - La mesure de la pression intra-oculaire chez l'enfant. TI - [Intraocular pressure measurement in children] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19515328 VL - 32 ID - 1451 ER - TY - JOUR AB - Since about 20 years, the large panel of the antiglaucoma eyedrops has drastically changed the management of glaucoma. Indications for filtering surgery had decreased in frequency. A great number of patients are controlled only by medications. However ocular intolerance and side effects have been reported until in 50% of the cases with 10% of severe manifestations of intolerance. Ocular side effects to topical medications may very often alter compliance. Ocular intolerance had been shown to be secondary to immunological mechanisms and direct or indirect toxicity. The immunological or allergic mechanisms are induced by a type I or IV hypersensibility and only represent 3% to 10% of all the side effects induced by topical medications. Toxic effect can be a direct through different mechanisms: pure toxic effect, acid pH, osmolarity of the solution, photosensibilisation. This will induce inflammatory reaction that will produce fibrosis in the long term. This toxic effect can be worsened by eye dryness or rosacea. Toxicity can also be indirect through an alteration of the conjunctival microbial flora and/or the lacrymal secretion. Concomitant obstruction of the lacrymal ducts may also contribute to this effect. These mechanisms could have been elucidated thank to histological studies from conjunctival mark, and more recently with confocal HRT, which gives an analysis of the ocular surface in vivo. Appropriate and early detection of intolerance to antiglaucoma medications is mandatory to adjust management strategies accordingly. These are based on the suppression or the reduction of conservative agents whenever possible, the use of fixed combinations, the reduction of the number of the instillations and the associated treatment of the ocular surface. AU - Bresson-Dumont, H. IS - 315 KW - Administration, Topical *Antihypertensive Agents/ae [Adverse Effects] Conjunctivitis/ci [Chemically Induced] *Drug Hypersensitivity/et [Etiology] Fibrosis/ci [Chemically Induced] *Glaucoma/dt [Drug Therapy] Humans Inflammation/ci [Chemically Induced] *Ophthalmic Solutions/ae [Adverse Effects] PY - 2010 SE - Bresson-Dumont, H. Clinique Sourdille, Nantes, France. h.bd@free.fr SN - 0081-0746 SP - 47-53 ST - [Ocular intolerance to antiglaucoma medications is underestimated] T2 - Tolerance locale des medications antiglaucomateuses un probleme sous-estime. TI - [Ocular intolerance to antiglaucoma medications is underestimated] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21114054 ID - 1321 ER - TY - JOUR AB - Purpose: To understand risk factors for failure of glaucoma filtering surgery. Patients: A retrospective study of 67 eyes (16 nonpenetrating trabeculectomies, 51 trabeculectomies [31 with 5FU and 20 with mitomycin]) of 61 patients in whom 5FU bleb revision was needed because of increasing intraocular pressure. Postoperative incidents were analyzed to explain excessive subconjunctival fibroblastic proliferation. Results: In eight cases, IOP increased after 6.16 months (±2) and for 59 eyes, after 33.5 days after surgery (±11.4). Postoperative incidents were 24 (35.9%) bleb leaks, nine cases (13.4%) of hypotony with choroidal detachment, six (9.0%) iris incarcerations, seven (10.4%) cystic blebs, and 21 (31.3%) inflammatory flat blebs. After a mean follow-up of 27 months ± 18, the success of bleb 5FU revision was 84.6% for nonpenetrating trabeculectomy (without glaucoma treatment, 69.2%; with medical treatment, 15.4%) and 73.9% for trabeculectomy (47.8% and 32.6%). Conclusion: Postoperative outcomes favor an inner or outer obstacle to conjunctival filtration. Aqueous humor can no longer remain in the subconjunctival spaces, increasing the risk of glaucoma surgery failure. Early follow-up of glaucoma surgery is crucial to obtaining long-lasting filtration. © 2008 Elsevier Masson SAS. All rights reserved. AD - Clinique Sourdille, 3, place Anatole-France, 44046 Nantes, France AU - Bresson-Dumont, H. AU - Lehoux, A. AU - Baroux, C. AU - Foucher, J. AU - Santiago, P. Y. DB - Scopus DO - 10.1016/S0181-5512(08)73688-X IS - 6 PART 2 KW - bleb bleb surgical revision Filtering surgery glaucoma gonioscopy leaking bleb postoperative follow-up M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2008 SP - 2S74-2S77 ST - Facteurs cliniques favorisant la cicatrisation conjonctivale excessive après chirurgie du glaucome T2 - Journal Francais d'Ophtalmologie TI - Clinical factors favoring excessive subconjunctival fibroblastic proliferation after glaucoma surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-49549115555&doi=10.1016%2fS0181-5512%2808%2973688-X&partnerID=40&md5=b4292a5f0a875b9d73f09ef7fcab7d28 VL - 31 ID - 5479 ER - TY - JOUR AB - Purpose: To understand risk factors for failure of glaucoma filtering surgery. Patients: A retrospective study of 67 eyes (16 nonpenetrating trabeculectomies, 51 trabeculectomies [31 with 5FU and 20 with mitomycin)) of 61 patients in whom 5FU bleb revision was needed because of increasing intraocular pressure. Postoperative incidents were analyzed to explain excessive subconjunctival fibroblastic proliferation. Results: in eight cases, IOP increased after 6.16 months (+/- 2) and for 59 eyes, after 33.5 days after surgery (+/- 11.4). Postoperative incidents were 24 (35.9%) bleb leaks, nine cases (13.4%) of hypotony with choroidal detachment, six (9.0%) iris incarcerations, seven (10.4%) cystic blebs, and 21 (31.3%) inflammatory flat blebs. After a mean follow-up of 27 months 18, the success of bleb 5FU revision was 84.6% for nonpenetrating trabeculectomy (without glaucoma treatment, 69.2%, with medical treatment, 15.4%) and 73.9% for trabeculectomy (47.8% and 32.6%). Conclusion: Postoperative outcomes favor an inner or outer obstacle to conjunctival filtration. Aqueous humor can no longer remain in the subconjunctival spaces, increasing the risk of glaucoma surgery failure, Early follow-up of glaucoma surgery is crucial to obtaining long-lasting filtration. AN - WOS:000258861200015 AU - Bresson-Dumont, H. AU - Lehoux, A. AU - Baroux, C. AU - Foucher, J. AU - Santiago, P. Y. DA - JUN IS - 6 PY - 2008 SN - 0181-5512 SP - 74-77 ST - Clinical factors favoring excessive subconjunctival fibroblastic proliferation after glaucoma surgery T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Clinical factors favoring excessive subconjunctival fibroblastic proliferation after glaucoma surgery VL - 31 ID - 5981 ER - TY - JOUR AB - Purpose: To determine the use of medical services for eye problems in Fiji, and barriers to seeking that care. Methods: An interview-based questionnaire was administered as part of a population-based cross-sectional survey of adults selected by multistage random sampling from those aged ≥40 years living on Fiji's main island. Results: Participation rate was 73.0% (n=1381). A current vision or eye problem was reported by 931 participants, and a further 235 recalled a previous difficulty. Urban dwellers (P=0.002) and those aged ≥50 years (P=0.017) were more likely to report a problem. Gender was not predictive (P=0.215). "Blurred/poor vision" was the most common complaint (78.5%). Over half (53.3%) had not sought care for the problem most important to them. For current problems, being younger (P<0.001) and from a household without paid income (P=0.007) were predictive of being less likely to seek treatment. Gender was not (P=0.416). The most frequently cited principal reason for not seeking care was "able to manage/accept the problem" (66.5%; of whom 84.7% claimed vision problems). Direct and indirect costs were mentioned as deterrents. "Thought nothing could be done" (P=0.032) and "lack of awareness of service availability" (P=0.026) were more common among rural dwellers. Of participants who sought care, 75.6% used government services. Most participants requiring spectacles or medication incurred costs for these. Satisfaction with overall care was independent of provider (P=0.062) and user gender (P=0.851). Conclusion: With expanding service delivery, increased eye health promotion, and attention to the financing of treatments, improved service use ought to be possible in Fiji. © 2012 Informa Healthcare USA, Inc. AD - G. Brian, Fred Hollows Foundation New Zealand, Private Bag 99909, Newmarket, Auckland 1023, New Zealand AU - Brian, G. AU - Maher, L. AU - Ramke, J. AU - Palagyi, A. DB - Embase Medline DO - 10.3109/09286586.2011.628135 IS - 2 KW - adult aged article awareness blurred vision cataract controlled study cross-sectional study eye care eye disease eye injury female Fiji gender glaucoma government health care cost health care delivery health care survey health care utilization health promotion human income interview major clinical study male medical service patient satisfaction population research priority journal pterygium questionnaire sampling urban rural difference LA - English M3 - Article N1 - L364520918 2012-04-04 2012-04-06 PY - 2012 SN - 0928-6586 1744-5086 SP - 43-51 ST - Eye Care in Fiji: A population-based study of use and Barriers T2 - Ophthalmic Epidemiology TI - Eye Care in Fiji: A population-based study of use and Barriers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364520918&from=export http://dx.doi.org/10.3109/09286586.2011.628135 VL - 19 ID - 3093 ER - TY - JOUR AB - OBJECTIVE: To assess the efficacy and tolerability of a fixed combination of bimatoprost and timolol (BTFC) in a large patient sample in a clinical setting., METHODS: In this multicenter, observational, noncontrolled, open-label study, patients (n = 1862) with primary open-angle glaucoma or ocular hypertension were treated with BTFC. Assessments were made at baseline, six weeks, and three months., RESULTS: Prior to starting BTFC, 92.3% of patients were taking other ocular hypotensive medications. In the overall group at three months, mean intraocular pressure was reduced from baseline (21.7 +/- 4.5 mmHg and 21.8 +/- 4.9 mmHg for the right and left eye, respectively) to 16.1 +/- 3.0 mmHg for each eye (P < 0.0001). The majority of patients (92%) reported no adverse events. The most commonly reported adverse events (in >1% of patients) were eye irritation, and ocular and conjunctival hyperemia. Adherence to treatment was generally better than (35.4%) or the same as (57.5%) with prior therapy. BTFC tolerability was rated as excellent or good by 92.3% of physicians and 85.8% of patients., CONCLUSIONS: In a large group of patients with primary open-angle glaucoma or ocular hypertension, treatment with BTFC was associated with consistent reductions in IOP, improved adherence to treatment, and good tolerability. AU - Brief, Gerrett AU - Lammich, Tobias AU - Nagel, Edgar AU - Pfennigsdorf, Stefan AU - Spraul, Christoph W. AU - Ho, Selwyn DO - https://dx.doi.org/10.2147/OPTH.S13074 N1 - Erratum in (EIN) PY - 2010 SE - Brief, Gerrett. Facharzt fur Augenheilkunde, Dortmund, Germany. gerrett.brief@dgn.de SN - 1177-5483 1177-5467 SP - 1125-9 ST - Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment T2 - Clinical ophthalmology (Auckland, N.Z.) T3 - Erratum in: Clin Ophthalmol. 2012;6:1271 Note: Pfennigsdorf, Sabine [correted to Pfennigsdorf, Stefan]. TI - Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=20957059 VL - 4 Y2 - 20101005// ID - 1210 ER - TY - JOUR AB - OBJECTIVES: To understand the reasons that hinder people from uptake of sponsored cataract surgery., METHODS: A mixed methods (qualitative and quantitative) approach was used. During routine screening activities at Kwale District, Kenya, local residents with visually impairing cataract were clinically assessed and offered free surgery. Interviews were conducted using a semi-structured guide that covered different aspects related to acceptance of cataract surgery including knowledge of others who underwent surgery and their outcome. Analysis focused on differences between people accepting and people refusing surgery and the reasons for non-acceptance of surgery., RESULTS: Ninety interviews were conducted, 48 with people accepting and 42 with people refusing free surgery. Those who accepted surgery generally reported good outcome in others, while people who refused surgery often reported to know someone who worsened or even become blind after surgery. Many of these 'failed cases' were prominent figures in the local community, and most of them had already died. Glaucoma was the single most common underlying medical condition. On being re-interviewed, several people admitted that they had actually never met someone who had unsuccessful surgery but only heard rumours., CONCLUSION: In Africa, a rumour of blinding eye surgery is not uncommonly being used by patients to justify their refusal to have cataract surgery. Underlying reasons appear to be related to shame, fear of surgery or missing social support. Improved awareness of the general population regarding eye conditions and their management, involvement of the family and local community in decision making, good surgical outcomes and appropriate counselling are possible methods to enhance acceptance. AU - Briesen, Sebastian AU - Geneau, Robert AU - Roberts, Helen AU - Opiyo, Jael AU - Courtright, Paul DO - https://dx.doi.org/10.1111/j.1365-3156.2010.02486.x IS - 5 KW - Adult Aged *Anecdotes as Topic Cataract/ec [Economics] *Cataract/px [Psychology] Cataract Extraction/ec [Economics] *Cataract Extraction/px [Psychology] Communication Decision Making Female Glaucoma/ec [Economics] Glaucoma/th [Therapy] Health Knowledge, Attitudes, Practice Health Services Accessibility/ec [Economics] Humans Kenya Male Middle Aged Qualitative Research Quality of Life *Treatment Refusal/px [Psychology] Treatment Refusal/sn [Statistics & Numerical Data] Visual Acuity PY - 2010 SE - Briesen, Sebastian. Kwale District Eye Centre, Mombasa, Kenya. SN - 1365-3156 1360-2276 SP - 534-9 ST - Understanding why patients with cataract refuse free surgery: the influence of rumours in Kenya T2 - Tropical medicine & international health : TM & IH TI - Understanding why patients with cataract refuse free surgery: the influence of rumours in Kenya UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20214758 VL - 15 Y2 - 20100301// ID - 1368 ER - TY - JOUR AB - The ophthalmological service for disabled and old age pensioners in the rural districts of Norway is at present very insufficient. A pioneer project was therefore initiated by The National Association for the Prevention of Blindness during the spring of 1980 by equipping a mini-bus with the instruments and examination facilities for ophthalmological cases. The service was designed to take care of those categories of patients who would have great difficulty in being transported over long distances to have an ophthalmological examination. Four districts within the county of Hordaland were selected for a pilot study, revealing a great demand for an eye service by patients in old age homes and in other institutions for chronically disabled persons. 153 patients were examined and 76 had senile cataract, 32 showed a senile macular degeneration and glaucoma was discovered in 10 patients. Minor disorders were diagnosed in many patients. 31 patients (20%) were classified as blind or visually disabled, 15 were referred to hospital for ophthalmological treatment, while 24 started medical treatment or changed previous treatment. 66 persons needed new spectacle correction for optima visual function. AD - Oyeavd., 5016 Haukeland Sykeh., Bergen AU - Brinck, H. P. AU - Aasved, H. AU - Eriksen, H. L. AU - Sorheim, H. DB - Embase Medline IS - 29 KW - ambulatory care geographic distribution Norway ophthalmology prevention therapy visual system LA - Norwegian N1 - L12194656 1982-02-15 PY - 1981 SN - 0029-2001 SP - 1630-1631+1656 ST - The 'eye-bus'. A mobile eye service for the district public health service T2 - Tidsskrift for den Norske Laegeforening TI - The 'eye-bus'. A mobile eye service for the district public health service UR - https://www.embase.com/search/results?subaction=viewrecord&id=L12194656&from=export VL - 101 ID - 4096 ER - TY - JOUR AB - Purpose To report the outcome of 5-fluorouracil (5-FU)-augmented bleb needling revision of failed and failing filtration blebs and to identify risk factors for failure, indicators for success, and any complications of the procedure. Design Prospective, observational, noncomparative, interventional case series with survival analysis. Methods The results of 101 bleb needling procedures augmented with subconjunctival 5-FU injection were determined after a minimum follow-up of 9 months. Kaplan-Meier plots were constructed and a Cox proportional hazards regression analysis was performed to assess the association between study factors and time to failure. Main outcome measures Reduction in intraocular pressure (IOP) by 2 criteria (<22 mmHg, >30%), glaucoma medications, complications, and factors associated with outcome. Results At the time of their last follow-up visit, 60 eyes had an IOP <22 mmHg, mean IOP being reduced from 26.5 mmHg to 18 mmHg after a median of 1 needling procedure (mean, 1.6). The median interval between the "index" filtration surgery and the first (or only) needling procedure was 3.1 months, with a range of 10 days to 11 years. There was a reduction in mean number of topical antiglaucoma agents from 0.7 to 0.2 per successful eye and a median follow-up duration of 18.7 months (range, 9.3-52.0 months). Thus, the overall cross-sectional success rate of the procedure at the time of the last visit was 59.4%. Strong evidence was found for an association between the immediate attainment of a low IOP (<11 mmHg) and longer survival times. None of the other proposed factors that may have affected outcome were identified as having a statistically significant effect; however, this may have been the result of the low statistical power for some of the factors in this study. Conclusions These data suggest that bleb needling augmented with 5-FU is a safe and effective method by which a significant number of failed or failing filtration blebs can be rescued from failure. Attaining an immediate reduction in IOP to <11 mmHg seems to be a favorable factor with respect to reasonably long-term efficacy. © 2004 by the American Academy of Ophthalmology. AD - D.C. Broadway, Norfolk and Norwich Univ. Hospital, Colney Lane, Norwich, Norfolk NR4 7UZ, United Kingdom AU - Broadway, D. C. AU - Bloom, P. A. AU - Bunce, C. AU - Thiagarajan, M. AU - Khaw, P. T. DB - Embase Medline DO - 10.1016/j.ophtha.2003.07.009 IS - 4 KW - antiglaucoma agent bleb fluorouracil unclassified drug adult aged article case study clinical trial female follow up glaucoma human intraocular pressure Kaplan Meier method major clinical study male patient compliance postoperative complication priority journal regression analysis risk assessment risk factor statistical significance surgical technique survival trabeculectomy treatment failure LA - English M3 - Article N1 - L38429662 2004-04-21 PY - 2004 SN - 0161-6420 SP - 665-673 ST - Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: Survival analysis T2 - Ophthalmology TI - Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: Survival analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38429662&from=export http://dx.doi.org/10.1016/j.ophtha.2003.07.009 VL - 111 ID - 3768 ER - TY - JOUR AB - Glaucoma is a leading cause of visual morbidity throughout the world and is an age-related condition, the prevalence of which rises significantly with increasing age. Glaucoma, a condition affecting the optic nerve, has a variety of subtypes with multiple aetiological factors, the most important of which are intraocular pressure (IOP) and increasing age. Treatment by lowering of IOP is the only current method, for which there is evidence, by which the rate of progressive visual deterioration can be slowed or halted. Although there are surgical and laser treatments that are efficacious in lowering IOP, the most common manner in which patients with glaucoma control their IOP is with administration of daily topical ocular hypotensive drugs (eye drops). The variety of topical drugs utilised in the management of glaucoma all have the potential to have adverse effects and/or interactions with concomitant medications, many of which may be used for other age-related conditions. Adherence with appropriate medicines has a major effect on the outcome of medical conditions and this aspect applies to the management of glaucoma. There are certain specific issues that relate to the administration of topical agents, with respect to both adverse effects and adherence. Although many suspect poor adherence in elderly patients with glaucoma, relative to younger patients, adequate evidence for this is lacking. Furthermore, the manner by which adherence issues could be improved remains inadequately understood and poorly addressed. The aims of this article were to review, from a clinical perspective, the medical therapies currently used for glaucoma and discuss adherence issues with respect to the population of patients with glaucoma, who tend to be relatively elderly. AU - Broadway, David C. AU - Cate, Heidi DO - https://dx.doi.org/10.1007/s40266-015-0282-9 IS - 7 KW - Age Factors Aged Antihypertensive Agents/ad [Administration & Dosage] *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Medication Adherence Ophthalmic Solutions PY - 2015 SE - Broadway, David C. Department of Ophthalmology, Norfolk and Norwich University Hospital, Colney Lane, Norwich, Norfolk, NR4 7UY, UK, david.broadway@nnuh.nhs.uk. SN - 1179-1969 1170-229X SP - 569-81 ST - Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma T2 - Drugs & aging TI - Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26136215 VL - 32 ID - 787 ER - TY - JOUR AB - BACKGROUND/OBJECTIVES: to determine whether mass case review, carried out by glaucoma sub-specialist consultants, for patients for whom there was insufficient clinic capacity, could aid reduction of the glaucoma clinic appointment backlog., SUBJECTS/METHODS: patient hospital notes were reviewed by a glaucoma fellowship trained consultant and a decision was made as to whether the planned review was appropriate. Decisions were made with respect to timing, clinic-type and necessity for follow-up, together with an assessment as to whether visual field testing was required., RESULTS: in a 3-year study a total of 9290 cases were included in the study. After consultant review, 5521 (59.5%) patients were kept within the hospital eye service (HES) and an additional 1350 (14.5%) had their next appointment delayed, 384 (4%) were discharged to specialist community glaucoma optometrists and 2035 (22%) were discharged to their standard community optometrists. Overall, therefore 26% of patients were discharged from the HES. Of the planned 9290 appointments, simultaneous visual field testing had been planned for 5393 patients (58%), but after consultant review only 65% (n = 3482) of these were considered necessary, reducing the number of required visual field tests by 35% (n = 1911)., CONCLUSIONS: the authors suggest that ophthalmology departments experiencing significant clinic appointment backlog issues, consider utilising trained glaucoma sub-specialist consultants to review planned follow-up management of patients within a backlog deficit. AU - Broadway, David Charles AU - Tibbenham, Karen DO - https://dx.doi.org/10.1038/s41433-019-0468-1 IS - 11 KW - *Continuity of Patient Care/og [Organization & Administration] *Delivery of Health Care/og [Organization & Administration] Female *Glaucoma/di [Diagnosis] *Glaucoma/th [Therapy] Health Policy *Health Services Accessibility/og [Organization & Administration] Humans Intraocular Pressure Male Medical Audit Middle Aged *Ophthalmology/og [Organization & Administration] Referral and Consultation Specialization State Medicine United Kingdom/ep [Epidemiology] Visual Field Tests Visual Fields *Waiting Lists PY - 2019 SE - Broadway, David Charles. Directorate of Ophthalmology, Norfolk & Norwich University Hospital NHS Foundation Trust Colney Lane, Norwich, NR4 7UY, UK. davidbroadway@waitrose.com. Broadway, David Charles. School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR45 7TJ, UK. davidbroadway@waitrose.com. Tibbenham, Karen. Directorate of Ophthalmology, Norfolk & Norwich University Hospital NHS Foundation Trust Colney Lane, Norwich, NR4 7UY, UK. SN - 1476-5454 0950-222X SP - 1715-1721 ST - Tackling the NHS glaucoma clinic backlog issue T2 - Eye (London, England) TI - Tackling the NHS glaucoma clinic backlog issue UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31110230 VL - 33 Y2 - 20190520// ID - 217 ER - TY - JOUR AD - D.C. Broering, University Hospital of Schleswig-Holstein Campus, Kiel, Germany AU - Broering, D. C. AU - Walter, J. AU - Braun, F. AU - Rogiers, X. C1 - OKT 3 DB - Embase Medline DO - 10.1067/j.cpsurg.2008.05.002 IS - 9 KW - alemtuzumab azathioprine basiliximab calcineurin inhibitor corticosteroid cyclosporine daclizumab everolimus lymphocyte antibody mammalian target of rapamycin inhibitor methylprednisolone mycophenolate mofetil OKT 3 peginterferon prednisolone prednisone rapamycin ribavirin tacrolimus thymocyte antibody acne alopecia anatomical variation article biliary tract disease bone marrow suppression cardiovascular disease chemoembolization clinical trial Cushing syndrome drug substitution drug withdrawal gastrointestinal symptom gingiva hyperplasia glaucoma hepatitis C human hyperglycemia hyperlipidemia immunosuppressive treatment liver cancer liver cell carcinoma liver cirrhosis liver disease liver failure liver graft liver toxicity liver transplantation living donor medical ethics mouth ulcer nephrotoxicity nonhuman osteopenia patient compliance patient selection pediatrics postoperative care postoperative complication radiofrequency ablation recipient side effect stem cell transplantation surgical anatomy surgical technique treatment contraindication treatment indication vascular disease virus replication LA - English M3 - Article N1 - L352117400 2008-08-22 PY - 2008 SN - 0011-3840 SP - 587-661 ST - Current Status of Hepatic Transplantation T2 - Current Problems in Surgery TI - Current Status of Hepatic Transplantation UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352117400&from=export http://dx.doi.org/10.1067/j.cpsurg.2008.05.002 VL - 45 ID - 3431 ER - TY - JOUR AB - Ocular infections are still quite common and their clinical presentation is variable; some of them may lead to blindness. In this paper only severe infections like keratitis and endophthalmitis are considered. The rationale for treatment and prophylaxis is based upon bacteriological findings, understanding of ocular barriers and pharmacokinetics of antibacterial agents. AU - Bron, A. IS - 8 KW - Drug Administration Schedule Endophthalmitis/dt [Drug Therapy] *Eye Infections/dt [Drug Therapy] Eye Infections/mi [Microbiology] Humans Keratitis/dt [Drug Therapy] PY - 1992 SE - Bron, A. Service d'ophtalmologie, hopital general, CHU, Dijon. SN - 0035-2640 SP - 943-5 ST - [Principles of the treatment of ocular infections] T2 - Principes du traitement des infections oculaires. TI - [Principles of the treatment of ocular infections] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1621052 VL - 42 ID - 2105 ER - TY - JOUR AB - OBJECTIVES: To evaluate satisfaction and compliance in glaucoma and ocular hypertensive patients receiving a fixed combination treatment., MATERIALS AND METHODS: After instilling a fixed combination, patients were asked to fill out a questionnaire about their satisfaction and compliance at baseline and 15 days after the onset of new therapy., RESULTS: 1693 glaucoma patients (G) and 621 ocular hypertensive (OHT) patients were included. Mean age was 65.6+/-11.7 years. Onset of disease was 7.2+/-6.6 years and 5.2+/-4.9 years for G and OHT patients, respectively. Insufficient efficacy of the previous topical treatment (monotherapy in 55% of cases) was the main cause for shifting to a fixed combination in 70% of cases. Satisfaction was increased in 15% of the patients and compliance was increased in 25% of the patients., DISCUSSION: Fixed combination provides an easier regimen and therefore encourages better compliance, a key issue in a chronic disease such as glaucoma. AU - Bron, A. AU - Baudouin, C. AU - Denis, P. AU - Nordmann, J. P. AU - Renard, J. P. AU - Rouland, J. F. AU - Sellem, E. IS - 7 KW - *Adrenergic beta-Antagonists/ad [Administration & Dosage] Adrenergic beta-Antagonists/tu [Therapeutic Use] Aged *Carbonic Anhydrase Inhibitors/ad [Administration & Dosage] Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] Drug Combinations Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions *Patient Compliance *Patient Satisfaction Prospective Studies *Prostaglandins/ad [Administration & Dosage] Prostaglandins/tu [Therapeutic Use] Treatment Outcome PY - 2008 SE - Bron, A. Service d'Ophtalmologie, CHU Hopital General, Dijon, France. alain.bron@chu-dijon.fr SN - 1773-0597 0181-5512 SP - 659-65 ST - [Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy] T2 - Satisfaction et observance des patients presentant une hypertonie oculaire ou un glaucome a angle ouvert apres instauration d'une bitherapie fixe. TI - [Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18971850 VL - 31 ID - 1507 ER - TY - JOUR AB - AIM: To evaluate the efficacy and safety of a single daily instillation of nonpreserved timolol in patients with chronic glaucoma or ocular hypertension previously treated with a twice-daily regimen of timolol 0.25% or 0.50%., PATIENTS AND METHODS: A prospective open clinical trial was undertaken by 220 ophthalmologists in 435 patients with chronic glaucoma or ocular hypertension controlled with twice-daily instillations of timolol 0.25% or 0.50%. In this population, the previous regimen was substituted with a single daily instillation of preservative-free timolol 0.25% or 0.50% for 3 months. The changes in intraocular pressure (IOP) were recorded as well as local and systemic tolerance and patient compliance., RESULTS: It was found that 398 patients (93.6%) maintained stable IOP: in 92%, IOP increased no more than 2 mmHg. The mean IOP was 17.0 +/- 2.2 mmHg at D0, 16.5 +/- 2.4 mmHg at D28/42 and 16.6 +/- 2.4 mmHg at D84. The proportion of patients with at least one ocular symptom upon instillation or at another time decreased (p<0.0001 and p=0.03, respectively). The proportion of conjunctival hyperemia reduced from 24.4% to 14.6% (p=0.0002). The rate of folliculopapillar reactions and superficial punctate keratitis was halved (p=0.005 and p=0.02, respectively)., CONCLUSION: During this study in daily practice, the switch from a twice-daily regimen of timolol to a once-daily application maintained stable intraocular pressure with a notable improvement in tolerance. AU - Bron, A. AU - Chiambaretta, F. AU - Pouliquen, P. AU - Rigal, D. AU - Rouland, J. F. IS - 7 KW - *Adrenergic beta-Antagonists/ad [Administration & Dosage] Adrenergic beta-Antagonists/ae [Adverse Effects] Adrenergic beta-Antagonists/tu [Therapeutic Use] Aged Aqueous Humor/me [Metabolism] Chronic Disease Circadian Rhythm Comorbidity Drug Administration Schedule Female *Glaucoma/dt [Drug Therapy] Humans Male Middle Aged *Ocular Hypertension/di [Diagnosis] Ophthalmic Solutions Patient Acceptance of Health Care Prospective Studies Safety *Timolol/ad [Administration & Dosage] Timolol/ae [Adverse Effects] Timolol/tu [Therapeutic Use] PY - 2003 SE - Bron, A. Service d'Ophtalmologie, CHU de Dijon, Hopital General, 3, rue du Faubourg Raines, BP 1519, 21033 Dijon Cedex. Alain.bron@CHU-Dijon.fr SN - 0181-5512 SP - 668-74 ST - [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension] T2 - Interet de la substitution d'un traitement journalier de 2 instillations de timolol par 1 instillation quotidienne de betabloquant non conserve chez des patients presentant un glaucome chronique ou une hypertonie oculaire. TI - [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=13130253 VL - 26 ID - 1828 ER - TY - JOUR AB - PURPOSE: Several recent clinical studies have shown the benefit of lowering intraocular pressure in both ocular hypertensive and glaucoma patients. However, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), there is no consensus on the value of intraocular pressure (IOP) to be reached to prevent the progression of visual field defects. This IOP value, called target IOP, is defined by the ophthalmologist according to the patient and the progression of the disease, without a clear explicit justification of this decision. In France, ophthalmologists' education is mainly based on scientific meetings and the European Guidelines. This study was conducted to investigate the position of the IOP target in the treatment strategy for patients with glaucoma or OHT., MATERIAL: and methods: A cross-sectional descriptive survey was conducted in France among ophthalmologists in private practice. Patients with simple OHT or with OAG who required an initiation or a modification of treatment were included., RESULTS: We included 1735 patients (805 males, 46.4%) in the study. An OAG was diagnosed in 1338 patients (77.1%) and a simple OHT in 397 patients (22.9%). The patients with OAG were older than the OHT patients (65 years vs 61.7 years, p<0.0001). Most patients (73.5%) were included for treatment modification (77.5% of the patients with OAG and 59.9% of the patients with simple OHT; p<0.0001). The main reason for treatment change was an unsatisfactory IOP value. The main therapeutic objective was to reach a target IOP in 46.0% of the patients. The choice of the ocular hypotensive drugs depended on the IOP value in 51.9% of the patients. When the treatment was modified, monotherapy was preferred in 60.8% of the patients., CONCLUSION: Among ophthalmologists, the main objective for the treatment of patients with simple OHT or with OAG was to reach a target IOP. About half the participants were used to set up a target pressure for their patients. This fairly good ratio shows the comprehensiveness and the adaptation of our colleagues to relatively new concepts in treating and managing patients with ocular hypertension or chronic open-angle glaucoma. If a modification in the treatment was necessary, then monotherapy was preferred. This decision was motivated by the efficacy of the treatment but also by expected better patient compliance. AU - Bron, A. AU - Nordmann, J. P. AU - Baudouin, C. AU - Rouland, J. F. AU - Kadi, A. AU - Sartral, M. IS - 9 KW - Adult Aged Cross-Sectional Studies Decision Making Disease Progression Drug Monitoring Female France Glaucoma, Open-Angle/di [Diagnosis] *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Intraocular Pressure Male Manometry Middle Aged Ocular Hypertension/di [Diagnosis] *Ocular Hypertension/dt [Drug Therapy] Ophthalmology/ed [Education] *Ophthalmology/mt [Methods] Ophthalmology/sn [Statistics & Numerical Data] Patient Compliance/px [Psychology] *Patient Selection Practice Guidelines as Topic Practice Patterns, Physicians'/sn [Statistics & Numerical Data] *Practice Patterns, Physicians' Private Practice Risk Factors Surveys and Questionnaires Treatment Outcome Visual Fields PY - 2003 SE - Bron, A. Service d'Ophtalmologie, CHU Hopital General, 21000 Dijon. Alain.bron@chu-dijon.fr SN - 0181-5512 SP - 895-903 ST - [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France] T2 - Glaucome et hypertonie oculaire: importance de la pression intraoculaire cible dans la prise en charge therapeutique en France. TI - [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=14631273 VL - 26 ID - 1814 ER - TY - JOUR AB - AIM: To ascertain why ophthalmologists shift therapy to a fixed-combination or non-fixed-combination drug therapy., PATIENTS AND METHODS: A prospective multicenter observational study was conducted among French ophthalmologists working in private or mixed practice. The study included adult patients with open-angle glaucoma or ocular hypertension, treated with monotherapy or dual therapy and needing to modify their initial treatment. The patients had to fill out a self-questionnaire 15 days after the change in therapy, evaluating the compliance and assessment of the new treatment., RESULTS: The analysis was made on 775 questionnaires filled out by ophthalmologists between March 1st and July 31st 2003 on 5734 patients. The mean age was 66.4+/-12.4 years and women represented 53.6% of the patients. The diagnosis had been made, on average, 7.5+/-7.3 years before. The mean initial intraocular pressure under treatment was 19.8+/-4.1 mmHg in both eyes. Initially, 58.2% of the patients had monotherapy, 40.4% dual therapy and 1.4% triple therapy. The main reasons for shifting therapy were "high intraocular pressure under treatment" for 63.5% of the patients and "simplification of the treatment" for 39.1% of the patients (several reasons per patient were accepted). Most of the patients were satisfied with their new therapy (71%), which in most cases was a fixed-combination therapy (95.2%)., DISCUSSION: This study has shown that the use of at least two active principles is a common practice in the treatment of glaucoma and ocular hypertension. An additive therapy is given in order to better control the intraocular pressure, mainly with a fixed combination. AU - Bron, A. AU - Nordmann, J. P. AU - Rouland, J. F. AU - Baudouin, C. AU - Sartral, M. IS - 2 KW - Adolescent Adult Aged Aged, 80 and over Drug Therapy, Combination Female Glaucoma, Open-Angle/dt [Drug Therapy] Humans Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Practice Patterns, Physicians' Prospective Studies Surveys and Questionnaires PY - 2006 SE - Bron, A. Service d'Ophtalmologie, CHU, Dijon. alain.bron@chu-dijon.fr SN - 1773-0597 0181-5512 SP - 164-8 ST - [Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment] T2 - Enquete observationnelle sur les conditions d'utilisation des bitherapies dans le traitement de l'hypertonie oculaire ou du glaucome a angle ouvert en France. TI - [Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16523158 VL - 29 ID - 1678 ER - TY - JOUR AB - AIM: To compare the efficacy and safety of a single daily instillation of nonpreserved timolol to a timolol maleate gel-forming solution in patients with chronic glaucoma or ocular hypertension already treated with latanoprost., PATIENTS AND METHODS: A randomized, prospective, multicenter, open, parallel-group clinical trial was undertaken with 73 patients with chronic glaucoma treated with latanoprost and a timolol maleate gel-forming solution. In 36 patients, the previous regimen was substituted by nonpreserved timolol given instead of timolol maleate gel for 3 months. The changes in intraocular pressure (IOP) were recorded as well as local and systemic tolerance and patient compliance., RESULTS: At 3 months, both regimens were found equivalent in maintaining IOP control between D0 and D84. The difference with baseline was -0.08 +/- 2.22 mmHg and -0.38 +/- 2.41 mmHg in the nonpreserved timolol group and in the timolol maleate gel-forming solution group, respectively (CI 95% [-0.79; 1.38]). After 84 days of treatment, blurred vision (5.9%) and eyelid deposits (5.9%) were reduced in the preservative-free timolol group compared to the other group (respectively, 33.3% and 24.2%). These differences were statistically significant for both signs (blurred vision: p < 0.0001 and for eyelid deposits: p = 0.03)., CONCLUSION: This short-term study has demonstrated the equivalence of nonpreserved timolol to timolol maleate gel-forming solution in terms of IOP control. Moreover, the local tolerance of nonpreserved timolol was better. AU - Bron, A. AU - Velasque, L. AU - Rebica, H. AU - Pouliquen, P. AU - Elena, P. P. AU - Rouland, J. F. IS - 9 Pt 1 KW - Aged *Antihypertensive Agents/ad [Administration & Dosage] Delayed-Action Preparations Drug Administration Schedule Female *Glaucoma/dt [Drug Therapy] Humans Latanoprost Male Middle Aged Prospective Studies *Prostaglandins F, Synthetic/ad [Administration & Dosage] Time Factors *Timolol/ad [Administration & Dosage] PY - 2004 SE - Bron, A. Service d'Ophtalmologie, CHU de Dijon, Hopital General, 3, rue du Faubourg Raines, BP 1519, 21033 Dijon Cedex, France. Alain.bron@CHU-Dijon.fr SN - 0181-5512 SP - 971-7 ST - [Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost] T2 - Comparaison du timolol sans conservateur et du timolol a delivrance prolongee donnes une fois par jour en association a du latanoprost. TI - [Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15557857 VL - 27 ID - 1763 ER - TY - JOUR AB - We reviewed available data comparing latanoprost and combined timolol and dorzolamide and the additive effect of latanoprost in patients receiving timolol and dorzolamide in combination using a literature search through the electronic Medline database and presentations from proceedings of recent glaucoma meetings. Several studies have shown that the intraocular pressure (IOP)-lowering effect of latanoprost once a day is equivalent to timolol 0.5% twice a day and concomitant or combined dorzolamide 2% twice a day. Adding latanoprost to timolol and dorzolamide leads to a further 16% reduction of IOP. We conclude that the effect on IOP reduction of latanoprost is similar to combined timolol and dorzolamide, and the additive effect of latanoprost to a combination of timolol and dorzolamide is clinically relevant. In most cases, the overall safety profile of latanoprost is better than combined timolol and dorzolamide. © 2002 by Elsevier Science Inc. All rights reserved. AD - A.M. Bron, Department of Ophthalmology, Hôpital Général, 3 rue du Faubourg Raines, 21000 Dijon, France AU - Bron, A. M. AU - Emmerich, K. H. C1 - cosopt(Merck and Co,United States) xalatan(Pharmacia Upjohn,United States) C2 - Merck and Co(United States) Pharmacia Upjohn(United States) DB - Embase Medline DO - 10.1016/S0039-6257(02)00290-4 IS - 4 SUPPL. 1 KW - dorzolamide dorzolamide plus timolol latanoprost prostaglandin derivative timolol aqueous humor flow blepharitis circadian rhythm clinical practice clinical trial conjunctiva disease conjunctival hyperemia cornea disease drug activity drug cost drug efficacy drug indication drug safety dry eye epiphora eye color eye irritation eye pain flu like syndrome headache human intraocular hypertension intraocular pressure meta analysis metabolic disorder open angle glaucoma patient compliance photophobia prescription priority journal respiratory tract disease review side effect skin disease uveitis visual impairment cosopt xalatan LA - English M3 - Review N1 - L35232229 2002-11-12 PY - 2002 SN - 0039-6257 SP - S148-S154 ST - Latanoprost versus combined timolol and dorzolamide T2 - Survey of Ophthalmology TI - Latanoprost versus combined timolol and dorzolamide UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35232229&from=export http://dx.doi.org/10.1016/S0039-6257(02)00290-4 VL - 47 ID - 3859 ER - TY - JOUR AB - The results of argon laser trabeculoplasty (ALT) in a series of 252 patients are presented with follow-up of up to five years. The procedure is effective in chronic open-angle glaucoma (COAG), ocular hypertension and pseudoexfoliative (PXF) glaucoma. Most cases were treated initially over 180 degrees of the angle and repeat treatment of the remaining 180 degrees usually resulted in an additional fall in IOP which was maintained at two, three and four year follow-up with only a small number of these retreated cases having no fall on later follow-up. ALT was not very effective in further lowering IOP in eyes with IOP controlled to a low level before treatment or in low tension glaucoma. It was effective in most of a number of miscellaneous glaucomas including pigmentary glaucoma. Apart from the immediate high rise in IOP the main complication was a late high rise in IOP which was serious in degree and appeared mainly in PXF but also in two cases of ocular hypertension. The presence of a concomitant fall in IOP in the fellow untreated eye is important and probably due to better compliance with treatment. Almost all cases required medical treatment for glaucoma which could not be ceased after ALT. ALT should be seen as an adjunct to, but not a substitute for, medical treatment. AU - Brooks, A. M. AU - West, R. H. AU - Gillies, W. E. IS - 4 KW - Adult Aged Female Follow-Up Studies *Glaucoma/su [Surgery] Glaucoma, Open-Angle/su [Surgery] Humans *Laser Therapy/mt [Methods] Male Middle Aged *Trabeculectomy/mt [Methods] PY - 1988 SE - Brooks, A M. Glaucoma Investigation and Research Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia. SN - 0814-9763 SP - 343-51 ST - Argon laser trabeculoplasty five years on T2 - Australian and New Zealand journal of ophthalmology TI - Argon laser trabeculoplasty five years on UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=3073798 VL - 16 ID - 2189 ER - TY - JOUR AD - A.M.V. Brooks, Royal Victorian Eye and Ear Hosp., East Melbourne, Vic., Australia AU - Brooks, A. M. V. DB - Embase IS - PROC. KW - acetazolamide apraclonidine betaxolol brimonidine dipivefrine fluorouracil latanoprost pilocarpine timolol adult argon laser case report chronic disease clinical protocol conference paper diode laser eye disease human intraocular hypertension intraocular pressure male open angle glaucoma optic disk patient compliance red eye respiratory function trabeculotomy visual disorder visual field visual system examination YAG laser LA - English M3 - Conference Paper N1 - L38049218 2004-01-19 PY - 2003 SN - 1442-6404 SP - 36-40 ST - Difficult drug regimens, poor compliance and erratic attendance in chronic open-angle glaucoma T2 - Clinical and Experimental Ophthalmology TI - Difficult drug regimens, poor compliance and erratic attendance in chronic open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38049218&from=export VL - 31 ID - 3782 ER - TY - JOUR AB - Purpose To describe the clinical appearance of corneal epithelial cell microerosions associated with keratomycosis in the horse. METHODS: Retrospective clinical study. RESULTS: Multifocal, punctate, superficial corneal opacities with positive rose bengal retention were noted in six horses with presumed 'viral keratitis'. Faint fluorescein staining was also present in three cases. Equine herpesvirus tissue culture inoculation was negative for a cytopathic effect in three cases. Aspergillus (n = 3), Curvularia (n = 1), and an unidentified fungus (n = 1) were cultured in five horses, and hyphae found on corneal cytology from the sixth. Mixed bacterial infections were present in three eyes. The eyes of two horses with Aspergillus progressed to deep melting corneal ulcers that required surgical therapy. The microerosions remained superficial, but persistent in the other four eyes. Natamycin was utilized topically in all six horses. Transmission electron microscopy from case 6 revealed mucin layer disruption, an intact corneal epithelial cell layer, and fungal attachment to degenerating epithelial cells. The visual outcome was positive in all six horses, although healing was prolonged (48.5 +/- 14.5 days on average in the horses with no surgery; 62 days on average in the two horses that required surgery). CONCLUSIONS : Complete removal or full-thickness penetration of the corneal epithelial cell barrier may not be necessary to allow fungal adherence and initiation of keratomycosis in the horse. Prior to colonization and invasion of the horse cornea, fungi may induce changes in the mucin layer of the tear film that result in or are associated with rose bengal positive microerosions of the superficial corneal epithelium. Horses with painful eyes, and eyes with superficial, multifocal corneal opacities should have their corneas stained with both fluorescein and rose bengal as fungal microerosions may stain weakly, or not at all, with fluorescein, and may thus be mistaken for presumed 'viral keratitis' of the horse. AU - Brooks, D. E. AU - Andrew, S. E. AU - Denis, H. AU - Strubbe, D. T. AU - Biros, D. J. AU - Cutler, T. J. AU - Samuelson, D. A. AU - Gelatt, K. N. IS - 2-3 PY - 2000 SE - Brooks, D.E.. Departments of Large and Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, 2015 SW 16 Ave, Gainesville, FL 32601-0126, USA. SN - 1463-5224 1463-5216 SP - 83-86 ST - Rose bengal positive epithelial microerosions as a manifestation of equine keratomycosis T2 - Veterinary ophthalmology TI - Rose bengal positive epithelial microerosions as a manifestation of equine keratomycosis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=11397287 VL - 3 ID - 1232 ER - TY - JOUR AD - Ophthalmic technologist and low vision consultant with Light and Magnify Technologies AN - 142254209. Language: English. Entry Date: 20200318. Revision Date: 20200318. Publication Type: Article. Journal Subset: Core Nursing AU - Brown, Barbara DA - Winter2020 DB - ccm DP - EBSCOhost IS - 1 KW - Vision, Subnormal Functional Status Patient Care Support, Psychosocial Ophthalmic Nursing Nurses -- Education Office Visits Patient Education Patient Attitudes Macular Degeneration -- In Adulthood Adult United States Nurse-Patient Relations Glaucoma Corneal Diseases Diabetes Mellitus -- Complications Nursing Assessment N1 - Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PY - 2020 SN - 1060-135X SP - 21-23 ST - How Low Vision Affects the Functional Ability of Patients and What You Can Do to Help T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - How Low Vision Affects the Functional Ability of Patients and What You Can Do to Help UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142254209&site=ehost-live&scope=site VL - 45 ID - 4197 ER - TY - JOUR AD - G.C. Brown, 6010 West Mill Rd, Flourtown, PA 19031-1404, United States AU - Brown, G. C. C1 - avastin lucentis macugen DB - Embase Medline DO - 10.1097/01.icu.0000193103.15336.fd IS - 3 KW - antiglaucoma agent benzoporphyrin derivative bevacizumab hydroxymethylglutaryl coenzyme A reductase inhibitor pegaptanib ranibizumab triamcinolone clinical practice comparative study cost benefit analysis cost effectiveness analysis digestive system perforation economic aspect editorial endophthalmitis eye color glaucoma headache health care health care utilization human hyperemia hyperlipidemia hypertension thermotherapy laser coagulation neovascularization (pathology) ophthalmology photodynamic therapy phototoxicity priority journal quality of life respiratory distress macular degeneration side effect skin discoloration subretinal neovascularization wound dehiscence avastin lucentis macugen LA - English M3 - Editorial N1 - L44309743 2006-09-10 PY - 2006 SN - 1040-8738 SP - 219-222 ST - 56 000 ways? No way! T2 - Current Opinion in Ophthalmology TI - 56 000 ways? No way! UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44309743&from=export http://dx.doi.org/10.1097/01.icu.0000193103.15336.fd VL - 17 ID - 3608 ER - TY - JOUR AB - PURPOSE: To perform patient preference-based comparative effectiveness and cost-utility (cost-effectiveness) analyses to evaluate topical bimatoprost 0.01%, latanoprost 0.005%, travoprost 0.004%, tafluprost 0.0015%, and timolol 0.5% for the treatment of open-angle glaucoma (OAG)., METHODS: Value-Based Medicine R, incremental cost-utility analysis, and average cost-utility analysis were performed using published systematic review and network meta-analyses with 3-month clinical data for a base case of OAG with an untreated intraocular pressure of 26 mm Hg. Visual acuity and visual field changes were converted to time tradeoff utility format. A 20-year model was undertaken; bilateral therapy was presumed; a national average Medicare Fee Schedule was used; and ophthalmic, third party insurer, and societal cost perspectives were utilized. Patient value outcomes (QALYs or quality-adjusted life-years) and costs were discounted at 3% annually., RESULTS: Bimatoprost conferred a mean 2.56 QALY gain (22.9% patient quality-of-life gain) for the average OAG patient, while latanoprost for the average OAG patient, while latanoprost conferred a 2.00 QALY gain (17.8% quality-of-life gain), tafluprost a 1.99 QALY gain (17.9% quality-of-life gain), travoprost a l.92 QALY gain (17.2% quality-of-life gain), and timolol a 1.42 QALY gain (12.8% quality-of-life gain). The ophthalmic cost-perspective, incremental cost-utility ratio of bimatoprost referent to travoprost was $6,034/QALY, to latanoprost was $27,973/QALY, and to timolol was $16,063/QALY. Bimatoprost dominated tafluprost, meaning that it conferred greater patient value for lesser cost than tafluprost., CONCLUSIONS: Topical bimatoprost delivers greater patient value than the other prostamides and topical timolol for the treatment of OAG. Bimatoprost is incrementally cost-effective referent to the other prostamides and timolol. AU - Brown, Gary C. AU - Brown, Melissa M. DO - https://dx.doi.org/10.1089/jop.2018.0114 IS - 3 KW - Bimatoprost/ec [Economics] *Bimatoprost/tu [Therapeutic Use] Cost-Benefit Analysis *Glaucoma, Open-Angle/dt [Drug Therapy] Health Care Costs Humans Intraocular Pressure/de [Drug Effects] Latanoprost/ec [Economics] *Latanoprost/tu [Therapeutic Use] Patient Preference Prostaglandins F/ec [Economics] *Prostaglandins F/tu [Therapeutic Use] Timolol/ec [Economics] *Timolol/tu [Therapeutic Use] Travoprost/ec [Economics] *Travoprost/tu [Therapeutic Use] Visual Acuity/de [Drug Effects] PY - 2019 SE - Brown, Gary C. 1 Center for Value-Based Medicine R, Hilton Head, South Carolina. Brown, Gary C. 2 Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Brown, Gary C. 3 The Eye Research Institute, Philadelphia, Pennsylvania. Brown, Gary C. 4 Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia. Brown, Melissa M. 1 Center for Value-Based Medicine R, Hilton Head, South Carolina. Brown, Melissa M. 2 Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Brown, Melissa M. 3 The Eye Research Institute, Philadelphia, Pennsylvania. Brown, Melissa M. 4 Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia. SN - 1557-7732 1080-7683 SP - 145-160 ST - Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics TI - Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30920338 VL - 35 Y2 - 20190328// ID - 346 ER - TY - JOUR AD - M.M. Brown, Center for Value-Based Medicine, Flourtown, PA, United States AU - Brown, M. M. DB - Embase IS - 4 KW - antiglaucoma agent eye drops latanoprost drug use glaucoma health behavior human illness behavior intraocular pressure monotherapy note patient care patient compliance patient education prescription priority journal probability LA - English M3 - Note N1 - L41507739 2005-11-15 PY - 2005 SN - 1555-9203 1555-9211 SP - 207-208 ST - Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? T2 - Evidence-Based Ophthalmology TI - Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41507739&from=export VL - 6 ID - 3663 ER - TY - JOUR AB - Possible sequelae of improper administration of eyedrops include treatment failure, unnecessary use of additional medications and spread of infection. To determine the extent of improper topical self-application of ocular medications, 150 patients with glaucoma who were already using eyedrops were studied. Employing their customary methods of administration 19 (13%) of the patients were unable to place drops in both eyes after one or more attempts, and 120 (80%) of the patients failed to maintain the bottle's sterility during application. No significant relation was found between performance and age, sex, educational level, visual acuity or field, intraocular pressure, length of time the patient had been using eyedrops or, among the 100 clinic patients, whether the patient had received prior instruction in their use. The 50 private practice patients had all received prior instruction, by one physician, whereas only 62% of the clinic patients had, and there had been several instructors at the clinic. Significantly more (p less than 0.05) of the clinic patients than of the private practice patients failed to wash their hands before instilling the drops (97% v. 78%) and were unable to properly instil the drops in both eyes after one or more attempts (18% v. 2%). Therefore, uniform teaching probably improves the ability of patients to topically administer ocular medication. AU - Brown, M. M. AU - Brown, G. C. AU - Spaeth, G. L. IS - 1 KW - Administration, Topical Adult Aged Ambulatory Care Facilities Cross-Sectional Studies Female *Glaucoma/dt [Drug Therapy] Humans Male Middle Aged *Ophthalmic Solutions/ad [Administration & Dosage] Patient Compliance Private Practice Self Administration PY - 1984 SN - 0008-4182 SP - 2-5 ST - Improper topical self-administration of ocular medication among patients with glaucoma T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - Improper topical self-administration of ocular medication among patients with glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=6608974 VL - 19 ID - 2225 ER - TY - JOUR AU - Brown, R. H. IS - 2 KW - Adrenergic beta-Antagonists/tu [Therapeutic Use] Drug Therapy, Combination Epinephrine/aa [Analogs & Derivatives] Epinephrine/tu [Therapeutic Use] *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Ophthalmic Solutions/tu [Therapeutic Use] Patient Compliance PY - 1991 SE - Brown, R H. Emory University, Atlanta, GA. SN - 0733-8902 SP - 135-6 ST - Combination therapy T2 - The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc TI - Combination therapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1675596 VL - 17 ID - 2140 ER - TY - JOUR AB - Mini-scleral lenses are an increasingly popular contact lens modality; however, there are relatively few reports regarding the unique aspects of their fitting and potential complications. We report a complication of mini-scleral lens wear in a 44-year-old female patient using the lenses for keratoconus. Her mini-scleral contact lenses were non-fenestrated and fitted to vault over the cornea and seal at the periphery. The patient presented with an acute red eye (non-ulcerative keratitis), characterised by unilateral severe conjunctival and limbal hyperaemia, corneal infiltration and pain. Refitting the lens to increase the corneal vault clearance did not prevent recurrence of the keratitis, some five months later. Successful prevention of further episodes of the acute red eye was achieved through improved patient compliance with lens cleaning, disinfection and lens case procedures. Lens hygiene may be particularly important for mini-scleral lenses with a sealed fitting. Copyright © 2013 The Authors. Clinical and Experimental Optometry © 2013 Optometrists Association Australia. AU - Bruce, Adrian S. AU - Nguyen, Leanne M. DO - https://dx.doi.org/10.1111/cxo.12033 IS - 2 KW - Acute Disease Adult *Contact Lenses/ae [Adverse Effects] Female Humans *Keratitis/et [Etiology] *Keratoconus/th [Therapy] *Sclera PY - 2013 SE - Bruce, Adrian S. Australian College of Optometry, Carlton, Victoria, Australia; Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Victoria, Australia. abruce@aco.org.au SN - 1444-0938 0816-4622 SP - 245-8 ST - Acute red eye (non-ulcerative keratitis) associated with mini-scleral contact lens wear for keratoconus T2 - Clinical & experimental optometry TI - Acute red eye (non-ulcerative keratitis) associated with mini-scleral contact lens wear for keratoconus UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23387325 VL - 96 Y2 - 20130206// ID - 992 ER - TY - JOUR AB - PURPOSE: Over the next 10 years, the prevalence of glaucoma in the United Kingdom (UK) is predicted to rise by 22%,(The Way Forward: Glaucoma, The Royal College of Ophthalmologists, London, 2017) posing a considerable challenge to already overstretched hospital eye services. To help address this problem, services traditionally offered in hospital such as managing stable glaucoma patients, could be transferred to community optometrists. The aim of this study was to identify whether optometrists in Scotland have an interest in managing primary open angle glaucoma (POAG) in primary care and to assess perceived barriers., METHODS: All optometrists on the NHS Education Scotland (NES) database were invited to participate in an online survey over a 7-week period. Optometrists were asked if they had an interest in being accredited to manage POAG in the community and a free text question was used to elicit perceived barriers. Responders with an interest in managing POAG were invited to take part in two further rounds of electronic surveying, using a modified Delphi approach, with the aim of reaching a consensus on perceived barriers., RESULTS: Two hundred and ninety-nine of 1566 optometrists (19%) responded to the survey. 229 (79%) expressed an interest in managing patients with POAG in primary care. The most commonly perceived barriers after two rounds of Delphi surveying were remuneration (29%), communication with secondary care (18%), perceived ophthalmology resistance (13%), training (11%) and capacity (10%). Multivariate regression revealed fewer years in practice and comfort using and interpreting results of pachymetry were associated with higher odds of interest in managing glaucoma in the community., CONCLUSIONS: Among survey responders, there was significant interest from community optometrists to being accredited to manage POAG in primary care. A collaborative approach between primary and secondary care will be required to address the concerns of community optometrists in any future expansion of their role in glaucoma management. Copyright © 2018 The Authors Ophthalmic & Physiological Optics © 2018 The College of Optometrists. AU - Bruce, Gillian AU - Tatham, Andrew J. DO - https://dx.doi.org/10.1111/opo.12591 IS - 6 KW - *Attitude of Health Personnel *Disease Management Female *Glaucoma/th [Therapy] Humans Male *Optometrists/st [Standards] *Optometry/mt [Methods] Pilot Projects *Primary Health Care/mt [Methods] Retrospective Studies Scotland *Surveys and Questionnaires PY - 2018 SE - Bruce, Gillian. University of Edinburgh, Edinburgh, UK. Tatham, Andrew J. University of Edinburgh, Edinburgh, UK. Tatham, Andrew J. Princess Alexandra Eye Pavilion, Edinburgh, UK. SN - 1475-1313 0275-5408 SP - 629-639 ST - Glaucoma management in primary care: barriers perceived by optometrists in Scotland T2 - Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) TI - Glaucoma management in primary care: barriers perceived by optometrists in Scotland UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30575069 VL - 38 ID - 392 ER - TY - JOUR AB - The behavior and effects of medications may be modified in the elderly. Factors contributing to such alterations may involve differences in drug pharmacokinetics and response and/or social and economic factors that affect nutrition and compliance to medications. Many studies have been devoted to such factors, but most of them have not taken into account chronopharmacologic data. Indeed, drug-administration time constitutes an additional factor of variability in drug response in the elderly. Biological rhythm-dependent differences in the kinetics and dynamics of medications seem to be diminished or altered with aging. Chronopathological (rhythmic aspects of disease) data in the elderly are of particular importance, taking into account frequently associated diseases, such as chronic obstructive pulmonary disease, cancer, diabetes, glaucoma, hypertension, and inflammatory conditions, among others. Although some chronobiological data are available, chronopharmacologic phenomena have yet to be extensively investigated in the elderly. Most of the sparse studies concern drug chronokinetics, but the data found in the literature do not reveal a clear trend in the age-related changes. Chronokinetic variations in the elderly, compared to young adults, suggest an amplification of the administration-time effects, as demonstrated for digoxin; dampening, as demonstrated for indomethacin; or detection of administration-time effects only in aged but not in young subjects, as found for others medications. Additional studies are needed to better understand the influence of age on the chronokinetics of medications. Moreover, the literature on possible administration-time differences in drug dynamics in the elderly is also very sparse. Altered receptor and/or post-receptor properties and impaired sensitivity of homeostatic mechanisms have yet to be studied from a chronopharmacological point of view. Thus, additional studies are needed to properly understand how drug responses in the elderly may vary in relation to the circadian timing of medications. AU - Bruguerolle, Bernard DO - https://dx.doi.org/10.1080/07420520801909247 IS - 1 KW - Aged *Chronobiology Phenomena Disease Health Humans Kinetics Pharmaceutical Preparations PY - 2008 SE - Bruguerolle, Bernard. Medical and Clinical Pharmacology, Faculty of Medicine of Marseille, Universite de la Mediterranee, and CHU, Marseilles, France. bruguerolle@medecine.univ-mrs.fr SN - 0742-0528 SP - 1-15 ST - Clinical chronopharmacology in the elderly T2 - Chronobiology international TI - Clinical chronopharmacology in the elderly UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18293146 VL - 25 ID - 1546 ER - TY - JOUR AU - Bruynseels, A. AU - Cross, V. AU - Sii, F. AU - Shah, P. AU - Abbott, J. DO - https://dx.doi.org/10.1038/eye.2017.115 IS - 12 KW - Child *Diffusion of Innovation Disease Management *Glaucoma/th [Therapy] Health Promotion/mt [Methods] Humans *Medical Records Patient Education as Topic/mt [Methods] Patient Participation Self Care PY - 2017 SE - Bruynseels, A. Frimley Park Hospital, Camberley, UK. Cross, V. Institute of Health, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, UK. Sii, F. Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Sii, F. Birmingham Institute for Glaucoma Research, Institute for Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Shah, P. Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Shah, P. Birmingham Institute for Glaucoma Research, Institute for Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Shah, P. Centre of Health and Social Care Improvement, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, UK. Shah, P. University College London, London, UK. Abbott, J. Birmingham Institute for Glaucoma Research, Institute for Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Abbott, J. Birmingham Children's Hospital, Birmingham, UK. SN - 1476-5454 0950-222X SP - 1635-1638 ST - Developing a children's glaucoma passport: mapping innovations in healthcare T2 - Eye (London, England) TI - Developing a children's glaucoma passport: mapping innovations in healthcare UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28622315 VL - 31 Y2 - 20170616// ID - 508 ER - TY - JOUR AU - Bryan, J. C1 - alderlin(Astra Zeneca) alderlin(ICI) inderal tenormin(ICI) C2 - Astra Zeneca ICI DB - Embase IS - 7477 KW - amiloride plus hydrochlorothiazide atenolol beta adrenergic receptor blocking agent calcium channel blocking agent carvedilol dipeptidyl carboxypeptidase inhibitor diuretic agent fibrinolytic agent guanethidine labetalol methyldopa metoprolol oxprenolol pindolol placebo practolol pronetalol propranolol reserpine thiazide diuretic agent add on therapy article clinical trial coronary artery disease drug design drug eruption drug indication drug marketing drug mechanism drug potency drug targeting drug tolerability eye injury glaucoma heart death heart failure heart infarction heart output heart rate human hypertension migraine mortality patient compliance renin angiotensin aldosterone system risk reduction cerebrovascular accident sympathetic blocking systemic lupus erythematosus alderlin inderal tenormin LA - English M3 - Article N1 - L350193476 2008-01-16 PY - 2007 SN - 0031-6873 SP - 638-639 ST - Inderal - A forerunner of a radically new generation of products T2 - Pharmaceutical Journal TI - Inderal - A forerunner of a radically new generation of products UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350193476&from=export VL - 279 ID - 3498 ER - TY - JOUR AU - Buchan, John Cameron AU - Siddiqui, Salina AU - Gilmour, David IS - 2 KW - *Antihypertensive Agents/ad [Administration & Dosage] Drug Administration Schedule *Glaucoma/dt [Drug Therapy] Humans *Patient Compliance Surveys and Questionnaires N1 - Comment on (CON) PY - 2007 SN - 0721-832X SP - 327-8 ST - Once daily drop regimes help reduce involuntary non-compliance T2 - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie T3 - Comment on: Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):293-4; PMID: 16636837 [https://www.ncbi.nlm.nih.gov/pubmed/16636837] TI - Once daily drop regimes help reduce involuntary non-compliance UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17955593 VL - 245 ID - 1573 ER - TY - JOUR AD - J.C. Buchan, Department of Opthalmology, Leeds General Infirmary, Leeds, United Kingdom AU - Buchan, J. C. AU - Siddiqui, S. AU - Gilmour, D. DB - Embase Medline DO - 10.1007/s00417-006-0438-8 IS - 2 KW - antiglaucoma agent consultation general practitioner glaucoma human intraocular pressure letter medical specialist medication error patient attitude patient compliance prescription priority journal questionnaire LA - English M3 - Letter N1 - L46291471 2007-03-26 PY - 2007 SN - 0721-832X SP - 327-328 ST - Simplification of eye drop regimes helps reduce involuntary non-compliance with glaucoma treatment [1] T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - Simplification of eye drop regimes helps reduce involuntary non-compliance with glaucoma treatment [1] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46291471&from=export http://dx.doi.org/10.1007/s00417-006-0438-8 VL - 245 ID - 3544 ER - TY - JOUR AB - Migraine therapeutics are pharmacological, including acute and preventive, nonpharmacological and/or both. Preventive pharmacological strategies serendipitously were discovered to be effective and include drugs from various pharmacological classes (e.g., β-adrenergic blocker, anticonvulsant, tricyclic antidepressants, serotonin receptor antagonist). Converging level I evidence and clinical experience support the use of the antidepressant amitriptyline, the anticonvulsants divalproex and topiramate, and the β-adrenergic blockers propranolol, timolol, and metoprolol in migraine prevention. Other options for migraine prophylaxis exist, but the level of evidence in support of their use is not as robust. All of these drugs have varying degrees of adverse effects, some of which can limit their use. Balancing potential efficacy with risk of adverse effects, addressing patients' expectations and desires, complying with management recommendations, adequate follow up, and accurate assessment of treatment goals are key to migraine prevention. Finally, future migraine-preventive drugs likely will target migraine mechanisms more specifically, which undoubtedly will enhance the therapeutic index. Copyright © 2006 by Thieme Medical Publishers, Inc. AD - N.M. Ramadan, Department of Neurology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, United States AU - Buchanan, T. M. AU - Ramadan, N. M. DB - Embase Medline DO - 10.1055/s-2006-939919 IS - 2 KW - alpha 2 adrenergic receptor stimulating agent amitriptyline angiotensin angiotensin 2 receptor antagonist anticonvulsive agent beta adrenergic receptor blocking agent calcium channel blocking agent candesartan clonidine dipeptidyl carboxypeptidase inhibitor flunarizine gabapentin guanfacine imipramine lisinopril metoprolol nortriptyline oxcarbazepine pregabalin propranolol serotonin antagonist serotonin uptake inhibitor timolol tizanidine topiramate tricyclic antidepressant agent unindexed drug valproate semisodium venlafaxine verapamil abdominal pain attention disturbance cardiotoxicity clinical trial closed angle glaucoma comorbidity concentration loss constipation coughing depression dizziness drowsiness drug classification drug efficacy drug mechanism evidence based medicine extrapyramidal symptom fatigue follow up hair loss headache heart muscle conduction disturbance heart muscle fibrosis human hyperchloremic acidosis hypotension increased appetite language disability lung fibrosis memory disorder migraine nausea nephrolithiasis nerve cell excitability orthostatic hypertension orthostatic hypotension outcome assessment paresthesia patient compliance patient satisfaction polypharmacy priority journal prophylaxis psychomotor disorder retroperitoneal fibrosis review risk benefit analysis sedation sexual dysfunction side effect somnolence speech disorder spreading cortical depression body weight gain xerostomia LA - English M3 - Review N1 - L43658839 2006-05-11 PY - 2006 SN - 0271-8235 SP - 188-198 ST - Prophylactic pharmacotherapy for migraine headaches T2 - Seminars in Neurology TI - Prophylactic pharmacotherapy for migraine headaches UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43658839&from=export http://dx.doi.org/10.1055/s-2006-939919 VL - 26 ID - 3617 ER - TY - JOUR AB - During November 1985 a survey was carried out to determine the prevalence and causes of blindness in the Elim Hospital district of Gazankulu in the Northern Transvaal, South Africa, and to assess the Eye Department's effectiveness in preventing blindness. Using a random cluster sample technique, we screened 18,962 of the estimated 71,200 inhabitants of the district (26.6%). We found 109 blind people. The prevalence of blindness was 0.57% (95% confidence interval 0.46%-0.68%). The main causes of blindness were senile cataract (55%), corneal scarring due to trachoma (10%), uncorrected aphakia (9%), and open-angle glaucoma (6%). There were 14 aphakic blind persons who did not have aphakia glasses (43% of all persons operated on for cataract). Women had a significantly higher prevalence of blindness than men. After the age of 60 years the prevalence of blindness increased sharply. Women were 1.6 times less likely to have undergone cataract surgery than men. The two most effective steps to reduce the prevalence of blindness in the Elim district further are to provide aphakia glasses to all aphakic patients and to improve the accessibility of the Eye Department's surgical services. AU - Bucher, P. J. AU - Ijsselmuiden, C. B. IS - 10 KW - Adolescent Adult Aged Aphakia/co [Complications] *Blindness/ep [Epidemiology] Blindness/et [Etiology] Cataract/co [Complications] Child Child, Preschool Cross-Sectional Studies Female Glaucoma, Open-Angle/co [Complications] Humans Infant Infant, Newborn Male Middle Aged South Africa Trachoma/co [Complications] PY - 1988 SE - Bucher, P J. Department of Ophthalmology, Elim Hospital, South Africa. SN - 0007-1161 SP - 721-6 ST - Prevalence and causes of blindness in the northern Transvaal T2 - The British journal of ophthalmology TI - Prevalence and causes of blindness in the northern Transvaal UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=3263882 VL - 72 ID - 2181 ER - TY - JOUR AB - PURPOSE: To establish whether, in a well-informed population, the use of extended wear disposable soft contact lenses (EWDSCL) poses an unacceptable risk to vision and corneal health due to complications associated with their use., METHODS: A 4 year retrospective review of EWDSCL, involving 371 patients in Melbourne from a single general ophthalmology practice. The important aspects of this group were that all patients were given written instructions about the methods of ensuring initial and ongoing cleanliness of lenses, no lenses were cleaned and reinserted, and no solutions other than the saline in the original packaging, and comfort crops, were used. Two types of EWDSCL were used in powers from -9.0 to +6.0 D, and with an initial aim of 4 weeks uninterrupted extended wear. Follow-up was from 2 to 52 months, with an average of 24 months., RESULTS: Of the 354 patients followed up, 236 (66%) regularly wore them on an extended overnight basis, and of these 180 (76%) wore them for the suggested 4 week period before renewal of lenses. In the 471 eyes of 236 patients, adverse reactions occurred at the following rates, marginal infiltrates (12 cases, 2.5%); corneal oedema (10 cases, 2%) peripheral corneal vascularization (2 cases, 0.4%); and presumed infective keratitis (1 case, 0.2%). No eyes lost one or more lines of Snellen acuity., CONCLUSIONS: When disposable soft contact lenses do not come into contact with cleaning solutions, saline from bottles or aerosol cans, or storage cases, their use on an extended wear basis (up to 4 weeks continuous) appears to be associated with a low risk of minor or major complications. The results of this review indicate that controlled usage of EWDSCL is safer than previous reports have indicated. AU - Buckley, C. A. AU - Buckley, C. J. AU - Griffiths, J. IS - 2 KW - Adolescent Adult Aged Child Contact Lenses, Extended-Wear/ae [Adverse Effects] *Contact Lenses, Extended-Wear Cornea/pp [Physiopathology] *Disposable Equipment Female Follow-Up Studies Humans Lasers, Excimer Male Middle Aged Patient Satisfaction *Photorefractive Keratectomy Refractive Errors/pp [Physiopathology] *Refractive Errors/th [Therapy] Retrospective Studies Time Factors Treatment Outcome Visual Acuity/ph [Physiology] PY - 1997 SE - Buckley, C A. Monash Medical Centre, Clayton, Victoria, Australia. SN - 0814-9763 SP - 111-6 ST - Extended wear disposable soft contact lenses as an alternative to photorefractive keratectomy: report of 4 years experience T2 - Australian and New Zealand journal of ophthalmology TI - Extended wear disposable soft contact lenses as an alternative to photorefractive keratectomy: report of 4 years experience UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9267596 VL - 25 ID - 2015 ER - TY - JOUR AB - PURPOSE: To apply lessons learned in the treatment of systemic hypertension to the problem of nonadherence in glaucoma medical therapy., CLINICAL RELEVANCE: Although physicians recognize that nonadherence with glaucoma medication is a problem, most lack the skill set to identify nonadherent patients, to identify the causes of nonadherence, and to provide solutions to address nonadherence., METHODS: A PubMed search was conducted using the terms "adherence" OR "compliance" AND "hypertension," with the following limitations: title, English language, humans, from 2000 through 2009. Other studies identified outside of the PubMed search were included if relevant., RESULTS: Studies from the systemic hypertension literature suggest that simplifying medication regimens, lowering costs, and patient education about the disease and the importance of taking medications are successful strategies for improving adherence. In addition, good family or social support, frequent physician visits, and pairing medication administration with specific activities (such as meals or brushing one's teeth) can help improve adherence., CONCLUSIONS: The body of literature on adherence interventions in chronic diseases such as systemic hypertension shows that although many interventions have been tested and evaluated, only some are successful. Paradigms derived from behavioral medicine and nursing offer valuable lessons on how to motivate patients to change behavior, but these activities require skill sets not traditionally taught in medical school. Just as there are myriad causes of nonadherence, the interventions most likely will need to be multifaceted and tailored to the individual patient., FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. AU - Budenz, Donald L. DO - https://dx.doi.org/10.1016/j.ophtha.2009.06.022 IS - 11 Suppl KW - Allied Health Personnel/px [Psychology] *Antihypertensive Agents/ad [Administration & Dosage] Blindness/pc [Prevention & Control] *Glaucoma/dt [Drug Therapy] Health Behavior Humans Motivation *Ophthalmic Solutions/ad [Administration & Dosage] *Patient Compliance/px [Psychology] Patient Education as Topic Physician-Patient Relations PY - 2009 SE - Budenz, Donald L. Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Florida 33136, USA. dbudenz@med.miami.edu SN - 1549-4713 0161-6420 SP - S43-7 ST - A clinician's guide to the assessment and management of nonadherence in glaucoma T2 - Ophthalmology TI - A clinician's guide to the assessment and management of nonadherence in glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19837260 VL - 116 ID - 1417 ER - TY - JOUR AB - The authors draw on the peer review literature and 8 years of personal experience to provide an overview of the prevalence and management of glaucoma in West Africa. AD - D.L. Budenz, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, United States AU - Budenz, D. L. AU - Singh, K. AU - Grehn, F. DB - Embase Medline DO - 10.1097/00061198-200108000-00016 IS - 4 KW - Africa diagnostic procedure disease course glaucoma glaucoma surgery health care access human onset age prevalence priority journal review LA - English M3 - Review N1 - L32781352 2001-09-05 PY - 2001 SN - 1057-0829 SP - 348-353 ST - Glaucoma care in West Africa T2 - Journal of Glaucoma TI - Glaucoma care in West Africa UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32781352&from=export http://dx.doi.org/10.1097/00061198-200108000-00016 VL - 10 ID - 3890 ER - TY - JOUR AB - In Fall 1981, an outbreak of acute infectious conjunctivitis with keratitis (EKC) occurred in patients who had visited a private ophthalmology clinic just prior to onset of illness. Among an estimated 2,200 patient visits to the office from August 10 to October 15, 1981 for problems unrelated to infectious conjunctivitis, 39 (1.8%) persons subsequently developed EKC. The median incubation period was 6.5 days (range, 1 to 14 days). A case-control study was done to identify risk factors associated with contracting EKC; patients with EKC were more likely than control patients to have been examined by one or the other of two of the four ophthalmologists at the clinic and to have undergone procedures such as tonometry or foreign body removal. Adenovirus was isolated from conjunctival swabs from four of five persons with conjunctivitis; three were type 8 and one was type 7. Recognition of the problem and improved handwashing practices were associated with terminating the outbreak. This outbreak illustrates the potential for transmission of adenovirus infection during the provision of eye care. Infection control practitioners should be familiar with measures for the prevention of such infections among ophthalmology patients. AU - Buehler, J. W. AU - Finton, R. J. AU - Goodman, R. A. AU - Choi, K. AU - Hierholzer, J. C. AU - Sikes, R. K. AU - Elsea, W. R. IS - 8 KW - *Adenoviridae Infections/ep [Epidemiology] *Adenovirus Infections, Human/ep [Epidemiology] Adenovirus Infections, Human/tm [Transmission] Adolescent Adult Aged Child Child, Preschool *Disease Outbreaks/ep [Epidemiology] Female Georgia Hand Disinfection Humans *Keratoconjunctivitis/ep [Epidemiology] Keratoconjunctivitis/tm [Transmission] Male Middle Aged *Office Visits *Ophthalmology Risk Tonometry, Ocular/is [Instrumentation] PY - 1984 SN - 0195-9417 SP - 390-4 ST - Epidemic keratoconjunctivitis: report of an outbreak in an ophthalmology practice and recommendations for prevention T2 - Infection control : IC TI - Epidemic keratoconjunctivitis: report of an outbreak in an ophthalmology practice and recommendations for prevention UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=6090333 VL - 5 ID - 2232 ER - TY - JOUR AB - OBJECTIVES: Corticosteroids (CSs) are used concomitantly with life-extending therapies (LETs) in patients with castration-resistant prostate cancer (CRPC). This study examined time to LETs, LETs and concomitant CS adherence, and monthly all-cause healthcare utilization and costs in patients with CPRC with and without CS-sensitive comorbidities in the Veterans Health Administration population., METHODS: Patients had CRPC if records showed prostate cancer diagnosis, medical/surgical castration and >=2 prostate-specific antigen increases through 1 June 2007-31 May 2012. CS-sensitive comorbidities were assessed 6 months prior to the index date. Adherence, defined as medication possession ratio (MPR) >=0.8, among patients initiating LETs (cabazitaxel, docetaxel, or abiraterone acetate) before 30 November 2011, resource utilization and costs among patients with concomitant CS were assessed. Statistical analysis included descriptive, Cox proportional hazards, and logistic regression models., RESULTS: Common CS-sensitive conditions among 12,128 patients with CRPC included hypertension (75.74%) and hyperlipidemia (54.69%). Those with glaucoma (hazard ratio [HR] = 0.67), ischemic heart disease (HR = 0.78), and peripheral vascular disease (PVD) (HR = 0.78) were less likely to be prescribed LETs (all p < 0.01). Duration of LET was shorter among patients with CS-sensitive comorbidities (125.02 vs 133.08 days; p = 0.04) in the 6 month follow-up period. Among LET-treated patients with and without CS-sensitive comorbidities, less than half had MPR >= 0.8 (LET: 48.72% vs 54.05%; concomitant CS: 42.19% vs 40.54%, respectively). Cerebrovascular disease (odds ratio = 0.107; 95% confidence interval = 0.012 to 0.966) and PVD (odds ratio = 0.523; 95% confidence interval = 0.276 to 0.991) were associated with reduced CS adherence. Among patients with concomitant CS, those with CS-sensitive comorbidities had more inpatient stays than those without (20.45% vs 12.88%; p = 0.033), incurring higher monthly inpatient costs ($1157 vs $342; p < 0.0001) and total costs ($5725 vs $4772; p = 0.036)., CONCLUSION: CS-sensitive conditions influence initiation and duration of LETs, concomitant CS adherence, inpatient stays, and total costs. Future efforts should focus on specific strategies for treating prostate cancer patients with CS-sensitive comorbidities to ensure that they have appropriate access to LETs and to reduce costs and inpatient stays. Study limitations include the use of retrospective claims data and the relatively restricted subpopulation of older North American males. AU - Bui, Cat N. AU - Wang, Li AU - Baser, Onur DO - https://dx.doi.org/10.1185/03007995.2014.955170 IS - 11 KW - Adult Aged Contraindications *Glucocorticoids/tu [Therapeutic Use] *Health Care Costs *Health Services/sn [Statistics & Numerical Data] Humans Logistic Models Male Medication Adherence Middle Aged *Prostatic Neoplasms/co [Complications] *Prostatic Neoplasms/dt [Drug Therapy] Prostatic Neoplasms/pa [Pathology] Retrospective Studies United States PY - 2014 SE - Bui, Cat N. Astellas Scientific and Medical Affairs, Northbrook, IL, USA. SN - 1473-4877 0300-7995 SP - 2355-64 ST - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities T2 - Current medical research and opinion TI - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25133961 VL - 30 Y2 - 20140903// ID - 865 ER - TY - JOUR AB - OBJECTIVES: Patient noncompliance with recommended hygienic practices in contact lens wear is often considered a significant risk factor for microbial keratitis and adverse contact lens-related events. Despite advancements in lens materials and care solutions, noncompliant behavior continues to hinder efforts to maximize contact lens safety. The objective of this pilot study was to assess the relationship between perceived and actual compliance with awareness of risk and behavior., METHODS: One hundred sixty-two established contact lens wearers were sequentially evaluated after their routine contact lens examination at the Optometry Clinic at the University of Texas Southwestern Medical Center at Dallas, TX. Each patient was questioned by a single trained interviewer regarding his or her lens care practices and knowledge of risk factors associated with lens wear., RESULTS: Eighty-six percent of patients believed they were compliant with lens wear and care practices; 14% identified themselves as noncompliant. Using a scoring model, 32% demonstrated good compliance, 44% exhibited average compliance, and 24% were noncompliant; age was a significant factor (P = 0.020). Only 34% of patients who perceived themselves as compliant exhibited a good level of compliance (P<0.001). Eighty percent of patients reported an awareness of risk factors, but awareness did not influence negative behavior. Replacing the lens case was the only behavior associated with a positive history for having experienced a prior contact lens-related complication (P = 0.002)., CONCLUSIONS: Perceived compliance is not an indicator for appropriate patient behavior. A large proportion of patients remain noncompliant despite awareness of risk. Education alone is not a sufficient strategy to improve behavior; newer approaches aimed at improving compliance with lens care practices are urgently needed. AU - Bui, Thai H. AU - Cavanagh, H. Dwight AU - Robertson, Danielle M. DO - https://dx.doi.org/10.1097/ICL.0b013e3181f579f7 IS - 6 KW - Adolescent Adult Aged Contact Lens Solutions Contact Lenses/ae [Adverse Effects] *Contact Lenses Female *Health Knowledge, Attitudes, Practice Humans Interviews as Topic Male Middle Aged *Patient Compliance Risk Factors Self-Assessment Young Adult PY - 2010 SE - Bui, Thai H. Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9057, USA. SN - 1542-233X 1542-2321 SP - 334-9 ST - Patient compliance during contact lens wear: perceptions, awareness, and behavior T2 - Eye & contact lens TI - Patient compliance during contact lens wear: perceptions, awareness, and behavior UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20935569 VL - 36 ID - 1328 ER - TY - JOUR AB - Loss of sight due to irreversible retinal neurodegeneration imposes a significant disease burden on both patients and society. Glaucoma and age-related macular degeneration are the commonest neurodegenerative blinding diseases in the developed world, and both are becoming increasingly prevalent as populations age. Our heavy reliance on our sense of sight means that visual loss often severely restricts day-to-day life, making it difficult to function without additional support. Visual impairment also limits employment possibilities, adding to the economic burden. Current therapies for many degenerative retinopathies are limited in their efficacy, often treating the effects of disease rather than the underlying causes. Consequently, the development of novel adjunctive neuroprotective and neuroregenerative treatments are important goals. Evidence from animal models suggests that stem cells could be useful as part of novel new treatment strategies for eye disease. The accessibility of the eye and extensive repertoire of available surgical techniques may facilitate the translation of stem cell-based therapies, for example, via transplantation, to the retina more rapidly than to other parts of the central nervous system. This concise review will examine how cell therapies are being applied experimentally for neuroregenerative and neuroprotective treatment of currently incurable degenerative retinal diseases. Furthermore, recent progress toward clinical translation of such therapies will be highlighted. Copyright © 2011 AlphaMed Press. AU - Bull, Natalie D. AU - Martin, Keith R. DO - https://dx.doi.org/10.1002/stem.676 IS - 8 KW - Animals Humans Neural Stem Cells/tr [Transplantation] *Neurodegenerative Diseases/th [Therapy] *Retinal Diseases/th [Therapy] *Stem Cell Transplantation PY - 2011 SE - Bull, Natalie D. Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom. ndb30@cam.ac.uk SN - 1549-4918 1066-5099 SP - 1170-5 ST - Concise review: toward stem cell-based therapies for retinal neurodegenerative diseases T2 - Stem cells (Dayton, Ohio) TI - Concise review: toward stem cell-based therapies for retinal neurodegenerative diseases UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21674700 VL - 29 ID - 1266 ER - TY - JOUR AU - Buller, Alex AU - Hercules, Brian L. IS - 1 KW - *Antihypertensive Agents/ad [Administration & Dosage] Drug Administration Schedule Glaucoma/dt [Drug Therapy] Humans *Ophthalmic Solutions/ad [Administration & Dosage] *Patient Satisfaction Surveys and Questionnaires Time Factors PY - 2006 SN - 1395-3907 SP - 150-1 ST - Should patients choose their own eyedrops? T2 - Acta ophthalmologica Scandinavica TI - Should patients choose their own eyedrops? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16445459 VL - 84 ID - 1684 ER - TY - JOUR AU - Buller, A. J. AU - Connell, B. AU - Spencer, A. F. IS - 10 KW - *Antihypertensive Agents/ad [Administration & Dosage] Communication *Glaucoma/dt [Drug Therapy] Humans *Patient Compliance Physician-Patient Relations PY - 2005 SN - 0007-1161 SP - 1370 ST - Compliance: clear communication's critical T2 - The British journal of ophthalmology TI - Compliance: clear communication's critical UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16170136 VL - 89 ID - 1719 ER - TY - JOUR AB - BACKGROUND: The relationship between complexity of eye drop regime and compliance is not straightforward, i.e. fewer drops may not mean better compliance. We investigated the level of inconvenience different eye drop regimes incurred in comparison with a once-daily (OD) regime for patients experienced with using topical anti-glaucoma medication., METHODS: Patients indicated the level of inconvenience from drop regimes of 1, 2, 3 or 4 times daily on 10-cm visual analogue scales. The score for the OD regime was then compared with the scores for the other regimes using paired t-tests with Bonferroni correction., RESULTS: At a significance limit of p = 0.05, five of six subgroups indicated once-a-day drops were significantly more convenient than other regimes. Patients who had used the OD regime considered this difference greater than those who had not., CONCLUSIONS: This study's results offer some pragmatic guidance on choice of therapy and on counselling patients about compliance. We would suggest starting patients on OD drops in preference to alternatives to promote compliance. AU - Buller, Alex J. AU - Morgan, Laurence H. AU - Hercules, Brian L. IS - 2 KW - *Antihypertensive Agents/ad [Administration & Dosage] Drug Administration Schedule Drug Delivery Systems *Glaucoma/dt [Drug Therapy] Humans *Ophthalmic Solutions/ad [Administration & Dosage] Patient Compliance *Patient Satisfaction Surveys and Questionnaires N1 - Comment in (CIN) PY - 2007 SE - Buller, Alex J. Stepping Hill Hospital, Poplar Grove, Stockport, Cheshire, UK. alexbuller@mac.com SN - 0721-832X SP - 293-4 ST - Patients prefer once-daily glaucoma drops T2 - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie T3 - Comment in: Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):327-8; PMID: 17955593 [https://www.ncbi.nlm.nih.gov/pubmed/17955593] TI - Patients prefer once-daily glaucoma drops UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16636837 VL - 245 ID - 1622 ER - TY - JOUR AB - PURPOSE: A root cause analysis of the Fusarium keratitis epidemic of 2004-2006 was performed., METHODS: Three US Food and Drug Administration (FDA) documents were analyzed. Poisson and case-control studies were performed on outbreak data from Singapore. Irreversible thermochromic labels were applied to cartons of contact lens solution bottles, which were then subjected to elevated temperatures., RESULTS: The 1997 FDA guidance document concerning storage temperatures of contact lens care products predicted temperature-related solution instability. Bausch & Lomb (B&L) requested FDA approval for ReNu with MoistureLoc, claiming that it was substantially equivalent to other products. FDA Form 483 stated that cases of ReNu-related Fusarium keratitis from Asia had not been reported, the removal of the product from the Asian markets was unreported, and B&L had not performed biocidal testing on samples associated with Asian cases. The outbreak in Singapore could have been recognized after only 3 cases (Pr = .0067). The cause of the Singapore outbreak could have been determined after the recognition of only 3 (P = .0429), 5 (95% confidence interval [CI], 1.15-126.0), or 15 cases (95% CI, 1.60-14.1). Thermochromic labels can irreversibly change color when exposed to elevated temperatures, thus warning of potential antimicrobial failure., CONCLUSIONS: The worldwide Fusarium keratitis epidemic of 2004-2006 could, theoretically, have been prevented entirely, recognized much earlier, or mitigated by much more rigorous oversight by the FDA, by strict adherence by B&L to FDA guidelines and requirements, by the application of basic statistical methods, and/or by the use of temperature indication technology. The lessons learned from a root cause analysis of this pharmacologic catastrophy may help avert or mitigate future epidemics. AU - Bullock, John D. KW - Asia/ep [Epidemiology] *Contact Lens Solutions/ae [Adverse Effects] *Disease Outbreaks/pc [Prevention & Control] Drug Stability Drug Storage *Fusarium Global Health Guideline Adherence Hot Temperature/ae [Adverse Effects] Humans Keratitis/ci [Chemically Induced] *Keratitis/ep [Epidemiology] *Keratitis/mi [Microbiology] *Mycoses *Primary Prevention/mt [Methods] Statistics as Topic/mt [Methods] United States/ep [Epidemiology] United States Food and Drug Administration PY - 2009 SE - Bullock, John D. Wright State University Boonshoft School of Medicine, Dayton, Ohio, USA. SN - 1545-6110 0065-9533 SP - 194-204 ST - Root cause analysis of the fusarium keratitis epidemic of 2004-2006 and prescriptions for preventing future epidemics T2 - Transactions of the American Ophthalmological Society TI - Root cause analysis of the fusarium keratitis epidemic of 2004-2006 and prescriptions for preventing future epidemics UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=20126495 VL - 107 ID - 1403 ER - TY - JOUR AB - Pursuit of a new FP-agonist prodrug led to the identification of an interesting series of neutral C1-substituted prostaglandin F2α analogues. Although these initial analogues were devoid of any inherent pharmacological activity at the FP-receptor, two compounds AGN-190910 and AGN-191129, were found to have pronounced effects in lowering intraocular pressure (IOP) in normotensive dogs and monkeys. The cat iris sphincter assay was quickly developed as a primary screen for these analogues, leading to rapid identification of AGN-192024 (17-phenyl PGF2α ethyl amide, bimatoprost). While bimatoprost is structurally similar to naturally occurring mammalian hormones of the prostanoid family, surprisingly it demonstrates no significant activity at any of the known prostanoid receptors. Furthermore, results of considerable additional pharmacological studies provide evidence that it may indeed act through a unique receptor yet to be identified. The effect of Bimatoprost on lowering IOP has also been found to be unique in comparison to prostanoids. Bimatoprost reduces human IOP by increasing aqueous humor outflow through a dual mechanism of action where it improves both pressure-dependent and pressure-independent outflow pathways. First introduced to the market in 2002, bimatoprost is currently the most potent single therapy available for control of ocular hypertension. ©2007 Wiley-Liss, Inc. AD - R.M. Burk, Allergan, Inc., Gavin Herbert Research Building, 2525 Dupont Drive, Irvine, CA 92612, United States AU - Burk, R. M. AU - Woodward, D. F. C1 - agn 190910 agn 190911 agn 190988 agn 191045 agn 192024 agn 204396 AGN 211334 al 8810 DB - Embase DO - 10.1002/ddr.20176 IS - 4 KW - 11 fluoro 9,15 dihydroxy 15 (2 indanyl) 16,17,18,19,20 pentanorprosta 5,13 dienoic acid 11 pivaloylprostaglandin F2 alpha 11,15 dipivaloylprostaglandin F2 alpha agn 190910 agn 190911 agn 190988 agn 191045 agn 191129 agn 204396 AGN 211334 bimatoprost latanoprost prostaglandin F2 alpha prostamide prostanoid unclassified drug antihypertensive activity aqueous humor flow drug research drug screening drug structure glaucoma human hyperemia intraocular hypertension intraocular pressure nonhuman patient compliance review sphincter pupillae muscle agn 192024 al 8810 LA - English M3 - Review N1 - L350089894 2007-12-04 PY - 2007 SN - 0272-4391 1098-2299 SP - 147-155 ST - Bimatoprost, a novel efficacious ocular hypotensive drug now recognized as a member of a new class of agents called prostamides T2 - Drug Development Research TI - Bimatoprost, a novel efficacious ocular hypotensive drug now recognized as a member of a new class of agents called prostamides UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350089894&from=export http://dx.doi.org/10.1002/ddr.20176 VL - 68 ID - 3519 ER - TY - JOUR AB - In summary, our findings have found the Registered Nurse Led Group Medical Appointments for preoperative cataract patients to be very beneficial for both our patients and providers. This type of preoperative education fully utilizes the expertise of the CRNO in a way that is professionally rewarding to the nurse and adds value to the entire ophthalmic team. Due to the success of this program, we are now considering building a nurse led group educational program that would meet the needs of our patients with macular degeneration and glaucoma. Additionally, as a result of this study a new position (0.75 FTE) was created in the Ophthalmology Department at Palo Alto Medical Foundation for an Ophthalmic Nurse Educator. AU - Burlew-Quartey, Julie A. IS - 2 KW - *Appointments and Schedules *Cataract Extraction/nu [Nursing] Georgia Humans *Nursing, Supervisory/og [Organization & Administration] *Practice Guidelines as Topic *Preoperative Care/nu [Nursing] PY - 2009 SE - Burlew-Quartey, Julie A. Palo Alto Medical Foundation, 795 El Camino Real, Palo Alto, CA 94301, USA. Burlewj@pamf.org SN - 1060-135X SP - 28-31 ST - Registered nurse-led Group Medical Appointments for preoperative cataract patients T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Registered nurse-led Group Medical Appointments for preoperative cataract patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19534234 VL - 34 ID - 1445 ER - TY - JOUR AB - OBJECTIVES: To evaluate neutrophil-enhanced Pseudomonas aeruginosa (PA) biofilm formation on silicone hydrogel contact lenses and to determine the effect of epithelial biodebris on PA adherence in contact lens storage cases., METHODS: A fully invasive PA corneal isolate stably conjugated to green fluorescent protein was used. Unworn lotrafilcon A contact lenses were incubated at various ratios of PA to polymorphonuclear neutrophil (PMN) for 24 hours at 37degreeC. Lens-associated PA was evaluated using laser scanning confocal microscopy and nonviable PA were visualized using propidium iodide. Viable bacteria were enumerated by colony-forming unit (CFU) analysis. For acute epithelial cell studies, PA viability was determined after coincubation with freeze-thaw epithelial cell lysates in 96-well polystyrene plates. Levels of residual cellular debris and bacterial viability were further assessed in used contact lens storage cases., RESULTS: Laser scanning confocal microscopy demonstrated that cotreatment with PMA-stimulated neutrophils increased PA adherence over 24 hours to lens surfaces with a striking alteration of PA architecture. Propidium iodide staining showed that the adherent bacteria consisted of a mixture of viable and nonviable PA; a PMN-associated increase in viable PA was confirmed by CFU (PA:PMN 0.1:1, P = 0.025; PA:PMN 1:1, P = 0.005). Acute epithelial cell debris studies revealed a significant increase in viable PA in 96-well plates in the presence of epithelial freeze-thaw lysates (PA:debris 1:1, P = 0.002; PA:debris 100:1, P = 0.002). Crystal violet staining of used lens storage cases revealed residual cellular debris at all time points, which was independent of microbial contamination; all lens cases used for periods of 9 months or more were uniformly associated with high levels of viable microorganisms., CONCLUSION: These results demonstrate that prolonged corneal inflammation with the presence of PMNs when confronted with simultaneous PA challenge in extended contact lens wear has the potential to stimulate biofilm formation on silicone hydrogel contact lenses. These findings further suggest that a persistent buildup of extracellular debris in lens storage cases may contribute to the heavy biofilms reported on these surfaces. AU - Burnham, Geoffrey W. AU - Cavanagh, H. Dwight AU - Robertson, Danielle M. DO - https://dx.doi.org/10.1097/ICL.0b013e31823bad0e IS - 1 KW - *Bacterial Adhesion/ph [Physiology] Biofilms/gd [Growth & Development] Cell Survival Colony Count, Microbial *Contact Lenses, Hydrophilic/mi [Microbiology] Disposable Equipment/mi [Microbiology] Epithelial Cells/ph [Physiology] Equipment Contamination Humans Hydrogels Neutrophils/ph [Physiology] *Pseudomonas aeruginosa/ph [Physiology] Silicones PY - 2012 SE - Burnham, Geoffrey W. Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9057, USA. SN - 1542-233X 1542-2321 SP - 7-15 ST - The impact of cellular debris on Pseudomonas aeruginosa adherence to silicone hydrogel contact lenses and contact lens storage cases T2 - Eye & contact lens TI - The impact of cellular debris on Pseudomonas aeruginosa adherence to silicone hydrogel contact lenses and contact lens storage cases UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22138709 VL - 38 ID - 1161 ER - TY - JOUR AB - Well over three-quarters of the total referrals to ophthalmologists for suspected glaucoma are initiated by optometrists. This study was conducted to investigate the experiences of patients with suspected glaucoma. As very little is known about how this group of people is affected, a qualitative study was chosen to investigate this phenomenon.The participants were identified from referrals by their optometrists or general practitioners to Moorfields Glaucoma Clinic at Ealing General Hospital, London, for investigation of suspected glaucoma. In-depth interviews were conducted to collect primary data and a focus group discussion was carried out in order to expand the interview data.The findings revealed that some patients were unaware of the reason for their referral to the eye clinic and even after of the consultation the outcome was not always clear to them. Furthermore, the combination of downplay of the findings by the optometrist and general practitioners, and lack of knowledge of the condition could be the reason for a significant number of non-attendances to the glaucoma clinic. Communication and collaboration among health professionals could lead to better use of resources and more time could be spent with existing and newly diagnosed glaucoma patients. AD - Ophthalmic Department Manager, Warrington Hospital NHS Trust, Lovely Lane, Warrington WA5 1QG AN - 106926459. Language: English. Entry Date: 20020531. Revision Date: 20150820. Publication Type: Journal Article AU - Burns, J. AU - Barrett, G. AU - Murdoch, I. DB - ccm DP - EBSCOhost IS - 3 KW - Glaucoma Patient Attitudes England Purposive Sample Qualitative Studies Interviews Audiorecording Prospective Studies Thematic Analysis Patient Attitudes -- Evaluation Referral and Consultation Focus Groups Middle Age Aged Male Female Funding Source Human N1 - research. Journal Subset: Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Nursing; Peer Reviewed; UK & Ireland. Grant Information: Funded by the International Glaucoma Association, London. PY - 2001 SN - 1368-1249 SP - 8-11 ST - The experiences of patients with suspected glaucoma. A qualitative study T2 - Ophthalmic Nursing: International Journal of Ophthalmic Nursing TI - The experiences of patients with suspected glaucoma. A qualitative study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106926459&site=ehost-live&scope=site VL - 5 ID - 4514 ER - TY - JOUR AB - OBJECTIVES: To determine effective and efficient monitoring criteria for ocular hypertension [raised intraocular pressure (IOP)] through (i) identification and validation of glaucoma risk prediction models; and (ii) development of models to determine optimal surveillance pathways., DESIGN: A discrete event simulation economic modelling evaluation. Data from systematic reviews of risk prediction models and agreement between tonometers, secondary analyses of existing datasets (to validate identified risk models and determine optimal monitoring criteria) and public preferences were used to structure and populate the economic model., SETTING: Primary and secondary care., PARTICIPANTS: Adults with ocular hypertension (IOP > 21 mmHg) and the public (surveillance preferences)., INTERVENTIONS: We compared five pathways: two based on National Institute for Health and Clinical Excellence (NICE) guidelines with monitoring interval and treatment depending on initial risk stratification, 'NICE intensive' (4-monthly to annual monitoring) and 'NICE conservative' (6-monthly to biennial monitoring); two pathways, differing in location (hospital and community), with monitoring biennially and treatment initiated for a >= 6% 5-year glaucoma risk; and a 'treat all' pathway involving treatment with a prostaglandin analogue if IOP > 21 mmHg and IOP measured annually in the community., MAIN OUTCOME MEASURES: Glaucoma cases detected; tonometer agreement; public preferences; costs; willingness to pay and quality-adjusted life-years (QALYs)., RESULTS: The best available glaucoma risk prediction model estimated the 5-year risk based on age and ocular predictors (IOP, central corneal thickness, optic nerve damage and index of visual field status). Taking the average of two IOP readings, by tonometry, true change was detected at two years. Sizeable measurement variability was noted between tonometers. There was a general public preference for monitoring; good communication and understanding of the process predicted service value. 'Treat all' was the least costly and 'NICE intensive' the most costly pathway. Biennial monitoring reduced the number of cases of glaucoma conversion compared with a 'treat all' pathway and provided more QALYs, but the incremental cost-effectiveness ratio (ICER) was considerably more than 30,000. The 'NICE intensive' pathway also avoided glaucoma conversion, but NICE-based pathways were either dominated (more costly and less effective) by biennial hospital monitoring or had a ICERs > 30,000. Results were not sensitive to the risk threshold for initiating surveillance but were sensitive to the risk threshold for initiating treatment, NHS costs and treatment adherence., LIMITATIONS: Optimal monitoring intervals were based on IOP data. There were insufficient data to determine the optimal frequency of measurement of the visual field or optic nerve head for identification of glaucoma. The economic modelling took a 20-year time horizon which may be insufficient to capture long-term benefits. Sensitivity analyses may not fully capture the uncertainty surrounding parameter estimates., CONCLUSIONS: For confirmed ocular hypertension, findings suggest that there is no clear benefit from intensive monitoring. Consideration of the patient experience is important. A cohort study is recommended to provide data to refine the glaucoma risk prediction model, determine the optimum type and frequency of serial glaucoma tests and estimate costs and patient preferences for monitoring and treatment., FUNDING: The National Institute for Health Research Health Technology Assessment Programme. AU - Burr, J. M. AU - Botello-Pinzon, P. AU - Takwoingi, Y. AU - Hernandez, R. AU - Vazquez-Montes, M. AU - Elders, A. AU - Asaoka, R. AU - Banister, K. AU - van der Schoot, J. AU - Fraser, C. AU - King, A. AU - Lemij, H. AU - Sanders, R. AU - Vernon, S. AU - Tuulonen, A. AU - Kotecha, A. AU - Glasziou, P. AU - Garway-Heath, D. AU - Crabb, D. AU - Vale, L. AU - Azuara-Blanco, A. AU - Perera, R. AU - Ryan, M. AU - Deeks, J. AU - Cook, J. DO - https://dx.doi.org/10.3310/hta16290 IS - 29 KW - Administration, Ophthalmic Age Factors Antihypertensive Agents/ad [Administration & Dosage] *Antihypertensive Agents/ec [Economics] *Antihypertensive Agents/tu [Therapeutic Use] Cohort Studies Cost-Benefit Analysis *Glaucoma, Open-Angle/pc [Prevention & Control] Humans Intraocular Pressure Mass Screening Models, Theoretical *Ocular Hypertension/dt [Drug Therapy] *Ocular Hypertension/ec [Economics] Ocular Hypertension/ep [Epidemiology] Quality-Adjusted Life Years Randomized Controlled Trials as Topic Risk Assessment PY - 2012 SE - Burr, J M. Health Services Research Unit, University of Aberdeen, Aberdeen, UK. SN - 2046-4924 1366-5278 SP - 1-iv ST - Surveillance for ocular hypertension: an evidence synthesis and economic evaluation T2 - Health technology assessment (Winchester, England) TI - Surveillance for ocular hypertension: an evidence synthesis and economic evaluation UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22687263 VL - 16 ID - 1096 ER - TY - JOUR AN - 105207168. Language: English. Entry Date: 20100716. Revision Date: 20150711. Publication Type: Journal Article AU - Busacco, D. DB - ccm DP - EBSCOhost KW - Audiology Hearing Disorders -- In Old Age Vision Disorders -- In Old Age Age Factors Aged Assistive Technology Devices Cataract Diabetic Retinopathy Glaucoma Health Services Accessibility Hearing Disorders -- Complications Hearing Loss, Sensorineural Macular Degeneration Male Rehabilitation of Hearing Impaired Rehabilitation of Vision Impaired Vision Disorders -- Classification -- In Old Age Vision Disorders -- Complications N1 - case study. Journal Subset: Allied Health; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. PY - 2010 SN - 1947-9735 SP - 6p-6p ST - Dual sensory loss in adults: an overview for audiologists T2 - AudiologyOnline TI - Dual sensory loss in adults: an overview for audiologists UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105207168&site=ehost-live&scope=site ID - 4775 ER - TY - JOUR AB - A hand-held noncontact tonometer (Pulsair, Keeler Ltd., UK) was tested in 42 children, from 5 months to 12 years of age. At least 1 intraocular pressure (IOP) reading was obtained in all of the 84 eyes studied, whereas with a Goldman applanation tonometer measurements could be obtained in only 26 eyes (14 subjects). Time required for examination with the Pulsair was quite variable and related to age (p less than 0.0001). Compliance in children was reported as "good" in the majority of cases; it was also age-related (p less than 0.005). Although its reliability could not be definitely evaluated, the results of this study indicate that this instrument may be a valuable choice for screening and follow-up purposes in childhood. AU - Buscemi, M. AU - Capoferri, C. AU - Garavaglia, A. AU - Nassivera, C. AU - Nucci, P. IS - 6 KW - Child Child, Preschool Female Glaucoma/di [Diagnosis] Humans Infant *Intraocular Pressure Male Patient Compliance *Tonometry, Ocular/is [Instrumentation] Vision Tests/is [Instrumentation] PY - 1991 SE - Buscemi, M. Department of Ophthalmology, University of Milan, San Raffaele Hospital, Italy. SN - 1040-5488 SP - 461-4 ST - Noncontact tonometry in children T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Noncontact tonometry in children UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1891199 VL - 68 ID - 2129 ER - TY - JOUR AB - BACKGROUND: Poor compliance can be dangerous to successful medical treatment of glaucoma. Among other things one reason for non-compliance represents the inability of the patients to place drops in the eye appropriately. Therefore information regarding the patients ability to administer an eyedrop safely are a prerequisite to determining a therapy scheme which ensures the compliance of glaucoma patients., PATIENTS AND METHODS: 100 glaucoma patients on medical therapy who first presented in the outpatient glaucoma clinic of the University Eye Hospital of Wurzburg were examined by standardised questionnaire and ability tests. We evaluated: 1. Can the eyedrop administration of glaucoma patients be improved by a standardised instruction? 2. Can the eyedrop administration be improved by the use of a drop aid (Autodrop)? 3. Can the accuracy of aiming and the manual ability be evaluated with a target-test on a sheet of paper with a series of concentric circles? 4. How do patients on combined therapy distinguish between their different bottles and where is the dosage regimen noted? 5. What kind of distinguishing marks of eyedrop-bottles do the patients prefer?, RESULTS: 1. Before verbal instruction 76% of the patients applied the eyedrops appropriately, after instruction 94% (p < 0.001) were capable. Touching the eye with the tip of the dropper was reduced significantly. Touching the eye before instruction was found in 63% of the patients, after instruction it was found in 41% (p < 0.001). 2. When patients used the drop aid 81% were able to place a drop in the eye appropriately. Only by 46% of the patients the Autodrop was welcomed. 3. 16% of the patients were not able to place a drop within 1.5 cm of the center of the target (according to the size of an eye). 4. 47% of the patients who use more than one eyedrop bottle admitted problems in distinguishing the bottles, only 38% of the patients read the labels. 5. 76% of the patients would prefer markable stickers of different colours for the bottom of the bottles to improve distinguishing the bottles in combined therapy., CONCLUSION: Instruction improves eyedrop administration in 18% of our patients. In combined therapy with several drugs new distinguishing marks are requested by the patients. To improve compliance combination preparations should be administered if available. AU - Busche, S. AU - Gramer, E. IS - 4 KW - Adolescent Adult Aged Aged, 80 and over *Drug Delivery Systems/is [Instrumentation] Drug Therapy, Combination Equipment Design Female *Glaucoma/dt [Drug Therapy] Glaucoma/px [Psychology] Humans Male Middle Aged *Miotics/ad [Administration & Dosage] Ophthalmic Solutions *Parasympathomimetics/ad [Administration & Dosage] Patient Acceptance of Health Care *Patient Compliance *Self Administration/is [Instrumentation] Self Administration/px [Psychology] PY - 1997 SE - Busche, S. Universitats-Augenklinik Wurzburg. SN - 0023-2165 SP - 257-62 ST - [Improved eyedrop administration and compliance in glaucoma patients. A clinical study] T2 - Verbesserung der Augentropfenapplikation und Compliance bei Glaukompatienten. Eine klinische Studie. TI - [Improved eyedrop administration and compliance in glaucoma patients. A clinical study] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9445914 VL - 211 ID - 2008 ER - TY - JOUR AB - Background. Poor compliance can be dangerous to successful medical treatment of glaucoma. Among other things one reason for non-compliance represents the inability of the patients to place drops in the eye appropriately. Therefore information regarding the patients ability to administer an eyedrop safely are a prerequisite to determining a therapy scheme which ensures the compliance of glaucoma patients. Patients and methods. 100 glaucoma patients on medical therapy who first presented in the outpatient glaucoma clinic of the University Eye Hospital of Wurzburg were examined by standardised questionnaire and ability tests. We evaluated: 1. Can the eyedrop administration of glaucoma patients be improved by a standardised instruction? 2. Can the eyedrop administration be improved by the use of a drop aid (Autodrop®)? 3. Can the accuracy of aiming and the manual ability be evaluated with a target-test on a sheet of paper with a series of concentric circles? 4. How do patients on combined therapy distinguish between their different bottles and where is the dosage regimen noted? 5. What kind of distinguishing marks of eyedrop-bottles do the patients prefer? Results. 1. Before verbal instruction 76% of the patients applied the eyedrops appropriately, after instruction 94% (p < 0.001) were capable. Touching the eye with the tip of the dropper was reduced significantly. Touching the eye before instruction was found in 63% of the patients, after instruction it was found in 41% (p < 0.001). 2. When patients used the drop aid 81% were able to place a drop in the eye appropriately. Only by 46% of the patients the Autodrop® was welcomed. 3. 16% of the patients were not able to place a drop within 1.5 cm of the center of the target (according to the size of an eye). 4. 47% of the patients who use more than one eyedrop bottle admitted problems in distinguishing the bottles, only 38% of the patients read the labels. 5. 76% of the patients would prefer markable stickers of different colours for the bottom of the bottles to improve distinguishing the bottles in combined therapy. Conclusion. Instruction improves eyedrop administration in 18% of our patients. In combined therapy with several drugs new distinguishing marks are requested by the patients. To improve compliance combination preparations should be administered if available. AD - E. Gramer, Universitats-Augenklinik Wurzburg, Josef-Schneider-Str. 11, D-97080 Wurzburg, Germany AU - Busche, S. AU - Gramer, E. DB - Embase Medline DO - 10.1055/s-2008-1035132 IS - 4 KW - beta adrenergic receptor blocking agent carbachol dipivefrine eye drops adult aged article drug formulation female glaucoma human major clinical study male patient compliance LA - German M3 - Article N1 - L27477368 1997-12-04 PY - 1997 SN - 0023-2165 SP - 257-262 ST - Improvement of compliance and eyedrop administration in glaucoma patients with combined therapy T2 - Klinische Monatsblatter fur Augenheilkunde TI - Improvement of compliance and eyedrop administration in glaucoma patients with combined therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L27477368&from=export http://dx.doi.org/10.1055/s-2008-1035132 VL - 211 ID - 3964 ER - TY - JOUR AB - In a retrospective study, the authors analyzed visual results and postoperative complications in a series of 14 consecutive patients who had undergone penetrating keratoplasty and implantation of a posterior chamber intraocular lens (PC IOC) in the absence of the posterior capsule. Seven patients suffered from aphakic bullous keratopathy and seven from pseudophakic bullous keratopathy. Postoperative follow-up was 7.6 months on the average. Bestcorrected postoperative visual acuity was 20/60 or better in four cases and 20/200 or better in eight. Glaucoma was present before surgery in four eyes, which persisted in all cases and developed in four new cases. Results of gonioscopic examination showed the postoperative development of goniosynechiae in four eyes. Pseudophakodonesis of various extent was present in ten eyes. Preoperatively, cystoid macular edema was diagnosed angiographically in one case. It did not improve after surgery and was seen in three additional eyes postoperatively. Causes for postoperative visual acuity lower than 20/200 were cystoid macular edema in three cases, graft rejection in one case, central retinal scar in one case, and optic nerve atrophy in one case. A distortion of the pupil was seen in three eyes in miosis and in four additional eyes in mydriasis. Corneal thickness as well as anterior chamber depth were within normal limits. Fluorophotometric evaluation of the blood-aqueous barrier showed values comparable with those obtained after intracapsular cataract extraction and implantation of an iris-fixated IOL. Despite the relatively good visual results, the high postoperative incidence of cystoid macular edema and/or glaucoma may discourage the use of this technique. © 1990, American Academy of Ophthalmology, Inc. All rights reserved. AD - University Eye Hospital, Bonn, Germany AU - Busin, M. AU - Brauweiler, P. AU - Böker, T. AU - Spitznas, M. DB - Scopus DO - 10.1016/S0161-6420(90)32570-8 IS - 4 M3 - Article N1 - Cited By :28 Export Date: 19 July 2021 PY - 1990 SP - 401-406 ST - Complications of Sulcus-supported Intraocular Lenses with Iris Sutures, Implanted during Penetrating Keratoplasty after Intracapsular Cataract Extraction T2 - Ophthalmology TI - Complications of Sulcus-supported Intraocular Lenses with Iris Sutures, Implanted during Penetrating Keratoplasty after Intracapsular Cataract Extraction UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025360904&doi=10.1016%2fS0161-6420%2890%2932570-8&partnerID=40&md5=2969f6177e20ba898be1ec839010e574 VL - 97 ID - 5077 ER - TY - JOUR AB - There are a wide variety of topical treatment options for psoriasis. Despite their effectiveness in clinical trials, control of psoriasis in clinical practice remains a challenge. A multitude of factors limits patients' use of medication, including frustration with poor efficacy, inconvenience, fear of side effects, financial restraints, vague application instructions, complicated regimens and unpleasant treatment characteristics. The first step to optimize topical therapy is to develop a physician-patient relationship that contributes to realistic expectations and proper use of medication. Patients should be involved in the choice of medications and vehicles. Topical corticosteroids form the foundation of treatment and topical vitamin D analogs and other noncorticosteroid agents can be used as complements to optimize long-term results. © 2009 Expert Reviews Ltd. AD - S.R. Feldman, Department of Dermatology, Department of Pathology and Public Health Sciences, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071, United States AU - Busse, K. L. AU - Alikhan, A. AU - Feldman, S. R. C1 - daivonex dovonex elidel keralyt protopic vectical DB - Embase DO - 10.1586/edm.09.32 IS - 4 KW - 2 hydroxyacid 22 oxacalcitriol allantoin becocalcidiol betamethasone betamethasone dipropionate betamethasone valerate calcineurin inhibitor calcipotriol calcitriol clobetasol clobetasol propionate coal tar colecalciferol derivative corticosteroid dithranol fluocinonide hydrocortisone lactic acid mometasone furoate pimecrolimus placebo salicylic acid steroid tacalcitol tacrolimus tazarotene ulobetasol propionate unclassified drug unindexed drug vitamin D derivative acne acute toxicity application site burning application site reaction atopic dermatitis bone necrosis caregiver support cataract clinical feature clinical trial combination chemotherapy Cushing syndrome dermatitis disease exacerbation doctor patient relationship drug absorption drug antagonism drug contraindication drug cost drug dose sequence drug efficacy drug eruption drug excretion drug formulation drug indication drug mechanism drug potency drug potentiation drug protein binding drug safety drug use drug withdrawal dry skin edema erythema erythroderma fatigue folliculitis gastrointestinal symptom glaucoma headache hirsutism hormone deficiency human hypercalcemia hypercalciuria hyperpigmentation hypoglycemia hypopigmentation keratoacanthoma mycosis nausea and vomiting oral mucosal disease patient compliance patient education patient participation patient satisfaction perioral dermatitis photosensitivity photosensitization pigment disorder priority journal pruritus psoriasis purpura recommended drug dose review rosacea scalp pruritus side effect skin allergy skin atrophy skin contusion skin discoloration skin infection skin irritation skin ulcer staining stria systemic disease telangiectasia teratogenicity tinnitus topical treatment treatment planning unpleasant sensation daivonex dovonex elidel keralyt protopic vectical LA - English M3 - Review N1 - L355241831 2009-11-04 PY - 2009 SN - 1746-9872 SP - 385-402 ST - Optimizing topical therapy for psoriasis T2 - Expert Review of Dermatology TI - Optimizing topical therapy for psoriasis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355241831&from=export http://dx.doi.org/10.1586/edm.09.32 http://www.expert-reviews.com/doi/pdf/10.1586/edm.09.32 VL - 4 ID - 3313 ER - TY - JOUR AB - Recent outbreaks of microbial keratitis in contact lens wearers have involved various pathogens, including Acanthamoeba and Fusarium species. Specific reasons for the marked increase in microbial keratitis, particularly those involving species typically rarely involved in contact lens infection, remain unknown. Possible contributing factors include inadequacies of various multipurpose solutions against certain pathogens; inadequate lens care hygiene, including elimination of the digital rubbing step; poor contact lens storage case hygiene; and the introduction of new soft contact lens materials that may promote adherence of certain pathogens, particularly when a digital rubbing step is eliminated. Although there is some conflict of opinion in the literature regarding the necessity for a mechanical rub during lens cleaning and disinfection, growing evidence supports the reestablishment of a digital rub component to multipurpose solution lens care systems. This article reviews the literature on whether such a process should be recommended to contact lens wearers. AU - Butcko, Victoria AU - McMahon, Timothy T. AU - Joslin, Charlotte E. AU - Jones, Lyndon IS - 6 Pt 2 KW - Acanthamoeba Keratitis/et [Etiology] Acanthamoeba Keratitis/pc [Prevention & Control] *Contact Lens Solutions/pd [Pharmacology] *Contact Lenses/ae [Adverse Effects] *Eye Infections/et [Etiology] Eye Infections, Bacterial/et [Etiology] Eye Infections, Bacterial/pc [Prevention & Control] Eye Infections, Parasitic/et [Etiology] Eye Infections, Parasitic/pc [Prevention & Control] Humans *Hygiene *Keratitis/mi [Microbiology] *Keratitis/pc [Prevention & Control] PY - 2007 SE - Butcko, Victoria. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA. SN - 1542-2321 SP - 421-5 ST - Microbial keratitis and the role of rub and rinsing T2 - Eye & contact lens TI - Microbial keratitis and the role of rub and rinsing UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17975438 VL - 33 ID - 1570 ER - TY - JOUR AB - Research is pointing the way to new therapies for the eye diseases of aging. A gene that appears related to glaucoma has been identified, and a safe and effective inhibitor for aldose reductase is being sought for patients with diabetic retinopathy. Refinements in cataract surgery continue to improve the high success rate of this procedure. Physicians can educate their patients to participate in vision protection, through control of blood sugars, compliance with glaucoma medications, and the use of the Amsler grid by those at risk for macular degeneration. When vision cannot be corrected to the normal range, low vision rehabilitation offers magnification and new high-tech devices for optimizing independent patient function. AU - Butler, R. N. AU - Faye, E. E. AU - Guazzo, E. AU - Kupfer, C. IS - 9 KW - Age Factors *Aged Cataract/et [Etiology] Cataract/pc [Prevention & Control] Diabetic Retinopathy/et [Etiology] Diabetic Retinopathy/pc [Prevention & Control] Eye Diseases/di [Diagnosis] *Eye Diseases/pc [Prevention & Control] Female Glaucoma/et [Etiology] Glaucoma/pc [Prevention & Control] Humans Macular Degeneration/et [Etiology] Macular Degeneration/pc [Prevention & Control] Male Research Risk Factors Vision Disorders/et [Etiology] *Vision Disorders/rh [Rehabilitation] PY - 1997 SE - Butler, R N. Department of Geriatrics and Adult Development, Mount Sinai Medical Center, New York, USA. SN - 0016-867X SP - 48-6 ST - Keeping an eye on vision: new tools to preserve sight and quality of life. A roundtable discussion, Part 2 T2 - Geriatrics TI - Keeping an eye on vision: new tools to preserve sight and quality of life. A roundtable discussion, Part 2 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9307572 VL - 52 ID - 2012 ER - TY - JOUR AB - The adherence of microorganisms to contact lenses may be an important initial step in the pathogenesis of contact lens-associated infectious keratitis. Using a strain of Candida albicans whose interaction with various polymers has been well characterized we systematically investigated the adherence of this pathogen to hard hydrophobic and soft hydrophilic extended-wear contact lenses. Yeasts adhere to the hydrophobic lenses in direct proportion to the wetting angle of the lens whereas yeasts adhere to the hydrophilic lenses in direct proportion to the water content of the lens. Tear proteins such as albumin, lactoferrin, and lysozyme in addition to fibronectin enhance yeast adherence to both types of lenses (P less than 0.01). Concanavalin A reduces adherence of yeasts to both lens types (P less than 0.01). Among tear components however, only mucin (0.5%) consistently reduced yeast adherence to both lens types. Hydrophilic extended wear lenses worn for at least 28 days by normal patients consistently had greater adherence of yeasts than unworn lenses of the same type, often as much as ten-fold or greater yeasts/mm2 of lens surface area (P less than 0.05). These investigations indicate that tear components both in solution and adsorbed to the lens surface enhance microorganism adherence to contact lenses. AU - Butrus, S. I. AU - Klotz, S. A. IS - 10 KW - *Candida albicans Cell Adhesion *Contact Lenses Contact Lenses, Hydrophilic Tears/ph [Physiology] PY - 1986 SN - 0271-3683 SP - 745-50 ST - Blocking Candida adherence to contact lenses T2 - Current eye research TI - Blocking Candida adherence to contact lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=3533431 VL - 5 ID - 2210 ER - TY - JOUR AB - The adherence of Pseudomonas aeruginosa to extended-wear soft contact lenses (EWSCLs) may be an important initial step in the pathogenesis of EWSCL-associated infectious keratitis. P. aeruginosa tend to adhere more to worn EWSCLs than unworn EWSCLs (P less than 0.05). Normal tear components such as aqueous solutions of albumin, lysozyme, and lactoferrin all significantly enhance adherence of P. aeruginosa to unworn EWSCLs often by as much as 300%. The presence of a 1% solution of sialic acid in the bathing medium significantly reduces the adherence of P. aeruginosa to both unworn and worn lenses. Inhibition of bacterial adherence could also be achieved with the addition of mucin (which contains terminal sialic acid residues in its major sugar chains). Therefore, selective adherence by P. aeruginosa to a specific sugar (sialic acid) may be important in the initial attachment of the bacterium to soft contact lenses. AU - Butrus, S. I. AU - Klotz, S. A. AU - Misra, R. P. IS - 10 KW - *Bacterial Adhesion *Contact Lenses, Extended-Wear/ae [Adverse Effects] *Contact Lenses, Hydrophilic/ae [Adverse Effects] Eye Proteins/ph [Physiology] Humans *Keratitis/mi [Microbiology] *Pseudomonas Infections/mi [Microbiology] Pseudomonas aeruginosa/py [Pathogenicity] PY - 1987 SE - Butrus, S I. Department of Ophthalmology, Veterans Administration Medical Center, Shreveport. SN - 0161-6420 SP - 1310-4 ST - The adherence of Pseudomonas aeruginosa to soft contact lenses T2 - Ophthalmology TI - The adherence of Pseudomonas aeruginosa to soft contact lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=3120075 VL - 94 ID - 2199 ER - TY - JOUR AB - Glaucoma is the most common optic neuropathy characterized by normal to raised intraocular pressure (IOP), visual field defects, loss of retinal nerve fiber layer, thinning of the neuroretinal rim, and cupping of the optic disc. IOP reduction by medical, laser, or surgical therapies remains the only clinically proven treatment of glaucoma. The challenges in glaucoma management are diverse. They include early detection and diagnosis, setting of appropriate target IOP, choice of treatment, monitoring of quality of life and sight, and compliance with the treatment. Early diagnosis can be made by assessing optic nerve structure using imaging devices and optic nerve function through perimetry. Reducing IOP and controlling its fluctuations are considered to be the most important factors in limiting progression of glaucoma. Selection of the best suitable therapy out of medical, surgical, or laser treatment options is yet another management challenge. Patients suffering from glaucoma experience poor quality of life owing to the diagnosis itself, functional visual loss, inconvenience and cost of treatment, and side effects of treatment. All these factors lead to poor compliance, adherence, and persistence to treatment, and further progression of the disease. It is, therefore, important that ophthalmologists keep all the aforementioned factors in mind when managing patients with glaucoma. AU - Butt, Nadeem Hafeez AU - Ayub, Muhammad Hammad AU - Ali, Muhammad Hassaan DO - https://dx.doi.org/10.1016/j.tjo.2016.01.004 IS - 3 PY - 2016 SE - Butt, Nadeem Hafeez. Department of Ophthalmology, Allama Iqbal Medical College/Jinnah Hospital, Lahore, Pakistan. Ayub, Muhammad Hammad. Department of Ophthalmology, Allama Iqbal Medical College/Jinnah Hospital, Lahore, Pakistan. Ali, Muhammad Hassaan. Department of Ophthalmology, Allama Iqbal Medical College/Jinnah Hospital, Lahore, Pakistan. SN - 2211-5056 SP - 119-122 ST - Challenges in the management of glaucoma in developing countries T2 - Taiwan journal of ophthalmology TI - Challenges in the management of glaucoma in developing countries UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=29018725 VL - 6 Y2 - 20160420// ID - 1025 ER - TY - JOUR AD - Y. Buys, Department of Ophthalmology, University of Toronto, Toronto, ON, Canada AU - Buys, Y. AU - Goldberg, I. AU - Lambrou, G. N. AU - Ritch, R. DB - Embase Medline DO - 10.1111/j.1442-9071.2008.01677.x IS - 1 KW - age blindness diagnostic imaging disease predisposition early diagnosis editorial family history follow up glaucoma health care cost high myopia human hypotension incidence intraocular pressure abnormality laser surgery medical information Black person optic nerve lesion patient compliance prevalence prognosis public health quality of life risk factor vasospasm visual field defect visual impairment LA - English M3 - Editorial N1 - L351285185 2008-03-11 PY - 2008 SN - 1442-6404 1442-9071 SP - 6-7 ST - World Glaucoma Day, 6 March 2008: Tackling glaucoma internationally T2 - Clinical and Experimental Ophthalmology TI - World Glaucoma Day, 6 March 2008: Tackling glaucoma internationally UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351285185&from=export http://dx.doi.org/10.1111/j.1442-9071.2008.01677.x VL - 36 ID - 3481 ER - TY - JOUR AB - OBJECTIVE: To determine the proportion of glaucoma patients in Ontario aged 25-64 who lack insurance coverage for glaucoma medications and to assess the frequency of cost-related nonadherence to glaucoma medications., DESIGN: Cross-sectional study., PARTICIPANTS: Glaucoma patients on medication from 2 glaucoma clinics in Toronto, Ontario., METHODS: 100 consecutive glaucoma patients aged 25-64 (not entitled to provincial drug benefit) and 100 consecutive glaucoma patients aged 65+ (entitled to provincial drug benefit), all on topical glaucoma therapy, completed a standardized questionnaire. Questions included insurance coverage for glaucoma medications, cost concerns when paying for glaucoma medications, cost-related nonadherence, and sociodemographics., RESULTS: 25.8% of those aged 25-64 express concerns about the cost of their glaucoma medications compared to 7.1% of those aged 65+ (p < 0.001). Patients aged 25-64 were also significantly more likely to report at least one form of cost-related nonadherence (15.5% vs 2.0%, p=0.001) and significantly more likely to report missing eye drops in a given week than patients aged 65+ (32.0% vs 16.7%, p=0.01). 17% (95% confidence interval 11%-26%) of patients aged 25-64 self-reported having no insurance coverage for their glaucoma medications. Of those with coverage, the most common source of insurance was employer-sponsored (68.6%) with 44% requiring a copayment. The average copayment was $18 (range $2-$250) for those aged 25-64 compared with $5 in the 65+ group (range $0.62-$100)., CONCLUSIONS: 17% of glaucoma patients aged 25-64 do not have coverage for their drops. One in four expressed concerns about the cost of their glaucoma medications, and 15.5% reported cost-related nonadherence. Copyright © 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. AU - Buys, Yvonne M. AU - Kagan, Dov AU - Jin, Ya-Ping AU - Trope, Graham E. DO - https://dx.doi.org/10.1016/j.jcjo.2021.01.008 PY - 2021 SE - Buys, Yvonne M. Department of Ophthalmology and Vision Sciences. Electronic address: y.buys@utoronto.ca. Kagan, Dov. Department of Ophthalmology and Vision Sciences. Jin, Ya-Ping. Department of Ophthalmology and Vision Sciences; Dalla Lana School of Public Health University of Toronto, Toronto, Ont. Trope, Graham E. Department of Ophthalmology and Vision Sciences. SN - 1715-3360 0008-4182 ST - Cost-related nonadherence with glaucoma medications in Ontario T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - Cost-related nonadherence with glaucoma medications in Ontario UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=33548175 Y2 - 20210203// ID - 25 ER - TY - JOUR AB - AIM: To assess the utilization of eye care services by Australians most likely to benefit from eye assessment., METHODS: The Melbourne Visual Impairment Project was a population-based study that collected demographic, health and vision-related information including use of eye care services. A standardized detailed ophthalmic examination was performed. Utilization of eye care services by those who might most benefit from eye care was assessed and compared to the general population. These participants include those with undiagnosed glaucoma, unoperated visually significant cataract, undercorrected refractive error, diabetes mellitus, age-related macular degeneration and visual acuity < 6/12. Sociodemographic characteristics were assessed for their influence on eye care utilization among these participants., RESULTS: A total of 4744 urban and rural residents participated (86% of those eligible) and 4612 (83% of total eligible) of these had a complete data set for the use of eye care services and were included. There were 933 participants (20.2%) who did not report eye assessment in the previous 5 years, and 891 participants (19.3%) had one or more aforementioned conditions potentially benefiting from eye care. Of these, between 34.4% and 59.4% reported no examination in the previous year and between 9% and 25% reported no examination within the previous 5 years. These participants were more likely to seek eye care within the short term (1 year) if they had a family history of eye disease, otherwise a noticed change in vision was the main influence in the longer term (2-5 years). Male participants, younger participants and those whose main spoken language was not English were less likely to seek eye care in the longer term., CONCLUSIONS: In Victoria 19% of those >40 years of age have potentially unmanaged eye disease including glaucoma, unoperated visually significant cataract, undercorrected refractive error, age-related macular degeneration, diabetes mellitus or visual acuity < 6/12. A substantial proportion of these report no eye assessment in the previous 1, 2 or 5 years or ever before. Younger age, male sex and main language other than English make assessment less likely. Many may have these conditions despite having had a recent eye assessment. AU - Bylsma, Guy W. AU - Le, Anhchuong AU - Mukesh, Bickol N. AU - Taylor, Hugh R. AU - McCarty, Catherine A. IS - 6 KW - Adult Aged Aged, 80 and over *Delivery of Health Care/sn [Statistics & Numerical Data] *Eye Diseases/ep [Epidemiology] *Eye Diseases/th [Therapy] Female *Health Services/sn [Statistics & Numerical Data] Health Services Accessibility Humans Male Middle Aged *Ophthalmology/sn [Statistics & Numerical Data] *Optometry/sn [Statistics & Numerical Data] Prevalence Rural Population Urban Population Victoria/ep [Epidemiology] *Visually Impaired Persons/sn [Statistics & Numerical Data] PY - 2004 SE - Bylsma, Guy W. Centre for Eye Research Australia, University of Melbourne, Victoria, Australia. guyandbron@optusnet.com.au SN - 1442-6404 SP - 573-7 ST - Utilization of eye care services by Victorians likely to benefit from eye care T2 - Clinical & experimental ophthalmology TI - Utilization of eye care services by Victorians likely to benefit from eye care UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15575826 VL - 32 ID - 1762 ER - TY - JOUR AB - Describes the case of a 63-yr-old male bipolar patient who developed thyrotoxicosis with severe exophthalmos (EXT) while on lithium therapy. The patient had required 2 surgical decompressions of the right orbit to relieve pressure, which occurred secondary to progression of the EXT and was scheduled for further surgery. Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria. The EXT improved dramatically within 72 hrs of the withdrawal of lithium. A severe form of EXT resulting from lithium therapy has not been described in the literature. The case described here adds to the body of information about the possible causes of thyrotoxic ophthalmopathy. (French abstract) (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1994-26665-001 AU - Byrne, Alan P. AU - Delaney, W. J. DB - psyh DP - EBSCOhost IS - 10 KW - lithium development of thyrotoxicosis with severe exophthalmos bipolar male 63 yr old case report Bipolar Disorder Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Graves Disease Humans Male Middle Aged Substance Withdrawal Syndrome Eye Disorders Side Effects (Drug) Thyrotoxicosis Drug Therapy N1 - U Alberta, Dept of Psychiatry, Edmonton, Canada. Other Publishers: Sage Publications. Release Date: 19940701. Correction Date: 20160901. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: EnglishMajor Descriptor: Bipolar Disorder; Eye Disorders; Lithium; Side Effects (Drug); Thyrotoxicosis. Minor Descriptor: Case Report; Drug Therapy. Classification: Clinical Psychopharmacology (3340). Population: Human (10). Age Group: Adulthood (18 yrs & older) (300). Methodology: Clinical Case Study; Empirical Study. Page Count: 3. Issue Publication Date: Dec, 1993. PY - 1993 SN - 0706-7437 1497-0015 SP - 635-637 ST - Regression of thyrotoxic ophthalmopathy following lithium withdrawal T2 - The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie TI - Regression of thyrotoxic ophthalmopathy following lithium withdrawal UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1994-26665-001&site=ehost-live&scope=site VL - 38 ID - 4897 ER - TY - JOUR AB - The panel meeting, convened by Bausch & Lomb at the AOA Congress, addressed questions about the outbreak and the product recall. AN - 106330745. Language: English. Entry Date: 20060908. Revision Date: 20150711. Publication Type: Journal Article AU - Byrne, J. DB - ccm DP - EBSCOhost IS - 15 KW - Disease Outbreaks Keratitis -- Microbiology Mycoses -- Physiopathology Product Recall Contact Lenses -- Adverse Effects Eye Care Patient Compliance Patient Safety Solutions -- Adverse Effects N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 61-62 ST - Panel addresses questions about Fusarium investigation T2 - Ocular Surgery News TI - Panel addresses questions about Fusarium investigation UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106330745&site=ehost-live&scope=site VL - 24 ID - 4773 ER - TY - JOUR AB - Objective: Patients with diabetic macular oedema (DME) are known to have significantly greater medical treatment burden than patients with non-DME. Frequent injections and office visits can have a substantial impact on patient adherence and quality of life. This analysis assesses the impact of the 0.19 mg fluocinolone acetonide (FAc) implant (or injection) on treatment burden and practice resource utilisation in patients with DME., Methods and analysis: This study is a single-centre retrospective chart review of 30 eyes (23 patients) that received a single FAc implant. Data was collected for a 12-month period pre-injection and post-injection of the FAc implant. Primary outcomes included the frequency of injections and ophthalmology office visits. Secondary outcomes included visual acuity (VA), intraocular pressure (IOP) and central subfield thickness (CSFT)., Results: The injection frequency significantly decreased from one injection every 2.6 months pre-injection to one injection every 8.8 months post-injection of the FAc implant (p<0.001). Sixty-three percent of the subjects did not require additional injections post-FAc implant. The mean number of ophthalmology office visits significantly decreased from 12.7 visits pre-FAc to 9.3 visits post-FAc implant (p<0.001). The mean VA (p=0.24) and CSFT (p=0.39) showed a mild numerical improvement that was not statistically significant. Thirty-seven percent of the eyes required additional IOP lowering drops. No eyes required incisional glaucoma surgeries., Conclusions: The FAc implant significantly decreased the treatment burden and improved practice resource utilisation while maintaining or improving VA and CSFT. IOP events were mostly well-controlled with drops and no eyes required incisional glaucoma surgery. Copyright © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. AU - Byun, Matthew AU - Osher, James AU - Riemann, Christopher D. DO - https://dx.doi.org/10.1136/bmjophth-2019-000416 IS - 1 PY - 2020 SE - Byun, Matthew. Retina, University of Illinois at Chicago, Chicago, Illinois, United States. Byun, Matthew. University Retina and Macula Associates, Oak Forest, Illinois, United States. Osher, James. Retina, Cincinnati Eye Institute, Cincinnati, Ohio, United States. Osher, James. Retina, University of Cincinnati, Cincinnati, Ohio, United States. Riemann, Christopher D. Retina, Cincinnati Eye Institute, Cincinnati, Ohio, United States. Riemann, Christopher D. Retina, University of Cincinnati, Cincinnati, Ohio, United States. SN - 2397-3269 SP - e000416 ST - Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema T2 - BMJ open ophthalmology TI - Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=32518834 VL - 5 Y2 - 20200408// ID - 136 ER - TY - JOUR AB - Purpose: Studies have shown that patients with diabetic macular edema (DME) have significantly greater treatment burden than non-DME patients due to frequent total health care visits.[i] Frequent injections and office visits can have a substantial impact on patient adherence and quality of life. This analysis of real-world data assesses the impact of a 0.19 mg fluocinolone acetonide (FAC) implant on treatment burden in patients with DME. Methods: This study is a single-center retrospective chart review of 30 eyes (23 patients) that received a single intravitreal injection of 0.19 mg FAc implant (ILUVIEN, Alimera Science Inc., Alpharetta, GA). Data was collected for a 12-month period pre-and post-FAc injection. Primary outcomes included the number of injections and ophthalmology-related office visits. Secondary outcomes included visual acuity (VA), intraocular pressure (IOP) and central sub-field thickness (CSFT) on optical coherence tomography (OCT). Results: The injection frequency significantly decreased from one injection every 2.6 months pre-FAc to one injection every 8.8 months post-FAc (P<0.001). 63% of the eyes did not require additional injections post-FAc. The mean number of ophthalmology-related office visits also significantly decreased from 12.7 visits pre-FAc to 9.3 visits post-FAc (P<0.001). At 12 months post-FAc, the mean VA and CSFT showed a mild improvement. In regards to IOP events, 37% of the eyes required additional IOP lowering drops post-FAc. No eyes required an incisional glaucoma surgery post-FAc. Conclusions: Our results showed that a single intravitreal injection of 0.19 mg FAc implant significantly decreased the treatment burden while maintaining/improving the VA and the CSFT. Specifically, both the frequency of injections and office visits decreased significantly post-FAc. IOP events were in-line with FAME trial and other real-world data with zero eyes requiring an incisional glaucoma surgery. AD - M. Byun, Ophthalmology, University of Cincinnati, Cincinnati, OH, United States AU - Byun, M. AU - Riemann, C. D. AU - Osher, J. AU - Patel, Y. DB - Embase IS - 9 KW - fluocinolone acetonide adult ambulatory care clinical article conference abstract controlled study diabetic macular edema drug therapy female glaucoma surgery human injection intraocular pressure intravitreal drug administration intravitreal implant male medical record review ophthalmology optical coherence tomography outcome assessment retrospective study thickness visual acuity LA - English M3 - Conference Abstract N1 - L628537674 2019-07-22 PY - 2018 SN - 1552-5783 ST - Fluocinolone acetonide (0.19 mcg/day) intravitreal implant and improved treatment burden for patients with diabetic macular edema (DME) T2 - Investigative Ophthalmology and Visual Science TI - Fluocinolone acetonide (0.19 mcg/day) intravitreal implant and improved treatment burden for patients with diabetic macular edema (DME) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628537674&from=export VL - 59 ID - 2579 ER - TY - JOUR AB - PURPOSE: To develop and measure the uptake of a local guideline for herpes simplex keratitis (HSK) and to standardize initial antiviral therapy in Australia., METHODS: The Registered Nurses' Association of Ontario Toolkit: "Implementation of Best Practice Guidelines" was used to develop, implement, and evaluate the guideline at Sydney Eye Hospital. An implementation team was established to reach consensus on antiviral therapy guidelines through review of available evidence, identifying stakeholders, facilitators and barriers, creating strategies for implementation, and developing a sustainability plan. An audit of all adult HSK cases during a 6-month postguideline implementation period was conducted, and the results were compared with a preimplementation audit. A web-based survey was created to assess clinician awareness, usage, and level of knowledge of the guideline., RESULTS: Clinicians, pharmacists, and administrative staff were identified as stakeholders. Changing clinician's behavior was the major barrier to implementation. Implementation strategies included printed and online materials and lectures to clinicians. A postimplementation audit included 85 patients, and 95 clinicians received a web-based survey. The dose of the prescribed antiviral medication was in alignment with the local guideline in 80% (51/64) of the patients compared with 73% (163/223) before implementation (P = 0.331). Stromal HSK with ulceration and keratouveitis were excluded because there were no recommendations before implementation. Over 70% of clinicians (30/41) were aware of the guideline and accessed them through educational resources., CONCLUSIONS: Guidelines for the management of HSK may improve standardization of initial antiviral therapy in HSK. In practice, most clinicians were aware of and adhered to the local guideline. AU - Cabrera-Aguas, Maria AU - Kerdraon, Yves AU - Symes, Richard J. AU - McCluskey, Peter AU - Samarawickrama, Chameen AU - Rawlinson, William AU - Watson, Stephanie L. DO - https://dx.doi.org/10.1097/ICO.0000000000002273 IS - 7 KW - *Disease Management *Eye Infections, Viral/th [Therapy] Humans *Keratitis, Herpetic/th [Therapy] New South Wales *Practice Guidelines as Topic PY - 2020 SE - Cabrera-Aguas, Maria. Discipline of Ophthalmology, The University of Sydney, Save Sight Institute, Sydney Medical School, Sydney, New South Wales, Australia. Cabrera-Aguas, Maria. Department of Opthalmology, Sydney Eye Hospital, Sydney Australia. Kerdraon, Yves. Discipline of Ophthalmology, The University of Sydney, Save Sight Institute, Sydney Medical School, Sydney, New South Wales, Australia. Kerdraon, Yves. Department of Opthalmology, Sydney Eye Hospital, Sydney Australia. Symes, Richard J. Discipline of Ophthalmology, The University of Sydney, Save Sight Institute, Sydney Medical School, Sydney, New South Wales, Australia. Symes, Richard J. Department of Opthalmology, Sydney Eye Hospital, Sydney Australia. McCluskey, Peter. Discipline of Ophthalmology, The University of Sydney, Save Sight Institute, Sydney Medical School, Sydney, New South Wales, Australia. McCluskey, Peter. Department of Opthalmology, Sydney Eye Hospital, Sydney Australia. Samarawickrama, Chameen. Discipline of Ophthalmology, The University of Sydney, Save Sight Institute, Sydney Medical School, Sydney, New South Wales, Australia. Samarawickrama, Chameen. Department of Opthalmology, Westmead Hospital, Westmead, Australia; and. Rawlinson, William. Serology and Virology Division, Microbiology, NSW Health Pathology, and University of NSW, Sydney, Australia. Watson, Stephanie L. Discipline of Ophthalmology, The University of Sydney, Save Sight Institute, Sydney Medical School, Sydney, New South Wales, Australia. Watson, Stephanie L. Department of Opthalmology, Sydney Eye Hospital, Sydney Australia. SN - 1536-4798 0277-3740 SP - 834-840 ST - Development, Implementation, and Evaluation of Treatment Guidelines for Herpes Simplex Keratitis in Sydney, Australia T2 - Cornea TI - Development, Implementation, and Evaluation of Treatment Guidelines for Herpes Simplex Keratitis in Sydney, Australia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32049680 VL - 39 ID - 200 ER - TY - JOUR AB - The article suggests that until glaucoma drug delivery methods beyond eye drops are developed and made available, clinicians must coach patients on better drop use and teach healthcare payers about the importance of compliance. Topics include drawback of eye drops as well as novel drug delivery systems targeting better glaucoma systems. Also mentioned are a peer-reviewed paper from Singapore on a liposomal-sustained release of latanoprost as well as other delivery systems such as corneal rings. AN - 112544027. Language: English. Entry Date: 20160201. Revision Date: 20160201. Publication Type: Article AU - Caceres, Vanessa DB - ccm DP - EBSCOhost IS - 1 KW - Glaucoma -- Drug Therapy Drug Delivery Systems Ophthalmic Solutions Treatment Outcomes N1 - brief item. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2016 SN - 0193-032X SP - 19-19 ST - Novel drug delivery systems will target better glaucoma treatment T2 - Ophthalmology Times TI - Novel drug delivery systems will target better glaucoma treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112544027&site=ehost-live&scope=site VL - 41 ID - 4502 ER - TY - JOUR AB - The article presents a discussion of the steps that ophthalmologists must take before cataract surgery in advanced glaucoma patients, designed to lower the chance for vision loss, adapted from Dr. Yvonne Ou's presentation at the American Glaucoma Society annual meeting. It includes setting expectations for patients and physicians before the surgery, the use of careful surgical planning, and using all methods to minimize inflammation. AN - 137713104. Language: English. Entry Date: 20190729. Revision Date: 20190730. Publication Type: Article AU - Caceres, Vanessa DB - ccm DP - EBSCOhost IS - 12 KW - Motivation Goal-Setting Physician-Patient Relations Preoperative Period Attitude to Medical Treatment Cataract Extraction -- Psychosocial Factors Glaucoma -- Surgery Strategic Planning Ophthalmologists -- Psychosocial Factors Treatment Outcomes Inflammation -- Prevention and Control Fluorouracil -- Administration and Dosage Postoperative Care Office Visits Risk Assessment Steroids -- Therapeutic Use After Care N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2019 SN - 0193-032X SP - 16-18 ST - Setting expectations for glaucoma patients having cataract surgery: Pearls can ensure physicians get best outcomes, help patients set realistic goals T2 - Ophthalmology Times TI - Setting expectations for glaucoma patients having cataract surgery: Pearls can ensure physicians get best outcomes, help patients set realistic goals UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137713104&site=ehost-live&scope=site VL - 44 ID - 4291 ER - TY - JOUR AB - The article offers tips in managing rock-hard cataract in glaucoma patients. Topics discussed include insight from Dr. Garry P. Condon, Ophthalmology associate at Allegheny Ophthalmic on the use of a divide-and-conquer approach in phaco energy being expended in the capsular bag, and taking advantage of an adherent dispersive viscoelastic material to protect the endothelium. Also mentioned are postoperative use of intra-ocular pressure (IOP) lowering medication. AN - 137043017. Language: English. Entry Date: 20190620. Revision Date: 20190621. Publication Type: Article AU - Caceres, Vanessa DB - ccm DP - EBSCOhost IS - 10 KW - Cataract Extraction -- Methods Glaucoma Intraocular Pressure N1 - brief item. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2019 SN - 0193-032X SP - 21-21 ST - Managing cataracts in glaucoma patients: A rock-hard case: Challenging procedures often require a deft approach by surgeons T2 - Ophthalmology Times TI - Managing cataracts in glaucoma patients: A rock-hard case: Challenging procedures often require a deft approach by surgeons UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137043017&site=ehost-live&scope=site VL - 44 ID - 4333 ER - TY - JOUR AB - AIM: Assessment of trabeculectomy in South-East Scotland (SESTS) with comparison to National Survey of Trabeculectomy (NST) and outcomes of consultant and trainee surgery., METHOD: A retrospective study of 304 consecutive, primary trabeculectomies, in two Scottish centres (Edinburgh and Dunfermline) with two glaucoma specialists and higher surgical trainees, was performed. The study group had primary open angle glaucoma (65.5%), pseudoexfoliation (6.9%), normal tension glaucoma (7.6%), pigment dispersion syndrome (1.6%), and other complicated glaucoma (18.4%). All patients underwent trabeculectomy by the glaucoma specialist (57.6%) and higher surgical trainee (42.4%) with close scrubbed supervision., RESULTS: Compared to the NST, the waiting time for surgery (<3 months) was significantly less in the SESTS (P<0.001). There was also significantly more use of intraoperative antimetabolites (P<0.01), bleb intervention (P<0.001), and a higher rate of early complications (P<0.025). There was no significant difference in outcome at intraocular pressure (IOP)<2/3 listing IOP (qualified and unqualified) between the SESTS and the NST. Significantly, more patients achieved an unqualified success of IOP<21 mmHg (P<0.01) and an unqualified success of IOP<16 mmHg in the SESTS than the NST (P<0.05). At 1 year post surgery, visual loss of greater than one Snellen line was more common in the NST (P<0.01) as was the use of anti-glaucoma medication (P<0.001). Trainee cases returned to theatre more frequently (P<0.025) and merited more bleb intervention (P<0.01) than consultant cases, but the long-term outcome was similar., CONCLUSION: Our study highlights significant changes in the practice and outcome of trabeculectomy compared to the national survey conducted a decade ago. AU - Cackett, P. AU - Vallance, J. AU - Cobb, C. AU - Devlin, H. AU - Simpson, A. AU - Sanders, R. IS - 1 KW - Aged Aged, 80 and over Antihypertensive Agents/ad [Administration & Dosage] Clinical Competence Consultants Drug Administration Schedule Female Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] *Glaucoma/su [Surgery] Health Care Surveys Humans Intraocular Pressure Male Middle Aged Retrospective Studies Scotland Trabeculectomy/ae [Adverse Effects] *Trabeculectomy/mt [Methods] Trabeculectomy/st [Standards] Treatment Outcome Waiting Lists PY - 2007 SE - Cackett, P. Princess Alexandra Eye Pavilion, Chalmers Street, Edinburgh, UK. pete@pdcackett.demon.co.uk SN - 0950-222X SP - 46-51 ST - South-East Scotland trabeculectomy survey T2 - Eye (London, England) TI - South-East Scotland trabeculectomy survey UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16215540 VL - 21 Y2 - 20051007// ID - 1624 ER - TY - JOUR AD - Boston Veterans Health Care, Boston, MA AN - 107842494. Language: English. Entry Date: 20140423. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Core Nursing AU - Cakiner-Egilmez, Tulay DA - Spring2014 DB - ccm DP - EBSCOhost IS - 2 KW - Research Ophthalmic Nursing Intraocular Pressure Delayed-Action Preparations Glaucoma -- Drug Therapy Aging Home Environment Lighting Corneal Transplantation Age Factors Aged Cataract Extraction -- Trends Health Services Accessibility N1 - Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Advanced Nursing Practice; Gerontologic Care. NLM UID: 9111431. PY - 2014 SN - 1060-135X SP - 26-27 ST - LITERATURE REVIEW T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - LITERATURE REVIEW UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107842494&site=ehost-live&scope=site VL - 39 ID - 4527 ER - TY - JOUR AU - Cakiner-Egilmez, Tulay IS - 3 KW - *Antihypertensive Agents/tu [Therapeutic Use] *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure *Medication Adherence *Patient Compliance PY - 2015 SN - 1060-135X SP - 5-11 ST - Glaucoma Medications Update: How to Improve Compliance and Adherence T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Glaucoma Medications Update: How to Improve Compliance and Adherence UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26364497 VL - 40 ID - 774 ER - TY - JOUR AD - Boston Veterans Health Care, Boston, MA AN - 108301689. Language: English. Entry Date: 20150714. Revision Date: 20191029. Publication Type: Article AU - Cakiner-Egilmez, Tulay DA - Summer2015 DB - ccm DP - EBSCOhost IS - 3 KW - Glaucoma -- Drug Therapy Medication Compliance Ophthalmic Solutions -- Therapeutic Use Health Status Age Factors Comorbidity Socioeconomic Factors Physician-Patient Relations Communication Ophthalmic Solutions -- Economics Reminder Systems Teaching Materials Patient Education Patient Centered Care Education, Continuing (Credit) N1 - pictorial; review. Note: For CE see webiste. Journal Subset: Core Nursing; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PY - 2015 SN - 1060-135X SP - 5-10 ST - How to Improve Compliance and Adherence T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - How to Improve Compliance and Adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108301689&site=ehost-live&scope=site VL - 40 ID - 4411 ER - TY - JOUR AU - Cakiner-Egilmez, Tulay AU - Lara-Smalling, Agueda IS - 2 KW - *Antihypertensive Agents/ad [Administration & Dosage] *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] *Medication Adherence *Patient Compliance PY - 2012 SE - Cakiner-Egilmez, Tulay. Ophthalmology Department, Boston VA Healthcare System, JP Campus. SN - 1060-135X SP - 5-10 ST - Glaucoma medications. How to improve compliance and adherence T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Glaucoma medications. How to improve compliance and adherence UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22685875 VL - 37 ID - 1128 ER - TY - JOUR AB - BACKGROUND: To determine the temperament and character profile of glaucoma patients., METHODS: A total of 234 patients (104 with primary open angle glaucoma, and 130 control subjects without any ocular disease) were selected for this prospective, cross-sectional study. All the participants underwent a comprehensive ophthalmological examination, including the best corrected visual acuity, intraocular pressure measurement, gonioscopy, and visual field analysis. All the participants were given the Turkish version of the Temperament and Character Inventory (TCI). The TCI is a self-reported evaluate, with 240 true/false items measuring four domains of temperament; harm avoidance (HA), persistence (PS), novelty seeking (NS), reward dependence (RD), and three domains of character; self-transcendence (ST), cooperativeness (C), self-directedness (SD)., RESULTS: The glaucoma patients achieved the higher scores than the controls for the HA and SD dimensions (p < 0.001 and p = 0.033). The glaucoma patients scored lower than the controls for the NS, P and ST dimensions (p < 0.001, p < 0.001 and p = 0.002). There were no differences in the RD and C scores between the patients and the controls (p = 0.944 and p = 0.343). There was no correlation between the duration of illness and the TCI dimensions. Disease severity was positively associated with HA (r = 0,220, p = 0,025) and the anticipatory worry (r = 0.227, p = 0.021) dimension., CONCLUSIONS: Glaucoma patients had a different personality profile to healthy individuals. This may affect treatment compliance and is also important when coping with maladaptive patient attitudes. AU - Cakmak, Harun AU - Altinyazar, Vesile AU - Yilmaz, Suzan Guven AU - Omurlu, Imran Kurt AU - Kocaturk, Tolga AU - Yazici, Alper AU - Degirmenci, Cumali AU - Dundar, Sema Oruc AU - Ates, Halil DO - https://dx.doi.org/10.1186/s12886-015-0117-9 KW - Aged *Character Cross-Sectional Studies Female *Glaucoma, Open-Angle/px [Psychology] Humans Intraocular Pressure Male Medication Adherence Middle Aged *Personality Assessment Prospective Studies *Temperament Visual Acuity PY - 2015 SE - Cakmak, Harun. Department of Ophthalmology, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100, Aytepe, Aydin, Turkey. dharuncakmak@gmail.com. Altinyazar, Vesile. Department of Psychiatry, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100, Aytepe, Aydin, Turkey. valtinyazar2000@yahoo.com. Yilmaz, Suzan Guven. Department of Ophthalmology, Ege University Medical Faculty, Ege Universitesi Tip Fakultesi Hastanesi, 35040, Bornova, Izmir, Turkey. suzan2003@yahoo.com. Omurlu, Imran Kurt. Department of Statistic, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100, Aytepe, Aydin, Turkey. imrankurt@hotmail.com. Kocaturk, Tolga. Department of Ophthalmology, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100, Aytepe, Aydin, Turkey. tolgakocaturk@gmail.com. Yazici, Alper. Department of Ophthalmology, Balikesir University Medical Faculty, Usak yolu uzeri Cagis yerleskesi, 10145, Balikesir, Turkey. lpryzc@yahoo.com. Degirmenci, Cumali. Department of Ophthalmology, Ege University Medical Faculty, Ege Universitesi Tip Fakultesi Hastanesi, 35040, Bornova, Izmir, Turkey. cumalidegirmenci@hotmail.com. Dundar, Sema Oruc. Department of Ophthalmology, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100, Aytepe, Aydin, Turkey. orucs@yahoo.com. Ates, Halil. Department of Ophthalmology, Ege University Medical Faculty, Ege Universitesi Tip Fakultesi Hastanesi, 35040, Bornova, Izmir, Turkey. ateshalil@hotmail.com. SN - 1471-2415 SP - 125 ST - The temperament and character personality profile of the glaucoma patient T2 - BMC ophthalmology TI - The temperament and character personality profile of the glaucoma patient UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26427803 VL - 15 Y2 - 20151001// ID - 769 ER - TY - JOUR AB - OBJECTIVE: To determine the frequency of patient visits in which an unplanned treatment modification was required in chronic patients attending a glaucoma clinic for routine follow-up and to identify the treatment interventions most commonly employed., DESIGN: Prospective, cross-sectional study., PARTICIPANTS: A total of 630 previously stable patients attending a glaucoma clinic for routine follow-up., METHODS: This was a single-centre survey of all eligible patients returning to an academic glaucoma clinic. Data regarding whether patients' visit remained routine or required intervention, which clinical parameter had changed, and any alterations in treatment regimens were studied., RESULTS: The percentage of patients found to require a change in management was 20.79% (131 of 630 patients); 16.9% were found to have a cause for change because of glaucoma, and the remaining 4% required intervention because of a nonglaucomatous condition. The most common parameter that changed treatment was intraocular pressure (43.87%), followed by visual fields (21.29%). The frequency of abnormal parameters varied within each subtype of glaucoma. The frequency of treatment changes among those with primary open-angle glaucoma was 22.58% compared with 16.5% of glaucoma suspects, 14% of ocular hypertensives, 32% of pseudoexfoliative glaucoma, and 50% of normal tension glaucoma patients. The most common intervention (32.84%) was a change in antiglaucoma medications. The next most frequent interventions were laser procedures (21.90%) and surgery (16.06%)., CONCLUSIONS: This study suggests that a significant minority of patients attending a glaucoma clinic for a routine appointment require treatment modification. Copyright © 2016 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. AU - Calafati, Jennifer AU - Pradhan, Zia S. AU - Birt, Catherine M. DO - https://dx.doi.org/10.1016/j.jcjo.2016.05.003 IS - 6 KW - Adult Aged Ambulatory Care Antihypertensive Agents/tu [Therapeutic Use] Appointments and Schedules Cross-Sectional Studies Exfoliation Syndrome/pp [Physiopathology] *Exfoliation Syndrome/th [Therapy] Female Filtering Surgery/mt [Methods] Follow-Up Studies Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/th [Therapy] Humans *Intraocular Pressure/ph [Physiology] Low Tension Glaucoma/pp [Physiopathology] *Low Tension Glaucoma/th [Therapy] Male Middle Aged Ocular Hypertension/pp [Physiopathology] *Ocular Hypertension/th [Therapy] *Precision Medicine Prospective Studies Tonometry, Ocular Visual Acuity/ph [Physiology] Visual Fields/ph [Physiology] PY - 2016 SE - Calafati, Jennifer. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont. Pradhan, Zia S. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont. Birt, Catherine M. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont.. Electronic address: catherine.birt@sunnybrook.ca. SN - 1715-3360 0008-4182 SP - 426-430 ST - Frequency of unplanned interventions in patients attending for a presumed routine glaucoma follow-up appointment T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - Frequency of unplanned interventions in patients attending for a presumed routine glaucoma follow-up appointment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27938953 VL - 51 Y2 - 20160930// ID - 652 ER - TY - JOUR AB - To identify patterns of health care use among diabetic patients with multimorbidity across primary, specialised, hospital and emergency care, depending on their type of chronic comorbidity. Methods Longitudinal study of a population-based retrospective cohort conformed by adult patients with type-2 diabetes assigned to any of the primary care centres in Aragon during 2010 and 2011 (n = 65,716). Negative binomial regressions were run to model the effect of the type of comorbidity on the number of visits to each level of care. Comorbidities were classified as concordant, discordant or mental based on expert consensus and depending on whether they shared the same overall pathophysiologic risk profile and disease management plan designed for type-2 diabetes. Results Mental comorbidity was independently associated with total and unplanned admissions (incidence rate ratio [IRR]:1.25; 95% confidence interval [CI]:1.12-1.39, IRR:1.21; 95% CI:1.06-1.39), average length of stay (IRR:1.47; 95% CI:1.25-1.73), and total and priority emergency room visits (IRR:1.26; 95% CI:1.17-1.35, IRR:1.30; 95% CI:1.18-1.42). Patients with discordant comorbidities showed the strongest associations with the number of visits to specialists (IRR:1.38; 95% CI:1.33-1.43) and to different specialties (IRR:1.36; 95% CI:1.32-1.39). Differences regarding GP visits were lower but still significant for patients with discordant comorbidity (IRR:1.08; 95% CI:1.06-1.11), but especially for those with mental comorbidity (IRR:1.17; 95% CI:1.14-1.21). Conclusion In patients with type-2 diabetes, the coexistence of mental comorbidity significantly increases the use of unplanned hospital services, and discordant comorbidities have an important effect on specialised care use. Differences with respect to primary care use are not as prominent. AD - A. Calderón-Larrañaga, EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, Zaragoza, Spain AU - Calderón-Larrañaga, A. AU - Abad-Díez, J. M. AU - Gimeno-Feliu, L. A. AU - Marta-Moreno, J. AU - González-Rubio, F. AU - Clerencia-Sierra, M. AU - Poblador-Plou, B. AU - Poncel-Falcó, A. AU - Prados-Torres, A. DB - Embase Medline DO - 10.1016/j.ejim.2015.02.011 IS - 3 KW - acquired immune deficiency syndrome acute heart infarction acute leukemia adult affective psychosis anxiety disorder aortic aneurysm aphakia aplastic anemia arthropathy article asthma atherosclerosis attention deficit disorder autoimmune disease behavior disorder bladder cancer blindness blood clotting disorder breast cancer cardiomyopathy cardiovascular disease cataract cerebral palsy cerebrovascular disease chromosome aberration chronic kidney failure chronic liver disease chronic obstructive lung disease chronic pancreatitis cleft lip clinical assessment colorectal cancer comorbidity congenital heart disease congenital hip dislocation congenital malformation congestive heart failure connective tissue disease cystic fibrosis deep vein thrombosis delirium dementia depression dermatitis developmental disorder diabetic patient diabetic retinopathy disorders of lipid metabolism diverticulosis eczema emergency ward emphysema endocrine disease endometriosis esophagus cancer female gallstone formation gastroesophageal reflux glaucoma gout hair disease health care utilization hearing impairment heart arrhythmia hematologic disease hemolytic anemia hemophilia hospital service human Human immunodeficiency virus infection hypertension hypospadias hypothyroidism immunopathology iron deficiency anemia irritable colon ischemic heart disease kidney disease kyphoscoliosis lactose intolerance leg varicosis length of stay longitudinal study low back pain lung embolism lymphoma major clinical study male malignant neoplasm medical specialist metabolic disorder multiple sclerosis muscular dystrophy nephritis neuritis neurologic disease neurosis non insulin dependent diabetes mellitus obesity organ transplantation osteoarthritis osteoporosis ovary cancer paralysis Parkinson disease peripheral neuropathy peripheral vascular disease personality disorder primary medical care prostate hypertrophy prostatitis psoriasis quadriplegia respiratory tract disease retina disease schizophrenia seizure skin cancer skin ulcer sleep disordered breathing spinal cord injury stomach cancer substance use thrombophlebitis tracheostomy tuberculosis uterus prolapse valvular heart disease LA - English M3 - Article N1 - L602903213 2015-03-17 2015-04-21 PY - 2015 SN - 1879-0828 0953-6205 SP - 203-210 ST - Global health care use by patients with type-2 diabetes: Does the type of comorbidity matter? T2 - European Journal of Internal Medicine TI - Global health care use by patients with type-2 diabetes: Does the type of comorbidity matter? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L602903213&from=export http://dx.doi.org/10.1016/j.ejim.2015.02.011 VL - 26 ID - 2818 ER - TY - JOUR AB - Fixed combinations represent a combination of two ocular hypotensive agents into one single ophthalmic solution. Current commercially available fixed combinations used in glaucoma treatment include Combigan, Cosopt, Xalcom, Duotrav and Ganfort. Statistically significant superiority of the ocular hipotensive efficacy of the fixed combinations vs monotherapy with the two individual constituents is present connected with Cosopt and Xalcom. It also exists vs timolol ophthalmic solution relative to Combigan, Duotrav and Ganfort but is missing within these fixed combinations vs brimonidine, travatan and bimatoprost respectively. A slight reduction, that is clinically and statistically insignificant relative to fixed combination efficacy vs the nonfixed combinations (e.g. concomitant but separate administration of the two individual components) is acceptable when this is balanced by potential benefits of the fixed combinations therapy (improved tolerability and convenience,increased compliance,cost and time economies,decreased washout effect and reduced exposure to preservatives). AU - Calugaru, D. AU - Calugaru, M. IS - 3 KW - Amides/ad [Administration & Dosage] *Antihypertensive Agents/ad [Administration & Dosage] Bimatoprost Brimonidine Tartrate Cloprostenol/ad [Administration & Dosage] Cloprostenol/aa [Analogs & Derivatives] Drug Combinations Drug Therapy, Combination *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Humans Intraocular Pressure/de [Drug Effects] Latanoprost Ophthalmic Solutions/ad [Administration & Dosage] Prostaglandins F, Synthetic/ad [Administration & Dosage] Quinoxalines/ad [Administration & Dosage] Sulfonamides/ad [Administration & Dosage] Thiophenes/ad [Administration & Dosage] Timolol/ad [Administration & Dosage] Travoprost Treatment Outcome PY - 2008 SN - 1220-0875 SP - 23-31 ST - [Fixed combinations of glaucoma medications] T2 - Combinatii fixe medicamintoase topice in tratamentul glaucomului. TI - [Fixed combinations of glaucoma medications] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19149113 VL - 52 ID - 1497 ER - TY - JOUR AB - Modern fixed-combination products simplify medication dose regimen without sacrificing their effectiveness.Potential benefits of the therapy with fixed-combination products are enhanced tolerability increased convenience,better compliance,cost and time economy and removal of the wash out effect. Regarding intraocular pressure lowering effect, fixed-combination agents are superior to monotherapy with the two medication components, with the exception of Duotrav that is not superior to travoprost action.Fixed-combination products are noninferior to concomitant administration of the two components of medication (nonfixed-combination agents) relative to their ocular hypotensive efficacy with the exception of Ganfort that is however inferior to concurrent administration of both the bimatoprost and timolol. AU - Calugaru, M. AU - Calugaru, D. IS - 3 KW - Amides/tu [Therapeutic Use] Antihypertensive Agents/ad [Administration & Dosage] *Antihypertensive Agents/tu [Therapeutic Use] Bimatoprost Brimonidine Tartrate, Timolol Maleate Drug Combination Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] Cloprostenol/aa [Analogs & Derivatives] Cloprostenol/tu [Therapeutic Use] Drug Combinations Drug Therapy, Combination Glaucoma/dt [Drug Therapy] *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Latanoprost Ophthalmic Solutions/ad [Administration & Dosage] Prostaglandins F, Synthetic/tu [Therapeutic Use] Quinoxalines/tu [Therapeutic Use] Sulfonamides/tu [Therapeutic Use] Thiazines/tu [Therapeutic Use] Thiophenes/tu [Therapeutic Use] Timolol/tu [Therapeutic Use] Travoprost Treatment Outcome PY - 2011 SN - 1220-0875 SP - 53-69 ST - [The latest developments in glaucoma therapy using fixed combination products] T2 - Actualitati in tratamentul glaucomului cu combinatii fixe medicamentoase. TI - [The latest developments in glaucoma therapy using fixed combination products] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=22428293 VL - 55 ID - 1235 ER - TY - JOUR AB - Bronchial asthma is now recognised to be a major cause of morbidity and even mortality in people of all ages. Two important ideas have changed our approach to asthma management. The first is understanding that asthma is a chronic inflammatory disorder which needs regular treatment with anti-inflammatory drugs such as inhaled corticosteroids to prevent further attacks. The second development is the availability of prescribable peak flow meters, which allows both confident diagnosis and early prediction of relapse. Asthma management guidelines provide a logical treatment framework for most patients, but a few difficult cases still consume large amounts of medical time. The commonest problem is one of compliance with treatment which may respond to patient education, although this is not universally so. Other problems include misdiagnosis, acid reflux and, rarely, true corticosteroid-resistant asthma. Several potentially important new treatments have been developed. These include longer acting anticholinergic drugs, drugs with bronchodilator and some anti-inflammatory properties which antagonise or inhibit the production of leukotrienes, sub-types of phosphodiesterase inhibitor with anti-inflammatory properties and immunosuppressive drugs such as cyclosporin. Ultimately these new treatments must be rigorously tested and integrated into a care plan that remains centred on patient education. AD - P.M.A. Calverley, Fazakerley Hospital, Longmore Lane, Liverpool L9 7AL, United Kingdom AU - Calverley, P. M. A. DB - Embase Medline DO - 10.1136/pgmj.72.843.12 IS - 843 KW - aminophylline antiinflammatory agent bronchodilating agent cholinergic receptor blocking agent corticosteroid cyclosporine immunosuppressive agent leukotriene phosphodiesterase inhibitor theophylline asthma bone disease convulsion Cushing syndrome diagnostic error gastroesophageal reflux glaucoma headache heart arrhythmia hoarseness human hypokalemia inhalational drug administration intravenous drug administration morbidity mortality nausea oral drug administration patient compliance patient education peak expiratory flow practice guideline relapse review skin disease tachycardia taste disorder tremor vomiting xerostomia LA - English M3 - Review N1 - L26018002 1996-01-24 PY - 1996 SN - 0032-5473 SP - 12-18 ST - Asthma T2 - Postgraduate Medical Journal TI - Asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L26018002&from=export http://dx.doi.org/10.1136/pgmj.72.843.12 VL - 72 ID - 3976 ER - TY - JOUR AB - Introduction. Topical corticosteroids are the treatment of reference in atopic dermatitis in children, but their administration may lead to a certain number of side effects. Methods. They are based on a review of the literature and the author's personal experience. Results. Topical corticosteroids are classed in four groups: weak, moderate, strong and very strong, depending on their efficacy. Their side effects are usually proportional to their efficacy. The complications with topical corticosteroids are well known, not only on local but also systemic level. Appropriate use of such topicals avoids these side effects, which depend on the product used, the age of the child and the extent and age of the lesions. Discussion. For the past 50 years, topical corticosteroids represent the most effective treatment in the management of atopic dermatitis in children. When used correctly, they are safe. Failures are related to corticosteroid phobia and poor compliance, and their complications to inappropriate use. The modalities of their withdrawal and the interest of immunosuppressive macrolides are discussed. AD - F. Cambazard, Service de Dermatologie, Hôpital Nord, 42055 Saint-Étienne Cedex 2, France AU - Cambazard, F. DB - Embase Medline IS - SPEC. ISS. 1 KW - corticosteroid acne atopic dermatitis cataract child conference paper drug efficacy drug mechanism drug safety eczema glaucoma granuloma human hypertrichosis infection patient compliance phobia pigment disorder skin atrophy systematic review LA - French M3 - Conference Paper N1 - L40487681 2005-05-02 PY - 2005 SN - 0151-9638 SP - 1S64-1S67 ST - The use of topical corticosteroids in atopic dermatitis in children T2 - Annales de Dermatologie et de Venereologie TI - The use of topical corticosteroids in atopic dermatitis in children UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40487681&from=export VL - 132 ID - 3706 ER - TY - JOUR AB - Introduction: Diarrhea-predominant irritable bowel syndrome (IBS-D) affects about one-third of patients with IBS, which is observed in about 12% of people across five continents. The ultimate goal in this field is to identify the underlying cause of symptoms in order to individualize education of the patient, and to provide optimal treatment of this highly prevalent condition. Areas covered: This review addresses the pharmacological treatments for IBS-D under three categories: drugs for IBS-D (i.e., the 5-HT3 antagonist, alosetron); drugs approved for other indications that are used in IBS-D (e.g., opioid agonists; other 5-HT3 antagonists; serotonergic psychoactive agents; bile acid binders; 5-ASA compounds; probiotics and non-absorbable antibiotics); as well as development of drugs that are likely to impact the management of IBS-D in the future (e.g., drug absorbents; TPH1 inhibitors; mast cell stabilizers; centrally acting benzodiazepines). The final section addresses key findings: regulatory roadblocks; weaknesses in the current research in this field so far and opportunities to address unmet needs including restoration of normal intestinal barrier function or permeability, and suppression within the intestines of local immune activation that is thought to trigger abnormal motor, sensory and secretory functions in IBS-D. Expert opinion: While symptomatic treatment of diarrhea is effective, there is a need for new treatments for the IBS-D complex. Greater understanding of the mechanisms in IBS-D has led to promising approaches to develop more efficacious therapies. © 2013 Informa UK, Ltd. AD - M. Camilleri, Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Charlton 8-110, 200 First St. S.W., Rochester, MN 55905, United States AU - Camilleri, M. DB - Embase Medline DO - 10.1517/14656566.2013.794223 IS - 9 KW - alosetron aminosalicylic acid amitriptyline asimadoline ast 120 codeine colesevelam colestyramine cromoglycate disodium desipramine diphenoxylate doxepin duloxetine fluphenazine imipramine ketotifen loperamide lx 1031 mebeverine mesalazine nortriptyline placebo probiotic agent ramosetron rifaximin tofisopam trimipramine unclassified drug abdominal pain bladder dysfunction blood brain barrier colon motility constipation diarrhea drug efficacy drug safety gastrointestinal transit genetic variability glaucoma human intestinal secretion intestine function irritable colon ischemic colitis low drug dose meta analysis (topic) nonhuman palliative therapy patient compliance patient satisfaction pharmacogenetics phase 2 clinical trial (topic) phase 3 clinical trial (topic) quality of life randomized controlled trial (topic) recommended drug dose review risk management tachycardia LA - English M3 - Review N1 - L368939115 2013-05-27 2013-05-30 PY - 2013 SN - 1465-6566 1744-7666 SP - 1151-1160 ST - Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome T2 - Expert Opinion on Pharmacotherapy TI - Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368939115&from=export http://dx.doi.org/10.1517/14656566.2013.794223 VL - 14 ID - 2993 ER - TY - JOUR AB - Purpose: To evaluate the frequency of ocular surface symptoms and their potential impact on dry eye specific quality of life (QoL) in patients using versus not using glaucoma medications. Material and methods: The study was a single-center, cross-sectional survey of patients seen at the Miami Veterans Affairs (VA) ophthalmology and optometry clinics from June to August, 2010. Patients were invited to complete the Dry Eye Questionnaire 5 (DEQ5) and the Impact of Dry Eye on Everyday Life (IDEEL) at their visit. Of 1348 patients seen in the Miami VA eye clinics during this three-month period, 467 patients completed the DEQ5 and 391 responded to both questionnaires. Outcome measures comprised ocular surface symptoms and their impact on dry eye specific QoL in patients using versus not using glaucoma drops. Results: An increasing number of glaucoma drops was significantly associated with an increased percentage of severe dry eye symptoms: no medications, 25% (n = 89/353); 1 or 2 medications, 27% (n = 17/62); 3 or more medications, 40% (n = 21/52); p = 0.03 (Armitage's test for linear-trend in proportions). There was an association between increasing number of drops and decreasing emotional well-being scores (linear p < 0.001; quadratic p = 0.029). Black patients had higher dry eye symptoms and lower emotional QoL scores compared to white patients at every level of medication use. Conclusion: An increasing number of glaucoma medications were associated with an increased frequency of severe dry eye symptoms and decreased emotional QoL. Additionally, dry eye specific emotional QoL was more severely affected in black versus white patients. Published by Elsevier Ltd on behalf of British Contact Lens Association AN - WOS:000355824600015 AU - Camp, A. AU - Wellik, S. R. AU - Tzu, J. H. AU - Feuer, W. AU - Arheart, K. L. AU - Sastry, A. AU - Galor, A. DA - JUN DO - 10.1016/j.clae.2015.02.001 IS - 3 PY - 2015 SN - 1367-0484 1476-5411 SP - 220-225 ST - Dry eye specific quality of life in veterans using glaucoma drops T2 - CONTACT LENS & ANTERIOR EYE TI - Dry eye specific quality of life in veterans using glaucoma drops VL - 38 ID - 6261 ER - TY - JOUR AB - Objective: To compare patient adherence and persistence with bimatoprost 0.01%, a new formulation that offers equivalent intraocular pressure-lowering efficacy to bimatoprost 0.03% and improved tolerability, with that of the original bimatoprost 0.03% formulation. Methods: Pharmacy claims from a longitudinal database of prescription and medical claims for >115 million patients were analyzed. Patients with an initial (index) prescription for bimatoprost 0.01% or 0.03% between April and June 2011, and with no claim for ophthalmic prostaglandin or prostamide analogs during the preceding 18 months, were identified. Treatment adherence was expressed as the proportion of days covered (PDC) with study medication over the first 365 days after the index prescription. Treatment persistence over the first 12 months following the index prescription was assessed using Kaplan-Meier analyses, assuming a 30 day grace period for prescription refill. Treatment status (on/off study medication) was determined monthly for 12 months post-index. Results: In total, 6150 patients were assessed for treatment adherence and 7660 for persistence. Adherence was significantly better with bimatoprost 0.01% than bimatoprost 0.03% (mean PDC 0.540 vs. 0.438; p < 0.001). Significantly more patients had high adherence (PDC > 0.80) with bimatoprost 0.01% than 0.03% (29.1% vs. 17.3%; p < 0.001). Persistence was also significantly better with bimatoprost 0.01%, with 29.5% (95% confidence interval [CI]: 28.3%, 30.8%) versus 18.3% (95% CI: 16.8%, 19.9%) of patients remaining on continuous treatment for 12 months (p < 0.001). At 12 months, significantly more patients were 'on treatment' (continuing/restarting treatment) with bimatoprost 0.01% than 0.03% (48.8% vs. 33.9%; p < 0.001). Sensitivity analyses demonstrated similar findings in cohorts of ocular hypotensive treatment-naïve and elderly (≥65 years) patients. Conclusions: Bimatoprost 0.01% offers adherence and persistency advantages over bimatoprost 0.03% in patients requiring ocular hypotensive therapy. Study limitations included the observational design, lack of control for imbalances in patient characteristics, and assumption that prescription refill is synonymous with medication use. © 2013 Informa UK Ltd. AD - J.H. Campbell, Allergan Inc., 2525 Dupont Drive, MI3-450A, Irvine, CA 92612-1599, United States AU - Campbell, J. H. AU - Schwartz, G. AU - Labounty, B. AU - Kowalski, J. AU - Patel, V. D. DB - Embase Medline DO - 10.1185/03007995.2013.815160 IS - 9 KW - bimatoprost adult aged article cohort analysis comparative study cross-sectional study drug dose comparison drug efficacy drug tolerability female glaucoma human intraocular pressure major clinical study male observational study outcome assessment patient compliance prescription retrospective study topical treatment LA - English M3 - Article N1 - L369629896 2013-08-30 2013-09-04 PY - 2013 SN - 0300-7995 1473-4877 SP - 1201-1209 ST - Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions T2 - Current Medical Research and Opinion TI - Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369629896&from=export http://dx.doi.org/10.1185/03007995.2013.815160 VL - 29 ID - 2971 ER - TY - JOUR AB - BACKGROUND: Effective control of intraocular pressure is predicated upon patient compliance with pharmacotherapy. We compared patient adherence and persistence with two new ocular hypotensive formulations, using real-world utilization data., METHODS: This observational cohort study employed pharmacy claims data from the Source( R) Lx (Wolters Kluwer Pharma Solutions) database. Patients with an initial (index) prescription for topical bimatoprost 0.01% or travoprost Z (April to June 2011) and no claim for ophthalmic prostaglandin or prostamide analogs within the previous 18 months were identified. Treatment adherence was expressed as proportion of days covered with study medication during the first 365 days after the index prescription. Treatment persistence with study medication was assessed over the first 12 months using Kaplan-Meier survival analyses, allowing a maximum 30-day gap for prescription refill. Treatment status was determined monthly over this period., RESULTS: A total of 12,985 patients were assessed for treatment adherence, and 10,470 for treatment persistence. Adherence was better with bimatoprost 0.01% than with travoprost Z (mean proportion of days covered 0.540 versus [vs] 0.486, P<0.001), and more patients showed high adherence (proportion of days covered >0.80) with bimatoprost 0.01% than travoprost Z (29.1% vs 22.3%, P<0.001). Continuous 12-month persistence was higher with bimatoprost 0.01% than with travoprost Z (29.5% vs 24.2%, P<0.001). At month 12, more patients were on treatment with bimatoprost 0.01% than travoprost Z (48.8% vs 45.7%, P<0.01). Similar findings were demonstrated in cohorts of ocular hypotensive treatment-naive patients, branded latanoprost switchers, and older patients (age >=65 years), and after inclusion of patient characteristics as covariates., CONCLUSION: For patients with glaucoma or ocular hypertension, bimatoprost 0.01% offers compliance advantages over travoprost Z. AU - Campbell, Joanna H. AU - Schwartz, Gail F. AU - LaBounty, Britni AU - Kowalski, Jonathan W. AU - Patel, Vaishali D. DO - https://dx.doi.org/10.2147/OPTH.S49467 PY - 2014 SE - Campbell, Joanna H. Allergan, Inc., Irvine, CA, USA. Schwartz, Gail F. Greater Baltimore Medical Center and Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. LaBounty, Britni. Principled Strategies, Inc., Encinitas, CA, USA. Kowalski, Jonathan W. Allergan, Inc., Irvine, CA, USA. Patel, Vaishali D. Allergan, Inc., Irvine, CA, USA. SN - 1177-5467 SP - 927-35 ST - Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=24868144 VL - 8 Y2 - 20140514// ID - 1082 ER - TY - JOUR AB - PURPOSE: To evaluate the impact of surgeon practice profile on clinic-based glaucoma care., DESIGN: Population-based study of glaucoma care patterns in Ontario, Canada from 2000-2010., METHODS: Using comprehensive physician services data from the Ontario Health Insurance Plan database, ophthalmologists were divided into 5 surgical practice subgroups. The role of each subgroup in the provision of glaucoma care was evaluated. Consultations and office visits were used to assess nonsurgical care, while laser trabeculoplasty procedures were used to assess clinic-based procedural care., RESULTS: Between 2000 and 2010, the population rate of glaucoma consultations and follow-up visits provided by ophthalmologists who do not perform incisional glaucoma surgery increased at average annual rates of 1.6% (P < .0002) and 3.3% (P < .0001), respectively. In contrast, no significant growth in the rate of glaucoma consultations or follow-up visits provided by glaucoma surgeons was observed (0.8%/year [P = .2] for consultations; 0.2%/year [P = .6] for follow-up visits). Between 2000 and 2010, the rate of laser trabeculoplasty procedures provided by ophthalmologists who do not perform incisional glaucoma surgery increased 19.3% annually (P < .0001), while growth among glaucoma surgeons was more modest (annual growth of 9.2% [P = .0002])., CONCLUSIONS: While subspecialization is a growing reality in most areas of medicine, we found that the provision of clinic-based glaucoma care remains dependent on ophthalmologists who do not perform incisional glaucoma surgery. With increasing focus on integrated care, these findings will have important implications for residency education programs and their accrediting bodies and will inform decisions of health care policymakers, hospitals, and academic departments. Copyright © 2014 Elsevier Inc. All rights reserved. AU - Campbell, Robert J. AU - Bell, Chaim M. AU - Gill, Sudeep S. AU - Whitehead, Marlo AU - Campbell, Erica de L. P. AU - Xu, Kunyong AU - El-Defrawy, Sherif R. DO - https://dx.doi.org/10.1016/j.ajo.2013.11.019 IS - 3 KW - Antihypertensive Agents/tu [Therapeutic Use] *Delivery of Health Care/sn [Statistics & Numerical Data] *Glaucoma/su [Surgery] Humans Intraocular Pressure Laser Therapy/sn [Statistics & Numerical Data] Office Visits Ontario *Ophthalmology/sn [Statistics & Numerical Data] *Practice Patterns, Physicians'/sn [Statistics & Numerical Data] Referral and Consultation Retrospective Studies Specialties, Surgical *Trabeculectomy/sn [Statistics & Numerical Data] PY - 2014 SE - Campbell, Robert J. Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada; Department of Ophthalmology, Hotel Dieu and Kingston General Hospitals, Kingston, Ontario, Canada; Institute for Clinical Evaluative Sciences - Queen's University Site, Queen's University, Kingston, Ontario, Canada. Electronic address: rob.campbell@queensu.ca. Bell, Chaim M. Institute for Clinical Evaluative Sciences - Sunnybrook Site, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. Gill, Sudeep S. Division of Geriatric Medicine, Queen's University, Kingston, Ontario, Canada; Institute for Clinical Evaluative Sciences - Queen's University Site, Queen's University, Kingston, Ontario, Canada; Division of Geriatric Medicine, St. Mary's of the Lake Hospital, Kingston, Ontario, Canada. Whitehead, Marlo. Institute for Clinical Evaluative Sciences - Queen's University Site, Queen's University, Kingston, Ontario, Canada; Queen's University, Kingston, Ontario, Canada. Campbell, Erica de L P. Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada; Department of Ophthalmology, Hotel Dieu and Kingston General Hospitals, Kingston, Ontario, Canada. Xu, Kunyong. Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada; Department of Ophthalmology, Hotel Dieu and Kingston General Hospitals, Kingston, Ontario, Canada. El-Defrawy, Sherif R. Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology, Kensington Eye Institute, Toronto, Ontario, Canada. SN - 1879-1891 0002-9394 SP - 631-2 ST - Clinic-based glaucoma care in the era of surgical subspecialization T2 - American journal of ophthalmology TI - Clinic-based glaucoma care in the era of surgical subspecialization UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24321471 VL - 157 Y2 - 20131207// ID - 913 ER - TY - JOUR AB - Acanthamoeba keratitis (AK) is a serious ocular infection caused by a ubiquitous free-living amoeba, Acanthamoeba. This infection often results in extensive corneal damage and blindness, and is notoriously difficult to cure. While Acanthamoeba is an abundant organism, AK is most associated with contact lens hygiene noncompliance and inadequate contact lens care (CLC) disinfection regimens. Thus, accurate and timely antimicrobial efficacy testing of CLC solutions is paramount. Published methods for antimicrobial efficacy testing of Acanthamoeba trophozoites requires 14 days for results. Presently, alternate and/or rapid methods for evaluating CLC products rarely demonstrate equivalent results compared to commonly-reported methods. Propidium iodide is a cellular stain that can only bind to cells with damaged outer membranes. We evaluated propidium iodide staining as an alternative method for determining the relative antimicrobial efficacy of 11 different CLC products against Acanthamoeba trophozoites. Following exposure to a CLC product, the fluorescence intensity of propidium iodide in an Acanthamoeba population demonstrated a strong correlation to the log reduction determined by established, growth-based Acanthamoeba testing used to evaluate the antimicrobial efficacy of CLC products. Thus, propidium iodide was found to be an effective rapid tool for determining cell death in Acanthamoeba trophozoites following exposure to CLC solutions. AU - Campolo, Allison AU - Shannon, Paul AU - Crary, Monica DO - https://dx.doi.org/10.3390/pathogens10020126 IS - 2 PY - 2021 SE - Campolo, Allison. Alcon Research, LLC, Fort Worth, TX 76134, USA. Shannon, Paul. Alcon Research, LLC, Fort Worth, TX 76134, USA. Crary, Monica. Alcon Research, LLC, Fort Worth, TX 76134, USA. SN - 2076-0817 ST - Evaluating Alternate Methods of Determining the Antimicrobial Efficacy of Contact Lens Care Products against Acanthamoeba Trophozoites T2 - Pathogens (Basel, Switzerland) TI - Evaluating Alternate Methods of Determining the Antimicrobial Efficacy of Contact Lens Care Products against Acanthamoeba Trophozoites UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33513702 VL - 10 Y2 - 20210127// ID - 106 ER - TY - JOUR AB - Objective. To estimate the prevalence of blindness and visual impairment among adults in Peru and to determine their causes, to evaluate the coverage and quality of the cataract surgical services and to investigate the barriers that inhibit access to these services. Methods. A cross-sectional population study with two-stage random cluster sampling of individuals of ≥ 50 years old, representative of the entire country, using the standard methodology of the Rapid Assessment of Avoidable Blindness. Visual acuity was assessed and the condition of the lens and posterior pole examined by direct ophthalmoscopy. Cataract surgical coverage was calculated. Its quality, as well as the causes of visual acuity < 20/60 and the barriers to accessing surgical treatment were assessed. Results. A total of 4 849 people were examined. Blindness prevalence was 2.0% (confidence interval of 95%: 1.5-2.5%). The main causes of blindness were cataract (58.0%), glaucoma (13.7%) and age-related macular degeneration (11.5%). Uncorrected refraction errors were the principal cause of moderate visual impairment (67.2%). Cataract surgical coverage was 66.9%. 60.5% of the eyes operated for cataracts achieved a visual acuity ≥ 20/60 with available correction. The main barriers to cataract surgery were the high cost (25.9%) and people being unaware that treatment was possible (23.8%). Conclusions. The prevalence of blindness and visual impairment in Peru is similar to that of other Latin American countries. Given the low cataract surgical coverage and the aging of the population, access to the services could be improved by increasing the population education on eye health and the response capacity of the ophthalmological and cataract surgical services, and by reducing the costs of the latter. Objetivo. Estimar la prevalencia de ceguera y deficiencia visual en adultos de Perú y precisar sus causas, evaluar la cobertura y la calidad de los servicios de cirugía de catarata y determinar las barreras que impiden acceder a esos servicios. Métodos. Estudio poblacional transversal con muestreo aleatorio por conglomerado en dos pasos de personas de 50 años o más, representativo de todo el país, mediante la metodología estándar de la Evaluación Rápida de Ceguera Evitable. Se midió la agudeza visual y se examinó el cristalino y el polo posterior por oftalmoscopía directa. Se calculó la cobertura de cirugía de catarata y se evaluó su calidad, además de las causas de tener una agudeza visual < 20/60 y las barreras para acceder a ese tratamiento. Resultados. Se examinaron 4 849 personas. La prevalencia de ceguera fue 2,0% (intervalo de confianza de 95%: 1,5-2,5%). La catarata fue la causa principal de ceguera (58,0%), seguida por el glaucoma (13,7%) y la degeneración macular relacionada con la edad (11,5%). Los errores de refracción no corregidos fueron la principal causa de deficiencia visual moderada (67,2%). La cobertura de cirugía de catarata fue de 66,9%, y 60,5% de los ojos operados de catarata logró una AV ≥ 20/60 con la corrección disponible. Las principales barreras para someterse a la cirugía de catarata fueron el alto costo (25,9%) y no saber que el tratamiento es posible (23,8%). Conclusiones. La prevalencia de ceguera y deficiencia visual en Perú es similar a la de otros países latinoamericanos. La baja cobertura de cirugía de catarata y el envejecimiento poblacional indican que para aumentar el acceso a estos servicios se debe mejorar la educación de la población en salud ocular y la capacidad resolutiva de los servicios oftalmológicos y de cirugía de catarata, y reducir su costo. AD - Instituto Nacional de Oftalmología, Lima, Perú Asociación Divino Niño Jesús, Lima, Perú Visión 2020, Agencia Internacional para la Prevención de la Ceguera, México, D.F., México Organización Panamericana de la Salud, Bogotá, Colombia Health Information Services, Grootebroek, Países Bajos AN - 100666015. Language: Spanish. Entry Date: 20150128. Revision Date: 20190308. Publication Type: Article AU - Campos, Betty AU - Cerrate, Amelia AU - Montjoy, Enrique AU - Dulanto Gomero, Víctor AU - Gonzales, César AU - Tecse, Aldo AU - Pariamachi, Andrés AU - Lansingh, Van C. AU - Dulanto Reinoso, Víctor AU - Minaya Barba, Jean AU - Carlos Silva, Juan AU - Limburg, Hans DB - ccm DP - EBSCOhost IS - 5 KW - Blindness -- Epidemiology -- Peru Prevalence Blindness -- Etiology -- Peru Vision Disorders -- Epidemiology -- Peru Human Cross Sectional Studies Descriptive Statistics Peru Confidence Intervals Middle Age Visual Acuity Cataract Extraction -- Economics -- Peru Male Female Aged Aged, 80 and Over N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. NLM UID: 9705400. PY - 2014 SN - 1020-4989 SP - 283-289 ST - Investigación original. Prevalencia y causas de ceguera en Perú: encuesta nacional T2 - Revista Panamericana de Salud Pública TI - Investigación original. Prevalencia y causas de ceguera en Perú: encuesta nacional UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=100666015&site=ehost-live&scope=site VL - 36 ID - 4457 ER - TY - JOUR AB - OBJECTIVE: To estimate the prevalence of blindness and visual impairment among adults in Peru and to determine their causes, to evaluate the coverage and quality of the cataract surgical services and to investigate the barriers that inhibit access to these services., METHODS: A cross-sectional population study with two-stage random cluster sampling of individuals of >= 50 years old, representative of the entire country, using the standard methodology of the Rapid Assessment of Avoidable Blindness. Visual acuity was assessed and the condition of the lens and posterior pole examined by direct ophthalmoscopy. Cataract surgical coverage was calculated. Its quality, as well as the causes of visual acuity < 20/60 and the barriers to accessing surgical treatment were assessed., RESULTS: A total of 4 849 people were examined. Blindness prevalence was 2.0% (confidence interval of 95%: 1.5-2.5%). The main causes of blindness were cataract (58.0%), glaucoma (13.7%) and age-related macular degeneration (11.5%). Uncorrected refraction errors were the principal cause of moderate visual impairment (67.2%). Cataract surgical coverage was 66.9%. 60.5% of the eyes operated for cataracts achieved a visual acuity >= 20/60 with available correction. The main barriers to cataract surgery were the high cost (25.9%) and people being unaware that treatment was possible (23.8%)., CONCLUSIONS: The prevalence of blindness and visual impairment in Peru is similar to that of other Latin American countries. Given the low cataract surgical coverage and the aging of the population, access to the services could be improved by increasing the population education on eye health and the response capacity of the ophthalmological and cataract surgical services, and by reducing the costs of the latter. AU - Campos, Betty AU - Cerrate, Amelia AU - Montjoy, Enrique AU - Dulanto Gomero, Victor AU - Gonzales, Cesar AU - Tecse, Aldo AU - Pariamachi, Andres AU - Lansingh, Van C. AU - Dulanto Reinoso, Victor AU - Minaya Barba, Jean AU - Silva, Juan Carlos AU - Limburg, Hans IS - 5 KW - Aged Aged, 80 and over *Blindness/ep [Epidemiology] Blindness/et [Etiology] Cataract/co [Complications] Cataract/ep [Epidemiology] Cataract Extraction Cross-Sectional Studies Female Glaucoma/co [Complications] Glaucoma/ep [Epidemiology] Health Services Needs and Demand Health Surveys Humans Macular Degeneration/co [Complications] Macular Degeneration/ep [Epidemiology] Male Middle Aged Peru/ep [Epidemiology] Prevalence Sampling Studies PY - 2014 SE - Campos, Betty. Instituto Nacional de Oftalmologia, Lima, Peru Cerrate, Amelia. Instituto Nacional de Oftalmologia, Lima, Peru Montjoy, Enrique. Instituto Nacional de Oftalmologia, Lima, Peru Dulanto Gomero, Victor. Instituto Nacional de Oftalmologia, Lima, Peru Gonzales, Cesar. Asociacion Divino Nino Jesus, Lima, Peru Tecse, Aldo. Instituto Nacional de Oftalmologia, Lima, Peru Pariamachi, Andres. Instituto Nacional de Oftalmologia, Lima, Peru Lansingh, Van C. Vision 2020, Agencia Internacional para la Prevencion de la Ceguera, Mexico, D.F., Mexico, vlansingh@iapb.org. Dulanto Reinoso, Victor. Vision 2020, Agencia Internacional para la Prevencion de la Ceguera, Mexico, D.F., Mexico, vlansingh@iapb.org. Minaya Barba, Jean. Instituto Nacional de Oftalmologia, Lima, Peru Silva, Juan Carlos. Organizacion Panamericana de la Salud, Bogota, Colombia. Limburg, Hans. Health Information Services, Grootebroek, Paises Bajos. SN - 1680-5348 1020-4989 SP - 283-9 ST - [National survey on the prevalence and causes of blindness in Peru] T2 - Prevalencia y causas de ceguera en Peru: encuesta nacional. TI - [National survey on the prevalence and causes of blindness in Peru] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25604097 VL - 36 ID - 848 ER - TY - JOUR AB - In a randomized, double-masked, placebo-controlled study, 0.25 microgram (n = 11) or 0.5 microgram (n = 13) of prostaglandin F2 alpha-1-isopropyl ester (PGF2 alpha-IE) was applied topically twice daily for 8 days to one eye of ocular hypertensive or chronic open-angle glaucoma patients. Compared with contralateral, vehicle-treated eyes, PGF2 alpha-IE significantly (P less than 0.05) reduced intraocular pressure (IOP), beginning 4 hours after the first 0.5-microgram dose and lasting at least 12 hours after the fourteenth dose, with a significant (P less than 0.005) mean reduction of 4 to 6 mmHg maintained throughout the last day of therapy with either dose. A contralateral effect was not observed. Mean tonographic outflow facility was significantly (P less than 0.05) higher in PG-treated compared with vehicle-treated eyes (0.17 +/- 0.02 versus 0.12 +/- 0.01 microliter/minute/mmHg, respectively; +/- standard error of the mean) for the 0.5 microgram dose. Conjunctival hyperemia reached a maximum at 30 to 60 minutes after PGF2 alpha-IE application. Some patients reported mild irritation lasting several minutes after some doses. Visual acuity, accommodative amplitude, pupillary diameter, aqueous humor flare, anterior chamber cellular response, Schirmer's test, pulse rate, and blood pressure were not significantly altered. Our findings show that PGF2 alpha-IE is a potent ocular hypotensive agent and a promising drug for glaucoma therapy. AU - Camras, C. B. AU - Siebold, E. C. AU - Lustgarten, J. S. AU - Serle, J. B. AU - Frisch, S. C. AU - Podos, S. M. AU - Bito, L. Z. IS - 9 KW - Aged Conjunctiva/de [Drug Effects] Dinoprost/ae [Adverse Effects] *Dinoprost/aa [Analogs & Derivatives] Dinoprost/pd [Pharmacology] Dose-Response Relationship, Drug Double-Blind Method Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Hyperemia/ci [Chemically Induced] *Intraocular Pressure/de [Drug Effects] Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Patient Compliance Random Allocation Tonometry, Ocular PY - 1989 SE - Camras, C B. Department of Ophthalmology, Mount Sinai School of Medicine, New York 10029. SN - 0161-6420 SP - 1329-7 ST - Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients T2 - Ophthalmology TI - Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2780003 VL - 96 ID - 2157 ER - TY - JOUR AB - Allergic rhinitis (AR) is caused by an immediate type hypersensitivity reaction in sensitized subjects after exposure to airborn allergens. The interaction of the allergen with a specific IgE antibody attached to the nasal mast cells leads to the local release of vasoactive and inflammatory mediators such as histamine, leukotriene C4 and prostaglandin D2. These mediators cause the nasal allergic symptoms complex of rhinorrhea, nasal obstruction, nasal itching and sneezing, which improve spontaneously or with treatment. Cromolyn sodium and nedocromil sodium are often termed anti-allergic drugs', which are defined here as drugs capable of inhibiting both the early-phase response to challenge and chronic allergic inflammation. They act at the cell membrane levels. Intranasal and ocular formulations of cromones, such as cromoglycate, are available without medical prescription in many countries. Sodium, cromoglycate or nedocromil have a good safety profile They reduce the symptoms of AR, and should be used profilactically but limited efficacy and the need for frequent dosing are disadvantages. © 2008 Bentham Science Publishers Ltd. AD - I.H. Can, Ministry of Health Ankara Education and Research Hospital, ENT Clinic, Camlica Bulvar Sitesi F Blok No: 19, 06800 Umitkoy, Ankara, Turkey AU - Can, I. H. AU - Samim, E. E. C1 - intal nasalcrom opticrom DB - Embase DO - 10.2174/187152308783769177 IS - 1 KW - antihistaminic agent azelastine cholinergic receptor blocking agent chymase corticosteroid cromoglycate disodium decongestive agent glucocorticoid granulocyte colony stimulating factor histamine interleukin 3 interleukin 4 interleukin 5 kallikrein leukotriene C4 leukotriene D4 leukotriene E4 nedocromil prostaglandin prostaglandin D2 thrombocyte activating factor tryptase tumor necrosis factor agitation airborne particle allergic conjunctivitis allergic reaction allergic rhinitis antibody production article asthma bedtime dosage bitter taste bronchospasm burning sensation chemical structure clinical trial conjunctivitis drug mechanism drug safety food allergy genetic predisposition glaucoma growth retardation headache heart palpitation human hypertension immunotherapy insomnia mast cell degranulation mastocytosis mediator release mucosal dryness nose allergy nose irritation pathogenesis pathophysiology patient compliance patient education restlessness rhinitis rhinorrhea sedation sensitization side effect sneezing thyrotoxicosis tremor urine retention intal nasalcrom opticrom LA - English M3 - Article N1 - L351445067 2008-04-07 PY - 2008 SN - 1871-5230 SP - 9-15 ST - Mast cell stabilizers in the treatment of allergic rhinitis T2 - Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry TI - Mast cell stabilizers in the treatment of allergic rhinitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351445067&from=export http://dx.doi.org/10.2174/187152308783769177 http://www.ingentaconnect.com/content/ben/aiaamc/2008/00000007/00000001/art00003 VL - 7 ID - 3468 ER - TY - JOUR AD - G. Cânciu AU - Cânciu, G. DB - Medline IS - 2 KW - aged ambulatory care aphakia article female glaucoma human male methodology middle aged multimodality cancer therapy LA - Romanian M3 - Article N1 - L18808346 1988-11-03 PY - 1988 SN - 0377-7863 SP - 111-113 ST - Glaucoma secondary to aphakia and its outpatient therapeutic management T2 - Revista de chirurgie, oncologie, radiologie, o. r. l., oftalmologie, stomatologie. Oftalmologie TI - Glaucoma secondary to aphakia and its outpatient therapeutic management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L18808346&from=export VL - 32 ID - 4057 ER - TY - JOUR AB - In the 21st century there are more highly effective medical management options for glaucoma than there were in the 1980s and 1990s. In deciding among them, the clinician's challenge is to select what is clinically relevant from the large amounts of available data. In evaluating different drugs the clinician must consider not only the mean intraocular pressure (IOP) of a trial population, but also the percentage of patients achieving clinically relevant low IOPs. The consistency of IOP control throughout the day and night is also critical. Other factors such as safety, tolerability, and cost-effectiveness must also be kept in mind, with an awareness (both in human and monetary terms) of the cost of treatment failure. This overview concludes that newer medical regimens for IOP lowering address efficacy and safety issues more successfully than older ones. © 2003 Elsevier Science Inc. All rights reserved. AD - L. Cantor, Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202, United States AU - Cantor, L. DB - Embase Medline DO - 10.1016/S0039-6257(03)00009-2 IS - 2 SUPPL. 1 KW - bimatoprost brimonidine dorzolamide latanoprost timolol travoprost clinical trial cost effectiveness analysis drug cost drug efficacy drug mechanism drug safety drug tolerability glaucoma high risk patient human intraocular hypertension intraocular pressure abnormality oculoplethysmography patient compliance priority journal review treatment failure LA - English M3 - Review N1 - L41126690 2005-10-25 PY - 2003 SN - 0039-6257 SP - S8-S16 ST - Achieving low target pressures with today's glaucoma medications T2 - Survey of Ophthalmology TI - Achieving low target pressures with today's glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41126690&from=export http://dx.doi.org/10.1016/S0039-6257(03)00009-2 VL - 48 ID - 3787 ER - TY - JOUR AB - Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression and vision loss. The alpha2-adrenergic receptor agonist brimonidine effectively lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle glaucoma and ocular hypertension. A fixed combination of brimonidine and timolol, available in some countries, reduces IOP as effectively as concomitant therapy with brimonidine and timolol and offers the convenience of 2 drugs in a single eyedrop. Brimonidine is safe and well tolerated. Its most common side-effects are conjunctival hyperemia, allergic conjunctivitis, and ocular pruritus. The newest formulation of brimonidine, brimonidine-Purite 0.1%, has a higher pH to improve the ocular bioavailability of brimonidine. This formulation contains the lowest effective concentration of brimonidine and is preserved with Purite® to enhance ocular tolerability. Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% solution preserved with benzalkonium chloride. Recent results from preclinical and clinical studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP. The potential for neuroprotection with brimonidine is an added benefit of its use in glaucoma and ocular hypertension. © 2006 Dove Medical Press Limited. All rights reserved. AD - L.B. Cantor, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN 6202, United States AU - Cantor, L. B. C1 - alphagan(Allergan,United States) combigan(Allergan,United States) C2 - Allergan(United States) DB - Embase IS - 4 KW - antiglaucoma agent benzalkonium chloride beta adrenergic receptor blocking agent bimatoprost brimonidine brimonidine plus timolol brimonidine purite carbonate dehydratase inhibitor dorzolamide eye drops latanoprost placebo prostaglandin derivative timolol travoprost add on therapy allergic conjunctivitis apnea asthenia bradycardia clinical trial conjunctival hyperemia depression disease course dosage schedule comparison drowsiness drug bioavailability drug blood level drug dosage form comparison drug formulation drug hypersensitivity drug withdrawal eye burning eye discharge eyelid erythema fatigue human hyperemia hypotension hypothermia insomnia intraocular hypertension lethargy monotherapy muscle hypotonia neuroprotection nonhuman ocular pruritus open angle glaucoma patient compliance pH retina ganglion cell review risk reduction somnolence visual impairment xerostomia alphagan combigan LA - English M3 - Review N1 - L44895985 2007-01-31 PY - 2006 SN - 1176-6336 SP - 337-346 ST - Brimonidine in the treatment of glaucoma and ocular hypertension T2 - Therapeutics and Clinical Risk Management TI - Brimonidine in the treatment of glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44895985&from=export VL - 2 ID - 3573 ER - TY - JOUR AB - Objective: Despite the significant clinical and economic burden associated with glaucoma, studies evaluating the long-term costs of existing treatments are limited. This study compared the 5-year costs of three treatment strategies: medication, laser trabeculoplasty, and filtering surgeries in managing patients with primary open-angle glaucoma whose intra-ocular pressures were not adequately controlled by two medications. Research design and methods: A Markov model was developed to simulate the transition of treatment progression over a 5-year period to evaluate the total treatment costs associated with each strategy. In the medication arm, medications were the only available treatment, whereas in the laser trabeculoplasty and surgery arms, patients would receive concomitant medications both at the time of the procedure and in subsequent years. Treatment states were determined by the rate of success in controlling patients' intra-ocular pressure in each year. The distribution of treatment states and the transition probabilities between these states were derived from published literature, adjusted or supplemented by the authors' own treatment experiences. Costs assessed in the model included treatment, complications associated with each treatment, and physician office visits obtained from published literature and standardized fees and schedules. Results: The 5-year cumulative costs were approximately $6571, $4838 and $6363 for patients in the medication, laser trabeculoplasty, and filtering surgery arms, respectively. Costs of third-line medication, first-line medication following laser trabeculoplasty, and post-surgery complications had the greatest impact on the model results in the medication, laser trabeculoplasty, and filtering surgery arms, respectively. Probabilistic sensitivity suggested the results were statistically significant (p<0.001), favoring the use of laser trabeculoplasty. Conclusions: Over 5 years laser trabeculoplasty was associated with the lowest total costs compared to treatment by medication alone or by filtering surgery for patients who were not adequately controlled by two medications. Future development of glaucoma treatment should focus on reducing the need for post-procedure medical therapy as well as lowering the rate of post-procedure complications. Limited by the availability of the transition probabilities in published literature, the model results need to be validated by prospective or retrospective observational studies. © 2008 Informa UK Ltd. AD - E. Chen, Quorum Consulting Inc., 222 Kearny Street, San Francisco, CA 94108, United States AU - Cantor, L. B. AU - Katz, L. J. AU - Cheng, J. W. AU - Chen, E. AU - Tong, K. B. AU - Peabody, J. W. C1 - alphagan p azopt istalol lumigan timoptic travatan z travatan trusopt xalatan DB - Embase Medline DO - 10.1185/03007990802379996 IS - 10 KW - alpha adrenergic receptor stimulating agent brimonidine beta adrenergic receptor blocking agent bimatoprost brinzolamide carbonate dehydratase inhibitor carteolol dorzolamide latanoprost levobunolol metipranolol prostaglandin prostaglandin derivative timolol timolol maleate travoprost unclassified drug ambulatory care article drug cost economic evaluation filtering operation health care cost hidden Markov model human intraocular pressure open angle glaucoma patient care postoperative complication probability simulation statistical significance trabeculoplasty United States alphagan p azopt istalol lumigan timoptic travatan z travatan trusopt xalatan LA - English M3 - Article N1 - L352623097 2008-12-08 PY - 2008 SN - 0300-7995 SP - 2905-2918 ST - Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US T2 - Current Medical Research and Opinion TI - Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352623097&from=export http://dx.doi.org/10.1185/03007990802379996 VL - 24 ID - 3425 ER - TY - JOUR AB - Acanthamoeba keratitis is a vision-threatening corneal infection. The mannose-binding protein of Acanthamoeba is thought to mediate adhesion of parasites to host cells. We characterized the amoeba lectin with respect to its carbohydrate binding properties and the role in amoeba-induced cytopathic effect (CPE). Sugar inhibition assays revealed that the amoeba lectin has the highest affinity for alpha-Man and Man(alpha1-3)Man units. In vitro cytopathic assays indicated that mannose-based saccharides which inhibit amoeba adhesion to corneal epithelial cells were also potent inhibitors of amoeba-induced CPE. Another major finding was that N-acetyl-D-glucosamine (GlcNAc) which does not inhibit adhesion of amoeba to host cells is also an inhibitor of amoeba-induced CPE. The Acanthamoebae are thought to produce CPE by secreting cytotoxic proteinases. By zymography, one metalloproteinase and three serine proteinases were detected in the conditioned media obtained after incubating amoebae with the host cells. The addition of free alpha-Man and GlcNAc to the co-culture media inhibited the secretion of the metalloproteinase and serine proteinases, respectively. In summary, we have shown that the lectin-mediated adhesion of the Acanthamoeba to host cells is a prerequisite for the amoeba-induced cytolysis of target cells and have implicated a contact-dependent metalloproteinase in the cytopathogenic mechanisms of Acanthamoeba. AU - Cao, Z. AU - Jefferson, D. M. AU - Panjwani, N. IS - 25 KW - *Acanthamoeba/py [Pathogenicity] Acanthamoeba Keratitis/ps [Parasitology] *Acanthamoeba Keratitis/pa [Pathology] *Acute-Phase Proteins/me [Metabolism] Animals *Carrier Proteins/me [Metabolism] Cell Adhesion/de [Drug Effects] Humans Lectins/me [Metabolism] Mannans/me [Metabolism] *Mannose/me [Metabolism] Mannose-Binding Lectins Rabbits Serine Proteinase Inhibitors/pd [Pharmacology] PY - 1998 SE - Cao, Z. New England Eye Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA. SN - 0021-9258 SP - 15838-45 ST - Role of carbohydrate-mediated adherence in cytopathogenic mechanisms of Acanthamoeba T2 - The Journal of biological chemistry TI - Role of carbohydrate-mediated adherence in cytopathogenic mechanisms of Acanthamoeba UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9624184 VL - 273 ID - 1855 ER - TY - JOUR AB - Objective: To outline the severity and long-term sequelae of eye injuries in soccer. Design: Prospective observational study of 163 patients who sustained soccer-related ocular injuries between April 1, 1992, and March 31, 2000 (8 years). Methods: Patients were observed at a sports ophthalmology unit located in the largest university hospital of the northern region of the country and central to all major soccer fields in town. The data were recorded using the United States Eye Injury Registry report forms for initial and follow-up observation. Main Outcome Measures: (1) Self-reported history surrounding the ocular trauma, initial visual acuity, diagnosis, and operations and (2) final visual acuity, late diagnosis, and additional operations. Results: Injuries occurred predominantly in young men (mean±SD age, 23.2±8.8 years) practicing indoor soccer (50.9%) or outdoor soccer (47.2%), and most resulted from a kicked ball (79.1%) near the goalpost (60.1%). Angle recession and peripheral vitreoretinal lesions were more likely to occur in the superotemporal quadrant (54.7%; 95% confidence interval, 44.2%-65.0%; and 57.6%; 95% confidence interval, 48.4%-66.4%; respectively). Vitreoretinal lesions were present in 42.2% (95% confidence interval, 33.1%-51.8%) of patients with "normal" visual acuity (≥20/40) and in 50.0% (95% confidence interval, 38.1%-61.8%) of patients without hyphema. No significant association was found between severity of injury and age, sex, type of soccer, level of athletic expertise, or player position. Conclusions: Severe ocular lesions can occur in soccer players without symptoms and at all skill levels. The development of laboratory models will be essential to explain the tendency for lesions to be in the superotemporal quadrant. The data support the need for protective eyewear designed specifically for soccer. AD - Department of Ophthalmology, Univ. of Porto School of Medicine, S João Hospital, 4200-319 Porto, Portugal Department of Epidemiology, Univ. of Porto School of Medicine, S João Hospital, Porto, Portugal AU - Capão Filipe, J. A. AU - Fernandes, V. L. AU - Barros, H. AU - Falcão-Reis, F. AU - Castro-Correia, J. DB - Scopus DO - 10.1001/archopht.121.5.687 IS - 5 M3 - Article N1 - Cited By :28 Export Date: 19 July 2021 PY - 2003 SP - 687-694 ST - Soccer-related ocular injuries T2 - Archives of Ophthalmology TI - Soccer-related ocular injuries UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037991501&doi=10.1001%2farchopht.121.5.687&partnerID=40&md5=0ab9ebfd9dbca1db77a2503d1d3383d9 VL - 121 ID - 5076 ER - TY - JOUR AB - Purpose of Review: In this article, we review new and emerging drug delivery methods used in the treatment of glaucoma. Recent Findings: Several methods for sustained delivery of glaucoma medications have shown promise recently. Drug-eluting punctal plugs, contact lenses, and fornix-based silicone rings as well as subconjunctival and intracameral injections or implants are either in development or clinical trials. Thus far, those studied have demonstrated significant intraocular pressure (IOP) lowering ability with favorable safety profiles. However, long-term clinical safety data and comparative trials with existing therapies have been limited. Summary: Patient adherence with medication regimens remains a major obstacle in preventing glaucoma progression. Emerging patient-independent platforms that can deliver IOP lowering therapeutics hold promise for enhancement of adherence to treatments while remaining safe and effective. Each of these systems has their own unique advantages and disadvantages. It is still unclear where each of these products will fit into individual patient and practitioner treatment algorithms. AD - L.K. Seibold, Department of Ophthalmology, University of Colorado, 1675 Aurora Court, Aurora, CO, United States AU - Capitena Young, C. E. AU - Kahook, M. Y. AU - Seibold, L. K. DB - Embase DO - 10.1007/s40135-019-00210-3 IS - 2 KW - contact lens intravitreal implant punctal plug atropine bimatoprost latanoprost timolol travoprost disease exacerbation drug delivery system drug efficacy drug manufacture drug tolerance feasibility study glaucoma human intracameral drug administration intraocular pressure particle size patient compliance patient safety priority journal review subconjunctival drug administration visual acuity LA - English M3 - Review N1 - L627854632 2019-06-05 PY - 2019 SN - 2167-4868 SP - 143-149 ST - Novel Drug Delivery Systems for the Treatment of Glaucoma T2 - Current Ophthalmology Reports TI - Novel Drug Delivery Systems for the Treatment of Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627854632&from=export http://dx.doi.org/10.1007/s40135-019-00210-3 VL - 7 ID - 2502 ER - TY - JOUR AU - Caprioli, J. IS - 2 KW - Automation Differential Threshold *Glaucoma/di [Diagnosis] Humans Patient Compliance Psychophysics/mt [Methods] Pupil Sensory Thresholds Vision Tests *Visual Field Tests Visual Fields PY - 1991 SE - Caprioli, J. Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut 06510-8061. SN - 0002-9394 SP - 235-9 ST - Automated perimetry in glaucoma T2 - American journal of ophthalmology TI - Automated perimetry in glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1992746 VL - 111 ID - 2122 ER - TY - JOUR AB - PURPOSE: To review the role of intervisit intraocular pressure (IOP) fluctuation as an independent risk factor for glaucoma., DESIGN: Perspective after literature review., METHODS: Analysis of pertinent publications in the peer-reviewed literature., RESULTS: Disparate findings regarding the role of intervisit IOP variation have been published. IOP variation was a significant risk factor in the Advanced Glaucoma Intervention Study (AGIS), the Collaborative Initial Glaucoma Treatment Study, and other smaller studies. These studies have in common low IOPs (often after surgery) and moderately advanced disease. In the AGIS, when patients were stratified by mean IOP, only those patients with low IOPs showed the detrimental effects of IOP variation. IOP variation was not a significant risk factor in the Early Manifest Glaucoma Treatment Trial, and in 2 separate studies of ocular hypertensives. These studies have in common generally higher IOPs and an earlier stage of glaucoma (or no glaucoma at all). We believe these results are complementary rather than contradictory: existing data suggest that the effects of IOP variation depend on the characteristics of the patient, the baseline IOP, their stage of damage, the type of glaucoma, and other as-yet unknown factors., CONCLUSIONS: Practitioners should consider whether patients who are progressing at low mean IOP may benefit from having IOP variation reduced. Single elevated measures of IOP may not be an anomaly or may not be related to compliance, but may identify patients who are at high risk for progressive glaucomatous damage, and thus should be monitored more carefully and potentially treated more aggressively. Copyright © 2011 Elsevier Inc. All rights reserved. AU - Caprioli, Joseph AU - Varma, Rohit DO - https://dx.doi.org/10.1016/j.ajo.2011.05.029 IS - 3 KW - Antihypertensive Agents/tu [Therapeutic Use] *Glaucoma/dt [Drug Therapy] *Glaucoma/pp [Physiopathology] Humans *Intraocular Pressure/de [Drug Effects] Intraocular Pressure/ph [Physiology] Risk Factors Tonometry, Ocular Vision Disorders/pp [Physiopathology] Visual Acuity/ph [Physiology] PY - 2011 SE - Caprioli, Joseph. Jules Stein Eye Institute, The David Geffen School of Medicine, Los Angeles, California. Varma, Rohit. Doheny Eye Institute, University of Southern California, Los Angeles, California. SN - 1879-1891 0002-9394 SP - 340-344.e2 ST - Intraocular pressure: modulation as treatment for glaucoma T2 - American journal of ophthalmology TI - Intraocular pressure: modulation as treatment for glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21855671 VL - 152 ID - 1254 ER - TY - JOUR AB - Antiepileptic drugs have proven their efficacy in the prophylactic treatment of migraine. Our study comprises a clinical trial that examines the efficacy of gabapentin and topiramate and a description of the pharmacologic characteristics and the efficacy of tiagabine, lamotrigine, levetiracetam and zonisamide. Antiepileptic drugs have multiple modes of action which can explain their efficacy in reducing neuronal excitability which is proven in epilepsy and postulated in migraine. The relationship between epilepsy and migraine has, in fact, been much debated but never convincingly proven. Antiepileptic drugs coud be useful in migraine prophylaxis as some of these have determined a reduction in the monthly frequency and intensity of crises in subjects suffering from migraine with and without aura. These are the aims that have been proposed by the U.S. Headache Consortium Evidence-Based Guidelines. Further double-blind placebo-controlled studies are necessary in order to assess their safety and efficacy. AD - D. Mei, Istituto di Neurologia, Policlinico A. Gemelli, L.go A. Gemelli 8, 00168 Roma, Italy AU - Capuano, A. AU - Vollono, C. AU - Mei, D. AU - Pierguidi, L. AU - Ferraro, D. AU - Di Trapani, G. DB - Embase Medline IS - 2-3 KW - acetylsalicylic acid aciclovir anticonvulsive agent carbamazepine erythromycin etiracetam felbamate gabapentin imipenem isoniazid lamotrigine oxacarbamazepine paracetamol phenobarbital phenytoin primidone rifampicin sodium divalproate tiagabine topiramate valproic acid zonisamide abdominal cramp adjuvant therapy agitation alopecia amnesia anorexia aphasia ataxia bleeding brain depth stimulation clinical trial concentration loss confusion depression diarrhea diplopia disease association dose response drug activity drug bioavailability drug dose increase drug efficacy drug mechanism drug megadose drug metabolism drug safety drug structure drug tolerability dysarthria enzyme inhibition epilepsy pure red cell anemia evidence based practice fatigue glaucoma headache hematocrit human infection irritability lack of energy Lennox Gastaut syndrome leukopenia low drug dose migraine migraine aura migraine with aura monotherapy morbidity nausea nausea and vomiting nephrolithiasis neuropathic pain nystagmus paresthesia patient compliance review side effect skin necrosis somnolence Stevens Johnson syndrome thrombocytopenia tonic clonic seizure tremor unspecified side effect vertigo weakness body weight gain body weight loss infantile spasm LA - English M3 - Review N1 - L44910114 2007-01-11 PY - 2004 SN - 0009-9074 SP - 79-87 ST - Antiepileptic drugs in migraine prophylaxis: State of the art T2 - Clinica Terapeutica TI - Antiepileptic drugs in migraine prophylaxis: State of the art UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44910114&from=export VL - 155 ID - 3756 ER - TY - JOUR AB - The economic costs of age-related ocular diseases and vision loss are increasing rapidly as our society ages. In addition to the direct costs of treating age-related eye diseases, elderly persons with vision loss are at significantly increased risk for falls and fractures, experiencing social isolation, and suffering from an array of comorbid medical conditions compared with individuals with normal vision. Recent studies estimate the total economic burden (direct and indirect costs) of adult vision impairment in the United States at $51.4 billion. This figure is expected to increase as the baby boomer generation continues to age. While a number of highly effective new therapies have caused a paradigm shift in the management of several major age-related ocular diseases in recent years, these treatments come at a substantial cost. This article reviews the economic burdens and treatment-related costs of 4 major ocular diseases of aging-glaucoma, age-related macular degeneration, diabetic retinopathy, and dry eye disease-and the implications for managed care. AU - Cardarelli, William J. AU - Smith, Roderick A. IS - 5 Suppl KW - Aged Antibodies, Monoclonal, Humanized/ec [Economics] Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] Bevacizumab Clinical Trials as Topic Cyclosporine/ec [Economics] Cyclosporine/tu [Therapeutic Use] *Diabetic Retinopathy/ec [Economics] Diabetic Retinopathy/ep [Epidemiology] Diabetic Retinopathy/th [Therapy] *Drug Costs *Dry Eye Syndromes/ec [Economics] Dry Eye Syndromes/ep [Epidemiology] Dry Eye Syndromes/th [Therapy] Glaucoma, Open-Angle/dt [Drug Therapy] *Glaucoma, Open-Angle/ec [Economics] Glaucoma, Open-Angle/ep [Epidemiology] Humans Laser Therapy Medicare Medication Adherence Ranibizumab Severity of Illness Index United States Vascular Endothelial Growth Factor A/ai [Antagonists & Inhibitors] Vision Disorders/ec [Economics] *Wet Macular Degeneration/ec [Economics] Wet Macular Degeneration/ep [Epidemiology] PY - 2013 SE - Cardarelli, William J. Atrius Health/Harvard Vanguard Medical Associates, Watertown, MA, USA. William_Cardarelli@vmed.org. SN - 1936-2692 1088-0224 SP - S85-91 ST - Managed care implications of age-related ocular conditions T2 - The American journal of managed care TI - Managed care implications of age-related ocular conditions UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23725500 VL - 19 ID - 969 ER - TY - JOUR AB - CASE DESCRIPTION: Corneal thinning and an increased risk of corneal perforation, resulting from recurrent episodes of microbial keratitis, required a 38-year-old Caucasian female to undergo bilateral corneal grafting. Although strongly advised otherwise, the patient had been a long time user of low oxygen permeability hydrogel contact lenses in a flexible wear regime, with frequent overnight use., DISCUSSION: Microbial keratitis is a potentially severe contact lens related complication which, if not properly treated, may lead to permanent visual loss. The introduction of silicone-hydrogel materials and daily replacement modalities has not resulted in a significant decrease in the incidence of microbial keratitis, thus suggesting that the condition is mainly dependent on patient hygiene and wearing habits. Non-compliance, which is endemic in contact lens wear, may be combated by increasing patient awareness of the potential risk factors of contact lens misuse. This is accomplished through constant, rigorous information provided by contact lens practitioners. AU - Cardona, Genis AU - Saona-Santos, Carlos Luis DO - https://dx.doi.org/10.1016/j.clae.2009.10.001 IS - 1 KW - *Blindness/di [Diagnosis] *Blindness/et [Etiology] Blindness/su [Surgery] *Contact Lenses, Hydrophilic/ae [Adverse Effects] *Eye Infections, Bacterial/di [Diagnosis] *Eye Infections, Bacterial/et [Etiology] Eye Infections, Bacterial/su [Surgery] Female Humans Hydrogel, Polyethylene Glycol Dimethacrylate *Keratitis/di [Diagnosis] *Keratitis/et [Etiology] Keratitis/su [Surgery] Middle Aged Recurrence PY - 2010 SE - Cardona, Genis. Research Group of Centre Universitari de la Visio, Optics and Optometry Department, Technical University of Catalonia, Spain. gcardona@oo.upc.edu SN - 1476-5411 1367-0484 SP - 30-2 ST - Corneal thinning associated with recurrent microbial keratitis resulting from 7-day extended wear of low Dk hydrogel contact lenses: a case report T2 - Contact lens & anterior eye : the journal of the British Contact Lens Association TI - Corneal thinning associated with recurrent microbial keratitis resulting from 7-day extended wear of low Dk hydrogel contact lenses: a case report UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=19896890 VL - 33 Y2 - 20091106// ID - 1390 ER - TY - JOUR AB - Chronic glucocorticoid (GC) therapy is associated with an increased risk of developing cataracts and glaucoma, and recommendations have been developed for monitoring these side effects in patients with rheumatic diseases. The aim of this study was to assess the prevalence of cataracts and glaucoma and the adherence to the existing recommendations for monitoring eye toxicity of chronic GC therapy among systemic lupus erythematosus (SLE) patients in routine clinical practice. Clinical charts of 170 patients were examined, and 34 (20%) of them never underwent an eye assessment. The remaining 136 underwent an eye assessment with an interval of 75 +/- 61.7 months. Only 45 (33%) had received an evaluation during the previous 12 months. All these 170 patients were taking chronic CG therapy at a mean daily dose of 5.4 +/- 2.4 mg prednisone and a mean cumulative dose of 27.6 +/- 20.5 g. Out of the 136 patients with at least one eye assessment, cataracts were observed in 39 patients (29%) and glaucoma in 4 patients (3%). Cataracts were diagnosed at a mean age of 46.5 +/- 10 years; the development of cataracts was associated with age, disease duration, and cumulative GC dose. Glaucoma was diagnosed at a mean age of 40.5 +/- 16 years; due to the small number of patients, no correlations were made. The prevalence of cataracts and glaucoma is higher than in the general population, and these conditions occur early in the life of SLE patients. An association between GC and cataracts is confirmed. The adherence to recommendations is suboptimal as only 33% of patients underwent an eye assessment over the previous 12 months. These data reinforce the need to improve adherence to recommendations for eye monitoring among SLE patients under chronic therapy with GC. AU - Carli, L. AU - Tani, C. AU - Querci, F. AU - Della Rossa, A. AU - Vagnani, S. AU - Baldini, C. AU - Talarico, R. AU - d'Ascanio, A. AU - Neri, R. AU - Tavoni, A. G. AU - Bombardieri, S. AU - Mosca, M. DO - https://dx.doi.org/10.1007/s10067-013-2214-6 IS - 7 KW - Adult *Cataract/co [Complications] *Cataract/ep [Epidemiology] *Eye Diseases/ci [Chemically Induced] Female *Glaucoma/co [Complications] *Glaucoma/ep [Epidemiology] *Glucocorticoids/ae [Adverse Effects] Guideline Adherence Humans *Lupus Erythematosus, Systemic/co [Complications] *Lupus Erythematosus, Systemic/ep [Epidemiology] Male Middle Aged Prevalence Regression Analysis Retrospective Studies Rheumatology/mt [Methods] Rheumatology/st [Standards] Time Factors PY - 2013 SE - Carli, L. Rheumatology Unit, University of Pisa, Via Roma, 67, 56126 Pisa, Italy. SN - 1434-9949 0770-3198 SP - 1071-3 ST - Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity T2 - Clinical rheumatology TI - Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23456414 VL - 32 Y2 - 20130303// ID - 986 ER - TY - JOUR AB - Health care utilization and costs associated with chronic obstructive pulmonary disease (COPD) continue to increase, notwithstanding evidence-based management strategies described by major respiratory societies. Cardiovascular diseases, asthma, diabetes and its precursors (obesity and metabolic syndrome), depression, cognitive impairment, and osteoporosis are examples of common comorbidities that can affect or be affected by COPD. Appropriate diagnosis and management (from a pharmacologic and nonpharmacologic perspective) of COPD and its associated comorbidities are important to ensure optimal patient care. An evolving understanding of COPD as a multimorbid disease that affects an aging population, rather than just a lung-specific disease, necessitates an integrated, tailored disease-management approach to improve prognoses and reduce costs. © Postgraduate Medicine. AD - B. W. Carlin, Sleep Medicine and Lung Health Consultants, PO Box 174, Ingomar, PA 15127, United States AU - Carlin, B. W. DB - Embase Medline DO - 10.3810/pgm.2012.07.2582 IS - 4 KW - beta 2 adrenergic receptor stimulating agent budesonide carbocisteine cholinergic receptor blocking agent corticosteroid fluticasone formoterol hydroxymethylglutaryl coenzyme A reductase kinase activator ipratropium bromide long acting drug methylxanthine derivative phosphodiesterase IV inhibitor prednisone roflumilast salbutamol salmeterol theophylline tiotropium bromide adrenal suppression aged aging article asthma blood pressure cardiovascular disease chronic obstructive lung disease cognitive defect comorbidity depression diabetes mellitus diagnostic test diarrhea disease association disease exacerbation drug megadose dysphonia evidence based medicine glaucoma health care access health care cost health care utilization health insurance heart arrhythmia heart failure heart palpitation human hypokalemia insomnia integrative medicine medical society metabolic syndrome X mucosal dryness myopathy nausea obesity osteoporosis palliative therapy patient care pneumonia practice guideline prognosis screening test seizure self care side effect skin atrophy tachycardia thrush tremor unspecified side effect urine retention vomiting body weight loss LA - English M3 - Article N1 - L368791276 2013-05-01 2013-06-07 PY - 2012 SN - 0032-5481 1941-9260 SP - 225-240 ST - COPD and associated Comorbidities: A review of current diagnosis and treatment T2 - Postgraduate Medicine TI - COPD and associated Comorbidities: A review of current diagnosis and treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368791276&from=export http://dx.doi.org/10.3810/pgm.2012.07.2582 https://postgradmed.org/fileServer.php?filepath=%2Fhome%2Fpostgrad%2Farticle_files_secure%2Fpdf%2Fpgm.2012.07.2582.pdf&doi=10.3810%2Fpgm.2012.07.2582 VL - 124 ID - 3077 ER - TY - JOUR AB - Many dermatological conditions will respond to a topical corticosteroid. The clinical outcome will depend on making a correct clinical diagnosis and applying the right molecule in the most appropriate vehicle for the correct duration. Topical corticosteroids are classified by their strength, but the same molecule will have different effects depending on the vehicle. The patient's age and the affected area of skin are other important factors. If used correctly the adverse effects of topical corticosteroids are usually minimal. Systemic effects can occur with high doses. AD - Westmead Clinical School, Sydney Medical School, The University of Sydney, Australia AU - Carlos, G. AU - Uribe, P. AU - Fernández-Peñas, P. DB - Embase IS - 5 KW - betamethasone dipropionate betamethasone valerate clobetasol propionate clobetasone corticosteroid desonide drug vehicle emulsifying agent hydrocortisone hydrocortisone acetate methylprednisolone aceponate mometasone furoate triamcinolone acetonide acne adrenal cortex insufficiency age article clinical trial (topic) cream diabetes mellitus drug absorption drug classification drug efficacy drug indication drug penetration drug potency drug safety drug use drug withdrawal glaucoma human hyperglycemia hypopigmentation hypothalamus hypophysis adrenal system lactation lotion ointment patient compliance perioral dermatitis pregnancy prescription rash rosacea side effect skin atrophy skin disease tachyphylaxis treatment duration treatment response unspecified side effect vasoconstriction wound healing impairment LA - English M3 - Article N1 - L369944739 2013-10-10 2013-10-24 PY - 2013 SN - 0312-8008 SP - 158-161 ST - Rational use of topical corticosteroids T2 - Australian Prescriber TI - Rational use of topical corticosteroids UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369944739&from=export http://www.australianprescriber.com/magazine/36/5/article/1452.pdf VL - 36 ID - 2963 ER - TY - JOUR AB - In many mucocutaneous disorders, corticosteroids therapy is currently central. Systemic therapy is restricted to severe disorders whereas topical applications are considered as the first-line treatment. The oral cavity environment, the medication form and other factors related to the delivery method are key factors for the therapy efficiency and effectiveness. Current marketed medications are not able to avoid wrong drug exposure and scarce patients' compliance. Innovative in situ delivery systems are able to prolong the drug retention time on the mucosa and to avoid the drawbacks of conventional formulations. This review is intended to give a general overview of oral mucocutaneous pathologies and highlight the potential of new technologies in designing innovative delivery systems able to release corticosteroids in situ for the treatment of various oral cavity disorders. AD - L.I. Giannola, Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università di Palermo, Via Archirafi 32, Palermo, Italy AU - Caro, V. D. AU - Sutera, F. M. AU - Giannola, L. I. C1 - corlan(Tiofarma) kenacort a orabase C2 - Tiofarma DB - Embase Medline DO - 10.4155/tde-2017-0055 IS - 10 KW - beclomethasone dipropionate betamethasone sodium phosphate betamethasone valerate carbopol 934 carboxymethylcellulose chitosan clobetasol propionate corticosteroid dexamethasone fluocinolone acetonide fluocinonide fluticasone propionate hydrocortisone sodium succinate hydroxypropylmethylcellulose kenacort a orabase liposome macrogol macrogol 6000 magnesium stearate mannitol methylprednisolone octadecylamine phosphatidylcholine poloxamer povidone prednisolone prednisone retinol silymarin triamcinolone acetonide unindexed drug allergic rhinitis antiinflammatory activity aphthous stomatitis cataract dose response drug delivery system drug efficacy drug formulation drug mechanism drug potency drug release drug response drug solubility erythema chronicum migrans erythema multiforme film gel glaucoma herpes labialis human immunomodulation incidence intraocular hypertension lichen planus lipodystrophy mental disease mouth cancer mouth disease mouth ulcer mucoadhesion mucous membrane pemphigoid nonhuman patient compliance pemphigus vulgaris periodontal disease priority journal psoriasis review systemic therapy tablet thrush unspecified side effect corlan LA - English M3 - Review N1 - L618495514 2017-10-03 2017-10-04 PY - 2017 SN - 2041-6008 2041-5990 SP - 899-914 ST - In situ delivery of corticosteroids for treatment of oral diseases T2 - Therapeutic Delivery TI - In situ delivery of corticosteroids for treatment of oral diseases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L618495514&from=export http://dx.doi.org/10.4155/tde-2017-0055 VL - 8 ID - 2631 ER - TY - JOUR AB - PURPOSE: Medication self-efficacy, or patients' confidence that they can perform medication-related behaviors, is associated with better glaucoma medication adherence. Little is known about how to enhance glaucoma patients' medication self-efficacy. Our purpose is to examine whether patient-provider communication increases glaucoma patients' medication self-efficacy., METHODS: During an 8-month cohort study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. A validated scale was used at baseline and 8-month follow-up to assess patients' confidence in overcoming adherence barriers (adherence barriers self-efficacy) and carrying out tasks to use eye drops correctly (eye drop task self-efficacy). We ran two generalized estimating equations to examine whether more frequent patient-provider communication during office visits predicted increased patient adherence barriers self-efficacy and eye drop task self-efficacy at 8-month follow-up., RESULTS: For each additional topic providers educated about, patients reported an average increase of 0.35 in self-efficacy in overcoming adherence barriers (p < 0.001). Patients also reported an average increase of 1.01 points in eye drop task self-efficacy when providers asked about patients' views of glaucoma and its treatment versus not (p < 0.001). Patients who asked more medication questions (p < 0.001) and African-American patients (p < 0.05) reported lower adherence barriers self-efficacy by 0.30 and 2.15 points, respectively. Women had a 0.63 lower eye drop task self-efficacy than men (p < 0.05)., CONCLUSIONS: When providers educate glaucoma patients and assess patient views about glaucoma and its treatment, patients report higher medication self-efficacy. Providers should be aware that patients who ask more medication questions may have less confidence in their ability to overcome barriers to adherence. AU - Carpenter, Delesha M. AU - Blalock, Susan J. AU - Sayner, Robyn AU - Muir, Kelly W. AU - Robin, Alan L. AU - Hartnett, Mary Elizabeth AU - Giangiacomo, Annette L. AU - Tudor, Gail E. AU - Sleath, Betsy L. DO - https://dx.doi.org/10.1097/OPX.0000000000000856 IS - 7 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] Cohort Studies Female *Glaucoma/dt [Drug Therapy] *Health Communication/mt [Methods] Humans Male *Medication Adherence Middle Aged Ophthalmic Solutions *Patient Education as Topic/mt [Methods] *Physician-Patient Relations Self Efficacy Surveys and Questionnaires Young Adult PY - 2016 SE - Carpenter, Delesha M. *PhD, MSPH PhD, MPH ++PharmD MD PhD Division of Pharmaceutical Outcomes and Policy (DMC), University of North Carolina at Chapel Hill, Asheville Satellite Campus, Asheville, North Carolina; Division of Pharmaceutical Outcomes and Policy (SJB, BLS), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; School of Medicine (RS), Stanford University, Stanford, California; Duke University School of Medicine & Durham VA Medical Center (KWM), Durham, North Carolina; Wilmer Institute and Bloomberg School of Public Health (ALR), Johns Hopkins University, Baltimore, Maryland; Department of Ophthalmology (ALR), University of Maryland, College Park, Maryland; John A. Moran Eye Center (MEH), University of Utah, Salt Lake City, Utah; School of Medicine (ALG), Emory University, Atlanta, Georgia; and Department of Mathematics and Statistics (GET), Husson University, Bangor, Maine. SN - 1538-9235 1040-5488 SP - 731-7 ST - Communication Predicts Medication Self-Efficacy in Glaucoma Patients T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Communication Predicts Medication Self-Efficacy in Glaucoma Patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27003815 VL - 93 ID - 699 ER - TY - JOUR AB - Education about how to administer eye drops may improve a patient's ability to instill his or her eye drops correctly. Our objectives were to (a) document the methods providers use to educate glaucoma patients about eye drop technique; (b) determine whether eye drop technique education varies by provider and patient characteristics; and (c) evaluate whether education predicts improved patient technique. We conducted an 8-month longitudinal study of 279 glaucoma patients and 15 providers in which we recorded on videotape the content of glaucoma office visits at two time points (baseline and 4- to 6-week follow-up) and videotaped patient eye drop technique at three time points (baseline, 4- to 6-week follow-up, and 8-month follow-up). Mann-Whitney rank sum tests were used to determine whether education was associated with improved patient eye drop technique over time. Ninety-four patients (34%) received technique education at either visit; 31% received verbal education and 10% received a technique demonstration. Only 24 patients (47%) who were new to eye drops received technique education at the baseline visit. Patients who were new to drops at baseline (p = .008) and patients who asked a question about drops (p < .001) were more likely to receive technique education. Education was not associated with improved technique. Eye drop technique education occurs infrequently during glaucoma office visits. Future studies should compare the effectiveness of different educational methods, such as patient demonstration versus provider verbal instruction, to determine which method is best at improving patient eye drop technique. AU - Carpenter, Delesha M. AU - Sayner, Robyn AU - Blalock, Susan J. AU - Muir, Kelly W. AU - Hartnett, Mary Elizabeth AU - Lawrence, Scott D. AU - Giangiacomo, Annette L. AU - Goldsmith, Jason A. AU - Tudor, Gail E. AU - Robin, Alan L. AU - Sleath, Betsy L. DO - https://dx.doi.org/10.1080/10410236.2015.1020263 IS - 8 KW - Adult Aged Female *Glaucoma/dt [Drug Therapy] *Health Communication Humans Longitudinal Studies Male Medication Adherence *Ophthalmic Solutions/ad [Administration & Dosage] Ophthalmologists *Patient Education as Topic *Self Administration Surveys and Questionnaires Videotape Recording PY - 2016 SE - Carpenter, Delesha M. a Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Sayner, Robyn. b School of Medicine, Stanford University. Blalock, Susan J. a Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Muir, Kelly W. c School of Medicine, Duke University. Hartnett, Mary Elizabeth. d John A. Moran Eye Center, University of Utah. Lawrence, Scott D. e Kittner Eye Center, University of North Carolina. Giangiacomo, Annette L. f School of Medicine, Emory University. Goldsmith, Jason A. d John A. Moran Eye Center, University of Utah. Tudor, Gail E. g Department of Mathematics and Statistics, Husson University. Robin, Alan L. h Wilmer Institute and Bloomberg School of Public Health, Johns Hopkins University, and Department of Ophthalmology, University of Maryland. Sleath, Betsy L. a Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. SN - 1532-7027 1041-0236 SP - 1036-42 ST - The Effect of Eye Drop Technique Education in Patients With Glaucoma T2 - Health communication TI - The Effect of Eye Drop Technique Education in Patients With Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26751938 VL - 31 Y2 - 20160111// ID - 727 ER - TY - JOUR AB - OBJECTIVE: We examined whether six patient-provider communication behaviors directly affected the intraocular pressure (IOP) of glaucoma patients or whether patient medication adherence and eye drop technique mediated the relationship between self-efficacy, communication, and IOP., METHODS: During an 8-month, longitudinal study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. Medication adherence was measured electronically and IOP was extracted from medical records. We ran generalized estimating equations to examine the direct effects of communication on IOP and used bootstrapping to test whether medication adherence and eye drop technique mediated the effect of communication on IOP., RESULTS: Provider education about medication adherence (B=-0.50, p<0.05) and inclusion of patient input into the treatment plan (B=-0.35, p<0.05) predicted improved IOP. There was no evidence of significant mediation., CONCLUSION: The positive effects of provider education and provider inclusion of patient input in the treatment plan were not mediated by adherence and eye drop technique., PRACTICE IMPLICATIONS: Providers should educate glaucoma patients about the importance of medication adherence and include patient input into their treatment plan. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved. AU - Carpenter, Delesha M. AU - Tudor, Gail E. AU - Sayner, Robyn AU - Muir, Kelly W. AU - Robin, Alan L. AU - Blalock, Susan J. AU - Hartnett, Mary Elizabeth AU - Giangiacomo, Annette L. AU - Sleath, Betsy L. DO - https://dx.doi.org/10.1016/j.pec.2015.07.001 PY - 2015 SE - Carpenter, Delesha M. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, USA. Electronic address: dmcarpenter@unc.edu. Tudor, Gail E. Department of Mathematics and Statistics, Husson University, Bangor, USA. Sayner, Robyn. School of Medicine, Stanford University, Stanford, CA, USA. Muir, Kelly W. School of Medicine, Duke University, & Durham VA Medical Center, Durham, USA. Robin, Alan L. Wilmer Institute and Bloomberg School of Public Health; Johns Hopkins University, & University of Maryland, Baltimore, MD, USA. Blalock, Susan J. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, USA. Hartnett, Mary Elizabeth. John A. Moran Eye Center, University of Utah, Salt Lake City, USA. Giangiacomo, Annette L. School of Medicine, Emory University, Atlanta, USA. Sleath, Betsy L. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, USA. SN - 1873-5134 0738-3991 ST - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients T2 - Patient education and counseling TI - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=26223851 Y2 - 20150706// ID - 40 ER - TY - JOUR AB - PURPOSE: To report the beneficial properties of subconjunctival amphotericin B as an adjunctive therapy in patients with severe fungal keratitis., METHODS: Case reports and review of medical literature. Four patients with advanced fungal keratitis were treated with repeated injections of subconjunctival amphotericin B in addition to topical and systemic antifungal treatment., RESULTS: Two to 8 injections were given to each patient. All patients showed rapid clinical improvement after the injections. No serious adverse effects were observed. However, all patients experienced pain during the injections., CONCLUSIONS: Subconjunctival injections of amphotericin B are useful as an adjunctive treatment of advanced fungal keratitis. This treatment assures compliance and may be an alternative to avoid a surgical intervention in an acute stage of advanced fungal keratitis. More cases are needed to validate our findings. AU - Carrasco, Maria Alejandra AU - Genesoni, Graciela DO - https://dx.doi.org/10.1097/ICO.0b013e3181fb826d IS - 5 KW - Acremonium/ip [Isolation & Purification] Adult Aged, 80 and over *Amphotericin B/tu [Therapeutic Use] *Antifungal Agents/tu [Therapeutic Use] Candida/ip [Isolation & Purification] Conjunctiva/de [Drug Effects] Corneal Ulcer/di [Diagnosis] *Corneal Ulcer/dt [Drug Therapy] Corneal Ulcer/mi [Microbiology] Eye Infections, Fungal/di [Diagnosis] *Eye Infections, Fungal/dt [Drug Therapy] Eye Infections, Fungal/mi [Microbiology] Female Fusarium/ip [Isolation & Purification] Humans Injections, Intraocular Male Mycoses/di [Diagnosis] *Mycoses/dt [Drug Therapy] Mycoses/mi [Microbiology] PY - 2011 SE - Carrasco, Maria Alejandra. Department of Ophthalmology, Hospital I. Perrupato, Mendoza, Argentina. macarras73@gmail.com SN - 1536-4798 0277-3740 SP - 608-11 ST - Treatment of severe fungal keratitis with subconjunctival amphotericin B T2 - Cornea TI - Treatment of severe fungal keratitis with subconjunctival amphotericin B UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21107247 VL - 30 ID - 1301 ER - TY - JOUR AB - Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at the C4 of the benzoyl ring position, which markedly affects its in vitro and in vivo potency, extends the duration of anti-inflammatory activity, and enhances its inhibitory effect on COX-2 absorption across the cornea and penetration into ocular tissues. The United States Food and Drug Administration approved bromfenac in 2005 for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), and among them bromfenac, could be even more effective than steroids at reestablishing the blood-aqueous barrier, as revealed by flare on slit-lamp examination and as quantitatively measured using ocular fluorophotometry. Similar to other NSAIDs, it has a role in inhibiting intraoperative miosis during cataract surgery. However, bromfenac also seems to be useful in other situations, such as refractive surgery, allergic conjunctivitis (not useful in dry eye), choroidal neovascularization, and even ocular oncology. No reports of systemic toxicity have been published and bromfenac has good topical tolerance with a low incidence of adverse effects. © 2012 Carreño et al, publisher and licensee Dove Medical Press Ltd. AD - E. Carreño, Ocular Immunology Unit-IOBA, Instituto Universitario de Oftalmobiología, University of Valladolid, Campus Miguel Delibes, Valladolid E-47011, Spain AU - Carreño, E. AU - Portero, A. AU - Galarreta, D. J. AU - Herreras, J. M. C1 - bromday(ISTA) bronuck(Senju,Japan) xibrom(ISTA,United States) yellox(Croma,Austria) C2 - Croma(Austria) ISTA(United States) Senju(Japan) DB - Embase DO - 10.2147/OPTH.S23381 IS - 1 KW - acetylsalicylic acid amfenac bromfenac corticosteroid diclofenac flurbiprofen indometacin ketorolac ketotifen nepafenac nonsteroid antiinflammatory agent pemirolast placebo ranibizumab steroid suprofen abnormal sensation adjuvant therapy adverse outcome allergic conjunctivitis antiinflammatory activity asthma blepharitis cancer chemotherapy cataract extraction chronic disease clinical effectiveness colon cancer conjunctival deposit conjunctival hyperemia conjunctivitis cornea disease cornea erosion cornea perforation cornea ulcer diabetic macular edema diabetic retinopathy disease control dosage schedule comparison dose response drug approval drug blood level drug effect drug efficacy drug half life drug indication drug marketing drug mechanism drug penetration drug potency drug safety drug structure drug tissue level drug tolerability dry eye episcleritis eye burning eye disease eye inflammation eye irritation eye pain eye tumor fulminant hepatic failure headache human IC50 iritis liver toxicity maintenance therapy mydriasis nonhuman ocular pruritus ocular surface disease outcome assessment patient compliance postoperative inflammation postoperative pain pterygium refractive surgery age related macular degeneration retina macula cystoid edema review scleritis single drug dose subretinal neovascularization systemic disease systemic therapy time to maximum plasma concentration treatment duration treatment planning unspecified side effect vernal conjunctivitis bromday bronuck xibrom yellox L1 - internal-pdf://3289099772/3092-Update on twice-daily bromfenac sodi-2012.pdf LA - English M3 - Review N1 - L365167544 2012-07-11 2012-07-16 PY - 2012 SN - 1177-5467 1177-5483 SP - 637-644 ST - Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction T2 - Clinical Ophthalmology TI - Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365167544&from=export http://dx.doi.org/10.2147/OPTH.S23381 VL - 6 ID - 3092 ER - TY - JOUR AB - Glaucoma has been recently characterized as a member of the group of anoikis-related diseases. Anoikis, a form of apoptosis, can be triggered by the unfastening of adherent junctions present in astrocytes. In those areas of the central nervous system in which the soma of the neurons or their axons and dendrites are metabolically dependent on the activity of astrocytes, a derangement of the lactate shuttle caused by a separation between the plasma membranes of neurons and astrocytes would result in metabolic impairment of the neurons themselves. In glaucoma, the triggering event has been attributed to the posterior deviation of aqueous humor towards the astrocyte-rich prelaminar tissue of the optic nerve head. The mean calcium content in the aqueous is able to interfere with calcium-dependent adherent junctions and induce anoikis of the astrocytes. As the cerebrospinal fluid has a similar base calcium concentration, a shunt of cerebrospinal fluid through the cerebral parenchyma would be able to interfere in the astrocytic architecture with dire consequences to the metabolically dependent neurons. Here the similitude between glaucoma, amyotrophic lateral sclerosis and Alzheimer's disease are discussed and the concept of the break in the fluid-brain barrier, as an event separated from the blood-brain barrier, is stressed. AU - Carreras, Francisco Javier DO - https://dx.doi.org/10.4103/1673-5374.249215 IS - 6 PY - 2019 SE - Carreras, Francisco Javier. Department of Surgery, Faculty of Medicine, University of Granada, Granada, Spain. SN - 1673-5374 SP - 962-966 ST - Lessons from glaucoma: rethinking the fluid-brain barriers in common neurodegenerative disorders T2 - Neural regeneration research TI - Lessons from glaucoma: rethinking the fluid-brain barriers in common neurodegenerative disorders UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=30762000 VL - 14 ID - 587 ER - TY - JOUR AB - AIMS: To compare the analgesic properties of lidocaine 2% jelly versus sub-Tenon's anaesthesia with lidocaine 2% without adrenaline (epinephrine) for trabeculectomy surgery., METHODS: A prospective randomised clinical trial. 59 consecutive patients scheduled for trabeculectomy at the Toronto Western Hospital were randomly assigned to topical unpreserved lidocaine 2% jelly or sub-Tenon's anaesthesia with 2% lidocaine. Both groups received a standardised sedative consisting of midazolam, fentanyl. and/or propofol. The visual analogue scale was utilised to measure intraoperative pain. Patient comfort, physician assessment of intraoperative patient compliance, volume of local anaesthetic used, need for supplemental anaesthesia, and any complications were recorded. The two groups were compared using the Student's t test., RESULTS: The sub-Tenon's anaesthesia group and the lidocaine 2% jelly group did not vary significantly in subjective pain score (18.3 (SD 16.2) v 19.8 (12.4) respectively, p = 0.739) and surgeons' satisfaction scale (3.6 (0.7) and 3.8 (0.6) respectively, p = 0.328). Four patients required additional anaesthesia, all of them in the sub-Tenon's group., CONCLUSION: Topical lidocaine 2% jelly is as effective as sub-Tenon's anaesthesia for pain control in patients undergoing trabeculectomy. Lidocaine 2% jelly is similar to sub-Tenon's anaesthesia in patient comfort and surgeon satisfaction. AU - Carrillo, M. M. AU - Buys, Y. M. AU - Faingold, D. AU - Trope, G. E. IS - 8 KW - Aged *Anesthesia, Local/mt [Methods] *Anesthetics, Local Female *Glaucoma/su [Surgery] Humans Hypnotics and Sedatives/ad [Administration & Dosage] *Lidocaine Male Middle Aged Pain/pc [Prevention & Control] Prospective Studies *Trabeculectomy/mt [Methods] PY - 2004 SE - Carrillo, M M. University Health Network, Toronto Western Hospital, University of Toronto, Ontario, Canada. SN - 0007-1161 SP - 1004-7 ST - Prospective study comparing lidocaine 2% jelly versus sub-Tenon's anaesthesia for trabeculectomy surgery T2 - The British journal of ophthalmology TI - Prospective study comparing lidocaine 2% jelly versus sub-Tenon's anaesthesia for trabeculectomy surgery UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15258014 VL - 88 ID - 1776 ER - TY - JOUR AB - Visual impairment becomes more prevalent with age. A person has "low vision" when legally blind or partially sighted. In addition, many older patients have functional visual impairment that affects their ability to read, even with corrective lenses. Normal visual changes that occur with aging include presbyopia, decreased contrast sensitivity, decreased dark/light adaptation, and delayed glare recovery. The four most prevalent age-related ocular diseases are macular degeneration, open-angle glaucoma, cataract, and diabetic retinopathy. The primary care practitioner can identify patients with visual problems with a careful history and in-office tests of visual acuity. Patients with visual impairments should be referred to an eye care practitioner for a more comprehensive ocular evaluation. AU - Carter, T. L. IS - 9 KW - Age Factors Aged *Geriatrics/mt [Methods] Humans Medical History Taking Office Visits Prevalence *Primary Health Care/mt [Methods] Referral and Consultation Vision Disorders/cl [Classification] Vision Disorders/di [Diagnosis] Vision Disorders/ep [Epidemiology] *Vision Disorders/th [Therapy] Vision Screening PY - 1994 SE - Carter, T L. College of Optometry, State University of New York (SUNY). SN - 0016-867X SP - 37-7 ST - Age-related vision changes: a primary care guide T2 - Geriatrics TI - Age-related vision changes: a primary care guide UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8088558 VL - 49 ID - 2076 ER - TY - JOUR AB - PURPOSE: To assess the ocular hypotensive effect of 15-keto fluprostenol, the oxidized metabolite of travoprost, on glaucoma patients, through a randomized double-masked placebo-controlled study., METHODS: Twelve patients with ocular normal tension glaucoma (NTG) (intraocular pressure [IOP] < 22 mmHg) were enrolled. In order to ensure patient compliance to treatment, all study subjects were hospitalized. In each patient, the eye to be submitted to the treatments was randomly chosen. After hospital admission (day 1), those patients received for 5 days at 8 P.M. either one drop of 15-keto fluprostenol (35 mug/ml) or one drop of placebo. IOP evaluation was performed within 8 A.M. and 8 P.M. for 6 days. Furthermore, we performed a determination of cardiovascular parameters before and after the treatments., RESULTS: Starting with the first IOP measurement after the first treatment (8 A.M. on day 2), IOP was reduced of about 14% in the eyes treated 15-keto fluprostenol, in comparison with baseline IOP values of 15-keto fluprostenol-treated patients. The IOP reduction in the 15-keto fluprostenol-treated group was significantly compared to placebo group (p < 0.05) starting from day 3 till day 6 of the study. Except for mild hyperemia in one 15-keto fluprostenol-treated eye, no other side effects were observed or reported by the enrolled patients., CONCLUSIONS: The travoprost metabolite 15-keto fluprostenol was effective in decrease IOP and maintained IOP reduction along 5 days of treatment. The 15-keto fluprostenol can be developed as a good candidate for once-a-day NTG patients' treatment. AU - Caruso, Ciro AU - Pacente, Luigi AU - Troiano, Pasquale AU - Ostacolo, Carmine AU - D'Andrea, Luca AU - Bartollino, Silvia AU - Costagliola, Ciro DO - https://dx.doi.org/10.1007/s10792-019-01243-0 IS - 4 KW - Adult Aged Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Humans *Intraocular Pressure/de [Drug Effects] Intraocular Pressure/ph [Physiology] Male Middle Aged Ophthalmic Solutions/ad [Administration & Dosage] Pilot Projects *Prostaglandins F, Synthetic/ad [Administration & Dosage] Treatment Outcome PY - 2020 SE - Caruso, Ciro. Corneal Transplant Center, Pellegrini Hospital, Via Portamedina alla Pignasecca 41, 80135, Naples, Italy. cirocarusoeye@gmail.com. Pacente, Luigi. Corneal Transplant Center, Pellegrini Hospital, Via Portamedina alla Pignasecca 41, 80135, Naples, Italy. Troiano, Pasquale. Eye Clinic Fatebenefratelli Hospital, Via Fatebenefratelli n. 20, 22036, Como, Italy. Ostacolo, Carmine. Department of Pharmaceutical Chemistry, University of Naples Federico II, Naples, Italy. D'Andrea, Luca. Eye Clinic, University of Naples Federico II, Via Sergio Pansini, 5, 80131, Naples, Italy. Bartollino, Silvia. Department of Medicine and Health Sciences "V. Tiberio", Universita Del Molise, Via Cesare Gazzani, 86100, Campobasso, Italy. Costagliola, Ciro. Department of Medicine and Health Sciences "V. Tiberio", Universita Del Molise, Via Cesare Gazzani, 86100, Campobasso, Italy. SN - 1573-2630 0165-5701 SP - 823-831 ST - Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients T2 - International ophthalmology TI - Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31792856 VL - 40 Y2 - 20191203// ID - 225 ER - TY - JOUR AB - BACKGROUND: There is a lack of published information on the causes of blindness in Ecuador and the Latin American region in general. This study is designed to enumerate the proportions of ocular conditions contributing to blindness in an outpatient population of an ophthalmology hospital in the coastal region of Ecuador., METHODS: All cases presenting to an ophthalmology outpatient clinic over a 3-week period during September 2004 were reviewed (n = 802). Visual acuity was measured using a Snellen acuity chart and those who met the criteria for blindness were included in the study (n = 118). Blindness was defined under the World Health Organization protocol as visual acuity of <3/60. Both unilateral and bilateral blindness were included in the study. The diagnosis of ocular pathology contributing to blindness was recorded., RESULTS: Among those considered to have unilateral blindness (n = 88), cataract was the most common cause (43%). This was followed by corneal pathologies (17%) and glaucoma (15%). Among those considered to have bilateral blindness (n = 30), refraction was the most common cause (37%), followed by cataract (23%) and glaucoma (17%)., CONCLUSION: The major causes of blindness found in this study reflected those in estimated data for the region. More studies are needed to improve the quality and quantity of epidemiological data on blindness in Ecuador and Latin America. Many obstacles to successful implementation of prevention of blindness programmes in South America still need to be overcome. AU - Cass, Helene AU - Landers, John AU - Benitez, Paul IS - 2 KW - Adolescent Adult Age Distribution Aged Aged, 80 and over *Blindness/ep [Epidemiology] Blindness/et [Etiology] Cataract/co [Complications] Cataract/ep [Epidemiology] Child Ecuador/ep [Epidemiology] Female Glaucoma/co [Complications] Glaucoma/ep [Epidemiology] Humans Male Middle Aged Ophthalmology/sn [Statistics & Numerical Data] *Outpatient Clinics, Hospital/sn [Statistics & Numerical Data] Refractive Errors/co [Complications] Refractive Errors/ep [Epidemiology] Sex Distribution Visual Acuity PY - 2006 SE - Cass, Helene. Hospital Centro Cristiano de Servicios Medicos, Milagro, Ecuador. hgc77@yahoo.com SN - 1442-6404 SP - 146-51 ST - Causes of blindness among hospital outpatients in Ecuador T2 - Clinical & experimental ophthalmology TI - Causes of blindness among hospital outpatients in Ecuador UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16626429 VL - 34 ID - 1668 ER - TY - JOUR AB - AIMS: To determine the visual outcome and complications of lens aspiration with intraocular lens implantation in children aged 5 years and under., METHODS: The hospital notes of all children aged 5 years and under, who had undergone lens aspiration with intraocular lens implantation between January 1994 and September 1998, and for whom follow up data of at least 1 year were available, were reviewed., RESULTS: Of 50 children who underwent surgery, 45 were eligible based on the follow up criteria. 34 children had bilateral cataracts and, of these, 30 had surgery on both eyes. Cataract was unilateral in 11 cases; thus, 75 eyes of 45 children had surgery. Cataracts were congenital in 28 cases, juvenile in 16, and traumatic in one case. The median age at surgery was 39 months (range 11-70 months). Follow up ranged from 12-64 months (median 36 months). Of 34 children with bilateral disease, 25 (73.5%) had a final best corrected visual acuity of 6/12 or better, while seven (20.5%) achieved 6/18 or less; in one child the vision improved from UCUSUM to CSM but another, who had only one eye operated on, was unable to fix or follow with this eye preoperatively or 2 years postoperatively. Of 11 children with unilateral cataract, five (45.5%) had a final best corrected visual of 6/12 or better, and six (54.5%) 6/18 or less. A mild fibrinous uveitis occurred in 20 (28.2%) eyes in the immediate postoperative period, but resolved with topical steroids. One child had a vitreous wick postoperatively requiring surgical division. Glaucoma, endophthalmitis, or retinal detachment have not been observed so far in any patient postoperatively., CONCLUSION: From this series the authors suggest that, in children aged 5 years and under, lens aspiration with intraocular lens implantation is a safe procedure, with a good visual outcome in the short term. Further studies are needed to investigate these outcomes in the long term. AU - Cassidy, L. AU - Rahi, J. AU - Nischal, K. AU - Russell-Eggitt, I. AU - Taylor, D. IS - 5 KW - Anti-Inflammatory Agents/tu [Therapeutic Use] Cataract/et [Etiology] *Cataract Extraction/mt [Methods] Child, Preschool Dexamethasone/tu [Therapeutic Use] Female Fixation, Ocular/ph [Physiology] Humans Infant *Lens Implantation, Intraocular/mt [Methods] Male Patient Compliance *Postoperative Complications/th [Therapy] Retrospective Studies Treatment Outcome Visual Acuity PY - 2001 SE - Cassidy, L. Department of Ophthalmology, Great Ormond Street Hospital for Children, Great Ormond Street, London. SN - 0007-1161 SP - 540-2 ST - Outcome of lens aspiration and intraocular lens implantation in children aged 5 years and under T2 - The British journal of ophthalmology TI - Outcome of lens aspiration and intraocular lens implantation in children aged 5 years and under UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11316711 VL - 85 ID - 1921 ER - TY - JOUR AB - This cross-sectional population-based study investigated the prevalence of eye care services utilization and the association with socioeconomic and demographic factors, need for health care, and type of service payment. The study evaluated 2,960 adults aged 20 and older. In the previous 5 years, 46% of the sample and 30% of those aged 50 and older had not visited an eye care service. Among the persons who used a service, 18% went to an optical store and only 17% used the public health system. The main reason for using eye care services was poor vision (69.5%). Lack of money (29%) and time (24.6%) were the most frequently cited reasons for non-utilization. Age, education, and economic status were directly associated with the outcome. Female gender, cataract, glaucoma, prescription eyewear, and private appointments were also associated with the outcome. It is necessary to increase the public health system's role, integrating ocular health with all levels of health care, expanding participation by other health professionals, and intensifying screening and prevention of eye problems. AU - Castagno, Victor Delpizzo AU - Fassa, Anaclaudia Gastal AU - da Silva, Marcelo Cozzensa AU - Carret, Maria Laura Vidal IS - 10 KW - Adult Age Factors Aged Brazil Cross-Sectional Studies Eye Diseases/di [Diagnosis] Eye Diseases/th [Therapy] *Eye Diseases Female *Health Services Accessibility/sn [Statistics & Numerical Data] *Health Services Research Humans Income Male Middle Aged *Primary Health Care/sn [Statistics & Numerical Data] Sex Factors Young Adult PY - 2009 SE - Castagno, Victor Delpizzo. Universidade Federal de Pelotas, Pelotas, Brasil. vicastagno@viacabo.com.br SN - 1678-4464 0102-311X SP - 2260-72 ST - [Shortage of ocular health care in the public system: a population-based study] T2 - Carencia de atencao a saude ocular no setor publico: um estudo de base populacional. TI - [Shortage of ocular health care in the public system: a population-based study] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19851625 VL - 25 ID - 1415 ER - TY - JOUR AB - PURPOSE: To evaluate compliance with diagnostic and therapeutic recommendations of the European Glaucoma Society (EGS) for the management of glaucoma in Spain, as determined using the Achievable Benchmarks of Care approach., METHODS: A panel of 3 experts extracted quality and process-of-care indicators from the EGS guidelines. Investigators from all over the country, representative of Spanish ophthalmologists, were invited to participate in the study, completing a questionnaire on quality indicators (pertaining to the center) and process-of-care indicators (pertaining to all patients) for the first, diagnostic visit (retrospective) and the study visit., RESULTS: A total of 495 Spanish ophthalmologists included 5,060 patients with glaucoma or intraocular hypertension. The treatment was initiated with monotherapy in 88.5% of the patients. Overall, the percentage compliance with diagnostic examinations was 84.6% for intraocular pressure measurement, 96.3% for optic nerve head evaluation, 76.6% for visual field evaluation, 29.5% for central corneal thickness evaluation, and 49.3% at the study visit. The benchmark performance was close to 100% for most examinations. Only 32.8% of the centres had a written protocol for the management of the patients with glaucoma, and in these centers the recommendations of the EGS were followed in a higher proportion (p<0.0001) than in the rest., CONCLUSIONS: The use of local protocols for the management of glaucoma seems to enhance compliance. Benchmark performance was close to 100% in most indicators, suggesting that EGS recommendations are attainable in Spain. The overall performance suggests that certain diagnostic procedures are, in practice, not as widely used as recommended. AU - Castejon-Cervero, Miguel A. AU - Jimenez-Parras, Rafael AU - Fernandez-Arias, Isabel AU - Teus-Guezala, Miguel A. AU - Group, Imca Study IS - 2 KW - Aged *Benchmarking/mt [Methods] Cross-Sectional Studies European Union Female Glaucoma, Open-Angle/di [Diagnosis] Glaucoma, Open-Angle/th [Therapy] *Glaucoma, Open-Angle *Guideline Adherence Humans Intraocular Pressure Male Middle Aged Ocular Hypertension/di [Diagnosis] Ocular Hypertension/th [Therapy] *Practice Guidelines as Topic *Quality Indicators, Health Care Societies, Medical Spain Surveys and Questionnaires Tonometry, Ocular PY - 2011 SE - Castejon-Cervero, Miguel A. Ophthalmology Department, University Hospital Principe de Asturias, Alcala de Henares, Madrid, Spain. SN - 1724-6016 1120-6721 SP - 149-55 ST - Evaluation of compliance with the EGS guidelines in Spain, using Achievable Benchmarks of Care (ABC R) methodology: the IMCA Study T2 - European journal of ophthalmology TI - Evaluation of compliance with the EGS guidelines in Spain, using Achievable Benchmarks of Care (ABC R) methodology: the IMCA Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21058273 VL - 21 ID - 1304 ER - TY - JOUR AB - INTRODUCTION: The treatment of glaucoma is made initially with the use of eyedrops, with the purpose to decrease intraocular pressure and to minimize the damages to the optic nerve. The lack of compliance with drug therapy can be influenced by factors related to patients, doctors and medicines., PURPOSES: To estimate the rate of noncompliance with the treatment with antiglaucoma eyedrops and to verify the intervenience of possible factors for noncompliance., METHODS: A study of the transversal type was carried out, in the Ophthalmologic Clinic of the Hospital Governador Israel Pinheiro, in Belo Horizonte, Minas Gerais. Questionnaires were applied to 102 glaucoma patients to collect information about the level of noncompliance and the intervenience of possible factors for noncompliance with drug therapy., RESULTS: The rate of noncompliance was 21.5%. The factors: not using the eyedrops due to money shortage (p=0.035) and accomplishment of corrective surgery (p=0.049), significantly contributed to noncompliance., CONCLUSION: More than one fifth of the glaucoma patients does not follow the drug treatment in an adequate way. Donation of eyedrops to all the glaucoma patients without favorable economic conditions, governmental actions for the reduction of the prices of the eyedrops, information on the continuity of the use of the eyedrops after the accomplishment of corrective surgeries would help to decrease the rates of noncompliance. AU - Castro, Aldemar Nemesio Brandao Vilela de AU - Mesquita, Wander Araujo IS - 2 KW - Adult Aged Aged, 80 and over Cross-Sectional Studies Female *Glaucoma/dt [Drug Therapy] Glaucoma/su [Surgery] Humans Male Medication Adherence/px [Psychology] *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ophthalmic Solutions/ae [Adverse Effects] *Ophthalmic Solutions/tu [Therapeutic Use] Risk Factors Socioeconomic Factors Surveys and Questionnaires Timolol/tu [Therapeutic Use] PY - 2008 SE - Castro, Aldemar Nemesio Brandao Vilela de. Clinica Oftalmologica do Hospital Israel Pinheiro, Instituto de Previdencia dos Servidores de Minas Gerais, Belo Horizonte, MG, Brasil. SN - 0004-2749 SP - 207-14 ST - [Noncompliance with drug therapy for glaucoma] T2 - Nao-adesao a terapeutica medicamentosa do glaucoma. TI - [Noncompliance with drug therapy for glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18516420 VL - 71 ID - 1528 ER - TY - JOUR AB - BACKGROUND: Improving adherence to ocular hypertension (OH)/glaucoma therapy is highly likely to prevent or reduce progression of optic nerve damage. The present study used a behaviour change counselling intervention to determine whether education and support was beneficial and cost-effective in improving adherence with glaucoma therapy., METHODS: A randomised controlled trial with a 13-month recruitment and 8-month follow-up period was conducted. Patients with OH/glaucoma attending a glaucoma clinic and starting treatment with travoprost were approached. Participants were randomised into two groups and adherence was measured over 8 months, using an electronic monitoring device (Travalert R dosing aid, TDA). The control group received standard clinical care, and the intervention group received a novel glaucoma education and motivational support package using behaviour change counselling. Cost-effectiveness framework analysis was used to estimate any potential cost benefit of improving adherence., RESULTS: Two hundred and eight patients were recruited (102 intervention, 106 control). No significant difference in mean adherence over the monitoring period was identified with 77.2% (CI, 73.0, 81.4) for the control group and 74.8% (CI, 69.7, 79.9) for the intervention group (p = 0.47). Similarly, there was no significant difference in percentage intraocular pressure reduction; 27.6% (CI, 23.5, 31.7) for the control group and 25.3% (CI, 21.06, 29.54) for the intervention group (p = 0.45). Participants in the intervention group were more satisfied with information about glaucoma medication with a mean score of 14.47/17 (CI, 13.85, 15.0) compared with control group which was 8.51 (CI, 7.72, 9.30). The mean intervention cost per patient was GB10.35 (=80%: adherent; <80%: non-adherent), EAM identified 36.7% as non-adherent and MMAS 12.2%. EAM data were used to classify five types of adherence behaviour including a category representing levels of >=97% maintained by 21% of participants., CONCLUSION: EAM revealed good adherence to glaucoma monotherapy but poor agreement with patient self-reported adherence. An adherence category of persistent and exceptionally high adherence to travoprost over a 2-month period was identified. AU - Cate, H. AU - Bhattacharya, D. AU - Clark, A. AU - Holland, R. AU - Broadway, D. C. DO - https://dx.doi.org/10.1038/eye.2012.294 IS - 4 KW - Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] *Cloprostenol/aa [Analogs & Derivatives] Cloprostenol/tu [Therapeutic Use] Cohort Studies Female *Glaucoma/dt [Drug Therapy] Humans Logistic Models Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Self Report Travoprost PY - 2013 SE - Cate, H. Eye Department, Norfolk and Norwich University Hospital, NHS Foundation Trust, Norwich, UK. heidi.cate@nnuh.nhs.uk SN - 1476-5454 0950-222X SP - 545-53 ST - Patterns of adherence behaviour for patients with glaucoma T2 - Eye (London, England) TI - Patterns of adherence behaviour for patients with glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23328800 VL - 27 Y2 - 20130118// ID - 1005 ER - TY - JOUR AB - BACKGROUND: Understanding the magnitude of non-adherence in pre-marketing clinical trials and clinical practice is essential. However, accurately measuring non-adherence to medication is problematic, and the variety of adherence measures and/or calculation methods has led to highly variable results., PURPOSE: To compare commonly used methods for measuring adherence to eye drop therapy in order to assess which methods achieve the most complete datasets over an 8-month monitoring period, to quantify the magnitude of variance in adherence estimations and to review the different methods used to calculate or interpret adherence data., METHODS: Adherence was measured electronically for 8 months by participants administering eye drops using a Travalert R dosing aid. The mean number of Travalert dosing aid recorded doses administered over the monitoring period was used to calculate a percentage adherence score. In addition, the value of graphically presenting Travalert dosing aid data to classify patterns of adherence behaviour was explored. The validated Morisky Measure of Adherence Scale and questions requesting participants to report the Frequency of Missed Doses were two measures of self-reported adherence calculated for each participant. Finally, medication possession ratio was calculated from expected repeat prescription orders compared with actual repeat prescription orders., RESULTS: For the 208 recruited participants, self-reported adherence was the most reliable method of collecting complete datasets over the 8-month period; 16% of self-reported adherence data were missing compared with 45% of Travalert dosing aid data missing at 8 months. The mean adherence measured over the monitoring period by the Travalert dosing aid was 77%. When adherence measures were dichotomised into adherent and non-adherent groups, the Travalert dosing aid found 54% of participants were adherent, compared to 60% Morisky Measure of Adherence Scale and 57% Frequency of Missed Dose self-report measures. However, there was poor agreement between the Travalert dosing aid measured adherence and self-report measures. Medication possession ratio was not a reliable measure of persistence with medication. Graphical Travalert dosing aid data presentation provided additional information about participant behaviour by indicating that most non-adherence was due to participants taking drug holidays rather than missing occasional doses., CONCLUSION: The analysis provided evidence about the inconsistencies between different monitoring strategies and adherence measures. Furthermore, the analysis highlighted the difficulties in collecting complete data for studies investigating chronic, slowly progressive conditions that require long-term follow-up. Future adherence studies could use multiple methods for quantifying and classifying adherence in parallel, both to maximise precision of adherence estimates and to facilitate comparison between studies. However, the authors are cautious of the effect of using multiple adherence measures on participant behaviour and their potential reactivity effects is an area for future research. Copyright © The Author(s) 2015. AU - Cate, Heidi AU - Bhattacharya, Debi AU - Clark, Allan AU - Holland, Richard AU - Broadway, David C. DO - https://dx.doi.org/10.1177/1740774515592636 IS - 6 KW - Aged Aged, 80 and over Female *Glaucoma/dt [Drug Therapy] Humans Male Medication Adherence/sn [Statistics & Numerical Data] *Medication Adherence Middle Aged *Ophthalmic Solutions/tu [Therapeutic Use] Research Design United Kingdom PY - 2015 SE - Cate, Heidi. Glaucoma Research Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK School of Pharmacy, University of East Anglia, Norwich, UK heidi.cate@nnuh.nhs.uk. Bhattacharya, Debi. School of Pharmacy, University of East Anglia, Norwich, UK. Clark, Allan. Norwich Medical School, University of East Anglia, Norwich, UK. Holland, Richard. Norwich Medical School, University of East Anglia, Norwich, UK. Broadway, David C. Glaucoma Research Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK School of Pharmacy, University of East Anglia, Norwich, UK Norwich Medical School, University of East Anglia, Norwich, UK. SN - 1740-7753 1740-7745 SP - 608-17 ST - A comparison of measures used to describe adherence to glaucoma medication in a randomised controlled trial T2 - Clinical trials (London, England) TI - A comparison of measures used to describe adherence to glaucoma medication in a randomised controlled trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26183437 VL - 12 Y2 - 20150716// ID - 783 ER - TY - JOUR AU - Cate, H. AU - Broadway, D. C. DO - https://dx.doi.org/10.1038/eye.2011.111 IS - 9 KW - *Antihypertensive Agents/ad [Administration & Dosage] *Cloprostenol/aa [Analogs & Derivatives] *Drug Monitoring/is [Instrumentation] Female *Glaucoma/dt [Drug Therapy] Humans Male *Medication Adherence/sn [Statistics & Numerical Data] N1 - Comment on (CON) PY - 2011 SN - 1476-5454 0950-222X SP - 1238-9 ST - Association between intraocular pressure and adherence: is there one? T2 - Eye (London, England) T3 - Comment on: Eye (Lond). 2010 Aug;24(8):1338-43; PMID: 20339390 [https://www.ncbi.nlm.nih.gov/pubmed/20339390] TI - Association between intraocular pressure and adherence: is there one? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21597482 VL - 25 Y2 - 20110520// ID - 1270 ER - TY - JOUR AB - Branhamella catarrhalis was formerly regarded as a common, essentially harmless inhabitant of the pharynx. This misapprehension was caused, in part, by confusion with another pharyngeal resident, Neisseria cinerea. The two organisms can now be differentiated by the positive reactions of B. catarrhalis in tests for nitrate reduction and hydrolysis of tributyrin and DNase. B. catarrhalis is currently recognized as the third most frequent cause of acute otitis media and acute sinusitis in young children. It often causes acute exacerbations of chronic bronchopulmonary disease in older or immunocompromised adults and is incriminated occasionally in meningitis, endocarditis, bacteremia, conjunctivitis, keratitis, and urogenital infections. Virulence-associated factors, such as pili, capsules, outer membrane vesicles, iron acquisition proteins, histamine-synthesizing ability, resistance to the bactericidal action of normal human serum, and binding to the C1q complement component, have been identified in some strains. beta-Lactamase producing strains, first detected in 1976, have risen to approximately 75% worldwide. Thus far, however, practically all American strains of B. catarrhalis remain susceptible to alternative antibiotics. A possible selective advantage of recent isolates is their reportedly heightened tendency for adherence to oropharyngeal cells from patients with chronic bronchopulmonary disease. AU - Catlin, B. W. IS - 4 KW - *Bacterial Infections/mi [Microbiology] Humans Moraxella catarrhalis/cl [Classification] Moraxella catarrhalis/de [Drug Effects] *Moraxella catarrhalis/py [Pathogenicity] Moraxella catarrhalis/ul [Ultrastructure] Virulence PY - 1990 SE - Catlin, B W. Department of Microbiology, Medical College of Wisconsin, Milwaukee 53226. SN - 0893-8512 SP - 293-320 ST - Branhamella catarrhalis: an organism gaining respect as a pathogen T2 - Clinical microbiology reviews TI - Branhamella catarrhalis: an organism gaining respect as a pathogen UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2121328 VL - 3 ID - 2050 ER - TY - JOUR AB - Each year, new glaucoma drug delivery systems are developed. Due to the chronic nature of the disease, it requires the inconvenient daily administration of medications. As a result of their elution from the eye surface and penetration to the bloodstream through undesired permeation routes, the bioavailability of active compounds is low, and systemic side effects occur. Despite numerous publications on glaucoma drug carriers of controlled drug release kinetics, only part of them consider drug permeation routes and, thus, carriers' location, as an important factor affecting drug delivery. In this paper, we try to demonstrate the importance of the delivery proximal to glaucoma drug targets. The targeted delivery can significantly improve drug bioavailability, reduce side effects, and increase patients' compliance compared to both commercial and scientifically developed formulations that can spread over the eye surface or stay in contact with conjunctival sac. We present a selection of glaucoma drug carriers intended to be placed on cornea or injected into the aqueous humor and that have been made by advanced materials using hi-tech forming methods, allowing for effective and convenient sustained antiglaucoma drug delivery. AU - Cegielska, Olga AU - Sajkiewicz, Pawel DO - https://dx.doi.org/10.3390/polym11111742 IS - 11 PY - 2019 SE - Cegielska, Olga. Laboratory of Polymers and Biomaterials, Institute of Fundamental Technological Research Polish Academy of Sciences, Pawinskiego 5b, 02-106 Warsaw, Poland. ocegiels@ippt.pan.pl. Sajkiewicz, Pawel. Laboratory of Polymers and Biomaterials, Institute of Fundamental Technological Research Polish Academy of Sciences, Pawinskiego 5b, 02-106 Warsaw, Poland. psajk@ippt.pan.pl. SN - 2073-4360 ST - Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review T2 - Polymers TI - Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=31652975 VL - 11 Y2 - 20191024// ID - 578 ER - TY - JOUR AB - Diabetic retinopathy (DR), glaucoma, and age-related macular degeneration (ARMD) are major causes of vision loss and blindness. Women have been found to have a higher prevalence of vision loss than men. Early detection and timely treatment by eye-care providers are necessary to delay disease progression and prevent vision loss. To assess the use of professional eye care among women aged > or = 40 years, CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) for 19 U.S. states for the period 2006-2008. This report summarizes the results of that analysis, which indicated that 21% of women with self-reported DR, 12% of women with self-reported glaucoma, and 8% of women with self-reported ARMD did not visit an eye-care provider in the recommended follow-up period. Women who did not have insurance coverage for eye care or who did not receive routine medical check-ups were more likely to report not having the recommended follow-up eye care. The two most commonly cited reasons for not having an eye-care visit were cost or not having insurance (range across diseases: 40%-46%) and having no reason to go for follow-up (range: 20%-29%). Compliance with obtaining eye examinations at recommended intervals among women aged > or = 40 years with eye diseases might be enhanced by improving access to health care and implementing and expanding existing educational programs to raise awareness regarding the importance of routine follow-up eye examinations. AU - Centers for Disease, Control AU - Prevention IS - 19 KW - Adult Aged Behavioral Risk Factor Surveillance System *Diabetic Retinopathy/di [Diagnosis] Female *Glaucoma/di [Diagnosis] *Health Services/sn [Statistics & Numerical Data] Health Services Accessibility Humans Insurance Coverage *Macular Degeneration/di [Diagnosis] Medically Uninsured Middle Aged Patient Compliance United States *Vision Screening/sn [Statistics & Numerical Data] N1 - (CDC) PY - 2010 SN - 1545-861X 0149-2195 SP - 588-91 ST - Eye-care utilization among women aged > or =40 years with eye diseases--19 states, 2006-2008 T2 - MMWR. Morbidity and mortality weekly report TI - Eye-care utilization among women aged > or =40 years with eye diseases--19 states, 2006-2008 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20489682 VL - 59 ID - 1354 ER - TY - JOUR AB - Aim: The aim of this study was to evaluate the efficacy and safety of preservative-free (PF) tafluprost compared with PF timolol in Indian subjects with open-angle glaucoma (OAG) or ocular hypertension. Methods: This was a randomised, multicentre, double-masked, phase III trial. Subjects aged 18–80 years, following washout of current medication, with intraocular pressure (IOP) ≥ 24 and ≤ 36 mmHg in at least one eye were randomised in a 1:1 ratio to 0.0015% PF tafluprost or 0.5% PF timolol for 4 weeks. IOP was measured at 08:00, 10:00 and 16:00 hours at baseline and at weeks 2 and 4. The primary efficacy end-point was the mean diurnal IOP change from baseline at week 4, and PF tafluprost was considered non-inferior to PF timolol if the upper bound of the 95% confidence interval (CI) for between-treatment differences was ≤ 1.5 mmHg. The secondary end-point was the proportion of subjects with ≥ 25% reduction in IOP from baseline at week 4. Results: In total, 190 subjects were randomised, 95 each, to PF tafluprost and PF timolol treatment. PF tafluprost was non-inferior to PF timolol with respect to diurnal IOP changes from baseline over 4 weeks. The mean PF tafluprost-PF timolol difference in the diurnal IOP change was −1.7 (95% CI −2.6 to −0.7), suggestive of superiority for PF tafluprost. The secondary end-point was achieved in a higher proportion of PF tafluprost group subjects. Both PF tafluprost and PF timolol were well-tolerated with similar incidences of adverse events. Conclusions: PF tafluprost was safe and efficacious in reducing IOP in Indian subjects. AD - W.J. Herring, Merck & Co., Inc., Kenilworth, NJ, United States AU - Chabi, A. AU - Baranak, C. AU - Lupinacci, R. AU - Herring, W. J. DB - Embase Medline DO - 10.1111/ijcp.12815 IS - 7 KW - NCT01254604 drug preservative tafluprost timolol adult aged article circadian rhythm conjunctival hyperemia controlled study double blind procedure drug efficacy drug safety drug withdrawal eye irritation eye pain female human India intraocular hypertension intraocular pressure major clinical study male ocular pruritus open angle glaucoma patient compliance phase 3 clinical trial priority journal randomized controlled trial LA - English M3 - Article N1 - L611156063 2016-07-14 2016-07-19 PY - 2016 SN - 1742-1241 1368-5031 SP - 577-586 ST - Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial T2 - International Journal of Clinical Practice TI - Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611156063&from=export http://dx.doi.org/10.1111/ijcp.12815 VL - 70 ID - 2730 ER - TY - JOUR AB - Purpose: To compare the efficacy and safety of tafluprost, a preservative-free (PF) prostaglandin analogue, with PF timolol in patients with open-angle glaucoma or ocular hypertension. Design: Randomized, double-masked, multicenter clinical trial. Methods: After discontinuation and washout of existing ocular hypotensive treatment, patients who had intraocular pressure (IOP) <23 and ≤36 mm Hg in at least 1 eye at the 08:00 hour time point were randomized 1:1 to 12 weeks of treatment with either PF tafluprost 0.0015% or PF timolol 0.5%. IOP was measured 3 times during the day (08:00, 10:00, 16:00 hours) at baseline and at weeks 2, 6, and 12. It was hypothesized that PF tafluprost would be noninferior to PF timolol over 12 weeks with regard to change from baseline IOP. The trial was powered for a noninferiority margin of 1.5 mm Hg at each of the 9 time points assessed. Results: A total of 643 patients were randomized and 618 completed (PF tafluprost = 306, PF timolol = 312). IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group. IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol. At all 9 time points, the upper limits of the 2-sided 95% confidence intervals for the difference between treatments in IOP lowering were less than the prespecified noninferiority margin. Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%). The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P =.016). Conclusions: The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol. PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent. © 2012 Elsevier Inc. All rights reserved. AD - A. Chabi, Merck Sharp and Dohme Corp, PO Box 1000, North Wales, PA 19454-1099, United States AU - Chabi, A. AU - Varma, R. AU - Tsai, J. C. AU - Lupinacci, R. AU - Pigeon, J. AU - Baranak, C. AU - Noble, L. AU - Lines, C. AU - Ho, T. W. DB - Embase Medline DO - 10.1016/j.ajo.2011.11.008 IS - 6 KW - NCT01026831 bimatoprost brinzolamide dorzolamide latanoprost tafluprost timolol travoprost adult article blurred vision colitis conjunctival hyperemia controlled study dizziness double blind procedure drug effect drug efficacy drug fatality drug safety evening dosage eye irritation eye pain female fracture headache atrial fibrillation heart infarction hernia human intraocular hypertension intraocular pressure joint dislocation keratitis lung embolism major clinical study male morning dosage multicenter study ocular pruritus open angle glaucoma patient compliance photophobia priority journal retina detachment tendon rupture treatment duration visual acuity LA - English M3 - Article N1 - L51845303 2012-02-21 2012-06-04 PY - 2012 SN - 0002-9394 1879-1891 SP - 1187-1196 ST - Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension T2 - American Journal of Ophthalmology TI - Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51845303&from=export http://dx.doi.org/10.1016/j.ajo.2011.11.008 VL - 153 ID - 3082 ER - TY - JOUR AB - Glaucoma is a common eye condition that affects millions of individuals worldwide, making it the second-leading cause of blindness. Because glaucoma is associated with increased IOP level, the primary goal in treatment of glaucoma includes lowering IOP to prevent further progression of the disease. While various surgical interventions exist, medical therapy is currently the first line of treatment. Medical treatment of glaucoma includes topical beta-blockers, alpha-2 agonists, prostaglandins, parasympathomimetics and CAIs. Anti-glaucoma agents help reduce IOP by affecting the production of aqueous humor or increasing the outflow of aqueous through the trabecular or uveoscleral pathway. Choosing an appropriate medical regimen can be challenging and various factors such as efficacy, safety, cost and patient compliance must be considered. First-line treatment is often topical beta-blockers or prostaglandin analogs. However, beta-blocking agents can be associated with systemic side effects and need to be used cautiously in patients with serious concomitant cardiopulmonary disease. Alpha-2 agonists and parasympathomimetics are often considered second- or third-line treatment options but good adjunctive agents. Oral CAIs are often indicated for patients with elevated IOP in an acute setting or for patients resistant to other glaucoma medications and patients who are not good surgical candidates. AU - Chae, Bora AU - Cakiner-Egilmez, Tulay AU - Desai, Manishi IS - 1 KW - *Antihypertensive Agents/tu [Therapeutic Use] Blindness/et [Etiology] *Blindness/pc [Prevention & Control] Glaucoma/co [Complications] *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Humans Intraocular Pressure *Parasympathomimetics/tu [Therapeutic Use] PY - 2013 SE - Chae, Bora. Boston University School of Medicine, Boston, MA, USA. SN - 1060-135X SP - 5-10 ST - Glaucoma medications T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Glaucoma medications UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23505792 VL - 38 ID - 982 ER - TY - JOUR AB - Glaucoma is the leading cause of irreversible blindness. Current treatments use drugs or surgery to reduce intraocular pressure (IOP). In this study, a drug-free, nonsurgical method is developed that lowers IOP for 4 months without requiring daily patient adherence. The approach involves expanding the suprachoroidal space (SCS) of the eye with an in situ-forming hydrogel injected using a microneedle. This study tests the hypothesis that SCS expansion increases the drainage of aqueous humor from the eye via the unconventional pathway, which thereby lowers IOP. SCS injection of a commercial hyaluronic acid (HA) hydrogel reduces the IOP of normotensive rabbits for more than 1 month and an optimized HA hydrogel formulation enables IOP reduction for 4 months. Safety assessment by clinical ophthalmic examinations indicate the treatment is well tolerated. Histopathology shows minor hemorrhage and fibrosis at the site of injection. Further analysis by ultrasound biomicroscopy demonstrates a strong correlation of IOP reduction with SCS expansion. Outflow facility measurements show no difference in pressure-dependent outflow by the conventional pathway between treated and untreated eyes, supporting the hypothesis. In conclusion, SCS expansion with an in situ-forming hydrogel can enable extended IOP reduction for treating ocular hypertension and glaucoma without drugs or surgery. Copyright © 2020 The Authors. Published by Wiley-VCH GmbH. AU - Chae, J. Jeremy AU - Jung, Jae Hwan AU - Zhu, Wei AU - Gerberich, Brandon G. AU - Bahrani Fard, Mohammad Reza AU - Grossniklaus, Hans E. AU - Ethier, C. Ross AU - Prausnitz, Mark R. DO - https://dx.doi.org/10.1002/advs.202001908 IS - 2 PY - 2021 SE - Chae, J Jeremy. School of Chemical and Biomolecular Engineering Georgia Institute of Technology Atlanta GA 30332 USA. Jung, Jae Hwan. School of Chemical and Biomolecular Engineering Georgia Institute of Technology Atlanta GA 30332 USA. Jung, Jae Hwan. Department of Pharmaceutical Engineering Dankook University Cheonan 16890 South Korea. Zhu, Wei. Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA. Zhu, Wei. Department of Pharmacology School of Pharmacy Qingdao University Qingdao 266021 China. Gerberich, Brandon G. Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA. Bahrani Fard, Mohammad Reza. George W. Woodruff School of Mechanical Engineering Georgia Institute of Technology Atlanta GA 30332 USA. Grossniklaus, Hans E. Department of Ophthalmology Emory University School of Medicine Atlanta GA 30322 USA. Ethier, C Ross. Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA. Ethier, C Ross. George W. Woodruff School of Mechanical Engineering Georgia Institute of Technology Atlanta GA 30332 USA. Prausnitz, Mark R. School of Chemical and Biomolecular Engineering Georgia Institute of Technology Atlanta GA 30332 USA. Prausnitz, Mark R. Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA. SN - 2198-3844 SP - 2001908 ST - Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel T2 - Advanced science (Weinheim, Baden-Wurttemberg, Germany) TI - Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33511001 VL - 8 Y2 - 20201207// ID - 110 ER - TY - JOUR AD - Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia Newcastle University, Newcastle-upon-Tyne, United Kingdom AU - Chakrabarti, R. AU - George, G. AU - Wells, K. AU - Crock, C. DB - Scopus DO - 10.5694/mja2.50554 IS - 5 KW - Emergency treatment Guidelines as topic Herpesviridae infections Ophthalmology M3 - Letter N1 - Export Date: 19 July 2021 PY - 2020 SP - 226-227 ST - Characteristics, treatment and complications of herpes zoster ophthalmicus at a tertiary eye hospital T2 - Medical Journal of Australia TI - Characteristics, treatment and complications of herpes zoster ophthalmicus at a tertiary eye hospital UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082038557&doi=10.5694%2fmja2.50554&partnerID=40&md5=8c247343f84e100e0f82a7020ad68d42 VL - 213 ID - 5692 ER - TY - JOUR AB - OBJECTIVES: In an attempt to increase the efficiency of their drug benefit policies, insurers are increasingly excluding drugs from their formularies that they deem to be of low value. Our objective was to identify and review empirical evaluations of drug exclusion policies and examine how they affected patients and healthcare costs. STUDY DESIGN: Literature review. METHODS: We performed a literature search to identify empirical studies that evaluated drug exclusion policies. We reviewed each study to determine how the policy impacted patients (ie, if disease control or frequency, or severity of symptoms, were affected) and if healthcare costs (eg, drug expenditures and costs associated with physician office visits, hospitalizations, laboratory tests) changed. RESULTS: We included 26 studies pertaining to 27 drug exclusion policies. Twenty studies reported the impact of 21 drug exclusion policies on patients: 6 (28.6%) policies were reported to have had a positive impact, 6 (28.6%) to have had a negative impact, and 9 (42.8%) to not have impacted patients. Eighteen studies reported the impact of 19 drug exclusion policies on overall healthcare costs: 14 (73.7%) policies were reported to have reduced costs, 1 (5.3%) to have had a neutral impact on costs, and 4 (21.1%) to have increased costs. CONCLUSIONS: Although there were important exceptions, most studies found that drug exclusion policies reduced costs and did not negatively impact patients. AD - J.D. Chambers, Institute for Clinical Research and Health Policy Studies, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Tufts University School of Medicine, 800 Washington St, 63, Boston, MA, United States AU - Chambers, J. D. AU - Rane, P. B. AU - Neumann, P. J. DB - Embase IS - 8 KW - antiglaucoma agent antihypertensive agent prescription drug proton pump inhibitor rabeprazole allergic rhinitis ambulatory care diabetes mellitus disease control disease severity drug cost drug formulary drug legislation gastroesophageal reflux glaucoma health care cost health service hospitalization cost human hyperlipidemia hypertension laboratory test medical service priority journal psychosis review LA - English M3 - Review N1 - L611857813 2016-09-01 2016-09-06 PY - 2016 SN - 1088-0224 SP - 524-531 ST - The impact of formulary drug exclusion policies on patients and healthcare costs T2 - American Journal of Managed Care TI - The impact of formulary drug exclusion policies on patients and healthcare costs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611857813&from=export VL - 22 ID - 2720 ER - TY - JOUR AB - PURPOSE: To describe the technique and present the outcomes of combined conjunctival limbal autografts (CLAU) and keratolimbal allografts (KLAL) for the treatment of unilateral severe ocular surface failure., METHODS: Interventional case series. Eleven eyes of 11 patients who sustained chemical burns (4 alkali and 2 acid) and combined chemical/thermal burns (5 eyes) from firework explosions had combined CLAU/KLAL surgery. Keratoplasty was performed subsequently for residual corneal stromal scarring limiting visual acuity. Inclusion criteria included eyes with severe unilateral total ocular surface failure, controlled glaucoma, and reasonable eyelid apposition with no exposure. Exclusion criteria included patients with any ocular surface abnormality in the fellow eye and those with contraindications to systemic immunosuppression (SI). Outcome measures included Snellen best-corrected visual acuity (BCVA), ocular surface stability, SI exposure, and complications., RESULTS: Preoperative BCVA was 20/400 or worse in all eyes. At the final follow-up (mean, 35.8 months; range, 12.1-105.9 months), 73% (8 of 11) eyes had BCVA of 20/80 or better (range, 20/25 to counting fingers), and ocular surface was stable in 82% (9 of 11). Ninety-one percent (10 of 11) had additional penetrating keratoplasty (PK) with a 60% (6 of 10 eyes) success rate. Three cases had subsequent Boston type 1 keratoprosthesis implantation after PK failure, and the fourth patient, at the time of his last follow-up visit, did not want further intervention for his edematous PK, which was a result of noncompliance-related corneal rejection. In eyes with more than 2 years of follow-up, SI was tapered at a mean of 16 months (range, 8-28 months). There were no intraoperative complications. No secondary tumors, cardiac events, or deaths occurred while patients were on SI. One patient developed secondary glaucoma refractory to medical management after subsequent PK, requiring cyclodiode laser., CONCLUSIONS: Combined CLAU/KLAL and staged keratoplasty is effective in improving vision and maintaining long-term ocular surface stability in patients with severe unilateral ocular surface disease and conjunctival deficiency. AU - Chan, Clara C. AU - Biber, Joseph M. AU - Holland, Edward J. DO - https://dx.doi.org/10.1097/ICO.0b013e31823f8e95 IS - 11 KW - Adolescent Adult Aged Blast Injuries/pp [Physiopathology] *Blast Injuries/su [Surgery] Burns, Chemical/pp [Physiopathology] *Burns, Chemical/su [Surgery] Combined Modality Therapy *Conjunctiva/tr [Transplantation] Corneal Diseases/pp [Physiopathology] *Corneal Diseases/su [Surgery] Drug Combinations Epithelium, Corneal/cy [Cytology] *Eye Burns/ci [Chemically Induced] Female Glucocorticoids/ad [Administration & Dosage] Humans Immunosuppressive Agents/ad [Administration & Dosage] Keratoplasty, Penetrating *Limbus Corneae/cy [Cytology] Male Middle Aged Prosthesis Implantation *Stem Cell Transplantation Sulfamethizole/ad [Administration & Dosage] Tissue Donors Transplantation, Autologous Transplantation, Homologous Trimethoprim/ad [Administration & Dosage] Visual Acuity/ph [Physiology] Young Adult PY - 2012 SE - Chan, Clara C. Cincinnati Eye Institute, Cincinnati, OH, USA. SN - 1536-4798 0277-3740 SP - 1264-72 ST - The modified Cincinnati procedure: combined conjunctival limbal autografts and keratolimbal allografts for severe unilateral ocular surface failure T2 - Cornea TI - The modified Cincinnati procedure: combined conjunctival limbal autografts and keratolimbal allografts for severe unilateral ocular surface failure UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22406944 VL - 31 ID - 1146 ER - TY - JOUR AB - PURPOSE: We determined the impact of lack of government insured routine eye examinations on the incidence of self-reported glaucoma, cataracts and vision loss., METHODS: We analyzed data from the Canadian longitudinal National Population Health Survey (1994-2011). White respondents aged 65+ in 1994/1995 were included (n = 2618). Three cohorts were established at baseline: those free of glaucoma, cataracts, and vision loss (i.e., unable to see close or distance when wearing glasses or contact lenses). Incident cases were identified through self-reporting of these conditions during the follow-up period., RESULTS: The incidence (per 1000 person-years) of glaucoma was lower in uninsured provinces (8.1; 95% confidence interval [CI], 5.5-10.7) than in insured provinces (12.8; 95% CI, 10.5-15.1). The incidence of cataracts was also lower in the uninsured (67.2; 95% CI, 55.7-78.6) versus insured provinces (75.7; 95% CI, 69.2-82.2). The incidence of vision loss was higher in the uninsured (26.6; 95% CI, 20.2-33.0) versus insured provinces (22.5; 95% CI, 20.0-25.5). Adjusting for confounders, seniors in insured provinces had a 59% increased risk of glaucoma (incidence rate ratio [IRR], 1.59; 95% CI, 1.07-2.37), a 13% greater risk of cataracts (IRR, 1.13; 95% CI, 0.93-1.37), and a 12% reduced risk of vision loss (IRR, 0.88; 95% CI, 0.67-1.16)., CONCLUSIONS: Lack of government-funded routine eye examinations is associated with a reduced incidence of self-reported glaucoma and cataracts, likely due to reduced detection. Lack of insurance also is associated with a higher incidence of self-reported vision loss, likely due to poorer access to eye care and late treatment. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc. AU - Chan, Christina H. AU - Trope, Graham E. AU - Badley, Elizabeth M. AU - Buys, Yvonne M. AU - Jin, Ya-Ping DO - https://dx.doi.org/10.1167/iovs.14-15361 IS - 12 KW - Aged Aged, 80 and over *Blindness/ep [Epidemiology] Canada/ep [Epidemiology] *Cataract/ep [Epidemiology] Cross-Sectional Studies Educational Status Female *Glaucoma/ep [Epidemiology] Government Programs *Health Services Accessibility/sn [Statistics & Numerical Data] Health Surveys Healthcare Disparities/sn [Statistics & Numerical Data] Humans Incidence *Insurance Coverage/sn [Statistics & Numerical Data] Longitudinal Studies Male *National Health Programs Regression Analysis Social Class *Vision Screening PY - 2014 SE - Chan, Christina H. Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada. Trope, Graham E. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. Badley, Elizabeth M. Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. Buys, Yvonne M. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. Jin, Ya-Ping. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. SN - 1552-5783 0146-0404 SP - 8544-9 ST - The impact of lack of government-insured routine eye examinations on the incidence of self-reported glaucoma, cataracts, and vision loss T2 - Investigative ophthalmology & visual science TI - The impact of lack of government-insured routine eye examinations on the incidence of self-reported glaucoma, cataracts, and vision loss UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25491296 VL - 55 Y2 - 20141209// ID - 851 ER - TY - JOUR AB - PURPOSE: To investigate the acceptance and preferences rates of 3 sustained drug delivery systems in glaucoma patients., MATERIALS AND METHODS: A cross-sectional study involving 250 Chinese patients recruited from outpatient glaucoma clinics in Singapore using an interviewer-administered survey. Beliefs toward medicines, eye drops, illness perception, medication adherence, and health literacy were assessed using validated questionnaires. After receiving standard information on the 3 sustained drug delivery systems, that is, subconjunctival, intracameral, and punctal routes; each route's acceptance and attitudes were determined., RESULTS: The subconjunctival (acceptance: 61.6%, n=154), intracameral (acceptance: 57.2%, n=143), and punctal (acceptance: 63.2%, n=158) routes were willing to be accepted by the majority of the interviewed patients. Among those, 78.6%, 79.1%, and 78.5% were willing to pay an equal or higher cost compared with their current eye drops for the subconjunctival, intracameral, and punctal plug routes, respectively. Independent factors associated with the acceptance for subconjunctival, intracameral, and punctal plug routes included: male sex (P=0.007, 0.014, 0.046, respectively), patients not on health care subsidies (P=0.022, 0.002, 0.016, respectively), and bilateral glaucoma disease (P=0.003, 0.013, 0.004, respectively). A total of 120 (48.0%) patients ranked punctal plug placement as the preferred route for sustained drug delivery followed by subconjunctival (n=76, 30.4%) and intracameral (n=54, 21.6%) routes., CONCLUSIONS: Sustained drug delivery for the medical treatment of glaucoma is an acceptable alternative to daily eye drop administration by most Singaporean Chinese individuals in this study. Male patients, nonsubsidized patients, and those with bilateral glaucoma were independently associated with preference of these 3 alternative routes of administration to traditional glaucoma drops. AU - Chan, Hiok Hong AU - Wong, Tina T. AU - Lamoureux, Ecosse AU - Perera, Shamira DO - https://dx.doi.org/10.1097/IJG.0000000000000197 IS - 7 KW - Adult Aged *Anterior Chamber/de [Drug Effects] *Antihypertensive Agents/ad [Administration & Dosage] Asian Continental Ancestry Group Attitude to Health *Conjunctiva/de [Drug Effects] Cross-Sectional Studies Delayed-Action Preparations *Drug Delivery Systems Female *Glaucoma/dt [Drug Therapy] Health Surveys Humans Intraocular Pressure/de [Drug Effects] *Lacrimal Apparatus/de [Drug Effects] Male Medication Adherence Middle Aged Ophthalmic Solutions Patient Acceptance of Health Care *Patient Preference/sn [Statistics & Numerical Data] Singapore Surveys and Questionnaires PY - 2015 SE - Chan, Hiok Hong. *Yong Loo Lin School of Medicine, National University of Singapore Singapore National Eye Centre ++Singapore Eye Research Institute Duke-NUS Graduate Medical School, Singapore, Republic of Singapore Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Vic, Australia. SN - 1536-481X 1057-0829 SP - 485-92 ST - A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes T2 - Journal of glaucoma TI - A Survey on the Preference of Sustained Glaucoma Drug Delivery Systems by Singaporean Chinese Patients: A Comparison Between Subconjunctival, Intracameral, and Punctal Plug Routes UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25580892 VL - 24 ID - 820 ER - TY - JOUR AD - H.H.L. Chan, Department of Ophthalmology, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia AU - Chan, H. H. L. AU - Brooks, A. M. V. DB - Embase Medline DO - 10.1111/ceo.13608 IS - 7 KW - glaucoma drainage implant nonvalved ophthalmic drainage device cataract extraction cost effectiveness analysis device safety editorial filtering operation glaucoma human hyphema intraocular pressure meta analysis (topic) patient compliance patient selection phacoemulsification quality of life stent complication stent malapposition Hydrus microstent iStent iStent inject LA - English M3 - Editorial N1 - L2003348308 2019-10-25 2019-11-04 PY - 2019 SN - 1442-9071 1442-6404 SP - 835-836 ST - What is the role of iStent in glaucoma management in 2019? T2 - Clinical and Experimental Ophthalmology TI - What is the role of iStent in glaucoma management in 2019? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003348308&from=export http://dx.doi.org/10.1111/ceo.13608 VL - 47 ID - 2482 ER - TY - JOUR AB - PURPOSE: Successful management of glaucoma and ocular hypertension requires patient compliance with the therapeutic regimen. Because ocular discomfort affects compliance, we compared the comfort of brimonidine 0.2%/timolol 0.5% and dorzolamide 2%/timolol 0.5%., METHODS: In this single-centre, randomized, double-masked, internally controlled/paired-eye study, 30 subjects without a significant ocular surface disease received brimonidine 0.2%/timolol 0.5% in 1 eye and dorzolamide 2%/timolol 0.5% in the fellow eye. They evaluated discomfort at 30-40 s and 5 min postinstillation., RESULTS: At 30-40 s, brimonidine 0.2%/timolol 0.5% provided significantly lower mean ocular discomfort scores than dorzolamide 2%/timolol 0.5% (P < 0.0001). This pattern persisted at 5 min but was not statistically significant. Significant differences were seen in the subjects' determination of the more comfortable treatment (P < 0.0001): brimonidine 0.2%/timolol 0.5% was rated as more comfortable than dorzolamide 2%/timolol 0.5% by 80% of subjects at 30-40 s and by 27% at 5 min. Only 10% of subjects at each time point rated dorzolamide 2%/timolol 0.5% as more comfortable. The remaining subjects reported no preference at either time point. No adverse events were reported., CONCLUSIONS: Brimonidine 0.2%/timolol 0.5% was significantly more comfortable than dorzolamide 2%/timolol 0.5% upon instillation. Patients with ocular hypertension or glaucoma may be more compliant with brimonidine 0.2%/timolol 0.5% treatment. AU - Chan, Kenny AU - Testa, Madalena AU - McCluskey, Peter IS - 4 KW - Administration, Topical Adult Aged *Antihypertensive Agents/ae [Adverse Effects] Brimonidine Tartrate Double-Blind Method Drug Combinations Female Humans Male Middle Aged Ophthalmic Solutions Patient Compliance Patient Satisfaction *Quinoxalines/ae [Adverse Effects] *Sulfonamides/ae [Adverse Effects] *Thiophenes/ae [Adverse Effects] *Timolol/ae [Adverse Effects] PY - 2007 SE - Chan, Kenny. Department of Ophthalmology, Liverpool Hospital, Liverpool, New South Wales, Australia. SN - 1080-7683 SP - 372-6 ST - Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5% T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics TI - Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5% UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17803436 VL - 23 ID - 1578 ER - TY - JOUR AB - BACKGROUND AND AIM: Undiagnosed glaucoma is an invisible but important public health issue. At least half of glaucoma cases are estimated to be undiagnosed in western populations. The aim of this study is to examine risk factors for previously undiagnosed primary open-angle glaucoma (POAG)., DESIGN: Cross-sectional study within the European Prospective Investigation of Cancer-Norfolk Eye Study, a large-scale cohort study in the UK., PARTICIPANTS: 314 study participants with POAG in either eye., METHODS: Logistic regression was used to examine associations with previously undiagnosed POAG compared with previously diagnosed POAG. The factors examined included sociodemographic, ocular, physical and economic factors that could be barriers to eye care access., RESULTS: 217 participants had previously diagnosed POAG and 107 participants were newly diagnosed with POAG during the study. After adjusting for covariables, the factors significantly associated with previously undiagnosed POAG were: a lower pretreatment intraocular pressure (IOP) (OR 0.71/mm Hg, 95% CI 0.63 to 0.80, p<0.0001), and to have reported no problems with their eyesight (OR 0.03, 95% CI 0.01 to 0.10, p<0.0001)., CONCLUSIONS: The risk factors for previously undiagnosed POAG identified in this study highlight the over-reliance on IOP level in glaucoma screening and the risk of missing glaucoma among lower IOP cases. It also suggests a role in improving glaucoma awareness in the community. Copyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. AU - Chan, Michelle P. Y. AU - Khawaja, Anthony P. AU - Broadway, David C. AU - Yip, Jennifer AU - Luben, Robert AU - Hayat, Shabina AU - Peto, Tunde AU - Khaw, Kay-Tee AU - Foster, Paul J. DO - https://dx.doi.org/10.1136/bjophthalmol-2020-317718 PY - 2021 SE - Chan, Michelle P Y. UCL Institute of Ophthalmology, UCL, London, UK michelle.chan@doctors.org.uk. Khawaja, Anthony P. NIHR Moorfields Biomedical Research Centre & UCL Institute of Ophthalmology, London, UK. Khawaja, Anthony P. MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. Broadway, David C. Department Ophthalmology, Norfolk & Norwich University Hospital, Norwich, UK. Yip, Jennifer. Clinical Research Department, International Centre for Evidence on Disability, London, UK. Luben, Robert. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Hayat, Shabina. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Peto, Tunde. Centre for Public Health, Blackwell's Queen's University Belfast, Belfast, UK. Khaw, Kay-Tee. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Foster, Paul J. NIHR Moorfields Biomedical Research Centre & UCL Institute of Ophthalmology, London, UK. SN - 1468-2079 0007-1161 ST - Risk factors for previously undiagnosed primary open-angle glaucoma: the EPIC-Norfolk Eye Study T2 - The British journal of ophthalmology TI - Risk factors for previously undiagnosed primary open-angle glaucoma: the EPIC-Norfolk Eye Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=34172506 Y2 - 20210625// ID - 11 ER - TY - JOUR AB - INTRODUCTION: Glaucoma, the second most common cause of blindness, is normally detected in clinic. With technological improvements, tele-glaucoma exams can identify these changes off-site. The quality of tele-glaucoma exams needs to be compared with that of traditional exams. This study's purpose was to validate the tele-glaucoma programme, which allows a physician comprehensive access to patients' data, by comparing results to clinical examinations., METHODS: A prospective study of 107 subjects evaluated in clinic and then tele-glaucoma stations, which consisted of non-mydriatic fundus photography, puff-tonometry, auto-refraction and Optical Coherence Tomography (OCT). The OCT captured central corneal thickness, angle anatomy, cup-to-disc ratio (CDR), retinal nerve fibre layer distribution and posterior-pole ganglion cell complex data., RESULTS: Intraocular pressure (IOP) comparisons between clinical and tele-glaucoma exams had strong positive Pearson correlation coefficients (0.8248 OD, 0.8672 OS). Strong positive correlations were seen for CDR (0.7835 OD, 0.8082 OS) as well as diagnosis (glaucoma, no glaucoma or glaucoma suspect). A moderate positive correlation was seen for return to clinic time (RTC). Tele-glaucoma had an average lower RTC (2.7 vs 3.9 months). Tele-glaucoma was more likely to elicit a non-glaucomatous diagnosis not found in clinic vs a diagnosis found only in clinic (18% vs 5% of subjects)., DISCUSSION: Tele-glaucoma allows for detecting glaucoma remotely. These advancements alleviate patient difficulties with obtaining adequate glaucoma screenings and helps ophthalmologists triage patients with more severe pathology. Our study indicates that our tele-glaucoma protocol is comparable to a clinical exam in its ability to detect glaucoma. Further studies will be needed for off-site testing and transferring data separately for analysis. AU - Chandrasekaran, Subhashini AU - Kass, William AU - Thangamathesvaran, Loka AU - Mendez, Nicole AU - Khouri, Peter AU - Szirth, Bernard C. AU - Khouri, Albert S. DO - https://dx.doi.org/10.1177/1357633X19845273 IS - 9 KW - Adolescent Adult Aged Aged, 80 and over *Diagnostic Techniques, Ophthalmological Female *Glaucoma/di [Diagnosis] Health Services Accessibility Humans Intraocular Pressure Male Middle Aged New Jersey Photography Prospective Studies Sensitivity and Specificity *Telemedicine/og [Organization & Administration] Waiting Lists Young Adult PY - 2020 SE - Chandrasekaran, Subhashini. Rutgers New Jersey Medical School, Newark, NJ, USA. Kass, William. Rutgers New Jersey Medical School, Newark, NJ, USA. Thangamathesvaran, Loka. Rutgers New Jersey Medical School, Newark, NJ, USA. Mendez, Nicole. Rutgers New Jersey Medical School, Newark, NJ, USA. Khouri, Peter. Rutgers New Jersey Medical School, Newark, NJ, USA. Szirth, Bernard C. Rutgers New Jersey Medical School, Newark, NJ, USA. Khouri, Albert S. Rutgers New Jersey Medical School, Newark, NJ, USA. SN - 1758-1109 1357-633X SP - 536-544 ST - Tele-glaucoma versus clinical evaluation: The New Jersey Health Foundation Prospective Clinical Study T2 - Journal of telemedicine and telecare TI - Tele-glaucoma versus clinical evaluation: The New Jersey Health Foundation Prospective Clinical Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31138016 VL - 26 Y2 - 20190528// ID - 244 ER - TY - JOUR AB - Purpose of Review: We sought to explore the current incidence and associated risk factors associated with fungal eye infections. We also reviewed new diagnostic strategies and recent clinical studies exploring the use of topical and oral antifungal agents. Recent Findings: Incidence and associated risks continue to vary with geographic region, and access to timely healthcare. Nosocomial fungal endophthalmitis can result from minor surgical procedures to the eye. Molecular methods offer increasing diagnostic utility. Clinical treatment studies have mainly focussed on the treatment of fungal keratitis and have been conducted in South Asia. Topical natamycin remains superior to topical reconstituted voriconazole and remains the preferred therapy including for Fusarium eye infections. Neither adjunctive oral ketoconazole nor oral voriconazole has been shown to have added clear benefit to topical treatment. Summary: Larger international studies with more heterogenous populations are required for future clinical studies which should include patients with contact lens fungal keratitis and those with fungal endophthalmitis. Basic science studies exploring the immunology of fungal eye infections and drug levels to understand the differences in clinical outcomes are encouraged. AD - S.C.-A. Chen, Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, New South Wales Health Pathology, Westmead Hospital, 3rd Level, ICPMR Building, Darcy Road, Westmead, NSW, Australia AU - Chang, C. C. AU - Chen, S. C. A. C1 - natacyn vfend DB - Embase DO - 10.1007/s12281-018-0315-z IS - 2 KW - ketoconazole natamycin placebo voriconazole article Aspergillus clinical trial (topic) diagnostic procedure eye surgery fungal endophthalmitis fungal eye infection fusariosis Fusarium geography health care access human keratomycosis morbidity nonhuman randomized controlled trial (topic) risk factor Scedosporium South Asia visual acuity natacyn vfend LA - English M3 - Article N1 - L621375920 2018-03-28 2018-06-05 PY - 2018 SN - 1936-377X 1936-3761 SP - 66-70 ST - Fungal Eye Infections: New Hosts, Novel Emerging Pathogens but No New Treatments? T2 - Current Fungal Infection Reports TI - Fungal Eye Infections: New Hosts, Novel Emerging Pathogens but No New Treatments? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621375920&from=export http://dx.doi.org/10.1007/s12281-018-0315-z VL - 12 ID - 2584 ER - TY - JOUR AB - Purpose: To evaluate the long-term intraocular pressure (IOP)-lowering effect and safety parameters following treatment with two trabecular micro-bypass stents and topical prostaglandin in phakic eyes with open-angle glaucoma (OAG) not controlled on two preoperative medications. Methods: This prospective, single-arm, unmasked study enrolled 39 qualified phakic eyes with OAG not controlled on 2 medications, preoperative medicated IOP of 18-30 mmHg, and IOP following medication washout of 22-38 mmHg. Two trabecular micro-bypass stents were implanted as a standalone procedure, and travoprost was started on postoperative day 1. Evaluations included IOP, best-corrected visual acuity, medication use, fundus and slit-lamp examinations, visual field, cup: disc ratio, central corneal thickness, and ocular complications. Data through 18 months were summarized previously. Thirty-seven of the original 39 subjects have been followed for 3 years postoperatively; follow-up is continuing for 5 years. Results: At 3 years postoperative, 97% of eyes had achieved an IOP reduction of >= 20% from baseline with a reduction of 1 medication. Eighty-six percent of eyes had IOP of <= 18 mmHg with a reduction of 1 medication. Mean medicated IOP decreased to 14.0 +/- 2.6 mmHg on 1 medication versus 22.4 +/- 2.3 mmHg on 2 medications preoperatively. The mean unmedicated IOP decreased to 17.7 +/- 1.7 mmHg at 37 months from 25.3 +/- 1.9 mmHg preoperatively. Longterm postoperative adverse events included cataract surgery in 3 eyes due to cataract progression, and trabeculectomy in 1 eye due to uncontrolled IOP of 23 mmHg. No intraoperative or device-related adverse events occurred. Conclusion: Significant and sustained reduction in IOP and medications with a favorable safety profile was shown through 3 years after implantation of 2 trabecular micro-bypass stents combined with postoperative travoprost in phakic OAG eyes uncontrolled on 2 preoperative medications. These findings demonstrate the long-term performance and safety of trabecular bypass stents in combination with topical prostaglandin for OAG patients. AN - WOS:000396784200001 AU - Chang, D. F. AU - Donnenfeld, E. D. AU - Katz, L. J. AU - Voskanyan, L. AU - Ahmed, I. I. K. AU - Samuelson, T. W. AU - Giamporcaro, J. E. AU - Hornbeak, D. M. AU - Solomon, K. D. DO - 10.2147/OPTH.S121041 PY - 2017 SN - 1177-5483 SP - 523-528 ST - Efficacy of two trabecular micro-bypass stents combined with topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 3-year follow-up T2 - CLINICAL OPHTHALMOLOGY TI - Efficacy of two trabecular micro-bypass stents combined with topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 3-year follow-up VL - 11 ID - 6231 ER - TY - JOUR AB - OBJECTIVE: To develop and validate a predictive model to estimate the probability of being nonadherent to topical glaucoma medications., DESIGN: Prospective cohort study., PARTICIPANTS: Patients being treated with once-daily prostaglandin eye drops., METHODS: A predictive model for nonadherence was developed from the Travatan Dosing Aid (TDA) study (n = 196) using stepwise logistic regression. The performance of the TDA-derived model was assessed using a separate cohort of subjects from the Automated Dosing Reminder Study (ADRS; n = 407). The assessment was based on regression coefficients, discrimination, and calibration. We also developed a scoring system from the TDA-derived model to simplify the estimation of risk for clinical use., MAIN OUTCOME MEASURES: Usage of drops was monitored electronically for 3 months in both studies. Adherence was calculated as the percentage of days on which a dose was taken within 4 hours of the average dosing time for that patient. Nonadherence was defined as taking <= 75% prescribed doses within a window starting 2 weeks after the baseline visit until 2 weeks before the follow-up visit., RESULTS: Six factors, including younger age, black race, worse general health status, shorter duration of glaucoma medication therapy, lower self-reported adherence, and admitting to not following doctors' orders, were associated with being nonadherent and were included in the predictive model. The coefficients for the TDA-derived and the ADRS-derived predictive models were similar. The risk scoring system developed from the TDA study had good discrimination (area under the receiver operating characteristic curve of 0.80) and calibration (Hosmer-Lemeshow goodness-of-fit test, P = 0.102) when applied to the ADRS population., CONCLUSIONS: The TDA-derived predictive model for nonadherence performed well in an independent population. A risk scoring system was developed using demographic data and patient responses to 4 questions to provide an estimate of the probability of being nonadherent. Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AU - Chang, Dolly S. AU - Friedman, David S. AU - Frazier, Travis AU - Plyler, Ryan AU - Boland, Michael V. DO - https://dx.doi.org/10.1016/j.ophtha.2013.01.002 IS - 7 KW - Administration, Topical Aged *Antihypertensive Agents/ad [Administration & Dosage] Cloprostenol/ad [Administration & Dosage] Cloprostenol/aa [Analogs & Derivatives] Cohort Studies Drug Monitoring Female Glaucoma/cl [Classification] *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged *Models, Statistical Ophthalmic Solutions/ad [Administration & Dosage] Probability Prospective Studies ROC Curve Risk Assessment Travoprost PY - 2013 SE - Chang, Dolly S. Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. SN - 1549-4713 0161-6420 SP - 1396-402 ST - Development and validation of a predictive model for nonadherence with once-daily glaucoma medications T2 - Ophthalmology TI - Development and validation of a predictive model for nonadherence with once-daily glaucoma medications UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23541760 VL - 120 Y2 - 20130328// ID - 979 ER - TY - JOUR AB - This study assesses the safety and efficacy of microinvasive glaucoma surgery (MIGS) with cataract extraction in patients with normal-tension glaucoma (NTG). In our sample of 45 NTG patients, mean intraocular pressure (IOP) decreased from 13.7 to 12.3 mmHg at 2.5 years, and mean medication burden decreased from 2.0 to 1.1 at 1.5 years. For success defined as IOP reduction >= 30% from baseline IOP with medication burden reduction from preoperative levels, success probability was 5.4% at 1.5 years. For success defined as medication burden reduction with an IOP reaching goal IOP as determined by the glaucoma specialist, success probabilities were 67.2% at 1.5 years and 29.4% at 2.5 years. At the last follow-up visit, eyes with two MIGS procedures with different mechanisms of action achieved successful medication reduction 68.8% of the time versus 35.7% achieved by a single MIGS procedure (p = 0.052). At their last visit, visual acuity was unchanged or improved in all eyes (100%). MIGS with cataract surgery results in modest reductions in IOP and medication burden in NTG patients, which may lead to lower costs and better therapeutic compliance. A combination of two MIGS procedures with different mechanisms of action may potentially be more effective in reducing medication burden than a single MIGS procedure in NTG patients. Further research is necessary to ascertain whether MIGS for NTG patients may help decrease medication burden while helping achieve goal IOP. AU - Chang, Enchi Kristina AU - Gupta, Sanchay AU - Chachanidze, Marika AU - Hall, Nathan AU - Chang, Ta Chen AU - Sola-Del Valle, David DO - https://dx.doi.org/10.1038/s41598-021-88358-6 IS - 1 PY - 2021 SE - Chang, Enchi Kristina. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Gupta, Sanchay. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Chachanidze, Marika. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Hall, Nathan. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Chang, Ta Chen. Bascom Palmer Eye Institute, Miami, FL, USA. Sola-Del Valle, David. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. david_sola-delvalle@meei.harvard.edu. SN - 2045-2322 SP - 8910 ST - Safety and efficacy of microinvasive glaucoma surgery with cataract extraction in patients with normal-tension glaucoma T2 - Scientific reports TI - Safety and efficacy of microinvasive glaucoma surgery with cataract extraction in patients with normal-tension glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=33903701 VL - 11 Y2 - 20210426// ID - 70 ER - TY - JOUR AB - Background: High-cost users in a period may not incur high-cost utilization in the next period. Consistent high-cost users (CHUs) may be better targets for cost-saving interventions. Objectives: To compare the characteristics of CHUs (patients with plan-specific top 20% medical costs in all 4 half-year periods across 2008 and 2009) and point high-cost users (PHUs) (top users in 2008 alone), and to build claims-based models to identify CHUs. Research Design: This is a retrospective cohort study. Logistic regression was used to predict being CHUs. Independent variables were derived from 2007 claims; 5 models with different sets of independent variables (prior costs, medications, diagnoses, medications and diagnoses, medications and diagnoses and prior costs) were constructed. Subjects: Three-year continuous enrollees aged from 18 to 62 years old from a large administrative database with $100 or more yearly costs (N=1,721,992). Measures: Correlation, overlap, and characteristics of top risk scorers derived from 5 CHUs models were presented. C-statistics, sensitivity, and positive predictive value were calculated. Results: CHUs were characterized by having increasing total and pharmacy costs over 2007-2009, and more baseline chronic and psychosocial conditions than PHUs. Individuals' risk scores derived from CHUs models were moderately correlated (∼0.6). The medication-only model performed better than the diagnosis-only model and the prior-cost model. Conclusions: Five models identified different individuals as potential CHUs. The recurrent medication utilization and a high prevalence of chronic and psychosocial conditions are important in differentiating CHUs from PHUs. For cost-saving interventions with long-term impacts or focusing on medication, CHUs may be better targets. AD - H.-Y. Chang, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, 624 N. Broadway, Baltimore, MD, United States AU - Chang, H. Y. AU - Boyd, C. M. AU - Leff, B. AU - Lemke, K. W. AU - Bodycombe, D. P. AU - Weiner, J. P. DB - Embase Medline DO - 10.1097/MLR.0000000000000566 IS - 9 KW - prescription drug addiction adult age related macular degeneration anxiety disorder article asthma attention deficit disorder billing and claims bipolar depression bipolar disorder chronic disease chronic obstructive lung disease cohort analysis congestive heart failure controlled study diabetes mellitus disorders of lipid metabolism drug cost female glaucoma health care cost health care utilization health insurance human Human immunodeficiency virus infection hypertension hypothyroidism ischemic heart disease kidney failure logistic regression analysis low back pain major clinical study male malignant neoplasm middle aged osteoporosis Parkinson disease personality disorder prediction predictive value prescription prevalence priority journal problem behavior psychosocial disorder retrospective study rheumatoid arthritis schizophrenia seizure sensitivity and specificity social problem substance use tobacco consumption LA - English M3 - Article N1 - L610941017 2016-06-30 2016-09-02 PY - 2016 SN - 1537-1948 0025-7079 SP - 852-859 ST - Identifying Consistent High-cost Users in a Health Plan: Comparison of Alternative Prediction Models T2 - Medical Care TI - Identifying Consistent High-cost Users in a Health Plan: Comparison of Alternative Prediction Models UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610941017&from=export http://dx.doi.org/10.1097/MLR.0000000000000566 VL - 54 ID - 2706 ER - TY - JOUR AB - A multi-site, open-labeled clinical trial was conducted to evaluate the ease of use and acceptance of a newly developed medication cap with a memory aid (C Cap Compliance Cap, Allergan, Inc.) and its effect on patient compliance and intraocular pressure. One-hundred-twenty-two patients with glaucoma or ocular hypertension received their prescribed eye drops in bottles with the compliance cap. Overall, 83% of the patients found the compliance cap very easy to use. By the end of the study, significantly more patients (67%) claimed 100% compliance than prior to using the compliance cap (41%). An overall drop in intraocular pressure of 0.8 mm Hg was seen. However, in a subset of patients who reported an increase in compliance, mean intraocular pressure decreased from baseline by 1.7 mm Hg. The results of this study suggest that the compliance cap helps patients with glaucoma or ocular hypertension remember to take their medication as prescribed. AU - Chang, J. S., Jr. AU - Lee, D. A. AU - Petursson, G. AU - Spaeth, G. AU - Zimmerman, T. J. AU - Hoskins, H. D. AU - Mills, R. AU - Brown, R. AU - Kass, M. AU - Lue, J. IS - 2 KW - Adolescent Adult Aged Aged, 80 and over Drug Labeling/mt [Methods] Epinephrine/ad [Administration & Dosage] Epinephrine/aa [Analogs & Derivatives] Female *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] *Patient Compliance Patient Satisfaction Pilocarpine/ad [Administration & Dosage] Prospective Studies *Reminder Systems Surveys and Questionnaires PY - 1991 SE - Chang, J S Jr. Jules Stein Eye Institute, UCLA School of Medicine. SN - 8756-3320 SP - 117-24 ST - The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure T2 - Journal of ocular pharmacology TI - The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1919269 VL - 7 ID - 2127 ER - TY - JOUR AB - BACKGROUND: To investigate the risk factors and probability of blindness in patients treated for glaucoma., METHODS: The study design was a retrospective, hospital-based, clinical chart, review study. Medical records were reviewed from patients seen between January 2003 and December 2003 at the Kaohsiung Chang Gung Memorial Hospital eye clinic, who had been diagnosed with glaucoma in 1986 or later and who had been treated for at least 2 years for glaucoma., RESULTS: A total of 186 charts were reviewed, which included 66 patients who were blind in at least one eye from glaucoma on presentation. A total of 172 patients and 290 eyes were followed-up for a mean duration of 10.6 +/- 4.67 years. Twenty seven patients and 31 eyes developed blindness from glaucoma during follow-up. The Kaplan-Meier survival estimate at 16 years was 28.6% for glaucoma-related blindness in at least one eye. A worse visual field on presentation, older age, and poor compliance during therapy were significantly associated with the development of blindness. Glaucoma type, a gender difference, systemic disease, greater intraocular pressure fluctuation in the last year of therapy and blindness in one eye on presentation did not show a significant relationship with the rate of development of blindness., CONCLUSION: Blindness from treated glaucoma is considerable. Our results gave a 28.6% probability of blindness at 16 years in at least one eye. An older age, poor compliance and a worse visual field on presentation were significant risk factors. AU - Chang, Li-Chun AU - Teng, Mei-Ching AU - Chang, Hsueh-Wen AU - Lai, Ing-Chou AU - Lin, Pei-Wen AU - Tsai, Jen-Chia IS - 7 KW - Adult Age Factors Aged *Blindness/et [Etiology] Female *Glaucoma/co [Complications] Humans Intraocular Pressure Male Middle Aged Probability Retrospective Studies Risk Factors PY - 2005 SE - Chang, Li-Chun. Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan. lichun@cgmh.org.tw SN - 2072-0939 SP - 492-7 ST - The probability of blindness in patients treated for glaucoma T2 - Chang Gung medical journal TI - The probability of blindness in patients treated for glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16231533 VL - 28 ID - 1711 ER - TY - JOUR AB - Background:Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in individuals older than 50 years. Demographic, ocular, and systemic risk factors for NAION have been identified, and we sought to determine which, if any, of these factors also increase risk of NAION in the fellow eye.Methods:We performed a retrospective chart review of patients with "ischemic optic neuropathy" (based on International Classification of Disease [ICD] codes) seen at a single eye center between 2007 and 2017. Patients who met diagnostic criteria for unilateral NAION without fellow eye optic neuropathy at diagnosis were included. Demographic information, ocular comorbidities, and systemic diagnoses were recorded, in addition to whether the fellow eye developed NAION during the follow-up period. Univariate and multivariate Cox proportional hazard regression were used to calculate hazard ratios (HRs) for fellow eye involvement.Results:Three hundred eighteen patients were identified by ICD codes, and 119 were included in the study. Twenty-nine (24%) patients developed NAION in the fellow eye over the mean follow-up period of 3.6 years (range: 1 month-11 years). Significant risk factors for fellow eye NAION included the presence of bilateral optic disc drusen (ODD, HR 2.78, 95% confidence interval [CI] 1.12-6.90, P = 0.02) and noncompliance with continuous positive airway pressure (CPAP) in patients with moderate-to-severe obstructive sleep apnea (HR 4.50, 95% CI 1.79-11.3, P = 0.0015).Conclusions:Bilateral ODD and noncompliance with CPAP when indicated are associated with increased risk of NAION in the fellow eye. Patients with these risk factors should be counseled on the potentially devastating visual consequences of bilateral NAION, and compliance with CPAP should be stressed when appropriate. © 2018 by North American Neuro-Ophthalmology Society. AD - Department of Ophthalmology and Vision Science, University of California, Davis, 4860 Y Street, Sacramento, CA 95817, United States AU - Chang, M. Y. AU - Keltner, J. L. AU - Moss, H. E. AU - Pineles, S. L. DB - Scopus DO - 10.1097/WNO.0000000000000715 IS - 2 M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2019 SP - 147-152 ST - Risk Factors for Fellow Eye Involvement in Nonarteritic Anterior Ischemic Optic Neuropathy T2 - Journal of Neuro-Ophthalmology TI - Risk Factors for Fellow Eye Involvement in Nonarteritic Anterior Ischemic Optic Neuropathy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066878049&doi=10.1097%2fWNO.0000000000000715&partnerID=40&md5=b3133d989c7eeb83ff0e33b9e22d9371 VL - 39 ID - 5197 ER - TY - JOUR AB - To evaluate the potential of the smartphone application assisted medical service to increase patient compliance in attendance of follow-up after pediatric cataract treatment. This prospective study enrolled a total of 163 pediatric cataract patients with uneventful surgery. According to their follow-up intervention method, patients were divided into the smartphone application assisted medical service group (WeChat group, 75 patients) or control group (88 patients). Attendance at five follow-up appointments after surgery was recorded. The percentage of patients that attend each follow-up appointment and the compliance of refractive correction were assessed. Although no significant difference was observed in the first appointment comparing the two groups (98.7% vs. 94.3%, p = 0.293), the attendance rates at the other appointments of the WeChat group were significantly higher than the control group (second: 98.7% vs. 89.8%, third: 97.3% vs. 83%, fourth: 93.3% vs. 78.4%, fifth: 80% vs. 56.8%, total: 93.6% vs. 80.5%, respectively). Compared with the control group, the odd ratios for adherence improvement were 4.4 for males (95% confidence index [CI] 2.54-7.65), 4.75 for patients more than 2 years old (95% CI 2.41-9.36), 4.19 for intraocular lens implantation (2.29-7.66), 6.93 for unilateral cataract (2.9-16.52), 4.87 for undeveloped cities (2.74-8.65), and 3.49 for cities far away (2.04-5.96), with all the p < 0.0001. This study demonstrates that the use of smartphone application assisted medical service can significantly improve follow-up attendance after pediatric cataract treatment. AN - WOS:000444744500016 AU - Chang, P. J. AU - Lin, L. AU - Zhang, H. F. AU - Zhao, Y. Y. AU - Xie, J. L. AU - Yu, Y. H. AU - Zhao, Y. E. DA - OCT DO - 10.1007/s00417-018-4080-z IS - 10 PY - 2018 SN - 0721-832X 1435-702X SP - 1923-1931 ST - Effect of smartphone application assisted medical service on follow-up adherence improvement in pediatric cataract patients T2 - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Effect of smartphone application assisted medical service on follow-up adherence improvement in pediatric cataract patients VL - 256 ID - 5871 ER - TY - JOUR AB - Atopic dermatitis, or eczema, usually begins in childhood but adults can also be affected due to either persistence of symptoms or late-onset disease. This article provides a guide to the topical and systemic treatments used for atopic dermatitis in adults, including administration, adherence and primary care prescribing data. AD - S. Chaplin AU - Chaplin, S. DB - Embase DO - 10.1002/psb.1505 IS - 10 KW - antibiotic agent antihistaminic agent azathioprine calcineurin inhibitor crisaborole cyclosporine dupilumab emollient agent methotrexate mycophenolic acid steroid adult application site burning application site irritation application site pruritus application site reaction atopic dermatitis drug cost flushing human hypertension infection intraocular hypertension leg ulcer medication compliance nephrotoxicity patient compliance patient education patient referral phototherapy prescription primary medical care pruritus recurrent disease relapse review scalp side effect skin atrophy skin cancer skin infection sleep disorder LA - English M3 - Review N1 - L613238701 2016-11-21 2016-12-09 PY - 2016 SN - 1931-2253 0959-6682 SP - 30-39 ST - Guide to treatments used for atopic dermatitis in adults T2 - Prescriber TI - Guide to treatments used for atopic dermatitis in adults UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613238701&from=export http://dx.doi.org/10.1002/psb.1505 VL - 27 ID - 2700 ER - TY - JOUR AB - The article examines the efficacy and safety of using selective laser trabeculoplast (SLT) in the treatment of patients with primary open-angle glaucoma (POAG). Topics discussed include progression of glaucoma medications for POAG, its efficacy in comparison to glaucoma drops, which may cause chronic toxicity and inflammation, and arguments for its cost-efficacy. AN - 143809500. Language: English. Entry Date: 20200622. Revision Date: 20200622. Publication Type: Article. Journal Subset: Biomedical AU - Chapman, Kristin O. DB - ccm DP - EBSCOhost IS - 10 KW - Glaucoma -- Therapy Laser Therapy -- Methods Laser Therapy -- Trends Trabeculectomy Medication Compliance Physicians Patient Compliance Cognition Disorders Laser Therapy -- Economics Ophthalmic Solutions N1 - USA. NLM UID: 9880041. PY - 2020 SN - 0193-032X SP - 13-15 ST - The dropless future: SLT as a first-line treatment for glaucoma T2 - Ophthalmology Times TI - The dropless future: SLT as a first-line treatment for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143809500&site=ehost-live&scope=site VL - 45 ID - 4220 ER - TY - JOUR AB - The extracellular matrix (ECM) is critical in all aspects of vascular development and health: supporting cell anchorage, providing structure, organization and mechanical stability, and serving as a sink for growth factors and sustained survival signals. Abnormal changes in ECM protein expression, organization, and/or properties, and the ensuing changes in vascular compliance affect vasodilator responses, microvascular pressure transmission, and collateral perfusion. The changes in microvascular compliance are independent factors initiating, driving, and/or exacerbating a plethora of microvascular diseases of the eye including diabetic retinopathy (DR) and vitreoretinopathy, retinopathy of prematurity (ROP), wet age-related macular degeneration (AMD), and neovascular glaucoma. Congruently, one of the major challenges with most vascular regenerative therapies utilizing localized growth factor, endothelial progenitor, or genetically engineered cell delivery, is the regeneration of blood vessels with physiological compliance properties. Interestingly, vascular cells sense physical forces, including the stiffness of their ECM, through mechanosensitive integrins, their associated proteins and the actomyosin cytoskeleton, which generates biochemical signals that culminate in a rapid expression of matricellular proteins such as cellular communication network 1 (CCN1) and CCN2 (aka connective tissue growth factor or CTGF). Loss or gain of function of these proteins alters genetic programs of cell growth, ECM biosynthesis, and intercellular signaling, that culminate in changes in cell behavior, polarization, and barrier function. In particular, the function of the matricellular protein CCN2/CTGF is critical during retinal vessel development and regeneration wherein new blood vessels form and invest a preformed avascular neural retina following putative gradients of matrix stiffness. These observations underscore the need for further in-depth characterization of the ECM-derived cues that dictate structural and functional properties of the microvasculature, along with the development of new therapeutic strategies addressing the ECM-dependent regulation of pathophysiological stiffening of blood vessels in ischemic retinopathies. AU - Chaqour, Brahim AU - Karrasch, Charles DO - https://dx.doi.org/10.3390/ijms21103487 IS - 10 KW - Animals Biomechanical Phenomena Blood Vessels/em [Embryology] *Blood Vessels/gd [Growth & Development] *Blood Vessels/pp [Physiopathology] *Extracellular Matrix/me [Metabolism] *Eye/bs [Blood Supply] Eye/em [Embryology] *Eye/pa [Pathology] Eye/pp [Physiopathology] Eye Diseases/pa [Pathology] Humans *Microvessels/pa [Pathology] *Microvessels/pp [Physiopathology] PY - 2020 SE - Chaqour, Brahim. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA. Chaqour, Brahim. Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA. Karrasch, Charles. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA. SN - 1422-0067 ST - Eyeing the Extracellular Matrix in Vascular Development and Microvascular Diseases and Bridging the Divide between Vascular Mechanics and Function T2 - International journal of molecular sciences TI - Eyeing the Extracellular Matrix in Vascular Development and Microvascular Diseases and Bridging the Divide between Vascular Mechanics and Function UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32429045 VL - 21 Y2 - 20200515// ID - 236 ER - TY - JOUR AB - The article discusses the effectiveness of the bimatoprost sustained-release implant in improving patients' adherence to topical intraocular pressure (IOP)-lowering glaucoma drugs. Topics covered include Doctor Thomas R. Walters saying that the implant is a biodegradable device placed intracamerally in the eye, the results of a controlled clinical trial in open-angle glaucoma patients aimed at evaluating the safety and efficacy of the implant, and the IOP reduction linked with the implant. AN - 117408721. Language: English. Entry Date: 20160817. Revision Date: 20160818. Publication Type: Article. Journal Subset: Biomedical AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 13 KW - Glaucoma -- Drug Therapy Bimatoprost -- Therapeutic Use Intraocular Pressure -- Drug Effects N1 - USA. NLM UID: 9880041. PY - 2016 SN - 0193-032X SP - 31-31 ST - Bimatoprost sustained-release device mitigates glaucoma adherence issue T2 - Ophthalmology Times TI - Bimatoprost sustained-release device mitigates glaucoma adherence issue UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=117408721&site=ehost-live&scope=site VL - 41 ID - 4398 ER - TY - JOUR AB - The article focuses on a retrospective claims analysis on the treatment and adherence in cases of open-angle glaucoma (OAG) diagnosis. It mentions findings of the study including 17% of patients who remain untreated four years following initial OAG diagnosis, the prescription of prostaglandin analogue and beta-blocker as common medical treatments and the performance of laser trabeculoplasty as first-line treatment. AN - 120778955. Language: English. Entry Date: 20170123. Revision Date: 20170124. Publication Type: Article AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 1 KW - Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Medication Compliance Guideline Adherence Early Intervention -- Evaluation N1 - statistics; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2017 SN - 0193-032X SP - 28-30 ST - Tracking treatment, adherence in cases of newly diagnosed OAG T2 - Ophthalmology Times TI - Tracking treatment, adherence in cases of newly diagnosed OAG UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120778955&site=ehost-live&scope=site VL - 42 ID - 4444 ER - TY - JOUR AB - The article discusses a study by Tavish Nanda of Columbia University that investigated the rate of intra-ocular pressure (IOP) medication noncompliance among aging glaucoma patients. The study found that glaucoma treatment incurs a high rate of medication noncompliance in the elderly that occurs mostly during transition of care from hospital to nursing home or assisted living facilities. It suggest that emphasis on appropriate medical reconciliation will improve rates of noncompliance. AN - 138841239. Language: English. Entry Date: 20190930. Revision Date: 20191029. Publication Type: Article. Journal Subset: Biomedical AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 15 KW - Ophthalmic Solutions -- Therapeutic Use Glaucoma -- Drug Therapy Medication Compliance -- Evaluation Eye Care Medication Reconciliation Disease Progression Glaucoma -- Diagnosis Treatment Outcomes Ophthalmic Solutions -- Administration and Dosage Glaucoma -- Rehabilitation Transfer, Discharge Age Factors Aging N1 - USA. NLM UID: 9880041. PY - 2019 SN - 0193-032X SP - 50-50 ST - Seeking the goal line for patients' glaucoma medication compliance: More than a third of patients do not receive anti-glaucoma drugs, study shows T2 - Ophthalmology Times TI - Seeking the goal line for patients' glaucoma medication compliance: More than a third of patients do not receive anti-glaucoma drugs, study shows UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138841239&site=ehost-live&scope=site VL - 44 ID - 4276 ER - TY - JOUR AB - The article reports on how sustained-release delivery systems will help address compliance in patients with glaucoma. The challenges of developing sustained-release platforms are also discussed. The risk-to-benefit ratio for patients with advanced disease can change if better efficacy and treatment duration can be achieved. It is noteworthy that intraocular pressure increases are asymptomatic when considering any sustained-release platform. AN - 134167885. Language: English. Entry Date: 20190121. Revision Date: 20190123. Publication Type: Article. Journal Subset: Biomedical AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 1 KW - Delayed-Action Preparations Glaucoma -- Drug Therapy Treatment Duration Patient Compliance Treatment Outcomes Drug Design Patient Safety Ocular Hypertension Risk Assessment Anterior Eye Segment Infusion Pumps, Implantable Patient Attitudes N1 - USA. NLM UID: 9880041. PY - 2019 SN - 0193-032X SP - 20-20 ST - Sustained-release delivery systems on horizon of glaucoma care: Novel platforms address adherence; clinicians look to efficacy, treatment duration T2 - Ophthalmology Times TI - Sustained-release delivery systems on horizon of glaucoma care: Novel platforms address adherence; clinicians look to efficacy, treatment duration UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134167885&site=ehost-live&scope=site VL - 44 ID - 4338 ER - TY - JOUR AB - The article reports that the bimatoprost implant from pharmaceutical firm Allergan has become the first intracameral, biodegradable, sustained-release implant dedicated to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Topics mentioned include the ARTEMIS phase III study, the impact of the implant on the corneal endothelial cells, and patients' lack of adherence to eyedrop treatment. AN - 142470276. Language: English. Entry Date: 20200401. Revision Date: 20200406. Publication Type: Article AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 5 KW - Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Intraocular Pressure -- Drug Effects Bimatoprost -- Administration and Dosage Drug Implants Delayed-Action Preparations Clinical Trials Patient Safety Treatment Outcomes N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2020 SN - 0193-032X SP - 1-16 ST - Sustained-release implant offers long-term IOP control, preserved visual function: Bimatoprost SR represents a paradigm shift in glaucoma treatment T2 - Ophthalmology Times TI - Sustained-release implant offers long-term IOP control, preserved visual function: Bimatoprost SR represents a paradigm shift in glaucoma treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142470276&site=ehost-live&scope=site VL - 45 ID - 4229 ER - TY - JOUR AB - The article examines the use of smartphone-based fundus photography and tablet-based visual field testing with fundus photography in evaluating the optic nerve and diagnosing glaucoma. It describes the results of a study conducted by Patricia Anne Santos Tecson from The Medical Center in the Philippines to determine whether the alternative technologies are as effective as standard fundus photographs and visual field tests. It describes the impact of accessibility and affordability on diagnosis. AN - 141850326. Language: English. Entry Date: 20200224. Revision Date: 20200225. Publication Type: Article. Journal Subset: Biomedical AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 3 KW - Technology, Medical Smartphone Computers, Portable Telehealth Optic Nerve -- Analysis Visual Fields -- Evaluation Glaucoma -- Diagnosis Diagnosis, Eye -- Methods Photography -- Methods Nerve Fibers -- Analysis Sensitivity and Specificity Predictive Value of Tests N1 - USA. NLM UID: 9880041. PY - 2020 SN - 0193-032X SP - 27-27 ST - Smartphones, tablets stepping up as diagnostic technology options: Portable devices can diagnose glaucoma, evaluate optic nerve T2 - Ophthalmology Times TI - Smartphones, tablets stepping up as diagnostic technology options: Portable devices can diagnose glaucoma, evaluate optic nerve UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141850326&site=ehost-live&scope=site VL - 45 ID - 4280 ER - TY - JOUR AB - The article discusses an innovative technique's effective rejuvenation of the outflow system which increases the number of eyes that will not need anti-glaucoma medications in 2020. It states that a hybrid minimally invasive glaucoma surgery, dual-blade goniotomy and direct viscodilation of the collector channels with cataract surgery allows access to diseased tissue by removing the trabecular meshwork. Also noted is the procedure's financial burden reduction and compliance improvement. AN - 146573348. Language: English. Entry Date: 20201030. Revision Date: 20201030. Publication Type: Article AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 17 KW - Rejuvenation Trabeculectomy Cataract Extraction -- Methods Intraocular Pressure Glaucoma -- Surgery Minimally Invasive Procedures N1 - brief item. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2020 SN - 0193-032X SP - 23-23 ST - Rejuvenation of outflow system: The time has come for procedure T2 - Ophthalmology Times TI - Rejuvenation of outflow system: The time has come for procedure UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146573348&site=ehost-live&scope=site VL - 45 ID - 4281 ER - TY - JOUR AB - The article discusses a study examined a new method for estimating the risk of glaucomatous conversion using deep learning predictions of the retinal nerve fiber layer (RNFL) thickness from optic disc photographs. Topics covered include the advantages of this method it feasibility for monitoring glaucoma risk in patients who were glaucoma suspects, and its ability to obtain updated predictions of glaucoma risk with the acquisition of more data over time. AN - 150212142. Language: English. Entry Date: 20210517. Revision Date: 20210517. Publication Type: Article AU - Charters, Lynda DB - ccm DP - EBSCOhost IS - 8 KW - Glaucoma -- Diagnosis Health Services Accessibility Disease Progression -- Prevention and Control Glaucoma -- Drug Therapy Early Diagnosis Tomography, Optical Coherence Deep Learning Ophthalmic Equipment and Supplies Technology, Medical N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2021 SN - 0193-032X SP - 24-24 ST - Method of predicting glaucoma conversion proves to be faster T2 - Ophthalmology Times TI - Method of predicting glaucoma conversion proves to be faster UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150212142&site=ehost-live&scope=site VL - 46 ID - 4185 ER - TY - JOUR AB - The article discusses the development of Preferred Practice Pattern (PPP) guidelines to help ophthalmologists not specialized to identify primary open-angle glaucoma (POAG) as of 2021. Topics covered include the recommendation of a periodic genioscopy to document angle status, the low gonioscopy patient adherence rates, and identification of patient adherence if one underwent the procedure within 12 months of initial POAG diagnosis. Also noted is a demographic chart on gonioscopy adherence. AN - 149823572. Language: English. Entry Date: 20210420. Revision Date: 20210420. Publication Type: Article AU - Charters, Lynda AU - Al-Rajhi, Ali A. DB - ccm DP - EBSCOhost IS - 7 KW - Practice Patterns Practice Guidelines Glaucoma -- Diagnosis Patient Compliance Diagnosis, Eye Glaucoma -- Complications Glaucoma -- Risk Factors N1 - statistics. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2021 SN - 0193-032X SP - 22-22 ST - Preferred practice pattern guidelines help identify POAG but are not always followed: Investigators determine that patient rates of adherence with gonioscopy are low T2 - Ophthalmology Times TI - Preferred practice pattern guidelines help identify POAG but are not always followed: Investigators determine that patient rates of adherence with gonioscopy are low UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149823572&site=ehost-live&scope=site VL - 46 ID - 4207 ER - TY - JOUR AB - The article discusses the evolution of glaucoma treatment specifically the introduction of new routes and delivery systems. Topics covered include the delivery challenges in glaucoma management, how the introduction of internal and external drug delivery systems will help ensure patient compliance for long periods, and the development of the use of gold nanoparticles aimed to increase drug penetration and reduce the amount of drug to reduce side effects. AN - 139005758. Language: English. Entry Date: 20191011. Revision Date: 20191016. Publication Type: Article AU - Charters, Lynda AU - Baudouin, Christophe DB - ccm DP - EBSCOhost IS - 16 KW - Glaucoma -- Drug Therapy Problem Solving Disease Progression Patient Education Drug Delivery Systems Patient Compliance Nanotechnology Anterior Chamber Conjunctiva Regeneration N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2019 SN - 0193-032X SP - 42-44 ST - Reshaping medical treatment of glaucoma management: Future therapies require problem-solving strategies to achieve efficiency T2 - Ophthalmology Times TI - Reshaping medical treatment of glaucoma management: Future therapies require problem-solving strategies to achieve efficiency UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139005758&site=ehost-live&scope=site VL - 44 ID - 4260 ER - TY - JOUR AN - 107777864. Language: English. Entry Date: 20150316. Revision Date: 20150712. Publication Type: Journal Article AU - Charters, Lynda AU - Eaton, Alexander M. DB - ccm DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy Medication Compliance -- Evaluation Digital Imaging -- Equipment and Supplies Ophthalmic Solutions -- Administration and Dosage N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2015 SN - 0193-032X SP - 8-9 ST - Device helps monitor patient eye drop regimen, adherence T2 - Ophthalmology Times TI - Device helps monitor patient eye drop regimen, adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107777864&site=ehost-live&scope=site VL - 40 ID - 4602 ER - TY - JOUR AB - The article discusses a nonrandomized comparative retrospective study which showed an increase in the topical glaucoma medication adherence rate among inpatients who have been educated about the importance of continuous glaucoma treatment. Topics covered are the educational interventions provided to patients, association of adherence with other factors including length of the hospital stay and numbers and types of medications and outpatient medication regimen and correct admission prescribing. AN - 141174519. Language: English. Entry Date: 20200116. Revision Date: 20200117. Publication Type: Article AU - Charters, Lynda AU - Mammo, Danny A. DB - ccm DP - EBSCOhost IS - 1 KW - Glaucoma Eye Care Medication Compliance Treatment Outcomes Inpatients Ophthalmologists -- Psychosocial Factors Attitude of Health Personnel Reminder Systems Patient Compliance N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2020 SN - 0193-032X SP - 7-8 ST - INPATIENT CARE: STICKING TO GLAUCOMA THERAPY REGIMENS KEY: Study finds medication rates increase when insurance providers are educated about importance T2 - Ophthalmology Times TI - INPATIENT CARE: STICKING TO GLAUCOMA THERAPY REGIMENS KEY: Study finds medication rates increase when insurance providers are educated about importance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141174519&site=ehost-live&scope=site VL - 45 ID - 4248 ER - TY - JOUR AN - 108099395. Language: English. Entry Date: 20121019. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Biomedical AU - Charters, Lynda AU - Rhee, Douglas J. DB - ccm DP - EBSCOhost IS - 17 KW - Glaucoma -- Drug Therapy Patient Compliance Patients Physicians Teamwork N1 - USA. NLM UID: 9880041. PY - 2012 SN - 0193-032X SP - 20-20 ST - Physicians, patients must work as team T2 - Ophthalmology Times TI - Physicians, patients must work as team UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108099395&site=ehost-live&scope=site VL - 37 ID - 4741 ER - TY - JOUR AB - The article offers guides to optimal, most effective and reasonable intraocular pressure (IOP) lowering glaucoma medications. Topics include insight from Dr. Janet Serle of the Icahn School of Medicine on finding the right balance surrounding the number of anti-glaucoma medications that take into considerations various factors including regimen complexity, cost, side effects, physical and mental status of patient. Also discussed are past treatment practices by ophthalmologists for glaucoma. AD - Consultant to Aerie Pharmaceuticals, Inc., Allergan, and Bausch + Lomb AN - 139646658. Language: English. Entry Date: 20191118. Revision Date: 20191119. Publication Type: Article. Journal Subset: Biomedical AU - Charters, Lynda AU - Serle, Janet B. DB - ccm DP - EBSCOhost IS - 18 KW - Glaucoma -- Drug Therapy Antihypertensive Agents -- Administration and Dosage Polypharmacy Drug Tolerance Medication Compliance Intraocular Pressure -- Drug Effects Treatment Outcomes Drug Therapy, Combination Prescribing Patterns Individualized Medicine N1 - USA. NLM UID: 9880041. PY - 2019 SN - 0193-032X SP - 1-21 ST - THE MAGNIFICENT 7: How many glaucoma medications are too many? Patient tolerance of and compliance with complex regimens are key T2 - Ophthalmology Times TI - THE MAGNIFICENT 7: How many glaucoma medications are too many? Patient tolerance of and compliance with complex regimens are key UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139646658&site=ehost-live&scope=site VL - 44 ID - 4242 ER - TY - JOUR AB - The article discusses findings of a study which determined if the availability of latanoprost for open-angle glaucoma had an effect on patient adherence. Topics covered include the compliance rates among patients for their glaucoma medication as reported in several studies, the various reasons cited by patients for their struggle with their regimens and the factors identified by regression analysis that were associated with improved adherence. AN - 103293525. Language: English. Entry Date: 20150714. Revision Date: 20150714. Publication Type: Article AU - Charters, Lynda AU - Stein, Joshua D. DB - ccm DP - EBSCOhost IS - 9 KW - Glaucoma -- Drug Therapy Medication Compliance -- Evaluation Drugs, Generic N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2015 SN - 0193-032X SP - 8-8 ST - Adherence to drug regimens may increase with generics T2 - Ophthalmology Times TI - Adherence to drug regimens may increase with generics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103293525&site=ehost-live&scope=site VL - 40 ID - 4576 ER - TY - JOUR AB - PURPOSE: The benefit of cataract surgery in the general population concerning visual acuity and subjective visual function has been well established. However, a small proportion of patients are dissatisfied after cataract surgery. Our study aims to evaluate patients' dissatisfaction after phacoemulsification cataract surgery related to low visual function and to analyze the factors associated with this outcome., METHODS: 397 patients, who underwent uneventful phacoemulsification cataract surgery, participated in the study. All the participants completed a self-administered questionnaire which evaluated their visual function pre- and post-operatively. Best Corrected Visual Acuity (BCVA) was measured before and after cataract surgery and patients' contentment if they were satisfied or not with the result of the surgery was also recorded., RESULTS: Macular disease, diabetic retinopathy and glaucoma were the main factors limiting the final visual result after phacoemulsification cataract surgery., CONCLUSIONS: It is very important for the patients to be preoperatively fully aware of the presentation of the aforementioned fundus pathology and to be warned about the predicted visual outcome after cataract surgery. AU - Chatziralli, I. P. AU - Kanonidou, E. AU - Papazisis, L. IS - 317 KW - Aged Aged, 80 and over Cataract/ep [Epidemiology] Comorbidity Diabetic Retinopathy/ep [Epidemiology] Female Glaucoma/ep [Epidemiology] Humans Macular Degeneration/ep [Epidemiology] Male *Patient Satisfaction/sn [Statistics & Numerical Data] Phacoemulsification/ae [Adverse Effects] *Phacoemulsification/sn [Statistics & Numerical Data] Population Surveillance Surveys and Questionnaires Treatment Outcome Truth Disclosure Visual Acuity PY - 2011 SE - Chatziralli, I P. Department of Ophthalmology, General Hospital of Veroia, Veroia, Greece. eirchat@yahoo.gr SN - 0081-0746 SP - 21-4 ST - Frequency of fundus pathology related to patients' dissatisfaction after phacoemulsification cataract surgery T2 - Bulletin de la Societe belge d'ophtalmologie TI - Frequency of fundus pathology related to patients' dissatisfaction after phacoemulsification cataract surgery UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21560852 ID - 1271 ER - TY - JOUR AU - Chaudhary, R. AU - Dhillon, N. AU - Jones, L. DO - https://dx.doi.org/10.1038/eye.2013.2 IS - 4 KW - *Glaucoma/di [Diagnosis] *Guideline Adherence/st [Standards] Humans *Practice Guidelines as Topic State Medicine United Kingdom N1 - Erratum in (EIN), Comment in (CIN) PY - 2013 SN - 1476-5454 0950-222X SP - 571-2 ST - Adherence to NICE guidelines for new glaucoma referrals T2 - Eye (London, England) T3 - Erratum in: Eye (Lond). 2013 Oct;27(10):1230 Note: Dhillion, N [corrected to Dhillon, N]Comment in: Eye (Lond). 2014 Feb;28(2):239; PMID: 24287897 [https://www.ncbi.nlm.nih.gov/pubmed/24287897] TI - Adherence to NICE guidelines for new glaucoma referrals UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23429410 VL - 27 Y2 - 20130222// ID - 988 ER - TY - JOUR AB - Background/Purpose: Disparities in health care utilization based on sex, race, education, or income affect outcomes in rheumatologic care. We have used ocular inflammatory and infectious disease, which complicates many rheumatic diseases, to study some of these disparities. These eye conditions, significantly increase disease burden, especially in people greater than 65 years of age and disproportionately affect females and racial minorities. However, there is lack of national level data in the US regarding influence of age, sex and race on utilization of medical care for inflammatory and infectious eye disease in people > 65 years. We have conducted an epidemiologic study using the Medicare database to analyze these trends and the influence of age, sex and race. Methods: We have used Medicare data available through National Vision and Eye Health Surveillance System (VEHSS). Medicare data are collected from research identifiable files obtained through the Center for Medicare and Medicaid Services (CMS) and include all fee for service beneficiaries. VEHSS uses ICD-10 codes to identify ocular disorders and organizes them into two level categorization, which are category and subgroup. Each code is categorized in one subgroup and multiple subgroups are combined to form a category. Inflammatory and infectious eye disease category includes subgroups of ocular inflammatory conditions, lacrimal system and orbital inflammation, keratitis, conjunctivitis, eyelid inflammation and infection and endophthalmitis. Utilization for the inflammatory and infectious eye disease caterogory, is stratified by age, sex and race. We have measured trends of utilization for the category and for the individual subgroups for the years 2014-2017. We have identified the effect of stratification on utilization; by race, sex, age alone; combining race and sex; age and sex; and the combination of race, sex and age. Results: There were 29,971,000, 30,027,208, 30,423,400 and 30,238,300 million Medicare beneficiaries enrolled for the years 2014 to 2017 respectively. There was a decrease in utilization for inflammatory and infectious eye diseases category and subgroups from the year, 2014 to 2015 followed by a steady increase from 2015-2017 (Figure 1). This trend remains, when utilization is stratified by sex, race and age. Asians and Hispanics have higher utilization for the inflammatory and infectious eye diseases category, and for the individual subgroups, for both males and females (Figure 2). This higher utilization remains, when further stratified by age. Females have higher utilization across all races. This holds true when utilization is stratified by race; an Asian female has higher utilization than an Asian male (Figure 3). And remains steady when we further stratify by age groups. An Asian female of age group: 65-84 has higher utilization than an Asian male of the same age group; for all the years of the study 2014 to 2017. Conclusion: Females, Asians and Hispanics have higher Medicare utilization for inflammatory and infectious eye diseases. These results may be due to higher disease prevalence or service utilization in these subgropus. Racial and sex-based disparitiies should be considered when making health care policy decisions. AD - K. Chauhan, Southern Illinois University - School of Medicine, Springfield, IL, United States AU - Chauhan, K. AU - Rosenbaum, J. DB - Embase DO - 10.1002/art.41538 IS - SUPPL 10 KW - aged Asian blepharitis communicable disease conference abstract conjunctivitis controlled study disease burden endophthalmitis female groups by age health care policy health care utilization health survey human ICD-10 inflammatory disease keratitis lacrimal apparatus male medicaid medical care medicare prevalence race rheumatic disease vision LA - English M3 - Conference Abstract N1 - L634235070 2021-03-01 PY - 2020 SN - 2326-5205 SP - 119-121 ST - Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm T2 - Arthritis and Rheumatology TI - Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634235070&from=export http://dx.doi.org/10.1002/art.41538 VL - 72 ID - 2377 ER - TY - JOUR AB - A 5-year-old boy who had undergone deep anterior lamellar keratoplasty (DALK) in the right eye 8 months earlier presented with a full-thickness graft-host junction dehiscence and iris prolapse following an injury with a rubber ball. The junction was resutured and the graft became clear within 5 weeks. To our knowledge, this is the first reported case of wound dehiscence after DALK in a child. Although Descemet's membrane might be considered a protective barrier following DALK, the graft-host junction remains vulnerable and can rupture with blunt trauma. Copyright © 2011 by the American Association for Pediatric Ophthalmology and Strabismus. AD - Cornea and Anterior Segment Service, LV Prasad Eye Institute, LV Prasad Marg, Banjara Hills, Hyderabad, 500034, India AU - Chaurasia, S. AU - Ramappa, M. DB - Scopus DO - 10.1016/j.jaapos.2011.06.006 IS - 5 M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2011 SP - 484-485 ST - Traumatic wound dehiscence after deep anterior lamellar keratoplasty T2 - Journal of AAPOS TI - Traumatic wound dehiscence after deep anterior lamellar keratoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-81855218084&doi=10.1016%2fj.jaapos.2011.06.006&partnerID=40&md5=e37e68c94474ec7d5d1233f7c24fc97e VL - 15 ID - 5258 ER - TY - JOUR AB - PURPOSE: To describe the results of endothelial keratoplasty (EK) in the management of irido-corneal endothelial (ICE) syndrome., DESIGN: Retrospective, consecutive, interventional case series., METHODS: Eight eyes of seven patients underwent EK for corneal edema owing to ICE syndrome. Simultaneous cataract surgery was performed in five eyes. The charts were reviewed for demographics, clinical findings, and outcomes after EK., RESULTS: Mean age was 50.4 years (range 35-59 years). Mean follow-up was 12.5 months (range 6-24 months). Corneal clarity was restored in all eyes and was maintained till the last follow-up. Four patients had acute rise in the intraocular pressure in the post-operative period, which was well controlled on medical treatment. One patient who was non-compliant with medications and regular follow-up advice had progression of glaucomatous disc changes and visual field loss. The best-corrected visual acuity ranged from 20/50-20/30., CONCLUSIONS: EK is a viable option in ICE syndrome. Adequate control of glaucoma is the paramount factor in maintaining good visual acuity in these eyes. AU - Chaurasia, S. AU - Ramappa, M. AU - Garg, P. AU - Murthy, S. I. AU - Senthil, S. AU - Sangwan, V. S. DO - https://dx.doi.org/10.1038/eye.2012.298 IS - 4 KW - Adult *Corneal Diseases/su [Surgery] Corneal Edema/et [Etiology] Corneal Edema/su [Surgery] Endothelium, Corneal/su [Surgery] Female Humans *Iris Diseases/su [Surgery] *Keratoplasty, Penetrating Male Middle Aged Retrospective Studies Syndrome PY - 2013 SE - Chaurasia, S. Cornea and Anterior Segment Services, LV Prasad Eye Institute, Hyderabad, India. sunita@lvpei.org SN - 1476-5454 0950-222X SP - 564-6 ST - Endothelial keratoplasty in the management of irido-corneal endothelial syndrome T2 - Eye (London, England) TI - Endothelial keratoplasty in the management of irido-corneal endothelial syndrome UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23348727 VL - 27 Y2 - 20130125// ID - 1001 ER - TY - JOUR AD - F.W.G. Costa, Division of Clinical Dentistry, School of Dentistry, Federal University of Ceará, Fortaleza, Ceará, Brazil AU - Chaves, F. N. AU - Fonteles, C. S. R. AU - Carvalho, F. S. R. AU - Ribeiro, T. R. AU - Pereira, K. M. A. AU - Costa, F. W. G. DB - Embase Medline DO - 10.1111/jdv.12460 IS - 6 KW - prednisone adult blindness case report corticosteroid therapy dental procedure disease course disease severity ecchymosis follow up gingiva bleeding glaucoma human hypertension idiopathic thrombocytopenic purpura letter lowest income group male medication compliance middle aged mouth discomfort mouth lesion oral blister patient compliance patient referral petechia physical examination priority journal platelet count thrombocytopenia treatment outcome treatment response LA - English M3 - Letter N1 - L53061753 2014-03-24 2015-06-08 PY - 2015 SN - 1468-3083 0926-9959 SP - 1235-1236 ST - An adult blind man presenting severe impairment of the right finger, ecchymosis in the thorax region, and haemorrhagic blisters on the oral mucosa T2 - Journal of the European Academy of Dermatology and Venereology TI - An adult blind man presenting severe impairment of the right finger, ecchymosis in the thorax region, and haemorrhagic blisters on the oral mucosa UR - https://www.embase.com/search/results?subaction=viewrecord&id=L53061753&from=export http://dx.doi.org/10.1111/jdv.12460 VL - 29 ID - 2826 ER - TY - JOUR AU - Chawla, Anand AU - McGalliard, Jim N. AU - Batterbury, Mark IS - 4 KW - *Antihypertensive Agents/ad [Administration & Dosage] Cross-Sectional Studies *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure *Ophthalmic Solutions/ad [Administration & Dosage] Surveys and Questionnaires *Treatment Refusal/sn [Statistics & Numerical Data] PY - 2007 SN - 1395-3907 SP - 464 ST - Use of eyedrops in glaucoma: how can we help to reduce non-compliance? T2 - Acta ophthalmologica Scandinavica TI - Use of eyedrops in glaucoma: how can we help to reduce non-compliance? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17286557 VL - 85 Y2 - 20070206// ID - 1617 ER - TY - JOUR AB - PURPOSE: To assess adherence patterns to the UK National Institute of Health and Clinical Excellence (NICE) guidelines on glaucoma management (2009) in a tertiary referral centre shared care setting and in a district general hospital (DGH) setting., METHOD: We performed a retrospective case note analysis of 200 patients from two centres between January and June 2010. The two centres involved were a consultant-guided teaching hospital optometry-led shared care setting (setting 1) and a consultant-led DGH clinic setting (setting 2). The main outcome measures were compliance with eight of the main NICE guidelines on glaucoma diagnosis and management (2009)., RESULTS: Both centres showed good adherence to the guidelines regarding the choice of initial treatment (96% vs 100%, settings 1 and 2, respectively) and arranging appropriate monitoring intervals (92% vs 86%). However, significant differences were seen when assessing whether an optic disc image was obtained at the initial visit (74% vs 10%), whether an appropriate initial assessment was performed (96% vs 58%), whether patients' review interval complied with the NICE guidance regardless of hospital cancellations (92% vs 66%), and whether concordance with medication was checked (88% vs 24%) (settings 1 and 2, respectively, P<0.01-Fisher's exact test)., CONCLUSION: Our study provides evidence to suggest that a hospital-based shared care service with trained optometrists using assessment sheets compares favourably to non-specialist glaucoma care delivered by ophthalmologists. AU - Chawla, A. AU - Patel, I. AU - Yuen, C. AU - Fenerty, C. DO - https://dx.doi.org/10.1038/eye.2012.171 IS - 11 KW - Aged Delivery of Health Care/st [Standards] Female *Glaucoma/di [Diagnosis] Gonioscopy *Guideline Adherence/st [Standards] Hospitals, District/st [Standards] Hospitals, Teaching/st [Standards] Humans *Intraocular Pressure Male Middle Aged National Health Programs/st [Standards] *Ophthalmology/st [Standards] *Optometry/st [Standards] *Patient Care Team/st [Standards] *Practice Guidelines as Topic/st [Standards] Retrospective Studies Tonometry, Ocular United Kingdom Visual Field Tests Visual Fields PY - 2012 SE - Chawla, A. Manchester Royal Eye Hospital and Manchester Academic and Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. anand001@hotmail.com SN - 1476-5454 0950-222X SP - 1412-7 ST - Patterns of adherence to NICE glaucoma guidance in two different service delivery models T2 - Eye (London, England) TI - Patterns of adherence to NICE glaucoma guidance in two different service delivery models UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22935671 VL - 26 Y2 - 20120831// ID - 1113 ER - TY - JOUR AB - Purpose. To report a sutureless method of amniotic membrane fixation using fibrin glue in two cases of symptomatic bullous keratopathy with poor visual potential. Methods. Under topical anesthesia, the loose epithelium was debrided up to 1.0 mm from the limbus and fibrin glue was applied uniformly and thinly onto the corneal surface. Cryopreserved amniotic membrane was evenly placed over the cornea and once a firm and uniform adhesion was achieved, excess membrane was trimmed off. A bandage contact lens was applied. Results. In both the cases, complete relief from symptoms was obtained and 3 weeks later, the ocular surface had completely re-epithelialized. At 6 months follow-up, both patients were symptom free without the need for any medication. No complications were observed. Conclusions. This technique of amniotic membrane fixation is a simple, effective, and safe procedure whereby a stable and secure adherence of the amniotic membrane with the corneal surface is achieved avoiding the use of sutures. © Wichtig Editore, 2008. AD - Cornea and Refractive Surgery Services, Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India AU - Chawla, B. AU - Tandon, R. DB - Scopus DO - 10.1177/112067210801800623 IS - 6 KW - Amniotic membrane Bullous keratopathy Fibrin glue M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2008 SP - 998-1001 ST - Sutureless amniotic membrane fixation with fibrin glue in symptomatic bullous keratopathy with poor visual potential T2 - European Journal of Ophthalmology TI - Sutureless amniotic membrane fixation with fibrin glue in symptomatic bullous keratopathy with poor visual potential UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-58149378613&doi=10.1177%2f112067210801800623&partnerID=40&md5=dfc98d9ec8808d298f1be9286a5b3d14 VL - 18 ID - 5364 ER - TY - JOUR AB - Background: Peripheral field loss from conditions such as retinitis pigmentosa and glaucoma can cause significant disabilities by limiting activities of daily living. Severe peripheral field loss causes mobility difficulties with activities such as identifying and adapting to obstacles in the environment. It can also cause emotional strain and impair quality of life. Because this visual field loss is often slow and progressive, patients may be unaware of these functional implications. In addition to orientation and mobility training, sector Fresnel prism therapy is a complementary visual field awareness technique to help the patients obtain information from the missing field. Case Reports: Two cases are presented with the characteristic functional impairments of severe overall visual field constriction. The first case involves a 58-year-old male with advanced retinitis pigmentosa. The second case is of a 52-yearold male with advanced primary open-angle glaucoma. Conclusion: The use of sector Fresnel prism to improve mobility and spatial awareness has long been a clinically accepted tool for rehabilitating patients with overall constricted peripheral visual fields. The prism reduces the degree of eye movement needed to detect peripheral objects in the environment. With in-office training and mobility training, sector Fresnel prism can be successful in helping the patients increase their peripheral awareness of objects, improve their navigational ability, and improve their quality of life. AD - State University of New York State College of Optometry, New York AN - 109006486. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Chea, Christine AU - Marinoff, Rebecca DB - ccm DP - EBSCOhost IS - 5 KW - Intraocular Pressure Visual Fields Rehabilitation of Vision Impaired Activities of Daily Living Retinitis Pigmentosa Eye Movements Cognition Male Middle Age N1 - case study; pictorial; tables/charts. Journal Subset: Peer Reviewed; USA. PY - 2015 SN - 2325-3479 SP - 197-202 ST - Case Reports: The Use of Sector Fresnel Prism for Increased Peripheral Visual Field Awareness for Patients with End-Stage Retinitis Pigmentosa and Glaucoma T2 - Optometry & Visual Performance TI - Case Reports: The Use of Sector Fresnel Prism for Increased Peripheral Visual Field Awareness for Patients with End-Stage Retinitis Pigmentosa and Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109006486&site=ehost-live&scope=site VL - 3 ID - 4277 ER - TY - JOUR AB - IMPORTANCE: Medication nonadherence, which has been estimated to affect 28% to 31% of US patients with hypertension, hyperlipidemia, and diabetes, may be improved by electronic medication packaging (EMP) devices (adherence-monitoring devices incorporated into the packaging of a prescription medication). OBJECTIVES: To investigate whether EMP devices are associated with improved adherence and to identify and describe common features of EMP devices. EVIDENCE REVIEW: Systematic review of peer-reviewed studies testing the effectiveness of EMP systems in the MEDLINE, EMBASE, PsycINFO, CINAHL, International Pharmaceutical Abstracts, and Sociological Abstracts databases from searches conducted to June 13, 2014, with extraction of associations between the interventions and adherence, as well as other key findings. Each study was assessed for bias using the Cochrane Handbook for Systematic Reviews of Interventions; features of EMP devices and interventions were qualitatively assessed. FINDINGS: Thirty-seven studies (32 randomized and 5 nonrandomized) including 4326 patients met inclusion criteria (10 patient interface-only "simple" interventions and 29 "complex" interventions integrated into the health care system [2 qualified for both categories]). Overall, the effect estimates for differences in mean adherence ranged from a decrease of 2.9% to an increase of 34.0%, and the those for differences in the proportion of patients defined as adherent ranged from a decrease of 8.0% to an increase of 49.5%. We identified 5 common EMP characteristics: recorded dosing events and stored records of adherence, audiovisual reminders to cue dosing, digital displays, real-time monitoring, and feedback on adherence performance. CONCLUSIONS AND RELEVANCE: Many varieties of EMP devices exist. However, data supporting their use are limited, with variability in the quality of studies testing EMP devices. Devices integrated into the care delivery system and designed to record dosing events are most frequently associated with improved adherence, compared with other devices. Higher-quality evidence is needed to determine the effect, if any, of these low-cost interventions on medication nonadherence and to identify their most useful components. AD - A.S. Kesselheim, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States AU - Checchi, K. D. AU - Huybrechts, K. F. AU - Avorn, J. AU - Kesselheim, A. S. DB - Embase Medline DO - 10.1001/jama.2014.10059 IS - 12 KW - amfebutamone antidiabetic agent antihypertensive agent candesartan cinacalcet clopidogrel fluticasone propionate hydrochlorothiazide hydroxymethylglutaryl coenzyme A reductase inhibitor immunosuppressive agent ipratropium bromide irbesartan lercanidipine lithium salt metformin neuroleptic agent pilocarpine steroid sulfonylurea derivative telmisartan travoprost asthma chronic obstructive lung disease cost benefit analysis data analysis diabetes mellitus electronic medication packaging device electronics glaucoma health care system heart failure highly active antiretroviral therapy human Human immunodeficiency virus infection hyperglycemia hyperlipidemia hyperparathyroidism hypertension inflammatory bowel disease information processing kidney graft medication compliance mental disease meta analysis packaging material patient compliance randomized controlled trial (topic) review smoking cessation systematic review thrombocyte LA - English M3 - Review N1 - L600114976 2014-10-15 2014-10-17 PY - 2014 SN - 1538-3598 0098-7484 SP - 1237-1247 ST - Electronic medication packaging devices and medication adherence: A systematic review T2 - JAMA - Journal of the American Medical Association TI - Electronic medication packaging devices and medication adherence: A systematic review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600114976&from=export http://dx.doi.org/10.1001/jama.2014.10059 VL - 312 ID - 2932 ER - TY - JOUR AB - Glaucoma comprises a group of progressive, neurodegenerative disorders characterized by retinal ganglion cell death and nerve fiber layer atrophy. Several randomized controlled trials have consistently demonstrated the efficacy of intraocular pressure lowering to slow or halt the measurable progression of the disease. Medical therapy, in places where it is easily accessible, is often the primary method to lower intraocular pressure. We review the medical options currently available and possible future options currently in development. The 5 contemporary classes of topical agents in use include prostaglandin analogs, beta blockers, carbonic anhydrase inhibitors, alpha agonists, and cholinergics. In addition, several fixed combination agents are commercially available. Agents from each of these classes have unique mechanisms of action, adverse effects, and other characteristics that impact how they are used in clinical practice. Despite the plethora of medical options available, there are limitations to topical ophthalmic therapy such as the high rate of noncompliance and local and systemic adverse effects. Alternate and sustained drug delivery models, such as injectable agents and punctal plug delivery systems, may in the future alleviate some such concerns and lead to increased efficacy of treatment while minimizing adverse effects. AU - Cheema, Anjum AU - Chang, Robert T. AU - Shrivastava, Anurag AU - Singh, Kuldev DO - https://dx.doi.org/10.1097/APO.0000000000000181 IS - 1 KW - Adrenergic alpha-Agonists/tu [Therapeutic Use] Adrenergic beta-Antagonists/tu [Therapeutic Use] Antihypertensive Agents/ad [Administration & Dosage] *Antihypertensive Agents/tu [Therapeutic Use] Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] Cholinergic Agents/tu [Therapeutic Use] Clinical Trials as Topic Drug Therapy, Combination *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Prostaglandins, Synthetic/tu [Therapeutic Use] PY - 2016 SE - Cheema, Anjum. From the *Department of Ophthalmology, Kaiser Permanente, Atlanta, GA; Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA; and ++Department of Ophthalmology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY. SN - 2162-0989 SP - 51-8 ST - Update on the Medical Treatment of Primary Open-Angle Glaucoma T2 - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) TI - Update on the Medical Treatment of Primary Open-Angle Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26886120 VL - 5 ID - 712 ER - TY - JOUR AB - Purpose: Diabetic retinopathy (DR) is the leading cause of preventable blindness in working-aged adults, and compliance in ophthalmic follow-up appointments is critical to prevent vision loss. However, barriers to follow-up care have not been well studied, especially in socio-economically disadvantaged groups. We investigated the risk factors for non-compliance to DR follow-up appointments in a safety-net county hospital. Methods: Two hundred and nine patients who were treated for DR at the Zuckerberg San Francisco General Hospital retina clinic between 1 July 2015 and 30 January 2016 were enrolled in the study. Multivariate logistic regression analysis of demographic and medical information was used to determine independent risk factors for non-compliance to DR follow-up appointments. Results: The mean patient age was 58 years. Sixty-three percent (132/209) of patients were male; the mean haemoglobin A1c level was 8.5 (SD 0.14). Forty-six percent (97/209) of patients attended <80% of their DR follow-up appoinments. Independent risk factors for non-compliance after multivariate logistic regression analysis were diabetic foot involvement [OR: 2.40, 95% CI: (1.04-5.55)] and foot/kidney involvement [OR: 3.79 (1.35-10.5)], history of major depressive disorder (MDD) [OR: 2.11 (1.05-4.26), and having Medi-Cal [OR: 5.01 (2.00-12.5)] or SF Health insurance [OR: 6.79 (2.14-21.5)]. Conclusions and Relevance: In conclusion, this is the first study to identify diabetic end organ damage and MDD as independent risk factors for non-compliance in DR follow-up appointments. It is important that health care providers identify these patient subsets and increase efforts to more deliberately encourage follow-up in these high-risk patient groups for DR. AN - WOS:000445876500016 AU - Chen, A. J. AU - Hwang, V. AU - Law, P. Y. AU - Stewart, J. M. AU - Chao, D. L. DO - 10.1080/09286586.2018.1504311 IS - 5-6 PY - 2018 SN - 0928-6586 1744-5086 SP - 443-450 ST - Factors Associated with Non-compliance for Diabetic Retinopathy Follow-up in an Urban Safety-Net Hospital T2 - OPHTHALMIC EPIDEMIOLOGY TI - Factors Associated with Non-compliance for Diabetic Retinopathy Follow-up in an Urban Safety-Net Hospital VL - 25 ID - 5827 ER - TY - JOUR AB - OBJECTIVE: Fungal keratitis (FK) is a vision-threatening infection, whose treatment requires more effective and safer anti-fungal agent exploitation urgently. With this aim, we focused on the effect of an extracellular polysaccharide on fungal adhesion to human corneal epithelial cells., METHODS: We performed the cytotoxicity assays of the extracellular polysaccharide EPS-II from an antarctic bacterium Pseudoaltermonas and evaluated its inhibitory effect on Candida albicans cells' adherence to human corneal epithelial cells (HCECs)., RESULTS: EPS-II, which displayed minor cytotoxicity but also promoted proliferation of HCECs, could inhibit the adherence of yeast cells to HCECs in a dose-dependent manner. EPS-II could also suppress the subsequent PI3K/AKT signaling pathway, and thereby decrease the expression of early inflammatory cytokines., CONCLUSIONS: Extracellular polysaccharide EPS-II was suggested as a new natural agent for attenuating FK. AU - Chen, Hao AU - Zheng, Zhou AU - Chen, Peng AU - Wu, Xiang Gen AU - Zhao, Ge IS - 2 KW - Blotting, Western *Candida/de [Drug Effects] Candida/ph [Physiology] *Cell Adhesion/de [Drug Effects] *Cornea/mi [Microbiology] Humans Phosphorylation *Polysaccharides, Bacterial/pd [Pharmacology] Proto-Oncogene Proteins c-akt/me [Metabolism] *Pseudoalteromonas/me [Metabolism] PY - 2012 SE - Chen, Hao. State Key Lab Cultivation Base, Shandong Provincial Key Lab of Ophthalmology, Shandong Eye Institute, Qingdao 266071, Shandong, China. SN - 0895-3988 SP - 210-5 ST - Inhibitory effect of extracellular polysaccharide EPS-II from Pseudoalteromonas on Candida adhesion to cornea in vitro T2 - Biomedical and environmental sciences : BES TI - Inhibitory effect of extracellular polysaccharide EPS-II from Pseudoalteromonas on Candida adhesion to cornea in vitro UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22998829 VL - 25 ID - 1108 ER - TY - JOUR AB - Introduction: Glaucoma is a multiflactorial disease characterized by progressive optic nerve injury and visual field defects. Elevated intraocular pressure (IOP) is the most widely recognized risk factor for the onset and progression of open-angle glaucoma, and IOP-lowering medications comprise the primary treatment strategy. IOP elevation in glaucoma is associated with diminished or obstructed aqueous humor outflow. Pharmacotherapy reduces IOP by suppressing aqueous inflow and/or increasing aqueous outflow. Purpose: This review focuses on novel non-FDA approved ocular antihypertensive compounds being investigated for IOP reduction in ocular hypertensive and glaucoma patients in active clinical trials within approximately the past 2 years. Methods: The mode of IOP reduction, pharmacology, efficacy, and safety of these new agents were assessed. Relevant drug efficacy and safety trials were identified from searches of various scientific literature databases and clinical trial registries. Compounds with no specified drug class, insufficient background information, reformulations, and fixed-combinations of marketed drugs were not considered. Results: The investigational agents identified comprise those that act on the same targets of established drug classes approved by the FDA (ie, prostaglandin analogs and β-adrenergic blockers) as well as agents belonging to novel drug classes with unique mechanisms of action. Novel targets and compounds evaluated in clinical trials include an action polymerization inhibitor (ie, latrunculin), Rho-associated protein kinase inhibitors, adenosine receptor analogs, an angiotension II type 1 receptor antagonist, cannabinoid receptor agonists, and a serotonin receptor antagonist. Conclusion: The clinical value of novel compounds for the treatment of glaucoma will depend ultimately on demonstrating favorable efficacy and benefit-to-risk ratios relative to currently approved prostaglandin analogs and β-blockers and/or having complementary modes of action. © 2011 Chen et al, publisher and licensee Dove Medical Press Ltd. AD - J. Chen, Department of Biological Sciences, Allergan, inc, 2525 Dupont Dr, Irvine, CA 92612, United States AU - Chen, J. AU - Runyan, S. A. AU - Robinson, M. R. C1 - ar 102(Aerie) ar 12286(Aerie) atl 313(Santen) cf 101(Can Fite) ino 8875(Inotek) ins 115644(Inspire) ins 117548(Inspire) k 115(Kowa) opa 6566(Acucela) opa 6566(Otsuka) pf 04217329(Pfizer) sad 448(Novartis) y 39983(Novartis) y 39983(Senju) C2 - Acucela Aerie Alcon Allergan Can Fite Inotek Inspire Kowa Merck Frosst Novartis Otsuka Pfizer Santen Senju Vistakon DB - Embase DO - 10.2147/OPTH.S15971 IS - 1 KW - NCT00441883 NCT00515424 NCT00523250 NCT00572455 NCT00595101 NCT00650702 NCT00767793 NCT00824720 NCT00846989 NCT00902200 NCT00967811 NCT01016691 NCT01033422 NCT01037036 NCT01060579 NCT01123785 NCT01223378 NCT01227291 NCT01229982 piclidenoson actin adenosine derivative agents acting on the eye angiotensin 1 receptor antagonist antiglaucoma agent ar 102 verosudil evodenoson bimatoprost cannabinoid receptor agonist ino 8875 ins 115644 ins 117548 k 115 latanoprost latrunculin B olmesartan opa 6566 placebo Rho kinase Rho kinase inhibitor sad 448 serotonin antagonist syl 040012 taprenepag isopropyl ester timolol travoprost unclassified drug unindexed drug y 39983 conjunctival hemorrhage conjunctival hyperemia cornea disease cornea permeability cornea thickness drug delivery system drug dose escalation drug efficacy drug mechanism drug safety drug tolerability eye burn eye disease eye irritation glaucoma human intraocular hypertension intraocular pressure iritis nonhuman open angle glaucoma patient compliance photophobia review risk benefit analysis side effect sustained drug release vascular disease ar 12286 atl 313 cf 101 pf 04217329 L1 - internal-pdf://2040651434/3158-Novel ocular antihypertensive compou-2011.pdf LA - English M3 - Review N1 - L361952595 2011-06-23 2011-07-12 PY - 2011 SN - 1177-5467 1177-5483 SP - 667-677 ST - Novel ocular antihypertensive compounds in clinical trials T2 - Clinical Ophthalmology TI - Novel ocular antihypertensive compounds in clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361952595&from=export http://dx.doi.org/10.2147/OPTH.S15971 VL - 5 ID - 3158 ER - TY - JOUR AB - BACKGROUND: To assess the utilization of and satisfaction with ophthalmic healthcare provided by integrated delivery system (IDS) since 2000 and vision-related quality of life (VRQoL) for residents of an offshore island of Taiwan., METHODS: Facilitators interviewed residents (age >= 50 years) with the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) for VRQoL and a questionnaire on clinical information, ophthalmic care utilization and satisfaction., RESULTS: A total of 841 participants (response rate 93.4 %, 841/900) completed the questionnaire survey. Mean age was 63.7 (+/-10. 7) years. The common eye diseases were cataract (44.7 %), dry eye (15.5 %), and glaucoma (8.7 %). Among the participants, 61.0 % sought ophthalmic care under the IDS in the past year and 17.6 % experienced unmet ophthalmic needs in the past 6 months. Satisfaction with ophthalmic care under the IDS was 88.1 %. Determinants of dissatisfaction under the IDS were distance to healthcare facility and VRQoL. Predictors of VRQoL included age, residential area, marital status, occupation, comorbid condition, commercial insurance, household income, cataracts and glaucoma., CONCLUSIONS: The implementation of IDS improves accessibility of ophthalmic care for residents of an offshore island. Geographic proximity to avail healthcare facility and VRQoL affect satisfaction with the IDS. AU - Chen, Li-Ju AU - Chang, Yun-Jau AU - Shieh, Chun-Fu AU - Yu, Jy-Haw AU - Yang, Ming-Chin DO - https://dx.doi.org/10.1186/s12913-016-1501-8 KW - Aged Aged, 80 and over Delivery of Health Care, Integrated/sn [Statistics & Numerical Data] Eye Diseases/di [Diagnosis] Eye Diseases/th [Therapy] Female *Health Services Accessibility/sn [Statistics & Numerical Data] Humans Male Middle Aged National Health Programs Ophthalmology *Patient Satisfaction *Quality of Life Regression Analysis Surveys and Questionnaires Taiwan *Vision, Ocular PY - 2016 SE - Chen, Li-Ju. Institute of Health Policy and Management, College of Public Health, National Taiwan University, Room 637, No 17, Hsu-Chow Road, Taipei, 10055, Taiwan. Chen, Li-Ju. Department of Ophthalmology, Heping Branch, Taipei City Hospital, Taipei, Taiwan. Chang, Yun-Jau. Department of General Surgery, National Taiwan University Hospital, Taipei, Taiwan. Chang, Yun-Jau. Department of General Surgery, Zhongxing branch, Taipei City Hospital, Taipei, Taiwan. Shieh, Chun-Fu. Public Health Bureau, Lienchiang County, Matsu, Taiwan. Yu, Jy-Haw. Department of Ophthalmology, Heping Branch, Taipei City Hospital, Taipei, Taiwan. Yang, Ming-Chin. Institute of Health Policy and Management, College of Public Health, National Taiwan University, Room 637, No 17, Hsu-Chow Road, Taipei, 10055, Taiwan. mcyang637@ntu.edu.tw. SN - 1472-6963 SP - 261 ST - Accessibility of ophthalmic healthcare for residents of an offshore island-an example of integrated delivery system T2 - BMC health services research TI - Accessibility of ophthalmic healthcare for residents of an offshore island-an example of integrated delivery system UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27412399 VL - 16 Y2 - 20160713// ID - 671 ER - TY - JOUR AB - Objective: To compare the efficacy and safety of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) and dexamethasone 0.1%/tobramycin 0.3% (DM/T) ophthalmic suspensions in a Chinese population with ocular inflammation associated with blepharokeratoconjunctivitis (BKC). Research design and methods: This study was a multicenter, randomized, investigator-masked, parallel-group clinical trial. Patients aged ≥18 years with a clinical diagnosis of BKC in at least one eye received LE/T or DM/T administered 4 times daily for 2 weeks. At baseline and on days 3, 8, and 15 (visits 2, 3, and 4), clinical assessments of ocular signs and symptoms, visual acuity (VA), biomicroscopy, and intraocular pressure (IOP) were performed in both eyes. Main outcome measures: The primary efficacy endpoint was the change from baseline (CFB) to visit 4 in the signs and symptoms composite score in designated study eyes using a non-inferiority metric to compare LE/T to DM/T. Safety evaluation included adverse events, biomicroscopy findings, and changes in VA and IOP. Clinical trial registration: NCT number, NCT01028027. Results: A total of 308 patients were included in the per protocol population (n=156 LE/T, n=152 DM/T). A significant CFB in composite signs and symptoms was seen with both treatments at each follow-up visit (p<0.0001). The mean (SD) CFB at visit 4 was -11.63 (4.56) and -12.41 (4.71) in the LE/T and DM/T groups, respectively, and the upper bound of the 90% confidence interval for the difference was less than the prespecified non-inferiority margin. Comparable results were found for secondary efficacy outcomes. Patients treated with DM/T experienced a significantly greater increase in mean CFB in IOP compared to those treated with LE/T at all follow-up visits (p≤0.0186) and nearly twice as many IOP elevations ≥5mmHg (p=0.0020). Conclusion: Treatment with LE/T was at least as effective as DM/T in Chinese patients with BKC and had a better safety profile with respect to change in IOP. © 2012 Informa UK Ltd All rights reserved. AD - Eye and ENT Hospital, Fudan University, No. 83, Fenyang Road, Shanghai, China First Affiliated Hospital, Zhejiang University, Hangzhou, China Daping Hospital, Third Military Medical University, Chongqing, China School of Ophthalmology and Optometry Affiliated with Wenzhou, Medical College, Wenzhou, China Nanjing General Hospital of Nanjing Military Command, Nanjing, China STU, CUHK, Joint Shantou International Eye Center, Shantou, China Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, China AU - Chen, M. AU - Gong, L. AU - Sun, X. AU - Gu, Y. AU - He, X. AU - Qu, J. AU - Wang, L. AU - Zhang, M. AU - Zhong, X. DB - Scopus DO - 10.1185/03007995.2012.659723 IS - 3 KW - Blepharokeratoconjunctivitis Dexamethasone Intraocular pressure Loteprednol etabonate Safety Tobramycin M3 - Article N1 - Cited By :24 Export Date: 19 July 2021 PY - 2012 SP - 385-394 ST - A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis T2 - Current Medical Research and Opinion TI - A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863280798&doi=10.1185%2f03007995.2012.659723&partnerID=40&md5=41a0d11dcd5406288ff3fcb354c9e725 VL - 28 ID - 5099 ER - TY - JOUR AB - PURPOSE: To investigate blindness in patients with treated open-angle glaucoma (OAG) and risk factors for blindness., DESIGN: Retrospective observational case series., PARTICIPANTS: One hundred eighty-six patients seen between April and November 2000 at the University of Washington Medical Center Eye Clinic, diagnosed in 1975 or later, and treated for at least 2 years for OAG., METHODS: Chart review with evaluation of visual acuity and visual field. Kaplan-Meier survival analysis was used to estimate the risk of blindness in one and both eyes. Variables considered to be possible risk factors for blindness were evaluated using chi-square test, t test, and Cox proportional hazards regression analysis., MAIN OUTCOME MEASURES: Blindness, defined as visual acuity of 20/200 or worse, and/or continuous constriction of the visual field to 20 degrees or less in all four quadrants with a size III4e Goldmann stimulus or the equivalent on automated perimetry, allowing a higher threshold level on one point in one quadrant on automated perimetry., RESULTS: The mean duration of disease was 10.2 +/- 4.9 years. Twelve patients were blind in at least one eye from OAG at diagnosis. Nineteen other patients became blind in at least one eye from OAG, and three patients became bilaterally blind from OAG. The Kaplan-Meier estimate for blindness at 15 years in one eye was 14.6%, and in both eyes was 6.4%. Noncompliance with the treatment regimen (P = 0.016) and worse initial visual field loss (P < 0.0001) were significantly associated with development of blindness. Nonwhite race was associated with blindness (P = 0.014) when all blindness, including that found at diagnosis, was considered in the analysis., CONCLUSIONS: Bilateral blindness from chronic OAG was uncommon in this population of treated patients diagnosed in 1975 or later. Of patients with a blind eye, 39% were blind at diagnosis, and worse visual field loss at diagnosis and noncompliance were associated with development of blindness. AU - Chen, Philip P. IS - 4 KW - *Blindness/et [Etiology] Chronic Disease Cohort Studies Female *Glaucoma, Open-Angle/co [Complications] Glaucoma, Open-Angle/di [Diagnosis] *Glaucoma, Open-Angle/th [Therapy] Humans Intraocular Pressure Male Middle Aged Retrospective Studies Risk Factors Time Factors Visual Acuity Visual Fields N1 - Comment on (CON) PY - 2003 SE - Chen, Philip P. Department of Ophthalmology, University of Washington, Seattle, Washington 98195-6485, USA. SN - 0161-6420 SP - 726-33 ST - Blindness in patients with treated open-angle glaucoma T2 - Ophthalmology T3 - Comment on: Ophthalmology. 2003 Apr;110(4):634-5; PMID: 12689878 [https://www.ncbi.nlm.nih.gov/pubmed/12689878] TI - Blindness in patients with treated open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=12689894 VL - 110 ID - 1848 ER - TY - JOUR AB - PURPOSE OF REVIEW: Estimates of blindness from glaucoma and risk factors for blindness remain of interest for all ophthalmologists., RECENT FINDINGS: Long-term retrospective studies of patients with open-angle glaucoma in developed countries have noted that progression to bilateral blindness among treated patients is relatively uncommon. Risk factors for development of blindness include advanced visual field loss at presentation and noncompliance with the treatment regimen. Age is a risk factor in some studies. Many of those with blindness are blind at presentation. Untreated rates of blindness are higher. Population-based studies of glaucoma in developing countries have highlighted the obstacles to prevention of blindness in such settings, with astonishingly high rates of blindness noted., SUMMARY: The risk of blindness from glaucoma is very high among patients in developing countries, the vast majority of whom do not know they are afflicted. When considering all glaucoma worldwide, the greatest risk factor for blindness is almost certainly being an average citizen of a developing country. Among those with open-angle glaucoma in developed countries, more advanced visual field loss at presentation and noncompliance are risk factors for development of blindness, as well as advanced age. Effective public education about glaucoma and targeted screening of those most likely to have glaucoma are necessary if the number of blind from glaucoma is to be reduced worldwide. Better treatment options for those in developing countries must also be developed. AU - Chen, Philip P. IS - 2 KW - *Blindness/ep [Epidemiology] *Blindness/et [Etiology] *Glaucoma/co [Complications] Glaucoma/ep [Epidemiology] Humans Risk Assessment Risk Factors PY - 2004 SE - Chen, Philip P. Department of Ophthalmology, University of Washington, Seattle, Washington, USA. pchen@u.washington.edu SN - 1040-8738 SP - 107-11 ST - Risk and risk factors for blindness from glaucoma T2 - Current opinion in ophthalmology TI - Risk and risk factors for blindness from glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15021221 VL - 15 ID - 1791 ER - TY - JOUR AB - PURPOSE: To evaluate continued visual field (VF) progression in eyes with prior VF progression from open-angle glaucoma, using event-based criteria., METHODS: Retrospective observational case series of 70 eyes (70 patients) with open-angle glaucoma, treated for at least 2 years, that had earlier shown 1 step of VF progression. Further VF progression required a worsening of 3 adjacent points at the same location on 2 consecutive VF tests. Potential risk factors for continued progression were evaluated., RESULTS: The mean follow-up was 127+/-43 months. Thirty-seven eyes (55%) continued to progress. At 5, 10, and 15 years after the initial VF, the Kaplan-Meier estimate of the risk of developing 2 steps of progression was 18%, 53%, and 71%. A shorter time to the first step of progression was significantly associated with further progression (P<0.001), as was slope of the VF mean deviation (P<0.001) and pattern standard deviation (P=0.041). Eyes with further progression had higher mean IOP after the first step of progression (P=0.026). Among 37 eyes with 2 steps of progression, the estimate of the risk of progressing further was 32% at 10 years after the initial VF., CONCLUSION: Eyes with a relatively shorter time to initial VF progression from open-angle glaucoma are likely to continue to progress over long-term follow-up. More aggressive treatment in such eyes might reduce the likelihood of further VF progression. AU - Chen, Philip P. AU - Cady, Robert Samuel AU - Mudumbai, Raghu C. AU - Ngan, Rose DO - https://dx.doi.org/10.1097/IJG.0b013e3181d12e1e IS - 9 KW - Aged Aged, 80 and over Antihypertensive Agents/ad [Administration & Dosage] Disease Progression Female Follow-Up Studies *Glaucoma, Open-Angle/pp [Physiopathology] Glaucoma, Open-Angle/th [Therapy] Humans Intraocular Pressure Male Middle Aged Patient Compliance Retrospective Studies Risk Factors Time Factors *Vision Disorders/pp [Physiopathology] Visual Field Tests *Visual Fields/ph [Physiology] PY - 2010 SE - Chen, Philip P. Department of Ophthalmology, University of Washington, Seattle, USA. pchen@u.washington.edu SN - 1536-481X 1057-0829 SP - 598-603 ST - Continued visual field progression in eyes with prior visual field progression in patients with open-angle glaucoma T2 - Journal of glaucoma TI - Continued visual field progression in eyes with prior visual field progression in patients with open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20179616 VL - 19 ID - 1374 ER - TY - JOUR AB - PURPOSE: To assess how general glaucoma patients understand their disease compared with patients from the Shanghai Glaucoma Club and various influencing factors as well. Shanghai Glaucoma Club was further evaluated to determine its efficacy on its members' understanding and knowledge of glaucoma., METHODS: A total of 301 glaucoma patients in Shanghai Glaucoma Club and 314 general glaucoma patients were investigated by a questionnaire, composed of three parts and consisting of 20 questions. The first part asked questions about 'level of cognition about glaucoma', the second part was about 'compliance of medication and follow-up', and the third part was about 'life style and habit'. Answers were graded on each question and scores were summed up separately for each part and as a total. Differences of scores and influencing effects were analysed using multivariate linear regression (stepwise) between the two groups., RESULTS: The average total scores of the general glaucoma patients and the glaucoma club members were 19.6 +/- 5.4 and 23.8 +/- 4.0 (t = -11.14 P < 0.01), respectively. After multivariate linear regression adjustment for the effects of age, diagnosis and educational level glaucoma club members still had 3.73 points edge over the general patients.(t = 8.14, P < 0.01). The club was shown to be the strongest positive factor influencing patients' cognition. Patients in Shanghai Glaucoma Club understood the nature and course of glaucoma significantly better than the general glaucoma patients (t = 10.97, P < 0.01) and also lived healthier lives (t = 7.55, P < 0.01). The level of background education was found to be a positive influencing factor although age was negatively correlated with total score. Primary glaucoma patients demonstrated better cognition of their diseases compared with secondary glaucoma patients, and those patients unaware of their type of glaucoma produced lower scores., CONCLUSIONS: This study demonstrated significant differences regarding the basic understanding of glaucoma between two groups: general glaucoma patients and members of the Shanghai Glaucoma Club. Club members presented with better cognition of glaucoma and self-management compared with general glaucoma patients. Therefore, the Shanghai Glaucoma Club is an effective medium to improve patients' knowledge of disease and compliance for medication. AU - Chen, Xueli AU - Chen, Yuhong AU - Sun, Xinghuai DO - https://dx.doi.org/10.1111/j.1442-9071.2009.02101.x IS - 6 KW - Adult Aged China Educational Status Female *Glaucoma *Health Knowledge, Attitudes, Practice Humans Male Middle Aged *Ophthalmology/ed [Education] Patient Compliance *Patient Education as Topic *Self-Help Groups/og [Organization & Administration] Surveys and Questionnaires PY - 2009 SE - Chen, Xueli. Eye and ENT Hospital, Fudan University, Shanghai, China. SN - 1442-9071 1442-6404 SP - 590-4 ST - Notable role of glaucoma club on patients' knowledge of glaucoma T2 - Clinical & experimental ophthalmology TI - Notable role of glaucoma club on patients' knowledge of glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19702709 VL - 37 ID - 1429 ER - TY - JOUR AB - There are much effective medicine currently available for treating glaucoma. However, their clinical efficacy is limited by traditional delivery systems, resulting in poor bioavailability, poor patient adherence, and increased side effects. By topical eye drops, intraocular injection or subconjunctival injection, and surgical implants, drug delivery systems can realize the purpose of sustained-release in target tissue. Poly (DL-lactide-co-glycolide), liposome, chitosan and other sustained-release materials with biodegradation and biocompatibility are becoming research focus gradually. Drug delivery systems have the possibility to become irreplaceable carriers for glaucoma therapy medicine. AD - L. Xie, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, China AU - Chen, X. AU - Xie, L. DB - Embase DO - 10.3969/j.issn.1672-5123.2012.02.20 IS - 2 KW - chitosan eye drops liposome polyglactin bioavailability biocompatibility drug delivery system drug efficacy glaucoma injection liposomal delivery patient compliance review sustained drug release LA - Chinese M3 - Review N1 - L364934447 2012-06-15 2012-06-19 PY - 2012 SN - 1672-5123 SP - 260-263 ST - Application of drug delivery systems in glaucoma therapy T2 - International Eye Science TI - Application of drug delivery systems in glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364934447&from=export http://dx.doi.org/10.3969/j.issn.1672-5123.2012.02.20 VL - 12 ID - 3112 ER - TY - JOUR AB - BACKGROUND: To determine the prevalence and causes of blindness and vision impairment (VI) in East Asia in 2015 and to forecast the trend to 2020., METHODS: Through a systematic literature review and meta-analysis, we estimated prevalence of blindness (presenting visual acuity <3/60 in the better eye), moderate-to-severe vision impairment (MSVI; 3/60<=presenting visual acuity <6/18), mild vision impairment (mild VI: 6/18<=presenting visual acuity <6/12) and uncorrected presbyopia for 1990, 2010, 2015 and 2020. A total of 44 population-based studies were included., RESULTS: In 2015, age-standardised prevalence of blindness, MSVI, mild VI and uncorrected presbyopia was 0.37% (80% uncertainty interval (UI) 0.12%-0.68%), 3.06% (80% UI 1.35%-5.16%) and 2.65% (80% UI 0.92%-4.91%), 32.91% (80% UI 18.72%-48.47%), respectively, in East Asia. Cataract was the leading cause of blindness (43.6%), followed by uncorrected refractive error (12.9%), glaucoma, age-related macular degeneration, corneal diseases, trachoma and diabetic retinopathy (DR). The leading cause for MSVI was uncorrected refractive error, followed by cataract, age-related macular degeneration, glaucoma, corneal disease, trachoma and DR. The burden of VI due to uncorrected refractive error, cataracts, glaucoma and DR has continued to rise over the decades reported., CONCLUSIONS: Addressing the public healthcare barriers for cataract and uncorrected refractive error can help eliminate almost 57% of all blindness cases in this region. Therefore, public healthcare efforts should be focused on effective screening and effective patient education, with access to high-quality healthcare. Copyright © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. AU - Cheng, Ching-Yu AU - Wang, Ningli AU - Wong, Tien Y. AU - Congdon, Nathan AU - He, Mingguang AU - Wang, Ya Xing AU - Braithwaite, Tasanee AU - Casson, Robert J. AU - Cicinelli, Maria Vittoria AU - Das, Aditi AU - Flaxman, Seth R. AU - Jonas, Jost B. AU - Keeffe, Jill Elizabeth AU - Kempen, John H. AU - Leasher, Janet AU - Limburg, Hans AU - Naidoo, Kovin AU - Pesudovs, Konrad AU - Resnikoff, Serge AU - Silvester, Alexander J. AU - Tahhan, Nina AU - Taylor, Hugh R. AU - Bourne, Rupert R. A. AU - Vision Loss Expert Group of the Global Burden of Disease, Study DO - https://dx.doi.org/10.1136/bjophthalmol-2018-313308 IS - 5 KW - *Blindness/ep [Epidemiology] Far East/ep [Epidemiology] Humans Prevalence *Visual Acuity PY - 2020 SE - Cheng, Ching-Yu. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore. Cheng, Ching-Yu. Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore. Wang, Ningli. Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Science Key Lab, Beijing, China. Wang, Ningli. Beijing Institute of Ophthalmology, Capital Medical University, Beijing, China. Wong, Tien Y. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore. Wong, Tien Y. Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore. Congdon, Nathan. Preventive Ophthalmology, Zhongshan Ophthalmic Center, Guangdong, China. Congdon, Nathan. Centre for Public Health, Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK. He, Mingguang. Ophthalmology Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, Australia. Wang, Ya Xing. Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China. Braithwaite, Tasanee. School of Medicine, Vision and Eye Research Unit (VERU), Anglia Ruskin University, Chelmsford, UK. Braithwaite, Tasanee. Moorfields Eye Hospital NHS Foundation Trust, London, UK. Casson, Robert J. Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Cicinelli, Maria Vittoria. Department of Ophthalmology, University Vita-Salute, San Raffaele Hospital, Milan, Italy. Das, Aditi. Ophthalmic Public Health, Leeds Teaching Hospital NHS Trust, London, UK. Flaxman, Seth R. Department of Mathematics and Data Science Institute, Imperial College, London, UK. Jonas, Jost B. Department of Ophthalmology, Ruprecht-Karls-University Heidelberg, Seegartenklinik Heidelberg, Mannheim, Germany. Keeffe, Jill Elizabeth. L V Prasad Eye Institute, Hyderabad, India. Kempen, John H. Ophthalmology and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Leasher, Janet. HPD/College of Optometry, Nova Southeastern University, Davie, Florida, USA. Limburg, Hans. Health Information Services, Grootebroek, The Netherlands. Naidoo, Kovin. African Vision Research Institute, Durban, South Africa. Pesudovs, Konrad. Pesudovs, GLENELG, South Australia, Australia. Resnikoff, Serge. Brien Holden Vision Institute, Sydney, New South Wales, Australia. Silvester, Alexander J. Ophthalmology, Royal Liverpool University Hospital, Liverpool, UK. Tahhan, Nina. Brien Holden Vision Institute, Sydney, New South Wales, Australia. Taylor, Hugh R. Melbourne School of Population Health, The University of Melbourne, Carlton, Victoria, Australia. Bourne, Rupert R A. School of Medicine, Vision and Eye Research Unit (VERU), Anglia Ruskin University, Chelmsford, UK rb@rupertbourne.co.uk. SN - 1468-2079 0007-1161 SP - 616-622 ST - Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections T2 - The British journal of ophthalmology TI - Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31462416 VL - 104 Y2 - 20190828// ID - 253 ER - TY - JOUR AB - PURPOSE: To investigate the prevalence and causes of distance-visual impairment and near-vision impairment in a rural Chinese population in Inner Mongolia., METHODS: A population-based, cross-sectional study design was used to identify visual impairment in the Chinese aged 40 years and older living in Kailu County, Inner Mongolia. Low vision, blindness and near-visual impairment (NVI) were defined according to World Health Organization (WHO) criteria., RESULTS: The overall prevalence of blindness and visual impairment based on the presenting visual acuity (VA) was 2.2% (95% CI: 1.8-2.6) and 9.8% (95% CI: 8.9-10.6), respectively, and was adjusted to 0.9% (95% CI: 0.6-1.2) and 4.7% (95% CI: 4.1-5.3) using best-corrected visual acuity (BCVA), respectively. Taking the presenting VA into consideration, the leading cause of visual impairment and blindness was cataract (40.3%, 40.9%), followed by uncorrected refractive error (26.6%, 28.2%). According to the BCVA, the main cause of visual impairment and blindness was cataract (48.3%, 41.3%) followed by glaucoma (19.0%, 23.9%). Among the examined subjects, 80.3% had NVI, and 51.7% had presbyopia. Major barriers reported by NVI persons without near correction were lack of money to purchase prescription glasses and poor quality of the available ones (43.2%)., CONCLUSION: Visual impairment is a serious public health problem, and the main causes leading to visual impairment are treatable and preventable in the rural Chinese population in Inner Mongolia. Presbyopia, together with the low rate of spectacles and lack of appropriate refractive and presbyopia spectacles, is highly prevalent in rural China. Copyright © 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. AU - Cheng, Fang AU - Shan, Li AU - Song, Wulian AU - Fan, Pan AU - Yuan, Huiping DO - https://dx.doi.org/10.1111/aos.12808 IS - 4 KW - Adult *Asian Continental Ancestry Group/eh [Ethnology] *Blindness/ep [Epidemiology] Cataract/ep [Epidemiology] China/ep [Epidemiology] Cross-Sectional Studies Eyeglasses/sn [Statistics & Numerical Data] Eyeglasses/sd [Supply & Distribution] Female Glaucoma/ep [Epidemiology] Humans Male Middle Aged Prevalence *Rural Population/sn [Statistics & Numerical Data] *Vision, Low/ep [Epidemiology] Visual Acuity/ph [Physiology] *Visually Impaired Persons/sn [Statistics & Numerical Data] PY - 2016 SE - Cheng, Fang. Department of Ophthalmology, the 2nd Affiliated Hospital, Harbin Medical University, Harbin, China. Shan, Li. Department of Ophthalmology, the 2nd Affiliated Hospital, Harbin Medical University, Harbin, China. Song, Wulian. Department of Ophthalmology, the 2nd Affiliated Hospital, Harbin Medical University, Harbin, China. Fan, Pan. Department of Ophthalmology, the 2nd Affiliated Hospital, Harbin Medical University, Harbin, China. Yuan, Huiping. Department of Ophthalmology, the 2nd Affiliated Hospital, Harbin Medical University, Harbin, China. SN - 1755-3768 1755-375X SP - 407-13 ST - Distance- and near-visual impairment in rural Chinese adults in Kailu, Inner Mongolia T2 - Acta ophthalmologica TI - Distance- and near-visual impairment in rural Chinese adults in Kailu, Inner Mongolia UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26289905 VL - 94 Y2 - 20150820// ID - 745 ER - TY - JOUR AB - BACKGROUND: To evaluate the surgical results of patients with persistent fetal vasculature (PFV), also known as persistent hyperplastic primary vitreous (PHPV)., METHODS: From 1991 to 2001, a retrospective, noncomparative study of 7 eyes of 7 patients diagnosed with PFV was conducted. In each case, type of anterior and/or posterior PHPV findings, preoperative testing, surgical procedures, and visual outcomes were obtained from the records. Follow-up ranged from 12 to 43 months, with a mean of 15 months., RESULTS: Of the 7 eyes, one (14%) had strictly anterior PFV, 1 (14%) had strictly posterior PFV, and 5 (71%) had components of both anterior and posterior disease. Initial lens aspiration only was performed in 3 (43%) eyes. Initial vitrectomy only was performed in 1 eye (14%). Initial lensectomy and vitrectomy was performed in 3 (42.8%) eyes. The reoperation rate was 43% for membrane reproliferation, glaucoma, vitreous hemorrhage, and retinal detachment. Final best-corrected visual acuity ranged from light perception only to 20/70 on the Snellen chart., CONCLUSIONS: Functional vision is possible in selected patients. However, poor final visual outcome despite adequate anatomic success were noted in this study. The poor outcomes might have been due to patients delaying vitrectomy until retinal detachment developed or that the patients had poor compliance with postoperative ocular rehabilitation. AU - Cheng, Li-Sheng AU - Kuo, Hsi-Kung AU - Lin, Sue-Ann AU - Kuo, Ming-Lun IS - 8 KW - Child Child, Preschool *Eye Abnormalities/su [Surgery] Female Humans Hyperplasia Infant Lens, Crystalline/su [Surgery] Male Postoperative Complications/et [Etiology] Retrospective Studies Visual Acuity Vitrectomy *Vitreous Body/ab [Abnormalities] PY - 2004 SE - Cheng, Li-Sheng. Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC. SN - 2072-0939 SP - 602-8 ST - Surgical results of persistent fetal vasculature T2 - Chang Gung medical journal TI - Surgical results of persistent fetal vasculature UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15553607 VL - 27 ID - 1764 ER - TY - JOUR AB - There are 34,492 registered with severe or partial sight impairment in Scotland, with 75% aged over 65. With the ageing population, the proportion of those who will develop sight impairing disease will only increase. Therefore, early presentation and treatment are important. Recently, new sight saving treatments and community screening programmes for sight impairing disease have been introduced with concomitant advance in ophthalmic digital imaging.In order to assess older patients’ attendance of free eye tests, awareness of different sight impairing disease and treatments. We describe the first electronic visual healthcare system within any global public healthcare service – ‘The Scottish Eyecare Integration Project’ – and potential improvements along with the General Ophthalmic Service (GOS) contract.A 14-point questionnaire was devised to assess 100 patients’ awareness of free annual eye tests, and the three most common causes and treatment for severe sight impairment: age-related macular degeneration (ARMD), glaucoma, and diabetic retinopathy (DR).In all, 82% of patients were aware of the free annual eye tests; however, 31% had not attended community optometrist for over 2 years. There was good awareness of glaucoma (77%), but poor understanding of glaucoma treatment (24%), ARMD (43%) and ARMD treatment (17%). Only 39% of patients had heard of free annual DR screening, but there was a significant difference between the two groups (p = .0263), with increased awareness in the middle-aged group.More education is required to encourage the older population to use existing and new eye services. The Scottish Eyecare Integration Project along with the GOS contract is a significant step of change towards meeting the demand for a multidisciplinary approach, bringing ophthalmic care closer to home and into the community. AD - Queen Margaret Hospital, UK Royal National Institute of Blind People (RNIB), UK Queen Margaret Hospital & Scottish Government, UK AN - 109292966. Language: English. Entry Date: 20151106. Revision Date: 20190708. Publication Type: Article AU - Cheng, Mei-Ling AU - Henderson, Clair AU - Sinclair, Anne AU - Sanders, Roshini DB - ccm DO - 10.1177/0264619615600009 DP - EBSCOhost IS - 3 KW - Vision Health Knowledge -- Scotland Optometry Community Programs Health Services Accessibility Vision Disorders -- Prevention and Control Scotland Human Early Intervention Questionnaires Patient Attitudes Health Screening -- Methods Data Analysis Software T-Tests Middle Age Aged Aged, 80 and Over Descriptive Statistics Adult N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 8607460. PY - 2015 SN - 0264-6196 SP - 220-226 ST - Visual health awareness, the Scottish community optometry service and Eyecare Integration Project: Breaking barriers in preventing visual impairment T2 - British Journal of Visual Impairment TI - Visual health awareness, the Scottish community optometry service and Eyecare Integration Project: Breaking barriers in preventing visual impairment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109292966&site=ehost-live&scope=site VL - 33 ID - 4362 ER - TY - JOUR AB - Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1min at 37degreeC. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy. Copyright © 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. AU - Cheng, Yung-Hsin AU - Hung, Kuo-Hsuan AU - Tsai, Tung-Hu AU - Lee, Chia-Jung AU - Ku, Ruy-Yu AU - Chiu, Allen Wen-Hsiang AU - Chiou, Shih-Hwa AU - Liu, Catherine Jui-Ling DO - https://dx.doi.org/10.1016/j.actbio.2014.05.031 IS - 10 KW - Animals Anti-Inflammatory Agents/ch [Chemistry] Anti-Inflammatory Agents/pd [Pharmacology] Antihypertensive Agents/ch [Chemistry] Antihypertensive Agents/pd [Pharmacology] *Antihypertensive Agents Chitosan/ch [Chemistry] Chitosan/pd [Pharmacology] *Chitosan Delayed-Action Preparations/ch [Chemistry] Delayed-Action Preparations/pk [Pharmacokinetics] Drug Evaluation, Preclinical Gelatin/ch [Chemistry] Gelatin/pd [Pharmacology] *Gelatin Humans Hydrogels/ch [Chemistry] Hydrogels/pd [Pharmacology] *Hydrogels Latanoprost Male *Ocular Hypertension/dt [Drug Therapy] Prostaglandins F, Synthetic/ch [Chemistry] *Prostaglandins F, Synthetic/pd [Pharmacology] Rabbits Triamcinolone Acetonide/ch [Chemistry] Triamcinolone Acetonide/pd [Pharmacology] PY - 2014 SE - Cheng, Yung-Hsin. Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; Department of Education and Research, Taipei City Hospital, Taipei, Taiwan. Hung, Kuo-Hsuan. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; National Yang-Ming University School of Medicine, Taipei, Taiwan; Division of Ophthalmology, National Yang-Ming University Hospital, I-Lan, Taiwan. Tsai, Tung-Hu. Department of Education and Research, Taipei City Hospital, Taipei, Taiwan; Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. Lee, Chia-Jung. Department of Education and Research, Taipei City Hospital, Taipei, Taiwan; Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. Ku, Ruy-Yu. National Yang-Ming University School of Medicine, Taipei, Taiwan. Chiu, Allen Wen-Hsiang. National Yang-Ming University School of Medicine, Taipei, Taiwan. Chiou, Shih-Hwa. Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: shchiou@vghtpe.gov.tw. Liu, Catherine Jui-Ling. National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan. Electronic address: jlliu@vghtpe.gov.tw. SN - 1878-7568 1742-7061 SP - 4360-6 ST - Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension T2 - Acta biomaterialia TI - Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24914827 VL - 10 Y2 - 20140607// ID - 878 ER - TY - JOUR AB - Using modern surgical treatment on patients that live in rural areas, with cataract and glaucoma is not sufficient. There is insufficient expertise of ophthalmologists, low level of human, logistical and financial resource support for eye hospitals, low level of motivation and socio-psychological problems among patients, creating a favorable situation in Ukraine for further growth of low vision and blindness in rural areas. Institutional solutions of existing problems are proposed. AU - Cheremukhina, O. M. IS - 3-4 KW - Blindness/ep [Epidemiology] Blindness/pa [Pathology] *Blindness/pc [Prevention & Control] Blindness/su [Surgery] Cataract/ep [Epidemiology] Cataract/pa [Pathology] *Cataract/pc [Prevention & Control] *Cataract Extraction/sn [Statistics & Numerical Data] Cataract Extraction/td [Trends] Female Glaucoma/ep [Epidemiology] Glaucoma/pa [Pathology] *Glaucoma/pc [Prevention & Control] Glaucoma/su [Surgery] Health Services Accessibility/ec [Economics] *Health Services Accessibility/og [Organization & Administration] Health Services Accessibility/sn [Statistics & Numerical Data] Humans *Lens, Crystalline/pa [Pathology] Lens, Crystalline/su [Surgery] Male Rural Health/ec [Economics] Rural Health/st [Standards] *Rural Health/sn [Statistics & Numerical Data] Ukraine/ep [Epidemiology] Vision, Low PY - 2011 SN - 1019-5297 SP - 138-43 ST - [Availability of patients living in rural areas, to have surgical method of treatment of cataract and glaucoma] T2 - Likars'ka sprava TI - [Availability of patients living in rural areas, to have surgical method of treatment of cataract and glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=22416380 ID - 1236 ER - TY - JOUR AD - I.N. Cherkasova AU - Cherkasova, I. N. DB - Medline IS - 1 KW - ambulatory care article differential diagnosis follow up glaucoma human intraocular hypertension risk LA - Russian M3 - Article N1 - L16703499 1986-04-24 PY - 1986 SN - 0042-465X SP - 51-53 ST - Principles of outpatient follow-up in ocular hypertension T2 - Vestnik oftalmologii TI - Principles of outpatient follow-up in ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L16703499&from=export VL - 102 ID - 4073 ER - TY - JOUR AB - Purpose: To report the clinical features, management, and outcomes of patients with ocular surface damage secondary to Roman candle explosion accidents. Methods: Retrospective, noncomparative, interventional case series of 11 patients with Roman candle explosion-related ocular surface injuries referred to the Cincinnati Eye Institute between 2007 and 2016. Results: Eleven patients (10 male, 1 female, mean age 22.4 years) sustained unilateral ocular surface injuries with presenting visual acuity ranging from count fingers to light perception. All patients had severe limbal stem cell deficiency with total ocular surface failure. Eight eyes received a conjunctival-limbal autograft (CLAU) with a keratolimbal allograft (KLAL), 1 eye received a living related-conjunctival limbal allograft (lr-CLAL) with a KLAL, and 2 eyes received a CLAU with lr-CLAL. Nine eyes underwent subsequent penetrating keratoplasty, and 7 eyes had reconstructive eyelid surgery. Nine eyes demonstrated improved visual acuity at last follow-up; seven eyes demonstrated a stable ocular surface at last follow-up. Nonadherence was noted in 7 patients, either with poor adherence with post-operative treatment or poor follow-up; this portended a worse visual result. Conclusions: Roman candle-related accidents can lead to severe ocular surface injury. Despite total ocular surface failure, these eyes can achieve good postoperative visual results following limbal stem cell transplantation and subsequent keratoplasty with appropriate compliance. AD - E.J. Holland, 580 South Loop Road, Suite 200, Edgewood, KY, United States AU - Cheung, A. Y. AU - Genereux, B. M. AU - Dautremont, B. AU - Govil, A. AU - Holland, E. J. DB - Embase Medline DO - 10.1016/j.jtos.2018.03.005 IS - 3 KW - general device keratoprosthesis Roman candle corticosteroid hydroxymethylglutaryl coenzyme A reductase inhibitor immunosuppressive agent adolescent adult amnion ankyloblepharon article autograft child clinical article conjunctival limbal autograft deep anterior lamellar keratoplasty explosion eye injury eye surgery eyelid reconstruction female glaucoma graft failure graft rejection human immunosuppressive treatment intraocular hypertension keratectomy keratitis keratolimbal allograft keratoplasty living related conjunctival limbal allograft male middle aged neutropenia ocular surface disease reconstructive surgery retrospective study school child side effect stem cell transplantation symblepharon tarsorrhaphy tissue transplantation young adult LA - English M3 - Article N1 - L2000609878 2018-04-03 2018-07-05 PY - 2018 SN - 1937-5913 1542-0124 SP - 294-300 ST - Surgical management of severe ocular surface injury due to Roman candle explosion accidents T2 - Ocular Surface TI - Surgical management of severe ocular surface injury due to Roman candle explosion accidents UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2000609878&from=export http://dx.doi.org/10.1016/j.jtos.2018.03.005 VL - 16 ID - 2574 ER - TY - JOUR AB - PURPOSE: To investigate normal flora of children with and without orthokeratology (ortho-k) treatment, and the associations between carriage of Staphylococcus aureus and Gram-negative rods with contamination of contact lenses and lens cases in ortho-k subjects and with spectacles of control subjects., METHODS: Twenty-three ortho-k subjects (treatment >12 months) and 20 control myopic subjects aged 7-14 years were recruited. Samples were collected from four sites surrounding the left eye (lower conjunctiva, upper and lower eyelids, and eyelashes) for all subjects, spectacles for control subjects and contact lens accessories for ortho-k subjects. Samples were cultured, total numbers enumerated, and isolates identified using chromogenic agars., RESULTS: Ortho-k subjects had significantly less total isolates in the conjunctiva than controls (p = 0.009). Otherwise, carriage rates in normal flora levels of the peri-orbital tissues were not significantly different between the two groups (p > 0.19). The total isolates and carriage rates of normal flora on spectacles, contact lenses, and lens cases were similar to those identified on the skin tissues. Small numbers of bacteria were identified from the multipurpose solution of two ortho-k subjects. Although the association between the carriage of S. aureus with contamination of accessories was statistically significant only in control subjects (p = 0.03), ortho-k subjects not yielding S. aureus and Gram-negative rods from samples of their peri-orbital tissues tended to be less likely to have these organisms in their accessories. No Pseudomonas was isolated from any of the sites sampled and no Acinetobacter was isolated from any of the accessories., CONCLUSIONS: Ortho-k may lower the total number of bacteria in conjunctiva due to the use of solution and lenses, but the physiologic effect of this treatment on the types of normal flora in children was minimal and should not increase the risk of microbial keratitis in children with good compliance. AU - Cheung, Sin Wan AU - Boost, Maureen AU - Shi, Guang Sen AU - Cho, Pauline DO - https://dx.doi.org/10.1097/OPX.0000000000000843 IS - 6 KW - Adolescent Child *Conjunctiva/mi [Microbiology] *Contact Lenses/mi [Microbiology] *Equipment Contamination *Eyelids/mi [Microbiology] Female *Gram-Negative Bacteria/gd [Growth & Development] Gram-Negative Bacteria/ip [Isolation & Purification] Humans Male Myopia/th [Therapy] Orthokeratologic Procedures/is [Instrumentation] *Orthokeratologic Procedures *Staphylococcus aureus/gd [Growth & Development] Staphylococcus aureus/ip [Isolation & Purification] PY - 2016 SE - Cheung, Sin Wan. *MPhil, FAAO DPhil ++MD PhD, FAAO School of Optometry (SWC, GSS, PC), and Squina Centre for Infection Control, School of Nursing (MB), The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China. SN - 1538-9235 1040-5488 SP - 612-8 ST - Microbial Contamination of Periorbital Tissues and Accessories of Children T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Microbial Contamination of Periorbital Tissues and Accessories of Children UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26945175 VL - 93 ID - 704 ER - TY - JOUR AB - BACKGROUND: Population-based data on prevalence, causes of blindness and extent of ophthalmological coverage is required for efficient implementation and evaluation of ocular health programs. In view of the scarcity of prevalence data for visual impairment and blindness in Malaysia, this study aims to estimate the prevalence and causes of visual impairment (VI) in the elderly, using Rapid Assessment of Avoidable Blindness (RAAB) survey technique., METHODS: Malaysia was divided into six regions, with each region consisting of 50 clusters. Multistage cluster sampling method was used and each cluster contained 50 residents aged 50 years and above. Eligible subjects were interviewed and pertinent demographic details, barriers to cataract surgery, medical and ocular history was noted. Subjects had visual acuity assessment with tumbling 'E' Snellen optotypes and ocular examination with direct ophthalmoscope. The primary cause of VI was documented. Results were calculated for individual zones and weighted average was used to obtain overall prevalence for the country. Inter-regional and overall prevalence for blindness, severe VI and moderate VI were determined. Causes of VI, cataract surgical coverage and barriers to cataract surgery were assessed., RESULTS: A total of 15,000 subjects were examined with a response rate of 95.3%. The age and gender-adjusted prevalence of blindness, severe visual impairment and moderate visual impairment were 1.2% (95% Confidence Interval: 1.0-1.4%), 1.0% (95%CI: 0.8-1.2%) and 5.9% (5.3-6.5%) respectively. Untreated cataract (58.6%), diabetic retinopathy (10.4%) and glaucoma (6.6%) were the commonest causes of blindness. Overall, 86.3% of the causes of blindness were avoidable. Cataract surgical coverage (CSC) in persons for blindness, severe visual impairment and moderate visual impairment was 90%, 86% and 66% respectively., CONCLUSION: Increased patient education and further expansion of ophthalmological services are required to reduce avoidable blindness even further in Malaysia. AU - Chew, Fiona L. M. AU - Salowi, Mohamad Aziz AU - Mustari, Zuraidah AU - Husni, Mohd Aziz AU - Hussein, Elias AU - Adnan, Tassha Hilda AU - Ngah, Nor Fariza AU - Limburg, Hans AU - Goh, Pik-Pin DO - https://dx.doi.org/10.1371/journal.pone.0198799 IS - 6 KW - Aged Aged, 80 and over Blindness/di [Diagnosis] *Blindness/ep [Epidemiology] Female Humans Malaysia/ep [Epidemiology] Male Middle Aged Prevalence Risk Factors Vision Disorders/di [Diagnosis] *Vision Disorders/ep [Epidemiology] Visual Acuity PY - 2018 SE - Chew, Fiona L M. Department of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, Malaysia. Salowi, Mohamad Aziz. Department of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, Malaysia. Salowi, Mohamad Aziz. Faculty of Medicine, Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu, Malaysia. Mustari, Zuraidah. Department of Ophthalmology, Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia. Husni, Mohd Aziz. Department of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, Malaysia. Hussein, Elias. Department of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, Malaysia. Adnan, Tassha Hilda. Clinical Research Centre, Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, Malaysia. Ngah, Nor Fariza. Department of Ophthalmology, Hospital Shah Alam, Shah Alam, Selangor, Malaysia. Limburg, Hans. Health Information Services, Grootebroek, The Netherlands. Goh, Pik-Pin. Clinical Research Centre, Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, Malaysia. SN - 1932-6203 SP - e0198799 ST - Estimates of visual impairment and its causes from the National Eye Survey in Malaysia (NESII) T2 - PloS one TI - Estimates of visual impairment and its causes from the National Eye Survey in Malaysia (NESII) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29944677 VL - 13 Y2 - 20180626// ID - 422 ER - TY - JOUR AB - PURPOSE: To evaluate the outcomes of the Boston Keratoprosthesis (KPro) at our institution., METHODS: A computerized database retrospectively identified all patients who received a Boston KPro from August 2005 to October 2007., RESULTS: There were 37 patients, 24 (65%) were male. Mean age was 66.3 years (median 69 years, range: 24-93 years; SD = 18.1 years). Mean follow-up was 16 months (range: 6-28 months; SD = 6.0 months). There were 36 type 1 (97%) and 1 type 2 (3%) KPros. The primary indication was failed penetrating keratoplasty in 29 patients (78%)-22 (59%) from multiple failures. Preoperative comorbidities included glaucoma [27 patients (73%)] and limbal stem cell deficiency [13 patients (35%)]. No intraoperative complications occurred. Postoperative complications included retroprosthetic membrane [24 patients (65%)], increased intraocular pressure [14 patients (38%)], glaucoma progression [5 patients (13.5%)], and endophthalmitis [4 patients (11%)-3 who discontinued prophylactic antibiotics secondary to compliance]. Thirty-six KPros (97%) were retained-1 type 2 KPro (3%) in a patient with ocular cicatricial pemphigoid extruded and was replaced. Mean best-corrected visual acuities were counting fingers preoperatively (range: light perception to 20/100) and 20/90 at last follow-up (range: light perception to 20/25). At last follow-up, 31 patients (84%) improved 2 lines or greater-3 patients (8%) had worse vision., CONCLUSIONS: Retention rates were excellent, and best-corrected visual acuities improved in the vast majority of patients. Complications can occur and require frequent follow-up to monitor and treat glaucoma progression, endophthalmitis, and inflammation. Patient compliance is of paramount importance. Despite the potential complications, the Boston KPro provides visual improvement in patients with an otherwise poor prognosis. AU - Chew, Hall F. AU - Ayres, Brandon D. AU - Hammersmith, Kristin M. AU - Rapuano, Christopher J. AU - Laibson, Peter R. AU - Myers, Jonathan S. AU - Jin, Ya-Ping AU - Cohen, Elisabeth J. DO - https://dx.doi.org/10.1097/ICO.0b013e3181a186dc IS - 9 KW - Adult Aged Aged, 80 and over *Artificial Organs *Cornea Corneal Diseases/su [Surgery] Female Graft Survival/ph [Physiology] Humans *Intraoperative Complications Male Middle Aged *Postoperative Complications *Prostheses and Implants *Prosthesis Implantation Retrospective Studies Treatment Outcome Visual Acuity/ph [Physiology] PY - 2009 SE - Chew, Hall F. Cornea Service, Wills Eye Institute, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA. hall.chew@utoronto.ca SN - 1536-4798 0277-3740 SP - 989-96 ST - Boston keratoprosthesis outcomes and complications T2 - Cornea TI - Boston keratoprosthesis outcomes and complications UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19724214 VL - 28 ID - 1427 ER - TY - JOUR AB - PURPOSE: To report the first case of fungal keratitis caused by presumed Carpoligna species., METHODS: A 37-year-old gardener sustained a full-thickness, stellate corneal laceration while cutting wood outdoors with a circular saw. Two months after surgical repair, he developed a severe infectious keratitis with descemetocoele at the apex of the original stellate laceration., RESULTS: Culture results confirmed fungal elements without evidence of bacteria. Oral and topical voriconazole were initiated. Due to compliance and cost issues, voriconazole was replaced with natamycin 5% prior to discharge from hospital. The patient improved and healed without perforation. The patient was left with a central stromal scar. DNA extraction from the fungal colony allowed PCR amplification of the 28s ribosomal RNA region of the fungus that led to the diagnosis of Carpoligna pleurothecii. Corticosteroids were never used during the patient's treatment., CONCLUSION: This is the first reported case of infectious keratitis caused by presumed Carpoligna species. The treatment for Carpoligna pleurothecii keratitis includes voriconazole, natamycin, and possibly amphotericin B. AU - Chew, Hall F. AU - Jungkind, Donald L. AU - Mah, Dean Y. AU - Raber, Irving M. AU - Toll, Adam D. AU - Tokarczyk, Mindy J. AU - Cohen, Elisabeth J. DO - https://dx.doi.org/10.1097/ICO.0b013e3181af3954 IS - 4 KW - Adult Amphotericin B/tu [Therapeutic Use] Antifungal Agents/tu [Therapeutic Use] Base Sequence *Corneal Injuries Corneal Ulcer/di [Diagnosis] Corneal Ulcer/dt [Drug Therapy] *Corneal Ulcer/mi [Microbiology] DNA, Fungal/ge [Genetics] Eye Infections, Fungal/di [Diagnosis] Eye Infections, Fungal/dt [Drug Therapy] *Eye Infections, Fungal/mi [Microbiology] Eye Injuries/di [Diagnosis] Eye Injuries/dt [Drug Therapy] *Eye Injuries/mi [Microbiology] Humans Lacerations/di [Diagnosis] Lacerations/dt [Drug Therapy] *Lacerations/mi [Microbiology] Male Mitosporic Fungi/ge [Genetics] *Mitosporic Fungi/ip [Isolation & Purification] Molecular Sequence Data Natamycin/tu [Therapeutic Use] Polymerase Chain Reaction Pyrimidines/tu [Therapeutic Use] RNA, Fungal/ge [Genetics] RNA, Ribosomal, 28S/ge [Genetics] Triazoles/tu [Therapeutic Use] Voriconazole PY - 2010 SE - Chew, Hall F. Cornea Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA, USA. hall.chew@utoronto.ca SN - 1536-4798 0277-3740 SP - 449-52 ST - Post-traumatic fungal keratitis caused by Carpoligna sp T2 - Cornea TI - Post-traumatic fungal keratitis caused by Carpoligna sp UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20168220 VL - 29 ID - 1376 ER - TY - JOUR AB - INTRODUCTION: Glaucoma is a common sight-threatening condition that is primarily treated by lowering intraocular pressure (IOP). Today the mainstay of treatment is topical ocular hypotensive medications; many patients require more than one agent to achieve target IOP. For such patients, fixed combination formulations have several advantages including simplicity of treatment regimen, adherence to the treatment regimen, efficacy, improved ocular surface comfort and reduced cost. All currently available fixed combinations contain a beta-blocker, which is contraindicated in some patients. Hence there is a clinical need for fixed-combination preparations without a beta-blocker. This paper reviews the current literature on a new fixed-combination drug containing brinzolamide 1% and brimonidine 0.2% (BBFC)., AREAS COVERED: A PubMed, Embase and ClinicalTrials.gov registry search was performed to identify all relevant studies. Four published clinical papers pertaining to three randomized controlled trials were identified for review. All studies demonstrated a significant reduction (p < 0.01) in mean IOP in patients administered with BBFC compared with its individual components, brinzolamide 1% or brimonidine 0.2%. Adverse effects from BBFC were no different from each of the individual components, the most common being blurred vision, eye irritation and dysgeusia (abnormal taste sensation). Although BBFC use was associated with more adverse effects compared with the individual components used as monotherapy (p < 0.001), the cumulative adverse effect profile from BBFC did not appear greater than one would expect from the simultaneous use of the two components., EXPERT OPINION: BBFC is a potential alternative to other fixed-combination medications and is especially useful when topical beta-blockers are contraindicated. Longer-term experience will determine if additional adverse effects occur or if efficacy is maintained over longer periods. AU - Chew, Sky K. AU - Skalicky, Simon E. AU - Goldberg, Ivan DO - https://dx.doi.org/10.1517/14656566.2014.966689 IS - 16 KW - *Adrenergic alpha-2 Receptor Agonists/tu [Therapeutic Use] *Antihypertensive Agents/tu [Therapeutic Use] Brimonidine Tartrate *Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] Clinical Trials as Topic Drug Combinations *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Humans Intraocular Pressure/de [Drug Effects] *Quinoxalines/tu [Therapeutic Use] *Sulfonamides/tu [Therapeutic Use] *Thiazines/tu [Therapeutic Use] PY - 2014 SE - Chew, Sky K. University of Melbourne, Royal Melbourne Hospital, Department of Ophthalmology, VIC, Australia. SN - 1744-7666 1465-6566 SP - 2461-71 ST - Brinzolamide plus brimonidine for the treatment of glaucoma: an update T2 - Expert opinion on pharmacotherapy TI - Brinzolamide plus brimonidine for the treatment of glaucoma: an update UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25267543 VL - 15 Y2 - 20140930// ID - 859 ER - TY - JOUR AB - PURPOSE: The aim of this consensus article was to provide comprehensive recommendations in the management of diabetic macular edema (DME) by reviewing recent clinical evidence., DESIGN: A questionnaire containing 47 questions was developed which encompassed clinical scenarios such as treatment response to anti-vascular endothelial growth factor and steroid, treatment side effects, as well as cost and compliance/reimbursement in the management of DME using a Dephi questionnaire as guide., METHODS: An expert panel of 12 retinal specialists from Singapore, Malaysia, Philippines, India and Vietnam responded to this questionnaire on two separate occasions. The first round responses were compiled, analyzed and discussed in a round table discussion where a consensus was sought through voting. Consensus was considered achieved, when 9 of the 12 panellists (75%) agreed on a recommendation., RESULTS: The DME patients were initially profiled based on their response to treatment, and the terms target response, adequate response, nonresponse, and inadequate response were defined. The panellists arrived at a consensus on various aspects of DME treatment such as need for classification of patients before treatment, first-line treatment options, appropriate time to switch between treatment modalities, and steroid-related side effects based on which recommendations were derived, and a treatment algorithm was developed., CONCLUSIONS: This consensus article provides comprehensive, evidence-based treatment guidelines in the management of DME in Asian population. In addition, it also provides recommendations on other aspects of DME management such as steroid treatment for stable glaucoma patients, management of intraocular pressure rise, and recommendations for cataract development. AU - Chhablani, Jay AU - Wong, Kelvin AU - Tan, Gavin S. AU - Sudhalkar, Aditya AU - Laude, Augustinus AU - Cheung, Chui Ming Gemmy AU - Zhao, Paul AU - Uy, Harvey AU - Lim, Jeffrey AU - Valero, Sherman AU - Ngah, Nor Fariza AU - Koh, Adrian DO - https://dx.doi.org/10.1097/APO.0000000000000312 IS - 5 KW - *Angiogenesis Inhibitors/ad [Administration & Dosage] *Consensus Diabetic Retinopathy/co [Complications] Diabetic Retinopathy/di [Diagnosis] *Diabetic Retinopathy/dt [Drug Therapy] Follow-Up Studies *Glucocorticoids/ad [Administration & Dosage] Humans Intravitreal Injections Macular Edema/di [Diagnosis] *Macular Edema/dt [Drug Therapy] Macular Edema/et [Etiology] Retrospective Studies Surveys and Questionnaires Treatment Outcome Vascular Endothelial Growth Factor A/ai [Antagonists & Inhibitors] *Visual Acuity PY - 2020 SE - Chhablani, Jay. University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, PA. Chhablani, Jay. Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad, India. Wong, Kelvin. American Eye Centre, Ho Chi Min, Vietnam. Tan, Gavin S. Surgical Retinal Department of the Singapore National Eye Centre; Clinician scientist, Singapore Eye Research Institute, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore. Sudhalkar, Aditya. Alphavision Augenzentrum Bremerhaven, Germany. Sudhalkar, Aditya. Sudhalkar Eye Hospital and Retina Centre in Baroda, India and Raghudeep Eye Hospital, Ahmedabad, India. Laude, Augustinus. National Healthcare Group Eye Institute, Tan Tock Seng Hospital; Adjunct associate professor, Lee Kong Chian School of Medicine Nanyang Technological University, Singapore. Cheung, Chui Ming Gemmy. Duke-NUS Medical School, National University of Singapore, Singapore. Zhao, Paul. Department of Ophthalmology, National University Hospital; Chief, Alexandria Hospital Eye Surgery Center, Singapore. Uy, Harvey. University of the Philippines and Medical Director, Peregrine Eye and Laser Institute in Makati, Philippines. Lim, Jeffrey. Chong Hua Hospital, Cebu; Head, Retina section, Vicente Sotto Memorial Medical Center, Philippines. Valero, Sherman. The Medical City, Pasig City, Philippines. Ngah, Nor Fariza. National Head, Ophthalmology Service, Ministry of Health Malaysia; Ophthalmology Service, Ministry of Health Malaysia; Head of Department, Ophthalmology Unit, Hospital Shah Alam, Malaysia. Koh, Adrian. The Eye and Retina Surgeons, Camden Medical Center, Singapore. SN - 2162-0989 SP - 426-434 ST - Diabetic Macular Edema Management in Asian Population: Expert Panel Consensus Guidelines T2 - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) TI - Diabetic Macular Edema Management in Asian Population: Expert Panel Consensus Guidelines UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=mesx&NEWS=N&AN=32956188 VL - 9 ID - 151 ER - TY - JOUR AB - PURPOSE: This study aimed to identify patient and appointment characteristics associated with no-shows to new patient appointments at a US academic ophthalmology department., DESIGN: Cross-sectional study., METHODS: This was a study of all adult patients with new patient appointments scheduled with an attending ophthalmologist at Penn State Eye Center between January 1st and December 31st of 2019. A multiple logistic regression model was used to assess the association between characteristics and no-show status., RESULTS: Of 4,628 patients, 759 (16.4%) were no-shows. From the multiple logistic regression model, characteristics associated with no-shows were age (Odds Ratio (OR) for 18-40 years vs. >60 years: 3.41, 95% Confidence Interval (CI) 2.57, 4.51, p <0.001 and OR for 41-60 years vs. >60 years: 2.14, 95% CI 1.67, 2.74, p<0.001), median household income (OR for <$35,667 vs. >$59,445: 1.59, 95% CI 1.08, 2.34, p<0.001), insurance (OR for None vs. Medicare: 6.92, 95% CI 4.41, 10.86, p<0.001 and OR for Medicaid vs. Medicare: 1.54, 95% CI 1.18, 2.01, p=0.002), race (OR for Black vs. White: 2.62, 95% CI 2.00, 3.43, p<0.001 and OR for Other vs. White: 2.02, 95% CI 1.58, 2.59, p<0.001), and commute distance (OR for 5-10 mi vs. <=5 mi: 1.73, 95% CI 1.17, 2.55, p=0.006). Appointments with longer lead times and scheduled with glaucoma or retina specialists were also significantly associated with greater no-shows., CONCLUSION: Certain patient and appointment characteristics were associated with no-show status. These findings may assist in the development of targeted interventions at the patient, practice, and health system levels to improve appointment attendance. Copyright © 2021 Elsevier Inc. All rights reserved. AU - Chiam, Mckenzee AU - Kunselman, Allen R. AU - Chen, Michael C. DO - https://dx.doi.org/10.1016/j.ajo.2021.02.020 PY - 2021 SE - Chiam, Mckenzee. From the Department of Ophthalmology (MC, MCC), Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA. Kunselman, Allen R. Department of Public Health Sciences (ARK), Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA. Chen, Michael C. From the Department of Ophthalmology (MC, MCC), Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA. Electronic address: mchen3@pennstatehealth.psu.edu. SN - 1879-1891 0002-9394 SP - 210-219 ST - Characteristics Associated With New Patient Appointment No-Shows at an Academic Ophthalmology Department in the United States T2 - American journal of ophthalmology TI - Characteristics Associated With New Patient Appointment No-Shows at an Academic Ophthalmology Department in the United States UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=33626367 VL - 229 Y2 - 20210221// ID - 3 ER - TY - JOUR AB - PURPOSE: In an in vitro study, fixed-combination fortified vancomycin and amikacin ophthalmic solutions (VA solution) had the same potency and stable physical properties as the separate components. In this retrospective clinical study, we evaluated the efficacy of the topical VA solution in the treatment of bacterial corneal ulcer and comparison with separate topical fortified vancomycin and amikacin., METHODS: Separate topical fortified eye drops was used prior to January 2004 and switched to the VA solution afterwards in the treatment of bacterial corneal ulcer. The medical records of 223 patients diagnosed with bacterial corneal ulcers between January 2002 and December 2005 were reviewed retrospectively. There were 122 patients in the VA group and 101 in the separate group. Cure was defined as complete healing of the ulcer accompanied by a nonprogressive stromal infiltrate on two consecutive visits., RESULTS: No significant difference was found between the VA and separate therapy group. The mean treatment duration was 15.4 days in the VA group and 16.1 days in the separate therapy group. The average hospital stay was 5.4 days (VA) and 7.2 days (separate antibiotics). Stromal infiltration regressed significantly without further expansion in both groups. All corneal ulcers completely re-epithelialized without complications related to drugs., CONCLUSION: VA solution provided similar efficacy to the conventional separate therapy in the treatment of bacterial corneal ulcers; however, it is more convenient and tolerable, promotes patient's compliance, avoids the washout effect, and reduces nurse utilization. Hence, VA solution is a good alternative to separate therapy. AU - Chiang, C. C. AU - Lin, J. M. AU - Chen, W. L. AU - Chiu, Y. T. AU - Tsai, Y. Y. DO - https://dx.doi.org/10.1038/sj.eye.6703078 IS - 2 KW - Adolescent Adult Aged Aged, 80 and over *Amikacin/ad [Administration & Dosage] Amikacin/tu [Therapeutic Use] *Anti-Bacterial Agents/ad [Administration & Dosage] Anti-Bacterial Agents/tu [Therapeutic Use] Chemistry, Pharmaceutical Child *Corneal Ulcer/dt [Drug Therapy] Corneal Ulcer/mi [Microbiology] Drug Combinations Drug Therapy, Combination *Eye Infections, Bacterial/dt [Drug Therapy] Eye Infections, Bacterial/mi [Microbiology] Female Humans Male Middle Aged Ophthalmic Solutions Retrospective Studies Risk Factors Treatment Outcome *Vancomycin/ad [Administration & Dosage] Vancomycin/tu [Therapeutic Use] Young Adult PY - 2009 SE - Chiang, C-C. Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan. SN - 1476-5454 0950-222X SP - 294-8 ST - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer T2 - Eye (London, England) TI - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18188174 VL - 23 Y2 - 20080111// ID - 1493 ER - TY - JOUR AB - Background: To describe a scleral indentation technique to enhance donor adherence in Descemet's stripping and automated endothelial keratoplasty (DSAEK) in patients with abnormal anterior segment. Methods: In patients with visual potential, we performed transscleral fixation of a foldable intraocular lens (IOL) and DSAEK. In patients only for pain relief, we performed DSAEK without IOL implantation. During air tamponade, we injected only a medium air bubble instead of big bubble into anterior chamber and used scleral indentation technique as an aid. The position of the grafts was checked by the slit lamp and anterior segment optical coherence tomography (AS-OCT). Results: Five eyes of five patients of aphakic bullous keratopathy (ABK) or pseudophakic bullous keratopathy (PBK) with anterior chamber IOL (AC IOL) were included in this non-comparative interventional case series. The grafts attached well in all patients without any graft dislocation intraoperatively and during the follow-up period. There was no pupillary block or peripheral anterior synechiae postoperatively. Conclusions: Scleral indentation technique with or without transscleral fixation of a foldable IOL in DSAEK can facilitate the air tamponade and enhance the donor adherence in certain anterior segment abnormities. © 2013 Springer-Verlag Berlin Heidelberg. AD - Department of Ophthalmology, China Medical University Hospital, No. 2, Yuh Der Road, Taichung, Taiwan School of Medicine, China Medical University, Taichung, Taiwan AU - Chiang, C. C. AU - Lin, J. M. AU - Tsai, Y. Y. DB - Scopus DO - 10.1007/s00417-013-2264-0 IS - 6 KW - Aphakia Bullous keratopathy Descemet's stripping automated endothelial keratoplasty (DSAEK) Scleral indentation Transscleral fixation of a foldable IOL M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2013 SP - 1557-1563 ST - Descemet's stripping automated endothelial keratoplasty in abnormal anterior segment: Scleral indentation technique to enhance donor adherence T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - Descemet's stripping automated endothelial keratoplasty in abnormal anterior segment: Scleral indentation technique to enhance donor adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878707026&doi=10.1007%2fs00417-013-2264-0&partnerID=40&md5=3ab5f96c2c7d0cc403b7af5b714f53a2 VL - 251 ID - 5522 ER - TY - JOUR AB - Purpose: To describe the characteristics of the patient population included in the 2016 IRIS® Registry (Intelligent Research in Sight) database for analytic aims. Design: Description of a clinical data registry. Participants: The 2016 IRIS Registry database consists of 17 363 018 unique patients from 7200 United States–based ophthalmologists in the United States. Methods: Electronic health record (EHR) data were extracted from the participating practices and placed into a clinical database. The approach can be used across dozens of EHR systems. Main Outcome Measures: Demographic characteristics. Results: The 2016 IRIS Registry database includes data about patient demographics, top-coded disease conditions, and visit rates. Conclusions: The IRIS Registry is a unique, large, real-world data set that is available for analytics to provide perspectives and to learn about current ophthalmic care and treatment outcomes. The IRIS Registry can be used to answer questions about practice patterns, use, disease prevalence, clinical outcomes, and the comparative effectiveness of different treatments. Limitations of the data are the same limitations associated with EHR data in terms of documentation errors or missing data and the lack of images. Currently, open access to the database is not available, but there are opportunities for researchers to submit proposals for analyses, for example through a Research to Prevent Blindness and American Academy of Ophthalmology Award for IRIS Registry Research. AD - F. Lum, American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA, United States AU - Chiang, M. F. AU - Sommer, A. AU - Rich, W. L. AU - Lum, F. AU - Parke, D. W. DB - Embase Medline DO - 10.1016/j.ophtha.2017.12.001 IS - 8 KW - adult age distribution age related macular degeneration article clinical outcome comparative effectiveness data base demography diabetic retinopathy disease registry dry eye electronic health record female glaucoma health care quality health care utilization human Intelligent Research in Sight major clinical study male middle aged patient care prevalence priority journal treatment outcome United States LA - English M3 - Article N1 - L2000601566 2018-04-03 2018-07-18 PY - 2018 SN - 1549-4713 0161-6420 SP - 1143-1148 ST - The 2016 American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Database: Characteristics and Methods T2 - Ophthalmology TI - The 2016 American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Database: Characteristics and Methods UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2000601566&from=export http://dx.doi.org/10.1016/j.ophtha.2017.12.001 VL - 125 ID - 2568 ER - TY - JOUR AB - INTRODUCTION: The purpose of this study was to evaluate medication adherence of glaucoma patients through the "Glaucoma treatment compliance assessment tool (GTCAT)" questionnaire and to correlate the results with clinical parameters., PATIENTS AND METHODS: This multicenter prospective observational study was performed in the Departement hospitalo-universitaire (DHU) Sight Restore, Paris, France. All patients had been followed for chronic open angle glaucoma (COAG) for at least 3 years. A French version of the GTCAT questionnaire was administered to patients. The results were correlated with clinical parameters of glaucoma, such as duration of disease, medications used, intraocular pressure (IOP) and mean deviation (MD) of the most recent visual field., RESULTS: Seventy-three patients were included in our study, with 60.9% declaring that they fully adhered to the treatment. There was a correlation between the amount of days missing treatment and difficulties using the eye drops. The main cause of missing the drops was forgetfulness (75%), followed by unavailability of the drop when it was time to take it (37.5%). The impact of glaucoma on quality of life was correlated to the amount of adverse effects of topical medications. The patient's perception of the importance of preserving vision was correlated to the level of confidence in the physician concerning the diagnosis of glaucoma., CONCLUSION: In glaucoma patients, the use of the GTCAT questionnaire confirmed the complex relationship between the patient, the disease and its treatment, and even his or her relationship with the ophthalmologist. These results emphasized the importance of therapeutic education but also the negative role of side effects of the eye drops on treatment adherence in glaucoma patients. Copyright © 2017 Elsevier Masson SAS. All rights reserved. AU - Chiche, A. AU - Martin, G. AU - Brasnu de Cenival, E. AU - Rousseau, A. AU - Giocanti, A. AU - Fel, A. AU - Kallel, S. AU - Lombardi, M. AU - Hamard, P. AU - Baudouin, C. AU - Labbe, A. DO - https://dx.doi.org/10.1016/j.jfo.2017.01.009 IS - 6 KW - Adult Aged *Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/ae [Adverse Effects] Attitude to Health Female *Glaucoma/dt [Drug Therapy] Glaucoma/ep [Epidemiology] *Glaucoma/px [Psychology] Humans Male Medication Adherence/px [Psychology] *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ophthalmic Solutions/ad [Administration & Dosage] Ophthalmic Solutions/ae [Adverse Effects] Paris/ep [Epidemiology] *Perception Surveys and Questionnaires PY - 2017 SE - Chiche, A. Service d'ophtalmologie 3, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France. Martin, G. Service d'ophtalmologie, hopital Ambroise-Pare, AP-HP, 9, avenue Charles-De-Gaulle, 92100 Boulogne-Billancourt, France. Brasnu de Cenival, E. Service d'ophtalmologie 3, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France; DHU Sight Restore, universite de Versailles Saint-Quentin-en-Yvelines, Versailles, France. Rousseau, A. Service d'ophtalmologie, hopital Kremlin-Bicetre, DHU Sight Restore, AP-HP, 78, rue du General-Leclerc, 94275 Le Kremlin-Bicetre, France. Giocanti, A. Service d'ophtalmologie, hopital Avicenne, DHU Sight Restore, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France. Fel, A. Service d'ophtalmologie, hopital de la Salpetriere, AP-HP, 47-83, boulevard de l'Hopital, 75013 Paris, France. Kallel, S. Service d'ophtalmologie 3, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France; DHU Sight Restore, universite de Versailles Saint-Quentin-en-Yvelines, Versailles, France; Service d'ophtalmologie, hopital Ambroise-Pare, AP-HP, 9, avenue Charles-De-Gaulle, 92100 Boulogne-Billancourt, France. Lombardi, M. DHU Sight Restore, universite de Versailles Saint-Quentin-en-Yvelines, Versailles, France. Hamard, P. Service d'ophtalmologie 3, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France; DHU Sight Restore, universite de Versailles Saint-Quentin-en-Yvelines, Versailles, France. Baudouin, C. Service d'ophtalmologie 3, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France; DHU Sight Restore, universite de Versailles Saint-Quentin-en-Yvelines, Versailles, France; Service d'ophtalmologie, hopital Ambroise-Pare, AP-HP, 9, avenue Charles-De-Gaulle, 92100 Boulogne-Billancourt, France; Inserm, U968, CNRS, UMR 7210, institut de la vision, universite UPMC Paris VI, 75012 Paris, France. Labbe, A. Service d'ophtalmologie 3, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France; DHU Sight Restore, universite de Versailles Saint-Quentin-en-Yvelines, Versailles, France; Service d'ophtalmologie, hopital Ambroise-Pare, AP-HP, 9, avenue Charles-De-Gaulle, 92100 Boulogne-Billancourt, France; Inserm, U968, CNRS, UMR 7210, institut de la vision, universite UPMC Paris VI, 75012 Paris, France. Electronic address: alabbe@15-20.fr. SN - 1773-0597 0181-5512 SP - 477-486 ST - [Perception of glaucoma and therapeutic adherence: A multicenter observational study] T2 - Perception du glaucome et observance therapeutique : une etude observationnelle multicentrique. TI - [Perception of glaucoma and therapeutic adherence: A multicenter observational study] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28571839 VL - 40 Y2 - 20170530// ID - 513 ER - TY - JOUR AB - A number of programmable rate-controlled drug delivery technologies have been developed during the last two decades with the aim of regulating the rate of drug delivery, sustaining the duration of therapeutic action and/or targeting the delivery of drug to a specific tissue. As a result, several therapeutically beneficial outcomes can be achieved, such as: (i) controlled delivery of a therapeutic dose at a desirable rate of delivery; (ii) maintenance of drug concentrations within an optimal therapeutic range for prolonged duration of treatment; (iii) maximisation of efficacy-dose relationship; (iv) reduction of adverse effects; (v) minimisation of the need for frequent dose intake; and (vi) enhancement of patient compliance. The treatment of illness can thus be optimised. To gain a better understanding of how to optimise the treatment of illnesses by applying programmable rate-controlled drug delivery technologies, this article reviews the scientific concepts and technical principles behind the development of various programmable rate-controlled drug delivery systems that have been marketed or are under active development. Finally, the roles of these technologies in optimising therapeutic outcomes in nine therapeutic areas are discussed. AD - S. Lin, Coll. Pharm./All. Hlth. Professions, St. John's University, 8000 Utopia Parkway, Jamaica, NY 11439, United States AU - Chien, Y. W. AU - Lin, S. C1 - acutrim alora androderm catapres tts climara combipatch compudose depo provera deponit duragesic estraderm habitrol lupron depot minitran nicotrol nitro dur nitrodisc norplant ocusert procardia xl progestasert prostep testoderm transderm nitro transderm scop tussionex vivelle dot vivelle zoladex DB - Embase Medline DO - 10.2165/00003088-200241150-00003 IS - 15 KW - clonidine diazepam estradiol estradiol plus norethisterone acetate fentanyl glyceryl trinitrate goserelin leuprorelin levonorgestrel medroxyprogesterone acetate microsphere nicotine nifedipine phenylpropanolamine pilocarpine polymer progesterone scopolamine testosterone chlorpheniramine polistirex plus hydrocodone polistirex androgen therapy angina pectoris anxiety disorder contraception controlled drug release dose response drug delivery system drug diffusion drug efficacy drug implant drug targeting encapsulation estrogen therapy feedback system human hydration hydrodynamics hydrolysis hypertension iontophoresis magnetism membrane permeability motion sickness open angle glaucoma osmotic pressure osmotic pump pain partition coefficient patient compliance pH priority journal prostate cancer review smoking cessation ultrasound vapor pressure acutrim alora androderm catapres tts climara combipatch compudose depo provera deponit duragesic estraderm habitrol lupron depot minitran nicotrol nitro dur nitrodisc norplant ocusert procardia xl progestasert prostep testoderm transderm nitro transderm scop tussionex vivelle dot vivelle zoladex Alzet Syrijet Vitajet LA - English M3 - Review N1 - L36026766 2003-01-16 PY - 2002 SN - 0312-5963 SP - 1267-1299 ST - Optimisation of treatment by applying programmable rate-controlled drug delivery technology T2 - Clinical Pharmacokinetics TI - Optimisation of treatment by applying programmable rate-controlled drug delivery technology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36026766&from=export http://dx.doi.org/10.2165/00003088-200241150-00003 VL - 41 ID - 3841 ER - TY - JOUR AB - Chronic persistent asthma has a significant burden in terms of healthcare-related expenses, decreased productivity and reduced quality of life for patients. Currently available guideline-directed therapy can control the majority of patients, but roughly one-third of patients will require additional care. This article reviews the barriers that hinder the ability of practitioners and patients to gain and maintain control of asthma, including inaccurate assessment measures, variability in patient response, and poor adherence. Strategies aimed at controlling difficult-to-treat disease, such as the use of biomarkers to assess control, are discussed. Newer and developing therapies that cater to specific types of asthmatic patients and may lead to improved outcomes in those patients for whom standard care is insufficient are also looked at. © 2007 Informa UK Ltd. AD - B.E. Chipps, Capital Allergy and Respiratory Disease Center, Sacramento, CA 95819, United States AU - Chipps, B. E. AU - Harder, J. M. C1 - gsk 159797(Glaxo SmithKline) gsk 597901(Glaxo SmithKline) C2 - Glaxo SmithKline DB - Embase Medline DO - 10.1517/14728222.11.1.11 IS - 1 KW - arformoterol beclometasone beta 2 adrenergic receptor stimulating agent biological marker budesonide carmoterol ciclesonide corticosteroid etanercept fluticasone fluticasone propionate fluticasone propionate plus salmeterol milveterol gsk 597901 indacaterol leukotriene receptor blocking agent long acting drug montelukast omalizumab phosphodiesterase IV inhibitor placebo roflumilast suplatast tosylate tumor necrosis factor inhibitor unclassified drug adrenal suppression asthma cataract chronic obstructive lung disease clinical protocol clinical trial cytokine production diagnostic accuracy disease control drug bioavailability drug dose increase drug dose reduction drug dose titration drug half life drug induced headache drug mechanism drug megadose drug protein binding drug targeting dysphonia fracture glaucoma glucose intolerance growth retardation human hydrocortisone release low drug dose monotherapy nausea patient care patient compliance pharyngitis review side effect skin disease systematic review thrush treatment response gsk 159797 LA - English M3 - Review N1 - L46099750 2007-02-26 PY - 2007 SN - 1472-8222 SP - 11-20 ST - Targeted interventions for difficult-to-treat asthma T2 - Expert Opinion on Therapeutic Targets TI - Targeted interventions for difficult-to-treat asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46099750&from=export http://dx.doi.org/10.1517/14728222.11.1.11 VL - 11 ID - 3553 ER - TY - JOUR AB - PURPOSE: To evaluate the situation of glaucoma patients' management in Romania., METHOD: A questionnaire was presented to 400 ophthalmologists with experience in glaucoma management; they have responded anonymously to 32 questions. The obtained data were subject to statistical analysis (mean, standard deviation, statistical significance)., RESULTS: 327 ophthalmologists have responded; 70% have more than 10 years of practice; 50% are each managing 100 to 500 glaucoma patients. 2/3 of participants are using the Goldmann aplanotonometer, 38% are assessing visual field in automated perimetry, 61% are examining the optic discs using an direct ophthalmoscope and 80% are currently performing gonioscopy. 55% are treating ocular hypertension under special circumstances, 93% are using initial monotherapy, 3/4 are using prostaglandin derivates as initial therapy and 79% are resorting to fixed combinations when the initial monotherapy has become inefficient. Most participants desire to use modern diagnostic methods and treatments in glaucoma, to continuously improve the education in glaucoma management and to collaborate efficiently with other healthcare partners., CONCLUSIONS: The questionnaire has provided useful information on the quality of glaucoma patients care in Romania; if it is periodically repeated (with necessary updates) it will reflect the dynamic of this issue in our country AU - Chiselita, D. AU - Apreutesei, Nicoleta IS - 1 KW - *Clinical Competence/st [Standards] *Glaucoma/di [Diagnosis] *Glaucoma/th [Therapy] Humans Patient Compliance *Physician's Role Quality of Health Care/st [Standards] Romania *Surveys and Questionnaires PY - 2009 SN - 1220-0875 SP - 64-70 ST - [The management of glaucoma patients in Romania: analysis of an evaluation questionnaire] T2 - Asistenta pacientilor cu glaucom in Romania; analiza unui chestionar de evaluare. TI - [The management of glaucoma patients in Romania: analysis of an evaluation questionnaire] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19569606 VL - 53 ID - 1438 ER - TY - JOUR AB - PURPOSE: To assess the frequency of visual field defects in frequency doubling technology (FDT) perimetry performed in healthy volunteers and the correlations between FDT and standard automated perimetry (SAP)., METHOD: A transversal study that included 57 healthy volunteers who were subject to visual field testing in both FDT and SAP (randomly effectuated in the same day). The studied parameters were: the frequency of visual field defects in the two techniques, the correlation of the quantitative parameters (MD, PSD) with the C/D ratio and also between techniques, the test reliability and the test duration. The subjects have been questioned about their preference for one test or another., RESULTS: The frequency of visual field defects was 47.35% in FDT and 22.8% in SAP. The MD values were significantly higher in FDT (MD FDT= -1.45+/-1.91, MD SITA= -0.77+/-1.58, p< 0.0001). Also the PSD values were higher in FDT (PSD FDT= 3.76+/-0.96, PSD SITA= 1.94+/-1.05). The correlation of quantitative parameters between the two techniques was low (r = 0.369 for MD and 0.206 for PSD). The correlation between the PSD value and the C/D ratio was extremely weak in both methods (because the subjects were healthy). The mean duration of a FDT test (4 '29") was significantly lower than that of a SITA test (5'18") - p < 0.00001. The reliability indices (fixation losses, false negative and false positive errors) were significantly better in FDT, and 3/4 of subjects declared that they preferred the FDT test., CONCLUSIONS: In normal subjects the frequency of visual field defects was greater in FDT than in SAP. There was a low correlation of quantitative parameters (MD, PSD) between SAP and FDT, and also with the C/D ratio. Better reliability indices, shorter test duration and better patient compliance are arguments for using FDT as a screening test for glaucoma. AU - Chiselita, D. AU - Ioana, Marcu Crenguta AU - Danielescu, C. AU - Mihaela, Nitu Miruna IS - 3 KW - Adult Algorithms Cross-Sectional Studies Humans Middle Aged Predictive Value of Tests Romania Sensitivity and Specificity Vision Disorders/di [Diagnosis] *Visual Field Tests/mt [Methods] *Visual Fields PY - 2006 SE - Chiselita, D. Universitatea de Medicina si Farmacie GR. T. POPA, Iasi. SN - 1220-0875 SP - 99-104 ST - [FDT versus automated standard perimetry in healthy subjects] T2 - FDT vs. perimetria statica automata la voluntari sanatosi. TI - [FDT versus automated standard perimetry in healthy subjects] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17144515 VL - 50 ID - 1630 ER - TY - JOUR AB - OBJECTIVE: Comparative analysis of the results of trabeculectomy in the surgery of primary open angle glaucoma (POAG) as the primary therapeutical approach and after the medical treatment failure., MATERIALS AND METHOD: Retrospective study including two therapeutical groups: A (59 patients) with primary trabeculectomy; and B (60 patients) with trabeculectomy following a medical treatment failure; mean follow-up period was 3 years and 5 months., RESULTS: Postoperative drop in intraocular pressure was similar in the two groups; there is no statistical significant difference between the two groups regarding stationary disease (76.27% in group A, versus 73.33% in group B), regressive disease (6.8% versus 6.7% respectively) and progressive disease (18.6% in group A, versus 21.6% in group B). At an intraocular pressure < or = 21 mmHg 13.6% of glaucoma cases do progress. The rate of peroperative and postoperative complications is similar in the two groups., CONCLUSIONS: The prior medical treatment of glaucoma doesn't affect the evolution of operated POAG. Primary trabeculectomy is indicated for non-compliant patients and for patients in whom administration of combined medical treatment for short time periods doesn't lower the intraocular pressure at safe levels. Surgical treatment has the advantage of an important and constant lowering of the intraocular pressure which is an absolute requirement for an efficient control of advanced glaucoma. AU - Chiselita, D. AU - Poiata, I. AU - Tiutiuca, C. AU - Stanciu, D. AU - Vancea, P. P. IS - 2 KW - Aged Algorithms Glaucoma, Open-Angle/dt [Drug Therapy] *Glaucoma, Open-Angle/su [Surgery] Humans Middle Aged Ophthalmic Solutions/tu [Therapeutic Use] Retrospective Studies *Trabeculectomy Treatment Outcome PY - 1997 SE - Chiselita, D. Clinica oftalmologica Iasi. SN - 1220-0875 SP - 80-6 ST - [Primary trabeculectomy in the surgery of primary open angle glaucoma] T2 - Trabeculectomia tratament primar al glaucomului primitiv cu unghi deschis. TI - [Primary trabeculectomy in the surgery of primary open angle glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=15328651 VL - 41 ID - 2002 ER - TY - JOUR AB - OBJECTIVE: Comparative analysis of the results of trabeculectomy in the surgery of primary open angle glaucoma (POAG) as the primary therapeutical approach and after the medical treatment failure. MATERIALS AND METHOD: Retrospective study including two therapeutical groups: A (59 patients) with primary trabeculectomy; and B (60 patients) with trabeculectomy following a medical treatment failure; mean follow-up period was 3 years and 5 months. RESULTS: Postoperative drop in intraocular pressure was similar in the two groups; there is no statistical significant difference between the two groups regarding stationary disease (76.27% in group A, versus 73.33% in group B), regressive disease (6.8% versus 6.7% respectively) and progressive disease (18.6% in group A, versus 21.6% in group B). At an intraocular pressure < or = 21 mmHg 13.6% of glaucoma cases do progress. The rate of peroperative and postoperative complications is similar in the two groups. CONCLUSIONS: The prior medical treatment of glaucoma doesn't affect the evolution of operated POAG. Primary trabeculectomy is indicated for non-compliant patients and for patients in whom administration of combined medical treatment for short time periods doesn't lower the intraocular pressure at safe levels. Surgical treatment has the advantage of an important and constant lowering of the intraocular pressure which is an absolute requirement for an efficient control of advanced glaucoma. AD - Clinica oftalmologica Iaşi AU - Chiseliţa, D. AU - Poiata, I. AU - Tiutiuca, C. AU - Stanciu, D. AU - Vancea, P. P. DB - Scopus IS - 2 M3 - Article N1 - Export Date: 19 July 2021 PY - 1997 SP - 80-86 ST - Trabeculectomia tratament primar al glaucomului primitiv cu unghi deschis. T2 - Oftalmologia (Bucharest, Romania : 1990) TI - Primary trabeculectomy in the surgery of primary open angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-6044255964&partnerID=40&md5=23060b439020dcd7a0624aa60bd0fc42 VL - 41 ID - 5790 ER - TY - JOUR AB - Medical care in Taiwan is well known for its low cost, high efficiency, high quality, excellent medical accessibility, and high equity. We investigate the trends in medication expenditures for glaucoma from 1997 to 2010. The results show that higher medical expenditures were incurred by patients who were aged >=40 years, male patients, and patients in the highest salary population whereas lower medical expenditures were incurred by blue-collar workers. The medications with the most significant increases in expenditure were prostaglandin analogs (PGAs), alpha-agonists, and fixed combinations, whereas the medications with the most significant decreases in expenditure were beta-blockers and cholinergic agonists. The number of trabeculectomies shows two downward break points in 1999 and 2000 when PGAs were listed and were reimbursed. These results suggest socioeconomic disparities in glaucoma care, as well as understanding of the changes in the expenditure of glaucoma medications under such universal health insurance coverage system. AU - Chiu, Shin-Lin AU - Chu, Chiao-Lee AU - Muo, Chih-Hsin AU - Chen, Chiu-Liang AU - Lan, Shou-Jen DO - https://dx.doi.org/10.1155/2015/243401 PY - 2015 SE - Chiu, Shin-Lin. Department of Ophthalmology, Changhua Christian Hospital, 135 Nanxiao Street, Changhua City, Changhua County 500, Taiwan ; Department of Healthcare Administration Management, Asia University, 500 Lioufeng Road, Wufeng, Taichung 41354, Taiwan. Chu, Chiao-Lee. Department of Healthcare Administration Management, Asia University, 500 Lioufeng Road, Wufeng, Taichung 41354, Taiwan. Muo, Chih-Hsin. Management Office for Health Data, China Medical University Hospital, 2 Yude Road, Taichung 40447, Taiwan. Chen, Chiu-Liang. Department of Ophthalmology, Changhua Christian Hospital, 135 Nanxiao Street, Changhua City, Changhua County 500, Taiwan ; Department of Orthopedics, Changhua Christian Hospital, 135 Nanxiao Street, Changhua City, Changhua County 500, Taiwan. Lan, Shou-Jen. Department of Healthcare Administration Management, Asia University, 500 Lioufeng Road, Wufeng, Taichung 41354, Taiwan. SN - 2090-004X SP - 243401 ST - Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan T2 - Journal of ophthalmology TI - Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26137315 VL - 2015 Y2 - 20150602// ID - 1064 ER - TY - JOUR AB - PRCIS: Higher levels of near-vision related quality of life were associated with higher adherence to glaucoma medications after adjusting for important confounding variables among participants in the SEE personalized glaucoma coaching pilot study., PURPOSE: To investigate the association between vision-related quality of life (VRQoL) and glaucoma medication adherence., MATERIALS AND METHODS: Subjects were recruited for the Support, Educate, Empower (SEE) program, a prospective non-controlled cohort study examining the impact of a personalized coaching program on glaucoma medication adherence. Glaucoma patients seen at the University of Michigan over 40 years old, taking >=1 glaucoma medication, and self-reported poor adherence on two validated scales were recruited. Demographic details and VRQoL using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) were collected. Participants ' medication use for each prescribed glaucoma medication was captured electronically using a medication events monitoring system (Adheretech, New York, NY). The association between VRQoL and medication adherence was assessed with Pearson's correlation coefficient (r) and linear regression., RESULTS: Among the 95 eligible participants 49.5% were female, 55.3% were Caucasian, and mean age (+/-standard deviation) was 63.8+/-10.5 years. Mean adherence to glaucoma medication was 73.8%+/-21.0%. Mean NEI VFQ-25 composite score was 81.6+/-14.5. Better medication adherence was significantly and positively correlated with better functioning in domains of ocular pain (r=0.20, P=0.048), near activities (r=0.29, P=0.004), and role difficulties (r=0.22, P=0.036). Linear regression models adjusting for known correlates of medication adherence (age, gender, race, income), showed a 10-unit increase in self-perceived near activities function was associated with a 2.2% increase in medication adherence (95% confidence interval 1.0%-5.4%; P=0.0056)., CONCLUSION: Better self-perceived near activities function was associated with increased glaucoma medication adherence. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. AU - Cho, Juno AU - Niziol, Leslie M. AU - Heisler, Michele AU - Newman-Casey, Paula Anne DO - https://dx.doi.org/10.1097/IJG.0000000000001824 PY - 2021 SE - Cho, Juno. Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI Department of Internal Medicine, University of Michigan, Ann Arbor, MI. SN - 1536-481X 1057-0829 ST - Increased Near Activities Function Associated with Increased Glaucoma Medication Adherence among Support, Educate, Empower (SEE) Participants T2 - Journal of glaucoma TI - Increased Near Activities Function Associated with Increased Glaucoma Medication Adherence among Support, Educate, Empower (SEE) Participants UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=33675338 Y2 - 20210305// ID - 24 ER - TY - JOUR AD - P. Cho, School of Optometry, The Hong Kong Polytechnic University, Hong Kong AU - Cho, P. AU - Boost, M. DB - Embase Medline DO - 10.1016/j.clae.2020.05.011 IS - 4 KW - contact lens face mask orthokeratology lens spectacles sunglasses surgical mask hand sanitizer aerosol body temperature measurement China conjunctiva epithelium conjunctivitis consultation coronavirus disease 2019 disease severity editorial general practitioner glaucoma hand washing health care access health care personnel human hypoxia immune response incubation time infection risk lacrimal duct myopia nasal tissue ophthalmologist optometrist optometry pandemic pediatric hospital priority journal quarantine risk reduction social distance treatment withdrawal United States viral contamination viral eye infection virus transmission virus virulence LA - English M3 - Editorial N1 - L2006090738 2020-06-05 2020-08-07 PY - 2020 SN - 1476-5411 1367-0484 SP - 313-314 ST - COVID 19—An eye on the virus T2 - Contact Lens and Anterior Eye TI - COVID 19—An eye on the virus UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2006090738&from=export http://dx.doi.org/10.1016/j.clae.2020.05.011 VL - 43 ID - 2392 ER - TY - JOUR AB - Purpose. To determine the rates of microbial contamination of solutions and lens accessories of existing ortho-k lens wearers and-the effect on contamination rates of monthly replacement and warnings. To investigate self-reported levels of compliance with care of the lenses and lens accessories and correlation of these levels with the rates of microbial contamination. Methods. Asymptomatic ortho-k lens wearers with at least 6-month successful use were requested to bring their lenses, solutions, and accessories to their next aftercare visit. All items, except the lenses, were replaced at each data collection visit. Samples collected from the lens surface, solution, and accessories were Cultured for pathogens. These procedures were repeated twice at 1-month intervals. At the first visit, each subject and/or parent was interviewed about the care/use of the lens and accessories. Results. Thirty-eight subjects completed the study. Initial contamination rates of the lenses, lens cases, and tweezers were 29, 34, and 46%, respectively. Rates of contamination dropped for lenses, suction holders, and tweezers during the three-visit intervention. Contact lens solutions, except lens cleaner were contaminated on all occasions with the most contaminated product being artificial tears [33% (n = 18)]. There was no improvement in the contamination rate of the lens cases. The most common pathogens isolated were Staphylococcus aureus and Serratia marcescens. Compliance was lowest for care of lens cases and highest for care of lenses. However, correlation between reported compliance and presence of pathogens failed to reach significance. Conclusions. Subjects' awareness of the importance of lens cleanliness is high and can be improved by regular reinforcements. However, attitudes toward cleaning of accessories was far less satisfactory and while replacement and warnings resulted in significant improvements of contamination rates of tweezers and suction holders, more emphasis should be placed on educating patients on correct care of lens accessories. (Optom Vis Sci 2009;86:1227-1234) AN - WOS:000271368000003 AU - Cho, P. AU - Boost, M. AU - Cheng, R. DA - NOV DO - 10.1097/OPX.0b013e3181bbc55d IS - 11 PY - 2009 SN - 1040-5488 1538-9235 SP - 1227-1234 ST - Non-Compliance and Microbial Contamination in Orthokeratology T2 - OPTOMETRY AND VISION SCIENCE TI - Non-Compliance and Microbial Contamination in Orthokeratology VL - 86 ID - 6259 ER - TY - JOUR AB - Purpose: To evaluate the effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy in the treatment of patients with glaucoma. Methods: To measure the main treatment effects of a fixed combination of brimonidine 0.2%-timolol 0.5%, we conducted three small studies: (1) a comparison of diurnal intraocular pressure (IOP) at baseline and at 6 months after brimonidine/timolol fixed-combination therapy (n = 81); (2) an assessment of the effects of one drop of the brimonidine/timolol fixed combination on diurnal IOP (n = 25); and (3) the effects of brimonidine/timolol fixed-combination therapy on the anterior ocular segment over time (n = 64). Results: (1) After 6 months of treatment with the brimonidine/timolol fixed combination, the mean diurnal IOP in primary open-angle glaucoma (POAG) decreased from 21.4 ± 2.0 to 14.5 ± 3.1 mmHg (32.2%, P < 0.001), and the mean diurnal IOP in normal-tension glaucoma (NTG) decreased from 13.5 ± 2.8 to 10.9 ± 2.0 mmHg (19.3%, P < 0.001). (2) After instillation with one drop of the brimonidine/timolol fixed combination, the IOP in the instilled eye was lowest at 9:00 p.m. and had decreased by 1.7 mmHg compared with the baseline IOP in the instilled eye. The difference in IOP between the instilled eye and untreated fellow eye was largest at 3:00 p.m., measuring 1.7 mmHg (P = 0.011). (3) Brimonidine/timolol fixed-combination therapy caused significant miosis over time (P = 0.003). Conclusions: The results of this study suggest that brimonidine/timolol fixed-combination therapy has beneficial IOP-lowering effects and significant effects on pupil size. © 2010 Japanese Ophthalmological Society (JOS). AD - J. M. Kim, Department of Ophthalmology, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, 108 Pyung-Dong, Jongro-Ku, Seoul 110-746, South Korea AU - Cho, S. W. AU - Kim, J. M. AU - Park, K. H. AU - Choi, C. Y. DB - Embase Medline DO - 10.1007/s10384-010-0855-4 IS - 5 KW - brimonidine plus timolol adult allergic conjunctivitis anterior eye segment article burning sensation circadian rhythm controlled study drug efficacy drug safety drug therapy drug withdrawal female fixed combination therapy glaucoma human intraocular pressure major clinical study male miosis outcome assessment patient compliance priority journal somnolence treatment response LA - English M3 - Article N1 - L360013162 2010-12-01 2010-12-07 PY - 2010 SN - 0021-5155 SP - 407-413 ST - Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma T2 - Japanese Journal of Ophthalmology TI - Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L360013162&from=export http://dx.doi.org/10.1007/s10384-010-0855-4 VL - 54 ID - 3238 ER - TY - JOUR AB - Purpose: To understand the epidemiology, severity, types of pathology, clinical features, precipitating factors, and treatment outcomes of patients with allergic conjunctivitis in a tropical climate receiving corneal subspecialist intervention. A total of 33 patients with severe allergic conjunctivitis under corneal subspecialist care in National University Hospital, Singapore were studied. Design: A retrospective, noncomparative case series. Main outcome measures: epidemiological data, clinical features, complete ophthalmological examination, and treatment types. Methods: Both eyes of 33 patients seen at the cornea subspecialist clinic between May 2005 and July 2006 were examined at baseline, and followed up. Clinical features, treatment given, and outcome variables through case sheet review were analyzed. Results: Twenty-five patients (75.8%) were male, and 8 (24.2%) were female. Seventeen patients (51.5%) had concomitant allergic rhinitis, 16 patients (48.5%) had asthma, and 17 (51.5%) had associated dermatitis. Only 9 patients (27.3%) had documented precipitating factors. None of the 33 patients said that their symptoms were seasonal; 22 (66.7%) said their symptoms were perennial. Twenty-nine patients (87.9%) had punctate epithelial erosions, and 12 patients eventually progressed to have a corneal epithelial defect or shield ulcer (36.4%). Eleven out of the 33 patients (33.3%) received topical cyclosporine 0.5%. Of these, only 1 (9.1%) had documented complaints of intolerable side effects. Conclusion: Allergic conjunctivitis in a non-temperate, non-seasonal climate has different clinical presentations, and varied precipitating factors. The disease in such conditions may respond differently to the usual anti-allergy drug options used in temperate countries. Copyright © Informa Healthcare USA, Inc. AD - H. Choi, Department of Ophthalmology, National University Hospital, Main Building, 5 Lower Kent Ridge Road, Singapore 119074, Singapore AU - Choi, H. AU - Lee, S. B. DB - Embase Medline DO - 10.1080/09273940802184182 IS - 4 KW - antiallergic agent antihistaminic agent cetirizine corticosteroid cromoglycate disodium cyclosporine dexamethasone fluorometholone glutamic acid derivative hydroxyzine ketotifen lodoxamide loratadine loteprednol etabonate n aspartylacetylglutamic acid naphazoline olopatadine pheniramine prednisolone promethazine triamcinolone unclassified drug adolescent adult allergic conjunctivitis allergic rhinitis article asthma burning sensation child clinical article clinical feature contact lens controlled study cornea disease cornea epithelium cornea erosion cornea ulcer dermatitis disease severity drug withdrawal eczema epidemiological data eye examination eye surgery female follow up glaucoma homeopathy human intraocular pressure male medical specialist outcome assessment outcome variable patient compliance retrospective study side effect Singapore skin defect symptom tertiary health care tropic climate tropics university hospital unspecified side effect LA - English M3 - Article N1 - L352209939 2008-10-01 PY - 2008 SN - 0927-3948 1744-5078 SP - 141-145 ST - Nonseasonal allergic conjunctivitis in the tropics: Experience in a tertiary care institution T2 - Ocular Immunology and Inflammation TI - Nonseasonal allergic conjunctivitis in the tropics: Experience in a tertiary care institution UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352209939&from=export http://dx.doi.org/10.1080/09273940802184182 VL - 16 ID - 3440 ER - TY - JOUR AB - OBJECTIVES: Open-angle glaucoma (OAG) imposes high disease burden in South Korea. Although various effective interventions are available to manage the progression of OAG, there is limited data on the cost-effectiveness of these treatment strategies in South Korea., METHODS: Using a Markov cohort model, we evaluated the cost-effectiveness of 3 major treatment strategies (medication, laser trabeculoplasty, and trabeculectomy) for South Korean patients with OAG. We projected a 25-year time horizon to study a hypothetical cohort of 10,000 patients of age 40 with mild OAG. The outcome measures were quality-adjusted life-years (QALYs) gained, cost from the societal perspective, and the incremental cost-effectiveness ratio (ICER) of medication, laser trabeculoplasty, and trabeculectomy. Interventions were evaluated at a willingness-to-pay (WTP) threshold of 30,000,000 KRW ($29,152) per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted to address the model uncertainty., RESULTS: The mean costs for medication, laser trabeculoplasty, and trabeculectomy were 29,661,740 KRW, 17,34,1342 KRW, and 22,275,438 KRW, respectively. The mean QALYs gained were 15.7, 15.3, and 14.8 for medication, laser trabeculoplasty, and trabeculectomy, respectively. Surgery was strongly dominated because it generated fewer expected QALYs but incurred greater expected cost than laser. The ICER was 30,885,179 KRW per QALY for medication versus laser trabeculoplasty. Laser was cost-effective, however, at a lower WTP threshold of 21,000,000 KRW per QALY gained or below. The results were most sensitive to the progression rates from mild to moderate glaucoma under laser treatment., CONCLUSION: Under the WTP threshold of 30,000,000 KRW per QALY, medication was cost-effective compared with laser trabeculoplasty and trabeculectomy for treating mild OAG in South Korean population. Laser, however, can be a cost-effective alternative in more resource-limited settings. AU - Choi, Jin A. AU - Song, Lina D. AU - Choi, Seulggie AU - Park, Sang Min AU - Kwon, Jin Woo AU - Jee, Donghyun DO - https://dx.doi.org/10.1097/MD.0000000000014026 IS - 2 KW - Adult Cost-Benefit Analysis *Glaucoma, Open-Angle/ec [Economics] *Glaucoma, Open-Angle/th [Therapy] Humans *Laser Therapy/ec [Economics] Laser Therapy/mt [Methods] Markov Chains Models, Theoretical *Neuroprotective Agents/ec [Economics] Neuroprotective Agents/tu [Therapeutic Use] Patient Acceptance of Health Care Quality-Adjusted Life Years Republic of Korea *Trabeculectomy/ec [Economics] Trabeculectomy/mt [Methods] PY - 2019 SE - Choi, Jin A. Department of Ophthalmology and Visual Science, St Vincent's Hospital College of Medicine, Catholic University of Korea, Seoul, South Korea. Song, Lina D. PhD Program in Health Policy, Harvard University, Cambridge, MA. Choi, Seulggie. Seoul National University Graduate School, Department of Biomedical Sciences. Park, Sang Min. Seoul National University Graduate School, Department of Biomedical Sciences. Park, Sang Min. Seoul National University Hospital, Department of Family Medicine, Seoul, South Korea. Kwon, Jin Woo. Department of Ophthalmology and Visual Science, St Vincent's Hospital College of Medicine, Catholic University of Korea, Seoul, South Korea. Jee, Donghyun. Department of Ophthalmology and Visual Science, St Vincent's Hospital College of Medicine, Catholic University of Korea, Seoul, South Korea. SN - 1536-5964 0025-7974 SP - e14026 ST - The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea T2 - Medicine TI - The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30633194 VL - 98 ID - 294 ER - TY - JOUR AB - Due to the rapidly increasing life-expectancy, the prevalence of glaucoma has increased steadily in recent years. We aimed to evaluate the patterns of care and primary treatment strategy patterns in Korea according to glaucoma subtypes to assess the quality of care for glaucoma patients. In this serial cross-sectional survey, the claims data from the Korean National Health Insurance Service was used to identify and group glaucoma patients into primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACG), other types of glaucoma, and ocular hypertension from 2002 to 2013. Records for outpatient visits, hospitalizations, drug prescriptions, admissions, and surgical interventions were used to determine the patterns of care and identify primary treatment strategies. Both the prevalence (0.11% in 2002 to 0.43% in 2013) and incidence rates (0.06% in 2003 to 0.11% in 2013) for glaucoma increased over time. The mean number of outpatient visits increased (4.9-6.0 visits per year), while the proportion of hospitalized patients (2.3-1.0% of patients) and duration of hospital stay (4.5-3.4 days among hospitalized patients) decreased between 2002 and 2013 for patients with POAG. The proportion of patients not being managed by medication or surgery decreased, with POAG and PACG patients receiving medications increasing from 70.9% and 59.2% in 2002 to 88.4% and 63.3% in 2013, respectively. Finally, while the proportion of trabeculectomy decreased (22.2% to 10.0% of surgical procedures in 2002 and 2013, respectively), more patients with PACG have received iridectomy (59.3% to 86.0% of surgical procedures in 2002 and 2013, respectively). Between 2002 and 2013, the pattern of care for both patients with POAG and PACG has shifted toward management by outpatient visits and intervention with anti-glaucoma medications in Korea. AU - Choi, Seulggie AU - Choi, Jin A. AU - Kwon, Jin Woo AU - Park, Sang Min AU - Jee, Donghyun DO - https://dx.doi.org/10.1097/MD.0000000000012357 IS - 38 KW - Adolescent Adult Aged Aged, 80 and over Child Child, Preschool Cross-Sectional Studies Female *Glaucoma, Angle-Closure/ep [Epidemiology] Glaucoma, Angle-Closure/th [Therapy] *Glaucoma, Open-Angle/ep [Epidemiology] Glaucoma, Open-Angle/th [Therapy] *Hospitalization/td [Trends] Humans Incidence Infant Infant, Newborn Insurance, Health/sn [Statistics & Numerical Data] Male Middle Aged National Health Programs/sn [Statistics & Numerical Data] *Office Visits/td [Trends] Prevalence Republic of Korea/ep [Epidemiology] *Trabeculectomy/td [Trends] Young Adult PY - 2018 SE - Choi, Seulggie. Department of Biomedical Sciences, Seoul National University Graduate School, Seoul Division of Vitreous and Retina, Department of Ophthalmology, St Vincent's Hospital, College of Medicine, Catholic University of Korea, Suwon Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea. SN - 1536-5964 0025-7974 SP - e12357 ST - Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data T2 - Medicine TI - Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30235694 VL - 97 ID - 388 ER - TY - JOUR AD - E. Chong, Canadian Network of Asthma Care (CNAC), Canada AU - Chong, E. C1 - accolate advair airomir alvesco atrovent berotec bricanyl choledyl combivent duovent flovent foradil oxeze phyllocontin pulmicort qvar serevent singulair spiriva symbicort uniphyl ventolin xolair DB - Embase DO - 10.3821/1913-701X(2008)140[s12:PSOAAG]2.0.CO;2 IS - SUPPL. 3 KW - acetylsalicylic acid aminophylline beclomethasone dipropionate beta 2 adrenergic receptor stimulating agent budesonide budesonide plus formoterol carbamazepine choline theophyllinate ciclesonide corticosteroid erythromycin fenoterol fenoterol plus ipratropium bromide fluticasone fluticasone propionate fluticasone propionate plus salmeterol formoterol formoterol fumarate ipratropium bromide ipratropium bromide plus salbutamol leukotriene receptor blocking agent montelukast omalizumab enprofylline phenobarbital phenytoin prednisolone rifampicin salbutamol salbutamol sulfate salmeterol salmeterol xinafoate terbutaline theophylline tiotropium bromide unclassified drug unindexed drug warfarin zafirlukast add on therapy asthma bronchospasm cigarette smoking clinical practice clinical trial combination chemotherapy coughing disease control disease exacerbation disease severity drug blood level drug dose increase drug inhibition drug mechanism drug megadose drug potentiation drug substitution drug withdrawal dust evidence based medicine exercise glaucoma heart palpitation human hypokalemia inhaler low drug dose lung function metallic taste metered dose inhaler monotherapy multiple cycle treatment mydriasis nervousness patient assessment patient compliance patient counseling patient education pollen practice guideline review side effect smoking cessation tachycardia taste disorder tremor unspecified side effect urine retention wheezing xerostomia accolate advair airomir alvesco atrovent berotec bricanyl choledyl combivent duovent flovent foradil oxeze phyllocontin pulmicort qvar serevent singulair spiriva symbicort uniphyl ventolin xolair LA - English M3 - Review N1 - L350260628 2008-01-23 PY - 2007 SN - 1715-1635 SP - S12-S17 ST - Pharmacist-specific summary of adult asthma guidelines T2 - Canadian Pharmacists Journal TI - Pharmacist-specific summary of adult asthma guidelines UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350260628&from=export http://dx.doi.org/10.3821/1913-701X(2008)140[s12:PSOAAG]2.0.CO;2 VL - 140 ID - 3547 ER - TY - JOUR AB - PURPOSE: Nonadherence to glaucoma medications may be a major cause of treatment failure. We examined the acceptance of glaucoma patients toward a possible new route of administering glaucoma medication by subconjunctival injection., PATIENTS AND METHODS: Patients were recruited from specialist glaucoma clinics on a voluntary basis. Trained interviewers administered a 30-item questionnaire and an information sheet with details of an alternative subconjunctival injection route involving injections at 3-month intervals. Outcome measures regarding acceptance of the new procedure, social situational factors, disease factors, and treatment factors were assessed., RESULTS: A total of 151 patients participated in this study. Of the 151 patients 112 (74.2%) were willing to have their glaucoma medication given by the new method of subconjunctival injection, 101 of 112 (90.2%) were willing to accept it at the same cost as their present medication, and 87 of 101 (86.1%) were willing to accept it even at a higher cost. These patients tended to be on a greater number of medications (P=0.006), and medicating more frequently in a day (P=0.003). Nine of 10 (90%) patients who were admitted to nonadherence were willing to accept subconjunctival injections at 3-month intervals in place of their topical medication., CONCLUSIONS: Our study found that 74% of glaucoma patients were willing to accept an alternative form of glaucoma treatment through 3-monthly subconjunctival injections. A large proportion of patients who were admitted to nonadherence to topical medication were willing to consider this alternative method of medication. Our findings are helpful when developing patient-acceptable drug-delivery regimes, which may alleviate the need for daily medication. AU - Chong, Rachel S. AU - Su, Daniel H. W. AU - Tsai, Andrew AU - Jiang, Yuzhen AU - Htoon, Hla Myint AU - Lamoureux, Ecosse L. AU - Aung, Tin AU - Wong, Tina T. DO - https://dx.doi.org/10.1097/IJG.0b013e318237c6c4 IS - 3 KW - Administration, Topical Aged Antihypertensive Agents/ad [Administration & Dosage] *Antihypertensive Agents/tu [Therapeutic Use] *Attitude to Health *Conjunctiva/de [Drug Effects] Cross-Sectional Studies Drug Administration Routes Female *Glaucoma, Angle-Closure/dt [Drug Therapy] *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Injections Intraocular Pressure/de [Drug Effects] Male *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Patient Compliance Surveys and Questionnaires PY - 2013 SE - Chong, Rachel S. Singapore National Eye Centre, Singapore, Republic of Singapore. SN - 1536-481X 1057-0829 SP - 190-4 ST - Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma T2 - Journal of glaucoma TI - Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=22036716 VL - 22 ID - 1021 ER - TY - JOUR AB - Objective: Previous research has suggested a link between typical antipsychotic use and the development of cataracts, but the association between atypical antipsychotics and cataracts remains unclear in schizophrenia (SZ). Methods: A retrospective nested case-control study was conducted using data from the National Health Insurance Database of Taiwan between the year of 2000 and 2011. A total of 2144 SZ patients with cataracts and 2222 controls matched for age, sex, and index date were included. Antipsychotic exposure was categorized by type and duration, and the association between antipsychotic exposure and cataract development was assessed using a conditional logistic regression analysis. Results: We found that the severity of physical comorbidities, concurrent antidepressant use, and comorbidity with glaucoma or other retinal disorders were associated with an increased risk for cataract development. Alternatively, we did not find significant associations between continuous use of clozapine, risperidone, paliperidone, ziprasidone, olanzapine, quetiapine, amisulpride, zotepine or aripiprazole and risk of cataract development in SZ patients. Conclusions: We did not detect any association between atypical antipsychotic use and risk of cataract development in SZ patients. Future studies with longitudinal ocular evaluations in patients using atypical antipsychotics are warranted to confirm our findings. AD - P.-H. Chou, Department of Psychiatry, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung City, Taiwan AU - Chou, P. H. AU - Chu, C. S. AU - Lin, C. H. AU - Cheng, C. AU - Chen, Y. H. AU - Lan, T. H. AU - Huang, M. W. DB - Embase Medline DO - 10.1016/j.schres.2016.03.027 IS - 1-3 KW - amisulpride aripiprazole atypical antipsychotic agent clozapine olanzapine paliperidone quetiapine risperidone steroid ziprasidone zotepine adult article case control study cataract comorbidity controlled study disease severity drug efficacy drug response drug use female glaucoma health care utilization human major clinical study male population research priority journal retina disease risk assessment risk factor schizophrenia Taiwan LA - English M3 - Article N1 - L609642887 2016-01-05 2016-06-30 PY - 2016 SN - 1573-2509 0920-9964 SP - 137-143 ST - Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study T2 - Schizophrenia Research TI - Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609642887&from=export http://dx.doi.org/10.1016/j.schres.2016.03.027 VL - 174 ID - 2729 ER - TY - JOUR AB - Purpose: L. V. Prasad Eye Institute has adopted horizontal approach of eye care delivery for the past 22 years at one of its rural secondary centers. The recent implementation of a diagonal model for enhancing glaucoma care at this center and its outcomes are reported. Methods: This was a retrospective case-control study. We included newly and consecutively diagnosed adult glaucoma patients. A comprehensive ophthalmologist provided glaucoma care. During the study period, an experienced glaucoma specialist supported the care for 2 days every month in a structured format that consisted of triaging glaucoma patients for defined protocols of therapy along with hands-on and remote online guidance to the comprehensive ophthalmologist. The data from the worst or single eye were analyzed. Results: We have included 231 patients (151 study and 80 historical controls). Sixty (75%) control patients were managed at the study center and 20 (25%) were referred. The comprehensive ophthalmologist managed 70 (48.2%) study patients and co-managed 75 (51.7%) with the glaucoma specialist. The latter changed the diagnosis in 15 eyes and altered the treatment plan in 44 eyes. Six were excluded. Successful outcome was achieved in 52 (65%) eyes in the control group and 120 (84.5%) eyes in the study group (P < .01). Additionally, study group did better in terms of case detection rate, compliance to treatment and saving on expenses for patients. Conclusion: The new model has shown better clinical outcomes of glaucoma care in an under-served geographic area. The model has the potential for wider applicability. AU - Choudhari, Nikhil S. AU - Mundhe, Gajendra AU - Khanna, Rohit AU - Rathi, Varsha AU - Garudadri, Chandra Sekhar DO - https://dx.doi.org/10.1080/09286586.2019.1646292 IS - 6 KW - Adult Aged Aged, 80 and over Case-Control Studies *Delivery of Health Care/og [Organization & Administration] Female *Glaucoma/th [Therapy] Humans Male Middle Aged *Ophthalmology/og [Organization & Administration] Retrospective Studies *Rural Health Services/og [Organization & Administration] PY - 2019 SE - Choudhari, Nikhil S. VST Glaucoma Center, Dr. Kallam Anji Reddy campus, L. V. Prasad Eye Institute, Hyderabad, India. Choudhari, Nikhil S. Bhosle Gopal Rao Patil Eye Center, L. V. Prasad Eye Institute, Nirmal, Telangana, India. Mundhe, Gajendra. Bhosle Gopal Rao Patil Eye Center, L. V. Prasad Eye Institute, Nirmal, Telangana, India. Khanna, Rohit. Gullapalli Pratibha Rao International Center for Advancement of Rural Eye Care (GPR-ICARE), L. V. Prasad Eye Institute, Hyderabad, India. Rathi, Varsha. Gullapalli Pratibha Rao International Center for Advancement of Rural Eye Care (GPR-ICARE), L. V. Prasad Eye Institute, Hyderabad, India. Garudadri, Chandra Sekhar. VST Glaucoma Center, Dr. Kallam Anji Reddy campus, L. V. Prasad Eye Institute, Hyderabad, India. SN - 1744-5086 0928-6586 SP - 420-429 ST - Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute's Diagonal Model of Glaucoma Care T2 - Ophthalmic epidemiology TI - Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute's Diagonal Model of Glaucoma Care UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31340705 VL - 26 Y2 - 20190725// ID - 322 ER - TY - JOUR AB - PURPOSE: To compare the intraocular pressure (IOP) lowering effect of fixed combination dorzolamide 2% and timolol 0.5% therapy to that of concomitant administration of a topical beta-blocker and dorzolamide. METHODS: Seventy-four consecutive glaucoma patients were changed from a regimen including a topical beta-blocker and dorzolamide to the fixed combination dorzolamide-timolol in 1 eye, with the other eye used as the control. The average IOP readings before and 1 month after the change were compared. RESULTS: The mean baseline IOP in the entire study population was 19.4 ± 4.2 mm Hg in the study eyes and 16.9 ± 4.2 mm Hg in the control eyes. Four weeks after the medication change, the mean IOP was 17.3 ± 3.9 mm Hg in the study eyes (P < .001) and 16.1 ± 4.1 mm Hg in the control eyes (P = .02). The difference between the mean IOP change of 2.1 mm Hg in the study eyes and 0.8 mm Hg in the control eyes was found to be statistically significant (P = .01). CONCLUSION: These findings suggest that the fixed combination dorzolamide-timolol therapy achieves additional lowering of the intraocular pressure compared with the concomitant administration of a beta-blocker and dorzolamide. Copyright (C) 2000 Elsevier Science Inc. AD - M. Wand, 85 Seymour Street, Hartford, CT 06106, United States AU - Choudhri, S. AU - Wand, M. AU - Shields, M. B. C1 - cosopt(Merck,United States) C2 - Merck(United States) DB - Embase Medline DO - 10.1016/S0002-9394(00)00717-0 IS - 6 KW - beta adrenergic receptor blocking agent betaxolol dorzolamide dorzolamide plus timolol levobunolol timolol adult aged article clinical trial controlled clinical trial controlled study drug efficacy female glaucoma human intraocular pressure major clinical study male patient compliance priority journal cosopt LA - English M3 - Article N1 - L32000869 2001-01-04 PY - 2000 SN - 0002-9394 SP - 832-833 ST - A comparison of dorzolamide-timolol combination versus the concomitant drugs T2 - American Journal of Ophthalmology TI - A comparison of dorzolamide-timolol combination versus the concomitant drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32000869&from=export http://dx.doi.org/10.1016/S0002-9394(00)00717-0 VL - 130 ID - 3898 ER - TY - JOUR AB - The purpose of this systematic review and meta-analysis was to examine the availability of evidence for one of the earliest available minimally invasive glaucoma surgery (MIGS) procedures, the Trabectome. Various databases were searched up to December 20, 2016, for any published studies assessing the use of the Trabectome as a solo procedure in patients with primary open-angle glaucoma (POAG). The standardized mean differences (SMD) were calculated for the change in intraocular pressure (IOP) and number of glaucoma mediations used at 1-month, 6-month, and 12-month follow-up. After screening, three studies and one abstract with analyzable data were included. The meta-analysis showed statistically significant reductions in IOP and number of glaucoma medications used at all time points. Though the Trabectome as a solo procedure appears to lower IOP and reduces the number of glaucoma medications, more high-quality studies are required to make definitive conclusions. The difficulty of obtaining evidence may be one of the many obstacles that limit a full understanding of the potential safety and/or efficacy benefits compared to standard treatments. The time has come for a thoughtful and integrated approach with stakeholders to determine optimal access to care strategies for our patients. AU - Chow, Jeffrey T. Y. AU - Hutnik, Cindy M. L. AU - Solo, Karla AU - Malvankar-Mehta, Monali S. DO - https://dx.doi.org/10.1155/2017/2965725 PY - 2017 SE - Chow, Jeffrey T Y. Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Hutnik, Cindy M L. Department of Ophthalmology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Solo, Karla. Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Malvankar-Mehta, Monali S. Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Malvankar-Mehta, Monali S. Department of Ophthalmology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. SN - 2090-004X SP - 2965725 ST - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma T2 - Journal of ophthalmology TI - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=28740733 VL - 2017 Y2 - 20170627// ID - 624 ER - TY - JOUR AB - Purpose: To evaluate the prognostic value of anterior chamber (AC) laser flare (LF) in uveitis associated with juvenile idiopathic arthritis (JIA). Methods: Monocentre, retrospective study of 150 JIA children (girls n = 107, 71.3%) with unilateral or bilateral chronic anterior uveitis (statistical analysis of one eye per patient). LF values (KOWA FM-500), visual acuity, intraocular pressure, glaucoma treatment and uveitis complications were investigated longitudinally. Results: Patients were followed up for a mean of 8.7 months (range 1-36). High LF values correlated with poor visual acuity (p < 0.0001). Patients with low LF values (LF ≤ 20 photon units per millisecond) less often required glaucoma medication (p = 0.0005) or surgery (p = 0.01) and showed a lower prevalence of cataract, band keratopathy, posterior synechiae, epiretinal membrane, optic disc oedema and glaucoma/ocular hypertension (p < 0.05, each). Baseline LF > 20 photon units per millisecond was a better prognosticator for the development of subsequent complications than baseline AC cells (p = 0.04). Conclusions: High LF values in patients with JIA uveitis are associated with poor vision and a higher prevalence of uveitis complications. © 2011 Acta Ophthalmologica Scandinavica Foundation. AD - Department of Ophthalmology, St. Franziskus Hospital, Hohenzollernring 74, 48145 Muenster, Germany Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland Department of Ophthalmology, University Duisburg-Essen, Essen, Germany AU - Christoph, T. AU - Carsten, H. AU - Martin, R. AU - Arnd, H. DB - Scopus DO - 10.1111/j.1755-3768.2011.02162.x IS - 6 KW - juvenile idiopathic arthritis laser flare outcome uveitis M3 - Article N1 - Cited By :41 Export Date: 19 July 2021 PY - 2011 SP - e521-e527 ST - Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis T2 - Acta Ophthalmologica TI - Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052080591&doi=10.1111%2fj.1755-3768.2011.02162.x&partnerID=40&md5=3739b5e5bbb5c44ba404d58ab64238fd VL - 89 ID - 5015 ER - TY - JOUR AB - Background: The purpose of this study was to describe comorbidities, healthcare costs, and resource utilization among patients with chronic non-infectious uveitis initiating corticosteroid, immunosuppressants, or biologics. In this retrospective cohort study, patients with a non-infectious uveitis diagnosis and continuous insurance coverage during a 6-month baseline were selected from a privately insured claims database with 80.7 million enrollees. Index dates were defined as the first prescription/administration of a corticosteroid, immunosuppressant, or biologic between 2003 and 2009. Comorbidities, healthcare costs, and utilization were analyzed in a per-member-per-month (PMPM) framework to account for varying between-patient treatment periods, defined as continuous medication use within the same class. Wilcoxon rank-sum and chi-square tests were used for comparisons of costs and categorical outcomes. Results: Patients on corticosteroids (N = 4,568), immunosuppressants (N = 5,466), and biologics (N = 1,694) formed the study population. Baseline PMPM inpatient admission rates were 0.029 for patients on corticosteroids, 0.044 for patients on immunosuppressants, and 0.045 for patients on biologics (p < 0.001 immunosuppressants or biologics versus corticosteroids); during treatment, PMPM inpatient admissions increased to 0.044 and 0.048 for patients taking corticosteroids and immunosuppressants, respectively, but decreased to 0.024 for patients taking biologics (p < 0.001 versus corticosteroids and p = 0.003 versus immunosuppressants). Baseline average PMPM costs for patients taking corticosteroids, immunosuppressants, and biologics were US$935, US$1,738, and US$1,439 (p < 0.001 between groups), while on-treatment PMPM costs excluding drug costs increased to US$1,129 for patients taking corticosteroids but lowered to US$1,592 for patients taking immunosuppressants, and US$918 for patients taking biologics (p < 0.001 versus corticosteroids or immunosuppressants). Conclusions: There is significant economic burden associated with existing treatments of uveitis. Corticosteroids may be overused as a treatment for uveitis. © 2013 Chu et al. AD - D. S. Chu, Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, 90 Bergen Street, Suite 6100, Newark, NJ 07960, United States AU - Chu, D. S. AU - Johnson, S. J. AU - Mallya, U. G. AU - Davis, M. R. AU - Sorg, R. A. AU - Duh, M. S. DB - Embase DO - 10.1186/1869-5760-3-64 IS - 1 KW - biological product corticosteroid immunosuppressive agent adolescent adult ankylosing spondylitis article blindness cataract child cohort analysis comorbidity corticosteroid therapy Crohn disease drug cost female glaucoma health care cost health care utilization hospital admission human infant major clinical study male middle aged newborn preschool child prescription priority journal private health insurance psoriasis reference database retina detachment retina macula cystoid edema macular degeneration retrospective study rheumatoid arthritis school child United States uveitis visual disorder young adult LA - English M3 - Article N1 - L372023974 2014-01-08 2014-01-15 PY - 2013 SN - 1869-5760 SP - 1-10 ST - Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA T2 - Journal of Ophthalmic Inflammation and Infection TI - Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372023974&from=export http://dx.doi.org/10.1186/1869-5760-3-64 VL - 3 ID - 2949 ER - TY - JOUR AB - PURPOSE: To investigate differences in the utilization of healthcare services between subjects with open-angle glaucoma (OAG) and comparison subjects without OAG using Taiwan's National Health Insurance population-based database., PATIENTS AND METHODS: The study comprised 2204 subjects with OAG and 2204 sex-matched and age-matched subjects without OAG. We individually followed each subject for a 1-year period to evaluate their healthcare resource utilization. Outcome variables of the healthcare resource utilization were as follows: numbers of outpatient visits and inpatient days and the mean costs of outpatient and inpatient treatment. In addition, we divided healthcare resource utilization into ophthalmologic and nonophthalmologic services., RESULTS: As for the utilization of ophthalmologic services, OAG subjects had significantly more outpatient visits (7.4 vs. 1.3, P<0.001) and significantly higher outpatient costs (US$272 vs. US$39, P<0.001) than comparison subjects. For nonophthalmologic services, OAG subjects also had significantly more outpatient visits (29.4 vs. 21.8, P<0.001) and significantly higher outpatient costs (US$1263 vs. US$847, P<0.001) than comparison subjects. Furthermore, OAG subjects incurred significantly higher inpatient costs compared with comparison subjects (US$434 vs. US$234, P<0.001). For all healthcare services, OAG subjects had significantly more outpatient visits (36.8 vs. 23.1, P<0.001) and significantly higher outpatient (US$1535 vs. US$887, P<0.001) and total (US$2245 vs. US$1122, P<0.001) costs than comparison subjects. In other words, the total cost was about 2-fold greater for OAG subjects than comparison subjects., CONCLUSIONS: We concluded that subjects with OAG had significantly higher utilization of all healthcare services than comparison subjects. AU - Chung, Shiu-Dong AU - Ho, Jau-Der AU - Lin, Herng-Ching AU - Kao, Li-Ting AU - Tsai, Ming-Chieh DO - https://dx.doi.org/10.1097/IJG.0000000000000222 IS - 5 KW - Adolescent Adult Aged Aged, 80 and over Cross-Sectional Studies Databases, Factual Female *Glaucoma, Open-Angle/ec [Economics] Glaucoma, Open-Angle/pp [Physiopathology] Glaucoma, Open-Angle/th [Therapy] *Health Care Costs/sn [Statistics & Numerical Data] *Health Services/ec [Economics] *Health Services/sn [Statistics & Numerical Data] Health Services Research Humans Intraocular Pressure/ph [Physiology] Male Middle Aged National Health Programs/sn [Statistics & Numerical Data] *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Taiwan/ep [Epidemiology] Young Adult PY - 2015 SE - Chung, Shiu-Dong. *Department of Surgery, Far Eastern Memorial Hospital, New Taipei City Sleep Research Center, Taipei Medical University Hospital ++Department of Ophthalmology, Taipei Medical University Hospital Department of Ophthalmology, Taipei Medical University School of Health Care Administration, Taipei Medical University PGraduate Institute of Life Science, National Defense Medical Center #Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan. SN - 1536-481X 1057-0829 SP - e116-20 ST - Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-Based Study T2 - Journal of glaucoma TI - Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-Based Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25642815 VL - 24 ID - 815 ER - TY - JOUR AB - Purpose. To evaluate the control of diurnal intraocular pressure (IOP) and the safety profile of bimatoprost in pseudoexfoliative glaucoma (PXG) compared to primary open angle glaucoma (POAG). Methods. A prospective, observer-masked, nonrandomized study was performed. Seventy consecutive patients with either POAG (35 eyes) or PXG (35 eyes) drug-naive for glaucoma were assigned to receive bimatoprost 0.03% once daily for 12 weeks. Diurnal IOP was measured at baseline and after 12 weeks at three time points (8 AM, noon, and 4 PM). Main outcomes were diurnal IOP control and achievement of target IOP (CIGTS criteria). Mean diurnal IOP, hour-by-hour IOP measurements, and safety, including serious adverse events, were also evaluated. Results. A significant IOP reduction from baseline was found in both groups (p<0.001). Mean and hour-by-hour IOP differences between groups were not statistically significant (NS). The observed IOP values and percentages of IOP reduction were 17.0 mmHg (31.5%) and 16.4 mmHg (31.9%) in PXG and POAG eyes, respectively; the differences were not statistically significant. Six eyes (1 POAG and 5 PXG, respectively) responded with a <20% IOP reduction (NS). Twenty-seven POAG (77.1%) and 23 PXG (65.7%) eyes achieved target IOP. Consequently, 20 eyes (8 POAG and 12 PXG, respectively) were classified as unable to achieve the IOP target values (NS). Conclusions. Bimatoprost was effective and safe in lowering IOP both in open angle and pseudoexfoliative glaucoma, achieving target pressure in most patients. However, long-term efficacy in PXG must be evaluated. © Wichtig Editore, 2009. AD - M. Ciancaglini, Piazza della Rinascita 79, 65122 Pescara, Italy AU - Ciancaglini, M. AU - Carpineto, P. AU - Agnifili, L. AU - Nubile, M. AU - Toto, L. AU - Mastropasqua, L. DB - Embase Medline DO - 10.1177/112067210901900412 IS - 4 KW - bimatoprost adult aged article blurred vision clinical trial controlled clinical trial controlled study dermatitis drug efficacy drug induced headache drug response drug safety eye color eye pain female glaucoma human intraocular foreign body intraocular pressure lid dermatitis major clinical study male ocular pruritus open angle glaucoma patient compliance pigmentation priority journal pseudoexfoliative glaucoma side effect treatment duration LA - English M3 - Article N1 - L355706724 2010-01-11 PY - 2009 SN - 1120-6721 SP - 594-600 ST - A 12-week study evaluating the efficacy of bimatoprost 0.03% in patients with pseudoexfoliative and open-angle glaucoma T2 - European Journal of Ophthalmology TI - A 12-week study evaluating the efficacy of bimatoprost 0.03% in patients with pseudoexfoliative and open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355706724&from=export http://dx.doi.org/10.1177/112067210901900412 VL - 19 ID - 3398 ER - TY - JOUR AB - Prostaglandins are the best option, but should not be used alone. The need for multiple medications raises the problem of compliance. AN - 106362708. Language: English. Entry Date: 20061117. Revision Date: 20150711. Publication Type: Journal Article AU - Cimberle, M. DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Prostaglandins -- Therapeutic Use Disease Progression -- Prevention and Control Drug Therapy, Combination Glaucoma -- Complications Glaucoma -- Trends Medication Compliance Practice Guidelines Surgeons Surveys N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 52-53 ST - Treatment of advanced glaucoma aims for target pressure of 12 mm Hg T2 - Ocular Surgery News TI - Treatment of advanced glaucoma aims for target pressure of 12 mm Hg UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106362708&site=ehost-live&scope=site VL - 24 ID - 4722 ER - TY - JOUR AB - Compliance and quality of life decline with the number of daily doses of glaucoma medications. AN - 106356335. Language: English. Entry Date: 20061103. Revision Date: 20150711. Publication Type: Journal Article AU - Cimberle, M. DB - ccm DP - EBSCOhost IS - 19 KW - Glaucoma -- Epidemiology -- France Ocular Hypertension -- Epidemiology -- France Adrenergic Beta-Antagonists -- Therapeutic Use Age Factors France Glaucoma -- Drug Therapy Glaucoma -- Economics Intraocular Pressure -- Drug Effects Medication Compliance Prevalence Prostaglandins -- Therapeutic Use Quality of Life N1 - tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 32-32 ST - Study finds higher than expected medical glaucoma treatment rate in France T2 - Ocular Surgery News TI - Study finds higher than expected medical glaucoma treatment rate in France UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106356335&site=ehost-live&scope=site VL - 24 ID - 4734 ER - TY - JOUR AB - Non-adherence is mostly due to lack of motivation by younger patients and to poor eye-drop application technique by older patients. AN - 105968265. Language: English. Entry Date: 20080215. Revision Date: 20150711. Publication Type: Journal Article AU - Cimberle, M. DB - ccm DP - EBSCOhost IS - 21 KW - Glaucoma -- Drug Therapy Medication Compliance Aging Motivation Patient Compliance Prospective Studies Quality of Life Questionnaires Self Care -- Methods Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2007 SN - 8750-3085 SP - 40-40 ST - Study: factors associated with poor treatment compliance in glaucoma patients T2 - Ocular Surgery News TI - Study: factors associated with poor treatment compliance in glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105968265&site=ehost-live&scope=site VL - 25 ID - 4726 ER - TY - JOUR AB - The article discusses role of sustained-release implants to offer opportunity to repurpose glaucoma drugs to overcome noncompliance issues; and presents the views of James D. Brandt, doctor of medicine, on effectiveness of intraocular implants having advantage of avoiding allergic reactions on ocular surfaces. AN - 117029296. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Cimberle, Michela DB - ccm DP - EBSCOhost IS - 14 KW - Glaucoma Drugs Physicians Intraocular Pressure Medicine Prostheses and Implants N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2016 SN - 8750-3085 SP - 14-14 ST - Glaucoma drugs may be repurposed with sustained-release implants T2 - Ocular Surgery News TI - Glaucoma drugs may be repurposed with sustained-release implants UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=117029296&site=ehost-live&scope=site VL - 34 ID - 4569 ER - TY - JOUR AN - 124903816. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Cimberle, Michela DB - ccm DP - EBSCOhost IS - 16 KW - Glaucoma -- Surgery Glaucoma Retinal Ganglion Cells Pediatric Surgery Cataract Extraction N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2017 SN - 8750-3085 SP - 1-12 ST - Advances in glaucoma management blur the barriers between subspecialties T2 - Ocular Surgery News TI - Advances in glaucoma management blur the barriers between subspecialties UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124903816&site=ehost-live&scope=site VL - 35 ID - 4282 ER - TY - JOUR AN - 133542809. Language: English. Entry Date: 20181217. Revision Date: 20191029. Publication Type: Article AU - Cimberle, Michela DB - ccm DP - EBSCOhost IS - 23 KW - Protein Kinases -- Antagonists and Inhibitors Enzyme Inhibitors -- Therapeutic Use Anterior Eye Segment -- Physiology Glaucoma -- Therapy Enzyme Inhibitors -- Administration and Dosage Ocular Hypertension -- Prevention and Control Disease Resistance Minimally Invasive Procedures -- Methods Prostaglandins -- Therapeutic Use Patient Compliance Anterior Eye Segment -- Surgery N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2018 SN - 8750-3085 SP - 6-8 ST - ROCK inhibitor represents 'breakthrough' treatment with disease-modifying potential T2 - Ocular Surgery News TI - ROCK inhibitor represents 'breakthrough' treatment with disease-modifying potential UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133542809&site=ehost-live&scope=site VL - 36 ID - 4374 ER - TY - JOUR AN - 136810299. Language: English. Entry Date: 20190608. Revision Date: 20191029. Publication Type: Article AU - Cimberle, Michela DB - ccm DP - EBSCOhost IS - 11 KW - Laser Therapy -- Methods Trabeculectomy -- Methods Glaucoma -- Surgery Glaucoma -- Diagnosis Ocular Hypertension -- Diagnosis Ocular Hypertension -- Prevention and Control Health Care Costs Trabeculectomy -- Adverse Effects Laser Therapy -- Adverse Effects Health Services Accessibility Ophthalmic Solutions -- Therapeutic Use Treatment Outcomes Severity of Illness Medical Practice Paradigms N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2019 SN - 8750-3085 SP - 1-13 ST - Laser as first line therapy could change paradigm of treatment for glaucoma T2 - Ocular Surgery News TI - Laser as first line therapy could change paradigm of treatment for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136810299&site=ehost-live&scope=site VL - 37 ID - 4236 ER - TY - JOUR AN - 145020918. Language: English. Entry Date: 20200925. Revision Date: 20200925. Publication Type: Article AU - Cimberle, Michela DB - ccm DP - EBSCOhost IS - 14 KW - COVID-19 Pandemic Artificial Intelligence Health Care Industry Telehealth Data Analytics Health Services Accessibility Patient Safety Glaucoma Disease Progression Risk Assessment N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2020 SN - 8750-3085 SP - 1-13 ST - Pandemic spurs paradigm shift in artificial intelligence T2 - Ocular Surgery News TI - Pandemic spurs paradigm shift in artificial intelligence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145020918&site=ehost-live&scope=site VL - 38 ID - 4222 ER - TY - JOUR AN - 141184455. Language: English. Entry Date: 20200122. Revision Date: 20200122. Publication Type: Article. Journal Subset: Biomedical AU - Cimberle, Michela DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Surgery Shunts, Surgical Intraocular Pressure Aqueous Humor Patient Safety Health Services Accessibility N1 - Peer Reviewed; USA. NLM UID: 9882135. PY - 2020 SN - 8750-3085 SP - 1-9 ST - Microshunt moves aqueous to ocular surface T2 - Ocular Surgery News TI - Microshunt moves aqueous to ocular surface UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141184455&site=ehost-live&scope=site VL - 38 ID - 4404 ER - TY - JOUR AD - J. B. Ciolino, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, United States AU - Ciolino, J. B. AU - Kohane, D. S. DB - Embase DO - 10.1586/eop.09.50 IS - 6 KW - agents acting on the eye eye drops anterior eye segment biocompatibility chronic disease contact lens cost effectiveness analysis device therapy drug blood level drug delivery system drug design drug penetration drug release drug storage drug transport editorial equipment design glaucoma human hydrogel patient compliance patient safety sustained release preparation unspecified side effect LA - English M3 - Editorial N1 - L358234702 2010-02-12 2010-03-25 PY - 2009 SN - 1746-9899 SP - 569-571 ST - General considerations in designing a drug-eluting contact lens T2 - Expert Review of Ophthalmology TI - General considerations in designing a drug-eluting contact lens UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358234702&from=export http://dx.doi.org/10.1586/eop.09.50 VL - 4 ID - 3303 ER - TY - JOUR AB - Large population-based health administrative databases, clinical registries, and data linkage systems are a rapidly expanding resource for health research. Ophthalmic research has benefited from the use of these databases in expanding the breadth of knowledge in areas such as disease surveillance, disease etiology, health services utilization, and health outcomes. Furthermore, the quantity of data available for research has increased exponentially in recent times, particularly as e-health initiatives come online in health systems across the globe. We review some big data concepts, the databases and data linkage systems used in eye research—including their advantages and limitations, the types of studies previously undertaken, and the future direction for big data in eye research. AD - A. Clark, Centre for Population Health Research, Faculty of Health Sciences, Curtin University, Bentley, Western Australia, Australia AU - Clark, A. AU - Ng, J. Q. AU - Morlet, N. AU - Semmens, J. B. DB - Embase Medline DO - 10.1016/j.survophthal.2016.01.003 IS - 4 KW - amantadine antiglaucoma agent bevacizumab hydroxymethylglutaryl coenzyme A reductase inhibitor phosphodiesterase inhibitor quinoline derived antiinfective agent ranibizumab abducens nerve paralysis age related macular degeneration anterior ischemic optic neuropathy blindness cataract cataract extraction closed angle glaucoma cornea edema data base diabetic retinopathy disease surveillance dry eye endophthalmitis eye disease eye injury glaucoma government health care planning health care utilization health economics health services research heart infarction human ischemic optic neuropathy medical record medical research medicare online system open angle glaucoma ophthalmic epidemiology ophthalmoscopy optic nerve disease pharmacoepidemiology postmarketing surveillance priority journal register retina detachment retina vein occlusion retrolental fibroplasia review strabismus visual impairment LA - English M3 - Review N1 - L609470359 2016-04-11 2016-11-02 PY - 2016 SN - 1879-3304 0039-6257 SP - 443-465 ST - Big data and ophthalmic research T2 - Survey of Ophthalmology TI - Big data and ophthalmic research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609470359&from=export http://dx.doi.org/10.1016/j.survophthal.2016.01.003 VL - 61 ID - 2728 ER - TY - JOUR AB - BACKGROUND/AIMS: To examine the agreement in clinical decisions of glaucoma status made in a virtual glaucoma clinic with those made during a face-to-face consultation., METHODS: A trained nurse and technicians entered data prospectively for 204 patients into a proforma. A subsequent face-to-face clinical assessment was completed by either a glaucoma consultant or fellow. Proformas were reviewed remotely by one of two additional glaucoma consultants, and 12 months later, by the clinicians who had undertaken the original clinical examination. The interobserver and intraobserver decision-making agreements of virtual assessment versus standard care were calculated., RESULTS: We identified adverse disagreement between face-to-face and virtual review in 7/204 (3.4%, 95% CI 0.9% to 5.9%) patients, where virtual review failed to predict a need to accelerated follow-up identified in face-to-face review. Misclassification events were rare, occurring in 1.9% (95% CI 0.3% to 3.8%) of assessments. Interobserver kappa (95% CI) showed only fair agreement (0.24 (0.04 to 0.43)); this improved to moderate agreement when only consultant decisions were compared against each other (kappa=0.41 (0.16 to 0.65)). The intraobserver agreement kappa (95% CI) for the consultant was 0.274 (0.073 to 0.476), and that for the fellow was 0.264 (0.031 to 0.497)., CONCLUSIONS: The low rate of adverse misclassification, combined with the slowly progressive nature of most glaucoma, and the fact that patients will all be regularly reassessed, suggests that virtual clinics offer a safe, logistically viable option for selected patients with glaucoma. Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. AU - Clarke, Jonathan AU - Puertas, Renata AU - Kotecha, Aachal AU - Foster, Paul J. AU - Barton, Keith DO - https://dx.doi.org/10.1136/bjophthalmol-2016-308993 IS - 7 KW - Adult Aged Aged, 80 and over Appointments and Schedules *Decision Making Female Follow-Up Studies *Glaucoma/di [Diagnosis] Humans Male Middle Aged *Ophthalmology/mt [Methods] *Outpatient Clinics, Hospital/og [Organization & Administration] Prospective Studies ROC Curve *Referral and Consultation Time Factors PY - 2017 SE - Clarke, Jonathan. Glaucoma Service, Moorfields Eye Hospital London, London, UK. Clarke, Jonathan. NIHR BRC at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. Puertas, Renata. Glaucoma Service, Moorfields Eye Hospital London, London, UK. Kotecha, Aachal. Glaucoma Service, Moorfields Eye Hospital London, London, UK. Kotecha, Aachal. NIHR BRC at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. Foster, Paul J. Glaucoma Service, Moorfields Eye Hospital London, London, UK. Foster, Paul J. NIHR BRC at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. Barton, Keith. Glaucoma Service, Moorfields Eye Hospital London, London, UK. Barton, Keith. NIHR BRC at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. SN - 1468-2079 0007-1161 SP - 892-895 ST - Virtual clinics in glaucoma care: face-to-face versus remote decision-making T2 - The British journal of ophthalmology TI - Virtual clinics in glaucoma care: face-to-face versus remote decision-making UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=27729310 VL - 101 Y2 - 20161011// ID - 559 ER - TY - JOUR AB - Because of the risk of serious complication that accompanies the extended wear of contact lenses, clinical management should emphasize adequate communication with the patient and a systematic program of examination and follow-up. Management should be in compliance with informed consent requirements, which obligate practitioners to document instructions, findings, warnings, and recall examinations. The most likely legal claim is one of negligence, and the most common causes of liability are inappropriate patient selection, improper wearing schedules, improper management of contact lens-related complications (especially corneal abrasions), and inadequate monitoring of ocular health. In determining the liability of optometrists, a medical standard of care may be applied. AU - Classe, J. G. IS - 3 KW - *Contact Lenses, Extended-Wear/ae [Adverse Effects] Corneal Ulcer/et [Etiology] Disposable Equipment Humans Liability, Legal *Malpractice *Optometry/lj [Legislation & Jurisprudence] Patient Compliance Risk Factors PY - 1991 SN - 1050-6918 SP - 51-62 ST - Liability for extended-wear contact lenses T2 - Optometry clinics : the official publication of the Prentice Society TI - Liability for extended-wear contact lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1797240 VL - 1 ID - 2135 ER - TY - JOUR AU - Clearkin, L. IS - 6965 KW - Fees and Charges *Glaucoma/di [Diagnosis] Glaucoma/th [Therapy] Humans Patient Acceptance of Health Care United Kingdom *Vision Tests/ec [Economics] N1 - Comment on (CON) PY - 1994 SN - 0959-8138 SP - 1369-1372 ST - The sight test fee. Effectiveness of treatment for glaucoma remains unproved T2 - BMJ (Clinical research ed.) T3 - Comment on: BMJ. 1994 Sep 10;309(6955):634-6; PMID: 8086985 [https://www.ncbi.nlm.nih.gov/pubmed/8086985] TI - The sight test fee. Effectiveness of treatment for glaucoma remains unproved UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7726954 VL - 309 ID - 2086 ER - TY - JOUR AB - Purpose: This multicenter study evaluated 2-year effectiveness and safety following implantation of two second-generation trabecular micro-bypass stents (iStent inject (R)) with phacoemulsification. Materials and Methods: This was a retrospective study of iStent inject implantation with phacoemulsification by nine surgeons across Australia. Eyes had mild to advanced glaucoma (predominantly primary open-angle/POAG, appositional angle-closure/ACG, or normal-tension /NTG) or ocular hypertension (OHT), and cataract Evaluations included intraocular pressure (TOP); medications; proportions of eyes with 0 or >= 2 medications, reduced/stable medications versus preoperative, and TOP <= 15 mmHg; visual acuity; cup-to-disc ratio (CDR); visual fields (VF); adverse events; and secondary surgery. Results: A total of 340 eyes underwent surgery and had 24-month follow-up data. At 24 months, mean IOP decreased by 16% from 16.4 +/- 4.7 mmHg preoperatively to 13.7 +/- 3.1 mmHg (p<0.001), and 77% of eyes achieved IOP of <= 15 mmHg versus 49% preoperatively (p<0.001). Mean number of medications decreased by 67% to 0.49 +/- 0.95 versus 1.49 +/- 1.20 preoperatively (p<0.001), with 74% of eyes medication-free versus 25% preoperatively (p<0.001), and 14% of eyes on >= 2 medications versus 46% preoperatively (p<0.001). Medication burden was reduced or stable in 98% of eyes versus preoperative. Stratified analyses showed significant IOP and medication reductions across glaucoma subtypes (POAG, ACG, NTG, OHT): 13-22% for IOP (p<0.01 for all) and 62-100% for medication (p<0.001 for all). Favorable safety included few adverse events; stable CDR, VF, and visual acuity; and filtering surgery in only 8 eyes (2.4%) over 2 years. Conclusion: This 340-eye multicenter dataset provides robust evidence of the safety and efficacy of iStent inject implantation with phacoemulsification, with significant and sustained IOP and medication reductions through 2 years. Results were similarly favorable across glaucoma subtypes (including POAG, ACG, NTG, OHT) and were attained across various glaucoma severities, clinical sites, and surgeons, highlighting the real-world versatility and utility of this treatment modality. AN - WOS:000586849100001 AU - Clement, C. AU - Howes, F. AU - Ioannidis, A. S. AU - Shiu, M. AU - Manning, D. AU - Lusthaus, J. AU - Lim, R. AU - Skalicky, S. E. AU - Goodwin, T. DO - 10.2147/OPTH.S271646 PY - 2020 SN - 1177-5483 SP - 3507-3517 ST - Two-Year Multicenter Outcomes of iStent inject Trabecular Micro-Bypass Stents Combined with Phacoemulsification in Various Types of Glaucoma and Ocular Hypertension T2 - CLINICAL OPHTHALMOLOGY TI - Two-Year Multicenter Outcomes of iStent inject Trabecular Micro-Bypass Stents Combined with Phacoemulsification in Various Types of Glaucoma and Ocular Hypertension VL - 14 ID - 6118 ER - TY - JOUR AB - Prostaglandin analogs (PGA) have been the initial treatment of choice in many patients with glaucoma. However, there is an increasing awareness that non adherence and disruption of the ocular surface may limit PGA utility and tolerability respectively in some patients. In an eye with an open iridocorneal angle, these issues can potentially be addressed with the use of laser trabeculoplasty (LT). This therapy can achieve long-term intraocular pressure reduction following 1 to 2 treatment sessions without the ongoing need to apply medication (and preservatives) to the ocular surface. Whether PGAs or LT should be used in a given individual will also be influenced by other important factors including efficacy, response rate, tolerability, complications, cost and accessibility. This review examines these issues in relation to the initiation of primary therapy. How to cite this article: Clement CI. Initial Treatment: Prostaglandin Analog of Selective Laser Trabeculoplasty. J Current Glau Prac 2012;6(3):99-103. AU - Clement, Colin I. DO - https://dx.doi.org/10.5005/jp-journals-10008-1114 IS - 3 PY - 2012 SE - Clement, Colin I. Glaucoma Unit, Sydney Eye Hospital, NSW, Australia; Central Clinical School Faculty of Medicine, The University of Sydney, NSW, Australia. SN - 0974-0333 SP - 99-103 ST - Initial Treatment: Prostaglandin Analog or Selective Laser Trabeculoplasty T2 - Journal of current glaucoma practice TI - Initial Treatment: Prostaglandin Analog or Selective Laser Trabeculoplasty UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=26997763 VL - 6 Y2 - 20121016// ID - 1173 ER - TY - JOUR AB - Purpose: To assess the utility and safety of implanting two second-generation trabecular micro-bypass stents following cataract surgery in eyes with mild to advanced glaucoma or ocular hypertension (OHT). Patients and methods: Retrospective study of iStent (R) inject trabecular micro-bypass implantation with cataract surgery by five surgeons at five sites in Australia. Eyes had mild to advanced glaucoma (predominantly primary open-angle, appositional angle-closure, or pseudoexfoliative glaucoma) or OHT and cataract requiring surgery. Effectiveness measures included intraocular pressure (IOP); medication burden; and proportions of eyes with no medications, >= 2 medications, stable or decreased medications vs preoperative, and IOP <= 18 mmHg. Safety measures included visual acuity, cup-to-disc ratio (CDR), visual field (VF), complications, adverse events, and secondary surgical interventions. Patients have been followed for 12 months, and follow-up is ongoing. Results: Of the 290 total eyes that underwent surgery, 165 eyes had 12-month outcomes at the time of data collection and are included in this report. In these eyes, mean Month 12 IOP reduced by 23.2% from 18.27 +/- 5.41 mmHg preoperatively to 14.04 +/- 2.98 mmHg (P<0.001), with 95.8% of eyes achieving Month 12 IOP of <= 18 mmHg vs 60.6% preoperatively. Mean number of medications at 12 months decreased by 71.5%, 0.47 +/- 0.95 vs 1.65 +/- 1.28 preoperatively; 76.4% of eyes were on zero medications vs 17.6% preoperatively (P<0.001); 14.5% of eyes were on >2 medications vs 46.7% preoperatively (P<0.001); and 98.2% of eyes maintained or reduced medications vs their preoperative regimen. Favorable safety included no stent-related intraoperative complications; limited and transient postoperative adverse events; and stable CDR, VF, and visual acuity. Three eyes with more advanced disease underwent additional glaucoma surgeries. Conclusion: iStent inject implantation with cataract surgery significantly and safely reduced medications and IOP in eyes with various types and severities of glaucoma within a multicenter, multi-provider, real-life setting. AN - WOS:000461334800001 AU - Clement, C. I. AU - Howes, F. AU - Ioannidis, A. S. AU - Shiu, M. AU - Manninge, D. DO - 10.2147/OPTH.S187272 PY - 2019 SN - 1177-5483 SP - 491-499 ST - One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study T2 - CLINICAL OPHTHALMOLOGY TI - One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study VL - 13 ID - 6108 ER - TY - JOUR AB - Aims/background: This investigation determined eye care utilisation patterns in a rural county in Ireland. Population based estimates of visual impairment and glaucoma were available, so the two studies will optimise planning for eye care services for the county. Methods: Roscommon has a population of 55,000 served by one ophthalmologist and two optometrists. Data were collected on all outpatient visits for all providers for a 3 month period. Information was abstracted on demographics, presenting and final diagnoses. Expected number of visits for glaucoma were calculated using the population structure and rates of glaucoma, and assuming one visit per year per glaucoma patient. Results: 1398 patients had a total of 1442 visits in 3 months. A third of the visits were to optometrists, and all but 21 visits were for normal eye examinations or glasses. The majority of children aged less than 16 years, and people older than 60 years were seen by the ophthalmologist. Among children, 81% of all visits were to the ophthalmologist and 92% were classified as a normal examination. Only an estimated 188 visits per year for glaucoma were observed, compared with 1100 expected. Conclusion: In this rural county, many of the visits to the ophthalmologist were for normal eye examination, particularly among children. Screening algorithms which would free the ophthalmologist to see more complicated problems could be considered. There is an underutilisation of services by glaucoma patients. Reasons for this are described. AD - S. West, Johns Hopkins University, Wilmer Eye Institute, 600 North Wolfe Street, Baltimore, MD 21287-9019, United States AU - Clendenin, C. AU - Coffey, M. AU - Marsh, M. AU - West, S. DB - Embase Medline DO - 10.1136/bjo.81.11.972 IS - 11 KW - adolescent adult aged algorithm article child demography female glaucoma health care planning health care utilization human information processing Ireland major clinical study male ophthalmology optometry priority journal rural population screening spectacles visual impairment LA - English M3 - Article N1 - L27493984 1997-12-02 PY - 1997 SN - 0007-1161 SP - 972-975 ST - Eye care utilisation patterns in a rural county in Ireland: Implications for service delivery T2 - British Journal of Ophthalmology TI - Eye care utilisation patterns in a rural county in Ireland: Implications for service delivery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L27493984&from=export http://dx.doi.org/10.1136/bjo.81.11.972 VL - 81 ID - 3955 ER - TY - JOUR AN - 141717181. Language: English. Entry Date: 20200224. Revision Date: 20200224. Publication Type: Article AU - Clermont, Joshua M. DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma Private Practice Management Appointments and Schedules -- Education Coding -- Education Optometrists -- Education Referral and Consultation Decision Making Diagnosis, Eye Insurance, Health, Reimbursement Billing and Claims N1 - tables/charts. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2020 SN - 0030-4085 SP - 30-32 ST - MASTER GLAUCOMA SERVICES: Learn how to schedule these patients and code appropriately T2 - Optometric Management TI - MASTER GLAUCOMA SERVICES: Learn how to schedule these patients and code appropriately UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141717181&site=ehost-live&scope=site VL - 55 ID - 4330 ER - TY - JOUR AB - Corneal complications of herpes zoster ophthalmicus include pseudodendritic keratitis, late mucous adherent keratopathy, varied forms of stromal keratitis, and exposure/neurotrophic keratopathy. Prophylactic therapy of acute herpes zoster ophthalmicus with oral acyclovir is of proven benefit in reducing the incidence of early pseudodendritic keratopathy and stromal keratitis but has no evident effect on exposure/neurotrophic keratopathy. Although early pseudodendritic keratitis is due to virus infection of epithelial cells, it is self-limited and does not require topical antiviral therapy. Stromal keratitis and associated epithelial mucous adherent keratopathy are responsive to topical corticosteroids but chronic therapy is often required and may prolong the duration of keratitis and result in cataract or secondary glaucoma. Exposure and neurotrophic keratopathy may respond to topical lubricants and correction of lid abnormalities but severely affected corneas may require tarsorrhaphy or conjunctival flap to maintain corneal integrity. AU - Cobo, L. M. IS - 1 KW - Acyclovir/tu [Therapeutic Use] Administration, Oral Administration, Topical Adrenal Cortex Hormones/tu [Therapeutic Use] Antiviral Agents/tu [Therapeutic Use] Cornea/pa [Pathology] Corneal Diseases/cl [Classification] Corneal Diseases/dt [Drug Therapy] *Corneal Diseases/et [Etiology] Corneal Diseases/pc [Prevention & Control] Corneal Stroma *Herpes Zoster Ophthalmicus/co [Complications] Humans Keratitis/dt [Drug Therapy] Keratitis/et [Etiology] Lubrication PY - 1988 SE - Cobo, L M. Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina 27710. SN - 0277-3740 SP - 50-6 ST - Corneal complications of herpes zoster ophthalmicus. Prevention and treatment T2 - Cornea TI - Corneal complications of herpes zoster ophthalmicus. Prevention and treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=3258220 VL - 7 ID - 2182 ER - TY - JOUR AB - Maximal drug treatment can be absolute, using all the combinations possible if no surgery can reasonably be undertaken, or relative, with surgery as the next step. The drug treatment is chosen in collaboration with the patient, who should always receive attentive explanations, detailing the prescription and adapting it to each situation so as to achieve maximum compliance. AU - Cochereau, I. KW - *Glaucoma/dt [Drug Therapy] Humans PY - 2005 SE - Cochereau, I. Service d'ophtalmologie, 4 rue Larrey 49933 Angers Cedex 9. SN - 1773-0597 0181-5512 SP - 2S45-2S47 ST - [Medical treatments and practices. Ascertaining maximal drug treatment] T2 - Traitements medicaux. Quel doit etre un "traitement medical maximal"? TI - [Medical treatments and practices. Ascertaining maximal drug treatment] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16208241 VL - 28 Spec No 2 ID - 1716 ER - TY - JOUR AB - Compliance is a major issue in glaucoma, a chronic and asymptomatic disease. The management of the disease by the patient himself is a key point in the prognosis of glaucoma. Ophthalmologists can increase glaucoma patient compliance through education and medicopsychological assistance. AU - Cochereau, I. IS - 5 Pt 2 KW - *Glaucoma/dt [Drug Therapy] Glaucoma/px [Psychology] Humans *Patient Compliance *Patient Education as Topic Quality of Life PY - 2007 SE - Cochereau, I. Service d'ophtalmologie, CHU d'Angers, 4, rue Larrey, 49033 Angers cedex 01. SN - 1773-0597 0181-5512 SP - 3S79-81 ST - [Increasing compliance in glaucoma patients through education ] T2 - Depister, informer, participer, autoriser....? Nos patients et leur glaucome. TI - [Increasing compliance in glaucoma patients through education ] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17646810 VL - 30 ID - 1590 ER - TY - JOUR AB - OBJECTIVE : The aims of this review are to define open angle glaucoma, to outline its prevalence and its financial and personal costs, to discuss the difficulties encountered in establishing the diagnosis and monitoring treatment, and to suggest initial clinical guidelines for the comanagement of glaucoma between ophthalmologists and optometrists. METHODS: The literature was selectively reviewed to permit deductions that can be directed toward an effective comanagement strategy for patients with open angle glaucoma. CONCLUSIONS : Comanagement of patients having open angle glaucoma is a viable option, provided the opportunity for improved monitoring and better compliance is available. The basis for successful management rests with the ability to detect change in the optic disc and surrounding retina, visual fields and intraocular pressure. All these signs are continuous variables for which there are no known limits of normality. The division of responsibilities of management will be established initially by legislation and in the future modified according to experience and the emergence of new therapies. AU - Cockburn, David M. IS - 3 PY - 2000 SE - Cockburn, David M. Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Victoria, 3052, Australia. SN - 1444-0938 0816-4622 SP - 119-127 ST - Diagnosis and management of open angle glaucoma: suggested guidelines for optometrists T2 - Clinical & experimental optometry TI - Diagnosis and management of open angle glaucoma: suggested guidelines for optometrists UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=12472444 VL - 83 ID - 1231 ER - TY - JOUR AB - Glaucoma is the second leading cause of blindness globally. Stereophotogrammetry-based optic nerve head topographical imaging systems could potentially allow for objective glaucoma assessment in settings where technologies such as optical coherence tomography and the Heidelberg Retinal Tomograph are prohibitively expensive. In the development of such systems, eye phantoms are invaluable tools for both system calibration and performance evaluation. Eye phantoms developed for this purpose need to replicate the optical configuration of the eye, the related causes of measurement artefacts, and give the possibility to present to the imaging system the targets required for system calibration. The phantoms in the literature that show promise of meeting these requirements rely on custom lenses to be fabricated, making them very costly. Here, we propose a low-cost eye phantom comprising a vacuum formed cornea and commercially available stock bi-convex lens, that is optically similar to a gold-standard reference wide-angle schematic eye model and meets all the compliance and configurability requirements for use with stereo-photogrammetry-based ONH topographical imaging systems. Moreover, its modular design, being fabricated largely from 3D-printed components, lends itself to modification for other applications. The use of the phantom is successfully demonstrated in an ONH imager. AU - Coghill, Ian AU - Black, Richard A. AU - Livingstone, Iain A. T. AU - Giardini, Mario E. DO - https://dx.doi.org/10.1109/EMBC44109.2020.9175326 KW - *Glaucoma Humans Imaging, Three-Dimensional *Optic Disk Phantoms, Imaging Photogrammetry PY - 2020 SN - 2694-0604 2375-7477 SP - 1604-1607 ST - Low-Cost Eye Phantom for Stereophotogrammetry-Based Optic Nerve Head Topographical 3D Imaging T2 - Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference TI - Low-Cost Eye Phantom for Stereophotogrammetry-Based Optic Nerve Head Topographical 3D Imaging UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med17&NEWS=N&AN=33018301 VL - 2020 ID - 268 ER - TY - JOUR AB - BACKGROUND: Primary open-angle glaucoma is a leading cause of irreversible blindness., OBJECTIVES: To identify factors associated with adherence to glaucoma pharmacotherapy in the primary care setting, focusing on physicians' role., METHODS: Patients were recruited from primary care clinics and telephone-interviewed using a structured questionnaire that addressed patient-, medication-, environment- and physicians-related factors. Patients' data on pharmacy claims were retrieved to calculate the medication possession ratio for measuring adherence., RESULTS: Seven hundred thirty-eight glaucoma patients were interviewed. The multivariate analysis identified eight variables that were associated independently with adherence. Barriers to adherence were found to be low income, believing that 'It makes no difference to my vision whether I take the drops or not' and relying on someone else for drop instillation (exp(B) = 1.91, P = 0.002; exp(B) = 2.61, P < 0.0001; exp(B) = 2.17, P = 0.001, respectively). Older age, having a glaucoma patient among close acquaintances, taking a higher number of drops per day, taking a prostaglandin drug and reporting that the ophthalmologist had discussed the importance of taking eye drops as prescribed, were found to promote adherence (exp(B) = 0.96, P < 0.0001; exp(B) = 0.54, P = 0.014; exp(B) = 0.81, P = 0.001; exp(B) = 0.37, P < 0.0001; exp(B) = 0.60, P = 0.034, respectively). No association was found between the patient's relationship with the family physician and adherence to glaucoma treatment., CONCLUSION: Adherence to glaucoma pharmacotherapy is associated with patient-related, medication-related, physician-related and environmental factors. Ophthalmologists have a significant role in promoting adherence. However, the potential role of family physicians is unfulfilled and unrecognized. Copyright © The Author 2014. Published by Oxford University Press. AU - Cohen Castel, Orit AU - Keinan-Boker, Lital AU - Geyer, Orna AU - Milman, Uzi AU - Karkabi, Khaled DO - https://dx.doi.org/10.1093/fampra/cmu031 IS - 4 KW - Aged Aged, 80 and over Antihypertensive Agents/tu [Therapeutic Use] Cross-Sectional Studies Female *Glaucoma/dt [Drug Therapy] Humans Israel Male *Medication Adherence Ophthalmology *Physician's Role Physicians, Family *Primary Health Care Surveys and Questionnaires PY - 2014 SE - Cohen Castel, Orit. Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, hforitco@gmail.com. Keinan-Boker, Lital. Faculty of Social Welfare and Health Sciences, School of Public Health, University of Haifa, Haifa. Geyer, Orna. Department of Ophthalmology, Carmel Medical Center, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa and. Milman, Uzi. Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Department of Family Medicine and Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel. Karkabi, Khaled. Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Department of Family Medicine and. SN - 1460-2229 0263-2136 SP - 453-61 ST - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting T2 - Family practice TI - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24927725 VL - 31 Y2 - 20140612// ID - 877 ER - TY - JOUR AB - Herpes zoster (HZ) is caused by reactivation of latent varicella zoster virus (VZV) in people who have had chicken pox, usually resulting in a painful, unilateral, dermatomal, vesicular rash. Herpes zoster ophthalmicus occurs when the first division of cranial nerve V is involved. HZ is common, with approximately 1 million new cases per year in the United States, and occurs in 1 in 3 persons. Although the rate of HZ increases with age, over half of all cases occur under the age of 60 years. Complications of herpes zoster ophthalmicus include eye disease, postherpetic neuralgia (PHN), and strokes. VZV has also been found in temporal arteritis biopsies. There is growing evidence that HZ is followed by chronic active VZV infection contributing to these complications. In view of this, and the efficacy of suppressive antiviral treatment in reducing recurrent herpes simplex keratitis, a randomized controlled trial of suppressive valacyclovir to reduce new or worsening anterior segment disease and/or PHN is needed. The zoster vaccine (ZV) is safe and effective in reducing the burden of illness, severity of PHN, and incidence of HZ. It is Centers for Disease Control and Prevention recommended for persons aged 60 years and above without impaired cellular immunity, and Food and Drug Administration approved for those aged 50 and older. It is most effective in preventing HZ in recipients in their 50s. Because of underusage of the ZV, it has not impacted the epidemiology of the disease. Barriers to its use include cost, variable reimbursement, frozen storage, and lack of a strong recommendation by doctors. AU - Cohen, Elisabeth J. DO - https://dx.doi.org/10.1097/ICO.0000000000000503 KW - Age of Onset Antiviral Agents/tu [Therapeutic Use] *Herpes Zoster Ophthalmicus/di [Diagnosis] *Herpes Zoster Ophthalmicus/pc [Prevention & Control] Herpes Zoster Vaccine/ad [Administration & Dosage] *Herpesvirus 3, Human/ph [Physiology] Humans Middle Aged Virus Activation/ph [Physiology] Virus Latency PY - 2015 SE - Cohen, Elisabeth J. Department of Ophthalmology, New York University (NYU) School of Medicine, NYU Langone Medical Center, New York, NY. SN - 1536-4798 0277-3740 SP - S3-8 ST - Management and Prevention of Herpes Zoster Ocular Disease T2 - Cornea TI - Management and Prevention of Herpes Zoster Ocular Disease UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26114827 VL - 34 Suppl 10 ID - 788 ER - TY - JOUR AB - OBJECTIVE: This article investigates the prevalence and attributes of patients with open-angle glaucoma who exhibit improvement of visual field loss in a clinical setting., DESIGN: We conducted a retrospective chart review of patients in a clinical glaucoma practice., PARTICIPANTS: We identified 719 glaucoma patients with at least 5 SITA strategy visual field tests and a minimum continuous follow-up period of 5 years., METHODS: The change in the slope of the visual field index (VFI) over time was illustrated using histogram analysis for the study eye with the worst VFI at baseline. Multiple variables were analyzed to determine their impact on rates of visual field progression, including sex, age, disease staging, intraocular pressure (IOP), and incisional surgeries. Eyes with severe nonophthalmic and ophthalmic comorbidities were excluded., RESULTS: Considering 582 eligible eyes, 232 (39.9%) showed significantly positive slopes of the VFI as a function of time, 76 (13.1%) showed nonsignificant slopes, and 276 (47.4%) showed significantly negative slopes. In all, 10 eyes (1.7%) demonstrated VFI slope improvement of >=2% per year, whereas 21 (3.6%) demonstrated VFI slope reduction >=2% per year. More advanced disease stage was significantly associated with a negative VFI slope (p < 0.0001). Trabeculectomy and poor compliance were not associated with a negative VFI slope, whereas cataract surgery correlated with higher odds of a negative VFI slope (p = 0.048)., CONCLUSIONS: In a clinical setting, a significant VFI improvement over time was observed over an interval of greater than 5 years. Copyright © 2016 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. AU - Cohen, Shawn L. AU - Rosen, Aaron I. AU - Tan, Xianming AU - Kingdom, Frederick A. A. DO - https://dx.doi.org/10.1016/j.jcjo.2016.10.001 IS - 6 KW - Aged Aged, 80 and over Female *Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] Humans Intraocular Pressure/ph [Physiology] Male Middle Aged Retrospective Studies Tonometry, Ocular *Trabeculectomy *Vision Disorders/pp [Physiopathology] Visual Acuity Visual Field Tests *Visual Fields/ph [Physiology] PY - 2016 SE - Cohen, Shawn L. McGill University, Montreal, Que. Electronic address: shawn.cohen@mcgill.ca. Rosen, Aaron I. McGill University, Montreal, Que. Tan, Xianming. University of North Carolina, Chapel Hill, North Carolina. Kingdom, Frederick A A. McGill University, Montreal, Que. SN - 1715-3360 0008-4182 SP - 445-451 ST - Improvement of the visual field index in clinical glaucoma care T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - Improvement of the visual field index in clinical glaucoma care UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27938956 VL - 51 Y2 - 20161115// ID - 651 ER - TY - JOUR AD - Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, United States AU - Colby, K. AU - Pavan-Langston, D. DB - Embase Medline DO - 10.1016/j.ophtha.2013.01.035 IS - 6 KW - aciclovir ganciclovir trifluridine anterior eye segment astigmatism blepharitis differential diagnosis disease predisposition eye infection health care cost herpes simplex herpes simplex keratitis human letter patient compliance practice guideline priority journal randomized controlled trial (topic) topical treatment LA - English M3 - Letter N1 - L369046882 2013-06-12 PY - 2013 SN - 0161-6420 1549-4713 SP - e28-e29 ST - Author reply T2 - Ophthalmology TI - Author reply UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369046882&from=export http://dx.doi.org/10.1016/j.ophtha.2013.01.035 VL - 120 ID - 2995 ER - TY - JOUR AD - A.L. Coleman, Los Angeles, CA, United States AU - Coleman, A. L. DB - Embase Medline DO - 10.1016/j.ophtha.2007.05.046 IS - 9 KW - antiglaucoma agent prostaglandin derivative blindness cataract extraction clinical practice diagnostic procedure disease course disease severity editorial human open angle glaucoma optic nerve patient compliance priority journal visual field LA - English M3 - Editorial N1 - L47332690 2007-09-01 PY - 2007 SN - 0161-6420 SP - 1597-1598 ST - Gathering Evidence from Claims Data: Caveats T2 - Ophthalmology TI - Gathering Evidence from Claims Data: Caveats UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47332690&from=export http://dx.doi.org/10.1016/j.ophtha.2007.05.046 VL - 114 ID - 3506 ER - TY - JOUR AD - A.L. Coleman, Jules Stein Eye Institute, the Department of Ophthalmology, David Geffen School of Medicine, Los Angeles, CA, United States AU - Coleman, A. L. AU - Caprioli, J. DB - Embase Medline DO - 10.1016/j.ajo.2008.10.027 IS - 3 KW - antihypertensive therapy blood pressure measurement clinical practice disease course editorial Europe glaucoma hypertension intraocular hypertension intraocular pressure medical society medical specialist medicare open angle glaucoma patient compliance practice guideline priority journal smoking cessation United States vision LA - English M3 - Editorial N1 - L354158382 2009-02-26 PY - 2009 SN - 0002-9394 SP - 379-380 ST - The Logic Behind Target Intraocular Pressure T2 - American Journal of Ophthalmology TI - The Logic Behind Target Intraocular Pressure UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354158382&from=export http://dx.doi.org/10.1016/j.ajo.2008.10.027 VL - 147 ID - 3368 ER - TY - JOUR AB - Evaluation of: Ramdas WD, Wolfs RC, Hofman A, de Jong PT, Vingerling JR, Jansonius NM. Lifestyle and risk of developing open-angle glaucoma: the Rotterdam Study. Arch. Ophthalmol. DOI: 10.1001/archophthalmol.2010.373 (2011) (Epub ahead of print). According to the Rotterdam Study, which was conducted in The Netherlands, socioeconomic status, alcohol consumption and smoking were not related to the onset of open-angle glaucoma. Because participants were from a homogeneous suburb and The Netherlands ranks number one in terms of equity in healthcare for all individuals regardless of income, the lack of an association between socioeconomic status and open-angle glaucoma is not surprising. © 2011 Expert Reviews Ltd. AD - A.L. Coleman, UCLA Center for Eye Epidemiology, David Geffen School of Medicine, UCLA, Los Angeles, CA, United States AU - Coleman, A. L. AU - Kodjebacheva, G. DB - Embase DO - 10.1586/eop.11.35 IS - 3 KW - article disease association educational status employment status health care access health care disparity human income open angle glaucoma social status LA - English M3 - Article N1 - L362047153 2011-07-07 2011-07-12 PY - 2011 SN - 1746-9899 1746-9902 SP - 295-296 ST - Socioeconomic status and open-angle glaucoma T2 - Expert Review of Ophthalmology TI - Socioeconomic status and open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362047153&from=export http://dx.doi.org/10.1586/eop.11.35 VL - 6 ID - 3170 ER - TY - JOUR AB - Purpose: Sub-Saharan Africa has fewer than 1 Ophthalmologist per million population. Sight preserving support services, including optometry and access to glaucoma medications, are absent in all but a few urban populations. Our experience in Africa since 2006, working in partnership with African eye surgeons, has revealed a remarkably high incidence of untreated early and advanced glaucoma. This study reports initial experience using SLT in adult glaucoma patients in Durban, South Africa. Methods: Lumenis Selecta SLT was performed on either or both eyes of consecutive glaucoma patients. After recording pre-treatment IOP by applanation,1800 treatment with ∼50 spots was performed, titrating from 0.5 mJ, in +.1 mJ increments until bubbles arose from ∼1 in every 3 spots placed. Repeat tonometry was scheduled at 1 and 6 months post-SLT. Significance of change in IOP from baseline was assessed by 2-tailed paired t-test. Results: Among 90 treated patients (65 black, 22 Indian, 3 white; 48M, 42F; mean age 59 ±[sem]1.3yrs ), 63 (70%) returned for at least one of the two scheduled follow-up visits. 20 patients (31.7%) had a prior history of glaucoma filtration surgery in at least one eye. At 1 mo, treated right eyes (n=35) showed reduction of -4.6mmHg (-25.3%) from the associated pre-treatment IOP, from 19.1 to 14.5mmHg. Among left eyes the corresponding findings were n=38; Δ-7.6 (-36.0%) from 21.2 to 13.6mmHg. The 6 mo values were OD n=33; Δ-4.7 (-24.9%) from 18.9 to 14.2mmHg, and OS n=32; Δ-5.9 (-30%). All results had P < 0.0001. No evidence for any systematic bias influencing follow-up attrition was evident from the available clinical data. Conclusions: SLT appears to be a very effective choice of treatment to reduce intraocular pressure among glaucomatous eyes of South African adults, with or without a history of medical and surgical glaucoma therapy. Mean reductions of IOP of 25-30% were sustained for 6 months without supplementary therapy. If such findings can be confirmed among other populations on the continent, the potential for SLT to help prevent visual loss in Africa would be inestimable. Further investigation is needed to identify duration of effect, utility of supplementary therapy, and to improve follow-up compliance. The impact of these findings may be highly significant where glaucoma medications and general services are essentially unavailable. AD - K. Coleman, Glaucoma, Right to Sight, Dublin, Ireland AU - Coleman, K. AU - Visser, L. AU - Goosen, E. AU - Sponsel, W. E. AU - Dalmar, A. AU - Galley, J. DB - Embase IS - 7 KW - adult blindness clinical trial drug dose titration female filtering operation follow up glaucoma human intraocular pressure major clinical study male middle aged prevention South Africa South African statistical bias Student t test tonometry LA - English M3 - Conference Abstract N1 - L615918356 2017-05-15 PY - 2015 SN - 0146-0404 SP - 933 ST - SLT as an essential tool for management of glaucoma in the African eye T2 - Investigative Ophthalmology and Visual Science TI - SLT as an essential tool for management of glaucoma in the African eye UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615918356&from=export VL - 56 ID - 2809 ER - TY - JOUR AB - PURPOSE: To evaluate the incidence and severity of glistenings in hydrophobic acrylic intraocular lenses (IOLs) and assess the potential correlation between glistenings and clinical and demographic factors. SETTING: Service d'Ophtalmologie, Centre Hospitalier et Universitaire Bordeaux, Bordeaux, France. METHODS: Eligible patients received an AcrySof IOL between September 2000 and December 2007 and had a routine ophthalmic visit between January 2007 and March 2008. The incidence and severity of glistenings were graded subjectively and analyzed in relation to patient age and sex, length of follow-up, IOL model, IOL power, neodymium:YAG laser capsulotomy, corrected distance visual acuity (CDVA), spherical equivalent (SE), and selected ocular and systemic diseases and medications. RESULTS: Glistenings occurred in 157 (60.4%) of the 260 eyes; they were absent in 103 eyes (39.6%). Glistenings were of grade 1 severity in 87 eyes (33.5%) and of grade 2 severity in 70 eyes (26.9%). CONCLUSIONS: The results suggest a potential association between the incidence of glistenings and IOL power and glaucoma, but not between glistenings and age, sex, IOL model, length of follow-up, CDVA, SE, or most ocular and systemic diseases and medications. AN - WOS:000277410400016 AU - Colin, J. AU - Orignac, I. AU - Touboul, D. DA - DEC DO - 10.1016/j.jcrs.2009.06.029 IS - 12 PY - 2009 SN - 0886-3350 SP - 2121-2126 ST - Glistenings in a large series of hydrophobic acrylic intraocular lenses T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Glistenings in a large series of hydrophobic acrylic intraocular lenses VL - 35 ID - 6004 ER - TY - JOUR AB - Purpose: This study was designed to uncover a new sensitive and specific factor for predicting the progression of glaucoma. Methods: The 24-hour ambulatory blood pressure and diurnal curve of intra-ocular pressure were recorded in seventy patients: 51 primary open angle glaucoma (POAG) and 19 normal tension glaucoma (NTG). The mean systolic, diastolic and average arterial blood pressure were calculated, along with the nocturnal dip of systolic pressure and diastolic blood pressure. Two-year disease progression was assessed for all patients by means of retrospective analysis of visual fields defects on repeated perimetries. Results: Abnormal (absence or increased) nocturnal dip of systolic blood pressure was found to be correlated with disease progression in POAG and NTG patients with a sensitivity of 86% and a specificity of 85%, whereas no significant correlation was found for the other risks factors envisaged. Furthermore, a significant relationship between stable visual field defects and the use of diuretics/laser procedure was evidenced. Conclusion: The nocturnal dip of systolic blood pressure should be considered as a predictive factor of disease progression in NTG and POAG. Further prospective studies are needed to ascertain whether dip normalization could help slow down the visual field loss in these patients. AD - N. Collignon, Department of Ophthalmology, Glaucoma Unit, University of Liege, 4000 Liege, Belgium AU - Collignon, N. AU - Dewe, W. AU - Guillaume, S. AU - Collignon-Brach, J. DB - Embase Medline DO - 10.1023/A:1006113109864 IS - 1 KW - anticoagulant agent antilipemic agent antithrombocytic agent beta adrenergic receptor blocking agent calcium channel blocking agent dipeptidyl carboxypeptidase inhibitor diuretic agent adult aged ambulatory monitoring article blood pressure monitoring disease course female glaucoma human hypertension major clinical study male visual field defect LA - English M3 - Article N1 - L29083231 1999-03-10 PY - 1998 SN - 0165-5701 SP - 19-25 ST - Ambulatory blood pressure monitoring in glaucoma patients. The nocturnal systolic dip and its relationship with disease progression T2 - International Ophthalmology TI - Ambulatory blood pressure monitoring in glaucoma patients. The nocturnal systolic dip and its relationship with disease progression UR - https://www.embase.com/search/results?subaction=viewrecord&id=L29083231&from=export http://dx.doi.org/10.1023/A:1006113109864 VL - 22 ID - 3935 ER - TY - JOUR AB - Cataract surgery in glaucoma patients remains a controversial subjects. Indication of surgery depends on a lot of clinical parameters: diagnosis, state, evolution of glaucoma as well as compliance with medical treatment--surgical procedures of cataract and glaucoma--sites of the surgery--use of antifibrosis agents and surgeon's experience. As cataract extraction alone decreases the intraocular pressure in open angle glaucoma and mainly in uncomplicated closed angle glaucoma and trabeculectomy alone reduces the intraocular pressure more than combined surgery with less complications we recommended the following surgical options: Cataract extraction alone in patients with controlled open angle glaucoma and in patients with closed angle glaucoma. A two step procedure: filtering surgery followed by cataract extraction in patients with poorly controlled open angle glaucoma or mixed closed angle glaucoma. Ambulatory surgery and topical anesthesia permit a two stages surgery with less inconveniences. A combined procedure in patients with a chronic closed angle glaucoma where filtering procedure alone is associated with important complications. Actually, the best surgical cataract procedure is phacoemulsification with a small supero-corneal incision and implantation of a foldable intraocular lens. The best filtering procedure remains trabeculectomy, or the new non penetrating trabecular surgery for experimented surgeons, in the superior quadrant. In the future new surgical procedures and new safe and non toxic pharmacologic drugs which modulate wound healing could be found in order to increase the efficacity and indications of combined surgery. AU - Collignon-Brach, J. D. AU - Ravet, O. AU - Robe-Collignon, N. KW - *Cataract/co [Complications] *Cataract Extraction *Glaucoma/co [Complications] *Glaucoma/su [Surgery] Humans *Ophthalmologic Surgical Procedures PY - 2000 SE - Collignon-Brach, J D. Centre Hospitalier Universitaire Service d'Ophtalmologie Unite Glaucome Domaine du Sart Tilman B-4000 Liege. SN - 0081-0746 SP - 11-36 ST - [Surgical indications in coexisting cataracts and glaucoma] T2 - Indications chirurgicales dans la coexistence de cataracte et de glaucome. TI - [Surgical indications in coexisting cataracts and glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11262885 VL - Suppl ID - 1934 ER - TY - JOUR AB - Vasculitic neuropathy can occur as an isolated entity (nonsystemic vasculitic neuropathy) but more commonly evolves in the setting of primary systemic vasculitides or secondary vasculitides related to infections, drugs, or connective tissue disorders. Vasculitic neuropathies are usually but not always painful and tend to produce sensory motor or sensory symptoms. Patients with purely motor or small-fiber dysfunction are unlikely to have vasculitis. Deficits are typically multifocal or asymmetric, but distal symmetric polyneuropathy occurs uncommonly. Evaluation requires laboratory tests, electrodiagnostic studies, and nerve or nerve/muscle biopsy. This article reviews classification, clinical presentation, diagnostic evaluation, and management of peripheral nerve vasculitis. © 2013 Elsevier Inc. AD - M.P. Collins, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 52366, United States AU - Collins, M. P. AU - Arnold, W. D. AU - Kissel, J. T. DB - Embase Medline DO - 10.1016/j.ncl.2013.01.007 IS - 2 KW - azathioprine C reactive protein capsaicin carbamazepine cidofovir corticosteroid cyclophosphamide foscarnet gabapentin ganciclovir hepatitis B surface antigen immunoglobulin lidocaine methotrexate mycophenolate mofetil neutrophil cytoplasmic antibody prednisone pregabalin rituximab serotonin noradrenalin reuptake inhibitor tramadol tricyclic antidepressant agent valganciclovir valproic acid acne action potential analgesia anterior horn cell antigen antibody complex antigen presenting cell antiviral therapy arthralgia atherosclerosis Behcet disease blood vessel injury bone density cataract CD4+ T lymphocyte CD8+ T lymphocyte Churg Strauss syndrome Cogan syndrome corticosteroid therapy cranial neuropathy cryoglobulinemia dermatomyositis disease activity electrodiagnosis electromyography enteritis eosinophilic granuloma fatigue fracture giant cell arteritis glaucoma glomerulus basement membrane granulomatosis granulomatous vasculitis helper cell hepatitis B hepatitis C hirsutism human hyperglycemia hypertension hypokalemia immune complex deposition immunosuppressive treatment immunotherapy insomnia intestine perforation kidney failure macrophage maintenance therapy microscopic polyangiitis mixed connective tissue disease mononeuropathy monotherapy muscle biopsy myalgia myelinated nerve myopathy nerve biopsy nerve conduction nerve potential neuropathic pain neuropathy non insulin dependent diabetes mellitus occupational therapy osteoporosis outcome assessment pancreatitis patient compliance physiotherapy plasmapheresis polyarteritis nodosa polyneuropathy polyradiculoneuropathy priority journal protein cerebrospinal fluid level randomized controlled trial (topic) rapidly progressive glomerulonephritis recurrence risk review rheumatoid arthritis rheumatoid vasculitis sarcoidosis Schwann cell sensory nerve Sjoegren syndrome skin contusion small fiber neuropathy small vessel vasculitis sodium restriction stomach ulcer systemic lupus erythematosus systemic sclerosis systemic vasculitis tendon rupture treatment failure vasculitis Wegener granulomatosis body weight loss wound healing impairment LA - English M3 - Review N1 - L52457270 2013-02-26 2013-05-21 PY - 2013 SN - 0733-8619 1557-9875 SP - 557-595 ST - The neuropathies of vasculitis T2 - Neurologic Clinics TI - The neuropathies of vasculitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52457270&from=export http://dx.doi.org/10.1016/j.ncl.2013.01.007 VL - 31 ID - 3008 ER - TY - JOUR AB - Herpes simplex disciform keratitis is a difficult condition. The general feeling is that it is an immune disease, mediated by the virus, possibly located in the endothelial cells. It is frequently combined with inflammation in the trabecular meshwork and with uveitis. There is some controversy in relation to treatment and it has been suggested that anti-virals will control herpetic disciform keratitis, particularly if the patient has never had steroids previously. The authors of this paper have, in the past, published data which showed that Acyclovir, with corticosteroid, was necessary in the management of disciform keratitis. The data suggested that Acyclovir on its own was not effective. It remained to be answered whether Acyclovir on its own would be effective in patients who never had steroids for any reason previously. This paper demonstrates clearly that it is necessary, irrespective of whether patients have had steroids in the past or not, to combine corticosteroids with Acyclovir in the management of herpetic disciform keratitis. Acyclovir, on its own, is shown to be ineffective. It has also been suggested that Acyclovir is non-toxic. In a general way this is true, but the authors suggest that Acyclovir ointment does produce a punctate keratitis in patients with tear film disease, and that oral Acyclovir is preferable in such patients. AU - Collum, L. M. AU - Power, W. J. AU - Collum, A. IS - 2 KW - *Acyclovir/tu [Therapeutic Use] *Betamethasone/tu [Therapeutic Use] Double-Blind Method Humans *Keratitis, Herpetic/dt [Drug Therapy] Ointments Patient Compliance Placebos PY - 1992 SE - Collum, L M. Royal Victoria Eye and Ear Hospital, Dublin, Ireland. SN - 0012-4486 SP - 201-5 ST - The current management of herpetic eye disease T2 - Documenta ophthalmologica. Advances in ophthalmology TI - The current management of herpetic eye disease UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1425135 VL - 80 ID - 2116 ER - TY - JOUR AB - BACKGROUND: It is known that office-hour measurements might not adequately estimate IOP mean, peaks and fluctuations in healthy subjects. The purpose of the present study is to verify whether office-hour measurements in patients in different body positions can estimate the characteristics of 24-hour intraocular pressure (IOP) in treated POAG patients., METHODS: The 24-hour IOP curves of 70 eyes of 70 caucasian patients with treated glaucoma were analyzed. Measurements were taken at 9 AM; 12, 3, 6, and 9 PM; and 12, 3, and 6 AM, both in the supine (TonoPen XL) and sitting (Goldmann tonometer) positions. The ability of five strategies to estimate IOP mean, peak and fluctuation was evaluated. Each method was analyzed both with regression of the estimate error on the real value and with "hit or miss" analysis., RESULTS: The least biased estimate of the Peak IOP was obtained using measurements from both supine and sitting positions, also yielding the highest rate of correct predictions (which was significantly different from 3 of the remaining 4 strategies proposed, p < 0.05). Strategies obtained from the combination of supine, sitting and peak measurements resulted to be least biased for the Mean IOP and the IOP Fluctuation estimate, but all strategies were not found significantly different in terms of correct prediction rate (the only significant difference being between the two strategies based on sitting or supine measurements only, with the former being the one with the highest correct prediction rate)., CONCLUSIONS: The results of this study remark the concept that IOP is a dynamic parameter and that intensive measurement is helpful in determining its characteristics. All office-hour strategies showed a very poor performance of in correctly predicting the considered parameters within the thresholds used in this paper, all scoring a correct prediction rate below 52%. AU - Colombo, Leonardo AU - Fogagnolo, Paolo AU - Montesano, Giovanni AU - De Cilla, Stefano AU - Orzalesi, Nicola AU - Rossetti, Luca DO - https://dx.doi.org/10.1186/s12886-016-0191-7 KW - Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] Brimonidine Tartrate/tu [Therapeutic Use] *Circadian Rhythm/ph [Physiology] Drug Combinations Female *Glaucoma, Open-Angle/dt [Drug Therapy] *Glaucoma, Open-Angle/pp [Physiopathology] Humans Intraocular Pressure/de [Drug Effects] *Intraocular Pressure/ph [Physiology] Latanoprost Male Middle Aged Office Visits Physicians' Offices Posture Prostaglandins F, Synthetic/tu [Therapeutic Use] Timolol/tu [Therapeutic Use] Tonometry, Ocular PY - 2016 SE - Colombo, Leonardo. Eye Clinic, San Paolo Hospital, University of Milan, Via A. Di Rudini 8, 20142, Milan, Italy. leonardo.colombo.82@gmail.com. Fogagnolo, Paolo. Eye Clinic, San Paolo Hospital, University of Milan, Via A. Di Rudini 8, 20142, Milan, Italy. Montesano, Giovanni. Eye Clinic, San Paolo Hospital, University of Milan, Via A. Di Rudini 8, 20142, Milan, Italy. De Cilla, Stefano. Eye Clinic, San Paolo Hospital, University of Milan, Via A. Di Rudini 8, 20142, Milan, Italy. Orzalesi, Nicola. Eye Clinic, San Paolo Hospital, University of Milan, Via A. Di Rudini 8, 20142, Milan, Italy. Rossetti, Luca. Eye Clinic, San Paolo Hospital, University of Milan, Via A. Di Rudini 8, 20142, Milan, Italy. SN - 1471-2415 SP - 15 ST - Strategies to estimate the characteristics of 24-hour IOP curves of treated glaucoma patients during office hours T2 - BMC ophthalmology TI - Strategies to estimate the characteristics of 24-hour IOP curves of treated glaucoma patients during office hours UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26818941 VL - 16 Y2 - 20160127// ID - 724 ER - TY - JOUR AB - OBJECTIVE: To objectively evaluate the ability and skills of patients older than 65 years to successfully administer a topical ocular eye drop., METHODS: A prospective study was conducted on a group of 25 patients with a diagnosis of dry eye or glaucoma, undergoing daily treatment with eye drops for at least one year. The procedure was recorded with a video camera at the time of the application., RESULTS: Of the total, 64% were diagnosed with glaucoma and 36% with dry eye. Almost half (44%) needed a single attempt to apply the drop, and 56% required 2 attempts. In terms of the number of eye drops applied, 52% managed with a single drop, 16% 2 drops, a 12% 3 drops, and 20% 4 or more eye drops. Areas where the eye drop was deposited in the first attempt was, 32% into the conjunctival sac, 32% on the outer corner of the eye, 8% in the inner angle, 8% in the nose, 12% on the cheek, 8% in other areas., CONCLUSIONS: Self-administration of eye drops by the elderly is a complex activity that can have an effect on the expected results. Copyright © 2013 Sociedad Espanola de Oftalmologia. Published by Elsevier Espana. All rights reserved. AU - Colome-Campos, J. AU - Martinez-Salcedo, I. AU - Martorell-Hallado, M. C. AU - Romero-Aroca, P. DO - https://dx.doi.org/10.1016/j.oftal.2014.02.008 IS - 5 KW - Aged Female Humans Male *Medication Adherence *Ophthalmic Solutions/ad [Administration & Dosage] Prospective Studies *Psychomotor Performance PY - 2014 SE - Colome-Campos, J. Servicio de Oftalmologia, Hospital Comarcal de Mora, Mora d'Ebre, Espana. Electronic address: colomecampos@gmail.com. Martinez-Salcedo, I. Servicio de Oftalmologia, Hospital Comarcal de Mora, Mora d'Ebre, Espana. Martorell-Hallado, M C. Universidad Rovira y Virgili, Tortosa, Espana. Romero-Aroca, P. Servicio de Oftalmologia, Hospital Universitario San Juan, Reus. Espana. SN - 1989-7286 0365-6691 SP - 177-81 ST - [Objective evaluation of applying eye drops by elderly patients] T2 - Evaluacion objetiva de la aplicacion de colirios en personas mayores de 65 anos. TI - [Objective evaluation of applying eye drops by elderly patients] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24746444 VL - 89 Y2 - 20140417// ID - 890 ER - TY - JOUR AB - Objectives: To assess the clinical effectiveness and cost-effectiveness of ranibizumab and pegaptanib for subfoveal choroidal neovascularisation (CNV) associated with wet age-related macular degeneration (AMD). Data sources: Electronic databases were searched from inception to September 2006. Experts in the field were consulted and manufacturers' submissions were examined. Review methods: The quality of included studies was assessed using standard methods and the clinical effectiveness data were synthesised through a narrative review with full tabulation of results. A model was developed to estimate the cost-effectiveness of ranibizumab and of pegaptanib (separately), compared with current practice or best supportive care, from the perspective of the NHS and Personal Social Services. Two time horizons were adopted for each model. The first adopted time horizons determined by the available trial data. The second analysis extrapolated effects of treatment beyond the clinical trials, adopting a time horizon of 10 years. Results: The combined analysis of two randomised controlled trials (RCTs) of pegaptanib [0.3 mg (licensed dose), 1.0 mg and 3.0 mg] versus sham injection in patients with all lesion types was reported by three publications (the VISION study). Three published RCTs of ranibizumab were identified (MARINA, ANCHOR, FOCUS), and an additional unpublished RCT was provided by the manufacturer (PIER). Significantly more patients lost less than 15 letters of visual acuity at 12 months when taking pegaptanib (0.3 mg: 70% of patients; 1.0 mg: 71% of patients; 3.0 mg: 65% of patients) or ranibizumab (0.3 mg: 94.3-94.5%; 0.5 mg: 94.6-96.4%) than sham injection patients (55% versus pegaptanib and 62.2% versus ranibizumab) or, in the case of ranibizumab, photodynamic therapy (PDT) (64.3%). The proportion of patients gaining 15 letters or more (a clinically important outcome having a significant impact on quality of life) was statistically significantly greater in the pegaptanib group for doses of 0.3 and 1.0 mg but not for 3.0 mg, and for all ranibizumab groups compared to the sham injection groups or PDT. This was also statistically significant for patients receiving 0.5 mg ranibizumab plus PDT compared with PDT plus sham injection. Pegaptanib patients lost statistically significantly fewer letters after 12 months of treatment than the sham group [mean letters lost: 7.5 (0.3 mg), 6.5 (1.0 mg) or 10 (3.0 mg) vs 14.5 (sham)]. In the MARINA and ANCHOR trials, ranibizumab patients gained letters of visual acuity at 12 months whereas patients with sham injection or PDT lost about 10 letters (p < 0.001) and in the PIER study, ranibizumab patients lost significantly fewer than the sham injection group. Significantly fewer patients receiving pegaptanib or ranibizumab deteriorated to legal blindness compared with the control groups. Adverse events were common for both pegaptanib and ranibizumab but most were mild to moderate. Drug costs for 1 year of treatment were estimated as £4626 for pegaptanib and £9134 for ranibizumab. Non-drug costs accounted for an additional £2614 for pegaptanib and £3120 for ranibizumab. Further costs are associated with the management of injection-related adverse events, from £1200 to £2100. For pegaptanib compared with usual care, the incremental cost-effectiveness ratio (ICER) ranged from £163,603 for the 2-year model to £30,986 for the 10-year model. Similarly, the ICERs for ranibizumab for patients with minimally classic and occult no classic lesions, compared with usual care, ranged from £152,464 for the 2-year model to £25,098 for the 10-year model. Conclusions: Patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. Patients who continued treatment with either drug appeared to maintain benefits after 2 years of follow-up. When comparing pegaptanib and ranibizumab, the evidence was less clear due to the lack of direct comparison through head-to-head trials and the lack of opp rtunity for indirect statistical comparison due to heterogeneity. The cost-effectiveness analysis showed that the two drugs offered additional benefit over the comparators of usual care and PDT but at increased cost. Future research should encompass trials to compare pegaptanib with ranibizumab and bevacizumab, and to investigate the role of verteporfin PDT in combination with these drugs. Studies are also needed to assess adverse events outside the proposed RCTs, to consider the optimal dosing regimes of these drugs and the benefits of re-treatment after initial treatment, and to review costing in more detail. Health state utilities and their relationship with visual acuity and contrast sensitivity, the relationship between duration of vision loss and the quality of life and functional impact of vision loss, behavioural studies of those genetically at risk are other topics requiring further research. © Queen's Printer and Controller of HMSO 2008. All rights reserved. AD - J.L. Colquitt, Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research and Development (WIHRD), University of Southampton, Southampton, United Kingdom AU - Colquitt, J. L. AU - Jones, J. AU - Tan, S. C. AU - Takeda, A. AU - Clegg, A. J. AU - Price, A. C1 - lucentis(Genentech) lucentis(Novartis,United Kingdom) macugen(Pfizer) C2 - Genentech Novartis(United Kingdom) Pfizer DB - Embase Medline DO - 10.3310/hta12160 IS - 16 KW - antibiotic agent pegaptanib ranibizumab steroid verteporfin bleeding blepharitis blindness blurred vision brain infarction cataract choroid hemorrhage clinical trial combination chemotherapy conjunctival hemorrhage controlled clinical trial cornea edema cost benefit analysis cost control cost effectiveness analysis cryotherapy deterioration digestive system perforation dose response drug cost drug dose comparison drug dose reduction drug efficacy drug fatality drug hypersensitivity drug safety drug tolerability drug withdrawal economic evaluation endophthalmitis eye discharge eye disease eye inflammation eye irritation eye pain eye surgery follow up health care cost health economics heart infarction human hypertension information retrieval injection site reaction intraocular foreign body intraocular hypertension iridocyclitis iritis lacrimation laser coagulation lens disease low level laser therapy monotherapy national health service ocular fibrosis patient compliance photodynamic therapy punctate keratitis quality adjusted life year quality of life randomized controlled trial retina detachment retina hemorrhage age related macular degeneration macular degeneration retina tear review side effect statistical significance cerebrovascular accident subretinal neovascularization systematic review thromboembolism treatment duration treatment outcome unspecified side effect uveitis visual acuity visual disorder vitrectomy vitreous body detachment vitreous floaters vitreous hemorrhage vitreous opacity lucentis macugen LA - English M3 - Review N1 - L351959401 2008-07-21 PY - 2008 SN - 1366-5278 SP - iii-107 ST - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation T2 - Health Technology Assessment TI - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351959401&from=export http://dx.doi.org/10.3310/hta12160 VL - 12 ID - 3457 ER - TY - JOUR AB - THE REMOVAL OF large acoustic tumors is associated with increased mortality and cranial nerve injury. One method for treating these difficult lesions is staged resection. Between 1972 and 1992, more than 600 acoustic tumors were resected at our institution. Of these, 83 were removed in stages. This represents the largest series of staged acoustic tumor resections reported to date. A review of available films and patient records was performed for all acoustic tumors resected in stages between 1972 and early 1993 to analyze demographic information, tumor size, operative technique, outcome, and complications. The information was collected on standardized data sheets and entered into a computer database. Virtually all tumors were large, with the average size being 4 cm in greatest diameter. The average patient age was 41 years, and there was a slight preponderance of female patients. Ten patients had neurofibromatosis Type 2. The suboccipital approach was used in most patients. Anatomic preservation of the VIIth cranial nerve was achieved in >72% of patients, with an average House-Brackmann score of Grade 3 at the longest follow-up (mean, 43 mo). Facial reanimation was performed in 19 of 23 patients with transected VIIth cranial nerves. Complications included cerebrospinal fluid fistulas in 11 patients, with 8 of 11 fistulas resolving after lumbar drainage. Six patients had meningitis (bacterial in three and aseptic in three). Two patients developed wound infections, and 10 patients developed exposure keratitis. There were two documented recurrences. There were no operative deaths. In most series, the incidence of cranial nerve deficits as well as morbidity and mortality is directly related to tumor size. Our operative strategy involved debulking the lateral aspect of large tumors during Stage I. Second stage removal is performed after the remaining turner is shown to decompress out of the pens on computed tomographic or magnetic resonance images. During the second procedure, the residual tumor is less vascular and no longer densely adherent to the brain stem. Although staged removal is not without risk, there seems to be no apparent increase in morbidity when these results are compared with the results of series from the literature. Although there remain no absolute indications for staged resection of acoustic tumors, we think that it may represent the safest option for these difficult lesions. AN - WOS:A1995TC38100030 AU - Comey, C. H. AU - Jannetta, P. J. AU - Sheptak, P. E. AU - Jho, H. D. AU - Burkhart, L. E. DA - NOV DO - 10.1227/00006123-199511000-00010 IS - 5 PY - 1995 SN - 0148-396X SP - 915-920 ST - STAGED REMOVAL OF ACOUSTIC TUMORS - TECHNIQUES AND LESSONS LEARNED FROM A SERIES OF 83 PATIENTS T2 - NEUROSURGERY TI - STAGED REMOVAL OF ACOUSTIC TUMORS - TECHNIQUES AND LESSONS LEARNED FROM A SERIES OF 83 PATIENTS VL - 37 ID - 6360 ER - TY - JOUR AB - The removal of large acoustic tumors is associated with increased mortality and cranial nerve injury. One method for treating these difficult lesions is staged resection. Between 1972 and 1992, more than 600 acoustic tumors were resected at our institution. Of these, 83 were removed in stages. This represents the largest series of staged acoustic tumor resections reported to date. A review of available films and patient records was performed for all acoustic tumors resected in stages between 1972 and early 1993 to analyze demographic information, tumor size, operative technique, outcome, and complications. The information was collected on standardized data sheets and entered into a computer database. Virtually all tumors were large, with the average size being 4 cm in greatest diameter. The average patient age was 41 years, and there was a slight preponderance of female patients. Ten patients had neurofibromatosis Type 2. The suboccipital approach was used in most patients. Anatomic preservation of the VIIth cranial nerve was achieved in > 72% of patients, with an average House-Brackmann score of Grade 3 at the longest follow-up (mean, 43 mo). Facial reanimation was performed in 19 of 23 patients with transected VIIth cranial nerves. Complications included cerebrospinal fluid fistulas in 11 patients, with 8 of 11 fistulas resolving after lumbar drainage. Six patients had meningitis (bacterial in three and aseptic in three). Two patients developed wound infections, and 10 patients developed exposure keratitis. There were two documented recurrences. There were no operative deaths. In most series, the incidence of cranial nerve deficits as well as morbidity and mortality is directly related to tumor size. Our operative strategy involved debulking the lateral aspect of large tumors during Stage I. Second stage removal is performed after the remaining tumor is shown to decompress out of the pons on computed tomographic or magnetic resonance images. During the second procedure, the residual tumor is less vascular and no longer densely adherent to the brain stem. Although staged removal is not without risk, there seems to be no apparent increase in morbidity when these results are compared with the results of series from the literature. Although there remain no absolute indications for staged resection of acoustic tumors, we think that it may represent the safest option for these difficult lesions. AU - Comey, C. H. AU - Jannetta, P. J. AU - Sheptak, P. E. AU - Joh, H. D. AU - Burkhart, L. E. IS - 5 KW - Adult Female Humans Male Middle Aged Neoplasm Staging Neurofibromatosis 2/mo [Mortality] Neurofibromatosis 2/pa [Pathology] Neurofibromatosis 2/su [Surgery] Neuroma, Acoustic/mo [Mortality] Neuroma, Acoustic/pa [Pathology] *Neuroma, Acoustic/su [Surgery] Postoperative Complications/et [Etiology] Postoperative Complications/su [Surgery] Reoperation Survival Rate Tomography, X-Ray Computed Treatment Outcome PY - 1995 SE - Comey, C H. Department of Neurosurgery, University of Pittsburgh, Pennsylvania, USA. SN - 0148-396X SP - 915-1 ST - Staged removal of acoustic tumors: techniques and lessons learned from a series of 83 patients T2 - Neurosurgery TI - Staged removal of acoustic tumors: techniques and lessons learned from a series of 83 patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8559340 VL - 37 ID - 2056 ER - TY - JOUR AB - Importance of the field: The treatment of ocular inflammation continues to be a challenge. Topical corticosteroids are effective in reducing ocular inflammation but are limited by adverse events including elevation of intraocular pressure, development of cataracts, glaucoma and inhibition of wound healing with associated risk of infection. Loteprednol etabonate (LE) is a unique C-20 ester corticosteroid designed to produce a predictable therapeutic effect with a low incidence of side effects. Zylet® (LE/T) a combination of LE and tobramycin (T) is indicated for the treatment of steroid-responsive ocular inflammatory conditions in which there exists either superficial bacterial ocular infection or a potential risk of bacterial infection. Areas covered in this review: The current review of the literature (Medline and the Cochrane Library, 1996 2009) examines the safety and efficacy of LE/T in the treatment of ocular inflammation. What the reader will gain: Studies with either LE or LE/T indicate that LE has a lower risk of IOP elevation compared with C-20 ketone corticosteroids owing to its rapid de-esterification to inactive metabolites. LE also lacks the ability to form Schiff base intermediates with lens proteins, a common first step in cataractogenesis. LE/T was noninferior to dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Take home message: LE/T may be a safer treatment option for ocular inflammation in which there is risk of superficial bacterial infections. © 2010 Informa UK Ltd. AD - T. L. Comstock, Bausch and Lomb Incorporated, 1400 North Goodman Street, Rochester, NY 1460, United States AU - Comstock, T. L. AU - Holland, E. J. C1 - tobradex(Alcon) zylet(Bausch and Lomb,United States) C2 - Alcon Bausch and Lomb(United States) Rochester(United States) DB - Embase Medline DO - 10.1517/14656561003667532 IS - 5 KW - corticosteroid dexamethasone dexamethasone plus tobramycin fluorometholone loteprednol etabonate loteprednol etabonate plus tobramycin placebo prednisolone acetate rimexolone tobramycin abnormal sensation allergic conjunctivitis aqueous humor aqueous humor outflow bactericidal activity binding affinity blepharitis blepharokeratoconjunctivitis burning sensation cataract clinical trial conjunctivitis cornea injury disease course disease severity drug binding drug bioavailability drug effect drug efficacy drug labeling drug safety dry eye eye burning eye infection eye inflammation eye irritation eye pain foreign body sensation giant papillary conjunctivitis glaucoma human incidence infection resistance infection risk intraocular pressure keratitis keratoconjunctivitis nonhuman ocular pruritus optimal drug dose pain patient compliance photosensitivity postoperative inflammation pruritus review risk assessment seasonal allergic conjunctivitis side effect stinging sensation treatment duration uveitis vision visual acuity wound healing impairment tobradex zylet LA - English M3 - Review N1 - L358459597 2010-03-24 2020-01-23 PY - 2010 SN - 1465-6566 SP - 843-852 ST - Loteprednol and tobramycin in combination: A review of their impact on current treatment regimens T2 - Expert Opinion on Pharmacotherapy TI - Loteprednol and tobramycin in combination: A review of their impact on current treatment regimens UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358459597&from=export http://dx.doi.org/10.1517/14656561003667532 VL - 11 ID - 3283 ER - TY - JOUR AU - Congdon, Nathan G. AU - He, Mingguang DO - https://dx.doi.org/10.1016/j.ajo.2010.04.003 IS - 2 KW - Asia/ep [Epidemiology] Cataract/di [Diagnosis] Cataract/ep [Epidemiology] Cataract/pc [Prevention & Control] Delivery of Health Care Developing Countries Diabetic Retinopathy/di [Diagnosis] Diabetic Retinopathy/ep [Epidemiology] Diabetic Retinopathy/pc [Prevention & Control] Eye Diseases/di [Diagnosis] Eye Diseases/ep [Epidemiology] Eye Diseases/pc [Prevention & Control] *Eye Diseases Glaucoma/di [Diagnosis] Glaucoma/ep [Epidemiology] Glaucoma/pc [Prevention & Control] Health Care Rationing Humans Refractive Errors/di [Diagnosis] Refractive Errors/ep [Epidemiology] Refractive Errors/pc [Prevention & Control] Resource Allocation PY - 2010 SE - Congdon, Nathan G. Zhongshan Ophthalmic Center, State Key Ophthalmology Laboratory and Preventive Ophthalmology Unit, Sun Yat Sen University, Guangzhou, China. SN - 1879-1891 0002-9394 SP - 141-3 ST - Screening and managing eye disease in 2010: an Asian perspective T2 - American journal of ophthalmology TI - Screening and managing eye disease in 2010: an Asian perspective UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20670738 VL - 150 ID - 1339 ER - TY - JOUR AB - Purpose: To compare initial glaucoma therapy with medications and trabeculectomy in southern India. Methods: Patients aged >= 30 years newly diagnosed with glaucoma were randomized to trabeculectomy with 5-fluorouracil or medical therapy. Subjects with best-corrected vision <6/18 due to cataract underwent phacoemulsification (phaco/intraocular lens, IOL). Intraocular pressure (IOP), vision and visual function were assessed at 12 months. Results: Patients assigned to medications and surgery received the expected therapy in 86% (172/199) and 64% (126/199) of cases, respectively. Forty patients (20%) assigned to surgery refused any treatment and 33 (17%) received medications. Among 199 patients randomized to medications, 52 (26.1%) underwent phaco/IOL, as did 89/199 (43.7%) of patients randomized to trabeculectomy. Baseline parameters of the two groups did not differ, nor did 1-year follow-up rates (medication 65%, trabeculectomy 58%, P = 0.15). Final IOP was lower with randomization to trabeculectomy (16.3 +/- 5.1 mmHg) than medication (18.8 +/- 6.7 mmHg, P < 0.0001). In regression models, randomization to trabeculectomy (P < 0.0001) was associated with lower IOP, and simultaneous trabeculectomy and cataract surgery was associated with higher IOP (P = 0.008) than trabeculectomy alone. Subjects receiving Phaco/IOL had significantly better final acuity (P < 0.0001) and visual function (P = 0.035), despite concurrent glaucoma treatment. Final visual acuity was worse in those receiving trabeculectomy in addition to cataract surgery, but this was of borderline significance (P = 0.06). Conclusions: Trabeculectomy lowered IOP significantly more than medical treatment, but with slightly greater loss of visual acuity. Combined phaco/IOL and trabeculectomy improved visual acuity with substantial IOP lowering. AN - WOS:000303832000006 AU - Congdon, N. G. AU - Krishnadas, R. AU - Friedman, D. S. AU - Goggins, W. AU - Ramakrishnan, R. AU - Kader, M. A. AU - Gilbert, D. AU - Tielsch, J. AU - Quigley, H. A. DA - JUN DO - 10.3109/09286586.2012.667493 IS - 3 PY - 2012 SN - 0928-6586 1744-5086 SP - 149-158 ST - A Study of Initial Therapy for Glaucoma in Southern India: India Glaucoma Outcomes and Treatment (INGOT) Study T2 - OPHTHALMIC EPIDEMIOLOGY TI - A Study of Initial Therapy for Glaucoma in Southern India: India Glaucoma Outcomes and Treatment (INGOT) Study VL - 19 ID - 6204 ER - TY - JOUR AB - INTRODUCTION: Endophthalmitis is a sight-threatening condition defined as any inflammation of the internal ocular spaces. It is classified as either endogenous or exogenous depending on the route of infection. Exogenous endophthalmitis results from direct inoculation as a complication of intra-ocular surgery, penetrating ocular trauma, intra-ocular foreign bodies, corneal ulceration and following a breach of ocular barriers from a periocular infection. We report a rare case of exogenous endophthalmitis with both unusual etiology and microbiology., CASE PRESENTATION: A 41-year-old Caucasian man with a history of depressive illness presented to our eye department with painful acute visual loss on a background history of chronic uveitis. Ocular examination revealed a dense fibrinous panuveitis with a suspicion of a focal lesion in the posterior segment. Microbiological sampling from his anterior chamber and posterior segment revealed a culture of Elizabethkingia meningoseptica. On closer questioning, he volunteered the occurrence of multiple episodes of deliberate needle ocular penetration. Following vitrectomy for associated retinal detachment, a final Snellen visual acuity of 6/60 was obtained., CONCLUSIONS: Elizabethkingia meningoseptica endophthalmitis is a rare condition, and visual results to date are poor. AU - Connell, Paul P. AU - Wickremasinghe, Sanj AU - Devi, Uma AU - Waters, Mary Jo AU - Allen, Penelope J. DO - https://dx.doi.org/10.1186/1752-1947-5-303 PY - 2011 SE - Connell, Paul P. Centre for Eye Research Australia, The Royal Victorian Eye and Ear Hospital, University of Melbourne, 32 Gisborne Street, East Melbourne, Victoria 3002, Australia. drpaulconnell@gmail.com. SN - 1752-1947 SP - 303 ST - Self-induced Elizabethkingia meningoseptica endophthalmitis: a case report T2 - Journal of medical case reports TI - Self-induced Elizabethkingia meningoseptica endophthalmitis: a case report UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=21745367 VL - 5 Y2 - 20110711// ID - 1200 ER - TY - JOUR AD - A.J. Connor, Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, Tyne and Wear SR2 9HP, United Kingdom AU - Connor, A. J. AU - Fraser, S. C1 - xalatan DB - Embase Medline DO - 10.1136/bjophthalmol-2013-303159 IS - 6 KW - latanoprost health survey human letter clinical audit open angle glaucoma ophthalmology patient compliance prescription priority journal questionnaire xalatan LA - English M3 - Letter N1 - L52486936 2013-03-14 2013-06-06 PY - 2013 SN - 0007-1161 1468-2079 SP - 795 ST - Authors' response: Generic medications in ophthalmology T2 - British Journal of Ophthalmology TI - Authors' response: Generic medications in ophthalmology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52486936&from=export http://dx.doi.org/10.1136/bjophthalmol-2013-303159 http://bjo.bmj.com/content/97/6/795.1.full.pdf VL - 97 ID - 3000 ER - TY - JOUR AB - PURPOSE: In 2009, the National Institute for Clinical Excellence (NICE) published guidance on the treatment of ocular hypertension and glaucoma. The aim of the present study was to describe the impact this guidance had on glaucoma prescribing and to describe recent prescribing trends in England., METHOD: Prescribing cost analysis data held by NHS Business Authority for the years 2000-2012 was analysed., RESULTS: The number of prescriptions dispensed increased by 67% from 4.76 million in 2000 to 7.96 million in 2012. Over the same time period, drug costs increased by 88% from 55.2 million to 103.7 million. Prescriptions for prostaglandin analogues increased fourfold, while there was a threefold decrease in the use of beta-blockers. The most commonly prescribed glaucoma medication was latanoprost. The introduction of generic latanoprost in 2012 more than halved the cost associated with this medication. NICE guidance appeared to have had no effect on the total number of prescriptions or the classes of medications prescribed., CONCLUSION: The introduction of the NICE guidelines did not change glaucoma prescribing practice, although it is not clear whether this represents non-adherence to the guidelines or whether the guidelines embodied pre-existing practice. AU - Connor, A. J. AU - Fraser, S. G. DO - https://dx.doi.org/10.1038/eye.2014.114 IS - 7 KW - Administration, Topical *Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/ec [Economics] Drug Costs Drug Prescriptions/ec [Economics] *Drug Prescriptions/sn [Statistics & Numerical Data] England *Glaucoma/dt [Drug Therapy] Guideline Adherence Humans *Intraocular Pressure/de [Drug Effects] Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions Practice Guidelines as Topic *Practice Patterns, Physicians'/td [Trends] N1 - Comment in (CIN) PY - 2014 SE - Connor, A J. Department of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne and Wear, UK. Fraser, S G. Sunderland Eye Infirmary, Sunderland, Tyne and Wear, UK. SN - 1476-5454 0950-222X SP - 863-9 ST - Glaucoma prescribing trends in England 2000 to 2012 T2 - Eye (London, England) T3 - Comment in: Eye (Lond). 2015 Jan;29(1):147-8; PMID: 25277301 [https://www.ncbi.nlm.nih.gov/pubmed/25277301] TI - Glaucoma prescribing trends in England 2000 to 2012 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24858531 VL - 28 Y2 - 20140523// ID - 883 ER - TY - JOUR AB - IntroductionPatient compliance is essential to ensure efficacious treatment. The ease of topical drop delivery is of paramount importance. At least 50% of patients report difficulty in self-administration of topical ocular medicine. The two most frequently reported causes of difficulty include aiming the bottle and squeezing the bottle.PurposeThe aims of this study were to identify (I) the force required to deliver a single drop from a bottle (the squeezability factor), (II) are some bottle designs easier to use than others? (III) Do compliance aids reduce the finger strength required to deliver an eye drop?MethodWe measured the force required to deliver a single drop from a variety of commonly used ophthalmic preparations. Force was slowly applied at the midpoint along the bottle until a drop fell from the tip. Compliance aids were also tested with this technique.ResultsWe report a wide variation in the force requirements needed to use topical medicines. Three of the four compliance aids tested increased force requirements but may have had other beneficial effects by altering the grip on the medicine bottle.ConclusionThis study highlights the large variability in force required to deliver a single drop using the ophthalmic preparations and compliance aids tested. We feel our results will be of interest and relevant to prescribing physicians and manufactures alike. © 2011 Macmillan Publishers Limited All rights reserved. AD - A. J. Connor, Department of Ophthalmology, James Cook University Hospital, Middlesbrough, Marton Road, Middlesborough, Cleveland TS4 3BW, United Kingdom AU - Connor, A. J. AU - Severn, P. S. C1 - acular(Allergan,United States) alphagan(Allergan,United States) azarga(Alcon,Switzerland) azopt(Alcon,Switzerland) betagan(Allergan,United States) betnesol(UCB,Belgium) betnesol n(UCB,Belgium) betoptic(Alcon,Switzerland) celluvisc(Allergan,United States) ciloxan(Alcon,Switzerland) cosopt(Merck,United States) exocin(Allergan,United States) ganfort(Allergan,United States) genticin(Amdipharm,United States) hypromellose(pharma global,India) iopidine(Alcon,Switzerland) liquifilm tears(Allergan,United States) lumigan(Allergan,United States) maxidex(Alcon,Switzerland) mydrilate(intrapharm,United Kingdom) oculotect(Novartis,Switzerland) predforte(Allergan,United States) predsol(UCB,Belgium) tears naturale(Alcon,Switzerland) teoptic(Novartis,Switzerland) timoptol(Merck Sharp and Dohme,United Kingdom) travatan(Alcon,Switzerland) trusopt(Merck,United States) voltarol(Novartis,Switzerland) xalacom(Pfizer,United States) xalatan(Pfizer,United States) C2 - UCB(Belgium) Alcon(Switzerland) Novartis(Switzerland) intrapharm(United Kingdom) Merck Sharp and Dohme(United Kingdom) pharma global(India) Allergan(United States) Amdipharm(United States) Merck(United States) Pfizer(United States) DB - Embase Medline DO - 10.1038/eye.2011.5 IS - 4 KW - apraclonidine betamethasone sodium phosphate betamethasone sodium phosphate plus neomycin betaxolol bimatoprost bimatoprost plus timolol brimonidine brinzolamide brinzolamide plus timolol carboxymethylcellulose carteolol ciprofloxacin cyclopentolate dexamethasone diclofenac dorzolamide dorzolamide plus timolol eye drops gentamicin hydroxypropylmethylcellulose ketorolac trometamol latanoprost latanoprost plus timolol levobunolol ofloxacin polyvinyl alcohol prednisolone acetate prednisolone sodium phosphate retinol palmitate tears naturale timolol maleate travoprost unindexed drug article drug packaging experimental design eye drop delivery aid finger force general medical device glaucoma human sterile bottle patient compliance product parameters squeezability factor strength topical treatment acular alphagan azarga azopt betagan betnesol betnesol n betoptic celluvisc ciloxan cosopt exocin ganfort genticin hypromellose iopidine liquifilm tears lumigan maxidex mydrilate oculotect predforte predsol teoptic timoptol travatan trusopt voltarol xalacom xalatan Eyot optive Opticare optive Opticare artho Xalaease LA - English M3 - Article N1 - L361612865 2011-04-25 2011-05-03 PY - 2011 SN - 1476-5454 0950-222X SP - 466-469 ST - Force requirements in topical medicine usethe squeezability factor T2 - Eye TI - Force requirements in topical medicine usethe squeezability factor UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361612865&from=export http://dx.doi.org/10.1038/eye.2011.5 VL - 25 ID - 3200 ER - TY - JOUR AB - • Almost all people with diabetes eventually develop some evidence of diabetec retinopathy. • Regular screening is essential because diabetic retinophathy, is common and has an effective treatment with laser photocoagulation. • Make sure each of your diabetic patients has two normal eyes, by formal screening at the time of diagnosis and every one to two years thereafter. • Tight control of blood glucose and glycosylated haemoglobin levels over many years can greatly decrease the risk of eye problems or their progression to visual loss. AD - I.J. Constable, Lions Eye Institute, University of Western Australia, Perth, WA, Australia AU - Constable, I. J. DB - Embase IS - 9 KW - antidiabetic agent glucose glycosylated hemoglobin article blood glucose monitoring cataract cataract extraction diabetic retinopathy diet therapy disease course disease severity early diagnosis exercise fluorescence angiography follow up glaucoma health care access high risk patient human insulin dependent diabetes mellitus ischemic optic neuropathy laser coagulation laser surgery mass screening mydriasis native species non insulin dependent diabetes mellitus ophthalmoscopy patient education risk assessment rural area smoking cessation visual impairment visual system examination vitrectomy body weight loss LA - English M3 - Article N1 - L37121522 2003-09-28 PY - 2003 SN - 1443-430X SP - 33-40 ST - Diabetes: Don't forget the eyes T2 - Medicine Today TI - Diabetes: Don't forget the eyes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37121522&from=export VL - 4 ID - 3802 ER - TY - JOUR AB - Objective: For a cohort of patients with tuberculosis in Carabayllo, Peru, we describe the prevalence of medical comorbidities and socio-economic needs, the efforts required by a comprehensive support programme (‘TB Cero’) to address them and the success of this programme in linking patients to care. Methods: Patients diagnosed with tuberculosis in Carabayllo underwent evaluations for HIV, diabetes, mental health and unmet basic needs. For patients initiating treatment during 14 September, 2015–15 May, 2016, we abstracted data from evaluation forms and a support request system. We calculated the prevalence of medical comorbidities and the need for socio-economic support at the time of tuberculosis diagnosis, as well as the proportion of patients successfully linked to care or support. Results: Of 192 patients, 83 (43%) had at least one medical comorbidity other than tuberculosis. These included eight (4%) patients with HIV, 12 (6%) with diabetes and 62 (32%) deemed at risk for a mental health condition. Of patients who required follow-up for a comorbidity, 100% initiated antiretroviral therapy, 71% attended endocrinology consultations and 66% attended psychology consultations. Of 126 (65%) patients who completed the socio-economic evaluation, 58 (46%) reported already receiving food baskets from the municipality, and 79 (63%) were given additional support, most commonly food vouchers and assistance in accessing health care. Conclusion: Carabayllo tuberculosis patients face many challenges in addition to tuberculosis. A collaborative, comprehensive treatment support programme can achieve high rates of linkage to care for these needs. © 2017 John Wiley & Sons Ltd AD - Socios En Salud Sucursal Peru, Lima, Peru Ministry of Health, Lima, Peru Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, United States Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, United States AU - Contreras, C. C. AU - Millones, A. K. AU - Santa Cruz, J. AU - Aguilar, M. AU - Clendenes, M. AU - Toranzo, M. AU - Llaro, K. AU - Lecca, L. AU - Becerra, M. C. AU - Yuen, C. M. DB - Scopus DO - 10.1111/tmi.12844 IS - 4 KW - comorbidity mental health Peru tuberculosis M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2017 SP - 505-511 ST - Addressing tuberculosis patients’ medical and socio-economic needs: a comprehensive programmatic approach T2 - Tropical Medicine and International Health TI - Addressing tuberculosis patients’ medical and socio-economic needs: a comprehensive programmatic approach UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013449822&doi=10.1111%2ftmi.12844&partnerID=40&md5=f237dcc5e3427267ebcb85c91a897bd1 VL - 22 ID - 5413 ER - TY - JOUR AB - Pseudoexfoliation syndrome (PEX) is a common ocular condition often associated with the need for intraocular surgery. Although results of cataract and glaucoma filtering surgery in eyes with PEX in the early stages of the disease may be comparable to those in eyes without PEX, in the later stages morbidity is significantly increased due to periocular surgical complications and the outcome is worse. Surgical and postoperative difficulties are often multifactorial and are directly related to the pathological changes of PEX on intraocular structures. Recent years have seen a large increase in the understanding of the effects of PEX on the various ocular tissues. Although the visible areas of the anterior capsule are most obviously involved, this is only a small part of the picture and of least significance. Biomicroscopically invisible changes of the zonules and their attachments are of greatest consequence. There is also distinct, often active, involvement of almost all tissues of the anterior segment of the eye, many of which have important implications for the anterior segment surgeon including iridopathy, iris vasculopathy (including persistent breakdown of the blood-aqueous barrier and anterior segment hypoxia), ciliary body involvement and keratopathy. Trabecular dysfunction is evident by the deposition of PEX material derived from both in situ and extra-trabecular production as well as protein and melanin deposition. These changes should be kept in mind by all intraocular surgeons as a source of potential difficulties in the perioperative period. Additionally, in light of these changes, patients need to be given realistic expectations regarding the increased risk of complications and more prolonged expected recovery time. In this short review, current reports relating to PEX pathological changes of practical interest to the intraocular surgeon are summarized. AN - WOS:000220627500017 AU - Conway, R. M. AU - Schlotzer-Schrehardt, U. AU - Kuchle, M. AU - Naumann, G. O. H. DA - APR DO - 10.1111/j.1442-9071.2004.00806.x IS - 2 PY - 2004 SN - 1442-6404 SP - 199-210 ST - Pseudoexfoliation syndrome: pathological manifestations of relevance to intraocular surgery T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Pseudoexfoliation syndrome: pathological manifestations of relevance to intraocular surgery VL - 32 ID - 6293 ER - TY - JOUR AD - University of Colorado College of Nursing, Aurora University of Colorado School of Medicine, Aurora AN - 104469401. Language: English. Entry Date: 20120809. Revision Date: 20200708. Publication Type: Journal Article AU - Cook, Paul AU - Schmiege, Sarah AU - McClean, Margaret AU - Aagaard, Laurra AU - Kahook, Malik DB - ccm DO - 10.1177/0193945911427153 DP - EBSCOhost IS - 5 KW - Medication Compliance -- Evaluation Electronics -- Utilization Reminder Systems Measurement Issues and Assessments Glaucoma -- Drug Therapy Research Methodology Medication Compliance -- Classification Pilot Studies Time Factors Sensitivity and Specificity T-Tests Pearson's Correlation Coefficient Age Factors Descriptive Statistics Effect Size Secondary Analysis Funding Source N1 - research; tables/charts. Journal Subset: Core Nursing; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: contract #2517807 from Merck & Co. to the University of Colorado Anschutz Medical Campus, and by the Biostatistics, Epidemiology, and Research Design Core of the Colorado Clinical and Translational Research Institute (NIH grant #1UL1RR025780-01).. NLM UID: 7905435. PMID: NLM22101392. PY - 2012 SN - 0193-9459 SP - 598-620 ST - Practical and Analytic Issues in the Electronic Assessment of Adherence T2 - Western Journal of Nursing Research TI - Practical and Analytic Issues in the Electronic Assessment of Adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104469401&site=ehost-live&scope=site VL - 34 ID - 4536 ER - TY - JOUR AB - INTRODUCTION: Adherence to glaucoma treatment is poor, potentially reducing therapeutic effects. A glaucoma educator was trained to use motivational interviewing (MI), a patient-centered counseling style, to improve adherence. This study was designed to evaluate whether MI was feasible in a busy ophthalmology practice., METHODS: Feasibility was assessed using five criteria from the National Institutes of Health Behavior Change consortium: fidelity of intervention components to MI theory; success of the training process; delivery of MI-consistent interventions by the glaucoma educator; patient receipt of the intervention based on enrollment, attrition, and satisfaction; and patient enactment of changes in motivation and adherence over the course of the intervention., RESULTS: A treatment manual was designed by a multidisciplinary team with expertise in health psychology, public health, and ophthalmology. The glaucoma educator received 6 hours of training including role-play exercises, self-study, and individual supervision. His MI-related knowledge and skills increased following training, and he delivered exclusively MI-consistent interventions in 66% of patient encounters. 86% (12/14) of eligible patients agreed to be randomized into glaucoma educator support or a control condition. All 8 patients assigned to the glaucoma educator completed at least 2 of 6 planned contacts, and 50% (4/8) completed all 6 contacts. Patients assigned to the glaucoma educator improved over time in both motivation and adherence., CONCLUSION: The introduction of a glaucoma educator was feasible in a busy ophthalmology practice. Patients improved their adherence while participating in the glaucoma educator program, although this study was not designed to show a causal effect. The use of a glaucoma educator to improve glaucoma patients' medication adherence may be feasible at other ophthalmology clinics, and can be implemented with a standardized training approach. Pilot data show the intervention can be implemented with fidelity, is acceptable to patients and providers, and has the potential to improve adherence. AU - Cook, Paul F. AU - Bremer, Robert W. AU - Ayala, A. J. AU - Kahook, Malik Y. DO - https://dx.doi.org/10.2147/OPTH.S12765 PY - 2010 SE - Cook, Paul F. College of Nursing, University of Colorado Denver, Aurora, CO, USA. paul.cook@ucdenver.edu SN - 1177-5483 1177-5467 SP - 1091-101 ST - Feasibility of motivational interviewing delivered by a glaucoma educator to improve medication adherence T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Feasibility of motivational interviewing delivered by a glaucoma educator to improve medication adherence UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=20957054 VL - 4 Y2 - 20101005// ID - 1211 ER - TY - JOUR AB - BACKGROUND: Poor adherence hinders glaucoma treatment. Studies have identified demographic and clinical predictors of adherence but fewer psychological variables., PURPOSE: We examined predictors from four health behavior theories and past research., METHODS: In the baseline phase of a three-site adherence study, before any intervention, 201 participants used electronic Medication Event Monitoring System (MEMS) bottles to monitor eyedrop use for 2 months, and completed questionnaires including self-reported adherence., RESULTS: MEMS showed 79% adherence and self-report 94% (0.5-1.5 missed weekly doses), but they correlated only r(s) = 0.31. Self-efficacy, motivation, dose frequency, and nonminority race/ethnicity predicted 35% of variance in MEMS. Cues to action, self-efficacy, and intention predicted 20% of variance in self-reported adherence., CONCLUSIONS: Self-efficacy, motivation, intention, cues to action, dose frequency, and race/ethnicity each independently predicted adherence. Predictors from all theories were supported in bivariate analyses, but additional study is needed. Researchers and clinicians should consider psychological predictors of adherence. (ClinicalTrials.gov ID# NCT01409421.). AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Mansberger, Steven L. AU - Kammer, Jeffrey AU - Fitzgerald, Timothy AU - Kahook, Malik Y. DO - https://dx.doi.org/10.1007/s12160-014-9641-8 IS - 1 KW - Adult Aged Aged, 80 and over Female *Glaucoma/dt [Drug Therapy] *Health Behavior *Health Knowledge, Attitudes, Practice Humans Male *Medication Adherence Middle Aged Motivation Self Efficacy Self Report Young Adult N1 - Comment in (CIN) PY - 2015 SE - Cook, Paul F. University of Colorado College of Nursing, University of Colorado, Campus Box C288-04, Aurora, CO, 80045, USA, paul.cook@ucdenver.edu. SN - 1532-4796 0883-6612 SP - 29-39 ST - Predictors of adherence to glaucoma treatment in a multisite study T2 - Annals of behavioral medicine : a publication of the Society of Behavioral Medicine T3 - Comment in: Ann Behav Med. 2015 Feb;49(1):5-6; PMID: 25212508 [https://www.ncbi.nlm.nih.gov/pubmed/25212508] TI - Predictors of adherence to glaucoma treatment in a multisite study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25248302 VL - 49 ID - 830 ER - TY - JOUR AB - OBJECTIVE: Nonadherence reduces glaucoma treatment efficacy. Motivational interviewing (MI) is a well-studied adherence intervention, but has not been tested in glaucoma. Reminder interventions also may improve adherence., DESIGN: 201 patients with glaucoma or ocular hypertension were urn-randomised to receive MI delivered by an ophthalmic technician (OT), usual care or a minimal behavioural intervention (reminder calls)., MAIN OUTCOME MEASURES: Outcomes included electronic monitoring with Medication Event Monitoring System (MEMS) bottles, two self-report adherence measures, patient satisfaction and clinical outcomes. Multilevel modelling was used to test differences in MEMS results by group over time; ANCOVA was used to compare groups on other measures., RESULTS: Reminder calls increased adherence compared to usual care based on MEMS, p = .005, and self-report, p = .04. MI had a nonsignificant effect but produced higher satisfaction than reminder calls, p = .007. Treatment fidelity was high on most measures, with observable differences in behaviour between groups. All groups had high baseline adherence that limited opportunities for change., CONCLUSION: Reminder calls, but not MI, led to better adherence than usual care. Although a large literature supports MI, reminder calls might be a cost-effective intervention for patients with high baseline adherence. Replication is needed with less adherent participants. AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Mansberger, Steven L. AU - Sheppler, Christina AU - Kammer, Jeffrey AU - Fitzgerald, Timothy AU - Kahook, Malik Y. IS - 2 KW - Aged *Behavior Therapy/mt [Methods] Female *Glaucoma/dt [Drug Therapy] Glaucoma/px [Psychology] Humans Male *Medication Adherence/px [Psychology] *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged *Motivational Interviewing Patient Satisfaction/sn [Statistics & Numerical Data] *Reminder Systems Self Report Treatment Outcome PY - 2017 SE - Cook, Paul F. a College of Nursing, University of Colorado, Aurora, CO, USA. Schmiege, Sarah J. a College of Nursing, University of Colorado, Aurora, CO, USA. Mansberger, Steven L. b Devers Eye Institute, Legacy Health, Portland, OR, USA. Sheppler, Christina. b Devers Eye Institute, Legacy Health, Portland, OR, USA. Kammer, Jeffrey. c Vanderbilt Eye Institute, Vanderbilt University, Nashville, TN, USA. Fitzgerald, Timothy. d Global Health Outcomes, Merck & Co. Inc., White Horse Station, NJ, USA. Kahook, Malik Y. e School of Medicine, University of Colorado, Aurora, CO, USA. SN - 1476-8321 0887-0446 SP - 145-165 ST - Motivational interviewing or reminders for glaucoma medication adherence: Results of a multi-site randomised controlled trial T2 - Psychology & health TI - Motivational interviewing or reminders for glaucoma medication adherence: Results of a multi-site randomised controlled trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=27701902 VL - 32 Y2 - 20161024// ID - 561 ER - TY - JOUR AB - Many older patients attending ophthalmic out-patient clinics have been prescribed eye drops for long-term use to treat glaucoma but do not continue with their treatment. This review looks at chronic simple glaucoma, the problems of compliance with long-term medical treatment in older people and the current and future treatment of glaucoma. Recommendations are made on the nurses' role in supporting these patients. AU - Cooper, J. IS - 32 KW - Aged *Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/nu [Nursing] Humans *Patient Compliance *Patient Education as Topic PY - 1996 SN - 0954-7762 SP - 36-7 ST - Improving compliance with glaucoma eye-drop treatment T2 - Nursing times TI - Improving compliance with glaucoma eye-drop treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=8826416 VL - 92 ID - 2036 ER - TY - JOUR AB - Doug Johnson was a clinician-scientist who made great contributions to the understanding of outflow from the eye. This lecture is in honour of Doug and explores the author's understanding of outflow in the surgical context., HOW TO CITE THIS ARTICLE: Coote M. Blebs, Barriers, and Bagpipes: Why is It so Hard? J Curr Glaucoma Pract 2016; 10(3):79-84. AU - Coote, Michael IS - 3 PY - 2016 SE - Coote, Michael. Associate Professor, Department of Center for Eye Research Australia, The University of Melbourne, Parkville, Victoria, Australia. SN - 0974-0333 SP - 79-84 ST - Blebs, Barriers, and Bagpipes: Why is It so Hard? T2 - Journal of current glaucoma practice TI - Blebs, Barriers, and Bagpipes: Why is It so Hard? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=27857486 VL - 10 Y2 - 20161029// ID - 1027 ER - TY - JOUR AB - Contact lenses, when worn and cared for properly, are a safe and effective form of vision correction used by an estimated 45 million Americans. However, contact lens wearers are at risk for contact lens-related eye infections, especially when wearers do not practice proper contact lens wear and care habits. These infections, affecting the cornea and known as microbial keratitis (Figure), can lead to serious adverse health outcomes. Because contact lenses are regulated by the Food and Drug Administration (FDA) as medical devices, contact lens-related corneal infections should be reported to FDA as an adverse event. To illustrate their serious health implications, six cases of contact lens-related corneal infection, in which sleeping in lenses was reported as the main risk factor, are presented. Consequences of infection reported among the identified cases included the need for frequent administration of antibiotic eye drops, multiple follow-up medical appointments, and permanent eye damage. Health education measures directed toward contact lens wearers should emphasize raising awareness of the risks of sleeping in contact lenses as well as adherence to all recommendations for the wear and care of contact lenses. Additional measures are needed to educate eye care professionals about the need to report contact lens-related corneal infections to MedWatch, the FDA Safety Information and Adverse Event Reporting program (https://www.fda.gov/MedWatch/). AU - Cope, Jennifer R. AU - Konne, Nuadum Muriel AU - Jacobs, Deborah S. AU - Dhaliwal, Deepinder K. AU - Rhee, Michelle K. AU - Yin, Jia AU - Steinemann, Thomas L. DO - https://dx.doi.org/10.15585/mmwr.mm6732a2 IS - 32 KW - Adolescent Adult *Contact Lenses/ae [Adverse Effects] Contact Lenses/px [Psychology] *Corneal Diseases/di [Diagnosis] Corneal Diseases/ep [Epidemiology] *Eye Infections/di [Diagnosis] Eye Infections/ep [Epidemiology] Female Humans Male Middle Aged *Risk-Taking *Sleep United States/ep [Epidemiology] PY - 2018 SN - 1545-861X 0149-2195 SP - 877-881 ST - Corneal Infections Associated with Sleeping in Contact Lenses - Six Cases, United States, 2016-2018 T2 - MMWR. Morbidity and mortality weekly report TI - Corneal Infections Associated with Sleeping in Contact Lenses - Six Cases, United States, 2016-2018 UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30114003 VL - 67 Y2 - 20180817// ID - 413 ER - TY - JOUR AB - Topical glaucoma medications are widely used for childhood glaucoma, although little is known concerning the use of the newer glaucoma medications in this population. The majority of the references cited were extracted from PubMed. A literature review of all English language reports related to glaucoma medication in the pediatric population since 1980 was performed. Medical therapy of pediatric glaucoma contains four groups of drugs: β-blockers (timolol and betaxolol), carbonic anhydrase inhibitors (dorzolamide), α2-agonists (brimonidine), and prostaglandin analogs (latanoprost). Timolol is the first choice in pediatric glaucoma. In cases with insufficient reduction of the intraocular pressure (IOP), the combination of timolol once a day and dorzolamide twice a day brings about a good control of the IOP. Both medications are effective and well tolerated. The α2-agonists have more and potentially serious adverse effects in children and are contraindicated for children younger than 2 years of age. Latanoprost tends to be less effective in lowering IOP in children than in adults. However, no studies are reported where latanoprost is used in monotherapy. Additional study may further delineate this drug's role in treating pediatric glaucoma. The safety profile of latanoprost in children appears excellent. AD - I. Casteels, Department of Ophthalmology, University Hospitals Leuven, Capucijnenvoer 33, B-3000 Leuven, Belgium AU - Coppens, G. AU - Stalmans, I. AU - Zeyen, T. AU - Casteels, I. DB - Embase Medline DO - 10.3928/01913913-20090101-05 IS - 1 KW - acetazolamide acetylsalicylic acid alpha 2 adrenergic receptor stimulating agent antiglaucoma agent apraclonidine beta adrenergic receptor blocking agent betaxolol bicarbonate bimatoprost brimonidine brinzolamide carbonate dehydratase inhibitor chloride clonidine creatinine dorzolamide electrolyte latanoprost metipranolol nitrogen prostaglandin derivative timolol travoprost urea adjuvant therapy angioneurotic edema apnea asthenia asthma bicarbonate blood level bitter taste blepharitis blurred vision bradycardia bronchospasm burning sensation chloride blood level choroid disease clinical trial coma conjunctiva disease conjunctivitis cornea disease cornea edema creatinine blood level depression dizziness drowsiness drug absorption drug blood level drug choice drug contraindication drug distribution drug dosage form comparison drug effect drug efficacy drug eruption drug half life drug hypersensitivity drug induced headache drug megadose drug metabolism drug response drug safety drug tolerability drug withdrawal dry eye dyspnea epistaxis erythema eye inflammation eye irritation eye toxicity fatigue glaucoma glaucoma surgery growth retardation heart rate human hyperemia allergic reaction hypoglycemia hypotension intraocular hypertension intraocular pressure iris disease iritis lacrimation low level laser therapy metabolic acidosis monotherapy muscle hypotonia myopia nausea neurotoxicity open angle glaucoma pain paresthesia patient compliance pruritus punctate keratitis recommended drug dose respiration depression respiratory function macular edema review rhinitis sedation side effect sinusitis skin discoloration sleep disorder somnolence sweating tachyphylaxis urea nitrogen blood level urolithiasis urticaria uveitis LA - English M3 - Review N1 - L354483219 2009-04-28 PY - 2009 SN - 0191-3913 SP - 12-18 ST - The safety and efficacy of glaucoma medication in the pediatric population T2 - Journal of Pediatric Ophthalmology and Strabismus TI - The safety and efficacy of glaucoma medication in the pediatric population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354483219&from=export http://dx.doi.org/10.3928/01913913-20090101-05 http://www.journalofpediatricophthalmology.com/showPdf.asp?thing=36334 VL - 46 ID - 3358 ER - TY - JOUR AU - Coppola, D. DB - Embase IS - 8 KW - eye drops nanoparticle contact lens cornea drug delivery system drug release drug targeting eyelid reflex glaucoma note patient compliance soft contact lens LA - English M3 - Note N1 - L39079862 2004-08-30 PY - 2004 SN - 1543-2521 SP - 15+17 ST - Nanoparticle contact lenses deliver ophthalmic drugs T2 - Pharmaceutical Technology TI - Nanoparticle contact lenses deliver ophthalmic drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39079862&from=export VL - 28 ID - 3734 ER - TY - JOUR AB - Therapeutic contact lenses are useful in a variety of ocular surface diseases. Their main indications are: to relieve the pain; protect ocular surface; promote corneal healing and epithelial regeneration; seal a leaking corneal wound and deliver ophthalmic drugs on the ocular surface. There are several kinds of lens designs and materials, and their choice is dependent on the specific disease to be treated, the duration of treatment and the physiologic needs of the diseased cornea. Bullous keratopathy, recurrent epithelial erosion syndrome, dry eye and postoperative epithelial defects are amongst their indications. Therapeutic contact lenses should not be indicated in the presence of active infectious keratitis or when the patient is not compliant. Corneal neovascularization, giant papillary conjunctivitis and infectious keratitis are serious complications, which can be prevented by correctly fitting and maintaining the therapeutic contact lenses. Silicon-hydrogel therapeutic contact lenses, due to their higher oxygen permeability, allow extended wear schedules, decreasing the need for frequent lens replacement. AU - Coral-Ghanem, Cleusa AU - Ghanem, Vinicius Coral AU - Ghanem, Ramon Coral IS - 6 Suppl KW - *Contact Lenses *Corneal Diseases/th [Therapy] Disinfection Humans Hydrogel, Polyethylene Glycol Dimethacrylate *Oxygen/me [Metabolism] Permeability Silicon PY - 2008 SE - Coral-Ghanem, Cleusa. Area de Concentracao Oftalmologia - Faculdade de Medicina da Universidade de Sao Paulo - USP - Sao Paulo (SP) - Brasil. coral.joi@terra.com.br SN - 1678-2925 0004-2749 SP - 19-22 ST - [Therapeutic contact lenses and the advantages of high Dk materials] T2 - Lentes de contato terapeuticas e as vantagens dos materiais de alto Dk. TI - [Therapeutic contact lenses and the advantages of high Dk materials] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19274406 VL - 71 ID - 1495 ER - TY - JOUR AD - J. Corcos, Department of Urology, Jewish General Hospital, McGill University, Montreal, QC, Canada AU - Corcos, J. AU - Przydacz, M. AU - Campeau, L. AU - Gray, G. AU - Hickling, D. AU - Honeine, C. AU - Radomski, S. B. AU - Stothers, L. AU - Wagg, A. C1 - detrol detrol la ditropan ditropan xl enablex gelnique mictoryl myrbetriq oxytrol toviaz trosec vesicare DB - Embase DO - 10.5489/cuaj.4586 IS - 5 KW - beta 3 adrenergic receptor stimulating agent botulinum toxin A cholinergic receptor blocking agent cholinesterase inhibitor darifenacin fesoterodine galantamine herbaceous agent mirabegron muscarinic receptor blocking agent oxybutynin placebo propiverine solifenacin tolterodine trospium chloride warfarin abdominal pain accommodation disorder adult disease aging backache bacteriuria behavior therapy bladder reconstruction blurred vision Canada cardiovascular mortality cardiovascular risk central nervous system disease closed angle glaucoma cognitive defect constipation cystalgia cystoscopy daily life activity delirium dementia device infection dietary intake dietary supplement drug fatality drug potentiation drug withdrawal dry eye dyspepsia dysuria exercise exhaustion eye toxicity fatigue fluid intake follow up gastrointestinal symptom headache health care organization heart arrhythmia heart palpitation heat intolerance hematuria human hypertension indwelling catheter injection site reaction lifestyle modification medical history meta analysis (topic) multicenter study (topic) nausea nephrotoxicity nerve stimulation neurotoxicity overactive bladder patient compliance patient education patient isolation pelvic floor muscle training peripheral tibial nerve stimulation phase 2 clinical trial (topic) phase 3 clinical trial (topic) physical activity physical examination postvoid residual urine volume potentially inappropriate medication practice guideline prevalence productivity pruritus psychological aspect QT prolongation quality of life questionnaire randomized controlled trial (topic) review rhinopharyngitis sacral nerve stimulation sexuality skin manifestation smoking cessation social psychology somnolence systematic review (topic) tachycardia treatment response ultrasound unspecified side effect urinalysis urinary diversion urinary tract infection urine culture urine incontinence urine retention urodynamics urogenital tract disease urologist visual impairment walking speed weakness body weight control body weight loss xerostomia detrol detrol la ditropan ditropan xl enablex gelnique mictoryl myrbetriq oxytrol toviaz trosec vesicare LA - English M3 - Review N1 - L616804037 2017-06-20 2017-06-26 PY - 2017 SN - 1911-6470 1920-1214 SP - E142-E173 ST - CUA guideline on adult overactive bladder T2 - Canadian Urological Association Journal TI - CUA guideline on adult overactive bladder UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616804037&from=export http://dx.doi.org/10.5489/cuaj.4586 VL - 11 ID - 2655 ER - TY - JOUR AB - This editorial discusses the current issue of Acta Neuropathologica. This issue includes a cluster of three review papers on different aspects of neurodegeneration involving the retina, from experts in ophthalmology, neuro-ophthalmology, and neuroscience and covering glaucoma, Alzheimer’s disease, and Leber’s hereditary optic neuropathy (LHON). In each case, they address the neuropathological mechanisms that highlight why the retina may serve as a valuable model to study brain disease. They include molecular advances, evidence for commonalities between brain and eye changes, cell death processes, and recent updates on targets for therapy. Furthermore, they promote the idea that due to its accessibility, the eye can be a tool through which disease activity and treatment response can be assessed with widespread applications for neurological disease. This cluster will hopefully be of interest to neuropathologists, ophthalmic pathologists, neuroscientists, and neurologists intrigued by how and why it might be possible to eye the brain. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Cordeiro, M. Francesca, Institute of Ophthalmology, UCL Institute of Ophthalmology, 11-43 Bath Street, London, United Kingdom, EC1V 9EL AN - 2016-55202-001 AU - Cordeiro, M. Francesca DB - psyh DO - 10.1007/s00401-016-1628-z DP - EBSCOhost IS - 6 KW - scientific communication neuropathology glaucoma Alzheimer’s disease Leber’s hereditary optic neuropathy Alzheimer's Disease Neuropathy N1 - Institute of Ophthalmology, UCL Institute of Ophthalmology, London, United Kingdom. Release Date: 20161128. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Editorial. Language: EnglishGrant Information: Cordeiro, M. Francesca. Major Descriptor: Alzheimer's Disease; Glaucoma; Neuropathology; Neuropathy. Minor Descriptor: Scientific Communication. Classification: Neurological Disorders & Brain Damage (3297). Population: Human (10). References Available: Y. Page Count: 2. Issue Publication Date: Dec, 2016. Publication History: First Posted Date: Oct 15, 2016. Copyright Statement: This article is published with open access at Springerlink.com. The Author(s). 2016. Sponsor: Wellcome Trust. Recipients: Cordeiro, M. Francesca PY - 2016 SN - 0001-6322 1432-0533 SP - 765-766 ST - Eyeing the brain T2 - Acta Neuropathologica TI - Eyeing the brain UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-55202-001&site=ehost-live&scope=site m.cordeiro@ucl.ac.uk VL - 132 ID - 4836 ER - TY - JOUR AB - Fusarium solani has drawn phytopathogenic, biotechnological, and medical interest. In humans, it is associated with localized infections, such as onychomycosis and keratomycosis, as well as invasive infections in immunocompromised patients. One pathogenicity factor of filamentous fungi is biofilm formation. There is still only scarce information about the in vitro mechanism of the formation and composition of F. solani biofilm. In this work, we describe the biofilm formed by a clinical keratomycosis isolate in terms of its development, composition and susceptibility to different antifungals and ultraviolet light (UV) at different biofilm formation stages. We found five biofilm formation stages using scanning electron microscopy: adherence, germination, hyphal development, maturation, and cell detachment. Using epifluorescence microscopy with specific fluorochromes, it was elucidated that the extracellular matrix consists of carbohydrates, proteins, and extracellular DNA. Specific inhibitors for these molecules showed significant biofilm reductions. The antifungal susceptibility against natamycin, voriconazole, caspofungin, and amphotericin B was evaluated by metabolic activity and crystal violet assay, with the F. solani biofilm preformation to 24 h increased in resistance to natamycin, voriconazole, and caspofungin, while the biofilm preformation to 48 h increased in resistance to amphotericin B. The preformed biofilm at 24 h protected and reduced UV light mortality. F. solani isolate could produce a highly structured extra biofilm; its cellular matrix consists of carbohydrate polymers, proteins, and eDNA. Biofilm confers antifungal resistance and decreases its susceptibility to UV light. The fungal biofilm functions as a survival strategy against antifungals and environmental factors. AU - Cordova-Alcantara, Itzel Margarita AU - Venegas-Cortes, Diana Laura AU - Martinez-Rivera, Maria Angeles AU - Perez, Nestor Octavio AU - Rodriguez-Tovar, Aida Veronica DO - https://dx.doi.org/10.1007/s12275-019-8637-2 IS - 6 KW - *Antifungal Agents/pd [Pharmacology] *Biofilms/de [Drug Effects] *Biofilms/gd [Growth & Development] *Biofilms/re [Radiation Effects] Drug Resistance, Fungal/de [Drug Effects] Drug Resistance, Fungal/re [Radiation Effects] *Eye Infections, Fungal/mi [Microbiology] Fungi/de [Drug Effects] Fungi/re [Radiation Effects] *Fusarium/de [Drug Effects] Fusarium/py [Pathogenicity] *Fusarium/re [Radiation Effects] Humans Hyphae/de [Drug Effects] Hyphae/re [Radiation Effects] *Keratitis/mi [Microbiology] Mexico Microbial Sensitivity Tests Microbial Viability/de [Drug Effects] Microbial Viability/re [Radiation Effects] Microscopy, Electron, Scanning PY - 2019 SE - Cordova-Alcantara, Itzel Margarita. Medical Micology Laboratory, Microbiology Department National School of Biological Sciences, National Polytechnique Institute (IPN), C.P. 11340, Ciudad de Mexico, Mexico. Venegas-Cortes, Diana Laura. Medical Micology Laboratory, Microbiology Department National School of Biological Sciences, National Polytechnique Institute (IPN), C.P. 11340, Ciudad de Mexico, Mexico. Martinez-Rivera, Maria Angeles. Medical Micology Laboratory, Microbiology Department National School of Biological Sciences, National Polytechnique Institute (IPN), C.P. 11340, Ciudad de Mexico, Mexico. Perez, Nestor Octavio. Research and Development Department, Probiomed S.A. de C.V. Cruce de Carreteras Acatzingo-Zumpahuacan S/N, C.P. 52400, Tenancingo, Estado de Mexico, Mexico. nestor.perez@probiomed.com.mx. Rodriguez-Tovar, Aida Veronica. Medical Micology Laboratory, Microbiology Department National School of Biological Sciences, National Polytechnique Institute (IPN), C.P. 11340, Ciudad de Mexico, Mexico. avrodriguez@ipn.mx. SN - 1976-3794 1225-8873 SP - 485-497 ST - Biofilm characterization of Fusarium solani keratitis isolate: increased resistance to antifungals and UV light T2 - Journal of microbiology (Seoul, Korea) TI - Biofilm characterization of Fusarium solani keratitis isolate: increased resistance to antifungals and UV light UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31134579 VL - 57 Y2 - 20190527// ID - 329 ER - TY - JOUR AB - Glaucoma refers to a group of related eye disorders that have in common an optic neuropathy associated with visual function loss. It is the second leading cause of blindness in developed countries and Romania and the first cause of irreversible blindness worldwide. In Europe, 2% of the population over 40 and 7% of the population over 80 have glaucoma. In Romania, there are no official statistics concerning glaucoma disease, but it was estimated that over 160000 Romanians suffer from this disease and only 50% of them are undergoing treatment. The silent evolution of the disease, the deficient sanitary education, the lack of well structured national programs for screening and follow-up and the lack of adherence to treatment and check-ups, are the causes of late diagnosis and irreversible visual function loss. The article emphasizes the need for national centers specialized in managing patients with glaucoma, from prevention, screening, early diagnosis to treatment and monitoring. AU - Cornel, Stefan AU - Mihaela, Timaru Cristina AU - Adriana, Iliescu Daniela AU - Speranta, Schmitzer AU - Algerino, De Simone AU - Mehdi, Batras AU - Jalaladin, Hosseini-Ramhormozi IS - 4 PY - 2015 SE - Cornel, Stefan. Central Military Emergency University Hospital "Dr.Carol Davila", Ophthalmology Department. Mihaela, Timaru Cristina. Central Military Emergency University Hospital "Dr.Carol Davila", Ophthalmology Department. Adriana, Iliescu Daniela. Central Military Emergency University Hospital "Dr.Carol Davila", Ophthalmology Department. Speranta, Schmitzer. Ophthalmologic Emergency Clinical Hospital. Speranta, Schmitzer. "Carol Davila" University of Medicine and Pharmacy, Ophthalmology Clinic. Algerino, De Simone. Central Military Emergency University Hospital "Dr.Carol Davila", Ophthalmology Department. Mehdi, Batras. Central Military Emergency University Hospital "Dr.Carol Davila", Ophthalmology Department. Jalaladin, Hosseini-Ramhormozi. Central Military Emergency University Hospital "Dr.Carol Davila", Ophthalmology Department. SN - 2457-4325 SP - 223-229 ST - National centers of excellence in glaucoma T2 - Romanian journal of ophthalmology TI - National centers of excellence in glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=29450311 VL - 59 ID - 1050 ER - TY - JOUR AB - The article reports a study which demonstrated poor repeatability of intraocular pressure (IOP) measurements in patients with untreated glaucoma; comments on the study emphasize the unreliability of a single test for management purposes. AN - 85689509. Language: English. Entry Date: 20130228. Revision Date: 20130302. Publication Type: Article AU - Correa, Mark AU - Hasson, Matt DB - ccm DP - EBSCOhost IS - 4 KW - Intraocular Pressure -- Drug Effects Treatment Outcomes -- Evaluation Decision Making, Clinical Research Tonometry Office Visits N1 - brief item; commentary. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Diagnostic Imaging. NLM UID: 9882135. PY - 2013 SN - 8750-3085 SP - 28-28 ST - Measurements of therapeutic effect, IOP control unreliable over time...including commentary by Rhee DJ T2 - Ocular Surgery News TI - Measurements of therapeutic effect, IOP control unreliable over time...including commentary by Rhee DJ UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=85689509&site=ehost-live&scope=site VL - 31 ID - 4744 ER - TY - JOUR AB - Purpose: To estimate the prevalence and causes of blindness and visual impairment, cataract surgical coverage (CSC), visual outcome of cataract surgery, and barriers to uptake cataract surgery in Timor-Leste. Method: In a nationwide rapid assessment of avoidable blindness (RAAB), the latest population (1,066,409) and household data were used to create a sampling frame which consists of 2,227 population units (study clusters) from all 13 districts, with populations of 450-900 per unit. The sample size of 3,350 was calculated with the assumed prevalence of blindness at 4.5% among people aged ≥50 years with a 20% tolerable error, 95% CI, and a 90% response rate. The team was trained in the survey methodology, and inter-observer variation was measured. Door-to-door visits, led by an ophthalmologist, were made in preselected study clusters, and data were collected in line with the RAAB5 survey protocol. An Android smart phone installed with mRAAB software was used for data collection. Result: The age-gender standardized prevalence of blindness, severe visual impairment, and visual impairment were 2.8%, (1.8-3.8), 1.7% (1.7-2.3), and 8.1% (6.6-9.6), respectively. Cataract was the leading cause of blindness (79.4%). Blindness was more prevalent in the older age group and in women. CSC was 41.5% in cataract blind eyes and 48.6% in cataract blind people. Good visual outcome in the cataract-operated eyes was 62% (presenting) and 75.2% (best corrected). Two important barriers to not using available cataract surgical services were accessibility (45.5%) and lack of attendants to accompany (24.8%). Conclusion: The prevalence of blindness and visual impairment in Timor-Leste remains high. CSC is unacceptably low; gender inequity in blindness and CSC exists. Lack of access is the prominent barrier to cataract surgery. AD - Y. Sapkota, International Agency for Prevention of Blindness South East Asia Regional Office, LV Prasad Eye Institute, Road No 2, Banjara Hills, Hyderabad, India AU - Correia, M. AU - Das, T. AU - Magno, J. AU - Pereira, B. M. AU - Andrade, V. AU - Limburg, H. AU - Trevelyan, J. AU - Keeffe, J. AU - Verma, N. AU - Sapkota, Y. DB - Embase DO - 10.2147/OPTH.S146901 KW - smartphone adult age aged article best corrected visual acuity blindness cataract cataract extraction central nervous system disease cornea opacity eye disease female glaucoma health care access human information processing lung tuberculosis major clinical study male middle aged observer variation ophthalmologist pathogenesis prevalence refraction error sample size sex ratio Timor-Leste treatment outcome very elderly visual impairment visual system examination LA - English M3 - Article N1 - L621351459 2018-03-29 2018-04-06 PY - 2017 SN - 1177-5483 1177-5467 SP - 2125-2131 ST - Prevalence and causes of blindness, visual impairment, and cataract surgery in Timor-Leste T2 - Clinical Ophthalmology TI - Prevalence and causes of blindness, visual impairment, and cataract surgery in Timor-Leste UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621351459&from=export http://dx.doi.org/10.2147/OPTH.S146901 VL - 11 ID - 2623 ER - TY - JOUR AB - BACKGROUND: Ab externo trabeculectomy (AET) is the most common surgical procedure to treat glaucoma; topical anesthesia supplemented by conscious sedation is one of the diverse anesthetic methods to perform such type of surgery. The efficacy and safety of using topical anesthesia supplemented with conscious sedation for performing trabeculectomy were assessed in this prospective study., METHODS: Twenty-six eyes of 26 consecutive patients underwent trabeculectomy under the effect of topical anesthesia and sedation. All cases were prospectively assessed during five different intra-operative times in which the degree of pain was measured using a visual analog scale (VAS)., RESULTS: One patient was excluded from the study due to excessive somnolence. Performing the iridectomy caused less tolerance (p = 0.03) but with acceptable scores according to the VAS (score 2 = minimal and tolerable pain; p = 0.02), followed by conjunctival closure (nonsignificant p values). The entire procedure did not cause either moderate to extreme pain (scores 4 and 5 of the scale, respectively) in any of the patients. Levels of pain, blood pressure, heart rate, and oxygen saturation were compared among the different intra-operative times. No statistically significant (p >0.05) differences were demonstrated. Eighty percent (n = 4) of the patients with green or blue iris had symptoms during the surgery, but this was of borderline statistical significance (p = 0.053). No ocular or systemic side effects appeared related to the reported anesthesia regime., CONCLUSIONS: Topical anesthesia associated with conscious sedation seems to be efficacious and safe and can be recommended for performing trabeculectomy. AU - Cortes-Gastelum, Marco Antonio AU - Paczka-Zapata, Jose Antonio AU - Mendoza-Barbosa, Jossue Fernando IS - 3 KW - Adjuvants, Anesthesia/ad [Administration & Dosage] Administration, Topical Aged *Anesthesia, Local/mt [Methods] *Anesthetics, Local/ad [Administration & Dosage] *Conscious Sedation Epinephrine/ad [Administration & Dosage] Eye Color Female Hemodynamics Humans *Lidocaine/ad [Administration & Dosage] Male Middle Aged Oxygen/bl [Blood] Pain Measurement Pain, Postoperative/ep [Epidemiology] Pain, Postoperative/pc [Prevention & Control] Patient Acceptance of Health Care Prospective Studies *Tetracaine/ad [Administration & Dosage] *Trabeculectomy/mt [Methods] PY - 2011 SE - Cortes-Gastelum, Marco Antonio. Direccion del Instituto de Subespecialidades Oftalmologicas, Tijuana, Baja California, Mexico. SN - 2444-054X 0009-7411 SP - 215-8 ST - Ab externo trabeculectomy performed under topical anesthesia supplemented by conscious sedation T2 - Cirugia y cirujanos TI - Ab externo trabeculectomy performed under topical anesthesia supplemented by conscious sedation UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=22380990 VL - 79 ID - 1237 ER - TY - JOUR AB - INTRODUCTION:: To report the case of a high hyperopic refractive shift associated with significant shortening of the ocular axial length following glaucoma filtering surgery., METHODS:: Case report. Patient's records were consulted retrospectively., RESULTS:: A 57-year-old woman, highly myopic, with a history of bilateral intraocular refractive surgery in 1998 (phakic lens ZB5M) and bilensectomy in 2011 (phakic intraocular lens extraction plus cataract surgery with pseudophakic intraocular lens implantation), presented with consistently high intraocular pressure. Despite the treatment with different topical antiglaucomatous medications and good compliance, her intraocular pressure values remained consistently above 20 mmHg. In 2016, the patient was submitted for glaucoma filtering surgery and the mini shunt Ex-Press was implanted in both the eyes (3 months between surgeries). On the first postoperative day, the eyes were hypotonic (intraocular pressure of 5 mmHg) and bilateral macular edema was observed. Three days later, the intraocular pressure in both the eyes reached values higher than 6 mmHg (between 6 and 14 mmHg). Five months after the surgery the macular edema resolved and a significant shortening of the axial length and an important hyperopic refractive shift was observed. When comparing the preoperative and postoperative (18 months) measurements, the variation of the axial length was 2.49 mm in the right eye and 2.19 mm in the left eye; the patient refraction (spherical equivalent) shifted 2.50 diopters in the right eye and 1.75 diopters in the left eye., CONCLUSION:: To the best of our knowledge, we report herein the first documented case of an axial length change of this magnitude after glaucoma filtering surgery. AU - Costa, Joao C. AU - Alio, Jorge DO - https://dx.doi.org/10.1177/1120672118794564 IS - 1 KW - *Axial Length, Eye/pp [Physiopathology] Female *Filtering Surgery/ae [Adverse Effects] *Glaucoma/su [Surgery] Humans *Hyperopia/et [Etiology] Hyperopia/pp [Physiopathology] Intraocular Pressure/ph [Physiology] Middle Aged *Myopia, Degenerative/co [Complications] *Ocular Hypotension/et [Etiology] Ocular Hypotension/pp [Physiopathology] Pseudophakia/et [Etiology] Retrospective Studies Tonometry, Ocular Visual Acuity/ph [Physiology] PY - 2019 SE - Costa, Joao C. 1 Department of Ophthalmology, Centro Hospitalar Vila Nova Gaia/Espinho, Portugal. Alio, Jorge. 2 Cornea, Cataract and Refractive Surgery Unit, Vissum Corporacion, Alicante, Spain. Alio, Jorge. 3 Division of Ophthalmology, Universidad Miguel Hernandez, Alicante, Spain. SN - 1724-6016 1120-6721 SP - NP6-NP9 ST - Significant hyperopic shift in a patient with extreme myopia following severe hypotonia caused by glaucoma filtering surgery T2 - European journal of ophthalmology TI - Significant hyperopic shift in a patient with extreme myopia following severe hypotonia caused by glaucoma filtering surgery UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30175614 VL - 29 Y2 - 20180903// ID - 378 ER - TY - JOUR AB - Introduction: Glaucoma therapy is typically started with a single drug that is considered most effective for IOP control and is relatively safe. Several classes of agents are available, including prostaglandin analogs (PGAs), β-blockers, carbonic anhydrase inhibitors (CAIs), cholinergic agonists, and α2-agonists. Most patients will require combined therapy to achieve predetermined target intraocular pressure (IOP), which can be difficult to sustain over time. Currently, maximum medical therapy (MMT) in glaucoma refers to ≤3 classes of medications combined to substantially lower IOP. MMT can be achieved using multiple single agents, double, or triple fixed-dose combinations. Areas covered: Several randomized controlled clinical trials demonstrated that 3-drug combination regimens are superior to 2-drug regimens for lowering 24-hour IOP, which may prevent glaucoma progression. However, long-term clinical evidence with 3- or 4-drug MMT regimens is scarce. Expert commentary: The next logical step in evolution of effective MMT may be the use of 4 classes of medications, adding triple fixed-combination to single agent or combining fixed-dose combinations of CAI plus α2-agonist and fixed-dose β-blocker plus PGA. Availability of novel fixed-dose combinations may optimize efficacy, tolerability, adherence, and improve long-term outcomes. Further controlled evidence is required to accurately delineate the value of current and future MMT regimens. AD - Department of Ophthalmology, University Campinas, São Paulo, Brazil Singapore National Eye Centre, Singapore Eye Research Institute, Singapore, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 1st and 3rd University Departments of Ophthalmology, Aristotle University, Thessaloniki, Greece AN - 134433870. Language: English. Entry Date: 20190205. Revision Date: 20190710. Publication Type: Article AU - Costa, Vital Paulino AU - Aung, Tin AU - Konstas, Anastasios G. DB - ccm DO - 10.1080/17469899.2019.1570138 DP - EBSCOhost IS - 1 KW - Evolution -- Evaluation Paradigms -- Utilization Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Drug Therapy, Combination Glaucoma -- Prevention and Control N1 - review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 101278197. PY - 2019 SN - 1746-9899 SP - 33-42 ST - Evolution of the treatment paradigm for maximum medical therapy in glaucoma T2 - Expert Review of Ophthalmology TI - Evolution of the treatment paradigm for maximum medical therapy in glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134433870&site=ehost-live&scope=site VL - 14 ID - 4350 ER - TY - JOUR AB - Elevated intraocular pressure (IOP) has been recognized as the major risk factor for the development of glaucoma and a wide range of options are now available to reduce it: medical treatment, laser, filtering, or cyclodestructive surgery (alone or in combination). All these modalities act by decreasing eye pressure and, thereby, protecting the optic nerve head from a mechanic direct and/or vascular indirect insult. Topical medical therapy represents the first-choice treatment and, in most cases, it effectively controls IOP, avoiding the occurrence of further optic nerve damage. All medications lower IOP in two main ways: decreasing the production of aqueous humour or by increasing its outflow from the eye. Consequently, antiglaucoma drugs either suppress aqueous humour formation (β-adrenergic antagonists, carbonic anhydrase inhibitors, and alpha-2-adrenergic agonists) or raise aqueous humour outflow throughout the conventional (e.g., pilocarpine) or uveoscleral (prostaglandin FP receptor agonists, and prostamides) route. In addition, fixed and unfixed combinations of antiglaucoma compounds have also been available for patients requiring more than one type of medication. This review, which is part one of two (please see Expert Opinion on Pharmacotherapy 10 (17)) briefly considers the characteristics of sympathomimetic, sympatholytics and parasympathomimetic commonly employed in the medical treatment of glaucoma, mainly the primary open-angle form, focusing the discussion on the clinical evidence supporting the use of these three classes of compound. © 2009 Informa UK Ltd. AD - C. Costagliola, Università Degli Studi Del Molise, Dipartmento di Scienze per la Salute, Via F De Sanctis, 86100 Campobasso, Italy AU - Costagliola, C. AU - Dell'Omo, R. AU - Romano, M. R. AU - Rinaldi, M. AU - Zeppa, L. AU - Parmeggiani, F. DB - Embase Medline DO - 10.1517/14656560903300103 IS - 16 KW - acetylcholine epinephrine adrenergic receptor blocking agent adrenergic receptor stimulating agent apraclonidine atenolol beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brimonidine plus timolol carbachol carteolol cholinergic receptor stimulating agent clonidine dapiprazole dipivefrine latanoprost levobunolol metipranolol noradrenalin pilocarpine placebo timolol timolol maleate abnormal sensation absence of side effects accommodation acetylcholine release allergic conjunctivitis aqueous humor flow aqueous humor formation asthma blepharoconjunctivitis blood pressure bronchospasm burning sensation chemical structure chemosis cholesterol blood level ciliary muscle spasm ciliary vasoconstriction clinical trial closed angle glaucoma conjunctiva disease conjunctiva toxicity conjunctival blanching conjunctival deposit conjunctivitis cornea epithelium cornea sensibility dermatitis diarrhea diastolic blood pressure drug absorption drug blood level drug contraindication drug dosage form comparison drug half life drug induced headache drug mechanism drug potentiation drug tolerability dry nose dyslipidemia dyspnea epiphora eye burning eye inflammation eye irritation eye pain eye redness eye stinging eye synechia eye toxicity eyelid disease eyelid edema fatigue foreign body reaction gastrointestinal cramp gastrointestinal symptom glaucoma headache heart arrhythmia heart palpitation heart rate human hydrolysis hyperemia hyperhidrosis hypotension intraocular hypertension intraocular pressure iridocyclitis keratitis lacrimal duct occlusion lacrimation lipoprotein blood level lung edema lung function miosis muscle cramp muscle spasm mydriasis nonhuman low tension glaucoma ocular pruritus open angle glaucoma optic nerve lesion patient compliance periorbital dermatitis pigment glaucoma pigmented conjunctival deposite pseudoexfoliation glaucoma pupil macular edema review salivation sedation side effect single drug dose skin allergy skin manifestation faintness systolic blood pressure tachycardia tachyphylaxis triacylglycerol blood level unspecified side effect urge incontinence vasoconstriction vision visual acuity visual field defect vomiting xerostomia LA - English M3 - Review N1 - L358009813 2010-02-16 PY - 2009 SN - 1465-6566 SP - 2663-2677 ST - Pharmacotherapy of intraocular pressure: Part I. Parasympathomimetic, sympathomimetic T2 - Expert Opinion on Pharmacotherapy TI - Pharmacotherapy of intraocular pressure: Part I. Parasympathomimetic, sympathomimetic UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358009813&from=export http://dx.doi.org/10.1517/14656560903300103 VL - 10 ID - 3298 ER - TY - JOUR AB - The second part of this two part review (please see Expert Opinion on Pharmacotherapy 10(16)) reports the characteristics of other antiglaucoma medications: systemic (acetazomide) and topical (dorzolamide and brinzolamide) carbonic anhydrase inhibitors, which suppress aqueous humour formation; and prostaglandin analogues (latanoprost and travoprost) and prostamides (bimatoprost), which raise aqueous humour outflow. The pharmacologic properties of each compound and its efficacy in the medical treatment of glaucoma, mainly the primary open-angle form, are discussed briefly, focusing on the clinical evidence supporting their use. © 2009 Informa UK Ltd. AD - C. Costagliola, Università Degli Studi Del Molise, Dipartmento di Scienze per la Salute, Via F De Sanctis, 86100 Campobasso, Italy AU - Costagliola, C. AU - Dell'Omo, R. AU - Romano, M. R. AU - Rinaldi, M. AU - Zeppa, L. AU - Parmeggiani, F. C1 - aspirin diamox DB - Embase Medline DO - 10.1517/14656560903300129 IS - 17 KW - aceclidine acetazolamide acetylcholine acetylsalicylic acid epinephrine apraclonidine betaxolol bimatoprost brimonidine brinzolamide carbachol carbonate dehydratase inhibitor carteolol clonidine dorzolamide latanoprost levobunolol pilocarpine propranolol derivative prostaglandin derivative prostamide derivative prostanoid sulfonamide timolol travoprost unclassified drug aplastic anemia aqueous humor formation aqueous humor outflow asthenia bitter taste blood analysis blood pressure blurred vision bone marrow suppression burning sensation clinical trial conjunctival hyperemia conjunctivitis cyst drug efficacy drug mechanism drug megadose drug withdrawal dry eye epiphora evening dosage eyelash eyelid inflammation fatigue foreign body reaction glaucoma headache heart rate hirsutism human inflammation insect sting intraocular hypotension intraocular pressure iris cyst iris disease iris pigmentation keratitis leukopenia liver function test malaise metabolic acidosis morning dosage nausea nausea and vomiting nephrolithiasis nonhuman pancytopenia paresthesia patient compliance pigmentation pruritus rash recommended drug dose macular edema review side effect skin manifestation skin pigmentation thrombocytopenia transamination urinalysis urolithiasis uveitis aspirin diamox LA - English M3 - Review N1 - L358026091 2010-02-15 PY - 2009 SN - 1465-6566 SP - 2859-2870 ST - Pharmacotherapy of intraocular pressure part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides T2 - Expert Opinion on Pharmacotherapy TI - Pharmacotherapy of intraocular pressure part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358026091&from=export http://dx.doi.org/10.1517/14656560903300129 VL - 10 ID - 3299 ER - TY - JOUR AB - Glaucoma is a pathological condition whose most important risk factor is increased intraocular pressure (IOP). The medical treatment of glaucoma essentially consists of compounds that are able to decrease the IOP. The compounds discussed in this review act in a different way, beta-blockers mainly inhibit the production of aqueous humor, whereas latanoprost decreases the resistance in the outflow channels. beta-Blockers are compounds with a well-known efficacy and safety profile and they are fairly inexpensive. Their systemic and local side effects are mainly cardiovascular and pulmonary adverse events, dry eye and keratopathy. Latanoprost, which has recently been introduced into the market, has been shown to be equally as effective, or better in lowering IOP in patients than timolol, although it is more expensive. Systemic reported side effects are anecdotal; local hyperaemia, keratopathy, hypertrichosis, increased pigmentation of eyelashes and iris, uveitis and cystoid macular oedema have been reported. A comparison of costs reveals that a 1-year therapy with timolol ophthalmic solution starts from 11.00 Euros and can reach 146.00 Euros for the most expensive preservative-free 1-day dispenser packages (approximately 13.5 times higher). For latanoprost once-daily administration, the cost for 1 years therapy is 98.55 Euros, approximately six times higher than generic or brand 0.5% timolol applied twice-daily. What are the factors influencing a change in therapy from beta-blockers to latanoprost? The only good reason is represented by a further deterioration in the visual field. This may occur, despite a significant reduction in IOP, because the reached IOP is not sufficient enough to avoid further deterioration because the patient's work or social activities do not allow a correct daily dosage of the compound (bad compliance); or as a result of treatment suspension, because of the development of systemic and/or local side effects. Changes in therapy must always be related to a failing control of the disease, as any therapeutic modification leading to an increase in the number of visits and additional examinations, consequently enhances the costs. AU - Costagliola, Ciro AU - Parmeggiani, Francesco AU - Sebastiani, Adolfo IS - 10 KW - Adrenergic beta-Antagonists/ae [Adverse Effects] Adrenergic beta-Antagonists/ec [Economics] *Adrenergic beta-Antagonists/tu [Therapeutic Use] Antihypertensive Agents/ae [Adverse Effects] Antihypertensive Agents/ec [Economics] *Antihypertensive Agents/tu [Therapeutic Use] Cost-Benefit Analysis Humans Intraocular Pressure/de [Drug Effects] Latanoprost *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions Prostaglandins F, Synthetic/ae [Adverse Effects] Prostaglandins F, Synthetic/ec [Economics] *Prostaglandins F, Synthetic/tu [Therapeutic Use] PY - 2003 SE - Costagliola, Ciro. Department of Ophthalmology, University of Ferrara, Ferrara, Italy. costaciro@libero.it SN - 1465-6566 SP - 1775-88 ST - Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension T2 - Expert opinion on pharmacotherapy TI - Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=14521487 VL - 4 ID - 1824 ER - TY - JOUR AB - Background and aims: Thiopurines represent the mainstay of immunosuppressive therapy in inflammatory bowel diseases. Since it is likely that response to therapy and adverse events depends on the genetic background of patients our study aimed to evaluate retrospectively response to therapy and safety in a mixed IBD population in Southern Europe. Methods: We evaluated demographic and clinical data of our patients treated with thiopurines. after 6. months in responders and non-responders to therapy. Moreover the likelihood to remain in thiopurine monotherapy was evaluated in responders, whereas adverse events were investigated in all patients. Results: Among disease- and patient-related parameters a shorter disease duration, female gender and ileal disease in Crohn's patients were associated with better response. By ROC analysis, the best predictors of response were decreasing values of C-reactive protein and erythrocyte sedimentation rate. In the long-term more than half of IBD patients who responded at 6. months remained on monotherapy at 42. months. Flu-like syndrome represented the most frequent adverse event followed by abnormalities of liver function tests and myelotoxicity. Adverse events did occur at any time and were frequently impredictable. Conclusions: In this retrospective study, thiopurines showed a good clinical efficacy, especially in patients with short duration of disease. Normalization of markers of systemic inflammation represents the most useful tool to assess response. Careful monitoring of patients is required during the whole duration of treatment although it may not prevent all severe complications. © 2011 European Crohn's and Colitis Organisation. AD - Dept. of Internal Medicine, University of Messina, Messina, Italy Dept. of Economical, Financial, Social, Environmental, Statistical and Territorial Sciences (S.E.FI.S.A.S.T.), University of Messina, Messina, Italy AU - Costantino, G. AU - Furfaro, F. AU - Belvedere, A. AU - Alibrandi, A. AU - Fries, W. DB - Scopus DO - 10.1016/j.crohns.2011.11.007 IS - 5 KW - 6-mercaptopurine 6-MMP 6-TGN Azathioprine Safety TPMT M3 - Article N1 - Cited By :37 Export Date: 19 July 2021 PY - 2012 SP - 588-596 ST - Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up T2 - Journal of Crohn's and Colitis TI - Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860837896&doi=10.1016%2fj.crohns.2011.11.007&partnerID=40&md5=4de30c163d6a7d6b0850282349c6f18d VL - 6 ID - 5029 ER - TY - JOUR AB - Several notifications of eye pain and blurred vision associated with treatment with nifedipine were received by New Zealand's Intensive Medicines Monitoring Programme. A questionnaire survey of patients taking nifedipine was undertaken to test the importance of these associations, with disturbance of taste associated with captopril taken as a methodological control. Altogether 961 patients taking nifedipine and 368 taking captopril were sent a questionnaire that asked whether any eye problems and changes in the sense of taste had occurred while they were taking the drug and whether these had resolved after treatment was stopped. Compliance was high: of 922 and 343 questionnaires that were assumed to have been delivered to patients taking nifedipine and captopril, respectively, 770 (84%) and 295 (86%) were returned satisfactorily completed. The distribution of sex was comparable in the two groups; patients taking captopril were slightly younger. Eye symptoms were reported in both groups, but eye pain was significantly more common in patients taking nifedipine (107 (14%) compared with 26 (9%) patients taking captopril). This is a new finding and may be related to ocular vasodilatation. Theoretically, glaucoma is a possible adverse reaction. Loss of taste was significantly associated with captopril, but no other disturbances of taste showed significant associations. Loss of taste persisted in 27 out of 35 patients who continued to take captopril and in three out of eight patients when the drug was withdrawn. This study showed a method of assessing early signs of adverse drug reactions, which has been used once before and identified previously unrecognised reactions. AU - Coulter, D. M. IS - 6629 KW - Adolescent Adult Aged Captopril/ae [Adverse Effects] Child *Evaluation Studies as Topic/mt [Methods] *Eye Diseases/ci [Chemically Induced] Eye Diseases/pp [Physiopathology] Female Humans Male Middle Aged *Nifedipine/ae [Adverse Effects] *Pain/ci [Chemically Induced] *Product Surveillance, Postmarketing/mt [Methods] Taste Disorders/ci [Chemically Induced] Vision Disorders/ci [Chemically Induced] PY - 1988 SE - Coulter, D M. National Toxicology Group, Medical School, Dunedin, New Zealand. SN - 0267-0623 SP - 1086-8 ST - Eye pain with nifedipine and disturbance of taste with captopril: a mutually controlled study showing a method of postmarketing surveillance T2 - British medical journal (Clinical research ed.) TI - Eye pain with nifedipine and disturbance of taste with captopril: a mutually controlled study showing a method of postmarketing surveillance UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=3132219 VL - 296 ID - 2187 ER - TY - JOUR AU - Courtright, P. AU - Bassett, K. DB - Embase IS - 45 KW - article blindness cataract eye disease female gender glaucoma health care utilization health service human hygiene lagophthalmos leprosy male policy quality of life socioeconomics trachoma LA - English M3 - Article N1 - L36717776 2003-07-01 PY - 2003 SN - 0953-6833 SP - 11-12 ST - Gender and blindness: Eye disease and the use of eye care services T2 - Journal of Community Eye Health TI - Gender and blindness: Eye disease and the use of eye care services UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36717776&from=export VL - 16 ID - 3810 ER - TY - JOUR AB - PURPOSE: This study contrasts the utilization of adjunctive medication associated with travoprost, bimatoprost, or latanoprost, as primary glaucoma therapies., METHODS: Patients in the Medco Health database who initiated prostaglandin analog therapy on travoprost, bimatoprost or latanoprost between January 1, 2002 and July 31, 2002 were selected if they had no prostaglandin analog use in the prior 6 months. Patients were also required to have 12 months of prostaglandin therapy subsequent to the initial prescription. Data were available through July 31, 2003. The t-test and chi-square were used where appropriate to calculate p-values and assess significant differences., RESULTS: A total of 13 171 benefit-eligible subjects were identified of which 8381 (64%), 2637 (20%), and 2153 (16%) patients were treated with latanoprost, bimatoprost, and travoprost, respectively. There were no significant differences in mean age or gender between the three study groups with the exception that latanoprost patients were statistically older than travoprost patients (69.0 vs. 68.0). This was not considered a clinically meaningful difference. Overall, patients using travoprost or bimatoprost had a significantly lower rate of adjunctive medication use compared to patients starting on latanoprost monotherapy (22.5%, 23.2%, and 30.2 %, respectively). Therefore, for every 14 patients treated with latanoprost instead of travoprost or bimatoprost, one additional patient would be expected to need adjunctive therapy with another agent. The difference between travoprost and bimatoprost patients was not significant., CONCLUSIONS: The use of adjunctive medications to control intraocular pressure was significantly higher for latanoprost patients compared to travoprost and bimatoprost patients. This finding should be interpreted in the context that this study was based only on prescription claims data. It is important to simplify ophthalmic medical regimen as it is more cost effective, better for the patient, and minimizes the washout effect from administering two eye medications within 5 min. Decreasing the complexity of the patients' drug regimen may lead to increased adherence to prescribed therapy and a decreased risk of the incidence of blindness. AU - Covert, David AU - Robin, Alan L. IS - 5 KW - Aged *Amides/tu [Therapeutic Use] Bimatoprost *Cloprostenol/aa [Analogs & Derivatives] Cloprostenol/tu [Therapeutic Use] Drug Therapy, Combination Female *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Latanoprost *Lipids/tu [Therapeutic Use] Male *Prostaglandins F, Synthetic/tu [Therapeutic Use] *Prostaglandins, Synthetic/tu [Therapeutic Use] Travoprost PY - 2006 SE - Covert, David. Alcon Research Ltd., Fort Worth, TX, USA. David.Covert@AlconLabs.com SN - 0300-7995 SP - 971-6 ST - Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost T2 - Current medical research and opinion TI - Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16709319 VL - 22 ID - 1664 ER - TY - JOUR AU - Covert, David AU - Robin, Alan L. AU - Novack, Gary D. IS - 10 KW - Adult Aged Aged, 80 and over Arthritis/dt [Drug Therapy] Arthritis/ec [Economics] Cardiovascular Diseases/dt [Drug Therapy] Cardiovascular Diseases/ec [Economics] Comorbidity Depressive Disorder/dt [Drug Therapy] Depressive Disorder/ec [Economics] Drug Costs Drug Prescriptions *Drug Therapy Estrogen Replacement Therapy Female *Glaucoma/dt [Drug Therapy] Glaucoma/ec [Economics] Humans Hyperlipidemias/dt [Drug Therapy] Hyperlipidemias/ec [Economics] Male Middle Aged *Patient Compliance Randomized Controlled Trials as Topic PY - 2005 SN - 1549-4713 0161-6420 SP - 1849 ST - Systemic medications and glaucoma patients T2 - Ophthalmology TI - Systemic medications and glaucoma patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16199278 VL - 112 ID - 1718 ER - TY - JOUR AU - Cowan, E. C. AU - Linton, D. AU - Bryars, J. H. IS - 4 KW - Appointments and Schedules Equipment and Supplies, Hospital Glaucoma/di [Diagnosis] *Glaucoma *Hospital Design and Construction *Hospital Units Medical Records Ophthalmology/is [Instrumentation] Punched-Card Systems Research PY - 1974 SN - 0078-5334 SP - 1055-7 ST - Design and planning of a specialized glaucoma unit T2 - Transactions of the ophthalmological societies of the United Kingdom TI - Design and planning of a specialized glaucoma unit UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=4534137 VL - 94 ID - 2285 ER - TY - JOUR AB - AIMS: To evaluate the current visual status and ophthalmic history of a sample of elderly patients with fractured neck of femur and to study the relationship between visual status and demographic factors., METHODS: A four-centre study of all patients admitted to hospital with fractured neck of femur. The setting was two district (Ayr, Dunfermline) and two teaching (Glasgow, Dundee) hospitals in Scotland. The study examined 537 patients aged 65 years and over admitted with acute fractured neck of femur to hospital., RESULTS: Bilateral visual impairment (binocular visual acuity worse than 6/12) was found in 239 of 518 patients (46%). Of this group, the principal causes for visual deficit were untreated cataract (49%), macular degeneration (21%), uncorrected refractive error (17%), and glaucoma (3%). The visually impaired group were more likely to have symptomatic visual complaints (58 vs 26%), however, were less likely to be under optometric care (71 vs 85%). A higher proportion of the group with visual impairment lived in areas of social deprivation (40 vs 26%)., CONCLUSIONS: Patients with fractured neck of femur represent a frail elderly group that have poorer vision than that documented in any other elderly population. The visual defect was potentially remediable in the majority of cases but this group of individuals are not generally in touch with the ophthalmic services. Social deprivation appears to be associated with this groups' inability to access ophthalmic care. AU - Cox, A. AU - Blaikie, A. AU - MacEwen, C. J. AU - Jones, D. AU - Thompson, K. AU - Holding, D. AU - Sharma, T. AU - Miller, S. AU - Dobson, S. AU - Sanders, R. IS - 6 KW - Aged Aged, 80 and over Causality Chi-Square Distribution Cross-Sectional Studies Female *Femoral Neck Fractures/co [Complications] Femoral Neck Fractures/pp [Physiopathology] *Frail Elderly Health Services Accessibility Humans Male Psychosocial Deprivation Scotland *Vision Disorders/et [Etiology] PY - 2005 SE - Cox, A. Department of Ophthalmology, Ninewells Hospital, Dundee DD1 9SY, UK. alan.cox@tuht.scot.nhs.uk SN - 0950-222X SP - 652-6 ST - Visual impairment in elderly patients with hip fracture: causes and associations T2 - Eye (London, England) TI - Visual impairment in elderly patients with hip fracture: causes and associations UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=15332096 VL - 19 ID - 1751 ER - TY - JOUR AB - Purpose We use modern geodemographic tools to interrogate large volumes of patient data to examine factors that are associated with late presentation of disease and poor adherence to follow-up in glaucoma. Methods Over 500,000 Humphrey visual fields (VFs) recorded in four regionally different glaucoma clinics/services in England (Cheltenham, Huddersfield, London and Portsmouth) in the last decade were retrospectively investigated. Surrogate measures for late presentation of glaucoma and adherence to treatment were estimated by a patient s VF damage (mean deviation [MD] at first visit) and frequency of VF tests respectively. Socioeconomic status and consumer/community segmentation data was defined by patients postcodes (ZIP codes) using the IMD (Index of Multiple Deprivation) and ACORN (A Classification Of Residential Neighbourhoods) geodemographic tools. Results Data from 57090 patients were analysed. There were strong links between geodemographic measures of socioeconomic status and later presentation of disease. There was significant correlation between MD at presentation and IMD score (Spearman s rho = -0.20; p < 0.0001; partial correlation corrected for age); geodemographic maps highlight this relationship (see figure). Patients from the least deprived areas, on average, are predicted to present with significantly less MD damage (MD = -5 dB; 95% confidence interval [CI] = -4 to -6 dB) than patients from the most deprived regions (MD = -9 dB; 95% CI = -8 to -10 dB). Other associations between socioeconomic status and a surrogate measure for adherence to treatment were indicated. Other geodemographic maps reveal relationships between late detection of disease and proximity to primary health care providers (optometrists). Conclusions Big data from glaucoma clinics can be used to reveal associations between socioeconomic status, late presentation of disease and adherence to follow-up care. Interactive geodemographic mapping tools can help illuminate public health requirements for glaucoma. AD - D.P. Crabb, Optometry and Visual Science, City University London, London, United Kingdom AU - Crabb, D. P. AU - Russell, R. A. AU - Ceccon, S. DB - Embase IS - 13 KW - biostatistics confidence interval consumer economics England female follow up glaucoma human major clinical study male workforce neighborhood optometrist patient coding perimetry primary health care public health social status LA - English M3 - Conference Abstract N1 - L616116690 2017-05-16 PY - 2014 SN - 0146-0404 SP - 845 ST - Tell us where you live and we will tell you something about your glaucoma T2 - Investigative Ophthalmology and Visual Science TI - Tell us where you live and we will tell you something about your glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616116690&from=export VL - 55 ID - 2889 ER - TY - JOUR AB - Topical application of prostaglandin (PG) analogues are currently the most commonly used intraocular pressure lowering drugs in glaucoma. They have been available since the mid 1990's, and are efficacious and generally well tolerated, the compliance rates are good due to the once a day application regime. The mode of action of PGs is by increasing the aqueous humour outflow primarily via the uveoscleral route, and also (but to a lesser degree) the conventional trabecular meshwork pathway. Increased outflow is primarily accomplished by remodelling the extracellular matrix components in both of the outflow pathways. PGs are associated with very few systemic side effects. The side effects of concern are all concentrated in the eye. Conjunctival hyperaemia is a common mild but transient complication. Since the development of this class of drug the most worrying and unusual side effect is a change in the pigmentation of the melanin-containing tissues close to the application site, i.e. eyelid skin, eyelashes and iris. As the prostaglandin induced iris darkening (PIID) is irreversible on cessation of the drugs it was of particular concern. We report here the findings from many studies which strongly indicate that there are no histopathological changes occurring in the iris tissue that has developed the darkening side effect. The only definitive change that has been detected in the cases of PIID is a small enlargement of the size of the existing melanin granule population and it has been shown that this change in melanin granule size is sufficient to account for the PIID. These findings point to the conclusion that the darkening developed following PG use is of a purely cosmetic effect with little or no serious consequences. AU - Cracknell, Kathryn P. B. AU - Grierson, Ian DO - https://dx.doi.org/10.1016/j.exer.2008.08.022 IS - 4 KW - *Antihypertensive Agents/ae [Adverse Effects] Antihypertensive Agents/pd [Pharmacology] *Eye Diseases/ci [Chemically Induced] Humans *Hyperpigmentation/ci [Chemically Induced] *Intraocular Pressure/de [Drug Effects] Iris Diseases/ci [Chemically Induced] *Prostaglandins, Synthetic/ae [Adverse Effects] Prostaglandins, Synthetic/pd [Pharmacology] PY - 2009 SE - Cracknell, Kathryn P B. Department of Medicine, Royal Liverpool University Hospital, Liverpool, UK. eye123@liv.ac.uk SN - 1096-0007 0014-4835 SP - 786-91 ST - Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects T2 - Experimental eye research TI - Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18930047 VL - 88 Y2 - 20081002// ID - 1486 ER - TY - JOUR AB - At Issue posed the following questions to a panel of experts: 'How has the availability of latanoprost affected glaucoma management, and why?' AD - Vice Chairman of Clinical Services, John A Moran Eye Center, University of Utah, 50 N Medical Dr, Salt Lake City, UT 84132; alan.crandall@hsc.utah.edu AN - 106337033. Language: English. Entry Date: 20060922. Revision Date: 20150711. Publication Type: Journal Article AU - Crandall, A. S. AU - Lewis, R. A. AU - Rhee, D. J. AU - Shingleton, B. J. AU - Spaeth, G. L. DB - ccm DP - EBSCOhost IS - 16 KW - Glaucoma -- Drug Therapy Latanoprost -- Therapeutic Use Glaucoma -- Complications Intraocular Pressure -- Drug Effects Latanoprost -- Administration and Dosage Latanoprost -- Analogs and Derivatives Latanoprost -- Pharmacodynamics Ophthalmic Solutions Patient Compliance Surgeons Treatment Outcomes N1 - questions and answers. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2006 SN - 8750-3085 SP - 26-28 ST - At issue: latanoprost and glaucoma management T2 - Ocular Surgery News TI - At issue: latanoprost and glaucoma management UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106337033&site=ehost-live&scope=site VL - 24 ID - 4707 ER - TY - JOUR AB - PURPOSE: To assess the long-term safety and efficacy of a single trabecular micro-bypass stent with concomitant cataract surgery versus cataract surgery alone for mild to moderate open-angle glaucoma. SETTING: Twenty-nine investigational sites, United States. DESIGN: Prospective randomized controlled multicenter clinical trial. METHODS: Eyes with mild to moderate glaucoma with an unmedicated intraocular pressure (IOP) of 22 mm Hg or higher and 36 mm Hg or lower were randomly assigned to have cataract surgery with iStent trabecular micro-bypass stent implantation (stent group) or cataract surgery alone (control group). Patients were followed for 24 months postoperatively. RESULTS: The incidence of adverse events was low in both groups through 24 months of follow-up. At 24 months, the proportion of patients with an 10P of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036). Overall, the mean 10P was stable between 12 months and 24 months (17.0 mm Hg +/- 2.8 [SD] and 17.1 +/- 2.9 mm Hg, respectively) in the stent group but increased (17.0 +/- 3.1 mm Hg to 17.8 +/- 3.3 mm Hg, respectively) in the control group. Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant. CONCLUSIONS: Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better 10P control on no medication through 24 months than patients having cataract surgery alone. Both groups had a similar favorable long-term safety profile. Financial Disclosure: Dr. Craven was an investigator in the clinical trial of the iStent. Dr. Katz is a consultant to Glaukos and was the medical monitor for the clinical trial of the iStent. Dr. Katz is a stockholder in Glaukos. Mr. Wells and Ms. Giamporcaro are employees of Glaukos. J Cataract Refract Surg 2012; 38:1339-1345 (C) 2012 ASCRS and ESCRS AN - WOS:000307322700007 AU - Craven, E. R. AU - Katz, L. J. AU - Wells, J. M. AU - Giamporcaro, J. E. AU - iStent Study, Grp DA - AUG DO - 10.1016/j.jcrs.2012.03.025 IS - 8 PY - 2012 SN - 0886-3350 SP - 1339-1345 ST - Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-up T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-up VL - 38 ID - 6228 ER - TY - JOUR AB - Purpose: To analyze characteristics and indications for corneal transplantation in patients undergoing penetrating, lamellar, and endothelial keratoplasty in Auckland, New Zealand (NZ). Methods: Corneal transplantation data from the NZ National Eye Bank and hospital records of corneal transplant recipients in the Auckland region from January 1, 2000, to December 31, 2009, were collated. Patient demographics, preoperative diagnosis, indication, ocular and medical history, visual acuity, deprivation index, and access to transplantation surgery were analyzed. Results: A total of 941 corneal transplants involving 770 patients were included for analysis. Mean age was 46 years. Age and ethnicity varied according to the transplant indication. A male preponderance and disproportionally high rates of Māori and Pacific ethnicity with a mean age of 30 years were observed in transplants for keratoconus. A total of 67.2% of corneal transplants were completed in the public health system and were associated with higher levels of deprivation than those completed in private facilities. Preoperative visual acuity varied according to the transplant type and indication. The most common clinical indication for corneal transplantation was keratoconus (41.3%), followed by repeat transplantation (21.0%). There was no significant change in the relative proportion of transplant indications in any year over the duration of this study (P = 0.41). A contralateral corneal transplant was present in 24.4% and glaucoma in 12.8% of penetrating keratoplasty recipients. Conclusions: Keratoconus is the leading indication for corneal transplantation in Auckland, NZ, and involves a disproportionately high rate of Māori and Pacific transplant recipients with a male preponderance and comparatively low mean age at the time of surgery. AD - C.N.J. McGhee, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand AU - Crawford, A. Z. AU - McKelvie, J. AU - Craig, J. P. AU - McGhee, C. N. J. AU - Patel, D. V. DB - Embase Medline DO - 10.1097/ICO.0000000000001159 IS - 5 KW - adolescent adult aged article child cornea transplantation deep lamellar endothelial keratoplasty endothelial keratoplasty ethnicity European female glaucoma graft recipient health care access human Indian keratoconus lens implant major clinical study male Maori (people) New Zealand Pacific Islander penetrating keratoplasty preoperative evaluation priority journal public health service reoperation social isolation treatment indication visual acuity LA - English M3 - Article N1 - L614664702 2017-03-08 2017-05-01 PY - 2017 SN - 1536-4798 0277-3740 SP - 546-552 ST - Corneal transplantation in Auckland, New Zealand, 1999-2009: Indications, patient characteristics, ethnicity, social deprivation, and access to services T2 - Cornea TI - Corneal transplantation in Auckland, New Zealand, 1999-2009: Indications, patient characteristics, ethnicity, social deprivation, and access to services UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614664702&from=export http://dx.doi.org/10.1097/ICO.0000000000001159 VL - 36 ID - 2678 ER - TY - JOUR AU - Crawford, A. Z. AU - Meyer, J. J. AU - Patel, D. V. AU - Ormonde, S. E. AU - McGhee, C. N. DB - Embase Medline DO - 10.1111/ceo.12635 IS - 2 KW - ophthalmic suture age distribution controlled study cornea dystrophy cornea injury cornea transplantation cornea ulcer device safety endophthalmitis graft failure health care access human keratoconus keratopathy keratoplasty letter major clinical study medical device complication postoperative complication private hospital public hospital sex difference social status surgical wound suture abscess suture erosion suture loosening suture removal treatment duration treatment indication virus keratitis wound dehiscence wound leak LA - English M3 - Letter N1 - L607290086 2015-12-22 2016-04-22 PY - 2016 SN - 1442-9071 1442-6404 SP - 142-143 ST - Complications related to sutures following penetrating and deep anterior lamellar keratoplasty T2 - Clinical and Experimental Ophthalmology TI - Complications related to sutures following penetrating and deep anterior lamellar keratoplasty UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607290086&from=export http://dx.doi.org/10.1111/ceo.12635 VL - 44 ID - 2753 ER - TY - JOUR AD - J.M. Crewe, Curtin Health Innovation Research Institute, Curtin University, Australia AU - Crewe, J. M. AU - Morgan, W. H. AU - Morlet, N. AU - Crowley, M. AU - Semmens, J. B. DB - Embase Medline DO - 10.1111/j.1442-9071.2010.02310.x IS - 7 KW - adolescent adult aged analgesia Australia blindness braille child diabetic retinopathy female glaucoma health care cost health care utilization health service health survey human letter major clinical study male occupational therapy optic nerve disease patient transport pension preschool child retina dystrophy age related macular degeneration school child sporting event trichiasis vision visual acuity visual aid LA - English M3 - Letter N1 - L359827151 2010-11-02 2010-11-08 PY - 2010 SN - 1442-6404 1442-9071 SP - 736-737 ST - Utilization of services by legally blind patients in Western Australia T2 - Clinical and Experimental Ophthalmology TI - Utilization of services by legally blind patients in Western Australia UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359827151&from=export http://dx.doi.org/10.1111/j.1442-9071.2010.02310.x VL - 38 ID - 3228 ER - TY - JOUR AB - Purpose To determine whether blindness in older people is associated with increased health service use and mortality. Design Retrospective matched cohort study from July 1, 1999, through June 30, 2010. Participants A blind cohort 65 years of age and older from a volunteer blind register and a cohort of age- and gender-matched controls selected randomly from the Western Australian electoral roll. Methods Person-level linked hospital, emergency department (ED), mental health, and death records for the blind and control cohorts were used. Generalized estimating equations assuming a negative binomial distribution were used to estimate relative rates of hospital admissions, lengths of stay, and mortality after adjusting for sociodemographic variables and comorbidity. Emergency department and mental health service visits also were quantified. Main Outcome Measures Relative rates of hospital admissions, lengths of stay, and mortality, as well as crude proportions of ED and mental health service visits. Results The blind cohort comprised 1726 individuals alongside 1726 matched controls; 39% were men, and the mean age was 83 years. Combined, the cohorts accumulated a total of 34 130 hospital admissions amounting to 201 867 bed-days. After adjusting for the principal reason for hospital admission and comorbidity, the blind cohort was admitted to the hospital 11% (95% confidence interval [CI], 6%-17%) more often than the control cohort. The blind cohort also stayed in the hospital longer than the controls, but this effect varied by age. Blind participants 65 to 69 years of age spent 88% more days (95% CI, 27%-178%) in the hospital compared with age-matched controls, whereas there was no difference in length of stay between the cohorts by 80 years of age (rate ratio, 1.10; 95% CI, 0.97-1.25). A larger proportion of the blind cohort visited a hospital ED and accessed mental health services compared with the control cohort. Conclusions Health service use is increased for the elderly blind compared with age-matched controls after accounting for comorbidity. The elderly blind have more hospital admissions, ED visits, and mental health-related visits. The younger elderly blind stay longer in hospital. However, there was no evidence of worse mortality outcomes after adjusting for comorbidity. AD - J.M. Crewe, Centre for Population Health Research, Faculty of Health Science, Curtin University, G. P. O. Box U1987, Perth, WA, Australia AU - Crewe, J. M. AU - Spilsbury, K. AU - Morlet, N. AU - Morgan, W. H. AU - Mukhtar, A. AU - Clark, A. AU - Semmens, J. B. DB - Embase Medline DO - 10.1016/j.ophtha.2015.07.001 IS - 11 KW - age related macular degeneration aged article binomial distribution blindness cataract cohort analysis comorbidity controlled study cornea disease diabetic retinopathy emergency ward female geriatric patient glaucoma groups by age health care access health care utilization hospital admission human length of stay lens disease major clinical study male mental health service mortality optic nerve disease priority journal retina dystrophy retina vein occlusion retrospective study social status LA - English M3 - Article N1 - L606077595 2015-09-24 2016-08-19 PY - 2015 SN - 1549-4713 0161-6420 SP - 2344-2350 ST - Health Service Use and Mortality of the Elderly Blind T2 - Ophthalmology TI - Health Service Use and Mortality of the Elderly Blind UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606077595&from=export http://dx.doi.org/10.1016/j.ophtha.2015.07.001 VL - 122 ID - 2782 ER - TY - JOUR AD - Dept. Ophthalmic Surg., King's Coll. Hosp., London AU - Crick, R. P. C1 - daranide diamox oratrol DB - Embase IS - 2 KW - acetazolamide epinephrine carbachol demecarium diclofenamide ecothiopate iodide glycerol guanethidine mannitol methylcellulose neostigmine physostigmine pilocarpine polyvinyl alcohol drug therapy glaucoma intraocular pressure patient compliance therapy visual system daranide diamox oratrol LA - English N1 - L10119166 1980-07-24 PY - 1978 SN - 0140-7317 SP - 48-50 ST - The treatment of glaucoma T2 - Journal of Pharmacotherapy TI - The treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L10119166&from=export VL - 1 ID - 4108 ER - TY - JOUR AB - Aim: To evaluate the recently introduced Travatan Dosing Aid (TDA) for its accuracy in recording and dispensing eyedrops. Methods: The number of eyedrops dispensed with each lever depression and agreement of total number of drops dispensed with that recorded by the device was evaluated in a controlled setting. Results: The TDA correctly recorded a drop being dispensed 100% of the time with full TDA lever depression for <3 s. Under these conditions, agreement between numbers of drops dispensed and recorded was 99%. However, failure to fully depress the lever or prolonged lever depression for >4 s resulted in unreliable TDA recording. Conclusion: Eyedrops were reliably recorded by the TDA after each full lever depression. However, patients need to be instructed about optimal technique so that evaluation of compliance is not confounded by mechanical factors. AD - R.J. Noecker, University of Pittsburgh, 203 Lothrop Street, Pittsburgh, PA 15213, United States AU - Cronin, T. H. AU - Kahook, M. Y. AU - Lathrop, K. L. AU - Noecker, R. J. DB - Embase Medline DO - 10.1136/bjo.2006.103093 IS - 4 KW - antiglaucoma agent eye drops article devices drug delivery system drug dose regimen glaucoma human patient compliance priority journal travatan LA - English M3 - Article N1 - L46623684 2007-04-01 PY - 2007 SN - 0007-1161 SP - 497-499 ST - Accuracy and performance of a commercially available Dosing Aid T2 - British Journal of Ophthalmology TI - Accuracy and performance of a commercially available Dosing Aid UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46623684&from=export http://dx.doi.org/10.1136/bjo.2006.103093 VL - 91 ID - 3536 ER - TY - JOUR AB - Major problems in pediatric cataract patients include noncompliance with contact lenses resulting in amblyopia. Advances in intraocular cataract surgery have provided a better environment to perform intraocular lens (IOL) implantation in children. We prospectively analyzed the results of 34 consecutive pediatric patients who underwent cataract removal and insertion of an IOL. Operative technique performed was posterior scleral beveled or frown incision and IOL endocapsular fixation. Subgroups included 10 eyes with traumatic cataract, and 24 eyes with developmental cataracts. Six patients had bilateral IOLs. Data presented in each subgroup included initial and final visual acuity, age, sex, type of cataract, A and B scan biometry, early and late postoperative complications, time of YAG capsulotomy, postoperative refractive correction, and state of binocular vision. Preoperative visual acuity ranged from 20/70 to light perception. The success rate for postoperative visual acuity of 20/40 or better occurred in 29 of 34 eyes, or 85.3%. In the traumatic cataracts, 8 of 10 eyes (80%) obtained 20/40 vision or better. In developmental cataracts, 21 of 24 eyes (88%) achieved visual acuity of 20/40 or better. Amblyopia (three patients) or macular scar (two patients) accounted for reduced visual acuity in the five eyes with vision less than 20/40. Early complications included posterior synechiae and lens deposits. The primary late complication was opacification of the posterior capsule in 18 of 34 eyes. The average time for YAG capsulotomy post-cataract removal was 17 months. None of the 28 patients (34 eyes) developed glaucoma, IOL dislocation, or other significant postoperative problems related to IOL insertion.(ABSTRACT TRUNCATED AT 250 WORDS) AU - Crouch, E. R., Jr. AU - Pressman, S. H. AU - Crouch, E. R. IS - 4 KW - Adolescent Cataract/cn [Congenital] Cataract/et [Etiology] *Cataract Extraction Child Child, Preschool Eye Injuries/co [Complications] Eye Injuries/su [Surgery] Female Humans Lens, Crystalline/in [Injuries] *Lenses, Intraocular Longitudinal Studies Male Postoperative Complications Prognosis Prospective Studies Refraction, Ocular Sclera/su [Surgery] Surgical Flaps Vision, Binocular Visual Acuity PY - 1995 SE - Crouch, E R Jr. Department of Ophthalmology, Eastern Virginia Medical School, Norfolk 23502, USA. SN - 0191-3913 SP - 210-8 ST - Posterior chamber intraocular lenses: long-term results in pediatric cataract patients T2 - Journal of pediatric ophthalmology and strabismus TI - Posterior chamber intraocular lenses: long-term results in pediatric cataract patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7494155 VL - 32 ID - 2068 ER - TY - JOUR AB - OBJECTIVE: This study was conducted to provide the financial underpinnings necessary for effective planning for the provision of eye health services in Canada. Canada is facing an aging demographic and all the major eye diseases are diseases associated with aging. It is essential that we have information based on the best available data to support national and provincial vision health plans., DESIGN: The design associated with the prevalence-based approach used in this study was outlined previously in detail in The Cost of Vision Loss in Canada: Methodology., METHODS: The methods associated with the prevalence-based approach used in this study were previously outlined in detail in The Cost of Vision Loss in Canada: Methodology., RESULTS: The financial cost of VL in Canada in 2007 was estimated to be $15.8 billion per annum: $8.6 billion (54.6%) represents direct health system expenditure; $4.4 billion (28.0%) was productivity lost due to lower employment, higher absenteeism, and premature death of Canadians with VL; $1.8 billion (11.1%) was the dead weight losses (DWL) from transfers including welfare payments and taxation forgone; $0.7 billion (4.4%) was the value of the care for people with VL; $305 million (1.9%) was other indirect costs such as aids and home modifications and the bring forward of funeral costs. Additionally, the value of the lost well-being (disability and premature death) was estimated at a further $11.7 billion. In per capita terms, this amounts to a financial cost of $19370 per person with VL per annum. Including the value of lost well-being, the cost is $33704 per person per annum., CONCLUSIONS: There is a growing awareness in Canada and around the world of the impact of VL on health costs and on the economy in general. This awareness is supported by the growing number of independent studies on the cost of vision loss both nationally and globally. Because most of these studies are limited by the minimal amount of available data, the overall cost of vision loss is likely underestimated. Nevertheless, this study reports the cost of vision loss in Canada as being greater than previously reported, making the problem even more urgent to address. A comprehensive national vision health plan, that is a coordinated federal, provincial and territorial initiative dealing with all aspects of vision loss prevention, sight restoration, and vision rehabilitation is called for. Copyright © 2011 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. AU - Cruess, Alan F. AU - Gordon, Keith D. AU - Bellan, Lorne AU - Mitchell, Scott AU - Pezzullo, M. Lynne DO - https://dx.doi.org/10.1016/j.jcjo.2011.06.006 IS - 4 KW - *Blindness/ec [Economics] Blindness/ep [Epidemiology] Canada/ep [Epidemiology] Cataract/ep [Epidemiology] Cost of Illness Delivery of Health Care Diabetic Retinopathy/ep [Epidemiology] Glaucoma/ep [Epidemiology] *Health Care Costs *Health Expenditures/sn [Statistics & Numerical Data] Health Resources/sn [Statistics & Numerical Data] Health Services Research Humans Macular Degeneration/ep [Epidemiology] Prevalence Quality-Adjusted Life Years Refractive Errors/ep [Epidemiology] *Vision, Low/ec [Economics] Vision, Low/ep [Epidemiology] PY - 2011 SE - Cruess, Alan F. Dalhousie University, Halifax Nova Scotia, Canada. SN - 1715-3360 0008-4182 SP - 315-8 ST - The cost of vision loss in Canada. 2. Results T2 - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie TI - The cost of vision loss in Canada. 2. Results UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21816249 VL - 46 Y2 - 20110707// ID - 1257 ER - TY - JOUR AB - BACKGROUND: Annual retinal screening of patients with diabetes is the standard clinical practice to prevent visual impairment and blindness from diabetic retinopathy. Telemedicine-based diabetic retinopathy screening (DRS) in primary care settings can effectively detect sight-threatening retinopathy and significantly increase compliance with annual retinal exams. EyePACS is a license-free Web-based DRS system designed to simplify the process of image capture, transmission, and review. The system provides a flexible platform for collaboration among clinicians about diabetic retinopathy., METHODS: Primary clinic personnel (i.e., nursing, technical, or administrative staff) are trained and certified by the EyePACS program to acquire retinal images from standard digital retinal cameras. Relevant clinical data and eight high-resolution images per patient (two external and six retinal images) are encrypted and transmitted to a secure Internet server, using a standard computer and Web browser. Images are then interpreted by certified EyePACS reviewers or local eye care providers who are certified through the EyePACS Retinopathy Grading System. Reports indicating retinopathy level and referral recommendations are transmitted back to primary care providers through the EyePACS Web site or through interfaces between EyePACS and Health Level 7-compliant electronic medical records or chronic disease registries., RESULTS: The pilot phase of the EyePACS DRS program in California (2005-2006) recorded 3562 encounters. Since 2006, EyePACS has been expanded to over 120 primary care sites throughout California and elsewhere recording over 34,000 DRSs. The overall rate of referral is 8.21% for sight-threatening retinopathy and 7.83% for other conditions (e.g., cataract and glaucoma)., CONCLUSION: The use of license-free Web-based software, standard interfaces, and flexible protocols has allowed primary care providers to adopt retinopathy screening with minimal effort and resources. Copyright 2009 Diabetes Technology Society. AU - Cuadros, Jorge AU - Bresnick, George IS - 3 KW - *Diabetic Retinopathy/di [Diagnosis] Diabetic Retinopathy/pa [Pathology] Electronic Health Records Humans Internet *Mass Screening/is [Instrumentation] *Mass Screening/mt [Methods] Referral and Consultation Remote Consultation Retrospective Studies Severity of Illness Index Software *Telemedicine/is [Instrumentation] *Telemedicine/mt [Methods] PY - 2009 SE - Cuadros, Jorge. University of California, Berkeley, Meredith Morgan Optometric Eye Center, Berkeley, CA 94720, USA. jcuadros@berkeley.edu SN - 1932-2968 SP - 509-16 ST - EyePACS: an adaptable telemedicine system for diabetic retinopathy screening T2 - Journal of diabetes science and technology TI - EyePACS: an adaptable telemedicine system for diabetic retinopathy screening UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=20144289 VL - 3 Y2 - 20090501// ID - 1401 ER - TY - JOUR AB - Diabetes is the main cause of blindness among working age adults, although treatment is highly effective in preventing vision loss. Eye examinations are recommended on a yearly basis for most patients for timely detection of retinal disease. Telemedicine-based diabetic retinopathy screening (TMDRS) programs have been developed to identify patients with sight-threatening diabetic eye disease because patients are often noncompliant with recommended live eye examinations. This article reviews the cost-effectiveness of the various forms of TMDRS. A review of relevant articles, mostly published since 2008, shows that societal benefits generally outweigh the costs of TMDRS. However, advances in technology to improve efficacy, lower costs, and broaden screening to other sight-threatening conditions, such as glaucoma and refractive error, are necessary to improve the sustainability of TMDRS within health care organizations. Patient satisfaction with these telemedicine programs is generally high. New models of shared care with primary care providers and staff are emerging to improve patient engagement and follow-up care when individuals are found to have sight-threatening eye disease. TMDRS programs are growing and provide valuable clinical benefit. The cost-utility is currently well proven in locations with limited access to regular eye care services, such as rural areas, poor communities, and prison systems; however, improvements over time are necessary for these programs to be cost-effective in mainstream medical settings in the future. AN - WOS:000219682500012 AU - Cuadros, J. A. DO - 10.2147/SHTT.S64448 PY - 2015 SN - 2253-1564 SP - 119-127 ST - Telemedicine-based diabetic retinopathy screening programs: an evaluation of utility and cost-effectiveness T2 - SMART HOMECARE TECHNOLOGY AND TELEHEALTH TI - Telemedicine-based diabetic retinopathy screening programs: an evaluation of utility and cost-effectiveness VL - 3 ID - 6312 ER - TY - JOUR AU - Cui, Qi N. AU - Singh, Kuldev AU - Spaeth, George L. DO - https://dx.doi.org/10.1016/j.ajo.2016.09.020 KW - *Filtering Surgery/st [Standards] *Glaucoma/su [Surgery] Humans *Minimally Invasive Surgical Procedures/st [Standards] *Patient Outcome Assessment *Patient Preference Sickness Impact Profile PY - 2016 SE - Cui, Qi N. Wills Eye Hospital, Philadelphia, Pennsylvania. Singh, Kuldev. Stanford University, Palo Alto, California. Spaeth, George L. Wills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: gspaeth@willseye.org. SN - 1879-1891 0002-9394 SP - xii-xiv ST - From the Patient's Point of View, How Should Minimally Invasive Glaucoma Surgeries Be Evaluated? T2 - American journal of ophthalmology TI - From the Patient's Point of View, How Should Minimally Invasive Glaucoma Surgeries Be Evaluated? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=28327295 VL - 172 Y2 - 20161027// ID - 647 ER - TY - JOUR AB - BACKGROUND: Keratitis due to by filamentous fungi are not easy to diagnose thus causing a delay in correct therapy. There are many descriptions of keratitis due to Candida, Fusarium and Aspergillus genera. Subramaniula genus has only recently been reported to cause human infections and there are few descriptions of eye infections due to this filamentous fungus. Diagnosis of fungal keratitis is usually based on microscopic and cultural techniques of samples obtained by corneal swabbing or scraping. Considering the amount of time required to obtain culture results it is wise to use other diagnostic methods, such as molecular analyses. Therapeutic options against these fungi are limited by low tissue penetration in the eye due to ocular barriers. We describe the first case of S. asteroides human keratitis treated with isavuconazole., CASE PRESENTATION: We describe a rare case of fungal keratitis unresponsive to antimicrobial treatment in a 65-year-old male patient without a history of diabetes or immunological diseases. He reported that the onset of symptoms occurred during a long holiday in Cape Verde Island. Initial treatment with topical antibiotics associated to steroids were ineffective, allowing a slow clinical progression of disease to corneal perforation. On admission in our Hospital, slit-lamp examination of the left eye showed conjunctival congestion and hyperemia, a large inferior corneal ulceration with brown pigment, corneal edema, about 3 mm of hypopyon and irido-lenticular synechiae. The slow clinical progression of the disease to corneal perforation and the aspect of the ulcer were consistent with a mycotic etiology. Molecular methods used on fungal colonies isolated by Sabouraud's dextrose agar cultures allowed the identification of Subramaniula asteroids from corneal scraping. Antimicrobial test showed a good susceptibility of this filamentous fungus to voriconazole and isavuconazole. Moreover, this fungal keratitis was successfully treated with isavuconazole, without side effects, observing a progressive clinical improvement., CONCLUSIONS: Molecular methods may be useful for the identification of filamentous fungal keratitis on scraping samples thus shortening the time of diagnosis. Systemic therapy by isavuconazole could be useful to treat the filamentous fungal keratitis, reducing the possible adverse effects due to the use of voriconazole by systemic administration. AU - Cultrera, Rosario AU - Torelli, Riccardo AU - Sarnicola, Caterina AU - Segala, Daniela AU - Mengoli, Andrea AU - Chiaretto, Giuseppina AU - Perri, Paolo AU - Sanguinetti, Maurizio DO - https://dx.doi.org/10.1186/s12879-021-05768-7 IS - 1 KW - Aged Antifungal Agents/ad [Administration & Dosage] Antifungal Agents/tu [Therapeutic Use] *Corneal Ulcer/di [Diagnosis] Corneal Ulcer/dt [Drug Therapy] Corneal Ulcer/mi [Microbiology] Diagnosis, Differential *Eye Infections, Fungal/di [Diagnosis] Eye Infections, Fungal/dt [Drug Therapy] Eye Infections, Fungal/mi [Microbiology] Humans Male Nitriles/ad [Administration & Dosage] Nitriles/tu [Therapeutic Use] Ophthalmic Solutions Pyridines/ad [Administration & Dosage] Pyridines/tu [Therapeutic Use] *Sordariales/ip [Isolation & Purification] Triazoles/ad [Administration & Dosage] Triazoles/tu [Therapeutic Use] PY - 2021 SE - Cultrera, Rosario. Department of Morphology, Surgery and Experimental Medicine, Infectious Diseases Unit, University 'S. Anna' Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. ctr@unife.it. Torelli, Riccardo. Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy. Sarnicola, Caterina. Department of Biomedical and Surgical Sciences, Ophthalmology Unit, 'S. Anna' University Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. Segala, Daniela. Department of Morphology, Surgery and Experimental Medicine, Infectious Diseases Unit, University 'S. Anna' Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. Mengoli, Andrea. Department of Biomedical and Surgical Sciences, Ophthalmology Unit, 'S. Anna' University Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. Chiaretto, Giuseppina. Clinical Microbiology, 'S. Anna' University Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. Perri, Paolo. Department of Biomedical and Surgical Sciences, Ophthalmology Unit, 'S. Anna' University Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. Sanguinetti, Maurizio. Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy. Sanguinetti, Maurizio. Dipartimento di Scienze Biotecnologiche di base, Cliniche Intensivologiche e Perioperatorie, Universita Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy. SN - 1471-2334 SP - 82 ST - Identification and molecular characterization of Subramaniula asteroides causing human fungal keratitis: a case report T2 - BMC infectious diseases TI - Identification and molecular characterization of Subramaniula asteroides causing human fungal keratitis: a case report UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33461505 VL - 21 Y2 - 20210118// ID - 242 ER - TY - JOUR AD - J. Cumming, Health Services Research Centre, School of Government, P O Box 600, Wellington 6035, New Zealand AU - Cumming, J. AU - Mays, N. AU - Daubé, J. C1 - herceptin DB - Embase Medline DO - 10.1136/bmj.c2441 IS - 7758 KW - atypical antipsychotic agent beta interferon cilazapril cyclosporine fluindostatin fluoxetine hydroxymethylglutaryl coenzyme A reductase inhibitor influenza vaccine morphine paracetamol quinapril simvastatin tacrolimus trastuzumab article breast cancer cost effectiveness analysis drug cost drug industry epilepsy glaucoma health care access health care cost health care management health care system health service human multiple sclerosis New Zealand priority journal schizophrenia herceptin LA - English M3 - Article N1 - L359026422 2010-06-28 2019-08-14 PY - 2010 SN - 1756-1833 SP - 1224-1227 ST - How New Zealand has contained expenditure on drugs T2 - BMJ (Online) TI - How New Zealand has contained expenditure on drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359026422&from=export http://dx.doi.org/10.1136/bmj.c2441 VL - 340 ID - 3250 ER - TY - JOUR AD - M.E. Cupples, Department of General Practice, Queen's University, Belfast BT9 7HR, United Kingdom AU - Cupples, M. E. AU - Hart, P. M. AU - Johnston, A. AU - Jackson, A. J. DB - Embase Medline DO - 10.1136/bmj.e542 IS - 7842 KW - ADL disability awareness congenital glaucoma family interaction friendship health care access health care delivery health care facilities and services health care need health care personnel health care planning help seeking behavior human information dissemination medical device nurse patient relationship patient attitude patient guidance priority journal age related macular degeneration review verbal communication visual acuity visual hallucination visual impairment LA - English M3 - Review N1 - L364202547 2012-02-14 2012-02-22 PY - 2012 SN - 0959-8146 1756-1833 ST - Improving healthcare access for people with visual impairment and blindness T2 - BMJ (Online) TI - Improving healthcare access for people with visual impairment and blindness UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364202547&from=export http://dx.doi.org/10.1136/bmj.e542 http://www.bmj.com/highwire/filestream/563296/field_highwire_article_pdf/0.pdf VL - 344 ID - 3110 ER - TY - JOUR AB - Ophthalmic nurses at Sydney Hospital Sydney Eye Hospital aimed to assess and evaluate the knowledge and resulting behaviours of patients using eye drop therapy for glaucoma and the effect that using interpreters or English speaking family members had on patients' understanding and compliance. Non-compliance is known to lead to progression of the disease with resulting loss of vision. The study showed that patients undergoing long-term therapy for glaucoma have areas of non-compliance that may not be apparent to staff who see them in a clinic setting. It also showed that ineffectual use or missed doses of eye drops occur in both male and female groups, young and older groups and those from non-English and English speaking backgrounds. This is in spite of the same patients' assurances that they have received clear instructions. It has been shown that the use of interpreters or English speaking family members has not affected compliance. This study has shown that even patients who have been on therapy for over 12 months are likely to benefit from continuing education and reinforcement of good technique. Poor understanding of glaucoma in the over 65 age group was not associated with a higher rate of non-compliance. AU - Curtis, Cheryl AU - Lo, Eva AU - Ooi, Linda AU - Bennett, Lydia AU - Long, Janet IS - 2 KW - Adolescent Adult Aged Aged, 80 and over *Ambulatory Care *Cultural Diversity Female *Glaucoma/dt [Drug Therapy] Humans Male Middle Aged New South Wales *Ophthalmic Solutions *Patient Compliance Surveys and Questionnaires Young Adult PY - 2009 SE - Curtis, Cheryl. Outpatients Department, Sydney Eye Hospital, Sydney NSW, Australia. SN - 1037-6178 SP - 121-8 ST - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting T2 - Contemporary nurse TI - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19379114 VL - 31 ID - 1460 ER - TY - JOUR AB - INTRODUCTION: Administrative claims data have a limited ability to identify persons with high compliance to oral bisphosphonates. We tested whether adding information on compliance with other drugs used to treat chronic, asymptomatic conditions would improve the predictive ability of administrative data to identify adherent individuals., METHODS: Using data from a large, US healthcare organization, we identified new bisphosphonate users and their 1-year compliance to oral bisphosphonates, quantified by the Medication Possession Ratio (MPR). Multivariable logistic regression models evaluated the relationship between high bisphosphonate compliance (MPR >or=80%) and patient demographics, comorbidities, and health services utilization. To these logistic regression models, we evaluated the incremental change in the area under the receiver operator curve (AUC) after adding information regarding compliance with other drug classes. These included antihyperlipidemics (statins), antihypertensives, antidepressants, oral diabetes agents, and glaucoma medications. Results from the logistic regression models were evaluated in parallel using recursive partitioning trees with 10-fold cross-validation., RESULTS: Among 101,038 new bisphosphonate users, administrative data identified numerous nonmedication factors (eg, age, gender, use of preventive services) significantly associated with high bisphosphonate compliance at 1 year. However, all these factors in aggregate had low discriminant ability to identify persons highly adherent with bisphosphonates (AUC = 0.62). For persons who were new users of >or=1 of the other asymptomatic condition drugs, MPR data on the other drugs substantially improved the prediction of high bisphosphonate compliance. The impact on prediction was largest for concomitant statin users (AUC = 0.70)., CONCLUSIONS: Information on compliance with drugs used to treat chronic asymptomatic conditions improves the prediction of compliance with oral bisphosphonates. This information may help identify persons who should receive targeted interventions to promote compliance to osteoporosis medications. AU - Curtis, Jeffrey R. AU - Xi, Juan AU - Westfall, Andrew O. AU - Cheng, Hong AU - Lyles, Kenneth AU - Saag, Kenneth G. AU - Delzell, Elizabeth DO - https://dx.doi.org/10.1097/MLR.0b013e31818afa1c IS - 3 KW - Administration, Oral Age Factors Aged Antidepressive Agents/tu [Therapeutic Use] Antihypertensive Agents/tu [Therapeutic Use] Bone Density Conservation Agents/ad [Administration & Dosage] *Bone Density Conservation Agents/tu [Therapeutic Use] *Chronic Disease/dt [Drug Therapy] Comorbidity Diphosphonates/ad [Administration & Dosage] *Diphosphonates/tu [Therapeutic Use] Female Humans Hypoglycemic Agents/tu [Therapeutic Use] Hypolipidemic Agents/tu [Therapeutic Use] Insurance Claim Review Insurance, Pharmaceutical Services Logistic Models Male *Medication Adherence/px [Psychology] Medication Adherence/sn [Statistics & Numerical Data] Middle Aged *Osteoporosis/dt [Drug Therapy] *Preventive Health Services/sn [Statistics & Numerical Data] Sex Factors United States PY - 2009 SE - Curtis, Jeffrey R. Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. jcurtis@uab.edu SN - 1537-1948 0025-7079 SP - 334-41 ST - Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis T2 - Medical care TI - Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19194337 VL - 47 ID - 1477 ER - TY - JOUR AB - PURPOSE: To evaluate and compare the accuracy of self-measurement of intraocular pressure using Icare Home rebound tonometer with Goldmann applanation tonometer and assess acceptability of self-tonometry in patients with glaucoma and ocular hypertension., METHODS: In the study, 117 subjects were trained to use Icare Home for self-measurement. Icare Home tonometer readings were compared with Goldmann applanation tonometer, including one eye per patient. Agreement between the two methods of measurement was evaluated by Bland and Altmann analysis. Questionnaire was used to evaluate patients' perception of self-tonometry., RESULTS: One hundred and three out of 117 patients (88%) were able to measure their own intraocular pressure and 96 (82%) fulfilled the requirements for certification. The mean (SD) difference Goldmann applanation tonometer minus Icare Home was 1.2 (2.4) mmHg (95% limits of agreement, -3.4 to 5.9 mmHg). The magnitude of bias between the two methods depended on central corneal thickness, with greater bias at central corneal thickness <500 microm. In 65 out of 96 subjects (67.7%), Icare Home results were within 2 mmHg of the Goldmann applanation tonometer. Seventy-three out of 93 (78.5%) felt that self-tonometry was easy to use and 75 patients (80.6%) responded that they would use the device at home., CONCLUSION: Icare Home tonometry tends to slightly underestimate intraocular pressure compared to Goldmann applanation tonometer. Most patients were able to perform self-tonometry and found it acceptable for home use. Measurements using rebound self-tonometry could improve the quality of intraocular pressure data and optimize treatment regimen. AU - Cvenkel, Barbara AU - Velkovska, Makedonka Atanasovska AU - Jordanova, Vesna Dimovska DO - https://dx.doi.org/10.1177/1120672118823124 IS - 2 KW - Adolescent Adult Aged Aged, 80 and over Feasibility Studies Female *Glaucoma, Open-Angle/pp [Physiopathology] Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged Ocular Hypertension/pp [Physiopathology] Patient Acceptance of Health Care Prospective Studies Reproducibility of Results *Self Care/mt [Methods] Surveys and Questionnaires *Tonometry, Ocular/mt [Methods] Young Adult PY - 2020 SE - Cvenkel, Barbara. Department of Ophthalmology, University Medical Centre Ljubljana, Ljubljana, Slovenia. Cvenkel, Barbara. University of Ljubljana, Ljubljana, Slovenia. Velkovska, Makedonka Atanasovska. Department of Ophthalmology, University Medical Centre Ljubljana, Ljubljana, Slovenia. Jordanova, Vesna Dimovska. University Eye Clinic, Skopje, Republic of Macedonia. Jordanova, Vesna Dimovska. Saints Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia. SN - 1724-6016 1120-6721 SP - 258-263 ST - Self-measurement with Icare HOME tonometer, patients' feasibility and acceptability T2 - European journal of ophthalmology TI - Self-measurement with Icare HOME tonometer, patients' feasibility and acceptability UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med17&NEWS=N&AN=30632407 VL - 30 Y2 - 20190111// ID - 289 ER - TY - JOUR AB - AIM OF THE STUDY: The purpose of this study was to estimate and evaluate costs of glaucoma therapy in Poland in 1998-2000 years., MATERIAL AND METHODS: 315 patients (591 eyes) including 364 POAG eyes and 227 PACG eyes were evaluated. Progression of the disease was measured in two modes: by changes in the optical nerve disc (c/d) and by IOP level. Duration of the study was 12 months. Total costs (e.g. number of visits, amount of medications used, surgical and laser procedures performed) were calculated on 100 eyes/12 months., RESULTS: Pharmacological therapy constitutes 40-50% of the total costs in both glaucoma types. Timolol was the mostly prescribed drug in POAG, while pilocarpine led in PACG group. Dorzolamide was on the third place, but it generated the biggest part of total costs. Patients with advanced forms of the disease more frequently saw doctor on visits (average 6 visits per year); patients with elevated IOP (> 21 mm Hg) underwent surgical procedures more commonly than these with optical nerve disc changes (c/d > 0.6). The total costs of the therapy of non-advanced cases amounted 70.243 PLN on the average, while in advanced cases it reached the average of 155.230 PLN., CONCLUSION: 1. The total cost of glaucoma therapy depends on progression of the disease. 2. The most cost-generating part is the pharmacological therapy of glaucoma. AU - Czechowicz-Janicka, K. AU - Orlewska, E. AU - Tobota, Z. AU - Anielska, E. AU - Dyczkowska, A. IS - 6 KW - Adult Aged Aged, 80 and over Costs and Cost Analysis Disease Progression Female *Glaucoma/ec [Economics] *Glaucoma/th [Therapy] Humans Intraocular Pressure Laser Therapy/ec [Economics] Male Middle Aged Office Visits/ec [Economics] *Pilocarpine/ec [Economics] Pilocarpine/tu [Therapeutic Use] Poland *Sulfonamides/ec [Economics] Sulfonamides/tu [Therapeutic Use] *Thiophenes/ec [Economics] Thiophenes/tu [Therapeutic Use] *Timolol/ec [Economics] Timolol/tu [Therapeutic Use] PY - 2000 SE - Czechowicz-Janicka, K. Kliniki Okulistycznej Centrum Medycznego Ksztalcenia Podyplomowego w Warszawie. SN - 0023-2157 SP - 417-22 ST - [Analysis of glaucoma therapy costs in Poland. I--population of the Mazovian District] T2 - Analiza kosztow leczenia jaskry w Polsce. Czesc I--Populacja mazowiecka. TI - [Analysis of glaucoma therapy costs in Poland. I--population of the Mazovian District] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11392801 VL - 102 ID - 1932 ER - TY - JOUR AB - INTRODUCTION: Successful non-perforating trabeculectomy (NPT) results in filtration of aqueous humor out of the anterior chamber and into a filtration bleb, without surgical excision of tissue from the anterior chamber angle, and without penetration into the anterior chamber. The complications of perforating trabeculectomy, due to early postoperative hypotony (shallow anterior chamber, hyphema, macular folds, suprachoroidal effusion, and ciliochoroidal hemorrhage) (3, 4, 5, 6, 7, 8, 9) are regarded by many surgeons as significant risks. Nonperforating surgery has been reported to reduce the incidence of early hypotony-related complications (10), because it has the advantage of creating gradual filtration of aqueous humor, through a thin trabeculodescemetic membrane (TDM), which markedly reduces postoperative complications seen after a conventional trabeculectomy (11), and also has been reported to provide better long-term intraocular pressure (IOP) control (12, 13). NPT is reported to be a procedure with a significant learning curve, sometimes necessitating conversion to perforating trabeculectomy, and requiring careful postoperative monitoring (14, 15, 16, 17). Zimmerman et al. reported filtration of aqueous humor under a filtering bleb, by resecting the roof of Schlemms canal and removing corneal stroma overlying the trabecular meshwork (18) Mermoud et al. reported filtration of aqueous humor under a filtering, bleb by unroofing Schlemms canal and removing corneal stroma overlying the trabecular meshwork as well Descemets membrane (19); he found that resistance across the TDM sometimes increased with time. When this resistance to aqueous humor outflow occurred, Mermoud found TDM resistance could be eliminated by performance of goniopuncture (ab interno Nd:YAG laser membranotomy via gonioprism), to enhance aqueous humor outflow into the filtration bleb. Failure to filter adequately through the TDM is a potential complication following NPT which can result in a rise in intraocular pressure (IOP). In this paper we examine the effectiveness of adjunctive Nd:YAG laser goniopuncture (YGP) in patients who underwent NPT, to reduce post-operative IOP rise, secondary to scarring at or poor aqueous outflow through the TDM. Iris prolapse (IP) is another potential complication following NPT which can result in a rise in IOP. In this paper we examine the effectiveness of adjunctive argon laser peripheral iridoplasty (ALPI) in patients who underwent NPT, to reduce post-operative IOP rise, secondary to IP obstructing outflow across the TDM., BACKGROUND: Nd:YAG laser goniopuncture consists of placing several laser shots on the undersurface of the trabeculodescemetic membrane. The result is a microperforation in this membrane, with flow of aqueous into the filtration bleb, which converts a non-perforating filtration procedure into a partial thickness filtration procedure. In this technique, several high power, multi-burst shots are applied, ab interno, by a Nd:YAG laser via a gonioprism, to the underside of the TDM, to facilitate aqueous outflow out from the anterior chamber. YGP can be effective when increased aqueous outflow is desired postoperatively. After this procedure, patent perforation in the TDM is usually observed gonioscopically, generally accompanied with reduction in IOP, and increase in bleb elevation (in height and in circumferential extent). Argon laser peripheral iridoplasty consists of placing several laser burns on the surface of the peripheral iris to contract the iris stroma, in a centripetal fashion, between the site of the burn and the anterior chamber angle. The result is iris stromal tissue contraction and compaction, movement of IP away from the angle and toward the pupil, which physically widens the angle and clears the synechial apposition of the peripheral iris against the TDM. In this technique, a series of low power, long duration, and large size burns is applied to the iris periphery to contract the iris stroma, to open the angle, and to clear IP causing synechial obstruction of the TDM after succe sful NPT. Used previously in acute angle closure glaucoma, ALPI may be effective in controlling IOP and clearing corneal edema when systemic and topical anti-glaucoma treatments fail to control high IOP, and when laser peripheral iridotomy (LPI) is not possible (e.g. in cases of severe corneal edema). Additionally, ALPI can be effective in permanently reopening the anterior chamber angle of iridectomized eyes with plateau iris syndrome; in this technique a full 360 degrees ring of spots is often applied, but a more limited area of treatment may also be effective., TECHNIQUE: When a post-operative elevation in IOP was detected in a patients eye which had undergone NPT, careful indentation gonioscopy was performed to examine the TDM at the surgical site. If the peripheral iris was flat, the anterior chamber angle was open, and the TDM did not appear obstructed by IP, YGP was performed. First, the eyes were pre-treated with aproclonodine 1% and pilocarpine 2% (if needed to allow visualization of the TDM). Next, a Nd:YAG laser was set on triple burst mode and shots were applied to the underside of the TDM at the NPT site, using a Goldman 3-mirror lens in the following manner: Energy - 3-5 mJ; Mode - Triple burst. The power and amount of spots were titrated in order to achieve partial or microperforation of TDM at the NPT surgical site, thus resulting in restoration of aqueous outflow into the filtration bleb. When a post-operative elevation in IOP was detected in a patients eye which had undergone NPT and or YGP, careful indentation gonioscopy was performed to examine the TDM at the surgical site. If irreducible synechial IP were detected, which obstructed filtration through the TDM at the NPT surgical site, ALPI was performed. First, the eyes were pre-treated with aproclonodine 1% and pilocarpine 2%. Next, an argon laser was set on blue-green mode and shots were applied to the IP adherent to cornea or to the TDM at the NPT site, using a Goldman 3-mirror lens in the following manner: Spot Size - 500 mM; Duration - 0.5 s; Power - 200 to 400 mW. The power and amount of burns were titrated in order to achieve partial or complete centripetal retraction of the IP from the TDM at the NPT surgical site, causing a clearance of the obstruction to the TDM, thus resulting in restoration of aqueous outflow into the filtration bleb. AU - D, Lawrence F. Jindra M. IS - 1 KW - Humans *Intraocular Pressure *Iris/su [Surgery] *Laser Therapy *Lasers, Solid-State/tu [Therapeutic Use] *Trabeculectomy/mt [Methods] PY - 2013 SE - D, Lawrence F Jindra M. Edwards S. Harkness Institute of Ophthalmology, Columbia University, New York, New York, USA. DrLFJind@optonline.net SN - 1211-9059 SP - 3-7 ST - Aductive laser iridoplasty and laser goniopuncture after non-perforating trabeculectomy T2 - Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti TI - Aductive laser iridoplasty and laser goniopuncture after non-perforating trabeculectomy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23822595 VL - 69 ID - 960 ER - TY - JOUR AB - Background: Gefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease progression. Patients and methods: In all, 63 patients with chemotherapy-naive stage IIIB/IV NSCLC received gefitinib 250 mg/day. At disease progression, gefitinib was replaced by cisplatin 80 mg/m2 on day 1 and gemcitabine 1250 mg/m2 on days 1, 8 for up to six 3-week cycles. Primary end point was the disease stabilization rate (DSR) after 12 weeks of gefitinib. Results: After 12 weeks of gefitinib, the DSR was 24% and the response rate (RR) was 8%. Median time to progression (TtP) was 2.5 months and median overall survival (OS) 11.5 months. Never smokers (n = 9) had a DSR of 56% and a median OS of 20.2 months; patients with epidermal growth factor receptor (EGFR) mutation (n = 4) had a DSR of 75% and the median OS was not reached after the follow-up of 21.6 months. In all, 41 patients received chemotherapy with an overall RR of 34%, DSR of 71% and median TtP of 6.7 months. Conclusions: First-line gefitinib monotherapy led to a DSR of 24% at 12 weeks in an unselected patients population. Never smokers and patients with EGFR mutations tend to have a better outcome; hence, further trials in selected patients are warranted. © The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. AD - G. D'Addario, Onkologie Schaffhausen, Rheinstrasse 17, 8200 Schaffhausen, Switzerland AU - D'Addario, G. AU - Rauch, D. AU - Stupp, R. AU - Pless, M. AU - Stahel, R. AU - Mach, N. AU - Jost, L. AU - Widmer, L. AU - Tapia, C. AU - Bihl, M. AU - Mayer, M. AU - Ribi, K. AU - Lerch, S. AU - Bubendorf, L. AU - Betticher, D. C. DB - Embase Medline DO - 10.1093/annonc/mdm564 IS - 4 KW - carboplatin cisplatin epidermal growth factor receptor erythropoietin gefitinib gemcitabine granulocyte colony stimulating factor serotonin antagonist steroid abdominal pain adult advanced cancer aged anemia anorexia appendix perforation article cancer chemotherapy cancer growth cancer staging cardiotoxicity clinical trial combination chemotherapy confusion creatinine clearance deep vein thrombosis dehydration diarrhea drug efficacy drug safety drug substitution drug tolerability drug withdrawal dry skin fatigue febrile neutropenia female fluorescence in situ hybridization gene mutation glaucoma hearing impairment human hyperbilirubinemia hypoalbuminemia hyponatremia inappropriate vasopressin secretion infection interstitial lung disease lung embolism non small cell lung cancer major clinical study male metastasis monotherapy mucosa inflammation multicenter study multiple cycle treatment musculoskeletal pain nausea nephrotoxicity neurologic disease neutropenia overall survival patient compliance phase 2 clinical trial priority journal pruritus quality of life side effect skin toxicity treatment outcome vomiting weakness LA - English M3 - Article N1 - L351461046 2008-04-14 PY - 2008 SN - 0923-7534 1569-8041 SP - 739-745 ST - Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 T2 - Annals of Oncology TI - Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351461046&from=export http://dx.doi.org/10.1093/annonc/mdm564 VL - 19 ID - 3459 ER - TY - JOUR AB - BACKGROUND: Provision of eye care services for competitors and their support teams has become an integral part of the modern Olympic Games., AIM: To describe the organisation of the eye clinic at London 2012 over a 4-week period and provide outline audit data., METHODS: The clinic employed multidisciplinary eye care professionals and utilised state-of-the-art instrumentation to provide the highest level of eye care., RESULTS: A total of 1406 patients from 154 countries attended the clinic over the Olympic Games, of which, 276 were competitors. All individuals received a comprehensive refractive and ocular health examination. Minor ocular injuries, glaucoma, diabetic retinopathy and macular degeneration were among the conditions detected and managed. Most patients attended the clinic to have their refractive status checked: 973 spectacles and 50 pairs of contact lenses were dispensed., CONCLUSIONS: It is hoped that this account of the provision of eye care at London 2012 will assist with the planning of this service at future events. AU - D'Ath, Penny J. AU - Thomson, W. David AU - Wilson, Clare M. DO - https://dx.doi.org/10.1136/bjsports-2013-092152 IS - 7 KW - Adolescent Adult Aged *Ambulatory Care/sn [Statistics & Numerical Data] Ambulatory Care Facilities/sn [Statistics & Numerical Data] Anniversaries and Special Events *Athletes/sn [Statistics & Numerical Data] Eyeglasses/sd [Supply & Distribution] Female Humans London Male Middle Aged Ophthalmology/sn [Statistics & Numerical Data] *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Sports Sports Medicine/sn [Statistics & Numerical Data] Vision Disorders/et [Etiology] *Vision Disorders/th [Therapy] Vision Tests/sn [Statistics & Numerical Data] Young Adult PY - 2013 SE - D'Ath, Penny J. Division of Optometry and Visual Science, City University London, London, UK. penny.dath@gmail.com SN - 1473-0480 0306-3674 SP - 463-6 ST - Seeing you through London 2012: eye care at the Olympics T2 - British journal of sports medicine TI - Seeing you through London 2012: eye care at the Olympics UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23486936 VL - 47 Y2 - 20130313// ID - 983 ER - TY - JOUR AB - Acanthamoeba spp. consists of free-living amoebae, widespread in nature, which occasionally can cause human infections including granulomatous amoebic encephalitis and amoebic keratitis. Acanthamoeba pathogenesis is not entirely known and correlations between pathogenic potential and taxonomy are complex issues. In order to decipher the definition of a pathogenic amoeba, the objective of this work was to decipher the definition of pathogenic amoeba by characterizing two isolates of Acanthamoeba polyphaga obtained from different origins (a keratitis patient and freshwater), looking for differences among them. The clinical isolate grew faster in Peptone-yeast extract-glucose (PYG) medium, transformed more rapidly from a trophozoite to cyst and exhibited increased cytopathic effect on cultured cells. Morphological differences were also noted, since freshwater amoebae presented more acanthopodia than the clinical isolate. Moreover, actin labeling demonstrated that microfilament organization varies between isolates, with the presence of locomotory structures as lobopodia and lamellipodia in the keratitis isolate, which were less adherent on plastic. Zymography demonstrated that the keratitis isolates presented higher proteolytic activity and also were more able to invade collagen matrices. Altogether, we conclude that a group of stable physiological characteristics exist in Acanthamoeba that can be related to pathogenicity. AU - da Rocha-Azevedo, Bruno AU - Costa e Silva-Filho, Fernando IS - 5 KW - Acanthamoeba/cl [Classification] Acanthamoeba/ip [Isolation & Purification] Acanthamoeba/py [Pathogenicity] Acanthamoeba/ph [Physiology] *Acanthamoeba *Acanthamoeba Keratitis/ps [Parasitology] Animals Cell Adhesion Cell Line Epithelial Cells/ps [Parasitology] *Fresh Water/ps [Parasitology] Humans Microscopy, Confocal Microscopy, Electron, Scanning Phenotype PY - 2007 SE - da Rocha-Azevedo, Bruno. Programa de Bioengenharia e Biotecnologia Animal, Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, UFRJ-CCS, bloco G, sala G0-044, Cidade Universitaria, Ilha do Fundao, Rio de Janeiro, RJ, CEP 21949-900, Brazil. SN - 0302-8933 SP - 441-9 ST - Biological characterization of a clinical and an environmental isolate of Acanthamoeba polyphaga: analysis of relevant parameters to decode pathogenicity T2 - Archives of microbiology TI - Biological characterization of a clinical and an environmental isolate of Acanthamoeba polyphaga: analysis of relevant parameters to decode pathogenicity UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17569030 VL - 188 Y2 - 20070614// ID - 1601 ER - TY - JOUR AB - PURPOSE: To report a rare association of sympathetic ophthalmia with an antecedent adherent leucoma., METHOD: A 40-year-old patient with an adherent leucoma developed sympathetic ophthalmia in the fellow eye, 15 years after the occurrence of a perforated corneal ulcer., RESULTS: Intravenous pulse dexamethasone therapy followed by tapering oral prednisolone led to complete resolution of the disease process in the sympathising eye., CONCLUSION: Patients with an adherent leucoma subsequent to a perforated corneal ulcer may remain at an increased risk of developing sympathetic ophthalmia during their lifetime. AU - Dada, T. AU - Kumar, A. AU - Sharma, N. IS - 3 KW - Administration, Oral Adult *Corneal Opacity/et [Etiology] *Corneal Ulcer/co [Complications] Dexamethasone/tu [Therapeutic Use] Glucocorticoids/tu [Therapeutic Use] Humans Infusions, Intravenous Male Ophthalmia, Sympathetic/dt [Drug Therapy] *Ophthalmia, Sympathetic/et [Etiology] Prednisolone/tu [Therapeutic Use] Rupture, Spontaneous PY - 1998 SE - Dada, T. Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi. SN - 1395-3907 SP - 380-1 ST - Sympathetic ophthalmia associated with antecedent adherent leucoma--a rare association T2 - Acta ophthalmologica Scandinavica TI - Sympathetic ophthalmia associated with antecedent adherent leucoma--a rare association UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9686861 VL - 76 ID - 1990 ER - TY - JOUR AB - The aim of this study was to investigate the demographic and clinical characteristics of Syrian immigrants visiting an ophthalmology clinic, and to evaluate the causes of severe vision loss and blindness in this population. The data of 1,498 Syrian patients who presented to our clinic with eye complaints between January 2013 and January 2019 were analyzed retrospectively. The cases were divided into three groups based on age: under 18, 18–65, and over 65 years old. Their diagnoses, severe vision loss incidences, and causes of blindness were investigated. The mean age was 36.15 ± 23 (0–91) years old, with 385 (25.7%) of the patients under the age of 18, 780 (52.1%) between the ages of 18 and 65, and 333 (22.2%) over 65 years old. In all three groups, the most common reasons for admission were treatable conditions, such as conjunctivitis, blepharitis, and dry eye. The most important cause of severe vision loss under the age of 18 was a refractive error, while the most important cause of blindness was a congenital cataract. Cataracts were the most important causes of severe vision loss in the 18–65 and over 65 years old age groups, while the most important causes of blindness were traumas and cataracts. By providing immigrants with fast, easy, and free access to health care services, the severe vision loss and blindness rates can be minimized. AD - M. Çağlayan, Department of Ophthalmology, University of Health Sciences, Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey AU - Dağ, U. AU - Çağlayan, M. AU - Alakuş, M. F. AU - Öncül, H. DB - Embase DO - 10.5505/ejm.2021.91489 IS - 1 KW - adolescent adult age related macular degeneration aged article blepharitis blindness cataract child clinical feature congenital cataract conjunctivitis diabetic retinopathy dysphagia ectropion error eye surgery female glaucoma groups by age health care access health care cost health service human immigrant incidence major clinical study male ophthalmology ptosis (eyelid) refraction error retrospective study senescence strabismus Syrian Syrian Arab Republic tertiary care center uveitis visiting nursing service visual acuity visual impairment LA - English M3 - Article N1 - L2005971748 2021-02-12 2021-03-01 PY - 2021 SN - 1309-3886 1301-0883 SP - 11-16 ST - Analysis of the eye clinic visits of syrian immigrants at a state tertiary hospital T2 - Eastern Journal of Medicine TI - Analysis of the eye clinic visits of syrian immigrants at a state tertiary hospital UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005971748&from=export http://dx.doi.org/10.5505/ejm.2021.91489 VL - 26 ID - 2327 ER - TY - JOUR AB - Background: Infectious keratitis is a major global cause of visual impairment and irreversible blindness among the corneal diseases. Its diagnosis and management remain getting challenge. The clinical and visual outcome remains poor in developing countries. The aim of this study was to determine treatment outcome and its predictors among patients with infectious keratitis., Methods: Prospective observational study was conducted among adult patients diagnosed with infectious keratitis at the Ophthalmology Department in Jimma University Medical Center from April 1 to September 30, 2019. The primary outcome indicator was response of the ulcer to empirical treatment. Ulcers that did not heal and required surgery had a poor outcome. Variables with a p-value of <0.25 were entered into a multivariate logistic regression model to determine the independent predictors of poor treatment outcome and variables with a p-value of <0.05 were considered statistically significant., Results: The research involved 131 adult patients. Eighty-seven (66.4%) were males. The mean age was 39.38 (+/-18.9) years. Eighty-three (63.4%) patients had poor treatment outcome. Mean length of hospital stay was 17.38 (+/-12.563) days. Poor visual outcome was observed among 71 (54.2%) participants. Evisceration was done for seven (5.3%) patients. Independent predictors of poor treatment outcome include perforation at admission (AOR=6.1, 95%CI: 1.5-25.1), presence of comorbidity (AOR=7.7, 95%CI: 2.16-27.3), poor adherence (AOR=5.3, 95%CI: 1.8-25.9), traditional medicine use (AOR=6.7, 95%CI: 1.8-25.4), ulcer depth >1/3 (AOR=7.6, 95%CI: 2.48-48.23) and farm workers (AOR=3.59, 95%CI: 1.09-11.77). Major complications occurred after admissions were perforation (14.5%), followed by endophthalmitis (7.63%) and corneal opacity (6.87%)., Conclusion and Recommendation: Our study found high poor treatment outcomes and high poor visual outcomes. Presence of comorbidity, perforation at admission, traditional medicine use, working on a farm, poor adherence, and ulcer depth were the predictors of poor treatment outcome. This high poor outcome requires a nationwide interventional study and urgent intervention that may reach rural communities. Copyright © 2021 Dago et al. AU - Dago, Tolcha Regasa AU - Woldemichael, Dagmawit Kifle AU - Daba, Fekede Bekele DO - https://dx.doi.org/10.2147/OPTH.S291880 PY - 2021 SE - Dago, Tolcha Regasa. School of Pharmacy, College of Medicine and Health Science, Mizan Tepi University, Mizan-Aman, Ethiopia. Woldemichael, Dagmawit Kifle. Department of Ophthalmology, Institute of Health, Jimma University, Jimma, Ethiopia. Daba, Fekede Bekele. School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia. SN - 1177-5467 SP - 1223-1237 ST - Medical History, Clinical Features, Treatment Outcome and Its Predictors Among Infectious Keratitis Patients in Jimma University Medical Center, Southwest Ethiopia: Prospective Observational Study T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Medical History, Clinical Features, Treatment Outcome and Its Predictors Among Infectious Keratitis Patients in Jimma University Medical Center, Southwest Ethiopia: Prospective Observational Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33790530 VL - 15 Y2 - 20210322// ID - 102 ER - TY - JOUR AB - PURPOSE: To evaluate the perioperative complications of intraocular lens (IOL) exchange in 25 eyes of 22 patients with opacified Aqua-Sense IOLs (Ophthalmic Innovations International)., SETTING: Department of Ophthalmology, University Hospital Aintree, Liverpool, United Kingdom., METHODS: The study comprised 22 patients (25 eyes) who had previous phacoemulsification and implantation of Aqua-Sense single-piece hydrophilic acrylic IOLs in the capsular bag and developed severe late opacification of the IOL. All patients reported glare and deterioration in vision. The IOLs were explanted and replaced with new lenses. The perioperative complications were evaluated. The best corrected visual acuity (BCVA) before and after surgery was compared., RESULTS: In 24 eyes, the opacification was complete, involving the optic, haptics, and substance of the IOLs. Uneventful IOL exchange and placement of a new IOL in the bag was achieved in 13 eyes (52%). Complications occurred in the remaining 12 eyes (48%). Ten eyes (40%) developed zonular dehiscence, 4 (16%) of which were managed with anterior chamber IOL implantation. One eye (4%) developed posterior capsule rupture and 1 eye (4%), posterior capsule rupture and zonular dehiscence. The cornea decompensated in 2 eyes (8%). One eye (4%) developed Pseudomonas keratitis. The mean BCVA (decimal scale) before and after IOL exchange was 0.57 +/- 0.24 and 0.60 +/- 0.28, respectively. There was no significant difference in visual acuity between before and after IOL exchange (P=.782, paired t test)., CONCLUSIONS: Explantation of Aqua-Sense IOLs was challenging because of the tight adherence of the optic and haptics to the capsule. Long-term follow-up of patients with Aqua-Sense IOLs should be maintained. AU - Dagres, Evgenios AU - Khan, Mushtaq A. AU - Kyle, Graham M. AU - Clark, David IS - 12 KW - Aged Device Removal Female Humans *Intraoperative Complications *Lens Implantation, Intraocular *Lenses, Intraocular Male Phacoemulsification *Prosthesis Failure Reoperation Visual Acuity PY - 2004 SE - Dagres, Evgenios. Department of Ophthalmology, University Hospital Aintree, Liverpool, United Kingdom. edagres@yahoo.com SN - 0886-3350 SP - 2569-73 ST - Perioperative complications of intraocular lens exchange in patients with opacified Aqua-Sense lenses T2 - Journal of cataract and refractive surgery TI - Perioperative complications of intraocular lens exchange in patients with opacified Aqua-Sense lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15617926 VL - 30 ID - 1760 ER - TY - JOUR AB - Asthma is a complex disease of the respiratory tract associated with chronic inflammation in which an intricate network of cells and cellular factors plays a major role. Asthma is one of the most common chronic diseases, with an estimated 300 million cases worldwide, imposing a considerable burden on society in morbidity, quality of life, and healthcare costs. Inhaled corticosteroids (ICSs) form the gold standard, first-line therapy in the effective management of persistent asthma and reduce morbidity and mortality from asthma. However, long-term use of high-dose ICS therapy has potential to cause systemic side effects-impaired growth in children, decreased bone mineral density, skin thinning and bruising, and cataracts. Hypothalamic-pituitary-adrenal-axis suppression, measured by serum or urine cortisol decrease, correlates with the occurrence of systemic side effects of high-dose ICSs. Therefore, cortisol may be a relevant surrogate marker to identify the potential for adverse effects from ICS therapy. Ciclesonide is a new generation ICS with demonstrable safety and efficacy in the treatment of asthma. The unique pharmacologic characteristics of ciclesonide, such as reduced local adverse effects, lack of cortisol suppression, and the option for once-daily dosing, may improve compliance with therapy and allow long-term use of ICSs without fear of systemic adverse effects. AU - Dahl, Ronald IS - 8 KW - Administration, Inhalation *Adrenal Cortex Hormones/ae [Adverse Effects] Adrenal Insufficiency/ci [Chemically Induced] Adult Anti-Allergic Agents/ae [Adverse Effects] *Asthma/dt [Drug Therapy] Bone Density/de [Drug Effects] Cataract/ci [Chemically Induced] Child Child Development/de [Drug Effects] Contusions/ci [Chemically Induced] Glaucoma/ci [Chemically Induced] Humans Hydrocortisone/bl [Blood] Hydrocortisone/ur [Urine] Hypothalamo-Hypophyseal System/de [Drug Effects] Osteoporosis/ci [Chemically Induced] Pituitary-Adrenal System/de [Drug Effects] Pregnenediones/ae [Adverse Effects] Skin Diseases/ci [Chemically Induced] PY - 2006 SE - Dahl, Ronald. Department of Respiratory Diseases, Aarhus University Hospital, Norrebrogade, DK 8000 Aarhus C, Denmark. rdahl@as.aaa.dk SN - 0954-6111 SP - 1307-17 ST - Systemic side effects of inhaled corticosteroids in patients with asthma T2 - Respiratory medicine TI - Systemic side effects of inhaled corticosteroids in patients with asthma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16412623 VL - 100 Y2 - 20060118// ID - 1687 ER - TY - JOUR AB - INTRODUCTION: Development of mobile health (m-health) in China carries tremendous potential, especially for glaucoma, one of the major chronic ophthalmic diseases afflicting millions of people. However, little research has been undertaken to investigate the willingness of glaucoma patients to use m-health and the factors influencing their decisions., SUBJECTS AND METHODS: This was a cross-sectional study. A self-administered or face-to-face interview survey was performed on 1,487 patients with glaucoma at the outpatient glaucoma service, Zhongshan Ophthalmic Center, Sun Yat-sen University. Questionnaires captured patients' demographic data, WeChat access, and willingness to receive m-health. The data were analyzed by single factor chi-square test. Multiple logistic regression revealed the motivators and barriers to accept m-health adoption., RESULTS: One thousand ninety-seven valid questionnaires were obtained. Seven hundred twenty-five respondents (66.1%) were willing to participate in m-health programs. 65.4% were younger than 60 years old. 40.9% had travel time from home to hospital of >3 h. 63.6% had more than four follow-up visits for glaucoma. 86.5% experienced trouble events during clinic visits. The overall WeChat usage rate was 61.7%. Age, travel time, number of visits, trouble events in clinic, and WeChat access in patients with glaucoma were related to the willingness to use m-health (p < 0.05)., CONCLUSIONS: Most patients with glaucoma were willing to participate in m-health programs, which are essential to increasing and improving access to care. AU - Dai, Miaomiao AU - Xu, Jianan AU - Lin, Jialiu AU - Wang, Zhonghao AU - Huang, Wenmin AU - Huang, Jingjing DO - https://dx.doi.org/10.1089/tmj.2016.0254 IS - 10 KW - Adult Age Factors Aged China Cross-Sectional Studies Female Glaucoma/co [Complications] *Glaucoma/px [Psychology] *Glaucoma/th [Therapy] Health Services Accessibility Humans Interviews as Topic Jet Lag Syndrome Male Middle Aged *Patient Preference Socioeconomic Factors *Telemedicine/og [Organization & Administration] Transportation PY - 2017 SE - Dai, Miaomiao. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China . Xu, Jianan. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China . Lin, Jialiu. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China . Wang, Zhonghao. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China . Huang, Wenmin. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China . Huang, Jingjing. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China . SN - 1556-3669 1530-5627 SP - 822-827 ST - Willingness to Use Mobile Health in Glaucoma Patients T2 - Telemedicine journal and e-health : the official journal of the American Telemedicine Association TI - Willingness to Use Mobile Health in Glaucoma Patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28418773 VL - 23 Y2 - 20170418// ID - 519 ER - TY - JOUR AB - South America comprises of heterogeneous topographies, populations, and health care systems. Therefore, it is not surprising to see differences among the countries regarding expertise, education, and practices of ophthalmic genetics for patients with rare eye diseases. Nevertheless, common challenges such as limited genetics training in medical schools and among ophthalmologists, scarcity of diagnostic tools for phenotyping, and expensive genetic testing not covered by the public healthcare systems, are seen in all of them. Here, we provide a detailed report of the current status of ophthalmic genetics, described by the personal views of local ophthalmologists from Brazil, Colombia, Argentina, and Chile. By reporting our strengths and weaknesses as a region, we intend to highlight the need for guidelines on how to manage these patients aligned with public health policies. Our region contributes to research worldwide, with thousands of well diagnosed patients from a number of unique and genetically diverse populations. The constant expansion of ophthalmic genetics and molecular diagnostics requires us to join forces to collaborate across South America and with other countries to improve access to next-generation diagnostics and ultimately improve patient care. AD - M. Daich Varela, Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, MD, United States M. Daich Varela, University of Buenos Aires, Buenos Aires, Argentina AU - Daich Varela, M. AU - Moya, R. AU - Schlottmann, P. G. AU - Hufnagel, R. B. AU - Arberas, C. AU - Fernández, F. M. AU - Inga, M. E. AU - Lores, J. AU - Pachajoa, H. AU - Prada, C. E. AU - Sallum, J. M. F. DB - Embase Medline DO - 10.1002/ajmg.c.31832 IS - 3 KW - age related macular degeneration anophthalmia Argentina article autofluorescence imaging Brazil Chile choroideremia chromosome analysis Colombia comparative genomic hybridization congenital cataract congenital glaucoma cornea dystrophy electrophysiological procedures eye photography Fabry disease fluorescence in situ hybridization gelatinous drop-like corneal dystrophy gene genetic counseling genetic heterogeneity genetic variability genetics health care access health care organization health care policy health care system high throughput sequencing human karyotyping Leber congenital amaurosis microarray analysis microphthalmia molecular diagnosis multiplex ligation dependent probe amplification NMNAT1 gene ocular albinism ophthalmic genetics optical coherence tomography perimetry practice guideline priority journal retina detachment retina dystrophy retinitis pigmentosa retinoschisis Sanger sequencing spectral domain optical coherence tomography Stargardt disease support group LA - English M3 - Article N1 - L2005993059 2020-09-01 PY - 2020 SN - 1552-4876 1552-4868 SP - 753-761 ST - Ophthalmic genetics in South America T2 - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics TI - Ophthalmic genetics in South America UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005993059&from=export http://dx.doi.org/10.1002/ajmg.c.31832 VL - 184 ID - 2384 ER - TY - JOUR AB - Cellular signaling is regulated by several biochemical reactions, whose dynamics depends on changes in the fluxes of specific ligands through the containment barriers that are the biological membranes. The regulation of this complex dynamic equilibrium is mainly due to the activity of border proteins, that must be able to interact simultaneously with the lipid bilayer and the extracellular milieu. Endocannabinoid receptors, that include type-1 and type-2 cannabinoid receptors, the transient vanilloid potential receptors and the peroxisome proliferator-activated receptors, represent one of the most intriguing examples of "border" proteins. They have also been identified as important drug discovery targets with potential therapeutic applications, from antiemesis, appetite enhancement, analgesia, glaucoma treatment, and immune suppression. However, as yet the molecular details of endocannabinoid receptor regulation remain elusive. In this review we summarize the most relevant aspects of the structural/functional characterization of these receptors, with a focus on the active role played by biological membranes (in particular lipid rafts) in the modulation of their accessibility and mode of ligand binding. Based on available evidence, we propose that endocannabinoid receptors can be regulated by the rate of interlayer exchange and lateral diffusion of endocannabinoid/cholesterol complexes within lipid bilayers, thus suggesting innovative approaches for the therapeutic exploitation of the membrane component of endocannabinoid signaling. AU - Dainese, E. AU - Oddi, S. AU - Maccarrone, M. IS - 14 KW - Cannabinoid Receptor Modulators/ch [Chemistry] Cannabinoid Receptor Modulators/pd [Pharmacology] Cholesterol/me [Metabolism] Endocannabinoids *Lipid Bilayers/me [Metabolism] Peroxisome Proliferator-Activated Receptors/me [Metabolism] *Receptors, Cannabinoid/me [Metabolism] Signal Transduction TRPV Cation Channels/me [Metabolism] PY - 2010 SE - Dainese, E. Department of Biomedical Sciences, University of Teramo, Italy. SN - 1875-533X 0929-8673 SP - 1487-99 ST - Interaction of endocannabinoid receptors with biological membranes T2 - Current medicinal chemistry TI - Interaction of endocannabinoid receptors with biological membranes UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20166920 VL - 17 ID - 1377 ER - TY - JOUR AB - PURPOSE: To evaluate the use of fibrin glue and its complications in different ophthalmic surgeries., METHODS: A retrospective and non-comparative case series study. 161 eyes were evaluated. The mean age was 51.8 years. Fibrin glue (Beriplast--Aventis Behring, Germany) was used in all patients for tissue adherence or incisional closure., RESULTS: Main preoperatives diseases were pterygium (76 patients), superior limbic keratoconjunctivitis (4 patients), limbal tumor (4 patients), conjunctivochalasis (21 patients), bullous keratopathy (31 patients), limbal stem cell deficiency (7 patients), alkali injury (6 patients), Stevens-Johnson syndrome (2 patients), cataract (5 patients) and glaucoma (5 patients). Complications occurred in 28 patients (17.4%). Detachment of the fixed tissue and granulomatous foreign body reaction were the main complications. Detachment occurred in 10 cases (5.6%) (7 in amniotic membrane transplantation in bullous keratopathy, 2 in autologous conjunctival grafting for pterygium surgery, 1 in autologous limbal transplantation in a Stevens-Johnson syndrome). Granulomatous foreign body reaction was described in 9 patients (5.6%) (5 in amniotic membrane transplantation due to acute alkali injury, 1 in autologous limbal graft due to chronic burn injury, and 3 in autologous conjunctival transplant due to pterygium surgery). All the complications described occurred in the first week after surgery., CONCLUSION: Despite the limitations related to the retrospective and non-comparative setting, this study suggests that the use of fibrin glue seems to be safe and effective for tissue fixation or incisional closure presenting low rates of complications in ocular surface and anterior segment surgeries. AU - Dal Pizzol, Melissa Manfroi AU - Roggia, Murilo Felix AU - Kwitko, Sergio AU - Marinho, Diane Ruschel AU - Rymer, Samuel IS - 3 KW - Adolescent Adult Aged Aged, 80 and over Brazil Child Child, Preschool Eye Diseases/cl [Classification] *Eye Diseases/su [Surgery] *Fibrin Tissue Adhesive/ae [Adverse Effects] Fibrin Tissue Adhesive/tu [Therapeutic Use] Granuloma, Foreign-Body/ci [Chemically Induced] Humans Middle Aged Ophthalmologic Surgical Procedures/cl [Classification] Ophthalmologic Surgical Procedures/mt [Methods] *Ophthalmologic Surgical Procedures Retrospective Studies Time Factors *Tissue Adhesives/ae [Adverse Effects] Tissue Adhesives/tu [Therapeutic Use] Young Adult PY - 2009 SE - Dal Pizzol, Melissa Manfroi. Setor de Cornea e Doencas Externas, Servico de Oftalmologia, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brasil. SN - 1678-2925 0004-2749 SP - 308-12 ST - [Use of fibrin glue in ocular surgery] T2 - Utilizacao de adesivo de fibrina em cirurgias oftalmologicas. TI - [Use of fibrin glue in ocular surgery] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19668958 VL - 72 ID - 1431 ER - TY - JOUR AB - The article reviews Phase I/II interim data for a bimatoprost sustained-release (SR) implant showing the device has favorable safety and efficacy and may address the issue of patient nonadherence. Topics include the primary endpoint of research being the intraocular pressure (IOP) change from baseline and the use of rescue medication. Also mentioned are glaucoma specialist Doctor Richard A. Lewis and colleagues undertaking the study as well as several potential barriers to patient adherence. AN - 112544029. Language: English. Entry Date: 20160201. Revision Date: 20160201. Publication Type: Article. Journal Subset: Biomedical AU - Dalton, Michelle DB - ccm DP - EBSCOhost IS - 1 KW - Bimatoprost Drug Implants Intraocular Pressure Glaucoma -- Drug Therapy N1 - USA. NLM UID: 9880041. PY - 2016 SN - 0193-032X SP - 24-24 ST - Sustained-release bimatoprost implant addresses challenges of adherence T2 - Ophthalmology Times TI - Sustained-release bimatoprost implant addresses challenges of adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112544029&site=ehost-live&scope=site VL - 41 ID - 4538 ER - TY - JOUR AB - The article reports on the advances and new options in the treatment of open-angle glaucoma which is the leading cause of irreversible blindness in the U.S. as of April 2020. Topics discussed include intraocular pressure (IOP) reduction as a modifiable risk factor for open-angle glaucoma, causes of IOP fluctuations including poor treatment compliance and genetics, and developments in the use of bimatoprost sustained release biodegradable implant. AN - 142531684. Language: English. Entry Date: 20200406. Revision Date: 20200408. Publication Type: Article. Journal Subset: Biomedical AU - Dalton, Michelle DB - ccm DP - EBSCOhost IS - 6 KW - Pharmacological and Biological Treatments -- Methods Glaucoma -- Surgery Disease Management Intraocular Pressure Disease Progression Individualized Medicine Glaucoma -- Drug Therapy Drug Therapy, Combination Ophthalmic Solutions Medication Compliance N1 - USA. NLM UID: 9880041. PY - 2020 SN - 0193-032X SP - 10-12 ST - PHARMACOLOGIC TREATMENT AN OPTION FOR OPEN-ANGLE GLAUCOMA: Therapies can help manage disease, lowering and stabilizing IOP T2 - Ophthalmology Times TI - PHARMACOLOGIC TREATMENT AN OPTION FOR OPEN-ANGLE GLAUCOMA: Therapies can help manage disease, lowering and stabilizing IOP UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142531684&site=ehost-live&scope=site VL - 45 ID - 4191 ER - TY - JOUR AB - Aims: Patient-held records are becoming more commonly used in health care, particularly in chronic diseases like glaucoma. There is a lack of evidence to support their use, however. This study examines the change in knowledge scores within a group following the introduction of a newly designed glaucoma logbook. Methods: This analysis uses a test and retest method where patients undergoing treatment for glaucoma or ocular hypertension were assessed using a validated knowledge questionnaire. They were then given a personalized glaucoma logbook and their knowledge scores retested after 4 to 8 weeks. The change in knowledge score was examined using a Wilcoxon signed-rank test. Results: A total of 56 patients were recruited and 35 completed both questionnaires equating to a 62.5% retention rate. The analysis showed a significant increase in the knowledge score attained following introduction of the questionnaire (Z=-4.176, P<0.001). Conclusions: In this format, the glaucoma logbook has a positive impact on patient knowledge. Further research will be necessary to show if this result is maintained in a larger sample group and to investigate whether this improvement in knowledge is associated with any improvement in long-term structural and functional outcomes. AN - WOS:000431515400019 AU - Daly, R. AU - Agarwal, P. K. DA - MAY DO - 10.1097/IJG.0000000000000943 IS - 5 PY - 2018 SN - 1057-0829 1536-481X SP - 470-475 ST - Is Patient Knowledge of Glaucoma Improved by Using a Glaucoma Logbook? T2 - JOURNAL OF GLAUCOMA TI - Is Patient Knowledge of Glaucoma Improved by Using a Glaucoma Logbook? VL - 27 ID - 5976 ER - TY - JOUR AU - Dalzell, Michael D. IS - 11 Suppl KW - Adult Aged Female Glaucoma/dt [Drug Therapy] *Glaucoma/ec [Economics] *Glaucoma/ep [Epidemiology] Glaucoma/eh [Ethnology] *Health Services/sn [Statistics & Numerical Data] Humans Male Middle Aged Office Visits/td [Trends] Prevalence United States PY - 2002 SN - 1062-3388 SP - 10-5 ST - Glaucoma: prevalence, utilization, and economic implications T2 - Managed care (Langhorne, Pa.) TI - Glaucoma: prevalence, utilization, and economic implications UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=15357534 VL - 11 ID - 1858 ER - TY - JOUR AB - PURPOSE: To determine the effect of a glaucoma team care model on resource utilization and efficiency in glaucoma management., METHODS: Retrospective cohort study of 358 patients diagnosed and treated for glaucoma. Analysis included number of patient visits, diagnostic tests, and glaucoma procedures performed before (2005-2007) and after (2008-2010) implementation of a team care model in 2008. Patients not involved in the model served as controls., RESULTS: Number of patient visits did not change significantly after model implementation (p > .05). Diagnostic tests significantly increased in comprehensive ophthalmologist and glaucoma subspecialist groups 25 months after diagnosis (p = .03 and p = .001). Procedures increased for glaucoma subspecialists but was not statistically significant (p = .06). Optometrists used billing codes with significantly lower reimbursement than other providers (p < .001)., CONCLUSIONS: Team care model had neutral effect on patient visits and increased testing. Continued evaluation of this model is required to determine its effect on disease progression and outcomes. AU - Damento, Gena M. AU - Winkler, Nelson S. AU - Hodge, David O. AU - Khanna, Sunil S. AU - Khanna, Cheryl L. DO - https://dx.doi.org/10.1080/08820538.2018.1514059 IS - 7-8 KW - Aged Female Follow-Up Studies *Glaucoma/th [Therapy] Humans Male Middle Aged *Ophthalmologists/st [Standards] *Patient Acceptance of Health Care *Practice Patterns, Physicians' Retrospective Studies PY - 2018 SE - Damento, Gena M. a Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA. Winkler, Nelson S. a Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA. Hodge, David O. b Mayo Clinic, Jacksonville, FL, USA. Khanna, Sunil S. a Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA. Khanna, Cheryl L. a Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA. SN - 1744-5205 0882-0538 SP - 829-837 ST - Healthcare Utilization by Glaucoma Patients in a Team Care Model T2 - Seminars in ophthalmology TI - Healthcare Utilization by Glaucoma Patients in a Team Care Model UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30240281 VL - 33 Y2 - 20180921// ID - 404 ER - TY - JOUR AD - K.F. Damji, Department of Ophthalmology, University of Alberta, Canada AU - Damji, K. F. DB - Embase Medline DO - 10.4103/0974-9233.110601 IS - 2 KW - Africa cornea thickness glaucoma health care access health care financing health care management health care policy health care quality human information technology intraocular pressure knowledge leadership learning environment medical education medical information medical research priority journal public health problem public health service review risk factor LA - English M3 - Review N1 - L368829362 2013-05-08 2013-05-16 PY - 2013 SN - 0974-9233 0975-1599 SP - 107-110 ST - Strengthening institutional capacity for glaucoma care in Sub-Saharan Africa T2 - Middle East African Journal of Ophthalmology TI - Strengthening institutional capacity for glaucoma care in Sub-Saharan Africa UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368829362&from=export http://dx.doi.org/10.4103/0974-9233.110601 VL - 20 ID - 3014 ER - TY - JOUR AB - Introduction: Glaucoma in Sub Saharan Africa (SSA) poses a daunting challenge. Communities are often unaware of the serious implications of glaucoma and are faced with limited access to specialists, making early detection and management difficult. For those who have been diagnosed, socioeconomic barriers limit access to treatment. Since 2006, we have been involved in an innovative program we term ‘STOP Glaucoma in SSA’. The four main pillars of this program include building capacity, enhancing awareness, and improving glaucoma detection and management. The aim of this initiative is to train the first generation of highly qualified glaucoma subspecialist leaders and to develop centers of excellence for glaucoma care throughout SSA that are interconnected. Our ultimate aim is to reduce the burden of blindness from glaucoma in SSA. Areas covered: Our review addresses background context, provides learning from the first decade of this program, and offers solutions to help tackle the scourge of glaucoma in SSA. Expert commentary: Research in ocular genetics, primary congenital glaucoma, ophthalmic nanomedicine, and cost effective therapies will continue to improve our understanding of glaucoma as well as access to quality care for glaucoma in SSA. AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada Faculty of Medicine, University of Ottawa, Ontario, Canada Department of Ophthalmology, Faculty of Medicine, Addis Ababa University, Addis Ababa, Ethiopia Innovation Eye Centre, Kisii, Kenya Department of Ophthalmology, University of Nairobi, Nairobi, Kenya Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro, Tanzania Department of Ophthalmology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania AN - 122900212. Language: English. Entry Date: 20170531. Revision Date: 20191120. Publication Type: Article AU - Damji, Karim F. AU - Nazarali, Samir AU - Giorgis, Abeba AU - Kiage, Dan AU - Marco, Sheila AU - Philippin, Heiko AU - Daniel, Neema AU - Amin, Samreen DB - ccm DO - 10.1080/17469899.2017.1295848 DP - EBSCOhost IS - 3 KW - Glaucoma -- Prevention and Control -- Africa South of the Sahara Program Development Glaucoma -- Diagnosis Glaucoma -- Therapy Ophthalmologists -- Education Glaucoma -- Education Africa South of the Sahara Blindness -- Prevention and Control Glaucoma -- Psychosocial Factors Community Health Services Health Promotion Quality of Health Care N1 - review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 101278197. PY - 2017 SN - 1746-9899 SP - 197-206 ST - STOP Glaucoma in Sub Saharan Africa: enhancing awareness, detection, management, and capacity for glaucoma care T2 - Expert Review of Ophthalmology TI - STOP Glaucoma in Sub Saharan Africa: enhancing awareness, detection, management, and capacity for glaucoma care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122900212&site=ehost-live&scope=site VL - 12 ID - 4466 ER - TY - JOUR AB - The pharmacological management of glaucoma and ocular hypertension has significantly changed over the last 18 years with the introduction of PGF2alpha analogues, more specifically latanoprost (6), travoprost (8), bimatoprost (10) and tafluprost (12). Prostanoids are currently the first-line medicines among ocular antihypertensive drugs in terms of efficacy, safety, patient compliance and medical economy. Their ability to effectively reduce intraocular pressure with once-per-day dosing, ocular tolerability comparable to timolol and general lack of systemic adverse effects have made them the mainstay of pharmacological therapy for glaucoma and ocular hypertension all over the world. The present review reports a novel, convergent and highly diastereoselective method for the synthesis of PGF2alpha analogues from the structurally advanced prostaglandin phenylsulfone (5Z)-(+)-15 and new omega-chain synthons. The biochemistry, clinical efficacy and side effects of four commercially available PGF2alpha analogues, currently used as first-line agents for reducing intraocular pressure in patients with glaucoma or ocular hypertension, are also discussed. Copyright © 2013 Elsevier Inc. All rights reserved. AU - Dams, Iwona AU - Wasyluk, Jaromir AU - Prost, Marek AU - Kutner, Andrzej DO - https://dx.doi.org/10.1016/j.prostaglandins.2013.01.001 KW - Amides/cs [Chemical Synthesis] Amides/pd [Pharmacology] *Antihypertensive Agents/cs [Chemical Synthesis] *Antihypertensive Agents/pd [Pharmacology] Bimatoprost Cloprostenol/aa [Analogs & Derivatives] Cloprostenol/cs [Chemical Synthesis] Cloprostenol/pd [Pharmacology] *Dinoprost/aa [Analogs & Derivatives] *Dinoprost/cs [Chemical Synthesis] *Dinoprost/pd [Pharmacology] *Glaucoma/dt [Drug Therapy] Glaucoma/me [Metabolism] Glaucoma/pp [Physiopathology] Humans Intraocular Pressure/de [Drug Effects] Latanoprost *Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/me [Metabolism] Ocular Hypertension/pp [Physiopathology] Prostaglandins F/cs [Chemical Synthesis] Prostaglandins F/pd [Pharmacology] Prostaglandins F, Synthetic/cs [Chemical Synthesis] Prostaglandins F, Synthetic/pd [Pharmacology] Randomized Controlled Trials as Topic Travoprost PY - 2013 SE - Dams, Iwona. R&D Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland. i.dams@ifarm.eu SN - 1098-8823 SP - 109-21 ST - Therapeutic uses of prostaglandin F(2alpha) analogues in ocular disease and novel synthetic strategies T2 - Prostaglandins & other lipid mediators TI - Therapeutic uses of prostaglandin F(2alpha) analogues in ocular disease and novel synthetic strategies UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23353557 VL - 104-105 Y2 - 20130123// ID - 994 ER - TY - JOUR AB - The pharmacological management of glaucoma and ocular hypertension has significantly changed over the last 18 years with the introduction of PGF 2α analogues, more specifically latanoprost (6), travoprost (8), bimatoprost (10) and tafluprost (12). Prostanoids are currently the first-line medicines among ocular antihypertensive drugs in terms of efficacy, safety, patient compliance and medical economy. Their ability to effectively reduce intraocular pressure with once-per-day dosing, ocular tolerability comparable to timolol and general lack of systemic adverse effects have made them the mainstay of pharmacological therapy for glaucoma and ocular hypertension all over the world. The present review reports a novel, convergent and highly diastereoselective method for the synthesis of PGF2α analogues from the structurally advanced prostaglandin phenylsulfone (5Z)-(+)-15 and new ω-chain synthons. The biochemistry, clinical efficacy and side effects of four commercially available PGF2α analogues, currently used as first-line agents for reducing intraocular pressure in patients with glaucoma or ocular hypertension, are also discussed. © 2012 Elsevier Inc. All rights reserved. AD - I. Dams, RandD Chemistry Department, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland AU - Dams, I. AU - Wasyluk, J. AU - Prost, M. AU - Kutner, A. C1 - lumigan(Allergan,United States) rescula(Ciba Geigy,United States) taflotan(Santen,Finland) travatan xalatan(Pfizer,United States) C2 - Allergan(United States) Ciba Geigy(United States) Pfizer(United States) Santen(Finland) DB - Embase Medline DO - 10.1016/j.prostaglandins.2013.01.001 KW - bimatoprost fluprostenol latanoprost nonsteroid antiinflammatory agent promethazine prostaglandin F2 alpha prostanoid tafluprost timolol travoprost unoprostone unoprostone isopropyl ester alopecia behavior blood vessel permeability conference paper drug efficacy drug marketing drug safety eye disease glaucoma hair loss health care cost human hyperemia hyperpigmentation intraocular hypertension intraocular pressure leisure low level laser therapy miosis movement (physiology) nonhuman open angle glaucoma patient compliance retina macula cystoid edema skin discoloration structure activity relation trichiasis lumigan rescula taflotan travatan xalatan LA - English M3 - Conference Paper N1 - L52442373 2013-02-20 2013-07-16 PY - 2013 SN - 1098-8823 SP - 109-121 ST - Therapeutic uses of prostaglandin F2α analogues in ocular disease and novel synthetic strategies T2 - Prostaglandins and Other Lipid Mediators TI - Therapeutic uses of prostaglandin F2α analogues in ocular disease and novel synthetic strategies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52442373&from=export http://dx.doi.org/10.1016/j.prostaglandins.2013.01.001 VL - 104-105 ID - 2985 ER - TY - JOUR AB - PURPOSE: To study the effect of multimedia education on acceptance of comprehensive eye examinations (CEEs), critical for detecting glaucoma and diabetic eye disease, among rural Chinese patients using a randomized, controlled design., METHODS: Patients aged >=40 years were recruited from 52 routine clinic sessions (26 intervention, 26 control) conducted at seven rural hospitals in Guangdong, China. Subjects answered demographic questionnaires, were tested on knowledge about CEEs and chronic eye disease, and were told the cost of examination (range US$0-8). At intervention sessions, subjects were cluster-randomized to view a 10-minute video on the value of CEEs and retested. Control subjects were not retested. Trial outcomes were acceptance of CEEs (primary outcome) and final knowledge scores (secondary outcome)., RESULTS: At baseline, >70% (p = 0.70) of both intervention (n = 241, 61.2 +/- 12.3 years) and control (n = 218, 58.4 +/- 11.7 years) subjects answered no knowledge questions correctly, but mean scores on the test (maximum 5 points) increased by 1.39 (standard deviation 0.12) points (p < 0.001) after viewing the video. Intervention (73.0%) and control (72.9%) subjects did not differ in acceptance of CEEs (p > 0.50). In mixed-effect logistic regression models, acceptance of CEEs was associated with availability of free CEEs (odds ratio 18.3, 95% confidence interval 1.32-253.0), but not group assignment or knowledge score. Acceptance was 97.5% (79/81) when free exams were offered., CONCLUSIONS: Education increased knowledge about but not acceptance of CEEs, which was generally high. Making CEEs free could further increase acceptance. AU - Dan, Aihua AU - Raubvogel, Graham AU - Chen, Tingting AU - Ye, Tiantian AU - Jin, Ling AU - Xiao, Baixiang AU - Sanchez, Ana AU - Congdon, Nathan DO - https://dx.doi.org/10.3109/09286586.2015.1056812 IS - 4 KW - Adult Aged Asian Continental Ancestry Group/eh [Ethnology] China/ep [Epidemiology] Diabetic Retinopathy/di [Diagnosis] Diabetic Retinopathy/ep [Epidemiology] Female Glaucoma/di [Diagnosis] Glaucoma/ep [Epidemiology] *Health Knowledge, Attitudes, Practice *Health Promotion/mt [Methods] Humans Male Middle Aged *Multimedia *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] *Patient Education as Topic/mt [Methods] *Physical Examination/sn [Statistics & Numerical Data] *Rural Population/sn [Statistics & Numerical Data] Surveys and Questionnaires Vision Tests PY - 2015 SE - Dan, Aihua. Translational Research for Equitable Eyecare (TREE), Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. SN - 1744-5086 0928-6586 SP - 283-90 ST - The Impact of Multimedia Education on Uptake of Comprehensive Eye Examinations in Rural China: A Randomized, Controlled Trial T2 - Ophthalmic epidemiology TI - The Impact of Multimedia Education on Uptake of Comprehensive Eye Examinations in Rural China: A Randomized, Controlled Trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26218111 VL - 22 ID - 781 ER - TY - JOUR AB - Wide variations in the response to intraocular (IOP)-lowering medications may be due to the normal response of the subjects or to variables unrelated to the effect of medication, eg, noncompliance or recording errors. We used data from a previous study of medications designed to lower IOP to investigate the influence of readings showing an unusually large increase in IOP from baseline on the statistical analysis and conclusions. These readings, which could have been due to variables unrelated to the effect of medication, were defined as "outliers" by a statistical method. A statistically insignificant difference between two IOP-lowering medications became significant on excluding two subjects with outlier IOP readings. We explain how reporting results obtained with and without including outliers in the analysis may provide clinicians with more complete information. AU - Dandona, L. AU - Morrison, J. C. AU - Robin, A. L. AU - Quigley, H. A. IS - 10 KW - Analysis of Variance Clinical Trials as Topic Clonidine/ad [Administration & Dosage] Clonidine/aa [Analogs & Derivatives] Clonidine/tu [Therapeutic Use] *Data Interpretation, Statistical Double-Blind Method Drug Therapy, Combination Epinephrine/ad [Administration & Dosage] Epinephrine/aa [Analogs & Derivatives] Epinephrine/tu [Therapeutic Use] Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Ocular Hypertension/dt [Drug Therapy] Random Allocation Timolol/ad [Administration & Dosage] Timolol/tu [Therapeutic Use] PY - 1989 SE - Dandona, L. Glaucoma Service, Wilmer Ophthalmological Institute, Johns Hopkins University, School of Medicine, Baltimore, MD 21205. SN - 0022-023X SP - 737-744 ST - "Outlier" intraocular pressure readings: valid or invalid for statistical analysis? T2 - Ophthalmic surgery TI - "Outlier" intraocular pressure readings: valid or invalid for statistical analysis? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2694044 VL - 20 ID - 2162 ER - TY - JOUR AB - AIM/BACKGROUND: The public health significance of corneal transplantation in dealing with corneal blindness in the developing world would depend upon the survival rate of transplants. This study was done to analyse the survival rate of corneal transplants in a large series in India, and to evaluate the influence of various risk factors on transplant survival., METHODS: The records of a series of 1725 cases of corneal transplants carried out during 1987-95 at a tertiary eye care institution in India were reviewed. The Kaplan-Meier method was used to determine 5 year survival rates of corneal transplants performed for the various categories of preoperative diagnosis. Multivariate Cox proportional hazards regression was used to assess how preoperative diagnosis, socioeconomic status, age, sex, vascularisation of host cornea, quality of donor cornea, and training status of surgeon influenced transplant survival. The effect of these variables on visual outcome was assessed using multiple logistic regression., RESULTS: The survival rates at 1, 2, and 5 years for all corneal transplants performed for the first time in 1389 cases were 79.6% (95% confidence interval = 77.3-81.9%), 68.7% (65.7-71.7%) and 46.5% (41.7-51.3%). The 5 year survival rate was highest if the corneal transplant was done for keratoconus (95.1% (84.8-100%)) and lowest if carried out for previous transplant failure (21.2% (13.8-28.6%)). The relative risk of transplant failure was higher if the preoperative diagnosis was previous transplant failure (2.04 (1.62-2.55)), aphakic bullous keratopathy (1.78 (1.38-2.28)), corneal clouding due to miscellaneous causes including congenital conditions and glaucoma (1.63 (1.21-2.19)), or adherent leucoma (1.11 (0.81-1.51)) than for the other preoperative diagnoses. Patients with lower socioeconomic status had higher relative risk of transplant failure (1.28 (1.16-1.42)), as did patients < 10 years of age (1.42 (1.23-1.64)). Higher relative risk of transplant failure was associated with vascularisation of the host cornea before transplantation (1.15 (1.04-1.27)), and with the use of fair quality donor cornea for transplantation compared with excellent, very good, or good quality donor cornea (1.26 (1.06-1.52)). Before corneal transplant 80.2% of the eyes were blind (visual acuity < 3/60), whereas at last follow up 41.8% eyes were blind. The odds of having visual acuity > 6/18 were higher if the transplant was done for keratoconus (9.99 (6.10-16.36)) or corneal dystrophies (1.77 (1.21-2.58)) than for the other preoperative diagnoses., CONCLUSION: Reasonable success with corneal transplantation is possible in the developing world if data from this part of the world regarding the different survival rates for the various preoperative diagnoses and the influence of risk factors on transplant survival and visual outcome are taken into account while determining priority for transplant cases in the present situation of limited availability of donor corneas. AU - Dandona, L. AU - Naduvilath, T. J. AU - Janarthanan, M. AU - Ragu, K. AU - Rao, G. N. IS - 9 KW - Adolescent Adult Aged Aged, 80 and over Blindness/ep [Epidemiology] *Blindness/su [Surgery] Child Corneal Diseases/ep [Epidemiology] *Corneal Diseases/su [Surgery] Female *Graft Survival Humans India/ep [Epidemiology] *Keratoplasty, Penetrating/sn [Statistics & Numerical Data] Male Middle Aged Postoperative Care Preoperative Care Proportional Hazards Models Risk Factors Treatment Failure Visual Acuity PY - 1997 SE - Dandona, L. Public Health Ophthalmology Service, L V Prasad Eye Institute, Hyderabad, India. SN - 0007-1161 SP - 726-31 ST - Survival analysis and visual outcome in a large series of corneal transplants in India T2 - The British journal of ophthalmology TI - Survival analysis and visual outcome in a large series of corneal transplants in India UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9422922 VL - 81 ID - 2010 ER - TY - JOUR AB - Indications for penetrating keratoplasty (PK) in the developing world from a large series are not well documented. This study was done to evaluate the indications for PK in a major eye care institution in India. The records for a consecutive series of 1,964 PKs were analysed and multiple logistic regression was used to study the effect of age, socioeconomic status and sex on the indications for PK. The indications for PK were corneal scarring in 551 (28.1%) including adherent leukoma in 147 (7.5%), regrafts in 336 (17.1%), active infectious keratitis in 239 (12.2%), aphakic bullous keratopathy in 231 (11.8%), pseudophakic bullous keratopathy in 209 (10.6%), corneal dystrophies in 165 (8.4%) including Fuchs' dystrophy in 23 (1.2%), keratoconus in 118 (6%), and miscellaneous in 115 (5.9%). The odds that the patient belonged to lower socioeconomic status were significantly higher if the PK was done for active infectious keratitis (odds ratio 2.73, p < 0.0001), corneal scarring (odds ratio 1.72, p = 0.0009) or regraft (odds ratio 1.44, p = 0.047). Corneal scarring, including adherent leukoma, and active infectious keratitis are relatively more common indications whereas keratoconus, pseudophakic bullous keratopathy and Fuchs' dystrophy are less common indications for PK in India than reported from the developed world. Indications for PK which carry a poorer prognosis for graft survival are relatively more common in India than in the developed world. AU - Dandona, L. AU - Ragu, K. AU - Janarthanan, M. AU - Naduvilath, T. J. AU - Shenoy, R. AU - Rao, G. N. IS - 3 KW - Adolescent Adult Aged Aged, 80 and over Child Child, Preschool Corneal Diseases/di [Diagnosis] *Corneal Diseases/su [Surgery] Developing Countries Female Graft Survival Humans India Infant Infant, Newborn Keratoplasty, Penetrating/td [Trends] *Keratoplasty, Penetrating Male Middle Aged Regression Analysis Retrospective Studies Social Class Treatment Outcome PY - 1997 SE - Dandona, L. Public Health Opthalmology Service, L.V. Prasad Eye Institute, Hyderabad, India. dandona@lvpeye.stph.net SN - 0301-4738 SP - 163-8 ST - Indications for penetrating keratoplasty in India T2 - Indian journal of ophthalmology TI - Indications for penetrating keratoplasty in India UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9475018 VL - 45 ID - 2006 ER - TY - JOUR AB - The cornea on the front surface of the eye provides our window to the world. Maintenance of corneal transparency is dependent on the integrity and functionality of the outermost corneal epithelium which itself is maintained throughout life by a population of limbal epithelial stem cells (LESC). If this adult stem cell population is depleted by injury or disease, the transparency of the cornea and therefore vision is threatened. LESC deficiency results in corneal opacification, inflammation, vascularization, and severe discomfort. Cultured LESC therapy is one of only several examples of the successful use of an adult stem cell therapy in patients. Hence, the ready accessibility of a transparent stem cell niche and the clinical precedence for use of stem cell therapy make the cornea a unique and excellent model for the study of adult stem cells in health and disease. This review will discuss our current understanding of LESC biology, pathology, and therapeutic application. AU - Daniels, Julie T. AU - Harris, Anna R. AU - Mason, Chris IS - 3 KW - Animals *Disease *Epithelium, Corneal/cy [Cytology] *Health Humans Limbus Corneae/cy [Cytology] *Stem Cells/cy [Cytology] PY - 2006 SE - Daniels, Julie T. Cells for Sight Transplantation and Research Programme, Ocular Repair and Regeneration Biology Unit, Division of Pathology, UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL. SN - 1550-8943 SP - 247-54 ST - Corneal epithelial stem cells in health and disease T2 - Stem cell reviews TI - Corneal epithelial stem cells in health and disease UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17625261 VL - 2 ID - 1626 ER - TY - JOUR AU - Dannelly, H. K. AU - Waworuntu, R. DB - Embase DO - 10.1097/01.ICL.0000163535.34189.C8 IS - 4 KW - cornea ulcer education human incidence keratitis letter patient patient compliance priority journal LA - English M3 - Letter N1 - L43197023 2006-02-21 PY - 2005 SN - 1542-2321 SP - 179 ST - Response from the authors [2] T2 - Eye and Contact Lens TI - Response from the authors [2] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43197023&from=export http://dx.doi.org/10.1097/01.ICL.0000163535.34189.C8 VL - 31 ID - 3682 ER - TY - JOUR AB - PURPOSE. To evaluate microbial contamination in silver-impregnated contact lens (CL) storage cases while establishing the effect of "wet " and "dry " case maintenance and to determine its association with clinical signs, symptoms, and compliance. METHODS. Two noncontemporaneous prospective studies were conducted. Regular storage cases in study 1 (n = 40) and silver-impregnated cases in study 2 (n = 41) were used in conjunction with CL solution and CLs (balafilcon A). Cases were replaced monthly and collected at 1, 3, and 4 (for silverimpregnated cases only) months. Regular cases and the fourthmonth silver-impregnated cases were maintained dry, and the other cases were maintained wet between uses. At collection, storage cases were sampled and cultured for microbial identification and enumeration. Ocular clinical findings, subjective responses to CL wear, and compliance were recorded at each visit. RESULTS. The percentages of microbial contamination for silverimpregnated and regular cases were 71% and 82% respectively. There were significantly (P < 0.005) fewer organisms in silverimpregnated cases (1.7 log CFU per well) than in regular cases (4.1 log CFU per well). In particular, silver-impregnated cases showed lower levels of Gram-negative bacteria (P = 0.04), Gram-positive bacilli (P = 0.03), and fungi (P = 0.006). Maintaining the silver-impregnated cases wet resulted in a lower percentage of contamination (71%; P < 0.01) than maintaining them dry (94%). There was no association between any clinical signs, symptoms, or compliance and microbial contamination of storage cases. CONCLUSIONS. More than 70% of the storage cases used in daily wear CL care for a month was contaminated irrespective of the types of cases. However, silver-impregnated cases were colonized by reduced levels of Gram-negative bacteria. © 2012 The Association for Research in Vision and Ophthalmology, Inc. AD - Brien Holden Vision Institute, Sydney, Australia School of Optometry and Vision Science, University of New South Wales, Sydney, Australia AU - Dantam, J. AU - Zhu, H. AU - Willcox, M. AU - Ozkan, J. AU - Naduvilath, T. AU - Thomas, V. AU - Stapleton, F. DB - Scopus DO - 10.1167/iovs.11-8197 IS - 3 M3 - Article N1 - Cited By :27 Export Date: 19 July 2021 PY - 2012 SP - 1641-1648 ST - In vivo assessment of antimicrobial efficacy of silver-impregnated contact lens storage cases T2 - Investigative Ophthalmology and Visual Science TI - In vivo assessment of antimicrobial efficacy of silver-impregnated contact lens storage cases UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860697921&doi=10.1167%2fiovs.11-8197&partnerID=40&md5=ce66e3356b5feeac4f338c87abeadeba VL - 53 ID - 5080 ER - TY - JOUR AB - PURPOSE OF REVIEW: Endothelial keratoplasty has been adopted worldwide as an alternative to penetrating keratoplasty in the treatment of corneal endothelial disorders. Descemet stripping (automated) endothelial keratoplasty (DSEK/DSAEK) may be the current standard, whereas Descemet membrane endothelial keratoplasty (DMEK), that is, isolated transplantation of Descemet membrane, may allow further improvement of clinical outcome. RECENT FINDINGS: DSEK/DSAEK may still have three major challenges: suboptimal visual acuity and relatively slow visual rehabilitation, limited accessibility due to required investments in equipment or the purchase of predissected tissue, and a drop in donor endothelial cell density in the early postoperative phase. Although DMEK may allow much quicker and (near) complete visual rehabilitation as well as easier logistics in donor preparation, the surgical technique may initially require more training to obtain consistent outcomes. SUMMARY: Compared with DSEK/DSAEK, DMEK may have higher clinical potential with 75% of cases reaching 20/25 or better (> or =0.8) within 1-3 months. Furthermore, preparation of isolated Descemet grafts does not require large investments and may increase overall donor tissue availability. Hence, corneal surgeons may consider 'to make the switch' from DSEK/DSAEK to DMEK. AD - Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands. AN - 105364029. Language: English. Entry Date: 20090807. Revision Date: 20150711. Publication Type: Journal Article AU - Dapena, I. AU - Ham, L. AU - Melles, G. R. J. DB - ccm DO - 10.1097/ICU.0b013e32832b8d18 DP - EBSCOhost IS - 4 KW - Corneal Transplantation -- Methods Eye Surgery Endothelium -- Physiology Glaucoma -- Etiology Graft Rejection Grafts -- Adverse Effects Ophthalmology Surgery, Operative -- Methods Transplant Donors Visual Acuity -- Evaluation N1 - diagnostic images; pictorial; review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM19417653. PY - 2009 SN - 1040-8738 SP - 299-307 ST - Endothelial keratoplasty: DSEK/DSAEK or DMEK--the thinner the better? T2 - Current Opinion in Ophthalmology TI - Endothelial keratoplasty: DSEK/DSAEK or DMEK--the thinner the better? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105364029&site=ehost-live&scope=site VL - 20 ID - 4771 ER - TY - JOUR AN - WOS:A1993KH11900014 AU - Dart, J. K. G. DA - JAN DO - 10.1136/bjo.77.1.49 IS - 1 PY - 1993 SN - 0007-1161 SP - 49-53 ST - DISEASE AND RISKS ASSOCIATED WITH CONTACT-LENSES T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - DISEASE AND RISKS ASSOCIATED WITH CONTACT-LENSES VL - 77 ID - 5807 ER - TY - JOUR AB - PURPOSE: To study the clinical profile and distribution of various subtypes of glaucoma in a referral practice in North India., METHOD: A retrospective analysis was done of 2425 patients who attended the glaucoma clinic in a tertiary eye-care centre for five years from January 1995 to December 1999. A detailed history was obtained and a thorough examination was performed, including gonioscopy, disc assessment, applanation tonometry and automated perimetry. Diurnal variation of IOP and provocative tests for glaucoma were done where applicable., RESULT: Primary angle closure glaucoma (PACG) was the most common glaucoma subtype. The primary open angle glaucoma (POAG) to the PACG ratio was 37:63. Chronic angle closure glaucoma (CACG) was the most common PACG subtype. The majority of CACG cases were relatively asymptomatic. Male dominance was seen for POAG, juvenile open angle glaucoma (JOAG), CACG, normal tension glaucoma (NTG) and secondary glaucomas. Female dominance was seen for ocular hypertension (OHT), acute or intermittent ACG and developmental glaucomas. The mean age in years at presentation was POAG:60.54 years (males 61.54 years, females 59.01 years) and PACG: 55.13 years (males 57.25 years, females 53.60). The three common secondary glaucomas were: glaucoma secondary to adherent leucoma, aphakic and pseudophakic glaucomas and traumatic glaucomas. Advanced glaucoma was detected in 42 to 53% of patients and bilateral blindness in 8 to 14% of patients in various subtypes., CONCLUSION: Compared to Caucasians, glaucoma patients in North India seem to present nearly a decade earlier and the disease is more advanced at presentation. While PACG is the most commonly encountered glaucoma, NTG and exfoliative glaucoma are relatively rare. AU - Das, J. AU - Bhomaj, S. AU - Chaudhuri, Z. AU - Sharma, P. AU - Negi, A. AU - Dasgupta, A. IS - 1 KW - Adolescent Adult Age Distribution Aged Aged, 80 and over Child Child, Preschool Female Glaucoma/di [Diagnosis] *Glaucoma/ep [Epidemiology] Glaucoma/pp [Physiopathology] Gonioscopy *Hospitals, Special/sn [Statistics & Numerical Data] Humans India/ep [Epidemiology] Infant Infant, Newborn Intraocular Pressure/ph [Physiology] Male Middle Aged Ophthalmology Retrospective Studies Sex Distribution Tonometry, Ocular Visual Field Tests PY - 2001 SE - Das, J. Guru Nanak Eye Centre, Maulana Azad Medical College, University of Delhi, New Delhi. SN - 0301-4738 SP - 25-30 ST - Profile of glaucoma in a major eye hospital in north India T2 - Indian journal of ophthalmology TI - Profile of glaucoma in a major eye hospital in north India UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=15887712 VL - 49 ID - 1904 ER - TY - JOUR AB - PURPOSE: The International Agency for Prevention of Blindness (IAPB) South East Asia region (SEAR) that consists of 11 countries contains 26% of the world's population (1,761,000,000). In this region 12 million are blind and 78.5 million are visually impaired. This amounts to 30% of global blindness and 32% of global visual impairment., DESIGN: Rapid assessment of avoidable blindness (RAAB) survey analysis., METHODS: RAAB, either a repeat or a first time survey, was completed in 8 countries in this decade (2010 onwards). These include Bangladesh, Bhutan, India, Indonesia, Maldives, Sri Lanka, Thailand, and Timor Leste., RESULTS: Cataract is the principal cause of blindness and severe visual impairment in all countries. Refractive error is the principal cause of moderate visual impairment in 4 countries: Bangladesh, India, Maldives, and Sri Lanka; cataract continues to be the principal cause of moderate visual impairment in 4 other countries: Bhutan, Indonesia, Thailand, and Timor Leste. Outcome of cataract surgery is suboptimal in the Maldives and Timor Leste., CONCLUSIONS: Rigorous focus is necessary to improve cataract surgery outcomes and correction of refractive error without neglecting the quality of care. At the same time allowances must be made for care of the emerging causes of visual impairment and blindness such as glaucoma and posterior segment disorders, particularly diabetic retinopathy. Copyright 2018 Asia-Pacific Academy of Ophthalmology. AU - Das, Taraprasad DO - https://dx.doi.org/10.22608/APO.2017425 IS - 5 KW - Asia, Southeastern/ep [Epidemiology] *Blindness/ep [Epidemiology] Blindness/et [Etiology] Blindness/pc [Prevention & Control] Cataract/co [Complications] Delivery of Health Care/st [Standards] Health Services Accessibility/st [Standards] Humans Prevalence Refractive Errors/co [Complications] *Vision, Low/ep [Epidemiology] Vision, Low/et [Etiology] Vision, Low/pc [Prevention & Control] PY - 2018 SE - Das, Taraprasad. L V Prasad Eye Institute, Hyderabad, India. Das, Taraprasad. International Agency for Prevention of Blindness, South East Asia. SN - 2162-0989 SP - 312-315 ST - Blindness and Visual Impairment Profile and Rapid Assessment of Avoidable Blindness in South East Asia: Analysis of New Data. 2017 APAO Holmes Lecture T2 - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) TI - Blindness and Visual Impairment Profile and Rapid Assessment of Avoidable Blindness in South East Asia: Analysis of New Data. 2017 APAO Holmes Lecture UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29532647 VL - 7 Y2 - 20180313// ID - 445 ER - TY - JOUR AB - India has done well in eye care delivery by recognizing visual impairment and blindness as a major medical challenge. Major contributions have come from ophthalmologists (mass cataract surgery in the early 1900s; major participation of non-government organizations), policy makers (National Program for Control of Blindness and Visual Impairment 1976; systematic development under the World Bank assisted India Cataract Project, 1995-2002), and the industry (manufacturing of affordable surgical instruments and medicines). Although the country could boast of higher cataract surgical coverage and near-total elimination of trachoma, there is increasing prevalence of diabetic retinopathy and undetected glaucoma. India is in the crossroad of adherence to old successful models of service delivery and adoption of new innovative methods of teaching and training, manpower development and skill-based training, relevant medical research and product development. In the absence of these new approaches, the initial gains in eye care could not be furthered in India. A new approach, that will combine the best of the "old" tradition of empathy and the "new" technology of analytics, is required to imagine the future of eye care in India. AU - Das, Taraprasad AU - Panda, Lapam DO - https://dx.doi.org/10.4103/ijo.IJO_872_18 IS - 11 KW - *Diagnostic Imaging/mt [Methods] Diagnostic Imaging/td [Trends] *Diagnostic Techniques, Ophthalmological/td [Trends] *Eye Diseases/di [Diagnosis] Humans India PY - 2018 SE - Das, Taraprasad. Srimati Kanuri Santhamma Centre for Vitreoretinal Diseases, L V Prasad Eye Institute, Hyderabad, Telangana; Indian Oil Center for Rural Eye Health, L V Prasad Eye Institute, Bhubaneswar, Odisha, India. Panda, Lapam. Indian Oil Center for Rural Eye Health, L V Prasad Eye Institute, Bhubaneswar, Odisha, India. SN - 1998-3689 0301-4738 SP - 1532-1538 ST - Imagining eye care in India (2018 Lalit Prakash Agarwal lecture) T2 - Indian journal of ophthalmology TI - Imagining eye care in India (2018 Lalit Prakash Agarwal lecture) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=30355857 VL - 66 ID - 401 ER - TY - JOUR AB - BACKGROUND: Persistency with drug therapy reflects a number of factors, including patient tolerability of adverse events resulting from therapy and clinician satisfaction with the medication's effectiveness in reducing intraocular pressure., OBJECTIVE: This study assesses persistency with topical glaucoma medications administered as initial therapy by evaluating rates of discontinuation and change in therapy., METHODS: A retrospective cohort study was conducted using pharmacy claims data from 3 geographically diverse healthcare plans. Newly treated glaucoma patients younger than 65 years of age were selected based on an initial glaucoma medication fill during a 12-month period. Patients were followed for persistency, defined as discontinuation or change (switch or add-on) of initial glaucoma therapy; discontinuation of therapy was also evaluated as a separate end point., RESULTS: In all, 1330 patients (followed for 1126 person-years) met the eligibility criteria. Compared with latanoprost users, patients initiated on other topical monotherapies were more likely to discontinue or change therapy, and patients initiated on other topical monotherapies were more likely than latanoprost users to discontinue therapy., CONCLUSION: Population-based data indicate that latanoprost offers superior persistency compared to agents from other popular classes of topical ocular hypotensives. AU - Dasgupta, Samaresh AU - Oates, Vikki AU - Bookhart, Brahim K. AU - Vaziri, Baze AU - Schwartz, Gail F. AU - Mozaffari, Essy IS - 10 Suppl KW - Administration, Topical *Antihypertensive Agents/ad [Administration & Dosage] Female *Glaucoma/dt [Drug Therapy] Humans Insurance Claim Review Intraocular Pressure/de [Drug Effects] Latanoprost Male Middle Aged *Ophthalmic Solutions/ad [Administration & Dosage] *Patient Compliance Proportional Hazards Models *Prostaglandins F, Synthetic/ad [Administration & Dosage] Retrospective Studies Self Administration Survival Analysis PY - 2002 SN - 1088-0224 SP - S255-61 ST - Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data T2 - The American journal of managed care TI - Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=12188168 VL - 8 ID - 1879 ER - TY - JOUR AB - Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of direct reduction in trabecular outflow resistance in addition to a decrease in episcleral venous pressure and aqueous humor production. The efficacy of netarsudil has been shown in animal studies and human clinical trials. It has been shown to be noninferior to the therapy with topical timolol in individuals with baseline IOP <25 mmHg. Importantly, netarsudil has been shown to reduce IOP to the same degree, regardless of baseline levels. There are no known systemic safety issues associated with netarsudil. The most common local adverse effects relate to conjunctival hyperemia. The once-daily dosing schedule is advantageous for individuals who have difficulties with medication adherence. Further studies of a combination of netarsudil and latanoprost agents are currently underway. AU - Dasso, Lily AU - Al-Khaled, Tala AU - Sonty, Sriram AU - Aref, Ahmad A. DO - https://dx.doi.org/10.2147/OPTH.S154001 PY - 2018 SE - Dasso, Lily. Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA, ssonty@msn.com. Al-Khaled, Tala. Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA, ssonty@msn.com. Sonty, Sriram. Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA, ssonty@msn.com. Aref, Ahmad A. Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA, ssonty@msn.com. SN - 1177-5467 SP - 1939-1944 ST - Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=30323550 VL - 12 Y2 - 20181004// ID - 593 ER - TY - JOUR AB - BackgroundA major obstacle that academic institutions face is the steep learning curve for cornea fellows initially learning to perform Descemet Stripping Endothelial Keratoplasty (DSEK). The purpose of this study is to evaluate the outcomes of complex DSEK performed by cornea fellow supervised by an attending surgeon at an academic institution.MethodsPatients who underwent a complex DSEK procedure performed by a cornea fellow during the years 2009-2013 were included. All the surgeries were supervised by the same cornea attending. All patients had a minimum follow-up of 6months. Charts were reviewed for demographic data, intraoperative and postoperative complications and clinical outcomes. Corneal graft survival was calculated using the Kaplan-Meier analysis.ResultsFifty-seven eyes of 55 patients (mean age 77.58.5years) were included in the study with a mean follow-up time of 16.4 +/- 15.6months. Previous graft failure, presence of a tube and history of trabeculectomy were the leading diagnoses to define the surgery as complex. No intraoperative complications occurred. In 21.1% of cases a corneal graft detachment was documented in the first postoperative day. Mean visual acuity improved from 1.06 LogMAR (20/230) preoperatively to 0.39 LogMAR (20/50, p<0.001) by the sixth postoperative month and to 0.52 LogMAR (20/65, p<0.001) at the last follow-up visit. Graft failure rate was 29.8%. Kaplan-Meier analysis found a 67.2% graft survival rate at 20months.Conclusions Complex DSEK can be performed successfully with an acceptable postoperative complication rate by cornea fellows during their training period when supervised by an experienced attending. AN - WOS:000448748700001 AU - Daubert, J. AU - O'Brien, T. P. AU - Adler, E. AU - Spierer, O. DA - OCT 30 DO - 10.1186/s12886-018-0946-4 PY - 2018 SN - 1471-2415 ST - Outcomes of complex Descemet Stripping Endothelial Keratoplasty performed by cornea fellows T2 - BMC OPHTHALMOLOGY TI - Outcomes of complex Descemet Stripping Endothelial Keratoplasty performed by cornea fellows VL - 18 ID - 6115 ER - TY - JOUR AB - PURPOSE: To determine the accuracy of patient-physician communication regarding topical ophthalmic medication use based on bottle cap color, particularly among individuals who may have acquired color vision deficiency from glaucoma., DESIGN: Cross-sectional, clinical study., PARTICIPANTS: Patients aged >=18 years with primary open-angle, primary angle-closure, pseudoexfoliation, or pigment dispersion glaucoma, bilateral visual acuity of >=20/400, and no concurrent conditions that may affect color vision., METHODS: A total of 100 patients provided color descriptions of 11 distinct medication bottle caps. Color descriptors were then presented to 3 physicians. Physicians matched each color descriptor to the medication they thought the descriptor was describing., MAIN OUTCOME MEASURES: Frequency of patient-physician agreement, occurring when all 3 physicians accurately matched the color descriptor to the correct medication. Multivariate regression models evaluated whether patient-physician agreement decreased with degree of better-eye visual field (VF) damage, color descriptor heterogeneity, or color vision deficiency, as determined by the Hardy-Rand-Rittler (HRR) score and Lanthony D15 color confusion index (D15 CCI)., RESULTS: Subjects had a mean age of 69 (+/-11) years, with VF mean deviation of -4.7 (+/-6.0) and -10.9 (+/-8.4) decibels (dB) in the better- and worse-seeing eyes, respectively. Patients produced 102 unique color descriptors to describe the colors of the 11 bottle caps. Among individual patients, the mean number of medications demonstrating agreement was 6.1/11 (55.5%). Agreement was less than 15% for 4 medications (prednisolone acetate [generic], betaxolol HCl [Betoptic; Alcon Laboratories Inc., Fort Worth, TX], brinzolamide/brimonidine [Simbrinza; Alcon Laboratories Inc.], and latanoprost [Xalatan; Pfizer, Inc., New York, NY]). Lower HRR scores and higher D15 CCI (both indicating worse color vision) were associated with greater VF damage (P < 0.001). Extent of color vision deficiency and color descriptor heterogeneity significantly predicted agreement in multivariate models (odds of agreement = 0.90 per 1 point decrement in HRR score, P < 0.001; odds of agreement = 0.30 for medications exhibiting high heterogeneity [>=11 descriptors], P = 0.007)., CONCLUSIONS: Physician understanding of patient medication use based solely on bottle cap color is frequently incorrect, particularly in patients with glaucoma who may have color vision deficiency. Errors based on communication using bottle cap color alone may be common and could lead to confusion and harm. Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AU - Dave, Pujan AU - Villarreal, Guadalupe, Jr. AU - Friedman, David S. AU - Kahook, Malik Y. AU - Ramulu, Pradeep Y. DO - https://dx.doi.org/10.1016/j.ophtha.2015.06.013 IS - 12 KW - Administration, Topical Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Color Color Perception Tests *Communication Cross-Sectional Studies *Drug Packaging/st [Standards] Drug Utilization Female *Glaucoma/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Male Medication Adherence Medication Errors/pc [Prevention & Control] Middle Aged Ophthalmic Solutions *Physician-Patient Relations Surveys and Questionnaires Visual Acuity N1 - Comment in (CIN) PY - 2015 SE - Dave, Pujan. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Villarreal, Guadalupe Jr. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Friedman, David S. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Kahook, Malik Y. Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Colorado. Ramulu, Pradeep Y. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Electronic address: pramulu1@jhmi.edu. SN - 1549-4713 0161-6420 SP - 2373-9 ST - Ability of Bottle Cap Color to Facilitate Accurate Patient-Physician Communication Regarding Medication Identity in Patients with Glaucoma T2 - Ophthalmology T3 - Comment in: Ophthalmology. 2015 Dec;122(12):2368-70; PMID: 26592669 [https://www.ncbi.nlm.nih.gov/pubmed/26592669] TI - Ability of Bottle Cap Color to Facilitate Accurate Patient-Physician Communication Regarding Medication Identity in Patients with Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26260280 VL - 122 Y2 - 20150808// ID - 780 ER - TY - JOUR AB - Development of new drug candidates and novel delivery techniques for treatment of ocular diseases has recently accelerated. The field of ocular drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist for past 10-20 years. In ophthalmic formulation to the eye like solutions, suspensions, and ointments are available in the market shows drawbacks such as increased precorneal elimination, blurred vision and high variability in efficiency. The major setback associated with the conventional dosage forms is the bioavailability of drug. In the last three decades to improve the bioavailability by common to adding viscosity-enhancing agents or mucoadhesive polymers into dosage formulations. To prevail over to conventional dosage formulations there were non-conventional technologies such as lipososme, niosome, microspheres, nanoparticle, implant, gene therapy and ocular inserts could be developed in pharmaceutical market. In this article, we have summarized the different types of commonly used ophthalmic formulations and compared the conventional formulations with the advanced formulation in many respects like their applicability, acceptance, characteristics and utility. "Ocular drug delivery is one of the most interesting and challenging endeavours facing the pharmaceutical scientist...The anatomy, physiology and biochemistry of the eye render this organ exquisitely impervious to foreign substances...The challenge to the formulator is to outwit the protective barriers of the eye without causing permanent tissue damage...The ancient ophthalmic solutions, suspensions and ointment dosage forms are clearly no longer sufficient to combat some present virulent diseases...". AD - V. Dave, Department of Pharmacy, Banasthali University, Banasthali, Rajasthan 304022, India AU - Dave, V. AU - Sharma, S. AU - Yadav, S. AU - Paliwal, S. DB - Embase IS - 1 KW - epinephrine carbomer carboxymethylcellulose dexamethasone dipivefrine ganciclovir gentamicin hydroxypropylcellulose microRNA microsphere pilocarpine polyglactin polylactic acid prednisolone acetate prodrug small interfering RNA biodegradability cardiovascular disease cell encapsulation controlled release formulation Cytomegalovirus retinitis drug absorption drug bioavailability drug delivery system drug hypersensitivity drug implant drug research drug stability drug tolerance dry eye eye burning eye irritation eye pain eye redness eye swelling gene targeting human intraocular hypertension liposomal delivery microencapsulation nanopharmaceutics nonhuman nonviral gene delivery system ocular pruritus patient compliance photosensitivity macular edema review risk benefit analysis scleral plug visual disorder Ocusert Posurdex Vitasert LA - English M3 - Review N1 - L366297354 2012-12-26 2013-01-02 PY - 2012 SN - 0975-4415 SP - 1-8 ST - Advancement and tribulations in ocular drug delivery T2 - International Journal of Drug Delivery TI - Advancement and tribulations in ocular drug delivery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L366297354&from=export http://www.arjournals.org/index.php/ijdd/article/view/665/pdf VL - 4 ID - 3046 ER - TY - JOUR AB - The Clinical Pharmacy Congress held in London in May focused on the ever-growing importance of pharmacists in a variety of healthcare settings. The presentations covered a diverse range of subject areas, from tackling issues of antimicrobial resistance in urinary tract infections to the management of long-term conditions. AD - F. David AU - David, F. C1 - bricanyl seretide symbicort ventolin DB - Embase DO - 10.1002/psb.1579 IS - 6 KW - amoxicillin plus clavulanic acid anticoagulant agent antivitamin K beclomethasone dipropionate beta 2 adrenergic receptor stimulating agent budesonide plus formoterol ciprofloxacin corticosteroid fluticasone fluticasone propionate plus salmeterol xinafoate fosfomycin low molecular weight heparin nitrofurantoin pivmecillinam salbutamol street drug terbutaline sulfate trimethoprim adrenal suppression antibiotic resistance anticoagulant therapy asthma bloodstream infection chronic disease diabetes mellitus drug megadose dry powder inhaler glaucoma Gram negative infection human inappropriate prescribing intravenous drug abuse metered dose inhaler mortality note osteoporosis patient compliance pharmacist pregnant woman primary medical care side effect skin disease skin thinning urinary tract infection venous thromboembolism bricanyl seretide symbicort ventolin Accuhaler LA - English M3 - Note N1 - L617077373 2017-07-06 2017-07-10 PY - 2017 SN - 1931-2253 0959-6682 SP - 10-12 ST - The expanding role of the clinical pharmacist T2 - Prescriber TI - The expanding role of the clinical pharmacist UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617077373&from=export http://dx.doi.org/10.1002/psb.1579 VL - 28 ID - 2647 ER - TY - JOUR AU - Davidson, S. I. AU - Akingbehin, T. IS - Pt 2 KW - Acetazolamide/ad [Administration & Dosage] Acetazolamide/tu [Therapeutic Use] Drug Packaging *Glaucoma/dt [Drug Therapy] Humans Middle Aged *Patient Dropouts Tablets PY - 1980 SN - 0078-5334 SP - 286-90 ST - Compliance in ophthalmology T2 - Transactions of the ophthalmological societies of the United Kingdom TI - Compliance in ophthalmology UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=6943851 VL - 100 ID - 2264 ER - TY - JOUR AB - PURPOSE OF REVIEW: The purpose is to provide an overview of the recent advancements in the diagnosis and treatment of microbial keratitis and endophthalmitis after keratoprosthesis implantation., RECENT FINDINGS: The addition of vancomycin daily to a fluoroquinolone in the postoperative management of keratoprosthesis patients successfully reduced the number of cases of bacterial keratitis and endophthalmitis with an increased number of fungal infections now documented both in the United States and abroad., SUMMARY: Compliance with the regimen of a fluoroquinolone and vancomycin daily for life after keratoprosthesis implantation should be stressed with the patient. Further research is needed to investigate whether intermittent use of 5% povidone-iodine and frequent replacement of the bandage contact lens could reduce fungal infection after keratoprosthesis surgery. Future advancements in the Boston keratoprosthesis design and/or postoperative management are needed to further reduce infection after keratoprosthesis placement. AU - Davies, Emma AU - Chodosh, James DO - https://dx.doi.org/10.1097/ICU.0000000000000270 IS - 4 KW - *Anti-Bacterial Agents/tu [Therapeutic Use] Artificial Organs Cornea/su [Surgery] Endophthalmitis/di [Diagnosis] *Endophthalmitis/et [Etiology] Endophthalmitis/th [Therapy] Eye Infections, Bacterial/di [Diagnosis] *Eye Infections, Bacterial/et [Etiology] Eye Infections, Bacterial/th [Therapy] Eye Infections, Fungal/di [Diagnosis] *Eye Infections, Fungal/et [Etiology] Eye Infections, Fungal/th [Therapy] Humans Keratitis/di [Diagnosis] *Keratitis/et [Etiology] Keratitis/th [Therapy] *Postoperative Complications/mi [Microbiology] *Prostheses and Implants/ae [Adverse Effects] *Prosthesis Implantation/ae [Adverse Effects] Retrospective Studies PY - 2016 SE - Davies, Emma. Cornea and External Disease Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA. SN - 1531-7021 1040-8738 SP - 373-7 ST - Infections after keratoprosthesis T2 - Current opinion in ophthalmology TI - Infections after keratoprosthesis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27138637 VL - 27 ID - 686 ER - TY - JOUR AB - Misoprostol, a prostaglandin E1 analog, is a racemate of four stereoisomers. On administration it rapidly de-esterifies to its active form, misoprostolic acid. Misoprostolic acid is 85% albumin bound and has a half-life of approximately 30 minutes. It is excreted in urine as inactive metabolites. No significant drug interactions have been reported. Besides its gastrointestinal protective and uterotonic activities, misoprostol regulates various immunologic cascades. It inhibits platelet-activating factor and leukocyte adherence, and modulates adhesion molecule expression. It protects against gut irradiation injury, experimental gastric cancer, enteropathy, and constipation. It improves nutrient absorption in cystic fibrosis. Misoprostol has utility in acetaminophen and ethanol hepatotoxicity, hepatitis, and fibrosis. It is effective in asthmatics and aspirin-sensitive asthmatic and allergic patients. It lowers cholesterol and severity of peripheral vascular diseases, prolongs survival of cardiac and kidney transplantation, synergizes cyclosporine, and protects against cyclosporine-induced renal damage. It works against drug-induced renal damage, interstitial cystitis, lupus nephritis, and hepatorenal syndrome. It is useful in periodontal disease and dental repair. Misoprostol enhances glycosoaminoglycan synthesis in cartilage after injury. It prevents ultraviolet-induced cataracts and reduces intraocular pressure in glaucoma and ocular hypertension. It synergizes antiinflammatory and analgesic effects of diclofenac or colchicine and has been administered to treat trigeminal neuralgic pain. It reduces chemotherapy-induced hair loss and recovery time from burn injury, and is effective in treating sepsis, multiple sclerosis, and pancreatitis. AU - Davies, N. M. AU - Longstreth, J. AU - Jamali, F. IS - 1 KW - Animals Anti-Inflammatory Agents, Non-Steroidal/ae [Adverse Effects] Anti-Ulcer Agents/ad [Administration & Dosage] Anti-Ulcer Agents/pk [Pharmacokinetics] Anti-Ulcer Agents/pd [Pharmacology] *Anti-Ulcer Agents/tu [Therapeutic Use] Humans Misoprostol/ad [Administration & Dosage] Misoprostol/pk [Pharmacokinetics] Misoprostol/pd [Pharmacology] *Misoprostol/tu [Therapeutic Use] Stomach Ulcer/ci [Chemically Induced] *Stomach Ulcer/pc [Prevention & Control] PY - 2001 SE - Davies, N M. Faculty of Pharmacy, University of Sydney, New South Wales, Australia. SN - 0277-0008 SP - 60-73 ST - Misoprostol therapeutics revisited T2 - Pharmacotherapy TI - Misoprostol therapeutics revisited UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11191738 VL - 21 ID - 1928 ER - TY - JOUR AB - Purpose Lost to follow-up and delays in follow-up care are a major problem in chronic diseases, particularly when irreversible progression precedes symptoms. The NPSA Glaucoma Safety Alert in 2009 highlighted the risk and requirements for consistent robust review systems in ophthalmology. In response, Moorfields Eye Hospital reviewed the records of all patients in all subspecialties without review appointments booked. The purpose of this study was to determine whether ophthalmic patients lost to follow-up had come to harm and develop investigation techniques to optimise safety, which do not put excessive demands on clinical staff time. Methods The health records of all patients lost to follow-up (LTFU) between July 2007 and November 2012 were reviewed for evidence of clinical harm using a risk-based strategy involving an initial administrative review, then a clinician led electronic patient record review, followed by a review of paper records by clinicians. The final stage was a clinical outpatient review where required determined by clinical risk. Results Patients identified as lost to follow-up were 145 234; 79 562 episodes were closed following administrative review; 50 519 were discharged following clinician examination of paper records; 12 316 patients required clinical review; and 16 serious incidents were identified, of which 14 patients had glaucoma, 1 a medical retinal condition with secondary glaucoma, and 1 an oculoplastic condition. A number of actions implemented hospital wide are described which minimise future risk. Conclusion Risk from delays or lost to follow-up care continue and require better capacity and more accurate data nationally. AN - WOS:000395991400015 AU - Davis, A. AU - Baldwin, A. AU - Hingorani, M. AU - Dwyer, A. AU - Flanagan, D. DA - MAR DO - 10.1038/eye.2016.225 IS - 3 PY - 2017 SN - 0950-222X 1476-5454 SP - 422-429 ST - A review of 145234 ophthalmic patient episodes lost to follow-up T2 - EYE TI - A review of 145234 ophthalmic patient episodes lost to follow-up VL - 31 ID - 5862 ER - TY - JOUR AB - SIGNIFICANCE: Glaucoma patients express a strong need for practical instruction on instilling eye drops correctly. To maximize the benefit of a video intervention to improve eye drop technique, patients recommend that video education be provided both in the clinic setting and online., PURPOSE: The purposes of this study were to (1) describe glaucoma patients' perspectives on how to improve an online eye drop technique video and how to disseminate it to other glaucoma patients and (2) examine how these perspectives differ across demographics., METHODS: Glaucoma patients (N = 43) who viewed an online eye drop technique educational video as part of a randomized controlled trial were interviewed to assess their overall rating of the video on a 4-point scale, with whom they had watched the video, whether they would recommend the video to others, how the video helped them, how they would recommend improving the video, and how they would like the video to be disseminated to other glaucoma patients., RESULTS: Patients' mean (SD) rating of the video was 3.4 (0.8), with a higher mean rating of 3.8 among African Americans (P = .02). All 43 patients said that they would recommend that others watch the video. Patients most commonly said that the video helped them learn to block the tear duct correctly, put the cap down on its side, mix the medication correctly, and close the eye after instillation. Patients preferred viewing the video in the doctor's office examination room and a website., CONCLUSIONS: Eye drop technique videos should be disseminated in the doctor's office and online. Health systems that integrate educational videos into their everyday practice may be able to use technique videos to improve patient technique at low cost and little time burden to the provider. AU - Davis, Scott A. AU - Carpenter, Delesha M. AU - Blalock, Susan J. AU - Budenz, Donald L. AU - Lee, Charles AU - Muir, Kelly W. AU - Robin, Alan L. AU - Sleath, Betsy DO - https://dx.doi.org/10.1097/OPX.0000000000001375 IS - 5 KW - Administration, Ophthalmic Adult Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Health Communication Humans Intraocular Pressure/de [Drug Effects] Male Medication Adherence Middle Aged *Ophthalmic Solutions/ad [Administration & Dosage] *Patient Education as Topic/mt [Methods] *Patient Preference/sn [Statistics & Numerical Data] Self Administration *Videotape Recording/sn [Statistics & Numerical Data] Young Adult PY - 2019 SE - Carpenter, Delesha M. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina. Blalock, Susan J. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina. Budenz, Donald L. Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Lee, Charles. First Databank, Morrisville, North Carolina. Muir, Kelly W. Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina. Muir, Kelly W. Durham VA HSR&D, Durham, North Carolina. Robin, Alan L. Department of Ophthalmology, University of Michigan, Ann Arbor, Michigan. Robin, Alan L. Wilmer Institute, Johns Hopkins School of Medicine, Baltimore, Maryland. Sleath, Betsy. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina. Sleath, Betsy. Cecil G. Sheps Center for Health Services Research, Chapel Hill, North Carolina *sdavis81@email.unc.edu. SN - 1538-9235 1040-5488 SP - 325-330 ST - Glaucoma Patient Preferences for Video Education on Eye Drop Technique T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Glaucoma Patient Preferences for Video Education on Eye Drop Technique UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31046014 VL - 96 ID - 336 ER - TY - JOUR AB - PURPOSE OF REVIEW: To describe the current state of knowledge regarding glaucoma patients' eye drop technique, interventions attempting to improve eye drop technique, and methods for assessing eye drop technique., RECENT FINDINGS: In observational studies, between 18.2 and 80% of patients contaminate their eye drop bottle by touching their eye or face, 11.3-60.6% do not instill exactly one drop, and 6.8-37.3% miss the eye with the drop. Factors significantly associated with poorer technique include older age, lack of instruction on eye drop technique, female sex, arthritis, more severe visual field defect, lack of positive reinforcement to take eye drops, lower educational level, low self-efficacy, and being seen at a clinic rather than a private practice. Among intervention studies, four of five studies using a mechanical device and three of four studies using educational interventions to improve technique showed positive results, but none of the studies were randomized controlled trials., SUMMARY: Poor eye drop technique is a significant impediment to achieving good control of intraocular pressure in glaucoma. Both mechanical device interventions and educational interventions offer promise to improve patients' technique, but studies with stronger designs need to be done followed by introduction into clinical practice. AU - Davis, Scott A. AU - Sleath, Betsy AU - Carpenter, Delesha M. AU - Blalock, Susan J. AU - Muir, Kelly W. AU - Budenz, Donald L. DO - https://dx.doi.org/10.1097/ICU.0000000000000451 IS - 2 KW - *Administration, Ophthalmic *Antihypertensive Agents/ad [Administration & Dosage] Drug Packaging *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Medication Adherence *Ophthalmic Solutions/ad [Administration & Dosage] Patient Education as Topic Tonometry, Ocular PY - 2018 SE - Davis, Scott A. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy. Sleath, Betsy. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy. Sleath, Betsy. Cecil G. Sheps Center for Health Services Research, Chapel Hill, North Carolina. Carpenter, Delesha M. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy. Blalock, Susan J. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy. Muir, Kelly W. Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina. Budenz, Donald L. Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. SN - 1531-7021 1040-8738 SP - 171-177 ST - Drop instillation and glaucoma T2 - Current opinion in ophthalmology TI - Drop instillation and glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29140818 VL - 29 ID - 469 ER - TY - JOUR AU - Dawson, C. R. AU - Beck, R. AU - Wilhelmus, K. R. AU - Cohen, E. J. IS - 1 KW - *Acyclovir/tu [Therapeutic Use] Administration, Oral Anti-Inflammatory Agents/tu [Therapeutic Use] *Antiviral Agents/tu [Therapeutic Use] Clinical Trials as Topic Humans Keratitis, Herpetic/dt [Drug Therapy] *Keratitis, Herpetic/pc [Prevention & Control] Multicenter Studies as Topic Ophthalmic Solutions Patient Participation Prednisolone/tu [Therapeutic Use] Randomized Controlled Trials as Topic Recurrence PY - 1996 SN - 0003-9950 SP - 89-90 ST - Herpetic eye disease study. You can help T2 - Archives of ophthalmology (Chicago, Ill. : 1960) TI - Herpetic eye disease study. You can help UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=8540857 VL - 114 ID - 2042 ER - TY - JOUR AB - PURPOSE: To evaluate the outcomes of phacoemulsification and intraocular lens (100 implantation in microphthalmos and nanophthalmos. SETTING: Moorfields Eye Hospital, London, United Kingdom. DESIGN: Retrospective case series. METHODS: Eyes with an axial length (AL) less than 21.0 mm had elective phacoemulsification and IOL implantation. RESULTS: One hundred three eyes (63 patients) were enrolled. The median AL was 20.65 mm (interquartile range [IQR], 20.26 to 20.86) and the median follow-up, 6.3 months. Complications occurred in 16 cases (15.5%). Zonular dehiscence, severe uveitis, and aqueous misdirection accounted for the majority of complications. Complication rates were 6 (7.3%) of 82 cases with an AL from 20.0 to 21.00 mm and 10 (47.6%) of 21 cases with an AL less than 20.0 mm (P=.0001). Only AL (odds ratio [OR], 0.52 per mm; P <=.0005) and abnormal intraocular pressure (IOP) of 22 mm Hg or more or on topical IOP control (OR, 10.1; P=.001) were significant independent risk factors for complications. For the cohort after adjusting for abnormal IOP, an AL less than 20.5 mm was associated with a 4 times higher odds of any complication (P=.028), an AL less than 20.0 mm was associated with a 15 times higher odds of any complication (P <=.0005), and an AL less than 19.00 mm was associated with a 21 times higher odds of any complication (P <=.0005). CONCLUSIONS: Phacoemulsification and IOL implantation in microphthalmos/nanophthalmos was challenging but appears safer than previously reported. A shorter AL and abnormal IOP were significant risk factors for complications. Financial Disclosure: No author has a financial or proprietary interest in any material or method mentioned. J Cataract Refract Surg 2013; 39:87-96 (C) 2013 ASCRS and ESCRS AN - WOS:000312965900015 AU - Day, A. C. AU - MacLaren, R. E. AU - Bunce, C. AU - Stevens, J. D. AU - Foster, P. J. DA - JAN DO - 10.1016/j.jcrs.2012.08.057 IS - 1 PY - 2013 SN - 0886-3350 1873-4502 SP - 87-96 ST - Outcomes of phacoemulsification and intraocular lens implantation in microphthalmos and nanophthalmos T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Outcomes of phacoemulsification and intraocular lens implantation in microphthalmos and nanophthalmos VL - 39 ID - 6341 ER - TY - JOUR AB - PURPOSE: The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients., METHODS: This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were prescribed with ocular hypotensive monotherapy between September 1996 and August 2002., RESULTS: 1,182 patients were included. The Kaplan Meier life table analysis showed that latanoprost was continued longest among the groups for the first year of therapy (p=0.02). A significant difference existed between groups in the final intraocular pressure for latanoprost (17.3+/-3.9, N=357), for bimatoprost (18.0+/-3.6, N=146), and for the beta-blockers (17.9+/-3.7, N=335) (p=<0.0001). The average number of visits was statistically higher for beta-blockers (3.3), compared to latanoprost (2.9) and bimatoprost (3.1) (p=0.01). Further, the mean number of medicine changes was greater for bimatoprost (0.45) and beta-blockers (0.47) than for latanoprost (0.27) (p=0.0008). The cost of visits and medications was lowest for beta-blockers ($119.3+/-$78.9) and highest for bimatoprost ($163.8+/-$51.2) (p<0.0001)., CONCLUSIONS: Patients were more persistent with latanoprost and demonstrated lower intraocular pressure, fewer visits, and fewer medicine changes when compared to bimatoprost or beta-blocker therapy. In contrast, the beta-blocker group provided lower overall cost. AU - Day, Douglas G. AU - Schacknow, Paul N. AU - Sharpe, Elizabeth D. AU - Ellyn, John C. AU - Kulze, John C., 3rd AU - Threlkeld, Anisa B. AU - Jones, Evan D. AU - Brown, Reay H. AU - Jenkins, Jessica N. AU - Stewart, William C. IS - 5 KW - *Adrenergic beta-Antagonists/ec [Economics] Aged Amides *Antihypertensive Agents/ec [Economics] Bimatoprost Cloprostenol/aa [Analogs & Derivatives] Drug Costs Economics, Pharmaceutical Female Glaucoma, Open-Angle/dt [Drug Therapy] *Glaucoma, Open-Angle/ec [Economics] Health Care Costs Humans Intraocular Pressure/de [Drug Effects] Latanoprost *Lipids/ec [Economics] Male Middle Aged Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/ec [Economics] Office Visits *Patient Compliance *Prostaglandins F, Synthetic/ec [Economics] Retrospective Studies Safety N1 - Comment in (CIN) PY - 2004 SE - Day, Douglas G. Atlanta Research Company, Atlanta, GA, USA. SN - 1080-7683 SP - 383-92 ST - A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics T3 - Comment in: J Ocul Pharmacol Ther. 2005 Aug;21(4):349-50; author reply 350-2; PMID: 16117699 [https://www.ncbi.nlm.nih.gov/pubmed/16117699] TI - A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15650513 VL - 20 ID - 1759 ER - TY - JOUR AB - PURPOSE: To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure (TSS-IOP) quality-of-life survey that analyses specific issues related to side effects, patient satisfaction, and compliance., METHODS: A prospective, observational cohort of 250 consecutive patients with primary open-angle glaucoma or ocular hypertension was administered the TSS-IOP survey., RESULTS: Factors that correlated with patient satisfaction included perceived effectiveness of the medicine (F=7.47, P<0.001), ocular irritation (F=6.06, P<0.001), conjunctival hyperaemia (F=4.40, P<0.001), ease of use (F=8.52, P<0.001), and convenience of use (F=6.90, P<0.001). Patient compliance, acceptance of their illness, and knowledge of glaucoma were also related to perceived effectiveness of the medicine (P<0.001), ease of use (P<0.05) and convenience (P<0.001). Physician ratings of patient pressure control, side effects, and instillation problems also were significantly correlated to patient satisfaction (R=0.13-0.26, P=0.05-0.001). The physician ratings of patient compliance, however, were not significantly related to any dimension of patient satisfaction (P>0.05). Among monotherapy prostaglandin treatments, latanoprost demonstrated statistically greater satisfaction than bimatoprost or travoprost regarding conjunctival hyperaemia (P<0.05) and eye irritation (P<0.01)., CONCLUSIONS: This study provides initial evidence that patient satisfaction may be related to compliance, perceived effectiveness of treatment, adverse side effects, ease and convenience of use, acceptance of illness, and knowledge of glaucoma. AU - Day, D. G. AU - Sharpe, E. D. AU - Atkinson, M. J. AU - Stewart, J. A. AU - Stewart, W. C. IS - 5 KW - Aged Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Drug Administration Schedule Female Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Glaucoma/px [Psychology] Health Knowledge, Attitudes, Practice Health Status Indicators Humans Intraocular Pressure Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/pp [Physiopathology] Ocular Hypertension/px [Psychology] Ophthalmic Solutions Patient Compliance *Patient Satisfaction Psychometrics Surveys and Questionnaires Treatment Outcome PY - 2006 SE - Day, D G. Atlanta Research Company, Atlanta, GA, USA. SN - 0950-222X SP - 583-90 ST - The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients T2 - Eye (London, England) TI - The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=15933751 VL - 20 ID - 1694 ER - TY - JOUR AB - AIMS: Glaucoma is a significant health problem, with associated inequalities. Equity profiles are an established public health tool to examine the scale of health inequalities and to imbed action into the commissioning cycle. This is the first equity profile conducted in the United Kingdom for an ophthalmic condition. This methodology also provides a model for use in other localities and for other eye conditions., METHODS: Existing services were mapped and need identified. A wide variety of data sources were analysed. Mapping was undertaken using Mapinfo Professional Geographical Information Systems software. Statistical analysis was conducted using Microsoft Excel 2003., RESULTS: No single data source provided a fully informed perspective. A clear mismatch between areas of deprivation and location of optometry was observed. Secondary analysis of electronic patient records revealed a significant association between 'late presentation' and older age (mean age of late presenters=76.4 years, 95% CI=75.1-77.6 compared with earlier presenters, 72.4 years, 95% CI=71.7-73.1). Late presentation was also associated with living in an area of high deprivation (chi(2)=7.1, df, P<0.05). Ethnicity data was poorly recorded. Qualitative data provided invaluable insights., CONCLUSIONS: Increasing access to services involves collaboration with optometrists, ophthalmologists, public health, and commissioners. It is no longer acceptable to rely on private high street optometry to provide primary eye care services in areas of high need. Outreach services must be developed and evaluated in areas of relative deprivation if world class eye services are to be achieved. AU - Day, F. AU - Buchan, J. C. AU - Cassells-Brown, A. AU - Fear, J. AU - Dixon, R. AU - Wood, F. DO - https://dx.doi.org/10.1038/eye.2010.73 IS - 9 KW - Age Factors Aged Aged, 80 and over England/ep [Epidemiology] Female Glaucoma/ep [Epidemiology] Glaucoma/eh [Ethnology] *Glaucoma *Health Services Accessibility/og [Organization & Administration] Health Services Accessibility/st [Standards] *Health Services Needs and Demand Humans Male Middle Aged *Ophthalmology/og [Organization & Administration] Public Health Socioeconomic Factors State Medicine/og [Organization & Administration] PY - 2010 SE - Day, F. Public Health, NHS Yorkshire and Humber, Leeds, UK. Fiona.day@yorksandhumber.nhs.uk SN - 1476-5454 0950-222X SP - 1478-85 ST - A glaucoma equity profile: correlating disease distribution with service provision and uptake in a population in Northern England, UK T2 - Eye (London, England) TI - A glaucoma equity profile: correlating disease distribution with service provision and uptake in a population in Northern England, UK UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20508654 VL - 24 Y2 - 20100528// ID - 1352 ER - TY - JOUR AB - Background: To determine if the intraocular pressure (IOP) reduction in one-eye trial correlates with the IOP reduction in the fellow eye when IOP variability during office hours is taken into account. Methods: This retrospective observational case series includes 50 high tension (primary open-angle glaucoma, exfoliative glaucoma and ocular hypertension; Group 1) and 21 normal tension (Group 2) glaucoma patients. Charts of bilateral open-angle glaucoma patients at Glaucoma Unit, School of Medicine, Adnan Menderes University who had pretreatment baseline office IOP measurements at 9:30, 11:30 and 15:30; were put on a one-eye trial with prostaglandin analogues, and then subsequently received the same medication in the fellow eye were reviewed. Pretreatment baseline office IOP measurements and reductions in the first and second eyes were compared to determine variability and correlation, respectively. Results: Both groups showed significant variability in pretreatment baseline office IOP measurements. Peak IOP level was before noon in at least 70% of eyes in Group 1, 50% in Group 2. IOP dropped a mean of 8.8±4.8 mmHg (34%, P=<0.0001) in Group 1 and 4.9±2.4 mmHg (30%, P=<0.0001) in Group 2 during the one-eye trial. Following bilateral use of the medication a mean drop of 7.5±4.0 mmHg (31%, P=<0.0001) in Group 1 and 2.9±1.9 mmHg (18%, P=<0.0001) in Group 2 were obtained. The IOP reduction between fellow-eye pairs were significantly correlated in Group 1 (r=0.541, P=<0.0001) but not Group 2 (r=-0.310, P=0.171). Conclusions: One-eye trial is a feasible method to determine the effectiveness of prostaglandin analogues and to predict the amount of IOP reduction in the fellow eye in patients with high tension glaucoma. © Journal compilation © 2008 Royal Australian and New Zealand College of Ophthalmologists. AD - V. Dayanir, Adnan Menderes University, Tip Fakultesi, Goz Hast. A.D., Aydin 09100, Turkey AU - Dayanir, V. AU - Cakmak, H. AU - Berkit, I. C1 - lumigan travatan xalatan DB - Embase Medline DO - 10.1111/j.1442-9071.2008.01698.x IS - 2 KW - bimatoprost latanoprost prostaglandin derivative travoprost adult aged ambulatory care article case study controlled study correlation analysis drug efficacy drug response pseudoexfoliation feasibility study female glaucoma human intraocular hypertension intraocular pressure major clinical study male observational study open angle glaucoma prediction pressure measurement retrospective study lumigan travatan xalatan LA - English M3 - Article N1 - L351445146 2008-04-07 PY - 2008 SN - 1442-6404 1442-9071 SP - 136-141 ST - The one-eye trial and fellow eye response to prostaglandin analogues T2 - Clinical and Experimental Ophthalmology TI - The one-eye trial and fellow eye response to prostaglandin analogues UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351445146&from=export http://dx.doi.org/10.1111/j.1442-9071.2008.01698.x VL - 36 ID - 3469 ER - TY - JOUR AB - BACKGROUND: Neuroprotective drugs are needed to slow or prevent neurodegeneration and disability accrual in secondary progressive multiple sclerosis. Amiloride, fluoxetine and riluzole are repurposed drugs with potential neuroprotective effects., OBJECTIVES: To assess whether or not amiloride, fluoxetine and riluzole can reduce the rate of brain volume loss in people with secondary progressive multiple sclerosis over 96 weeks. The secondary objectives that were assessed were feasibility of a multiarm trial design approach, evaluation of anti-inflammatory effects, clinician- and patient-reported efficacy and three mechanistic substudies., DESIGN: A multicentre, multiarm, randomised, double-blind, placebo-controlled, parallel-group Phase IIb trial with follow-up at 4, 8, 12, 24, 36, 48, 72 and 96 weeks. Patients, investigators (including magnetic resonance imaging analysts), and treating and independent assessing neurologists were blinded to the treatment allocation. The target sample size was 440 patients., SETTING: Thirteen UK clinical neuroscience centres., PARTICIPANTS: Participants were aged 25-65 years, had secondary progressive multiple sclerosis with evidence of disease progression independent of relapses in the previous 2 years, and had an Expanded Disability Status Scale score of 4.0-6.5. Patients were ineligible if they could not have a magnetic resonance imaging scan; had a relapse or steroids in the previous 3 months; or had epilepsy, depression, bipolar disorder, glaucoma, bleeding disorders or significant organ comorbidities. Exclusion criteria were concurrent disease-modified treatments, immunosuppressants or selective serotonin reuptake inhibitors., INTERVENTIONS: Participants received amiloride (5 mg), fluoxetine (20 mg), riluzole (50 mg) or placebo (randomised 1 : 1 : 1 : 1) twice daily., MAIN OUTCOME MEASURES: The primary end point was magnetic resonance imaging-derived percentage brain volume change at 96 weeks. Secondary end points were new/enlarging T2 lesions, pseudoatrophy, and clinician- and patient-reported measures (including the Expanded Disability Status Scale, Multiple Sclerosis Functional Composite, Symbol Digit Modalities Test, low-contrast letter visual acuity, Multiple Sclerosis Impact Scale 29 items, version 2, Multiple Sclerosis Walking Scale, version 2, and questionnaires addressing pain and fatigue). The exploratory end points included measures of persistent new T1 hypointensities and grey matter volume changes. The substudies were advanced magnetic resonance imaging, optical coherence tomography and cerebrospinal fluid analyses., RESULTS: Between December 2014 and June 2016, 445 patients were randomised (analysed) to amiloride [n = 111 (99)], fluoxetine [n = 111 (96)], riluzole [n = 111 (99)] or placebo [n = 112 (99)]. A total of 206 randomised patients consented to the advanced magnetic resonance imaging substudy, 260 consented to the optical coherence tomography substudy and 70 consented to the cerebrospinal fluid substudy. No significant difference was seen between the active drugs and placebo in percentage brain volume change at week 96 as follows (where negative values mean more atrophy than placebo): amiloride minus placebo 0.0% (Dunnett-adjusted 95% confidence interval -0.4% to 0.5%), fluoxetine minus placebo -0.1% (Dunnett-adjusted 95% confidence interval -0.5% to 0.3%); riluzole minus placebo -0.1% (Dunnett-adjusted 95% confidence interval -0.6% to 0.3%). There was good adherence to study drugs. The proportion of patients experiencing adverse events was similar in the treatment and placebo groups. There were no emergent safety issues., LIMITATIONS: There was a lower than expected uptake in the cerebrospinal fluid substudy., CONCLUSIONS: A multiarm Phase II paradigm is efficient in determining which neuroprotective agents to take through to Phase III trials. Amiloride, fluoxetine and riluzole were not effective in reducing the brain atrophy rate in people with secondary progressive multiple sclerosis. Mechanistic pathobiological insight was gained., FUTURE WORK: To use he information gained from the Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART) to inform future trial design as new candidate agents are identified., TRIAL REGISTRATION: Current Controlled Trials ISRCTN28440672, NCT01910259 and EudraCT 2012-005394-31., FUNDING: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 7, No. 3. See the NIHR Journals Library website for further project information. This trial also received funding from the UK MS Society and the US National Multiple Sclerosis Society. Copyright © Queen's Printer and Controller of HMSO 2020. This work was produced by De Angelis et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. AU - De Angelis, Floriana AU - Connick, Peter AU - Parker, Richard A. AU - Plantone, Domenico AU - Doshi, Anisha AU - John, Nevin AU - Stutters, Jonathan AU - MacManus, David AU - Prados, Ferran AU - Marshall, Ian AU - Solanky, Bhavana AU - Samson, Rebecca S. AU - Barkhof, Frederik AU - Ourselin, Sebastien AU - Braisher, Marie AU - Ross, Moira AU - Cranswick, Gina AU - Pavitt, Sue H. AU - Gnanapavan, Sharmilee AU - Giovannoni, Gavin AU - Wheeler-Kingshott, Claudia A. M. Gandini AU - Hawkins, Clive AU - Sharrack, Basil AU - Bastow, Roger AU - Weir, Christopher J. AU - Stallard, Nigel AU - Chandran, Siddharthan AU - Chataway, Jeremy DO - https://dx.doi.org/10.3310/eme07030 PY - 2020 SE - De Angelis, Floriana. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Connick, Peter. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK Parker, Richard A. Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK Plantone, Domenico. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Doshi, Anisha. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK John, Nevin. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Stutters, Jonathan. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK MacManus, David. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Prados, Ferran. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Prados, Ferran. Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, University College London, London, UK Prados, Ferran. eHealth Centre, Universitat Oberta de Catalunya, Barcelona, Spain Marshall, Ian. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK Solanky, Bhavana. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Samson, Rebecca S. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Barkhof, Frederik. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Barkhof, Frederik. Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, University College London, London, UK Barkhof, Frederik. Department of Radiology and Nuclear Medicine, Vrije Universiteit University Medical Centre, Amsterdam, the Netherlands Ourselin, Sebastien. School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK Braisher, Marie. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Ross, Moira. Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK Cranswick, Gina. Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK Pavitt, Sue H. Dental Translational and Clinical Research Unit (part of the National Institute for Health Research Leeds Clinical Research Facility), University of Leeds, Leeds, UK Gnanapavan, Sharmilee. Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK Giovannoni, Gavin. Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK Wheeler-Kingshott, Claudia AM Gandini. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Wheeler-Kingshott, Claudia AM Gandini. Brain MRI 3T Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Mondino Foundation, Pavia, Italy Hawkins, Clive. Keele Medical School and Institute for Science and Technology in Medicine, Keele University, Keele, UK Sharrack, Basil. Department of Neuroscience, Royal Hallamshire Hospital, Sheffield, UK Bastow, Roger. UK MS Society patient representative, MS National Centre, London, UK Weir, Christopher J. Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK Stallard, Nigel. Statistics and Epidemiology, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK Chandran, Siddharthan. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK Chataway, Jeremy. Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK Chataway, Jeremy. National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=32453521 ID - 36 ER - TY - JOUR AB - Glaucoma is defined as an optic neuropathy, characterized for loss of visual field and injury of the optic nerve, being considered as the second cause of blindness in the world, which could be prevented by the use of antiglaucoma eyedrops. The lack of adhesion of the patient to the drug treatment can culminate with loss of the vision. The objective was to revise possible literature data regarding intervening factors for noncompliance and explain estimated rates of noncompliance. A systematic review about the subject was carried out in the period of January to June of 2006. Articles had been searched in two data bases, in the National Library of Medicine (PUBMED) and in the Literature Latin American and Caribbean Health Sciences (LILACS) using the following keywords: glaucoma, compliance of the patient, noncompliance of the patient, treatment and eyedrops. In PUBMED, 199 articles were collected, written in English and French languages. No article was found in LILACS. Considering the inclusion and exclusion criteria, 27 articles were selected, with 25 originals and two reviews. Twelve possible intervening factors for noncompliance were raised, as well as estimates for rates of noncompliance. The noncompliance rates varied from 4.6% up to 59%. Two factors, forgetfulness and inadequate between-doses interval, had been associated to noncompliance of the drug therapy. The factors race, adverse effects, treatment cost, number of instilled doses, coexisting illnesses and number of eyedrops used, had resulted contradictory, being impossible to affirm that they have contributed for noncompliance. Age, sex, educational level and loss of visual field, had not been associated with noncompliance. The glaucoma patients tended to disregard the drug treatment. The wide variation in noncompliance rates could be an influence from the authors' difficulty to define the noncompliance and the variety of methodologies used to estimate it. More studies are necessary for a better evaluation of these 12 raised factors. AD - W. A. Mesquita, Alameda Ezequiel Dias, 225, 12 andar, CEP - Santa Efigênia - Belo Horizonte - MG, Brazil AU - De Castro, A. N. B. V. AU - Mesquita, W. A. DB - Embase DO - 10.1590/S1984-82502009000300010 IS - 3 KW - pilocarpine timolol maleate ankle edema dyspnea educational status ethnicity evening dosage glaucoma health care cost human Medline methodology migraine patient compliance review systematic review visual field defect L1 - internal-pdf://1869470124/3348-Noncompliance with drug therapy of g-2009.pdf LA - English M3 - Review N1 - L358253032 2010-02-16 2010-03-23 PY - 2009 SN - 1516-9332 SP - 453-459 ST - Noncompliance with drug therapy of glaucoma: A review about intervening factors T2 - Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences TI - Noncompliance with drug therapy of glaucoma: A review about intervening factors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358253032&from=export http://dx.doi.org/10.1590/S1984-82502009000300010 VL - 45 ID - 3348 ER - TY - JOUR AB - Due to their permanent and close proximity to neurons, glial cells perform essential tasks for the normal physiology of the retina. Astrocytes and Müller cells (retinal macroglia) provide physical support to neurons and supplement them with several metabolites and growth factors. Macroglia are involved in maintaining the homeostasis of extracellular ions and neurotransmitters, are essential for information processing in neural circuits, participate in retinal glucose metabolism and in removing metabolic waste products, regulate local blood flow, induce the blood-retinal barrier (BRB), play fundamental roles in local immune response, and protect neurons from oxidative damage. In response to polyetiological insults, glia cells react with a process called reactive gliosis, seeking to maintain retinal homeostasis. When malfunctioning, macroglial cells can become primary pathogenic elements. A reactive gliosis has been described in different retinal pathologies, including age-related macular degeneration (AMD), diabetes, glaucoma, retinal detachment, or retinitis pigmentosa. A better understanding of the dual, neuroprotective, or cytotoxic effect of macroglial involvement in retinal pathologies would help in treating the physiopathology of these diseases. The extensive participation of the macroglia in retinal diseases points to these cells as innovative targets for new drug therapies. AD - Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain Departamento de Oftalmología y ORL, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, 28037 Madrid, Spain Departamento de Oftalmología y ORL, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain AN - 115420129. Language: English. Entry Date: 20160524. Revision Date: 20160524. Publication Type: Article AU - de Hoz, Rosa AU - Rojas, Blanca AU - Ramírez, Ana I. AU - Salazar, Juan J. AU - Gallego, Beatriz I. AU - Triviño, Alberto AU - Ramírez, José M. DB - ccm DO - 10.1155/2016/2954721 DP - EBSCOhost KW - Retina -- Physiology Health Disease Nervous System Cells Retinal Diseases -- Physiopathology Homeostasis Biological Transport Neurotransmitters Neural Pathways Immune System Inflammation Cytokines Neurons N1 - pictorial; review; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 101600173. PY - 2016 SN - 2314-6133 SP - 1-13 ST - Retinal Macroglial Responses in Health and Disease T2 - BioMed Research International TI - Retinal Macroglial Responses in Health and Disease UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115420129&site=ehost-live&scope=site VL - 2016 ID - 4395 ER - TY - JOUR AB - PURPOSE: We examined selective laser trabeculoplasty (SLT) as a replacement therapy for medically controlled open-angle glaucoma (OAG) or ocular hypertensive patients., METHODS: A prospective randomized interventional clinical trial on 143 glaucoma patients. Patients were randomized to either receiving SLT or to the control group that continued on pressure lowering medication. Data were recorded 1 hr, 1 week, 1, 3, 6, 12 and 18 months after SLT. Primary outcome was number of medications at 12 and 18 months while maintaining a predetermined target intraocular pressure (IOP)., RESULTS: Selective laser trabeculoplasty (SLT) reduced number of medications from a mean of 1.5 at baseline, to 0.35 after 12 months and 0.29 after 18 months. Meanwhile, SLT achieved more than 20% IOP lowering in 95% of eyes and more than 30% IOP lowering in 86% of eyes after 18 months. Seventy-seven per cent of our eyes no longer needed any medication after SLT at 18 months., CONCLUSION: Selective laser trabeculoplasty (SLT) enabled a reduction in number of medications while maintaining good IOP control. Selective laser trabeculoplasty (SLT) was able to completely replace medical therapy in 77% of eyes after 18 months. Selective laser trabeculoplasty (SLT) as replacement therapy may reduce local and systemic side-effects and prevent adherence issues. Copyright © 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. AU - De Keyser, Myrjam AU - De Belder, Maya AU - De Belder, Jonas AU - De Groot, Veva DO - https://dx.doi.org/10.1111/aos.13509 IS - 5 KW - Aged *Antihypertensive Agents/tu [Therapeutic Use] Female Follow-Up Studies Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] *Glaucoma/su [Surgery] Humans *Intraocular Pressure/ph [Physiology] *Laser Therapy/mt [Methods] *Lasers, Solid-State/tu [Therapeutic Use] Male Prospective Studies Time Factors *Trabeculectomy/mt [Methods] Treatment Outcome *Visual Acuity PY - 2018 SE - De Keyser, Myrjam. Department of Medicine, University of Antwerp, Antwerp, Belgium. De Belder, Maya. Department of Experimental Psychology, Ghent University, Ghent, Belgium. De Belder, Jonas. Department of Medicine, University of Antwerp, Antwerp, Belgium. De Groot, Veva. Department of Medicine, University of Antwerp, Antwerp, Belgium. De Groot, Veva. Department of Ophthalmology, University Hospital Antwerp, Edegem, Belgium. SN - 1755-3768 1755-375X SP - e577-e581 ST - Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients T2 - Acta ophthalmologica TI - Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=28636188 VL - 96 Y2 - 20170621// ID - 476 ER - TY - JOUR AB - Purpose: The purpose of this paper is to explore in a specific hospital care process the applicability in practice of the theories of quality costing and value chains. Design/methodology/approach: In a retrospective case study an in-depth evaluation of the use of a quality cost model (QCM) and the applicability of Porter's care delivery value chain (CDVC) was performed in a specific care process: glaucoma care over the period 2001 to 2006 in the Rotterdam Eye Hospital in The Netherlands. Findings: The case study shows a reduction of costs per product by increasing the number of outpatient visits and surgery combined with a higher patient satisfaction. Reduction of costs of non-compliance by using the QCM is small, due to the absence of (external) financial incentives for both the hospital and individual physicians. For CDVC to be supportive to an integrated quality and cost management the notion "patient value" needs far more specification as mutually agreed on by the stakeholders involved and related reimbursement needs to depend on realised outcomes. Research limitations/implications: The case study just focused on one specific care process in one hospital. To determine effects in other areas of health care, it is important to study the use and applicability of the QCM and the CDVC in other care processes and settings. Originality/value: QCM and a CDVC can be useful tools for hospital management to manage the outcomes on both quality and costs, but impact is dependent on the incentives in the context of the existing organisational and reimbursement system and asks for an agreed on operationalisation among the various stakeholders of the notion of patient value. © Emerald Group Publishing Limited. AD - Institute of Health Policy and Management, Erasmus University, Rotterdam, Netherlands Rotterdam Eye Hospital, Rotterdam, Netherlands Department of Social Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands School of Public Health, Catholic University, Leuven, Belgium AU - de Korne, D. F. AU - Kees Sol, J. C. A. AU - Custers, T. AU - van Sprundel, E. AU - van Ineveld, M. B. AU - Lemij, H. G. AU - Klazinga, N. S. DB - Scopus DO - 10.1108/09526860910953511 IS - 3 KW - Eyes Health services Quality costs The Netherlands Value chain M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2009 SP - 232-251 ST - Creating patient value in glaucoma care: Applying quality costing and care delivery value chain approaches: A five-year case study in the Rotterdam Eye Hospital T2 - International Journal of Health Care Quality Assurance TI - Creating patient value in glaucoma care: Applying quality costing and care delivery value chain approaches: A five-year case study in the Rotterdam Eye Hospital UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649769099&doi=10.1108%2f09526860910953511&partnerID=40&md5=5126f6b1c3dfd1fc2e75982508cc043d VL - 22 ID - 5531 ER - TY - JOUR AB - PURPOSE: The purpose of this paper is to explore in a specific hospital care process the applicability in practice of the theories of quality costing and value chains., DESIGN/METHODOLOGY/APPROACH: In a retrospective case study an in-depth evaluation of the use of a quality cost model (QCM) and the applicability of Porter's care delivery value chain (CDVC) was performed in a specific care process: glaucoma care over the period 2001 to 2006 in the Rotterdam Eye Hospital in The Netherlands., FINDINGS: The case study shows a reduction of costs per product by increasing the number of outpatient visits and surgery combined with a higher patient satisfaction. Reduction of costs of non-compliance by using the QCM is small, due to the absence of (external) financial incentives for both the hospital and individual physicians. For CDVC to be supportive to an integrated quality and cost management the notion "patient value" needs far more specification as mutually agreed on by the stakeholders involved and related reimbursement needs to depend on realised outcomes., RESEARCH LIMITATIONS/IMPLICATIONS: The case study just focused on one specific care process in one hospital. To determine effects in other areas of health care, it is important to study the use and applicability of the QCM and the CDVC in other care processes and settings., ORIGINALITY/VALUE: QCM and a CDVC can be useful tools for hospital management to manage the outcomes on both quality and costs, but impact is dependent on the incentives in the context of the existing organisational and reimbursement system and asks for an agreed on operationalisation among the various stakeholders of the notion of patient value. AU - de Korne, Dirk F. AU - Sol, Kees AU - Custers, Thomas AU - van Sprundel, Esther AU - van Ineveld, B. Martin AU - Lemij, Hans G. AU - Klazinga, Niek S. IS - 3 KW - Costs and Cost Analysis Data Collection Delivery of Health Care/ec [Economics] *Delivery of Health Care/og [Organization & Administration] *Glaucoma/th [Therapy] Health Services Accessibility/og [Organization & Administration] Health Services Needs and Demand/og [Organization & Administration] Humans Netherlands *Organizational Case Studies *Patient Satisfaction Process Assessment, Health Care/og [Organization & Administration] Quality Indicators, Health Care/og [Organization & Administration] Quality of Health Care/ec [Economics] *Quality of Health Care/og [Organization & Administration] Reimbursement, Incentive Retrospective Studies PY - 2009 SE - de Korne, Dirk F. Institute of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands. d.dekorne@oogziekenhuis.nl SN - 0952-6862 SP - 232-51 ST - Creating patient value in glaucoma care: applying quality costing and care delivery value chain approaches--a five-year case study in the Rotterdam Eye Hospital T2 - International journal of health care quality assurance TI - Creating patient value in glaucoma care: applying quality costing and care delivery value chain approaches--a five-year case study in the Rotterdam Eye Hospital UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19537185 VL - 22 ID - 1444 ER - TY - JOUR AU - De Land, P. N. AU - Chase, W. W. IS - 1 KW - *Contact Lenses Humans *Ocular Hypertension/dt [Drug Therapy] *Patient Satisfaction/sn [Statistics & Numerical Data] Probability PY - 1992 SE - De Land, P N. California State University, Fullerton. SN - 1040-5488 SP - 82-4 ST - Statistics Notebook: entry III.E: statistical significance and significance level, and entry III.F: P value T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Statistics Notebook: entry III.E: statistical significance and significance level, and entry III.F: P value UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1741118 VL - 69 ID - 2103 ER - TY - JOUR AB - Purpose: To determine the association of visual field (VF) progression with medication persistence in a cohort on glaucoma therapy. Patients and Methods: Pharmacy records were examined over 3 years for patients started on glaucoma monotherapy. A patient was persistent if a prescription was refilled for the same medication <90 days after the previous prescription had lapsed; otherwise was nonpersistent. Only patients with >5 reliable VFs within 1-year pretherapy and 6-year posttherapy were included. Progression was analyzed with pointwise linear regression and defined using 2 criteria: (A) Z2 adjacent progressing points (slope P<0.01) in 1 hemifield; and (B) Z3 progressing points (slope P<0.01). The mean number and mean slope of progressing points and the mean global slopes were determined. Results: Of 1206 patient eyes (131 persistent, 1075 nonpersistent), 941 were excluded leaving 175 (47 persistent and 128 nonpersistent) for analysis. The mean follow-up durations were 59.3±10.9 and 58.2±9.7 months (P=0.07) for persistent and nonpersistent eyes, respectively. Overall, 2/47 (4.3%) and 10/128 (7.8%) eyes progressed among persistent and nonpersistent patients, respectively (P=0.52) using criterion A and 1/47 (2.1%) and 12/128 (9.4%; P=0.19) eyes using criterion B. Mean number of progressing points (0.3±0.9 vs. 0.7±1.8; P=0.17), mean slope of progressing points (-2.2±1.1 vs.-2.8±1.3 dB/y; P=0.27), and mean global slope (0.7±0.5 vs.-0.1±0.8 dB/y; P=0.07) were similar for persistent and nonpersistent patients, respectively. Conclusion: There were small but appreciable differences in VF progression rates between persistent and nonpersistent patient eyes on glaucoma drops, but differences were not significant. AD - T. Aung, Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, Singapore AU - De Leon, J. M. S. AU - Quek, D. T. AU - Htoon, H. M. AU - Tun, T. A. AU - Perera, S. A. AU - Lamoureux, E. L. AU - Aung, T. DB - Embase Medline DO - 10.1097/IJG.0000000000000345 IS - 4 KW - antiglaucoma agent adult article closed angle glaucoma cohort analysis disease association disease course female follow up glaucoma human intraocular hypertension juvenile open angle glaucoma low tension glaucoma major clinical study male middle aged monotherapy open angle glaucoma patient compliance prescription priority journal pseudoexfoliative glaucoma retrospective study secondary glaucoma treatment outcome visual field LA - English M3 - Article N1 - L606847150 2015-11-17 2016-04-29 PY - 2016 SN - 1536-481X 1057-0829 SP - e336-e339 ST - Persistence of glaucoma therapy and visual field progression T2 - Journal of Glaucoma TI - Persistence of glaucoma therapy and visual field progression UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606847150&from=export http://dx.doi.org/10.1097/IJG.0000000000000345 VL - 25 ID - 2762 ER - TY - JOUR AD - L.A. Hark, Ophthalmic Sciences (Ophthalmology), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Edward S. Harkness Eye Institute, 635 West 165th Street, Room 504, New York, NY, United States AU - De Moraes, C. G. AU - Hark, L. A. AU - Saaddine, J. DB - Embase Medline DO - 10.1097/IJG.0000000000001782 IS - 5 KW - follow up glaucoma health care access health care cost health care utilization health equity health hazard human intervention study mass screening priority journal quality of life review risk factor social determinants of health telemedicine LA - English M3 - Review N1 - L634474133 2021-03-19 2021-05-28 PY - 2021 SN - 1536-481X 1057-0829 SP - 369-370 ST - Screening and Interventions for Glaucoma and Eye Health through Telemedicine (SIGHT) Studies T2 - Journal of Glaucoma TI - Screening and Interventions for Glaucoma and Eye Health through Telemedicine (SIGHT) Studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634474133&from=export http://dx.doi.org/10.1097/IJG.0000000000001782 VL - 30 ID - 2298 ER - TY - JOUR AB - Objective: This study aimed to compare the cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol as first-line therapies for ocular hypertension or glaucoma. Methods: Patient charts were extracted from the UK General Practitioner Research Database. Patients with ocular hypertension or glaucoma who received first-line treatment with either travoprost or latanoprost/timolol and were followed up for > 6 months were included. Treatment failure was defined as a treatment change or a glaucoma intervention (laser therapy or surgery). Time to treatment failure was compared using a Cox model and adjusted by the propensity score method. Results: Eligible patients received either travoprost (n = 639) or latanoprost/ timolol (n = 176). Their mean age was 70 years at diagnosis and 48.2% of patients were male. Patient characteristics did not differ significantly between treatment groups. Treatment failure rates at 1 year were 31.3% (travoprost) and 39.4% (latanoprost/timolol) and yielded a hazard ratio for failure in favour of travoprost (0.75; p < 0.04) after adjusting for age, sex, co-morbidities and duration of follow-up. Adjusted annual costs of glaucoma management were significantly (p < 0.001) less with travoprost (215.86) pound than with latanoprost/timolol (327.83) pound. Conclusions: In everyday practice, travoprost was maintained longer than latanoprost/timolol as first-line therapy for glaucoma. The mean daily costs of travoprost were 50.8% less per patient than those of latanoprost/timolol. Despite adjustments, these results might be confounded, at least partially, by disease severity. AN - WOS:000262820000005 AU - De Natale, R. AU - Lafuma, A. AU - Berdeaux, G. DO - 10.2165/0044011-200929020-00005 IS - 2 PY - 2009 SN - 1173-2563 1179-1918 SP - 111-120 ST - Cost Effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma Analysis Based on the UK General Practitioner Research Database T2 - CLINICAL DRUG INVESTIGATION TI - Cost Effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma Analysis Based on the UK General Practitioner Research Database VL - 29 ID - 5949 ER - TY - JOUR AB - BACKGROUND: Primary vitreous floaters can be highly bothersome in some patients. In the case of persistently bothersome floaters, pars plana vitrectomy may be the most effective treatment. The aim of this study is to evaluate the incidence of complications, and patient satisfaction, after pars plana vitrectomy for disabling primary vitreous opacities., METHODS: We included a total of 110 eyes that underwent pars plana vitrectomy between February 1998 and August 2010. Fifty-seven eyes (51.8%) underwent 20-gauge vitrectomy, whereas 53 eyes (48.2%) underwent 23-gauge vitrectomy. In a retrospective manner, we assessed intraoperative and postoperative complications. There was a considerable range of time between surgery and questionnaire (range: 4-136 months). Patient satisfaction was assessed by a questionnaire based on a modified NEI VFQ-25 questionnaire., RESULTS: A retinal detachment occurred in 10.9% of cases, and the incidence did not differ significantly between the 20-gauge and 23-gauge vitrectomy groups. In 4.5% of the eyes, a retinal detachment developed within the first 3 months, and 6.4% occurred later in the postoperative period. Cystoid macular edema occurred in 5.5%, and an epiretinal membrane was seen postoperatively in 3.6% of cases. Development of glaucoma requiring glaucoma surgery, a macular hole, and postoperative scotoma, each occurred in 0.9% of cases. No cases of endophthalmitis occurred. Eighty-five percent of patients were satisfied or very satisfied with the results of the vitrectomy. Eighty-four percent of all patients were completely cured from their troublesome vitreous floaters, and an additional 9.3% of patients were less troubled by vitreous floaters. Ten patients (9.3%) were dissatisfied, and six of these patients (5.6%) had a serious complication that resulted in permanent visual loss., CONCLUSIONS: Pars plana vitrectomy is an effective approach to treat primary vitreous floaters, resulting in a high rate of patient satisfaction. Postoperative complications may be more frequent than previously reported, so patients should be well-informed about the complication rate before reaching informed consent about this surgical intervention. Additional preventive measures should be considered to reduce this complication rate. AU - de Nie, Karlijn F. AU - Crama, N. AU - Tilanus, Maurits A. D. AU - Klevering, B. Jeroen AU - Boon, Camiel J. F. DO - https://dx.doi.org/10.1007/s00417-012-2205-3 IS - 5 KW - Adult Aged Aged, 80 and over *Eye Diseases/su [Surgery] Female Follow-Up Studies Humans Intraoperative Complications Male Microsurgery/mt [Methods] Middle Aged *Patient Satisfaction/sn [Statistics & Numerical Data] Postoperative Complications Refraction, Ocular/ph [Physiology] Sickness Impact Profile Treatment Outcome Visual Acuity/ph [Physiology] *Vitrectomy *Vitreous Body/su [Surgery] PY - 2013 SE - de Nie, Karlijn F. Institute of Ophthalmology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. SN - 1435-702X 0721-832X SP - 1373-82 ST - Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction T2 - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie TI - Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23250478 VL - 251 Y2 - 20121219// ID - 1009 ER - TY - JOUR AB - Zika virus (ZIKV) is an arbovirus mainly transmitted to humans by mosquitoes from Aedes genus. Other ways of transmission include the perinatal and sexual routes, blood transfusion, and laboratory exposure. Although the first human cases were registered in 1952 in African countries, outbreaks were only reported since 2007, when entire Pacific islands were affected. In March 2015, the first cases of ZIKV acute infection were notified in Brazil and, to date, 48 countries and territories in the Americas have confirmed local mosquito-borne transmission of ZIKV. Until 2015, ZIKV infection was thought to only cause asymptomatic or mild exanthematous febrile infections. However, after explosive ZIKV outbreaks in Polynesia and Latin American countries, it was confirmed that ZIKV could also lead to Guillain-Barre syndrome and congenital birth abnormalities. These abnormalities, which can include neurologic, ophthalmologic, audiologic, and skeletal findings, are now considered congenital Zika syndrome (CZS). Brain abnormalities in CZS include cerebral calcifications, malformations of cortical development, ventriculomegaly, lissencephaly, hypoplasia of the cerebellum and brainstem. The ocular findings, which are present in up to 70% of infants with CZS, include iris coloboma, lens subluxation, cataract, congenital glaucoma, and especially posterior segment findings. Loss of retinal pigment epithelium, the presence of a thin choroid, a perivascular choroidal inflammatory infiltrate, and atrophic changes within the optic nerve were seen in histologic analyses of eyes from deceased fetuses. To date, there is no ZIKV licensed vaccines or antiviral therapies are available for treatment. Preventive measures include individual protection from mosquito bites, control of mosquito populations and the use of barriers measures such as condoms during sexual intercourse or sexual abstinence for couples either at risk or after confirmed infection. A literature review based on studies that analyzed ocular findings in mothers and infants with CZS, with or without microcephaly, was conducted and a theoretical pathophysiologic explanation for ZIKV-ocular abnormalities was formulated. Copyright © 2018 Elsevier Ltd. All rights reserved. AU - de Oliveira Dias, Joao Rafael AU - Ventura, Camila V. AU - de Paula Freitas, Bruno AU - Prazeres, Juliana AU - Ventura, Liana O. AU - Bravo-Filho, Vasco AU - Aleman, Tomas AU - Ko, Albert Icksang AU - Zin, Andrea AU - Belfort, Rubens, Jr. AU - Maia, Mauricio AU - Zika Virus Study, Group DO - https://dx.doi.org/10.1016/j.preteyeres.2018.04.004 KW - Eye Infections, Viral/co [Complications] *Eye Infections, Viral/cn [Congenital] Eye Infections, Viral/tm [Transmission] Female Humans Microcephaly/co [Complications] Microcephaly/vi [Virology] Pregnancy *Pregnancy Complications, Infectious/vi [Virology] Zika Virus/py [Pathogenicity] *Zika Virus Zika Virus Infection/co [Complications] *Zika Virus Infection/cn [Congenital] Zika Virus Infection/tm [Transmission] PY - 2018 SE - de Oliveira Dias, Joao Rafael. Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil. Ventura, Camila V. Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil; Altino Ventura Foundation, Recife, Pernambuco, Brazil; HOPE Eye Hospital, Recife, Pernambuco, Brazil. de Paula Freitas, Bruno. Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil; Department of Ophthalmology, Roberto Santos General Hospital, Salvador, Brazil. Prazeres, Juliana. Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil. Ventura, Liana O. Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil; Altino Ventura Foundation, Recife, Pernambuco, Brazil; HOPE Eye Hospital, Recife, Pernambuco, Brazil. Bravo-Filho, Vasco. Altino Ventura Foundation, Recife, Pernambuco, Brazil; HOPE Eye Hospital, Recife, Pernambuco, Brazil. Aleman, Tomas. Scheie Eye Institute at the Perelman Center for Advanced Medicine, Perelman School of Medicine, Department of Ophthalmology, University of Pennsylvania, Philadelphia, United States. Ko, Albert Icksang. Goncalo Moniz Research Center, Oswaldo Cruz Foundation, Salvador, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States. Zin, Andrea. Clinical Research Unit, Fernandes Figueira Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Belfort, Rubens Jr. Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil. Maia, Mauricio. Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil; Brazilian Institute of Fight Against Blindness, Assis and Presidente Prudente, Sao Paulo, Brazil. Electronic address: mmaia@unifesp.br. SN - 1873-1635 1350-9462 SP - 85-106 ST - Zika and the Eye: Pieces of a Puzzle T2 - Progress in retinal and eye research TI - Zika and the Eye: Pieces of a Puzzle UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29698814 VL - 66 Y2 - 20180424// ID - 435 ER - TY - JOUR AB - AIM: To compare the monotheraphy efficacy of the brand latanoprost Xalatan and a similar latanoprost (Drenatan) regarding intraocular pressure (IOP) reduction in patients with primary open angle glaucoma (POAG). METHODS: Sixty two patients (119 eyes) were enrolled in this observational, retrospective study. In the first visit, the patient came in using the brand latanoprost (Xalatan) and it was changed to the similar latanoprost (Drenatan). In the second visit, 12wk later, a complete ophtalmologic exam including slit lamp examination, Goldmann applanation tonometry, stereoscopic fundus examination, gonioscopy, ultrasound pachymetry, automated visual field testing was performed. RESULTS: The mean IOP was 12.30±2.02mmHg and 12.38±2.05mmHg with using Xalatan and Drenatan, respectively. The P=0.559 demonstrates this relation. In fact, a correlation between the groups of R=0.987 points out the remarkable resemblance of both groups. CONCLUSION: Both Drenatan and Xalatan have similar efficacy in reducing IOP. Such finding is pivotal to public health to reduce cost and maintain its policies concerning drug efficacy and safety, this is especially significant in countries in which treatment cost is a barrier for patient adhesion to treatment. Copyright 2017 by the IJO Press. AD - Department of Ophthalmology, Eye Institute of the Medical Science School, R. Pouso Alegre, 407 Floresta, Belo Horizonte, Minas Gerais 31015065, Brazil Department of Ophthalmology, The Royal Victorian Eye and Ear Hospital, 32 Gisborne St, East Melbourne, Melbourne, VIC 3002, Australia Department of Ophthalmology, Federal University of São Paulo, R. Sena Madureira, 1500 Vila Clementino, Sao Paulo, 04021001, Brazil AU - de Pádua Soares Bezerra, B. AU - Vieira, A. A. P. AU - Nascimento, M. AU - Barbosa, J. C. AU - Kanadani, F. N. DB - Scopus DO - 10.3980/j.issn.1672-5123.2017.10.01 IS - 10 KW - Drug comparison Generic drug Latanoprost Open angle glaucoma M3 - Article N1 - Export Date: 19 July 2021 PY - 2017 SP - 1803-1806 ST - Comparing the efficacy of Xalatan and a similar latanoprost (Drenatan) in open angle glaucoma patients T2 - International Eye Science TI - Comparing the efficacy of Xalatan and a similar latanoprost (Drenatan) in open angle glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034823072&doi=10.3980%2fj.issn.1672-5123.2017.10.01&partnerID=40&md5=577f6e3067af9368af86c8b8f5362688 VL - 17 ID - 5734 ER - TY - JOUR AB - Glaucoma is the second leading cause of blindness worldwide and intraocular pressure (IOP) is currently its only modifiable risk factor. Peak IOP has for a long time been considered as a major contributor to glaucoma progression, but its effects may depend not only on its magnitude, but also on its time course. The IOP is nowadays considered to be a dynamic parameter with a circadian rhythm and spontaneous changes. The current practice of punctual measuring the IOP during office hours is therefore a suboptimal approach, which does not take into account the natural fluctuation of IOP. Because of its static nature a single IOP measurement in sitting position fails to document the true range of an individual’s IOP, peak IOP, or variation throughout the day. Phasing means monitoring a patient’s IOP during the daytime or over a 24-hour period. This can provide additional information in the management of glaucoma patients. This review focuses on the current insight of non-invasive IOP monitoring as a method of obtaining more complete IOP profiles. Invasive techniques using an implantable sensor are beyond the scope of this review. AD - S. De Smedt, Department of Ophthalmology, AZ St Maarten, Leopoldstraat 2, Mechelen, Belgium AU - De Smedt, S. DB - Embase DO - 10.2147/OPTH.S53772 KW - biosensor contact lens contact lens sensor arterial pressure blurred vision circadian rhythm clinical effectiveness conjunctival hyperemia device safety diagnostic test accuracy study disease course eye pressure monitor eye structural assessment equipment false positive result Goldmann applanation tonometer human intraocular pressure intraocular pressure monitoring low tension glaucoma non invasive measurement nonhuman oculoplethysmography patient compliance pressure measurement punctate keratitis reproducibility review self tonometry time to treatment Proview SENSIMED Triggerfish Tiolat iCare tonometer Tono-pen LA - English M3 - Review N1 - L605706615 2015-08-31 2015-09-03 PY - 2015 SN - 1177-5483 1177-5467 SP - 1385-1392 ST - Noninvasive intraocular pressure monitoring: Current insights T2 - Clinical Ophthalmology TI - Noninvasive intraocular pressure monitoring: Current insights UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605706615&from=export http://dx.doi.org/10.2147/OPTH.S53772 VL - 9 ID - 2795 ER - TY - JOUR AB - The authors report a case of second degree heart block associated with topical latanoprost treatment. The authors discuss the possibility of a causative effect as the cessation of this treatment resulted in improvement of the arrhythmia. The authors highlight previous reports and research in humans and animals which demonstrate an association of arrhythmias with prostaglandin analogues. This report draws attention to the possibility that an extremely commonly prescribed topical drug may trigger arrhythmias in susceptible individuals. It is important that prescribers are aware of this possible side-effect. Copyright 2011 BMJ Publishing Group. All rights reserved. AD - E. De Smit, Eye Unit, Croydon University Hospital, Croydon, United Kingdom AU - De Smit, E. AU - Theodorou, M. AU - Hildebrand, G. D. AU - Bloom, P. DB - Embase Medline DO - 10.1136/bcr.08.2011.4607 KW - beta adrenergic receptor blocking agent latanoprost adult article artificial heart pacemaker atrioventricular conduction bradycardia case report disease control dizziness drug administration route drug safety drug withdrawal dyspnea electrocardiography fatigue female heart palpitation human intraocular pressure lethargy mitral valve regurgitation open angle glaucoma patient attitude patient compliance priority journal second degree atrioventricular block topical treatment LA - English M3 - Article N1 - L362742745 2011-10-21 2011-11-01 PY - 2011 SN - 1757-790X ST - Heart block following topical latanoprost treatment T2 - BMJ Case Reports TI - Heart block following topical latanoprost treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362742745&from=export http://dx.doi.org/10.1136/bcr.08.2011.4607 http://casereports.bmj.com/content/2011/bcr.08.2011.4607.full.pdf?sid=0d927831-f49e-40af-99ab-9115f9dc25b8 ID - 3136 ER - TY - JOUR AB - Alcohol dependence is a major health problem worldwide. Various pharmacological agents have been used in the management of alcohol dependence. This review looks at the role of topiramate and other anticonvulsants in the management of alcohol dependence. Topiramate is the most widely used anticonvulsant in the treatment of alcohol dependence. The literature on topiramate is reviewed and critically analyzed, along with its proposed mechanism of action in alcohol dependence. A review of data available on other anticonvulsants like carbamazepine, oxcarbazepine, sodium valproate, gabapentin and levetiracetam are presented and their potential in the treatment of alcohol dependence is considered, together with future research directions. © 2010 Bentham Science Publishers Ltd. AD - A. De Sousa, Carmel, 18, St. Francis Avenue, Off S.V. Road, Santacruz (West), Mumbai - 400054, State - Maharashtra, India AU - De Sousa, A. DB - Embase Medline DO - 10.2174/187152710790966696 IS - 1 KW - acamprosate anticonvulsive agent buspirone carbamazepine disulfiram etiracetam gabapentin lorazepam naltrexone oxcarbazepine placebo topiramate valproic acid alcohol abstinence alcohol withdrawal syndrome alcoholism clinical trial closed angle glaucoma cognitive defect cognitive therapy drug binding drug bioavailability drug dose increase drug efficacy drug excretion drug half life drug mechanism drug safety drug tolerability drug withdrawal human kidney tubule acidosis myopia nephrolithiasis paresthesia patient compliance psychosocial care quality of life review time to maximum plasma concentration titrimetry withdrawal seizure LA - English M3 - Review N1 - L358519063 2010-04-01 2010-05-04 PY - 2010 SN - 1871-5273 SP - 45-49 ST - The role of topiramate and other anticonvulsants in the treatment of alcohol dependence: A clinical review T2 - CNS and Neurological Disorders - Drug Targets TI - The role of topiramate and other anticonvulsants in the treatment of alcohol dependence: A clinical review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358519063&from=export http://dx.doi.org/10.2174/187152710790966696 http://www.benthamdirect.org/pages/b_getarticlebyissue.php VL - 9 ID - 3272 ER - TY - JOUR AB - PURPOSE: To determine the feasibility and specificity of glaucoma screening during regular optician visits., METHODS: In four optician shops, glaucoma screening was offered to 400 consecutive visitors aged 45 years or above. If the visitor agreed to participate, an intraocular pressure measurement and - in those with a pressure below 25 mmHg - a frequency-doubling perimeter (FDT) C20-1 visual field screening test were performed. Those with an elevated pressure or at least one reproducibly abnormal test location on FDT were referred to our hospital., RESULTS: Three-hundred and fifty-two of 400 consecutive visitors (88%) were screened. Fifteen of the unscreened visitors were not screened because they were already regularly checked by an ophthalmologist related to glaucoma. Forty-two of 352 screened participants (12%) were referred. Of these 42 referrals, seven were diagnosed with glaucoma, 10 were diagnosed with ocular hypertension (OHT), 12 did not have any eye disease, seven had an eye disease other than glaucoma or OHT that was diagnosed previously and six were newly diagnosed with an eye disease other than glaucoma or OHT. The specificity of the screening protocol was 91% (95% confidence interval 88-94%)., CONCLUSIONS: Glaucoma screening at the optician shop was feasible, but the specificity of the screening protocol was rather low. With more stringent cut-off points (30 mmHg; at least two reproducibly abnormal test locations), the specificity could be improved to 96% (94-98%), apparently without a significant loss of sensitivity. This suggests that screening during regular optician visits might be a viable approach. Copyright © 2012 The Authors. Acta Ophthalmologica © 2012 Acta Ophthalmologica Scandinavica Foundation. AU - de Vries, Margriet M. AU - Stoutenbeek, Remco AU - Muskens, Rogier P. H. M. AU - Jansonius, Nomdo M. DO - https://dx.doi.org/10.1111/j.1755-3768.2011.02355.x IS - 2 KW - Aged Aged, 80 and over Feasibility Studies Female *Glaucoma, Open-Angle/di [Diagnosis] Humans Intraocular Pressure Male Middle Aged Ocular Hypertension/di [Diagnosis] *Office Visits Optometry Predictive Value of Tests Reproducibility of Results Sensitivity and Specificity Surveys and Questionnaires Tonometry, Ocular *Vision Screening/mt [Methods] Vision Screening/st [Standards] Visual Field Tests PY - 2012 SE - de Vries, Margriet M. Department of Ophthalmology, University Medical Center Groningen, University of Groningen, 9700 R B Groningen, The Netherlands. SN - 1755-3768 1755-375X SP - 115-21 ST - Glaucoma screening during regular optician visits: the feasibility and specificity of screening in real life T2 - Acta ophthalmologica TI - Glaucoma screening during regular optician visits: the feasibility and specificity of screening in real life UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22268769 VL - 90 Y2 - 20120123// ID - 1153 ER - TY - JOUR AB - PURPOSE: To test whether general nurses, trained in screening for glaucoma, can increase the number of glaucoma cases seen by eye-care professionals in a rural setting in Africa., METHODS: In two districts in Malawi, 87 clinic nurses and two ophthalmic clinical officers were trained in case detection and referral of patients with suspect glaucoma. Data were collected on the number of patients screened and referred over a 12-month period. The clinic nurses and ophthalmic clinical officers received supportive supervision four times during the period and interviews were used to elicit their perspectives on the training and referral procedures., RESULTS: The 87 nurses screened 294 people (mean 3.4 per nurse) and referred 147 (50%) of them. Of the 147 referred, 56 (38%) were seen by the ophthalmic clinical officers who referred 15 (27%) to the ophthalmologist. Only two people were seen by the ophthalmologist. Testing visual acuity in people over 40 years of age was not seen as a priority by primary level clinic nurses. Nurses reported that cost and distance were barriers precluding attendance by patients at the next level. Women were two times less likely to be referred. About one quarter of patients who were offered surgery refused. Fewer than half the patients who had surgery attend for follow-up., CONCLUSIONS: Training general nurses to screen for and refer suspect glaucoma cases did not lead to increased glaucoma service delivery. Other strategies to identify high risk patients need to be tested. AU - Dean, William H. AU - Courtright, Paul AU - Cook, Colin DO - https://dx.doi.org/10.3109/09286586.2012.712193 IS - 5 KW - Adult Aged Aged, 80 and over Delivery of Health Care/sn [Statistics & Numerical Data] *Education, Nursing/sn [Statistics & Numerical Data] Female *Glaucoma/di [Diagnosis] Humans *Inservice Training/sn [Statistics & Numerical Data] Malawi/ep [Epidemiology] Male Middle Aged Ophthalmology/sn [Statistics & Numerical Data] Pilot Projects *Referral and Consultation/sn [Statistics & Numerical Data] Rural Population/sn [Statistics & Numerical Data] Vision Screening/is [Instrumentation] *Vision Screening/mt [Methods] *Visual Acuity/ph [Physiology] PY - 2012 SE - Dean, William H. Nkhoma Eye Hospital, Malawi. whd1_uk@hotmail.com SN - 1744-5086 0928-6586 SP - 293-6 ST - Does training clinic nurses to test pinhole visual acuity as a screen for glaucoma increase glaucoma referrals to eye care professionals? A pilot study in Malawi T2 - Ophthalmic epidemiology TI - Does training clinic nurses to test pinhole visual acuity as a screen for glaucoma increase glaucoma referrals to eye care professionals? A pilot study in Malawi UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22978530 VL - 19 ID - 1109 ER - TY - JOUR AB - PURPOSE: To evaluate clinical characteristics, risk factors, management and outcome of contact lens induced keratitis (CLIK) associated with contact lens wear., METHODS: The study comprised all consecutive patients presenting with contact lens related presumed microbial keratitis during a 12-month period at our department. Detailed demographic data, type of contact lens, duration of lens wear, wearing schedule and lens hygiene were derived from a self-administered questionnaire. Severity of ulcer, corneal scrapings, treatment and final outcome were evaluated., RESULTS: 27 patients with CLIK, some of which may have been sterile peripheral infiltrates, due to contact lens wear were detected. In the majority of the cases patients had used disposable soft contact lenses (89%) and most of them had a daily wearing schedule (78%). 51.8% patients cleaned their lenses regularly. 6 (22%) applied no disinfection since their lenses were disposable on removal. In 3 of our cases with CLIK, penetrating keratoplasty had to be performed., CONCLUSION: Disposable contact lenses seem to have been a predisposing factor for contact lens induced keratitis also when used on a daily wear schedule. Insufficient contact lens care products and/or manufacturing characteristics may be responsible for CLIK, which is also observed in otherwise compliant contact lens users. In 3 of our patients with CLIK keratoplasty became necessary, indicating that contact lens induced keratitis may result in severe corneal complications. AU - Dejaco-Ruhswurm, I. AU - Scholz, U. AU - Hanselmayer, G. AU - Skorpik, C. IS - 5 KW - Adult Contact Lens Solutions/tu [Therapeutic Use] *Contact Lenses, Hydrophilic/ae [Adverse Effects] *Corneal Ulcer/et [Etiology] Corneal Ulcer/su [Surgery] Disinfection/mt [Methods] Disposable Equipment Female Humans Keratoplasty, Penetrating Male Risk Factors Surveys and Questionnaires Time Factors Visual Acuity PY - 2001 SE - Dejaco-Ruhswurm, I. Department of Ophthalmology, University of Vienna Medical School, Vienna, Austria. irene.ruhswurm@univie.ac.at SN - 1395-3907 SP - 479-83 ST - Contact lens induced keratitis associated with contact lens wear T2 - Acta ophthalmologica Scandinavica TI - Contact lens induced keratitis associated with contact lens wear UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11594983 VL - 79 ID - 1910 ER - TY - JOUR AB - PURPOSE: The first objective of the present study was to estimate the prevalence of patients treated for glaucoma or ocular hypertension (OHT) with an IOP (intraocular pressure) -lowering topical medication. Subjects were 40 years old and living in continental France. The second objective was to describe the type of therapy, compliance, and the quality of life of the subjects treated., METHODS: This study was a telephone survey conducted in a general population on a representative sample of 5726 subjects in 2004. Subjects treated for glaucoma or OHT were defined as those declaring use of eye drops for more than 1 month and mentioning one of the 52 registered IOP-lowering topical medications and/or stating that they were taking eye drops for glaucoma or OHT. Quality of life was measured using the GlauQOL-17 questionnaire., RESULTS: 237 subjects (4.1%) corresponded to this definition. The prevalence increased with age, from 0.7% in subjects aged 40-44 years to 10.6% in those aged 80 years or more. The age-standardized prevalence was higher in the Paris area (5.3%), the Mediterranean (4.5%), and the Southwest (4.7%), and lower in rural areas (3.2%), and in subjects with less than high school education (2.9%). Beta-blockers (49.5%) and prostaglandins (37.4%) were the most frequent treatments, followed by carbonic anhydrase inhibitors (15.3%), sympathomimetics (5.7%), and myotics (1.3%). Compliance was not total in 39% of the patients (22% of those treated with once-a-day dosage)., DISCUSSION: The results of the present study are in line with French health authority data and with the results of the French "Glaucoma and intraocular high pressure, one day" study results. Moreover, the lower prevalence in regions with low medical density, low socioeconomic level, and rural areas, suggest that glaucoma or OHT might be underdiagnosed., CONCLUSION: On the basis of this first nationwide study, it can be estimated that the prevalence of subjects treated with IOP-lowering topical medications is about 1.2 million in France. The number of daily doses appears to influence compliance. AU - Delcourt, C. AU - Bron, A. AU - Baudouin, C. AU - Denis, P. AU - Nordmann, J. P. AU - Renard, J. P. AU - Rouland, J. F. AU - Sellem, E. AU - Stephan, M. AU - Levrat, F. AU - Solesse, A. IS - 10 KW - Adult Aged Aged, 80 and over Data Collection France/ep [Epidemiology] Humans Intraocular Pressure Middle Aged *Ocular Hypertension/cl [Classification] *Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/ep [Epidemiology] Prevalence Telephone PY - 2006 SE - Delcourt, C. Inserm, Unite U593, Epidemiologie, Sante Publique et Developpement, Universite Victor Segalen Bordeaux 2, Bordeaux, France. SN - 1773-0597 0181-5512 SP - 1098-106 ST - [Prevalence and description of treatment with intraocular pressure-lowering topical medications in continental France] T2 - Prevalence et description du traitement par hypotonisants pour glaucome et hypertonie oculaire en France. TI - [Prevalence and description of treatment with intraocular pressure-lowering topical medications in continental France] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17211318 VL - 29 ID - 1628 ER - TY - JOUR AB - Glaucoma is the leading cause of blindness in the developed and developing world. Not only is the clinical impact of this disease considerable, but associated economic and humanistic burdens - affecting patients, caregivers, and society - are substantial. Since glaucoma is an age-related disorder and populations in many developing countries are aging at a faster pace than in the developed world, increasing attention is being focused on ways to ameliorate the burdens of illness. In this paper, we examine the burdens of glaucoma with particular focus on developing countries, discuss some of the challenges that exist in delivering optimal glaucoma management within budget constraints, and bring into perspective how we could improve current healthcare systems, leverage technology, and strike an appropriate balance between cost and quality of care, thereby offering considerations to payors and policymakers in these countries that may result in longer-term cost savings, while concurrently striving to achieve the WHO Vision on the prevention of blindness and visual impairment. AD - Y. Hadjiat, Mundipharma Singapore Holding Pte Limited, 12 Marina View, #22-01, Asia Square Tower 2, Singapore, Singapore AU - Delgado, M. F. AU - Abdelrahman, A. M. AU - Terahi, M. AU - Woll, J. J. M. Q. AU - Gil-Carrasco, F. AU - Cook, C. AU - Benharbit, M. AU - Boisseau, S. AU - Chung, E. AU - Hadjiat, Y. AU - Gomes, J. A. P. DB - Embase DO - 10.2147/CEOR.S218277 KW - antiglaucoma agent article blindness budget cost control developing country disease burden drug cost dry eye glaucoma health care access health care cost health care policy health care quality human incidence ocular surface disease primary medical care primary prevention quality of life systematic review telemedicine visual impairment LA - English M3 - Article N1 - L2002710452 2019-10-29 2019-11-06 PY - 2019 SN - 1178-6981 SP - 591-604 ST - Management of glaucoma in developing countries: Challenges and opportunities for improvement T2 - ClinicoEconomics and Outcomes Research TI - Management of glaucoma in developing countries: Challenges and opportunities for improvement UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002710452&from=export http://dx.doi.org/10.2147/CEOR.S218277 VL - 11 ID - 2544 ER - TY - JOUR AB - The objective of this study was to compare a cohort of geriatric patients with operatively managed isolated fractures below the hip to a cohort of geriatric patients with operatively managed isolated hip fractures. All patients greater than 59 years of age admitted to our institution for surgical care of an isolated lower extremity fracture during a 3-year period were included. Patients were divided into 2 cohorts: BTH (fracture below the subtrochanteric region of the femur) and HIP (proximal femoral fracture at subtrochanteric region or proximal). We identified 141 patients included in cohort BTH and 205 patients included in cohort HIP. HIP patients were older (P <.01) and less obese (P <.01) but were otherwise very similar. An extensive comorbidity review revealed that the 2 cohorts were similar, with the exception of an increased incidence of dementia (P =.012) or glaucoma (P =.04) in HIP patients and of peripheral neuropathy (P =.014) in BTH patients. HIP patients were more likely to be under active antiosteoporotic medication management and were more likely to be receiving pharmacological anticoagulation at the time of admission. HIP patients and BTH patients were similar with regard to necessity of assistance with ambulation preinjury, but HIP patients were less likely to reside independently at home than were BTH patients (P <.001). HIP patients were also less likely to be discharged directly home from the hospital (P <.001). Geriatric patients with fractures below the hip are medically similar to geriatric patients with hip fracture. Medical comanagement protocols have been extensively published that improve care of geriatric patients with hip fracture; consideration should be given to similar protocol-driven medical comanagement programs for geriatric patients with fractures below the hip. AD - G.J. Della Rocca, Department of Orthopaedic Surgery, University of Missouri, 1 Hospital Drive, N116, DC053.10, Columbia, MO, United States AU - Della Rocca, G. J. AU - Uppal, H. S. AU - Copeland, M. E. AU - Crist, B. D. AU - Volgas, D. A. DB - Embase DO - 10.1177/2151458514565662 IS - 1 KW - adult aged ambulatory care ankle fracture article below the hip fracture Charlson Comorbidity Index female femur intertrochanteric fracture femoral neck fracture femoral shaft femur shaft fracture femur subtrochanteric fracture foot fracture geriatric patient hip fracture human incidence major clinical study male osteoporosis patella fracture priority journal tibia fracture LA - English M3 - Article N1 - L602244410 2015-02-19 2015-02-23 PY - 2015 SN - 2151-4593 2151-4585 SP - 28-32 ST - Geriatric Patients With Fractures Below the Hip are Medically Similar to Geriatric Patients With Hip Fracture T2 - Geriatric Orthopaedic Surgery and Rehabilitation TI - Geriatric Patients With Fractures Below the Hip are Medically Similar to Geriatric Patients With Hip Fracture UR - https://www.embase.com/search/results?subaction=viewrecord&id=L602244410&from=export http://dx.doi.org/10.1177/2151458514565662 VL - 6 ID - 2838 ER - TY - JOUR AB - Compliance to examinations performed in a specialised department was studied in patients with chronic open-angle glaucoma. A total of 429 case reports from patients treated from 1974 to 1977 were analyzed, follow up being for a period of up to 7 years. Examinations were performed two or three times a year and any patient who didn't return for two consecutive years was considered as lost. The number of lost patients was very few, about 10 percent a year, and this did not increase during the whole follow-up period. Overall, compliance was not related to sex. However, a higher proportion of women were lost between the second and third year of follow up. The distance between patient's homes and the medical center, near or far away, was not significant. As expected, a higher proportion of patients over sixty were lost after one year of follow up. AU - Demailly, P. AU - Pittman, S. AU - Abadie, P. IS - 11 KW - Adult Age Factors Aged Female *Glaucoma, Open-Angle/th [Therapy] Humans Male Middle Aged *Patient Compliance Residence Characteristics Sex Factors Time Factors PY - 1982 SN - 0181-5512 SP - 711-5 ST - [Monitoring of patients with primary chronic open-angle glaucoma] T2 - La surveillance des malades porteurs d'un glaucome chronique primitif a angle ouvert. TI - [Monitoring of patients with primary chronic open-angle glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=7153472 VL - 5 ID - 2246 ER - TY - JOUR AB - Compliance to examinations performed in a specialised department was studied in patients with chronic open-angle glaucoma. A total of 429 case reports from patients treated from 1974 to 1977 were analyzed, follow-up being for a period of up to 7 years. Examinations were performed 2 or 3 times a year, and any patient who did not return for 2 consecutive years was considered as lost. The number of lost patients was very few, about 10% a year, and this did not increase during the whole follow-up period. Overall, compliance was not related to sex. However, a higher proportion of women were lost between the second and third year of follow-up. The distance between patient's homes and the medical center, near or far away, was not significant. As expected, a higher proportion of patients over 60 were lost after 1 year of follow-up. AD - Serv. Ophtalmol., Hop. St.-Joseph, F-75674 Parix Cedex 14 AU - Demailly, Ph AU - Pittman, S. AU - Abadie, P. DB - Embase Medline IS - 11 KW - clinical article glaucoma human open angle glaucoma visual system LA - French M3 - Article N1 - L13240962 1983-01-14 PY - 1982 SN - 0181-5512 SP - 711-715 ST - The follow-up of patients with chronic open-angle glaucoma T2 - Journal Francais d'Ophtalmologie TI - The follow-up of patients with chronic open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L13240962&from=export VL - 5 ID - 4089 ER - TY - JOUR AB - Compliance to examinations performed in a specialised department was studied in patients with chronic open-angle glaucoma. A total of 429 case reports from patients treated from 1974 to 1977 were analyzed, follow-up being for a period of up to 7 years. Examinations were performed 2 or 3 times a year, and any patient who did not return for 2 consecutive years was considered as lost. The number of lost patients was very few, about 10% a year, and this did not increase during the whole follow-up period. Overall, compliance was not related to sex. However, a higher proportion of women were lost between the second and third year of follow-up. The distance between patient's homes and the medical center, near or far away, was not significant. As expected, a higher proportion of patients over 60 were lost after 1 year of follow-up. AD - Serv. Ophtalmol., Hop. St.-Joseph, F-75674 Parix Cedex 14, France AU - Demailly, Ph AU - Pittman, S. AU - Abadie, P. DB - Scopus IS - 11 M3 - Article N1 - Export Date: 19 July 2021 PY - 1982 SP - 711-715 ST - LA SURVEILLANCE DES MALADES PORTEURS D'UN GLAUCOME CHRONIQUE PRIMITIF A ANGLE OUVERT T2 - Journal Francais d'Ophtalmologie TI - The follow-up of patients with chronic open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020450802&partnerID=40&md5=1e194fac0da9bbe3a88d445169be4a65 VL - 5 ID - 5804 ER - TY - JOUR AB - This survey has investigated the occurence of psychopathological affections and their relationship with compliance in open angle glaucomatous patients. Three groups have been considered: 48 severe glaucomas, 37 early glaucomas and 48 control patients, under treatment for other ophthalmological affections. These groups have taken a psychiatric interview, compliance evaluating scale and psychological assessment (inducling: Vocabulaire Binois Pichot, Cattel's 16 Personality Factors and Autoanalyse, Thematic Aperception Test and the Rorschach Test analysed through Exner's Synthetic System). Anxiety personality and disoders are more frequent in the glaucomatous group than the control or early (P = 0.0156). Patients in the early group appeared to be most compliant. Personality structure play a role in the acceptance of the disease and in the degree of cooperation with treatment. Maximal compliance is observed at the beginning of the disease. Personality scales show that glaucomatous patients have difficulties in coping with aggressive pulsions and tend to react to affect loaded situations by a defensive or avoiding attitude. AU - Demailly, P. AU - Zoute, C. AU - Castro, D. IS - 8-9 KW - Adult Chronic Disease Female Glaucoma, Open-Angle/co [Complications] *Glaucoma, Open-Angle/px [Psychology] Glaucoma, Open-Angle/th [Therapy] Humans Male Mental Disorders/et [Etiology] Middle Aged Patient Compliance *Personality Psychological Tests Psychometrics PY - 1989 SE - Demailly, P. Chef de service, Hopital Saint-Joseph, Paris. SN - 0181-5512 SP - 595-601 ST - [Personalities and chronic glaucoma] T2 - Personnalites et glaucome chronique. TI - [Personalities and chronic glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2635202 VL - 12 ID - 2169 ER - TY - JOUR AB - Purpose: An estimated 2.2 billion people are visually impaired worldwide. Given that age-related vision loss is a primary cause of vision impairment, this number is projected to rise with increases in average lifespan. Vision loss often results in significant disability and is associated with a substantial economic burden, reduced quality-of-life, concurrent medical issues, and mental health problems. In this review, the mental health needs of people with vision impairment are examined. Patients and methods: A review of recent literature on mental health outcomes and current treatments in people with visual impairment was conducted. Results: Considerable data indicate that rates of depression and anxiety are elevated among people with visual impairments. Moreover, individuals of lower socioeconomic status may be at increased risk for vision impairment and subsequent mental health problems. Existing psychosocial interventions for improving mental health in people with visual impairment show some promise, but are limited by low adherence and lack generalizability. Conclusion: In order to improve outcomes, a better understanding of the mechanisms linking visual impairment and poor mental health is needed. It will also be essential to develop more effective interventions and expand access to services to improve the detection and treatment of mental health problems in this population. AD - D.L. Demmin, Department of Psychology, Rutgers University, Piscataway, NJ, United States AU - Demmin, D. L. AU - Silverstein, S. M. DB - Embase DO - 10.2147/OPTH.S258783 KW - adult anxiety article cataract cognition depression diabetic retinopathy disability economic aspect female glaucoma health care access health care need health service human macular degeneration male mental health prevalence quality of life social psychology social status socioeconomics visual acuity visual impairment LA - English M3 - Article N1 - L2005607213 2020-12-22 2021-01-18 PY - 2020 SN - 1177-5483 1177-5467 SP - 4229-4251 ST - Visual impairment and mental health: Unmet needs and treatment options T2 - Clinical Ophthalmology TI - Visual impairment and mental health: Unmet needs and treatment options UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005607213&from=export http://dx.doi.org/10.2147/OPTH.S258783 VL - 14 ID - 2452 ER - TY - JOUR AD - J. Bousquet, Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex-5, France AU - Demoly, P. AU - Chanez, P. AU - Godard, P. DB - Embase Medline DO - 10.1006/pupt.1999.0197 IS - 2 KW - beclometasone beta 2 adrenergic receptor stimulating agent corticosteroid theophylline antiinflammatory activity asthma behavior disorder bone atrophy cataract conference paper disease severity forced expiratory volume glaucoma growth inhibition human inhalational drug administration metabolic disorder metered dose inhaler oral drug administration patient compliance patient education priority journal skin disease LA - English M3 - Conference Paper N1 - L29366494 1999-08-15 PY - 1999 SN - 1094-5539 SP - 63-65 ST - Unmet needs in the pharmacological treatment of asthma T2 - Pulmonary Pharmacology and Therapeutics TI - Unmet needs in the pharmacological treatment of asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L29366494&from=export http://dx.doi.org/10.1006/pupt.1999.0197 VL - 12 ID - 3927 ER - TY - JOUR AD - Arena Eye Surgeons, Columbus, OH AN - 107879714. Language: English. Entry Date: 20140127. Revision Date: 20150712. Publication Type: Journal Article AU - DeNaeyer, Gregory W. DB - ccm DP - EBSCOhost IS - 1 KW - Sterilization and Disinfection -- Methods Contact Lenses Sterilization and Disinfection -- Evaluation Infection -- Prevention and Control Acanthamoeba Keratitis -- Diagnosis United States Food and Drug Administration Cleaning Compounds Patient Compliance -- Evaluation Outcomes (Health Care) N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 8610268. PY - 2014 SN - 0885-9175 SP - 49-49 ST - Topping Off Happens: Disinfection Efficacy Matters T2 - Contact Lens Spectrum TI - Topping Off Happens: Disinfection Efficacy Matters UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107879714&site=ehost-live&scope=site VL - 29 ID - 4794 ER - TY - JOUR AB - Achieving an adequate intraocular pressure (IOP) is critical to the successful management of children affected with juvenile glaucoma, in whom medical therapy is often insufficient to control IOP. Anti-glaucoma eyedrops are usually not approved for use in children but, however, are frequently used in pediatrics. Although ocular hypotensive eyedrops may be well tolerated in young patients, their chronic use is often problematic because of systemic side effects or noncompliance. Glaucoma filtering surgery with adjunctive antifibrosis therapy (particularly with mitomycin C), aqueous shunt surgery and cyclodestructive procedures are currently undertaken in patients with juvenile glaucoma. Filtration surgery is usually less successful in patients with juvenile glaucoma: the higher failure rate stems from the excessive wound healing response in younger patients, resulting in subconjunctival fibrosis. AU - Denis, P. KW - Adolescent Age Factors Child Glaucoma/dt [Drug Therapy] Glaucoma/su [Surgery] *Glaucoma/th [Therapy] Humans PY - 2005 SE - Denis, P. Service d'Ophtalmologie Pavillon C, Hopital Edouard Herriot, Place d'Arsonval, 69437 Lyon Cedex 03. SN - 1773-0597 0181-5512 SP - 2S35-2S40 ST - [Glaucoma in the young patient. Therapeutic problems] T2 - Le glaucome du sujet jeune. Problemes therapeutiques. TI - [Glaucoma in the young patient. Therapeutic problems] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16208239 VL - 28 Spec No 2 ID - 1717 ER - TY - JOUR AB - Even if glaucoma treatment often begins with monotherapy, combined treatments are in fact frequent. However, they are associated with poorer compliance, which may lead to lower efficacy, notably if the delay between two eyedrops is too short. The main advantages of fixed combinations are better therapeutic compliance and a lesser effect of dilution of the first eyedrops by the second. Nevertheless, it is impossible to change the dosing interval of one or the other of the components and adverse side effects cannot be controlled. The fixed combinations available today or in the near future are based for the most part on the combination of timolol and a prostaglandin. Their efficacy is comparable to the efficacy of each of the components or of nonfixed combinations, but it is not strictly equivalent. This difference (on the order of 1 mmHg) could be explained by unsuitable frequency or poor timing of the instillation. AU - Denis, P. KW - Drug Therapy, Combination *Glaucoma/dt [Drug Therapy] Humans PY - 2006 SE - Denis, P. Service d'Ophtalmologie Pavillon C, Hopital Edouard Herriot, Lyon. philippe.denis@chu-lyon.fr SN - 1773-0597 0181-5512 SP - 45-8 ST - [Practical measures. Advantages of fixed combination treatments] T2 - Attitudes pratiques. Interet des traitements par combinaisons fixes. TI - [Practical measures. Advantages of fixed combination treatments] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17072222 VL - 29 Spec No 2 ID - 1640 ER - TY - JOUR AD - P. Denis, Department of Ophthalmology, Edouard Herriot Hospital, Lyon, France AU - Denis, P. AU - Cucherat, M. AU - Aptel, F. DB - Embase DO - 10.1097/IJG.0b013e3181a98d0f IS - 6 KW - bimatoprost latanoprost latanoprost plus timolol prostaglandin derivative analytical error clinical evaluation clinical practice clinical trial conjunctival hyperemia disease course drug effect drug efficacy drug substitution drug tolerability glaucoma human intraocular hypertension intraocular pressure letter open angle glaucoma patient compliance priority journal risk factor trabeculoplasty treatment outcome visual field LA - English M3 - Letter N1 - L355256362 2009-10-27 PY - 2009 SN - 1057-0829 SP - 498-499 ST - Response to D. Eisenbergs Comments T2 - Journal of Glaucoma TI - Response to D. Eisenbergs Comments UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355256362&from=export http://dx.doi.org/10.1097/IJG.0b013e3181a98d0f VL - 18 ID - 3346 ER - TY - JOUR AB - Objective: The aim of this study was to confirm randomized clinical trial results showing that a fixed timolol/travoprost combination (TT; DuoTrav (R)) controls intraocular pressure (IOP) better than a fixed timolol/latanoprost combination (TL; Xalacom (R)) in everyday ophthalmic practice, when measured in the morning and >24 hours after instillation. Methods: Patients with ocular hypertension or primary open angle glaucoma stabilized on TT or TL were included in this retrospective cross-sectional study. Data on demographics, medical history and previous treatments were extracted from the patients' medical records. Last treatment instillation times and IOP values were recorded at clinic visits. Treatments were compared by analyses of variance, logistic regressions and propensity scores adjusted for confounding factors. Results: Out of 316 patients included, 124 instilled TT, 192 instilled TL and 266 (84.2%) overall had instilled their eye drops within 24 hours. The patients' mean age was 64.5 years and 51.6% were female. Treatment groups were comparable except for longer disease and treatment durations in TL recipients. Worse eye mean IOPs were 25.8 mmHg at diagnosis and 21.9 mmHg on starting their designated fixed combination treatment. The best IOP control was provided by Tr instillations (mean IOP 17.1 and 19.0 mmHg in the Tr and TL groups, respectively; p < 0.001). This difference was reinforced by results in the subgroup of patients who instilled treatment >24 hours prior to IOP measurement (mean IOP 17.0 and 20.3 mmHg in the TT and TL groups, respectively; p < 0.004). Also, 82.6% of TT patients satisfied their ophthalmologists' IOP targets versus 51.1% of TL patients (p < 0.001). All significant differences persisted after adjustment for confounding factors. Conclusion: This study, conducted in routine ophthalmic practice, confirmed published clinical trial results showing that TT provides better IOP control than TL when measured in the morning, and that travoprost has longer-lasting residual effects than latanoprost when IOP is measured >24 hours after instillation. However, readers should interpret these findings in the context of a cross-sectional observational study conducted in a naturalistic setting. AN - WOS:000261312900003 AU - Denis, P. AU - Lafuma, A. AU - Jeanbat, V. AU - Laurendeau, C. AU - Berdeaux, G. DO - 10.2165/0044011-200828120-00004 IS - 12 PY - 2008 SN - 1173-2563 1179-1918 SP - 767-776 ST - Intraocular Pressure Control with Latanoprost/Timolol and Travoprost/Timolol Fixed Combinations A Retrospective, Multicentre, Cross-Sectional Study T2 - CLINICAL DRUG INVESTIGATION TI - Intraocular Pressure Control with Latanoprost/Timolol and Travoprost/Timolol Fixed Combinations A Retrospective, Multicentre, Cross-Sectional Study VL - 28 ID - 6288 ER - TY - JOUR AB - PURPOSE: To study the awareness of the nature of the disease, compliance with treatment, and prevalence of systemic symptoms in a group of patients with chronic open angle glaucoma (COAG)., METHOD: A structured questionnaire was designed and given to 260 consecutive COAG patients attending a general ophthalmology clinic. Questions related to the increased risk of COAG amongst family members, screening of family members, nature of field defects, variation in IOP, topical treatment and availability of a free eye test for a COAG patient in the UK were asked. Compliance and systemic symptoms were also assessed., RESULTS: Forty-one per cent (107 of 260) of patients in the study group were aware of the increased risk of COAG in family members and 45.5% (118 of 260) of patient's family members had undergone screening for COAG. Seventy-three per cent (191 of 260) of the patients were aware of their own and their family members' entitlement to a free eye test. Seventy-seven per cent of patients claimed full compliance. Thirty per cent of patients were noted to have systemic symptoms., CONCLUSIONS: The awareness of the nature of COAG in this population was low and incidence of perceived drug related systemic symptoms very high. Both of these may contribute to poor compliance. AU - Deokule, Sunil AU - Sadiq, Saghir AU - Shah, Sunil IS - 1 KW - Administration, Topical Adrenergic beta-Antagonists/ad [Administration & Dosage] Aged Aged, 80 and over *Awareness Chronic Disease Female Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/px [Psychology] Humans Male Middle Aged *Patient Compliance/px [Psychology] Risk Factors Surveys and Questionnaires Vision, Ocular/ph [Physiology] PY - 2004 SE - Deokule, Sunil. Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QP, UK. SN - 0275-5408 SP - 9-15 ST - Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms T2 - Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) TI - Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=14687196 VL - 24 ID - 1801 ER - TY - JOUR AB - Background Rash is a common epidermal growth factor receptor inhibitor-induced toxicity that can impair quality of life and treatment compliance. Objective We sought to evaluate the efficacy of doxycycline in preventing erlotinib-induced rash (folliculitis) in patients with non-small-cell lung cancer. Methods This open-label, randomized, prospective, phase II trial was conducted in 147 patients with locally advanced or metastatic non-small-cell lung cancer progressing after first-line chemotherapy, randomized for 4 months with erlotinib alone 150 mg/d per os (control arm) or combined with doxycycline 100 mg/d (doxycycline arm). Incidence and severity of rash, compliance, survival, and safety were assessed. Results Baseline characteristics of the 147 patients were well balanced in the intent-to-treat population. Folliculitis occurred in 71% of patients in the doxycycline arm and 81% in the control arm (P =.175). The severity of folliculitis and other skin lesions was lower in the doxycycline arm compared with the control arm. Other adverse events were reported at a similar frequency across arms. There was no significant difference in survival between treatment arms. Limitations The open-label design of the study and the duration of the treatment with doxycycline are limitations. Conclusion Doxycycline did not reduce the incidence of erlotinib-induced folliculitis, but significantly reduced its severity. © 2016 American Academy of Dermatology, Inc. AD - Swiss Cancer Center Lausanne, Département DOncologie, Service DOncologie Médicale, Bureau BH 09/737, Rue du Bugnon 46, Lausanne, CH-1011, Switzerland Centre Régional de Lutte Contre le Cancer Baclesse, Caen, France Hopital du Cluzeau, Limoges, France Centre Hospitalier de Villefranche, Villefranche sur Saône, France Centre Hospitalier Lyon-Sud, Pierre-Bénite, France Centre Hospitalier d'Antibes, Antibes, France Centre Médical N. de Pontoux, Chalon Sur Saône, France Centre Hospitalier René Dubos, Pontoise, France Laboratoires Roche, Boulogne-Billancourt, France Institut Gustave Roussy, Villejuif, France Hôpital Henri Mondor, Créteil, France AU - Deplanque, G. AU - Gervais, R. AU - Vergnenegre, A. AU - Falchero, L. AU - Souquet, P. J. AU - Chavaillon, J. M. AU - Taviot, B. AU - Fraboulet, G. AU - Saal, H. AU - Robert, C. AU - Chosidow, O. DB - Scopus DO - 10.1016/j.jaad.2016.01.019 IS - 6 KW - doxycycline erlotinib folliculitis non-small-cell lung cancer rash M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2016 SP - 1077-1085 ST - Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial T2 - Journal of the American Academy of Dermatology TI - Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959492351&doi=10.1016%2fj.jaad.2016.01.019&partnerID=40&md5=f8e3791e4732b7b41db116ca72edc8e5 VL - 74 ID - 5105 ER - TY - JOUR AB - The authors executed a two-period, randomized, double-masked, crossover study comparing once-daily to twice-daily levobunolol hydrochloride (0.5%) in 20 patients with elevated intraocular pressure (IOP). Modified diurnal curves were performed at four times for each study arm: baseline, day 1, day 14, and day 28. The mean diurnal corrected decrease in IOP from baseline ranged from 16% ± 11% to 22% ± 9% when the subjects were treated twice daily, and from 14% ± 10% to 18% ± 8% when the same subjects were treated once daily. At day 1, patients had a significantly greater IOP lowering after twice-daily therapy than after once-daily therapy (P < 0.05). At 14 and 28 days, there was no clinically significant difference between the two treatment regimens. The results of our crossover study suggest that once-daily treatment with levobunolol (0.5%) is as effective as twice-daily treatment. AD - A.L. Robin, 6115 Falls Rd., Baltimore, MD 21209-2226, United States AU - Derick, R. J. AU - Robin, A. L. AU - Tielsch, J. AU - Wexler, J. L. AU - Kelley, E. P. AU - Stoecker, J. F. AU - Novack, G. D. AU - Coleman, A. L. DB - Embase Medline IS - 3 KW - levobunolol timolol adult aged circadian rhythm clinical article conference paper demography dose response drug cost drug efficacy female heart rate human intraocular hypertension intraocular pressure male open angle glaucoma patient compliance phase 1 clinical trial phase 2 clinical trial priority journal topical drug administration LA - English M3 - Conference Paper N1 - L22174455 1992-06-18 PY - 1992 SN - 0161-6420 SP - 424-429 ST - Once-daily versus twice-daily levobunolol (0.5%) therapy: A crossover study T2 - Ophthalmology TI - Once-daily versus twice-daily levobunolol (0.5%) therapy: A crossover study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L22174455&from=export VL - 99 ID - 4025 ER - TY - JOUR AB - Normal-tension glaucoma (NTG) is generally defined as visual field loss and optic nerve defects consistent with glaucoma and an intraocular pressure (IOP) that does not exceed 21 mmHg (Allingham, R.R., Damji, K., Freedman, S., Moroi, S., Shafranov, G., Shields, M.B. (2005). In: Pine J. and Murphy J. (Eds.), Shields' Textbook of Glaucoma, 5th edn., Lippincott Williams & Wilkins, Philadelphia, PA, pp. 197-207, Chapter 11). If a patient has an atypical presentation (unilateral disease, decreased central visual acuity or visual field loss not consistent with optic disk appearance) then the clinician should rule out medical or neurologic etiologies. IOP-dependent and IOP-independent mechanisms play a role in NTG nerve damage. The exact mechanisms of IOP-independent damage are not currently known. Research has shown that vascular etiologies, such as vascular insufficiency and vasospasm, may be possible mechanisms for IOP-independent damage. The mainstay of glaucoma treatment remains robust IOP reduction. The chief goal of ongoing glaucoma research is to more clearly identify IOP-independent mechanisms of damage and to find neuroprotective treatment strategies to prevent retinal ganglion cell death and consequent visual loss. AU - Desai, Priya V. AU - Caprioli, Joseph DO - https://dx.doi.org/10.1016/S0079-6123(08)01114-X KW - Aged Cornea/pa [Pathology] Disease Progression Glaucoma/di [Diagnosis] Glaucoma/pa [Pathology] Glaucoma/th [Therapy] *Glaucoma Humans *Intraocular Pressure Middle Aged Optic Disk/pa [Pathology] Patient Compliance Risk Factors Tomography Visual Fields/ph [Physiology] PY - 2008 SE - Desai, Priya V. Jules Stein Eye Institute, UCLA, 100 Stein Plaza, Suite 2-118, Los Angeles, CA 90095, USA. Desai@jsei.ucla.edu SN - 1875-7855 0079-6123 SP - 195-210 ST - The treatment of normal-tension glaucoma T2 - Progress in brain research TI - The treatment of normal-tension glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18929110 VL - 173 ID - 1511 ER - TY - JOUR AB - The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which is involved in aqueous humor secretion. These characteristics, along with good ocular bioavailability, make brinzolamide maximally effective in lowering intraocular pressure (IOP) by locally inhibiting CA-II in the ciliary processes and suppressing aqueous humor secretion. Notable among its attributes as a safe and efficacious glaucoma drug is brinzolamide's superior ocular comfort profile because of its optimized suspension formulation at physiologic pH. The degree of tolerability in the eye is considered an important determinant of a patient's willingness to comply with the dosing regimen for a long-term glaucoma medication. Results from the preclinical pharmacologic evaluation of brinzolamide indicated that it acts specifically to inhibit CA without significant other pharmacologic actions that could introduce undesired side effects. Moreover, the typical side effects associated with systemically administered CAIs are expected to occur at a lower incidence or not occur at all with brinzolamide, as its therapeutic dose and low systemic absorption do not produce a problematic level of systemic CA inhibition. Brinzolamide's long tissue half-life in the eye, particularly in the iris-ciliary body, favors a prolonged duration of IOP lowering. This was substantiated in clinical trials, which showed that twice-daily brinzolamide provides as significant an IOP reduction as three-times-daily brinzolamide or dorzolamide in a relatively high percentage of patients. Brinzolamide has been shown by the laser Doppler flowmetry technique to improve blood flow to the optic nerve head in pigmented rabbits after topical administration, without producing an increase of blood pCO2, indicating a potential for a local vasodilatory effect involving the optic nerve head circulation. The mean concentration of brinzolamide found in the retina of pigmented rabbits (0.338 microg equivalents/g) after a single dose of 14C-brinzolamide is sufficient to inhibit CA-II. These data suggest that topical brinzolamide could improve the blood flow in the optic nerve head in humans should it inhibit carbonic anhydrase in that vascular bed. Brinzolamide is a new topically active CAI that is safe and efficacious for reducing intraocular pressure. It offers the convenience of topical dose administration and greater freedom from side effects related to the inhibition of CA seen with the systemic administration of CAIs. Its formulation has been optimized to provide greater comfort upon instillation, and this can result in a higher compliance rate by the patient. Results of studies in animals show that brinzolamide has promise for increasing blood flow to the optic nerve head; however, this requires further assessment in the clinic. Brinzolamide represents a significant technical achievement and an important addition to the medical treatment of glaucoma as both a primary and an adjunctive drug. AU - DeSantis, L. KW - Absorption Animals Blood Flow Velocity/de [Drug Effects] Carbonic Anhydrase Inhibitors/me [Metabolism] Carbonic Anhydrase Inhibitors/pk [Pharmacokinetics] *Carbonic Anhydrase Inhibitors/pd [Pharmacology] Drug Evaluation, Preclinical Eye/me [Metabolism] Half-Life Humans Intraocular Pressure/de [Drug Effects] Ophthalmic Solutions/pk [Pharmacokinetics] Ophthalmic Solutions/pd [Pharmacology] Rabbits Sulfonamides/me [Metabolism] Sulfonamides/pk [Pharmacokinetics] *Sulfonamides/pd [Pharmacology] Thiazines/me [Metabolism] Thiazines/pk [Pharmacokinetics] *Thiazines/pd [Pharmacology] Tissue Distribution PY - 2000 SE - DeSantis, L. Alcon Research, Ltd., Fort Worth, Texas 76134, USA. SN - 0039-6257 SP - S119-29 ST - Preclinical overview of brinzolamide T2 - Survey of ophthalmology TI - Preclinical overview of brinzolamide UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10665514 VL - 44 Suppl 2 ID - 1955 ER - TY - GEN AB - Glaucoma is a disorder of the eyes that can lead to blindness. Its incidence increases with age. While there is no cure, numerous topical medications are used to reduce the elevated intraocular pressure seen in patients. Topical prostaglandin analogues and beta-blockers are the most commonly used medications. Pharmacists can be effective partners in the treatment of glaucoma by monitoring adherence, counseling patients on the proper use of eyedrops, and recommending preservative-free or combination products when problems arise. AU - DeSimone, E. M. AU - Pietig, B. A. DB - Embase J2 - U.S. Pharm. KW - acetazolamide adrenergic receptor stimulating agent alpha 2 adrenergic receptor stimulating agent apraclonidine beta adrenergic receptor blocking agent brimonidine carbonate dehydratase inhibitor cholinergic receptor stimulating agent cholinesterase inhibitor dipivefrine dorzolamide eye drops methazolamide prostaglandin derivative timolol African American age article blindness clinical feature closed angle glaucoma glaucoma goniolens gonioscopy human intraocular pressure laser surgery open angle glaucoma optic nerve lesion patient compliance patient counseling perimetry pharmacist prevalence tonometry trabeculectomy trabeculoplasty visual field visual field defect LA - English M1 - (DeSimone E.M.; Pietig B.A.) Creighton University, School of Pharmacy and Health Professions, Omaha, NE, United States M3 - Article N1 - L605001418 2015-07-01 2015-07-10 PY - 2015 SN - 0148-4818 SP - 39-44 ST - Current considerations in the treatment of glaucoma TI - Current considerations in the treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605001418&from=export VL - 40 ID - 2850 ER - TY - JOUR AB - The safety profile of the different glaucoma medications is an important issue when initiating therapy in glaucomatous patients. The decision on which medication to prescribe depends not only on the type of glaucoma, but also on the patient's medical history and needs a detailed knowledge of the potential side-effects of each medication. Medications side effects may be an important cause of non adherence for the individual patient The properties of the drugs, the composition of the glaucoma eyedrops and the dynamics of ocular drug absorption must be considered. The ocular surface changes induced by long-term antiglaucomatous treatment especially by their preservatives are a major cause of intolerance or poor tolerance to glaucoma eyedrops. Moreover topically applied ophthalmic medications can attain sufficient serum levels through absorption into conjunctival and nasal mucosas to have systemic effects and to potentially interact with other drugs. Then this presentation will deal with the ocular and systemic side-effects which can be encountered with the different classes of the currently available glaucoma topical medications. Recommendations than can be applied to reduce both frequency and severity of side-effects of glaucoma medications will be stressed on. Concurrently patients should be fully informed not only about their disease but also the medications they used and what side-effects they have to expect. AU - Detry-Morel, M. IS - 299 KW - Administration, Topical Adrenergic alpha-Agonists/ae [Adverse Effects] Adrenergic beta-Antagonists/ae [Adverse Effects] Aged Antihypertensive Agents/ad [Administration & Dosage] *Antihypertensive Agents/ae [Adverse Effects] Carbonic Anhydrase Inhibitors/ae [Adverse Effects] Dry Eye Syndromes/ci [Chemically Induced] Eye Diseases/ci [Chemically Induced] *Glaucoma/dt [Drug Therapy] Humans Latanoprost Prostaglandins F, Synthetic/ae [Adverse Effects] Prostaglandins, Synthetic/ae [Adverse Effects] PY - 2006 SE - Detry-Morel, M. St. Luc University Hospital, Department of Ophthalmology, UCL, Brussels. detry@ofta.ucl.afc.be SN - 0081-0746 SP - 27-40 ST - Side effects of glaucoma medications T2 - Bulletin de la Societe belge d'ophtalmologie TI - Side effects of glaucoma medications UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16681086 ID - 1665 ER - TY - JOUR AB - PURPOSE: 1) To summarize the literature on compliance (the extent to which the patient's behaviors correspond with the provider's recommendations) and persistence (total time on therapy) in patients with open-angle glaucoma or ocular hypertension. 2) To suggest guidelines to improve these two parameters, which are both essential and integral elements of optimizing patient care., METHODS: Compliance-related research published between 1980 and March 2005., RESULTS: Medication compliance has mostly been investigated and measured using patient self-reports, electronic monitoring, and medication possession ratio. Noncompliance-related problems are underestimated, complex, unpredictable and frequent. Noncompliance rates of at least 25% have been reported. The main obstacles to medication compliance are situational/environmental or related to the side effects or complexity of the medication regimen. Persistence with glaucoma medications has also been proven to be poor. Based on retrospective studies using survival analyses, fewer than 25% of patients may be persistent over 12 months. Persistence rates differ from one treatment to another and may fluctuate with time in the same patient., CONCLUSIONS: Improving the quality of information, the patient-physician relationship, and educating patients are all crucial. Simplification of the treatment regimen and selection of medications with the fewest systemic and ocular side effects must be a priority. Accurately assessing patient compliance and persistence are indispensable to reducing mistakes from either medication noncompliance or lack of persistence with poor efficacy and to avoid unnecessary changes in a patient's therapeutic regimen or surgery. AU - Detry-Morel, M. IS - 2 KW - *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Ocular Hypertension/dt [Drug Therapy] *Patient Compliance/sn [Statistics & Numerical Data] Patient Education as Topic Physician-Patient Relations Time Factors PY - 2006 SE - Detry-Morel, M. Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Bruxelles, Belgique. detry@ofta.ucl.ac.be SN - 1773-0597 0181-5512 SP - 216-25 ST - [Compliance and persistence] T2 - Compliance et persistance. TI - [Compliance and persistence] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16523165 VL - 29 ID - 1677 ER - TY - JOUR AB - Purpose: 1) To summarize the literature on compliance (the extent to which the patient's behaviors correspond with the provider's recommendations) and persistence (total time on therapy) in patients with open-angle glaucoma or ocular hypertension. 2) To suggest guidelines to improve these two parameters, which are both essential and integral elements of optimizing patient care. Methods: Compliance-related research published between 1980 and March 2005. Results: Medication compliance has mostly been investigated and measured using patient self-reports, electronic monitoring, and medication possession ratio. Noncompliance-related problems are underestimated, complex, unpredictable and frequent. Noncompliance rates of at least 25% have been reported. The main obstacles to medication compliance are situational/ environmental or related to the side effects or complexity of the medication regimen. Persistence with glaucoma medications has also been proven to be poor. Based on retrospective studies using survival analyses, fewer than 25% of patients may be persistent over 12 months. Persistence rates differ from one treatment to another and may fluctuate with time in the same patient. Conclusions: Improving the quality of information, the patient-physician relationship, and educating patients are all crucial. Simplification of the treatment regimen and selection of medications with the fewest systemic and ocular side effects must be a priority. Accurately assessing patient compliance and persistence are indispensable to reducing mistakes from either medication noncompliance or lack of persistence with poor efficacy and to avoid unnecessary changes in a patient's therapeutic regimen or surgery. © Masson, 2006. AD - M. Detry-Morel, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), 10, avenue Hippocrate, B-1200 Bruxelles, Belgium AU - Detry-Morel, M. DB - Embase Medline DO - 10.1016/S0181-5512(06)73775-5 IS - 2 KW - environmental factor human intraocular hypertension monitoring open angle glaucoma patient compliance review self report survival LA - French M3 - Review N1 - L43357249 2006-03-21 PY - 2006 SN - 0181-5512 SP - 216-225 ST - Compliance and persistance T2 - Journal Francais d'Ophtalmologie TI - Compliance and persistance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43357249&from=export http://dx.doi.org/10.1016/S0181-5512(06)73775-5 VL - 29 ID - 3634 ER - TY - JOUR AB - Due to the recent rapid increase in the aging population, glaucoma in the over-eighties population will become a significant problem of ocular health in the coming decades. It is important to determine the natural effects of aging on the optic nerve head and aqueous humor dynamics in these patients for early diagnosis and monitoring of glaucoma. Its characteristics, context, management, and treatment are very perceptibly different from those of the younger glaucomatous patient. For many reasons, such as its frequent association with macular age-related degeneration, diagnosis of glaucoma in the over-eighties may be difficult. Management of the over-eighties glaucoma is frequently difficult and time-consuming. Less aggressive than in a younger patient and based on topical medications in most cases, it must be discussed case by case and will be based on the general context, the quality of compliance, and especially on the potential consequences of the glaucomatous visual-field defects on the patient's quality of life. In any case, overtreatment as well as treatments that are too complex must be avoided. Given the reduced metabolism in the very elderly, the safest medications must also be selected. It is important to always consider glaucoma medications as part of the patient's medicine regimen. Associated risk factors, especially concomitant systemic hypotension, will be simultaneously treated. Laser trabeculoplasties probably have broader indications than in younger patients. Except for phacoextraction, which is very frequently helpful in controlling IOP, incisional filtering procedures or laser diode cyclophotocoagulations remain infrequently indicated in over-eighties glaucoma patients. AU - Detry-Morel, M. IS - 9 KW - Age Factors Aged, 80 and over Aging Antihypertensive Agents/tu [Therapeutic Use] Glaucoma/di [Diagnosis] Glaucoma/dt [Drug Therapy] Glaucoma/su [Surgery] *Glaucoma Humans Neurodegenerative Diseases/co [Complications] Quality of Life PY - 2007 SE - Detry-Morel, M. Cliniques Universitaires St Luc, Universite Catholique de Louvain, Bruxelles, Belgique. detry@ofta.ucl.ac.be SN - 1773-0597 0181-5512 SP - 946-52 ST - [Glaucoma in the over-eighties] T2 - Le glaucome du 4e age. TI - [Glaucoma in the over-eighties] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=18046281 VL - 30 ID - 1565 ER - TY - JOUR AB - Treatment of glaucoma aims at preserving the visual function and the Quality of Life (QoL) of the patients. To slow down the progression of the disease, the IOP should be decreased to a level where the risk of further deterioration is reduced to a minimum. Rates of progression vary between patients. Detection of glaucoma progression should be based on the assessment of structure and function. When making a treatment plan, one should take into consideration the rate of progression and the impact of visual field deterioration on the QoL. Therefore, a careful and reliable baseline examination is crucial. Furthermore, yearly documentation of the optic disc and frequent examinations of the visual field, especially during the first two years of follow-up, are mandatory to evaluate how aggressive the treatment should be. Slowing down progression of the disease is closely related to a good communication with the patient, the quality of the information provided, and the tolerance of the medications, all keys to a good adherence. Other risk factors than IOP should be looked for and treated if possible, especially when worsening of glaucoma damage is observed despite apparently good IOP control and compliance. Modern monitoring of the glaucoma patient can be summarized in six keys. Current limitations of this approach will be briefly discussed. AU - Detry-Morel, M. IS - 316 KW - Disease Progression Follow-Up Studies *Glaucoma/di [Diagnosis] *Glaucoma/th [Therapy] Humans Intraocular Pressure Patient Compliance Patient Education as Topic Physician-Patient Relations Quality of Life Risk Factors Trabeculectomy Visual Field Tests PY - 2010 SE - Detry-Morel, M. Service d'Ophtalmologie, Cliniques Universitaires St. Luc, Universite Catholique de Louvain, Bruxelles, Belgique. Michele.Morel@uclouvain.be SN - 0081-0746 SP - 63-84 ST - [The six keys of the monitoring of the glaucoma patient] T2 - Les six points cles du suivi du patient glaucomateux. TI - [The six keys of the monitoring of the glaucoma patient] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21309143 ID - 1316 ER - TY - JOUR AB - Treatment of glaucoma aims at preserving the visual function and the Quality of Life (QoL) of the patients. To slow down the progression of the disease, the IOP should be decreased to a level where the risk of further deterioration is reduced to a minimum. Rates of progression vary between patients. Detection of glaucoma progression should be based on the assessment of structure and function. When making a treatment plan, one should take into consideration the rate of progression and the impact of visual field deterioration on the QoL. Therefore, a careful and reliable baseline examination is crucial. Furthermore, yearly documentation of the optic disc and frequent examinations of the visual field, especially during the first two years of follow-up, are mandatory to evaluate how aggressive the treatment should be. Slowing down progression of the disease is closely related to a good communication with the patient, the quality of the information provided, and the tolerance of the medications, all keys to a good adherence. Other risk factors than IOP should be looked for and treated if possible, especially when worsening of glaucoma damage is observed despite apparently good IOP control and compliance. Modern monitoring of the glaucoma patient can be summarized in six keys. Current limitations of this approach will be briefly discussed. AD - Service d'Ophtalmologie, Cliniques Universitaires St. Luc, Université Catholique de Louvain, Bruxelles, Belgique. AU - Detry-Morel, M. DB - Scopus IS - 316 M3 - Review N1 - Cited By :1 Export Date: 19 July 2021 PY - 2010 SP - 63-84 ST - Les six points clés du suivi du patient glaucomateux. T2 - Bulletin de la Société belge d'ophtalmologie TI - [The six keys of the monitoring of the glaucoma patient] UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952261227&partnerID=40&md5=17dcde22219140dadbff9d26a9757ac2 ID - 5640 ER - TY - JOUR AB - For more than 2 years we have been trying out a microprocessor-controlled self-tonometer to determine its clinical usefulness. Most of the measurements were taken with two instruments (A and B). In vitro calibration series on human donor corneas gave good results over the whole pressure range. In a patient series both instruments were compared with the established hand-held applanation tonometer put out by Draeger (HAT). Each self-tonometer was applied three times, followed by a controlling measurement with the HAT. The correlation coefficient between instrument A and HAT was 0.85 with a standard deviation of +/- 1.9126 mmHg. Instrument B showed a better correlation (r = 0.904), the standard deviation was similar to tonometer A (SD = +/- 1.8598 mmHg). Most of the values obtained by the self-tonometers-about 50%-deviated from the corresponding HAT values by +/- 1 mmHg. The new measurement principle was accepted by 75% of all patients. Improvements in the details are planned in order to simplify tonometer handling and increase the accuracy and precision of the measurements. AU - Deutsch, C. AU - Draeger, J. AU - Groenhoff, S. IS - 6 KW - Adolescent Adult Aged Aged, 80 and over Child Female Follow-Up Studies *Glaucoma/di [Diagnosis] Glaucoma/pp [Physiopathology] Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged Patient Acceptance of Health Care *Self Care/is [Instrumentation] *Signal Processing, Computer-Assisted/is [Instrumentation] *Tonometry, Ocular/is [Instrumentation] PY - 1992 SE - Deutsch, C. Universitats-Augenklinik, Hamburg. SN - 0941-293X SP - 489-92 ST - [2 years self-tonometry. Acceptance and results] T2 - 2 Jahre Selbsttonometrie. Akzeptanz und Ergebnisse. TI - [2 years self-tonometry. Acceptance and results] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1486265 VL - 89 ID - 2112 ER - TY - JOUR AB - A 60-year-old black woman on continuous ambulatory peritoneal dialysis (CAPD) presented with Tenckhoff catheter malfunction. She exhibited no signs or symptoms of acute peritonitis. Darkly pigmented plaques were adherent to the inner wall of the catheter and exchange tubing focally throughout its length. Similar material was adherent to the protein coagulum in the dialysis bag. The Tenckhoff catheter and tubing were removed, and hemodialysis was initiated. Cultures of the catheter and the dialysate protein coagulum grew the saprophytic soil fungus, Curvularia lunata. Histologic examination of the catheter and tubing demonstrated penetration of each by hyphae. Catheter removal alone was sufficient to eradicate the fungus since recurrence of colonization or peritonitis has not occurred following the resumption of CAPD. Peritonitis produced by opportunistic pathogens especially fungi is increasingly common. Although Curvularia species have been implicated in pulmonary and cerebral mycetomas, allergic bronchoalveolar disease, and keratitis, they have not been reported previously to cause peritonitis or catheter malfunction in CAPD patients. Fungal invasion of CAPD catheters can produce mechanical obstruction even in the absence of peritonitis. Such colonization does not preclude resumption of chronic peritoneal dialysis at a later date. AU - DeVault, G. A., Jr. AU - Brown, S. T., 3rd AU - King, J. W. AU - Fowler, M. AU - Oberle, A. IS - 2 KW - Catheters, Indwelling Female Humans Kidney Failure, Chronic/et [Etiology] *Kidney Failure, Chronic/th [Therapy] Middle Aged Mitosporic Fungi/ip [Isolation & Purification] Mycoses/mi [Microbiology] *Mycoses *Peritoneal Dialysis/ae [Adverse Effects] *Peritoneal Dialysis, Continuous Ambulatory/ae [Adverse Effects] *Peritonitis/et [Etiology] Peritonitis/mi [Microbiology] Polycystic Kidney Diseases/co [Complications] PY - 1985 SN - 0272-6386 SP - 124-7 ST - Tenckhoff catheter obstruction resulting from invasion by Curvularia lunata in the absence of peritonitis T2 - American journal of kidney diseases : the official journal of the National Kidney Foundation TI - Tenckhoff catheter obstruction resulting from invasion by Curvularia lunata in the absence of peritonitis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=4025332 VL - 6 ID - 2214 ER - TY - JOUR AB - Considerable research over the last few years has revealed dysregulation of growth factors in various retinal diseases, such as glaucoma, diabetic retinopathy and photoreceptor degenerations. The use of messengerRNA (mRNA) to transiently overexpress a specific factor could compensate for this imbalance. However, a critical challenge of this approach lies in the ability to efficiently deliver mRNA molecules to the retinal target cells. In this study we found that intravitreal (IVT) injection is an attractive approach to deliver mRNA to the retina, providing two critical barriers can be overcome: the vitreous and the inner limiting membrane (ILM). We demonstrated that the vitreous is indeed a major hurdle in the delivery of the cationic mRNA-complexes to retinal cells, both in terms of vitreal mobility and cellular uptake. To improve their intravitreal mobility and avoid unwanted extracellular interactions, we evaluated the use of hyaluronic acid (HA) as an electrostatic coating strategy. This HA-coating provided the complexes with a negative surface charge, markedly enhancing their mobility in the vitreous humor, without reducing their cellular internalization and transfection efficiency. However, although this coating strategy allows the mRNA-complexes to successfully overcome the vitreal barrier, the majority of the particles accumulated at the ILM. This study therefore underscores the crucial barrier function of the ILM toward non-viral retinal gene delivery and the need to smartly design mRNA-carriers able to surmount the vitreous as well as the ILM. Copyright © 2019 Elsevier B.V. All rights reserved. AU - Devoldere, Joke AU - Wels, Mike AU - Peynshaert, Karen AU - Dewitte, Heleen AU - De Smedt, Stefaan C. AU - Remaut, Katrien DO - https://dx.doi.org/10.1016/j.ejpb.2019.05.023 KW - Animals Cattle Cell Line Gene Transfer Techniques Genetic Therapy/mt [Methods] Humans *Hyaluronic Acid/me [Metabolism] Intravitreal Injections/mt [Methods] RNA, Messenger/me [Metabolism] *Retina/me [Metabolism] Retinal Diseases/me [Metabolism] Static Electricity Transfection/mt [Methods] Vitreous Body/me [Metabolism] PY - 2019 SE - Devoldere, Joke. Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium. Wels, Mike. Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium. Peynshaert, Karen. Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium. Dewitte, Heleen. Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Medical School of the Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1050 Jette, Belgium; Cancer Research Institute Ghent (CRIG), Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. De Smedt, Stefaan C. Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Remaut, Katrien. Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Electronic address: Katrien.Remaut@ugent.be. SN - 1873-3441 0939-6411 SP - 161-171 ST - The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane T2 - European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V TI - The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31150809 VL - 141 Y2 - 20190528// ID - 327 ER - TY - JOUR AB - Treatment of children with rheumatic diseases has advanced with novel therapeutics and the use of early aggressive treatment to achieve better long-term functional outcome. Many of the current treatments in pediatric rheumatology are based on studies in adults on medications without U.S. Food and Drug Administration labeling for pediatric use. This is not ideal because the pharmacokinetics (absorption, distribution, metabolism, and elimination) of many medications when used in children vary according to age, somatic growth, sexual maturity, and ontogeny of drug-metabolizing enzymes. Special dosing, administration considerations, and toxicity screening are reviewed for the more commonly used medications. Vaccinations for children on antirheumatic drugs are also discussed. Continued study of the long-term impact of medications and biologic treatments on children is necessary, but given the paucity of children with rheumatic diseases, this will require multicentered trials and collaborations. Lastly, this article reviews recent regulatory and legislative action on pediatric drug testing. Passage of the Pediatric Research Equity Act of 2003, which requires 'testing of pharmaceuticals in children, will facilitate more rational use of drugs in pediatric rheumatic diseases in the future. AD - R.Q. Cron, Children's Hospital of Philadelphia, Abramson Research Center, 3615 Civic Center Blvd., Philadelphia, PA 19104-4318, United States AU - DeWitt, E. M. AU - Sherry, D. D. AU - Cron, R. Q. C1 - advil aspirin azulfidine celebrex clinoril daypro enbrel feldene indocin sr indocin lodine xl medipren mobic motrin naprosyn nuprin orapred pediapred plaquenil prelone relafen remicade rheumatrex solumedrol tolectin trexall trilisate voltaren xr voltaren DB - Embase Medline DO - 10.1097/01.rhu.0000152151.12999.76 IS - 1 KW - acetylsalicylic acid celecoxib choline magnesium trisalicylate cotrimoxazole deflazacort diclofenac disease modifying antirheumatic drug drug metabolizing enzyme etanercept etodolac hydroxychloroquine ibuprofen indometacin infliximab meloxicam methotrexate methylprednisolone sodium succinate nabumetone naproxen nonsteroid antiinflammatory agent prednisolone sodium phosphate oxaprozin piroxicam prednisolone rofecoxib salazosulfapyridine sulindac tolmetin trimethoprim tumor necrosis factor antibody unclassified drug unindexed drug abdominal pain acne allergic pneumonitis anaphylaxis anorexia asthma blood clotting disorder body growth bullous skin disease cardiovascular disease cataract central nervous system disease chickenpox cholecystitis corticosteroid induced osteoporosis Cushing syndrome cytopenia diabetes mellitus drug absorption drug bioavailability drug distribution drug dose regimen drug elimination drug hypersensitivity drug metabolism drug potentiation drug screening drug use duodenum injury eye toxicity fatty liver Food and Drug Administration gastrointestinal symptom glaucoma growth retardation headache histoplasmosis human hypertension immunoglobulin deficiency kidney disease legal aspect listeriosis liver cell carcinoma liver cirrhosis liver disease liver fibrosis lymphoma mood disorder obesity opportunistic infection optic nerve disease osteopenia pancytopenia patient compliance photosensitivity disorder phototoxicity pneumocystosis priority journal pseudoporphyria retinopathy review Reye syndrome rheumatic disease seizure sepsis sexual maturity skin disease skin scar stomach disease stomach injury stria sustained drug release systemic lupus erythematosus tuberculous arthritis tuberculous peritonitis upper respiratory tract infection urinary tract infection vaccination advil aspirin azulfidine celebrex clinoril daypro enbrel feldene indocin sr indocin lodine xl medipren mobic motrin naprosyn nuprin orapred pediapred plaquenil prelone relafen remicade rheumatrex solumedrol tolectin trexall trilisate voltaren xr voltaren LA - English M3 - Review N1 - L40223877 2005-02-23 PY - 2005 SN - 1076-1608 SP - 21-33 ST - Pediatric rheumatology for the adult rheumatologist I: Therapy and dosing for pediatric rheumatic disorders T2 - Journal of Clinical Rheumatology TI - Pediatric rheumatology for the adult rheumatologist I: Therapy and dosing for pediatric rheumatic disorders UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40223877&from=export http://dx.doi.org/10.1097/01.rhu.0000152151.12999.76 VL - 11 ID - 3699 ER - TY - JOUR AB - PURPOSE: To evaluate the long-term efficacy and side effects of off-label topical tacrolimus 0.03% ointment (Protopic; Fujisawa Health, Deerfield, IL) as a sole second-line immunosuppressive agent in the management of high-risk corneal grafts. METHODS: Four consecutive patients underwent high-risk penetrating keratoplasty (4 grafts) with a prior diagnosis of corneal scar secondary to herpetic keratitis, keratoconus, acanthamoeba keratitis, and Fuchs endothelial dystrophy, respectively. All 4 patients developed steroid-induced glaucoma and failed traditional immunosuppressant therapy. Patients were started on topical tacrolimus ointment 0.03%, twice daily, which was tapered to the lowest possible therapeutic dose that maintained its antirejection efficacy. Patients were monitored for adverse treatment effects. The mean follow-up was 33 months (range, 26-48 months), and the mean treatment duration was 22.6 months (range, 13-32 months). RESULTS: All 4 high-risk corneal transplant patients experienced episodes of acute rejection that was successfully reversed with topical tacrolimus treatment. During tacrolimus treatment, there were no further episodes of graft rejection and no incidents of herpes simplex virus infection or reactivation, with the longest follow-up being 4 years. Two patients have been successfully tapered off tacrolimus, and 2 patients are currently on once-daily dosing. No adverse effects were observed. CONCLUSIONS: Topical tacrolimus 0.03% ointment seems to be a promising second-line immunosuppressant in management of high-risk grafts. © 2008 Lippincott Williams & Wilkins, Inc. AD - S. C. Kaufman, University of Minnesota, Department of Ophthalmology, MMC 493, 420 Delaware Street SE, Minneapolis, MN 55455, United States AU - Dhaliwal, J. S. AU - Mason, B. F. AU - Kaufman, S. C. C1 - alphagan(Allergan,United States) bacquacil(Zeneca,United States) fk 506 lotemax(Bausch & Lomb,United States) neosporin(Johnson & Johnson,United States) pred forte(Allergan,United States) protopic(Fujisawa,United States) restasis(Allergan) valtrex(Glaxo SmithKline,United Kingdom) C2 - Allergan(United States) Bausch & Lomb(United States) Fujisawa(United States) Glaxo SmithKline(United Kingdom) Johnson & Johnson(United States) Zeneca(United States) DB - Embase Medline DO - 10.1097/ICO.0b013e3181606086 IS - 4 KW - bacquacil brimonidine cyclosporine gramicidin loteprednol etabonate neomycin neosporin poly(hexamethylenebiguanide) polymyxin B prednisolone acetate prednisone tacrolimus timolol trifluridine valaciclovir absence of side effects Acanthamoeba keratitis acute graft rejection adult article case report cataract chronic drug administration hereditary corneal dystrophy cornea transplantation cornea ulcer drug dose increase drug dose reduction drug efficacy drug substitution drug withdrawal eye epithelium toxicity eye toxicity female follow up glaucoma herpes simplex keratitis Herpes simplex virus high risk patient human immunosuppressive treatment intraocular pressure keratoconus male monotherapy patient compliance penetrating keratoplasty priority journal treatment duration virus reactivation alphagan fk 506 lotemax pred forte protopic restasis valtrex LA - English M3 - Article N1 - L351591489 2008-05-19 PY - 2008 SN - 0277-3740 SP - 488-493 ST - Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty T2 - Cornea TI - Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351591489&from=export http://dx.doi.org/10.1097/ICO.0b013e3181606086 VL - 27 ID - 3453 ER - TY - JOUR AB - Earlier colon was considered as a black-box, acting as a site for production and temporary storage of excreta and responsible for absorption of electrolytes and water. But, with the discovery of sulfasalazine as colon-specific pro-drug, the promising and challenging issue of treating local pathologies was presented with colon as an organ of significance for target-specific delivery of drugs. The need and desirable attributes of colon-specific drug delivery systems have been well recognized, extensively explored and documented in the literature. The success of a colon-specific prodrug depends on its rational design and understanding the demands of the organ to be targeted and the delivery system to be developed. The present review mainly focuses on anatomy/physiology of colon, colonic microbiota, enzymatic set up of colon, pathophysiology of local diseases of colon, factors, obstacles and rationale for designing colon specific drug delivery system, various targets, potential drug candidates and novel colon-targeting carriers along with varied linkages that could be explored, merits and demerits of this design and recent trends in this field. Brief review of methodologies for characterization and in vitro/in vivo release studies is presented. The available animal models with quantifying parameters for evaluating colon-targeting potential and effectiveness of the colon-specific prodrugs for inflammatory bowel disease is also included in this review. © 2011 Bentham Science Publishers. AD - S. S. Dhaneshwar, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth University, Poona College of Pharmacy, Pune-411 038, Maharashtra, India AU - Dhaneshwar, S. S. AU - Vadnerkar, G. C1 - colazal dipentum imodium intestinol salazopyrin DB - Embase Medline DO - 10.2174/156802611797183249 IS - 18 KW - aminosalicylic acid azathioprine balsalazide bevacizumab budesonide cetuximab corticosteroid cyclosporine fluorouracil interleukin 6 interleukin 8 intestinol loperamide mercaptopurine mesalazine methotrexate metronidazole mycophenolic acid mycophenolate mofetil olsalazine peroxisome proliferator activated receptor gamma polyamidoamine prednisolone prodrug rifaximin ademetionine salazosulfapyridine taurine thalidomide tumor necrosis factor unclassified drug unindexed drug abdominal pain acne agranulocytosis amebiasis anorexia antiinflammatory activity antioxidant activity arthralgia congenital malformation bone marrow disease bone marrow suppression cancer adjuvant therapy cancer combination chemotherapy cataract cell differentiation colon flora colorectal cancer congenital disorder connective tissue disease convulsion Crohn disease cytokine production depression diabetes mellitus diarrhea digestive system ulcer disease association drug bioavailability drug conjugation drug design drug efficacy drug eruption drug fever drug formulation drug hypersensitivity drug induced headache drug megadose drug safety drug solubility drug stability drug targeting drug tolerance enteritis fatigue fetus death first pass effect gastrointestinal absorption gastrointestinal tract glaucoma glossitis hemolytic anemia hepatitis hirsutism histopathology human hydrophilicity hypertension ileitis in vitro study in vivo study infection sensitivity insomnia intestine transit time irritability irritable colon kidney failure kidney injury leukemia leukopenia lipid peroxidation liver disease lymphocyte function macrophage activation male infertility menstrual irregularity muscle atrophy nausea nephritis neutropenia nonhuman opportunistic infection osteoporosis oxidative stress pancreatitis paresthesia patient compliance personality disorder pneumonia psychosis quality of life respiratory tract infection review rheumatoid arthritis shelf life side effect spontaneous abortion stomach motility stomach pH stomach pressure stomach secretion taste disorder thrombocytopenia treatment duration ulcerative colitis urticaria vomiting body weight gain colazal dipentum imodium salazopyrin LA - English M3 - Review N1 - L362454990 2011-09-07 2011-09-14 PY - 2011 SN - 1568-0266 1873-4294 SP - 2318-2345 ST - Rational design and development of colon-specific prodrugs T2 - Current Topics in Medicinal Chemistry TI - Rational design and development of colon-specific prodrugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362454990&from=export http://dx.doi.org/10.2174/156802611797183249 VL - 11 ID - 3150 ER - TY - JOUR AB - Disease summary: Allgrove Syndrome (AS) is rare autosomal recessive disorder characterised by achalasia cardia, alacrimia and adrenal insufficiency, which is generally adrenocorticotropic hormone (ACTH) resistant, and neurological abnormalities. Mutations have been identified in the AAAS gene, located on chromosome 12q13 (type-2 keratin gene), that codes for the ALADIN protein. IVS14 and EVS9 are the most common mutations. Alacrimia is an early and pathognomic symptom, but achalasia (50-100 %) and adrenal insufficiency (20-54%) are the more common presenting features. Autonomic disturbances and other neurological symptoms (10-23%) are rare. Patients may develop a variable combination of sensory-motor polyneuropathy amyotrophy, dysarthria, hyperreflexia, muscle weakness, dementia, abnormal autonomic function, erectile dysfunction (adult) and intellectual impairment. Diagnosis is generally made in the first decade of life when they present with dysphagia, vomiting and failure to thrive due to achalasia, hyperpigmentation of skin, shock due to adrenal insufficiency or seizures and coma due to severe hypoglycaemia. Typical dysmorphic faces including long thin face, long philthrum, narrow upper lip, down-turned mouth and sparse eyelashes may also be seen. Keratitis punctata is the most common complication of alacrimia. Patients with adrenal insufficiency are generally on a maintenance dose of a glucocorticoid like hydrocortisone. Most patients with achalasia require frequent pneumatic dilatations or surgical interventions like Heller’s myotomy. AU - Dhar, M. AU - Arun, B. G. AU - Tebaibia, A. DB - Embase DO - 10.19224/ai2019.S001 IS - 1 KW - endotracheal tube anesthetic agent corticotropin glucocorticoid hydrocortisone Allgrove syndrome ambulatory care anesthesia anticoagulant therapy article blood transfusion cardioesophagomyotomy chromosome 12q diagnostic procedure differential diagnosis esophagus dilatation gene mutation general anesthesia human long term care mobilization obstetric anesthesia patient monitoring patient positioning patient transport postoperative care postoperative complication preoperative evaluation respiration control LA - English M3 - Article N1 - L626297736 2019-02-13 2019-02-18 PY - 2019 SN - 1439-0256 0170-5334 SP - S1-S7 ST - Synonyms: Triple A syndrome, 4 A Syndrome, Achalasia-Addisonianism-Alacrima syndrome T2 - Anasthesiologie und Intensivmedizin TI - Synonyms: Triple A syndrome, 4 A Syndrome, Achalasia-Addisonianism-Alacrima syndrome UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626297736&from=export http://dx.doi.org/10.19224/ai2019.S001 VL - 60 ID - 2549 ER - TY - JOUR AB - Purpose: The objective of this study was to estimate the cost impact of neodymium-doped yttrium aluminum garnet (Nd:YAG) laser capsulotomy and its complications due to single-piece acrylic monofocal intraocular lenses (IOLs) in the healthcare setting of United Kingdom, Italy, and Denmark. Materials and methods: A hypothetical cost-consequence model was developed to estimate economic burden of Nd:YAG laser capsulotomy due to different single-piece acrylic monofocal IOLs. Cumulative incidence of Nd:YAG laser capsulotomy at 3 years after cataract surgery with five single-piece monofocal acrylic IOLs was sourced from retrospective data analysis of electronic medical records of cataract patients in the United Kingdom. Risk probability of post-Nd:YAG laser complications, ie, retinal detachment, glaucoma, and cystoid macular edema at 3 years was derived using published literature. Unit costs were taken from publicly available sources with all costs converted to euro (€). Number of cataract procedures per year for each country was sourced from Eurostat statistics. Results: For the estimated cataract procedures carried out nationally every year, single-piece monofocal hydrophobic AcrySof IOL was associated with substantially lower cases of Nd:YAG laser capsulotomy procedures and subsequent complications in 3 years after cataract surgery when compared to other single-piece monofocal acrylic IOLs. The total cost savings with the use of AcrySof over other IOLs in countries assessed ranged from €0.5 to €4.7 million (vs AMO Tecnis) and €2.1 to €17.9 million (vs Rayner C-/Super-flex). Conclusion: Incidence of Nd:YAG capsulotomy due to the choice of IOL could significantly affect healthcare budgets in the post-cataract surgery period. Our analysis indicates that single-piece monofocal AcrySof IOLs is the most cost-saving treatment option for health care systems when compared to other acrylic single-piece IOLs. AD - M. Dhariwal, Alcon Laboratories, Inc., 6201 South Freeway, TA3-8, Fort Worth, TX, United States AU - Dhariwal, M. AU - Bouchet, C. AU - Jawla, S. DB - Embase DO - 10.2147/OPTH.S190754 KW - AMO Tecnis B and L Akreos lens implant Lenstec Softec neodymium YAG laser Rayner C punctal plug acrylic acid article capsulotomy cataract extraction comparative study controlled study cost effectiveness analysis Denmark economic aspect equipment design glaucoma health care cost health care utilization human incidence Italy lens implantation major clinical study retina detachment retina macula cystoid edema retrospective study sensitivity analysis United Kingdom AcrySof Super-flex LA - English M3 - Article N1 - L2001563619 2019-03-25 2019-03-29 PY - 2019 SN - 1177-5483 1177-5467 SP - 169-176 ST - Comparing the long-term impact on health care resources utilization and costs due to various single-piece acrylic monofocal intraocular lens implantation during cataract surgery: A cost-consequence analysis for the United Kingdom, Italy, and Denmark T2 - Clinical Ophthalmology TI - Comparing the long-term impact on health care resources utilization and costs due to various single-piece acrylic monofocal intraocular lens implantation during cataract surgery: A cost-consequence analysis for the United Kingdom, Italy, and Denmark UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001563619&from=export http://dx.doi.org/10.2147/OPTH.S190754 VL - 13 ID - 2539 ER - TY - JOUR AB - The vernal ulcer is a peculiar corneal complication of vernal conjunctivitis. Clinically, the ulcer is oval, grey, and resistant to medical treatment. Histological study by light and electron microscopy reveal the lesion to be composed of fibrin deposits adherent to a well-preserved Bowman's membrane. These deposits impede lateral progression of the epithelium, thus, opposing spontaneous healing. Resolution of the ulcer can be obtained, however, by superficial keratectomy. AU - Dhermy, P. AU - Pouliquen, Y. AU - Foels, M. O. AU - Savoldelli, M. IS - 11 KW - Adolescent Conjunctiva/pa [Pathology] *Conjunctivitis, Allergic/co [Complications] Conjunctivitis, Allergic/pa [Pathology] Cornea/pa [Pathology] Cornea/su [Surgery] Cornea/ul [Ultrastructure] Corneal Stroma/ul [Ultrastructure] *Corneal Ulcer/et [Etiology] Corneal Ulcer/pa [Pathology] Corneal Ulcer/th [Therapy] Epithelium/pa [Pathology] Epithelium/ul [Ultrastructure] Fibrin/an [Analysis] Humans Male Microscopy, Electron PY - 1985 SN - 0181-5512 SP - 711-9 ST - [The vernal plaque, a complication of so-called spring conjunctivitis] T2 - La plaque vernale, complication de la conjonctivite dite "printaniere". TI - [The vernal plaque, a complication of so-called spring conjunctivitis] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=3833887 VL - 8 ID - 2221 ER - TY - GEN AB - Patients non responsive to the treatment of AMT or tarsorrhaphy were post penetrating keratoplasty patients with large PED's. Indication for penetrating keratoplasty in all these patients was deep corneal opacities with adherent leucoma (healed corneal ulcers). REFERENCES 1 Srirampur A, Kola P, Mansoori T, Vemuganti S. Comments on: A comparative study of tarsorrhaphy and amniotic membrane transplantation in the healing of persistent corneal epithelial defects. AD - Clinical Fellow, Medical Research Foundation, Department of Pediatric Ophthalmology and Strabismus, Sankara Nethralaya, Chennai, Tamil Nadu Associate Professor, Department of Ophthalmology, All India Institute of Medical Sciences, Bathinda, Punjab Professor, Department of Ophthalmology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Jolly Grant, Dehradun, Uttarakhand Clinical Fellow, Medical Research Foundation, Department of Pediatric Ophthalmology and Strabismus, Sankara Nethralaya, Chennai, Tamil Nadu, India AU - Dhillon, Hennaav AU - Raj, Anuradha AU - Bahadur, Harsh AU - Dhillon, Hennaav Kaur DB - ccm DO - 10.4103/ijo.IJO_163_20 DP - EBSCOhost J2 - Indian Journal of Ophthalmology KW - Amnion -- Transplantation Epithelium -- Surgery Wound Healing Eyelids Psychological Tests N1 - Accession Number: 144299414. Language: English. Entry Date: 20201125. Revision Date: 20201212. Publication Type: letter; commentary. Journal Subset: Asia; Biomedical; Peer Reviewed. Instrumentation: Abbreviated Mental Test (AMT). NLM UID: 0405376. PMID: NLM32587225. PB - Wolters Kluwer India Pvt Ltd PY - 2020 SN - 0301-4738 SP - 1504-1505 ST - Response to comments on: A comparative study of tarsorrhaphy and amniotic membrane transplantation in the healing of persistent corneal epithelial defects TI - Response to comments on: A comparative study of tarsorrhaphy and amniotic membrane transplantation in the healing of persistent corneal epithelial defects UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144299414&site=ehost-live&scope=site VL - 68 ID - 4323 ER - TY - JOUR AB - BACKGROUND/AIM: Prostaglandin analogues (PGAs) are a first-line medical treatment for glaucoma because of their powerful intraocular pressure (IOP) lowering effect, few systemic side-effects (SEs), and the once daily administration. Despite the high systemic safety profile, the chronic use of PGAs may induce periocular and ocular surface (OS)-related side effects, which affect a significant proportion of glaucomatous patients. In this review, we summarize the current knowledge about SEs of PGAs on periocular structures and OS, and their implications in clinical practice., MATERIALS AND METHODS: A comprehensive literature search on the PubMed platform was performed. Two hundred fifty articles fulfilling key words were identified, of which 180 were excluded since they did not concern the effects of PGAs on the periocular tissues and OS, or because of their limited relevance. The following key words were used and combined, to narrow-down the literature: "prostaglandin" and "ocular surface," which identified 184 unique publications, of which 68 were selected; "prostaglandin" and "periocular" which identified 46 unique publications, of which 11 were selected. An additional search was conducted using "prostaglandin" and "Meibomian glands (MGs)", which identified twenty unique publications, of which 8 were selected. Thus, a total of 70 articles were chosen based on their relevance and were included in this review., RESULTS: Prostaglandin-associated peri-orbitopathy, skin pigmentation and hypertrichosis, eyelash growth, and MGs dysfunction are the most frequent modifications of periocular tissues. They are induced by the tissue accumulation of PGAs, and FP receptor stimulation. Without preservatives, PGAs act as stimulators of conjunctival goblet cells, which are the main source of ocular surface mucoproteins, and seem to increase conjunctival epithelium microcysts proposed as in vivo hallmark of the trans-scleral aqueous humour outflow. Additional PGA-induced modifications can be recognized in the cornea, corneo-scleral limbus, conjunctival stroma and, conjunctiva-associated lymphoid tissue, mainly appearing as inflammatory changes. OS epithelia desquamation, chemosis, apoptosis, dendritic cell activation, conjunctival or episcleral vasodilation, and sub-basal nerve plexus disruption were also described in patients receiving preserved PGAs., CONCLUSION: PGAs induce several modifications of the OS structures and adnexa; nonetheless, none of them significantly reduces the local safety profile of this class of drugs. Moreover, the OS changes do not affect the IOP lowering efficacy of PGAs. On these bases, local SEs of PGAs should not discourage clinicians in using this class of medications because of their efficacy, the systemic safety profile, and the better adherence. Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. AU - Di Staso, Silvio AU - Agnifili, Luca AU - Cecannecchia, Sara AU - Di Gregorio, Angela AU - Ciancaglini, Marco IS - 2 KW - Animals *Conjunctiva/de [Drug Effects] *Conjunctiva/pa [Pathology] Corneal Stroma Endothelium, Corneal/de [Drug Effects] Endothelium, Corneal/me [Metabolism] Endothelium, Corneal/pa [Pathology] Glaucoma/di [Diagnosis] *Glaucoma/dt [Drug Therapy] *Glaucoma/pa [Pathology] Goblet Cells/de [Drug Effects] Goblet Cells/me [Metabolism] Goblet Cells/pa [Pathology] Humans Meibomian Glands/me [Metabolism] Meibomian Glands/pa [Pathology] Microscopy, Confocal Prostaglandins, Synthetic/pd [Pharmacology] *Prostaglandins, Synthetic/tu [Therapeutic Use] PY - 2018 SE - DI Staso, Silvio. Ophthalmology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. Agnifili, Luca. Ophthalmology Clinic, Department of Medicine and Aging Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy. Cecannecchia, Sara. Ophthalmology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. DI Gregorio, Angela. Ophthalmology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. Ciancaglini, Marco. Ophthalmology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy marco.ciancaglini@cc.univaq.it. SN - 1791-7549 0258-851X SP - 211-220 ST - In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma T2 - In vivo (Athens, Greece) TI - In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29475902 VL - 32 ID - 448 ER - TY - JOUR AB - The cornea is the most commonly transplanted tissue in medicine. The main cause of corneal graft failure is allograft rejection. The incidence of graft rejection depends on the presence of high-risk characteristics, most notably corneal neovascularization. Although corneal grafting has high success rates in the absence of these risk factors, high-risk keratoplasty is associated with low success rates because of a high incidence of immune-mediated graft rejection. To improve the survival of high-risk corneal transplantation, various preoperative, intraoperative, and postoperative measures can be considered; however, the key step in the management of these grafts is the long-term use of local and/or systemic immunosuppressive agents. Although a number of immunosuppressive agents have been used for this purpose, the results vary significantly across different studies. This is partly due to the lack of an optimized method for their use, as well as the lack of a precise stratification of the degree of risk in each individual patient. New targeted biologic treatments, as well as tolerance-inducing methods, show promising horizons in the management of high-risk corneal transplantation in near future. AD - R. Dana, 243 Charles Street, Boston, MA, United States AU - Di Zazzo, A. AU - Kheirkhah, A. AU - Abud, T. B. AU - Goyal, S. AU - Dana, R. C1 - fk 506 DB - Embase Medline DO - 10.1016/j.survophthal.2016.12.010 IS - 6 KW - aciclovir aflibercept bevacizumab corticosteroid cyclosporine dexamethasone dexamethasone sodium phosphate difluprednate loteprednol methylprednisolone mycophenolate mofetil prednisolone prednisolone acetate ranibizumab rapamycin tacrolimus vasculotropin A anemia artery thrombosis atopic keratoconjunctivitis cataract chronic graft versus host disease cornea neovascularization cornea transplantation Cushing syndrome cytokine release drug withdrawal dry eye gastrointestinal symptom gastrointestinal toxicity glaucoma graft failure graft rejection graft survival graft versus host reaction headache human hyperglycemia hyperlipidemia hypertension immunomodulation immunosuppressive treatment infection intraocular hypertension intrastromal drug administration leukopenia liver toxicity malaise nephrotoxicity nonhuman osteoporosis pathophysiology patient compliance penetrating keratoplasty postoperative inflammation preoperative care priority journal review suture technique uveitis vernal conjunctivitis wound healing impairment fk 506 LA - English M3 - Review N1 - L618448882 2017-09-28 2017-11-24 PY - 2017 SN - 1879-3304 0039-6257 SP - 816-827 ST - Management of high-risk corneal transplantation T2 - Survey of Ophthalmology TI - Management of high-risk corneal transplantation UR - https://www.embase.com/search/results?subaction=viewrecord&id=L618448882&from=export http://dx.doi.org/10.1016/j.survophthal.2016.12.010 VL - 62 ID - 2625 ER - TY - JOUR AD - J.P. Diamond, Bristol Eye Hospital, Lower Maudlin Street, Bristol BS2 2LX, United Kingdom AU - Diamond, J. P. DB - Embase Medline DO - 10.1038/sj.eye.6701601 IS - 3 KW - prostaglandin cataract disease severity editorial ethnic difference geography glaucoma health care access health care availability human hypothesis intraocular pressure medical decision making Black person outcomes research postoperative complication prediction prevalence resource allocation risk assessment surgical technique trabeculectomy treatment failure visual field defect LA - English M3 - Editorial N1 - L40484813 2005-04-24 PY - 2005 SN - 0950-222X SP - 241-242 ST - Trabeculectomy around the globe T2 - Eye TI - Trabeculectomy around the globe UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40484813&from=export http://dx.doi.org/10.1038/sj.eye.6701601 VL - 19 ID - 3697 ER - TY - JOUR AB - Moraxella keratitis can lead to important complications. Moraxella nonliquefaciens(M. nonliquefaciens) has the worst prognosis. Only three cases of corneal infections due to M. nonliquefaciens have been published. The case is presented of a 79-year-old man with bullous keratopathy, recently affected with severe infectious keratitis. Dense, deep, and central stromal infiltrates and hyphaema were detected. After the identification of M. nonliquefaciens in the culture, and given the progression of the condition, the initial empirical treatment was modified to topical ciprofloxacin and ceftazidime in accordance with the antibiogram, combining oral ciprofloxacin and amoxicillin-clavulanate. After 27 days, there was total resolution of the lesion, with central residual leucoma. Keratitis caused by M. nonliquefaciens is rare and must be suspected in elderly patients with local predisposing factors, such as corneal damage or previous eye surgery. Early antibiogram-guided treatment and close monitoring are important to avoid complications and poor compliance. Copyright © 2020. Publicado por Elsevier Espana, S.L.U. AU - Diaz Barron, A. AU - Sanz Gallen, L. AU - Hervas Hernandis, J. M. AU - Tarrago Simon, E. AU - Duch-Samper, A. M. DO - https://dx.doi.org/10.1016/j.oftal.2020.02.012 IS - 7 KW - Aged Amoxicillin-Potassium Clavulanate Combination/tu [Therapeutic Use] Anti-Bacterial Agents/tu [Therapeutic Use] Ceftazidime/tu [Therapeutic Use] Ciprofloxacin/tu [Therapeutic Use] Corneal Opacity/et [Etiology] Corneal Ulcer/dt [Drug Therapy] *Corneal Ulcer/mi [Microbiology] Drug Substitution Eye Infections, Bacterial/dt [Drug Therapy] *Eye Infections, Bacterial/mi [Microbiology] Humans Hyphema/et [Etiology] Male *Moraxella/ip [Isolation & Purification] Moraxellaceae Infections/dt [Drug Therapy] *Moraxellaceae Infections/mi [Microbiology] Vancomycin/tu [Therapeutic Use] PY - 2020 SE - Diaz Barron, A. Departamento de Oftalmologia, Hospital Clinico Universitario de Valencia, Valencia, Espana. Electronic address: andrea.dazbarrn@gmail.com. Sanz Gallen, L. Departamento de Oftalmologia, Hospital Clinico Universitario de Valencia, Valencia, Espana. Hervas Hernandis, J M. Departamento de Oftalmologia, Hospital Clinico Universitario de Valencia, Valencia, Espana. Tarrago Simon, E. Departamento de Oftalmologia, Hospital Clinico Universitario de Valencia, Valencia, Espana. Duch-Samper, A M. Departamento de Oftalmologia, Hospital Clinico Universitario de Valencia, Valencia, Espana; Facultad de Medicina, Universidad de Valencia, Valencia, Espana. SN - 2173-5794 SP - 357-360 ST - Bacterial keratitis due to Moraxella nonliquefaciens T2 - Queratitis bacteriana por Moraxella nonliquefaciens. TI - Bacterial keratitis due to Moraxella nonliquefaciens UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32241585 VL - 95 Y2 - 20200330// ID - 172 ER - TY - JOUR AB - Recent technological innovations in cataract surgery have made the procedure even more precise and safe and the odds of having a highly satisfied patient even higher. These innovations include visualisation systems - such as intraoperative aberrometry - which are particularly helpful when it comes to implanting toric IOLs, where even a slight rotation or misalignment can significantly reduce the postoperative visual quality. Another way to ensure the exact positioning of a toric IOL is to create a mark by making an intrastromal incision using the femtosecond laser. The latter technology has increased the precision of capsulotomy and other steps of the operation and has been successfully employed in patients with a challenging clinical profile, including paediatric and hypermature cataracts. The femtosecond laser, however, induces an increase in intraocular prostaglandins, which can lead to miosis. Applying topical NSAIDs before starting surgery has proved to be effective in coping with the consequences of the increase in prostaglandins. Good vision without using glasses for near, intermediate and far distances remains a goal for many patients. IOLs with extended depths of focus (EDOF) technology can provide this comfort - to some but not all patients. An intraocular sensor, Eyemate, that is implanted during cataract surgery, enables the glaucoma patient to check his or her IOP at any time and improves the management of glaucoma and its main risk factor, elevated IOP. Several methods - drugs or nutritive agents - are said to prevent cataractogenesis. These studies have probably to be taken with the proverbial grain of salt. Copyright Georg Thieme Verlag KG Stuttgart . New York. AU - Dick, H. B. AU - Schultz, T. DO - https://dx.doi.org/10.1055/s-0042-121423 IS - 8 KW - Aberrometry/mt [Methods] Aberrometry/td [Trends] *Cataract Extraction/mt [Methods] *Cataract Extraction/td [Trends] Diffusion of Innovation Humans Intraocular Pressure Laser Therapy/mt [Methods] Laser Therapy/td [Trends] Lenses, Intraocular Optics and Photonics Patient Satisfaction Refraction, Ocular PY - 2017 SE - Dick, H B. Universitats-Augenklinik, Knappschaftskrankenhaus Bochum. Schultz, T. Universitats-Augenklinik, Knappschaftskrankenhaus Bochum. SN - 1439-3999 0023-2165 SP - 979-985 ST - [New Developments in Cataract Surgery] T2 - Interessantes aus der Kataraktchirurgie. TI - [New Developments in Cataract Surgery] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28086250 VL - 234 Y2 - 20170113// ID - 543 ER - TY - JOUR AB - In the management of glaucoma, recent and upcoming innovations have the potential to contribute to both the efficacy of intraocular pressure (IOP) monitoring and the number of available treatment options. These new devices and procedures have two things in common: they are part of the trend in medicine towards miniaturization, and they require a limited surgical procedure to become effective. This review focuses on the Eyemate (Argos) intraocular sensor, which offers a new way to reliably measure 24 h IOP, and on intraocular sustained release systems for pharmacological glaucoma therapy. It also briefly reflects on the miniature implants currently used in minimally invasive glaucoma surgery (MIGS). © 2019, The Author(s). AD - University Eye Clinic, Ruhr University, Bochum, Germany AU - Dick, H. B. AU - Schultz, T. AU - Gerste, R. D. DB - Scopus DO - 10.1007/s40123-019-0161-2 IS - 1 KW - Adherence CyPass microstent Eyemate (Argos) sensor Glaucoma Hydrus microstent Intraocular drug delivery systems Intraocular pressure (IOP) iStent inject Minimally invasive glaucoma surgery (MIGS) XEN gel M3 - Review N1 - Cited By :12 Export Date: 19 July 2021 PY - 2019 SP - 19-30 ST - Miniaturization in Glaucoma Monitoring and Treatment: A Review of New Technologies That Require a Minimal Surgical Approach T2 - Ophthalmology and Therapy TI - Miniaturization in Glaucoma Monitoring and Treatment: A Review of New Technologies That Require a Minimal Surgical Approach UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066421462&doi=10.1007%2fs40123-019-0161-2&partnerID=40&md5=efbb1686148b632e1e351feb299a9900 VL - 8 ID - 5225 ER - TY - JOUR AB - Purpose: To compare two standard small incision techniques for cataract surgery - clear corneal incision and sclerocorneal incision - with regard to postoperative disturbance of the blood-aqueous barrier (BAB). Setting: Department of Ophthalmology, University of Vienna, Austria. Methods: This prospective comparative study comprised 108 eyes with senile cataract. A clear corneal tunnel incision was made in 53 eyes and a sclerocorneal incision with tunnel preparation in 55. All other surgical procedures and postoperative medication were standardized. Postoperative BAB disruption was measured with a laser flare-cell meter (Kowa FC 1000) in an undilated pupil on 1, 3, 7, 14, 28, 60, and 90 days postoperatively. The values were compared using a two-sided t-test. Results: In both groups, flare and cell values were highest on the first postoperative day. They gradually declined but without recovery of preoperative flare values on day 28. At no time was there a noticeable between-group difference in mean cell and flare values except for flare at day 14 (P = .04). Conclusion: Postoperative trauma, measured by the BAB disturbance, was equally low after clear corneal and sclerocorneal incisions. AD - Department of Ophthalmology, Johannes Gutenberg-University, Mainz, Germany Department of Medical Statistics and Documentation, Johannes Gutenberg-University, Mainz, Germany AU - Dick, H. B. AU - Schwenn, O. AU - Krummenauer, F. AU - Krist, R. AU - Pfeiffer, N. DB - Scopus DO - 10.1016/s0886-3350(98)80296-4 IS - 4 M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 1998 SP - 524-528 ST - Postoperative inflammation after clear corneal and sclerocorneal incisions T2 - Journal of Cataract and Refractive Surgery TI - Postoperative inflammation after clear corneal and sclerocorneal incisions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032471816&doi=10.1016%2fs0886-3350%2898%2980296-4&partnerID=40&md5=4ba916c6eceff8ea21d852325bcd0184 VL - 24 ID - 5118 ER - TY - JOUR AB - Nanocarriers, such as nanoparticles, have the capacity to deliver ocular drugs to specific target sites and hold promise to revolutionize the therapy of many eye diseases. Results to date strongly suggest that ocular medicine will benefit enormously from the use of this nanometric scale technology. One of the most important handicaps of the eye as a target organ for drugs is the presence of several barriers that impede direct and systemic drug access to the specific site of action. Superficial barriers include the ocular surface epithelium and the tear film, and internal barriers include the blood-aqueous and blood-retina barriers. Topical application is the preferred route for most drugs, even when the target tissues are at the back part of the eye where intraocular injections are currently the most common route of administration. Direct administration using any of these two routes faces many problems related to drug bioavailability, including side effects and repeated uncomfortable treatments to achieve therapeutic drug levels. In this regard, the advantages of using nanoparticles include improved topical passage of large, poorly water-soluble molecules such as glucocorticoid drugs or cyclosporine for immune-related, vision-threatening diseases. Other large and unstable molecules, such as nucleic acids, delivered using nanoparticles offer promising results for gene transfer therapy in severe retinal diseases. Also, nanoparticle-mediated drug delivery increases the contact time of the administered drug with its target tissue, such as in the case of brimonidine, one of the standard treatments for glaucoma, or corticosteroids used to treat autoimmune uveitis, a severe intraocular inflammatory process. In addition, nanocarriers permit the non-steroidal anti-inflammatory drug indomethacin to reach inner eye structures using the transmucosal route. Finally, nanoparticles allow the possibility of targeted delivery to reach specific types of cancer, such as melanoma, leaving normal cells untouched. This review summarizes experimental results from our group and others since the beginnings of nanocarrier technology to deliver drugs to different locations in the eye. Also, it explores the future possibilities of nanoparticles not only as drug delivery systems but also as aides for diagnostic purposes. Copyright © 2010 Elsevier Ltd. All rights reserved. AU - Diebold, Yolanda AU - Calonge, Margarita DO - https://dx.doi.org/10.1016/j.preteyeres.2010.08.002 IS - 6 KW - Animals Drug Delivery Systems/mt [Methods] Humans Nanoparticles/sn [Statistics & Numerical Data] *Nanoparticles/tu [Therapeutic Use] *Ophthalmology *Retinal Diseases/th [Therapy] PY - 2010 SE - Diebold, Yolanda. Instituto de Oftalmobiologia Aplicada (IOBA), Universidad de Valladolid, Valladolid, Spain. yol@ioba.med.uva.es SN - 1873-1635 1350-9462 SP - 596-609 ST - Applications of nanoparticles in ophthalmology T2 - Progress in retinal and eye research TI - Applications of nanoparticles in ophthalmology UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20826225 VL - 29 Y2 - 20100906// ID - 1335 ER - TY - JOUR AB - OBJECTIVES: To evaluate clinical performance of three lens types disposed of on a daily disposable (DD) basis., METHOD: A total of 120 participants were randomized into one of three lens types (etafilcon A, narafilcon A, and senofilcon A), all worn bilaterally on a DD regime. Participants were observed at baseline, 2-week, and 1- and 3-month visits where ocular physiology and lens performance variables were collected on a 0 to 4 grading scale in 0.1 increments. Subjective comfort and vision ratings were collected on a 1 to 100 rating scale and in the form of symptom severity., RESULTS: Forty participants wore each lens type with no differences in age or gender between groups (P>0.05). Etafilcon A exhibited more limbal redness compared with either of the other lens types (P<0.01). More superior corneal staining was noted with narafilcon A lenses compared with senofilcon A (P<0.01), and more superior conjunctival indentation was noted for narafilcon A compared with etafilcon A (P=0.001). No differences were found between lenses in the 1 to 100 rating scale (P>0.05). Narafilcon A showed more moderate to severe dryness symptoms and symptoms of blurred vision at lens wearing visits (P<0.05). One bilateral contact lens papillary conjunctivitis, one unilateral superior epithelial arcuate lesion, and one infiltrative keratitis were associated with narafilcon A only. Of the seven discontinuations, six were from the narafilcon A group., CONCLUSION: Different contact lens materials and designs, worn on the same DD modality, elicit different ocular and patient responses. Narafilcon A did not perform clinically as well as etafilcon A and senofilcon A worn on a DD modality. AU - Diec, Jennie AU - Lazon de la Jara, Percy AU - Willcox, Mark AU - Holden, Brien A. DO - https://dx.doi.org/10.1097/ICL.0b013e31826586c3 IS - 5 KW - Adult Contact Lenses, Hydrophilic/ae [Adverse Effects] *Contact Lenses, Hydrophilic/st [Standards] Cornea/ph [Physiology] *Disposable Equipment Female Humans Logistic Models Male Myopia/pp [Physiopathology] *Myopia/rh [Rehabilitation] Patient Satisfaction Prospective Studies Severity of Illness Index Vision, Ocular/ph [Physiology] PY - 2012 SE - Diec, Jennie. Brien Holden Vision Institute, Sydney, Australia. j.diec@brienholdenvision.org SN - 1542-233X 1542-2321 SP - 313-8 ST - The clinical performance of lenses disposed of daily can vary considerably T2 - Eye & contact lens TI - The clinical performance of lenses disposed of daily can vary considerably UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22890226 VL - 38 ID - 1117 ER - TY - JOUR AD - E. Dienstbier AU - Dienstbier, E. DB - Medline IS - 4 KW - cholinesterase inhibitor aged ambulatory care article community care Czechoslovakia female follow up glaucoma human intraocular pressure national health service visual field LA - Czech M3 - Article N1 - L89179416 1969-10-04 PY - 1969 SN - 0009-059X SP - 200-204 ST - The most frequent errors in the diagnosis and observation of primary glaucoma in the ophthalmological field practice T2 - Ceskoslovenská oftalmologie TI - The most frequent errors in the diagnosis and observation of primary glaucoma in the ophthalmological field practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L89179416&from=export VL - 25 ID - 4129 ER - TY - JOUR AD - M. Diestelhorst, Cologne, Germany AU - Diestelhorst, M. DB - Embase Medline DO - 10.1016/j.ophtha.2006.07.033 IS - 11 KW - latanoprost timolol chronotherapy clinical observation clinical protocol clinical trial drug effect drug efficacy glaucoma human intraocular hypotension intraocular pressure letter patient compliance priority journal LA - English M3 - Letter N1 - L44635736 2006-11-14 PY - 2006 SN - 0161-6420 SP - 2108 ST - The State of Being Noninferior T2 - Ophthalmology TI - The State of Being Noninferior UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44635736&from=export http://dx.doi.org/10.1016/j.ophtha.2006.07.033 VL - 113 ID - 3577 ER - TY - JOUR AB - Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP. Timolol reduces the production rate of aqueous humor to achieve the IOP decrease. Latanoprost and pilocarpine both affect aqueous outflow, although by different mechanisms. The IOP efficacy of combined therapy with timolol and pilocarpine compared with timolol and latanoprost or with latanoprost alone has been investigated in three multicenter, randomized, clinical trials in Europe. This is a review of those published trials. In 2 of the 3 studies, the additional IOP lowering effect of latanoprost 0.005% administered once daily was compared with pilocarpine 2% administered 3 times daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension currently on monotherapy with timolol 0.5% twice daily. These 6-month studies found that the timolol and latanoprost combination reduced IOP more and was better tolerated with fewer side-effects than the timolol and pilocarpine combination. At 6 months, there was no evidence of long-term drift in IOP with timolol and latanoprost. This combined therapy provides an effective and safe option for lowering IOP in glaucoma patients. These results suggest that the timolol/latanoprost combination is preferable to the timolol/pilocarpine combination not only with regard to side effects but also to the magnitude of IOP reduction. Two of the 3 studies compared latanoprost monotherapy with timolol and pilocarpine combined therapy in patients with POAG, various other glaucomas, or ocular hypertension. Treatment was for 6 weeks or 6 months. In both studies, latanoprost was more effective and better tolerated than the combination of timolol and pilocarpine. These results suggest that latanoprost alone should be tried before the addition of pilocarpine to timolol therapy is considered. The convenience of daily administration of a single drop of latanoprost versus multiple drops of timolol and pilocarpine should improve patient compliance. AU - Diestelhorst, Michael AU - Nordmann, Jean-Philippe AU - Toris, Carol B. KW - Adrenergic beta-Antagonists/tu [Therapeutic Use] *Antihypertensive Agents/tu [Therapeutic Use] Drug Therapy, Combination *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Intraocular Pressure/de [Drug Effects] Latanoprost *Muscarinic Agonists/tu [Therapeutic Use] Ocular Hypertension/dt [Drug Therapy] *Pilocarpine/tu [Therapeutic Use] *Prostaglandins F, Synthetic/tu [Therapeutic Use] *Timolol/tu [Therapeutic Use] PY - 2002 SE - Diestelhorst, Michael. Department of Ophthalmology, University of Cologne, Joseph-Stelzmann-Strasse 9, Cologne 50931, Germany. michael.diestelhorst@medizin.uni-koeln.de SN - 0039-6257 SP - S155-61 ST - Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy T2 - Survey of ophthalmology TI - Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=12204713 VL - 47 Suppl 1 ID - 1874 ER - TY - JOUR AB - Background: We studied the effect of argon laser trabeculoplasty (ALT) on the blood-aqueous barrier (BAB) in 41 eyes of 41 patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, or pigment dispersion glaucoma using the Fluorotron Master II. Methods: Fluorophotometry was performed the day before ALT and on the 3rd day after surgery at 30 and 60 min after intravenous injection of 7 mg/kg body weight sodium fluorescein 10%. Intraocular pressure (IOP) was measured using Goldmann applanation tonometry on the day before surgery and at 3rd days and 1 year (mean) after ALT. Patients were treated with argon laser by one surgeon (180 degrees, 0.1 s, 50 mu m 0.6-1.0 W, 56 laser burns). Eyes were randomly assigned to either diclofenac-sodium 0.1% eye drops or vehicle. Eye drops were applied six times 1 h before ALT into the operated eyes and five times daily for 3 days postoperatively. Results: On the 3rd day after ALT there was significant disruption of the BAB in the placebo-treated eyes compared to the diclofenac 0.1%-treated eyes. In the placebo-treated eyes as well as in diclofenac-sodium 0.1%-treated eyes there was a significant decrease of IOP postoperatively for up to 1 year. There was no significant difference concerning the IOP reduction after 1 year. Diclofenac-sodium 0.1% eye drops significantly stabilized the BAB on the 3rd day after ALT, compared to placebo, in this model. Conclusion: Diclofenac-sodium 0.1% significantly stabilized the disruption of the blood-aqueous barrier on the 3rd day after ALT. Concerning the IOP-lowering effect of ALT, the postoperative application of steroids should be avoided. AN - WOS:A1995RQ44900004 AU - Diestelhorst, M. AU - Thull, D. AU - Krieglstein, G. K. DA - SEP DO - 10.1007/BF00404706 IS - 9 PY - 1995 SN - 0721-832X SP - 559-562 ST - THE EFFECT OF ARGON-LASER TRABECULOPLASTY ON THE BLOOD-AQUEOUS BARRIER AND INTRAOCULAR-PRESSURE IN HUMAN GLAUCOMATOUS EYES TREATED WITH DICLOFENAC 0.1-PERCENT T2 - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - THE EFFECT OF ARGON-LASER TRABECULOPLASTY ON THE BLOOD-AQUEOUS BARRIER AND INTRAOCULAR-PRESSURE IN HUMAN GLAUCOMATOUS EYES TREATED WITH DICLOFENAC 0.1-PERCENT VL - 233 ID - 6213 ER - TY - JOUR AB - Glaucoma is a relatively common ocular disease among adults aged >65 years. However, knowledge about glaucoma, the physical capacity to perform self-application of antiglaucomatous drops, and general compliance may be massively restricted in the older population owing to significantly increasing comorbidity and other factors (e.g. their social and financial situation). Additional efforts by ophthalmologists, the pharmaceutical industry and health politics are required to improve knowledge and compliance among elderly glaucoma patients. AU - Dietlein, T. S. IS - 9 KW - Aged Aged, 80 and over Germany *Glaucoma/dt [Drug Therapy] Humans *Ophthalmic Solutions/tu [Therapeutic Use] *Patient Compliance *Quality of Life *Self Medication/mt [Methods] PY - 2006 SE - Dietlein, T S. Zentrum fur Augenheilkunde, Universitat Koln, Joseph-Stelzmann-Strasse 9, 50931 Koln, Germany. Thomas.Dietlein@uk-koeln.de SN - 0941-293X SP - 755-8 ST - [Glaucoma in the aged--barriers to understanding and compliance] T2 - Glaukom im Alter--Barrieren fur Aufklarung und Compliance. TI - [Glaucoma in the aged--barriers to understanding and compliance] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16912858 VL - 103 ID - 1648 ER - TY - JOUR AB - Glaucoma is a relatively common ocular disease among adults aged >65 years. However, knowledge about glaucoma, the physical capacity to perform self-application of antiglaucomatous drops, and general compliance may be massively restricted in the older population owing to significantly increasing comorbidity and other factors (e.g. their social and financial situation). Additional efforts by ophthalmologists, the pharmaceutical industry and health politics are required to improve knowledge and compliance among elderly glaucoma patients. © 2006 Springer Medizin Verlag. AD - T.S. Dietlein, Zentrum für Augenheilkunde, Universität Köln, Joseph-Stelzmann-Straße 9, 50931 Köln, Germany AU - Dietlein, T. S. DB - Embase Medline DO - 10.1007/s00347-006-1408-6 IS - 9 KW - article comorbidity eye disease geriatric care glaucoma health education health program human patient compliance patient education pharmacy (shop) quality of life self medication LA - German M3 - Article N1 - L44407475 2006-10-01 PY - 2006 SN - 0941-293X SP - 755-758 ST - Glaucoma in the aged - Barriers to understanding and compliance T2 - Ophthalmologe TI - Glaucoma in the aged - Barriers to understanding and compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44407475&from=export http://dx.doi.org/10.1007/s00347-006-1408-6 VL - 103 ID - 3588 ER - TY - JOUR AB - BACKGROUND: In order to look for conceptual improvements in the practical management of patients sent to our glaucoma department, we analyzed the structures, behaviour, and knowledge about the disease in this patient group., METHODS: Glaucoma patients who were sent for the first time to our department were included prospectively. Before being examined 129 patients were asked to answer a questionnaire concerning their individual characteristics, their behaviour, and patterns of treatment., RESULTS: Of the patients 74% had open-angle glaucoma (including normal tension, exfoliative, and pigment glaucoma), 22% had secondary glaucoma (including neovascular, congenital, and chronic closed-angle glaucoma), and 4% had suspected glaucoma. Written documentation of previously performed intraocular pressure measurements was not available for 84% of the patients. Younger patients had significantly more knowledge about glaucoma and used more possibilities to get information about the disease than elder patients., CONCLUSION: Education about glaucoma disease should be optimized especially for elder glaucoma patients. Documentation of intraocular pressure measurements is insufficient in our patient group. AU - Dietlein, T. S. AU - Jordan, J. AU - Dinslage, S. AU - Jacobi, P. C. AU - Krieglstein, G. K. IS - 5 KW - Adult Age Factors Aged Aged, 80 and over Female Glaucoma/cn [Congenital] Glaucoma/dt [Drug Therapy] *Glaucoma/th [Therapy] Glaucoma, Angle-Closure/th [Therapy] Glaucoma, Neovascular/th [Therapy] Glaucoma, Open-Angle/th [Therapy] Humans Intraocular Pressure Male Middle Aged Patient Compliance *Patient Education as Topic Prospective Studies Surveys and Questionnaires PY - 2005 SE - Dietlein, T S. Zentrum fur Augenheilkunde, Universitat, Koln. aia47@uni-koeln.de SN - 0941-293X SP - 502-6 ST - [Patient characteristics in a tertiary glaucoma center. Circumstances of treatment and attitudes of patients] T2 - Profil einer universitaren Glaukomsprechstunde. Objektive Behandlungsumstande und subjektive Einstellungen der Patienten. TI - [Patient characteristics in a tertiary glaucoma center. Circumstances of treatment and attitudes of patients] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=15490182 VL - 102 ID - 1749 ER - TY - JOUR AB - BACKGROUND: Although interaction between doctor and patient is undoubtedly influenced by their mutual expectations, little information is available about the knowledge and expectations of glaucoma doctors concerning their patients' attitudes and treatment patterns. The aim of our prospective study was to compare the actual responses of glaucoma patients concerning various issues related to their disease and the responses the glaucoma doctors expected their patients to give., METHODS: Glaucoma patients consecutively sent to our glaucoma centre were asked to complete a standardised questionnaire about their glaucoma history, treatment routines and opinions on issues related to glaucoma. Ophthalmologists at the glaucoma centre were asked to predict patients' answers., RESULTS: One hundred and twenty-eight consecutive glaucoma patients completed the patients' questionnaire and 12 glaucoma specialists completed the corresponding questionnaire for doctors. Frequency of intraocular pressure (IOP) measurements and visual field testing, as well as the number of topical medications, were relatively accurately predicted by the glaucoma doctors. Differences between the doctors' predictions and patients' responses were found concerning discomfort after surgery and the influence of stress or environmental factors on IOP. The largest range of doctors' predictions (0-100%) was observed concerning the portion of patients claiming a 100% adherence to glaucoma medication., CONCLUSION: Glaucoma specialists are familiar with the treatment patterns of their patients. The knowledge of glaucoma specialists of their patients' subjective attitudes to glaucoma-related issues deserves further investigation, as discrepancies between doctors' and patients' responses were observed in this area. AU - Dietlein, Thomas S. AU - Jordan, Jens AU - Dinslage, Sven AU - Krieglstein, Gunter K. IS - 7 KW - Adult Aged Aged, 80 and over Antihypertensive Agents/tu [Therapeutic Use] Filtering Surgery Glaucoma/px [Psychology] *Glaucoma/th [Therapy] *Health Knowledge, Attitudes, Practice Humans Intraocular Pressure Medicine Middle Aged Ophthalmology Patient Compliance Physician's Role *Physician-Patient Relations Pilot Projects Prospective Studies Specialization Surveys and Questionnaires PY - 2006 SE - Dietlein, Thomas S. Department of Ophthalmology, University of Cologne, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany. Thomas.Dietlein@uk-koeln.de SN - 0721-832X SP - 859-62 ST - What do glaucoma specialists know about their patients? T2 - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie TI - What do glaucoma specialists know about their patients? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16292519 VL - 244 Y2 - 20051115// ID - 1693 ER - TY - JOUR AB - In order to treat glaucoma with medication successfully, the patient needs to participate actively in the process. "Adherence", formerly "compliance", describes the willingness and capacity to follow the prescribed regimen every day. It is not trivial to measure adherence and persistence, as this quite often relies on self reports by the patient or speculations by the physician. Hence, the overall reported adherence may vary from 5 to 95 %. In general, the following categories have been defined for reduced adherence: medication-related factors, patient-related factors, environmental factors and social factors. Age has been found to intensify or modify many of these factors. Older adults often face various challenges, due to motor disabilities, reduced visual acuity or impaired cognitive capabilities. In patients with movement disorders or tactile limitations, the target area can be reached more successfully with standard eye drop bottles than with single-use dose units. This should be considered if antiglaucoma eye drops are prescribed in the elderly. Frequency of application is a main factor influencing adherence. Monotherapy--as provided with prostaglandins--or drops with a fixed combination have proven to support adherence significantly. A significant boost for self-monitoring activities is initiated by the growing market of electronic devices, like smartphones. For instance, they can provide acoustic alarms as reminders to apply the eye drops. It is evident that any external support or disease-related information by family members, the medical practitioners, support groups or even electronic devices may improve adherence and persistence, even in patients with severe impairments. Copyright Georg Thieme Verlag KG Stuttgart . New York. AU - Dietlein, T. S. AU - Rosentreter, A. AU - Lappas, A. DO - https://dx.doi.org/10.1055/s-0041-110447 IS - 2 KW - Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] *Drug Monitoring/mt [Methods] Drug Monitoring/px [Psychology] Female Glaucoma/di [Diagnosis] *Glaucoma/dt [Drug Therapy] Glaucoma/px [Psychology] Health Services for the Aged/og [Organization & Administration] Humans Male *Medication Adherence/px [Psychology] *Reminder Systems *Self Care/mt [Methods] Self Care/px [Psychology] PY - 2016 SE - Dietlein, T S. Augenklinik, Universitatskliniken Koln. Rosentreter, A. Augenklinik, Universitat Wurzburg. Lappas, A. Augenklinik, Universitatskliniken Koln. SN - 1439-3999 0023-2165 SP - 138-42 ST - [Complexities of Medical Glaucoma Therapy--the Elderly Patient in Focus] T2 - Umsetzung und Schwierigkeiten bei Tropftherapien--der altere Glaukompatient im Fokus. TI - [Complexities of Medical Glaucoma Therapy--the Elderly Patient in Focus] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26878728 VL - 233 Y2 - 20160215// ID - 714 ER - TY - JOUR AB - In order to treat glaucoma with medication successfully, the patient needs to participate actively in the process. Adherence, formerly compliance, describes the willingness and capacity to follow the prescribed regimen every day. It is not trivial to measure adherence and persistence, as this quite often relies on self reports by the patient or speculations by the physician. Hence, the overall reported adherence may vary from 5 to 95%. In general, the following categories have been defined for reduced adherence: Medication-related factors, patient-related factors, environmental factors and social factors. Age has been found to intensify or modify many of these factors. Older adults often face various challenges, due to motor disabilities, reduced visual acuity or impaired cognitive capabilities. In patients with movement disorders or tactile limitations, the target area can be reached more successfully with standard eye drop bottles than with single-use dose units. This should be considered if antiglaucoma eye drops are prescribed in the elderly. Frequency of application is a main factor influencing adherence. Monotherapy - as provided with prostaglandins - Or drops with a fixed combination have proven to support adherence significantly. A significant boost for self-monitoring activities is initiated by the growing market of electronic devices, like smartphones. For instance, they can provide acoustic alarms as reminders to apply the eye drops. It is evident that any external support or disease-related information by family members, the medical practitioners, support groups or even electronic devices may improve adherence and persistence, even in patients with severe impairments. AD - T.S. Dietlein, Augenklinik, Universitätskliniken Köln, Kerpener Strae 62, Köln, Germany AU - Dietlein, T. S. AU - Rosentreter, A. AU - Lappas, A. DB - Embase Medline DO - 10.1055/s-0041-110447 IS - 2 KW - antiglaucoma agent age aged article environmental factor geriatric patient glaucoma human medication compliance monotherapy motor dysfunction patient compliance self monitoring self report smartphone visual acuity LA - German M3 - Article N1 - L608332397 2016-03-01 2016-03-08 PY - 2016 SN - 1439-3999 0023-2165 SP - 138-142 ST - Complexities of Medical Glaucoma Therapy - The Elderly Patient in Focus T2 - Klinische Monatsblatter fur Augenheilkunde TI - Complexities of Medical Glaucoma Therapy - The Elderly Patient in Focus UR - https://www.embase.com/search/results?subaction=viewrecord&id=L608332397&from=export http://dx.doi.org/10.1055/s-0041-110447 VL - 233 ID - 2755 ER - TY - JOUR AB - There are more treatment options for reducing intraocular pressure in glaucoma than ever before and currently ophthalmologists are combining eye drops to achieve lower therapeutic targets. However, often they forget the systemic side effects - and physicians are unaware of them. Drs Paul Diggory, Alexander Spratt and Lola Ogunbowale review the risks of, and barriers to, effective glaucoma therapy. AD - Consultant in Elderly Care Medicine, Mayday University Hospital AN - 106215657. Language: English. Entry Date: 20070119. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Diggory, P. AU - Spratt, A. AU - Ogunbowale, L. DB - ccm DP - EBSCOhost IS - 10 KW - Glaucoma -- Drug Therapy Ophthalmic Solutions -- Therapeutic Use Adrenergic Beta-Antagonists -- Adverse Effects Adrenergic Beta-Antagonists -- Therapeutic Use Aged Medication Compliance Ophthalmic Solutions -- Adverse Effects Pilocarpine -- Adverse Effects Pilocarpine -- Therapeutic Use Prostaglandins -- Analogs and Derivatives N1 - Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 8510398. PY - 2006 SN - 0268-201X SP - 81-84 ST - Topical glaucoma medication: risks and treatment T2 - Geriatric Medicine TI - Topical glaucoma medication: risks and treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106215657&site=ehost-live&scope=site VL - 36 ID - 4492 ER - TY - JOUR AB - Recent studies have shown that ocular hemodynamics and eye tissue biomechanical properties play an important role in the pathophysiology of glaucoma. Nevertheless, better, non-invasive methods to assess these characteristics in vivo are essential for a thorough understanding of degenerative mechanisms. Here, we propose to measure ocular tissue movements induced by cardiac pulsations and study the ocular pulse waveform as an indicator of tissue compliance. Using a novel, low-cost and non-invasive device based on spectral-domain low coherence interferometry (SD-LCI), we demonstrate the potential of this technique to differentiate ocular hemodynamic and biomechanical properties. We measured the axial movement of the retina driven by the pulsatile ocular blood flow in 11 young healthy individuals, 12 older healthy individuals and 15 older treated glaucoma patients using our custom-made SD-OCT apparatus. The cardiac pulse was simultaneously measured through the use of an oximeter to allow comparison. Spectral components up to the second harmonic were obtained and analyzed. For the different cohorts, we computed a few parameters that characterize the three groups of individuals by analyzing the movement of the retinal tissue at two locations, using this simple, low-cost interferometric device. Our pilot study indicates that spectral analysis of the fundus pulsation has potential for the study of ocular biomechanical and vascular properties, as well as for the study of ocular disease. AU - Dion, Carolyne AU - Singh, Kanwarpal AU - Ozaki, Tsuneyuki AU - Lesk, Mark R. AU - Costantino, Santiago DO - https://dx.doi.org/10.1371/journal.pone.0054207 IS - 1 KW - Adult Aged Eye/bs [Blood Supply] *Eye/pp [Physiopathology] Eye Movements/ph [Physiology] Female Glaucoma/di [Diagnosis] *Glaucoma/pp [Physiopathology] Heart Rate Hemodynamics Humans Male Middle Aged *Ocular Physiological Phenomena Regional Blood Flow/ph [Physiology] *Retina/pp [Physiopathology] Tonometry, Ocular/is [Instrumentation] Tonometry, Ocular/mt [Methods] Young Adult PY - 2013 SE - Dion, Carolyne. Institut National de la Recherche Scientifique-Energie, Materiaux et Telecommunications, Varennes, Quebec, Canada. SN - 1932-6203 SP - e54207 ST - Analysis of pulsatile retinal movements by spectral-domain low-coherence interferometry: influence of age and glaucoma on the pulse wave T2 - PloS one TI - Analysis of pulsatile retinal movements by spectral-domain low-coherence interferometry: influence of age and glaucoma on the pulse wave UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23382879 VL - 8 Y2 - 20130130// ID - 993 ER - TY - JOUR AB - Purpose: Few studies to date have compared MicroPulse laser trabeculoplasty (MLT), a newer laser utilized in lowering intraocular pressure (IOP), to selective laser trabeculoplasty (SLT), a traditional laser procedure used to treat open-angle glaucoma (OAG). The purpose of this study is to compare MLT to SLT and look at their respective effcacy and safety. Methods: A retrospective chart review of OAG patients treated at a single urban academic institution in the past 2 years was performed. Baseline IOP and number of IOP lowering medications were recorded prior to trabeculoplasty and at all subsequent visits at the following intervals: <1 mo, 1-4 mo, and >5 mo. Exclusion criteria included non-standard laser parameters and visual field defects unrelated to OAG. Utilized MLT parameters were 1000 mW power, 300-μm spot size, 300-ms duration, and >80 spots placed over 360° at 15% duty cycle. SLT parameters were .6-1.0 mJ power, 400-μm spot size, 3-ns duration, with >50 spots over >180°. Student t-tests aided in statistical analysis of pre- and postprocedural IOP and topical IOP lowering medications. Results: 14 patients and 15 eyes (MLT 7; SLT 8) with otherwise uncomplicated eye pathology met inclusion criteria. 64% were African American and 29% Hispanic. The mean pretreatment IOP for the MLT cohort was 25.7 mm Hg and 20.1 mm Hg for the SLT cohort. In comparison to baseline pre-procedural IOP, data collected through 1 month postprocedure showed MLT lowered IOP by 10.9%, while after SLT IOP increased by 12.3%. At 4 months post-treatment, both lasers decreased IOP (MLT -7.3%; SLT -8.9%). At the end of our study period, MLT lowered IOP by 39.4%, a twofold difference from SLT's 14.8% reduction. One MLT patient required the addition of 1 glaucoma medication during the study. In the SLT arm, 2 patients required 1 additional medication, and 1 required micropulse transscleral cyclodiode treatment. No complications were noted. Small sample size, medication non-compliance, and follow-up variability potentially affected our initial data. Conclusions: In this predominantly African American and Hispanic population, MLT demonstrated a greater decrease in mean IOP percentage from baseline. Additionally, subsequent interventions were minimized in the MLT cohort. We are continuing to expand our sample size as well as analyze additional end points. Thus far, MLT shows effcacy and safety in lowering IOP as compared to SLT. AD - R.G. Dionisio, School of Medicine, Chicago Medical School, Chicago, IL, United States AU - Dionisio, R. G. AU - German, O. L. AU - Patrianakos, T. AU - Giovingo, M. DB - Embase IS - 9 KW - adult African American clinical article complication conference abstract controlled study eye disease female follow up Hispanic human intraocular hypotension intraocular pressure laser low drug dose male medical record review open angle glaucoma retrospective study sample size topical drug administration trabeculoplasty visual field defect LA - English M3 - Conference Abstract N1 - L628582574 2019-07-23 PY - 2018 SN - 1552-5783 ST - MLT vs SLT in the hispanic and African American population for treatment of open-angle glaucoma T2 - Investigative Ophthalmology and Visual Science TI - MLT vs SLT in the hispanic and African American population for treatment of open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628582574&from=export VL - 59 ID - 2581 ER - TY - JOUR AB - Glucocorticoids are one of the most frequently prescribed therapies in rheumatology, a reflection of their effectiveness as a powerful anti-inflammatory drug. Glucocorticoids are also, however, associated with a wide range of adverse events, particularly at higher doses. To make appropriate decisions, doctors and patients need to weigh these bene fits against the potential harms. This article describes the many uncertainties which make informed prescribing difficult. We lack knowledge, for example, on the magnitude of risk, the relationship to dose and duration, and what happens to risk on stopping therapy. Beyond safety, we describe how patients may lack understanding of the nature of the benefits and harms, and how to incorporate value judgements which are crucial to the decision making process. We conclude by exploring how future research might fill these knowledge gaps to enable a better informed decision process. AD - W.G. Dixon, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, University of Manchester, Manchester M13 9PT, United Kingdom AU - Dixon, W. G. AU - Bansback, N. DB - Embase Medline DO - 10.1136/annrheumdis-2012-202021 IS - 11 KW - biological product generic drug glucocorticoid methotrexate adrenal insufficiency adverse drug reaction cardiovascular disease cataract corticosteroid therapy diabetes mellitus disease severity drug research drug safety glaucoma high risk patient human low drug dose medical decision making patient compliance practice guideline prescription priority journal probability review rheumatoid arthritis risk benefit analysis treatment duration treatment response unspecified side effect body weight gain LA - English M3 - Review N1 - L52142591 2012-08-04 2012-10-26 PY - 2012 SN - 0003-4967 1468-2060 SP - 1761-1764 ST - Understanding the side effects of glucocorticoid therapy: Shining a light on a drug everyone thinks they know T2 - Annals of the Rheumatic Diseases TI - Understanding the side effects of glucocorticoid therapy: Shining a light on a drug everyone thinks they know UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52142591&from=export http://dx.doi.org/10.1136/annrheumdis-2012-202021 http://ard.bmj.com/content/71/11/1761.full.pdf+html VL - 71 ID - 3059 ER - TY - JOUR AB - PURPOSE: To determine whether two sessions of a glaucoma educational intervention resulted in better persistence to glaucoma eye drop therapy compared to normal care., METHODS: A total of 165 patients newly diagnosed with glaucoma who required eye drop therapy were recruited into a randomized clinical trial from the glaucoma clinic at Maisonneuve-Rosemont Hospital in Montreal, Canada. Patients were randomized to either an immediate intervention or normal care. The intervention consisted of two 60-90 minute sessions of education on glaucoma and its management, given in a small group format by a non-practicing ophthalmologist. Persistence to glaucoma medication was examined for 1 year by the use of Hospital medical records and by pharmacy claims records from the Regie de l'assurance maladie du Quebec (Quebec Health Insurance Program). A questionnaire was administered, and medication possession ratio calculated. The primary outcome was persistence, defined as having medication available at least 75% of the time. Secondary outcomes included eye drop instillation technique and perception of the importance of eye drop therapy., RESULTS: The intervention group achieved better persistence to eye drop therapy, as 77% of controls and 89% of people receiving the intervention were persistent (p = 0.049). The intervention also resulted in better eye drop instillation technique (p < 0.001) and greater perception of the importance of eye drop therapy (p < 0.001)., CONCLUSIONS: Brief instructional sessions offered to newly diagnosed glaucoma patients can result in better persistence rates over 1-year follow-up. Strategies to permanently offer these types of initiatives should be considered. AU - Djafari, Fawzia AU - Lesk, Mark R. AU - Giguere, Charles-Edouard AU - Siam, Ghada AU - Freeman, Ellen E. DO - https://dx.doi.org/10.3109/09286586.2015.1083036 IS - 6 KW - Administration, Topical Aged *Antihypertensive Agents/ad [Administration & Dosage] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Health Promotion Humans Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ophthalmic Solutions *Patient Education as Topic Surveys and Questionnaires PY - 2015 SE - Djafari, Fawzia. a Research Centre, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada and. Lesk, Mark R. a Research Centre, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada and. Lesk, Mark R. b Department of Ophthalmology, Universite de Montreal, Montreal, Quebec, Canada. Giguere, Charles-Edouard. a Research Centre, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada and. Siam, Ghada. a Research Centre, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada and. Freeman, Ellen E. a Research Centre, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada and. Freeman, Ellen E. b Department of Ophthalmology, Universite de Montreal, Montreal, Quebec, Canada. SN - 1744-5086 0928-6586 SP - 380-6 ST - Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial T2 - Ophthalmic epidemiology TI - Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26653260 VL - 22 ID - 758 ER - TY - JOUR AB - PURPOSE: Estimate patient adherence to glaucoma medications and identify potential determinants of nonadherence., DESIGN: Descriptive study., METHODS: Two hundred patients with open angle glaucoma, ocular hypertension, or glaucoma suspects were interviewed regarding their glaucoma and its treatment and their charts were reviewed. Their ophthalmologist completed a brief assessment form. Drug utilization data were extracted from the provincial drug program database. Patients were defined as adherent if they filled at least 75% of the prescribed medication necessary for their treatment., RESULTS: Data were available for 181 patients. About 62.9% were female and the mean age (+/-SD) was 75.1+/-8.8 years. The mean number of years of glaucoma treatment was 10.7+/-9.3. Self-reported treatment adherence was 88.3%. On the basis of the drug database, the proportion of patients who were adherent to treatment was 71.8%. According to physicians, 74.6% of patients were adherent. Among patients considered by physicians as nonadherent, 71.1% (32/45) were adherent and among patients predicted as adherent, 72.1% (98/136) were adherent. There was no significant difference in adherence according to age, sex, education, and income. However, patients using fewer agents (P=0.041), who were widowed (P=0.041), or who lived alone (P=0.042) were more adherent. Patients using prostaglandins analogs or beta-blockers were more adherent than those using carbonic anhydrase inhibitors (P<0.05)., CONCLUSIONS: Fewer medications, use of prostaglandin analogs or beta-blockers, living alone, and being widowed were significantly associated with adherence. Physicians were unable to significantly predict which patients are adherent. AU - Djafari, Fawzia AU - Lesk, Mark R. AU - Harasymowycz, Paul J. AU - Desjardins, Daniel AU - Lachaine, Jean DO - https://dx.doi.org/10.1097/IJG.0b013e3181815421 IS - 3 KW - Aged *Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/cl [Classification] Drug Utilization/sn [Statistics & Numerical Data] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Male Ocular Hypertension/dt [Drug Therapy] *Patient Compliance/sn [Statistics & Numerical Data] Surveys and Questionnaires PY - 2009 SE - Djafari, Fawzia. Department of Ophthalmology, University of Montreal, Quebec, Canada. SN - 1536-481X 1057-0829 SP - 238-43 ST - Determinants of adherence to glaucoma medical therapy in a long-term patient population T2 - Journal of glaucoma TI - Determinants of adherence to glaucoma medical therapy in a long-term patient population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19295380 VL - 18 ID - 1465 ER - TY - JOUR AB - Purpose: This study aims to compare the impact of traditional counseling versus patient-centered counseling including recorded audio reinforcement on clinical follow-up rates and patient retention of basic glaucoma knowledge. Methods: This prospective randomized controlled trial compared three types of glaucoma counseling: (1) traditional counseling which consisted of one-way information sharing, (2) patient-centered counseling which focused on filling in gaps in patient knowledge and empowering patients to understand their disease, and (3) patient-centered counseling with recorded audio information reinforcement. 399 consecutive patients newly diagnosed with glaucomatous disease at the Aravind Eye Hospital glaucoma clinic in South India were enrolled and randomized to receive the either the standard glaucoma counseling or one of the two new methods of patientcentered counseling. All subjects completed an 8-point glaucoma knowledge questionnaire before and after counseling sessions at diagnosis and 1-month follow-up. Patients were advised to return to clinic for routine follow-up and repeat counseling at 1, 3, 6, 9, and 12 months after enrollment. Multivariate logistic regression model was used to determine factors associated with appropriate followup, defined as at least 3 follow-up visits. Main outcome measures included Glaucoma Knowledge Assessment Score (GKAS) and the proportion of subjects with adequate follow-up. Results: Overall, only 13.5% of the 399 subjects completed the three-visit requirement for appropriate follow-up. There was no significant difference in follow-up rate among the three groups (12.8% with traditional counseling, 11.3% with patient-centered counseling, and 16.5% with patient-centered counseling and audio reinforcement). The mean GKAS improved an average of 77.6% with counseling and did not differ amongst the three groups (p<0.0001). While the GKAS gradually decreased with time and increased with repeat counseling, no difference in this parameter was found between groups at any time point. Conclusions: While initial and repeat patient-centered counseling significantly improved patient knowledge regarding glaucomatous disease and the importance of appropriate follow-up, the majority of newly diagnosed glaucoma patients did not return for care, suggesting that factors other than disease information likely impact adherence to appropriate follow-up schedules. AD - A. Do, Ophthalmology, Stanford University, Stanford, CA, United States AU - Do, A. AU - Singh, K. AU - Pilai, M. AU - Balakrishnan, V. AU - Chang, R. AU - Lee, B. DB - Embase IS - 7 KW - controlled clinical trial controlled study counseling diagnosis doctor patient relationship female follow up glaucoma human India logistic regression analysis major clinical study male model questionnaire randomized controlled trial reinforcement (psychology) LA - English M3 - Conference Abstract N1 - L615919014 2017-05-15 PY - 2015 SN - 0146-0404 SP - 3704 ST - Effectiveness of glaucoma counseling on patient follow-up rates and glaucoma knowledge in a South Indian population T2 - Investigative Ophthalmology and Visual Science TI - Effectiveness of glaucoma counseling on patient follow-up rates and glaucoma knowledge in a South Indian population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615919014&from=export VL - 56 ID - 2810 ER - TY - JOUR AB - PURPOSE: To evaluate the impact of traditional counseling and patient-centered counseling, either alone or with recorded audio counseling reinforcement, on glaucoma knowledge and clinical follow-up., DESIGN: Prospective randomized controlled trial., METHODS: Newly diagnosed adult glaucoma patients were randomized to 1 of 3 categories of glaucoma counseling: traditional counseling, patient-centered counseling, or patient-centered counseling with audio counseling reinforcement. Demographic and clinical information from each subject was ascertained, and all subjects completed the Glaucoma Knowledge Assessment before and after counseling sessions at the time of diagnosis and at 1-month follow-up. Patients were instructed to return to clinic for routine follow-up at 1, 3, 6, 9, and 12 months after enrollment. A multivariate logistic regression model was used to determine factors associated with appropriate clinical follow-up., RESULTS: Overall, only 13.5% of subjects had appropriate clinical follow-up at 1 year, defined as attending at least 3 follow-up visits during that interval, and there was no significant difference between counseling groups. The mean glaucoma knowledge assessment score (GKAS) improved by 77.6% with the initial counseling intervention (P < .0001), decreased by 17.4% within a 1-month period following initial counseling, and improved by 22.8% (P < .001) after the second counseling intervention. Monthly household income over 2500 rupees, GKAS greater than 5 after initial counseling, and undergoing any ocular surgical procedure were all independent predictors of appropriate follow-up., CONCLUSION: While all 3 counseling methods resulted in transient improvement of patient knowledge regarding glaucomatous disease, follow-up rates were poor for all groups. Poor retention of glaucoma knowledge may impact the likelihood of patient follow-up, and reinforcement with repeated counseling may be beneficial with regard to both disease knowledge and follow-up. Copyright © 2016 Elsevier Inc. All rights reserved. AU - Do, Anna T. AU - Pillai, Manju R. AU - Balakrishnan, Vijayakumar AU - Chang, Robert T. AU - Robin, Alan L. AU - Singh, Kuldev AU - Lee, Bradford W. DO - https://dx.doi.org/10.1016/j.ajo.2015.12.009 KW - Adult Aged Aged, 80 and over *Counseling/mt [Methods] Female Follow-Up Studies *Glaucoma, Angle-Closure/th [Therapy] *Glaucoma, Open-Angle/th [Therapy] *Health Knowledge, Attitudes, Practice Humans India Intraocular Pressure Male Middle Aged *Patient Compliance/sn [Statistics & Numerical Data] Patient-Centered Care/mt [Methods] Prospective Studies Risk Factors Treatment Outcome Visual Acuity/ph [Physiology] PY - 2016 SE - Do, Anna T. Department of Ophthalmology, Stanford University, Palo Alto, California. Pillai, Manju R. Aravind Eye Care System, Madurai, India. Electronic address: manjurpillai@hotmail.com. Balakrishnan, Vijayakumar. Aravind Eye Care System, Madurai, India. Chang, Robert T. Department of Ophthalmology, Stanford University, Palo Alto, California. Robin, Alan L. Wilmer Eye Institute, Baltimore, Maryland. Singh, Kuldev. Department of Ophthalmology, Stanford University, Palo Alto, California. Lee, Bradford W. Department of Ophthalmology, Stanford University, Palo Alto, California; Bascom Palmer Eye Institute, Miami, Florida. SN - 1879-1891 0002-9394 SP - 180-189.e4 ST - Effectiveness of Glaucoma Counseling on Rates of Follow-up and Glaucoma Knowledge in a South Indian Population T2 - American journal of ophthalmology TI - Effectiveness of Glaucoma Counseling on Rates of Follow-up and Glaucoma Knowledge in a South Indian Population UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26705095 VL - 163 Y2 - 20151215// ID - 731 ER - TY - JOUR AD - A.N. Dobromyslov AU - Dobromyslov, A. N. AU - Alekseev, V. N. AU - Kugleev, M. A. DB - Medline IS - 1 KW - ambulatory care article human open angle glaucoma Russian Federation LA - Russian M3 - Article N1 - L16703493 1986-04-24 PY - 1986 SN - 0042-465X SP - 4-6 ST - Improved outpatient care for patients in the initial stages of glaucoma T2 - Vestnik oftalmologii TI - Improved outpatient care for patients in the initial stages of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L16703493&from=export VL - 102 ID - 4072 ER - TY - JOUR AD - A.N. Dobromyslov AU - Dobromyslov, A. N. AU - Panina, N. B. DB - Medline IS - 8 KW - aged ambulatory care article female glaucoma human male middle aged postoperative care LA - Russian M3 - Article N1 - L18723863 1988-05-05 PY - 1987 SN - 0030-0675 SP - 505-506 ST - Ambulatory care of patients with (surgically treated) glaucoma T2 - Oftalmologicheskii zhurnal TI - Ambulatory care of patients with (surgically treated) glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L18723863&from=export ID - 4059 ER - TY - JOUR AD - A.N. Dobromyslov AU - Dobromyslov, A. N. AU - Skripnichenko, L. I. DB - Medline IS - 2 KW - adult aged ambulatory care article glaucoma human middle aged Moldova LA - Russian M3 - Article N1 - L89174472 1969-09-29 PY - 1968 SN - 0030-0675 SP - 147-149 ST - Organization of the detection and ambulatory care of patients in the Moldavian Republic Glaucoma Office T2 - Oftalmologicheskii zhurnal TI - Organization of the detection and ambulatory care of patients in the Moldavian Republic Glaucoma Office UR - https://www.embase.com/search/results?subaction=viewrecord&id=L89174472&from=export VL - 23 ID - 4134 ER - TY - JOUR AB - Purpose: To describe whether subconjunctival bevacizumab decreases corneal neovascularization in patients with ocular surface inflammatory diseases. Methods: The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. Morphologic changes were assessed clinically by the same investigator at each visit. Results: Subconjunctival bevacizumab was well-tolerated without obvious corneal side effects. All 8 eyes of the 7 patients showed a reduction in the neovascularized area. Conclusions: Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients. © 2008 by Lippincott Williams & Wilkins. AD - P. P. Doctor, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institute, Harvard Medical School, Cambridge, MA AU - Doctor, P. P. AU - Bhat, P. V. AU - Foster, C. S. C1 - avastin(Genentech,United States) C2 - Genentech(United States) DB - Embase Medline DO - 10.1097/ICO.0b013e31817786ad IS - 9 KW - aciclovir amoxicillin plus clavulanic acid antibiotic agent azathioprine bevacizumab corticosteroid cyclosporine dapsone lubricating agent methotrexate prednisolone prednisone retinoic acid rituximab steroid triamcinolone adolescent adult aged article astigmatism case study clinical article conjunctival biopsy cornea disease cornea neovascularization cornea transplantation corticosteroid therapy drug dose reduction drug efficacy drug tolerability drug withdrawal female hemolytic anemia herpes simplex keratitis human human tissue local therapy male microscopic polyangiitis mucous membrane pemphigoid patient compliance penetrating keratoplasty priority journal pseudopterygium pterygium age related macular degeneration retrospective study steroid therapy Stevens Johnson syndrome symblepharon systemic therapy treatment outcome trichiasis unspecified side effect uveitis vision avastin LA - English M3 - Article N1 - L354618454 2009-06-11 PY - 2008 SN - 0277-3740 SP - 992-995 ST - Subconjunctival bevacizumab for corneal neovascularization T2 - Cornea TI - Subconjunctival bevacizumab for corneal neovascularization UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354618454&from=export http://dx.doi.org/10.1097/ICO.0b013e31817786ad VL - 27 ID - 3427 ER - TY - JOUR AB - Preventive medications reduce migraine frequency and severity, and improve migraine-specific quality of life. Recent evidence also suggests that these same medications enhance the patient's response to acute migraine therapies, and may also reduce the likelihood of developing chronic daily headache. However, many patients who should receive or be offered preventive treatment are not. Most patients can be successfully managed when patient and physician expectations are realistic and aligned, the selection of preventive medications is individualised, and the initiation and titration strategy is appropriate and carefully followed. Rational combinations of preventive medications may also be useful. This review provides an evidence and experience-based approach to the preventive treatment of migraine. AD - D.W. Dodick, Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, United States AU - Dodick, D. W. AU - Silberstein, S. D. DB - Embase Medline DO - 10.1136/jnnp.2007.134023 IS - 6 KW - alpha adrenergic receptor stimulating agent amitriptyline analgesic agent anticoagulant agent anticonvulsive agent antidepressant agent antihistaminic agent antimigraine agent atenolol beta adrenergic receptor blocking agent calcium channel blocking agent dipeptidyl carboxypeptidase inhibitor ibuprofen liver enzyme methysergide metoprolol nadolol naproxen nonsteroid antiinflammatory agent Petasites hybridus extract propranolol serotonin antagonist timolol topiramate tricyclic antidepressant agent ubiquinone unindexed drug valproate semisodium valproic acid warfarin abdominal pain acupuncture acute disease agitation agranulocytosis allergic reaction alopecia analgesic activity appetite disorder asthenia behavior therapy bloating blurred vision bronchospasm chronic disease clinical effectiveness clinical trial closed angle glaucoma comorbidity constipation depression diarrhea disease severity dizziness dose response drug choice drug contraindication drug dose reduction drug dose titration drug indication drug megadose drug potentiation drug safety drug tolerability drug tolerance lack of drug effect dysgeusia dyspepsia encephalomyopathy evidence based medicine fatigue flatulence headache heart arrhythmia heartburn hormonal therapy human hyperammonemia hyperthermia insomnia irritability low drug dose manipulative medicine memory disorder menstruation metabolic acidosis migraine migraine with aura migraine without aura morbidity myopia nausea nausea and vomiting nephrolithiasis nonhuman optimal drug dose orthostatic hypotension pancreatitis pancytopenia paresthesia patient compliance pruritus rash relaxation training repeated drug dose rest review side effect somnolence Stevens Johnson syndrome stress management faintness teratogenicity tremor unspecified side effect vivid dream body weight gain body weight loss xerostomia LA - English M3 - Review N1 - L350237714 2008-01-30 PY - 2007 SN - 1474-7758 SP - 383-393 ST - Migraine prevention T2 - Practical Neurology TI - Migraine prevention UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350237714&from=export http://dx.doi.org/10.1136/jnnp.2007.134023 VL - 7 ID - 3489 ER - TY - JOUR AB - Although attention deficit hyperactivity disorder (ADHD) has been officially recognized as persisting into adulthood for more than 25 years, only recently has the condition been studied in adults. There is great syndromatic continuity between childhood and adult ADHD, and thus much of the medication management of adults with ADHD can be based on the experience gained from treating children and adolescents. Stimulant medications remain the treatment of choice and are generally as effective in adults as they are in children. Several extended-release delivery systems that improve convenience and compliance have become available. Several second-line medications are also reviewed. The medications must be fine-tuned to the needs of the individual patient in regard to the dose and timing of dose that achieve optimal therapeutic benefit. Medication adjustment must be done by trial and error because no parameter yet identified predicts the molecule or dose that will provide optimal performance. © 2005 Wiley Periodicals, Inc. AD - W.W. Dodson, 1777 South Harrison St., Denver, CO 80210, United States AU - Dodson, W. W. C1 - adderall xr benzedrine concerta cylert depakote dexedrine spansules focalin metadate cd(Celltech) metadate er methylin er paxil ritalin la ritalin sr ritalin strattera wellbutrin sr zoloft C2 - Celltech DB - Embase Medline DO - 10.1002/jclp.20122 IS - 5 KW - amfebutamone amphetamine antidepressant agent atomoxetine cocaine desipramine dexamphetamine dexmethylphenidate ephedrine imipramine methylphenidate noradrenalin uptake inhibitor paroxetine pemoline magnesium pseudoephedrine psychostimulant agent sedative agent serotonin uptake inhibitor sertraline tricyclic antidepressant agent valproate semisodium addiction adolescent adult anorexia anxiety disorder attention deficit disorder behavior therapy child child behavior clinical practice clinical trial cocaine dependence community care comorbidity constipation controlled clinical trial controlled study depression drug approval drug contraindication drug cost drug delivery system drug efficacy drug formulation drug overdose drug safety dysphoria Food and Drug Administration glaucoma group therapy headache heart arrhythmia heart palpitation human hyperactivity hypertension impulsiveness irritability isomer lactation liver failure meta analysis mood narcolepsy nervousness orthostatic hypertension patient compliance patient monitoring practice guideline pregnancy psychopharmacotherapy review side effect somnolence substance abuse sustained release formulation systematic review treatment outcome tremor urine retention adderall xr benzedrine concerta cylert depakote dexedrine spansules focalin metadate cd metadate er methylin er paxil ritalin la ritalin sr ritalin strattera wellbutrin sr zoloft LA - English M3 - Review N1 - L40776546 2005-06-16 PY - 2005 SN - 0021-9762 SP - 589-606 ST - Pharmacotherapy of adult ADHD T2 - Journal of Clinical Psychology TI - Pharmacotherapy of adult ADHD UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40776546&from=export http://dx.doi.org/10.1002/jclp.20122 VL - 61 ID - 3691 ER - TY - JOUR AB - Adherence to medicines is a major determinant of their effectiveness. However, estimates of non-adherence in the older-aged (defined as those aged ≥65 years) with chronic conditions vary from 40 to 75. The problems caused by non-adherence in the older-aged include residential care and hospital admissions, progression of the disease and increased costs to society. The reasons for non-adherence in the older-aged include items related to the medicine (e.g. cost, number of medicines, adverse effects) and those related to the person (e.g. cognition, vision, depression). It is also known that there are many ways adherence can be increased (e.g. use of blister packs, cues).Although it is assumed that interventions by allied health professionals (i.e. other than the prescriberdoctor), including a discussion of adherence, will improve adherence to medicines in the older-aged, the evidence for this has not been reviewed. There is some evidence that telephone counselling concerning adherence by a nurse or pharmacist improves short-and long-term adherence. However, face-to-face intervention counselling at the pharmacy or during a home visit by a pharmacist has shown variable results, with some studies showing improved adherence and some not. Broad-based education programmes during hospital stays have not been shown to improve medication adherence following discharge, whereas education programmes specifically for subjects with hypertension have been shown to improve adherence. In combination with an education programme, both counselling and a medicine review programme have been shown to improve short-term adherence in the older-aged.Thus, there are many unanswered questions about the most effective interventions for promoting adherence. More studies are needed to determine the most appropriate interventions by allied health professionals, and such studies need to consider the disease state, demographics and socioeconomic status of the older-aged subject, and the intensity and duration of intervention required. © 2010 Adis Data Information BV. All rights reserved. AD - S. A. Doggrell, School of Life Sciences, Queensland University of Technology, GPO Box 2334, Brisbane, QLD 4001, Australia AU - Doggrell, S. A. C1 - aspirin DB - Embase Medline DO - 10.2165/11532870-000000000-00000 IS - 3 KW - acetylsalicylic acid alpha adrenergic receptor blocking agent amiodarone atenolol beta adrenergic receptor blocking agent bile acid sequestrant bisphosphonic acid derivative calcitonin calcium channel blocking agent colestipol colestyramine dipeptidyl carboxypeptidase inhibitor diuretic agent estradiol hydroxymethylglutaryl coenzyme A reductase inhibitor latanoprost loop diuretic agent mevinolin nicotinic acid tolterodine age distribution aged aging chronic disease clinical trial cost effectiveness analysis disease course drug cost education program glaucoma health care cost health education heart arrhythmia heart infarction hospital admission human hypercholesterolemia hypertension nursing home osteoporosis overactive bladder paramedical profession patient compliance patient counseling priority journal residential care review teleconsultation aspirin LA - English M3 - Review N1 - L358444275 2010-03-23 2010-05-19 PY - 2010 SN - 1170-229X 1179-1969 SP - 239-254 ST - Adherence to medicines in the older-aged with chronic conditions: Does intervention by an allied health professional help? T2 - Drugs and Aging TI - Adherence to medicines in the older-aged with chronic conditions: Does intervention by an allied health professional help? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358444275&from=export http://dx.doi.org/10.2165/11532870-000000000-00000 VL - 27 ID - 3256 ER - TY - JOUR AB - PURPOSE: Glaucoma is a frequent and often severe problem in patients needing keratoprosthesis (KPro) surgery. Standard glaucoma shunts in these cases often develop a very dense capsule that obstructs flow and causes intraocular pressure elevation. Therefore, we developed shunts that deliver aqueous to distant epithelialized cavities where an obstructing capsule is less likely to form. In this retroactive study of such shunts, the risk of postoperative infection (especially endophthalmitis) has been assessed. METHODS: Ahmed shunts were connected with a tube to the lacrimal sac or ethmoid sinuses. In subsequent designs the polypropylene plate was eliminated, the valve was enclosed and a distal tube added (New World Medical Inc, Rancho Cucamonga, CA). The latter shunts were connected to the maxillary sinus or lower lid fornix. Between 2001 and 2005 the devices were implanted in 34 patients with very severe ocular disease. (31 had KPro implanted). Thus, the distal tube was led to the lacrimal sac (2 cases), to the ethmoid sinuses (6), to the maxillary sinus (16 cases), and to the lower lid fornix (10 cases). The patients were followed for cumulatively 145 shunt years, with a mean follow-up of 4 years and 3 months. They were instructed to administer low-dose topical antibiotics indefinitely. RESULTS: Only 1 case of acute bacterial endophthalmitis occurred, thus an incidence of 0.7% per shunt year. A slow-growing Mycobacterium was cultured in a disintegrating eye and 1 bacterial maxillary sinusitis occurred, both in autoimmune diseases. Three valves became exposed and had to be removed (1 replaced). Four eyes developed hypotony, probably from valve failure. CONCLUSIONS: The shunt arrangement, which connects the anterior chamber to potentially microbe-populated cavities or to the lower lid fornix and its flora, might be suspected to allow rapid retrograde invasion of infective agents, resulting in endophthalmitis. In this series of KPro patients, however, the incidence of severe infection was very low, in fact comparable to that after standard trabeculectomy. © 2010 Lippincott Williams & Wilkins, Inc. AD - C. H. Dohlman, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States AU - Dohlman, C. H. AU - Grosskreutz, C. L. AU - Chen, T. C. AU - Pasquale, L. R. AU - Rubin, P. A. D. AU - Kim, E. C. AU - Durand, M. DB - Embase Medline DO - 10.1097/IJG.0b013e3181a2fbeb IS - 2 KW - antibiotic agent prednisolone acetate quinoline derived antiinfective agent vancomycin anterior eye chamber aphakia aqueous humor article bacterium culture case report cellulitis clinical article endophthalmitis ethmoid sinus follow up glaucoma glaucoma drainage implant human keratoprosthesis lacrimal sac maxilla sinusitis maxillary sinus Mycobacterium neodymium laser nonhuman patient compliance priority journal LA - English M3 - Article N1 - L358333663 2010-03-02 2010-03-29 PY - 2010 SN - 1057-0829 SP - 111-115 ST - Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery T2 - Journal of Glaucoma TI - Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358333663&from=export http://dx.doi.org/10.1097/IJG.0b013e3181a2fbeb VL - 19 ID - 3277 ER - TY - JOUR AB - After 5 years of use in more than 100,000 European women, RU 486, an antiprogestin medication used as a medical abortifacient, has recently come under scrutiny in the United States. This article discusses the current and potential uses of RU 486. Also addressed are the history, advantages, and disadvantages of medical abortion (including the acceptability of the method from a woman-centered perspective); new clinical trials; and ethical issues. AU - Donaldson, K. AU - Briggs, J. AU - McMaster, D. IS - 7 KW - *Abortion, Induced/mt [Methods] Breast Neoplasms/dt [Drug Therapy] Endometrium/de [Drug Effects] Ethics, Professional Female Humans Mifepristone/pd [Pharmacology] Mifepristone/tu [Therapeutic Use] *Mifepristone Patient Education as Topic Pregnancy N1 - Comment in (CIN), Comment in (CIN) PY - 1994 SE - Donaldson, K. Department of Maternal Fetal Medicine and Reproductive Endocrinology, Mercer Medical Center, Trenton, NJ. SN - 0884-2175 0090-0311 SP - 555-9 ST - RU 486: an alternative to surgical abortion T2 - Journal of obstetric, gynecologic, and neonatal nursing : JOGNN T3 - Comment in: J Obstet Gynecol Neonatal Nurs. 1995 Jun;24(5):389-90; PMID: 7658247 [https://www.ncbi.nlm.nih.gov/pubmed/7658247]Comment in: J Obstet Gynecol Neonatal Nurs. 1995 Feb;24(2):117; PMID: 7745483 [https://www.ncbi.nlm.nih.gov/pubmed/7745483] TI - RU 486: an alternative to surgical abortion UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7996306 VL - 23 ID - 2082 ER - TY - JOUR AB - PURPOSE: To review the case of a 41-year-old woman who underwent bariatric surgery in 2000. She subsequently underwent laser in situ keratomileusis (LASIK) surgery in 2008 and complained of dry eye since the LASIK surgery. In November 2010, she was diagnosed with a corneal melt and was treated with aggressive lubrication, followed by eventual amniotic membrane placement and a tarsorrhaphy. She then presented for consultation at the Bascom Palmer Eye Institute when she developed a corneal infiltrate. She was diagnosed with fungal keratitis with corneal xerosis. At that time, vitamin A levels were measured and were less than 2 mu/dL. The patient admitted noncompliance with nutritional supplements., METHODS: Case report., RESULTS: The patient was treated with aggressive lubrication and natamycin. Vitamin supplements were restarted, and the patient experienced dramatic improvement in symptoms with resolution of the infection. A central corneal scar with corneal thinning remains. The patient underwent a penetrating keratoplasty for visual rehabilitation., CONCLUSIONS: Patient education with emphasis on compliance with nutritional supplements is essential after bariatric surgery. Consider vitamin A deficiency in the differential diagnosis of dry eye after LASIK surgery. AU - Donaldson, Kendall E. AU - Fishler, Jane DO - https://dx.doi.org/10.1097/ICO.0b013e318243e4ac IS - 12 KW - Adult Antifungal Agents/tu [Therapeutic Use] *Ascomycota/ip [Isolation & Purification] *Bariatric Surgery/ae [Adverse Effects] Corneal Ulcer/di [Diagnosis] *Corneal Ulcer/mi [Microbiology] Corneal Ulcer/th [Therapy] Eye Infections, Fungal/di [Diagnosis] *Eye Infections, Fungal/mi [Microbiology] Eye Infections, Fungal/th [Therapy] Female Humans Keratoconjunctivitis Sicca/et [Etiology] Keratoconjunctivitis Sicca/su [Surgery] *Keratomileusis, Laser In Situ Keratoplasty, Penetrating Mycoses/di [Diagnosis] *Mycoses/mi [Microbiology] Mycoses/th [Therapy] Visual Acuity Vitamin A/bl [Blood] Vitamin A/tu [Therapeutic Use] *Vitamin A Deficiency/et [Etiology] PY - 2012 SE - Donaldson, Kendall E. Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA. kdonaldson@med.miami.edu SN - 1536-4798 0277-3740 SP - 1497-9 ST - Corneal ulceration in a LASIK patient due to vitamin a deficiency after bariatric surgery T2 - Cornea TI - Corneal ulceration in a LASIK patient due to vitamin a deficiency after bariatric surgery UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22525781 VL - 31 ID - 1140 ER - TY - JOUR AB - PURPOSE: Neovascular glaucoma (NVG) is a severe secondary glaucoma with uncontrolled intraocular pressure that leads to serious eye pain and vision loss. Presently, the therapeutic strategies for NVG are diverse, but the therapeutic effects are still not ideal. We performed a network analysis to assess the effect of multiple therapeutic strategies on the treatment of NVG patients., METHODS: We searched public electronic databases through April 2017 using the following keywords "neovascular glaucoma," "iris neovascularization," "hemorrhagic glaucoma," and "random" without language restrictions. The outcome considered in the present analysis was treatment success rate. A network meta-analysis and multilevel mixed-effects logistic regression were used to compare regimens., RESULTS: We included 27 articles assessing a total of 1884 NVG patients in our analysis. According to the network analysis, interferon and mitomycin plus trabeculectomy (94.9%), glaucoma valve implantation (86.9%), and iris photocoagulation plus trabeculectomy (81.9%) were the most likely to improve treatment success rate in NVG patients. The multilevel logistic regression analysis showed that glaucoma valve, bevacizumab, interferon, cyclophotocoagulation, trabeculectomy, iris photocoagulation, ranibizumab, and mitomycin had advantages in terms of improving treatment success rate in NVG patients. However, the application of retinal photocoagulation and vitrectomy reduced patient treatment success rate., CONCLUSION: The regimen including mitomycin, interferon, and trabeculectomy was the most likely to improve the treatment success rate in NVG patients. The application of glaucoma valve and bevacizumab were more beneficial for improving patient treatment success rate as a surgery and as an agent, respectively. AU - Dong, Zixian AU - Gong, Jianyang AU - Liao, Rongfeng AU - Xu, Shaojun DO - https://dx.doi.org/10.1097/MD.0000000000009897 IS - 14 KW - *Angiogenesis Inhibitors/tu [Therapeutic Use] *Anti-Infective Agents/tu [Therapeutic Use] Bevacizumab/tu [Therapeutic Use] Combined Modality Therapy/mt [Methods] *Glaucoma, Neovascular/th [Therapy] Humans Interferons/tu [Therapeutic Use] Iris/su [Surgery] Light Coagulation/mt [Methods] Mitomycin/tu [Therapeutic Use] Network Meta-Analysis *Ophthalmologic Surgical Procedures/mt [Methods] Ranibizumab/tu [Therapeutic Use] Retina/su [Surgery] *Trabeculectomy/mt [Methods] Treatment Outcome Vitrectomy/mt [Methods] PY - 2018 SE - Dong, Zixian. Department of Ophthalmology, the First Affiliated Hospital of Anhui Medical University School of Public Health, Anhui Medical University, Hefei, China. SN - 1536-5964 0025-7974 SP - e9897 ST - Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis T2 - Medicine TI - Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29620670 VL - 97 ID - 390 ER - TY - JOUR AB - Since the introduction of commercial optical coherence tomography (OCT) systems, the ophthalmic imaging modality has rapidly expanded and it has since changed the paradigm of visualization of the retina and revolutionized the management and diagnosis of neuro-retinal diseases, including glaucoma. OCT remains a dynamic and evolving imaging modality, growing from time-domain OCT to the improved spectral-domain OCT, adapting novel image analysis and processing methods, and onto the newer swept-source OCT and the implementation of adaptive optics (AO) into OCT. The incorporation of AO into ophthalmic imaging modalities has enhanced OCT by improving image resolution and quality, particularly in the posterior segment of the eye. Although OCT previously captured in-vivo cross-sectional images with unparalleled high resolution in the axial direction, monochromatic aberrations of the eye limit transverse or lateral resolution to about 15-20 mum and reduce overall image quality. In pairing AO technology with OCT, it is now possible to obtain diffraction-limited resolution images of the optic nerve head and retina in three-dimensions, increasing resolution down to a theoretical 3 mum3. It is now possible to visualize discrete structures within the posterior eye, such as photoreceptors, retinal nerve fiber layer bundles, the lamina cribrosa, and other structures relevant to glaucoma. Despite its limitations and barriers to widespread commercialization, the expanding role of AO in OCT is propelling this technology into clinical trials and onto becoming an invaluable modality in the clinician's arsenal. Copyright © 2016 Elsevier Ltd. All rights reserved. AU - Dong, Zachary M. AU - Wollstein, Gadi AU - Wang, Bo AU - Schuman, Joel S. DO - https://dx.doi.org/10.1016/j.preteyeres.2016.11.001 KW - Equipment Design *Glaucoma/di [Diagnosis] Humans *Lenses *Tomography, Optical Coherence/is [Instrumentation] PY - 2017 SE - Dong, Zachary M. University of Pittsburgh Medical Center (UPMC) Eye Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Ophthalmology and Visual Science Research Center, Pittsburgh, PA, United States. Electronic address: dongzm@upmc.edu. Wollstein, Gadi. New York University (NYU) Langone Eye Center, NYU Langone Medical Center, Department of Ophthalmology, NYU School of Medicine, New York, NY, United States. Electronic address: gadi.wollstein@nyumc.org. Wang, Bo. University of Pittsburgh Medical Center (UPMC) Eye Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Ophthalmology and Visual Science Research Center, Pittsburgh, PA, United States. Electronic address: wangb4@upmc.edu. Schuman, Joel S. New York University (NYU) Langone Eye Center, NYU Langone Medical Center, Department of Ophthalmology, NYU School of Medicine, New York, NY, United States; Department of Electrical and Computer Engineering, New York University Tandon School of Engineering, Brooklyn, NY, United States. Electronic address: joel.schuman@nyu.edu. SN - 1873-1635 1350-9462 SP - 76-88 ST - Adaptive optics optical coherence tomography in glaucoma T2 - Progress in retinal and eye research TI - Adaptive optics optical coherence tomography in glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=27916682 VL - 57 Y2 - 20161201// ID - 552 ER - TY - JOUR AB - This paper presents a new system to measure the Intraocular Pressure (IOP) with very high accuracy (0.036 mbar) used for monitoring glaucoma. The system not only monitors the daily variation of the IOP (circadian IOP), but also allows to perform an spectral analysis of the pressure signal generated by the heartbeat (cardiac IOP). The system comprises a piezoresistive pressure sensor, an application-specific integrated circuit (ASIC) to read out the sensor data and an external reader installed on customized glasses. The ASIC readout electronics combines chopping modulation with correlated double sampling (CDS) in order to eliminate both the amplifier offset and the chopper ripple at the sampling frequency. In addition, programmable current sources are used to compensate for the atmospheric pressure ( 800-1200 mbar ) and the circadian component (± 7 mbar) thus allowing to read out the very weak cardiac signals (± 1.6 mbar) with a maximum accuracy of 0.036 mbar. AU - Donida, A. AU - Di Dato, G. AU - Cunzolo, P. AU - Sala, M. AU - Piffaretti, F. AU - Orsatti, P. AU - Barrettino, D. DB - Medline DO - 10.1109/TBCAS.2015.2501320 IS - 6 KW - ambulatory monitoring circadian rhythm devices genetic procedures glaucoma human intraocular pressure lens implant mobile application oculoplethysmography physiology procedures remote sensing LA - English M3 - Article N1 - L615994459 2017-05-16 PY - 2015 SN - 1940-9990 SP - 777-789 ST - A Circadian and Cardiac Intraocular Pressure Sensor for Smart Implantable Lens T2 - IEEE transactions on biomedical circuits and systems TI - A Circadian and Cardiac Intraocular Pressure Sensor for Smart Implantable Lens UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615994459&from=export http://dx.doi.org/10.1109/TBCAS.2015.2501320 VL - 9 ID - 2780 ER - TY - JOUR AD - E.J. Donner, Division of Neurology, The Hospital for Sick Children, 555 University Ave., Toronto, Ont. M5G 1X8, Canada AU - Donner, E. J. AU - Snead Iii, O. C. C1 - cerebyx felbatol gabitril keppra lamictal lyrica neurontin sabril topamax trileptal zonegran DB - Embase Medline DO - 10.1016/j.cppeds.2005.09.004 IS - 10 KW - 4 aminobutyric acid alpha amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid anticonvulsive agent benzodiazepine derivative calcium ion carbamazepine clonazepam contraceptive agent cytochrome P450 cytochrome P450 3A ethosuximide etiracetam felbamate fosphenytoin sodium gabapentin glutamate decarboxylase lamotrigine n methyl dextro aspartic acid nitrazepam oxcarbazepine phenobarbital phenytoin pregabalin primidone tiagabine topiramate unindexed drug valproic acid vigabatrin zonisamide agitation anticonvulsant activity anticonvulsant therapy anxiety aplastic anemia asthenia ataxia behavior disorder body weight disorder cardiovascular disease caregiver childhood disease chronic disease clinical feature clinical trial closed angle glaucoma cognition differential diagnosis diplopia disease classification disease control dizziness drug cost drug efficacy drug mechanism electroencephalography employment epidermolysis epilepsy focal epilepsy tonic clonic seizure health care access health care cost health care need human hyperchloremia hyperthermia infection injection pain kidney dysfunction laboratory test learning liver dysfunction liver failure metabolic acidosis morbidity mortality myopia nausea nephrolithiasis neurotransmission ovary polycystic disease pathophysiology physical examination quality of life rash retina disease review sedation somnolence Stevens Johnson syndrome cerebyx felbatol gabitril keppra lamictal lyrica neurontin sabril topamax trileptal zonegran LA - English M3 - Review N1 - L43008956 2006-01-09 PY - 2005 SN - 1538-5442 SP - 398-419 ST - New drugs in the treatment of epilepsy in children T2 - Current Problems in Pediatric and Adolescent Health Care TI - New drugs in the treatment of epilepsy in children UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43008956&from=export http://dx.doi.org/10.1016/j.cppeds.2005.09.004 VL - 35 ID - 3655 ER - TY - JOUR AU - Dorgan, Julie AU - McGoldrick, Alan IS - 2 KW - *Acanthamoeba Keratitis/dt [Drug Therapy] Acanthamoeba Keratitis/nu [Nursing] Acanthamoeba Keratitis/ps [Parasitology] *Amoeba/de [Drug Effects] Amoeba/ip [Isolation & Purification] Animals *Antiprotozoal Agents/ad [Administration & Dosage] Cornea/ps [Parasitology] Cornea/pa [Pathology] Female Follow-Up Studies Humans Medication Adherence Ophthalmic Solutions/ad [Administration & Dosage] Tomography, Optical Coherence Young Adult PY - 2013 SE - Dorgan, Julie. Massachusetts Eye and Ear Infirmary, Quincy, MA, USA. Julie.dorgan@meei.harvard.edu SN - 1060-135X SP - 10-1 ST - Killing the amoebae T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Killing the amoebae UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23724556 VL - 38 ID - 971 ER - TY - JOUR AB - INTRODUCTION: The effects of antihypertensive therapy are often determined by patient compliance with the prescribed treatment plan. Acceptance of conservative-free forms of drugs leads to a decrease in the frequency and severity of side effects, reduces the need for the use of artificial tears, which lowers the cost of treatment for the patients., PURPOSE: to evaluate the hypotensive effectiveness of a fixed combination of bimatoprost (0.03%) and timolol (0.5%), and its effect on the ocular surface in patients with newly diagnosed advanced glaucoma., MATERIAL AND METHODS: The study was conducted during February-November 2018, and included 46 patients (76 eyes) with newly diagnosed POAG and healthy volunteers (control group). All patients underwent visometry, ICare rebound tonometry (Tiolat, Finland), elastometry with Maklakov tonometer (using 5 g, 10 g and 15 g loads), automated perimetry (AP) (Octopus-600, Haag-Streit diagnostics, Switzerland), optical coherence tomography (OCT) of the macular zone and optic nerve head, pachymetry (Spectralis OCT, Heidelberg Engineering, Germany). At the start of the study and one month after the start of treatment with the drug Ganfort (Allergan, USA), patients were examined to evaluate the state of their ocular surface: Norn's test, Schirmer's test, vital staining with lissamine green, and an OSDI questionnaire., RESULTS: At the start of treatment, administration of a fixed combination of bimatoprost and timolol led to a decrease in intraocular pressure by 7.9 (37.7%) mm Hg (V=271, p=5.496e-05) after 2 weeks of the use of Ganfort (Allergan, USA). During this period, the observation group did not exhibit statistically significant changes in the state of the ocular surface, which was comparable to the control group according to the data of the Norn's test, Schirmer's test, vital staining with lissamine green and the OSDI questionnaire (p>0.05)., CONCLUSION: The use of a fixed combination of bimatoprost and timolol, while effectively reducing IOP, did not result in statistically significant changes in the ocular surface. Some improvement of both objective and subjective indicators of the state of ocular surface associated with the use of the Ganfort drug was noted in patients of the observation group. AU - Dorofeev, D. A. AU - Kryzhanovskaya, A. V. AU - Ciganov, A. Z. DO - https://dx.doi.org/10.17116/oftalma202013602173 IS - 2 KW - Amides Antihypertensive Agents Bimatoprost Cloprostenol Drug Combinations Glaucoma, Open-Angle Humans Intraocular Pressure *Ocular Hypertension Timolol Treatment Outcome PY - 2020 SE - Dorofeev, D A. Chelyabinsk City Clinical Hospital No. 2, Chelyabinsk, Russia. Kryzhanovskaya, A V. South Ural State Medical University, Chelyabinsk, Russia. Ciganov, A Z. South Ural State Medical University, Chelyabinsk, Russia. SN - 0042-465X SP - 73-80 ST - [Effectiveness of antihypertensive conservative-free therapy with fixed combination of bimatoprost and timolol (intermediate results)] T2 - Effektivnost' gipotenzivnoi beskonservantnoi terapii fiksirovannoi kombinatsiei bimatoprosta i timolola (promezhutochnye rezul'taty). TI - [Effectiveness of antihypertensive conservative-free therapy with fixed combination of bimatoprost and timolol (intermediate results)] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med17&NEWS=N&AN=32366073 VL - 136 ID - 274 ER - TY - JOUR AB - The goal of antihypertensive therapy is to reduce intraocular pressure (IOP). Sometimes it can only be achieved by using two or more drugs, which can lead to undesirable side effects on the ocular surface. The use of drugs that do not contain preservatives leads to fewer undesirable side effects, while also reducing the need for instillations of artificial tears, making it economically beneficial for patients., PURPOSE: To assess the state of ocular surface in patients with POAG when switching to preservative-free carbonic anhydrase inhibitor (ICA) containing 0.18% sodium hyaluronate in combination with prostaglandin analogues and beta-adrenergic blocking agents., MATERIAL AND METHODS: The study was conducted in 2019; according to selection criteria, it included 46 patients (80 eyes) with POAG and a control group of healthy persons. At the start of the study and one month later, after a change of treatment to uninterrupted ICA containing 0.18% sodium hyaluronate, the patients had state of their ocular surface examined: Norn's test (tear break-up time; TBUT), Schirmer's test, vital staining with lissamine green and an Ocular Surface Disease Index (OSDI) survey., RESULTS: Replacing the ICA with benzalkonium chloride in the combination therapy of glaucoma with a preservative-free ICA containing 0.18% sodium hyaluronate - Dorzolan Solo (Solopharm, Russia) - expectedly did not lead to additional decrease of IOP, but resulted in a decrease in the width of the confidence interval according to both Maklakov's and Icare tonometers, which may be associated with increased treatment adherence. At the same time, the state of ocular surface in the observation group was statistically significantly improved according to Norn's test - from 3.57+/-1.3; 3.0 (3.0; 5.0) to 4.9+/-2.5; 5.0 (3.0; 6.0) (V=16.5; p=0.0039)., CONCLUSION: According to Schirmer's test and vital staining with lissamine green, no statistically significant changes have occurred. OSDI survey did not reveal changes in the study patients during 4 weeks of the follow-up, while the control group exhibited improvement. AU - Dorofeev, D. A. AU - Tur, E. V. AU - Vizgalova, L. O. AU - Tryapitsin, I. D. AU - Ciganov, A. Z. DO - https://dx.doi.org/10.17116/oftalma201913506152 IS - 6 KW - Antihypertensive Agents *Glaucoma, Open-Angle Humans Intraocular Pressure *Ocular Hypertension Ophthalmic Solutions Preservatives, Pharmaceutical Russia Tears Tonometry, Ocular PY - 2019 SE - Dorofeev, D A. Chelyabinsk City Clinical Hospital No. 2, 82 Lenina Pr., Chelyabinsk, Russian Federation, 454080. Tur, E V. South Ural State Medical University, 64 Vorovskogo St., Chelyabinsk, Russian Federation, 454092. Vizgalova, L O. South Ural State Medical University, 64 Vorovskogo St., Chelyabinsk, Russian Federation, 454092. Tryapitsin, I D. South Ural State Medical University, 64 Vorovskogo St., Chelyabinsk, Russian Federation, 454092. Ciganov, A Z. South Ural State Medical University, 64 Vorovskogo St., Chelyabinsk, Russian Federation, 454092. SN - 0042-465X SP - 52-59 ST - [The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)] T2 - Vliianie beskonservantnoi terapii pervichnoi otkrytougol'noi glaukomy na sostoianie glaznoi poverkhnosti pri kombinirovannom lechenii (promezhutochnye rezul'taty). TI - [The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=32015308 VL - 135 ID - 300 ER - TY - JOUR AB - IMPORTANCE: Low-socioeconomic urban children often do not have access to ophthalmic care. OBJECTIVE: To characterize the demographic characteristics and ophthalmic conditions in children attending Give Kids Sight Day (GKSD), an outreach ophthalmic care program held annually in Philadelphia, Pennsylvania, providing vision screening and immediate treatment when needed. DESIGN, SETTING, AND PARTICIPANTS: Retrospective case-series study of children attending GKSD in 2012 (GKSD 2012) at an ophthalmology center in Philadelphia. Registration forms and records of all children attending GKSD 2012 were reviewed. MAINOUTCOMESANDMEASURES: Demographic characteristics, insurance status, spoken languages, reasons for attending, prior failure of vision screening, and attendance pattern of previous events were analyzed. The ophthalmological findings of these children were examined, including refractive errors, need for optical correction, and diagnoses for which continuous ophthalmic care was necessary. For children who needed ophthalmic follow-up, the rate of return to clinic and barriers for continuous care were analyzed. RESULTS: We studied 924 children (mean age, 9 years; age range, 0-18 years; 51% female; 25% speaking a non-English language) coming from 584 families who attended GKSD 2012, of whom 27% were uninsured and 10% were not aware of their insurance status. Forty-two percent of participants had public insurance, which covered vision care and glasses, but 35% did not know their benefits and did not realize vision care was covered. Forty-nine percent of children attended because they failed community vision screening. Provision of free glasses and failure of previous vision screening were the most common reasons families elected to attend GKSD (64% and 49%, respectively). Eighty-five percent of children attended GKSD 2012 for the first time, whereas 15% attended prior events. Glasses were provided to 61% of attendees. Ten percent of the attendees needed continuous ophthalmic care, most commonly for amblyopia. Ten children needed ocular surgery for cataract, strabismus, nystagmus, ptosis, or nasolacrimal duct obstruction. With the assistance of a social worker, 59% of children requiring continuous treatment returned to the clinic, compared with 2% in prior years before social worker intervention. CONCLUSIONS AND RELEVANCE: Programs suchas GKSD can bridge the gap between successful vision screening and ophthalmic treatment, a gap that often occurs in low-socioeconomic urban populations. Those with public insurance coverage for vision services may not realize these services are covered. Social worker intervention is useful in overcoming common barriers to follow-up care. AD - A.V. Levin, Pediatric Ophthalmology and Ocular Genetics, Wills Eye Hospital, 840 Walnut St., Philadelphia, PA, United States AU - Dotan, G. AU - Truong, B. AU - Snitzer, M. AU - McCauley, C. AU - Martinez-Helfman, S. AU - Maria, K. S. AU - Levin, A. V. DB - Embase Medline DO - 10.1001/jamaophthalmol.2015.8 IS - 5 KW - adolescent amblyopia article cataract child child care congenital cataract eye disease eye surgery female glaucoma health care access health insurance health program human lacrimal duct occlusion major clinical study male neurofibromatosis type 1 nystagmus optic nerve atrophy preschool child priority journal ptosis (eyelid) refraction error school child social worker spectacles strabismus United States vision test visual impairment LA - English M3 - Article N1 - L604493373 2015-05-29 2015-06-11 PY - 2015 SN - 2168-6165 SP - 527-532 ST - OUTCOMES of an inner-city vision outreach program: Give Kids Sight Day T2 - JAMA Ophthalmology TI - OUTCOMES of an inner-city vision outreach program: Give Kids Sight Day UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604493373&from=export http://dx.doi.org/10.1001/jamaophthalmol.2015.8 VL - 133 ID - 2845 ER - TY - JOUR AB - Knowledge of the epidemiology of eye disease among the elderly becomes increasingly important as our population ages. Leading causes of blindness in the elderly include age-related macular degeneration, open-angle glaucoma and cataract. Few studies have examined the prevalence of these blinding eye diseases among senior citizens. A retrospective review of vision screening examinations from 429 patients seen at the UCLA Mobile Eye Clinic in visits to a Jewish senior citizens' center was performed to examine the distribution of best recorded visual acuity and prevalence of eye disease in a group of ambulatory Jewish senior citizens. Best recorded visual acuity was ≥20/40 in the better eye for 83.9% of the patients. The prevalence of age-related macular degeneration was 20.7%, and increased with increasing age (p<.00005). The prevalence of open-angle glaucoma was 6.3%. The prevalence of senile cataract was 59.0% and increased with increasing age (p<.00005). Despite the limitations imposed by a retrospective review of charts, our study provides an indication of the prevalence of blinding eye disease and distribution of visual acuity among ambulatory Jewish senior citizens in southern California. Except for the high prevalence of senile cataract, the prevalence data derived from this study are similar to other epidemiologic studies of eye disease in the elderly. AD - D.A. Lee, Jules Stein Eye Institute, 100 Stein Plaza, Los Angeles, CA 90024, United States AU - Dougherty, P. J. AU - Engelhardt, R. F. AU - Lee, D. A. DB - Embase Medline DO - 10.1007/BF02260386 IS - 4 KW - aged ambulatory care article blindness cataract disease predisposition elderly care female human Jew major clinical study male open angle glaucoma prevalence macular degeneration retrospective study risk factor senile cataract United States visual acuity LA - English M3 - Article N1 - L24233526 1994-08-14 PY - 1994 SN - 0094-5145 SP - 271-284 ST - Eye disease among ambulatory Jewish senior citizens in California T2 - Journal of Community Health TI - Eye disease among ambulatory Jewish senior citizens in California UR - https://www.embase.com/search/results?subaction=viewrecord&id=L24233526&from=export http://dx.doi.org/10.1007/BF02260386 VL - 19 ID - 3998 ER - TY - JOUR AU - Draeger, J. IS - 1 KW - Glaucoma/px [Psychology] *Glaucoma/rh [Rehabilitation] Humans Intraocular Pressure Patient Compliance/px [Psychology] Self Care/px [Psychology] *Self Care Tonometry, Ocular/px [Psychology] *Tonometry, Ocular PY - 1998 SN - 0023-2165 SP - aA9 ST - [Intraocular pressure self-monitoring in glaucoma patients] T2 - Selbstmessung des Augeninnendruckes durch den Glaukompatienten. TI - [Intraocular pressure self-monitoring in glaucoma patients] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9743930 VL - 213 ID - 1987 ER - TY - JOUR AB - Since 1975, four selected glaucoma patients and their relatives have attended the Department of Ophthalmology at Hamburg University, for instruction in home tonometry using the Draeger motor-driven hand applanation tonometer. Two glaucoma patients whose intraocular pressure (IOP) was measured by their physicians were also included, in order to analyse long-term monitoring of the IOP by medical staff. Home tonometry has been performed over several years and has proved to be a reliable and precise diagnostic tool allowing valuable treatment and close follow-up of glaucoma, especially in severe forms of glaucoma. The benefits of patient's participation in their own disease monitoring, e.g., self-measurement of blood pressure in patients with arterial hypertension, show that such involvement can lead to more diagnostic security and better compliance. On the basis of applanation tonometry calibrated by Goldmann, new concepts of microprocessor-controlled assessment of the applanation area are outlined. These sensor tonometers will allow automatic, precise and fast self-measurement of the intraocular pressure, opening up new perspectives in the management of glaucoma. AU - Draeger, J. AU - Groenhoff, S. IS - 6 KW - Adult Child Female Glaucoma/cn [Congenital] *Glaucoma/di [Diagnosis] *Home Nursing Humans Male *Ocular Hypertension/di [Diagnosis] *Self Care/is [Instrumentation] *Tonometry, Ocular/is [Instrumentation] PY - 1990 SE - Draeger, J. Universitats-Augenklinik, Hamburg, Bundersrepublik Deutschland. SN - 0723-8045 SP - 688-91 ST - [Self-tonometry--technical possibilities and clinical significance] T2 - Selbsttonometrie--Technische Moglichkeiten und klinische Bedeutung. TI - [Self-tonometry--technical possibilities and clinical significance] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2086419 VL - 87 ID - 2153 ER - TY - JOUR AB - INTRODUCTION/PURPOSE: To determine the associations between medical, demographic, socioeconomic, and ocular factors and adherence to topical glaucoma ocular hypotensive therapy., METHODS: One hundred sixteen patients with ocular hypertension or open-angle glaucoma from 2 tertiary glaucoma services participated in this prospective study. Adherence to ocular hypotensive therapy was measured using an electronic dose monitor (Travatan Dosing Aid, Alcon Laboratories Inc., Fort Worth, TX) and collected data at 3 months after enrollment. We used 3 different definitions of adherence: 1) Definition 1: the proportion of days taking the prescribed number of drops within 3 hours of the prescribed dosing time; 2) Definition 2: the proportion of days taking any drops within 3 hours of the prescribed dosing time; and 3) Definition 3: the proportion of days taking any drops within 6 hours of the prescribed dosing time. Univariate and multivariate models were used to determine the association between the 3 adherence definitions, medical, demographic, socioeconomic, and ocular factors at 3-month follow-up. The main outcome measures for this study were risk factors for poor objective medication adherence., RESULTS: Adherence, using Definition 1, Definition 2, and Definition 3, was 64%, 75%, and 80%, respectively. Age, total number of other eye diseases, and race were significantly associated with full treatment adherence (Definition 1), with race alone significantly predicting 11% of full treatment adherence. For Definition 2, age, income, level of education, and total number of eye diseases were significantly associated with partial adherence (3 h), again race alone significantly predicted 15% of partial adherence (any drops within 3 h). For Definition 3, race, income, level of education, and total number of other eye diseases significantly predicted partial adherence (any drops within 6 h), both race and income predicted 19% of partial treatment adherence. Significant differences for adherence rates between patients of European descent and those of African descent were found for all 3 definitions with those who were less adherent more likely to be of African descent., CONCLUSIONS: Electronic dose monitors provide important information regarding adherence to topical ocular hypotensive medications in glaucoma patients. Electronic dose monitors show low adherence in a significant number of participants. Future studies are needed to determine the reasons for these differences in health behaviors related to glaucoma treatment, which should guide treatment of poor adherence with glaucoma therapy. AU - Dreer, Laura E. AU - Girkin, Christopher AU - Mansberger, Steven L. DO - https://dx.doi.org/10.1097/IJG.0b013e31821dac86 IS - 4 KW - Administration, Topical Age Factors *Antihypertensive Agents/ad [Administration & Dosage] Continental Population Groups Drug Monitoring/is [Instrumentation] Drug Prescriptions/sn [Statistics & Numerical Data] Educational Status Female *Glaucoma, Open-Angle/dt [Drug Therapy] Health Knowledge, Attitudes, Practice Humans Income Intraocular Pressure Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions/ad [Administration & Dosage] Prospective Studies *Prostaglandins F, Synthetic/ad [Administration & Dosage] Tonometry, Ocular PY - 2012 SE - Dreer, Laura E. Department of Ophthalmology, School of Medicine, Birmingham, AL, USA. SN - 1536-481X 1057-0829 SP - 234-40 ST - Determinants of medication adherence to topical glaucoma therapy T2 - Journal of glaucoma TI - Determinants of medication adherence to topical glaucoma therapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=21623223 VL - 21 ID - 1167 ER - TY - JOUR AB - PURPOSE: To elucidate barriers and facilitators related to glaucoma medication adherence among African Americans (AA) with glaucoma and to elicit input from a community-based participatory research team to guide the development of a culturally informed health promotion program for improving glaucoma medication adherence among AAs., METHODS: The nominal group technique (NGT), a highly structured focus group methodology, was implemented with 12 separate groups of AA patients with glaucoma (N = 89) to identify barriers and facilitators related to glaucoma medication usage. Participant rank-ordering votes were summed across groups and categorized into themes. Next, an individually and culturally targeted health promotion program promoting appropriate medication adherence was developed based on focus group results and input from a community-based participatory research team., RESULTS: The top five barriers included problems with forgetfulness, side effects, cost/affordability, eyedrop administration, and the eyedrop schedule. The most salient top five facilitators were fear or thoughts about the consequences of not taking eyedrops; use of memory aids, cues, or strategies; maintaining a regular routine or schedule for eyedrop administration; ability to afford eyedrops; and keeping eyedrops in the same area. The resulting health promotion program was based on a multicomponent empowerment framework that included glaucoma education, motivational interviewing, and problem-solving training to improve glaucoma medication adherence., CONCLUSIONS: Barriers and facilitators related to glaucoma medication adherence among AAs are multifactorial. Based on the NGT themes and input from the community-based participatory research team, a culturally informed health promotion program was designed and holds great promise for improving medication adherence among this vulnerable population. AU - Dreer, Laura E. AU - Girkin, Christopher A. AU - Campbell, Lisa AU - Wood, Andy AU - Gao, Liyan AU - Owsley, Cynthia DO - https://dx.doi.org/10.1097/OPX.0000000000000009 IS - 8 KW - Adult *African Americans/sn [Statistics & Numerical Data] Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] Female Focus Groups *Glaucoma/dt [Drug Therapy] Glaucoma/eh [Ethnology] Health Promotion Humans Male Medication Adherence/px [Psychology] *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged *Program Development PY - 2013 SE - Dreer, Laura E. Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. dreer@uab.edu SN - 1538-9235 1040-5488 SP - 883-97 ST - Glaucoma medication adherence among African Americans: program development T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Glaucoma medication adherence among African Americans: program development UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23873033 VL - 90 ID - 954 ER - TY - JOUR AB - PURPOSE/AIMS: To examine the feasibility, patient acceptability, and preliminary effectiveness of a culturally informed, health promotion program designed to improve glaucoma medication adherence among African American's (AA's) with glaucoma., MATERIALS/METHODS: A sample of 11 AA glaucoma patients (mean age 61 years; 73% women and 27% men) completed a culturally informed and individually tailored, health promotion program developed for AAs titled, "Glaucoma Management Optimism for African Americans Living with Glaucoma" (GOAL)©. The aim of the brief 4-week program is to enhance glaucoma medication adherence through a combination of education, motivational interviewing (MI), and problem-solving training (PST). Feasibility was assessed on the basis of patient satisfaction with the program, number of sessions completed, and length of sessions. Preliminary efficacy was evaluated using a pre-post design to determine whether the program improved objective glaucoma medication adherence via an electronic Travalert dosing aid as well as satisfaction with aspects of glaucoma treatment, health beliefs about medications, glaucoma symptoms, emotional well-being, and intraocular pressure., RESULTS: Overall patient satisfaction and acceptability was high for the program, interactions with the health educator, program materials, and the length of sessions. Feasibility was also supported given the need for the program, success in recruitment/retention, and ease of implementing the program with AA glaucoma patients in clinic and/or over the telephone. In terms of preliminary efficacy, patients showed significant pre-post improvements in objective medication adherence rates by 15% (p = 0.03), self-efficacy for glaucoma management (p = 0.02), ease of use in administering eye drops (p = 0.03), glaucoma treatment satisfaction (p = 0.05), beliefs about the necessity of taking glaucoma medications (p = 0.05), and functional visual ocular symptoms (p = 0.03)., CONCLUSIONS: (GOAL)© holds great promise toward improving glaucoma medication adherence and beliefs among AA's with glaucoma. AU - Dreer, Laura E. AU - Owsley, Cynthia AU - Campbell, Lisa AU - Gao, Liyan AU - Wood, Andy AU - Girkin, Christopher A. DO - https://dx.doi.org/10.3109/02713683.2014.1002045 IS - 1 KW - *African Americans *Antihypertensive Agents/ad [Administration & Dosage] Feasibility Studies Female *Glaucoma/dt [Drug Therapy] Glaucoma/eh [Ethnology] Health Knowledge, Attitudes, Practice *Health Promotion/mt [Methods] Humans Intraocular Pressure/de [Drug Effects] Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Patient Satisfaction Surveys and Questionnaires Treatment Outcome PY - 2016 SE - Dreer, Laura E. a Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA and. Owsley, Cynthia. a Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA and. Campbell, Lisa. b Department of Psychology, East Carolina University, Greenville, NC, USA. Gao, Liyan. a Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA and. Wood, Andy. a Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA and. Girkin, Christopher A. a Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA and. SN - 1460-2202 0271-3683 SP - 50-8 ST - Feasibility, Patient Acceptability, and Preliminary Efficacy of a Culturally Informed, Health Promotion Program to Improve Glaucoma Medication Adherence Among African Americans: "Glaucoma Management Optimism for African Americans Living with Glaucoma" (GOAL) T2 - Current eye research TI - Feasibility, Patient Acceptability, and Preliminary Efficacy of a Culturally Informed, Health Promotion Program to Improve Glaucoma Medication Adherence Among African Americans: "Glaucoma Management Optimism for African Americans Living with Glaucoma" (GOAL) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=25625187 VL - 41 Y2 - 20150127// ID - 750 ER - TY - JOUR AB - AIM: To determine the force needed to extract a drop from a range of current prostaglandin monotherapy eye droppers and how this related to the comfortable and maximum pressure subjects could exert., METHODS: The comfortable and maximum pressure subjects could apply to an eye dropper constructed around a set of cantilevered pressure sensors and mounted above their eye was assessed in 102 subjects (mean 51.2+/-18.7 years), repeated three times. A load cell amplifier, mounted on a stepper motor controlled linear slide, was constructed and calibrated to test the force required to extract the first three drops from 13 multidose or unidose latanoprost medication eye droppers., RESULTS: The pressure that could be exerted on a dropper comfortably (25.9+/-17.7 Newtons, range 1.2-87.4) could be exceeded with effort (to 64.8+/-27.1 Newtons, range 19.9-157.8; F=19.045, p<0.001), and did not differ between repeats (F=0.609, p=0.545). Comfortable and maximum pressures exerted were correlated (r=0.618, p<0.001), neither were influenced strongly by age (r=0.138, p=0.168; r=-0.118, p=0237, respectively), but were lower in women than in men (F=12.757, p=0.001). The force required to expel a drop differed between dropper designs (F=22.528, p<0.001), ranging from 6.4 Newtons to 23.4 Newtons. The force needed to exert successive drops increased (F=36.373, p<0.001) and storing droppers in the fridge further increased the force required (F=7.987, p=0.009)., CONCLUSIONS: Prostaglandin monotherapy droppers for glaucoma treatment vary in their resistance to extract a drop and with some a drop could not be comfortably achieved by half the population, which may affect compliance and efficacy. Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. AU - Drew, Tom AU - Wolffsohn, James S. DO - https://dx.doi.org/10.1136/bjophthalmol-2014-306291 IS - 9 KW - Adult Aged Aged, 80 and over Analysis of Variance *Antihypertensive Agents/ad [Administration & Dosage] Female *Glaucoma/dt [Drug Therapy] Humans Instillation, Drug Latanoprost Male Middle Aged *Ophthalmic Solutions/ad [Administration & Dosage] Pressure *Prostaglandins/ad [Administration & Dosage] *Prostaglandins F, Synthetic/ad [Administration & Dosage] Young Adult PY - 2015 SE - Drew, Tom. Ophthalmic Research Group, Life and Health Sciences, Aston University, Birmingham, UK. Wolffsohn, James S. Ophthalmic Research Group, Life and Health Sciences, Aston University, Birmingham, UK. SN - 1468-2079 0007-1161 SP - 1251-4 ST - Usability of prostaglandin monotherapy eye droppers T2 - The British journal of ophthalmology TI - Usability of prostaglandin monotherapy eye droppers UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25761745 VL - 99 Y2 - 20150311// ID - 806 ER - TY - JOUR AB - Disposable and frequent replacement contact lenses were developed in order to improve the performance and safety of soft lens wear. This lecture will address the potential medical advantages of these lenses. The role of disposable lenses for extended wear and its impact on infectious keratitis and unscheduled office visits will be discussed. Other areas to be addressed include the use of these lenses for patients who experience problems with frequent lens deposits, giant papillary conjunctivitis, and solution reactions or toxicity. Their use for patients with significant keratoconjunctivitis sicca or blepharoconjunctivitis will also be discussed. AD - University of Florida, Dept. of Ophthalmology, P.O. Box 100284, Gainesville, FL 32610-0284, United States AU - Driebe W.T, Jr. DB - Scopus IS - 1 M3 - Review N1 - Export Date: 19 July 2021 PY - 1998 SP - 26-30 ST - Avantages medicaux des lentilles a remplacement frequent et a usage unique T2 - Contactologia TI - Medical advantages of disposable and frequent replacement contact lenses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031917322&partnerID=40&md5=60832b4cc5a00a0720bbc26b75d6e5f4 VL - 20 ID - 5788 ER - TY - JOUR AB - Disposable soft lenses are now available for extended wear. These lenses were designed to provide a more acceptable margin of safety than conventional extended wear soft lenses. Disposable lenses, which are intended to be discarded after 1-2 weeks of continuous wearing time, do offer a number of theoretical advantages. The short wearing schedule minimizes deposit formation which has been implicated in the development of giant papillary conjunctivitis and infectious keratitis. Lens disinfection systems, which are expensive and time consuming, and may become contaminated, are rarely needed if the manufacturer's guidelines are followed. Careful longterm follow-up of disposable soft lens patients will be needed to establish actual patient compliance and the safety of these lenses. AU - Driebe, W. T., Jr. IS - 1 KW - *Contact Lenses, Hydrophilic Corneal Diseases/co [Complications] *Disposable Equipment Humans Keratitis/co [Complications] PY - 1989 SE - Driebe, W T Jr. Department of Ophthalmology, University of Florida College of Medicine, Gainesville. SN - 0039-6257 SP - 44-6 ST - Disposable soft contact lenses T2 - Survey of ophthalmology TI - Disposable soft contact lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2678552 VL - 34 ID - 2164 ER - TY - JOUR AU - Drolsum, L. DB - Embase Medline DO - 10.1111/j.1600-0420.2006.00855.x IS - 2 KW - antiglaucoma agent antimetabolite poly(methyl methacrylate) aqueous humor developing country drug use editorial filtering operation glaucoma glaucoma drainage implant glaucoma surgery health care cost human intermethod comparison intraocular pressure laser surgery medical research patient compliance patient safety postoperative complication postoperative hemorrhage priority journal pseudoexfoliation sclerotomy Sturge Weber syndrome surgical technique suture technique trabeculectomy treatment outcome viscocanalostomy visual acuity LA - English M3 - Editorial N1 - L46243284 2007-03-25 PY - 2007 SN - 1395-3907 1600-0420 SP - 124-126 ST - The role of non-penetrating filtering procedures in glaucoma surgery T2 - Acta Ophthalmologica Scandinavica TI - The role of non-penetrating filtering procedures in glaucoma surgery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46243284&from=export http://dx.doi.org/10.1111/j.1600-0420.2006.00855.x VL - 85 ID - 3537 ER - TY - JOUR AB - Pseudoexfoliation syndrome is a risk factor in cataract surgery because of the increased weakness of zonular apparatus and reduced pupillary dilatation. The surgical outcome of using phacoemulsi. cation in the central zone, inducing minimal stress on the zonules, inserting a capsular tension ring in selected cases, and stretching the pupil mechanically in eyes with miotic pupils, may turn out to be uneventful in most cases. Postoperative fibrosis with subsequent shrinkage of the capsule is increased in these eyes, and these centripetal forces will further loosen the zonular fibres. Late in-the-bag intraocular lens dislocation is therefore anticipated to become a growing problem in the future. Despite the dysfunctioning of the blood-aqueous barrier in eyes with pseudoex-foliation syndrome, the frequency of postoperative inflammatory reaction is low due to the improvements made in surgical technique and equipment in recent years. Glaucoma frequently occurs in eyes with pseudoexfoliation syndrome. Compared with primary open-angle glaucoma, optic damage is more pronounced in these eyes at the time of diagnosis and response to medical therapy is poorer. Although responses to argon laser therapy and filtering surgery are roughly similar between the two types of glaucoma, there are indications that primary laser trabeculoplasty has a higher success rate in pseudoexfoliation glaucoma than in primary open-angle glaucoma. AN - WOS:000251025000002 AU - Drolsum, L. AU - Ringvold, A. AU - Nicolaissen, B. DA - DEC DO - 10.1111/j.1600-0420.2007.00903.x IS - 8 PY - 2007 SN - 1395-3907 SP - 810-821 ST - Cataract and glaucoma surgery in pseudoexfoliation syndrome: a review T2 - ACTA OPHTHALMOLOGICA SCANDINAVICA TI - Cataract and glaucoma surgery in pseudoexfoliation syndrome: a review VL - 85 ID - 6171 ER - TY - JOUR AB - PURPOSE: To investigate the long-term therapeutic effect of Hunan aqueous drainage (HAD) implantation with and without adjunctive intraoperative mitomycin C (MMC) for refractory glaucoma., METHODS: 154 cases (159 eyes) with refractory glaucoma underwent Hunan aqueous drainage (HAD) implantation from July 1995 to July 2001. Sixty-five eyes were combined with MMC (0.4 mg/ml, 1 to 5 mins). With success defined as the introcular pressure (IOP) greater than 6 mmHg but no greater than 21 mmHg at the last visit., RESULTS: The mean period of postoperative follow-up was 54.6 (range, 12-72) months. The IOP was lowered from preoperative (46.8 +/- 14.5) mmHg to postoperative (16.8 +/- 11.3) mmHg at the 1st year after surgery. The success rate with MMC and without MMC were 90.0%, 77.3% (P < 0.05) at the 1st year, 87.1%, 67.3% (P < 0.05) at the 2nd year, 83.3%, 61.1% (P < 0.05) at the 3rd year, 81.3%, 56.7% (P < 0.05) at the 4th year, and 75.0%, 50.0% (P < 0.05) at the 5th year using Kaplan-Meier life-table analysis. The height of the posterior bleb underwent standardized ocular echography at the 1st year was (3.8 +/- 0.9) mm and (2.1 +/- 1.4) mm, respectively. Ninty-five eyes (81.9%) with visual acuity remained or improved after the surgery (P > 0.05). The most frequent complications for long-term follow-up included elevated IOP (IOP > 22 mmHg) (19.8%), the iris adherent to the proximal orifice of the tube (15.5%), developed cataract formation (12.9%) and so on (P > 0.05). We didn't find any severe complications after using MMC., CONCLUSION: This study suggests that HAD implantation is an effective method in the management of refractory glaucoma in spite of its unneligible complications and combined with MMC can improve the prognosis. AU - Duan, Xuanchu AU - Jiang, Youqin AU - Qing, Guoping IS - 2 KW - Adolescent Adult Aged Child Female Follow-Up Studies Glaucoma/dt [Drug Therapy] *Glaucoma/su [Surgery] *Glaucoma Drainage Implants Humans Intraocular Pressure Male Middle Aged *Mitomycin/tu [Therapeutic Use] Visual Acuity PY - 2003 SE - Duan, Xuanchu. Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha 410011, China. SN - 1000-4432 SP - 81-5 ST - [Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin C for refractory glaucoma] T2 - Yan ke xue bao = Eye science TI - [Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin C for refractory glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=12870339 VL - 19 ID - 1834 ER - TY - JOUR AB - BACKGROUND: Diabetes is one of the most common chronic metabolic disorders which affect the quality of human life worldwide. As per the WHO report, between 1980 to 2014, the number of diabetes patients increases from 108 million to 422 million, with a global prevalence rate of 8.5% per year. Diabetes is the prime reason behind various other diseases like kidney failure, stroke, heart disorders, glaucoma, etc. It is recognized as the seventh leading cause of death throughout the world. The available therapies are painful (insulin injections) and inconvenient due to higher dosing frequency. Thus, to find out a promising and convenient treatment, extensive investigations are carried out globally by combining novel carrier system (like microparticle, microneedle, nanocarrier, microbeads etc.) and delivery devices (insulin pump, stimuli-responsive device, inhalation system, bioadhesive patch, insulin pen etc.) for more precise diagnosis and painless or less invasive treatment of disease., OBJECTIVE: The review article is made with an objective to compile information about various upcoming and existing modern technologies developed to provide greater patient compliance and reduce the undesirable side effect of the drug. These devices evade the necessity of daily insulin injection and offer a rapid onset of action, which sustained for a prolonged duration of time to achieve a better therapeutic effect., CONCLUSION: Despite numerous advantages, various commercialized approaches, like Afrezza (inhalation insulin) have been a failure in recent years. Such results call for more potential work to develop a promising system. The novel approaches range from the delivery of non-insulin blood glucose lowering agents to insulin-based therapy with minimal invasion are highly desirable. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. AU - Dubey, Sunil Kumar AU - Alexander, Amit AU - Pradhyut, K. Sai AU - Agrawal, Mukta AU - Jain, Rupesh AU - Saha, Ranendra Narayana AU - Singhvi, Gautam AU - Saraf, Swarnlata AU - Saraf, Shailendra DO - https://dx.doi.org/10.2174/1567201816666191106102020 IS - 1 KW - *Diabetes Mellitus, Type 1/dt [Drug Therapy] *Diabetes Mellitus, Type 2/dt [Drug Therapy] *Drug Delivery Systems Humans Hypoglycemic Agents/ad [Administration & Dosage] Hypoglycemic Agents/ae [Adverse Effects] *Hypoglycemic Agents/tu [Therapeutic Use] PY - 2020 SE - Dubey, Sunil Kumar. Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India. Alexander, Amit. Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER GUWAHATI), Ministry of Chemicals & Fertilizers, Govt. of India, NH 37, NITS Mirza, Kamrup- 781125, Guwahati (Assam), India. Pradhyut, K Sai. Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India. Agrawal, Mukta. Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER GUWAHATI), Ministry of Chemicals & Fertilizers, Govt. of India, NH 37, NITS Mirza, Kamrup- 781125, Guwahati (Assam), India. Jain, Rupesh. Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India. Saha, Ranendra Narayana. Department of Biotechnology, Faculty of Biotechnology, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Dubai Campus, Dubai, United Arab Emirates. Singhvi, Gautam. Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India. Saraf, Swarnlata. University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh 492 010, India. Saraf, Shailendra. University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh 492 010, India. SN - 1875-5704 1567-2018 SP - 3-14 ST - Recent avenues in Novel Patient-Friendly Techniques for the Treatment of Diabetes T2 - Current drug delivery TI - Recent avenues in Novel Patient-Friendly Techniques for the Treatment of Diabetes UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=31692441 VL - 17 ID - 258 ER - TY - JOUR AB - BACKGROUND: Many physicians recommend either brimonidine or latanoprost as firstline therapy for chronic open-angle glaucoma or ocular hypertension. However, a search of MEDLINE indicates that there have been few head-to-head comparisons of the 2 monotherapies in a clinical setting., OBJECTIVE: This study compared the clinical efficacy and tolerability of brimonidine 0.2% twice daily with those of latanoprost 0.005% once daily as monotherapy in patients with open-angle glaucoma or ocular hypertension., METHODS: In this 3-month, multicenter, double-masked, parallel-group, 4-visit study, treatment-naive and previously treated patients with open-angle glaucoma or ocular hypertension and bilateral intraocular pressure (IOP) after washout of between 22 and 34 mm Hg were randomized to receive either brimonidine or latanoprost. Patients who had received previous treatment with either study drug were excluded from the study. The primary outcome measure was response rate, defined as the percentage of patients achieving > or = 20% reduction in IOP from baseline to month 3. Secondary outcome measures were mean IOP reduction from baseline to month 3 and clinical success, defined as the investigator's recommendation that the patient continue using the assigned study medication., RESULTS: A total of 127 patients (55 treatment naive) were enrolled, 66 in the brimonidine group and 61 in the latanoprost group. After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline. The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively). Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01). In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively); however, the difference was not statistically significant. Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01)., CONCLUSIONS: At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP. In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine. This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension. In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine. Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy. AU - DuBiner, H. B. AU - Mroz, M. AU - Shapiro, A. M. AU - Dirks, M. S. AU - Brimonidine vs. Latanoprost Study, Group IS - 12 KW - Adrenergic alpha-Agonists/ae [Adverse Effects] *Adrenergic alpha-Agonists/tu [Therapeutic Use] Aged Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Brimonidine Tartrate Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Latanoprost Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Patient Satisfaction Prostaglandins F, Synthetic/ae [Adverse Effects] *Prostaglandins F, Synthetic/tu [Therapeutic Use] Quinoxalines/ae [Adverse Effects] *Quinoxalines/tu [Therapeutic Use] Treatment Outcome PY - 2001 SE - DuBiner, H B. Clayton Eye Center, Morrow, Georgia 30260, USA. SN - 0149-2918 SP - 1969-83 ST - A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial T2 - Clinical therapeutics TI - A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11813932 VL - 23 ID - 1908 ER - TY - JOUR AD - V.D.J.-P. Dubois, Ophthalmologist and Glaucoma Lead, Aintree University Hospital NHS Foundation Trust, Longmore Lane, Liverpool, Merseyside L9 7AL, United Kingdom AU - Dubois, V. D. J. P. C1 - xalatan DB - Embase Medline DO - 10.1038/eye.2013.129 IS - 9 KW - eye drops latanoprost timolol general practitioner glaucoma health care cost human medication compliance note outpatient care patient care patient compliance pharmacist prescription tonometry unspecified side effect xalatan LA - English M3 - Note N1 - L369793119 2013-09-19 2013-09-23 PY - 2013 SN - 1476-5454 0950-222X SP - 1002-1003 ST - Are generic topical prostanoids the way forward in the care of glaucoma patients? - No T2 - Eye (Basingstoke) TI - Are generic topical prostanoids the way forward in the care of glaucoma patients? - No UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369793119&from=export http://dx.doi.org/10.1038/eye.2013.129 VL - 27 ID - 3037 ER - TY - JOUR AB - The article reveals that there is no standard regimen for treating glaucoma. Ophthalmologist Louis B. Cantor claims that glaucoma patients faced different situations, so it is not possible to have a standard approach to glaucoma care management. The use of prostaglandin analogue is advised for primary-open glaucoma at an early disease stage. It describes the second-line therapies for the disease such as beta-blockers and carbonic anhydrase. The cost and compliance in the treatment of glaucoma are also noted. AN - 54394991. Language: English. Entry Date: 20101015. Revision Date: 20191029. Publication Type: Article AU - DuBosar, Ryan DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Drug Therapy Patient Selection Decision Making, Clinical Prostaglandins -- Therapeutic Use Glaucoma -- Complications Severity of Illness Prostaglandins -- Adverse Effects Patient Attitudes Adrenergic Beta-Antagonists Adrenergic Alpha-Antagonists Carbonic Anhydrase Inhibitors Costs and Cost Analysis Medication Compliance Treatment Failure Glaucoma -- Surgery N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 1-13 ST - Standard medication regimens hard to define for treatment of glaucoma T2 - Ocular Surgery News TI - Standard medication regimens hard to define for treatment of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=54394991&site=ehost-live&scope=site VL - 28 ID - 4269 ER - TY - JOUR AB - INTRODUCTION: Retinal vein occlusions (RVOs) are a common cause of severe or total loss of vision. Although the disease entity has long been known, its management is still controversial. We report five patients (six eyes) who experienced RVO even though they were taking anticoagulants or antiplatelet agents., CASE REPORTS: Two patients developed a central retinal vein occlusion (two eyes), two patients a branch retinal vein occlusion (two eyes), and one patient a bilateral central retinal vein occlusion (two eyes). Three patients were treated with anticoagulants, two for hemostatic pathologies and one for cardiopathy; two patients were treated with antiplatelet agents, one for auricular fibrillation and one for a cardiac graft. Retinal photocoagulation was performed in all cases to treat retinal ischemia. Neovascular glaucoma occurred in a single eye., DISCUSSION: Treatments for thromboembolic disorders are more and more commonly used for various indications. Nevertheless, many patients develop RVO while taking such treatments, even though the International Normalized Ratio (INR) shows good patient compliance. Many case reports and small case series illustrate the occurrence of RVO with such treatments. These examples seem to illustrate the lack of efficacy of anticoagulants and platelet aggregation inhibitors in preventing vascular complications in the retinal venous circulation., CONCLUSION: Anticoagulants and platelet aggregation inhibitors must only be used to treat systemic factors or thromboembolic disorders associated with RVO. These five case reports illustrate that anticoagulants and platelet aggregation inhibitors cannot guarantee that a severe RVO will not occur. A prospective study would be useful to analyze their advantages in RVO management. AU - Ducos de Lahitte, G. AU - Quintyn, J. C. AU - Leparmentier, A. AU - Mathis, A. IS - 2 KW - Adult Aged Aged, 80 and over *Anticoagulants/tu [Therapeutic Use] Humans International Normalized Ratio Male Middle Aged Patient Compliance *Platelet Aggregation Inhibitors/tu [Therapeutic Use] *Retinal Vein Occlusion/dt [Drug Therapy] Treatment Outcome PY - 2007 SE - Ducos de Lahitte, G. Service d'Ophtalmologie, Hopital de Rangueil, Toulouse, France. ducosg@yahoo.fr SN - 1773-0597 0181-5512 SP - 145-9 ST - [Retinal vein occlusions in patients treated with anticoagulant and/or platelet aggregation inhibitors. Five case studies] T2 - Occlusions veineuses retiniennes survenant chez des patients traites par anticoagulants et/ou antiagregants plaquettaires. A propos de 5 cas. TI - [Retinal vein occlusions in patients treated with anticoagulant and/or platelet aggregation inhibitors. Five case studies] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17318096 VL - 30 ID - 1613 ER - TY - JOUR AB - A 53-year-old female presented with keratitis (right eye) after fall of insect 10 days back. The ulcer worsened in spite of aggressive treatment with topical natamycin (5%) and amphotericin-B (0.15%) eye drops and finally perforated. Iris tissue sealed the perforation site, and ulcer healed with formation of adherent leucoma. This case represents first reported case of keratitis caused by Laetisaria arvalis and stresses on aggressive course of keratitis caused by this fungus. Importance of DNA sequencing in identification of unidentified fungal species is also highlighted. AU - Dudeja, Lakshey AU - Jeganathan, Lakshmipriya AU - Prajna, N. Venkatesh AU - Prajna, Lalitha DO - https://dx.doi.org/10.4103/ijmm.IJMM_15_532 IS - 1 KW - Amphotericin B/tu [Therapeutic Use] *Antifungal Agents/tu [Therapeutic Use] *Basidiomycota/de [Drug Effects] Basidiomycota/ge [Genetics] *Basidiomycota/ip [Isolation & Purification] *Corneal Ulcer/dt [Drug Therapy] Corneal Ulcer/mi [Microbiology] *Eye Infections, Fungal/dt [Drug Therapy] Eye Infections, Fungal/mi [Microbiology] Female Humans *Keratitis/dt [Drug Therapy] Keratitis/mi [Microbiology] Middle Aged Natamycin/tu [Therapeutic Use] PY - 2018 SE - Dudeja, Lakshey. Department of Cornea and Refractive Surgeries, Aravind Eye Care System, Madurai, Tamil Nadu, India. Jeganathan, Lakshmipriya. Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, Tamil Nadu, India. Prajna, N Venkatesh. Department of Cornea and Refractive Surgeries, Aravind Eye Care System, Madurai, Tamil Nadu, India. Prajna, Lalitha. Department of Ocular Microbiology, Aravind Eye Care System, Madurai, Tamil Nadu, India. SN - 1998-3646 0255-0857 SP - 140-142 ST - Fungal keratitis caused by Laetisaria arvalis T2 - Indian journal of medical microbiology TI - Fungal keratitis caused by Laetisaria arvalis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29735846 VL - 36 ID - 430 ER - TY - JOUR AB - Glaucoma is a group of chronic and evolutive optic neuropathies. It is caracterised by a progressive loss of optic nerve cells with specific modifications of the optic nerve head and of the visual field. A high intraocular pressure is one of the main risk factors. Thereby, the aim of glaucoma treatment is to reduce the intraocular pressure by medical, physical and/or surgical means. Eyedrops are used as initial treatment. As the most effective drops, prostaglandin analogs are the first-line therapy and have only few systemic side effects. Beta-blockers, local carbonic anhydrase inhibitors and alpha-agonists are the other most employed glaucoma drugs. Pilocarpine, acetazolamide and hyperosmotic agents are used in specific cases. Fixed combinations improve the compliance and the quality of life of patients who need several eyedrops. Preservative-free drops reduce ocular toxicity and improve the compliance of the patients. Trabeculoplasty or trabeculectomy are usefull in case of non response on ocular drops, or if the target pressure is not reached, or when dealing with toxicity or compliance matters. Nevertheless, the first procedure has a time-limited efficiency and the second-one exposes the patient to common surgery-related complications. Therefore, despite good results, they are rarely proposed as first-line therapy. AU - Dufrane, R. AU - Ehongo, A. IS - 4 KW - Adrenergic alpha-2 Receptor Agonists/tu [Therapeutic Use] Adrenergic beta-Antagonists/tu [Therapeutic Use] Antihypertensive Agents/tu [Therapeutic Use] Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] *Glaucoma/th [Therapy] Humans Laser Therapy Muscarinic Agonists/tu [Therapeutic Use] Neuroprotective Agents/tu [Therapeutic Use] Trabeculectomy PY - 2014 SN - 0035-3639 SP - 291-7 ST - [Treatment of glaucoma] T2 - Le traitement du glaucoma. TI - [Treatment of glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25675633 VL - 35 ID - 845 ER - TY - JOUR AB - PURPOSE: To evaluate the knowledge and compliance of patients with open-angle glaucoma in order to propose an approach by therapeutic education, validated for other chronic pathologies., METHODS: A questionnaire-based interview of all patients in the waiting room of the glaucoma center is performed by the same health care professional., RESULTS: Out of 200 patients, 73% know they will need to be treated throughout their lives and 95% are aware of the risk of blindness in the absence of appropriate treatment. However, 16% respond that they can be cured, and 54% believe that treatment can save their eyesight. Knowledge increases with the length of follow-up of patients at the glaucoma center beyond one year, but the progress is still insufficient in their confidence that treatment can save their eyesight (36% to 57%), and in the decrease in the number of patients who forget their treatment (56% to 30%)., CONCLUSION: Cognitive knowledge is insufficient to encourage the patient to comply with treatment. It is necessary to consider therapeutic patient education (TPE) techniques, such as described by WHO, in group and/or individual sessions, aimed at building the patient's confidence that treatment can delay the progression of the disease and blindness, strengthening his/her capacity to properly administer the eye drops, managing his/her treatment and coping with frequent side effects. Within this framework, our knowledge of the patients' representations of their glaucoma and its treatment must improve. Copyright © 2016 Elsevier Masson SAS. All rights reserved. AU - Dugast, P. AU - Thiboust, P. AU - Blumen-Ohana, E. AU - Nordmann, J. P. DO - https://dx.doi.org/10.1016/j.jfo.2016.02.004 IS - 6 KW - Adult Aged Aged, 80 and over Blindness/et [Etiology] Disease Progression Female Glaucoma, Open-Angle/et [Etiology] Glaucoma, Open-Angle/th [Therapy] *Glaucoma, Open-Angle Humans Knowledge Male Middle Aged *Needs Assessment Ophthalmic Solutions/tu [Therapeutic Use] Patient Compliance Patient Education as Topic/st [Standards] *Patient Education as Topic Perception Surveys and Questionnaires PY - 2016 SE - Dugast, P. CHNO des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France. Electronic address: pascale.dugast@sfr.fr. Thiboust, P. 5, place de la Republique, 75003 Paris, France. Blumen-Ohana, E. CHNO des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France. Nordmann, J-P. CHNO des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France. SN - 1773-0597 0181-5512 SP - 527-34 ST - [Is there a need for a therapeutic education with patients suffering with open-angle glaucoma? Preliminary inquiry regarding knowledge and patient adherence] T2 - Faut-il une education therapeutique des patients atteints de glaucome a angle ouvert ? Enquete preliminaire des connaissances et de l'observance aupres des patients. TI - [Is there a need for a therapeutic education with patients suffering with open-angle glaucoma? Preliminary inquiry regarding knowledge and patient adherence] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=27257110 VL - 39 Y2 - 20160530// ID - 676 ER - TY - JOUR AB - Purpose To evaluate the knowledge and compliance of patients with open-angle glaucoma in order to propose an approach by therapeutic education, validated for other chronic pathologies. Methods A questionnaire-based interview of all patients in the waiting room of the glaucoma center is performed by the same health care professional. Results Out of 200 patients, 73% know they will need to be treated throughout their lives and 95% are aware of the risk of blindness in the absence of appropriate treatment. However, 16% respond that they can be cured, and 54% believe that treatment can save their eyesight. Knowledge increases with the length of follow-up of patients at the glaucoma center beyond one year, but the progress is still insufficient in their confidence that treatment can save their eyesight (36% to 57%), and in the decrease in the number of patients who forget their treatment (56% to 30%). Conclusion Cognitive knowledge is insufficient to encourage the patient to comply with treatment. It is necessary to consider therapeutic patient education (TPE) techniques, such as described by WHO, in group and/or individual sessions, aimed at building the patient's confidence that treatment can delay the progression of the disease and blindness, strengthening his/her capacity to properly administer the eye drops, managing his/her treatment and coping with frequent side effects. Within this framework, our knowledge of the patients’ representations of their glaucoma and its treatment must improve. © 2016 Elsevier Masson SAS AD - CHNO des Quinze-Vingts, 28, rue de Charenton, Paris, 75012, France 5, place de la République, Paris, 75003, France AU - Dugast, P. AU - Thiboust, P. AU - Blumen-Ohana, E. AU - Nordmann, J. P. DB - Scopus DO - 10.1016/j.jfo.2016.02.004 IS - 6 KW - Adherence Compliance Knowledge Open-angle glaucoma Therapeutic patient education M3 - Article N1 - Export Date: 19 July 2021 PY - 2016 SP - 527-534 ST - Faut-il une éducation thérapeutique des patients atteints de glaucome à angle ouvert ? Enquête préliminaire des connaissances et de l'observance auprès des patients T2 - Journal Francais d'Ophtalmologie TI - Is there a need for a therapeutic education with patients suffering with open-angle glaucoma? Preliminary inquiry regarding knowledge and patient adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975143340&doi=10.1016%2fj.jfo.2016.02.004&partnerID=40&md5=bae5724237bbcf9e21024cbf261021ca VL - 39 ID - 5742 ER - TY - JOUR AB - Diabetic macular edema (DME) resembles a chronic, low-grade inflammatory reaction, and is characterized by blood–retinal barrier (BRB) breakdown and retinal capillary leakage. Corticosteroids are of therapeutic benefit because of their anti-inflammatory, antiangiogenic, and BRB-stabilizing properties. Delivery modes include periocular and intravitreal (via pars plana) injection. To offset the short intravitreal half-life of corticosteroid solutions (~3 hours) and the need for frequent intravitreal injections, sustained-release intravitreal corticosteroid implants have been developed. Dexamethasone intravitreal implant provides retinal drug delivery for 36 months and recently has been approved for use in the treatment of DME. Pooled findings (n=1,048) from two large-scale, randomized Phase III trials indicated that dexamethasone intravitreal implant (0.35 mg and 0.7 mg) administered at £6-month intervals produced sustained improvements in best-corrected visual acuity (BCVA) and macular edema. Significantly more patients showed a 315-letter gain in BCVA at 3 years with dexamethasone intravitreal implant 0.35 mg and 0.7 mg than with sham injection (18.4% and 22.2% vs 12.0%). Anatomical assessments showed rapid and sustained reductions in macular edema and slowing of retinopathy progression. Phase II study findings suggest that dexamethasone intravitreal implant is effective in focal, cystoid, and diffuse DME, in vitrectomized eyes, and in combination with laser therapy. Ocular complications of dexamethasone intravitreal implant in Phase III trials included cataract-related events (66.0% in phakic patients), intraocular pressure elevation 325 mmHg (29.7%), conjunctival hemorrhage (23.5%), vitreous hemorrhage (10.0%), macular fibrosis (8.3%), conjunctival hyperemia (7.2%), eye pain (6.1%), vitreous detachment (5.8%), and dry eye (5.8%); injection-related complications (eg, retinal tear/detachment, vitreous loss, endophthalmitis) were infrequent (<2%). Dexamethasone intravitreal implant offers a viable treatment option for DME, especially in cases that are persistent or treatment (anti-vascular endothelial growth factor/laser) refractory. AD - P.U. Dugel, Retinal Consultants of Arizona, 1101 East Missouri Avenue, PO Box 32530, Phoenix, AZ, United States AU - Dugel, P. U. AU - Bandello, F. AU - Loewenstein, A. C1 - ozurdex(Allergan,United States) C2 - Allergan(United States) DB - Embase DO - 10.2147/OPTH.S79948 KW - NCT01309451 NCT01492400 NCT01571232 NCT01613716 NCT01788475 NCT01790685 NCT01951066 drug implant corticosteroid dexamethasone fluocinolone acetonide triamcinolone acetonide best corrected visual acuity cataract chemosis conjunctival hemorrhage conjunctival hyperemia conjunctivitis device safety diabetic macular edema drug effect drug efficacy drug mechanism drug safety drug tolerability dry eye endophthalmitis human implant fracture intraocular hypertension low level laser therapy macular fibrosis medical device complication multicenter study (topic) nonhuman patient compliance phase 2 clinical trial (topic) phase 3 clinical trial (topic) randomized controlled trial (topic) retina detachment retina hemorrhage retina macula cystoid edema retina maculopathy retina tear retinopathy review sustained drug release visual acuity vitreous body detachment vitreous hemorrhage ozurdex Iluvien Kenalog Retisert Triesence Trivaris LA - English M3 - Review N1 - L605253370 2015-07-30 2015-08-03 PY - 2015 SN - 1177-5483 1177-5467 SP - 1321-1335 ST - Dexamethasone intravitreal implant in the treatment of diabetic macular edema T2 - Clinical Ophthalmology TI - Dexamethasone intravitreal implant in the treatment of diabetic macular edema UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605253370&from=export http://dx.doi.org/10.2147/OPTH.S79948 VL - 9 ID - 2797 ER - TY - JOUR AB - Purpose: To compare the surgical outcomes of trabeculectomy performed in elderly patients (above 80 y) with those of younger controls. Materials and Methods: We retrospectively reviewed the charts of patients who underwent trabeculectomy from January 1, 2009 through April 30, 2011 at the Wills Eye Hospital. Patients over 80 years of age were compared with younger controls. Outcome measures included intraocular pressure (IOP), visual acuity, number of glaucoma medications, surgical complications, and surgical failure. Surgical failure was defined as when IOP>21mm Hg or <20% reduction below baseline or IOP<5mm Hg or reoperation for glaucoma, or loss of light perception. Results: Eighty-six eyes of patients over 80 years of age (range, 81 to 94 y) were compared with 86 eyes of younger controls (range, 22 to 79 y). Mean follow-up time was 23.9±8.0 and 25.1±8.0 months for each group, respectively. After 1 year, the failure rate was 31.3% in the elderly group, compared with 29.5% in the control group (P=0.98). At last follow-up visit, the rate of failure between the groups was similar (P=0.35). Postoperative complications were similar between the groups (P=0.25). Conclusions: The surgical outcomes of trabeculectomy in patients older than 80 years were found to be similar to those of younger controls. Taking into consideration elderly glaucoma patients' general health condition and life expectancy, age alone may not be a barrier to performing glaucoma filtration surgery. Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved. AD - Glaucoma Service at Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA 19107, United States AU - Duman, F. AU - Waisbourd, M. AU - Faria, B. AU - Addis, V. AU - Hsieh, M. AU - Ekici, F. AU - Hark, L. A. AU - Spaeth, G. L. DB - Scopus DO - 10.1097/IJG.0000000000000230 IS - 3 KW - Elderly Glaucoma Trabeculectomy M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2016 SP - e123-e127 ST - Trabeculectomy in patients with glaucoma over 80 years of age: Relatively short-term outcomes T2 - Journal of Glaucoma TI - Trabeculectomy in patients with glaucoma over 80 years of age: Relatively short-term outcomes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962500959&doi=10.1097%2fIJG.0000000000000230&partnerID=40&md5=2a380c55f28583b6c42dc9e6827bc729 VL - 25 ID - 5514 ER - TY - JOUR AB - Purpose: To compare the surgical outcomes of trabeculectomy performed in elderly patients (>80 years) with those of younger controls. Methods: We retrospectively reviewed the charts of patients who underwent trabeculectomy from 1/1/2009 through 4/31/2011 at the Wills Eye Hospital. Patients over 80 years of age were compared with younger controls. Outcome measures included intraocular pressure (IOP), visual acuity, number of glaucoma medications, surgical complications and surgical failure. Surgical failure was deffned as IOP >21 mmHg, <20% reduction below baseline IOP, IOP<5 mmHg, reoperation for glaucoma, or loss of light perception. In addition, the number of missed postoperative visits was documented. Results: Eighty-six eyes of patients over 80 years of age (81-94) were compared with 86 eyes of younger controls (22-79). Mean follow-up time was 23.9±8.0 and 25.1±8.0 months for each group, respectively. Failure rate was 31.3% in the elderly group, compared with 29.5% in the control group (P=0.98). Post-operative complications were similar between the groups (P=0.25). Elderly patients were less likely to return for their follow-up appointments (P=0.04). Conclusions: The surgical outcomes of trabeculectomy in patients older than 80 years of age were similar to those of younger controls. Taking into consideration their general health condition and life expectancy, elderly patients with glaucoma may benefit from surgery in order to preserve their visual function. Appointment reminders and patient navigators may help improve follow-up adherence. AD - F. Duman, Ophthalmology, Antalya Ataturk State Hospital, Antalya, Turkey AU - Duman, F. AU - Waisbourd, M. AU - Faria, B. M. AU - Addis, V. AU - Hsieh, M. AU - Ekici, F. AU - Hark, L. A. AU - Spaeth, G. L. DB - Embase IS - 13 KW - aged aging control group controlled study female follow up glaucoma hospital human intraocular pressure jurisprudence life expectancy major clinical study male peroperative complication postoperative complication reoperation surgery trabeculectomy treatment failure very elderly vision visual acuity LA - English M3 - Conference Abstract N1 - L616122011 2017-05-16 PY - 2014 SN - 0146-0404 SP - 4277 ST - Surgical outcomes of trabeculectomy in patients with glaucoma over 80 years of age T2 - Investigative Ophthalmology and Visual Science TI - Surgical outcomes of trabeculectomy in patients with glaucoma over 80 years of age UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616122011&from=export VL - 55 ID - 2891 ER - TY - JOUR AB - To evaluate the relationship between compliance with replacement frequency (RF) and contact lens (CL)-related problems in silicone hydrogel (SiHy) wearers. Methods: 501 SiHy wearers from seven optometry offices completed surveys regarding their lens wear and any CL related problems which they may have experienced in the preceding 12 months. File review was subsequently conducted at their optometry offices to confirm the information provided. Results: 49% of respondents were wearing 2-week replacement (2WR) and 51% 1-month replacement (1MR) SiHy lenses. 67% wore their lenses for longer than the manufacturers' recommended RF (MRRF) and 60% for longer than their optometrist's recommended RF (ORRF). The mean RF was 2.6× the MRRF for 2WR and 1.5× for 1MR wearers (p< 0.001) with median values of 31 and 37 days, respectively. Twenty-three percent reported signs or symptoms consistent with potential complications relating to CL wear. This rate was significantly higher for wearers who were non-compliant with the ORRF than compliant wearers (26% versus 18%, p= 0.028). It was also higher for those multipurpose solution users who reported never/almost never rubbing and rinsing their lenses when compared with those who did this every night (29% versus 17%, p= 0.007). Conclusions: Two thirds of the SiHy wearers did not comply with the MRRF and 2WR wearers stretched the replacement interval of their lenses to a greater degree than 1MR wearers. Failing to replace lenses when recommended and failing to rub and rinse lenses were associated with a higher rate of patient-reported CL problems. © 2011 British Contact Lens Association. AD - Centre for Contact Lens Research, University of Waterloo, Waterloo, ON, Canada AU - Dumbleton, K. A. AU - Woods, C. A. AU - Jones, L. W. AU - Fonn, D. DB - Scopus DO - 10.1016/j.clae.2011.03.001 IS - 5 KW - Care and maintenance Complications Contact lens Patient compliance Replacement frequency Silicone hydrogels M3 - Article N1 - Cited By :51 Export Date: 19 July 2021 PY - 2011 SP - 216-222 ST - The relationship between compliance with lens replacement and contact lens-related problems in silicone hydrogel wearers T2 - Contact Lens and Anterior Eye TI - The relationship between compliance with lens replacement and contact lens-related problems in silicone hydrogel wearers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052970426&doi=10.1016%2fj.clae.2011.03.001&partnerID=40&md5=97469f7e790d02442ec87d3f2ffce97d VL - 34 ID - 4993 ER - TY - JOUR AB - The compliance to treatment of glaucoma patient has a big importance on the long term vision preservation, as well as on the quality of life of our patients. Unknowing and misunderstanding of disease real implications and the importance of the treatment are present in out every day practice in our patients. We want to identify and analyze these aspects in a glaucoma group of Romanian patients, knowing the implications of socio-economic aspects. AU - Dumitrica, Diana Melinte AU - Stefan, Cornel IS - 3 KW - Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] Female Glaucoma/dt [Drug Therapy] *Glaucoma, Open-Angle/dt [Drug Therapy] Health Knowledge, Attitudes, Practice Health Surveys Humans Intraocular Pressure/de [Drug Effects] Male Medication Adherence/sn [Statistics & Numerical Data] *Patient Compliance/sn [Statistics & Numerical Data] Physician-Patient Relations Quality of Life Reproducibility of Results Romania/ep [Epidemiology] Surveys and Questionnaires PY - 2009 SE - Dumitrica, Diana Melinte. Spitalul Clinic de Urgenta Militar Central "Dr Carol Davila". DIANAMELINTE_17@YAHOO.COM SN - 1220-0875 SP - 130-3 ST - [Compliance and ignorance in glaucoma in Romanian patients] T2 - Complianta si ignoranta in glaucom la pacientii romani. TI - [Compliance and ignorance in glaucoma in Romanian patients] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19899560 VL - 53 ID - 1411 ER - TY - JOUR AB - Background: The MIRO®CORNEA UR is a new keratoprosthesis made of a single piece of flexible, hydrophobic acrylic polymer. The geometry is based on the original Cardona design, allowing epicorneal as well as intrastromal implantation. The haptic is coated with genetically engineered fibronectin, supporting the adherence of surrounding tissue. The flexibility of the haptic minimizes shear stress between keratoprosthesis and ocular tissue, and supports intraocular pressure monitoring in patients with a high incidence of glaucoma.Material and methods: The MIRO®CORNEA UR was implanted into one eye each of four corneally blind patients suffering from autoimmune disease or severe burns. The haptic was implanted in a pocket between the ocular globe and beforehand transplanted autologous buccal mucosa, and additionally secured by a skirt of donor sclera or a collagen membrane.Results: In three out of four eyes, the surrounding tissue firmly adhered to the haptic and penetrated the holes in the haptic. Throughout the follow-up period of 20–52 months, the haptics were firmly integrated into the surrounding tissue without signs of inflammation. Postoperative medication included antibiotics and cortisone drops. The eyes remained stable, well pressurized and free from infection. Neither tissue melting nor ingrowth of epithelial cells along the tissue–keratoprosthesis interface were observed.Conclusions: The MIRO®CORNEA UR keratoprosthesis may be an alternative to the osteo-odonto-keratoprosthesis (OOKP) in the treatment of corneally blind patients with autoimmune disease or severe burns. In the future, indications may include deep corneal vascularization for example after ocular infection. © 2014, Springer-Verlag Wien. AD - Halle Institute of Ophthalmology, Rathenauplatz 12, Halle/Saale, 06114, Germany Fraunhofer Institute for Applied Polymer Research (IAP), Potsdam, Germany CORONIS GmbH Munich, Munich, Germany AU - Duncker, G. I. W. AU - Storsberg, J. AU - Müller-Lierheim, W. G. K. DB - Scopus DO - 10.1007/s00717-014-0243-4 IS - 6 KW - Keratoprosthesis KPro Lyell Pemphigoid Stevens-Johnson M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2014 SP - 250-260 ST - Die voll-synthetische, biologisch beschichtete MIRO® CORNEA UR Keratoprothese – Entwicklung, präklinische Untersuchungen und erste klinische Ergebnisse T2 - Spektrum der Augenheilkunde TI - The fully synthetic, bio-coated MIRO® CORNEA UR keratoprosthesis: development, preclinical testing, and first clinical results UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922333164&doi=10.1007%2fs00717-014-0243-4&partnerID=40&md5=e585a809f3813b169eca4fdad1d0a2ad VL - 28 ID - 5251 ER - TY - JOUR AB - This study was undertaken to assess tolerability, quality of life, and persistency of use and to monitor changes in intraocular pressure (IOP) during the first 6 mo after a switch to fixed combination latanoprost/timolol. In Germany, 271 general ophthalmology practices enrolled patients who were switched from previous ocular hypotensive therapies to latanoprost/timolol for medical reasons. Usual care routines were followed, and IOP was measured at baseline and approximately 6 mo later. Adverse events were recorded throughout. Immediately before switching and at follow-up, patients completed a 29-item quality-of-life questionnaire. Of 1052 patients who met analysis criteria, 748 (71%) switched from combination therapy and 304 (29%) from monotherapy. An insufficient IOP reduction with the previous therapy was a reason for switching in 71% of patients; the desire to simplify to once-daily administration was cited in 66%. Ocular adverse events were reported in 19 patients after the switch, and 97% remained on therapy throughout the follow%up period. After switching, patients were less likely to forget to instill their eyedrops or to feel that their drops had adverse effects; they found it easier to include eyedrop administration in their routine; they were more satisfied with the frequency of instillation; and they were more likely to want to continue with the drops. Across all previous therapies, mean IOP decreased from 20.6+/-3.7 mm Hg to 17.2+/-2.8 mm Hg after the switch (P<.001)-a 14.8% difference. Fixed combination latanoprost/timolol is well tolerated and effective in patients who are switched from other monotherapies or combination therapies for medical reasons. Such a switch may be associated with improved quality of life. AU - Dunker, Stephan AU - Schmucker, Achmed AU - Maier, Hubert AU - Latanoprost/Timolol Fixed Combination Study, Group IS - 2 KW - Aged Aged, 80 and over Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Double-Blind Method Drug Combinations Female *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Latanoprost Male Middle Aged *Patient Compliance Patient Satisfaction Prospective Studies Prostaglandins F, Synthetic/ae [Adverse Effects] Prostaglandins F, Synthetic/tu [Therapeutic Use] *Quality of Life Timolol/ae [Adverse Effects] *Timolol/tu [Therapeutic Use] PY - 2007 SE - Dunker, Stephan. Troisdorf, Germany. stephandun@aol.com SN - 0741-238X SP - 376-86 ST - Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol T2 - Advances in therapy TI - Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17565929 VL - 24 ID - 1602 ER - TY - JOUR AB - Background: Delusional infestation (DI) is characterized by the fixed belief to be infested by small creatures or inanimate particles without medical evidence for this, and abnormal cutaneous sensations explained by these imaginary pathogens. DI has been described in several diseases. As for pathophysiology and neural basis of DI, some evidence suggest a pivotal role of dopamine and published cases secondary to localized brain lesions led to a hypothetical dysfunction in a frontostriato- thalamo-parietal network. We describe a unique case of Parkinson's Disease (PD) and ophtalmologic DI. Case History: A 62-year-old male, with a 5 year diagnosis of PD with poor treatment adherence presented a depressive episode two years before admission. He was hospitalized because he started referring pareidolias, visual and somatic hallucinations and the delirious idea of parasitosis, described as a Loa-loa nematode that moved around the right eye and sometimes exited across the lacrimal and toward the nose bones. He developed conjunctivitis and the ophtalmologic evaluation showed bilateral open angle glaucoma. He was given treatment with low dosis of clozapine with remission of the psychotic symptoms. Conclusions: The presence of psychotic symptoms in PD are considered a neuropsychiatric complication that may have many clinical presentations, being DI a rare symptom in PD. In this case we discuss the pathophysiology implications of PD, dopaminergic drugs, concomitant depressive disorder and ophtalmologic pathology in the development of a DI. AD - S. Durand-Arias AU - Durand-Arias, S. AU - De la Garza-Neme, Y. DB - Embase DO - 10.1176/appi.neuropsych.262 IS - 2 KW - dopamine clozapine delusional parasitosis American Parkinson disease psychosis pathophysiology depression infestation skin sensation diseases brain damage patient compliance nematode laryngeal mask male diagnosis human pathogenesis hallucination parasitosis Loa loa eye nasal bone conjunctivitis open angle glaucoma remission pathology LA - English M3 - Conference Abstract N1 - L71773274 2015-02-09 PY - 2014 SN - 0895-0172 SP - 13 ST - Ophtalmologic delusional parasitosis in parkinson's disease T2 - Journal of Neuropsychiatry and Clinical Neurosciences TI - Ophtalmologic delusional parasitosis in parkinson's disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L71773274&from=export http://dx.doi.org/10.1176/appi.neuropsych.262 http://neuro.psychiatryonline.org/doi/full/10.1176/appi.neuropsych.262abstract VL - 26 ID - 2900 ER - TY - JOUR AB - Micelles have been studied in the targeting of drug substances to different tissues as a nano-sized delivery system for many years. Sustained drug release, ease of production, increased solubility, and bioavailability of drugs with low water solubility are the most important superiorites of micellar carriers. These advantages paved the way for the use of micelles as a drug delivery system in the ocular tissues. The unique anatomical structure of the eye as well as its natural barriers and physiology affect ocular bioavailability of the drugs negatively. Conventional dosage forms can only reach the anterior segment of the eye and are used for the treatment of diseases of this segment. In the treatment of posterior segment diseases, conventional dosage forms are administered sclerally, via an intravitreal injection, or systemically. However, ocular irritation, low patient compliance, and high side effects are also observed. Micellar ocular drug delivery systems have significant promise for the treatment of ocular diseases. The potential of micellar systems ocular drug delivery has been demonstrated by in vivo animal experiments and clinical studies, and they are continuing extensively. In this review, the recent research studies, in which the positive outcomes of micelles for ocular targeting of drugs for both anterior and posterior segment diseases as well as glaucoma has been demonstrated by in vitro, ex vivo, or in vivo studies, are highlighted. AU - Durgun, Meltem Ezgi AU - Gungor, Sevgi AU - Ozsoy, Yildiz DO - https://dx.doi.org/10.1089/jop.2019.0109 IS - 6 PY - 2020 SE - Durgun, Meltem Ezgi. Department of Pharmaceutical Technology, Istanbul University, Istanbul, Turkey. Gungor, Sevgi. Department of Pharmaceutical Technology, Istanbul University, Istanbul, Turkey. Ozsoy, Yildiz. Department of Pharmaceutical Technology, Istanbul University, Istanbul, Turkey. SN - 1557-7732 1080-7683 SP - 323-341 ST - Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics TI - Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem1&NEWS=N&AN=32310723 VL - 36 Y2 - 20200420// ID - 636 ER - TY - JOUR AB - To develop recommendations for the management of medium to high-dose (ie, >7.5 mg but 7le;100 mg prednisone equivalent daily) systemic glucocorticoid (GC) therapy in rheumatic diseases. A multidisciplinary EULAR task force was formed, including rheumatic patients. After discussing the results of a general initial search on risks of GC therapy, each participant contributed 10 propositions on key clinical topics concerning the safe use of medium to high-dose GCs. The final recommendations were selected via a Delphi consensus approach. A systematic literature search of PubMed, EMBASE and Cochrane Library was used to identify evidence concerning each of the propositions. The strength of recommendation was given according to research evidence, clinical expertise and patient preference. The 10 propositions regarded patient education and informing general practitioners, preventive measures for osteoporosis, optimal GC starting dosages, risk-benefit ratio of GC treatment, GC sparing therapy, screening for comorbidity, and monitoring for adverse effects. In general, evidence supporting the recommendations proved to be surprisingly weak. One of the recommendations was rejected, because of conflicting literature data. Nine final recommendations for the management of medium to high-dose systemic GC therapy in rheumatic diseases were selected and evaluated with their strengths of recommendations. Robust evidence was often lacking; a research agenda was created. AD - M.C. Van Der Goes, Department of Rheumatology and Clinical Immunology (F02.127), University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands AU - Duru, N. AU - Van Der Goes, M. C. AU - Jacobs, J. W. G. AU - Andrews, T. AU - Boers, M. AU - Buttgereit, F. AU - Caeyers, N. AU - Cutolo, M. AU - Halliday, S. AU - Da Silva, J. A. P. AU - Kirwan, J. R. AU - Ray, D. AU - Rovensky, J. AU - Severijns, G. AU - Westhovens, R. AU - Bijlsma, J. W. J. DB - Embase Medline DO - 10.1136/annrheumdis-2013-203249 IS - 12 KW - azathioprine bisphosphonic acid derivative calcium cyclosporine etanercept glucocorticoid hydrocortisone infliximab methotrexate nonsteroid antiinflammatory agent placebo prednisone proton pump inhibitor vitamin D adjuvant therapy adrenal insufficiency adrenal suppression article asthma bone density bone necrosis cardiovascular disease cholesterol blood level chronic obstructive lung disease comorbidity consensus corticosteroid induced osteoporosis corticosteroid therapy Delphi study diabetes mellitus diet drug dose reduction drug dose titration drug efficacy drug megadose drug monitoring drug substitution drug withdrawal exercise eye disease fragility fracture giant cell arteritis glaucoma glucose intolerance heart infarction human hypertension immune deficiency increased appetite infection intraocular pressure kidney dysfunction medication compliance mental disease myopathy patient compliance patient education peptic ulcer priority journal recurrent infection rheumatic disease rheumatic polymyalgia rheumatoid arthritis side effect skin atrophy skin disease body weight gain wound care L1 - internal-pdf://3172686010/2952-EULAR evidence-based and consensus-b-2013.pdf LA - English M3 - Article N1 - L52722800 2013-08-13 2013-12-12 PY - 2013 SN - 0003-4967 1468-2060 SP - 1905-1913 ST - EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases T2 - Annals of the Rheumatic Diseases TI - EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52722800&from=export http://dx.doi.org/10.1136/annrheumdis-2013-203249 VL - 72 ID - 2952 ER - TY - JOUR AB - PURPOSE. To determine the ability of antimicrobial peptide melimine-coated contact lenses to reduce the incidence of microbial keratitis (MK) in a rabbit model of contact lens wear. METHODS. In vitro antimicrobial activity of melimine-coated contact lenses was determined against Pseudomonas aeruginosa by viable count and a radiolabeled assay. The amount of lipopolysaccharide (LPS) associated with bacteria bound to melimine-coated and control lenses was determined. Ocular swabs from rabbit eyes were collected for assessment of ocular microflora. A rabbit model for MK was developed that used overnight wear of contact lenses colonized by P. aeruginosa in the absence of a corneal scratch. During lens wear, detailed ocular examinations were performed, and the incidence of MK was investigated. Bacteria associated with worn lenses and infected corneas were determined by viable plate count. RESULTS. Inhibition in viable and total P. aeruginosa adhesion by melimine-coated contact lenses was 3.1 log10 and 0.4 log10, respectively. After colonization, the amount of LPS on lenses was approximately the same with or without melimine. Gram-positive bacteria were found in all the ocular swabs followed by fungus (42%). Melimine-coated lens wear was protective and significantly (odds ratio 10.12; P = 0.012) reduced the incidence of P. aeruginosa-driven MK in the rabbit model. The antimicrobial lenses were associated with significantly (P < 0.001) lower ocular scores, indicating improved ocular signs compared with controls. CONCLUSIONS. This study showed that contaminated contact lenses can produce MK without corneal epithelial defect in an animal model. Melimine-coated contact lenses reduced the incidence of MK associated with P. aeruginosa in vivo. Development of MK requires viable bacteria adherent to contact lenses, and bacterial debris adherent at the lens surface did not cause keratitis. © 2016, Association for Research in Vision and Ophthalmology Inc. All rights reserved. AD - School of Optometry and Vision Science, University of New South Wales, Sydney, Australia School of Chemistry, University of New South Wales, Sydney, Australia AU - Dutta, D. AU - Vijay, A. K. AU - Kumar, N. AU - Willcox, M. D. P. DB - Scopus DO - 10.1167/iovs.16-19882 IS - 13 KW - Antimicrobial Contact lens Melimine Microbial keratitis Pseudomonas Rabbit M3 - Article N1 - Cited By :30 Export Date: 19 July 2021 PY - 2016 SP - 5616-5624 ST - Melimine-coated antimicrobial contact lenses reduce microbial keratitis in an animal model T2 - Investigative Ophthalmology and Visual Science TI - Melimine-coated antimicrobial contact lenses reduce microbial keratitis in an animal model UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992389486&doi=10.1167%2fiovs.16-19882&partnerID=40&md5=824d410794f40a118ab1f478bfdff1a7 VL - 57 ID - 5059 ER - TY - JOUR AB - Our study included 71 patients (38 males and 33 females) with diagnosed open angle glaucoma and healthy 71 persons for control group. Their age ranged from 45 to 70. The patients and healthy persons were divided into three groups: I group--45-55 years old persons, II group--55-65 years old persons, III group--65-75 years old persons. Examination included ophthalmologic and hormonal research. To assess the function of pituitary-adrenal axis, we measured the concentrations of cortisol, aldosterone and adrenocorticotropic hormone (ACTH) in the plasma of patients and control groups by radioimmunoassay method. The level of ACTH was decreased in I and II groups of females and in III group of males. The level of cortisol was increased in all--I, II and III groups of males. Aldosterone was decreased in III group of males and in I and III groups of females. According to our studies there were some changes in secretion of these hormones as well as in their regulation. The findings confirmed the role pituitary-adrenal axis of in the regulation of IOP. In compliance to our data, the investigation of the hormonal status of patients with glaucoma is recommended for complete understanding of glaucoma etiology and pathogenesis. AU - Dzhodzhua, T. AU - Sumbadze, Ts IS - 126 KW - Adrenocorticotropic Hormone/bl [Blood] Adult Aged Aldosterone/bl [Blood] Female *Glaucoma, Open-Angle/pp [Physiopathology] Humans Hydrocortisone/bl [Blood] Male Middle Aged *Pituitary-Adrenal System/pp [Physiopathology] PY - 2005 SE - Dzhodzhua, T. Al. Natishvili Institute of Experimental Morphology of the Academy of Sciences of Georgia. SN - 1512-0112 SP - 74-6 ST - [Pituitary-adrenal axis system condition in patients with open angle glaucoma] T2 - Georgian medical news TI - [Pituitary-adrenal axis system condition in patients with open angle glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16234602 ID - 1710 ER - TY - JOUR AB - PURPOSE: To assess the ability of a novel imaging device to allow physicians to personalize therapeutic regimens based on objective patient drop administration data., METHODS: A novel imaging system was used to record video of the drop technique of subjects in clinic (n=25) or at home (n=17) for 1 week. Video assessment by a reading center was compared with patient reporting and their prescribed regimen with respect to how many drops were applied and how many landed in the eye., RESULTS: Reading center assessment of both drops dispensed and drops landing in the eye was significantly different from the prescribed regimen in the clinic (Pd=0.005, Pi<0.001, respectively) and at-home arms (Pd=0.003, Pi<0.001, respectively)., CONCLUSIONS: This imaging system is a powerful tool to help physicians tailor patient therapy more accurately, to help researchers evaluate new drop therapies with objective rather than subjective data, and to potentially facilitate better patient training for improved drug delivery. AU - Eaton, A. M. AU - Gordon, G. M. AU - Konowal, A. AU - Allen, A. AU - Allen, M. AU - Sgarlata, A. AU - Gao, G. AU - Wafapoor, H. AU - Avery, R. L. DO - https://dx.doi.org/10.1038/eye.2015.155 IS - 10 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] *Drug Delivery Systems/is [Instrumentation] Female *Glaucoma/dt [Drug Therapy] Humans Male *Medication Adherence Middle Aged Monitoring, Physiologic Ophthalmic Solutions Pilot Projects Prospective Studies Self Administration Surveys and Questionnaires *Video Recording/is [Instrumentation] Young Adult PY - 2015 SE - Eaton, A M. Retina Health Center, Fort Myers, FL, USA. Eaton, A M. EDIT Systems Inc., Fort Myers, FL, USA. Gordon, G M. Retina Health Center, Fort Myers, FL, USA. Gordon, G M. EDIT Systems Inc., Fort Myers, FL, USA. Gordon, G M. California Retina Consultants, Santa Barbara, CA, USA. Konowal, A. Konowal Vision Center, Fort Myers, FL, USA. Allen, A. Konowal Vision Center, Fort Myers, FL, USA. Allen, M. Konowal Vision Center, Fort Myers, FL, USA. Sgarlata, A. Retina Health Center, Fort Myers, FL, USA. Gao, G. Retina Health Center, Fort Myers, FL, USA. Gao, G. EDIT Systems Inc., Fort Myers, FL, USA. Wafapoor, H. Retina Health Center, Fort Myers, FL, USA. Wafapoor, H. EDIT Systems Inc., Fort Myers, FL, USA. Avery, R L. EDIT Systems Inc., Fort Myers, FL, USA. Avery, R L. California Retina Consultants, Santa Barbara, CA, USA. SN - 1476-5454 0950-222X SP - 1383-91 ST - A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study T2 - Eye (London, England) TI - A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26358235 VL - 29 Y2 - 20150911// ID - 776 ER - TY - JOUR AB - Examined the frequency of communication barriers among patients on a general medical inpatient service to assess the need for special accommodations for patients with these disabilities. A convenience sample of 611 patients admitted 679 times to a general medical service at a university hospital were evaluated. One or more severe disabilities were found affecting communication among 15.9% of the Ss. Nine percent had altered mental states, 4.7% vision impairments, 2.8% speech impairments, and .5% hearing impairments. Ss with these disabilities were more likely to be male and older than unaffected Ss. Communication disabilities were most commonly due to conditions such as diabetic retinopathy, glaucoma, cataracts, strokes, or other neurologic disorders, or head and neck cancers. Findings suggest that accommodations for communication disabilities may be needed frequently by hospitalized medical patients. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1998-10093-001 AU - Ebert, David A. AU - Heckerling, Paul S. DB - psyh DO - 10.1056/NEJM199807233390416 DP - EBSCOhost IS - 4 KW - communication disabilities among medical inpatients Communication Disorders Hospitals, University Humans Inpatients Vision Disorders Disability Evaluation Hospitalized Patients Medical Patients N1 - Mount Sinai Hosp, Chicago, IL, US. Release Date: 19980901. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Letter. Language: EnglishMajor Descriptor: Communication Disorders; Disability Evaluation. Minor Descriptor: Hospitalized Patients; Medical Patients. Classification: Inpatient & Hospital Services (3379). Population: Human (10); Male (30); Female (40); Inpatient (50). Methodology: Empirical Study. Page Count: 2. Issue Publication Date: Jul, 1998. PY - 1998 SN - 0028-4793 1533-4406 SP - 272-273 ST - Communication disabilities among medical impatients T2 - The New England Journal of Medicine TI - Communication disabilities among medical impatients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1998-10093-001&site=ehost-live&scope=site VL - 339 ID - 4895 ER - TY - JOUR AB - Purpose: Multimorbidity (MM) (presence of more than one chronic condition within a same patient) imposes a heavy burden on patients and health care systems. In contrast to high-income countries, the epidemiology of this phenomenon is unclear in low- and middle-income countries, particularly among Iranian population. Methods: This was a retrospective cohort study using Iranian Health Insurance Organization claims database. A framework was developed for identifying a set of 18 chronic conditions from the pharmacy claims data in Iran. All 2013 outpatient utilizers (aged 18 years or older) were included. Data were analyzed according to number of chronic conditions, gender, and age. The association between MM and utilizations of health services was examined for 2013 to 2016. Results: In total, 481 733 people were included. Cardiovascular diseases (including hypertension) (19.1%), depression/anxiety/sleep disorders (13.7%), and acid-related disorders (10.3%) were the three most prevalent conditions. MM was present in 21.1%. Although prevalence of MM is higher in older age groups and was present in 40% of individuals aged 65 and older, the absolute number of multimorbid patients was higher in those younger than 65 years (66 271 vs 35 386). MM was more prevalent among women (22.1%) compared with men (19.5). After multivariate adjustment for age group and sex, each additional chronic condition was associated with an increase of 2.23 physician visits, 2.86 drugs dispensed, 2.32 laboratory tests, and 1.6 medical imaging. Conclusions: Our findings challenge the current single-disease–based assumption implicit in Iranian health care system. To take account of MM, complementary strategies should be designed and implement in health care system. AD - H. Sadeghi-Bazargani, Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran AU - Ebrahimoghli, R. AU - Janati, A. AU - Sadeghi-Bazargani, H. AU - Hamishehkar, H. AU - Ghaffari, S. AU - Sanaat, Z. AU - Farahbakhsh, M. AU - Farhoudi, M. AU - Khalili-Azimi, A. DB - Embase Medline DO - 10.1002/pds.4925 IS - 1 KW - methotrexate prescription drug acid related disorder adult aged anxiety disorder article billing and claims bipolar disorder bone disease cancer chemotherapy cancer pain cardiovascular disease chronic obstructive lung disease cohort analysis consultation controlled study cross-sectional study dementia depression diabetes mellitus diagnostic imaging enteritis Ewing sarcoma female glaucoma gout groups by age health care system health care utilization health insurance health service human hyperlipidemia hypertension hyperuricemia inflammatory disease iron deficiency anemia laboratory test major clinical study male malignant neoplasm middle aged migraine multiple chronic conditions osteoporosis outpatient care Parkinson disease pharmacy (shop) prevalence priority journal psoriasis respiratory tract disease retrospective study rheumatoid arthritis schizophrenia sex difference sleep disorder thyroid disease very elderly young adult LA - English M3 - Article N1 - L2003631593 2019-11-22 PY - 2020 SN - 1099-1557 1053-8569 SP - 39-47 ST - Epidemiology of multimorbidity in Iran: An investigation of a large pharmacy claims database T2 - Pharmacoepidemiology and Drug Safety TI - Epidemiology of multimorbidity in Iran: An investigation of a large pharmacy claims database UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003631593&from=export http://dx.doi.org/10.1002/pds.4925 VL - 29 ID - 2436 ER - TY - JOUR AB - Aims-The primary objective was to determine which surgical technique gave the best long term visual outcome for infants and young children with bilateral symmetrical cataract in south India. Secondary objectives were to assess complications and the need for further surgical intervention. Methods-A randomised controlled clinical trial was undertaken. 65 children under 10 years old with bilateral cataract had one eye treated by lensectomy and the other by aspiration with primary capsulotomy. Results-56 children (86%) with a mean age at surgery of 53 months were reviewed 3 years after surgery. The overall binocular acuity was 6/18 or better in 57.1% and 6/60 or better in 94.6%. There was no difference in visual acuity between the matched pairs of eyes undergoing aspiration or lensectomy at the third year of follow up (p=0.57). Aspiration eyes were more likely to require a secondary procedure to restore vision than lensectomy eyes (66.1% v 1.8%). Conclusion-Aspiration with primary capsulotomy gives an acceptable visual outcome in this part of India providing that there is good follow up to manage capsule opacification. If secondary intervention is not possible owing to poor compliance with follow up, then lensectomy is likely to give better long term visual rehabilitation providing there is good maintenance and technical support for the lensectomy equipment. AN - WOS:000080190600006 AU - Eckstein, M. AU - Vijayalakshmi, P. AU - Gilbert, C. AU - Foster, A. DA - MAY DO - 10.1136/bjo.83.5.524 IS - 5 PY - 1999 SN - 0007-1161 SP - 524-529 ST - Randomised clinical trial of lensectomy versus lens aspiration and primary capsulotomy for children with bilateral cataract in south India T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - Randomised clinical trial of lensectomy versus lens aspiration and primary capsulotomy for children with bilateral cataract in south India VL - 83 ID - 6189 ER - TY - JOUR AB - Background: Lack of efficacy due to bad compliance caused by intolerance issues is the main reason for a change to a better tolerated ocular treatment, such as using preservative-free (PF) eye drops., Aim: To assess the efficacy and local tolerance after 12 months and patient satisfaction regarding local treatment tolerance and handling at inclusion and after 6 months of PF latanoprost compared to preserved glaucoma eye drops., Methods: This was an international, prospective, and observational real-life study. Up to three visits, one at inclusion and two follow-up visits (one after 6 and one after 12 months) were planned. Efficacy, local tolerance, and patient satisfaction were the main evaluation criteria., Results: Data from 721 patients were available for the statistical analysis. Overall, 64.8% (467/721) of patients switched treatment before inclusion: 62.2% in the preserved and 68.9% in the PF latanoprost group. IOP values were similar between PF latanoprost and preserved eye drops and remained stable at all visits. Ocular signs and symptoms improved after switching to PF latanoprost; the prevalence of conjunctival hyperemia was significantly lower (P=0.0015) at both follow-up visits. At follow-up visit 1, 49.5% of the patients who switched to PF latanoprost decreased or stopped the use of artificial tears. Satisfaction regarding tolerance in patients using PF latanoprost improved significantly after the switch from preserved eye drops to PF latanoprost (88.9% and 42.5%, respectively, P<0.0001)., Conclusion: This first real-life study showed that PF latanoprost was as efficacious but better tolerated than preserved eye drops over a sustained period of 12 months, while providing a significantly higher patient satisfaction and potentially allowing improvement in the patient's daily life. AU - Economou, Mario A. AU - Laukeland, Helene Kolstad AU - Grabska-Liberek, Iwona AU - Rouland, Jean-Francois DO - https://dx.doi.org/10.2147/OPTH.S176605 PY - 2018 SE - Economou, Mario A. Anterior Segment Department, St Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden, mario-alexander.economou@sll.se. Laukeland, Helene Kolstad. Department of Ophthalmology, University Hospital, Trondheim, Norway. Laukeland, Helene Kolstad. Department of Laboratory Medicine, Norwegian University of Science and Technology, Trondheim, Norway. Grabska-Liberek, Iwona. Department of Ophthalmology, Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland. Rouland, Jean-Francois. Department of Ophtalmology, Claude Huriez Hospital, University Hospital, Lille, France. SN - 1177-5467 SP - 2399-2407 ST - Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm4&NEWS=N&AN=30538423 VL - 12 Y2 - 20181126// ID - 591 ER - TY - JOUR AB - BACKGROUND/AIMS: The clinical course for childhood chronic anterior uveitis can vary from mild, self limiting disease to bilateral blindness. The purpose of this study was to identify those risk factors at onset that predict disease severity., METHODS: A retrospective case note review of all patients with painless anterior uveitis diagnosed from 1982 to 1998. Patients were divided into two cohorts based on route of referral, diagnosis, and compliance with treatment. The standard cohort consisted of only those diagnosed from routine screening of juvenile idiopathic arthritis., RESULTS: Complications-cataract surgery, ocular hypertension treatment, and visual acuity <6/24. Remission: inactive uveitis on no topical treatment for >6 months. Results -163 patients were included. 34 patients (21%) developed at least one complication. The most significant predictor of complications was severe disease at onset (p = 0.001). Other factors included uveitis at the first examination (p = 0.034), membership of the non-standard cohort (p = 0.0001), non-oligoarticular disease (p = 0.02), and late onset arthritis (p = 0.024). Male sex was associated with increased complications in the standard cohort (p = 0.001). Factors predisposing to remission included membership of the standard cohort (p = 0.003), onset after 1990 (p = 0.016), white race (p = 0.015), mild disease onset (p = 0.003), and a long gap between arthritis and uveitis onset (p = 0.015)., CONCLUSIONS: It is possible to characterise the severity of those with childhood chronic anterior uveitis at the onset of disease. The majority of patients remit without visually disabling complications. It may be possible to reduce the complication rate by targeting aggressive immunosuppression on high risk patients before complications develop. AU - Edelsten, Clive AU - Lee, Vickie AU - Bentley, Christopher R. AU - Kanski, Jack J. AU - Graham, Elizabeth M. IS - 1 KW - Adolescent Age of Onset *Arthritis, Juvenile/co [Complications] Blindness/et [Etiology] Child Child, Preschool Chronic Disease Cohort Studies Disease-Free Survival Female Follow-Up Studies Humans Infant Male Remission Induction Retrospective Studies Risk Factors Sex Factors Tissue Adhesions/et [Etiology] Uveitis, Anterior/dt [Drug Therapy] *Uveitis, Anterior/et [Etiology] N1 - Comment in (CIN) PY - 2002 SE - Edelsten, Clive. Medical Ophthalmology Department, Great Ormond Street Hospital and Prince Charles Eye Unit, King Edward VII Hospital, Windsor, UK. edelsten@easynet.co.uk SN - 0007-1161 SP - 51-6 ST - An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood T2 - The British journal of ophthalmology T3 - Comment in: Br J Ophthalmol. 2002 Jan;86(1):1-2; PMID: 11801490 [https://www.ncbi.nlm.nih.gov/pubmed/11801490] TI - An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11801504 VL - 86 ID - 1900 ER - TY - JOUR AB - PurposeAdvances in genomic technologies are prompting a realignment of diagnostic and management pathways for rare inherited disease. New models of care are being developed as genomic-based diagnostic testing becomes increasingly relevant within more and more aspects of medicine. This study describes current care models for the provision of a genomic-based diagnosis for patients with inherited retinal dystrophy (IRD) in UK clinical practice.MethodsA structured telephone survey, conducted (in 2014) with all 23 UK Regional Genetics Centres and a sample of specialist ophthalmology centres (n=4), was used to describe models of service delivery and current levels of genomic-based diagnostic testing. Quantitative data were summarised using descriptive statistics. Responses to open-ended questions were summarised using thematic analysis.ResultsOf the 27 centres 10 of them saw IRD patients in 'generic' clinics and 17 centres offered ophthalmic-specific clinics. Extensive regional variation was observed in numbers of patients seen and in how care for the diagnosis and management of IRD was provided.ConclusionsUnderstanding current practice is a necessary first step in the development and evaluation of complex interventions, such as care models for the genomic-based diagnosis of inherited eye conditions. Presented findings here relating to disparities in care provision are potentially linked to previously reported evidence of perceived unmet needs and expectations of IRD service users. This work provides a foundation for the integration of new care models in mainstream medicine. © 2016 Macmillan Publishers Limited All rights reserved. AD - Manchester Centre for Health Economics, University of Manchester, Manchester, United Kingdom Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Saint Mary's Hospital, Oxford Road, Manchester, United Kingdom Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Saint Mary's Hospital, Oxford Road, Manchester, M13 9WL, United Kingdom Centre for Medical Education, School of Medicine, Cardiff University, Cardiff, United Kingdom AU - Eden, M. AU - Payne, K. AU - Jones, C. AU - Wright, S. J. AU - Hall, G. AU - McAllister, M. AU - Black, G. DB - Scopus DO - 10.1038/eye.2016.74 IS - 7 M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2016 SP - 966-971 ST - Identifying variation in models of care for the genomic-based diagnosis of inherited retinal dystrophies in the United Kingdom T2 - Eye (Basingstoke) TI - Identifying variation in models of care for the genomic-based diagnosis of inherited retinal dystrophies in the United Kingdom UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979026567&doi=10.1038%2feye.2016.74&partnerID=40&md5=4051d81a16c73e2b4cdb9f4bb8f4fb37 VL - 30 ID - 5511 ER - TY - JOUR AD - F. Ederer, Advanced Glaucoma Intervention Study, AGIS Coordinating Center, 401 North Washington Street, Rockville, MD 20850, United States AU - Ederer, F. AU - Shields, M. B. DB - Embase IS - 4 KW - antiglaucoma agent ambulatory care argon laser blindness Caucasian clinical trial controlled study deterioration disease control disease severity drug use financial management follow up functional assessment glaucoma glaucoma surgery human incidence intermethod comparison intraocular pressure major clinical study monotherapy Black person optic disk anomaly outcomes research patient monitoring patient selection pressure measurement priority journal race difference randomized controlled trial short survey statistical significance time trabeculectomy trabeculoplasty treatment failure United States vision visual acuity visual field defect LA - English M3 - Short Survey N1 - L40310075 2005-03-16 PY - 2004 SN - 1525-8599 SP - 198-200 ST - The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results T2 - Evidence-Based Eye Care TI - The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40310075&from=export VL - 5 ID - 3729 ER - TY - JOUR AB - PURPOSE: The National Survey of Trabeculectomy was designed to evaluate current practices of glaucoma surgery in the United Kingdom and to determine the success and complication rates of trabeculectomy on a national basis. This paper reports the survey methods, levels of consultant activity, waiting times, indications for surgery and the demographic and clinical characteristics of the patient sample., METHODS: Consultant ophthalmologists performing trabeculectomy in the United Kingdom were studied. Four consecutive patients undergoing trabeculectomy under each consultant prior to 18 June 1996 were retrospectively sampled. Patients were followed prospectively and evaluated 6 and 12 months after surgery. Data were collected by self-administered postal questionnaires. To determine the effects of selection and reporting bias a validation study of 14 randomly selected units was also conducted., RESULTS: Three hundred and eighty-two consultants recruited 1454 eligible patients for analysis. The mean age of patients was 69.2 years (standard deviation 10.9) and 51.7% were male. The underlying diagnosis was primary open angle glaucoma in 89.2%, pseudoexfoliation glaucoma in 5.4%, normal tension glaucoma in 3.8% and pigmentary glaucoma in 1.6%. There was advanced visual field damage in 50.5% of the cohort by the time of listing. The main indications for surgery were failure of medication to control intraocular pressure in 57.1%, progressive visual field loss in 26.5% and progressive optic disc damage in 4.8%. Primary surgery was undertaken in 4.8% of patients. In 80% trabeculectomy was performed within 3 months of listing. However, almost a third of consultants considered individual patient's waiting time too long. Validation studies confirmed that systematic bias did not operate in the selection of patients for the survey or in the reporting of outcomes., CONCLUSION: The findings of this survey are representative of current practices of trabeculectomy by consultants throughout the United Kingdom and show considerable variation in practice. Failure to control intraocular pressure with topical medications was the main indication for surgery. Advanced glaucomatous visual field damage was present at the time of surgery in half the sample. Though most patients were operated on within 3 months of listing, almost a third of consultants considered the wait unacceptably long. AU - Edmunds, B. AU - Thompson, J. R. AU - Salmon, J. F. AU - Wormald, R. P. KW - Age Factors Aged Aged, 80 and over Female Follow-Up Studies *Glaucoma, Open-Angle/su [Surgery] *Health Care Surveys/mt [Methods] Humans Intraocular Pressure Long-Term Care/mt [Methods] Male Middle Aged Patient Selection Prospective Studies Retrospective Studies State Medicine/sn [Statistics & Numerical Data] Trabeculectomy/ae [Adverse Effects] Trabeculectomy/mt [Methods] *Trabeculectomy/sn [Statistics & Numerical Data] United Kingdom/ep [Epidemiology] Waiting Lists N1 - Comment in (CIN) PY - 1999 SE - Edmunds, B. Royal College of Ophthalmologists, London, UK. beth@RCOphth2.win-uk.net SN - 0950-222X SP - 524-30 ST - The National Survey of Trabeculectomy. I. Sample and methods T2 - Eye (London, England) T3 - Comment in: Eye (Lond). 1999 Aug;13 ( Pt 4):493-4; PMID: 10692921 [https://www.ncbi.nlm.nih.gov/pubmed/10692921] TI - The National Survey of Trabeculectomy. I. Sample and methods UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10692924 VL - 13 ( Pt 4) ID - 1959 ER - TY - JOUR AB - AIM: A retrospective case-control study was conducted at a tertiary referral hospital to determine the characteristics of and risk factors for contact lens (CL) related presumed microbial keratitis., METHODS: Two hundred and ninety-one cases of presumed microbial keratitis were retrospectively identified over a 2-year period. Records were reviewed for a history of CL wear and, where identified, CL, demographic, and clinical data were collected. Lens wearing controls (n=186) were identified by a community telephone survey. Multiple logistic regression estimated risk factors for infection and vision loss., RESULTS: Ninety-nine (34%) new cases of presumed microbial keratitis were associated with CL wear. Overnight soft CL use was associated with an increased risk of infection compared to daily disposable CL wear (odds ratio (OR): 8.03, 95% confidence interval (CI): 1.82-35.46). Compared with older CL wearers, 15-24 year olds had a 3.5 times greater risk of infection (OR, 95% CI: 1.7-7.4). Of the 84 cases with available data, 24 (29%) lost two or more lines of best-corrected visual acuity. Delaying treatment by 49-72 h had a 4.5 times (OR, 95% CI: 1.4-14.9) greater risk of visual loss compared to seeking treatment early. Of the 99 cases of infection, 88 were scraped and 78% (69/88) of these returned a positive culture. Gram-positive bacteria were the predominant causative organisms., CONCLUSION: Overnight use of CL and youth carry a greater risk of infection. Practitioners should reinforce the importance of proper CL care at all times, and early presentation following the onset of symptoms. AU - Edwards, K. AU - Keay, L. AU - Naduvilath, T. AU - Snibson, G. AU - Taylor, H. AU - Stapleton, F. IS - 1 KW - Adolescent Adult Blindness/mi [Microbiology] *Contact Lenses/ae [Adverse Effects] Epidemiologic Methods *Eye Infections/et [Etiology] Female Humans *Keratitis/mi [Microbiology] Male Middle Aged Patient Acceptance of Health Care Seasons Travel Young Adult PY - 2009 SE - Edwards, K. School of Optometry and Vision Science, The University of New South Wales, Sydney, Australia. SN - 1476-5454 0950-222X SP - 153-60 ST - Characteristics of and risk factors for contact lens-related microbial keratitis in a tertiary referral hospital T2 - Eye (London, England) TI - Characteristics of and risk factors for contact lens-related microbial keratitis in a tertiary referral hospital UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=17704759 VL - 23 Y2 - 20070817// ID - 1494 ER - TY - JOUR AB - OBJECTIVES: To test the hypothesis that a shopping centre Pop-Up health check combining an intraocular pressure (IOP) check with a general health check (blood pressure (BP)) is more readily accepted by the general public than an IOP check only. We investigate public awareness of IOP compared with BP and the feasibility of measuring IOP in large numbers in a Pop-Up., DESIGN: A cross-sectional study using a tailor-made healthcare Pop-Up., SETTING: The 'Feeling the Pressure' Pop-Up was sited in eight regionally-different shopping centres in England., PARTICIPANTS: Adult members of the public in shopping centres., METHODS: On one day we measured IOP only and on another measured BP and IOP. IOP was measured by Icare IC100 tonometer (Helsinki, Finland). Potential participants were asked about their awareness of IOP and BP and when they last visited their optometrist., RESULTS: More people attended the combined BP + IOP days (461; 60%; 95% CI 56% to 64%) than IOP-only days (307; 40%, 95% CI 37% to 43%) over 16 days of testing. We recorded IOP in 652 participants (median (IQR) age and IOP of 54 (42 to 68) years and 13 (11 to 15) mm Hg, respectively). Fewer people reported awareness about IOP (19%, 95% CI 16% to 23%) compared with BP (71%, 95% CI 66% to 75%). Of 768 participants, 60 (8%) reported no previous optometric eye examination and 185 (24%) reported >2 years since their most recent examination., CONCLUSIONS: Measuring IOP in large numbers of the public via a shopping centre Pop-Up is feasible. Public engagement was greater when a BP check was offered alongside an IOP check, suggesting unfamiliar health checks can be promoted by aligning them with a more familiar check. Our findings hint at strategies for public health schemes that engage the public with their eye health. Copyright © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. AU - Edwards, Laura A. AU - Taylor, Deanna J. AU - Campbell, Peter AU - Shah, Rakhee AU - Edgar, David F. AU - Crabb, David P. DO - https://dx.doi.org/10.1136/bmjopen-2019-030523 IS - 11 KW - Adult Aged *Ambulatory Care Blood Pressure Determination Cross-Sectional Studies England Feasibility Studies Female *Glaucoma/di [Diagnosis] *Health Knowledge, Attitudes, Practice Humans Male Middle Aged *Patient Acceptance of Health Care *Tonometry, Ocular PY - 2019 SE - Edwards, Laura A. Division of Optometry and Visual Science, School of Health Sciences, City University London, London, UK. Taylor, Deanna J. Division of Optometry and Visual Science, School of Health Sciences, City University London, London, UK. Campbell, Peter. Division of Optometry and Visual Science, School of Health Sciences, City University London, London, UK. Shah, Rakhee. Division of Optometry and Visual Science, School of Health Sciences, City University London, London, UK. Edgar, David F. Division of Optometry and Visual Science, School of Health Sciences, City University London, London, UK. Crabb, David P. Division of Optometry and Visual Science, School of Health Sciences, City University London, London, UK david.crabb.1@city.ac.uk. SN - 2044-6055 SP - e030523 ST - Feeling the pressure: a cross-sectional study exploring feasibility of a healthcare Pop-Up for intraocular pressure measurements in shopping centres in England T2 - BMJ open TI - Feeling the pressure: a cross-sectional study exploring feasibility of a healthcare Pop-Up for intraocular pressure measurements in shopping centres in England UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31748291 VL - 9 Y2 - 20191119// ID - 309 ER - TY - JOUR AB - Daratumumab is an anti-CD38 monoclonal antibody approved for use in multiple myeloma in 2015 and under investigation for use in light-chain amyloidosis. We report a case of a patient with amyloidosis who developed bilateral, acute secondary angle closure during an infusion of daratumumab. Ultrasound biomicroscopy obtained 3 days after the onset of her symptoms demonstrated the cause to be bilateral choroidal effusions. Taken together with several previous case reports, the evidence suggests that, like topiramate, daratumumab is associated with the idiosyncratic reaction of choroidal effusions, resulting in a spectrum of clinical outcomes from myopic shift to acute angle closure. The treating oncologist and eye care provider should be aware of these adverse outcomes in any patient undergoing treatment with this medication, as swift recognition and intervention may be vision-saving. AD - R.G. Edwards, 1675 Aurora Court, F731, Aurora, CO, United States AU - Edwards, R. G. AU - Vanderhoof, S. AU - Palestine, A. AU - Seibold, L. K. DB - Embase Medline DO - 10.1097/IJG.0000000000001562 IS - 8 KW - slit lamp ultrasound biomicroscope aciclovir brimonidine cotrimoxazole daratumumab dexamethasone diphenhydramine famotidine hydrocortisone methylprednisolone montelukast ondansetron paracetamol prednisolone adult amyloidosis anterior eye chamber article autologous bone marrow transplantation biomicroscopy case report chemosis choroidal effusion ciliary body clinical article drug infusion evening dosage eye disease eye pain female gonioscopy headache human infection intraocular hypertension intraocular pressure middle aged patient compliance penicillin allergy priority journal secondary angle closure virus infection LA - English M3 - Article N1 - L632947284 2020-09-30 2020-11-09 PY - 2020 SN - 1536-481X 1057-0829 SP - E83-E86 ST - Bilateral Secondary Angle Closure during Daratumumab Infusion: A Case Report and Review of the Literature T2 - Journal of Glaucoma TI - Bilateral Secondary Angle Closure during Daratumumab Infusion: A Case Report and Review of the Literature UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632947284&from=export http://dx.doi.org/10.1097/IJG.0000000000001562 VL - 29 ID - 2394 ER - TY - JOUR AB - Therapeutic compliance in normal tension glaucoma (NTG) patients remains a challenge as NTG can result in irreversible blindness. This study will provide data on medication compliance among patients with NTG, and factors associated with medication compliance.This cross-sectional observational study was performed at the Saiful Anwar Hospital (RSSA), Malang. Data on sex, distance to the hospital, marital status, employment status, living alone or not, and educational level were collected. Respondents were interviewed with the Glaucoma Treatment and Compliance Assessment Tool (GTCAT), and underwent eyedrop weighing to determine therapeutic compliance. Data analysis comprised correlations and regression tests.Data from 40 NTG patients were collected, 42.5% were men and 57.5% were women, aged 58.43 ± 12.5 years. The rate of treatment compliance was 40%. Educational level and glaucoma knowledge were significantly correlated with therapeutic compliance. Other variables which showed higher compliance rates were male gender, lives within 7.5 km from hospital, married, does not work, does not live alone, uses eye drops three times a day, good doctor and patient relationship, and does not forget to bring drugs while traveling. Many factors are associated with higher compliance rates, but only educational level and glaucoma knowledge were significantly correlated with compliance. This highlights the need for patient education to ensure better medication compliance, leading to effective NTG management. AD - M.M. Effendi, Department of Opthamology, Brawijaya University, Saiful Anwar Hospital Malang, East Java, Indonesia AU - Effendi, M. M. AU - Aulia, N. DB - Embase IS - Special Issue KW - eye drops adult aged article blindness clinical article cross-sectional study doctor patient relationship female Glaucoma Treatment and Compliance Assessment Tool human Indonesia knowledge low tension glaucoma male medication compliance observational study patient compliance patient education questionnaire travel LA - English M3 - Article N1 - L627957681 2019-06-11 2019-06-14 PY - 2018 SN - 0974-6005 1755-6783 SP - S603 ST - Topical medication compliance among patients with normal tension glaucoma at the saiful anwar hospital, malang T2 - Annals of Tropical Medicine and Public Health TI - Topical medication compliance among patients with normal tension glaucoma at the saiful anwar hospital, malang UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627957681&from=export VL - 9 ID - 2618 ER - TY - JOUR AD - N. Efron, Eurolens Research, Dept. of Optometry/Vision Sciences, UMIST, Manchester, United Kingdom AU - Efron, N. DB - Embase DO - 10.1016/S1367-0484(01)80032-1 IS - 4 KW - hydrogen peroxide naproxen oxygen animal experiment animal model confocal microscopy contact lens contrast sensitivity controlled study cornea edema cornea ulcer disposable equipment editorial gas permeability history human hydration microbiology Haplorhini nonhuman patient compliance priority journal rating scale soft contact lens temperature measurement LA - English M3 - Editorial N1 - L33115210 2001-12-18 PY - 2001 SN - 1367-0484 SP - 131-142 ST - 2001: A contact lens (space) odyssey T2 - Contact Lens and Anterior Eye TI - 2001: A contact lens (space) odyssey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33115210&from=export http://dx.doi.org/10.1016/S1367-0484(01)80032-1 VL - 24 ID - 3882 ER - TY - JOUR AB - The evolution of contact lens technology and clinical practice over the past three decades has been remarkable, with dramatic improvements in material biocompatibility, better lens designs and care systems, and more flexible and convenient modalities of wear. However, our approach to the aftercare examination has remained conservative, with the general modus operandi having not fully evolved from the difficult, early years of fitting non-regular replacement rigid and low water content hydrogel lenses. In this paper, we review current aftercare practice and in particular, the preferred frequency that lens wearers should return for routine visits and the appropriateness of regulations governing contact lens prescription expiry. Four key clinical reasons for conducting a routine aftercare visit are identified: preserving ocular health, maintaining good vision, optimising comfort and ensuring satisfactory lens fitting performance. Commercial reasons for conducting aftercare visits are also considered. A decision matrix is presented to help practitioners decide on an appropriate time interval between routine aftercare visits. The first aftercare visit should always take place within one to two weeks of lens dispensing. After this, the following time intervals between routine aftercare visits are advised as a general guideline: soft daily disposable, 24-months; soft daily reusable and rigid daily wear, 12-months; soft and rigid extended wear, six months. These aftercare visit frequencies may need to be adjusted when rapid rates of refractive change are anticipated, such as every six months during child/teenager myopic progression and every 12-months during the advancement of presbyopia. Numerous clinical caveats for varying these recommended aftercare frequencies are also discussed. Those new to lens wear should be seen within the first two months of lens dispensing. Regulatory authorities charged with the responsibility of stipulating the validity of a contact lens prescription should continue to allow optometrists to set an expiry date relevant to the circumstances of individual lens wearers. AN - WOS:000640419100002 AU - Efron, N. AU - Morgan, P. B. DA - SEP 1 DO - 10.1111/cxo.12588 IS - 5 PY - 2017 SN - 0816-4622 1444-0938 SP - 411-431 ST - Rethinking contact lens aftercare T2 - CLINICAL AND EXPERIMENTAL OPTOMETRY TI - Rethinking contact lens aftercare VL - 100 ID - 6301 ER - TY - JOUR AU - Egbert, P. R. DB - Embase IS - 3 KW - blindness cataract cataract extraction Ghana glaucoma health care availability health care utilization human India Nepal onchocerciasis Peru priority journal review trachoma xerophthalmia LA - English M3 - Review N1 - L23267260 1993-09-21 PY - 1993 SN - 0882-0538 SP - 163-165 ST - Issues in international ophthalmology T2 - Seminars in Ophthalmology TI - Issues in international ophthalmology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L23267260&from=export VL - 8 ID - 4016 ER - TY - JOUR AB - The aim of the research was to explore structural changes changes in the central departments of the visual analyzer for glaucoma. Materials and Methods: mortem examination was carried out in two people's death was not related to diseases of the central nervous system. Far-advanced glaucoma diagnosis was established and verified in life. There have been mortem, morphological and immunohistochemical studies, including a description of the material, morphometry of the optic nerve cells, optic chiasm, lateral geniculate body and visual cortex. Results: Macroscopic examination revealed severe atrophy of the second cranial nerve with the loss of a considerable number of axons and neurons in the lateral geniculate nucleus. Micrography showed the reduction of the cell layer’s thickness of the visual cortex, the puckering of the neurons’ radius and their nuclei’s radius. Examination also revealed grumose, granular cytoplasm, the presence of lipofuscin in vast numbers, which indicates an atrophic process. In either case, neurodegeneration processes were revealed in deceased patients, who suffered from POAG. All levels of the visual analyzer’s central division were involved in the degenerative process; however, the area of the visual cortex in the area of the calcarine fissure was most noticeable. It should be highlighted that in the optic nerve and IV-V layers cortical amyloid plaques were detected and calf. Conclusion: It was established as a result of autopsy that with POAG degenerative changes occur in the retina ganglion cells, fibers of the second cranial nerve, and the tissue of the visual analyzer’s pathways until visual cortex. This indicates a marked neurodegeneration character POAG, which is confirmed by the presence of the generally accepted criteria of neurodegenerative process as astrogliosis and the presence of beta-amyloid accumulation in the cortex and in the optic nerve. This pathology is similar to other neurodegenerative diseases such as Alzheimer's or Parkinson's. AD - I.R. Gazizova, Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Akademika Pavlova St., 12, Saint Petersburg, Russian Federation AU - Egorov, E. A. AU - Alekseev, V. N. AU - Gazizova, I. R. AU - Martynova, E. B. DB - Embase DO - 10.14704/nq.2020.18.7.NQ20194 IS - 7 KW - analyzer microtome rm 2125RT Visual Analyzer amyloid beta protein beta secretase glial fibrillary acidic protein lipofuscin neuron specific nuclear protein von Willebrand factor Alzheimer disease ambulatory care amyloid plaque anatomicopathological article astrocyte astrocytosis autopsy axon brain cortex calcarine sulcus clinical article confocal laser scanning microscopy cytoplasm degenerative disease geniculate body glaucoma human human cell human tissue immunohistochemistry medicine micrography microscopy morphological adaptation morphometry nerve cell oligodendroglia optic chiasm optic nerve optic nerve atrophy optic nerve cell Parkinson disease peripheral nervous system posthumous care structure analysis visual cortex LA - English M3 - Article N1 - L2005004650 2020-09-07 2021-04-26 PY - 2020 SN - 1303-5150 SP - 66-69 ST - Neurodegenerative change of the visual analyzer in glaucoma T2 - NeuroQuantology TI - Neurodegenerative change of the visual analyzer in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005004650&from=export http://dx.doi.org/10.14704/nq.2020.18.7.NQ20194 VL - 18 ID - 2443 ER - TY - JOUR AD - B. Ehinger AU - Ehinger, B. DB - Medline IS - 23 KW - acute disease adolescent adult aged ambulatory care article cataract child conjunctivitis eye disease glaucoma human middle aged refraction error register strabismus Sweden LA - Swedish M3 - Article N1 - L7526999 1977-07-22 PY - 1977 SN - 0023-7205 SP - 2287-2290 ST - 15,000 diagnoses in outpatient ophthalmologic care T2 - Läkartidningen TI - 15,000 diagnoses in outpatient ophthalmologic care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L7526999&from=export VL - 74 ID - 4113 ER - TY - JOUR AB - Objective: The objective of this article was to describe the incidence, clinical characteristics, and visual outcomes of Vogt- Koyanagi-Harada disease in First Nations and Metis individuals. Design: A retrospective chart review. Participants: Nineteen First Nation and Metis Canadian residents in Northern Alberta. Methods: Electronic records for a 17-year period (1994-2010) were reviewed. Charts were reviewed for age, sex, length of followup, location of primary residence, diagnostic criteria at presentation, disease stage at presentation, duration of symptoms before presentation, ocular and extraocular manifestations at presentation, treatments, compliance, and complications. The time to an eye reaching 20/40, 20/200, and a halving of the baseline visual angle was plotted using Kaplan-Meier methodology. Results: Of 19 First Nations and Metis individuals identified, 84.2% were female, and the average age at presentation was 30.8 years. The most common presenting symptom and sign were blurred vision (89.5%) and anterior segment inflammation (89.5%), respectively. Fifteen (78.9%) patients had extraocular manifestations, the most common being alopecia (26.3%) and cerebrospinal fluid pleocytosis (26.3%). All patients were initially treated with corticosteroids; immunomodulatory therapy was used for 2 (10.5%) patients. Twelve (63.2%) patients experienced ocular complications; 47.4% of patients had difficulty with treatment compliance and attending follow-up appointments. The median time to achieve 20/40 vision was shorter for compliant patients compared with noncompliant patients (P = 0.048). Conclusions: The features of Vogt-Koyanagi-Harada disease in First Nations and Metis Canadians are most similar to series of South Asian and Hispanic patients. Compliant patients were found to achieve 20/40 vision significantly sooner than noncompliant patients. © 2013 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. AD - C.J. Rudnisky, Department of Ophthalmology, University of Alberta, Royal Alexandra Hospital, 10240 Kingsway Avenue NW, Edmonton, AB, Canada AU - Ehmann, D. AU - Tennant, M. T. S. AU - Somani, R. AU - Rudnisky, C. J. DB - Embase Medline DO - 10.1016/j.jcjo.2012.10.008 IS - 3 KW - brimonidine corticosteroid cyclosporine dorzolamide dorzolamide plus timolol latanoprost methotrexate timolol adult alopecia anterior eye segment article blurred vision cataract cerebrospinal fluid child clinical article disease duration epiretinal membrane female follow up gastrointestinal hemorrhage glaucoma headache human immunosuppressive treatment incidence inflammation keratopathy lumbar puncture male medical record review meningism patient compliance pleocytosis retina macula cystoid edema subretinal neovascularization suicidal ideation tinnitus vision visual acuity vitiligo Vogt Koyanagi syndrome LA - English M3 - Article N1 - L369320198 2013-07-23 2013-07-25 PY - 2013 SN - 1715-3360 0008-4182 SP - 146-152 ST - Vogt-Koyanagi-Harada disease in first nations and metis of northern Alberta T2 - Canadian Journal of Ophthalmology TI - Vogt-Koyanagi-Harada disease in first nations and metis of northern Alberta UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369320198&from=export http://dx.doi.org/10.1016/j.jcjo.2012.10.008 VL - 48 ID - 3035 ER - TY - JOUR AB - PURPOSE: Improving adherence to practice guidelines can improve patient safety and quality of care. We sought to establish a regional glaucoma physician collaborative to evaluate and improve adherence to the American Academy of Ophthalmology's Primary Open-angle Glaucoma (POAG) Preferred Practice Pattern (PPP) guidelines., DESIGN: Prospective interventional study., METHODS: The collaborative consisted of 13 glaucoma specialists from 3 practices in Michigan. All consecutive POAG new patient visits were reviewed from each study site to determine physician adherence to the 13 major examination elements of the PPP. In phase 1 of the study, physician adherence rates for each of the recommended examination elements were combined and averaged for all groups. Averages for the collaborative were reported to each site, and each physician received his or her individual adherence rates. Physicians discussed strategies to improve overall adherence to the PPP. Adherence rates were collected in phase 2 to determine if feedback and sharing of strategies resulted in improved adherence., RESULTS: A total of 274 new POAG patient visits from phase 1 and 280 visits from phase 2 were reviewed. After accounting for multiple comparisons, overall improvement approached statistical significance for the evaluation of visual function (91.2% to 96.1%, P < .02) and target intraocular pressure determination (73.7% to 83.2%, P < .01). Improvement for other measures that had a high rate of adherence at baseline (eg, ocular history, pupil examination, and central corneal thickness measurement) was not statistically significant., CONCLUSIONS: It is feasible to establish a regional glaucoma physician collaborative to improve standardization of care for patients with newly diagnosed POAG. Copyright © 2017 Elsevier Inc. All rights reserved. AU - Ehrlich, Joshua R. AU - Wentzloff, Jeffrey N. AU - Imami, Nauman R. AU - Blachley, Taylor S. AU - Stein, Joshua D. AU - Lee, Paul P. AU - Weizer, Jennifer S. DO - https://dx.doi.org/10.1016/j.ajo.2017.04.022 KW - *Glaucoma, Open-Angle/th [Therapy] *Guideline Adherence/td [Trends] Humans Intraocular Pressure Michigan *Ophthalmology/st [Standards] *Practice Patterns, Physicians'/st [Standards] Prospective Studies *Quality Improvement PY - 2017 SE - Ehrlich, Joshua R. Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Wentzloff, Jeffrey N. Grand Traverse Ophthalmology Clinic, Traverse City, Michigan. Imami, Nauman R. Henry Ford Health System, Dearborn, Michigan. Blachley, Taylor S. Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Stein, Joshua D. Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Department of Health Policy and Management, School of Public Health, University of Michigan, Ann Arbor, Michigan. Lee, Paul P. Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Weizer, Jennifer S. Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Electronic address: jweizer@med.umich.edu. SN - 1879-1891 0002-9394 SP - 145-150 ST - Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care T2 - American journal of ophthalmology TI - Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28483494 VL - 179 Y2 - 20170505// ID - 516 ER - TY - JOUR AB - The major causes of impaired vision in the elderly population of the United States are cataracts, macular degeneration, and open-angle glaucoma. Cataracts and macular degeneration usually reduce central vision, especially reading and near activities, whereas chronic glaucoma characteristically attacks peripheral vision in a silent way, impacting balance, walking, and driving. Untreated, these visual problems lead to issues with regard to taking medications, keeping track of finances and personal information, walking, watching television, and attending the theater, and often create social isolation. Thus, visually impaired individuals enter nursing homes 3 years earlier, have twice the risk of falling, and have 4x the risk of hip fracture. Consequently, many elderly with low vision exercise greater demands on community services. With the prospect of little improvement and sustained visual loss, in the face of poor tolerance of low-vision services and not accepting magnification as the only way to read, clinical depression is common. In many instances, however, early and accurate diagnosis can result in timely treatment and can preserve quality of life. This review will look at current diagnostic and therapeutic considerations. Currently, about 20.5 million people in the United States have cataracts. The number will reach 30 million by 2020. About 1.75 million Americans currently have some form of macular degeneration, and the number is estimated to increase to 2.95 million in 2020. Approximately 2.2 million Americans have glaucoma, and by 2020 that number is estimated to be close to 3.4 million people. It is projectedthat by 2030 there will be 72.1 million seniors. With some overlap of the above 3 groups conservatively estimated (if you add the 2030 cataract group to the macular degeneration and glaucoma groups), then about 1 in 2 senior individuals by 2030 may have some significant ocular disease, which could account for about 50% of the healthcare budget for the elderly. © 2012 Mount Sinai School of Medicine. AD - J.W. Eichenbaum, Mount Sinai School of Medicine, New York, NY, United States AU - Eichenbaum, J. W. C2 - Genentech(United States) Regeneron(United States) DB - Embase Medline DO - 10.1002/msj.21303 IS - 2 KW - aflibercept alpha adrenergic receptor stimulating agent alpha tocopherol antiglaucoma agent antiinflammatory agent antioxidant ascorbic acid beta adrenergic receptor blocking agent beta carotene bevacizumab carbonate dehydratase inhibitor cholinergic receptor stimulating agent cupric oxide fluorescent dye prostaglandin derivative ranibizumab retinol steroid verteporfin zinc oxide ADL disability aged aqueous humor flow blindness bradycardia budget capsulotomy cataract ciliary body closed angle glaucoma cryosurgery cyclocryopexy depression diagnostic accuracy dietary intake differential diagnosis disease course drain drug delivery system environmental factor eye infection falling fluorescence angiography glaucoma groups by age health care cost hip fracture human hypokalemia intermethod comparison intraocular pressure iris disease laser surgery lens implant local anesthesia neodymium laser nursing home onset age open angle glaucoma ophthalmoscopy optical coherence tomography patient compliance patient education peripheral vision phacoemulsification pigment disorder postoperative complication preoperative care preoperative evaluation pseudoexfoliation quality of life age related macular degeneration review risk factor shunting side effect social isolation socioeconomics spectral domain optical coherence tomography cerebrovascular accident surgical drainage surgical technique trabeculectomy United States visual acuity visual aid visual field visual impairment CyPass EX-PRESS Glaucoma Filtration Device iStent LA - English M3 - Review N1 - L364631196 2012-04-24 2012-04-27 PY - 2012 SN - 0027-2507 1931-7581 SP - 276-294 ST - Geriatric vision loss due to cataracts, macular degeneration, and glaucoma T2 - Mount Sinai Journal of Medicine TI - Geriatric vision loss due to cataracts, macular degeneration, and glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364631196&from=export http://dx.doi.org/10.1002/msj.21303 VL - 79 ID - 3107 ER - TY - JOUR AB - PURPOSE. Glaucoma devices function in a variety of ways based on the design and materials of construction. A new seton produced by CellPlant, Inc. is simple in design and constructed of a specially modified cellulose. These studies were performed to help understand the relationship between the seton and ocular tissue and to determine if the seton had any adverse effects. METHODS. Rabbits were implanted with the CellPlant device and followed for one year. During this follow-up specimens were collected at 3,6,9 and 12 months. Specimens were preserved in 2% glutaraldehyde plus 2% paraformaldehyde in cacodylate buffer. Light microscopic preparations were embedded in paraffin, cut and stained with hemotoxylin and eosion. Transmission electron microscopy specimens were embedded in epoxy resin. Scanning EM specimens were critical point dried and sputter coated with gold. RESULTS. Morphological analysis revealed that the CellPlant device maintained an open fistula, while avoiding fibrous overgrowth and dense capsular formation. There was no evidence of an inflammatory response and there were no adherent cells or growths on the device. The surgical bed around the device was formed by a loose fibrovascular network that contained many small lymphatic vessels. CONCLUSION. The CellPlant device was well tolerated by the rabbit eye. Our morphological studies showed the device had maintained a large fistula throughout one year and appeared to be permanent; in addition, it effectively lowered intraocular pressure. P, C2,C5,C6,C7. AD - VA Medical Center, Louisville, KY, United States Dean A. McGee Eye Institute, Department of Ophthalmology, University of Oklahoma Health Science Center, Oklahoma City, OK, United States AU - Eiferman, R. A. AU - Li, B. AU - Nordquist, R. E. DB - Scopus IS - 3 M3 - Article N1 - Export Date: 19 July 2021 PY - 1996 ST - Morphological studies on a new seton implanted in rabbits T2 - Investigative Ophthalmology and Visual Science TI - Morphological studies on a new seton implanted in rabbits UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750182781&partnerID=40&md5=118eb36811cf960d4f98245e11ff0aa9 VL - 37 ID - 5794 ER - TY - JOUR AB - Objective: Thyroid eye disease (TED) is characterized by an inflammatory response leading to soft tissue expansion within the bony orbit, which may cause exophthalmos. Studies of glaucoma patients reported periorbital fat atrophy after treatment with prostaglandin analogue drops. We hypothesize that owing to this side effect, prostaglandin analogue drops may benefit patients with TED-induced exophthalmos. Design: Interventional prospective pilot study. Participants: Five adults with inactive TED and exophthalmos treated with a single daily drop of bimatoprost to both eyes for 6 months. Methods: The effect of treatment was evaluated by clinical examinations, Hertel exophthalmometry, marginal reflex distance (MRD), and comparison of digital photographs from before and after treatment by 3 masked oculoplastic surgeons. Patients’ subjective satisfaction was recorded as well. Results: Hertel exophthalmometry showed an improvement in exophthalmos after treatment in 3 patients and no change in 2. Both MRD1 and MRD2 increased (for MRD2 p = 0.007). Two observers correctly identified the photograph taken after treatment in 4 patients, and the third observer correctly identified 2 patients and was indecisive about the others. Four patients reported an improvement in their appearance, although additional eyelid retraction was observed. Adverse effects were minimal. Conclusion: Topical prostaglandin analogue treatment of TED-associated exophthalmos appears safe. Although this pilot study was statistically underpowered to show positive results, our findings suggest a treatment-related reduction in periorbital fat volume in most cases and a subjective improvement in appearance. These findings have potential implications for the treatment of exophthalmos in the clinical setting, but more research is required. AD - M. Eiger-Moscovich, Department of Ophthalmology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel AU - Eiger-Moscovich, M. AU - Stiebel-Kalish, H. AU - Yassur, I. AU - Barash, D. AU - Gaton, D. AU - Avisar, I. C1 - lumigan DB - Embase Medline DO - 10.1016/j.jcjo.2018.09.003 IS - 4 KW - exophthalmometer bimatoprost adult aged application site discomfort article clinical article clinical evaluation clinical examination clinical trial cohort analysis comparative study conjunctival hyperemia digital imaging diplopia drug efficacy drug safety drug withdrawal endocrine ophthalmopathy exophthalmos eye examination eye photography eyelid retraction female human intervention study male marginal reflex distance medication compliance middle aged oculoplastic surgeon patient compliance patient dropout patient satisfaction pilot study pregnancy prospective study side effect single drug dose soft tissue disease soft tissue expansion statistically significant result surgeon therapy effect topical treatment treatment outcome treatment response visual system examination lumigan LA - English M3 - Article N1 - L2001310763 2018-11-28 PY - 2019 SN - 1715-3360 0008-4182 SP - 426-430 ST - Prostaglandin analogue drops for the treatment of soft tissue expansion and exophthalmos in patients with inactive thyroid eye disease T2 - Canadian Journal of Ophthalmology TI - Prostaglandin analogue drops for the treatment of soft tissue expansion and exophthalmos in patients with inactive thyroid eye disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001310763&from=export http://dx.doi.org/10.1016/j.jcjo.2018.09.003 VL - 54 ID - 2490 ER - TY - JOUR AB - The biomechanical environment within the optic nerve head, important in glaucoma, depends strongly on scleral biomechanical properties. Here we use a range of measured nonlinear scleral stress-strain relationships in a finite element (FE) model of the eye to compute the biomechanical environment in the optic nerve head at three levels of intraocular pressure (IOP). Three stress-strain relationships consistent with the 5th, 50th and 95th percentiles of measured human scleral stiffness were selected from a pool of 30 scleral samples taken from 10 eyes and implemented in a generic FE model of the eye using a hyperelastic five-parameter Mooney-Rivlin material model. Computed strains within optic nerve head tissues depended strongly on scleral properties, with most of this difference occurring between the compliant and median scenarios. Also, the magnitudes of strains were found to be substantial even at normal IOP (up to 5.25% in the lamina cribrosa at 15 mmHg), being larger than previously reported values even at normal levels of IOP. We conclude that scleras that are "weak", but still within the physiologic range, will result in appreciably increased optic nerve head strains and could represent a risk factor for glaucomatous optic neuropathy. Estimations of the deformation at the optic nerve head region, particularly at elevated IOP, should take into account the nonlinear nature of scleral stiffness. AU - Eilaghi, Armin AU - Flanagan, John G. AU - Simmons, Craig A. AU - Ethier, C. Ross DO - https://dx.doi.org/10.1007/s10439-009-9879-7 IS - 4 KW - Compressive Strength/ph [Physiology] Computer Simulation Elastic Modulus/ph [Physiology] Humans *Models, Biological *Optic Nerve/ph [Physiology] *Sclera/ph [Physiology] PY - 2010 SE - Eilaghi, Armin. Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, Canada. SN - 1573-9686 0090-6964 SP - 1586-92 ST - Effects of scleral stiffness properties on optic nerve head biomechanics T2 - Annals of biomedical engineering TI - Effects of scleral stiffness properties on optic nerve head biomechanics UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20039133 VL - 38 Y2 - 20091229// ID - 1386 ER - TY - JOUR AB - PURPOSE: To assess glaucoma awareness and screening uptake in relatives of people with glaucoma., METHODS: A questionnaire was administered to 52 patients with primary open-angle glaucoma. They were asked about their awareness of glaucoma clustering within families, and the need for glaucoma screening in relatives of glaucoma patients. Patients were asked to identify one or more first-degree relatives, aged over 40 years and thus eligible for free glaucoma screening in the United Kingdom. These relatives were mailed a similar questionnaire. In performing the statistical analysis we corrected for possible clustering within families. The study was approved in advance by our local ethics committee, and all participants were informed of the United Kingdom's free screening service afterwards., RESULTS: Ninety relatives were identified, of whom 70 (78%) returned questionnaires. Only 53% of responding relatives thought they were at increased lifetime risk of developing glaucoma. Though 81% of relatives had been screened, many were screened infrequently. We compared the responses of patients' siblings and patients' offspring. Perceived lifetime glaucoma risk was similar in the two groups, but the (older) siblings had a significantly lower awareness of the free screening service (p = 0.03) and attended for screening less frequently (p = 0.07). Uptake of regular, free glaucoma screening at least every 2 years was 57% among offspring and 30% among siblings (p = 0.005). Because of selection bias (good communicators were more likely to be invited to participate) the true rates of glaucoma awareness and screening uptake are almost certainly lower than this., CONCLUSIONS: Relatives of people with glaucoma should be made more aware of the need for glaucoma screening and encouraged to use the free screening service. Older relatives should be particularly targeted. AU - Eke, T. AU - Reddy, M. A. AU - Karwatowski, W. S. KW - Aged Aged, 80 and over Communication England Female *Glaucoma, Open-Angle/di [Diagnosis] *Glaucoma, Open-Angle/ge [Genetics] *Health Knowledge, Attitudes, Practice Humans Male Middle Aged *Patient Acceptance of Health Care Risk Assessment *Vision Screening/px [Psychology] Vision Screening/sn [Statistics & Numerical Data] PY - 1999 SE - Eke, T. Department of Ophthalmology, Leicester Royal Infirmary, UK. SN - 0950-222X SP - 647-9 ST - Glaucoma awareness and screening uptake in relatives of people with glaucoma T2 - Eye (London, England) TI - Glaucoma awareness and screening uptake in relatives of people with glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10696318 VL - 13 ( Pt 5) ID - 1958 ER - TY - JOUR AB - Glaucoma, being asymptomatic for relatively late stage, is recognized as a worldwide cause of irreversible vision loss. The eye is an impervious organ that exhibits natural anatomical and physiological barriers which renders the design of an efficient ocular delivery system a formidable task and challenge scientists to find alternative formulation approaches. In the field of glaucoma treatment, smart delivery systems for targeting have aroused interest in the topical ocular delivery field owing to its potentiality to oppress many treatment challenges associated with many of glaucoma types. The current momentum of nano-pharmaceuticals, in the development of advanced drug delivery systems, hold promises for much improved therapies for glaucoma to reduce its impact on vision loss. In this review, a brief about glaucoma; its etiology, predisposing factors and different treatment modalities has been reviewed. The diverse ocular drug delivery systems currently available or under investigations have been presented. Additionally, future foreseeing of new drug delivery systems that may represent potential means for more efficient glaucoma management are overviewed. Finally, a gab-analysis for the required investigation to pave the road for commercialization of ocular novel-delivery systems based on the nano-technology are discussed. Copyright © 2020. Published by Elsevier B.V. AU - El Hoffy, Nada M. AU - Abdel Azim, Engy A. AU - Hathout, Rania M. AU - Fouly, Marwa A. AU - Elkheshen, Seham A. DO - https://dx.doi.org/10.1016/j.ejps.2020.105648 KW - Drug Delivery Systems Eye Glaucoma/dt [Drug Therapy] *Glaucoma Humans Nanotechnology PY - 2021 SE - El Hoffy, Nada M. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt. Abdel Azim, Engy A. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt. Hathout, Rania M. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Fouly, Marwa A. Research Institute of Ophthalmology, Cairo, Egypt. Elkheshen, Seham A. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Electronic address: seham.elkheshen@pharma.cu.edu.eg. SN - 1879-0720 0928-0987 SP - 105648 ST - Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities T2 - European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences TI - Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33227347 VL - 158 Y2 - 20201121// ID - 162 ER - TY - JOUR AB - AIM: The aim of this study was to assess the effect of iStent (trabecular micro-bypass stent) implantation in combination with phacoemulsification on IOP and glaucoma medications and to compare this to the outcome of phacoemulsification alone., PATIENTS AND METHODS: A retrospective consecutive comparative review was undertaken. 131 eyes with ocular hypertension and medically controlled glaucoma underwent phacoemulsification alone (n=78 group I) or combined with gonioscopic-guided implantation of one iStent (n=31, group II) or two iStents (n=22, group III). Patients were assessed at postoperative weeks 1, 3 and 6, and months 3 and 6. Pre- and post-operative measures included visual acuity, IOP and glaucoma medications., RESULTS: Post-operatively at 6 months, mean IOP decreased from 16.3 mmHg to 14.2 mmHg in group I (p<0.01), from 16.7 mmHg to 15.1 mmHg in group II (p<0.16) and from 17.0 to 13.8 in group III (p=0.05). Mean glaucoma medication decreased from 1.9 to 1.6 in group I (8%, p=0.12), from 2.5 to 0.8 in group II (27%, p=0.04), and from 2.1 to 1.0 in group III (45%, p<0.01)., CONCLUSIONS: iStent implantation resulted in similar IOP reduction to phacoemulsification alone but achieved a significantly greater reduction in glaucoma medications. This may improve compliance and quality of life, and reduce health care costs in patients with early to moderate glaucoma. Copyright Georg Thieme Verlag KG Stuttgart . New York. AU - El Wardani, M. AU - Bergin, C. AU - Achache, F. AU - Sharkawi, E. DO - https://dx.doi.org/10.1055/s-0035-1545798 IS - 4 KW - Aged *Antihypertensive Agents/tu [Therapeutic Use] Combined Modality Therapy/is [Instrumentation] Combined Modality Therapy/mt [Methods] Equipment Design Equipment Failure Analysis Female *Glaucoma/di [Diagnosis] *Glaucoma/su [Surgery] Humans Male Miniaturization *Phacoemulsification/is [Instrumentation] *Phacoemulsification/mt [Methods] Retrospective Studies *Stents Treatment Outcome PY - 2015 SE - El Wardani, M. Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland. Bergin, C. Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland. Achache, F. Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland. Sharkawi, E. Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland. SN - 1439-3999 0023-2165 SP - 442-5 ST - Evaluating the trabecular micro-bypass stent combined with phacoemulsification compared to phacoemulsification alone T2 - Klinische Monatsblatter fur Augenheilkunde TI - Evaluating the trabecular micro-bypass stent combined with phacoemulsification compared to phacoemulsification alone UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25902094 VL - 232 Y2 - 20150422// ID - 800 ER - TY - JOUR AB - BACKGROUND: Glaucoma is a progressive disease responsible for the second commonest cause of blindness in the UK. Identifying appropriate patients for hospital care remains an ongoing challenge for all UK hospital glaucoma services. The purpose of our study is to evaluate accuracy and outcome of community optometry referrals before and after implementation of the new general ophthalmic service contract in 2006, the Eyecare Integration Programme pilot in 2008 and the effect of NICE guidelines in glaucoma in 2009, over a 12-year period, METHODS: A retrospective case analysis using a glaucoma electronic patient record was performed encompassing two six-year periods, 2000-2006 (Group A), and 2007-2012 (Group B)., RESULTS: One thousand six hundred twenty-two new patients' records were analysed. Waiting times reduced from 12.3 to 9.4 weeks. Significantly more patients kept first appointment (p = 0.0002) in group B. Glaucoma symptoms were significantly more in group A (p <0.0001) and only three patients lost Snellen' visual acuity before appointment in group B compared to 12 in group A. Documentation of intraocular pressure was made in 74.1% of Group A and 75.9% of Group B, optic disc appearance in 85.4% of Group A, and 93% of Group B and visual fields in 84.4% of Group A and 81.3% of Group B. Significantly less normal (p < 0,0001), more glaucoma suspects (p < 0.0001), more open angle glaucoma (p = 0.0006) and fewer other conditions (p = 0.0024) were present in group B, compared to group A., CONCLUSION: Patients were referred earlier with shorter waiting times for hospital appointments with the new Scottish general ophthalmic service and Eyecare Integration Programme. Additionally there were fewer false positive referrals with more diagnosis of glaucomatous disease. We discuss the benefits of these national screening and referral pathways together with their limitations and further refinements. AU - El-Assal, Karim AU - Foulds, Jonathan AU - Dobson, Stuart AU - Sanders, Roshini DO - https://dx.doi.org/10.1186/s12886-015-0161-5 KW - Adult Aged Aged, 80 and over Contracts *Delivery of Health Care, Integrated/og [Organization & Administration] Documentation/sn [Statistics & Numerical Data] Female *Glaucoma/di [Diagnosis] Glaucoma/ep [Epidemiology] Guideline Adherence *Hospital Departments/st [Standards] Humans Intraocular Pressure/ph [Physiology] Male Middle Aged National Health Programs/og [Organization & Administration] *National Health Programs/st [Standards] Ophthalmology/st [Standards] Ophthalmoscopy *Optometry/st [Standards] Pilot Projects *Practice Guidelines as Topic/st [Standards] Referral and Consultation/og [Organization & Administration] *Referral and Consultation/st [Standards] Retrospective Studies Scotland/ep [Epidemiology] Tonometry, Ocular Visual Field Tests Visual Fields Waiting Lists PY - 2015 SE - El-Assal, Karim. Department of Ophthalmology, Queen Margaret Hospital, Whitefield Road, KY12 0SU, Dunfermline, Fife, UK. karim.el-assal@nhs.net. Foulds, Jonathan. Department of Ophthalmology, Ninewells Hospital, Dundee, UK. Dobson, Stuart. Medical Informatics, Queen Margaret Hospital, Dunfermline, Fife, UK. Sanders, Roshini. Department of Ophthalmology, Queen Margaret Hospital, Whitefield Road, KY12 0SU, Dunfermline, Fife, UK. SN - 1471-2415 SP - 172 ST - A comparative study of glaucoma referrals in Southeast Scotland: effect of the new general ophthalmic service contract, Eyecare integration pilot programme and NICE guidelines T2 - BMC ophthalmology TI - A comparative study of glaucoma referrals in Southeast Scotland: effect of the new general ophthalmic service contract, Eyecare integration pilot programme and NICE guidelines UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26643710 VL - 15 Y2 - 20151207// ID - 759 ER - TY - JOUR AB - Background: Voriconazole (VRC) is a triazole broad spectrum antifungal drug, used in the management of versatile fungal infections, particularly fungal keratitis. The obligatory use of niosomal delivery of VRC may reduce the frequency of dosing intervals resulting from its short biological half time and consequently improve patient compliance., Methods: VRC loaded proniosomes (VRC-PNs) were set by the coacervation technique and completely characterized. The developed formula was comprehensively assessed concerning in- vitro release behavior, kinetic investigation, and its conflict against refrigerated and room temperature conditions. A selected noisomal formula was incorporated into ocusert (VRC-PNs Ocu) formulated by 1% w/w hydroxypropyl methyl cellulose HPMC and 0.1% w/w carbopol 940. Eventually, in vitro antifungal activity against Candida albicans and Aspergillus nidulans was assessed by the cup diffusion method., Results: The optimized VRC-PNs (Pluronic F127: cholesterol weight ratio 1:1 w/w) exhibited the highest entrapment efficiency (87.4+/-2.55%) with a spherical shape, proper size in nano range and a suitable Zeta potential of 209.7+/-8.13 nm and -33.5+/-1.85 mV, respectively. Assurance of drug encapsulation in nanovesicles was accomplished by several means such as attenuated total reflection Fourier-transform infrared spectroscopy, differential scanning calorimetry in addition to powder X-ray diffraction investigations. It displayed a biphasic in vitro release pattern and after 6 months of storage at a refrigerated temperature, the optimized formula preserved its stability. VRC-PNs Ocu proved a very highly significant antifungal activity matched with the free drug or nanosuspension which was extra assured by comparing its mean inhibition zone with that of 5% natamycin market eye drops., Conclusion: In conclusion, VRC-PNs Ocu could be considered as a promising stable sustained release topical ocular nanoparticulate system for the management of fungal infections. Copyright © 2020 El-Emam et al. AU - El-Emam, Ghada Ahmed AU - Girgis, Germeen N. S. AU - El-Sokkary, Mohamed M. Adel AU - El-Azeem Soliman, Osama Abd AU - Abd El Gawad, Abd El Gawad H. DO - https://dx.doi.org/10.2147/IJN.S268208 KW - Animals *Antifungal Agents/ch [Chemistry] *Antifungal Agents/pd [Pharmacology] Antifungal Agents/tu [Therapeutic Use] Candida albicans/de [Drug Effects] Candida albicans/ph [Physiology] *Drug Carriers/ch [Chemistry] *Drug Compounding *Eye/de [Drug Effects] Eye/mi [Microbiology] Eye Infections, Fungal/dt [Drug Therapy] Gels Humans Particle Size Surface-Active Agents/ch [Chemistry] *Voriconazole/ch [Chemistry] *Voriconazole/pd [Pharmacology] Voriconazole/tu [Therapeutic Use] Water/ch [Chemistry] PY - 2020 SE - El-Emam, Ghada Ahmed. Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Girgis, Germeen N S. Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. El-Sokkary, Mohamed M Adel. Department of Microbiology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. El-Azeem Soliman, Osama Abd. Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Abd El Gawad, Abd El Gawad H. Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. SN - 1178-2013 1176-9114 SP - 7825-7840 ST - Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies T2 - International journal of nanomedicine TI - Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med17&NEWS=N&AN=33116503 VL - 15 Y2 - 20201012// ID - 267 ER - TY - JOUR AB - Purpose: The purpose of this study was to determine the factors associated with the outcomes of selective laser trabeculoplasty (SLT). Patients and Methods: This was a database analysis (Lausanne Laser Trabeculoplasty Registry) of patients who had SLT between 2015 and 2017. Exclusion criteria were age below 40 years and diagnosis other than ocular hypertension and open-angle glaucoma. Intraocular pressure (IOP) and number of medications were recorded before and at various follow-ups after laser treatment. Success was defined as "complete" if an IOP reduction of at least 20% was observed at a given time, and "qualified" if any reduction of IOP was observed with either at least a 20% difference from baseline or a reduction in IOP-lowering medications. Associations of complete and qualified success with patients' baseline characteristics, laser settings, and clinical examination findings were studied using multivariate regression and survival analysis. Results: A total of 170 eyes (126 patients) were included. Mean age was 68.3 +/- 12.2 years and 57.9% of the study cohort were female individuals. Average baseline IOP was 18.7 +/- 4.8 mm Hg, and average IOP reduction was 3.3 +/- 4.3 (-17.6% from baseline) and 3.5 +/- 3.9 mm Hg (-18.7% from baseline) at years 1 and 2, respectively. Male sex [odds ratio (OR)=2.79,P=0.02], baseline IOP (OR=1.15,P<0.01), and medical treatment before SLT (OR=2.57,P=0.03) were positive predictors of success. Total energy was associated with the duration of success. SLT outcome was strongly correlated to the outcome of the fellow eye, which represented the strongest predictor (OR=17.33,P<0.01). Conclusions: SLT achieved good IOP-lowering in a majority of patients with mild-to-moderate glaucoma, while it was inefficient in up to 35% of eyes. SLT success in the fellow eye was a strong predictive factor. AN - WOS:000559090500016 AU - Elahi, S. AU - Rao, H. L. AU - Dumitru, A. AU - Mansouri, K. DA - JUL DO - 10.1097/IJG.0000000000001534 IS - 7 PY - 2020 SN - 1057-0829 1536-481X SP - 550-555 ST - Predictors of Success in Selective Laser Trabeculoplasty: Data From the Lausanne Laser Trabeculoplasty Registry T2 - JOURNAL OF GLAUCOMA TI - Predictors of Success in Selective Laser Trabeculoplasty: Data From the Lausanne Laser Trabeculoplasty Registry VL - 29 ID - 6158 ER - TY - JOUR AB - Purpose To determine the extent of geographic variation in the proportion of patients with newly diagnosed open-angle glaucoma (OAG) undergoing visual field (VF) testing, fundus photography (FP), and other ocular imaging (OOI) among patients residing in different US communities. Design Retrospective, longitudinal cohort study. Participants All enrollees with newly diagnosed OAG enrolled in a managed care network between 2001 and 2014. Methods We identified all persons in the plan with incident OAG residing in 201 communities across the United States. All communities contributed ≥20 enrollees. The proportion of enrollees undergoing ≥1 VF test, FP, OOI, and no testing of any type in the 2 years after first OAG diagnosis was determined for each community, and comparisons were made to assess the extent of variation in use of diagnostic testing among patients residing in the different communities. Main Outcome Measures Receipt of VF testing, FP, OOI, or none of these tests in the 2 years after initial OAG diagnosis. Results Of the 56675 enrollees with newly diagnosed OAG, the mean proportion of patients undergoing VF testing within 2 years of initial diagnosis was 74%±7%, ranging from as low as 51% in Rochester, Minnesota, to as high as 95% in Lancaster, Pennsylvania. The mean proportion undergoing OOI was 63%±10% and varied from 34% in Palm Springs/Rancho Mira, California, to 85% in Charleston, South Carolina. The mean proportion receiving FP was 26%±10% and ranged from as low as 3% in Fresno, California, to as high as 57% in Harlingen, Texas. The proportion undergoing no glaucoma testing ranged from 0% in Binghamton, New York, to as high as 35% in 2 other communities. Conclusions In many US communities, a high proportion of patients are undergoing testing according to established practice guidelines. However, in several communities, less than 60% of patients with newly diagnosed OAG are undergoing VF testing in the 2 years after initial OAG diagnosis, and in a few communities >1 in 4 patients have no record of glaucoma diagnostic testing of any type. Additional research is needed to understand factors driving this variation in practice patterns and its impact on patient outcomes. © 2016 American Academy of Ophthalmology. AD - Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, W.K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI 48105, United States Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI, United States AU - Elam, A. R. AU - Blachley, T. S. AU - Stein, J. D. DB - Scopus DO - 10.1016/j.ophtha.2015.10.017 IS - 3 M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2016 SP - 522-531 ST - Geographic variation in the use of diagnostic testing of patients with newly diagnosed open-angle glaucoma presented in part at: The American Glaucoma Society meeting, February 28, 2014, Washington, DC, and the National Medical Association meeting, August 2, 2014, Honolulu, Hawaii T2 - Ophthalmology TI - Geographic variation in the use of diagnostic testing of patients with newly diagnosed open-angle glaucoma presented in part at: The American Glaucoma Society meeting, February 28, 2014, Washington, DC, and the National Medical Association meeting, August 2, 2014, Honolulu, Hawaii UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959287446&doi=10.1016%2fj.ophtha.2015.10.017&partnerID=40&md5=58ab501b18c07d92d04f4abc2b852afb VL - 123 ID - 5303 ER - TY - JOUR AB - Much work has been done to highlight and understand the significant disparities in the use of eye care services, but they continue to exist. We review the existing literature on utilization in high-risk populations to provide a context for understanding what "high-risk" means, to understand the utilization patterns among high-risk populations, and to highlight barriers to appropriate eye care utilization. We also discuss potential approaches to reduce these disparities. © 2013 Elsevier Inc. AD - A.R. Elam, Department of Ophthalmology, University of Pittsburgh Medical Center, 203 Lothrop Street, Pittsburgh, PA15213, United States AU - Elam, A. R. AU - Lee, P. P. DB - Embase Medline DO - 10.1016/j.survophthal.2012.07.005 IS - 4 KW - corticosteroid African American age distribution article awareness cardiovascular risk cataract comorbidity cultural factor denial diabetes mellitus diabetic retinopathy disease severity doctor patient relationship educational status ethnic difference European American eye care eye examination fear finance follow up glaucoma health belief health care access health care availability health care cost health care delivery health care planning health care utilization health education health literacy health program health promotion health service high risk population Hispanic human hypermetropia immigration knowledge language lifestyle medicare myopia open angle glaucoma patient attitude practice guideline prevalence priority journal age related macular degeneration risk factor self report social status social support trust visual impairment LA - English M3 - Article N1 - L52574644 2013-05-13 2013-07-10 PY - 2013 SN - 0039-6257 1879-3304 SP - 348-358 ST - High-Risk Populations for Vision Loss and Eye Care Underutilization: A Review of the Literature and Ideas on Moving Forward T2 - Survey of Ophthalmology TI - High-Risk Populations for Vision Loss and Eye Care Underutilization: A Review of the Literature and Ideas on Moving Forward UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52574644&from=export http://dx.doi.org/10.1016/j.survophthal.2012.07.005 VL - 58 ID - 2987 ER - TY - JOUR AD - D. Eldemire-Shearer, Dept. of Community Health/Psychiatry, The University of the West Indies, Kingston 7, Jamaica AU - Eldemire-Shearer, D. AU - Paul, T. J. AU - Morris, C. DB - Embase Medline IS - 3 KW - adult aged aging alcohol consumption arthritis article cigarette smoking controlled study diabetes mellitus female glaucoma health behavior health care access health care delivery health care facility health care utilization health promotion health status heart disease hospitalization human hypertension Jamaica life expectancy male medical decision making morbidity motivation patient attitude prostate cancer risk factor sex difference LA - English M3 - Article N1 - L35363828 2002-12-03 PY - 2002 SN - 0043-3144 SP - 139-142 ST - Ageing males - An emerging area of concern T2 - West Indian Medical Journal TI - Ageing males - An emerging area of concern UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35363828&from=export VL - 51 ID - 3853 ER - TY - JOUR AB - Diabetic Retinopathy (DR), glaucoma, and age-related macular degeneration (ARMD) are major causes of vision loss and blindness. Women have been found to have a higher prevalence of vision loss than men. Early detection and timely treatment by eye-care providers are necessary to delay disease progression and prevent vision loss. To assess the use of professional eye care among women aged ≥40 years, Centers for Disease Control and Prevention (CDC) analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) for 19 U.S. states for the period 2006-2008. Women who did not have insurance coverage for eye care or who did not receive routine medical check-ups were more likely to report not having the recommended follow-up eye care. The BRFSS vision module incorporated questions related to use of eye-care services. Respondents were asked to select the one main reason they had not visited an eye-care professional in the previous year. CDC continues to provide resources and technical assistance to state health departments to increase surveillance of visual impairment and eye diseases. The findings in this report can be used to help public health agencies plan, implement, and evaluate programs on vision-loss prevention and eye-health promotion at national, state, and local levels and can help allocate scarce resources and target effective intervention activities to similar populations. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 2011-02854-010 AU - Elliott, A. F. AU - Chou, C. F. AU - Zhang, X. AU - Crews, J. E. AU - Saaddine, J. B. AU - Beckles, G. L. AU - Owens-Gary, M. D. DB - psyh DP - EBSCOhost IS - 14 KW - eye-care utilization women eye disease diabetic retinopathy age-related macular degeneration glaucoma vision loss blindness Eye Disorders Health Care Utilization Vision Disorders Human Females N1 - Div of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA, US. Release Date: 20110228. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Eye Disorders; Glaucoma; Health Care Utilization; Vision Disorders. Minor Descriptor: Human Females. Classification: Vision & Hearing & Sensory Disorders (3299); Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). References Available: Y. Page Count: 3. Issue Publication Date: Oct 13, 2010. Copyright Statement: All rights reserved. American Medical Association. 2010. PY - 2010 SN - 0098-7484 1538-3598 SP - 1550-1552 ST - Eye-care utilization among women aged ≥40 years with eye diseases—19 states, 2006-2008 T2 - JAMA: Journal of the American Medical Association TI - Eye-care utilization among women aged ≥40 years with eye diseases—19 states, 2006-2008 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-02854-010&site=ehost-live&scope=site VL - 304 ID - 4868 ER - TY - JOUR AB - Objective: To examine the rate of self-reported vision impairment, eye disease, and eye care utilization among residents of subsidized senior housing (SSH) communities. Methods: In this cross-sectional, observational study, residents of 14 SSH communities in Jefferson County, AL, USA self-reported their vision status and eye care utilization as part of vision screening events held in their community. Results: Two hundred and thirty-seven residents self-reported their vision status, presence of eye disease, and eye care utilization. A third of participants (33.3%) reported difficulty with distance vision while 38% reported difficulty with near vision. Rates of eye disease among this sample were as follows: 40.3% reported having cataracts, 13.6% reported having glaucoma, 4.2% reported having age-related macular degeneration, and 5.5% reported having diabetic retinopathy. The majority of participants (52.8%) had not been to see an eye care provider within the last year. Persons with vision impairment were less likely to report having seen an eye care provider within the last year than those without impairment (p = .03). Conclusion: This study illuminates the low utilization of eye care among socioeconomically disadvantaged older adults residing in SSH, especially among those with vision impairment and eye disease. Vision-related health care is important in maintaining both physical and mental health in older adults. (PsycInfo Database Record (c) 2021 APA, all rights reserved) AD - Elliott, Amanda F. AN - 2019-68309-001 AU - Elliott, Amanda F. AU - Heskett, Megan AU - Spiker, Christopher AU - McGwin, Gerald, Jr. AU - Owsley, Cynthia DB - psyh DO - 10.1080/13607863.2019.1683813 DP - EBSCOhost IS - 2 KW - vision impairment eye care older adults Aged Alabama Blindness Cross-Sectional Studies Eye Diseases Housing Humans Vision Disorders Elder Care Eye Disorders Health Care Utilization Residential Care Institutions Geriatrics N1 - College of Nursing, University of Florida, Gainesville, FL, US. Release Date: 20191111. Correction Date: 20210701. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishGrant Information: Owsley, Cynthia. Major Descriptor: Elder Care; Eye Disorders; Health Care Utilization; Residential Care Institutions. Minor Descriptor: Geriatrics. Classification: Vision & Hearing & Sensory Disorders (3299); Nursing Homes & Residential Care (3377). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Behavioral Risk Factor Surveillance System. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Feb, 2021. Publication History: Accepted Date: Oct 15, 2019; First Submitted Date: Jun 12, 2019. Copyright Statement: Informa UK Limited, trading as Taylor & Francis Group. 2019. Sponsor: Lucille Beeson Trust. Recipients: No recipient indicated Sponsor: Prevent Blindness. Recipients: No recipient indicated Sponsor: EyeSight Foundation of Alabama, US. Recipients: No recipient indicated Sponsor: Able Trust. Recipients: No recipient indicated Sponsor: Alfreda J. Schuler Trust. Recipients: No recipient indicated Sponsor: National Institutes of Health, US. Grant: P30- AG22838. Recipients: Owsley, Cynthia Sponsor: Research to Prevent Blindness Inc.. Recipients: No recipient indicated PY - 2021 SN - 1360-7863 1364-6915 SP - 360-366 ST - Low rates of eye care utilization among visually impaired subsidized senior housing residents T2 - Aging & Mental Health TI - Low rates of eye care utilization among visually impaired subsidized senior housing residents UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-68309-001&site=ehost-live&scope=site Amanda.elliott@ufl.edu VL - 25 ID - 4800 ER - TY - JOUR AD - Addenbrookes Hospital, Cambridge AU - Elliott, A. J. DB - Embase Medline IS - 4 KW - clinical article education glaucoma human letter methodology patient compliance patient education patient information psychological aspect LA - English M3 - Letter N1 - L20018913 1990-02-02 PY - 1989 SN - 0950-222X SP - 485-486 ST - Glaucoma: Ignorance and apathy T2 - Eye TI - Glaucoma: Ignorance and apathy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L20018913&from=export VL - 3 ID - 4047 ER - TY - JOUR AB - AIMS: To evaluate whether diabetes mellitus is a risk factor for the development of primary open angle glaucoma or ocular hypertension (OHT)., METHODS: A historical cohort study of an unselected population comprising all residents of the Tayside region of Scotland was performed using record linkage techniques followed by case note review. Ascertainment of prevalent diabetes was achieved using the Diabetes Audit and Research in Tayside Study (DARTS) validated regional diabetes register. Glaucoma and treated OHT were defined by encashment of community prescriptions and the statutory surgical procedure coding database., RESULTS: The study population comprised 6631 diabetic subjects and 166 144 non-diabetic subjects aged >40 years without glaucoma or OHT at study entry. 65 patients with diabetes and 958 without diabetes were identified as new cases of glaucoma or treated OHT during the 24 month study period, yielding a standardised morbidity ratio of 127 (95% CI, 96-158). Case note review demonstrated non-differential misclassification of prevalent glaucoma and OHT as incident disease (diabetic cohort 20%, non-diabetic cohort 24%; p=0.56) primarily as a result of non-compliance in medically treated disease. Removing misclassified cases and adjusting for age yielded an incidence of primary open angle glaucoma in diabetes of 1.1/1000 patient years (95% CI, 0.89-1. 31) compared to 0.7/1000 patient years (95% CI, 0.54-0.86) in the non-diabetic cohort; RR 1.57 (95% CI, 0.99-2.48)., CONCLUSIONS: This study failed to confirm an association between diabetes mellitus and primary open angle glaucoma and ocular hypertension. A non-significant increase in diagnosed and treated disease in the diabetic population was observed, but evidence was also found that detection bias contributes to this association. AU - Ellis, J. D. AU - Evans, J. M. AU - Ruta, D. A. AU - Baines, P. S. AU - Leese, G. AU - MacDonald, T. M. AU - Morris, A. D. IS - 11 KW - Adult Bias Cohort Studies *Diabetes Complications Diabetes Mellitus/ep [Epidemiology] Diabetic Angiopathies/ep [Epidemiology] Diabetic Angiopathies/et [Etiology] Female Glaucoma, Open-Angle/ep [Epidemiology] Glaucoma, Open-Angle/et [Etiology] Humans Incidence Male Middle Aged Ocular Hypertension/ep [Epidemiology] *Ocular Hypertension/et [Etiology] Prevalence Risk Factors Scotland/ep [Epidemiology] N1 - Comment in (CIN) PY - 2000 SE - Ellis, J D. Department of Ophthalmology, Ninewells Hospital and Medical School, Ninewells Road, Dundee DD1 9SY, UK. JDE@14ing.freeserve.co.uk SN - 0007-1161 SP - 1218-24 ST - Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit T2 - The British journal of ophthalmology T3 - Comment in: Br J Ophthalmol. 2000 Nov;84(11):1216; PMID: 11049942 [https://www.ncbi.nlm.nih.gov/pubmed/11049942] TI - Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11049943 VL - 84 ID - 1946 ER - TY - JOUR AB - Aims-To evaluate whether diabetes mellitus is a risk factor for the development of primary open angle glaucoma or ocular hypertension (OHT). Methods-A historical cohort study of an unselected population comprising all residents of the Tayside region of Scotland was performed using record linkage techniques followed by case note review. Ascertainment of prevalent diabetes was achieved using the Diabetes Audit and Research in Tayside Study (DARTS) validated regional diabetes register. Glaucoma and treated OHT were defined by encashment of community prescriptions and the statutory surgical procedure coding database. Results-The study population comprised 6631 diabetic subjects and 166 144 non-diabetic subjects aged > 40 years without glaucoma or OHT at study entry. 65 patients with diabetes and 958 without diabetes were identified as new cases of glaucoma or treated OHT during the 24 month study period, yielding a standardised morbidity ratio of 127 (95% CI, 96-158). Case note review demonstrated non-differential misclassification of prevalent glaucoma and OHT as incident disease (diabetic cohort 20%, non-diabetic cohort 24%; p=0.56) primarily as a result of non-compliance in medically treated disease. Removing misclassified cases and adjusting for age yielded an incidence of primary open angle glaucoma in diabetes of 1.1/1000 patient years (95% CI, 0.89-1.31) compared to 0.7/1000 patient years (95% CI, 0.54-0.86) in the non-diabetic cohort; RR 1.57 (95% CI, 0.99-2.48). Conclusions-This study failed to confirm an association between diabetes mellitus and primary open angle glaucoma and ocular hypertension. A non-significant increase in diagnosed and treated disease in the diabetic population was observed, but evidence was also found that detection bias contributes to this association. AD - J.D. Ellis, Department of Ophthalmology, Ninewells Hospital/Medical School, Ninewells Road, Dundee DD1 9SY, United Kingdom AU - Ellis, J. D. AU - Evans, J. M. M. AU - Ruta, D. A. AU - Baines, P. S. AU - Leese, G. AU - MacDonald, T. M. AU - Morris, A. D. C1 - diamox ganda propine simplene trusopt DB - Embase Medline DO - 10.1136/bjo.84.11.1218 IS - 11 KW - acetazolamide epinephrine adrenalin plus guanethidine adrenergic receptor stimulating agent agents acting on the eye antiglaucoma agent antihypertensive agent beta adrenergic receptor blocking agent betaxolol carbachol carbonate dehydratase inhibitor carteolol dipivefrine dorzolamide guanethidine levobunalol metipranolol miotic agent pilocarpine timolol maleate unclassified drug adult aged article clinical protocol cohort analysis controlled study data base diabetes mellitus diagnostic procedure disease association disease classification eye surgery human incidence intraocular hypertension major clinical study clinical audit morbidity open angle glaucoma patient compliance population research prescription prevalence priority journal register risk assessment risk factor statistical analysis United Kingdom diamox ganda propine simplene trusopt LA - English M3 - Article N1 - L30814690 2000-11-18 PY - 2000 SN - 0007-1161 SP - 1218-1224 ST - Glaucoma incidence in an unselected cohort of diabetic patients: Is diabetes mellitus a risk factor for glaucoma? T2 - British Journal of Ophthalmology TI - Glaucoma incidence in an unselected cohort of diabetic patients: Is diabetes mellitus a risk factor for glaucoma? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30814690&from=export http://dx.doi.org/10.1136/bjo.84.11.1218 VL - 84 ID - 3906 ER - TY - JOUR AB - PURPOSE: To understand factors that influence African-Americans' attitude toward eye examinations., METHODS: Ten focus groups were conducted with 86 African-Americans. Four focus groups were conducted with people 65 years of age and older who had not received a dilated fundus examination (DFE) in the past 2 years, two groups were held with people 65 years of age and older who had had a recent DFE, and two groups each were held with people 40 to 64 years of age, with and without recent DFEs. Focus group interviews were conducted by using a moderator guide to address perceived benefits of and barriers to getting an eye examination; motivators for getting DFEs; and knowledge of eye examinations, glaucoma, and diabetic retinopathy. Participants also completed a questionnaire that provided demographic information. Quantitative and qualitative analyses were conducted., RESULTS: Cost or lack of sufficient insurance was identified as the most important barrier to getting a DFE. Also frequently mentioned was not having any symptoms and being too busy. The most frequently cited benefit of getting a DFE was to help prevent eye disease, whereas the most frequently reported motivating factor was experiencing a vision problem. Regarding knowledge, many people did not know the risk factors for glaucoma, but seemed to have a better understanding of how to reduce the effects of diabetes on their eyes., CONCLUSIONS: Study findings identified important links between financial resources and experiencing a vision problem and the adoption of preventive eye care in an urban African-American population. AU - Ellish, Nancy J. AU - Royak-Schaler, Renee AU - Passmore, Susan R. AU - Higginbotham, Eve J. IS - 5 KW - Adult *African Americans/px [Psychology] Aged Baltimore *Eye Diseases/di [Diagnosis] Female Focus Groups Health Care Costs *Health Knowledge, Attitudes, Practice Health Services Accessibility Humans Insurance, Health Male Middle Aged Motivation *Mydriatics/ad [Administration & Dosage] *Physical Examination *Pupil/de [Drug Effects] Surveys and Questionnaires PY - 2007 SE - Ellish, Nancy J. Departments of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. nellish@umaryland.edu SN - 0146-0404 SP - 1989-94 ST - Knowledge, attitudes, and beliefs about dilated eye examinations among African-Americans T2 - Investigative ophthalmology & visual science TI - Knowledge, attitudes, and beliefs about dilated eye examinations among African-Americans UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17460251 VL - 48 ID - 1605 ER - TY - JOUR AB - AIM: To study the particularities of late post-traumatic glaucoma with irido-corneal angle injuries in black Cameroonians., MATERIAL AND METHODS: Retrospective analysis of 1343 files of glaucomatous patients was carried out from January 1991 to December 2001 at the Douala General Hospital in Cameroon in Central Africa. Fifty seven of them had post-traumatic glaucoma. Of these 28 were secondary to irido-corneal angle injuries., RESULTS: The prevalence of post-traumatic glaucoma related to irido-corneal angle injuries in our population was 2.1%. The mean patients age was 45.9 +/- 18.3 years (range, 17 to 67 years). The time from injury to diagnosis ranged from 1 year 4 months to 7 years (median: 3.7 years). The follow-up period ranged from 3 months to 5 years 6 months, with a mean of 1.7 +/- 1.9 years. The prevalence of monocular blindness was 61.9% and 81% at the first and last examination respectively. The mean intraocular pressure was 36.9 +/- 13.8 mmHg (range: 22 and 66 mmHg) at the first examination and 24.3 +/- 13 mmHg (range: 12 and 29 mmHg) at the last examination. The mean recorded cup/disc ratio was 0.8 +/- 0.2. It was equal to 1.0 in 61.9% of cases. Irido-corneal angle recession was the most common lesion (61.9%) followed by iridodialysis (38.1%) and cyclodialysis (14.3%). Normalization of the intraocular pressure was achieved with medical treatment in 23.8% and with trabelectomy in 12.3% of the cases. Neovascular glaucoma was found in 4.8% of the cases., CONCLUSION: The treatment of secondary post-traumatic open angle glaucoma is disappointing. The patients are young, the disease is advanced, and the compliance and follow-up are poor. The prevention of post-traumatic glaucoma is based on the control of ocular trauma and the periodic follow-up of patients with and history of non perforating injury of the eye. AU - Ellong, A. AU - Ebana Mvogo, C. AU - Nyouma Moune, E. AU - Bella-Hiag, A. AU - Ngosso, A. AU - Njoh Litumbe, C. IS - 298 KW - Adolescent Adult Aged Blindness/ep [Epidemiology] Cameroon/ep [Epidemiology] Comorbidity Corneal Injuries *Eye Injuries/ep [Epidemiology] Female Follow-Up Studies Glaucoma, Open-Angle/di [Diagnosis] *Glaucoma, Open-Angle/ep [Epidemiology] *Glaucoma, Open-Angle/th [Therapy] Humans Iris/in [Injuries] Male Middle Aged Prevalence Retrospective Studies Treatment Outcome PY - 2005 SE - Ellong, A. Faculte de Medecine et des Sciences Biomedicales, Universite de Yaounde I, Cameroun. ellong_august@hotmail.com SN - 0081-0746 SP - 21-8 ST - [Post-traumatic glaucoma with irido-corneal angle injuries in Cameroon] T2 - Le glaucome post-traumatique a angle ouvert au Cameroun. TI - [Post-traumatic glaucoma with irido-corneal angle injuries in Cameroon] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16422218 ID - 1696 ER - TY - JOUR AB - AIM: To study the particularities of late post-traumatic glaucoma with irido-corneal angle injuries in black Cameroonians. MATERIAL AND METHODS: Retrospective analysis of 1343 files of glaucomatous patients was carried out from January 1991 to December 2001 at the Douala General Hospital in Cameroon in Central Africa. Fifty seven of them had post-traumatic glaucoma. Of these 28 were secondary to irido-corneal angle injuries. RESULTS: The prevalence of post-traumatic glaucoma related to irido-corneal angle injuries in our population was 2.1%. The mean patients age was 45.9 +/- 18.3 years (range, 17 to 67 years). The time from injury to diagnosis ranged from 1 year 4 months to 7 years (median: 3.7 years). The follow-up period ranged from 3 months to 5 years 6 months, with a mean of 1.7 +/- 1.9 years. The prevalence of monocular blindness was 61.9% and 81% at the first and last examination respectively. The mean intraocular pressure was 36.9 +/- 13.8 mmHg (range: 22 and 66 mmHg) at the first examination and 24.3 +/- 13 mmHg (range: 12 and 29 mmHg) at the last examination. The mean recorded cup/disc ratio was 0.8 +/- 0.2. It was equal to 1.0 in 61.9% of cases. Irido-corneal angle recession was the most common lesion (61.9%) followed by iridodialysis (38.1%) and cyclodialysis (14.3%). Normalization of the intraocular pressure was achieved with medical treatment in 23.8% and with trabelectomy in 12.3% of the cases. Neovascular glaucoma was found in 4.8% of the cases. CONCLUSION: The treatment of secondary post-traumatic open angle glaucoma is disappointing. The patients are young, the disease is advanced, and the compliance and follow-up are poor. The prevention of post-traumatic glaucoma is based on the control of ocular trauma and the periodic follow-up of patients with and history of non perforating injury of the eye. AD - Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Cameroun., Cameroon AU - Ellong, A. AU - Ebana Mvogo, C. AU - Nyouma Moune, E. AU - Bella-Hiag, A. AU - Ngosso, A. AU - Njoh Litumbe, C. DB - Scopus IS - 298 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2005 SP - 21-28 ST - Le glaucome post-traumatique a angle ouvert au Cameroun. T2 - Bulletin de la Société belge d'ophtalmologie TI - Post-traumatic glaucoma with irido-corneal angle injuries in Cameroon UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646076245&partnerID=40&md5=708b73116ae1ff6e6d81bc546edfcce7 ID - 5589 ER - TY - JOUR AB - OBJECTIVES: To determine the prevalence and the various types of glaucoma in a Black urban Cameroonian population., MATERIAL AND METHOD: A retrospective analysis of 1,343 glaucomatous patients' files (757 men and 586 women) from a total of 24,462 Cameroonian patients of all ages was carried out from January 1991 to December 2001 in the Douala General Hospital in Cameroon in Central Africa., RESULTS: The prevalence of glaucoma of all types is 5.5%. It increases with age. Of subjects with glaucoma, 79.6% had not been previously diagnosed. The mean patient's age is 53.3 (+/-17.1) years. The mean intraocular pressure is 29.6 (+/-12.6) mmHg. The mean vertical cup-disc ratio is 0.7 (+/-0.2). The prevalence of primary glaucoma of any type is 4.5%. The overall prevalence of primary open-angle glaucoma, primary angle-closure glaucoma and congenital glaucoma was 4.3%, 0.03% and 0.07%, respectively. The normal-tension glaucoma is rare in this study (6.3% of primary open-angle glaucoma). The most common form of primary angle closure glaucoma is chronic angle closure glaucoma (61,1%) and is usually undiagnosed due to a lack of gonioscopic evaluation. The prevalence of secondary glaucoma of any type is 1%. The most common forms of secondary angle closure glaucoma were neovascular glaucoma (47.4% of cases with the prevalence of 0.5%) and post-traumatic glaucoma (23.1% of cases with the prevalence of 0.2%). Prevalence of bilateral and monocular blindness due to glaucoma is 8% (108/1,343) and 32.9% (441/1,343) respectively of glaucoma patients., CONCLUSION: This study confirms the high prevalence of glaucoma in a black African population. Gonioscopy is an important diagnostic tool that should be promoted to guide more effective glaucoma treatment in our region. The very high rate of blindness among the glaucoma patients in Cameroon is due to a lack of care. The patients are young, the disease is advanced, and compliance and follow-up are poor. Glaucoma surgery therefore offers a favourable option from an economical standpoint. Glaucoma is a devastating disease and constitutes a significant public health problem. AU - Ellong, Augustin AU - Mvogo, Come Ebana AU - Bella-Hiag, Assumpta Lucienne AU - Mouney, Emilienne Nyouma AU - Ngosso, Angele AU - Litumbe, Calex Njoh IS - 2 KW - Adolescent Adult Age Factors Aged Aged, 80 and over Blindness/ep [Epidemiology] Cameroon/ep [Epidemiology] Child Child, Preschool Female Glaucoma/cl [Classification] Glaucoma/cn [Congenital] *Glaucoma/ep [Epidemiology] Glaucoma, Angle-Closure/ep [Epidemiology] Glaucoma, Neovascular/ep [Epidemiology] Glaucoma, Open-Angle/ep [Epidemiology] Humans Infant Intraocular Pressure Male Middle Aged Prevalence Retrospective Studies Urban Health/sn [Statistics & Numerical Data] PY - 2006 SE - Ellong, Augustin. Universite Yaounde I, Faculte de Medecine et des Sciences Biomedicales, BP 1364, Yaounde Cameroun. ellong_august@hotmail.com SN - 1157-5999 SP - 83-8 ST - [Prevalence of glaucomas in a Black Cameroonian population] T2 - La prevalence des glaucomes dans une population de Noirs camerounais. TI - [Prevalence of glaucomas in a Black Cameroonian population] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17116629 VL - 16 ID - 1632 ER - TY - JOUR AB - Objectives: To determine the prevalence and the various types of glaucoma in a Black urban Cameroonian population. Material and method: A retrospective analysis of 1,343 glaucomatous patients' files (757 men and 586 women) from a total of 24,462 Cameroonian patients of all ages was carried out from January 1991 to December 2001 in the Douala General Hospital in Cameroon in Central Africa. Results: The prevalence of glaucoma of all types is 5.5%. It increases with age. Of subjects with glaucoma, 79.6% had not been previously diagnosed. The mean patient's age is 53.3 (+/-17.1) years. The mean intraocular pressure is 29.6 (+/-12.6) mmHg. The mean vertical cup-disc ratio is 0.7 (+/-0.2). The prevalence of primary glaucoma of any type is 4.5%. The overall prevalence of primary open-angle glaucoma, primary angle-closure glaucoma and congenital glaucoma was 4.3%, 0.03% and 0.07%, respectively. The normal-tension glaucoma is rare in this study (6.3% of primary open-angle glaucoma).The most common form of primary angle closure glaucoma is chronic angle closure glaucoma (61,1%) and is usually undiagnosed due to a lack of gonioscopic evaluation. The prevalence of secondary glaucoma of any type is 1%. The most common forms of secondary angle closure glaucoma were neovascular glaucoma (47.4% of cases with the prevalence of 0.5%) and post-traumatic glaucoma (23.1% of cases with the prevalence of 0.2%). Prevalence of bilateral and monocular blindness due to glaucoma is 8% (108/1,343) and 32.9% (441/1,343) respectively of glaucoma patients. Conclusion: This study confirms the high prevalence of glaucoma in a black African population. Gonioscopy is an important diagnostic tool that should be promoted to guide more effective glaucoma treatment in our region. The very high rate of blindness among the glaucoma patients in Cameroon is due to a lack of care. The patients are young, the disease is advanced, and compliance and follow-up are poor. Glaucoma surgery therefore offers a favourable option from an economical standpoint. Glaucoma is a devastating disease and constitutes a significant public health problem. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Ellong, Augustin, Universite Yaounde I, Faculte de Medecine et des Sciences Biomedicales, BP 1364, Yaounde, Cameroon AN - 2007-00367-002 AU - Ellong, Augustin AU - Mvogo, Côme Ebana AU - Bella-Hiag, Assumpta Lucienne AU - Mouney, Emilienne Nyouma AU - Ngosso, Angèle AU - Litumbe, Calex Njoh DB - psyh DP - EBSCOhost IS - 2 KW - glaucoma prevalence Black Cameroonian population public health Adolescent Adult Age Factors Aged Aged, 80 and over Blindness Cameroon Child Child, Preschool Female Glaucoma Glaucoma, Angle-Closure Glaucoma, Neovascular Glaucoma, Open-Angle Humans Infant Intraocular Pressure Male Middle Aged Prevalence Retrospective Studies Urban Health Blacks Client Characteristics Ophthalmology Epidemiology Urban Environments N1 - Universite Yaounde I, Faculte de Medecine et des Sciences Biomedicales, Yaounde, Cameroon. Release Date: 20070709. Correction Date: 20130225. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: FrenchMajor Descriptor: Blacks; Client Characteristics; Glaucoma; Ophthalmology; Public Health. Minor Descriptor: Epidemiology; Urban Environments. Classification: Physical & Somatoform & Psychogenic Disorders (3290). Population: Human (10); Male (30); Female (40). Location: Cameroon. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 6. Issue Publication Date: Apr-Jun, 2006. PY - 2006 SN - 1157-5999 SP - 83-88 ST - La prévalence des glaucomes dans une population de Noirs camerounais = Prevalence of glaucomas in a Black Cameroonian population T2 - Cahiers D'Études et De Recherche Francophone / Santé TI - La prévalence des glaucomes dans une population de Noirs camerounais = Prevalence of glaucomas in a Black Cameroonian population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2007-00367-002&site=ehost-live&scope=site ellong_august@hotmail.com VL - 16 ID - 4864 ER - TY - JOUR AB - Objectives: To determine the prevalence and the various types of glaucoma in a Black urban Cameroonian population. Material and method: A retrospective analysis of 1,343 glaucomatous patients' files (757 men and 586 women) from a total of 24,462 Cameroonian patients of all ages was carried out from January 1991 to December 2001 in the Douala General Hospital in Cameroon in Central Africa. Results: The prevalence of glaucoma of all types is 5.5%. It increases with age. Of subjects with glaucoma, 79.6% had not been previously diagnosed. The mean patient's age is 533 (+/-17.1) years. The mean intraocular pressure is 29.6 (+/-12.6) mmHg. The mean vertical cup-disc ratio is 0.7 (+/-0.2). The prevalence of primary glaucoma of any type is 4.5%. The overall prevalence of primary open-angle glaucoma, primary angle-closure glaucoma and congenital glaucoma was 4.3%, 0.03% and 0.07%, respectively. The normal-tension glaucoma is rare in this study (6.3% of primary open-angle glaucoma).The most common form of primary angle closure glaucoma is chronic angle closure glaucoma (61,1%) and is usually undiagnosed due to a lack of gonioscopic evaluation. The prevalence of secondary glaucoma of any type is 1%. The most common forms of secondary angle closure glaucoma were neovascular glaucoma (47.4% of cases with the prevalence of 0.5%) and post-traumatic glaucoma (23.1% of cases with the prevalence of 0.2%). Prevalence of bilateral and monocular blindness due to glaucoma is 8% (108/1,343) and 32.9% (441/1,343) respectively of glaucoma patients. Conclusion: This study confirms the high prevalence of glaucoma in a black African population. Gonioscopy is an important diagnostic tool that should be promoted to guide more effective glaucoma treatment in our region. The very high rate of blindness among the glaucoma patients in Cameroon is due to a lack of care. The patients are young, the disease is advanced, and compliance and follow-up are poor. Glaucoma surgery therefore offers a favourable option from an economical standpoint. Glaucoma is a devastating disease and constitutes a significant public health problem. AD - Université Yaoundé I, Faculté de Médecine et des Sciences Biomédicales, BP 1364, Yaoundé, Cameroon Service Ophtalmologie, Hôpital Général Douala, BP 4856, Douala, Cameroon AU - Ellong, A. AU - Mvogo, C. E. AU - Bella-Hiag, A. L. AU - Mouney, E. N. AU - Ngosso, A. AU - Litumbe, C. N. DB - Scopus DO - 10.1684/san.2006.0018 IS - 2 KW - Blindness Cameroon Glaucoma Ophtalmology M3 - Article N1 - Cited By :20 Export Date: 19 July 2021 PY - 2006 SP - 83-88 ST - La prévalence des glaucomes dans une population de Noirs camerounais T2 - Cahiers Sante TI - Prevalence of glaucomas in a Black Cameroonian population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845504337&doi=10.1684%2fsan.2006.0018&partnerID=40&md5=7114bbd020f67d5e1fbc0df87f1a8e6c VL - 16 ID - 5144 ER - TY - JOUR AB - Objective: To examine trends in the utilization and cost of eye care in the Medicare population. Methods: Data were obtained from fee-for-service physician claims (Part B) from a 5% sample of Medicare beneficiaries 65 years and older. Use of eye care services and procedures, frequency of ocular diagnoses, and allowed charges were compared for each year from 1991 through 1998. Results: The proportion of beneficiaries receiving eye care increased from 41.4% to 48.1% during the 8-year period. Part B charges attributable to eye care decreased from 12.5% to 10.4%, with annual inflation-adjusted charges per beneficiary decreasing from $235 to $176 (1998 dollars). The proportion of beneficiaries with cataract-related claims increased from 23.4% to 27.3%, accounting for approximately 60% of eye care charges each year; beneficiaries with retinal disease claims increased from 7.8% to 11.4%, capturing 15.4% of eye care charges in 1998, up from 10.7% in 1991; and beneficiaries with glaucoma claims increased from 6.8% to 9.5%, accounting for nearly 10% of eye care charges each year. Conclusions: The proportion of the Medicare population receiving eye care increased between 1991 and 1998. Nevertheless, eye care costs did not increase, primarily because of constraints in charges associated with the management of cataract. AD - L.B. Ellwein, National Eye Institute, 31 Center Dr, Bethesda, MD 20892-2510, United States AU - Ellwein, L. B. AU - Urato, C. J. DB - Embase Medline DO - 10.1001/archopht.120.6.804 IS - 6 KW - aged article cataract cost benefit analysis cost of illness economic aspect eye disease female geriatric disorder glaucoma health care utilization human major clinical study male managed care medicare priority journal LA - English M3 - Article N1 - L34620361 2002-06-24 PY - 2002 SN - 0003-9950 SP - 804-811 ST - Use of eye care and associated charges among the Medicare population: 1991-1998 T2 - Archives of Ophthalmology TI - Use of eye care and associated charges among the Medicare population: 1991-1998 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34620361&from=export http://dx.doi.org/10.1001/archopht.120.6.804 VL - 120 ID - 3863 ER - TY - JOUR AB - Background: This study aims to identify interventions used to reduce medication regimen complexity and to assess their impact on medication adherence and clinical outcomes., Methods: A literature search was conducted using pre-defined search terms in three scientific databases, including ScienceDirect, ProQuest and MEDLINE. Original research articles published in English between 2009 and 2020 that assessed the impact of medication regimen simplification on medication adherence in patients with long-term medical conditions were eligible for inclusion. Review articles, meta-analysis studies and conference proceedings were excluded. Data charting was done in an iterative process using a study-specific extraction form., Results: Of the 684 studies identified through initial searches, 17 studies were included in the review. Nine studies involved simplification of medication regimen related to HIV, while three studies focused on patients with diabetes with or without coronary artery disease. The remaining five studies included medications used among elderly patients or medications related to hypertension, psychiatric disorders, glaucoma and kidney diseases. Three medication regimen simplification strategies were identified; fixed-dose combination (n = 7), once-daily dosing (n = 4) and the combination of both fixed-dose and once-daily dosing (n = 6). Overall, most of the regimen simplification strategies (14 out of 17) were found to be useful in improving medication adherence. There was no assessment of clinical outcomes in four out of 17 studies. Furthermore, more than half of the studies that assessed clinical outcomes did not show any additional impact on clinical outcomes., Conclusion: The findings suggest that there was an equal utilization of the three main approaches of regimen simplifications; fixed-dose combination, once-daily dosing and a combination of both. Overall, most of the regimen simplification strategies were found to be effective in improving medication adherence. However, the associated improvement in medication adherence did not extend to improvement in the clinical outcomes. Copyright © 2020 Elnaem et al. AU - Elnaem, Mohamed Hassan AU - Irwan, Nor Afifah AU - Abubakar, Usman AU - Syed Sulaiman, Syed Azhar AU - Elrggal, Mahmoud E. AU - Cheema, Ejaz DO - https://dx.doi.org/10.2147/PPA.S268499 PY - 2020 SE - Elnaem, Mohamed Hassan. Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia. Elnaem, Mohamed Hassan. Quality Use of Medicines Research Group, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia. Irwan, Nor Afifah. Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia. Abubakar, Usman. Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia. Syed Sulaiman, Syed Azhar. Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. Elrggal, Mahmoud E. Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia. Cheema, Ejaz. School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. SN - 1177-889X SP - 2135-2145 ST - Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions T2 - Patient preference and adherence TI - Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33173282 VL - 14 Y2 - 20201102// ID - 123 ER - TY - JOUR AB - The endothelium lining the posterior corneal surface performs physiologic pump functions essential to corneal clarity and integrity. A hallmark of keratitis, anterior ocular inflammation, and corneal allograft rejection is leukocyte adherence to the corneal endothelium (CE) forming keratitic precipitates. To elucidate mechanisms governing cornea-leukocyte interactions, cultured human CE cells and intact corneas were examined for expression of intercellular adhesion molecule-1 (ICAM-1), which binds the lymphocyte function-associated antigen-1 (LFA-1) on all leukocytes and enhances delayed-type hypersensitivity mediated by class II major histocompatibility complex antigens. Immunohistochemistry on culture CE cells using monoclonal anti-ICAM-1 antibody yield positive staining that increased after exposure to interleukin-1-beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (gamma-IFN). Standard leukocyte adherence assays demonstrated ICAM-1-mediated CE-neutrophil binding, which was specifically blocked by antibody to ICAM-1 or antibodies to LFA-1 on neutrophils. In whole human corneas, gamma-IFN increased CE and stromal keratocyte ICAM-1 immunoreactivity and enhanced CE-neutrophil adherence. As in CE cell cultures, antibody to ICAM-1 effectively blocked neutrophil binding to the CE cells of whole corneas. These results are the first to demonstrate ICAM-1 in ocular tissue. They indicate that CE cells express functional ICAM-1, which may be modulated by inflammatory cytokines, ICAM-1 provides mechanisms for keratitic precipitate formation, regulation of corneal leukocyte trafficking and the generation of immune responses that may be crucial to allograft rejection. AU - Elner, V. M. AU - Elner, S. G. AU - Pavilack, M. A. AU - Todd, R. F., 3rd AU - Yue, B. Y. AU - Huber, A. R. IS - 3 KW - *Cell Adhesion Molecules/me [Metabolism] Child, Preschool Endothelium, Corneal/cy [Cytology] *Endothelium, Corneal/me [Metabolism] Humans Immunohistochemistry/mt [Methods] Intercellular Adhesion Molecule-1 Interleukin-1/pd [Pharmacology] Neutrophils/me [Metabolism] Staining and Labeling Tumor Necrosis Factor-alpha/pd [Pharmacology] PY - 1991 SE - Elner, V M. Department of Ophthalmology (Kellogg Eye Center), University of Michigan, Ann Arbor 48105. SN - 0002-9440 SP - 525-36 ST - Intercellular adhesion molecule-1 in human corneal endothelium. Modulation and function T2 - The American journal of pathology TI - Intercellular adhesion molecule-1 in human corneal endothelium. Modulation and function UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1705751 VL - 138 ID - 2137 ER - TY - JOUR AB - Purpose. With today's excellent cure rates for Hodgkin lymphoma (HL), the number of long-term survivors is increasing. This study provides a global assessment of late effects for working-age HL survivors treated with contemporary protocols (intensive chemotherapy and lim-ited radiotherapy). Patients and Methods. From Swedish nationwide registers we identified 1017 HL survivors diagnosed in 2000-2009, aged 18-60 years (median 32) and surviving at least one year post-diagnosis, and 4031 age-, sex- and calendar-year-matched population comparators. Incidence rate ratios (IRR) and 95% confidence intervals (95%CI) for hospital outpatient visits and hospital bed-days after the first year and up to 2013 (maximum 14 years post-diagnosis) were estimated across treatment subgroups, considering relapse-free time and using negative binomial regression. Scheduled outpatient visits for HL were excluded but inpatient visits for HL were included in analysis of bed-days. Results. The rate of outpatient visits among relapse-free survivors was nearly double (IRR=1.8, 95%CI: 1.6-2.0) and the rate of bed-days was more than triple that among comparators (IRR=3.6, 95%CI: 2.7-4.7). The higher rates of outpatient visits persisted up to 10 years and bed-days up to four years post-diagnosis. However, absolute numbers of extra visits were low (mean=2 outpatient visits and 2 bed-days, respectively, during follow-up). Patients requiring 6-8 chemotherapy courses had higher rates of outpatient visits (IRR=1.4, 95%CI: 1.1-1.7) and bed-days (IRR=4.7, 95%CI: 2.9-7.8) than patients treated with 2-4 courses+radiotherapy. Established late effects including heart disease and second malignancies accounted for a minority of outpatient visits. Previously unstudied reasons for excess healthcare use included diabetes mellitus, keratitis, chest pain, and asthma (Figure 1). Conclusions. Chemotherapy, but not radiotherapy, appears to drive the slight excess healthcare use among contemporarily treated HL survivors. The diagnoses of healthcare visits reflected a broad panorama of disorders, indicating the need of comprehensive care in addition to specific screening programs.(Figure Presented). AD - S. Eloranta, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden AU - Eloranta, S. AU - Smedby, K. E. AU - Ekberg, S. AU - Chang, E. AU - Neovius, M. AU - Glimelius, I. DB - Embase KW - adult asthma chemotherapy confidence interval controlled study diabetes mellitus diagnosis follow up health care utilization heart disease Hodgkin disease hospital bed hospital patient human incidence keratitis major clinical study outpatient radiotherapy relapse remission screening second cancer survivor thorax pain young adult LA - English M3 - Conference Abstract N1 - L615421171 2017-04-21 PY - 2016 SN - 1592-8721 SP - 64-65 ST - Healthcare use among young Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy T2 - Haematologica TI - Healthcare use among young Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615421171&from=export VL - 101 ID - 2701 ER - TY - JOUR AB - Introduction: Overactive bladder (OAB) and its resultant urge urinary incontinence (UUI) are significant problems that medically, psychologically and financially affect people. The constellation of symptoms comprising OAB affects ∼ 16% of the adult population and its prevalence increases with aging. The typical class of medications used to treat OAB is antimuscarinics. Areas covered: OAB medications, with a focus on tolterodine for the treatment of UUI are reviewed. A thorough review of English language literature using EMBASE/Medline and PubMed has been performed. Expert opinion: Tolterodine provides a reasonable starting point when treating patients with OAB and UUI. Efficacy and tolerability are generally comparable between tolterodine and other newer antimuscarinics. Tolterodine is a good option as part of the algorithm in the treatment of OAB and UUI. © 2013 Informa UK, Ltd. AD - J. Barkin, University of Toronto, Humber River Hospital, Department of Urology, 960 Lawrence Avenue West, Suite 404, Toronto, ON, M6A 3B5, Canada AU - Elterman, D. S. AU - Chughtai, B. AU - Kaplan, S. A. AU - Barkin, J. DB - Embase Medline DO - 10.1517/14656566.2013.823158 IS - 14 KW - cytochrome P450 2D6 diuretic agent fesoterodine fluoxetine ketoconazole long acting drug moxifloxacin oral contraceptive agent oxybutynin placebo short acting drug tolterodine warfarin water abdominal pain age distribution anticholinergic effect area under the curve article bladder pressure closed angle glaucoma constipation detrusor muscle dose response drug blood level drug contraindication drug efficacy drug formulation drug hypersensitivity drug induced headache drug metabolism drug safety drug solubility drug structure drug tolerability drug withdrawal geriatric patient heart rate human maximum plasma concentration medication compliance micturition molecular weight multicenter study (topic) patient compliance pharmacodynamics phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) pKa plasma concentration-time curve postmarketing surveillance practice guideline QT interval randomized controlled trial (topic) recommended drug dose residual urine steady state torsade des pointes treatment outcome unspecified side effect urge incontinence urine retention xerostomia LA - English M3 - Article N1 - L369827500 2013-09-25 2013-09-27 PY - 2013 SN - 1465-6566 1744-7666 SP - 1987-1991 ST - Tolterodine for the treatment of urge urinary incontinence T2 - Expert Opinion on Pharmacotherapy TI - Tolterodine for the treatment of urge urinary incontinence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369827500&from=export http://dx.doi.org/10.1517/14656566.2013.823158 VL - 14 ID - 2962 ER - TY - JOUR AB - Purpose: To report the epidemiology of the surgical indications of pars plana vitrectomy in patients aged 75 years or older. Patients and Methods: The medical records of patients who underwent vitrectomy surgery in a single center between 2008 and 2018 were evaluated retrospectively for demographics, medical background, and surgical indications. Data on patients aged 75–85 were compared to those of patients older than 85 years and those recorded between 2008–2013 and 2014–2018. Results: A total of 592 patients were included, of whom 55% were males. The mean±standard deviation age of the cohort at presentation was 80.4±4.60 years, and the mean visual acuity was 1.3±0.93 logMAR. The main indications for surgery were retinal detachment (n=117, 19.7%), epiretinal-membrane/vitreomacular traction (n=140, 23.6%), dropped intraocular lens/retained lens (n=89, 15%), macular hole (n=64, 11%), submacular hemorrhage (n=40, 6.7%), diagnostic vitrectomy (n=37, 6.2%), non-diabetic vitreous hemorrhage (n=30, 5.1%), and diabetic vitreous hemorrhage and other diabetic complications (n=33, 5.6%). Patients aged 85 years and older had higher rates of urgent surgeries (65%), such as for submacular hemorrhage and trauma (p=0.0000039 and p=0.001, respectively), and lower rates of nonurgent surgeries, such as for epiretinal membrane and macular hole (p=0.000032 and p=0.02, respectively), compared to patients aged 75–84 years. Additionally, the surgical rate for submacular hemorrhage decreased during 2008–2014 compared to 2014–2018 (p=0.000014). Conclusion: Understanding the unique distribution of indications for vitrectomy among elderly patients is essential for appropriate management and treatment. Urgent cases represent 65% of the surgeries performed in the older population. AD - S. Elyashiv, Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel S. Elyashiv, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel AU - Elyashiv, S. AU - Levin, M. F. AU - Zloto, O. AU - Neimark, E. AU - Najjar, R. AU - Moisseiev, J. AU - Vidne-Hay, O. DB - Embase Medline DO - 10.2147/CIA.S304683 KW - lens implant age distribution aged aging article diabetic complication emergency surgery endophthalmitis epiretinal membrane female glaucoma health care utilization human major clinical study male pars plana vitrectomy retina detachment retina disease retina injury retina macula hemorrhage retina macula hole retrospective study risk factor treatment indication very elderly visual acuity vitreomacular traction vitreous hemorrhage LA - English M3 - Article N1 - L2007497023 2021-06-22 2021-06-25 PY - 2021 SN - 1178-1998 1176-9092 SP - 1007-1012 ST - Epidemiology of pars plana vitrectomy in the elderly: A retrospective 10-year survey of 592 cases T2 - Clinical Interventions in Aging TI - Epidemiology of pars plana vitrectomy in the elderly: A retrospective 10-year survey of 592 cases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2007497023&from=export http://dx.doi.org/10.2147/CIA.S304683 VL - 16 ID - 2333 ER - TY - JOUR AB - Herein, we report two clinical cases with acute temporary filtering bleb obstruction by gas tamponade after Descemet membrane endothelial keratoplasty (DMEK) surgery and postoperative intraocular pressure (IOP) peaks. Both patients underwent uncomplicated DMEK surgery with 20% sulfur hexafluoride (SF 6) anterior chamber tamponade and had previous trabeculectomy for glaucoma. Prior to surgery, both patients showed patent bleb function with low to normal IOP without antiglaucomatous medication. After uneventful DMEK surgery, both patients showed postoperative IOP peaks of up to 50 mm Hg despite patent inferior iridotomy and no sign of a pupillary block. In both cases, SF 6 gas bubbles could be visualized obstructing the bleb. Both patients were treated with IOP-lowering agents topically as well as systemically. In addition, anterior chamber paracenteses were performed to reduce the SF 6 volume within the anterior chamber. Under this treatment, IOP normalized within the first 18 h after surgery. We hypothesize that the SF 6 gas tamponade from the anterior chamber migrates into the ostium and below the bleb, leading to an acute temporary insufficiency of bleb function and to a consecutive IOP peak after surgery. In contrast to a pupillary block, this mechanism cannot be antagonized by preoperative iridotomy and needs to be taken into account for every glaucoma patient with functional bleb undergoing DMEK surgery. AU - Enders, P. AU - Avgitidou, G. AU - Heindl, L. M. AU - Dietlein, T. S. AU - Cursiefen, C. DB - Embase DO - 10.1159/000499376 IS - 1 KW - acetazolamide pilocarpine sulfur hexafluoride acute temporary filtering bleb obstruction aged ambulatory care anterior eye chamber aqueous humor formation article best corrected visual acuity case report clinical article cornea edema cornea transplantation Descemet membrane endothelial keratoplasty female Fuchs endothelial dystrophy hospital admission hospital discharge hospitalization human intraocular pressure iridotomy obstruction open angle glaucoma optical coherence tomography paracentesis postoperative complication postoperative period priority journal pseudoexfoliation slit lamp microscopy trabeculectomy very elderly LA - English M3 - Article N1 - L627126782 2019-04-12 2019-05-22 PY - 2019 SN - 1663-2699 SP - 120-126 ST - Temporary Filtering Bleb Failure Induced by Anterior Chamber Sulfur Hexafluoride Gas: A Complication after Descemet Membrane Endothelial Keratoplasty T2 - Case Reports in Ophthalmology TI - Temporary Filtering Bleb Failure Induced by Anterior Chamber Sulfur Hexafluoride Gas: A Complication after Descemet Membrane Endothelial Keratoplasty UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627126782&from=export http://dx.doi.org/10.1159/000499376 VL - 10 ID - 2550 ER - TY - JOUR AB - Purpose: Brimonidine is a relatively selective α-agonist, which reduces intraocular pressure (IOP) by decreasing aqueous production and increasing uveoscleral outflow. Brimonidine passes through the blood-brain barrier, potentially causing central nervous system (CNS) toxicity. There have been reports of bradycardia, hypotension, hypothermia, hypotonia, and apnea in infants after topical brimonidine. Methods: We reviewed the IOP data and side effects of children at the Duke University Eye Center placed on brimonidine from June 1997 to October 2000. Brimonidine 0.2% was used for patients whose glaucoma was uncontrolled on maximal tolerated medical therapy. A monocular trial was performed whenever possible, and brimonidine was not prescribed for infants. Included were 32 eyes of 30 patients with uncontrolled IOP and varied glaucoma diagnoses. Result: The mean patient age was 10.5 years, with a mean follow-up on brimonidine of 10.8 months. Most patients were on other glaucoma medications. In 11 of the 32 eyes the IOP data could be interpreted, and in these eyes the IOP decreased from a mean of 22.5 ± 4.9 mm Hg to a mean of 20.8 ± 4.0 mm Hg (a mean decrease of 6.7% ± 10%, P = .04) on brimonidine after a mean follow-up of 11.0 ± 6.9 months. Two young children (ages 2.4 and 3.7 years) repeatedly were unarousable soon after the administration of brimonidine. Five other children experienced extreme fatigue after brimonidine administration. All symptoms resolved after brimonidine was discontinued. Discussion/Conclusions: Brimonidine should be used with caution in young children because of the potential for CNS depression. In selected patients, brimonidine has a substantial ocular hypotensive effect. AD - Duke University, Durham, NC, United States Box 3802, Duke University Medical Center, Durham, NC 27710, United States AU - Enyedi, L. B. AU - Freedman, S. F. DB - Scopus DO - 10.1067/mpa.2001.117571 IS - 5 M3 - Article N1 - Cited By :91 Export Date: 19 July 2021 PY - 2001 SP - 281-284 ST - Safety and efficacy of brimonidine in children with glaucoma T2 - Journal of AAPOS TI - Safety and efficacy of brimonidine in children with glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035487977&doi=10.1067%2fmpa.2001.117571&partnerID=40&md5=5eb6c6a50f9b59bd61bba7cdc1d14d6f VL - 5 ID - 4938 ER - TY - JOUR AB - The purpose of this 'open-label' switch-over study was to evaluate the effect of substitution of levobunolol for timolol on intraocular pressure in patients with glaucoma or ocular hypertension. An appropriate baseline intraocular pressure was determined at the beginning of the study. The results show that intraocular pressure can be expected to be controlled at least as well when patients are switched to levobunolol 0.5% from timolol 0.5%. AD - R.W. Enzenauer, 8200 East Belleview, Englewood, CO 80111, United States AU - Enzenauer, R. W. AU - Butler, P. J. AU - Weller, R. W. AU - George, R. K. AU - Dirks, M. S. DB - Embase IS - 4 KW - beta adrenergic receptor blocking agent dipivefrine levobunolol timolol maleate article clinical article controlled study drug efficacy human intraocular hypertension intraocular pressure open angle glaucoma patient compliance priority journal topical drug administration LA - English M3 - Article N1 - L28355420 1998-08-17 PY - 1998 SN - 1079-4794 SP - 245-247 ST - Effect on intraocular pressure after substitution of levobunolol for timolol in patients controlled on timolol or timolol and dipivefrin T2 - Annals of Ophthalmology - Glaucoma TI - Effect on intraocular pressure after substitution of levobunolol for timolol in patients controlled on timolol or timolol and dipivefrin UR - https://www.embase.com/search/results?subaction=viewrecord&id=L28355420&from=export VL - 30 ID - 3942 ER - TY - JOUR AB - BACKGROUND: The purpose of this register was to determine the links between glaucoma, age, concomitant disease, medication, and dry eye in a large group of glaucoma patients., METHODS: A total of 20,506 patients from 900 centers across Germany were included. The first 30 consecutive glaucoma patients at each center were recruited. Epidemiological data as well as information on glaucoma, medication, concomitant diseases, dry eye, and local symptoms were elicited by means of a questionnaire. We analyzed primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PEX), and pigmentary glaucoma (PDG)., RESULTS: According to the register data, more women develop dry eye and glaucoma than men (56.9 vs. 45.7%). The most frequent concomitant systemic diseases were hypertension (48.1%), diabetes mellitus (22.5%), and dry mouth, nose, and skin (11.3%). As expected, the highest incidence of dry eye was found in those patients with dry mouth, nose, and skin. Dry eye occurred with dissimilar frequencies in association with the various glaucoma types: PEX>POAG>PDG. The incidence of dry eye increases with age. The gender difference in the occurrence of dry eye becomes apparent from the age of 50. Dry eye occurred more frequently when three or more antiglaucoma drugs were used and increased with the duration of glaucoma disease., CONCLUSIONS: We publish the first results from the German Glaucoma and Dry Eye Register. We found that the occurrence of dry eye is linked to several factors. Thus, the type of glaucoma has an impact on the risk of dry eye. The quantity of eye drops applied also plays a role in the development of the dry eye syndrome if more than three medications are used. While POAG is usually treated with one drug, PEX and PDG tend to be treated with multiple drugs. The gender difference in the occurrence of dry eye becomes apparent from the age 50 years. Because of the vicious circle of dry eye, antiglaucoma eye drops containing benzalkonium chloride compromises patient compliance. The results of the register are therefore of key relevance for the care of glaucoma patients. AU - Erb, Carl AU - Gast, Ulrike AU - Schremmer, Dieter DO - https://dx.doi.org/10.1007/s00417-008-0881-9 IS - 11 KW - Adolescent Adult Age Distribution Aged Aged, 80 and over Child Child, Preschool Diabetes Complications Drug Therapy, Combination Dry Eye Syndromes/ci [Chemically Induced] *Dry Eye Syndromes/co [Complications] Dry Eye Syndromes/di [Diagnosis] Dry Eye Syndromes/ep [Epidemiology] *Exfoliation Syndrome/co [Complications] Female Germany Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] *Glaucoma, Open-Angle/co [Complications] Humans Hypertension/co [Complications] Hypertension/ep [Epidemiology] Incidence Male Middle Aged Ophthalmic Solutions/ae [Adverse Effects] *Registries Risk Factors Sex Distribution Time Factors Vascular Diseases/et [Etiology] Young Adult PY - 2008 SE - Erb, Carl. Ophthalmology Department, Schlosspark Clinic, Heubnerweg 2, 14059, Berlin, Germany. carl.erb@schlosspark-klinik.de SN - 1435-702X 0721-832X SP - 1593-601 ST - German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye T2 - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie TI - German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18648841 VL - 246 Y2 - 20080722// ID - 1522 ER - TY - JOUR AB - Purpose: Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who had received preservative-free latanoprost (PFL) for at least 3 months., Patients and Methods: A total of 1872 patients from 6 European countries, treated with PFL for at least 3 months, were included in this survey. Prior to PFL treatment, patients were to be treatment naive or currently treated for their glaucoma. During a single routine consultation, patients completed a questionnaire concerning global satisfaction and satisfaction based on tolerability., Results: In total, 76.2% had been previously treated; 69.4% had received preserved and 6.8% preservative-free (PF) topical treatment. After 3 months of PFL treatment, a large majority of patients (95.3%) were satisfied or very satisfied with their PFL treatment and were, overall, significantly (p<0.0001) more satisfied with PFL than with their previous treatment; 4.2% were either unsatisfied or very unsatisfied. Overall, 97.3% of originally treatment-naive patients were satisfied (50.1%) or very satisfied (47.2%) with their PFL. Ocular surface disease was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Patient satisfaction with PFL was very high., Conclusion: PFL may be considered a valuable first-choice treatment in glaucoma patients. Copyright © 2021 Erb et al. AU - Erb, Carl AU - Stalmans, Ingeborg AU - Iliev, Milko AU - Munoz-Negrete, Francisco Jose DO - https://dx.doi.org/10.2147/OPTH.S295821 PY - 2021 SE - Erb, Carl. Eye Clinic Wittenbergplatz, Berlin, Germany. Stalmans, Ingeborg. Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium. Iliev, Milko. Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland. Munoz-Negrete, Francisco Jose. Servicio de Oftalmologia, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Espana. SN - 1177-5467 SP - 931-938 ST - Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33688161 VL - 15 Y2 - 20210302// ID - 104 ER - TY - JOUR AU - Erb, C. AU - Stubiger, N. AU - Schuller, S. AU - Rassmann, K. IS - 1 KW - Adult Aged Curriculum Female Germany Glaucoma/px [Psychology] *Glaucoma/rh [Rehabilitation] Glaucoma, Open-Angle/px [Psychology] Glaucoma, Open-Angle/rh [Rehabilitation] Hospitals, University Humans Male Middle Aged Patient Compliance/px [Psychology] *Patient Education as Topic/mt [Methods] PY - 1998 SE - Erb, C. Universitats-Augenklinik, Basel, Schweiz. SN - 0023-2165 SP - aA6-8 ST - [The glaucoma work group--an initiative of the Tubingen University Eye Clinic] T2 - Der Arbeitskreis Glaukom--eine Initiative der Universitats-Augenklinik Tubingen. TI - [The glaucoma work group--an initiative of the Tubingen University Eye Clinic] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9743929 VL - 213 ID - 1988 ER - TY - JOUR AB - Cataract is one of the common causes of reversible vision loss in people older than 50 years. Currently, the only way to treat it effectively is phacoemulsification with simultaneous implantation of an intraocular lens - a method that minimizes the amount of surgical trauma and the number of intra- and postoperative complications. Nevertheless, the problem of prevention and timely diagnosis of pathological changes in the retina, which may develop after extraction of cataracts, and in particular - macular edema, remains relevant. This problem becomes especially important when it comes to patients with concomitant cataract and glaucoma who use local antihypertensive drugs - in particular, prostaglandin analogues - for a long time. Having common properties with inflammatory mediators, in some cases they can cause vasodilation, increase vascular permeability and contribute to the development of exudative processes. Drugs of this group can cause impairment of the hematophthalmic and hematoretinal barriers provoking the development of cystoid macular edema, including in the early postoperative period after cataract extraction. As described by S. Irvine in 1953, macular edema is related to late postoperative complications and remains one of the main causes of visual impairment after lens removal. The review provides information about some studies concerning the effect of prostaglandin derivatives on the postoperative period after phacoemulsification. At this time, there is no consensus on this matter. AU - Erichev, V. P. AU - Kozlova, I. V. AU - Kosova, J. V. DO - https://dx.doi.org/10.17116/oftalma2019135052241 IS - 5. Vyp. 2 KW - *Cataract *Cataract Extraction *Glaucoma Humans Lens Implantation, Intraocular *Macular Edema *Phacoemulsification Postoperative Complications PY - 2019 SE - Erichev, V P. Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021. Kozlova, I V. Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021. Kosova, J V. Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021. SN - 0042-465X SP - 241-247 ST - [Frequency and type of macular edema after cataract surgery in patients with glaucoma] T2 - Chastota i kharakter makuliarnogo oteka pri sochetanii katarakty i glaukomy. TI - [Frequency and type of macular edema after cataract surgery in patients with glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31691667 VL - 135 ID - 311 ER - TY - JOUR AB - Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients' quality of life and may cause poor compliance, which leads to poor intraocular pressure control. To minimize the side effects of long-term treatment, preparations with lower benzalkonium chloride concentrations, preservative-free preparations and alternative preservatives have been developed and reported to have a lower rate of side effects. Tafluprost, launched on the ophthalmic market in 2008, is a new 16-phenoxy analogue of prostaglandin F(2alpha), clinically used as an ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. The safety and intraocular pressure-lowering efficacy of tafluprost has been demonstrated in various preclinical and clinical studies. AU - Ermis, Sitki Samet DO - https://dx.doi.org/10.2147/OPTH.S24248 PY - 2012 SE - Ermis, Sitki Samet. Faculty of Medicine, Balikesir University, Tip Fakultesi, Cagis Kampusu, Balikesir, Turkey. SN - 1177-5483 1177-5467 SP - 673-8 ST - Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=22654492 VL - 6 Y2 - 20120507// ID - 1189 ER - TY - JOUR AB - Current glaucoma treatments aim to lower intraocular pressure, often with topical ocular hypotensive medications. Unfortunately, the effectiveness of these medications depends on sustained patient adherence to regimens which may involve instilling multiple medications several times daily. Patient adherence to glaucoma medications is often low. Recent innovations in digital sensor technologies have been leveraged to confirm eyedrop medication usage in real-time and relay this information back to providers. Some sensors have also been designed to deliver medication reminders and notifications as well as assist with correct eyedrop administration technique. Here, we review recent innovations targeted at improving glaucoma medication adherence and discuss their limitations. Copyright © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. AU - Erras, Alaa AU - Shahrvini, Bita AU - Weinreb, Robert N. AU - Baxter, Sally L. DO - https://dx.doi.org/10.1136/bjophthalmol-2020-317918 PY - 2021 SE - Erras, Alaa. Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA. Shahrvini, Bita. Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA. Weinreb, Robert N. Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA. Baxter, Sally L. Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA s1baxter@health.ucsd.edu. Baxter, Sally L. Health Department of Biomedical Informatics, University of California San Diego, La Jolla, California, USA. SN - 1468-2079 0007-1161 ST - Review of glaucoma medication adherence monitoring in the digital health era T2 - The British journal of ophthalmology TI - Review of glaucoma medication adherence monitoring in the digital health era UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=33858837 Y2 - 20210415// ID - 22 ER - TY - JOUR AB - Acanthamoeba keratitis (AK) is an opportunistic protozoan infection caused by the pathogenic Acanthamoeba and associated with soft contact lens wear. If untreated, it can cause serious visual disability. A 23 year-old female wearing soft contact lenses applied to the Department of Ophthalmology of the Aydin Adnan Menderes University School of Medicine, with symptoms of redness, pain and blurred vision of both eyes. She was given a diagnosis of AK on clinical and laboratory grounds. The agent isolated was found to be T4 genotype "Acanthamoeba castellani". The patient regained visual ability following treatment. Although contact lens wear is the major risk factor for Acanthamoeba keratitis, the disease is usually seen unilaterally whereas in our case a bilateral involvement was observed. Great care should be practiced during contact lens use and there should be strict adherence to hygienic conditions if infections affecting the eye are to be avoided. AU - Ertabaklar, Hatice AU - Dayanir, Volkan AU - Apaydin, Pinar AU - Ertug, Sema AU - Walochnik, Julia IS - 4 KW - *Acanthamoeba Keratitis/et [Etiology] Acanthamoeba Keratitis/ps [Parasitology] Acanthamoeba castellanii/cl [Classification] Acanthamoeba castellanii/ge [Genetics] *Acanthamoeba castellanii/ip [Isolation & Purification] *Contact Lenses, Hydrophilic/ae [Adverse Effects] Female Genotype Humans Young Adult PY - 2009 SE - Ertabaklar, Hatice. Adnan Menderes Universitesi Tip Fakultesi, Parazitoloji Anabilim Dali, Aydin, Turkey. hatice@adu.edu.tr SN - 1300-6320 SP - 283-5 ST - [Case report: Acanthamoeba keratitis] T2 - Olgu sunumu: Acanthamoeba keratiti. TI - [Case report: Acanthamoeba keratitis] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=20101578 VL - 33 ID - 1405 ER - TY - JOUR AB - BACKGROUND: The specialist's role in caring for managed care patients is likely to grow. Thus, assessing the correlates of patient satisfaction with specialty care is essential., OBJECTIVE: To examine the association between characteristics of eye care practices and satisfaction with eye care among working age patients with open-angle glaucoma (OAG) or diabetic retinopathy (DR). SUBJECTS/STUDY SETTING: A total of 913 working age patients with OAG or DR enrolled in six commercial managed care health plans. The patients were treated in 144 different eye care practices., STUDY DESIGN: We used a patient survey to obtain information on patient characteristics and satisfaction with eye care, measured by scores on satisfaction subscales of the 18-item Patient Satisfaction Questionnaire. We used a survey of eye care practices to obtain information on practice characteristics, including provider specialties, practice organization, financial features, and utilization and quality management systems. We estimated logistic regression models to assess the association of patient and practice characteristics with high levels of patient satisfaction., PRINCIPAL FINDINGS: Treatment in a practice with a glaucoma specialist (for OAG patients) or a retina specialist (for DR patients) was associated with higher satisfaction, whereas treatment in a practice that obtained a high proportion of its revenues from capitation payments or in a group practice where providers obtained a high proportion of their incomes from bonuses was associated with lower satisfaction., CONCLUSIONS: Many eye care patients prefer to be treated by specialists with expertise in their conditions. Financial arrangement features of eye care practices also are associated with patient satisfaction with care. The most likely mechanisms underlying these associations are effects on provider behavior and satisfaction, which in turn influence patient satisfaction. Managed care plans and provider groups should aim to minimize the negative impact of managed care features on patient satisfaction. AU - Escarce, Jose J. AU - Kapur, Kanika AU - Solomon, Matthew D. AU - Mangione, Carol M. AU - Lee, Paul P. AU - Adams, John L. AU - Wickstrom, Steven L. AU - Quiter, Elaine S. IS - 4 KW - *Diabetic Retinopathy/th [Therapy] Female *Glaucoma, Open-Angle/th [Therapy] Health Care Surveys Humans Independent Practice Associations/og [Organization & Administration] *Independent Practice Associations/st [Standards] Logistic Models Male Middle Aged Ophthalmology/og [Organization & Administration] *Ophthalmology/st [Standards] Optometry/og [Organization & Administration] *Optometry/st [Standards] *Patient Satisfaction/sn [Statistics & Numerical Data] Physician-Patient Relations Practice Management, Medical/og [Organization & Administration] *Practice Management, Medical/st [Standards] *Quality Indicators, Health Care Surveys and Questionnaires United States PY - 2003 SE - Escarce, Jose J. RAND Health Program, Santa Monica, CA 90407-2138, USA. SN - 0017-9124 SP - 1135-55 ST - Practice characteristics and HMO enrollee satisfaction with specialty care: an analysis of patients with glaucoma and diabetic retinopathy T2 - Health services research TI - Practice characteristics and HMO enrollee satisfaction with specialty care: an analysis of patients with glaucoma and diabetic retinopathy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=12968821 VL - 38 ID - 1829 ER - TY - JOUR AB - Purpose. To describe a case of peripheral ulcerative keratitis in the setting of autoimmune hepatitis and possible overlap syndrome with primary sclerosing cholangitis. Case Report. A 48-year-old African American female with autoimmune hepatitis with possible overlap syndrome with primary sclerosing cholangitis presented with tearing, irritation, and injection of the left eye that was determined to be peripheral ulcerative keratitis. The patient was treated with topical and systemic steroids, immunosuppressant drugs (azathioprine and mycophenolate mofetil), a biologic (rituximab), and surgery (conjunctival resection), and the peripheral ulcerative keratitis epithelialized but ultimately led to corneal perforation. Conclusion. In this unique case, a patient with peripheral ulcerative keratitis who underwent treatment ultimately had a corneal perforation. This case may suggest a possible relationship between autoimmune hepatitis and peripheral ulcerative keratitis. AD - M.H. Dastjerdi, Department of Ophthalmology, Rutgers New Jersey Medical School, Newark, NJ, United States AU - Eshraghi, H. AU - Mahtabfar, A. AU - Dastjerdi, M. H. DB - Embase DO - 10.1155/2017/3939413 KW - slit lamp artificial tear azathioprine doxycycline methylprednisolone methylprednisolone sodium succinate moxifloxacin mycophenolate mofetil prednisolone acetate prednisone rituximab steroid adult article autoimmune hepatitis case report clinical article conjunctiva cornea perforation cornea ulcer disease association disease exacerbation endoscopic retrograde cholangiopancreatography epithelization eye irritation eye redness eye surgery female human intraocular pressure keratitis middle aged patient compliance patient monitoring peripheral ulcerative keratitis primary sclerosing cholangitis tear flow visual acuity LA - English M3 - Article N1 - L624180518 2018-10-16 2018-10-22 PY - 2017 SN - 1687-9635 1687-9627 ST - A case of peripheral ulcerative keratitis associated with autoimmune hepatitis T2 - Case Reports in Medicine TI - A case of peripheral ulcerative keratitis associated with autoimmune hepatitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624180518&from=export http://dx.doi.org/10.1155/2017/3939413 VL - 2017 ID - 2687 ER - TY - JOUR AB - AIM: To assess the efficacy and safety of patterned laser trabeculoplasty (PLT) as an adjunctive treatment in open angle glaucoma (OAG) or ocular hypertension (OHT) patients who were under antiglaucoma medical treatment. METHODS: This study was a retrospective review of primary or secondary OAG patients and OHT patients with medically uncontrolled (>= 18 mm Hg) intraocular pressure (IOP) who underwent 360 degrees PLT from June 2016 to August 2016. Follow-up visits at week 1, and 1, 3 and 6mo were performed. IOP, best corrected visual acuity (BCVA), complications and eye drop glaucoma medication were recorded at each follow-up visit. Success was defined as IOP reduction >= 20% from baseline. RESULTS: Forty-one eyes of 25 patients were included in this study. Pre-treatment mean IOP was 20.2 +/- 1.6 mm Hg. After PLT, IOP was 19.3 +/- 5.2, 16.1 +/- 2.7, 17.1 +/- 3.7 and 16.3 +/- 3.5 mm Hg, at 1wk, 1, 3 and 6mo, respectively. IOP reduction from baseline was statistically significant from the first month, remaining stable at 6mo (P<0.001). PLT success at 6mo of follow-up was 48.78%. The number of glaucoma medication per eye (P=0.10) and the mean BCVA both remained constant (P=0.37). Complications included transient IOP spikes in 4 eyes (9.8%) and peripheral anterior synechiae in 7 eyes (17.1%). CONCLUSION: PLT is an effective and safe method for the management of patients with OHT or OAG as an adjunctive therapy. Additional larger studies should be designed to verify the long-term stability of IOP reduction with this laser technology. AN - WOS:000430133900016 AU - Espinoza, G. AU - Castellanos, L. AU - Rodriguez-Una, I. AU - Camacho, P. A. AU - Parra, J. C. DA - APR 18 DO - 10.18240/ijo.2018.04.16 IS - 4 PY - 2018 SN - 2222-3959 2227-4898 SP - 635-640 ST - Clinical outcomes of patterned laser trabeculoplasty as adjuvant therapy in open angle glaucoma and ocular hypertension T2 - INTERNATIONAL JOURNAL OF OPHTHALMOLOGY TI - Clinical outcomes of patterned laser trabeculoplasty as adjuvant therapy in open angle glaucoma and ocular hypertension VL - 11 ID - 5872 ER - TY - JOUR AB - Objective: To assess the level of satisfaction of patients who access the Ophthalmic counselling services anchored by trained social workers of the University of Calabar Teaching Hospital, Calabar, Nigeria., Methods: A cross-sectional study of serial consenting participants was done. Ethical approval was obtained from the University of Calabar Teaching hospitals' ethics committee. Data was obtained using a semi-structured interviewer-administered questionnaire. Data were collated and analyzed using the SPSS for Windows (version 20, SPSS inc. Chicago, IL, USA). Modified Likert scale (very satisfied, satisfied and not satisfied) was used to rate the satisfaction level., Results: A total of 120 respondents met the inclusion criteria and were enrolled into the study. Majority of the respondents (60%) were male with an overall mean age of 45.32+/- 1.82. Over a quarter (28.3%) of the respondents were in the age bracket of 41-50. Glaucoma (48.3%) was the most common eye condition of the respondents. Seventy-five percent of the respondents were satisfied with the average time spent for the counselling services while 76.7% were satisfied with the overall ophthalmic counselling services they received with 46.7% believing that the service was provided by a social worker., Conclusion: Majority of the Patients were satisfied with the Ophthalmic counselling services mainly anchored by social workers. Training and retraining of allied support staff to render ophthalmic counselling services in order to ease the workload of the Ophthalmologist should be encouraged in resource-limited settings., Funding: None declared. Copyright © The Author(s). AU - Etim, Bassey A. AU - Ibanga, Affiong A. AU - Udoh, Martha-Mary E. AU - Nkanga, Elizabeth D. AU - Utam, Utam A. AU - Okwejie, John A. DO - https://dx.doi.org/10.4314/gmj.v54i2.4 IS - 2 KW - Adolescent Adult Aged Aged, 80 and over Child *Counseling/sn [Statistics & Numerical Data] Cross-Sectional Studies Female Hospitals, Teaching Humans Male Middle Aged Nigeria *Ophthalmology Patient Satisfaction/sn [Statistics & Numerical Data] Surveys and Questionnaires Young Adult PY - 2020 SE - Etim, Bassey A. Department of Ophthalmology, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria. Ibanga, Affiong A. Department of Ophthalmology, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria. Udoh, Martha-Mary E. Department of Ophthalmology, University of Calabar Teaching Hospital, Calabar, Nigeria. Nkanga, Elizabeth D. Department of Ophthalmology, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria. Utam, Utam A. Department of Ophthalmology, University of Calabar Teaching Hospital, Calabar, Nigeria. Okwejie, John A. Department of Ophthalmology, University of Calabar Teaching Hospital, Calabar, Nigeria. SN - 2616-163X 0016-9560 SP - 76-81 ST - Patients' satisfaction with ophthalmic counselling services in a tertiary hospital in Calabar, South-South Nigeria T2 - Ghana medical journal TI - Patients' satisfaction with ophthalmic counselling services in a tertiary hospital in Calabar, South-South Nigeria UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33536676 VL - 54 ID - 158 ER - TY - JOUR AB - Introduction Cochrane Eyes and Vision (CEV) is an international network of individuals working to prepare, maintain and promote access to systematic reviews of interventions to treat, prevent or diagnose eye diseases or vision impairment. CEV plans to undertake a priority setting exercise to identify systematically research questions relevant to our scope, and to formally incorporate input from a wide range of stakeholders to set priorities for new and updated reviews. Methods and analysis The scope of CEV is broad and our reviews include conditions that are common and have a high global disease burden, for example, cataract and dry eye disease, and conditions that are rare but have a high impact on quality of life and high individual cost such as eye cancer. We plan to focus on conditions prioritised by WHO during the development of the Package of Eye Care Interventions. These conditions were selected based on a combination of data on disease magnitude, healthcare use and expert opinion. We will identify priority review questions systematically by summarising relevant data on research in Eyes and Vision from a range of sources, and compiling a list of 10-15 potential review questions (new and/or updates) for each condition group. We will seek the views of external and internal stakeholders on this list by conducting an online survey. Equity will be a specific consideration. Ethics and dissemination The study has been approved by the ethics committee of the London School of Hygiene & Tropical Medicine. We will disseminate the findings through Cochrane channels and prepare a summary of the work for publication in a peer-reviewed journal. AD - J. Ramke, School of Optometry and Vision Science, University of Auckland, Auckland, New Zealand AU - Evans, J. R. AU - Gordon, I. AU - Lawrenson, J. G. AU - Parker, R. AU - Rowe, F. J. AU - Virgili, G. AU - Li, T. AU - Ramke, J. DB - Embase Medline DO - 10.1136/bmjopen-2020-046319 IS - 6 KW - adult cataract dry eye syndrome England exercise eye cancer eye care female glaucoma global disease burden health care utilization human male ophthalmology professional standard quality of life refractive surgery review school hygiene surgery systematic review tropical medicine visual impairment LA - English M3 - Review N1 - L635372928 2021-07-05 PY - 2021 SN - 2044-6055 ST - Identifying priority review questions for Cochrane Eyes and Vision: Protocol for a priority setting exercise T2 - BMJ Open TI - Identifying priority review questions for Cochrane Eyes and Vision: Protocol for a priority setting exercise UR - https://www.embase.com/search/results?subaction=viewrecord&id=L635372928&from=export http://dx.doi.org/10.1136/bmjopen-2020-046319 VL - 11 ID - 2293 ER - TY - JOUR AB - Background and aims: Primary wide-angle glaucoma (the most common form of glaucoma) is a multi-factorial disease of the optic nerve marked by the preceding loss of retinal ganglion cells, eventually leading to the atrophy of the optic nerve. Intraocular pressure (IOP) makes up the most important and most treatable risk factor. Methods: The study examined the eff ect of acupuncture therapy on eye pressure and the compliance in patients suff eringfrom primary wide-angle glaucoma (n = 21) and ocular hypertension (n = 13) against a group of test subjects not suff eringfrom any eye complaint (n = 16). Before commencing therapy, corneal thickness was determined by 4 Optics-Pachymeter. Before and after acupuncture treatment, an ophthalmologic determination of visual acuity according to DIN 58220 and a computer-aided visual field analysis were done. The IOP wasmeasured before and immediately after acupuncture as well as30 minutes after therapy. Changes in compliance were documented with a standardized questionnaire completed by eachpatient having received this treatment. Results: It was shown that for patients with primary wide angle glaucoma and ocular hypertension, acupuncture is able to significantly lower intraocular pressure. According to the questionnaire analysis, a subjective improvement of quality of life and better compliance of using anti-glaucomatous medication was achieved. Conclusions: Acupuncture is an appropriate method to treat patients with primary wide-angle glaucoma in addition tolowering eye pressure by anti-glaucomatous pharmacologicaltherapy. In patients suff ering from ocular hypertension, acupuncture can significantly lower intraocular pressure and therefore reduce the rate of conversion into a manifest glaucoma. Therefore this treatment can be suggested for ocular hypertension patients with contraindications against localanti-glaucomatous medicine (e. g. beta-blocker). However, it is absolutely necessary in this treatment that patients are continuously monitored regarding visual field, retinal nerve fibre thickness and micromorphological alterations of the disc in order to detect tissue damage of the optic nerve and functional loss caused by the onset of glaucoma. AD - H. Ewert, Oftalmólogo. Titulación Adicional en Acupuntura, Trienheider Weg 21, D-19288 Ludwigslust, Germany AU - Ewert, H. AU - Schwanitz, R. DB - Embase DO - 10.1016/S1887-8369(08)75610-2 IS - 4 KW - beta adrenergic receptor blocking agent acupuncture adult article clinical article controlled study cornea thickness follow up human intraocular hypertension intraocular pressure open angle glaucoma patient compliance quality of life questionnaire risk factor therapy effect visual acuity visual field LA - Spanish M3 - Article N1 - L358955854 2010-06-15 2010-06-21 PY - 2008 SN - 1887-8369 1988-6705 SP - 212-219 ST - Influence of acupuncture on intraocular pressure and compliance of patients with ocular hypertension or primary wide-angle glaucoma: First results of a controlled prospective follow-up study T2 - Revista Internacional de Acupuntura TI - Influence of acupuncture on intraocular pressure and compliance of patients with ocular hypertension or primary wide-angle glaucoma: First results of a controlled prospective follow-up study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358955854&from=export http://dx.doi.org/10.1016/S1887-8369(08)75610-2 VL - 2 ID - 3415 ER - TY - JOUR AB - Background and aims: Primary wide-angle glaucoma (the most common form of glaucoma) is a multi-factorial disease of the optic nerve marked by the preceding loss of retinal ganglion cells, eventually leading to the atrophy of the optic nerve. Intraocular pressure (IOP) makes up the most important and most treatable risk factor. Methods: The study examined the eff ect of acupuncture therapy on eye pressure and the compliance in patients suff eringfrom primary wide-angle glaucoma (n = 21) and ocular hypertension (n = 13) against a group of test subjects not suff eringfrom any eye complaint (n = 16). Before commencing therapy, corneal thickness was determined by 4 Optics-Pachymeter. Before and after acupuncture treatment, an ophthalmologic determination of visual acuity according to DIN 58220 and a computer-aided visual field analysis were done. The IOP wasmeasured before and immediately after acupuncture as well as30 minutes after therapy. Changes in compliance were documented with a standardized questionnaire completed by eachpatient having received this treatment. Results: It was shown that for patients with primary wide angle glaucoma and ocular hypertension, acupuncture is able to significantly lower intraocular pressure. According to the questionnaire analysis, a subjective improvement of quality of life and better compliance of using anti-glaucomatous medication was achieved. Conclusions: Acupuncture is an appropriate method to treat patients with primary wide-angle glaucoma in addition tolowering eye pressure by anti-glaucomatous pharmacologicaltherapy. In patients suff ering from ocular hypertension, acupuncture can significantly lower intraocular pressure and therefore reduce the rate of conversion into a manifest glaucoma. Therefore this treatment can be suggested for ocular hypertension patients with contraindications against localanti-glaucomatous medicine (e. g. beta-blocker). However, it is absolutely necessary in this treatment that patients are continuously monitored regarding visual field, retinal nerve fibre thickness and micromorphological alterations of the disc in order to detect tissue damage of the optic nerve and functional loss caused by the onset of glaucoma. AD - Oftalmólogo. Titulación Adicional en Acupuntura, Trienheider Weg 21, D-19288 Ludwigslust, Germany AU - Ewert, H. AU - Schwanitz, R. DB - Scopus DO - 10.1016/S1887-8369(08)75610-2 IS - 4 KW - Acupuncture Intraocular pressure Ocular hypertension Primary wide-angle glaucoma M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2008 SP - 212-219 ST - Influencia de la acupuntura sobre la presión ocular y el cumplimiento terapéutico de los pacientes con hipertensión ocular o glaucoma primario de ángulo abierto: Primeros resultados de un estudio prospectivo controlado de seguimiento a largo plazo T2 - Revista Internacional de Acupuntura TI - Influence of acupuncture on intraocular pressure and compliance of patients with ocular hypertension or primary wide-angle glaucoma: First results of a controlled prospective follow-up study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953210394&doi=10.1016%2fS1887-8369%2808%2975610-2&partnerID=40&md5=97fef7ec7511f09fb83ac24735f58456 VL - 2 ID - 5584 ER - TY - JOUR AB - Background and Aims: Primary wide-angle glaucoma (the most common form of glaucoma) is a multi-factorial disease of the optic nerve marked by the preceding loss of retinal ganglion cells, eventually leading to the atrophy of the optic nerve. Intraocular pressure (IOP) makes up the most important and most treatable risk factor. Methods: The study examined the effect of acupuncture therapy on eye pressure and the compliance in patients suffering from primary wide-angle glaucoma (n = 21) and ocular hypertension (n = 13) against a group of test subjects not suffering from any eye complaint (n = 16). Before commencing therapy, corneal thickness was determined by 4Optics-Pachymeter. Before and after acupuncture treatment, an ophthalmologic determination of visual acuity according to DIN 58220 and a computer-aided visual field analysis were done. The IOP was measured before and immediately after acupuncture as well as 30 minutes after therapy. Changes in compliance were documented with a standardized questionnaire completed by each patient having received this treatment. Results: It was shown that for patients with primary wide-angle glaucoma and ocular hypertension, acupuncture is able to significantly lower intraocular pressure. According to the questionnaire analysis, a subjective improvement of quality of life and better compliance of using anti-glaucomatous medication was achieved. Conclusions: Acupuncture is an appropriate method to treat patients with primary wide-angle glaucoma in addition to lowering eye pressure by anti-glaucomatous pharmacological therapy. In patients suffering from ocular hypertension, acupuncture can significantly lower intraocular pressure and therefore reduce the rate of conversion into a manifest glaucoma. Therefore this treatment can be suggested for ocular hypertension patients with contraindications against local anti-glaucomatous medicine (e. g. beta-blocker). However, it is absolutely necessary in this treatment that patients are continuously monitored regarding visual field, retinal nerve fibre thickness and micro-morphological alterations of the disc in order to detect tissue damage of the optic nerve and functional loss caused by the onset of glaucoma. AD - Facharzt für Augenheilkunde Zusatzbezeichnung Akupunktur, Trienheider Weg 21, D-19288 Ludwigslust, Germany AU - Ewert, H. AU - Schwanitz, R. DB - Scopus DO - 10.1016/J.DZA.2008.04.001 IS - 2 KW - Acupuncture Intraocular pressure Ocular hypertension Primary wide-angle glaucoma M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2008 SP - 13-20 ST - Einfluss der akupunktur auf den augendruck und die compliance bei patienten mit okulärer hypertension oder primärem offenwinkelglaukom: Erste ergebnisse einer prospektiven kontrollierten langzeitbeobachtung T2 - Deutsche Zeitschrift fur Akupunktur TI - Influence of acupuncture on intraocular pressure and compliance of patients with ocular hypertension or primary wide-angle glaucoma: First results of a controlled prospective follow-up study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-47749149577&doi=10.1016%2fJ.DZA.2008.04.001&partnerID=40&md5=3c5cda8d8ad60a2ce39a672bc85b864e VL - 51 ID - 5645 ER - TY - JOUR AB - PURPOSE: To compare the skills and knowledge of clinical ophthalmology among medical interns in Enugu, Nigeria, to the recommendations of the International Council of Ophthalmology (ICO)., MATERIALS AND METHODS: A questionnaire-based cross-sectional survey was conducted of Medical Interns attending the University of Nigeria Teaching Hospital and Enugu State University Teaching Hospital, from April 2010 to June 2010. Data on cohort demographics, undergraduate ophthalmology exposure, clinical skills and diagnostic competencies were collected and analyzed. Statistical significance was indicated by P < 0.05., RESULTS: The cohort comprised 81 males and 48 females (sex ratio = 1.7 : 1), aged 21-35 years (mean: 26.8 +/- 2.4 years). The gender difference was significant (P < 0.05). The response rate was 88.7%. The duration of undergraduate ophthalmology exposure ranged from 1 to 4 weeks. Exposure was often adequate in cornea/external eye (95.3%), lens/cataract (95.3%) and glaucoma (92.2%); but not in vitreo-retinal disease (47.3%), neuro-ophthalmology (45.7%) and refractive surgery (0.0). The majority were competent at visual acuity testing (97.7%) and visual field examination (93.0%). There was lower competency at anterior chamber assessment (49.6%) and slit-lamp examination (39.5%). The majority could confidently diagnose conjunctivitis (96.1%) and cataract (90.7%), but not strabismus (42.6%) or macular degeneration (20.2%)., CONCLUSIONS: Medical interns in Enugu displayed gaps in their undergraduate ophthalmology exposure, clinical knowledge and skills. This has implications for stakeholders in medical education and eye care delivery. Review of the curriculum, provision of training resources and compliance with ICO guidelines could address the deficiencies. AU - Eze, Boniface I. AU - Oguego, Ngozi C. AU - Uche, Judith N. AU - Shiwoebi, Jude O. AU - Mba, Chibuike N. DO - https://dx.doi.org/10.4103/0974-9233.92130 IS - 1 PY - 2012 SE - Eze, Boniface I. Department of Ophthalmology, University of Nigeria Teaching Hospital (UNTH), PMB 01139, Ituku-Ozalla, Enugu, Nigeria. SN - 0975-1599 0974-9233 SP - 135-40 ST - Assessing the knowledge and skills in clinical ophthalmology of medical interns: survey results from enugu, South-eastern Nigeria T2 - Middle East African journal of ophthalmology TI - Assessing the knowledge and skills in clinical ophthalmology of medical interns: survey results from enugu, South-eastern Nigeria UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm2&NEWS=N&AN=22346129 VL - 19 ID - 1192 ER - TY - JOUR AB - BACKGROUND: Glaucoma is a chronic and serious disease calling for consistent lifelong therapy. The patient's compliance requires that he/she be well informed about the disease. The purpose of the present study was to determine the level of knowledge about glaucoma, and compare young patients with older ones as well as glaucoma patients with nonglaucoma ones., METHODS: A total of 1110 questionnaires were distributed to patients and their relatives at the outpatient eye clinic of Hietzing Hospital (Vienna), of which 1041 were returned. The questionnaire comprised 18 questions. Patients were divided into two groups: group 1 consisted of those aged 18-60 years, while group 2 consisted of those older than 61 years., RESULTS: In total, 941 questionnaires were evaluated; 72.8% of the respondents were older than 60 years, and one-half of the respondents had glaucoma (51%). The majority of patients had "moderate knowledge" of the disease (41.87%), followed by "poor knowledge" (32.52%). Glaucoma patients had considerably better knowledge of the disease (p < 0.01) than did nonglaucoma patients. Younger patients were significantly better informed than older ones (p < 0.01). Nonglaucoma patients with a positive diagnosis of glaucoma among their circle of friends or family were significantly better informed (p < 0.01) than those without such persons in their circle of friends., CONCLUSION: Persons with glaucoma are much better informed about the disease than nonglaucoma patients, but the general level of knowledge is very low. Notably, younger patients were better informed than older ones. The present study, comprising a large number of patients, revealed poor knowledge of glaucoma among patients with the disease and especially among nonglaucoma patients in Vienna. AU - Fabjani, Sonja AU - Richter-Muksch, Sibylla AU - Cakmak, Nesrin AU - Markstaller, Monika AU - Weingessel, Birgit AU - Vecsei-Marlovits, Veronika Pia DO - https://dx.doi.org/10.1007/s00508-014-0687-1 IS - 15-16 KW - Adolescent Adult Age Distribution Aged Aged, 80 and over Austria/ep [Epidemiology] *Family Female *Glaucoma/ep [Epidemiology] *Health Knowledge, Attitudes, Practice *Health Literacy/sn [Statistics & Numerical Data] Humans Male Middle Aged *Patient Education as Topic/sn [Statistics & Numerical Data] Sex Distribution Surveys and Questionnaires Young Adult PY - 2015 SE - Fabjani, Sonja. Krankenhaus Hietzing (Hietzing Hospital), Wolkersbergenstrasse 1, 1130, Vienna, Austria. SN - 1613-7671 0043-5325 SP - 612-8 ST - Level of knowledge about glaucoma in Vienna T2 - Wiener klinische Wochenschrift TI - Level of knowledge about glaucoma in Vienna UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25595116 VL - 127 Y2 - 20150117// ID - 818 ER - TY - JOUR AB - Early diagnosis of congenital glaucoma allows surgery to be performed at the stage of reversible glaucomatous alterations of the optic disc and retina. In primary congenital glaucoma, the main reason for visual acuity reduction following surgical stabilization of the intraocular pressure are corneal changes. These include an increased corneal diameter, Haab's striae, areas of thickening and a greater posterior elevation. The resultant irregular astigmatism leads to amblyopia and a marked decrease in visual acuity. Active pleoptic treatment started from a very early age in children operated on for compensated congenital glaucoma provides them an opportunity to achieve high visual acuity and full rehabilitation. AU - Fabrikantov, O. L. AU - Nikolashin, S. I. AU - Matrosova, Yu V. AU - Kozlov, V. A. AU - Kopylov, A. E. AU - Pirogova, E. S. DO - https://dx.doi.org/10.17116/oftalma2017133292-98 IS - 2 KW - Aftercare Antihypertensive Agents/tu [Therapeutic Use] Combined Modality Therapy/mt [Methods] Corneal Injuries/dg [Diagnostic Imaging] Corneal Injuries/et [Etiology] Glaucoma/cn [Congenital] Glaucoma/di [Diagnosis] Glaucoma/pp [Physiopathology] Glaucoma/su [Surgery] *Glaucoma Humans Infant Male Medication Adherence Monitoring, Physiologic/mt [Methods] Ocular Hypertension/co [Complications] Ocular Hypertension/di [Diagnosis] Ocular Hypertension/th [Therapy] *Sclerostomy/mt [Methods] Tonometry, Ocular/mt [Methods] *Trabeculectomy/mt [Methods] Treatment Outcome Visual Acuity PY - 2017 SE - Fabrikantov, O L. Tambov branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 1 Rasskazovskoe shosse, Tambov, Russian Federation, 392000; Tambov State University named after G.R. Derzhavin, 93 Sovetskaya St., Tambov, Russian Federation, 392000. Nikolashin, S I. Tambov branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 1 Rasskazovskoe shosse, Tambov, Russian Federation, 392000. Matrosova, Yu V. Tambov branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 1 Rasskazovskoe shosse, Tambov, Russian Federation, 392000. Kozlov, V A. Tambov branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 1 Rasskazovskoe shosse, Tambov, Russian Federation, 392000. Kopylov, A E. Tambov branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 1 Rasskazovskoe shosse, Tambov, Russian Federation, 392000. Pirogova, E S. Tambov State University named after G.R. Derzhavin, 93 Sovetskaya St., Tambov, Russian Federation, 392000. SN - 0042-465X SP - 92-98 ST - [Complex treatment results in a congenital glaucoma patient (case report)] T2 - Rezul'taty kompleksnogo lecheniia patsienta s vrozhdennoi glaukomoi (klinicheskii sluchai). TI - [Complex treatment results in a congenital glaucoma patient (case report)] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28524147 VL - 133 ID - 515 ER - TY - JOUR AB - INTRODUCTION: The purpose of this study was to determine prescribing trends in a specialist glaucoma clinic in the UK. Specifically, the aims were to determine which drugs were prescribed as first-, second-, and third-line treatment, the persistence of first-, second-, and third-line treatment regimens, and the proportion of treatment decisions conforming to the European Glaucoma Society (EGS) guidelines., METHODS: A retrospective, non-interventional, single-center, case-note review was performed on a cohort of consecutive patients presenting to a specialist glaucoma clinic for follow-up. Inclusion criteria for the study were (1) a diagnosis of primary open-angle glaucoma or ocular hypertension, (2) glaucoma management entirely within the unit, and (3) minimum of 2 years of follow-up., RESULTS: A total of 114 case notes met the inclusion criteria. Mean age was 71 years (range 40-95 years). Mean length of follow-up was 56 months (range 24-180 months). Prostaglandin analogues (PGA) were the most popular first-line treatment in 73% of patients. As second-line treatment, PGA were again the predominant class, prescribed in 87% of cases, whereas beta-blockers (BB) were prescribed in 70% of cases. Carbonic anhydrase inhibitors (CAI) and alpha-2 agonists (AA) were more popular in third-line regimens. Second-line treatment was introduced at a mean of 28.0 months after first-line treatment (range 1-120 months, 95% CI 22.1-33.9 months). Third-line treatment was introduced at a mean of 22.9 months after second-line treatment (range 1-96 months, 95% CI 17.1-28.8 months). Breaches to EGS guidelines were most common for third-line treatment and included duplication of drug classes., DISCUSSION: There was a clear hierarchy of PGA as first-line, BB as second-line, while CAI and AA were considered third-line choices. First-line choices were generally in line with EGS guidelines. There was a tendency to breach guidelines by escalating treatment in dual steps rather than single steps (especially in third-line treatment). Combination drops were popular. In third-line treatment there was an increased incidence of prescribing errors. This data is important in terms of informing patients of the expected treatment course, to remind clinicians about best practice, and also to guide comparisons of cost-effectiveness with other treatment modalities. AU - Fajgenbaum, Mark AU - Ansari, Ejaz DO - https://dx.doi.org/10.1007/s12325-017-0593-9 IS - 8 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] *Drug Prescriptions/sn [Statistics & Numerical Data] Female *Glaucoma/dt [Drug Therapy] Humans Male Middle Aged Practice Guidelines as Topic *Practice Patterns, Physicians'/td [Trends] Prostaglandins, Synthetic/tu [Therapeutic Use] Retrospective Studies PY - 2017 SE - Fajgenbaum, Mark. Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK. Ansari, Ejaz. Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK. e.ansari@nhs.net. Ansari, Ejaz. University of Kent at Canterbury, Canterbury, UK. e.ansari@nhs.net. SN - 1865-8652 0741-238X SP - 2033-2042 ST - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study T2 - Advances in therapy TI - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28726170 VL - 34 Y2 - 20170719// ID - 502 ER - TY - JOUR AB - These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia. © 2005 Taylor & Francis. AD - T. Wobrock, Department of Psychiatry and Psychotherapy, University of Saarland, Kirrberger Strasse, D-66421 Homburg/Saar, Germany AU - Falkai, P. AU - Wobrock, T. AU - Lieberman, J. AU - Glenthoj, B. AU - Gattaz, W. F. AU - Möller, H. J. AU - Altamura, A. C. AU - Andreasen, N. AU - Barnes, T. R. E. AU - Beckmann, H. AU - Ciprian-Ollivier, J. AU - Crow, T. AU - David, A. AU - Davidson, M. AU - Deakin, B. AU - Elkis, H. AU - Farde, L. AU - Gaebel, W. AU - Gallhofer, B. AU - Gerlach, J. AU - Hirsch, S. R. AU - Hojaij, C. R. AU - Jablensky, A. AU - Kane, J. AU - Kojima, T. AU - von Knorring, L. AU - McGorry, P. AU - Meltzer, H. AU - Moussaoui, D. AU - Müller-Spahn, F. AU - Olie, J. P. AU - Palha, A. P. AU - Sato, M. AU - Sauer, H. AU - Schooler, N. AU - Weinberger, D. AU - Yamawaki, S. DB - Embase Medline DO - 10.1080/15622970510030090 IS - 3 KW - amisulpride anticonvulsive agent antidepressant agent aripiprazole benzodiazepine derivative chlorpromazine clozapine flupentixol fluphenazine haloperidol lithium salt mesoridazine mood stabilizer neuroleptic agent olanzapine pecazine perazine perphenazine pimozide promazine promethazine quetiapine risperidone sertindole sulpiride thioridazine unindexed drug ziprasidone zotepine zuclopenthixol accommodation paralysis adjuvant therapy agranulocytosis akathisia amenorrhea anticholinergic syndrome ataxia autonomic dysfunction body weight disorder breast cancer cardiotoxicity cardiovascular disease catalepsy cataract clinical trial Cochrane Library cognitive defect confusion consensus development constipation cornea edema cornea opacity delirium depression disease classification disease course drug absorption drug blood level drug choice drug competition drug efficacy drug elimination drug fever drug hypersensitivity drug metabolism drug receptor binding drug response drug tolerability dry eye dyslipidemia dysmenorrhea dysphoria dystonia ECG abnormality electroconvulsive therapy evidence based medicine extrapyramidal symptom galactorrhea glaucoma gynecomastia health care cost heart muscle conduction disturbance heart ventricle fibrillation hematologic disease human hyperglycemia hyperlipidemia hyperprolactinemia hypersalivation hypertriglyceridemia leukocytosis leukopenia liver toxicity low drug dose medical society Medline memory disorder meta analysis metabolic disorder motor dysfunction muscle rigidity myocarditis myoglobinuria neuroleptic malignant syndrome neurologic disease non insulin dependent diabetes mellitus obesity obstructive jaundice orthostatic hypotension osteoporosis parkinsonism pathogenesis patient compliance photosensitivity polyuria practice guideline prevalence priapism psychotherapy QT prolongation quality of life retinopathy review schizophrenia sedation seizure sexual dysfunction side effect skin disease systematic review tachycardia tardive dyskinesia therapy resistance torsade des pointes transcranial magnetic stimulation tremor urinary tract disease urine incontinence urine retention body weight gain xerostomia LA - English M3 - Review N1 - L43420449 2006-04-03 PY - 2005 SN - 1562-2975 SP - 132-191 ST - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia T2 - World Journal of Biological Psychiatry TI - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43420449&from=export http://dx.doi.org/10.1080/15622970510030090 VL - 6 ID - 3676 ER - TY - JOUR AB - Background: Epigallocatechin-gallate (EGCG) is a powerful antioxidant with suggested neuroprotective action. The aim of this study was to evaluate the effect of short-term supplementation of EGCG on inner retinal function in ocular hypertension (OHT) and open-angle glaucoma (OAG). Methods: Eighteen OHT and 18 OAG patients (perimetric mean deviation: >-10 dB) were randomly assigned to assume oral placebo or EGCG over a 3-month period in a randomized, placebo-controlled, double-blind, cross-over design clinical trial (clinicaltrials.gov identifier: NCT00476138). Pattern-evoked electroretinograms (PERGs) to 1.6 cycles/ degree square-wave gratings, counterphased at 16 reversals/second, and standard automated perimetry (Humphrey 30-2) were assessed at the study entry (baseline), and after 3 months of placebo or EGCG. Results: After EGCG, PERGs of OAG, but not OHT patients were increased in amplitude, compared either to baseline values (mean amplitude change: 0.06 log μV, p<0.05) or to PERG amplitude values found in the same patients after placebo administration (mean change: -0.02 log μV, p not significant; difference between EGCG and placebo: 0.08 log μV, p<0.05). In both OHT and OAG patients, standard automated perimetry did not show significant changes after either EGCG or placebo. In individual OAG patients, the magnitude of PERG amplitude increment after EGCG was inversely related (r=-0.8, plt;0.01) to corresponding baseline amplitudes. Conclusions: Although this study cannot provide evidence for long-term benefit of EGCG supplementation in OAG, and the observed effect is small, the results suggest that EGCG might favourably influence inner retinal function in eyes with early to moderately advanced glaucomatous damage. © Springer-Verlag 2009. AD - B. Falsini, Institute of Ophthalmology, Catholic University, Largo Francesco Vito 1, 00168 Rome, Italy AU - Falsini, B. AU - Marangoni, D. AU - Salgarello, T. AU - Stifano, G. AU - Montrone, L. AU - Landro, S. AU - Guccione, L. AU - Balestrazzi, E. AU - Colotto, A. DB - Embase Medline DO - 10.1007/s00417-009-1064-z IS - 9 KW - NCT00476138 betaxolol epigallocatechin gallate latanoprost plus timolol placebo timolol maleate absence of side effects action potential adult aged article cell function clinical article clinical trial controlled clinical trial controlled study crossover procedure double blind procedure drug effect drug efficacy electroretinogram electroretinography female human intraocular hypertension intraocular pressure male open angle glaucoma optical coherence tomography patient compliance pattern evoked electroretinogram perimetry priority journal randomized controlled trial retina ganglion cell short course therapy visual field visual system examination visual system function vitamin supplementation waveform LA - English M3 - Article N1 - L50474871 2009-09-14 PY - 2009 SN - 0721-832X SP - 1223-1233 ST - Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: A short-term study by pattern electroretinogram T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: A short-term study by pattern electroretinogram UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50474871&from=export http://dx.doi.org/10.1007/s00417-009-1064-z VL - 247 ID - 3333 ER - TY - JOUR AB - Glaucoma filtration surgery is regularly performed for the treatment of glaucoma and trabeculectomy is often regarded as the 'gold standard' glaucoma operation. The biggest risk of failure of the operation is bleb scarring. The advent of anti-fibrotic agents, such as mitomycin C (MMC) and 5-fluorouracil (5FU) has vastly prolonged the longevity of the bleb, but concerns remain regarding the potential increase in postoperative complications. More selective therapeutic targets have therefore been explored. One of these is vascular endothelial growth factor (VEGF) inhibition. Vascular endothelial growth factor inhi bition has a role not only in sub conjunctival angiogenesis inhi bition but also it has direct anti-fibrotic properties. Newer phar macological compounds and materials have also been developed in recent years in attempt to modulate the wound healing in different ways after glaucoma surgery. These include physical barriers to scarring and vehicles for sustained release of pharmacological agents, and early promising results have been demonstrated. This two-part review will provide a discussion of the application of anti-fibrotic agents in glaucoma filtration surgery and evaluate the newer agents that have been developed. How to cite this article: Fan Gaskin JC, Nguyen DQ, Ang GS, O'Connor J, Crowston JG. Wound Healing Modulation in Glaucoma Filtration Surgery-Conventional Practices and New Pers pectives: The Role of Antifibrotic Agents (Part I). J Curr Glaucoma Pract 2014;8(2):37-45. AU - Fan Gaskin, Jennifer C. AU - Nguyen, Dan Q. AU - Soon Ang, Ghee AU - O'Connor, Jeremy AU - Crowston, Jonathan G. DO - https://dx.doi.org/10.5005/jp-journals-10008-1159 IS - 2 PY - 2014 SE - Fan Gaskin, Jennifer C. Glaucoma Fellow, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia. Nguyen, Dan Q. Consultant, Department of Ophthalmology, Mid Cheshire Hospitals, NHS Foundation Trust, Cheshire; Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, UK. Soon Ang, Ghee. Consultant, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia. O'Connor, Jeremy. Consultant, Glaucoma Investigation and Research Unit, University Hospital Limerick, Ireland. Crowston, Jonathan G. Pofessor, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia. SN - 0974-0333 SP - 37-45 ST - Wound Healing Modulation in Glaucoma Filtration Surgery-Conventional Practices and New Perspectives: The Role of Antifibrotic Agents (Part I) T2 - Journal of current glaucoma practice TI - Wound Healing Modulation in Glaucoma Filtration Surgery-Conventional Practices and New Perspectives: The Role of Antifibrotic Agents (Part I) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26997807 VL - 8 Y2 - 20140612// ID - 1072 ER - TY - JOUR AB - BACKGROUND: Due to demographic change and societal transformation the number of elderly persons living in retirement homes is growing in Germany. Access to health care is more complicated in the setting of nursing homes. Different regional studies suggest unmet ophthalmological health care needs in institutionalized elderly people. This study assessed the current ophthalmological health care structure and supply status in nursing homes in Germany., METHODS: This prospective, multicenter cross-sectional study was conducted by 14 study centers in Germany. Elderly people living in 32 nursing homes were included after approval by the local institutional review boards. A standardized examination was performed which included a detailed medical and ocular history, refraction, visual acuity testing, tonometry, biomicroscopy and dilated funduscopy. Unmet ophthalmological health care needs were documented and the data were analyzed descriptively and via logistic regression modelling., RESULTS: A total of 600 participants (434 women and 166 men) aged 50-104 years were examined of which 368 (61%) had ophthalmological conditions requiring treatment. The most prevalent findings were cataracts (315; 53%), disorders of the eyelids (127; 21%), dry eye disease (57; 10%) and posterior capsule opacification (43; 7%). In 63 (11%) of the participants glaucoma was suspected and 55 (9%) of the examined population had a known diagnosis of glaucoma, of whom one third was not on any or on insufficient anti-glaucomatous therapy. 236 (39%) showed signs of age-related macular degeneration (AMD). Only 52% of the examined cohort had been examined by an ophthalmologist within the last 5 years and 39% stated that they would currently not be able to consult an ophthalmologist. Reported barriers were mainly transport and lack of support., CONCLUSION: This study demonstrates considerable unmet ophthalmological health care needs of the institutionalized elderly in Germany. Novel and reformed models of specialist care provision have to be developed. AU - Fang, P. P. AU - Schnetzer, A. AU - Kupitz, D. G. AU - Gobel, A. P. AU - Kohnen, T. AU - Reinhard, T. AU - Lorenz, B. AU - Hoerauf, H. AU - Wagenfeld, L. AU - Auffarth, G. AU - Schaub, F. AU - Thieme, H. AU - von Livonius, B. AU - Alten, F. AU - Robering, A. AU - Brandl, C. AU - Ziemssen, F. AU - Krummenauer, F. AU - Holz, F. G. AU - Finger, R. P. DO - https://dx.doi.org/10.1007/s00347-017-0557-0 IS - 9 KW - Age Factors Aged Aged, 80 and over Cross-Sectional Studies Diagnostic Techniques, Ophthalmological/sn [Statistics & Numerical Data] *Eye Diseases/di [Diagnosis] Eye Diseases/ep [Epidemiology] *Eye Diseases/th [Therapy] Female Germany *Health Services Accessibility/sn [Statistics & Numerical Data] *Health Services Needs and Demand/sn [Statistics & Numerical Data] *Homes for the Aged/sn [Statistics & Numerical Data] Humans Male Middle Aged *Nursing Homes/sn [Statistics & Numerical Data] *Ophthalmology/sn [Statistics & Numerical Data] PY - 2017 SE - Fang, P P. Universitats-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland. Schnetzer, A. Universitats-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland. Kupitz, D G. Universitats-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland. Gobel, A P. Universitats-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland. Kohnen, T. Augenklinik, Johann Wolfgang Goethe-Universitat Frankfurt, Frankfurt, Deutschland. Reinhard, T. Klinik fur Augenheilkunde, Universitatsklinikum Freiburg, Freiburg, Deutschland. Lorenz, B. Klinik und Poliklinik fur Augenheilkunde, Justus-Liebig-Universitat Giesen, Giesen, Deutschland. Hoerauf, H. Klinik fur Augenheilkunde, Universitatsmedizin Gottingen, Gottingen, Deutschland. Wagenfeld, L. Klinik und Poliklinik fur Augenheilkunde, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. Auffarth, G. Universitats-Augenklinik Heidelberg, Heidelberg, Deutschland. Schaub, F. Zentrum fur Augenheilkunde, Universitatsklinik Koln, Koln, Deutschland. Thieme, H. Universitatsaugenklinik Magdeburg, Magdeburg, Deutschland. von Livonius, B. Augenklinik und Poliklinik, Klinikum der Ludwig-Maximilians Universitat Munchen, Munchen, Deutschland. Alten, F. Klinik fur Augenheilkunde, Universitatsklinikum Munster, Munster, Deutschland. Robering, A. Augenklinik, St. Franziskus-Hospital Munster, Munster, Deutschland. Brandl, C. Klinik und Poliklinik fur Augenheilkunde, Universitatsklinikum Regensburg, Regensburg, Deutschland. Brandl, C. Lehrstuhl fur Genetische Epidemiologie, Universitat Regensburg, Regensburg, Deutschland. Ziemssen, F. Department fur Augenheilkunde, Eberhard Karls Universitat Tubingen, Tubingen, Deutschland. Krummenauer, F. Institut fur Medizinische Biometrie und Epidemiologie, Fakultat fur Gesundheit, Universitat Witten/Herdecke, Witten, Deutschland. Holz, F G. Universitats-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland. frank.holz@ukb.uni-bonn.de. Finger, R P. Universitats-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland. SN - 1433-0423 0941-293X SP - 818-827 ST - [Ophthalmological health care of the institutionalized elderly : The OVIS study] T2 - Ophthalmologische Versorgung in Seniorenheimen : Die OVIS-Studie. TI - [Ophthalmological health care of the institutionalized elderly : The OVIS study] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28831559 VL - 114 ID - 499 ER - TY - JOUR AB - Glaucoma is a common eye disease that can lead to irreversible vision loss if left untreated. The early diagnosis and treatment of primary open-angle glaucoma is challenging, and visual impairment in Chinese glaucoma patients is a serious concern. Most of these patients need more than one topical antiglaucoma agent to control their intraocular pressures (IOPs). In the People's Republic of China, the daily cost of different glaucoma medication varies greatly, and the treatment habits differ throughout the country. Prostaglandin analogs (PGAs) are recommended as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Fixed-combination drops, particularly PGA-based fixed combinations, have recently been developed and used in patients with progression or who have failed to achieve their target IOPs. Here, we reviewed the current literature on the use of bimatoprost-timolol fixed combination (BTFC) in the People's Republic of China. BTFC has achieved good efficacy and tolerability in Chinese clinical trials. In addition, BTFC is more cost effective compared with other fixed combinations available in the People's Republic of China. Fixed-combination drops may offer benefits, such as keeping the ocular surface healthy, convenience of administration, and improvement in long-term adherence and quality of life. Therefore, BTFC has great potential for the treatment of Chinese glaucoma patients. However, the long-term efficacy of BTFC, comparisons of BTFC with other fixed-combination drugs, and treatment adherence and persistence with treatment in Chinese patients are unknown and will require further study. AU - Fang, Yuan AU - Ling, Zhihong AU - Sun, Xinghuai DO - https://dx.doi.org/10.2147/DDDT.S80338 KW - Adrenergic beta-Antagonists/ae [Adverse Effects] *Adrenergic beta-Antagonists/tu [Therapeutic Use] Asian Continental Ancestry Group Bimatoprost/ae [Adverse Effects] *Bimatoprost/tu [Therapeutic Use] China Drug Combinations Glaucoma/dt [Drug Therapy] Humans *Ocular Hypertension/dt [Drug Therapy] Timolol/ae [Adverse Effects] *Timolol/tu [Therapeutic Use] PY - 2015 SE - Fang, Yuan. Department of Ophthalmology and Visual Science, Eye, Ear, Nose and Throat Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. Ling, Zhihong. Department of Ophthalmology and Visual Science, Eye, Ear, Nose and Throat Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. Sun, Xinghuai. Department of Ophthalmology and Visual Science, Eye, Ear, Nose and Throat Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China ; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, People's Republic of China ; Key Laboratory of Myopia, Ministry of Health, Fudan University, Shanghai, People's Republic of China ; State Key Laboratory of Medical Neurobiology, Institutes of Brain Science, Fudan University, Shanghai, People's Republic of China. SN - 1177-8881 SP - 2617-25 ST - Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol T2 - Drug design, development and therapy TI - Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25999695 VL - 9 Y2 - 20150513// ID - 795 ER - TY - JOUR AB - Obstructive sleep apnea (OSA) is a disease of obstructed airways during sleep that significantly impacts the quality of life and increases the risk of various systemic diseases. OSA has been studied as a risk factor for a number of neuro-ophthalmic conditions and a strong relationship has been established with non-arteritic anterior ischemic optic neuropathy (NAION). The incidence of glaucoma and stroke have also been significantly associated with OSA and are conditions that may also be seen by neuro-ophthalmologists. Patients with NAION have a significantly higher incidence of OSA and OSA diagnosis significantly increases the risk for NAION development. Non-compliance with continuous positive airway pressure (CPAP) in OSA patients has also been found to be a risk factor for fellow-eye involvement and there is increasing evidence to suggest that every patient with NAION should be formally evaluated with polysomnography. The relationship between OSA and idiopathic intracranial hypertension (IIH) has also been studied, but the relationship between these two conditions is less clear. There is insufficient evidence to recommend routine eye examinations in OSA patients for papilledema and conducting a sleep study for a newly diagnosed IIH patient should be left to the discretion of the clinician based on other symptoms and risk factors of OSA. Copyright © 2020 Farahvash and Micieli. AU - Farahvash, Armin AU - Micieli, Jonathan A. DO - https://dx.doi.org/10.2147/EB.S247121 PY - 2020 SE - Farahvash, Armin. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Micieli, Jonathan A. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. Micieli, Jonathan A. Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Micieli, Jonathan A. Kensington Vision and Research Centre, Toronto, Ontario, Canada. SN - 1179-2744 SP - 61-71 ST - Neuro-Ophthalmological Manifestations of Obstructive Sleep Apnea: Current Perspectives T2 - Eye and brain TI - Neuro-Ophthalmological Manifestations of Obstructive Sleep Apnea: Current Perspectives UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=32753994 VL - 12 Y2 - 20200707// ID - 132 ER - TY - JOUR AB - Primary open angle glaucoma (POAG) is the most common form of glaucoma and the 2nd most common cause of irreversible vision loss in the United States. Nearly 67 million people have the disease worldwide including >3 million in the United States. A major risk factor for POAG is an elevation in intraocular pressure (IOP). The increase in IOP is believed to be caused by an increase in the deposition of extracellular matrix proteins, in particular fibronectin, in a region of the eye known as the trabecular meshwork (TM). How fibronectin contributes to the increase in IOP is not well understood. The increased density of fibronectin fibrils is thought to increase IOP by altering the compliance of the trabecular meshwork. Recent studies, however, also suggest that the composition and organization of fibronectin fibrils would affect IOP by changing the cell-matrix signaling events that control the functional properties of the cells in the trabecular meshwork. In this article, we will discuss how changes in the properties of fibronectin and fibronectin fibrils could contribute to the regulation of IOP. AU - Faralli, Jennifer A. AU - Filla, Mark S. AU - Peters, Donna M. DO - https://dx.doi.org/10.3390/cells8121518 IS - 12 KW - Animals Biomarkers *Disease Susceptibility Extracellular Matrix Fibronectins/ch [Chemistry] Fibronectins/ge [Genetics] *Fibronectins/me [Metabolism] Gene Expression *Glaucoma, Open-Angle/et [Etiology] *Glaucoma, Open-Angle/me [Metabolism] Glaucoma, Open-Angle/pa [Pathology] Humans Protein Aggregates Protein Aggregation, Pathological Trabecular Meshwork/me [Metabolism] Trabecular Meshwork/pa [Pathology] PY - 2019 SE - Faralli, Jennifer A. Departments of Pathology & Laboratory Medicine, University of Wisconsin, Madison, WI 53706, USA. Filla, Mark S. Departments of Pathology & Laboratory Medicine, University of Wisconsin, Madison, WI 53706, USA. Peters, Donna M. Departments of Pathology & Laboratory Medicine, University of Wisconsin, Madison, WI 53706, USA. Peters, Donna M. Ophthalmology & Visual Sciences, University of Wisconsin, Madison, WI 53706, USA. SN - 2073-4409 ST - Role of Fibronectin in Primary Open Angle Glaucoma T2 - Cells TI - Role of Fibronectin in Primary Open Angle Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31779192 VL - 8 Y2 - 20191126// ID - 308 ER - TY - JOUR AN - 149855675. Language: English. Entry Date: 20210424. Revision Date: 20210424. Publication Type: Article AU - Farid, Marjan DB - ccm DP - EBSCOhost IS - 7 KW - Mite Infestations -- Diagnosis Eye Infections, Parasitic -- Diagnosis Blepharitis -- Diagnosis Mite Infestations -- Therapy Eye Infections, Parasitic -- Therapy Blepharitis -- Therapy Aged Male Vision Disorders Diagnosis, Eye Cataract -- Diagnosis Sclerosis -- Diagnosis Keratitis Meibomian Gland Dysfunction Tea Tree Oil Compression Therapy Ophthalmic Solutions Cataract Extraction Patient Compliance Postoperative Care N1 - case study; pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2021 SN - 8750-3085 SP - 8-8 ST - Demodex: Easy to find, not so easy to kill T2 - Ocular Surgery News TI - Demodex: Easy to find, not so easy to kill UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149855675&site=ehost-live&scope=site VL - 39 ID - 4266 ER - TY - JOUR AB - Purpose: To determine the efficacy and safety of per-operative mitomycin C injection during trabeculectomy and combined phaco-trabeculectomy in different types of glaucoma. Study Design: Interventional case series. Place and Duration of Study: Shifa International, between January 2018 to July 2020. Methods: Thirty one patients requiring trabeculectomy or Phaco-trabeculectomy with mitomycin C because of maximum tolerable anti-glaucoma treatment or poor compliance were included in the study. Out of these 15 in group A underwent simple trabeculectomy with intra-operative mitomycin C and 16 patients in group B underwent phacotrabeculectomy with intra-operative mitomycin C and IOL implantation. All patients underwent an eye examination (including IOP and visual acuity) before surgery and then afterwards at 1 week, 1 month, 2 months, 6 months and 1 year. Main outcome measures were best corrected visual acuity, intra-ocular pressure and number of medications at base line and post-operatively. Results: Demographic results of the two groups were similar. Mean follow-up period was 1 year, mean IOP was 11 in group Aand 15.5 in group B in last follow-up.Mean IOP reduction at 1 year was significant in both group A and B (p = 0.001, p = 0.022 respectively). Hypotony, post-operative inflammatory membrane and bleb fibrosis were the main complications in group A and group B. Conclusion: Trabeculectomy with mitomycin C and phaco-trabeculectomy with mitomycin C are equally successful at lowering IOP in common types of glaucoma permitting significant and safe reduction of anti-glaucoma medications for atleast 1 year after surgery. © 2021, Ophthalmological Society of Pakistan. All rights reserved. AD - Shifa International Hospital, Islamabad, Pakistan The Aga Khan University, Karachi, Pakistan AU - Farooq, S. AU - Farooq, H. AU - Faisal, M. DB - Scopus DO - 10.36351/pjo.v37i2.1204 IS - 2 KW - Glaucoma Intra ocular pressure Mitomycin M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 213-217 ST - Outcome of intraoperative mitomycin c injection in trabeculectomy and phacotrabeculectomy in patients with glaucoma T2 - Pakistan Journal of Ophthalmology TI - Outcome of intraoperative mitomycin c injection in trabeculectomy and phacotrabeculectomy in patients with glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109332704&doi=10.36351%2fpjo.v37i2.1204&partnerID=40&md5=450f33cac2135781a85f30552713b976 VL - 37 ID - 5669 ER - TY - JOUR AB - Background: For many years researchers have been striving for a non-invasive 24 h continuous method of ambulatory intraocular pressure monitoring. A wireless device with a contact lens sensor is now on the market for clinical use, which is not a quantitative measurement of the intraocular pressure but is at least a recording of qualitative changes. These changes of corneal curvature due to changes of the intraocular pressure result in a distinct profile which gives information about fluctuations of the intraocular pressure, the behaviour during supine sleeping time and the 24 h efficacy of glaucoma therapy. We investigated the practicability and tolerability of this device. Method: The sensor is embedded in a soft silicone contact lens and consists of 4 strain gauges. Additionally there is an antenna made out of gold and a microchip. A second antenna is fixed around the eye which sends impulses to the microchip and receives data from the microchip. The data are sent to a recorder via a wire. Measurements are made for 90 s every 8. 5 min resulting in 144 measurements within 24 h. Of the 4 strain gauges 2 sense changes in the corneal curvature due to changes of the intraocular pressure. This device was used in 11 patients with ocular hypertension or glaucoma. Results: The result of the 24 h continuous measurement is a pressure profile which may be flat, fluctuating and with no, some or many spikes. We describe 2 examples of profiles from patients with glaucoma. The changes in the profiles were mostly during the sleeping hours in a supine position. Due to the lack of validation of the results it is not known if intermittent spikes are true spikes or artefacts. Practicability was simple and tolerability was reported to be good by all patients. Conclusions: For the first time a practicable, well tolerated, non-invasive device for continuous 24 h monitoring of changes of the corneal curvature due to changes of the intraocular pressure is available. It is not a direct measurement of the intraocular pressure. The resulting profile gives additional information about the behaviour of the intraocular pressure, especially during out-of-office times and night times. Disadvantages are the high cost of the contact lens sensor and the lack of validation of the results and reproducibility in patients. © 2010 Springer-Verlag. AD - C. Faschinger, Universitäts-Augenklinik, Medizinische Universität Graz, Auenbruggerplatz 4, 8036 Graz, Austria AU - Faschinger, C. AU - Mossböck, G. DB - Medline DO - 10.1007/s00347-010-2198-4 IS - 10 KW - adult ambulatory monitoring article contact lens devices equipment design female glaucoma human intraocular pressure male manometry middle aged oculoplethysmography pathophysiology pilot study reproducibility sensitivity and specificity telemetry transducer LA - German English M3 - Article N1 - L50947535 2011-03-16 PY - 2010 SN - 0941-293X SP - 918-922 ST - Continuous 24 h monitoring of changes in intraocular pressure with the wireless contact lens sensor Triggerfish™.First results in patients T2 - Ophthalmologe TI - Continuous 24 h monitoring of changes in intraocular pressure with the wireless contact lens sensor Triggerfish™.First results in patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50947535&from=export http://dx.doi.org/10.1007/s00347-010-2198-4 VL - 107 ID - 3229 ER - TY - JOUR AB - The aim of this study was to evaluate the effect of Timolol maleate on tear film break-up time in a Nigerian population. 192 eyes of 96 subjects were examined in a hospital based case-control study after being administered pre-coded questionnaires. The mean tear film break-up time was measured. There was significant difference (t = 10.164, P < 0.001) in the mean break-up time of cases (10.45 secs) and controls (30.18 secs). Half of the cases had some ocular discomfort with the instillation of Timolol maleate, a significant number of them having just been commenced on the medication (chi2 = 8.889, P = 0.003). Long-term instillation of Timolol maleate impairs tear film stability. The ocular discomfort experienced by patients on Timolol may contribute to poor drug compliance observed in patients on chronic drug therapy. Regular screening of patients on Timolol maleate for tear film instability and dry eyes is important and drug manufacturers should explore the possibility of incorporating artificial tears in Timolol maleate preparation. AU - Fasina, O. AU - Ashaye, A. O. AU - Ajayi, B. G. K. IS - 1 KW - *Adrenergic beta-Agonists/pd [Pharmacology] Adult Aged Case-Control Studies Dry Eye Syndromes/ci [Chemically Induced] Dry Eye Syndromes/di [Diagnosis] Eye/de [Drug Effects] Female Glaucoma, Open-Angle/dt [Drug Therapy] Humans Male Middle Aged Nigeria Surveys and Questionnaires *Tears/de [Drug Effects] Time Factors *Timolol/pd [Pharmacology] Timolol/tu [Therapeutic Use] PY - 2008 SE - Fasina, O. Department of Ophthalmology, College of Medicine, University of Ibadan, Ibadan, Nigeria. yemifash2000@yahoo.com SN - 0309-3913 SP - 43-7 ST - The effect of timolol maleate on tear film break-up time in Nigerians T2 - African journal of medicine and medical sciences TI - The effect of timolol maleate on tear film break-up time in Nigerians UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18756854 VL - 37 ID - 1514 ER - TY - JOUR AB - The problem associated with the prevalence of retinal diseases, and age-related macular degeneration (AMD) in particular, is undoubtedly relevant. This aspect is based on steadily growing statistics on morbidity, a high number of randomized controlled trials (RCT) and published real world data (RWD). The analysis of RCT results being published by researchers on 15.05.19 showed 2915 studies were registered on the subject of retinal diseases; that exceeds the number of studies on glaucoma by approximately 1.38 times (2118 studies) and conjunctival lesions by 2.37 times (1230 studies). AMD is one of the leading causes of irreversible vision loss and blindness; its neovascular form leads to blindness in 80-90% of all cases. Even though the topic of nAMD therapy is widely highlighted in modern ophthalmology, today there are many aspects that require targeted solutions. The main controversial issues that determine the complexity of therapy and patient management include discrepancies in determination of reference points (disease activity criteria) for implementation of anti-VEGF dosing regimens, patients' compliance, prioritization issues in treatment, its continuity with potential for the increase of intervals between injections and monitoring visits. AU - Fayzrakhmanov, R. R. AU - Voropaev, V. Yu AU - Sukhanova, A. V. AU - Shatalova, E. O. DO - https://dx.doi.org/10.17116/oftalma202113701183 IS - 1 KW - Angiogenesis Inhibitors/tu [Therapeutic Use] Humans Intravitreal Injections Macular Degeneration/di [Diagnosis] Macular Degeneration/dt [Drug Therapy] *Macular Degeneration Ranibizumab/tu [Therapeutic Use] Treatment Outcome Vascular Endothelial Growth Factor A Visual Acuity Wet Macular Degeneration/di [Diagnosis] Wet Macular Degeneration/dt [Drug Therapy] *Wet Macular Degeneration PY - 2021 SE - Fayzrakhmanov, R R. N.I. Pirogov National Medical and Surgical Center, Moscow, Russia. Voropaev, V Yu. JSC Bayer, Moscow, Russia. Sukhanova, A V. N.I. Pirogov National Medical and Surgical Center, Moscow, Russia. Shatalova, E O. Clinics of doctor Shatalov, Orekhovo-Zuevo, Russia. SN - 0042-465X SP - 83-93 ST - [Antiangiogenic therapy of neovascular age-related macular degeneration] T2 - Antiangiogennaya terapiya neovaskulyarnoi vozrastnoi makulyarnoi degeneratsii. TI - [Antiangiogenic therapy of neovascular age-related macular degeneration] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33610155 VL - 137 ID - 233 ER - TY - JOUR AB - PURPOSE: The purpose of this study was to compare outcomes of subjects with open-angle glaucoma (OAG) not controlled on one medication who underwent either implantation of two iStent inject ( R) trabecular micro-bypass devices or received medical therapy consisting of a fixed combination of latanoprost/timolol., PATIENTS AND METHODS: Of 192 subjects who qualified for the study and were enrolled, 94 were randomized to surgery with implantation of two iStent inject( R) devices in the treated eye and 98 to receive medical therapy., RESULTS: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedicated intraocular pressure (IOP) reduction of >=20% versus baseline unmedicated IOP, and 91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction >=20% versus baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent inject group was statistically significant (P=0.02) at the >=50% level of IOP reduction. An IOP <=18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8% of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medical therapy groups, respectively. A high safety profile was also noted in this study in both the iStent inject and medical therapy groups, as measured by stable best corrected visual acuity, cup-to-disc ratio, and adverse events., CONCLUSION: These data show that the use of iStent inject is at least as effective as two medications, with the clinical benefit of reducing medication burden and assuring continuous treatment with full compliance to implant therapy as well as having a highly favorable safety profile. AU - Fea, Antonio M. AU - Belda, Jose I. AU - Rekas, Marek AU - Junemann, Anselm AU - Chang, Lydia AU - Pablo, Luis AU - Voskanyan, Lilit AU - Katz, L. Jay DO - https://dx.doi.org/10.2147/OPTH.S59932 PY - 2014 SE - Fea, Antonio M. Universita degli Studi di Torino, Clinica Oculistica, Torino, Italy. Belda, Jose I. Hospital Torrevieja Salud, UTE, Servicio de Oftalmologia, Alicante, Spain. Rekas, Marek. Military Institute of Medicine, Department of Ophthalmology, Warsaw, Poland. Junemann, Anselm. Universitatsaugenklinik, Erlangen, Germany. Chang, Lydia. Hinchingbrooke Hospital NHS Trust and Moorfields Bedford Hospital NHS Trust, United Kingdom. Pablo, Luis. Hospital Universitario Miguel Servet, Servicio Oftalmologico, Zaragoza, Spain. Voskanyan, Lilit. SV Malayan Ophthalmological Center, Yerevan, Armenia. Katz, L Jay. Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USA. SN - 1177-5467 SP - 875-82 ST - Prospective unmasked randomized evaluation of the iStent inject ( R) versus two ocular hypotensive agents in patients with primary open-angle glaucoma T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Prospective unmasked randomized evaluation of the iStent inject ( R) versus two ocular hypotensive agents in patients with primary open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=24855336 VL - 8 Y2 - 20140507// ID - 1083 ER - TY - JOUR AB - Purpose: The purpose of this study was to compare outcomes of subjects with open-angle glaucoma (OAG) not controlled on one medication who underwent either implantation of two iStent inject® trabecular micro-bypass devices or received medical therapy consisting of a fixed combination of latanoprost/timolol. Patients and methods: Of 192 subjects who qualified for the study and were enrolled, 94 were randomized to surgery with implantation of two iStent inject® devices in the treated eye and 98 to receive medical therapy. Results: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedicated intraocular pressure (IOP) reduction of ≥20% versus baseline unmedicated IOP, and 91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction ≥20% versus baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent inject group was statistically significant (P=0.02) at the ≥50% level of IOP reduction. An IOP ≤18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8% of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medical therapy groups, respectively. A high safety profile was also noted in this study in both the iStent inject and medical therapy groups, as measured by stable best corrected visual acuity, cup-to-disc ratio, and adverse events. Conclusion: These data show that the use of iStent inject is at least as effective as two medications, with the clinical benefit of reducing medication burden and assuring continuous treatment with full compliance to implant therapy as well as having a highly favorable safety profile. © 2014 Fea et al. AD - Università degli Studi di Torino, Clinica Oculistica, Torino, Italy Hospital Torrevieja Salud, UTE, Servicio de Oftalmologia, Alicante, Spain Military Institute of Medicine, Department of Ophthalmology, Warsaw, Poland Universitätsaugenklinik, Erlangen, Germany Hinchingbrooke Hospital NHS Trust, Moorfields Bedford Hospital NHS Trust, United Kingdom Hospital Universitario Miguel Servet, Servicio Oftalmologico, Zaragoza, Spain SV Malayan Ophthalmological Center, Yerevan, Armenia Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, United States AU - Fea, A. M. AU - Belda, J. I. AU - Rekas, M. AU - Jünemann, A. AU - Chang, L. AU - Pablo, L. AU - Voskanyan, L. AU - Katz, L. J. DB - Scopus DO - 10.2147/OPTH.S59932 KW - Ab interno Intraocular pressure IOP reduction OAG Trabecular bypass M3 - Article N1 - Cited By :94 Export Date: 19 July 2021 PY - 2014 SP - 875-882 ST - Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma T2 - Clinical Ophthalmology TI - Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84900411462&doi=10.2147%2fOPTH.S59932&partnerID=40&md5=1dc966234d8616d8efcb5892d90a6591 VL - 8 ID - 4933 ER - TY - JOUR AB - PURPOSE: To investigate the efficacy and safety of a cross-linked gel stent (XEN45) with or without cataract surgery in the treatment of glaucoma patients., SETTING: Five university hospitals., DESIGN: Prospective multicenter clinical trial., METHODS: Patients with glaucoma inadequately controlled by treatment or poor compliance or intolerance to topical therapy were included. Patients were divided into those who had an implant only (Solo Group; phakic and pseudophakic patients) and those who had an implant combined with cataract surgery (Combo Group). Differences in mean intraocular pressure (IOP) and number of medications between the baseline preoperative visit and study end (12 months), and the rate of qualified and complete success, were evaluated., RESULTS: The Solo Group comprised 115 glaucoma patients (43 phakic and 72 pseudophakic) and the Combo Group comprised 56 patients. Compared with baseline, mean IOP (23.9 +/- 7.6 to 15.5 +/- 3.9) and number of medications (3.0 +/- 1.1 to 0.5 +/- 1.0) decreased significantly at 12-month follow-up (P < .001 for both). A >20% and >30% reduction in IOP from baseline was achieved by 72.3% and 52.6% of patients, respectively. IOP at 1 week postoperatively was a predictor of success, and the needling rate was inversely correlated with early postoperative IOP. The number of preoperative medications and patient age were not significantly associated with failure., CONCLUSIONS: Insertion of a cross-linked gel stent alone or combined with phacoemulsification might be effective and safe in the treatment of open-angle glaucoma, with a substantial reduction in IOP and number of medications. AU - Fea, Antonio M. AU - Bron, Alain M. AU - Economou, Mario A. AU - Laffi, Gianluca AU - Martini, Enrico AU - Figus, Michele AU - Oddone, Francesco DO - https://dx.doi.org/10.1097/j.jcrs.0000000000000065 IS - 3 KW - Aged Aged, 80 and over Europe Female Follow-Up Studies *Glaucoma Drainage Implants Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] Humans Intraocular Pressure/ph [Physiology] Lens Implantation, Intraocular Male Middle Aged Phacoemulsification Prospective Studies *Stents Tonometry, Ocular Treatment Outcome Visual Acuity/ph [Physiology] PY - 2020 SE - Fea, Antonio M. From the Department of Surgical Sciences (Fea), Eye Clinic, University Hospital, Turin, Department of Ophthalmology (Laffi), S. Orsola Hospital, Bologna, Department of Ophthalmology (Martini), Sassuolo Hospital, Sassuolo, Department of Surgical, Medical, Molecular Pathology, and Critical Area (Figus), University of Pisa, Pisa, IRCCS GB Bietti Foundation (Oddone), Rome, Italy; Department of Ophthalmology, University Hospital (Bron), Dijon, France; and St Erik Eye Hospital (Economou), Karolinska Institute, Stockholm, Sweden. SN - 1873-4502 0886-3350 SP - 441-450 ST - European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma T2 - Journal of cataract and refractive surgery TI - European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32142041 VL - 46 ID - 237 ER - TY - JOUR AB - BACKGROUND: Guideline producers are increasingly producing versions of guidelines for the public, and knowledge of what the public want from them is also increasing. The aim of this study was to user test a patient version of a SIGN clinical guideline that was designed based on preliminary work for the DECIDE project. SIGN is the leading national guideline producer in Scotland., METHODS: People with a diagnosis of glaucoma and non-professional carers were recruited from across Scotland. User testing was conducted using a think-aloud protocol method. Each session was conducted by one interviewer and one observer. All sessions were recorded and transcribed. The data was analysed, problems with the guideline were identified and resolved and key findings were themed using a user experience model., RESULTS: Thirteen user testing sessions with people with glaucoma and one with a carer were conducted. Key facilitators of desirability and usability identified include clear branding as a patient version and a clearly described purpose, audience and contents page. Other facilitators include a "friendly" tone which is achieved by the use of colour, quotes, icons, simple language and charts, and brief chunked text. The value and usefulness of the patient guideline was influenced by its ability to: inform the public, link information to actions, and empower people in their interaction with healthcare professionals. Participants were disappointed by the lack of information on treatment in the patient version, which was outside its scope. Information on the evidence based guideline production process and the involvement of appropriately skilled professionals was key to the credibility of the guideline. Lack of awareness of guidelines and guideline producing bodies, is a potentially serious threat to findability/accessibility., CONCLUSIONS: It is important for guideline producers to maximise the user experience of the public when they access patient versions of guidelines, particularly given the current low level of access and awareness. One size does not fit all and guideline producers need to strike a balance between keeping the patient version simple and providing sufficient information to facilitate shared decision making and empower the public. Guideline producers may find the results of this study useful in designing their own patient versions. AU - Fearns, Naomi AU - Graham, Karen AU - Johnston, Gordon AU - Service, Duncan DO - https://dx.doi.org/10.1186/s12913-016-1287-8 KW - Aged Aged, 80 and over Attitude of Health Personnel Awareness Caregivers/px [Psychology] Decision Making Evidence-Based Medicine Female Glaucoma/px [Psychology] Glaucoma/th [Therapy] Health Personnel Humans Male Models, Theoretical Observer Variation Patient Education as Topic/mt [Methods] *Patient Education as Topic/st [Standards] Patient Satisfaction *Practice Guidelines as Topic/st [Standards] Professional-Patient Relations Quality Improvement Scotland PY - 2016 SE - Fearns, Naomi. Healthcare Improvement Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, EH12 9EB, Scotland, UK. n.fearns@nhs.net. Graham, Karen. Healthcare Improvement Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, EH12 9EB, Scotland, UK. Karen.graham2@nhs.net. Johnston, Gordon. Healthcare Improvement Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, EH12 9EB, Scotland, UK. g_johnston@btopenworld.com. Service, Duncan. Healthcare Improvement Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, EH12 9EB, Scotland, UK. duncan.service@nhs.net. SN - 1472-6963 SP - 37 ST - Improving the user experience of patient versions of clinical guidelines: user testing of a Scottish Intercollegiate Guideline Network (SIGN) patient version T2 - BMC health services research TI - Improving the user experience of patient versions of clinical guidelines: user testing of a Scottish Intercollegiate Guideline Network (SIGN) patient version UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26837683 VL - 16 Y2 - 20160202// ID - 722 ER - TY - JOUR AD - R.D. Fechtner, Department of Ophthalmology, Univ. of Med./Dent. of New Jersey, Newark, NJ 07103-2499, United States AU - Fechtner, R. D. DB - Embase Medline DO - 10.1097/00061198-200002000-00014 IS - 1 KW - beta adrenergic receptor blocking agent brimonidine latanoprost adult article case report clinical feature depression disease course disease predisposition drug choice gonioscopy human intraocular pressure male open angle glaucoma patient compliance priority journal risk assessment risk factor treatment indication treatment outcome treatment planning visual acuity LA - English M3 - Article N1 - L32440555 2001-05-27 PY - 2000 SN - 1057-0829 SP - 83-86 ST - Initial medical management of open-angle glaucoma T2 - Journal of Glaucoma TI - Initial medical management of open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32440555&from=export http://dx.doi.org/10.1097/00061198-200002000-00014 VL - 9 ID - 3913 ER - TY - JOUR AB - UNLABELLED: This study determined the degree of adherence to medications for glaucoma among patients refilling prescriptions in community pharmacies., METHODS: Data abstracted from the dispensing records for 3615 adult patients (18 years or older, predominantly over 45) receiving glaucoma medications from two retail pharmacy chains (64 stores in total) were analyzed. From a 24-month historic data capture period, the 12-month levels of adherence were determined using standard metrics, the proportion of days covered (PDC) and the medication possession ratio (MPR). The overall 12-month mean PDC was only 57%, and the mean MPR was 71%. Using a criterion by which 80% coverage was considered satisfactory adherence, only 30% had satisfactory overall 12-month PDC coverage, and only 37% had satisfactory overall 12-month MPR coverage. Refill adherence increased with age and was highest in the 65-and-older age group (p < 0.001). Differential adherence was found across medication classes, with the highest satisfactory coverage seen for those taking alpha2-adrenergic agonists (PDC = 36.0%; MPR = 47.6%) down to those taking direct cholinergic agonists (PDC = 25.0%; MPR = 31.2%) and combination products (PDC = 22.7%; MPR = 31.0%). Adherence to glaucoma medications in the community setting, as measured by pharmacy refill data, is very poor and represents a critical target for intervention. Community pharmacists are well positioned to monitor and reinforce adherence in this population. AU - Feehan, Michael AU - Munger, Mark A. AU - Cooper, Daniel K. AU - Hess, Kyle T. AU - Durante, Richard AU - Jones, Gregory J. AU - Montuoro, Jaime AU - Morrison, Margaux A. AU - Clegg, Daniel AU - Crandall, Alan S. AU - DeAngelis, Margaret M. DO - https://dx.doi.org/10.3390/jcm5090079 IS - 9 PY - 2016 SE - Feehan, Michael. Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA. mike.feehan@utah.edu. Feehan, Michael. Department of Ophthalmology & Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. mike.feehan@utah.edu. Munger, Mark A. Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA. mark.munger@hsc.utah.edu. Cooper, Daniel K. Hall & Partners, New York, NY 10022, USA. danny.cooper@themodellers.com. Hess, Kyle T. Hall & Partners, New York, NY 10022, USA. kylethess@gmail.com. Durante, Richard. Marketing and Planning Systems (MaPS), a Division of Millward Brown Analytics, Boston, MA 02116, USA. rdurante@mapsnet.com. Jones, Gregory J. Harmon City, Inc., West Valley City, UT 84120, USA. gregjones@harmonygrocery.com. Montuoro, Jaime. Smith's Food & Drug Centers, Inc., Salt Lake City, UT 84104, USA. jaime.montuoro@sfdc.com. Morrison, Margaux A. Department of Ophthalmology & Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. margaux.morrison@utah.edu. Clegg, Daniel. Department of Ophthalmology & Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. doc1@utah.edu. Crandall, Alan S. Department of Ophthalmology & Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. alan.crandall@hsc.utah.edu. DeAngelis, Margaret M. Department of Ophthalmology & Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. margaret.deangelis@utah.edu. SN - 2077-0383 ST - Adherence to Glaucoma Medications Over 12 Months in Two US Community Pharmacy Chains T2 - Journal of clinical medicine TI - Adherence to Glaucoma Medications Over 12 Months in Two US Community Pharmacy Chains UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=27618115 VL - 5 Y2 - 20160907// ID - 1035 ER - TY - JOUR AB - Since Pincus and White's claim in 1933 that diabetes mellitus is an inherited disease, the precise mode of inheritance remains a matter of dispute. The reason for the controversy is that the geneticist is confronted with a number of impediments to genetic analysis. As pointed by Neel, "diabetes mellitus is in many respects a geneticists nightmare". The obstacles are : 1) a precise definition of diabetes is difficult to establish, 2) the frequency of the disease which is sex and age dependent is not well known, 3) the probability of genetic heterogeneity is great but whether early onset and late onset diabetes are different genetic diseases or the same one remains controversial, 4) the basic defect (s) is unknown, 5) environmental factors (e.g. nutritional status) influence the frequency of the disease. Despite these problems many studies have been devoted to the mode of inheritance of diabetes mellitus. Many authors favour an autosomal recessive mechanism. However, low penetrance (25 %) is necessary to support this mode of inheritance. Simple autosomal dominant mode of inheritance has also been suggested, but this pattern fits only few families. The majority of geneticists think, at the present time, that diabetes has a multifactorial mode of inhritance. The heritability which express the extent to which the phenotypes exhibited by parents are transmitted to their offspring is in the neighbourhood of 50%. Many arguments favour this mode of inheritance: 1) low penetrance is necessary to aistinct genetic diseases, and especially in chronic glaucoma, which also have a multifactorial mode of inheritance; in particular, one must note the association between glucose intolerance and ocular hypertension induced by dexamethasone, 3) the association between diabetes and antigen A of the ABO system and antigens HL-A8 and W 15 of the HL-A system. AU - Feingold, J. IS - 2TNA-NA-761102-761104 KW - *Diabetes Mellitus/ge [Genetics] Female Genes Humans Male Models, Biological Nutritional Physiological Phenomena PY - 1976 SN - 0338-1684 SP - 123-9 ST - [Genetics of diabetes mellitus (author's transl)] T2 - Genetique du diabete sucre TI - [Genetics of diabetes mellitus (author's transl)] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=789146 VL - 1 ID - 2281 ER - TY - JOUR AB - OBJECTIVE: To examine the incidence, prevalence, resource use, and costs associated with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in elderly patients., RESEARCH DESIGN AND METHODS: In a retrospective cohort study of a nationally representative sample of Medicare beneficiaries from 2001 through 2006, the authors identified patients with BRVO (n = 10,682) and CRVO (n = 6236) and controls with hypertension (n = 49,524) and glaucoma (n = 49,569) but no retinal vein occlusion. Incident cases were those with no claims listing a diagnosis for the same type of retinal vein occlusion in the previous 12 months. Prevalence was defined as the number of beneficiaries with a diagnosis of BRVO or CRVO. The authors summed Medicare reimbursements for all claims and used generalized linear models to estimate the effects of BRVO and CRVO on 1-year and 3-year costs compared with hypertension and glaucoma control groups. The authors also examined trends in the use of diagnostic and treatment modalities., MAIN OUTCOME MEASURES: Resource use (fluorescein angiography, optical coherence tomography, intravitreal injection, laser photocoagulation, and vitrectomy) and direct medical costs (total Medicare reimbursement amounts as recorded on each inpatient, outpatient, home health, skilled nursing, hospice, durable medical equipment, and professional service claim) at 1 year and 3 years., RESULTS: After adjustment for baseline characteristics, BRVO was associated with 16% higher 1-year costs and 12% higher 3-year costs compared with hypertension and 18% higher 1-year costs and 13% higher 3-year costs compared with glaucoma. CRVO was associated with 22% higher 1-year costs and 15% higher 3-year costs compared with hypertension and 24% higher 1-year costs and 16% higher 3-year costs compared with glaucoma. Use of fluorescein angiography and optical coherence tomography increased during the study. Use of intravitreal injections increased from less than 1% of patients overall to greater than 13% for BRVO and 16% for CRVO. The incidence of BRVO declined slightly during the study period, whereas the incidence of CRVO remained relatively flat. Prevalence increased in both groups., LIMITATIONS: The results may not be generalizable to younger patients or managed-care beneficiaries. The study included only direct costs to Medicare, not nonmedical expenditures or outpatient prescription medications. Diagnosis and procedure codes may not have been complete. The study could not account for clinical variables, such as the amount of vision loss. It was not feasible to adjust for whether one or both eyes were affected or treated., CONCLUSIONS: Although not common in the Medicare population, BRVO and CRVO are important independent predictors of total medical costs. Diagnostic and treatment modalities have changed over time. AU - Fekrat, Sharon AU - Shea, Alisa M. AU - Hammill, Bradley G. AU - Nguyen, Hiep AU - Kowalski, Jonathan W. AU - Schulman, Kevin A. AU - Curtis, Lesley H. DO - https://dx.doi.org/10.1185/03007990903439046 IS - 1 KW - Aged Aged, 80 and over *Cost of Illness Female Fluorescein Angiography *Health Care Rationing Humans Laser Coagulation Male Retinal Vein Occlusion/ec [Economics] Retinal Vein Occlusion/pp [Physiopathology] *Retinal Vein Occlusion/th [Therapy] Tomography, Optical Coherence PY - 2010 SE - Fekrat, Sharon. Duke University School of Medicine, Durham, NC, USA. 27715 SN - 1473-4877 0300-7995 SP - 223-30 ST - Resource use and costs of branch and central retinal vein occlusion in the elderly T2 - Current medical research and opinion TI - Resource use and costs of branch and central retinal vein occlusion in the elderly UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=19921963 VL - 26 ID - 1389 ER - TY - JOUR AB - Poor compliance with prescribed medications limits the effectiveness of many pharmacologic therapies and enhances their potential toxicities. Traditional methods of measuring drug-taking behavior, including direct observation, patient self-report, pill counts, and therapeutic drug level monitoring, all have well-described limitations in validity and interpretability. Electronic medication event monitoring has been used to assess compliance with therapies for hypertension, glaucoma, anemia, and epilepsy, overcoming many problems of traditional approaches. However, no published reports describe the use of electronic monitoring with immunosuppressive agents, despite their increasing use for non-life-threatening conditions and their many dose-dependent toxicities. Transplant recipients are thought to be at particular risk from noncompliance. Therefore, we undertook this study to assess the feasibility of electronically monitoring compliance with immunosuppressive drugs among renal allograft recipients. Twenty-five kidney transplant patients receiving immunosuppressive medications from a single pharmacy were enrolled. Each subject received electronic monitors with their immunosuppressive serum drug refills for cyclosporine and azathioprine. Each subject returned their monitors after the first month of this 2-month study for downloading data. The frequency distribution of interdose intervals were described. Two measures of average non-compliance were calculated for both drugs: the proportion of monitored days that had missed doses, and the proportion of missed doses. Once daily and twice daily regimens of cyclosporine were compared. Concordance in drug compliance between the two drugs was calculated for each subject and averaged over the study population. Twenty-two of 25 subjects missed one or more doses of cyclosporine or azathioprine. Seventeen (68%) subjects never missed four or more consecutive doses. Subjects were non-compliant with cyclosporine on 8.7% of monitored days, and non-compliance with azathioprine on 9.8% of monitored days. Subjects were non-compliant with 6.8% of their cyclosporine doses and 9.8% of their azathioprine doses. Patients were compliant with both drugs on 86.6% of days and were non-compliant with both drugs on 5.1% of days. Subjects were non-compliant with cyclosporine during 5% and 13.2% of monitored days for once and twice daily dosing regimens, respectively. Concordance analysis demonstrated that for 91.7% of days of monitoring, compliance information was identical for both drugs. This study demonstrated the feasibility of electronic medication event monitoring among kidney transplant patients. This methodology represents an important tool for monitoring compliance of immunosuppressive agents essential to their safe and effective use, and should be considered for use in future studies of these drugs and others with substantial dose-dependent toxicity. Copyright 1999 John Wiley & Sons, Ltd. AU - Feldman, H. I. AU - Hackett, M. AU - Bilker, W. AU - Strom, B. L. IS - 1 PY - 1999 SE - Feldman, H I. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology and Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, 19104-6021, USA. SN - 1053-8569 SP - 1-14 ST - Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents T2 - Pharmacoepidemiology and drug safety TI - Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm1&NEWS=N&AN=15073941 VL - 8 ID - 2045 ER - TY - JOUR AB - The prostaglandin derivatives are thought to lower intraocular pressure (IOP) primarily by increasing uveoscleral outflow. The ocular side effect, hyperemia, appears to occur via a secondary, unrelated mechanism. Variations in the IOP-lowering effect and incidence of hyperemia associated with these drugs are a function of their different chemical structures. Among the currently approved prostaglandin derivatives, hyperemia occurs in as many as 50% of patients treated with travoprost and as few as 5% of patients treated with latanoprost. The side effect of hyperemia may be of concern to the ophthalmologist for at least 2 reasons: hyperemia may compromise the outcome of filtration surgery, and it may represent a cosmetic problem to the patient thereby leading to non-compliance. The extent to which hyperemia may contribute to patient noncompliance and the effect of administration of the prostaglandin derivatives on outcome of filtration surgery remain to be determined. Until more definitive data are available, when selecting a prostaglandin analogue for ocular hypotensive therapy, it seems prudent to choose an agent with a low incidence of hyperemia. AU - Feldman, Robert M. IS - 1 KW - Administration, Topical Cloprostenol/ae [Adverse Effects] *Cloprostenol/aa [Analogs & Derivatives] *Conjunctiva/bs [Blood Supply] *Glaucoma/dt [Drug Therapy] Humans *Hyperemia/ci [Chemically Induced] Hyperemia/ep [Epidemiology] Incidence Intraocular Pressure/de [Drug Effects] Latanoprost *Ocular Hypertension/dt [Drug Therapy] *Prostaglandins/ad [Administration & Dosage] Prostaglandins F, Synthetic/ae [Adverse Effects] Travoprost PY - 2003 SE - Feldman, Robert M. University of Texas Health Sciences Center, Houston, USA. SN - 1080-7683 SP - 23-35 ST - Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics TI - Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=12648301 VL - 19 ID - 1849 ER - TY - JOUR AB - Glaucoma is one of the leading causes of irreversible blindness worldwide. Although there is no cure for this chronic disease, medical treatment is aimed at reducing levels of intraocular pressure (IOP) using ocular hypotensive agents. Very often, patients require more than one IOP-reducing drug, resulting in complex medication regimens that may be difficult to maintain and that can lead to non-compliance. A fixed-combination (FC) ophthalmic solution consisting of the prostaglandin, latanoprost (0.005%), and the beta-blocker, timolol (0.5%), is now available. The primary mechanism of action of latanoprost is to increase uveoscleral outflow whereas timolol lowers IOP levels by decreasing the formation of aqueous humor in the ciliary epithelium. Due to the unique mechanism of action of latanoprost, once-daily dosing of one drop of FC latanoprost/timolol results in additional IOP reduction compared with either drug administered separately. FC latanoprost/timolol is well-tolerated and has a safety profile similar to that of its individual components. This combination drug provides a safe, effective and convenient alternative for the treatment of patients with elevated IOP levels uncontrolled with monotherapy. AU - Feldman, Robert M. IS - 4 KW - Antihypertensive Agents/pk [Pharmacokinetics] Antihypertensive Agents/pd [Pharmacology] *Antihypertensive Agents/tu [Therapeutic Use] Drug Combinations Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Latanoprost *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions Prostaglandins F, Synthetic/pk [Pharmacokinetics] Prostaglandins F, Synthetic/pd [Pharmacology] *Prostaglandins F, Synthetic/tu [Therapeutic Use] Randomized Controlled Trials as Topic Timolol/pk [Pharmacokinetics] Timolol/pd [Pharmacology] *Timolol/tu [Therapeutic Use] PY - 2004 SE - Feldman, Robert M. University of Texas Health Science, Houston Texas, USA. rmfeldman@swbell.net SN - 1465-6566 SP - 909-21 ST - An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension T2 - Expert opinion on pharmacotherapy TI - An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15102573 VL - 5 ID - 1784 ER - TY - JOUR AB - Background: Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the cost-effectiveness of intraocular pressure (IOP)-lowering pharmacotherapies. There is little published information on clinicians' knowledge and attitudes about cost-effectiveness in glaucoma treatment., Purpose: This pilot focus group study aimed to explore clinician attitudes and perspectives around the costs and cost drivers of glaucoma therapy; the implementation of cost-effectiveness decisions; the clinical utility of cost-effectiveness studies; and the cost-effectiveness of available treatments., Methods: Six US glaucoma specialists participated in two separate teleconferencing sessions (three participants each), managed by an independent, skilled moderator (also a glaucoma specialist) using a discussion guide. Participants reviewed recent publications (n=25) on health economics outcomes research in glaucoma prior to the sessions., Results: Participants demonstrated a clear understanding of the economic burden of glaucoma therapy and identified medications, diagnostics, office visits, and treatment changes as key cost drivers. They considered cost-effectiveness an appropriate component of treatment decision-making but identified the need for additional data to inform these decisions. Participants indicated that there were only a few recent studies on health economics outcomes in glaucoma which evaluate parameters important to patient care, such as quality of life and medication adherence, and that longitudinal data were scant. In addition to efficacy, participants felt patient adherence and side-effect profile should be included in economic evaluations of glaucoma pharmacotherapy. Recently approved medications were evaluated in this context., Conclusion: Clinicians deem treatment decisions based on cost-effectiveness data as clinically appropriate. Newer IOP-lowering therapies with potentially greater efficacy and favorable side-effect and adherence profiles may help optimize cost-effectiveness. Future studies should include: clinicians' perspectives; lack of commercial bias; analysis of long-term outcomes/costs; more comprehensive parameters; real-world (including quality-of-life) data; and a robust Markov model. Copyright © 2020 Feldman et al. AU - Feldman, Robert M. AU - Cioffi, George A. AU - Liebmann, Jeffrey M. AU - Weinreb, Robert N. DO - https://dx.doi.org/10.2147/OPTH.S236030 PY - 2020 SE - Feldman, Robert M. The University of Texas Medical School Houston, TX, USA. Cioffi, George A. Department of Ophthalmology, NewYork Presbyterian Hospital Columbia University Irving Medical Center, NY, New York, USA. Liebmann, Jeffrey M. Columbia University Medical Center, New York, NY, USA. Weinreb, Robert N. University of California San Diego, LaJolla, CA, USA. SN - 1177-5467 SP - 729-739 ST - Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=32184559 VL - 14 Y2 - 20200306// ID - 143 ER - TY - JOUR AB - Objective: To evaluate the 24-hour efficacy and tolerability of 2% dorzolamide/0.5% timolol fixed combination (DTFC) solution in open-angle glaucoma and ocular hypertension. Research design and methods: Randomized, parallel, double-masked, multicenter study. Patients with insufficiently controlled intraocular pressure (IOP ≥ 22 mmHg) were randomized to DTFC (N=117) or timolol (N=115). IOP was measured at baseline, 6 weeks, and 8 weeks, with measurements taken at 6 p.m., 8 p.m., 10 p.m., 2 a.m., 6 a.m., 8 a.m., 10 a.m., and 2 p.m. ClinicalTrials.gov identifier: NCT00108017 Main outcome measures: Statistically significant change in IOP from untreated baseline for DTFC at all hours at week 8. Secondary outcome measures included: IOP-lowering at week 6 at all individual time points, change from baseline to 8 weeks in mean daytime IOP (average of 8 a.m., 10 a.m., 2 p.m., 6 p.m., and 8 p.m. IOPs) and night-time IOP (10 p.m., 2 a.m., 6 a.m.), and comparison of DTFC with timolol after 8 weeks. Results: Patients receiving DTFC had a statistically significant and clinically relevant reduction in IOP at week 8 compared with baseline at all eight time points (p<0.001). Significant IOP reductions were also seen at all time points at week 6 (p<0.001). DTFC significantly lowered mean daytime IOP and night-time IOP (p<0.001 for both). Timolol alone also significantly reduced IOP from baseline at 8 weeks for all diurnal time points, and mean daytime and night-time IOP (p<0.001 for all). Compared with timolol alone, there were significantly greater reductions with DTFC at 10 a.m. (p=0.003) and 2 p.m. (p=0.016), and for mean daytime IOP (p=0.025) at 8 weeks. Significant between-treatment differences were not observed at other time points. Both treatments were well-tolerated, with no differences observed in the safety profiles between the treatment groups. Conclusions: Both DTFC and timolol provided significant IOP reduction over the entire 24-hour measurement period. Although this study was not designed or powered to compare DTFC and timolol, DTFC exhibited greater IOP-lowering than timolol during the daytime, but not at night. © 2008 Informa UK Ltd. All rights reserved. AD - R.M. Feldman, The University of Texas Health Science Center at Houston, Department of Ophthalmology, Cizik Eye Clinic, 6400 Fannin Street, Houston, TX 77030, United States AU - Feldman, R. M. AU - Stewart, R. H. AU - Stewart, W. C. AU - Jia, G. AU - Smugar, S. S. AU - Galet, V. A. C1 - timoptic(Merck and Co,United States) C2 - Merck and Co(United States) DB - Embase Medline DO - 10.1185/03007990802243366 IS - 8 KW - NCT00108017 dorzolamide plus timolol timolol maleate adult aged blurred vision cholelithiasis circadian rhythm clinical trial consciousness disorder controlled study diabetic neuropathy dose time effect relation double blind procedure drug efficacy drug induced disease drug safety drug tolerability drug withdrawal dry eye evening dosage eye disease eye irritation eye pain female human intraocular hypertension intraocular pressure major clinical study male morning dosage multicenter study open angle glaucoma papilledema patient compliance patient monitoring pressure measurement randomized controlled trial retina exudate review urinary tract infection vitreous floaters timoptic LA - English M3 - Review N1 - L352212520 2008-09-10 PY - 2008 SN - 0300-7995 SP - 2403-2412 ST - 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma T2 - Current Medical Research and Opinion TI - 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352212520&from=export http://dx.doi.org/10.1185/03007990802243366 VL - 24 ID - 3434 ER - TY - JOUR AD - R. L. Fellman, Glaucoma Associates of Texas, Dallas, TX, United States AU - Fellman, R. L. DB - Embase DO - 10.1097/IEB.0b013e3181920134 IS - 1 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor miotic agent prostaglandin derivative cost effectiveness analysis doctor patient relationship ethnicity glaucoma surgery health care utilization human medicaid medical society medicare note open angle glaucoma priority journal LA - English M3 - Note N1 - L354907741 2009-08-05 PY - 2008 SN - 1555-9203 1555-9211 SP - 13-14 ST - Rates of glaucoma medication utilization among persons with primary open-angle glaucoma, 1992 to 2002 T2 - Evidence-Based Ophthalmology TI - Rates of glaucoma medication utilization among persons with primary open-angle glaucoma, 1992 to 2002 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354907741&from=export http://dx.doi.org/10.1097/IEB.0b013e3181920134 VL - 10 ID - 3393 ER - TY - JOUR AB - In recent years, there has been increasing interest in the use of automatic computer-based systems for the detection of eye diseases including glaucoma. However, these systems are usually standalone software with basic functions only, limiting their usage in a large scale. In this paper, we introduce an online cloud-based system for automatic glaucoma screening through the use of medical image-based pattern classification technologies. It is designed in a hybrid cloud pattern to offer both accessibility and enhanced security. Raw data including patient's medical condition and fundus image, and resultant medical reports are collected and distributed through the public cloud tier. In the private cloud tier, automatic analysis and assessment of colour retinal fundus images are performed. The ubiquitous anywhere access nature of the system through the cloud platform facilitates a more efficient and cost-effective means of glaucoma screening, allowing the disease to be detected earlier and enabling early intervention for more efficient intervention and disease management. AU - Fengshou, Yin AU - Damon Wing Kee, Wong AU - Ying, Quan AU - Ai Ping, Yow AU - Ngan Meng, Tan AU - Gopalakrishnan, Kavitha AU - Beng Hai, Lee AU - Yanwu, Xu AU - Zhuo, Zhang AU - Jun, Cheng AU - Jiang, Liu DO - https://dx.doi.org/10.1109/EMBC.2015.7318679 KW - Algorithms Diagnostic Techniques, Ophthalmological Fundus Oculi *Glaucoma Humans Software PY - 2015 SN - 2694-0604 2375-7477 SP - 1596-9 ST - A cloud-based system for automatic glaucoma screening T2 - Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference TI - A cloud-based system for automatic glaucoma screening UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=26736579 VL - 2015 ID - 754 ER - TY - JOUR AB - Glaucoma, an irreversible blinding condition affecting 3–4% adults aged above 40 years worldwide, is set to increase with a rapidly aging global population. Raised intraocular pressure (IOP) is a major risk factor for glaucoma where the treatment paradigm is focused on managing IOP using medications, laser, or surgery regimens. However, notwithstanding IOP and other clinical parameters, patient-reported outcomes, including daily functioning, emotional well-being, symptoms, mobility, and social life, remain the foremost concerns for people being treated for glaucoma. These outcomes are measured using objective patient-centered outcome measures (PCOMs) and subjective patient-reported outcome measures (PROMs). Studies using PCOMs have shown that people with glaucoma have several mobility, navigational and coordination challenges; reading and face recognition deficits; and are slower in adapting to multiple real-world situations when compared to healthy controls. Similarly, studies have consistently demonstrated, using PROMs, that glaucoma substantially and negatively impacts on peoples’ self-reported visual functioning, mobility, independence, emotional well-being, self-image, and confidence in healthcare, compared to healthy individuals, particularly in those with late-stage disease undergoing a heavy treatment regimen. The patient-centred effectiveness of current glaucoma treatment paradigms is equivocal due to a lack of well-designed randomized controlled trials; short post-treatment follow-up periods; an inappropriate selection or availability of PROMs; and/or an insensitivity of currently available PROMs to monitor changes especially in patients with newly diagnosed early-stage glaucoma. We provide a comprehensive, albeit non-systematic, critique of the psychometric properties, limitations, and recent advances of currently available glaucoma-specific PCOMs and PROMs. Finally, we propose that item banking and computerized adaptive testing methods can address the multiple limitations of paper-pencil PROMs; customize their administration; and have the potential to improve healthcare outcomes for people with glaucoma. AD - E.L. Lamoureux, Singapore Eye Research Institute (SERI), Population Health, The Academia, 20 College Road, Level 6, Singapore AU - Fenwick, E. K. AU - Man, R. E. AU - Aung, T. AU - Ramulu, P. AU - Lamoureux, E. L. DB - Embase Medline DO - 10.1016/j.preteyeres.2019.100801 KW - ophthalmic argon laser antiglaucoma agent computerized adaptive testing coordination drug efficacy drug tolerability facial recognition follow up glaucoma glaucoma surgery human intraocular pressure medication compliance minimally invasive surgery patient compliance patient satisfaction patient-reported outcome priority journal quality of life reading review symptom trabeculoplasty watchful waiting LA - English M3 - Review N1 - L2003713686 2019-11-29 2020-08-25 PY - 2020 SN - 1873-1635 1350-9462 ST - Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma T2 - Progress in Retinal and Eye Research TI - Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003713686&from=export http://dx.doi.org/10.1016/j.preteyeres.2019.100801 VL - 76 ID - 2409 ER - TY - JOUR AB - This article provides guidelines for pharmacotherapy to maximize symptom relief from allergic rhinitis. Consideration of frequency, severity, and site of symptoms is important in directing pharmacotherapy efficacy and maximizing cost-effectiveness. The agents available include antihistamines, decongestants, steroids, mast cell stabilizers, anticholinergic agents, and mucolytics. Appropriate indications for each and combinations of various agents are discussed within the context of drug efficacy, side effects, affordability, and ease of compliance. The direct and indirect costs of allergic rhinitis are not well delineated but are explored to put the costs of therapy in perspective. AD - B.J. Ferguson, Eye and Ear Institute Building, Department of Otolaryngology, 200 Lothrop Street, Pittsburgh, PA 15213, United States AU - Ferguson, B. J. DB - Embase Medline DO - 10.1016/S0030-6665(05)70032-3 IS - 1 KW - antihistaminic agent astemizole cetirizine cholinergic receptor blocking agent clemastine decongestive agent diphenhydramine ephedrine fexofenadine ipratropium bromide levocabastine loratadine mucolytic agent naphazoline oxymetazoline phenylephrine phenylpropanolamine promethazine propylhexedrine pseudoephedrine steroid terfenadine tetryzoline tripelennamine unindexed drug xylometazoline allergic rhinitis cost effectiveness analysis drug cost dry eye epistaxis glaucoma headache human insomnia patient compliance review sedation tremor vertigo LA - English M3 - Review N1 - L28119975 1998-04-21 PY - 1998 SN - 0030-6665 SP - 91-110 ST - Cost-effective pharmacotherapy for allergic rhinitis T2 - Otolaryngologic Clinics of North America TI - Cost-effective pharmacotherapy for allergic rhinitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L28119975&from=export http://dx.doi.org/10.1016/S0030-6665(05)70032-3 VL - 31 ID - 3946 ER - TY - JOUR AB - Objectives: to report on trends in ophthalmology workload using linked statistical data; Design: analysis of linked abstracts of hospital inpatient and day case records for ophthalmology; Setting: six districts in Southern England covered by the Oxford record linkage study; Subjects: records for hospital admissions to ophthalmology from 1975 to 1985; Measurement and Main Results: Over the period of study, the number of episodes of inpatient and day case care increased by 16.3%. Notable increases in age-specific admission rates were seen among the elderly. An increase in the number of individuals treated contributed about 67% and an increase in multiple admissions per individual contributed about 33% to the increase in admission rates. Both average length of stay per episode and total time in hospital per individual decreased consistently during the 11 years; and there was no increase in emergency readmissions over time. No significant changes over time were found in admission rates for retinal detachments and defects or for glaucoma. There was a statistically significant increase averaging 4.8% per annum in admission rates for cataract, and a significant decrease averaging 5.2% per annum in admission rates for strabismus and other disorders of binocular eye movement between 1975 and 1985. Conclusions: Age-specific admission rates in ophthalmology are much higher in the very young and old than in other age groups. Patterns of work in the specialty are therefore particularly affected by variation in the age distribution of the population. The increase in cataract surgery reflected both the increase in numbers of old people in the population and an increase in age-specific operation rates for cataract. Attempts to alter attitudes and behaviour of the elderly regarding eye diseases, disability, and facilities for treatment may have had a positive impact on the use of services. The decrease in admissions for children probably reflects the impact made by child health surveillance programmes. As the child screening programme has expanded, the admission rates for strabismus have decreased. AD - Unit of Clinical Epidemiology, Oxford Regional Health Authority, Old Road, Headington, Oxford OX3 7LF AU - Ferguson, J. A. AU - Goldacre, M. J. AU - Henderson, J. AU - Bron, A. J. DB - Embase Medline IS - 3 KW - adolescent adult age aged ambulatory surgery article cataract cataract extraction child child health eye movement glaucoma health care utilization hospital admission hospital patient human infant length of stay ophthalmology patient attitude retina detachment strabismus United Kingdom workload LA - English M3 - Article N1 - L22106118 1992-04-05 PY - 1991 SN - 0950-222X SP - 379-384 ST - Ophthalmology in the Oxford region: Analysis of time trends from linked statistics T2 - Eye TI - Ophthalmology in the Oxford region: Analysis of time trends from linked statistics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L22106118&from=export VL - 5 ID - 4033 ER - TY - JOUR AB - We critically analyze available peer-reviewed literature, including clinical trials and case reports, on local ocular cancer treatments. Recent innovations in many areas of ocular oncology have introduced promising new therapies, but, for the most part, the optimal treatment of ocular malignancies remains elusive. © 2014 Elsevier Inc. AD - B.F. Fernandes, 3775 University Street, Room 216, Montreal, Quebec H3A-2B4, Canada AU - Fernandes, B. F. AU - Nikolitch, K. AU - Coates, J. AU - Novais, G. AU - Odashiro, A. AU - Odashiro, P. P. AU - Belfort, R. N. AU - Burnier, M. N. C1 - intron A(Schering Plough,United States) C2 - Schering Plough(United States) DB - Embase Medline DO - 10.1016/j.survophthal.2013.01.003 IS - 1 KW - alpha2b interferon carboplatin cytarabine dexamethasone doxorubicin etoposide fluorouracil melphalan methotrexate mitomycin placebo thiotepa topotecan vinblastine vincristine acute leukemia allergic reaction bladder carcinoma blepharitis bone marrow suppression breast adenocarcinoma breast cancer cancer chemotherapy cancer resistance carcinoma in situ carcinoma in situ of the conjunctiva carcinoma in situ of the cornea cataract cellulitis chorioretinal atrophy chorioretinopathy colon cancer condyloma acuminatum conjunctiva disease conjunctiva tumor conjunctival hyperemia conjunctival melanoma conjunctival scarring conjunctivitis cornea disease cornea edema cornea erosion cornea opacity cornea tumor corneal epithelial defect corneal scleral melt corneoconjunctival intraepithelial neoplasia diarrhea disciform keratitis disease free interval disease free survival drug administration route drug dose comparison drug efficacy drug mechanism drug megadose drug tissue level drug tolerability drug withdrawal dry eye encapsulation endophthalmitis epiphora event free survival Ewing sarcoma eye cancer eye irritation eye lavage eye movement disorder eye redness eye swelling eye toxicity eyelash loss eyelid erythema eyelid tumor fever filamentary keratitis flu like syndrome follicular conjunctivitis foreign body hair loss hairy cell leukemia headache hepatitis C Hodgkin disease human hydrogel hyperemia intraocular hypotension intraocular lymphoma intraocular pressure intraocular tumor invasive squamous carcinoma of the conjunctiva iontophoresis iris atrophy ischemic optic neuropathy Kaposi sarcoma keratitis keratoconjunctivitis keratopathy lacrimation large cell lymphoma leukemia limbal stem cell deficiency limbal stem cell failure liver venoocclusive disease local drug administration low drug dose lymphoma lymphosarcoma melanoma melanosis mucosa inflammation multiple cycle treatment myalgia myelodysplastic syndrome nausea and vomiting neovascular glaucoma neuroblastoma nonhodgkin lymphoma nonhuman ocular leukemia ocular surface disease ocular surface squamous neoplasia optic nerve atrophy optic nerve disease orbit cellulitis orbit inflammation ovary adenocarcinoma ovary cancer overall survival papillary carcinoma patient compliance periorbital edema periorbital inflammation periorbital redness photophobia primary acquired melanosis with atypia primary central nervous system lymphoma priority journal pseudo preseptal cellulitis punctual stenosis retina hemorrhage retinoblastoma retinopathy review rhabdomyosarcoma sebaceous carcinoma skin discoloration skin tumor squamous carcinoma of the conjunctiva squamous cell carcinoma subtenon drug administration superficial keratitis transcleral drug administration tumor recurrence tumor regression unspecified side effect visual impairment intron A LA - English M3 - Review N1 - L52805038 2013-10-15 2014-01-14 PY - 2014 SN - 0039-6257 1879-3304 SP - 97-114 ST - Local chemotherapeutic agents for the treatment of ocular malignancies T2 - Survey of Ophthalmology TI - Local chemotherapeutic agents for the treatment of ocular malignancies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52805038&from=export http://dx.doi.org/10.1016/j.survophthal.2013.01.003 VL - 59 ID - 2924 ER - TY - JOUR AB - PURPOSE: To study the success of visual rehabilitation in a group of 1,000 patients with low vision., METHOD: Clinical data on visual rehabilitation was studied in 1,000 subsequent patients suffering from visual impairment. Study focused on ocular disease, improvement in visual acuity and successful use of visual aids. A statistical analysis of results is presented., RESULTS: 25 cases dropped out due to issues in primary diagnosis. Remaining 975 patients were assigned to 9 groups: age-related macular degeneration (339) diabetic retinopathy (264 cases), myopic maculopathy (195 cases), glaucoma (96 cases), congenital maculopathy (39 cases), retinal detachment (12 patients), retinitis pigmentosa (13 cases), macular pucker (6 patients) and a miscellaneous group of 11 cases. The overall success in the improvement in visual acuity was 98% except for a group of patients with retinitis pigmentosa where a rate of only 46% success (p<0.01) was observed. 76% of cases finally accepted visual rehabilitation aids., CONCLUSIONS: The usefulness of visual rehabilitation in low vision patients is confirmed, with the exception of retinitis pigmentosa cases, probably due to features of the disease itself. The design of visual aids should be improved in order to benefit a greater number of patients. AU - Fernandez Guardiola, A. AU - Sierra Jane, I. IS - 9 KW - Adolescent Adult Aged Aged, 80 and over Child Female Humans *Lenses Male Middle Aged Patient Satisfaction Vision, Low/et [Etiology] *Vision, Low/rh [Rehabilitation] PY - 2001 SE - Fernandez Guardiola, A. Centro Medico Delfos. Barcelona, Spain. SN - 0365-6691 SP - 527-32 ST - [Analysis of eye disease and adaptation of visual aids in low vision patients: review of 1,000 cases] T2 - Analisis de la patologia ocular y de la adaptacion de ayudas visuales en pacientes afectos de baja vision: revision de 1.000 casos. TI - [Analysis of eye disease and adaptation of visual aids in low vision patients: review of 1,000 cases] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11592008 VL - 76 ID - 1911 ER - TY - JOUR AU - Ferrari, C. DB - Embase DO - 10.1089/clm.1995.13.113 IS - 2 KW - cataract follow up glaucoma human neodymium laser patient compliance sclerotomy short survey surgical drainage LA - English M3 - Short Survey N1 - L25162122 1995-06-11 PY - 1995 SN - 1044-5471 SP - 113-114 ST - Laser glaucoma treatment under development T2 - Journal of Clinical Laser Medicine and Surgery TI - Laser glaucoma treatment under development UR - https://www.embase.com/search/results?subaction=viewrecord&id=L25162122&from=export http://dx.doi.org/10.1089/clm.1995.13.113 VL - 13 ID - 3988 ER - TY - JOUR AB - OBJECTIVE: To evaluate the effectiveness of mobile ophthalmic unit screenings and to investigate barriers between community care and resolution of the problem at a tertiary center. METHODS: This prospective study evaluated a convenience sample from 10 municipalities in Sao Paulo State, Brazil. Patients were assessed in the municipality by a mobile ophthalmic unit and underwent a complete ophthalmic consultation. Patients were referred as warranted to a tertiary hospital. RESULTS: The mobile ophthalmic unit screened 1,928 individuals and 714 (37%) were referred. The mean age of the referred patients was 57.12 (SD = 19.5) years with best corrected visual acuity of 0.37 (SD = 0.36) logMAR. Forty-seven (6.6%) patients were blind and 185 (26.5%) were visually impaired. Cataracts (44.7%) and pterygium (14.7%) accounted for most referrals. Of those referred, 67.1% presented to the tertiary center. The diagnosis by the mobile ophthalmic unit corresponded to the one by the tertiary center in 88.5% of the cases. There were a significantly higher number of blind and visually impaired persons among those who presented to the hospital. There was a significantly greater attendance among patients living in more distant municipalities from the reference center with a higher number of inhabitants and a greater number of ophthalmologists in the cities of origin (p < 0.05, all comparisons). Complete treatment was performed in 65.6% of patients, and loss to follow-up was the main cause of incomplete treatment in 50.7% of patients. A total of 313 cataract surgeries were performed, which reduced the number of blind patients from 20 to 2 and of visually impaired individuals from 87 to 2 (p < 0.001). CONCLUSIONS: Only 37% of the patients assessed by a mobile ophthalmic unit required referral to a tertiary hospital. Among the referred patients, 67.1% presented to the hospital, and complete resolution after treatment was approximately 65.5%. There was a significant improvement in visual acuity and a reduction in the prevalence of blindness and visual impairment postoperatively. AN - WOS:000452457500001 AU - Ferreira, G. D. AU - Rezende, M. A. AU - Meneghim, Rlfd AU - Schellini, S. A. DO - 10.11606/S1518-8787.2018052000589 PY - 2018 SN - 0034-8910 1518-8787 ST - Barriers between community screening for visual problems and treatments in a tertiary center T2 - REVISTA DE SAUDE PUBLICA TI - Barriers between community screening for visual problems and treatments in a tertiary center VL - 52 ID - 6325 ER - TY - JOUR AB - Glucocorticoids (GCs) were discovered in the 1940s and were administered for the first time to patients with rheumatoid arthritis in 1948. However, side effects were subsequently reported. In the last 7 decades, the mechanisms of action for both therapeutic properties and side effects have been elucidated. Mechanisms for minimizing side effects were also developed. GCs are the most frequently used class of drugs in the treatment of rheumatoid arthritis because of their efficacy in relieving symptoms and their low cost. A review of clinical applications, side effects, and drug interactions is presented. AD - P. Emery, Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospital NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, United Kingdom AU - Ferreira, J. F. AU - Ahmed Mohamed, A. A. AU - Emery, P. DB - Embase Medline DO - 10.1016/j.rdc.2015.08.006 IS - 1 KW - betamethasone calcium carbamazepine clarithromycin deflazacort dexamethasone efavirenz fosphenytoin sodium gamma interferon glucocorticoid interleukin 17 interleukin 1beta interleukin 2 interleukin 3 interleukin 6 isoniazid itraconazole methylprednisolone oxcarbazepine parathyroid hormone[1-34] pentobarbital phenobarbital phenytoin placebo prednisolone prednisone triamcinolone tumor necrosis factor unindexed drug vitamin D acne adrenal insufficiency analgesia antiinflammatory activity anxiety atherosclerosis bone necrosis corticosteroid induced osteoporosis Cushing syndrome depression disease course drug absorption drug bioavailability drug blood level drug cost drug efficacy drug half life drug mechanism drug protein binding drug pulse therapy drug solubility ecchymosis fatigue fatty liver gastritis glaucoma hair loss hirsutism human hyperglycemia hypertension hypokalemia increased appetite infection insomnia intraocular pressure abnormality kidney dysfunction memory disorder meta analysis (topic) metabolic alkalosis morning stiffness myopathy pancreatitis patient compliance patient education patient monitoring priority journal psychosis randomized controlled trial (topic) restlessness review rheumatoid arthritis side effect skin atrophy skin contusion sleep disorder stomach hemorrhage stomach ulcer stria subcapsular cataract Th1 cell body weight gain wound healing impairment LA - English M3 - Review N1 - L609163061 2016-03-30 2016-04-05 PY - 2016 SN - 1558-3163 0889-857X SP - 33-46 ST - Glucocorticoids and Rheumatoid Arthritis T2 - Rheumatic Disease Clinics of North America TI - Glucocorticoids and Rheumatoid Arthritis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609163061&from=export http://dx.doi.org/10.1016/j.rdc.2015.08.006 VL - 42 ID - 2770 ER - TY - JOUR AB - PURPOSE: To report management of de novo vitreous amyloid opacities after previous pars plana vitrectomy in familial amyloidotic polyneuropathy transthyretin Val30Met., METHODS: This work is a retrospective observational consecutive case series of five eyes of four patients. Demographic data, transthyretin mutation involved, age at the beginning of disease, duration of disease, treatment (liver transplant or tafamidis), time between vitrectomy and re-intervention, and ophthalmologic changes were evaluated. Surgical re-intervention included phacoemulsification with intraocular lens implantation in phakic eyes, re-vitrectomy as complete as possible with posterior capsulectomy, and internal limiting membrane peeling if wrinkling of internal retinal surface was present., RESULTS: All patients had transthyretin Val30Met mutation, and three were women. Mean age of onset of the disease was 52 +/- 11.0 years, and average evolution time of the disease was 8 years. Three patients had been submitted to liver transplant 4, 9, and 15 years before. Time between first vitrectomy and surgical re-intervention was longer than 2 years in all cases. Two eyes had amyloid deposits on anterior lens surface and pupillary border with scalloped pupil. Two eyes were phakic. Glaucoma was present in two eyes; one of them had previous trabeculectomy. All cases had vitreous opacities behind posterior lens capsule and at vitreous base area. After re-intervention, no further recurrence was observed (average follow-up of 10 months)., CONCLUSION: De novo vitreous amyloid opacities may occur several years after pars plana vitrectomy. Amyloid deposition in vitreous cavity was observed only in strong vitreous adherence locations (behind posterior lens capsule and at vitreous base area). The authors expect that this procedure, an extensive re-vitrectomy associated with posterior capsulectomy, will prevent de novo vitreous amyloid opacities. AU - Ferreira, Natalia Novais AU - Cunha Dias, David Afonso AU - Afonso Carvalho, Rui Pedro AU - Pardal Monteiro Coelho, Maria Teresa DO - https://dx.doi.org/10.1097/ICB.0000000000000578 IS - 3 KW - Aged *Amyloid Neuropathies, Familial/co [Complications] *Eye Diseases/su [Surgery] Female Humans Male Middle Aged *Plaque, Amyloid/su [Surgery] Prealbumin/ge [Genetics] Reoperation Retrospective Studies *Vitrectomy/mt [Methods] *Vitreous Body/pa [Pathology] PY - 2019 SE - Ferreira, Natalia Novais. Department of Ophthalmology, Hospital Santo Antonio, Centro Hospitalar e Universitario do Porto, Porto, Portugal. Cunha Dias, David Afonso. Department of Ophthalmology, Hospital Santo Antonio, Centro Hospitalar e Universitario do Porto, Porto, Portugal. Afonso Carvalho, Rui Pedro. Department of Ophthalmology, Hospital Pedro Hispano, Matosinhos, Portugal. Pardal Monteiro Coelho, Maria Teresa. Unidade Corino de Andrade and Department of Neurophysiology, Hospital Santo Antonio, Centro Hospitalar e Universitario do Porto, Porto, Portugal. SN - 1937-1578 1935-1089 SP - 273-278 ST - RE-INTERVENTION IN DE NOVO VITREOUS OPACITIES AFTER PARS PLANA VITRECTOMY IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY TTR VAL30METPORTUGUESE PATIENTS T2 - Retinal cases & brief reports TI - RE-INTERVENTION IN DE NOVO VITREOUS OPACITIES AFTER PARS PLANA VITRECTOMY IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY TTR VAL30METPORTUGUESE PATIENTS UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=28333852 VL - 13 ID - 385 ER - TY - JOUR AB - PURPOSE: To determine the main causes of intrastromal corneal ring segment (ICRS) explantation and the relationship with the microscopic findings on the ICRS surface., SETTING: Vissum Corporation-Instituto Oftalmologico de Alicante, Alicante, Spain., METHODS: This study evaluated ICRS that were explanted in centers in Spain from 2000 to 2008. Clinical data (reasons for explantation, date of implantation/explantation, tunnel creation technique, ICRS type) and scanning electron microscopy findings on the ICRS surface (adherent tissue-like material, cell deposits, protein) were documented., RESULTS: Intrastromal corneal ring segments were explanted from 58 eyes (47 patients). The main cause was extrusion (48.2% of explanted segments), followed by refractive failure (ie, poor refractive outcome) (37.9%), keratitis (6.8%; 3.7% culture positive), and corneal melting and perforation (6.8%). Scanning electron microscopy showed cells and cell debris on the ICRS explanted by extrusion, a clean surface on the ICRS explanted for refractive failure, and bacteria (cocci) in the case of proven infectious keratitis., CONCLUSIONS: The main cause of explantation was extrusion of the ICRS followed by refractive failure. There was a clear correlation between the cause of explantation and the microscopic findings on the ICRS. Extrusion was accompanied by inflammatory cells and cell debris on the ICRS surface. No inflammatory reaction was observed on the ICRS explanted for refractive failure. Copyright (c) 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved. AU - Ferrer, Consuelo AU - Alio, Jorge L. AU - Montanes, Antonio Uceda AU - Perez-Santonja, Jose J. AU - del Rio, Miguel A. Diaz AU - de Toledo, Juan Alvarez AU - Teus, Miguel A. AU - Javaloy, Jaime DO - https://dx.doi.org/10.1016/j.jcrs.2009.12.042 IS - 6 KW - Adolescent Adult *Corneal Diseases/su [Surgery] *Corneal Stroma/su [Surgery] *Device Removal Female Humans Male Microscopy, Electron, Scanning Middle Aged Polymethyl Methacrylate Prostheses and Implants/mi [Microbiology] *Prostheses and Implants/ul [Ultrastructure] *Prosthesis Failure *Prosthesis Implantation Young Adult N1 - Comment in (CIN) PY - 2010 SE - Ferrer, Consuelo. Vissum Corporation-Instituto Oftalmologico de Alicante, Division of Ophthalmology, Universidad Miguel Hernandez, Alicante, Spain. cferrer@vissum.com SN - 1873-4502 0886-3350 SP - 970-7 ST - Causes of intrastromal corneal ring segment explantation: clinicopathologic correlation analysis T2 - Journal of cataract and refractive surgery T3 - Comment in: J Cataract Refract Surg. 2010 Nov;36(11):2014; author reply 2014-5; PMID: 21029923 [https://www.ncbi.nlm.nih.gov/pubmed/21029923] TI - Causes of intrastromal corneal ring segment explantation: clinicopathologic correlation analysis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=20494769 VL - 36 ID - 1353 ER - TY - JOUR AU - Ferreras, A. AU - Iester, M. AU - Figus, M. AU - Fogagnolo, P. AU - Frezzotti, P. DB - Embase Medline DO - 10.2174/092986732622190920092210 IS - 22 KW - antiglaucoma agent artificial tear benzalkonium chloride eye drops dry eye editorial glaucoma human ocular surface disease patient compliance quality of life tear film tear osmolarity LA - English M3 - Editorial N1 - L2003360709 2020-01-23 2020-01-31 PY - 2019 SN - 1875-533X 0929-8673 SP - 4223-4224 ST - Managing side effects on ocular surface caused by Glaucoma eye drops T2 - Current Medicinal Chemistry TI - Managing side effects on ocular surface caused by Glaucoma eye drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003360709&from=export http://dx.doi.org/10.2174/092986732622190920092210 VL - 26 ID - 2545 ER - TY - JOUR AB - Objective: To evaluate intraocular pressure (IOP)-lowering efficacy, tolerability, and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% (Ganforty) among German patients. Methods: Multicenter, observational, open-label study of patients with primary open angle glaucoma or ocular hypertension (n = 606). As determined by participating physicians, patients had insufficient IOP control and required a medication change. They were switched to once-daily fixed-combination bimatoprost/timolol with no wash-out period. IOP was recorded at treated baseline, 4-6 weeks and 12 weeks after switching. Tolerability was measured using a 4-step scale (excellent, good, moderate, poor) and all adverse events were recorded. Results: A total of 405 patients switched from monotherapy, 97 switched from other fixed combinations, and 104 switched from non-fixed combinations. Among all patients, 32.5% had used prostaglandin analog (PGA) monotherapy, 8.7% had been using a fixed combination that included a PGA, and 6.9% had been using an adjunctive combination of a PGA and a β-blocker. Mean treated baseline IOP (±SD) for all patients was 20.7 ± 3.5 mmHg. Overall, changing medication to fixed-combination bimatoprost/timolol lowered IOP to 16.6 ± 2.7 mmHg (p<0.001 vs. baseline) after 4-6 weeks and to 16.1 ± 2.6 mmHg (p<0.001) after 12 weeks; reductions of 19.8% and 22.2%, respectively. Combined bimatoprost/timolol provided an additional IOP reduction versus baseline in most subgroups based on prior treatment. At week 12, patients who had previously used a β-blocker achieved an additional 25.8% decrease from baseline and IOP was reduced by 22.6% in former PGA monotherapy patients. At week 12, 84.6% of all eyes reached a target pressure less than or equal to 18 mmHg. Tolerability of bimatoprost/timolol was rated excellent or good by the physicians for 98.7% of patients and by 96.7% of the patients themselves. Few adverse events occurred during the treatment period. Conclusions: Although this study was limited by its observational design, our results show that the fixed combination of bimatoprost 0.03%/timolol 0.5% was effective, well tolerated, and safe in a broad patient population. © 2009 Informa UK Ltd. All rights reserved. AD - C. Feuerhake, Burgdorfer Str. 19/21, 31275 Lehrte, Germany AU - Feuerhake, C. AU - Buchholz, P. AU - Kimmich, F. C1 - ganfort DB - Embase Medline DO - 10.1185/03007990902816947 IS - 4 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bimatoprost bimatoprost plus timolol brimonidine plus timolol carbonate dehydratase inhibitor dorzolamide plus timolol latanoprost plus timolol miotic agent prostaglandin derivative timolol timolol plus travoprost adolescent adult aged clinical trial conference paper conjunctival hyperemia drug efficacy drug mechanism drug safety drug substitution drug tolerability drug withdrawal dry eye eye irritation eyelid disease female Germany human intraocular pressure major clinical study male multicenter study observational study open angle glaucoma open study optic disk anomaly patient compliance rating scale risk factor visual field defect ganfort LA - English M3 - Conference Paper N1 - L354800276 2009-08-12 PY - 2009 SN - 0300-7995 1473-4877 SP - 1037-1043 ST - Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: Multicenter, open-label observational study T2 - Current Medical Research and Opinion TI - Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: Multicenter, open-label observational study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354800276&from=export http://dx.doi.org/10.1185/03007990902816947 http://www.informapharmascience.com/doi/pdf/10.1185/03007990902816947 VL - 25 ID - 3363 ER - TY - JOUR AB - Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that starts in the rectum and extends proximally. Typical presenting symptoms include bloody diarrhea, abdominal pain, urgency, and tenesmus. In some cases, extraintestinal manifestations may be present as well. In the right clinical setting, the diagnosis of ulcerative colitis is based primarily on endoscopy, which typically reveals evidence of continuous colonic inflammation, with confirmatory biopsy specimens having signs of chronic colitis. The goals of therapy are to induce and maintain remission, decrease the risk of complications, and improve quality of life. Treatment is determined on the basis of the severity of symptoms and is classically a step-up approach. 5-Aminosalycilates are the mainstay of treatment for mild to moderate disease. Patients with failed 5-aminosalycilate therapy or who present with more moderate to severe disease are typically treated with corticosteroids followed by transition to a steroid-sparing agent with a thiopurine, anti-tumor necrosis factor agent, or adhesion molecule inhibitor. Despite medical therapies, approximately 15% of patients still require proctocolectomy. In addition, given the potential risks of complications from the disease itself and the medications used to treat the disease, primary care physicians play a key role in optimizing the preventive care to reduce the risk of complications. AD - J.D. Feuerstein, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave E/DANA 501, Boston, MA, United States AU - Feuerstein, J. D. AU - Cheifetz, A. S. DB - Embase Medline DO - 10.1016/j.mayocp.2014.07.002 IS - 11 KW - 6 mercaptopurine derivative adalimumab aminosalicylic acid azathioprine balsalazide budesonide calcineurin inhibitor corticosteroid cyclosporine golimumab infliximab mercaptopurine mesalazine natalizumab nonsteroid antiinflammatory agent prednisone probiotic agent steroid tacrolimus tumor necrosis factor inhibitor vedolizumab adrenal insufficiency antibiotic therapy avascular necrosis bile duct carcinoma bone marrow suppression cataract clinical feature colon resection colorectal cancer congestive heart failure cost effectiveness analysis delirium demyelinating disease diabetes mellitus diarrhea disease severity general practitioner genetic risk genetic variability glaucoma headache hemolytic anemia hepatitis hepatitis B histopathology human hyperkalemia hypertension hypertrichosis ileostomy infection infusion related reaction injection site reaction insomnia interstitial nephritis intestine biopsy laboratory test leukopenia lupus erythematosus lymphoma melanoma mood disorder nausea nephrotoxicity non melanoma skin cancer nonhodgkin lymphoma osteopenia osteoporosis pancreatitis paradoxical drug reaction pathogenesis patient compliance pharynx disease physician attitude primary sclerosing cholangitis proctocolectomy progressive multifocal leukoencephalopathy psoriasis review risk assessment risk factor seizure skin cancer smoking habit treatment outcome tuberculosis ulcerative colitis vomiting wound healing impairment LA - English M3 - Review N1 - L600321086 2014-11-11 2014-12-16 PY - 2014 SN - 1942-5546 0025-6196 SP - 1553-1563 ST - Ulcerative colitis: Epidemiology, diagnosis, and management T2 - Mayo Clinic Proceedings TI - Ulcerative colitis: Epidemiology, diagnosis, and management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600321086&from=export http://dx.doi.org/10.1016/j.mayocp.2014.07.002 VL - 89 ID - 2933 ER - TY - JOUR AB - Chronic simple glaucoma, which affects two per cent of the population, is the most common preventable cause of blindness in the world. This article explores the causes and two of the medical treatments available, examining some of the reasons for non-compliance with treatment. Heightened awareness among clinical nurses who may have glaucoma sufferers in their care will help to ensure appropriate therapeutic interventions for this group of patients. AN - 107493370. Language: English. Entry Date: 19921101. Revision Date: 20150712. Publication Type: Journal Article AU - Field, D. DB - ccm DP - EBSCOhost IS - 18 KW - Glaucoma Glaucoma -- Drug Therapy Patient Education Pilocarpine -- Pharmacodynamics Timolol -- Pharmacodynamics Glaucoma -- Nursing Ophthalmic Nursing N1 - pictorial. Journal Subset: Double Blind Peer Reviewed; Europe; Expert Peer Reviewed; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 9012906. PMID: NLM1540521. PY - 1992 SN - 0029-6570 SP - 28-30 ST - Managing chronic simple glaucoma T2 - Nursing Standard TI - Managing chronic simple glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107493370&site=ehost-live&scope=site VL - 6 ID - 4730 ER - TY - JOUR AB - AIM: To evaluate goniotomy, trabeculotomy, transscleral cyclophotocoagulation (TSCPC) and trabeculectomy as initial procedures in children with primary childhood glaucoma from Northern Tanzania., METHODS: A retrospective analysis of consecutive interventions for primary childhood glaucoma from 2000 to 2013 was conducted at the Kilimanjaro Christian Medical Centre. Success was defined as postoperative intraocular pressure (IOP) below 22 mmHg. Success rates, IOP, visual acuity (VA), subsequent interventions and potential risk factors for failure were reported for the respective interventions., RESULTS: The study included 116 eyes of 70 children (age 4.6+/-5.9 years) with primary childhood glaucoma; 46 (65.7%) children were male. The preoperative IOP was 33.1+/-10.2 mmHg, the preoperative cup/disc (CD) ratio 0.71+/-0.3 and the corneal diameter 13.3+/-1.4 mm. As a primary intervention, 61 (52.6%) eyes underwent goniotomy, 10 (8.6%) eyes trabeculotomy, 12 (10.3%) TSCPC and 33 (28.4%) trabeculectomy. Follow-up data after 12 months were available for 63 (54.3%) eyes. Success rates at 12 months were 38% (goniotomy), 30% (trabeculotomy), 17% (TSCPC) and 64% (trabeculectomy). All interventions achieved a statistically significant IOP reduction at 3, 6 and 12 months, except for trabeculotomy after 6 months and TSCPC at all time points. Postoperative endophthalmitis occurred in one child treated with trabeculectomy. VA in 82% of all eyes was maintained or had improved after 12 months., CONCLUSIONS: Based on the success rates of this retrospective analysis, goniotomy or trabeculotomy for younger and trabeculectomy for older children can be recommended in our setting to reduce IOP. Late presentation in combination with advanced glaucomatous damage as well as erratic postoperative follow-up and treatment were likely factors that compromised overall success rates. More efforts are necessary to detect the blinding disease earlier and improve adherence to follow-up. Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. AU - Fies, Achim AU - Furahini, Godfrey AU - Bowman, Richard AU - Bauer, Jacqueline AU - Dithmar, Stefan AU - Philippin, Heiko DO - https://dx.doi.org/10.1136/bjophthalmol-2015-308137 IS - 2 KW - Child Child, Preschool Female Follow-Up Studies Glaucoma/pp [Physiopathology] *Glaucoma/su [Surgery] Humans Infant Intraocular Pressure/ph [Physiology] *Light Coagulation/mt [Methods] Male Optic Nerve Diseases/su [Surgery] Postoperative Complications Retrospective Studies Tanzania Tonometry, Ocular *Trabeculectomy/mt [Methods] Treatment Outcome Visual Acuity/ph [Physiology] PY - 2017 SE - Fies, Achim. Department of Ophthalmology, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany. Furahini, Godfrey. Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania. Furahini, Godfrey. Faculty of Infectious & Tropical Diseases, International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. Bowman, Richard. Faculty of Infectious & Tropical Diseases, International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. Bauer, Jacqueline. Paediatric Department, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany. Dithmar, Stefan. Department of Ophthalmology, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany. Philippin, Heiko. Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania. Philippin, Heiko. Faculty of Infectious & Tropical Diseases, International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. SN - 1468-2079 0007-1161 SP - 126-130 ST - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania T2 - The British journal of ophthalmology TI - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=27098747 VL - 101 Y2 - 20160420// ID - 563 ER - TY - JOUR AB - Purpose: The purpose is to describe the outcome of trabeculectomy with transscleral cyclophotocoagulation (TSCPC) as an initial intervention for secondary childhood glaucoma in Northern Tanzania. Methods: A retrospective, consecutive case series was analyzed of all children with secondary childhood glaucoma who underwent initial trabeculectomy or TSCPC between 2000 and 2013 at a referral eye unit in Northern Tanzania. Retrospective data were collected on causes of glaucoma, intraocular pressure (IOP), visual acuity, complications, and subsequent interventions. Outcomes were evaluated using Kaplan-Meier survival analysis and compared with Cox regression analysis. The main outcome measure was failure (IOP>21 mm Hg). Results: Thirty-six eyes of 27 children (male, 21; median age, 9 y; range, 0.3 to 15 y) with secondary childhood glaucoma underwent trabeculectomy (19 eyes, 53%) or TSCPC (17 eyes, 47%). Causes included ocular trauma (13, 36%), previous cataract surgery (12, 33%), congenital aniridia (5, 14%), Sturge-Weber syndrome (2, 6%), steroid-induced glaucoma (2, 6%), uveitis (1, 3%), and unspecified leucoma (1, 3%). After 12 months, success was achieved in 48% after trabeculectomy and 18% after TSCPC, with visual acuity remaining unchanged in 11 of 14 (79%) and 4 of 5 eyes (80%), respectively. One third of the children did not return for follow-up after 1 year. Distance to the hospital (>100 km) was a significant risk factor for trabeculectomy failure (P=0.031). Conclusions: A high proportion of secondary childhood glaucoma in Northern Tanzania was caused by trauma and previous cataract surgery. Trabeculectomy was associated with better IOP control but also a higher complication rate. The ability to maintain visual function was comparable after both interventions. Failure was associated with a journey to the eye hospital (>100 km) possibly leading to late presentation with advanced disease and erratic follow-up. AD - A. Fieß, Department of Ophthalmology, HELIOS Dr. Horst Schmidt Klinik Wiesbaden, Ludwig-Erhard-Strasse 100, Wiesbaden, Germany AU - Fieß, A. AU - Shah, P. AU - Sii, F. AU - Godfrey, F. AU - Abbott, J. AU - Bowman, R. AU - Bauer, J. AU - Dithmar, S. AU - Philippin, H. DB - Embase Medline DO - 10.1097/IJG.0000000000000682 IS - 7 KW - cyclopentolate dexamethasone ofloxacin steroid aniridia case study cataract extraction child clinical article conference paper controlled study disease severity endophthalmitis eye injury female health care access human intraocular pressure laser coagulation male preschool child priority journal retrospective study risk factor secondary glaucoma Sturge Weber syndrome survival rate Tanzania trabeculectomy treatment failure treatment outcome uveitis visual acuity vitrectomy LA - English M3 - Conference Paper N1 - L617381675 2017-07-24 2017-07-26 PY - 2017 SN - 1536-481X 1057-0829 SP - 657-660 ST - Trabeculectomy or Transscleral Cyclophotocoagulation as Initial Treatment of Secondary Childhood Glaucoma in Northern Tanzania T2 - Journal of Glaucoma TI - Trabeculectomy or Transscleral Cyclophotocoagulation as Initial Treatment of Secondary Childhood Glaucoma in Northern Tanzania UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617381675&from=export http://dx.doi.org/10.1097/IJG.0000000000000682 VL - 26 ID - 2684 ER - TY - JOUR AB - BACKGROUND: After a successful trabeculectomy, a sudden intraocular pressure decrease may alter the intracranial to intraocular pressure ratio and cause decompression retinopathy. Frequent Valsalva maneuvers may also play a role in its pathogenesis. This condition may manifest as multiple retinal hemorrhages, edema of the optic disc, macular edema, or a sudden decrease in visual acuity postoperatively. Outcomes for patients are usually good, with spontaneous resolution occurring within a matter of weeks. It has been rarely reported in the literature as a bilateral condition., CASE PRESENTATION: We present a case of consecutive bilateral decompression retinopathy in a 54-year-old severely obese Caucasian woman (body mass index 37 kg/m(2)) with open angle glaucoma and a poor history of medical therapeutic compliance, who chose surgical treatment based on her inability to consistently use ocular drops. Our patient underwent a trabeculectomy with mitomycin C in both eyes, with surgeries taking place 3 months apart. After the first surgery, 2 weeks postoperatively, she complained of decreased visual acuity. Examination of her right eye fundus revealed multiple retinal hemorrhages and disc edema. There was a similar pattern in her left eye, this time including maculopathy. Her visual acuity and fundoscopic changes resolved spontaneously over a period of a month in both cases. Currently, our patient has well-controlled bilateral intraocular pressure, ranging between 14 and 16 mmHg, without hypotensive medication., CONCLUSIONS: Decompression retinopathy is a potential complication after glaucoma surgery, but has rarely been described as a bilateral consecutive condition. A comprehensive approach could help to anticipate its occurrence and manage it. AU - Figueiredo, Ana Raquel Marcos AU - Sampaio, Isabel Coutinho AU - Meneres, Maria Joao Fernandes Dos Santos AU - Spaeth, George L. DO - https://dx.doi.org/10.1186/s13256-016-0814-x KW - Cross-Linking Reagents/tu [Therapeutic Use] Decompression Female Glaucoma, Open-Angle/su [Surgery] Humans Middle Aged Mitomycin/tu [Therapeutic Use] Papilledema/et [Etiology] *Retinal Diseases/et [Etiology] Retinal Hemorrhage/et [Etiology] *Trabeculectomy/ae [Adverse Effects] PY - 2016 SE - Figueiredo, Ana Raquel Marcos. Ophthalmology Department - Centro Hospital do Porto, EPE - Hospital de Santo Antonio, Largo Professor Abel Salazar, 4099-001, Porto, Portugal. anamarcosfigueiredo@gmail.com. Sampaio, Isabel Coutinho. Ophthalmology Department - Centro Hospital do Porto, EPE - Hospital de Santo Antonio, Largo Professor Abel Salazar, 4099-001, Porto, Portugal. Meneres, Maria Joao Fernandes Dos Santos. Ophthalmology Department - Centro Hospital do Porto, EPE - Hospital de Santo Antonio, Largo Professor Abel Salazar, 4099-001, Porto, Portugal. Spaeth, George L. Wills Eye Hospital, Jefferson Medical College, 840 Walnut Street, Philadelphia, PA, 19107, USA. SN - 1752-1947 SP - 32 ST - Consecutive bilateral decompression retinopathy after mitomycin C trabeculectomy: a case report T2 - Journal of medical case reports TI - Consecutive bilateral decompression retinopathy after mitomycin C trabeculectomy: a case report UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26846338 VL - 10 Y2 - 20160204// ID - 719 ER - TY - JOUR AB - Anti-VEGF drugs may be employed in the surgical treatment of diabetic retinopathy: 1. Prior to surgery. The intravitreal injection of anti-VEGF drugs leads to a significant reduction of neovascularization, with a reduction in the adherence of the fibrovascular complex to the retina. This simplifies viscodelamination and reduces intraoperative bleeding during delamination and segmentation. To minimize the risk of tractional retinal detachment due to the contraction of fibrovascular tissue, vitrectomy must be performed within one week after the injection. 2. To decrease the risk of postoperative bleeding. Recurrent vitreous hemorrhages after vitrectomy are often due to small bleeding from persistent neovascularization. The injection of anti-VEGF drugs at the end of vitrectomy could prevent bleeding from these vessels by blocking the pro-inflammatory stimulus of the surgical procedure. 3. To treat postoperative vitreous hemorrhage. The intravitreal injection of anti-VEGF drugs in patients with postoperative bleeding leads to resolution of the hemorrhage. 4. To treat rubeosis iridis. In eyes with complete panretinal photocoagulation, the combination of cryotherapy and intravitreal anti-VEGF injection in the same surgical procedure produces a disappearance of iris neovascularization together with a long term effect with no recurrences. In neovascular glaucoma, anti-VEGF drugs can also facilitate filtrating surgery. AU - Figueroa, Marta S. AU - Contreras, Ines AU - Noval, Susana IS - 1 KW - *Angiogenesis Inhibitors/tu [Therapeutic Use] Combined Modality Therapy *Diabetic Retinopathy/dt [Drug Therapy] *Diabetic Retinopathy/su [Surgery] Humans Light Coagulation/ae [Adverse Effects] Light Coagulation/mt [Methods] Postoperative Complications/dt [Drug Therapy] Vascular Endothelial Growth Factor A/ai [Antagonists & Inhibitors] *Vitrectomy/mt [Methods] PY - 2009 SE - Figueroa, Marta S. Hospital Universitario Ramon y Cajal, Madrid, Spain. figueroa@servicom2000.com SN - 1875-6417 1573-3998 SP - 52-6 ST - Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy T2 - Current diabetes reviews TI - Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19199899 VL - 5 ID - 1476 ER - TY - JOUR AB - The rising prevalence of neuropathic pain and the multifaceted sequelae of pain particularly within older adults are part of the increasing challenges in providing good geriatric pain management. Aging can lead to a higher sensitivity to pain within older adults, whereas physiological changes modify the absorption, bioavailability, and transit time of pharmaceutical agents. Ultimately, these differences within older adults require clinicians treating them to provide individually tailored analgesic approaches. Progressive age increases the variance in physiology among people; thus, the management approach should reflect an individual's unique requirements and limitations based on findings at the time of assessment. © 2009 U.S. Cancer Pain Relief Committee. AD - P.G. Fine, Pain Research Center, Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, UT, United States AU - Fine, P. G. DB - Embase Medline DO - 10.1016/j.jpainsymman.2009.05.002 IS - 2 SUPPL. KW - amitriptyline analgesic agent anticonvulsive agent buprenorphine cannabinoid derivative capsaicin carbamazepine clonidine duloxetine fentanyl gabapentin hydrocodone hydromorphone ketamine lamotrigine lidocaine memantine mexiletine mirtazapine nortriptyline opiate pregabalin serotonin noradrenalin reuptake inhibitor tapentadol tizanidine tramadol tricyclic antidepressant agent unindexed drug valproic acid venlafaxine age distribution allodynia anxiety application site reaction article Australia caudate nucleus central nervous system chronic kidney failure chronic pain Cochrane Library cognitive defect consensus constipation coping behavior daily life activity degenerative disease delayed diagnosis delirium dementia depression diagnostic error dizziness drowsiness drug absorption drug accumulation drug bioavailability drug formulation drug indication drug withdrawal fracture functional assessment gastrointestinal tract geriatric care glaucoma glomerulus filtration rate heart infarction human hyperalgesia hypertension hypesthesia inflammation intestine absorption intestine blood flow intestine motility intestinal secretion intestine transit time renal clearance kidney function length of stay liver blood flow liver function medical education nausea neuropathic pain nociception nursing home pain assessment pain threshold patient compliance perceptive threshold peripheral neuropathy personality physical examination polypharmacy postherpetic neuralgia practice guideline prescription putamen quality of life rash respiration depression scar formation senescence sensory dysfunction sleep disorder small intestine disease social behavior spine spinothalamic tract treatment contraindication trigeminus neuralgia United States vomiting LA - English M3 - Article N1 - L355049529 2009-09-29 PY - 2009 SN - 0885-3924 SP - S4-S14 ST - Chronic Pain Management in Older Adults: Special Considerations T2 - Journal of Pain and Symptom Management TI - Chronic Pain Management in Older Adults: Special Considerations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355049529&from=export http://dx.doi.org/10.1016/j.jpainsymman.2009.05.002 VL - 38 ID - 3345 ER - TY - JOUR AB - Background: Over the last decade inpatient treatment has been reduced in favor of outpatient care or markedly shortened inpatient stays in most organ-specific surgical specialties such as ophthalmology in Germany. Methods: Data from the federal statistics agency on the international classification of disease (ICD), diagnosis-related groups (DRG) and performed operations and procedures from 2000 to 2010 as well as data from the Institute for Reimbursements of Hospitals (InEK) on average costs per DRG in every German DRG (G-DRG) version from 2004 to 2010 were analyzed for ophthalmology. Results: From 2000 to 2010, the number of cases with a main ophthalmological diagnosis decreased (-19 %), which was mostly due to a reduction in the number of cataract inpatients (-56 %). All subspecialties such as glaucoma (+82 %) and retina (+68 %) with the exception of primary strabismus diagnoses (-15 %) gained in number of cases. Inpatient cataract surgery was the most common surgery in 2004 but numbers decreased to 2010 (-9 %). The most often performed inpatient procedure was vitreoretinal surgery in 2007 and 2010 (increase 2004-2010 + 46 %). Average hospital stay decreased between 2005 and 2010 from 3. 9 to 3. 4 days and the average cost per case increased by 3. 6 % overall and by 13. 4 % for surgical cases. Conclusion: Ophthalmic healthcare provided as inpatient services decreased with a trend towards more complex cases being treated as inpatients from 2000 to 2010. © 2013 Springer-Verlag Berlin Heidelberg. AD - R. P. Finger, Universitätsaugenklinik Bonn, Ernst-Abbe-Str. 2, 53127 Bonn, Germany AU - Finger, R. P. AU - Köberlein-Neu, J. AU - Gass, P. AU - Holz, F. G. AU - Bertram, B. DB - Medline DO - 10.1007/s00347-012-2751-4 IS - 3 KW - adolescent adult aged ambulatory care article child diagnosis related group eye disease female Germany hospital patient hospitalization human infant male middle aged newborn ophthalmology outpatient preschool child prevalence statistics utilization review very elderly young adult LA - English German M3 - Article N1 - L52431720 2014-01-13 PY - 2013 SN - 0941-293X SP - 224-229 ST - Trends in inpatient treatment in ophthalmology in Germany T2 - Ophthalmologe TI - Trends in inpatient treatment in ophthalmology in Germany UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52431720&from=export http://dx.doi.org/10.1007/s00347-012-2751-4 VL - 110 ID - 2951 ER - TY - JOUR AB - Patient education, done at the initiation of therapy, is crucial to the successful long-term management of open-angle glaucoma. How an individual understands his or her condition and appreciates what is required to manage it over the long-term can be the difference between the success or failure of the therapy. Patient education, though, is not a one-shot phenomenon but rather part of the ongoing dialogue that occurs at every visit. © 1992. AD - St. Alban's/Brooklyn VAMC, St. Albans, NY, United States AU - Fingeret, M. AU - Berger Israeloff, C. DB - Scopus IS - 2 KW - compliance Glaucoma patient education M3 - Article N1 - Export Date: 19 July 2021 PY - 1992 SP - 84-86 ST - Initiating therapy in open-angle glaucoma T2 - Clinical Eye and Vision Care TI - Initiating therapy in open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-44049123317&partnerID=40&md5=25a65aeadd04e026e6106bac48ff023a VL - 4 ID - 5800 ER - TY - JOUR AB - SIGNIFICANCE: Noncompliance is a problem affecting glaucoma patients. Approaches to improve adherence include the use of drug-delivery systems and safer forms of surgery. Minimally invasive glaucoma surgery (MIGS) has reduced complications, particularly in combination with cataract surgery, and with its good intraocular pressure (IOP) reduction may reduce or eliminate glaucoma medications.Glaucoma is a progressive disease and a leading cause of irreversible blindness. Elevated IOP is the most important risk factor, but effective medical management is dependent on patient adherence. This review summarizes the adherence problem in glaucoma and the efforts, including MIGS, to provide effective IOP control that is not dependent on patient compliance. The current understanding of patient adherence to pharmacological treatment of glaucoma is discussed including the challenges facing glaucoma patients. Historical approaches to providing IOP control in a sustained and reliable way are presented culminating in a review of the burgeoning use of MIGS devices.It is estimated that, in the United States, 27% of prescriptions written, across all medications, are not filled or are filled but not taken. For ocular hypotensive medications, even when filled, a large percentage (which varies widely by study) are not instilled as prescribed. To address this problem, methods for sustained drug delivery have been and continue to be developed, as well as surgical and laser approaches. Most recently, MIGS devices have gained popularity because of the ease of implantation during cataract surgery, favorable safety profile, and the possibility for effective and long-lasting IOP lowering, as well as the reduction or elimination of need for IOP-lowering medication.Poor adherence to treatment is relatively common among glaucoma patients and is associated with progression of disease. Recommending MIGS implantation during cataract surgery may offer optometrists a valuable treatment option in managing glaucoma patients, particularly where good adherence is in doubt. AU - Fingeret, Murray AU - Dickerson, Jaime E., Jr. DO - https://dx.doi.org/10.1097/OPX.0000000000001173 IS - 2 KW - Cataract Extraction Glaucoma/pp [Physiopathology] *Glaucoma/su [Surgery] Glaucoma Drainage Implants Humans *Intraocular Pressure/ph [Physiology] *Minimally Invasive Surgical Procedures Patient Compliance N1 - Erratum in (EIN) PY - 2018 SE - Fingeret, Murray. New York Harbor Health Care System, Department of Veterans Affairs, Brooklyn, New York. Dickerson, Jaime E Jr. Alcon Research, Ltd., Fort Worth, Texas. Dickerson, Jaime E Jr. University of North Texas Health Science Center, Fort Worth, Texas *murray.fingeret@va.gov. SN - 1538-9235 1040-5488 SP - 155-162 ST - The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma T2 - Optometry and vision science : official publication of the American Academy of Optometry T3 - Erratum in: Optom Vis Sci. 2018 Jun;95(6):554; PMID: 29851862 [https://www.ncbi.nlm.nih.gov/pubmed/29851862] TI - The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29370021 VL - 95 ID - 455 ER - TY - JOUR AB - Open-angle glaucoma is a chronic disease usually requiring a patient to take medications for the rest of his or her life. Because of the expense and side effects of the medications and due to a lack of understanding of the condition, many patients do not take their medications properly, often leading to progressive damage. A written instruction sheet completed for each patient covering their medication dosage schedule is an aid that may subtly remind individuals to use their medications, reducing the problems associated with noncompliance. AU - Fingeret, M. AU - Schuettenberg, S. P. IS - 6 KW - Drug Administration Schedule *Glaucoma, Open-Angle/dt [Drug Therapy] Humans *Patient Compliance Sympatholytics/tu [Therapeutic Use] PY - 1991 SE - Fingeret, M. St. Albans Veterans Administration, NY 11425. SN - 0003-0244 SP - 478-80 ST - Patient drug schedules and compliance T2 - Journal of the American Optometric Association TI - Patient drug schedules and compliance UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1813544 VL - 62 ID - 2133 ER - TY - JOUR AB - We describe a novel method for testing a visual field that employs a computer monitor with displays of varying contrast that permits unprecedented resolution and characterization of the structure of scotomas in three dimensions. Patients are placed in front of a touch-sensitive computer screen at a fixed distance. With one eye covered, they focus on a central fixation marker and trace with their finger the areas on an Amsler grid that are missing from their field of vision. Increasing degrees of contrast of the Amsler grid are simulated by repeating the test at different gray-scale levels. The results are recorded and then displayed as topographical contour rings by the computer test program. The results can also be rendered as an immediate 3-D depiction of the central hill-of-vision. Several clinical pilot studies have been conducted at the Doheny Eye Institute and more than 200 patients have been examined with this system so far. Conditions such as optic neuritis, anterior ischemic optic neuropathy (AION), age-related macular degeneration (AMD), glaucoma, and ocular hypertension have been successfully assessed by this test. Each condition provides unique patterns that are most evident in 3-D. The 3-D computer-automated threshold Amsler grid test is an innovative and noninvasive visual field test. It provides several advantages over state-of-the-art standard automated perimetry, including: (1) additional information through 3-D depiction of scotomas, such as location, extent, slope, depth, and shape; (2) high angular resolution (1 deg compared with typically 6 deg); (3) a simple test setup (merely a touch-sensitive computer monitor and the test software); (4) excellent patient compliance (spending 4 to 5 min per eye). In light of its promising initial tests, the 3-D visual field test appears to have the potential for the early detection and monitoring of various diseases over time. Copyright (c) 2004 Society of Photo-Optical Instrumentation Engineers. AU - Fink, Wolfgang AU - Sadun, Alfredo A. IS - 1 KW - Diagnosis, Computer-Assisted/is [Instrumentation] *Diagnosis, Computer-Assisted/mt [Methods] Equipment Design Equipment Failure Analysis *Glaucoma/di [Diagnosis] Humans *Macular Degeneration/di [Diagnosis] Optic Neuritis/di [Diagnosis] Optic Neuropathy, Ischemic/di [Diagnosis] Reproducibility of Results *Scotoma/di [Diagnosis] Sensitivity and Specificity Sensory Thresholds Vision Tests/is [Instrumentation] Vision Tests/mt [Methods] *Vision, Binocular *Visual Acuity Visual Field Tests/is [Instrumentation] *Visual Field Tests/mt [Methods] *Visual Fields PY - 2004 SE - Fink, Wolfgang. California Institute of Technology, Pasadena, California, USA. SN - 1083-3668 SP - 149-53 ST - Three-dimensional computer-automated threshold Amsler grid test T2 - Journal of biomedical optics TI - Three-dimensional computer-automated threshold Amsler grid test UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=14715067 VL - 9 ID - 1794 ER - TY - JOUR AB - BACKGROUND: Bilateral keratitis is rare and can have various causes. For a good outcome after treatment, the correct diagnosis is decisive., CASE REPORT: A 15-year-old boy presented to our clinic with recurrent keratoconjunctivitis and progressive loss of vision in both eyes since 6 years. The best corrected visual acuity was 0.1 in the right eye and 1/12 in the left eye. Slit-lamp examination verified keratitis disciformis with strongly vascularized corneal stromal scars without conjunctival follicles on both sides. Based on the clinical diagnosis, antiviral treatment was initiated. Best corrected visual acuity 8 weeks later increased to 0.4 in the right eye and 0.8 in the left eye and the corneal edema decreased in both eyes. Due to noncompliance the patient returned with a perforated corneal ulcer of the left eye, where an a chaud penetrating keratoplasty had to be performed., RESULTS: Herpes simplex virus is one of the most common causes of keratitis and has different manifestations. In the treatment of keratitis disciformis the use of topical steroids is mandatory as there is an active immunological process. The use of systemic and local antiviral treatment is necessary at the same time in order to avoid reactivation of viral replication. Bilateral keratitis is relatively frequent in children., CONCLUSION: Herpetic keratitis is now well treatable if the various manifestations of the disease are recognized early and an appropriate therapy is adjusted accordingly. AU - Fiorentzis, M. AU - Szentmary, N. AU - Seitz, B. DO - https://dx.doi.org/10.1007/s00347-014-3070-8 IS - 2 KW - Adolescent *Corneal Injuries/di [Diagnosis] Corneal Injuries/th [Therapy] Diagnosis, Differential Humans *Keratitis, Herpetic/di [Diagnosis] Keratitis, Herpetic/th [Therapy] Male *Neovascularization, Pathologic/di [Diagnosis] Neovascularization, Pathologic/th [Therapy] Treatment Outcome PY - 2015 SE - Fiorentzis, M. Klinik fur Augenheilkunde, Universitatsklinikum des Saarlandes, UKS, Kirrberger Str. 1, 66421, Homburg/Saar, Deutschland, fiorentzis@gmail.com. SN - 1433-0423 0941-293X SP - 162-5 ST - [Bilateral vascularized disciform corneal scar of herpetic origin in a child] T2 - Bilaterale vaskularisierte disziforme Hornhautnarbe herpetischer Genese bei einem Kind. TI - [Bilateral vascularized disciform corneal scar of herpetic origin in a child] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25030897 VL - 112 ID - 837 ER - TY - JOUR AB - Objectives: The objectives of the present study were to analyze the possibility of using pattern VEPs (VEP of pattern type) in glaucoma patients and their role in the follow-up and coordination/ management of anti-glaucoma treatment. Patients and Methods: This is a prospective study on 54 eyes of 30 consecutive glaucoma patients, whose compliance capacity did not allow automatic perimetry and OCT scan to be carried out. The patients were divided into two groups: group A - the study group and group B - the control group. All patients underwent FO exam and pachymetry, plus VEP exam for group A patients. Patients were analyzed at the initial visit and at 1 month, 3, 6, 12 months. Statistical analysis was made using t-test, ANOVA, Fisher test and Pearson correlation coefficient. Results: These participants presented a positive correlation between C/ D ratio and the latency of the P100 wave at 1 degree and a negative correlation between C/ D ratio and the amplitude of the P100 wave both at 1 degree (60 arc minutes) and at 0.25 degrees (15 arc minutes). During the study, the values of the latent P100 changed statistically at 6 months and at 1 year. Using all the data, the authors of the study considered it necessary to modify the treatment for 2 patients out of 13 in group B and for 9 patients out of 16 in group A (p = 0,02892). Conclusions: VEP supplies additional/ further data that significantly help guiding the treatment and monitoring the progression, therefore, it should be part of the routine examination for these patients. Further studies are necessary to deepen our understanding of the visual evoked potentials utility. Copyright ©Romanian Society of Ophthalmology. AU - Firan, Anne Marie AU - Iancu, Raluca Claudia AU - Bujor, Inna Adriana AU - Ciuluvica, Radu Constantin AU - Tudosescu, Ruxandra AU - Ungureanu, Emil AU - Pasca, Irena Gabriela AU - Voinea, Liliana AU - Istrate, Sinziana IS - 2 KW - Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] Disease Progression *Evoked Potentials, Visual/ph [Physiology] Female Follow-Up Studies Glaucoma/dt [Drug Therapy] *Glaucoma/pp [Physiopathology] *Guideline Adherence Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged *Monitoring, Physiologic/mt [Methods] *Patient Compliance Prospective Studies PY - 2020 SE - Firan, Anne Marie. Barnsley District Hospital, NHS trust, England. Iancu, Raluca Claudia. Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania. Bujor, Inna Adriana. Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania. Ciuluvica, Radu Constantin. "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. Tudosescu, Ruxandra. Department of Ophthalmology, "Regina Maria" Private Health Care, Bucharest, Romania. Ungureanu, Emil. Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania. Pasca, Irena Gabriela. Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania. Voinea, Liliana. Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania. Istrate, Sinziana. Department of Ophthalmology, "Regina Maria" Private Health Care, Bucharest, Romania. SN - 2501-2533 2457-4325 SP - 205-212 ST - The role of Visual Evoked Potential (VEP) in monitoring the progression and in guiding the treatment of glaucoma patients with poor compliance T2 - Romanian journal of ophthalmology TI - The role of Visual Evoked Potential (VEP) in monitoring the progression and in guiding the treatment of glaucoma patients with poor compliance UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32685788 VL - 64 ID - 171 ER - TY - JOUR AD - R. Fiscella, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, United States AU - Fiscella, R. DB - Embase Medline IS - 9 KW - brimonidine dorzolamide timolol allergic conjunctivitis clinical trial drug efficacy drug exposure drug tolerability glaucoma human hyperemia intraocular hypertension note ocular pruritus patient compliance priority journal LA - English M3 - Note N1 - L44536912 2006-10-18 jsessionid=FpfWhWpLJ0y3KbLVM7v1hFTjnprgtsZghPRVmLGQMgZFThQz2W6M!-910938601!-949856144!8091!-1 PY - 2006 SN - 1170-229X SP - 762-763 ST - Brimonidine/timolol: A viewpoint by Richard Fiscella T2 - Drugs and Aging TI - Brimonidine/timolol: A viewpoint by Richard Fiscella UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44536912&from=export http://aging.adisonline.com/pt/re/dra/pdfhandler.00002512-200623090-00008.pdf VL - 23 ID - 3581 ER - TY - JOUR AB - BACKGROUND: Glaucoma is a progressive, irreversible disease that can lead to vision loss and lower quality of life if treatment is not optimized. Effective glaucoma therapies are available to lower intraocular pressure (IOP) and minimize or delay disease progression. Nonetheless, adherence to treatment remains suboptimal for many patients., OBJECTIVE: To identify potentially nonadherent patients and evaluate the effect of patient- and physician-centric educational interventions on adherence by using a validated predictive model of nonadherence to glaucoma medication., METHODS: This prospective, randomized, controlled, and interventional study included Humana Medicare Advantage Prescription Drug plan patients with a glaucoma diagnosis between May and October 2014, >= 1 pharmacy claim for glaucoma medication, and >= 50% likelihood of nonadherence. Patients and physicians were randomized to cohorts A (no interventions), B (physician intervention), or C (patient and physician interventions). Physicians in cohorts B and C received information on the model, adherence, and patient profiles at baseline and months 3, 6, and 9. Patients in cohort C received educational materials on glaucoma and adherence (same schedule). The primary outcome was the proportion of days covered (PDC) with medication over 12 months. Adherence was defined as PDC >= 0.80., RESULTS: Overall, 23,306 patients and 2,955 physicians were eligible. After excluding physicians with < 3 nonadherent patients, each cohort included 200 physicians and 600 patients. Mean PDC was 0.54-0.56 across cohorts. At 12 months, >= 90.5% of physicians and >= 75.5% of patients remained in the study; mean PDC was 0.53-0.54 across cohorts. No statistically significant between-cohort differences in PDC and adherence were observed., CONCLUSIONS: Intensive educational mailings to patients and their physicians did not improve PDC or adherence in this large population of potentially nonadherent patients with glaucoma. Findings highlight the difficulty of improving adherence in a disease that requires lifelong therapy despite being largely asymptomatic and can inform development of future interventions aimed at improving adherence to glaucoma therapy., DISCLOSURES: This study was sponsored by Allergan plc (Dublin, Ireland). Fiscella and Chandwani are employees of Allergan plc. Caplan, Kamble, Bunniran, and Uribe are employees of Comprehensive Health Insights, a Humana company. The authors did not receive honoraria or other payments for authorship. AU - Fiscella, Richard AU - Caplan, Eleanor AU - Kamble, Pravin AU - Bunniran, Suvapun AU - Uribe, Claudia AU - Chandwani, Hitesh DO - https://dx.doi.org/10.18553/jmcp.2018.17465 IS - 12 KW - Aged Aged, 80 and over *Antihypertensive Agents/tu [Therapeutic Use] Disease Progression Female Forecasting *Glaucoma/dt [Drug Therapy] Glaucoma/ec [Economics] Humans Intraocular Pressure/de [Drug Effects] Ireland Male *Medication Adherence/sn [Statistics & Numerical Data] Medication Therapy Management/ec [Economics] *Medication Therapy Management/og [Organization & Administration] Models, Theoretical *Patient Education as Topic/ec [Economics] Prospective Studies Quality of Life PY - 2018 SE - Fiscella, Richard. 1 Allergan plc, Irvine, California. Caplan, Eleanor. 2 Comprehensive Health Insights, Louisville, Kentucky. Kamble, Pravin. 2 Comprehensive Health Insights, Louisville, Kentucky. Bunniran, Suvapun. 2 Comprehensive Health Insights, Louisville, Kentucky. Uribe, Claudia. 2 Comprehensive Health Insights, Louisville, Kentucky. Chandwani, Hitesh. 3 Allergan Singapore Pte. Ltd., Singapore. SN - 2376-1032 SP - 1284-1294 ST - The Effect of an Educational Intervention on Adherence to Intraocular Pressure-Lowering Medications in a Large Cohort of Older Adults with Glaucoma T2 - Journal of managed care & specialty pharmacy TI - The Effect of an Educational Intervention on Adherence to Intraocular Pressure-Lowering Medications in a Large Cohort of Older Adults with Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29848186 VL - 24 Y2 - 20180531// ID - 424 ER - TY - JOUR AU - Fiscella, Richard AU - Stewart, William C. IS - 4 KW - Analysis of Variance *Antihypertensive Agents/ad [Administration & Dosage] *Glaucoma/dt [Drug Therapy] Glaucoma/pp [Physiopathology] Humans *Intraocular Pressure/de [Drug Effects] Patient Compliance/sn [Statistics & Numerical Data] *Patient Compliance Treatment Outcome N1 - Comment on (CON) PY - 2005 SN - 1080-7683 SP - 349-2 ST - Letter to the editor: patient persistency with glaucoma therapy T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics T3 - Comment on: J Ocul Pharmacol Ther. 2004 Oct;20(5):383-92; PMID: 15650513 [https://www.ncbi.nlm.nih.gov/pubmed/15650513] TI - Letter to the editor: patient persistency with glaucoma therapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16117699 VL - 21 ID - 1726 ER - TY - JOUR AD - R.G. Fiscella, Department of Pharmacy Practice, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612, United States AU - Fiscella, R. G. DB - Embase Medline DO - 10.1093/ajhp/55.3.272 IS - 3 KW - adrenergic receptor stimulating agent alpha 2 adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor cholinergic receptor stimulating agent prostaglandin article cost benefit analysis cost control cost of illness drug cost drug marketing glaucoma health care cost intraocular hypertension patient compliance priority journal LA - English M3 - Article N1 - L28109900 1998-03-26 PY - 1998 SN - 1079-2082 SP - 272-275 ST - Costs of glaucoma medications T2 - American Journal of Health-System Pharmacy TI - Costs of glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L28109900&from=export http://dx.doi.org/10.1093/ajhp/55.3.272 VL - 55 ID - 3951 ER - TY - JOUR AD - R.G. Fiscella, 833 South Wood, Chicago, IL 60612, United States AU - Fiscella, R. G. AU - Green, A. AU - Patuszynski, D. H. AU - Wilensky, J. AU - Appel, A. AU - Brown, G. C. C2 - Alcon Bausch and Lomb DB - Embase IS - 4 KW - alpha 2 adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent brinzolamide carbonate dehydratase inhibitor prostaglandin timolol maleate burning sensation calculation cost minimization analysis cost utility analysis drug cost drug dose regimen drug efficacy experience experimentation glaucoma health care cost human medical care pain patient compliance priority journal prospective study pruritus quality of life short survey treatment failure United States validation process visual impairment LA - English M3 - Short Survey N1 - L38867694 2004-07-18 PY - 2003 SN - 1525-8599 SP - 214-215 ST - Medical therapy cost considerations for glaucoma T2 - Evidence-Based Eye Care TI - Medical therapy cost considerations for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38867694&from=export VL - 4 ID - 3799 ER - TY - JOUR AB - Cost-of-illness studies determine the total financial burden of a disease by considering direct and indirect costs, including medication, diagnostics and surgery. Studies of resource use and costs associated with primary open-angle glaucoma have used varying methodologies. Most have focused on consumption of healthcare resources at various stages of disease to anticipate costs. The direct costs associated with the disease often continue to increase as glaucoma progresses from the earliest to most advanced stages. Determinations of the costs associated with glaucoma progression and prevention should also incorporate the chance of patient non-compliance with treatment. Since glaucoma severity most often correlates with increased costs, minimizing or halting visual field loss and increasing patient treatment compliance may all contribute to a reduction in the overall economic burden of glaucoma. AU - Fiscella, Richard G. AU - Lee, Jeff AU - Davis, Elizabeth J. H. AU - Walt, John DO - https://dx.doi.org/10.2165/00019053-200927030-00002 IS - 3 KW - Canada Cost of Illness Europe *Glaucoma/dt [Drug Therapy] *Glaucoma/ec [Economics] Humans United States PY - 2009 SE - Fiscella, Richard G. University of Illinois at Chicago, Chicago, Illinois 60612, USA. fisc@uic.edu SN - 1170-7690 SP - 189-98 ST - Cost of illness of glaucoma: a critical and systematic review T2 - PharmacoEconomics TI - Cost of illness of glaucoma: a critical and systematic review UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19354339 VL - 27 ID - 1464 ER - TY - JOUR AB - Glaucoma is a worldwide disease and the second leading cause of blindness. Current treatments are associated with a number of side-effects and poor compliance, due to the requirement for treatment administration several times a day. These treatments typically aim to lower intraocular pressure (IOP); however, they are unable to protect retinal ganglion cells (RGCs) from undergoing apoptosis, which is the main cause of vision loss. A3 adenosine receptor (A3AR) agonists have been found to protect normal cells from undergoing apoptosis via the downregulation of death signals. Furthermore, A3AR agonists have been reported to have several ophthalmological effects, including the prevention of ganglion cell apoptosis in vitro and in vivo and anti-inflammatory effects in experimental models of autoimmune uveitis. CF101, an orally bioavailable A3AR agonist, has been analyzed in dry eye syndrome phase II clinical trials and was identified to be safe and well tolerated. The anti-inflammatory effect of CF101 was shown to significantly improve corneal staining, tear meniscus and tear break-up time in dry eye patients. In addition, CF101 was found to decrease IOP in patients. The safety and efficacy of CF101, together with its suitability for oral administration, indicates that it has potential as a candidate drug for the treatment of glaucoma. AU - Fishman, Pnina AU - Cohen, Shira AU - Bar-Yehuda, Sara DO - https://dx.doi.org/10.3892/mmr.2013.1413 IS - 6 KW - Adenosine/aa [Analogs & Derivatives] Adenosine/ch [Chemistry] Adenosine/pd [Pharmacology] Adenosine/tu [Therapeutic Use] Adenosine A3 Receptor Agonists/ch [Chemistry] *Adenosine A3 Receptor Agonists/tu [Therapeutic Use] Anti-Inflammatory Agents/ch [Chemistry] Anti-Inflammatory Agents/pd [Pharmacology] Anti-Inflammatory Agents/tu [Therapeutic Use] Apoptosis Dry Eye Syndromes/dt [Drug Therapy] *Glaucoma/dt [Drug Therapy] Glaucoma/pa [Pathology] Humans Intraocular Pressure/de [Drug Effects] *Receptor, Adenosine A3/ch [Chemistry] Receptor, Adenosine A3/me [Metabolism] Retinal Ganglion Cells/cy [Cytology] PY - 2013 SE - Fishman, Pnina. Can-Fite BioPharma, Petach-Tikva 49170, Israel. pnina@canfite.co.il SN - 1791-3004 1791-2997 SP - 1723-5 ST - Targeting the A3 adenosine receptor for glaucoma treatment (review) T2 - Molecular medicine reports TI - Targeting the A3 adenosine receptor for glaucoma treatment (review) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23563604 VL - 7 Y2 - 20130404// ID - 978 ER - TY - JOUR AB - Objective: We sought to understand barriers to hypertension self-management in patients with hypertension and comorbidities. Methods: We conducted semi-structured, qualitative interviews with 48 patients with uncontrolled hypertension and at least one comorbidity to learn about beliefs and behaviors that might affect hypertension self-management. Using a grounded theory strategy, we analyzed interview transcripts detailing patients' hypertension self-management behaviors vis-á-vis a framework including Explanatory Models-a patient's understanding of the pathophysiology, cause, course, treatment, and severity of an illness, such as hypertension. Results: We identified four factors that interfered with hypertension self-management. (1) Interdependence: Participants saw hypertension as interconnected to their comorbidities and subsequently had difficulty separating information about their illnesses. (2) Low priority: Compared to other conditions, participants assigned hypertension a lower priority. (3) Conflicts: Participants struggled with conflicts between hypertension self-management practices and those for comorbidities. (4) Managing multiple medications: Polypharmacy led to patients' confusion and concern about taking medications as prescribed. Discussion: Participants did not experience hypertension as a discreet clinical condition; rather, they self-managed hypertension concurrently with other conditions, leading to a breakdown in hypertension self-management. We provide strategies to address each of the four barriers to better equip providers in addressing their clinically salient concerns. © The Author(s) 2013. AD - G.M. Fix, Department of Veterans Affairs, Center for Healthcare Organization and Implementation Research (CHOIR) (152), ENRM Veterans Hospital, 200 Springs Road, Bedford, MA 01730, United States AU - Fix, G. M. AU - Cohn, E. S. AU - Solomon, J. L. AU - Cortés, D. E. AU - Mueller, N. AU - Kressin, N. R. AU - Borzecki, A. AU - Katz, L. A. AU - Bokhour, B. G. DB - Embase Medline DO - 10.1177/1742395313496591 IS - 2 KW - antihypertensive agent cholesterol adult aged alcoholism angina pectoris antihypertensive therapy anxiety arthritis article asthma backache cholesterol blood level chronic obstructive lung disease clinical article comorbidity controlled study depression diabetes mellitus disease course disease severity electronic medical record erectile dysfunction female glaucoma grounded theory headache health behavior health belief heart arrhythmia heart disease human hyperlipidemia hypertension insomnia kidney cancer knee arthroplasty knee disease larynx cancer leg disease male medical information medication compliance middle aged nerve injury obesity Parkinson disease pathophysiology patient compliance polypharmacy posttraumatic stress disorder prescription prostate cancer qualitative research self care semi structured interview shoulder surgery sleep disordered breathing LA - English M3 - Article N1 - L373073254 2014-05-22 2014-05-29 PY - 2014 SN - 1745-9206 1742-3953 SP - 81-92 ST - The role of comorbidities in patients' hypertension self-management T2 - Chronic Illness TI - The role of comorbidities in patients' hypertension self-management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373073254&from=export http://dx.doi.org/10.1177/1742395313496591 VL - 10 ID - 2907 ER - TY - JOUR AB - A 35-year-old woman presented with a bilateral palpebral follicular conjunctivitis. Subsequently, she developed a bilateral keratitis and, on a separate occasion, an episcleritis that was associated with a recrudescence of Lyme disease and poor compliance with the antibiotic regimen. Both the keratitis and episcleritis cleared completely after topical corticosteroid therapy and reinstitution of appropriate antibiotic treatment. This report emphasizes the importance of collaboration between internal medicine and ophthalmologic specialists during the long-term management of Lyme disease. AU - Flach, A. J. AU - Lavoie, P. E. IS - 8 KW - Adrenal Cortex Hormones/tu [Therapeutic Use] Adult Borrelia burgdorferi Group/de [Drug Effects] Borrelia burgdorferi Group/im [Immunology] *Conjunctivitis/et [Etiology] Female Fluorescent Antibody Technique Humans Keratitis/dt [Drug Therapy] *Keratitis/et [Etiology] *Lyme Disease/co [Complications] Lyme Disease/di [Diagnosis] Lyme Disease/dt [Drug Therapy] Minocycline/tu [Therapeutic Use] Scleritis/dt [Drug Therapy] *Scleritis/et [Etiology] PY - 1990 SE - Flach, A J. Department of Ophthalmology, University of California School of Medicine, San Francisco. SN - 0161-6420 SP - 973-5 ST - Episcleritis, conjunctivitis, and keratitis as ocular manifestations of Lyme disease T2 - Ophthalmology TI - Episcleritis, conjunctivitis, and keratitis as ocular manifestations of Lyme disease UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=2205817 VL - 97 ID - 2147 ER - TY - JOUR AB - Nausea and vomiting are mediated primarily by three neurotransmitter pathways: visceral stimulation releases dopamine and serotonin; vestibular and central nervous system activation release histamine and acetylcholine; and chemoreceptor trigger zone activation releases dopamine and serotonin. Clinicians can improve the effectiveness and cost-effectiveness of treatments by targeting the appropriate pathways. Antihistamines and anticholinergics are most effective in patients with vestibular-mediated nausea secondary to vertigo. Serotonin antagonists block serotonin in the intestines and chemoreceptor trigger zone, and are most effective for treating gastroenteritis. Dopamine antagonists block dopamine in the intestines and chemoreceptor trigger zone; indications for these agents are similar to those for serotonin antagonists. For treatment of mild pregnancy-induced nausea, pyridoxine with or without doxylamine is recommended, and ginger may also be effective. In patients with migraine headache–associated nausea, metoclopramide improves response to oral anti-migraine agents. Ondansetron reduces nausea and vomiting in children with acute gastroenteritis and in women with hyperemesis gravidarum. AD - Z.A. Flake, Banner Medical Group, 2701 Madison Square Dr, Loveland, CO, United States AU - Flake, Z. A. AU - Linn, B. S. AU - Hornecker, J. R. C1 - antivert benadryl depo medrol diclegis reglan transderm scop zofran DB - Embase Medline IS - 5 KW - antiemetic agent antihistaminic agent cholinergic receptor blocking agent corticosteroid dexamethasone diphenhydramine dopamine receptor blocking agent doxylamine plus pyridoxine ginger extract meclozine methylprednisolone acetate metoclopramide ondansetron prochlorperazine promethazine pyridoxine scopolamine serotonin antagonist allergic reaction ambulatory monitoring article blurred vision clinical effectiveness closed angle glaucoma constipation cost effectiveness analysis diarrhea extrapyramidal symptom fatigue gastroenteritis headache human hyperemesis gravidarum hyperglycemia hypertension hypotension mental disease migraine nausea and vomiting pregnancy QT prolongation sedation tardive dyskinesia urine retention xerostomia antivert benadryl depo medrol diclegis reglan transderm scop zofran LA - English M3 - Article N1 - L605145927 2015-07-14 PY - 2015 SN - 1532-0650 0002-838X SP - 293-296 ST - Practical selection of antiemetics in the ambulatory setting T2 - American Family Physician TI - Practical selection of antiemetics in the ambulatory setting UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605145927&from=export VL - 91 ID - 2852 ER - TY - JOUR AB - Vascular dysregulation refers to the regulation of blood flow that is not adapted to the needs of the respective tissue. We distinguish primary vascular dysregulation (PVD, formerly called vasospastic syndrome) and secondary vascular dysregulation (SVD). Subjects with PVD tend to have cold extremities, low blood pressure, reduced feeling of thirst, altered drug sensitivity, increased pain sensitivity, prolonged sleep onset time, altered gene expression in the lymphocytes, signs of oxidative stress, slightly increased endothelin-1 plasma level, low body mass index and often diffuse and fluctuating visual field defects. Coldness, emotional or mechanical stress and starving can provoke symptoms. Virtually all organs, particularly the eye, can be involved. In subjects with PVD, retinal vessels are stiffer and more irregular, and both neurovascular coupling and autoregulation capacity are reduced while retinal venous pressure is often increased. Subjects with PVD have increased risk for normal-tension glaucoma, optic nerve compartment syndrome, central serous choroidopathy, Susac syndrome, retinal artery and vein occlusions and anterior ischaemic neuropathy without atherosclerosis. Further characteristics are their weaker blood-brain and blood-retinal barriers and the higher prevalence of optic disc haemorrhages and activated astrocytes. Subjects with PVD tend to suffer more often from tinnitus, muscle cramps, migraine with aura and silent myocardial ischaemic and are at greater risk for altitude sickness. While the main cause of vascular dysregulation is vascular endotheliopathy, dysfunction of the autonomic nervous system is also involved. In contrast, SVD occurs in the context of other diseases such as multiple sclerosis, retrobulbar neuritis, rheumatoid arthritis, fibromyalgia and giant cell arteritis. Taking into consideration the high prevalence of PVD in the population and potentially linked pathologies, in the current article, the authors provide recommendations on how to effectively promote the field in order to create innovative diagnostic tools to predict the pathology and develop more efficient treatment approaches tailored to the person. AU - Flammer, Josef AU - Konieczka, Katarzyna AU - Flammer, Andreas J. DO - https://dx.doi.org/10.1186/1878-5085-4-14 IS - 1 PY - 2013 SE - Flammer, Josef. Department of Ophthalmology, University of Basel, Mittlere Strasse 91, Basel CH-4031, Switzerland. josef.flammer@usb.ch. SN - 1878-5077 SP - 14 ST - The primary vascular dysregulation syndrome: implications for eye diseases T2 - The EPMA journal TI - The primary vascular dysregulation syndrome: implications for eye diseases UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=23742177 VL - 4 Y2 - 20130607// ID - 1092 ER - TY - JOUR AB - Extended wear of soft contact lenses is associated with an increased risk of Pseudomonas aeruginosa infection of the cornea. To assess the role of bacterial adherence in the pathogenesis of these infections, superficial corneal epithelial cells and leukocytes from ten patients who use extended-wear soft lenses and ten control eyes were compared for their propensity to attach P. aeruginosa in vitro. Cells were washed from the cornea by saline irrigation, incubated with a 10-ml solution containing 10(7) colony-forming units/ml of bacteria at 35 degrees C for 30 min, collected on a filter, and prepared using a modified acridine orange staining method. Fluorescence microscopy showed bacterial adherence to corneal epithelial cells, leukocytes, and ocular mucus. The mean number of bacteria adhering to epithelial cells was 2.6 for control eyes and 6.6 for the lens-wearing eyes (P = 0.002). The percentage of epithelial cells attaching greater than or equal to four bacteria was higher for lens-wearing eyes than control eyes (57.4% versus 26.0%, P = 0.0005). There was no significant difference between contact lens-wearing eyes and control eyes in the number of leukocytes collected or in the number of bacteria attached to these cells. These results show that P. aeruginosa adherence to epithelial cells is enhanced in those who use extended-wear soft contact lenses, and this may contribute to the increased incidence of P. aeruginosa keratitis for this population. AU - Fleiszig, S. M. AU - Efron, N. AU - Pier, G. B. IS - 10 KW - Acridine Orange Adult *Bacterial Adhesion Colony Count, Microbial *Contact Lenses, Extended-Wear/ae [Adverse Effects] Contact Lenses, Hydrophilic/ae [Adverse Effects] Cornea/cy [Cytology] *Cornea/mi [Microbiology] Epithelial Cells Epithelium/mi [Microbiology] Female Humans Leukocytes Male Microscopy, Fluorescence *Pseudomonas aeruginosa/ph [Physiology] PY - 1992 SE - Fleiszig, S M. Department of Optometry, University of Melbourne, Victoria, Australia. SN - 0146-0404 SP - 2908-16 ST - Extended contact lens wear enhances Pseudomonas aeruginosa adherence to human corneal epithelium T2 - Investigative ophthalmology & visual science TI - Extended contact lens wear enhances Pseudomonas aeruginosa adherence to human corneal epithelium UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1526741 VL - 33 ID - 2108 ER - TY - JOUR AB - BACKGROUND: Staphylococcus epidermidis is a major causative agent of infectious keratitis associated with contact lens wear. Adhesion of this bacterium to contact lenses may contribute to the pathogenesis of infection and could be influenced by lens surface properties, packaging/storage solutions, and vary among different strains according to the level or type of adhesins expressed., METHODS: Adhesion of six clinical isolates of S. epidermidis to three different contact lens materials was tested. Adhesion assays were performed on lenses immediately after removal from their packages, and also after lenses were soaked in sterile phosphate buffered saline (PBS) for 7 days to dilute the packaging solution., RESULTS: For lenses tested immediately upon removal from their packaging, adhesion to polymacon (in PBS with 0.1% polyvinyl alcohol) was significantly greater than to etafilcon A (in borate buffered saline) and vifilcon A (in PBS). After soaking, adhesion to polymacon lenses was significantly less than to the other lens materials. This pattern was consistent for all strains, although major differences in baseline adhesion levels existed between strains, with exopolysaccharide (slime)-positive bacteria being more adherent to lenses., CONCLUSIONS: Properties of contact lens materials were not the sole determinant of viable S. epidermidis adhesion to lenses. Strain variability, including levels of exopolysaccharide expression, and the solution used for lens immersion also influenced adhesion. AU - Fleiszig, S. M. AU - Evans, D. J. AU - Mowrey-McKee, M. F. AU - Payor, R. AU - Zaidi, T. S. AU - Vallas, V. AU - Muller, E. AU - Pier, G. B. IS - 9 KW - *Bacterial Adhesion/ph [Physiology] *Contact Lenses, Hydrophilic Humans Staphylococcus epidermidis/ip [Isolation & Purification] *Staphylococcus epidermidis/ph [Physiology] PY - 1996 SE - Fleiszig, S M. School of Optometry, University of California, Berkeley, USA. SN - 1040-5488 SP - 590-4 ST - Factors affecting Staphylococcus epidermidis adhesion to contact lenses T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Factors affecting Staphylococcus epidermidis adhesion to contact lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=8887402 VL - 73 ID - 2035 ER - TY - JOUR AB - Pseudomonas aeruginosa is usually considered an extracellular pathogen. Using assays to determine intracellular survival in the presence of gentamicin, we have previously demonstrated that P. aeruginosa is able to invade corneal cells during infectious keratitis in mice. In vitro, P. aeruginosa was found to enter the following cells: human corneal cells removed by irrigation; epithelial cells in the cornea of rats, mice, and rabbits; and primary corneal epithelial cells cultured from rat and rabbit eyes. The level of invasion was related to the level of adherent or associated bacteria. In general, invasion was more efficient with cultured epithelial cells than with cells tested in situ. Invasion did not occur when assays were performed at 4 degrees C. Cytochalasin D but not colchicine inhibited bacterial invasion, suggesting that bacterial entry was an endocytic process dependent on actin microfilaments but not microtubules. Bacteria that invaded cultured corneal epithelial cells were found to multiply within cells. The ability of P. aeruginosa to invade and multiply within corneal epithelial cells may contribute to the virulence of this organism during infectious keratitis, since intracellular bacteria can evade host immune effectors and antibiotics commonly used to treat infection. AU - Fleiszig, S. M. AU - Zaidi, T. S. AU - Pier, G. B. IS - 10 KW - Animals *Cornea/mi [Microbiology] Cytochalasin D/pd [Pharmacology] Epithelium/mi [Microbiology] Gentamicins/pd [Pharmacology] Humans In Vitro Techniques Mice Mice, Inbred C57BL *Pseudomonas aeruginosa/ph [Physiology] Rats Rats, Wistar Temperature PY - 1995 SE - Fleiszig, S M. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. SN - 0019-9567 SP - 4072-7 ST - Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro T2 - Infection and immunity TI - Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7558321 VL - 63 ID - 2048 ER - TY - JOUR AB - To gain access to the corneal epithelium and cause infections keratitis, bacterial pathogens must first interact with ocular surface factors that could affect bacterial adherence. In this study, we demonstrated that the mucus layer, and, in particular, the mucin fraction of mucus, modulated adherence to intact corneal epithelium of Pseudomonas aeruginosa but not that of Staphylococcus aureus or Streptococcus pyogenes. Removal of endogenous mucus from rat or rabbit eyes increased the adherence of P. aeruginosa by 3- to 10-fold. Ocular mucus obtained from rat eyes, porcine stomach mucin, or bovine submaxillary gland mucin inhibited adherence of P. aeruginosa to uninjured corneal epithelium. The mucin fraction of ocular mucus, purified by ultracentrifugation, was found to contain the inhibitory activity, and inhibition was demonstrated at concentrations of mucin as low as 35 micrograms/ml. Ocular mucin was the only material tested that inhibited adherence of P. aeruginosa to an injured cornea. However, the binding of P. aeruginosa to immobilized substrates in vitro did not predict which fraction would possess antiadherence activity: bacteria bound well to whole ocular mucus, mucin, the nonmucin fraction of ocular mucus, and dilute human tears as well as to porcine stomach mucin and bovine submaxillary gland mucin. The effectiveness of the mucin fraction of ocular mucus at inhibiting the binding of P. aeruginosa to the cornea implies that this material is a barrier that protects the surface of the eye from P. aeruginosa adherence. AU - Fleiszig, S. M. AU - Zaidi, T. S. AU - Ramphal, R. AU - Pier, G. B. IS - 5 KW - Animals *Bacterial Adhesion *Cornea/mi [Microbiology] Female Humans Keratitis/et [Etiology] Male *Mucus/ph [Physiology] *Pseudomonas aeruginosa/py [Pathogenicity] Rabbits Rats Rats, Wistar PY - 1994 SE - Fleiszig, S M. Channing Laboratory Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115. SN - 0019-9567 SP - 1799-804 ST - Modulation of Pseudomonas aeruginosa adherence to the corneal surface by mucus T2 - Infection and immunity TI - Modulation of Pseudomonas aeruginosa adherence to the corneal surface by mucus UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=8168942 VL - 62 ID - 2047 ER - TY - JOUR AB - Contact lenses represent a widely utilized form of vision correction with more than 140 million wearers worldwide. Although generally well-tolerated, contact lenses can cause corneal infection (microbial keratitis), with an approximate annualized incidence ranging from ~2 to ~20 cases per 10,000 wearers, and sometimes resulting in permanent vision loss. Research suggests that the pathogenesis of contact lens-associated microbial keratitis is complex and multifactorial, likely requiring multiple conspiring factors that compromise the intrinsic resistance of a healthy cornea to infection. Here, we outline our perspective of the mechanisms by which contact lens wear sometimes renders the cornea susceptible to infection, focusing primarily on our own research efforts during the past three decades. This has included studies of host factors underlying the constitutive barrier function of the healthy cornea, its response to bacterial challenge when intrinsic resistance is not compromised, pathogen virulence mechanisms, and the effects of contact lens wear that alter the outcome of host-microbe interactions. For almost all of this work, we have utilized the bacterium Pseudomonas aeruginosa because it is the leading cause of lens-related microbial keratitis. While not yet common among corneal isolates, clinical isolates of P. aeruginosa have emerged that are resistant to virtually all currently available antibiotics, leading the United States CDC (Centers for Disease Control) to add P. aeruginosa to its list of most serious threats. Compounding this concern, the development of advanced contact lenses for biosensing and augmented reality, together with the escalating incidence of myopia, could portent an epidemic of vision-threatening corneal infections in the future. Thankfully, technological advances in genomics, proteomics, metabolomics and imaging combined with emerging models of contact lens-associated P. aeruginosa infection hold promise for solving the problem - and possibly life-threatening infections impacting other tissues. AD - School of Optometry, University of California, Berkeley, CA, USA Graduate Group in Vision Science, University of California, Berkeley, CA, USA Graduate Groups in Microbiology and Infectious Diseases & Immunity, University of California, Berkeley, CA, USA College of Pharmacy, Touro University California, Vallejo, CA, USA AN - 143767528. Language: English. Entry Date: 20210711. Revision Date: 20210716. Publication Type: journal article AU - Fleiszig, Suzanne M. J. AU - Kroken, Abby R. AU - Nieto, Vincent AU - Grosser, Melinda R. AU - Wan, Stephanie J. AU - Metruccio, Matteo M. E. AU - Evans, David J. DB - ccm DO - 10.1016/j.preteyeres.2019.100804 DP - EBSCOhost KW - Bacteria Antibiotics -- Therapeutic Use Prosthesis-Related Infections -- Microbiology Cornea -- Microbiology Keratitis -- Etiology Contact Lenses Eye Infections, Bacterial -- Etiology Keratitis -- Drug Therapy Eye Infections, Bacterial -- Microbiology Prosthesis-Related Infections -- Diagnosis Eye Infections, Bacterial -- Drug Therapy Keratitis -- Microbiology Scales N1 - review. Journal Subset: Biomedical; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Longitudinal Interval Follow-Up Evaluation (LIFE); Work Environment Scale (WES) (Moos et al). Grant Information: R01 EY030350/EY/NEI NIH HHS/United States. NLM UID: 9431859. PMID: NLM31756497. PY - 2020 SN - 1350-9462 SP - N.PAG-N.PAG ST - Contact lens-related corneal infection: Intrinsic resistance and its compromise T2 - Progress in Retinal & Eye Research TI - Contact lens-related corneal infection: Intrinsic resistance and its compromise UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143767528&site=ehost-live&scope=site VL - 76 ID - 4607 ER - TY - JOUR AB - BACKGROUND: Fungal keratitis is a fungal infection of the cornea. It is common in lower income countries, particularly in agricultural areas but relatively uncommon in higher income countries. Although there are medications available, their effectiveness is unclear., OBJECTIVES: To assess the effects of different antifungal drugs in the management of fungal keratitis., SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 2), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to March 2015), EMBASE (January 1980 to March 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to March 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 March 2015., SELECTION CRITERIA: We included randomised controlled trials of medical therapy for fungal keratitis., DATA COLLECTION AND ANALYSIS: Two review authors selected studies for inclusion in the review, assessed trials for risk of bias and extracted data. The primary outcome was clinical cure at two to three months. Secondary outcomes included best-corrected visual acuity, time to clinical cure, compliance with treatment, adverse outcomes and quality of life., MAIN RESULTS: We included 12 trials in this review; 10 trials were conducted in India, one in Bangladesh and one in Egypt. Seven of these trials were at high risk of bias in one or more domains, two of these studies were at low risk of bias in all domains. Participants were randomised to the following comparisons: topical 5% natamycin compared to topical 1% voriconazole; topical 5% natamycin compared to topical 2% econazole; topical 5% natamycin compared to topical chlorhexidine gluconate (0.05%, 0.1% and 0.2%); topical 1% voriconazole compared to intrastromal voriconazole 50 g/0.1 mL (both treatments combined with topical 5% natamycin); topical 1% voriconazole combined with oral voriconazole compared to both oral voriconazole and oral itraconazole (both combined with topical 5% natamycin); topical 1% itraconazole compared to topical 1% itraconazole combined with oral itraconazole; topical amphotericin B compared to topical amphotericin B combined with subconjunctival injection of fluconazole; intracameral injection of amphotericin B with conventional treatment compared to conventional treatment alone (severe fungal ulcers); topical 0.5% and 1% silver sulphadiazine compared to topical 1% miconazole. Overall the results were inconclusive because for most comparisons only one small trial was available. The exception was the comparison of topical natamycin and topical voriconazole for which three trials were available. In one of these trials clinical cure (healed ulcer) was reported in all 15 people allocated to natamycin and in 14/15 people allocated to voriconazole (risk ratio (RR) 1.07; 95% confidence interval (CI) 0.89 to 1.28, low quality evidence). In one trial people randomised to natamycin were more likely to have a microbiological cure at six days (RR 1.64; 95% CI 1.38 to 1.94, 299 participants). On average, people randomised to natamycin had better spectacle-corrected visual acuity at two to three months compared to people randomised to voriconazole but the estimate was uncertain and the 95% confidence intervals included 0 (no difference) (mean difference -0.12 logMAR, 95% CI -0.31 to 0.06, 434 participants; 3 studies, low quality evidence) and a decreased risk of corneal perforation or therapeutic penetrating keratoplasty, or both (RR 0.61; 95% CI 0.40 to 0.94, 434 participants, high quality evidence). There was inconclusive evidence on time to clinical cure. Compliance with treatment and quality of life were not reported. One tri l comparing natamycin and voriconazole found the effect of treatment greater in Fusarium species, but this subgroup analysis was not prespecified by this review., AUTHORS' CONCLUSIONS: The trials included in this review were of variable quality and were generally underpowered. There is evidence that natamycin is more effective than voriconazole in the treatment of fungal ulcers. Future research should evaluate treatment effects according to fungus species. AU - FlorCruz, Nilo Vincent AU - Evans, Jennifer R. DO - https://dx.doi.org/10.1002/14651858.CD004241.pub4 IS - 4 KW - *Antifungal Agents/tu [Therapeutic Use] *Eye Infections, Fungal/dt [Drug Therapy] Humans *Keratitis/dt [Drug Therapy] Keratitis/mi [Microbiology] Natamycin/tu [Therapeutic Use] Randomized Controlled Trials as Topic Voriconazole/tu [Therapeutic Use] N1 - Update of (UOF) PY - 2015 SE - FlorCruz, Nilo Vincent. Department of Ophthalmology and Visual Sciences, University of the Phillipines-Philippine General Hospital, Taft Avenue, Manila, Philippines, 1000. SN - 1469-493X 1361-6137 SP - CD004241 ST - Medical interventions for fungal keratitis T2 - The Cochrane database of systematic reviews T3 - Update of: Cochrane Database Syst Rev. 2012;(2):CD004241; PMID: 22336802 [https://www.ncbi.nlm.nih.gov/pubmed/22336802] TI - Medical interventions for fungal keratitis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med12&NEWS=N&AN=25855311 Y2 - 20150409// ID - 803 ER - TY - JOUR AB - OBJECTIVE: This study describes patients' and physicians' perceptions of issues related to dosing adherence with topical therapies for lowering intraocular pressure before and after use of the travoprost dosing aid (Travatan Dosing Aid, Alcon Research Ltd., Fort Worth, Texas)., METHODS: The study had an open-label, multicenter, single-treatment-arm design that included sequential patients with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension who were taking any prostaglandin analogue monotherapy. Ten participating physicians were chosen on the basis of factors such as their experience, qualifications, and previous clinical study participation. The study consisted of 2 visits: screening and week 4. Patients were asked to complete a survey about their medication adherence before study entry at the screening visit and at study exit during the week-4 visit. In addition, each physician was asked to complete an entry and exit survey on each patient as well as a survey to provide feedback on the travoprost dosing aid., RESULTS: Of the 87 enrolled patients, 6 did not complete the exit survey; therefore, 81 patients were included in the intent-to-treat analysis. Mean (SD) age at enrollment was 65.4 (11.6) years; 61.7% (50/81) of the patients were women and 60.5% (49/81) were white. Most patients (96.3% [78/81]) had open-angle glaucoma. Participating physicians perceived that problems involving dosing and adherence were reduced after patients used the dosing aid. Physicians indicated that they would recommend continued use of the travoprost dosing aid for 91.3% (73/80) of patients. All 10 participating physicians said that they would recommend the dosing aid to patients in the future. Of the 81 patients, the majority (68.8% [55/80]) indicated that they would like to continue using the travoprost dosing aid. For 67.5% (54/80) of patients, dosing adherence as recorded by the travoprost dosing aid was >70%. The dosing lever (39.7% [31/78]) and the visual alarm (29.5% [23/78]) were the 2 most favored features of the dosing aid reported by all evaluable patients. The majority of patients (58.8% [47/80]) indicated that they were "relieved" or "very relieved" that the doctor was able to monitor when they dosed their medication; few (7.5% [6/80]) were "concerned" or "very concerned" that the doctor was able to monitor their dosing., CONCLUSIONS: The travoprost dosing aid was perceived to be effective in reminding this group of patients to take their medication as prescribed. In this study, the device was well accepted by both patients and physicians. AU - Flowers, Brian AU - Wand, Martin AU - Piltz-Seymour, Jody AU - Berke, Stanley J. AU - Day, Douglas AU - Teague, James AU - Smoot, Tonya M. AU - Landry, Theresa A. AU - Bergamini, Michael V. W. AU - Mallick, Sushanta AU - Travatan Dosing Aid Study, Group IS - 11 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] *Attitude to Health Cloprostenol/ad [Administration & Dosage] *Cloprostenol/aa [Analogs & Derivatives] Female *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] *Physicians Prostaglandins, Synthetic/ad [Administration & Dosage] Travoprost PY - 2006 SE - Flowers, Brian. Ophthalmology Associates, Fort Worth, Texas, USA. SN - 0149-2918 SP - 1803-11 ST - Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension T2 - Clinical therapeutics TI - Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17213000 VL - 28 ID - 1627 ER - TY - JOUR AB - INTRODUCTION: In the last decades, the therapy of glaucoma has largely shifted from surgery to medical treatment thanks to the introduction of strongly effective formulations, that is, prostaglandin analogs and fixed combinations. This clinical scenario may dramatically change in the future thanks to the progresses in biochemistry, genetics and drug delivery technology., AREAS COVERED: This review covers the strategies currently used to achieve effective medical reduction of intraocular pressure in clinical practice; treatments that are currently been experimented in humans and that may be clinically available in the next few years; treatments at preclinical stages; and future goals of glaucoma treatment (gene therapy, ocular implants and neuroprotection)., EXPERT OPINION: Apart from an adequate reduction of intraocular pressure, effective glaucoma treatments should guarantee other characteristics: good tolerability, low problems of adherence and, possibly, multiple ways of action. From this viewpoint, a crucial clinical role may be played by drugs remodeling the trabecular meshwork (i.e., ROCK inhibitors, metalloproteinases). Other strategies such as the use of ocular implants for drug delivery, neuroprotection or gene therapy could renew glaucoma management in the future, but need long-term rigorous verification of safety and efficacy. AU - Fogagnolo, Paolo AU - Rossetti, Luca DO - https://dx.doi.org/10.1517/13543784.2011.579901 IS - 7 KW - Animals Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/me [Metabolism] *Glaucoma/dt [Drug Therapy] Glaucoma/me [Metabolism] *Glaucoma/su [Surgery] Humans Intraocular Pressure/de [Drug Effects] Intraocular Pressure/ph [Physiology] Neuroprotective Agents/ad [Administration & Dosage] Neuroprotective Agents/me [Metabolism] Ophthalmic Solutions/ad [Administration & Dosage] Ophthalmic Solutions/me [Metabolism] Predictive Value of Tests Prostaglandins/ad [Administration & Dosage] Prostaglandins/me [Metabolism] Treatment Outcome PY - 2011 SE - Fogagnolo, Paolo. G. B. Bietti Foundation - IRCC, Rome, Italy. fogagnolopaolo@googlemail.com SN - 1744-7658 1354-3784 SP - 947-59 ST - Medical treatment of glaucoma: present and future T2 - Expert opinion on investigational drugs TI - Medical treatment of glaucoma: present and future UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21534887 VL - 20 Y2 - 20110503// ID - 1272 ER - TY - JOUR AB - Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. AU - Fogagnolo, Paolo AU - Torregrossa, Giulia AU - Tranchina, Laura AU - Ferreras, Antonio AU - De Cilla, Stefano AU - Labbe, Antoine AU - Figus, Michele AU - Ottobelli, Laura AU - Rossetti, Luca DO - https://dx.doi.org/10.2174/0929867326666190725160621 IS - 22 KW - Animals Antihypertensive Agents/ch [Chemistry] *Antihypertensive Agents/pd [Pharmacology] *Corneal Diseases/dt [Drug Therapy] *Glaucoma/dt [Drug Therapy] Humans Osmolar Concentration Preservatives, Pharmaceutical/ch [Chemistry] *Preservatives, Pharmaceutical/pd [Pharmacology] Surface Properties *Tears/de [Drug Effects] PY - 2019 SE - Fogagnolo, Paolo. Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy. Torregrossa, Giulia. Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy. Tranchina, Laura. Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy. Ferreras, Antonio. Department of Ophthalmology, Miguel Servet University Hospital, University of Zaragoza, Zaragoza, Spain. De Cilla, Stefano. Unit of Ophthalmology, Ospedale Maggiore della Carita, Novara, Italy. Labbe, Antoine. Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, Vision Institute, Versailles Saint-Quentin en Yvelines University, 75012 Paris, France. Figus, Michele. Ophthalmology, Department of Neurosciences, University of Pisa, Pisa, Italy. Ottobelli, Laura. Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy. Rossetti, Luca. Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy. SN - 1875-533X 0929-8673 SP - 4241-4252 ST - Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review T2 - Current medicinal chemistry TI - Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31345142 VL - 26 ID - 321 ER - TY - JOUR AB - Drug delivery to the eye is made difficult by multiple barriers (such as the tear film, cornea, and vitreous) between the surface of the eye and the treatment site. These barriers are difficult to surmount for the purposes of drug delivery without causing toxicity. Using nanotechnology tools to control, manipulate, and study delivery systems, new approaches to delivering drugs, genes, and antigens that are effective and safe can be developed. Topical administration to the ocular surface would be the safest method for delivery, as it is noninvasive and painless compared with other delivery methods. However, there is only limited success using topical delivery methods, especially for gene therapy. Current thinking on treatments of the future enabled by nanodelivery systems and the identification of target specificity parameters that require deeper understanding to develop successful topical delivery systems for glaucoma is highlighted. AU - Foldvari, Marianna DO - https://dx.doi.org/10.1097/IJG.0000000000000122 IS - 8 Suppl 1 KW - Administration, Topical *Antihypertensive Agents/ad [Administration & Dosage] *Cornea/de [Drug Effects] *Drug Delivery Systems Exfoliation Syndrome/dt [Drug Therapy] *Glaucoma, Open-Angle/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Ophthalmic Solutions *Pharmaceutical Preparations/ad [Administration & Dosage] PY - 2014 SE - Foldvari, Marianna. School of Pharmacy and Waterloo Institute of Nanotechnology, University of Waterloo, Waterloo, ON, Canada. SN - 1536-481X 1057-0829 SP - S80-2 ST - Noninvasive ocular drug delivery: potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma T2 - Journal of glaucoma TI - Noninvasive ocular drug delivery: potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25275915 VL - 23 ID - 857 ER - TY - JOUR AB - Purpose : To compare healthcare utilization and visual field progression of glaucoma patients who add or switch topical therapies vs. patients managed on topical monotherapy. Methods : This was a retrospective analysis of Kaiser Permanente Southern California electronic health records between 2001 and 2011, with supplemental chart review. Records of newly-diagnosed glaucoma (ICD-9 365.xx) patients aged 18 years or older and prescribed a glaucoma agent within 90 days of diagnosis were included. Two cohorts were defined: patients treated with topical monotherapy for the study duration, and patients who switched or added drugs at any time during follow-up. Outcomes of interest included health care utilization measured by office visits, visual field testing, laser procedures, and surgery. The risk of visual field progression was assessed using multivariable Cox regression. Results : 6,014 newly diagnosed glaucoma patients were included for analyses; 1,783 remained on monotherapy and 4,231 switched/added medications. Mean follow-up was 8.2 years (SD=2.4). At baseline, 46.9% took beta-blockers, 35.0% prostaglandins, 16.2% adrenergic agents, and 1.4% carbonic anhydrase inhibitors. At 5 years, a greater proportion of patients who added or switched therapy had progressed compared to patients continuing on monotherapy (48.3% vs. 32.8%, p<0.001). Patients who switched/added therapy also had more office visits (20.4 vs. 15.8), more visual field tests (4.9 vs. 4.6) and higher prevalence of trabeculectomies (2.9% vs. 0%) (p<0.001 for all). In multivariable hazard models, predictors of progression from baseline included older age, Black or Hispanic vs. White race/ethnicity, and diabetes; switching or adding therapy was not a statistically significant predictor of progression (HR with 95% CI: 1.10 (1.00, 1.22)). Conclusions : Patients who switched or added medications had a larger healthcare burden. They had more office visits and procedures at 5 years from diagnosis, including a significantly higher number of procedures and visual field tests. Thus, this analysis supports the use of the most effective therapeutic option early. Using factors evaluated in the multivariable model, identifying glaucoma patients at higher risk of progression may be possible. AD - D.S. Fong, Ophthalmology, Kaiser Permanente Southern California, Baldwin Park, CA, United States AU - Fong, D. S. AU - Batech, M. AU - Hudson, S. M. AU - Luong, T. AU - Jimenez, J. AU - Chandwani, H. DB - Embase IS - 12 KW - adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor endogenous compound prostaglandin adult ambulatory care animal model California Caucasian controlled study diabetes mellitus diagnosis disease course electronic health record ethnicity female follow up glaucoma health care utilization Hispanic human ICD-9 laser major clinical study male medical record review monotherapy perimetry prevalence proportional hazards model retrospective study surgery topical drug administration trabeculectomy young adult LA - English M3 - Conference Abstract N1 - L616082574 2017-05-16 PY - 2016 SN - 0146-0404 SP - 2606 ST - Comparison of burden of care and visual field progression between newly diagnosed glaucoma patients managed on topical monotherapy and those who switch or add on therapies T2 - Investigative Ophthalmology and Visual Science TI - Comparison of burden of care and visual field progression between newly diagnosed glaucoma patients managed on topical monotherapy and those who switch or add on therapies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616082574&from=export VL - 57 ID - 2714 ER - TY - JOUR AB - Purpose: To determine the effect of glaucoma medication adherence on visual field (VF) progression among newly diagnosed glaucoma patients taking intraocular pressurelowering medication. Methods: Medication utilization and visual field data were assessed for patients with newly diagnosed glaucoma who filled a prescription within 90 days of diagnosis in 2001-2011. Pharmacy dispensary records were used to determine the medication proportion of days covered (PDC) in the year prior to each visual field, and averaged over the patient's entire length of follow-up. Adherence was classified as low (0 3 dB loss from baseline. Multivariable analysis of probability of progression included covariates measuring age, sex, race/ethnicity, baseline severity, and history of stroke or diabetic retinopathy. Results: 9,514 patients met study criteria; mean age was 66.3 years (SD = 10.8), 53.2% were male, and 30.7% White, non-Hispanic. At baseline, 38% patients had mild glaucoma (-280%). This risk persisted even after adjustment for factors such as age, sex, race/ethnicity, and baseline glaucoma severity. Additional research is needed to identify facilitators for and barriers to long-term medication adherence, particularly among patients presenting with moderate to severe glaucoma. AD - D.S. Fong, Ophthalmology, Kaiser Permanente Southern California, Baldwin Park, CA, United States AU - Fong, D. S. AU - Batech, M. AU - Mattox, C. AU - Luong, T. AU - Jimenez, J. AU - Campbell, J. AU - Chandwani, H. DB - Embase IS - 8 KW - age aged cerebrovascular accident conference abstract controlled study diabetic retinopathy diagnosis ethnicity female follow up glaucoma human information processing machine major clinical study male medication compliance pharmacy (shop) prescription probability race topical drug administration visual field LA - English M3 - Conference Abstract N1 - L621490712 2018-04-04 PY - 2017 SN - 1552-5783 ST - Lower levels of adherence to topical glaucoma medications are associated with increased risk of visual field progression T2 - Investigative Ophthalmology and Visual Science TI - Lower levels of adherence to topical glaucoma medications are associated with increased risk of visual field progression UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621490712&from=export VL - 58 ID - 2650 ER - TY - JOUR AB - Lack of or inadequate hand washing is a risk factor in the development of contact lens related microbial keratitis and corneal inflammatory events. In the public health domain there is compelling evidence that proper hand washing with soap can save lives. The purpose of this review is to draw attention to some of the public health literature in support of hand washing and how education can influence patients' hand hygiene behavior. Contact lens wearers are also guilty of poor hand washing behavior but there is scant evidence that education of hand washing procedures of lens wearers alters patient non-compliance. It is well known that pathogenic microbial contamination of contact lenses, lens cases, care solutions and anterior ocular components have been found with contact lens wear. However while the originating source may be hands or water, it is most likely both of these. Besides proper hand washing this paper will include mitigating strategies for avoiding microbial contamination. Copyright © 2018 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved. AU - Fonn, Desmond AU - Jones, Lyndon DO - https://dx.doi.org/10.1016/j.clae.2018.10.022 IS - 2 KW - *Contact Lenses Equipment Contamination *Eye Infections, Bacterial/mi [Microbiology] *Hand Hygiene Humans Inflammation/mi [Microbiology] *Keratitis/mi [Microbiology] Patient Compliance Risk Factors PY - 2019 SE - Fonn, Desmond. Centre for Ocular Research and Education, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada. Electronic address: dfonn@uwaterloo.ca. Jones, Lyndon. Centre for Ocular Research and Education, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada. Electronic address: lwjones@uwaterloo.ca. SN - 1476-5411 1367-0484 SP - 132-135 ST - Hand hygiene is linked to microbial keratitis and corneal inflammatory events T2 - Contact lens & anterior eye : the journal of the British Contact Lens Association TI - Hand hygiene is linked to microbial keratitis and corneal inflammatory events UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=30413375 VL - 42 Y2 - 20181107// ID - 372 ER - TY - JOUR AB - PURPOSE: We investigated patients' attitudes and perceptions toward a subconjunctival implant as a novel ocular drug delivery method for glaucoma., METHODS: We recruited 344 Chinese patients with primary open angle or angle closure glaucoma currently on topical antiglaucoma medication for a minimum of six months from specialist glaucoma clinics. Sociodemographic data, and information about patients' general and ocular health were collected. Beliefs about medicines, glaucoma, eye drops, and self-reported adherence were assessed by trained interviewers using validated questionnaires. A description about the implant was provided and patients subsequently were assessed on their understanding and acceptance., RESULTS: Of the 344 Chinese patients enrolled, 216 (62.8%) would accept the implant as a replacement for their current eye drops. Of those who accepted the implant, 99 (45.8%) were willing to accept it at similar costs, while 40 (18.5%) and 20 (9.3%) patients were willing to pay 1.5 and 2 times the cost of their present medication, respectively. Patients who accepted the implant had more severe glaucoma (P = 0.015) and felt that the implant was more helpful than eye drops (P < 0.001). Beliefs toward medicines, glaucoma, eye drops, self-reported adherence, and sociodemographic factors did not have a significant impact on the patients' decisions., CONCLUSIONS: An ocular drug implant would be an acceptable alternative to topical eye drops for subgroups of glaucoma patients. AU - Foo, Reuben Chao Ming AU - Lamoureux, Ecosse L. AU - Wong, Ryan C. K. AU - Ho, Sue-Wei AU - Chiang, Peggy P. C. AU - Rees, Gwyneth AU - Aung, Tin AU - Wong, Tina T. DO - https://dx.doi.org/10.1167/iovs.12-10393 IS - 13 KW - Adult Aged Aged, 80 and over Antihypertensive Agents/ad [Administration & Dosage] *Asian Continental Ancestry Group/eh [Ethnology] *Attitude to Health/eh [Ethnology] Cross-Sectional Studies *Drug Delivery Systems *Drug Implants Female Glaucoma, Angle-Closure/dt [Drug Therapy] *Glaucoma, Angle-Closure/eh [Ethnology] Glaucoma, Angle-Closure/px [Psychology] Glaucoma, Open-Angle/dt [Drug Therapy] *Glaucoma, Open-Angle/eh [Ethnology] Glaucoma, Open-Angle/px [Psychology] Humans Intraocular Pressure/de [Drug Effects] Male Medication Adherence Middle Aged *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] Singapore/ep [Epidemiology] Surveys and Questionnaires PY - 2012 SE - Foo, Reuben Chao Ming. Singapore National Eye Centre, Singapore. SN - 1552-5783 0146-0404 SP - 8240-5 ST - Acceptance, attitudes, and beliefs of Singaporean Chinese toward an ocular implant for glaucoma drug delivery T2 - Investigative ophthalmology & visual science TI - Acceptance, attitudes, and beliefs of Singaporean Chinese toward an ocular implant for glaucoma drug delivery UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=23188725 VL - 53 Y2 - 20121217// ID - 1100 ER - TY - JOUR AB - Purpose To determine the frequency of patients suffering harm due to delay in ophthalmic care in the UK over a 12-month period. Methods Patients with deterioration in vision in at least one eye of 3 lines of Snellen acuity or 15 letters on ETDRS chart or deterioration in visual field deviation of 3 decibels due to health service initiated delay in review or care were ascertained through the BOSU using prospective active surveillance involving all UK consultant ophthalmologists. Demographic details, diagnosis, cause and length of delay, and vision loss were then sought by questionnaire. Results 238 cases reported between March 2015 and February 2016. 197/238 questionnaires were returned (83%). Twenty-eight reports were out of the study period or did not meet the case definition. Median age was 76 years (range: 1 to 98 years). Median delay was 22 weeks (range: 2 days to 51/2 years). Seventy two per cent experienced permanent reduction in visual acuity, 23% permanent deterioration in visual field. Main diagnoses were Glaucoma 42%, Age-related Macular Degeneration (AMD) 23%, and Diabetic Retinopathy (DR) 16%. Eighteen patients were eligible for Severely Sight Impaired (SSI) or Sight Impaired (SI) registration. Main causes were delayed follow-up (76%), lost referral (7%), and delayed treatment (8%). Conclusion Patients are suffering preventable harm due to health service initiated delay leading to permanently reduced vision. This is occurring in patients of all ages, but most consistently in those with chronic conditions. Delayed follow-up or review is the cause in the majority of cases indicating a lack of capacity within the hospital eye service. AU - Foot, B. AU - MacEwen, C. DO - https://dx.doi.org/10.1038/eye.2017.1 IS - 5 KW - Adolescent Adult Aged Aged, 80 and over Child Child, Preschool *Delivery of Health Care/td [Trends] Female *Hospitals/st [Standards] Humans Infant Male Middle Aged *Ophthalmology *Patient Satisfaction *Professional Autonomy Prospective Studies *Referral and Consultation Surveys and Questionnaires United Kingdom *Vision Disorders/th [Therapy] Young Adult PY - 2017 SE - Foot, B. British Ophthalmological Surveillance Unit, The Royal College of Ophthalmologists, London, UK. MacEwen, C. Department of Ophthalmology, Ninewells Medical School, Dundee, UK. SN - 1476-5454 0950-222X SP - 771-775 ST - Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome T2 - Eye (London, England) TI - Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=28128796 VL - 31 Y2 - 20170127// ID - 541 ER - TY - JOUR AB - Objective: This meta-analysis investigated whether beliefs in the necessity and concerns of medicine and the necessity-concerns differential are correlated with medication adherence on a population level and in different conditions. Methods: An electronic search of Web of Science, EMBASE, PubMed and CINAHL was conducted for manuscripts utilising the Beliefs about Medicines Questionnaire and comparing it to any measure of medication adherence. Studies were pooled using the random-effects model to produce a mean overall effect size correlation. Studies were stratified for condition, adherence measure, power and study design. Results: Ninety-four papers were included in the meta-analysis. The overall effect size(r) for necessity, concerns, and necessity-concerns differential was 0.17, -0.18 and 0.24 respectively and these were all significant (p < 0.0001). Effect size for necessity was stronger in asthma and weaker in the cardiovascular group compared to the overall effect size. Conclusion: Necessity and concerns beliefs and the necessity-concerns differential were correlated with medication adherence on a population level and across the majority of included conditions. The effect sizes were mostly small with a magnitude comparable to other predictors of adherence. Practice implications: This meta-analysis suggests that necessity and concern beliefs about medicines are one important factor to consider when understanding reasons for non-adherence. AD - H. Foot, School of Pharmacy, Pharmacy Australia Centre of Excellence, University of Queensland, Level 4, 20 Cornwall St., Woolloongabba, QLD, Australia AU - Foot, H. AU - La Caze, A. AU - Gujral, G. AU - Cottrell, N. DB - Embase Medline DO - 10.1016/j.pec.2015.11.004 IS - 5 KW - asthma breast cancer cardiovascular disease chronic disease conceptual framework correlation analysis diabetes mellitus effect size epilepsy glaucoma health belief health care system health care utilization hemophilia human Marfan syndrome medical record medication compliance mental disease patient education prediction priority journal questionnaire review rheumatoid arthritis systematic review LA - English M3 - Review N1 - L609670636 2016-04-13 2016-04-22 PY - 2016 SN - 1873-5134 0738-3991 SP - 706-717 ST - The necessity-concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis T2 - Patient Education and Counseling TI - The necessity-concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609670636&from=export http://dx.doi.org/10.1016/j.pec.2015.11.004 VL - 99 ID - 2742 ER - TY - JOUR AB - The promise of short RNA or DNA segments such as siRNAs, antisense oligonucleotides, and transcription factor decoys to treat disease has prompted nearly 40 clinical trials for RNA interference (RNAi)-based therapeutics and more than 100 clinical trials for antisense oligonucleotide-based technologies; in fact, there are promising in vivo and preclinical studies for many hundreds of technologies. Current treatment strategies are largely injection-based, so effective oral delivery platforms for oligonucleotides may result in improved patient comfort and compliance. We analyze recently developed oral delivery methods for short RNA and DNA segments. © 2012 Elsevier B.V. AD - N.A. Peppas, Department of Chemical Engineering, University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, United States AU - Forbes, D. C. AU - Peppas, N. A. C1 - agn 211745 nucb 1000 pf 04523655 qpi 1007 syl 040012 syl 1001 DB - Embase Medline DO - 10.1016/j.jconrel.2012.06.037 IS - 2 KW - NCT00144589 NCT00259753 NCT00306904 NCT00363714 NCT00395057 NCT00499590 NCT00557791 NCT00658086 NCT00672542 NCT00689065 NCT00701181 NCT00713518 NCT00716014 NCT00722384 NCT00725686 NCT00802347 NCT00882180 NCT00927459 NCT00938574 NCT00990743 NCT01064505 NCT01065935 NCT01148953 NCT01158079 NCT01188785 NCT01227291 NCT01262235 NCT01437007 NCT01437059 NCT01438281 agn 211745 alginic acid antisense oligonucleotide bevasiranib chitosan eudragit microRNA nanoparticle nanosphere nucb 1000 pf 04523655 polyethyleneimine polylactide polyvinyl alcohol pr 04523655 qpi 1007 short hairpin RNA small interfering RNA syl 040012 syl 1001 unclassified drug acquired immune deficiency syndrome diabetic macular edema dry eye eye pain gene therapy glaucoma hepatitis B human Human immunodeficiency virus infection hydrogel lymphoma melanoma nonhuman ocluar pain patient compliance priority journal age related macular degeneration review RNA interference transcription regulation LA - English M3 - Review N1 - L52183053 2012-08-31 2012-09-24 PY - 2012 SN - 0168-3659 1873-4995 SP - 438-445 ST - Oral delivery of small RNA and DNA T2 - Journal of Controlled Release TI - Oral delivery of small RNA and DNA UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52183053&from=export http://dx.doi.org/10.1016/j.jconrel.2012.06.037 VL - 162 ID - 3065 ER - TY - JOUR AB - Background: Glaucoma involves progressive optic nerve fibre loss, subsequently leading to irreversible and disabling visual field defects. In Europe, the prevalence of glaucoma is approximately 2.2 % of all people aged over 40 years; this equates to 12 million people. Glaucoma patients require regular lifelong follow-up, contributing to a large financial and resource burden for the National Health Service (NHS) in the UK. This study aims to determine whether providing newly diagnosed glaucoma patients with a personalised client-held eye health summary ('glaucoma personal record'), improves patients' knowledge of their glaucoma condition. A potential long-term benefit could be improved self-management and henceforth a slower rate of deterioration. Methods/Design: HOPE Glaucoma is a 3-year, prospective, parallel-group, pragmatic, single-centred, randomised controlled trial. An anticipated 122 adults, newly diagnosed with glaucoma (including ocular hypertension, suspected glaucoma and/or chronic open-angle glaucoma) will be recruited from a nurse-led ophthalmology outpatient clinic at a medium-sized NHS Trust. Participants will be randomly allocated to receive standard clinical care (control arm) or standard care plus a glaucoma personal record, detailing the current state of their condition (interventional arm). Participant assessments are designed to test whether provision of a glaucoma personal record 1) improves patient knowledge of glaucoma and 2) contributes to improvements in clinical outcomes, i.e. delay of visual field loss. The primary outcome measure is better client knowledge of glaucoma at the 9-12 month follow-up visit. Secondary outcome measures include the rate of visual field loss and patient-reported outcome measures on visual function (National Eye Institute VFQ - 25) measured at baseline, 9-12 months, 24 months and 36 months. Estimating a 20 % drop-out rate, the study will have 90 % power to detect a mean two-point difference in glaucoma knowledge score between groups at 5 % significance - based on two-sided Mann-Whitney U test. Discussion: If a glaucoma personal record is found to significantly improve glaucoma patients' knowledge of their condition, this intervention could potentially provide a low-cost, straightforward tool to educate and engage glaucoma patients. Subsequently, this could have the potential to increase patient self-management and therefore allow glaucoma patients to prolong their sight functionality for longer. AN - WOS:000359041200002 AU - Forbes, M. AU - Fairlamb, H. AU - Jonker, L. DA - AUG 7 DO - 10.1186/s13063-015-0863-2 PY - 2015 SN - 1745-6215 ST - The Health Of Patients' Eyes (HOPE) Glaucoma study. The effectiveness of a 'glaucoma personal record' for newly diagnosed glaucoma patients: study protocol for a randomised controlled trial T2 - TRIALS TI - The Health Of Patients' Eyes (HOPE) Glaucoma study. The effectiveness of a 'glaucoma personal record' for newly diagnosed glaucoma patients: study protocol for a randomised controlled trial VL - 16 ID - 5936 ER - TY - JOUR AB - Purpose: To assess whether provision of a personalized patient-held eye health summary (glaucoma personal record) improves patients' knowledge of glaucoma at 1-year follow-up. The National Institute for Clinical Excellence has recommended such an approach to ascertain if this may ultimately help slow disease progression. Methods: Recruited patients, newly diagnosed with glaucoma conditions, were randomly allocated to receive standard clinical care or an additional glaucoma personal record, detailing the current state of each individual's eye condition. Mann-Whitney U test was applied for comparison of knowledge scores between groups at 1-year follow-up, using a validated questionnaire. Multiple linear regression analysis was applied to detect any factors significantly associated with a difference in glaucoma knowledge. Results: A total of 122 patients were recruited; 57 controls and 44 intervention patients were tested for their glaucoma knowledge, equating to 83% retention rate. Out of a maximum available 100% converted score, the median scores were 58% and 53% for the control and intervention arm, respectively (p = 0.85). Regression analysis showed that age (p = 0.015) had a negative association and level of education (p = 0.002) had a positive association with glaucoma knowledge. Conclusions: The glaucoma personal record does not impact on a patient's knowledge of glaucoma in either a positive or negative way. Other approaches to improve health literacy among glaucoma patients, particularly for patients who are elderly or have a limited educational background, must be considered to improve patients' awareness and knowledge of their own condition. AN - WOS:000415309800009 AU - Forbes, M. AU - Fairlamb, H. AU - Jonker, L. DA - SEP-OCT DO - 10.5301/ejo.5000939 IS - 5 PY - 2017 SN - 1120-6721 1724-6016 SP - 542-547 ST - Impact of patient-held record on knowledge at 1-year follow-up for glaucoma patients: single-center randomized controlled trial T2 - EUROPEAN JOURNAL OF OPHTHALMOLOGY TI - Impact of patient-held record on knowledge at 1-year follow-up for glaucoma patients: single-center randomized controlled trial VL - 27 ID - 5987 ER - TY - JOUR AB - PURPOSE: To determine if adherence and convenience of once-daily glaucoma medication is greater in the morning or the evening., DESIGN: Prospective, randomized crossover treatment trial., PATIENTS AND METHODS: Thirty patients newly diagnosed with glaucoma or ocular hypertension requiring intraocular pressure (IOP) reduction were started on travoprost eye drops and randomized to either morning or evening administration for 1 month. They were then crossed over to the opposite dosing schedule for the following month. Adherence was monitored using an automated dosing aid., MAIN OUTCOME MEASURES: Adherence was compared between morning versus evening dosing and first versus second month dosing. Demographic characteristics were obtained, treatment effect was measured, and patients completed a post-study questionnaire regarding the convenience of the 2 dosing regimens., RESULTS: Patient adherence overall was good (89.3%). There was no statistically significant difference (P=0.07) in adherence between morning dosing (90.9%) and evening dosing (87.3%). Adherence in the first month (91.7%) was superior to the second month (86.5%). There was no significant difference in IOP response between morning and evening dosing. Patients found morning dosing more convenient than evening dosing., CONCLUSIONS: Early adherence to treatment with a prostaglandin analogue is good, but patients prefer morning administration to evening administration. This may lead to greater adherence with morning administration, particularly among men. Adherence decreases from the first to second month after initiation of treatment. IOP response to this treatment is not significantly affected by morning versus evening administration. AU - Ford, Bryce A. AU - Gooi, Malcolm AU - Carlsson, Anthony AU - Crichton, Andrew C. DO - https://dx.doi.org/10.1097/IJG.0b013e31822e622f IS - 1 KW - Administration, Topical Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Cloprostenol/ad [Administration & Dosage] *Cloprostenol/aa [Analogs & Derivatives] Cross-Over Studies *Drug Chronotherapy Female *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Male *Medication Adherence Middle Aged Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions Prospective Studies Surveys and Questionnaires Travoprost PY - 2013 SE - Ford, Bryce A. Department of Surgery, Division of Ophthalmology, University of Calgary, Calgary, Alberta, Canada. SN - 1536-481X 1057-0829 SP - 1-4 ST - Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing T2 - Journal of glaucoma TI - Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=21946541 VL - 22 ID - 1023 ER - TY - JOUR AB - Of the various undesired side effects associated with antidepressants, minor tranquilizers and mood stabilizers commonly used in psychiatry, those affecting the eye and vision are often neglected and largely ignored. This review of published data calls the clinician's attention to the need for a better understanding of such adverse affects to ensure a correct, more rational pharmacotherapy with such agents, as they are also often employed in chronic treatment. Specifically, lesser known and not infrequently rare complications are examined, including mydriasis and tricyclic-antidepressant-induced cycloplegia, which may lead to the onset of acute glaucoma and augment the risk of irreversible severe eye damage, including blindness; the undesired effects of lithium salts are frequently a sign of neurotoxicity; the effects of carbamazepine and especially those caused by topyramate, an anticonvulsant increasingly used in psychiatry because of its therapeutic efficacy in the treatment of bipolar disorders and because of its ability to induce weight loss. The ocular side effects these agents cause may sometimes be so severe that compliance is reduced and health risks are increased. Close collaboration with the oculist and accurate monitoring of the patient's ophthalmic conditions are therefore recommended. AD - P. Fornaro, Dipartimento di Neuroscienze, Oftalmologia e Genetica, Sezione di Psichiatria, Università degli Studi di Genova, Largo Rosanna Benzi 10, 16132 Genova, Italy AU - Fornaro, P. AU - Venuti, S. AU - Fornaro, M. AU - Sartore, F. AU - Gabrielli, F. DB - Embase IS - 4 KW - amitriptyline anticonvulsive agent antidepressant agent anxiolytic agent bethanechol brofaromine carbamazepine citalopram clomipramine clorgyline desipramine escitalopram fluoxetine fluvoxamine imipramine isocarboxazid lithium moclobemide monoamine oxidase inhibitor mood stabilizer oxcarbazepine paroxetine phenelzine phenothiazine derivative sertraline topiramate tranylcypromine tricyclic antidepressant agent trifluoperazine trimipramine accommodation paralysis bipolar disorder blindness closed angle glaucoma drug mechanism extrapyramidal symptom eye disease eye injury health hazard human long term care mydriasis neurotoxicity patient compliance patient monitoring review body weight loss LA - Italian M3 - Review N1 - L43213323 2006-02-28 PY - 2005 SN - 0391-1772 SP - 301-313 ST - Ophthalmological side effects of antidepressant, anxiolytic and mood stabilizer agents T2 - Minerva Psichiatrica TI - Ophthalmological side effects of antidepressant, anxiolytic and mood stabilizer agents UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43213323&from=export VL - 46 ID - 3652 ER - TY - JOUR AB - PURPOSE: To describe a case of fungal keratitis in a soft contact lens wearer., METHODS AND RESULTS: A 57 year old female, compliant, frequent replacement soft contact lens wearer, with a possible prior history of herpes simplex keratitis, presented with pain and injection of her left eye of four weeks duration. Gram stain of a corneal ulcer of the left eye revealed fungal organisms and cultures grew Fusarium solani. The infiltrate responded to topical and systemic antifungal agents, but a corneal perforation developed which required a therapeutic penetrating keratoplasty., CONCLUSIONS: Fungal infections are a cause of corneal ulcers in contact lens wearers. Despite the use of topical and systemic antifungal agents, fungal ulcers frequently require surgical intervention. AU - Foroozan, R. AU - Eagle, R. C., Jr. AU - Cohen, E. J. IS - 3 KW - Antifungal Agents/ad [Administration & Dosage] *Contact Lenses, Hydrophilic/ae [Adverse Effects] Contact Lenses, Hydrophilic/mi [Microbiology] Cornea/mi [Microbiology] Cornea/pa [Pathology] *Corneal Ulcer/mi [Microbiology] Corneal Ulcer/pa [Pathology] Corneal Ulcer/th [Therapy] Diagnosis, Differential Eye Infections, Fungal/mi [Microbiology] Eye Infections, Fungal/pa [Pathology] Eye Infections, Fungal/th [Therapy] *Eye Infections, Fungal Female *Fusarium/ip [Isolation & Purification] Humans Keratoplasty, Penetrating Middle Aged *Mycoses/mi [Microbiology] Mycoses/pa [Pathology] Mycoses/th [Therapy] Ophthalmic Solutions Rupture, Spontaneous Visual Acuity PY - 2000 SE - Foroozan, R. Cornea Service, Wills Eye Hospital, Philadelphia, PA 19107, USA. SN - 0733-8902 SP - 166-8 ST - Fungal keratitis in a soft contact lens wearer T2 - The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc TI - Fungal keratitis in a soft contact lens wearer UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10946989 VL - 26 ID - 1949 ER - TY - JOUR AB - PURPOSE: To study how many of the patients with treated glaucoma or ocular hypertension go blind during their lifetime and which factors are associated with blindness., PATIENTS: The data on 106 consecutive patients who had died between 1991 and 2002 was retrospectively evaluated. At diagnosis 39 patients had primary open-angle glaucoma, 27 had exfoliation glaucoma, and 40 had ocular hypertension., METHODS: Clinical records and causes of death were reviewed. Visual disability at the last visit before death was evaluated. Outcome measures were visual handicap and blindness based on visual acuity and/or visual fields., RESULTS: At the last visit, 17 patients [16%, 95% confidence interval (CI) 9-23] were visually handicapped. Thirteen patients (14%) were bilaterally blind. Glaucoma was the cause of blindness in one or both eyes in 16 patients (15%, 95% CI 8-22) and in both eyes in 6 patients (6%, 95% CI 1-10). In the analysis of only 1 eye of each patient, the cumulative incidence of glaucoma-caused blindness was 6% (95% CI 2-11) at 5 years, 9% (95% CI 4-15) at 10 years, and 15% (95% CI 9-23) at 15 years. An advanced stage of glaucoma at diagnosis, fluctuation in intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance increased the occurrence of blindness. Positive family history of glaucoma and vascular causes of death had no effect on visual outcome., CONCLUSIONS: Glaucoma-caused blindness was associated with an advanced stage of glaucoma at diagnosis, fluctuation of intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance. The risk of going blind from glaucoma in both eyes was 6%. AU - Forsman, Eva AU - Kivela, Tero AU - Vesti, Eija IS - 3 KW - Aged Aged, 80 and over Blindness/ep [Epidemiology] *Blindness/et [Etiology] Cause of Death *Disability Evaluation Follow-Up Studies *Glaucoma, Open-Angle/co [Complications] Glaucoma, Open-Angle/ep [Epidemiology] Humans Incidence Intraocular Pressure Middle Aged Ocular Hypertension/co [Complications] Ocular Hypertension/ep [Epidemiology] Retrospective Studies Vision, Low/ep [Epidemiology] *Vision, Low/et [Etiology] Visual Acuity PY - 2007 SE - Forsman, Eva. Population Genetics Unit, Folkhalsan Institute of Genetics, University of Helsinki, Helsinki, Finland. eforsman@elisanet.fi SN - 1057-0829 SP - 313-9 ST - Lifetime visual disability in open-angle glaucoma and ocular hypertension T2 - Journal of glaucoma TI - Lifetime visual disability in open-angle glaucoma and ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17438426 VL - 16 ID - 1607 ER - TY - JOUR AB - Aim: In April 2017 the Italian Medicine Agency (AIFA) developed new criteria to grant any new medicinal product with an innovative designation. The aim of this study is to describe this new model and how it works. Methods: A retrospective descriptive analysis was performed on the results of the assessment process of innovativeness of new medicinal products (or therapeutic indications) based on the AIFA's new innovation criteria (therapeutic need, added therapeutic value and quality of clinical evidence through GRADE methodology) carried out between April 2017 and February 2019 and made publicly available on the AIFA website starting from January 2018. Results: A total of 37 full reports (22 for oncological indications) explaining the rationale for the AIFA's decision is made publicly available on the agency's website. A total of 12 therapeutic indications (5 oncological) were evaluated as fully innovative, 13 indications (11 oncological) were evaluated as conditionally innovative, while 12 indications (6 oncological) as non-innovative. Conclusion: The new AIFA innovation criteria resulted in a much more flexible and transparent model to define and assess what constitutes a therapeutic innovation. In particular, the choice of AIFA to use the GRADE methodology to evaluate the quality of clinical evidence within a process of drug innovativeness assessment is essential for the early identification of the discrepancy between the need for patients of a rapid access to innovative therapies and the available clinical data needed to make decisions on drug innovativeness. AD - F. Fortinguerra, Italian Medicines Agency (AIFA), Rome, Italy AU - Fortinguerra, F. AU - Tafuri, G. AU - Trotta, F. AU - Addis, A. C1 - alecensa(Hoffmann La Roche) bavencio(Merck Serono) besponsa(Pfizer) darzalex(Janssen Cilag) dupixent(Sanofi Aventis) hemlibra(Hoffmann La Roche) humira(AbbVie) ibrance(Pfizer) ilaris(Novartis) imbruvica(Janssen Cilag) kisquali(Novartis) maviret(AbbVie) ocaliva(Intercept) olumiant(Lilly) opdivo(Bristol Myers Squibb) oxervate(Dompe) prevymis(Merck Sharp and Dohme) qarziba(EUSA) revlimid(Celgene) rydapt(Novartis) spinraza(Biogen Idec) stivarga(Bayer) tecentriq(Hoffmann La Roche) vosevi(Gilead) xermelo(Ipsen) zavicefta(Pfizer) zejula(Tesaro) zinplava(Merck Sharp and Dohme) C2 - AbbVie Bayer Biogen Idec Bristol Myers Squibb Celgene Dompe EUSA Gilead Hoffmann La Roche Intercept Ipsen Janssen Cilag Lilly Merck Serono Merck Sharp and Dohme Novartis Pfizer Sanofi Aventis Tesaro DB - Embase Medline DO - 10.1111/bcp.14138 IS - 1 KW - adalimumab alectinib atezolizumab avelumab avibactam plus ceftazidime baricitinib bezlotoxumab canakinumab cenegermin daratumumab dinutuximab dupilumab emicizumab glecaprevir plus pibrentasvir ibrutinib inotuzumab ozogamicin kisquali lenalidomide letermovir midostaurin new drug niraparib nivolumab nusinersen obeticholic acid ocrelizumab palbociclib regorafenib ribociclib sofosbuvir plus velpatasvir plus voxilaprevir telotristat ethyl abdominal infection acute lymphoblastic leukemia acute myeloid leukemia adult advanced cancer article atopic dermatitis bleeding carcinoid syndrome chronic hepatitis C chronic lymphatic leukemia Clostridium difficile infection cornea ulcer cytomegalovirus infection decision making descriptive research diarrhea drug indication drug industry experimental therapy familial Mediterranean fever GRADE approach Gram negative infection head and neck squamous cell carcinoma health care access hospital acquired pneumonia human human epidermal growth factor receptor 2 negative breast cancer hyperimmunoglobulinemia D and periodic fever syndrome infection prevention iridocyclitis Italy liver cell carcinoma mast cell leukemia merkel cell carcinoma metastasis metastatic breast cancer monotherapy multiple myeloma multiple sclerosis neuroblastoma neurotrophic keratopathy non small cell lung cancer ovary carcinoma peritoneum cancer primary biliary cirrhosis primary tumor priority journal prophylaxis pyelonephritis recurrent disease recurrent infection refractory multiple myeloma retrospective study rheumatoid arthritis spinal muscular atrophy systemic mastocytosis tumor necrosis factor receptor associated periodic syndrome urinary tract infection uterine tube carcinoma ventilator associated pneumonia alecensa bavencio besponsa darzalex dupixent hemlibra humira ibrance ilaris imbruvica maviret ocaliva olumiant opdivo oxervate prevymis qarziba revlimid rydapt spinraza stivarga tecentriq vosevi xermelo zavicefta zejula zinplava LA - English M3 - Article N1 - L2003728958 2019-12-05 2020-02-11 PY - 2020 SN - 1365-2125 0306-5251 SP - 93-105 ST - Using GRADE methodology to assess innovation of new medicinal products in Italy T2 - British Journal of Clinical Pharmacology TI - Using GRADE methodology to assess innovation of new medicinal products in Italy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003728958&from=export http://dx.doi.org/10.1111/bcp.14138 VL - 86 ID - 2437 ER - TY - JOUR AD - A. Foster, International Centre for Eye Health, Institute of Ophthalmology, London, United Kingdom AU - Foster, A. AU - Johnson, G. G. DB - Embase Medline IS - 11 KW - Africa blindness chemical injury cornea disease cornea ulcer drug therapy editorial eye disease eye infection eye injury health care access hemorrhagic conjunctivitis herbal medicine human Malawi patient satisfaction priority journal traditional medicine Zimbabwe LA - English M3 - Editorial N1 - L24345939 1994-11-30 PY - 1994 SN - 0007-1161 SP - 807 ST - Traditional eye medicines - Good or bad news? T2 - British Journal of Ophthalmology TI - Traditional eye medicines - Good or bad news? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L24345939&from=export VL - 78 ID - 3991 ER - TY - JOUR AD - P. Foster, Institute of Ophthalmology, University College London, London, United Kingdom AU - Foster, P. DB - Embase IS - 2 KW - anterior eye chamber depth blindness closed angle glaucoma conference paper cost of illness disease course early diagnosis evidence based medicine health care access health care cost human medical examination morbidity primary prevention quality control risk benefit analysis risk factor risk reduction screening LA - English M3 - Conference Paper N1 - L40959748 2005-08-02 PY - 2005 SN - 1560-2133 SP - 62 ST - Preventing blindness from angle closure glaucoma T2 - Asian Journal of Ophthalmology TI - Preventing blindness from angle closure glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40959748&from=export VL - 7 ID - 3674 ER - TY - JOUR AB - PURPOSE: To summarize the present status of safety and efficacy of contact lens wear., DESIGN: Literature review., METHODS: Ovid Medline searches were performed on records from 1966 through 2005 using keywords: keratitis, contact lens complications, extended-wear contact lenses, and silicone-hydrogel contact lenses., RESULTS: Patients desire comfort, clarity of vision, and prolonged contact lens wear when contact lenses are used to correct refractive error. Practitioners desire patient satisfaction but also require maintenance of the integrity of the eye and no complications that jeopardize vision or health of the eye. Improvements in the oxygen permeability of the contact lens materials, design of the contact lens and its surface, and solutions for the maintenance of the lens have reduced but not eliminated the risks of infection, inflammation, and conjunctival papillary reaction associated with contact lens wear. The lessons of past and recent history suggest that patient education and practitioner participation in the management of contact lens wear continue to be critical factors for patient satisfaction and safety in the extended wear of contact lenses., CONCLUSIONS: The availability of highly oxygen permeable contact lenses has increased the tolerance and safety of extended contact lens wear, but patient instruction and education in proper use and care of lenses is required and caution is advised. AU - Foulks, Gary N. IS - 2 KW - Contact Lenses/ae [Adverse Effects] *Contact Lenses/sn [Statistics & Numerical Data] Contact Lenses, Extended-Wear/ae [Adverse Effects] Contact Lenses, Extended-Wear/sn [Statistics & Numerical Data] Equipment Safety Humans Oxygen/me [Metabolism] Patient Satisfaction Permeability *Refractive Errors/th [Therapy] PY - 2006 SE - Foulks, Gary N. University of Louisville, School of Medicine, Louisville, Kentucky 40202, USA. gnfoul01@louisville.edu SN - 0002-9394 SP - 369-373 ST - Prolonging contact lens wear and making contact lens wear safer T2 - American journal of ophthalmology TI - Prolonging contact lens wear and making contact lens wear safer UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16458698 VL - 141 ID - 1682 ER - TY - JOUR AB - BACKGROUND: A patient's perception of how their glaucoma is managed will influence both adherence to their medication and outcome measures such as quality of life., METHODS: Prospective consecutive study using a Glaucoma Patient-reported Outcome and Experience Measure (POEM) modified for an Australian ophthalmic private clinical practice setting. The Australian Glaucoma POEM consists of eight items related to the patient's understanding of the diagnosis and management, acceptability of the treatment, whether they feel their glaucoma is getting worse, interfering with their daily life and concerns regarding loss of vision as well as addressing whether they feel safe under the care of their glaucoma team and how well their care is organised., RESULTS: Two hundred and two patients (M:F 91:111) participated in the study. Mean +/- standard deviation for subject age was 69 +/- 13 years. Patient's overall perception of their treatment and outcome was favourable. Younger patients felt their glaucoma interfered more with their daily lives and were more worried about losing vision from glaucoma. The greater the number of medications in use, the more they felt their glaucoma was getting worse and that glaucoma interfered with their daily lives. With all other variables accounted for by the multivariate linear model, female patients more strongly agreed that they understood their glaucoma diagnosis and glaucoma management. The patients with a severe visual defect in their worse eye, reported a greater perceived understanding of their glaucoma diagnosis and management and that they felt that glaucoma had a greater interference on their daily life. They were also more concerned about losing vision from glaucoma than their fellow glaucoma patients with less severe or no visual field deficit in the worse eye., CONCLUSIONS: The modified POEM demonstrates potential to capture the concerns of a practice's glaucoma cohort with a view to enhancing the quality of glaucoma care delivered. AU - Fraenkel, Alison AU - Lee, Graham A. AU - Vincent, Stephen J. AU - Vincent, Roslyn A. AU - Bourne, Rupert R. A. AU - Shah, Peter DO - https://dx.doi.org/10.1186/s12886-019-1198-7 IS - 1 KW - Activities of Daily Living Adult Aged Aged, 80 and over Cross-Sectional Studies Female Glaucoma/ep [Epidemiology] Glaucoma/pp [Physiopathology] *Glaucoma/th [Therapy] Humans *Intraocular Pressure/ph [Physiology] Male Middle Aged Morbidity/td [Trends] *Patient Reported Outcome Measures Prospective Studies *Quality of Health Care Quality of Life Queensland/ep [Epidemiology] Surveys and Questionnaires *Visual Acuity *Visual Fields/ph [Physiology] Young Adult PY - 2019 SE - Fraenkel, Alison. City Eye Centre, 10/135 Wickham Terrace, Brisbane, Queensland, 4000, Australia. Lee, Graham A. City Eye Centre, 10/135 Wickham Terrace, Brisbane, Queensland, 4000, Australia. eye@cityeye.com.au. Lee, Graham A. University of Queensland, Brisbane, Queensland, Australia. eye@cityeye.com.au. Vincent, Stephen J. Queensland University of Technology, Brisbane, Australia. Vincent, Roslyn A. City Eye Centre, 10/135 Wickham Terrace, Brisbane, Queensland, 4000, Australia. Bourne, Rupert R A. Cambridge University Hospitals, Cambridge, UK. Shah, Peter. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Shah, Peter. Institute of Ophthalmology, University College London, London, UK. Shah, Peter. Centre for Health & Social Care Improvement, University of Wolverhampton, Wolverhampton, UK. SN - 1471-2415 SP - 192 ST - Lessons learned from the development and implementation of a patient-reported outcome and experience measure (POEM) in an Australian glaucoma practice T2 - BMC ophthalmology TI - Lessons learned from the development and implementation of a patient-reported outcome and experience measure (POEM) in an Australian glaucoma practice UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med16&NEWS=N&AN=31438884 VL - 19 Y2 - 20190822// ID - 317 ER - TY - JOUR AU - Francis, Brian A. AU - Winarko, Jonathan DO - https://dx.doi.org/10.1097/IIO.0b013e31821e53c8 IS - 3 KW - Antihypertensive Agents/tu [Therapeutic Use] Circadian Rhythm Glaucoma/cl [Classification] Glaucoma/su [Surgery] Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] Humans Intraocular Pressure Laser Therapy/ae [Adverse Effects] *Laser Therapy/mt [Methods] *Laser Therapy/td [Trends] Models, Biological Patient Compliance Postoperative Care Retreatment Risk Assessment Trabeculectomy/ae [Adverse Effects] *Trabeculectomy/mt [Methods] *Trabeculectomy/td [Trends] Treatment Outcome PY - 2011 SN - 1536-9617 0020-8167 SP - 165-77 ST - Laser trabeculoplasty in the treatment of open-angle glaucoma T2 - International ophthalmology clinics TI - Laser trabeculoplasty in the treatment of open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21633246 VL - 51 ID - 1268 ER - TY - JOUR AB - Glycerol is a potent osmotic dehydrating agent with additional effects on brain metabolism. In doses of 0.25-2.0 g/kg glycerol decreases intracranial pressure in numerous disease states, including Reye's syndrome, stroke, encephalitis, meningitis, pseudotumor cerebri, central nervous system tumor, and space occupying lesions. It is also effective in lowering intraocular pressure in glaucoma and shrinking the brain during neurosurgical procedures. Hyperosmolality with rebound cerebral overhydration is of concern, especially in patients with altered blood brain barriers. They may be avoided if glycerol is administered on an intermittent rather than a continuous basis. Intravascular hemolysis does not occur with oral use. When administered intravenously, hemolysis can be minimized by using glycerol 10% in dextrose 5% with normal saline at rates of 6 mg/kg/min or less. However, intravenous doses of 1-2 g/kg every 2 hr can be administered safely in severe cases of elevated ICP. In such patients, glycerol serum concentration, serum osmolality and ICP monitoring are required to optimize glycerol therapy. AU - Frank, M. S. AU - Nahata, M. C. AU - Hilty, M. D. IS - 2 KW - Animals Brain Injuries/dt [Drug Therapy] Brain Neoplasms/dt [Drug Therapy] Cerebrovascular Disorders/dt [Drug Therapy] Dehydration/ci [Chemically Induced] Encephalitis/dt [Drug Therapy] Glycerol/ae [Adverse Effects] Glycerol/me [Metabolism] Glycerol/pd [Pharmacology] *Glycerol/tu [Therapeutic Use] Humans Kinetics Meningitis/dt [Drug Therapy] Pseudotumor Cerebri/dt [Drug Therapy] Reye Syndrome/dt [Drug Therapy] Water-Electrolyte Balance/de [Drug Effects] PY - 1981 SN - 0277-0008 SP - 147-60 ST - Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use T2 - Pharmacotherapy TI - Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=6927604 VL - 1 ID - 2259 ER - TY - JOUR AB - Background: Optic nerve hypoplasia (ONH) is a developmental disorder in which the optic nerve is small and/or there are fewer than normal nerve fibers present. Visual acuity (VA) loss from ONH ranges from none to severe, depending on the extent of macular nerve fiber loss. It is common for patients with decreased vision from unilateral ONH to develop ipsilateral amblyopia secondary to constant unilateral strabismus or high refractive error. We report a case of unilateral ONH and relative amblyopia associated with anisometropia that is less than the expected amblyogenic amount. Case Report: A developmentally appropriate 5-year-old Hispanic female, without complaints or previous spectacle wear, presented for a comprehensive eye examination. Best-corrected distance VA through cycloplegic prescription of OD +0.50-1.00x180, OS -2.50-0.50x180 was OD 20/25, OS 20/100 (HOTV with matching). She was orthophoric at distance and near and showed no response to stereopsis testing. Color vision and pupils were normal. Fundus examination revealed ONH OS. Disc-macula to disc diameter ratio was larger OS. Disc area (Heidelberg Retina Tomograph 3) was noticeably smaller OS. VA improved to 20/40 OS after four months of treatment and has remained stable since then. Stereopsis testing after treatment showed a positive response to random dot forms. Conclusion: Our patient had ONH OS with less than the expected amblyogenic amount of anisometropia. However, VA in the ONH eye improved four logMAR lines with treatment. We conclude that reduced VA from ONH and secondary anisometropia likely led to suppression and relative amblyopia development. We suggest that eye care practitioners attempt patching for selected unilateral ONH patients even if an expected amblyogenic factor is not present. Treatment should be attempted only if the patient’s acuity is adequate for patient compliance. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Frantz, Kelly A. AN - 2015-06874-005 AU - Frantz, Kelly A. AU - Pang, Yi DB - psyh DP - EBSCOhost IS - 6 KW - amblyopia anisometropia occlusion optic nerve hypoplasia Eye Disorders Optic Nerve Treatment Vision Disorders Visual Acuity N1 - Illinois College of Optometry, Chicago, IL, US. Release Date: 20150525. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishConference Information: Annual Meeting of the American Academy of Optometry, Nov, 2010, San Francisco, CA, US. Conference Note: This article was presented, in part, as a poster at the aforementioned conference. Major Descriptor: Amblyopia; Eye Disorders; Optic Nerve; Treatment; Vision Disorders. Minor Descriptor: Visual Acuity. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Female (40). Age Group: Childhood (birth-12 yrs) (100); Preschool Age (2-5 yrs) (160). Methodology: Clinical Case Study. References Available: Y. Page Count: 5. Issue Publication Date: Dec, 2014. Copyright Statement: Optometric Extension Program Foundation. 2014. Sponsor: Illinois Society for the Prevention of Blindness, US. Recipients: No recipient indicated PY - 2014 SN - 2325-3479 2325-3487 SP - 297-301 ST - Relative amblyopia secondary to anisometropia in a patient with ipsilateral optic nerve hypoplasia T2 - Optometry & Visual Performance TI - Relative amblyopia secondary to anisometropia in a patient with ipsilateral optic nerve hypoplasia UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-06874-005&site=ehost-live&scope=site atkfrantz@ico.edu VL - 2 ID - 4856 ER - TY - JOUR AB - BACKGROUND: Children and patients with developmental delay frequently resist the procedure of tonometry. Intraocular pressure (IOP) readings, if obtained under stressful circumstances, may have questionable reliability because IOP is influenced by numerous factors characteristic of the uncooperative patient. These factors include possible increases in arterial blood pressure, intraocular vascular engorgement, and pressure on the globe. A study of the effect upon IOP of these factors occurring simultaneously has not been reported previously., METHODS: We measured IOP using the Tono-Pen on 40 cooperative adults under normal conditions and again under conditions simulating the resistant patient., RESULTS: Paired t-test revealed a statistically significant difference between IOP readings under the two conditions (p < 0.001), with IOP under "resistant" conditions showing more variability and averaging 6mmHg higher than under normal conditions., CONCLUSIONS: We conclude that IOP readings in resistant patients should be viewed with caution. The possibility of obtaining false high readings in these patients could lead to unnecessary glaucoma evaluations if based only on elevated IOP readings. AU - Frantz, K. A. AU - Peters, R. J. AU - Maino, D. M. AU - Gunderson, G. G. IS - 10 KW - Adult Female Humans *Intraocular Pressure/ph [Physiology] Male *Patient Compliance Reproducibility of Results Tonometry, Ocular/st [Standards] *Tonometry, Ocular Valsalva Maneuver PY - 1994 SE - Frantz, K A. Illinois College of Optometry, Chicago 60616. SN - 0003-0244 SP - 732-6 ST - Effect of resisting tonometry on intraocular pressure T2 - Journal of the American Optometric Association TI - Effect of resisting tonometry on intraocular pressure UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7995897 VL - 65 ID - 2083 ER - TY - JOUR AB - Objective In order to better understand the barriers that limit the social participation of older people with low vision, the aim of this study was to describe and clarify the factors that shape the social participation of older adults with vision loss. Methods As part of a study on rehabilitation access barriers, six qualitative focus groups were conducted in a private room in a hospital, with 21 individuals with low vision (aged 38-92 years) who had or had not accessed low vision services. During the focus groups, participants often spoke of the challenges they faced when interacting with people with 'normal' vision; this discussion led to a modification of the interview guide in order to capture barriers to social participation. Focus group discussions were audiotaped and transcribed, and content analysis was conducted. Results Content analysis revealed that personal as well as environmental factors influenced the social participation of older adults with low vision. Four themes emerged: 1) experiencing the onset of impairment and degenerating ability, 2) the physical environment, 3) attitudes and responses from others and 4) individual internal attitude and responses during social interactions. Lived and perceived stigma from the perspective of the insider (person living with low vision) interacting with an outsider (person with 'normal' vision) and difficult environmental contexts were described as barriers to social participation and optimal functioning. Conclusion At a personal level, transitioning from an outsider to an insider influenced self-identity and social participation. Further, insiders experiencing stereotypes associated with older adults who are blind had a negative impact on their social participation. Findings highlight the importance of stigma and stereotyping in the lived experience of older adults with low vision. Stigma is persistent, but strategies to reduce stigma will ultimately facilitate the social participation of older adults with low vision. AD - S. Fraser, Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada AU - Fraser, S. AU - Beeman, I. AU - Southall, K. AU - Wittich, W. DB - Embase Medline DO - 10.1136/bmjopen-2019-029940 IS - 9 KW - age related macular degeneration aged aging article clinical article content analysis daily life activity diabetic retinopathy emotion environmental factor female frustration functional status glaucoma health care access helplessness hopelessness human interpersonal communication locus of control low vision male patient attitude qualitative research rehabilitation care rehabilitation center retina detachment retinitis pigmentosa social interaction social participation social stigma stereotyping support group LA - English M3 - Article N1 - L629195250 2019-09-20 PY - 2019 SN - 2044-6055 ST - Stereotyping as a barrier to the social participation of older adults with low vision: A qualitative focus group study T2 - BMJ Open TI - Stereotyping as a barrier to the social participation of older adults with low vision: A qualitative focus group study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629195250&from=export http://dx.doi.org/10.1136/bmjopen-2019-029940 VL - 9 ID - 2488 ER - TY - JOUR AB - OBJECTIVE: To identify socioeconomic risk factors for first presentation advanced glaucomatous visual field loss., DESIGN: Hospital based case-control study with prospective identification of patients., SETTING: Three hospital eye departments., PARTICIPANTS: Consecutive patients newly diagnosed with glaucoma (n=220). Cases (late presenters) were those presenting with advanced glaucoma (n=110), controls were those with early glaucoma (n=110)., RESULTS: Median underprivileged area scores were higher among late presenters (29.5; interquartile range 9.0-42.2) than in the control group (21.3; 6.1-37.4) (P=0.035). Late presenters were more likely to be of lower occupational class (odds ratio adjusted for age and referral centre 20.1 (95% confidence interval 2.6 to 155) for group III compared with group I-II and 86.0 (11.0 to 673 for group IV-V compared with group I-II), to have no access to a car (2.2; 1.2 to 4.0), to have left full time education at age 14 or less (7.5; 2.3 to 24.7), and to be tenants rather than owner occupiers (local authority tenants 3.2; 1.7 to 5.8, private tenants 2.1; 0.7 to 5.8). Effects of deprivation were partly accounted for by family history of glaucoma, time since last visit to an optometrist, and lack of an initial diagnosis of glaucoma by an optometrist., CONCLUSIONS: Area and individual level deprivation were both associated with late presentation of glaucoma. Existing evidence shows that late presentation is an important risk factor for subsequent blindness. Deprived groups thus seem to be at greater risk of going blind from glaucoma. Material deprivation may be associated with more aggressive disease as well as later presentation. AU - Fraser, S. AU - Bunce, C. AU - Wormald, R. AU - Brunner, E. IS - 7287 KW - Adult Aged Aged, 80 and over Case-Control Studies England/ep [Epidemiology] Female Glaucoma/di [Diagnosis] *Glaucoma/ep [Epidemiology] Glaucoma/pa [Pathology] Humans Male Middle Aged Odds Ratio *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] *Poverty Prospective Studies Risk Factors Socioeconomic Factors Time Factors N1 - Comment in (CIN) PY - 2001 SE - Fraser, S. Glaxo Department of Ophthalmic Epidemiology, Institute of Ophthalmology, University College London, London EC1V 2PD, UK. SN - 0959-8138 SP - 639-43 ST - Deprivation and late presentation of glaucoma: case-control study T2 - BMJ (Clinical research ed.) T3 - Comment in: BMJ. 2001 Jul 7;323(7303):47; PMID: 11464819 [https://www.ncbi.nlm.nih.gov/pubmed/11464819] TI - Deprivation and late presentation of glaucoma: case-control study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11250847 VL - 322 ID - 1927 ER - TY - JOUR AB - Primary open-angle glaucoma (POAG) is a chronic optic neuropathy causing irreversible nerve fiber damage. Initially asymptomatic, it progresses slowly without any notable sign of vision loss, thus early detection and treatment is essential. The standard treatment being non-invasive topical administration of eye drops harbors the problem of patients not being adherent. This study aimed to explore the experiences and thoughts of glaucoma patients about their medication management to improve our knowledge on how adherence works for the individual patient. Narrative interviews were conducted with 21 glaucoma patients. Data were analyzed using inductive content analysis and the documentary method. Different patterns of adherence were identified which depended on personal biographies, living conditions, or the patient's knowledge about the disease. Interpreting eye drop medication as a ritual, a task, or routine was helpful for some patients, whereas other patients, who were aware of the consequences of not taking the drops, were motivated by intrinsic or extrinsic factors. The patterns identified here represent strategies for managing and adhering to daily glaucoma medication at an individual level. Linking daily drop application or medication intake to these patterns may help to promote correct medication management of patients with chronic diseases who lack a regular medication regimen. AU - Frech, Stefanie AU - Guthoff, Rudolf F. AU - Gamael, Amin AU - Helbig, Christian AU - Diener, Annette AU - Ritzke, Manuela AU - Wollny, Anja AU - Altiner, Attila DO - https://dx.doi.org/10.3390/healthcare9040426 IS - 4 PY - 2021 SE - Frech, Stefanie. Department of Ophthalmology, Rostock University Medical Center, Doberaner Str. 140, 18057 Rostock, Germany. Guthoff, Rudolf F. Department of Ophthalmology, Rostock University Medical Center, Doberaner Str. 140, 18057 Rostock, Germany. Gamael, Amin. Ophthalmic Care Unit, Rostock University Medical Center, Doberaner Str. 142, 18057 Rostock, Germany. Helbig, Christian. Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057 Rostock, Germany. Diener, Annette. Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057 Rostock, Germany. Ritzke, Manuela. Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057 Rostock, Germany. Wollny, Anja. Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057 Rostock, Germany. Altiner, Attila. Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057 Rostock, Germany. SN - 2227-9032 ST - Patterns and Facilitators for the Promotion of Glaucoma Medication Adherence-A Qualitative Study T2 - Healthcare (Basel, Switzerland) TI - Patterns and Facilitators for the Promotion of Glaucoma Medication Adherence-A Qualitative Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=33916976 VL - 9 Y2 - 20210407// ID - 100 ER - TY - JOUR AB - The goal of this study was to assess the adherence of primary open-angle glaucoma (POAG) patients to medication, and to determine co-factors influencing adherence, using a representative sample of members of the largest German public health insurer. The observational cohort study was based on a longitudinal data set from 2010-2013 and included 250,000 insured persons aged 50 and older with 10,120 diagnosed POAG patients. Uni- and multivariate analysis was performed to investigate several aspects of glaucoma, such as prevalence, adherence, and co-factors influencing adherence. The main outcome measured adherence with prescriptions filled within a year. Multivariate panel regression analysis was used to determine the co-factors influencing this adherence. Prevalence of POAG was 3.36% [CI: 3.28-3.43%], with 2.91% [CI: 2.81-3.01%] for males and 3.71% [CI: 3.61-3.81%] for females, increasing with age. The mean level of adherence in terms of prescriptions filled was 66.5% [CI: 65.50-67.60%]. The results of this analysis revealed a significant influence of age, duration of the disease, care need, distance to death, and multimorbidity as co-factors of non-adherence, whereas gender had no influence. The analysis provided detailed information about POAG health care aspects concerning prevalence and adherence. The most endangered risk groups for non-adherence were patients aged 50-59, patients older than 80 years, patients with a longer duration of POAG, patients with care needs, and patients with three or more severe diseases in addition to glaucoma. To know the predictors responsible for an increased risk to develop POAG is of importance for all persons involved in health care management. Therefore effective strategies to increase awareness of patients and medical care personnel about non-adherence and the importance of a regular and continuous medication to avoid further nerve fiber damage and possible blindness have to be developed. AU - Frech, Stefanie AU - Kreft, Daniel AU - Guthoff, Rudolf F. AU - Doblhammer, Gabriele DO - https://dx.doi.org/10.1371/journal.pone.0191185 IS - 1 KW - Aged Aged, 80 and over Cohort Studies Comorbidity Female Germany/ep [Epidemiology] *Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/ep [Epidemiology] Humans Male *Medication Adherence Middle Aged Multivariate Analysis Pharmacoepidemiology Prevalence Risk Factors N1 - Erratum in (EIN) PY - 2018 SE - Frech, Stefanie. Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany. Kreft, Daniel. Institute for Sociology and Demography, University of Rostock, Rostock, Germany. Kreft, Daniel. Rostock Center for the Study of Demographic Change, Rostock, Germany. Guthoff, Rudolf F. Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany. Doblhammer, Gabriele. Institute for Sociology and Demography, University of Rostock, Rostock, Germany. Doblhammer, Gabriele. Rostock Center for the Study of Demographic Change, Rostock, Germany. Doblhammer, Gabriele. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. SN - 1932-6203 SP - e0191185 ST - Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients-An observational cohort study T2 - PloS one T3 - Erratum in: PLoS One. 2018 Feb 23;13(2):e0193621; PMID: 29474468 [https://www.ncbi.nlm.nih.gov/pubmed/29474468] TI - Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients-An observational cohort study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&NEWS=N&AN=29329338 VL - 13 Y2 - 20180112// ID - 461 ER - TY - JOUR AB - SIGNIFICANCE: We propose an alternative method for eye drop self-administration. Similar IOP reductions were found with this method compared with clinician instillation. The alternative method of self-administration potentially benefits patients who have trouble successfully instilling drops., PURPOSE: The purpose of this study was to validate the efficacy of an alternative method of drop instillation., METHODS: This study is a randomized controlled crossover clinical trial. Thirty participants were recruited. A drop of 0.5% timolol maleate was instilled into subject's eye on two separate visits. On one visit, eye drop instillation was by a trained clinician, and on the other, self-instillation using an alternative method was used. The order was randomly chosen. Intraocular pressure was measured before drop instillation and 2 hours after drop instillation. The investigator was masked during measurement, and an observer recorded the IOP measurements., RESULTS: Mean +/- SD IOP measurement before 0.5% timolol maleate instillation measured 13.89 +/- 2.29 mmHg. An average reduction 3.75 +/- 2.36 mmHg was found with clinician administration, and an average reduction of 3.32 +/- 2.31 mmHg was recorded with the new method. No significance was found in IOP reduction between two groups P < .45. Percent reduction was 25.17 +/- 16.21% and 24.38 +/- 16.31% in clinician instillation and alternative instillation method group, respectively. No significant difference was found. This percentage reduction was similar to previously reported studies. No reported cases of eye infection or irritation were found in any case, within a 3-month follow-up period., CONCLUSIONS: We have proposed a more reliable method for instillation that provides a larger area for instillation and lessen the risk of contamination and patient's fear for eye drops. Similar efficacy was found compared with that of having a clinician directly administer the drop. This alternative method could potentially benefit patients who require topical eye drop therapy and result in increased compliance. AU - Freddo, Thomas F. AU - Ho, Derek Y. AU - Steenbakkers, Michelle AU - Furtado, Nadine DO - https://dx.doi.org/10.1097/OPX.0000000000001535 IS - 7 KW - *Administration, Ophthalmic Adult *Antihypertensive Agents/ad [Administration & Dosage] Cross-Over Studies Double-Blind Method Female Humans *Intraocular Pressure/de [Drug Effects] Male Middle Aged *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions/ad [Administration & Dosage] Reproducibility of Results Self Administration *Timolol/ad [Administration & Dosage] Tonometry, Ocular Young Adult PY - 2020 SE - Steenbakkers, Michelle. School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, Canada. Furtado, Nadine. School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, Canada. SN - 1538-9235 1040-5488 SP - 496-502 ST - Validation of a More Reliable Method of Eye Drop Self-Administration T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Validation of a More Reliable Method of Eye Drop Self-Administration UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32697556 VL - 97 ID - 195 ER - TY - JOUR AB - Peripheral iridectomy in trabeculectomy surgery should be larger than the scleral opening to prevent adherence of iris to the edges of the scleral opening. A method for the fashioning of such an iridectomy is described. AU - Freedman, J. IS - 2 KW - *Glaucoma/su [Surgery] Humans *Iris/su [Surgery] Scleral Buckling *Trabecular Meshwork/su [Surgery] PY - 1978 SN - 0022-023X SP - 45-7 ST - Iridectomy technique in trabeculectomy T2 - Ophthalmic surgery TI - Iridectomy technique in trabeculectomy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=263993 VL - 9 ID - 2273 ER - TY - JOUR AB - OBJECTIVE: To assess glaucoma medication adherence in children, hypothesizing that poor parental health literacy and eye drop instillation by the child are associated with worse adherence., METHODS: This prospective, observational study enrolled pediatric patients with glaucoma who were prescribed eye drops. Parent(s) reported who was responsible for eye drop instillation (parent vs child), took the Rapid Estimate of Adult Literacy in Medicine, and were instructed on the use and purpose of the Medication Event Monitoring System. Calculations included average adherence (proportion of prescribed doses taken), dosing errors (number of overdosing or underdosing events in 24 hours), and proportion of doses taken on schedule (doses taken within 2 hours of prescribed dosing interval). Results are reported as mean (SD) or median., RESULTS: The study included 46 of the 50 enrolled children who used the Medication Event Monitoring System for 30 days or more. Adherence ranged from 43% to 107% (93% [12%]) and was not associated with age (slope, 0.09 [0.52]; P = .86) but decreased with the parent's lower health literacy (slope, 0.62 [0.24]; P = .01). The mean number of dosing errors for medications prescribed daily vs twice daily was similar (3.3 vs 2.9; P = .66). The proportion of doses taken on schedule (within 2 hours of prescribed dosing interval) ranged from 3% to 97% (median, 34%; mean, 41% [24%]) and was better when the parent vs the child instilled eye drops (46% [26%] vs 23% [19%]; P < .001)., CONCLUSIONS: Time-dependent glaucoma medication adherence was better when the parent was responsible for eye drop instillation. Overall decreased adherence was associated with decreased parental health literacy. Children of parents with poor health literacy are vulnerable to poor medication adherence; efforts to address poor health literacy may improve outcomes. AU - Freedman, Rebecca B. AU - Jones, Sarah K. AU - Lin, Alice AU - Robin, Alan L. AU - Muir, Kelly W. DO - https://dx.doi.org/10.1001/archopthalmol.2011.1788 IS - 3 KW - Adolescent Adult Child Child, Preschool Drug Monitoring/sn [Statistics & Numerical Data] Female *Glaucoma/dt [Drug Therapy] *Health Literacy/sn [Statistics & Numerical Data] Health Surveys Humans Male *Medication Adherence/sn [Statistics & Numerical Data] Medication Errors/pc [Prevention & Control] Medication Errors/sn [Statistics & Numerical Data] *Ophthalmic Solutions/ad [Administration & Dosage] *Parents/ed [Education] Prospective Studies PY - 2012 SE - Freedman, Rebecca B. Duke Eye Center, Durham, North Carolina, USA. SN - 1538-3601 0003-9950 SP - 306-11 ST - Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence T2 - Archives of ophthalmology (Chicago, Ill. : 1960) TI - Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med9&NEWS=N&AN=22411659 VL - 130 ID - 1145 ER - TY - JOUR AB - Fifty-eight healthy, normolipidemic adult men participated in a prospective, masked, randomized crossover study designed to compare the effects of two topical nonselective β-adrenergic antagonists, carteolol and timolol, on plasma high-density lipoprotein cholesterol levels. Two eight- week treatment periods were separated by an eight-week drug-free period. Carteolol 1.0% or timolol 0.5% was used, one drop twice daily, in both eyes without nasolacrimal occlusion. Fresh plasma was assayed for levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and apolipoproteins A-I and B-100. With indistinguishable effects on intraocular pressure, carteolol and timolol induced different (P = .013) decrements in high-density lipoprotein cholesterol levels. Carteolol treatment decreased high-density lipoprotein cholesterol levels by 3.3% (-0.04 mmol/l) and raised the ratio of total to high-density lipoprotein cholesterol levels by 4.0% (0.15 unit); timolol treatment decreased high-density lipoprotein cholesterol levels by 8.0% (- 0.10 mmol/l) and raised the ratio of total to high-density lipoprotein cholesterol levels by 10.0% (0.37 unit). There was no differential drug effect on the other lipid variables measured. Ocular nonselective β- adrenergic antagonist therapy can produce clinically relevant decrements in high-density lipoprotein cholesterol levels in healthy men. AD - S.F. Freedman, Department of Ophthalmology, Clinical Sciences Bldg. No. 617, University of North Carolina, Chapel Hill, NC 27599, United States AU - Freedman, S. F. AU - Freedman, N. J. AU - Shields, M. B. AU - Lobaugh, B. AU - Samsa, G. P. AU - Keates, E. U. AU - Ollie, A. DB - Embase Medline DO - 10.1016/S0002-9394(14)73203-9 IS - 5 KW - apolipoprotein A1 apolipoprotein B100 carteolol cholesterol high density lipoprotein cholesterol low density lipoprotein cholesterol timolol triacylglycerol adult article cholesterol blood level controlled study crossover procedure drug efficacy drug mechanism glaucoma human human experiment lipoprotein blood level male normal human patient compliance priority journal statistical analysis topical drug administration triacylglycerol blood level LA - English M3 - Article N1 - L23337047 1993-11-30 PY - 1993 SN - 0002-9394 SP - 600-611 ST - Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level T2 - American Journal of Ophthalmology TI - Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level UR - https://www.embase.com/search/results?subaction=viewrecord&id=L23337047&from=export http://dx.doi.org/10.1016/S0002-9394(14)73203-9 VL - 116 ID - 4012 ER - TY - JOUR AB - Although eye drops are frequently used as an initial treatment option for open angle glaucoma (OAG), side effects, and poor adherence, among others, may compromise treatment efficacy. In this scenario, laser trabeculoplasty is an interesting therapeutic option for open angle glaucoma cases. Commonly used for many years as a last alternative prior to glaucoma incisional surgery, laser trabeculoplasty has been changing its indication after the advent of selective laser trabeculoplasty (SLT). In the current review, we critically evaluated the published data regarding the use of laser trabeculoplasty as a first treatment option for open angle glaucoma patients. Studies using SLT as a first-line treatment have encouraging findings. One-year efficacy results are comparable to those obtained with prostaglandin analogues, with a good safety profile. Although the laser's effect is known to be transitory, recent data suggest it can be successfully repeated in cases with good response to the first SLT treatment. AU - Freitas, Ana Lucia AU - Ushida, Michele AU - Almeida, Izabela AU - Dias, Diego T. AU - Dorairaj, Syril AU - Kanadani, Fabio Nishimura AU - Prata, Tiago Santos DO - https://dx.doi.org/10.5935/0004-2749.20160118 IS - 6 KW - *Elective Surgical Procedures *Glaucoma, Open-Angle/su [Surgery] Humans *Laser Therapy/mt [Methods] Randomized Controlled Trials as Topic *Trabeculectomy/mt [Methods] Treatment Outcome PY - 2016 SE - Freitas, Ana Lucia. Department of Ophthalmology, Hospital Universitario de Ciencias Medicas, Belo Horizonte, MG, Brazil. Ushida, Michele. Glaucoma Unit, Hospital Medicina dos Olhos, Osasco, SP, Brazil. Almeida, Izabela. Glaucoma Unit, Hospital Medicina dos Olhos, Osasco, SP, Brazil. Dias, Diego T. Glaucoma Unit, Hospital Medicina dos Olhos, Osasco, SP, Brazil. Dorairaj, Syril. Glaucoma Unit, Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA. Kanadani, Fabio Nishimura. Department of Ophthalmology, Hospital Universitario de Ciencias Medicas, Belo Horizonte, MG, Brazil. Prata, Tiago Santos. Glaucoma Unit, Hospital Medicina dos Olhos, Osasco, SP, Brazil. Prata, Tiago Santos. Glaucoma Service, Department of Ophthalmology and Visual Science, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, SP, Brazil. Prata, Tiago Santos. Glaucoma Service, Department of Ophthalmology, Hospital Oftalmologico de Sorocaba, Sorocaba, SP, Brazil. SN - 1678-2925 0004-2749 SP - 417-421 ST - Selective laser trabeculoplasty as an initial treatment option for open-angle glaucoma T2 - Arquivos brasileiros de oftalmologia TI - Selective laser trabeculoplasty as an initial treatment option for open-angle glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=28076575 VL - 79 ID - 649 ER - TY - JOUR AB - Objectives: To describe patterns of care for primary open-angle glaucoma (POAG) and assess conformance with the American Academy of Ophthalmology's Preferred Practice Pattern (PPP). Methods: We obtained administrative, survey, and eye care records data on 395 working-age patients with POAG enrolled in 6 managed care plans between 1997 and 1999. We assessed processes of care at the initial and follow-up visits, control of intraocular pressure (IOP), intervals between visits and visual field tests, and adjustments in therapy. Results: We found high rates of performance on most recommended processes during initial evaluations, although only 53% of patients received an optic nerve head photograph or drawing and only 1% had a target IOP level documented. Recommended processes were performed at 80% to 97% of follow-up visits. Using loose criteria for control, IOP was controlled in 66% of follow-up visits for patients with mild glaucoma and 52% of visits for patients with moderate to severe glaucoma. Intervals between visits and visual field tests were generally consistent with PPP recommendations. Adjustments in therapy were more likely with worse control of IOP, although adjustments occurred in only half of visits where the IOP was 30 mm Hg or higher. Conclusions: Our study suggests that, in many respects, patients with POAG are receiving care that is consistent with the PPP. However, care is falling short on several key aspects, and POAG may be undertreated relative to standards for IOP control established in recent clinical trials. AD - RAND Health Program, Santa Monica, CA, United States Ctr. for Hlth. Care Plcy./Evaluation, United Health Care, Minneapolis, MI, United States Department of Ophthalmology, Duke University Eye Center, Durham, NC, United States Department of Medicine, David Geffen School of Medicine, Univ. of California, Los Angeles, Los Angeles, CA, United States RAND Health Program, 1700 Main St, Santa Monica, CA 90407-2138, United States AU - Fremont, A. M. AU - Lee, P. P. AU - Mangione, C. M. AU - Kapur, K. AU - Adams, J. L. AU - Wickstrom, S. L. AU - Escarce, J. J. DB - Scopus DO - 10.1001/archopht.121.6.777 IS - 6 M3 - Article N1 - Cited By :88 Export Date: 19 July 2021 PY - 2003 SP - 777-783 ST - Patterns of care for open-angle glaucoma in managed care T2 - Archives of Ophthalmology TI - Patterns of care for open-angle glaucoma in managed care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038348797&doi=10.1001%2farchopht.121.6.777&partnerID=40&md5=86e81873e9efaa7cd548d6e12c982e2a VL - 121 ID - 4939 ER - TY - JOUR AB - PURPOSE: To evaluate the effects at 1 year of preservative-free timolol gel and preserved timolol eye drops on conjunctiva and tear parameters., METHODS: Forty patients with primary open-angle glaucoma or ocular hypertension were randomized to the two treatment groups and compared with 20 healthy age-matched controls. Clinical tests (IOP, Schirmer I test, and lacrimal film break-up time BUT) and in vivo conjunctival confocal microscopy (IVCM) were performed in all patients at baseline and after 12 months. IVCM (HRT II Rostock Cornea Module; Heidelberg Engineering GmbH, Heidelberg, Germany) was performed after topical anaesthesia in the four cardinal locations and at the corresponding limbus to analyse conjunctiva cells. The main IVCM outcomes were goblet cell density and epithelial regularity., RESULTS: IVCM and clinical parameters were similar in the three groups at baseline. After 12 months, intra-epithelial goblet cell density was significantly lower in the preserved (48.25 +/- 7.70) than in the preservative-free beta-blocker group (86.83 +/- 22.17, p < 0.001) and controls (88.9 +/- 18.33, p < 0.001). The epithelial layer was significantly more regular in the preserved beta-blocker medication group than in the preservative-free beta-blocker group (p < 0.001) and the control group (p < 0.001). A significant reduction in both Schirmer I and BUT was found in the group of preserved timolol (respectively, 11.3 +/- 2.97 and 8.12 +/- 0.99) compared with preservative-free timolol (16.8 +/- 1.83 and 11.27 +/- 1.27, p < 0.001) and controls (17.8 +/- 1.87 and 12.10 +/- 1.28, p < 0.001)., CONCLUSIONS: Based on our IVCM data, preservative-free beta-blocker gel induces less changes at ocular surface than preserved beta-blockers, a fact that should be considered to obtain less adverse effects and maximal adherence to treatment in a chronic condition such as glaucoma. Copyright © 2013 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. AU - Frezzotti, Paolo AU - Fogagnolo, Paolo AU - Haka, Gentiana AU - Motolese, Ilaria AU - Iester, Michele AU - Bagaglia, Simone A. AU - Mittica, Pietro AU - Menicacci, Cristina AU - Rossetti, Luca AU - Motolese, Eduardo DO - https://dx.doi.org/10.1111/aos.12261 IS - 2 KW - *Adrenergic beta-Antagonists/tu [Therapeutic Use] *Benzalkonium Compounds/tu [Therapeutic Use] Cell Count *Conjunctiva/de [Drug Effects] Conjunctiva/pa [Pathology] Female Gels *Glaucoma, Open-Angle/dt [Drug Therapy] Goblet Cells/pa [Pathology] Humans Intraocular Pressure/de [Drug Effects] Male Microscopy, Confocal Middle Aged *Ocular Hypertension/dt [Drug Therapy] Pharmaceutical Preparations *Preservatives, Pharmaceutical/tu [Therapeutic Use] Tears/me [Metabolism] *Timolol/tu [Therapeutic Use] Tonometry, Ocular PY - 2014 SE - Frezzotti, Paolo. Department of Surgery, Ophthalmology Unit, University of Siena, Siena, Italy. SN - 1755-3768 1755-375X SP - e133-40 ST - In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma T2 - Acta ophthalmologica TI - In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=24020826 VL - 92 Y2 - 20130911// ID - 918 ER - TY - JOUR AB - Purpose: To analyze the efficacy, safety, and accessibility of netarsudil 0.02% in patients with glaucoma (suspect, open or closed) at a safety-net academic medical center, Boston Medical Center (BMC). Methods: Retrospective chart review of patients prescribed netarsudil 0.02% for uncontrolled glaucoma at BMC between December 2017 and September 2019. Outcome measures included change in intraocular pressure (IOP) from baseline and evaluation of adverse events (AEs). Results: One hundred thirty patients (60% severe stage) were analyzed. The IOP reduction from baseline was about 3 mmHg. Fifty-four patients (42%) experienced an AE (eg, conjunctival hyperemia). Thirty-eight patients (29%) started netarsudil 0.02% in lieu of laser or surgery. Ninety-nine patients (71%) required prior authorization for insurance coverage of netarsudil 0.02%. Ten patients (7%) were unable to obtain netarsudil 0.02% due to issues with insurance coverage. Conclusion: Netarsudil 0.02% yielded significant IOP reduction in our cohort, however, to a smaller degree compared with prior studies that bore equivocal IOP reduction regardless of baseline IOP. Conjunctival hyperemia was the most common AE. In a limited number of patients, netarsudil 0.02% was not covered by insurance. AU - Fridman, Gabrielle AU - Sadlak, Natalie AU - Eliassi-Rad, Babak AU - Desai, Manishi A. DO - https://dx.doi.org/10.1089/jop.2020.0112 PY - 2021 SE - Fridman, Gabrielle. Department of Ophthalmology, Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts, USA. Sadlak, Natalie. Department of Ophthalmology, Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts, USA. Eliassi-Rad, Babak. Department of Ophthalmology, Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts, USA. Desai, Manishi A. Department of Ophthalmology, Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts, USA. SN - 1557-7732 1080-7683 ST - Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics TI - Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=33983847 Y2 - 20210513// ID - 19 ER - TY - JOUR AD - S.L. Friedlander, Case Western Reserve University, University Hospitals of Cleveland, 34055 Solon Road, Solon, OH 44139, United States AU - Friedlander, S. L. AU - Tichenor, W. S. AU - Skoner, D. P. C1 - nasacort aq(Sanofi Aventis,United States) C2 - Sanofi Aventis(United States) DB - Embase Medline DO - 10.1016/j.anai.2013.09.013 IS - 5 KW - beclometasone budesonide ciclesonide corticosteroid flunisolide fluticasone herbaceous agent itraconazole mometasone furoate non prescription drug placebo quinoline derived antiinfective agent retinoic acid ritonavir triamcinolone triamcinolone acetonide allergic rhinitis asthma atopic dermatitis bone density bone metabolism cataract diagnostic error drug antagonism drug efficacy drug monitoring drug potentiation drug safety drug sensitivity Food and Drug Administration glaucoma growth disorder growth inhibition growth rate health care access human intraocular pressure long term care note ossification patient care patient safety priority journal risk assessment side effect nasacort aq LA - English M3 - Note N1 - L370072964 2013-10-29 2013-11-21 PY - 2013 SN - 1081-1206 1534-4436 SP - 319-322 ST - Risk of Adverse Effects, Misdiagnosis, and Suboptimal Patient Care with the Use of Over-the-Counter Triamcinolone T2 - Annals of Allergy, Asthma and Immunology TI - Risk of Adverse Effects, Misdiagnosis, and Suboptimal Patient Care with the Use of Over-the-Counter Triamcinolone UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370072964&from=export http://dx.doi.org/10.1016/j.anai.2013.09.013 VL - 111 ID - 2954 ER - TY - JOUR AN - 105398024. Language: English. Entry Date: 20090911. Revision Date: 20150711. Publication Type: Journal Article AU - Friedman, D. S. DB - ccm DP - EBSCOhost IS - 2 KW - Ophthalmology Patient Compliance Physicians Glaucoma -- Drug Therapy Models, Psychological Patient Education Physician-Patient Relations N1 - interview; questions and answers. Journal Subset: Biomedical; USA. PY - 2008 SN - 1558-0199 SP - 61-63 ST - Challenges of implementing adherence psychology in ophthalmology clinical practice T2 - Johns Hopkins Advanced Studies in Ophthalmology TI - Challenges of implementing adherence psychology in ophthalmology clinical practice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105398024&site=ehost-live&scope=site VL - 5 ID - 4507 ER - TY - JOUR AU - Friedman, David S. DO - https://dx.doi.org/10.1016/j.ophtha.2009.06.026 IS - 11 Suppl KW - Administration, Topical *Antihypertensive Agents/ad [Administration & Dosage] Blindness/pc [Prevention & Control] *Glaucoma/dt [Drug Therapy] Humans *Ophthalmic Solutions/ad [Administration & Dosage] *Patient Compliance PY - 2009 SE - Friedman, David S. The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. dfriedma@jhsph.edu SN - 1549-4713 0161-6420 SP - S29 ST - Introduction: new insights on enhancing adherence to topical glaucoma medications T2 - Ophthalmology TI - Introduction: new insights on enhancing adherence to topical glaucoma medications UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19837257 VL - 116 ID - 1420 ER - TY - JOUR AB - PURPOSE: To evaluate which components of a vision screening process are most effective in identifying individuals who need eye care services., METHODS: Subjects visiting a free health clinic were screened using visual acuity and a questionnaire. Persons who failed screening were referred for a professional eye examination., RESULTS: A total of 1380 of 3004 screened persons (46%) screened positive on question(s) or distance visual acuity; 81% of screened positives were referred for an eye exam, <50% of the positives attended the examination, and one-third had >=1 problem requiring intervention or monitoring. The most common problem was distance refractive error that, once corrected, improved vision by two or more lines, followed by glaucoma or glaucoma suspect (8.9%), visually significant cataract (7.2%), and diabetic retinopathy (2.5%). Ninety-four subjects who screened negative ("normal") were examined; nearly half of these had 2+ lines of visual acuity improvement with refraction (from 20/40 or 20/32 to 20/20). Sensitivity for detecting specific eye conditions varied substantially, ranging from 0-83% for individual screening questions. Time since last exam and distance acuity <20/50 were the most sensitive questions for visually significant cataract; however, their specificity was low. No combination of questions and acuity testing had both high sensitivity and specificity., CONCLUSIONS: Vision problems requiring intervention were common among this relatively young population, but no combination of screening questions and vision testing proved effective for screening. More than half of those who screened positive never showed for an examination, indicating that on-site eye exams might be more effective. AU - Friedman, David S. AU - Cassard, Sandra D. AU - Williams, Sherill K. AU - Baldonado, Kira AU - O'Brien, Rebecca W. AU - Gower, Emily W. DO - https://dx.doi.org/10.3109/09286586.2013.789533 IS - 4 KW - Adolescent Adult *Eye Diseases/di [Diagnosis] *Eye Diseases/ep [Epidemiology] False Negative Reactions Female Health Services/sn [Statistics & Numerical Data] Health Services Accessibility Humans Male Middle Aged Outcome Assessment, Health Care Predictive Value of Tests *Program Evaluation Referral and Consultation Risk Assessment Sensitivity and Specificity Surveys and Questionnaires United States/ep [Epidemiology] *Vision Screening/mt [Methods] Visual Acuity/ph [Physiology] Visual Fields/ph [Physiology] *Vulnerable Populations/sn [Statistics & Numerical Data] Young Adult PY - 2013 SE - Friedman, David S. Dana Center for Preventive Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, MD 21287, USA. david.friedman@jhu.edu SN - 1744-5086 0928-6586 SP - 201-11 ST - Outcomes of a vision screening program for underserved populations in the United States T2 - Ophthalmic epidemiology TI - Outcomes of a vision screening program for underserved populations in the United States UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=23865601 VL - 20 ID - 957 ER - TY - JOUR AU - Friedman, David S. AU - Cramer, Joyce AU - Quigley, Harry IS - 8 KW - Antihypertensive Agents/tu [Therapeutic Use] Behavior Therapy *Delivery of Health Care Glaucoma/di [Diagnosis] *Glaucoma/th [Therapy] Humans Patient Compliance Patient Education as Topic Physician-Patient Relations PY - 2005 SN - 0003-9950 SP - 1134-5 ST - A more proactive approach is needed in glaucoma care T2 - Archives of ophthalmology (Chicago, Ill. : 1960) TI - A more proactive approach is needed in glaucoma care UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16087850 VL - 123 ID - 1729 ER - TY - JOUR AB - OBJECTIVE: To use multiple data sources to determine drivers of patient adherence to topical ocular hypotensive therapy., DESIGN: Retrospective database and chart reviews in combination with prospective patient surveys. Diverse medical environments where insured patients in the research database seek care., PARTICIPANTS: Three hundred patients with a new claim diagnosis for open-angle glaucoma who initially were prescribed one of three prostaglandins and 103 physicians participating in the same medical plans., METHODS: A structured interview addressing self-reported adherence, experiences with medication, communication with the physician, and health-related beliefs associated with adherence behavior was administered to surveyed patients. Phone interviews were conducted with participating ophthalmologists., MAIN OUTCOME MEASURE: Of adherence, medication possession ratio., RESULTS: Eight variables were associated independently with a lower medication possession ratio: (1) hearing all of what you know about glaucoma from your doctor (compared with some or nothing); (2) not believing that reduced vision is a risk of not taking medication as recommended; (3) having a problem paying for medications; (4) difficulty while traveling or away from home; (5) not acknowledging stinging and burning; (6) being nonwhite; (7) receiving samples; and (8) not receiving a phone call visit reminder. The multivariate model explained 21% of the variance., CONCLUSIONS: These findings indicate that doctor-patient communications and health-related beliefs of patients contribute to patient adherence. Patient learning styles that are associated with less concern about the future effects of glaucoma and the risks of not taking medications are associated with lower adherence. Specifically, knowledge about potential vision loss from glaucoma is a critical element that tends to be missed by more passive doctor-dependent patients who tend to be poorly adherent. These findings suggest that educational efforts in the office may improve patient adherence to medical therapies. AU - Friedman, David S. AU - Hahn, Steven R. AU - Gelb, Laurie AU - Tan, Jason AU - Shah, Sonali N. AU - Kim, Elizabeth E. AU - Zimmerman, Thom J. AU - Quigley, Harry A. DO - https://dx.doi.org/10.1016/j.ophtha.2007.11.023 IS - 8 KW - Adult *Antihypertensive Agents/tu [Therapeutic Use] *Attitude to Health Communication Female *Glaucoma, Open-Angle/dt [Drug Therapy] *Health Knowledge, Attitudes, Practice Humans Male *Patient Compliance *Physician-Patient Relations Prospective Studies Prostaglandins, Synthetic/tu [Therapeutic Use] Retrospective Studies PY - 2008 SE - Friedman, David S. Wilmer Eye Institute, Baltimore, Maryland 21287, USA. David.Friedman@jhu.edu SN - 1549-4713 0161-6420 SP - 1320-3 ST - Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study T2 - Ophthalmology TI - Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=18321582 VL - 115 Y2 - 20080305// ID - 1542 ER - TY - JOUR AB - PURPOSE: To assess doctor-patient communication in patients with glaucoma., DESIGN: Observational cohort study., PARTICIPANTS: Twenty-three ophthalmologists and 50 patients with glaucoma., METHODS: Doctor-patient encounters were audio- and videotaped and analyzed using validated sociolinguistic approaches. After the visit, the doctor and the patient completed questionnaires, and patients were interviewed using a semistructured, patient-centered protocol., MAIN OUTCOME MEASURES: Summary statistics about doctor-patient encounters, assessment of alignment of attitudes between patients and doctors, and patient admission to missing doses., RESULTS: Physicians spent an average of 8.0 (standard deviation [SD], 3.1; median, 7.8) minutes in the room with the patient and an average of 5.8 (SD, 2.4; median, 7.5) minutes talking with the patient, delivering 70% of all spoken words and asking two thirds of all questions. Glaucoma-related discussion occupied 50% of talk time and was focused primarily on examinations and treatment (25%). One third of discussions addressed ocular issues other than glaucoma. Virtually all physician questions (94%) were closed ended. Most patient questions were about intraocular pressure (20% of visits), details of the medication regimen (20%), disease status (14%), and testing (12%). Although physicians and patients were aligned in believing that the physician should control the visit agenda, physicians tended to support greater physician control of decision making than did patients. Physicians failed to identify most patients who admitted to missing doses, a surrogate for nonadherence, stating that 10 of 13 in this category were taking drops "all" or "most" of the time. Physician interviews detected 3 of the 11 patients whose postvisit questionnaire indicated missing a dose in the last week compared with 11 of the 11 detected by the postvisit research interview. Patients who stated they had missed doses recently reported being less satisfied with the doctor-patient encounter than those who did not., CONCLUSIONS: Doctor-patient dialogue was universally physician centered; physicians spoke 70% of the words and asked closed-ended questions that restricted the patient's contribution to "yes/no" or brief responses. A minority of physicians ever asked patients if they had questions. In contrast with the patient-centered research interview, doctors' physician-centered communication failed to identify most patients who had missed doses. AU - Friedman, David S. AU - Hahn, Steven R. AU - Quigley, Harry A. AU - Kotak, Sameer AU - Kim, Elizabeth AU - Onofrey, Meaghan AU - Eagan, Corey AU - Mardekian, Jack DO - https://dx.doi.org/10.1016/j.ophtha.2009.04.052 IS - 12 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Cohort Studies *Communication Female *Glaucoma/dt [Drug Therapy] Health Behavior Humans Male Middle Aged Motivation *Patient Compliance/px [Psychology] Patient Education as Topic *Patient-Centered Care *Physician-Patient Relations Surveys and Questionnaires Video Recording PY - 2009 SE - Friedman, David S. Wilmer Eye Institute, Baltimore, Maryland, USA. David.Friedman@jhu.edu SN - 1549-4713 0161-6420 SP - 2277-3 ST - Doctor-patient communication in glaucoma care: analysis of videotaped encounters in community-based office practice T2 - Ophthalmology TI - Doctor-patient communication in glaucoma care: analysis of videotaped encounters in community-based office practice UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19744715 VL - 116 Y2 - 20090910// ID - 1425 ER - TY - JOUR AB - Purpose: To assess the accuracy of Travatan Dosing Aid recordings. Design: Prospective evaluation of drop-recording accuracy. Methods: Physicians and patients used the Dosing Aid, and logs of usage were compared to the data obtained from the Dosing Aid. Results: Five physicians and 20 patients participated. Devices used by physicians recorded all drops dispensed. Extra readings were recorded when physicians carried the devices during the day. For patients, 93% of all drops were recorded, with 18 of 20 subjects having over 85% of the drops recorded. Seventy percent of patients would continue using the device. Conclusions: The Dosing Aid accurately recorded most eyedrops administered by patients and physicians. Given recent documentation of widespread undercompliance with medical therapy, the Dosing Aid could be a useful addition to clinical practice and research. © 2007 Elsevier Inc. All rights reserved. AD - D.S. Friedman, Glaucoma Division, the Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States AU - Friedman, D. S. AU - Jampel, H. D. AU - Congdon, N. G. AU - Miller, R. AU - Quigley, H. A. C1 - travatan(Alcon,United States) C2 - Alcon(United States) DB - Embase Medline DO - 10.1016/j.ajo.2006.11.036 IS - 4 KW - eye drops travoprost adult aged article clinical article clinical practice diagnostic accuracy dose calculation drug administration route drug delivery system drug dosing aid female glaucoma human male patient compliance priority journal prospective study technical aid travatan Travatan Dosing Aid LA - English M3 - Article N1 - L46452511 2007-05-06 PY - 2007 SN - 0002-9394 SP - 699-701 ST - The TRAVATAN Dosing Aid Accurately Records When Drops Are Taken T2 - American Journal of Ophthalmology TI - The TRAVATAN Dosing Aid Accurately Records When Drops Are Taken UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46452511&from=export http://dx.doi.org/10.1016/j.ajo.2006.11.036 VL - 143 ID - 3532 ER - TY - JOUR AB - Objective: To determine the management patterns for glaucoma and suspect glaucoma in a nationally representative sample of newly treated persons. Design: Retrospective cohort study of persons enrolled in a large managed care organization. Participants: One thousand seven hundred twelve diagnosed suspects and 3623 diagnosed glaucoma patients. Methods: Linked pharmacy and patient care data were used to examine the glaucoma management and treatment patterns in this cohort of persons insured by a single managed care organization. Rates of monitoring and treatment were calculated for the 3 study groups. Main Outcome Measures: Probability of monitoring (return visits, visual fields [VFs], and optic nerve head imaging or photography) and treatment (argon laser trabeculoplasty [ALT] and surgery) for newly treated persons with suspect and glaucoma diagnoses. Results: After a median follow-up of 440 days, 83% of treated diagnosed suspects had had a billed follow-up office visit to either an optometrist or an ophthalmologist at any time during follow-up, 46% had had at least one billed VF, and 13% had had some form of optic nerve head imaging. Rates were slightly higher for those with diagnosed glaucoma (P>0.05). Surgery and ALT were performed rarely in this treated population (1%-6% at 2 years). Conclusions: This study suggests that a large proportion of individuals felt to require treatment for glaucoma or suspect glaucoma are falling out of care and are being monitored at rates lower than expected from recommendations of published guidelines. More research is needed to confirm these findings and to determine the reasons for loss to follow-up and low monitoring rates. © 2005 by the American Academy of Ophthalmology. AD - Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD, United States Glaucoma Service, Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD, United States Ingenix Epidemiology, Auburndale, MA, United States Pfizer Inc., Worldwide Outcomes Research, New York, NY, United States Wilmer Eye Institute, 600 North Wolfe Street, Baltimore, MD 21287, United States AU - Friedman, D. S. AU - Nordstrom, B. AU - Mozaffari, E. AU - Quigley, H. A. DB - Scopus DO - 10.1016/j.ophtha.2005.02.030 IS - 9 M3 - Article N1 - Cited By :67 Export Date: 19 July 2021 PY - 2005 SP - 1500-1504 ST - Glaucoma management among individuals enrolled in a single comprehensive insurance plan T2 - Ophthalmology TI - Glaucoma management among individuals enrolled in a single comprehensive insurance plan UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-24944560540&doi=10.1016%2fj.ophtha.2005.02.030&partnerID=40&md5=971d69852fc264c248ce8793dc23b526 VL - 112 ID - 4961 ER - TY - JOUR AB - PURPOSE: To identify risk factors for poor adherence to topical once daily therapy for glaucoma., DESIGN: Prospective, observational cohort study., PARTICIPANTS: A total of 196 patients with glaucoma who were being treated with a prostaglandin analog in 1 or more eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007., METHODS: Demographics, ocular history, and responses to interview questions about glaucoma knowledge, health beliefs, and drop-taking behaviors were obtained from each patient. All patients used the Travatan Dosing Aid (DA; Alcon Laboratories Inc., Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months, and the data of drop use were downloaded using software provided with the DA. Patients taking 75% of doses., MAIN OUTCOME MEASURES: Risk factors for poor adherence., RESULTS: Eighty-seven patients (44.4% of the 196 subjects with evaluable data at 3 months) used the DA on 75% or less of the monitored days. In univariate analysis, poorer adherers were more likely to be <50 or >or=80 years of age, to be African American, to report less than excellent health, to report higher amounts of depression, to have lower income, and to be treated at the Scheie Eye Institute. Multivariate analysis (adjusting for education and income) found that age, race/ethnicity, and less than excellent health were associated with poor adherence., CONCLUSIONS: Those who failed to take more than 75% of eyedrop doses were more likely to be African American and to report poor health. Those in the youngest and oldest age groups were less adherent, although this finding was not always statistically significant. Further research into the factors driving these associations and into developing predictive models to assist in screening for low adherence are warranted., FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. AU - Friedman, David S. AU - Okeke, Constance O. AU - Jampel, Henry D. AU - Ying, Gui-shuang AU - Plyler, Ryan J. AU - Jiang, Yuzhen AU - Quigley, Harry A. DO - https://dx.doi.org/10.1016/j.ophtha.2009.01.021 IS - 6 KW - Age Factors Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] Cloprostenol/ad [Administration & Dosage] *Cloprostenol/aa [Analogs & Derivatives] Drug Monitoring/is [Instrumentation] Ethnic Groups Female Follow-Up Studies *Glaucoma/dt [Drug Therapy] Glaucoma/eh [Ethnology] Health Knowledge, Attitudes, Practice Humans Intraocular Pressure/de [Drug Effects] Male *Medication Adherence/sn [Statistics & Numerical Data] Middle Aged Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/eh [Ethnology] *Ophthalmic Solutions/ad [Administration & Dosage] Prospective Studies Risk Factors Surveys and Questionnaires Travoprost PY - 2009 SE - Friedman, David S. Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21210, USA. david.friedman@jhu.edu SN - 1549-4713 0161-6420 SP - 1097-105 ST - Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma T2 - Ophthalmology TI - Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19376591 VL - 116 Y2 - 20090419// ID - 1461 ER - TY - JOUR AB - PURPOSE: To develop methods for investigating adherence to glaucoma medications by using a modified claims data-based measure of adherence, validation by chart review, and patient and physician interviews., METHODS: Data from administrative claims of 13,956 subjects receiving an initial glaucoma medication, and data from overlapping samples of 300 patients' charts, 300 interviews of patients, and 103 interviews of physicians were analyzed and compared., RESULTS: The mean medication possession ratio (MPR) was 0.64 (median 0.57) for the 13,956 subjects. Although 59% potentially had an ocular hypotensive agent at 12 months, only 10% had such medication available continuously. Chart review revealed that 31% of subjects "new to therapy" in claims data had actually been previously treated; and that 90% of the 17% who had medication added to initial monotherapy were misclassified by claims-based algorithms as medication switches or no change. Twenty percent of surveyed patients received samples on a regular basis and had lower MPR than those who did not (P < 0.05)., CONCLUSIONS: Large pharmacy databases offer insight into medication usage but are vulnerable to errors from sampling (since patients who receive samples will be considered to have poor adherence), misidentification of newly treated patients, and misclassification of added versus switched medications. That a large proportion of patients stop and restart medications makes MPR a robust measure of adherence over time that reflects the resumption of medication after a gap in adherence. The data confirm that adherence to treatment with glaucoma medications is poor, similar to adherence in patients with other chronic diseases. AU - Friedman, David S. AU - Quigley, Harry A. AU - Gelb, Laurie AU - Tan, Jason AU - Margolis, Jay AU - Shah, Sonali N. AU - Kim, Elizabeth E. AU - Zimmerman, Thom AU - Hahn, Steven R. IS - 11 KW - Adult *Antihypertensive Agents Databases, Factual *Drug Prescriptions/sn [Statistics & Numerical Data] *Drug Utilization Review/mt [Methods] Female *Glaucoma/dt [Drug Therapy] Health Services Research Health Surveys Humans *Insurance Claim Review/sn [Statistics & Numerical Data] Male Managed Care Programs/sn [Statistics & Numerical Data] Middle Aged Ocular Hypertension/dt [Drug Therapy] *Patient Compliance/sn [Statistics & Numerical Data] Retrospective Studies PY - 2007 SE - Friedman, David S. Wilmer Eye Institute, Baltimore, MD, USA. david.friedman@jhu.edu SN - 0146-0404 SP - 5052-7 ST - Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS) T2 - Investigative ophthalmology & visual science TI - Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17962457 VL - 48 ID - 1572 ER - TY - JOUR AN - 105398020. Language: English. Entry Date: 20090911. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Friedman, D. S. AU - Schwartz, G. F. DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Patient Compliance N1 - USA. PY - 2008 SN - 1558-0199 SP - 42-43 ST - Enhancing adherence with glaucoma therapy: practical strategies for superior outcomes T2 - Johns Hopkins Advanced Studies in Ophthalmology TI - Enhancing adherence with glaucoma therapy: practical strategies for superior outcomes UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105398020&site=ehost-live&scope=site VL - 5 ID - 4549 ER - TY - JOUR AB - OBJECTIVE: To determine the prevalence and causes of low vision in a large sample of nursing home residents., METHODS: Twenty-eight nursing homes on the Eastern Shore of Maryland and Delaware were enrolled in a clinical trial to assess the impact of vision restoration/rehabilitation on nursing home residents. Visual acuity was measured using both recognition charts and preferential looking techniques. An ophthalmologist examined all residents with visual acuity worse than 20/40 in the better-seeing eye and determined the primary cause for decreased vision. Results are reported for the better-seeing eye., RESULTS: Of 2544 eligible residents, 1591 (63%) participated, but 286 residents were unable to respond to visual acuity testing. Of the remaining 1307 residents, 496 (37%) had best-corrected visual acuity worse than 20/40 in the better-seeing eye. Causes were ascribed for 412 subjects. Rates of low vision were similar between African American subjects and white subjects (39% and 38%, respectively; age-adjusted P =.18). Cataract was the leading cause of low vision, responsible for 37% of low vision among white subjects and 54% of low vision among African American subjects. Macular degeneration was responsible for 29% of low vision among white subjects but only 7% among African American subjects. Glaucoma caused low vision in 4% of white subjects and 10% of African American subjects. Refractive error was not a frequent cause of low vision in nursing home residents., CONCLUSIONS: Low vision is highly prevalent among nursing home residents, with 37% having visual acuity worse than 20/40 in the better-seeing eye. Differences in causes of low vision between African American subjects and white subjects were noted, with African American subjects more likely to have vision loss on the basis of cataract, a readily treated condition. Appropriate interventions for nursing home residents, who face significant obstacles in accessing eye care services, have the potential to improve the quality of life of this at-risk older population. AU - Friedman, David S. AU - West, Sheila K. AU - Munoz, Beatriz AU - Park, William AU - Deremeik, James AU - Massof, Robert AU - Frick, Kevin AU - Broman, Aimee AU - McGill, Wendy AU - Gilbert, Donna AU - German, Pearl IS - 7 KW - *African Continental Ancestry Group/sn [Statistics & Numerical Data] Aged Aged, 80 and over *Blindness/eh [Ethnology] Blindness/et [Etiology] Blindness/rh [Rehabilitation] Causality Delaware/ep [Epidemiology] *European Continental Ancestry Group/sn [Statistics & Numerical Data] Eye Diseases/co [Complications] Female *Homes for the Aged/sn [Statistics & Numerical Data] Humans Male Maryland/ep [Epidemiology] *Nursing Homes/sn [Statistics & Numerical Data] Prevalence *Vision, Low/eh [Ethnology] Vision, Low/et [Etiology] Vision, Low/rh [Rehabilitation] Visual Acuity PY - 2004 SE - Friedman, David S. Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA. david.friedman@jhu.edu SN - 0003-9950 SP - 1019-24 ST - Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study T2 - Archives of ophthalmology (Chicago, Ill. : 1960) TI - Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15249367 VL - 122 ID - 1777 ER - TY - JOUR AD - J. Friedman, College of Pharmacy, University of Illinois, Chicago, United States AU - Friedman, J. DB - Embase IS - DEC KW - cannabis ambulatory care anxiety disorder appetite disorder chronic pain drug industry human insomnia intraocular hypertension muscle spasm nausea and vomiting note pharmacist LA - English M3 - Note N1 - L370454837 2013-12-18 2014-01-07 PY - 2013 SN - 0012-6616 1937-8157 ST - Should you establish a medical marijuana dispensary? T2 - Drug Topics TI - Should you establish a medical marijuana dispensary? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370454837&from=export http://drugtopics.modernmedicine.com/drug-topics/news/should-you-establish-medical-marijuana-dispensary ID - 2943 ER - TY - JOUR AB - Adequate dosage forms are essential for achieving successful pharmacotherapy. Innovative dosage forms or delivery systems may direct a drug to its specific site of action, optimize the timing of the drug release, or increase comfort or convenience for the patient. Thus, such innovations may improve efficacy and tolerability and lead to improvements in health-related quality of life. Specialized dosage forms (e.g., depot injections, extended-release formulations) of several psychiatric agents have been extensively used. The latest addition is an orally disintegrating formulation of the antidepressant mirtazapine. This dosage form dissolves rapidly in the mouth and is convenient for the large proportion of patients who have difficulty in swallowing tablets. © 2003 Elsevier B.V./ECNP. All rights reserved. AD - H.W. Frijlink, Dept. Pharmaceutical Technol./B., Groningen Univ. Inst. Drug Explor., Groningen, Netherlands AU - Frijlink, H. W. C1 - implanon(Organon) mirena(Schering) mirtrazapine soltab nuvaring(Organon) remeron soltab C2 - Organon Schering DB - Embase Medline DO - 10.1016/S0924-977X(03)00096-8 IS - SUPPL. 3 KW - amfebutamone antibiotic agent antidepressant agent calcium channel blocking agent colistin ethinylestradiol plus etonogestrel etonogestrel flupentixol fluphenazine gestagen haloperidol immunosuppressive agent insulin levonorgestrel mirtazapine mirtrazapine soltab omeprazole proton pump inhibitor serotonin uptake inhibitor tobramycin venlafaxine verapamil allergy asthma bioequivalence malignant neoplasm chronic obstructive lung disease chronotherapy circadian rhythm circadian rhythm sleep disorder conference paper congestive heart failure cystic fibrosis diabetes mellitus drug absorption drug delivery system drug dosage form drug formulation drug release epilepsy glaucoma human Human immunodeficiency virus infection hyperlipidemia hypertension immunosuppressive treatment infection prevention inhaler kidney transplantation medical nebulizer mental disease nebulization patient compliance peptic ulcer postmenopause priority journal psychopharmacology quality of life rheumatoid arthritis tuberculosis implanon mirena nuvaring remeron soltab LA - English M3 - Conference Paper N1 - L37188778 2003-10-12 PY - 2003 SN - 0924-977X SP - S77-S84 ST - Benefits of different drug formulations in psychopharmacology T2 - European Neuropsychopharmacology TI - Benefits of different drug formulations in psychopharmacology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37188778&from=export http://dx.doi.org/10.1016/S0924-977X(03)00096-8 VL - 13 ID - 3804 ER - TY - JOUR AD - S. Frisch, Minneapolis, United States AU - Frisch, S. DB - Embase Medline DO - 10.1136/bmj.g6997 KW - cannabis derivative dronabinol medical cannabis nabilone acquired immune deficiency syndrome amyotrophic lateral sclerosis article cachexia cancer pain cannabis use chronic pain drug classification drug control drug delivery system drug efficacy drug research drug safety funding glaucoma government regulation health care access Human immunodeficiency virus infection migraine multiple sclerosis Parkinson disease seizure sickle cell anemia sickle cell crisis spasticity LA - English M3 - Article N1 - L600574083 2014-12-09 2014-12-12 PY - 2014 SN - 1756-1833 0959-8146 ST - Medical cannabis: US researchers battle for access to the plant T2 - BMJ (Online) TI - Medical cannabis: US researchers battle for access to the plant UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600574083&from=export http://dx.doi.org/10.1136/bmj.g6997 VL - 349 ID - 2869 ER - TY - JOUR AB - Purpose: To compare the effect of time on therapy, efficacy, tolerability and resource utilization of latanoprost or non-prostaglandin analogues (non-PGs) in patients who required a change in intraocular pressure (IOP)-lowering monotherapy. Methods: This open-label, multicentre study (Sweden, 19 sites; Finland, seven sites) included adults with glaucoma or ocular hypertension with mean diurnal IOP ≥ 21 mmHg on ocular hypotensive monotherapy. Patients were randomized to latanoprost monotherapy or non-PG therapy (commercially available therapy other than a PG) and followed for 36 months. End-points included: time to treatment failure (baseline to visit with a change in/addition to treatment); diurnal IOP (mean of 08.00, 12.00 and 16:00 hr measurements) at months 6, 12, 24 and 36; tolerability; and resource utilization, where analyses used Swedish and Finnish 2006 unit costs. Results: Three hundred and twenty-six patients received ≥ 1 dose of latanoprost (n = 162) or non-PGs (n = 164). Median time to treatment failure was longer for latanoprost (36 months) than for non-PGs (12 months; p < 0.001); 51% and 24% of patients remained on randomized therapy after 36 months, respectively (p < 0.001). Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01). No serious adverse events were judged to be treatment-related. Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs. Conclusion: Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost. Latanoprost's IOP-reducing effect and tolerability were sustained over the long term. Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy. © 2009 Acta Ophthalmol. AD - B. Friström, University Hospital, 581 85 Linköping, Sweden AU - Friström, B. AU - Uusitalo, H. DB - Embase Medline DO - 10.1111/j.1755-3768.2009.01663.x IS - 1 KW - NCT00140062 brimonidine brinzolamide dorzolamide plus timolol latanoprost adult aged article clinical trial controlled clinical trial controlled study drug cost drug efficacy drug marketing drug tolerability female Finland glaucoma health care utilization human intraocular hypertension intraocular pressure major clinical study male monotherapy multicenter study priority journal randomized controlled trial Sweden treatment failure unspecified side effect LA - English M3 - Article N1 - L358251674 2010-02-16 2010-03-23 PY - 2010 SN - 1755-375X 1755-3768 SP - 37-43 ST - A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension T2 - Acta Ophthalmologica TI - A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358251674&from=export http://dx.doi.org/10.1111/j.1755-3768.2009.01663.x VL - 88 ID - 3276 ER - TY - JOUR AD - S. Läer, Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf AU - Frobel, A. K. AU - Hsien, L. AU - Breddemann, A. AU - Läer, S. C1 - contergan DB - Embase IS - 5 KW - epinephrine captopril carboplatin carmustine carvedilol cephalosporin chloral hydrate ciprofloxacin cisplatin clonidine digoxin foscarnet furosemide hydrochlorothiazide hydroxyurea indometacin lomustine loracarbef meropenem metoprolol succinate prazosin propranolol ramipril spironolactone steroid thalidomide topiramate tramadol unindexed drug vincristine article asthma atopic dermatitis drug absorption drug elimination drug metabolism drug safety epilepsy esophagitis Food and Drug Administration gastroesophageal reflux glaucoma human Human immunodeficiency virus infection hydrophilicity medicinal plant meningitis migraine muscle hypertonia otitis media patient compliance psychosis sinusitis contergan LA - German M3 - Article N1 - L46350256 2007-03-23 PY - 2007 SN - 0011-9857 SP - 50-60 ST - Pharmacotherapy in children should become safer T2 - Deutsche Apotheker Zeitung TI - Pharmacotherapy in children should become safer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46350256&from=export VL - 147 ID - 3546 ER - TY - JOUR AB - A patient presented to our clinic with stage Ia open-angle glaucoma of the right eye and stage IIa surgically corrected open-angle glaucoma of the left eye. The condition of the ocular surface was interpreted as toxic/allergic conjunctivitis provoked by brimonidine 0.15 %. Brimonidine was substituted with non-selective 0.5%; additionally, topical steroids were prescribed. After steroids were discontinued, some of the symptoms came back, including moderate hyperemia and conjunctival edema, which was interpreted as intolerance to a preservative contained in the eye drops. A decision was made to switch from the β-blocker to its preservative-free formulation; regular IOP monitoring was continued. IOP measured during the next visit was above tolerated, so a preservative-free form of the ocular hypotensive combination drug (an analog of prostaglandin 0.005% with non-selective β-blocker 0.5%) was introduced to the regimen, with further IOP monitoring. Because the initial diagnosis was wrong, damage to the ocular surface had been aggravated by inadequate therapy. Preservative-free hypotensive eye drops are beneficial for the corneal surface and have a positive effect on a patient’s adherence to the regimen. © 2020 Pirogov Russian National Research Medical University. All rights reserved. AD - Peoples' Friendship University of Russia, Moscow, Russian Federation Multiprofile Clinic “SM-Clinic”, Moscow, Russian Federation AU - Frolov, M. A. AU - Kazakova, K. A. AU - Dushina, G. N. AU - Frolov, A. M. AU - Gonchar, P. A. DB - Scopus DO - 10.24075/BRSMU.2020.005 IS - 1 KW - Allergic reactions Brimonidine Glaucoma Preservative Preservative-free form M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 89-92 ST - НЕПЕРЕНОСИМОСТЬ КОНСЕРВАНТОСОДЕРЖАЩИХ ГЛАЗНЫХ КАПЕЛЬ ПРИ ГЛАУКОМЕ: ТРУДНОСТИ ДИАГНОСТИКИ, СЛОЖНОСТИ ЛЕЧЕНИЯ T2 - Bulletin of Russian State Medical University TI - Intolerance of preservative-containing eye drops in a glaucoma patient: Diagnostic and therapeutic challenges UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085550644&doi=10.24075%2fBRSMU.2020.005&partnerID=40&md5=5fa5dbdb839b9b1c5dbc249a69634020 ID - 5714 ER - TY - JOUR AB - A patient presented to our clinic with stage Ia open-angle glaucoma of the right eye and stage IIa surgically corrected open-angle glaucoma of the left eye. The condition of the ocular surface was interpreted as toxic/allergic conjunctivitis provoked by brimonidine 0.15 %. Brimonidine was substituted with non-selective 0.5%; additionally, topical steroids were prescribed. After steroids were discontinued, some of the symptoms came back, including moderate hyperemia and conjunctival edema, which was interpreted as intolerance to a preservative contained in the eye drops. A decision was made to switch from the beta-blocker to its preservative-free formulation; regular IOP monitoring was continued. IOP measured during the next visit was above tolerated, so a preservative-free form of the ocular hypotensive combination drug (an analog of prostaglandin 0.005% with non-selective beta-blocker 0.5%) was introduced to the regimen, with further IOP monitoring. Because the initial diagnosis was wrong, damage to the ocular surface had been aggravated by inadequate therapy. Preservative-free hypotensive eye drops are beneficial for the corneal surface and have a positive effect on a patient's adherence to the regimen. AN - WOS:000519629100013 AU - Frolov, M. A. AU - Kazakova, K. A. AU - Dushina, G. N. AU - Frolov, A. M. AU - Gonchar, P. A. DA - JAN-FEB DO - 10.24075/brsmu.2020.005 IS - 1 PY - 2020 SN - 2500-1094 2542-1204 SP - 94-97 ST - INTOLERANCE OF PRESERVATIVE-CONTAINING EYE DROPS IN A GLAUCOMA PATIENT: DIAGNOSTIC AND THERAPEUTIC CHALLENGES T2 - BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY TI - INTOLERANCE OF PRESERVATIVE-CONTAINING EYE DROPS IN A GLAUCOMA PATIENT: DIAGNOSTIC AND THERAPEUTIC CHALLENGES ID - 6243 ER - TY - JOUR AB - BACKGROUND: Central corneal pathologies can lead to an irreversible decrease of best corrected visual acuity if not diagnosed and treated appropriately. This article reviews the differential diagnosis of central corneal opacities in the newborn, of central infectious corneal ulcers, and the therapy of sterile, central keratolysis., MATERIAL AND METHODS: Authors' personal experience and review of the literature., RESULTS: Flow charts for diagnosis and treatment strategy have been elaborated., CONCLUSIONS: Corneal opacities in newborns create an emergency situation. In order to treat successfully and avoid or diminish amblyopia, it is imperative to rule out congenital glaucoma. The aetiology of central corneal ulcers should always be confirmed by positive cultures to be able to treat specifically. When the standard topic therapy fails, one has to consider rare bacteria, parasites, virus, or patients' compliance. The treatment of central sterile keratolysis in rheumatoid arthritis must be intensive and immunosuppression has to be performed early enough in the course of prevent the formation of a descemetocoele or spontaneous corneal perforation. AU - Frueh, B. E. IS - 5 KW - Arthritis, Rheumatoid/co [Complications] Arthritis, Rheumatoid/di [Diagnosis] Arthritis, Rheumatoid/th [Therapy] *Corneal Diseases/di [Diagnosis] Corneal Diseases/et [Etiology] Corneal Diseases/th [Therapy] Corneal Opacity/di [Diagnosis] Corneal Opacity/et [Etiology] Corneal Opacity/th [Therapy] Corneal Ulcer/di [Diagnosis] Corneal Ulcer/et [Etiology] Corneal Ulcer/th [Therapy] Humans Infant, Newborn Keratitis/di [Diagnosis] Keratitis/et [Etiology] Keratitis/th [Therapy] Prognosis Software Design PY - 1999 SE - Frueh, B E. Universitats-Augenklinik, Inselspital, CH-3010 Bern. beatrice.frueh.epstein@insel.ch SN - 0023-2165 SP - 291-4 ST - [Central corneal diseases] T2 - Zentrale Hornhauterkrankungen. TI - [Central corneal diseases] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10420370 VL - 214 ID - 1970 ER - TY - JOUR AB - In order to evaluate the prevalence and the incidence of glaucoma blindness in Denmark, all registration forms of persons ≥ 50 years of age at admission, admitted to the Danish Association of the Blind (DAB) between 1955 and 1987 with glaucoma as main, cause of blindness, were examined. In 1987 6.7% of DAB members ≥ 50 years of age suffered from blindness caused at least partially by glaucoma, equivalent to an estimated prevalence of 45 per 100,000 of the Danish population ≥ 50 years. The estimated annual incidence of blindness due to glaucoma was 7 per 100,000 ≥ 65 years, and in an equal number of patients glaucoma was a contributory cause of blindness. The incidence of blindness due to glaucoma was decreasing in the young age groups (< 65 years) throughout the study period. Glaucoma blindness seems to occur at a later age now than earlier, leaving the patients blind for a shorter time. This pattern may be explained by improved health services but could also be due to a change in the spontaneous course of glaucoma. The proportion of glaucoma blindness in the glaucoma population was estimated to be 4-5%. AD - J. Fuchs, Department of Ophthalmology, DK-3400 Hillerod, Denmark AU - Fuchs, J. AU - Nissen, K. R. AU - Goldschmidt, E. DB - Embase Medline IS - 1 KW - adult aged article blindness Denmark disease course female glaucoma health care quality human major clinical study male morbidity onset age patient compliance priority journal prognosis sex difference visual acuity LA - English M3 - Article N1 - L22080901 1992-03-13 PY - 1992 SN - 0001-639X SP - 73-78 ST - Glaucoma blindness in Denmark T2 - Acta Ophthalmologica TI - Glaucoma blindness in Denmark UR - https://www.embase.com/search/results?subaction=viewrecord&id=L22080901&from=export VL - 70 ID - 4029 ER - TY - JOUR AB - This paper investigates the patient response to a medical social worker in a glaucoma clinic. The literature suggests that medical social workers are effective in a variety of health care settings, yet the efficacy of a medical social worker in an adult ophthalmic setting has not been studied. We present the results of a retrospective chart review of 50 patients with glaucoma referred to a medical social worker between January 5, 2015 and June 31, 2015 in an outpatient clinic of an urban eye hospital. Clinical and demographic data, as well as the data from a quality of care questionnaire, were collected for each patient. Patients rated their interaction with the medical social worker as highly positive (mean = 4.75, 5-point Likert scale), and nearly 90 % of patients expressed interest in future contact with the social worker. Additionally, most patients reported that the social worker resolved the issues they were facing (61.1 %), supported them in seeing their ophthalmologist (70.6 %), and helped them to manage their glaucoma (69.7 %). Reported barriers to glaucoma care were emotional distress; cost of office visits and medications; lack of medical insurance; transportation; poor medication adherence; impairment of daily activities; follow-up adherence; and language. As vision loss from glaucoma is irreversible, it is important to detect and treat patients at early stages of the disease. Therefore, it is imperative for patients to regularly visit their eye care providers and adhere to treatment and follow-up recommendations. This study suggests that a medical social worker could play a pivotal role in helping patients with glaucoma overcome barriers to treatment and facilitate disease management. AU - Fudemberg, Scott J. AU - Amarasekera, Dilru C. AU - Silverstein, Marlee H. AU - Linder, Kathryn M. AU - Heffner, Paul AU - Hark, Lisa A. AU - Waisbourd, Michael DO - https://dx.doi.org/10.1007/s10900-016-0162-1 IS - 4 KW - Aged Aged, 80 and over Female *Glaucoma/th [Therapy] *Health Services Accessibility/sn [Statistics & Numerical Data] Humans Male Middle Aged Ophthalmology *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] *Social Workers PY - 2016 SE - Fudemberg, Scott J. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA. Amarasekera, Dilru C. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA. Silverstein, Marlee H. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA. Linder, Kathryn M. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA. Heffner, Paul. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA. Hark, Lisa A. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA. Waisbourd, Michael. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA. mwaisbourd@willseye.org. SN - 1573-3610 0094-5145 SP - 845-9 ST - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service T2 - Journal of community health TI - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26860278 VL - 41 ID - 717 ER - TY - JOUR AB - PURPOSE: To determine the rate of adherence to follow-up appointment recommendations in a resident glaucoma clinic with no mechanism for reminders, compared to a resident cataract and primary eye care (CPEC) clinic in which telephone reminders were used, and to identify factors that contribute to adherence in each patient group., METHODS: This retrospective cohort study included subjects in the CPEC clinic who received telephone reminders and those in the glaucoma clinic who did not. Each sample was selected to have a similar proportion of follow-up recommendations for 1, 3, and 6 months. Subjects were considered adherent if they returned within a specified timeframe., RESULTS: A total of 144 subjects from the glaucoma clinic and 151 subjects from the CPEC clinic were included. There was no significant difference between follow-up adherence rates of patients who received telephone reminders and those who did not (odds ratio [OR] =1.35, 95% confidence interval [CI] 0.79-2.32, P=0.28). Patients who were on more than two ocular medications were more likely to return for follow-up (OR=3.11, 95% CI 1.53-6.35, P=0.0018). Subjects between the ages 50 and 80 years were more likely to be adherent compared to their younger and older peers (P=0.02)., CONCLUSION: The follow-up adherence of patients in a CPEC clinic who received telephone reminders was similar to patients in a glaucoma clinic who did not receive any intervention to increase their adherence. Younger (50 years old) and elderly (80 years old) subjects, as well as patients using less than two glaucoma medications, were less likely to adhere to their follow-up appointments. AU - Fudemberg, Scott J. AU - Lee, Brian AU - Waisbourd, Michael AU - Murphy, Rachel A. AU - Dai, Yang AU - Leiby, Benjamin E. AU - Hark, Lisa A. DO - https://dx.doi.org/10.2147/PPA.S89336 PY - 2016 SE - Fudemberg, Scott J. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA. Lee, Brian. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA. Waisbourd, Michael. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA. Murphy, Rachel A. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA. Dai, Yang. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA. Leiby, Benjamin E. Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA. Hark, Lisa A. Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA. SN - 1177-889X SP - 19-25 ST - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic T2 - Patient preference and adherence TI - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26811672 VL - 10 Y2 - 20160108// ID - 1048 ER - TY - JOUR AB - Purpose: To evaluate changes in intraocular pressure before and after withdrawal of topical medications except latanoprost. Cases and Method: This study involved 7 eyes of 5 patients who had been treated by multiple topical medications including latanoprost. The series comprised primary open-angle glaucoma 4 eyes, secondary glaucoma 2 eyes and capsular glaucoma 1 eye. Tonometry was performed before withdrawal of medications except latanoprost and after 8 weeks following withdrawal. They were followed up for 61.7±6.5 weeks. Results: The intraocular pressure (OP) averaged 16.2 mmHg before withdrawal and 15.4 mmHg after withdrawal. The difference was not significant (p=0.21). Conclusion: Treatment with latanoprost alone was equally effective as multiple medications. Latanoprost monotherapy may lead to improved complicance and less damage to the cornea. AD - A. Fujikawa, Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan AU - Fujikawa, A. AU - Tsuiki, E. AU - Ogawa, T. AU - Kitaoka, T. DB - Embase IS - 9 KW - antihypertensive agent latanoprost adult aged capsular glaucoma clinical article conference paper cornea injury drug withdrawal female follow up glaucoma human intraocular pressure male monotherapy open angle glaucoma patient compliance secondary glaucoma tonometry LA - Japanese M3 - Conference Paper N1 - L41441800 2005-10-31 PY - 2005 SN - 0370-5579 SP - 1567-1569 ST - Intraocular pressure after withdrawal of hypotensive medications except latanoprost T2 - Japanese Journal of Clinical Ophthalmology TI - Intraocular pressure after withdrawal of hypotensive medications except latanoprost UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41441800&from=export VL - 59 ID - 3668 ER - TY - JOUR AB - PURPOSE: To describe the time course, diagnosis, clinical features, and treatment of seven patients with Mycobacterium szulgai keratitis that developed from 7 to 24 weeks after laser in situ keratomileusis (LASIK)., METHODS: Seven of 30 eyes of 18 patients were identified with keratitis after LASIK. The first two patients presented 12 to 14 weeks after LASIK; nontuberculous mycobacteria were identified 1 month after the flaps were cultured. Patient recall identified three additional cases by culture and two cases by clinical features alone. Pulsed-field gel electrophoresis (PFGE) was used to type the isolates, and treatment was modified based on susceptibilities., RESULTS: M. szulgai was identified in five patients for whom cultures were performed, but response to empiric therapy based on cultures proved unsatisfactory. The keratitis resolved in all patients with treatment including clarithromycin based on susceptibilities. Medical therapy was sufficient, although one patient required flap amputation. Six of seven patients recovered best-corrected visual acuity (BCVA), while one patient lost one line of BCVA. Two patients lost one line of postoperative uncorrected visual acuity (UCVA), two patients gained one line of UCVA, and three patients recovered postoperative UCVA. PFGE analysis revealed that the M. szulgai strains were identical, and the infection source was contaminated ice used to chill syringes for saline lavage., CONCLUSIONS: Nontuberculous mycobacterial keratitis after LASIK is a diagnostic and management challenge, but outcomes can be preserved with treatment based on susceptibilities. This cluster underscores the importance of adherence to sterile protocol during LASIK. AU - Fulcher, Samuel F. A. AU - Fader, Robert C. AU - Rosa, Robert H., Jr. AU - Holmes, Gary P. IS - 6 KW - Adult Anti-Bacterial Agents/tu [Therapeutic Use] Azithromycin/tu [Therapeutic Use] Equipment Contamination Female Humans Keratitis/dt [Drug Therapy] Keratitis/ep [Epidemiology] *Keratitis/mi [Microbiology] *Keratomileusis, Laser In Situ/ae [Adverse Effects] Keratomileusis, Laser In Situ/is [Instrumentation] Male Middle Aged Mycobacterium Infections, Nontuberculous/dt [Drug Therapy] Mycobacterium Infections, Nontuberculous/ep [Epidemiology] *Mycobacterium Infections, Nontuberculous/mi [Microbiology] *Nontuberculous Mycobacteria/ip [Isolation & Purification] Postoperative Complications/dt [Drug Therapy] Postoperative Complications/ep [Epidemiology] *Postoperative Complications/mi [Microbiology] Risk Factors Time Factors PY - 2002 SE - Fulcher, Samuel F A. Division of Ophthalmology, Scott & White Memorial Hospital and Clinic, 2401 South 31st Street, Temple, TX 76508, USA. sfulcher@mailbox.sw.org SN - 0277-3740 SP - 546-54 ST - Delayed-onset mycobacterial keratitis after LASIK T2 - Cornea TI - Delayed-onset mycobacterial keratitis after LASIK UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=12131028 VL - 21 ID - 1883 ER - TY - JOUR AB - It is unclear whether and at what dose vitamin D supplementation affects insulin resistance (IR). Objective: We sought to investigate whether vitamin D at doses higher than currently recommended decreases indexes of IR in an ambulatory population of overweight elderly subjects. Design: This double-blind, randomized, controlled multicenter trial enrolled 257 elderly overweight individuals aged ≥ 65 y with baseline 25-hydroxyvitamin D [25(OH)D] concentrations between 10 and 30 ng/mL. All subjects received 1000 mg calcium citrate/d, with vitamin D administered weekly at an equivalent dose of 600 or 3750 IU/d. The homeostasis model assessment (HOMA) of IR index at 1 y was the primary outcome.We also assessed the McAuley index. Results: In total, 222 subjects (55% women) with a mean ± SD age and body mass index (BMI; in kg/m2) of 71 ± 4 y and 30 ± 4, respectively, completed the study. Subjects' baseline characteristics, including IR indexes, were similar across groups: 69% had prediabetes, 54% had hypertension (47% were taking antihypertensive medications), and 60% had hyperlipidemia, nearly half of whom were receiving lipidlowering drugs. At 1 y, mean ± SD serum 25(OH)D increased from 20 ± 7 to 26 ± 7 ng/mL in the low-dose arm (P <0.0001) and from 21 ± 8 to 36 ± 10 ng/mL in the high-dose arm (P > 0.001). Median HOMA-IR indexes did not change compared with baseline concentrations and were similar in the high-[2.2 (IQR: 1.5, 2.9)] and low-dose [2.3 (IQR: 1.6, 3.3] treatment groups. Adjusted analyses showed that HOMA-IR was predicted by the baseline HOMA index and BMI but not by vitamin D dose, baseline serum 25(OH)D, or change in 25(OH)D. Conclusion: Vitamin D3 at 3750 IU/d did not improve HOMA-IR compared with the Institute of Medicine Recommended Dietary Allowance of 600 IU/d in elderly overweight individuals. AD - G.E.-H. Fuleihan, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, Collaborating Center for Metabolic Bone Disorders, American University of Beirut, Beirut, Lebanon AU - Fuleihan, G. E. H. AU - Baddoura, R. AU - Habib, R. H. AU - Halaby, G. AU - Arabi, A. AU - Rahme, M. AU - Singh, R. J. AU - Kassem, M. AU - Mahfoud, Z. AU - Hoteit, M. AU - Daher, R. T. AU - Kassir, M. F. C1 - citracal d(Europharm) euro d(Europharm) C2 - Europharm DB - Embase Medline DO - 10.3945/ajcn.116.132589 IS - 2 KW - NCT01315366 25 hydroxyvitamin D antihypertensive agent antilipemic agent C peptide calcium cholesterol citrate calcium colecalciferol creatinine glucose hemoglobin A1c high density lipoprotein hydroxymethylglutaryl coenzyme A reductase inhibitor insulin low density lipoprotein placebo triacylglycerol aged antihypertensive therapy article body mass calcium blood level cerebrovascular accident cholesterol blood level comparative effectiveness controlled study creatinine blood level diet restriction dietary reference intake dose response double blind procedure drug dose comparison drug efficacy drug megadose drug safety drug withdrawal female glaucoma heart infarction hemorrhoid homeostasis homeostasis model assessment of insulin resistance index human hypercholesterolemia hyperlipidemia hypertension impaired glucose tolerance insulin blood level insulin resistance kidney colic low drug dose major clinical study male mcauley index medication compliance metabolic parameters mobilization multicenter study obesity outcome assessment patient compliance randomized controlled trial retina detachment side effect sudden cardiac death thrombophlebitis treatment response triacylglycerol blood level very elderly vitamin blood level vitamin supplementation citracal d euro d LA - English M3 - Article N1 - L611538477 2016-08-09 2016-08-17 PY - 2016 SN - 1938-3207 0002-9165 SP - 315-323 ST - Effect of Vitamin D replacement on indexes of insulin resistance in overweight elderly individuals: A randomized controlled trial T2 - American Journal of Clinical Nutrition TI - Effect of Vitamin D replacement on indexes of insulin resistance in overweight elderly individuals: A randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611538477&from=export http://dx.doi.org/10.3945/ajcn.116.132589 VL - 104 ID - 2718 ER - TY - JOUR AB - Objective: To examine sex differences and trends in comorbid disease and health care utilization in individuals with newly diagnosed Parkinson disease. Background: There are known sex differences in the incidence of PD, as well as the burden of nonmotor symptoms, however, less is known about differences in health and health care utilization after PD diagnosis. Increased use of health care services may suggest barriers to preventative and therapeutic disease management, increased susceptibility to adverse outcomes or lack of social support. Improving quality survivorship for Parkinson's disease (PD) requires a better understanding of how health and health care use changes after PD diagnosis. Design/Methods: This is a retrospective cohort study of 131, 950 Medicare beneficiaries diagnosed with PD in the year 2002 and followed through December 31, 2008. The primary outcomes were comorbid disease diagnosis and health service use. Survival through 2008 was a secondary outcome. We compared the prevalence and cumulative incidence of common medical conditions, trends in survival and health care utilization between men and women with PD. Results: Female PD patients had higher adjusted incidence rate ratio (IRR) of depression (IRR: 1.52, 1.49-1.55), diabetes (IRR: 1.14, 1.10-1.18), glaucoma (IRR: 1.12, 1.06-1.17), hip fracture (IRR: 1.59, 1.53-1.66), osteoporosis (2.73, 2.64-2.81), rheumatoid/osteoarthritis (IRR: 1.51, 1.47-1.55), and stroke/TIA (IRR: 1.05, 1.02-1.08) than men. In spite of greater survival, women with PD used home health and skilled nursing facility care more often, and had less outpatient physician contact than men throughout the study period. Conclusions: Women experience a unique health trajectory after PD diagnosis as suggested by differing comorbid disease burden and health care utilization compared to men. Future studies of sex differences in care needs, care quality, comorbidity related disability, PD progression, and nonclinical factors associated with disability are needed to inform research agendas and clinical guidelines that may improve quality survival for women with PD. AD - M. Fullard, Neurology, University of Pennsylvania, Philadelphia VA PADRECC, Philadelphia, PA, United States AU - Fullard, M. AU - Thibault, D. AU - Todaro, V. AU - Foster, S. AU - Katz, L. AU - Morgan, R. AU - Kern, D. AU - Schwalb, J. AU - Mendoza, E. U. AU - Shulman, L. AU - Dahodwala, N. AU - Willis, A. DB - Embase IS - 15 KW - adult cerebrovascular accident cohort analysis comorbidity conference abstract controlled study depression diabetes mellitus diagnosis disability disease burden disease exacerbation female glaucoma health care utilization hip fracture human incidence male medicare nursing osteoarthritis osteoporosis outpatient Parkinson disease practice guideline prevalence retrospective study sex difference survivorship LA - English M3 - Conference Abstract N1 - L622308723 2018-05-30 PY - 2018 SN - 1526-632X ST - Sex disparities in health and health care utilization after parkinson diagnosis: Rethinking PD associated disability T2 - Neurology TI - Sex disparities in health and health care utilization after parkinson diagnosis: Rethinking PD associated disability UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622308723&from=export VL - 90 ID - 2599 ER - TY - JOUR AB - SIGNIFICANCE: This study affirms the long-term safety and efficacy of scleral contact lens use in patients with keratoconus., PURPOSE: This study aimed to evaluate the safety and efficacy of contemporary scleral contact lenses in the visual rehabilitation of the keratoconic population., METHODS: A retrospective study of keratoconic subjects examined between 2013 and 2018 was conducted. Subjects were included regardless of age, sex, pre-existing morbidity, or scleral lens design. Only eyes fit successfully with scleral contact lenses for >=1 year were included. Exclusion criteria were prior corneal surgery, dystrophy, degeneration, and trauma., RESULTS: A total of 157 eyes of 86 subjects met the study criteria. The mean Keratoconus Severity Score at initial fitting was 3.6 +/- 1.0. Lenses were gas-permeable and nonfenestrated, with a mean overall diameter of 15.8 +/- 0.6 mm and 70.1% toric scleral periphery. Physiological adverse events occurred in 9.6% of eyes, including microbial keratitis (0.6%), phlyctenulosis (0.6%), corneal abrasion (1.3%), contact lens-induced acute red eye (1.3%), corneal infiltrative events (1.3%), pingueculitis (1.3%), and hydrops (3.2%). Lens-related adverse events were documented in 55.4% of eyes. Adverse events related to surface issues included poor wetting in 1.9%, handling in 3.8%, reservoir fogging in 7.0%, lens intolerance in 7.6%, deposit in 8.9%, and broken lenses in 26.1% of eyes. The most common management strategies involved refits (54.0% of interventions), patient reeducation (29.5%), medical treatment (5.5%), surgical referral (6.8%), adjustment to wear time (2.5%), surface treatment (1.2%), and lens replacement (0.6%). Best-corrected distance logMAR visual acuity improved significantly from a mean of 0.50 in spectacles to a mean of 0.08 in scleral lenses (P < .0001). During the study period, 14.6% of eyes lost best-corrected scleral lens visual acuity, all from keratoconus progression., CONCLUSIONS: Consistent with other groups, our study demonstrates excellent safety and efficacy of scleral contact lenses in subjects with keratoconus. AU - Fuller, Daniel G. AU - Wang, Yueren DO - https://dx.doi.org/10.1097/OPX.0000000000001578 IS - 9 KW - Adolescent Adult *Contact Lenses Equipment Safety Female Humans Keratoconus/pp [Physiopathology] *Keratoconus/th [Therapy] Male Middle Aged Patient Compliance Prosthesis Fitting Refraction, Ocular/ph [Physiology] Retrospective Studies *Sclera Treatment Outcome Visual Acuity/ph [Physiology] Young Adult PY - 2020 SE - Fuller, Daniel G. Southern College of Optometry, Memphis, Tennessee. SN - 1538-9235 1040-5488 SP - 741-748 ST - Safety and Efficacy of Scleral Lenses for Keratoconus T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Safety and Efficacy of Scleral Lenses for Keratoconus UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32932400 VL - 97 ID - 202 ER - TY - JOUR AB - Aim: To estimate current clinical practice for frequency of visual field (VF) monitoring in glaucoma in England. Methods: A cross-sectional review of all patients with chronic open angle glaucoma (COAG) attending specialist glaucoma clinics at six hospitals in England was performed. The number of VF tests undertaken prior to the study date and during the first 2 years since diagnosis were recorded and compared with European Glaucoma Society (EGS) guidelines for newly-diagnosed patients. Clinician-requested monitoring intervals were compared with intervals from the National Institute of Clinical Excellence (NICE) guidelines, and the relationships with disease severity, intraocular pressure (IOP) and glaucoma progression status were reviewed. Results: One-hundred and four patients with COAG were included. 73 patients had at least 2 years of follow-up. Median (IQR) total number of VF tests and in the first 2 years of diagnosis were 4 (2-7) and 2 (2-3), respectively. No patients met EGS guidelines, but 87% of patients had their monitoring intervals requested in accordance with NICE guidelines. These intervals were not related to disease severity or VF stability (Kruskal- Wallis test, p=0.25) but shortened significantly when IOP control was inadequate or when the overall clinical impression was disease progression (p<0.001). Conclusions: Most newly-diagnosed COAG patients receive less than three VFs in the first 2 years following diagnosis and an average of 0.7 VF per year over the duration of follow-up. AD - Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom Diagnosis Limited, London, United Kingdom NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, United Kingdom Division of Optometry and Visual Science, School of Health Sciences, City University London, Northampton Square, London EC1V 0HB, United Kingdom AU - Fung, S. S. M. AU - Lemer, C. AU - Russell, R. A. AU - Malik, R. AU - Crabb, D. P. DB - Scopus DO - 10.1136/bjophthalmol-2012-302903 IS - 7 M3 - Article N1 - Cited By :35 Export Date: 19 July 2021 PY - 2013 SP - 843-847 ST - Are practical recommendations practiced? A national multi-centre cross-sectional study on frequency of visual field testing in glaucoma T2 - British Journal of Ophthalmology TI - Are practical recommendations practiced? A national multi-centre cross-sectional study on frequency of visual field testing in glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879355345&doi=10.1136%2fbjophthalmol-2012-302903&partnerID=40&md5=31a12c93316fdbb431efcbc487aa7c51 VL - 97 ID - 5036 ER - TY - JOUR AB - Background: Surgical glaucoma interventions such as trabeculectomy and tube shunt implantations require frequent follow-up to assess for function, evolution, and complications. Current guidelines attribute long-term surgical success to strict follow-up adherence but lack recommendations considering potential patient barriers to follow-up care. Methods: Retrospective longitudinal chart review of non-institutionalized adult glaucoma patients with trabeculectomy or drainage device implantations from April 4, 2014 to December 31, 2018. Straight-line distances from patients' residences to the UNC-Chapel Hill Kittner Eye Center were measured to create radii of incidence of postoperative complications measured by: number of corrective surgeries, visual fields, and visual acuity. Straight-line distance from residence to nearest interstate access categorized patients' rurality. Canceled appointments were noted. Means were compared via two-tailed Student's t-test and logistical regression analyses were performed to determine odds ratios (OR). Results: 203 patients met inclusion criteria. 6-months postoperatively, patients residing >50 miles from the Kittner Eye Center had significantly more cancellations (t(143) = 3.39, p < .001, MD = 1.050, p < .001 95% CI 0.44-1.66), higher rates of loss to follow-up (t(143) = 2.78, p < .01, MD = 23%, p < 0.01, 95% CI 0.071-0.389) and more worsened visual fields (t(143) = 2.14, p < .05, MD = 0.20, p < .05, 95% CI 0.021-0.380) than patients ≤25 miles from clinic. Significantly more patients >20 miles from interstate access were lost to follow-up compared to those ≤10 miles away (p < .001). Regression revealed that patients >50 away were 3.92 times more likely to be lost to follow up (OR 3.92 95% CI 1.46-10.44), and had increased OR of having worsened postoperative visual fields (OR 2.64 95% CI 1.14-4.49). Conclusions: Greater distance from clinic and interstate access is associated with higher rates of loss to follow-up and worsened visual field outcomes. Rural patients may be at higher risk for negative outcomes due to a paucity of convenient ophthalmic care. Glaucoma specialists should consider patients' distance from clinic when choosing a surgical intervention that requires frequent postoperative evaluations. . AD - I. Funk, School of Medicine, University of North Carolina, Chapel Hill, NC, United States AU - Funk, I. AU - Strelow, B. AU - Van Buren, E. AU - Lin, F. AU - Fleischman, D. DB - Embase DO - 10.1111/jgs.16431 IS - SUPPL 1 KW - adult complication conference abstract controlled study female follow up glaucoma surgery human implantation incidence major clinical study male medical record review plastic surgery postoperative complication retrospective study surgery trabeculectomy visual acuity visual field LA - English M3 - Conference Abstract N1 - L633776879 2021-01-01 PY - 2020 SN - 1532-5415 SP - S166 ST - The relationship between patient proximity to postoperative follow-up care and long-term glaucoma surgery outcomes T2 - Journal of the American Geriatrics Society TI - The relationship between patient proximity to postoperative follow-up care and long-term glaucoma surgery outcomes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633776879&from=export http://dx.doi.org/10.1111/jgs.16431 VL - 68 ID - 2424 ER - TY - JOUR AB - PReCIS:: This study addresses the paucity of literature examining glaucoma patients' distance from clinic on postoperative follow-up outcomes. Greater distance from clinic was associated with higher likelihood of loss to follow-up and missed appointments., PURPOSE: To investigate the relationship of patient travel distance and interstate access to glaucoma surgery postoperative follow-up visit attendance., METHODS AND PARTICIPANTS: Retrospective longitudinal chart review of all noninstitutionalized adult glaucoma patients with initial trabeculectomies or drainage device implantations between April 4, 2014 and December 31, 2018. Patients were stratified into groups on the basis of straight-line distance from residence to University of North Carolina at Chapel Hill's Kittner Eye Center and distance from residence to interstate access. Corrective procedures, visual acuity, appointment cancellations, no-shows, and insurance data were recorded. Means were compared using 2-tailed Student t-test, Pearson chi, analysis of variance, and multivariate logistical regression determined odds ratios for loss to follow-up., RESULTS: In total, 199 patients met all inclusion criteria. Six-month postoperatively, patients >50 miles from clinic had greater odds of loss to follow-up compared with patients <25 miles (odds ratios, 3.47; 95% confidence interval, 1.24-4.12; P<0.05). Patients >50 miles from clinic had significantly more missed appointments than patients 25 to 50 miles away, and patients <25 miles away (P=0.008). Patients >20 miles from interstate access had greater loss to follow-up than those <10 miles (t(150)=2.05; P<0.05). Mean distance from clinic was 12.59 miles farther for patients lost to follow-up (t(197)=3.29; P<0.01). Patients with Medicaid coverage had more missed appointments than those with Medicare plans (t(144)=-2.193; P<0.05)., CONCLUSIONS: Increased distance from clinic and interstate access are associated with increased missed appointments and loss to follow-up. Glaucoma specialists should consider these factors when choosing surgical interventions requiring frequent postoperative evaluations. AU - Funk, Ian T. AU - Strelow, Bryan A. AU - Klifto, Meredith R. AU - Knight, O'Rese J. AU - Van Buren, Eric AU - Lin, Feng-Chang AU - Fleischman, David DO - https://dx.doi.org/10.1097/IJG.0000000000001609 IS - 11 KW - Adult *Aftercare/sn [Statistics & Numerical Data] Aged Aged, 80 and over Ambulatory Care Facilities Female Follow-Up Studies *Glaucoma Drainage Implants Glaucoma, Angle-Closure/pp [Physiopathology] *Glaucoma, Angle-Closure/su [Surgery] Glaucoma, Open-Angle/pp [Physiopathology] *Glaucoma, Open-Angle/su [Surgery] Health Services Accessibility Humans Intraocular Pressure/ph [Physiology] Lost to Follow-Up Male Middle Aged Postoperative Care Retrospective Studies *Trabeculectomy *Travel/sn [Statistics & Numerical Data] Treatment Outcome United States Young Adult PY - 2020 SE - Funk, Ian T. School of Medicine. Strelow, Bryan A. Departments of Ophthalmology. Klifto, Meredith R. Departments of Ophthalmology. Knight, O'Rese J. Departments of Ophthalmology. Van Buren, Eric. Biostatistics and North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC. Lin, Feng-Chang. Biostatistics and North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC. Fleischman, David. Departments of Ophthalmology. SN - 1536-481X 1057-0829 SP - 1056-1064 ST - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes T2 - Journal of glaucoma TI - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32694285 VL - 29 ID - 227 ER - TY - JOUR AU - Furber, J. IS - 48 KW - Glaucoma/nu [Nursing] Humans *Job Description Nurse Practitioners/st [Standards] *Nurse Practitioners Nursing Research *Ophthalmology Optometry Patient Satisfaction PY - 1997 SE - Furber, J. Bristol Eye Hospital, United Bristol Healthcare NHS Trust. SN - 0954-7762 SP - 28 ST - A sight for sore eyes T2 - Nursing times TI - A sight for sore eyes UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9423475 VL - 93 ID - 2009 ER - TY - JOUR AB - Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. Topical steroids are the mainstay of treatment. However, the adverse effects of steroids on hormonal function are the major obstacle for their use as long-term topical therapy. Topical calcineurin inhibitors, such as tacrolimus, not only complement existing treatment options but also overcome some of the drawbacks of topical steroid therapy and fulfill the long-term needs of patients in preventing disease progression. Short- and long-term efficacy and safety of topical tacrolimus has been widely recognized and it is also accepted as a first-line treatment for the inflammation of AD. In order to reduce the possible long-term adverse effects, it is important to monitor the clinical dose in daily clinics. Copyright © Blackwell Publishing, Inc., 2006. AD - Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan AU - Furue, M. AU - Uchi, H. AU - Moroi, Y. AU - Ogawa, S. AU - Nakahara, T. AU - Urabe, K. DB - Scopus DO - 10.1111/j.1529-8019.2006.00064.x IS - 2 KW - Adverse effects Atopic dermatitis Dose Topical steroids Topical tacrolimus M3 - Review N1 - Cited By :3 Export Date: 19 July 2021 PY - 2006 SP - 118-126 ST - Topical tacrolimus in the management of atopic dermatitis in Japan T2 - Dermatologic Therapy TI - Topical tacrolimus in the management of atopic dermatitis in Japan UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645881082&doi=10.1111%2fj.1529-8019.2006.00064.x&partnerID=40&md5=182a84b702d52c37a32d0ce31df34ab9 VL - 19 ID - 5535 ER - TY - JOUR AB - BACKGROUND: Difficulty of use of eyedrops is a factor associated with poor patient compliance that reduces treatment efficacy. The aim of this study was to evaluate the handiness and global acceptability of the new Abak timolol bottle (multidose preservative-free eyedrops) in comparison with that of other administration systems (classical multidose eyedrops or single-doses) in patients treated for glaucoma or ocular hypertension., METHODS: Cross-sectional, retrospective and multicentre study involving 41 ophthalmologists in France. Selected patients were those who had been treated with the new Abak bottle since at least two months, as a replacement for other beta-blocker eyedrops. Handiness and acceptability of the new Abak bottle in comparison with other delivery systems were evaluated using a questionnaire filled by the investigator., RESULTS: Almost all the patients were unanimous regarding the handiness of the new Abak bottle: easy to open for 96.5% of them, easy to handle for 96.0%, and easy to get drops for 91.1%. For all these criteria and in a general manner, patients preferred the new Abak bottle in comparison with the previous eyedrop container. These results were confirmed in the oldest patients., CONCLUSION: The new Abak bottle had a greater acceptability compared to preserved multidose eyedrops or to single-doses. Its handiness and the absence of preservative which may improve local tolerance are in favor of a greater compliance in chronically treated patients. Copyright © 2010 Elsevier Masson SAS. All rights reserved. AU - Gabisson, P. AU - Briat, B. AU - Le Foll, J. AU - Conan, S. AU - Bale-Le Bescond, F. AU - Talmud, M. AU - Chibret, H. DO - https://dx.doi.org/10.1016/j.pharma.2010.10.001 IS - 1 KW - Adrenergic beta-Antagonists/ad [Administration & Dosage] Adult Aged Aged, 80 and over Cross-Sectional Studies *Drug Packaging Female France Glaucoma/dt [Drug Therapy] Humans Male Middle Aged Ocular Hypertension/dt [Drug Therapy] *Ophthalmic Solutions/ad [Administration & Dosage] Ophthalmic Solutions/ch [Chemistry] Patient Acceptance of Health Care Patient Compliance Retrospective Studies Young Adult PY - 2011 SE - Gabisson, P. Cabinet d'ophtalmologie, 74, avenue de Mazargues, 13008 Marseille, France. SN - 0003-4509 SP - 22-9 ST - [Handiness and acceptability of the new Abak bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study] T2 - Maniabilite et acceptabilite du flacon Abak nouvelle generation chez des patients traites au long cours. Etude transversale, retrospective et multicentrique. TI - [Handiness and acceptability of the new Abak bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21296214 VL - 69 Y2 - 20101124// ID - 1290 ER - TY - JOUR AB - Difficulty of use of eyedrops is a factor associated with poor patient compliance that reduces treatment efficacy. The aim of this study was to evaluate the handiness and global acceptability of the new Abak® timolol bottle (multidose preservative-free eyedrops) in comparison with that of other administration systems (classical multidose eyedrops or single-doses) in patients treated for glaucoma or ocular hypertension. Methods: Cross-sectional, retrospective and multicentre study involving 41 ophthalmologists in France. Selected patients were those who had been treated with the new Abak® bottle since at least two months, as a replacement for other beta-blocker eyedrops. Handiness and acceptability of the new Abak® bottle in comparison with other delivery systems were evaluated using a questionnaire filled by the investigator. Results: Almost all the patients were unanimous regarding the handiness of the new Abak® bottle: easy to open for 96.5% of them, easy to handle for 96.0%, and easy to get drops for 91.1%. For all these criteria and in a general manner, patients preferred the new Abak® bottle in comparison with the previous eyedrop container. These results were confirmed in the oldest patients. Conclusion: The new Abak® bottle had a greater acceptability compared to preserved multidose eyedrops or to single-doses. Its handiness and the absence of preservative which may improve local tolerance are in favor of a greater compliance in chronically treated patients. © 2010 Elsevier Masson SAS. AD - H. Chibret, Laboratoires Thea, Zone industrielle du Brezet, 12, rue Louis-Blériot, 63100 Clermont-Ferrand, France AU - Gabisson, P. AU - Briat, B. AU - Le Foll, J. AU - Conan, S. AU - Bale-Le Bescond, F. AU - Talmud, M. AU - Chibret, H. DB - Embase Medline DO - 10.1016/j.pharma.2010.10.001 IS - 1 KW - eye drops timolol Abak article chronic patient cross-sectional study drug delivery system France glaucoma human intraocular hypertension multicenter study (topic) outcome assessment patient compliance physician questionnaire retrospective study LA - French M3 - Article N1 - L51163968 2011-02-09 2011-02-22 PY - 2011 SN - 0003-4509 SP - 22-29 ST - Handiness and acceptability of the new Abak® bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study T2 - Annales Pharmaceutiques Francaises TI - Handiness and acceptability of the new Abak® bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51163968&from=export http://dx.doi.org/10.1016/j.pharma.2010.10.001 VL - 69 ID - 3210 ER - TY - JOUR AB - Ocular surface disease is a frequently seen condition in the elderly in the general population. In glaucoma patients the glaucoma- therapy related ocular surface disease is a particularly serious and common condition with complex pathogenenesis. Preservatives, most commonly benzalkonium chloride, employed in intraocular pressure lowering eye drops frequently cause or worsen ocular surface disease in glaucoma. The symptoms frequently undermine both the adherence to the prescribed intraocular pressure lowering drops and the vision related quality of life. Therefore the success of long-term glaucoma care in glaucoma-therapy related ocular surface disease is reduced. The current article summarizes the main pathogenetic aspects of glaucoma-therapy related ocular surface disease, and presents how to eliminate the main causative factor and normalize the ocular surface by using completely preservative free topical medication in glaucoma. A teljes népességet tekintve a szemfelszínbetegség (ocular surface disease) nem ritka probléma idôsebb személyeken. A glaucomás népességen belül a cseppkezelés által kiváltott szemfelszínbetegség különösen gyakori, súlyos és komplex patogenezisû. Ennek oka az, hogy a szemnyomás csökkentésére használt szemcseppek konzerválószerei, fôként a benzalkónium-klorid, gyakran váltják ki vagy súlyosbítják a szemfelszínbetegséget. A betegek szemtünetei jelentôsen csökkentik mind a kezeléshez mutatott adherenciát, mind a látással kapcsolatos életminôséget. Éppen ezért a glaucoma cseppkezelése által kiváltott szemfelszínbetegség rontja a glaucoma hosszú távú kezelési eredményét. A jelen közlemény összefoglalja a glaucomakezelés kiváltotta szemfelszínbetegség patogenetikai vonatkozásait, valamint bemutatja, hogyan lehet a fô patogenetikai tényezôt kiküszöbölni, és a szemfelszín állapotát normalizálni teljesen konzerválószer-mentes szemnyomáscsökkentô szemcseppek alkalmazásával. AD - Semmelweis Egyetem, Szemészeti Klinika, H-1085 Budapest, Mária u. 39 AN - 130606713. Language: Hungarian. Entry Date: 20180712. Revision Date: 20191029. Publication Type: Article. Journal Subset: Biomedical AU - Gábor, HollÓ DB - ccm DP - EBSCOhost IS - 4/5 KW - Glaucoma -- Drug Therapy Ophthalmic Solutions -- Therapeutic Use Ophthalmic Solutions -- Adverse Effects Eye Diseases -- Chemically Induced Eye Diseases -- Prevention and Control Administration, Topical N1 - Continental Europe; Europe. PY - 2018 SN - 0866-4811 SP - 203-206 ST - Konzerválószer-mentes krónikus kezelés glaucomában: a cseppkezelés okozta szemfelszínbetegség elkerülése T2 - LAM (Lege Artis Medicine) TI - Konzerválószer-mentes krónikus kezelés glaucomában: a cseppkezelés okozta szemfelszínbetegség elkerülése UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130606713&site=ehost-live&scope=site VL - 28 ID - 4325 ER - TY - JOUR AB - BACKGROUND: Cystoid macular edema is a common clinical finding following intraocular surgery. Certain medications have been associated with an increased incidence of cystoid macular edema. This article describes the clinical findings in two eyes of two patients in whom cystoid macular edema developed directly following treatment with the anti-glaucoma medication latanoprost, and assesses the possible causal relationship. CASE REPORTS: Clinical correlative and angiographic studies of two patients in a referral practice are presented. The main outcome measurement was visual acuity and fundus examination on discontinuation of latanoprost. RESULTS: Cystoid macular edema developed in two pseudophakic patients after the use of latanoprost. CONCLUSION: Latanoprost should be used with caution in pseudophakic and aphakic patients--especially those with retinal vascular fragility, any inflammatory uveal disease, or other factors that may predispose to the breakdown of the blood-retinal barrier. AD - Department of Optometry, Northeastern State University, College of Optometry, Tahlequah, Oklahoma, United States AU - Gaddie, I. B. AU - Bennett, D. W. DB - Scopus IS - 2 M3 - Article N1 - Cited By :29 Export Date: 19 July 2021 PY - 1998 SP - 122-128 ST - Cystoid macular edema associated with the use of latanoprost T2 - Journal of the American Optometric Association TI - Cystoid macular edema associated with the use of latanoprost UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031991106&partnerID=40&md5=52bc8c5327b324e2d66ac69677192d79 VL - 69 ID - 5067 ER - TY - JOUR AD - M.D. Gaevyǐ AU - Gaevyǐ, M. D. DB - Medline IS - 2 KW - adult aged ambulatory care article evaluation study female glaucoma human male mass screening middle aged oculoplethysmography Ukraine LA - Russian M3 - Article N1 - L8700372 1978-07-25 PY - 1978 SN - 0030-0675 SP - 142-143 ST - Effectiveness of mass screening and ambulatory care of patients with glaucoma under regional conditions T2 - Oftalmologicheskiǐ zhurnal TI - Effectiveness of mass screening and ambulatory care of patients with glaucoma under regional conditions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L8700372&from=export VL - 33 ID - 4109 ER - TY - JOUR AB - An expert in the field reviews 'anchor' and 'adjunct' regimens and discusses the right time to switch therapies. AN - 105990238. Language: English. Entry Date: 20080222. Revision Date: 20171109. Publication Type: Journal Article AU - Gagnon, L. DB - ccm DP - EBSCOhost IS - 1 KW - Glaucoma -- Drug Therapy Medication Compliance Decision Making, Clinical Drug Therapy, Combination Intraocular Pressure -- Drug Effects Prostaglandins -- Administration and Dosage Prostaglandins -- Therapeutic Use N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2008 SN - 8750-3085 SP - 25-26 ST - Patient adherence, drug response keys to selecting glaucoma therapy T2 - Ocular Surgery News TI - Patient adherence, drug response keys to selecting glaucoma therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105990238&site=ehost-live&scope=site VL - 26 ID - 4503 ER - TY - JOUR AB - The article discusses glaucoma patients' need for treatment options other than daily administration of eye drops in 2019. Topics covered include such innovations as a sustained delivery of intraocular pressure (IOP) drugs, the use of the Kali Drop wireless adherence monitoring device, and the identification of patients who will experience worsening. Also noted is the examination of the biomechanics of the lamina cribosa to help uncover such patients. AN - 139298797. Language: English. Entry Date: 20191029. Revision Date: 20191029. Publication Type: Article AU - Gagnon, Louise DB - ccm DP - EBSCOhost IS - 17 KW - Glaucoma -- Therapy Cell Therapy -- Methods Health Care Delivery Decision Making, Clinical Treatment Outcomes Ophthalmic Solutions -- Therapeutic Use Patient Compliance Disease Progression Diagnosis, Eye -- Methods Biological Markers Glaucoma -- Diagnosis Intraocular Pressure -- Evaluation Glaucoma -- Pathology Quality of Life N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2019 SN - 0193-032X SP - 31-33 ST - Can glaucoma patients benefit from cell therapy approach? Sustained delivery, other treatment options may change landscape T2 - Ophthalmology Times TI - Can glaucoma patients benefit from cell therapy approach? Sustained delivery, other treatment options may change landscape UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139298797&site=ehost-live&scope=site VL - 44 ID - 4271 ER - TY - JOUR AB - IMPORTANCE: Corneal transplantation restores visual function when visual impairment caused by a corneal disease becomes too severe. It is considered the world's most frequent type of transplantation, but, to our knowledge, there are no exhaustive data allowing measurement of supply and demand, although such data are essential in defining local, national, and global strategies to fight corneal blindness., OBJECTIVE: To describe the worldwide situation of corneal transplantation supply and demand., DESIGN, SETTING, AND PARTICIPANTS: Data were collected between August 2012 and August 2013 from a systematic review of published literature in parallel with national and international reports on corneal transplantation and eye banking. In a second step, eye bank staff and/or corneal surgeons were interviewed on their local activities. Interviews were performed during international ophthalmology or eye-banking congresses or by telephone or email. Countries' national supply/demand status was classified using a 7-grade system. Data were collected from 148 countries., MAIN OUTCOMES AND MEASURES: Corneal transplantation and corneal procurements per capita in each country., RESULTS: In 2012, we identified 184,576 corneal transplants performed in 116 countries. These were procured from 283,530 corneas and stored in 742 eye banks. The top indications were Fuchs dystrophy (39% of all corneal transplants performed), a primary corneal edema mostly affecting elderly individuals; keratoconus (27%), a corneal disease that slowly deforms the cornea in young people; and sequellae of infectious keratitis (20%). The United States, with 199.10-6 corneal transplants per capita, had the highest transplantation rate, followed by Lebanon (122.10-6) and Canada (117.10-6), while the median of the 116 transplanting countries was 19.10-6. Corneas were procured in only 82 countries. Only the United States and Sri Lanka exported large numbers of donor corneas. About 53% of the world's population had no access to corneal transplantation., CONCLUSIONS AND RELEVANCE: Our survey globally quantified the considerable shortage of corneal graft tissue, with only 1 cornea available for 70 needed. Efforts to encourage cornea donation must continue in all countries, but it is also essential to develop alternative and/or complementary solutions, such as corneal bioengineering. AU - Gain, Philippe AU - Jullienne, Remy AU - He, Zhiguo AU - Aldossary, Mansour AU - Acquart, Sophie AU - Cognasse, Fabrice AU - Thuret, Gilles DO - https://dx.doi.org/10.1001/jamaophthalmol.2015.4776 IS - 2 KW - *Cornea Corneal Diseases/rh [Rehabilitation] *Corneal Transplantation/sn [Statistics & Numerical Data] *Eye Banks/sn [Statistics & Numerical Data] *Global Health/sn [Statistics & Numerical Data] Health Surveys Humans Religion Surveys and Questionnaires *Tissue Donors/sd [Supply & Distribution] Tissue and Organ Procurement/lj [Legislation & Jurisprudence] *Tissue and Organ Procurement/sn [Statistics & Numerical Data] Waiting Lists PY - 2016 SE - Gain, Philippe. Ophthalmology Department, University Hospital, Saint-Etienne, France2Federative Institute of Research in Sciences and Health Engineering, Corneal Graft Biology, Engineering, and Imaging Laboratory, Faculty of Medicine, Jean Monnet University, Saint-Etienn. Jullienne, Remy. Ophthalmology Department, University Hospital, Saint-Etienne, France. He, Zhiguo. Federative Institute of Research in Sciences and Health Engineering, Corneal Graft Biology, Engineering, and Imaging Laboratory, Faculty of Medicine, Jean Monnet University, Saint-Etienne, France. Aldossary, Mansour. Ophthalmology Department, University Hospital, Saint-Etienne, France. Acquart, Sophie. Eye Bank of Saint-Etienne, Auvergne Loire Blood Centre, Saint-Etienne, France. Cognasse, Fabrice. Eye Bank of Saint-Etienne, Auvergne Loire Blood Centre, Saint-Etienne, France. Thuret, Gilles. Ophthalmology Department, University Hospital, Saint-Etienne, France2Federative Institute of Research in Sciences and Health Engineering, Corneal Graft Biology, Engineering, and Imaging Laboratory, Faculty of Medicine, Jean Monnet University, Saint-Etienn. SN - 2168-6173 2168-6165 SP - 167-73 ST - Global Survey of Corneal Transplantation and Eye Banking T2 - JAMA ophthalmology TI - Global Survey of Corneal Transplantation and Eye Banking UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&NEWS=N&AN=26633035 VL - 134 ID - 735 ER - TY - JOUR AB - Antiepileptic drugs (AEDs) are used by millions of people worldwide for the treatment of epilepsy, as well as in many other neurological and psychiatric conditions. They are frequently associated with adverse effects (AEs), which have an impact on the tolerability and success of treatment. Half the people who develop intolerable AEs discontinue treatment early on after initiation, while the majority of people will continue to be exposed to their effects for long periods of time. The long-term safety of AEDs reflects their potential for chronic, cumulative dose effects; rare, but potentially serious late idiosyncratic effects; late, dose-related effects; and delayed, teratogenic or neurodevelopmental effects. These AEs can affect every body system and are usually insidious. With the exception of delayed effects, most other late or chronic AEs are reversible. To date, there is no clear evidence of a carcinogenic effect of AEDs in humans. While physicians are aware of the long-term AEs of old AEDs (the traditional liver enzyme-inducing AEDs and valproate), information about AEs of new AEDs (such as lamotrigine, levetiracetam, oxcarbazepine, topiramate or zonisamide), particularly of their teratogenic effects, has emerged over the years. Sporadic publications have raised issues about AEs of the newer AEDs eslicarbazepine, retigabine, rufinamide, lacosamide and perampanel but their long-term safety profiles may take years to be fully appreciated. Physicians should not only be aware of the late and chronic AEs of AEDs but should systematically enquire and screen for these according to the individual AED AE profile. Care should be taken for individuals with comorbid conditions that may render them more susceptible to specific AEs. Prevention and appropriate management of long-term AED AEs is expected to improve adherence to treatment, quality of life and control of epilepsy. © 2013 Springer International Publishing Switzerland. AD - J.W. Sander, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, NIHR University College London Hospitals Biomedical Research Centre, Queen Square, London, WC1N 3BG, United Kingdom AU - Gaitatzis, A. AU - Sander, J. W. DB - Embase Medline DO - 10.1007/s40263-013-0063-0 IS - 6 KW - acetazolamide anticonvulsive agent carbamazepine cyanocobalamin eslicarbazepine ethosuximide etiracetam felbamate folic acid gabapentin lacosamide lamotrigine midazolam oxcarbazepine perampanel phenobarbital phenytoin pregabalin primidone retigabine rufinamide stiripentol tiagabine topiramate valproic acid vigabatrin zonisamide acne alopecia amenorrhea aplastic anemia atherosclerosis bladder function carcinogenicity cognition comorbidity complex regional pain syndrome type I B12 deficiency drug safety drug tolerability drug tolerance Dupuytren contracture female infertility fibromatosis frozen shoulder gingiva hypertrophy glaucoma hirsutism human hyperhomocysteinemia hyperlipidemia hyperthermia hypertrichosis impotence liver toxicity long term care male infertility nephrolithiasis obesity oligomenorrhea osteomalacia osteopenia osteoporosis patient compliance patient education Peyronie disease postnatal development pregnancy priority journal pseudolymphoma quality of life reproductive health review rickets semen abnormality side effect skin discoloration suicide sweating teratogenicity testosterone blood level visual field defect vitamin D deficiency body weight gain body weight loss LA - English M3 - Review N1 - L369162582 2013-07-02 2013-07-04 PY - 2013 SN - 1172-7047 1179-1934 SP - 435-455 ST - The long-term safety of antiepileptic drugs T2 - CNS Drugs TI - The long-term safety of antiepileptic drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369162582&from=export http://dx.doi.org/10.1007/s40263-013-0063-0 VL - 27 ID - 2997 ER - TY - JOUR AB - Purpose: To present long-term, real-world outcomes after implanting one trabecular micro-bypass stent with cataract surgery for primary open-angle glaucoma (POAG) in a predominantly Hispanic patient population. Patients and methods: This retrospective, consecutive case series evaluated intraocular pressure (RR), medications, and safety through 36 months after implanting one iStent (R) during phacoemulsification cataract surgery. Eyes were stratified into 2 subgroups classified by preoperative IOP and surgical goal. The Controlled Group had IOP <18 mmHg on >= 1 medications, and goal to reduce medications. The Uncontrolled Group had IOP >= 18 mmHg and/or maximum tolerated medication load, and goal to reduce IOP. Assessments included IOP, medications, visual fields (VF), retinal nerve fiber layer thickness (RNFL), adverse events, and secondary surgeries. Results: Of 168 total operated eyes, 87 eyes (49 Controlled, 38 Uncontrolled) completed 36 months of follow-up and comprise the Consistent Cohort in this report. At baseline, 79.6% (39/49) of Controlled eyes and 71.1% (27/38) of Uncontrolled eyes were from Hispanic patients. In the Controlled Group desiring medication reduction, mean medications were reduced by 77.3% (2.6 medications preoperatively vs 0.6 at 36 months; p<0.001. All Controlled eyes maintained or reduced medications versus preoperative; no eyes were on >= 3 medications (vs 61.2% preoperatively); and 58.3% were medication-free (vs 0% preoperatively). In the Uncontrolled Group desiring IOP reduction, mean IOP decreased by 31.2% (19.4 mmHg preoperatively vs 13.4 mmHg at 36 months; p<0.001), 91.7% of eyes achieved IOP <= 18 mmHg, 69.4% reached IOP <= 15 mmHg, and 77.8% decreased IOP >= 20% vs baseline. Uncontrolled eyes also experienced a 45.3% medication reduction (2.2 medications preoperatively vs 1.2 at 36 months; p<0.001). Favorable safety included no intraoperative complications, and stable VF and RNFL through 36 months. Conclusion: In this predominantly Hispanic patient cohort, significant IOP and medication reductions were sustained safely through 36 months after iStent implantation during cataract surgery. AN - WOS:000469354800001 AU - Gallardo, M. J. AU - Supnet, R. A. DO - 10.2147/OPTH.S189071 PY - 2019 SN - 1177-5483 SP - 869-879 ST - Three-year outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic population with primary open-angle glaucoma T2 - CLINICAL OPHTHALMOLOGY TI - Three-year outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic population with primary open-angle glaucoma VL - 13 ID - 6229 ER - TY - JOUR AB - OBJECTIVE: To investigate and describe the prevalence and causes of blindness and moderate and severe visual impairment in older adults living in Uruguay., METHODS: All individuals aged >= 50 years old living in randomly selected clusters were eligible to participate. In each census enumeration unit selected, 50 residents aged 50 years and older were chosen to participate in the study using compact segment sampling. The study participants underwent visual acuity (VA) measurement and lens examination; those with presenting VA (PVA) < 20/60 also underwent direct ophthalmoscopy. Moderate visual impairment (MVI) was defined as PVA < 20/60-20/200, severe visual impairment (SVI) was defined as PVA < 20/200-20/400, and blindness was defined as PVA < 20/400, all based on vision in the better eye with available correction., RESULTS: Out of 3 956 eligible individuals, 3 729 (94.3%) were examined. The age- and sex-adjusted prevalence of blindness was 0.9% (95% confidence interval (CI): 0.5-1.3). Cataract (48.6%) and glaucoma (14.3%) were the main causes of blindness. Prevalence of SVI and MVI was 0.9% (95% CI: 0.5-1.3) and 7.9% (95% CI: 6.0-9.7) respectively. Cataract was the main cause of SVI (65.7%), followed by uncorrected refractive error (14.3%), which was the main cause of MVI (55.2%). Cataract surgical coverage was 76.8% (calculated by eye) and 91.3% (calculated by individual). Of all eyes operated for cataract, 70.0% could see >= 20/60 and 15.3% could not see 20/200 post-surgery., CONCLUSIONS: Prevalence of blindness in Uruguay is low compared to other Latin American countries, but further reduction is feasible. Due to Uruguay's high cataract surgical coverage and growing proportion of people >= 50 years old, the impact of posterior pole diseases as a contributing factor to blindness might increase in future. AU - Gallarreta, Marcelo AU - Furtado, Joao M. AU - Lansingh, Van C. AU - Silva, Juan Carlos AU - Limburg, Hans IS - 4 KW - Aged Aged, 80 and over Aphakia/ep [Epidemiology] Blindness/di [Diagnosis] Blindness/ep [Epidemiology] Blindness/pc [Prevention & Control] Cataract/ep [Epidemiology] Cataract Extraction/px [Psychology] Cataract Extraction/sn [Statistics & Numerical Data] Diagnostic Techniques, Ophthalmological Fear Female Health Services Accessibility Health Services Needs and Demand Health Surveys/mt [Methods] Humans Lens Implantation, Intraocular/sn [Statistics & Numerical Data] Male Middle Aged Motivation Prevalence Pseudophakia/ep [Epidemiology] Uruguay/ep [Epidemiology] Vision Disorders/di [Diagnosis] *Vision Disorders/ep [Epidemiology] Vision Disorders/pc [Prevention & Control] PY - 2014 SE - Gallarreta, Marcelo. School of Medicine, Universidad de la Republica, Montevideo, Uruguay. Furtado, Joao M. Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirao Preto Medical School, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil. Lansingh, Van C. International Agency for the Prevention of Blindness, Mexico City, Mexico. Silva, Juan Carlos. Pan American Health Organization, Bogota, Colombia. SN - 1680-5348 1020-4989 SP - 219-24 ST - Rapid assessment of avoidable blindness in Uruguay: results of a nationwide survey T2 - Revista panamericana de salud publica = Pan American journal of public health TI - Rapid assessment of avoidable blindness in Uruguay: results of a nationwide survey UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med11&NEWS=N&AN=25563146 VL - 36 ID - 849 ER - TY - JOUR AB - PRECIS: The prevalence of depression in Mexican patients with glaucoma is higher than that reported in the general population. Depression prevalence and severity are directly associated with glaucoma severity and lower adherence to medical treatment., PURPOSE: To determine the prevalence of depression in patients with glaucoma and to describe the correlation between the severity of depression, glaucoma, and treatment adherence., PATIENTS AND METHODS: This cross-sectional study included 111 patients with glaucoma who answered the Beck Depression Inventory (BDI)-II and the Morisky-Green questionnaire that evaluated their depression severity and medical treatment adherence. Low treatment adherence was defined as having a score of >2 on the Morisky-Green questionnaire. Analysis of variance, Fisher exact test, and linear regression models were used for statistical analyses. The main outcomes were prevalence of depression, prevalence of depression according to glaucoma damage, and the association between depression severity, medical treatment adherence, and glaucoma damage., RESULTS: The average patient age was 67.6+/-13.8 years. The prevalence of depression was 50.4%. Analysis of variance revealed a statistically significant association between glaucoma severity of the "worse eye" and the BDI raw score. In the "better eye," there was no statistically significant difference in mean BDI raw scores across glaucoma severity categories. There was a statistically significant association between the presence of depression and the level of treatment adherence after adjusting for age, sex, type of glaucoma, and the glaucoma severity in both eyes. The risk of low treatment adherence in patients with depression was 38 times that of patients with no depression., CONCLUSION: Glaucoma is associated with a prevalence of depression nearly 10 times higher than that in the general population. Glaucoma, depression severity, and lower adherence to medical treatment are associated. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. AU - Gamiochipi-Arjona, Jorge E. AU - Azses-Halabe, Yael AU - Tolosa-Tort, Paulina AU - Lazcano-Gomez, Gabriel AU - Gonzalez-Salinas, Roberto AU - Turati-Acosta, Mauricio AU - Garcia-Huerta, Magdalena AU - Jimenez-Roman, Jesus DO - https://dx.doi.org/10.1097/IJG.0000000000001739 IS - 3 PY - 2021 SE - Gamiochipi-Arjona, Jorge E. Glaucoma Department. Azses-Halabe, Yael. Glaucoma Department. Tolosa-Tort, Paulina. Glaucoma Department. Lazcano-Gomez, Gabriel. Glaucoma Department. Gonzalez-Salinas, Roberto. Research Department, Association to prevent blindness, Mexico City, Mexico. Turati-Acosta, Mauricio. Glaucoma Department. Garcia-Huerta, Magdalena. Glaucoma Department. Jimenez-Roman, Jesus. Glaucoma Department. SN - 1536-481X 1057-0829 SP - 251-256 ST - Depression and Medical Treatment Adherence in Mexican Patients With Glaucoma T2 - Journal of glaucoma TI - Depression and Medical Treatment Adherence in Mexican Patients With Glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=33149105 VL - 30 ID - 76 ER - TY - JOUR AB - PURPOSE: To identify the type and frequency of ocular and orbital complications observed following treatment for primary rhabdomyosarcoma of the paranasal sinuses or the orbit., METHODS: An institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective chart review was conducted to identify all patients treated at one institution from 1966 to 2005 with biopsy-proven primary paranasal sinus or orbital rhabdomyosarcoma. Pretreatment, treatment, and follow-up data were collected., RESULTS: Forty-four patients (25 male) of a median age of 7.8 years (range 1.0-18.0 years) with primary paranasal sinus (17) or orbital (27) rhabdomyosarcoma were treated and followed for a median period of 5.3 years (range 0.6-32.0 years). The three most frequently observed ophthalmic complications were persistent eyelid erythema or cellulitis (12), epithelial keratitis (7), and conjunctival injection (6) in the paranasal sinus and epithelial keratitis (18), conjunctival injection (11), and cataract (10) in the orbit. Overall survival after treatment trended higher for the orbital rhabdomyosarcoma group (23 of 27) than the paranasal sinus group (9 of 17)., CONCLUSIONS: The most frequently observed treatment-induced ophthalmic complications in the paranasal sinus group were manageable with minimal patient morbidity, as in the patients with orbital disease. Vision-threatening complications were infrequently encountered. Despite maximal therapy, the mortality rate was higher in the paranasal sinus rhabdomyosarcoma group than in the orbital rhabdomyosarcoma group. AU - Gandhi, Parag D. AU - Fleming, James C. AU - Haik, Barrett G. AU - Wilson, Matthew W. DO - https://dx.doi.org/10.1097/IOP.0b013e318203d5e8 IS - 4 KW - Adolescent *Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects] Child Child, Preschool Combined Modality Therapy Cyclophosphamide/ae [Adverse Effects] Dactinomycin/ae [Adverse Effects] *Eye Diseases/ci [Chemically Induced] Female Humans Infant Male Orbital Neoplasms/dt [Drug Therapy] Orbital Neoplasms/mo [Mortality] Orbital Neoplasms/rt [Radiotherapy] *Orbital Neoplasms/th [Therapy] Paranasal Sinus Neoplasms/dt [Drug Therapy] Paranasal Sinus Neoplasms/mo [Mortality] Paranasal Sinus Neoplasms/rt [Radiotherapy] *Paranasal Sinus Neoplasms/th [Therapy] *Radiation Injuries/et [Etiology] *Radiotherapy/ae [Adverse Effects] Retrospective Studies Rhabdomyosarcoma/dt [Drug Therapy] Rhabdomyosarcoma/mo [Mortality] Rhabdomyosarcoma/rt [Radiotherapy] *Rhabdomyosarcoma/th [Therapy] Survival Rate Vincristine/ae [Adverse Effects] PY - 2011 SE - Gandhi, Parag D. Hamilton Eye Institute, University of Tennessee Health Science Center, St Jude Children's Research Hospital, Memphis, Tennessee, USA. SN - 1537-2677 0740-9303 SP - 241-6 ST - Ophthalmic complications following treatment of paranasal sinus rhabdomyosarcoma in comparison to orbital disease T2 - Ophthalmic plastic and reconstructive surgery TI - Ophthalmic complications following treatment of paranasal sinus rhabdomyosarcoma in comparison to orbital disease UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21242849 VL - 27 ID - 1292 ER - TY - JOUR AB - PURPOSE: To evaluate the early outcomes of pediatric corneal transplantation in patients with acquired, nontraumatic corneal pathology., METHODS: In this retrospective series, the records of children 15 years of age or younger who underwent optical penetrating keratoplasty for acquired nontraumatic corneal pathologies between December 2008 and June 2010 were reviewed. Demographic features, etiology of opacification, visual acuity, and other clinical findings were recorded., RESULTS: Nineteen eyes of 19 children (10 females) were included. Mean age at time of surgery was 9.1 +/- 3.01 years (range, 5-15 years). Adherent leukoma secondary to healed infectious keratitis (n = 12, 63%) and keratoconus (n = 7, 37%) were the leading indications for surgery. The mean follow-up period was 10.2 +/- 3.3 months (range, 6-18 months). Postoperatively, clear grafts were seen in 15 cases (79%). Graft failure was noted in 4 eyes secondary to allograft rejection (n = 1), graft infection (n = 1), primary graft failure (n = 1), and uncontrolled glaucoma (n = 1). The most common cause of moderate or poor visual outcome was amblyopia (80%). Overall, 13 patients (68%) had postoperative visual acuity better than the preoperative vision., CONCLUSIONS: Penetrating keratoplasty can yield good anatomic results in children with acquired, nontraumatic causes of corneal scarring, but amblyopia limits the visual outcomes. Copyright © 2011 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved. AU - Ganekal, Sunil AU - Gangangouda, Chandrashekar AU - Dorairaj, Syril AU - Jhanji, Vishal DO - https://dx.doi.org/10.1016/j.jaapos.2011.05.002 IS - 4 KW - Adolescent Amblyopia/di [Diagnosis] Child Child, Preschool *Corneal Diseases/su [Surgery] *Corneal Transplantation Female Follow-Up Studies Glaucoma/di [Diagnosis] Humans *Keratitis/su [Surgery] Male Postoperative Complications/di [Diagnosis] Retrospective Studies Treatment Outcome Visual Acuity PY - 2011 SE - Ganekal, Sunil. Nayana Super Specialty Eye Hospital and Research Centre, Davangere, India. SN - 1528-3933 1091-8531 SP - 353-5 ST - Early outcomes of primary pediatric keratoplasty in patients with acquired, atraumatic corneal pathology T2 - Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus TI - Early outcomes of primary pediatric keratoplasty in patients with acquired, atraumatic corneal pathology UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med8&NEWS=N&AN=21907118 VL - 15 ID - 1247 ER - TY - JOUR AB - Aim. To evaluate eye drop instillation technique and to explore its determinants in glaucoma patients. Methods. One hundred and thirteen patients diagnosed with glaucoma and self-administering topical antiglaucoma eye drops for at least 1 month were evaluated. All patients instilled artificial tear solution in one eye as they would do at home. The whole process was evaluated by two study staff. A comprehensive score system associated with eye drop instillation techniques was used to quantify the instillation technique and explore its determinants such as demographic and clinical characteristics. Results. Half of the patients (48.67%) finished the administration of eye drop on first attempt. 1.7 eye drops were squeezed out on average. 43 patients (37.17%) got contact with ocular surface or adnexa. Only 19.7% patients had eye drop instillation techniques being defined as well. 11 patients (9.7%) had prior instruction regarding using eye drops, while only 4 patients knew to occlude the tear duct by pressing the dacryocyst area. Older age and worse visual acuity were found to be independent risk factors for worse instillation technique. Conclusions. Eye drop instillation technique in glaucoma patients deserves great attention from eye care practitioners during their lifelong follow-up, especially those aged older and have worse visual acuity. AN - WOS:000430855700001 AU - Gao, X. B. AU - Yang, Q. M. AU - Huang, W. M. AU - Chen, T. T. AU - Zuo, C. G. AU - Li, X. Y. AU - Gao, W. Y. AU - Xiao, H. M. DO - 10.1155/2018/1376020 PY - 2018 SN - 2090-004X 2090-0058 ST - Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients T2 - JOURNAL OF OPHTHALMOLOGY TI - Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients VL - 2018 ID - 6182 ER - TY - JOUR AB - Objective: To investigate the ocular blood-aqueous barrier (BAB) alteration after laser peripheral iridotomy (LPI) or surgery peripheral iridectomy (SPI) in patients with primary chronic angle-closure glaucoma (PCACG). Methods: This was a clinical randomized controlled trial. Sixty eyes of 60 subjects with early stage of PCACG were randomly received either LPI or SPI and followed up postoperatively at day 3, week 1, 2, 3, and 4. Aqueous flare in anterior chamber was measured by FC-2000 flare-cell photometry, intraocular pressure (IOP) measured by tonometer, central corneal endothelium cell counted by endothelioscopy, peripheral anterior synechiae (PAS) detected by gonioscopy. Data were analyzed by using two-way ANOVA for repeated measures, independent samples t-test, paired t-test, nonparametric test, and Spearman rank correlation test. Results: On follow-ups of pre-operative and post-operative 3 days, 1 week (w), 2w, 3w and 4w respectively, the mean aqueous flare values for LPI group were (5.47±1.09), (11.96±3.07), (8.08±2.18), (5.68±0.83), (5.80±1.00), (5.69±1.12) PC/ms, and for SPI group were (5.43±1.13), (8.44±3.22), (6.42±1.77), (5.35±0.71), (5. 53±1.26), (5.45±1.23) PC/ms. During post-operative 1w the flare values in both LPI and SPI groups were significantly higher than that on pre-operation (t=-12.753, -8.101, P<0.05; t=-5.971, -3.870; P<0.05) and LPI group had a significantly higher mean flare value than SPI group (t=4.329, 3.231; P<0.05). The IOP spike in LPI group was significantly (χ 2=5.079, 4.022, P<0.05) higher than that in SPI group at week 1 of post-operation. Increased IOP was positively correlated with BAB damage (r=0.899, 0.833; P<0.05). The numbers of medications required to maintain IOP≤21 mm Hg(1 mm Hg =0.133 kPa) at week 4 of post-operation in LPI was significantly (Z=-1.984, P<0.05) more than that in SPI group. There were no significant differences in central corneal endothelium cell count at week 1 (t=0.696, 0.008) and in extension of PAS at week 4 (Z=-1.270, -1.490) of post-operation when compared to pre-operation (P>0.05). No obvious complications occurred in both groups. Conclusions: Our results demonstrated that IOP spike in both of LPI and SPI is due, at least in part, to BAB damage, which appears to be more severe in LPI group and can recover within two weeks. PAS progression and central corneal endothelium cell loss are not aggravated in 1 month after operation. AD - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China AU - Gao, X. B. AU - Zhang, X. L. AU - Chen, G. AU - Huang, X. K. AU - Zhong, X. J. AU - Lin, M. K. AU - Ge, J. DB - Scopus DO - 10.3760/cma.j.issn.0412-4081.2011.10.004 IS - 10 KW - Blood-aqueous barrier Glaucoma, angle-closure Iridectomy Laser therapy M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2011 SP - 876-880 ST - The blood-aqueous barrier changes after laser peripheral iridotomy or surgery peripheral iridectomy T2 - Chinese Journal of Ophthalmology TI - The blood-aqueous barrier changes after laser peripheral iridotomy or surgery peripheral iridectomy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863503826&doi=10.3760%2fcma.j.issn.0412-4081.2011.10.004&partnerID=40&md5=502ceb0c2f1436346b45c829fb65ccf9 VL - 47 ID - 5526 ER - TY - JOUR AB - Objective: To determine and compare the daily cost of various ophthalmic solutions for glaucoma in China. Design: Investigative study. Participants: The majority ophthalmic solutions for glaucoma available in our country were included in the research. Methods: Five bottles of each solution were tested separately by five researchers. After the number of drops and the actual volume for each bottle were calculated, the mean number of drops per bottle and the mean volume per bottle were determined. The volume per drop was calculated by dividing the mean volume per bottle by the mean number of drops per bottle, and the cost per drop was calculated by dividing the market price by the mean number of drops in a bottle. The number of days for both eyes usage per bottle was calculated by dividing the mean number of drops in a bottle by the number of drops required daily for both eyes. The cost per day was calculated by multiplying the cost per drop by the number of drops required daily for both eyes. Main outcome measures: The number of days for both eyes usage per bottle and the daily cost for both eyes usage per bottle. Results: 1. The volume per drop ranged from 0.027 ml(Lumigan) to.0.053 ml(Chengrui and 0.5%Zhenrui). 2. The cost per bottle ranged from 5.7Yuan(Malaisuan Saimaluo'er) to 338Yuan (Xalatan). 3. The number of days for both eyes usage per bottle ranged from 52d (Lumigan) to 12d (Zhenrui). 4. The daily cost for both eyes usage from expensive to cheap were Xalatan 7.51 Yuan, Travatan 6.30 Yuan, Lumigan 3.84 Yuan, Alphagan 3.36 Yuan, Dilijian 2.97 Yuan, Pailiming 2.83 Yuan, 2%Zhenrui 2.34 Yuan, Betagan 2.11 Yuan, Beiteshu 2.0 Yuan, 0.5% Zhenrui 1.49 Yuan, 2%Huming 1.29 Yuan, Mikelan1.21 Yuan, 1%Huming 0.85 Yuan, Chengrai 0.63 Yuan, Malaisuan Saimaluo'er 0.23 Yuan. Conclusions: The daily cost of ophthalmic solution for glaucoma ranged wildly. These data may be useful in selecting ophthalmic solution for glaucoma therapy. AD - L.-L. Wu, Peking University Eye Centre, Beijing 100083, China AU - Gao, Y. AU - Wu, L. L. AU - Li, A. J. C1 - alphagan betagan chengrui dilijian huming lumigan malaisuan saimaluoer travatan xalatan DB - Embase IS - 2 KW - antiglaucoma agent bimatoprost brimonidine carteolol dilijian eye drops huming latanoprost levobunolol timolol maleate travoprost unclassified drug article China commercial phenomena drug cost economic aspect glaucoma health care cost human outcomes research patient compliance alphagan betagan chengrui lumigan malaisuan saimaluoer travatan xalatan LA - Chinese M3 - Article N1 - L43796387 2006-06-27 PY - 2006 SN - 1004-4469 SP - 127-129 ST - Compare of daily cost of ophthalmic solutions for glaucoma T2 - Ophthalmology in China TI - Compare of daily cost of ophthalmic solutions for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43796387&from=export VL - 15 ID - 3622 ER - TY - JOUR AB - In spite of being preventable, Congenital syphilis (CS) is still an important, and growing health problem worldwide. Fetal infection can be particularly aggressive, but newborns can be asymptomatic at birth and, if left untreated, develop systemic compromise afterwards with poor prognosis. We analyzed 61 CS diagnosis cases between 1987–2019 presenting at the Buenos Aires Children’ Hospital. The distribution of cases showed a bimodal curve, with a peak in 1992–1993 and in 2014–2017. Median age at diagnosis was 2 months (IQ 1–6 months). The main clinical findings were: bone alterations (59%); hepatosplenomegaly (54.1%); anemia (62.8%); skin lesions (42.6%) and renal compromise (33.3%). Cerebrospinal fluid (CSF) was abnormal in 5 patients, normal in 45 and was not available for 11 patients. Remarkably, spinal lumbar puncture did not modify therapeutic decisions in any case. Between mothers, only 46% have been tested for syphilis during pregnancy and 60.5% patients had non-treponemal titers equal to or less than fourfold the maternal titer. Intravenous penicillin G was prescribed for all except one patient, who received ceftriaxone with good therapeutic response. During follow-up, 1.6% infants died, 6.5% had persistent kidney disorders and 1.6% showed bone sequelae damage. RPR titers decreased after treatment, reaching negative seroconversion in 43% subjects at a median of 26.4 months. Low adherence to follow up was observed due to inherent vulnerable and low-income population characteristics in our cohort. Our results highlight a rising tendency in cases referred for CS in our population with high morbidity related to delayed diagnosis. A good therapeutic response was observed. CS requires a greater effort from the health system to adequately screen for this disease during pregnancy, and to detect cases earlier, to provide an adequate diagnosis and treatment. © 2021 Garcia et al. AD - Servicio Parasitología-Chagas, Hospital de Niños Ricardo Gutierrez, Capital Federal, Buenos Aires, Argentina Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), CONICET, Buenos Aires, Argentina AU - Garcia, L. N. AU - Destito Solján, A. AU - Moroni, S. AU - Falk, N. AU - Gonzalez, N. AU - Moscatelli, G. AU - Ballering, G. AU - Bournissen, F. G. AU - Altcheh, J. M. C7 - e0009010 DB - Scopus DO - 10.1371/journal.pntd.0009010 IS - 1 M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 1-15 ST - Congenital syphilis in argentina: Experience in a pediatric hospital T2 - PLoS Neglected Tropical Diseases TI - Congenital syphilis in argentina: Experience in a pediatric hospital UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100279552&doi=10.1371%2fjournal.pntd.0009010&partnerID=40&md5=43522d90c42f4a669c3bcbc0d378dbac VL - 15 ID - 5679 ER - TY - JOUR AB - PURPOSE: this review aims to establish the easiest possible diagram to aid the ophthalmologist in the management of the numerous antiglaucomatous agents that have been increasing our therapeutic group., METHOD: we have analyzed the indications, advantages and inconveniences of the medical treatment successively and have reviewed the criteria used to choose a specific drug based on glaucoma severity, general clinical history of the patient, tolerance, local and general adverse effects., RESULTS: finally, we have also considered the ease of compliance, validity of associations and influence of these factors in the patient's quality of life., CONCLUSIONS: the final therapeutic outline is really an index that aims to facilitate a correct use standard. AU - Garcia Sanchez, J. AU - Garcia Feijoo, J. IS - 1 KW - Adrenergic alpha-Agonists/tu [Therapeutic Use] Adrenergic beta-Antagonists/tu [Therapeutic Use] Carbonic Anhydrase Inhibitors/tu [Therapeutic Use] *Glaucoma/dt [Drug Therapy] Humans Parasympathomimetics/tu [Therapeutic Use] Prostaglandins/tu [Therapeutic Use] PY - 2000 SE - Garcia Sanchez , J. Universidad Complutense de Madrid, Hospital Clinico de San Carlos, Madrid. SN - 0365-6691 SP - 11-20 ST - [Medical treatment of glaucoma] T2 - Tratamiento medico del glaucoma. TI - [Medical treatment of glaucoma] UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11151107 VL - 75 ID - 1937 ER - TY - JOUR AB - PURPOSE: Tissue adhesives have been used in ophthalmology instead of sutures to minimize the operating time. This case series investigated the effectiveness and safety of use of cyanoacrylate in Ahmed valve implantation through pars plana for refractory glaucoma., PATIENTS AND METHODS: Seventeen eyes of 17 patients with refractory glaucoma underwent Ahmed valve scleral suture-less implantation through pars plana with a cyanoacrylate suture of the plate. Refractory glaucoma was defined as intraocular pressure (IOP) >= 21 mm Hg with antiglaucoma eye drops, good adherence to treatment, and no previous glaucoma surgery. IOP control and development of complications were evaluated during the follow-up (mean follow-up, 13.23 mo, 6 to 28 mo)., RESULTS: IOP control, defined as IOP <= 21 mm Hg with or without antiglaucoma eye drops, was achieved in 82.2% of patients, and 58.8% were able to eliminate antiglaucoma eye drops. Mean surgical time was 9.76 +/- 2.60 and 6 +/- 0.81 minutes in patients with previous vitrectomy (4 cases). Postoperative complications included transiently increased IOP, transient hyphema, early postoperative hypotony (4 cases), and tube block by the vitreous (2 cases): 1 resolved by Nd:YAG and the other by second vitrectomy. No cases of tube or plate extrusion, plate migration, choroidal or retinal detachment, or vitreous hemorrhage were observed., CONCLUSIONS: These results are promising and demonstrate a safe and effective alternative to the traditional scleral suture. Our data suggest that Ahmed valve implantation through pars plana with cyanoacrylate is a safe and effective method for refractory glaucoma. Further studies are needed to confirm our observation. AU - Garcia-Delpech, Salvador AU - Sanz-Marco, Empar AU - Martinez-Castillo, Sebastian AU - Lopez-Prats, Maria Jesus AU - Udaondo, Patricia AU - Salom, David AU - Diaz-Llopis, Manuel DO - https://dx.doi.org/10.1097/IJG.0b013e318264ba4d IS - 9 KW - Adult Aged Aged, 80 and over Anterior Chamber/su [Surgery] Cyanoacrylates Female *Glaucoma/su [Surgery] *Glaucoma Drainage Implants Humans Intraocular Pressure/ph [Physiology] Male Middle Aged Pilot Projects Postoperative Complications Prospective Studies *Prosthesis Implantation/mt [Methods] *Suture Techniques Time Factors Tonometry, Ocular Treatment Outcome PY - 2013 SE - Garcia-Delpech, Salvador. *Ophthalmology Department, La Fe University Hospital Ophthalmology Department, Medicine Faculty, Catholic University of Valencia Ophthalmology Department, Medicine Faculty, University of Valencia ++Research Center for Rare Diseases (CIBERER), Valencia, Spain. SN - 1536-481X 1057-0829 SP - 750-6 ST - Ahmed valve, suture-less implantation: A new approach to an easier technique T2 - Journal of glaucoma TI - Ahmed valve, suture-less implantation: A new approach to an easier technique UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med10&NEWS=N&AN=24304908 VL - 22 ID - 929 ER - TY - JOUR AB - INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost., METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013. We enrolled adult patients with open-angle glaucoma or ocular hypertension who were receiving BAK-preserved latanoprost 0.005% or bimatoprost 0.01% and, in the opinion of the investigator, would benefit from transition to BAK-free travoprost 0.004% preserved with polyquaternium-1 because of tolerability concerns. Assessments included IOP, proportion of patients with IOP <=18 mmHg, ocular surface status, hyperemia, patient treatment preference, and adherence. Adverse events were recorded throughout the study., RESULTS: Of the 202 patients screened, 187 patients were included in the intent-to-treat population (mean age, 66.6 years; range, 19-90 years). The mean IOP significantly reduced from baseline (17.0 mmHg) to week 6 (mean change, -1.17 mmHg; P<0.001) and week 12 (-1.16 mmHg; P<0.001). At week 12, more patients achieved IOP <=18 mmHg (81.2% versus 73.3% at baseline), and ocular surface disease severity improved from baseline to week 12. Most patients preferred BAK-free travoprost (74.9%) versus their previous medication and were very confident in their adherence (84.1%). Reduced visual acuity and eye pruritus were the most common adverse events (2.5% each)., CONCLUSION: BAK-free travoprost 0.004% preserved with polyquaternium-1 was efficacious and well tolerated and may be an advantageous prostaglandin analog option for patients with open-angle glaucoma or ocular hypertension who are intolerant to BAK-preserved latanoprost or bimatoprost. AU - Garcia-Feijoo, Julian AU - Munoz-Negrete, Francisco J. AU - Hubatsch, Douglas A. AU - Rossi, Gemma C. PY - 2016 SE - Garcia-Feijoo, Julian. Department of Ophthalmology, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Universidad Complutense, OFTARED. Munoz-Negrete, Francisco J. Hospital UniversItario Ramon y Cajal, Universidad de Alcala, IRYCIS, OFTARED, Madrid, Spain. Hubatsch, Douglas A. Alcon Laboratories, Inc., Fort Worth, TX, USA. Rossi, Gemma C. Department of Ophthalmology, University Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. SN - 1177-5467 SP - 2085-2091 ST - Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost T2 - Clinical ophthalmology (Auckland, N.Z.) TI - Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=27799736 VL - 10 Y2 - 20161021// ID - 1028 ER - TY - JOUR AB - Purpose To evaluate the effect of oral antioxidant supplementation (OAS) on primary open-angle glaucoma (POAG) over a 2-year follow-up period. Patients and methods In this open-label, randomized controlled trial, 117 eyes of 117 patients with mild or moderate POAG and intraocular pressure under control with topical antiglaucoma medications were recruited and randomly divided into three groups according to supplementation: (1) OAS with (ICAPS R® - Alcon Laboratories, n = 26); (2) OAS without ω-3 fatty acids (OFTAN MACULA® - Laboratorios Esteve, n = 28); and (3) a control group without OAS (n = 63). They all underwent visual field (VF) tests (Humphrey 24-2) and scans using a Fourier-domain optical coherence tomography (FD-OCT) device (RTVue-100) at the beginning of the study and 2 years later. Mean deviation (MD), standard pattern deviation (PSD), peripapillary retinal nerve fibre layer (RNFL) and macular ganglion cell complex (GCC) parameters were considered for the analysis. Patients were also classified according to MD deterioration (fast deterioration vs. slow deterioration). Results Visual field global indices, peripapillary RNFL thickness and macular GCC thickness showed no differences among the groups at the beginning and end of the follow-up. Besides all the comparisons among groups for differences before and after the follow-up of the MD, PSD, RNFL and GCC parameters were also non-significant. The proportions of patients according to MD deterioration were similar among the groups and subgroups (p > 0.05 for all the comparisons). Conclusion Oral antioxidant supplementation with or without ω-3 fatty acids does not appear useful as an adjuvant treatment of mild/moderate POAG in the short term. AD - J.J. Garcia-Medina, Department of Ophthalmology, University Hospital Reina Sofia, Avenida Intendente Jorge Palacios, 1, Murcia, Spain AU - Garcia-Medina, J. J. AU - Garcia-Medina, M. AU - Garrido-Fernandez, P. AU - Galvan-Espinosa, J. AU - Garcia-Maturana, C. AU - Zanon-Moreno, V. AU - Pinazo-Duran, M. D. C1 - icaps r(Alcon,United States) oftan macula(Esteve,Spain) C2 - Esteve(Spain) Alcon(United States) DB - Embase Medline DO - 10.1111/aos.12629 IS - 6 KW - antiglaucoma agent antioxidant icaps r oftan macula omega 3 fatty acid unclassified drug adult conference paper controlled study disease severity female follow up Fourier domain optical coherence tomography device human Humphrey perimeter intraocular pressure macular ganglion cell complex major clinical study male middle aged multicenter study open angle glaucoma open study optical coherence tomography device outcome assessment patient compliance priority journal prospective study randomized controlled trial retinal nerve fiber layer thickness unspecified side effect visual system parameters LA - English M3 - Conference Paper N1 - L601107454 2015-01-09 2015-11-19 PY - 2015 SN - 1755-3768 1755-375X SP - 546-554 ST - A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: An open-label, randomized, controlled trial T2 - Acta Ophthalmologica TI - A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: An open-label, randomized, controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L601107454&from=export http://dx.doi.org/10.1111/aos.12629 VL - 93 ID - 2790 ER - TY - JOUR AB - PURPOSE: To compare the adherence of biofilm-producer and nonbiofilm-producer Staphylococcus epidermidis in vitro to different soft contact lenses (CLs) to study its possible contribution to the pathogenesis of keratitis., METHODS: Strains of S. epidermidis slime-positive ATCC 35984 (biofilm-producer) and slime-negative ATCC 12228 (nonbiofilm-producer) were used with eight types of soft CLs from the four groups determined by the United States Food and Drug Administration (FDA), according to the ionicity and water content. The lenses were incubated overnight with the bacteria, then sonicated and vortexed to separate the adhered bacteria. Quantitative cultures were performed and the results statistically analyzed., RESULTS: Slime-negative strains of S. epidermidis were able to adhere to all CLs but at a lower level than slime-positive strains. There were significant differences in bacterial attachment among the four FDA groups. On the whole, there was higher bacterial adhesion to nonionic and low-water content materials. Contact lenses produced by soft molding were less adherent than CLs produced by either lathe-cutting or spin-casting., CONCLUSIONS: Bacterial biofilm favors bacterial adhesiveness and colonization of soft CLs. Bacterial attachment was less in soft molding CLs (etafilcon A), which provide a more homogeneous and smoother surface. AU - Garcia-Saenz, Maria Carmen AU - Arias-Puente, Alfonso AU - Fresnadillo-Martinez, Maria Jose AU - Paredes-Garcia, Beatriz IS - 5 KW - *Bacterial Adhesion/ph [Physiology] Bacterial Typing Techniques Biofilms Colony Count, Microbial *Contact Lenses, Hydrophilic/mi [Microbiology] In Vitro Techniques *Staphylococcus epidermidis/ph [Physiology] PY - 2002 SE - Garcia-Saenz, Maria Carmen. Department of Ophthalmology, Fundacion Hospital Alcorcon, Calle Budapest 1, Alcorcon 28922 Madrid, Spain. mcgarcias@fhalcorcon.es SN - 0277-3740 SP - 511-5 ST - Adherence of two strains of Staphylococcus epidermidis to contact lenses T2 - Cornea TI - Adherence of two strains of Staphylococcus epidermidis to contact lenses UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=12072728 VL - 21 ID - 1886 ER - TY - JOUR AB - Purpose: To describe a case of plateau iris syndrome (PIS) and angle-closure glaucoma (ACG) in a patient with nail-patella syndrome (NPS). Observation: A 33 year-old woman of Slovakian ancestry from Norway with a history of NPS presented with angle-closure secondary to plateau iris. At the time of her NPS diagnosis, she had no ocular pathology. Genetic testing revealed a rare de novo mutation in LMX1B [c.668G>C (p.Arg223Pro)]. Two years later, she experienced acute bilateral ocular pain and blurred vision in the setting of one year of reported visual loss. Subsequent ophthalmic examinations revealed closed angles and plateau iris OU with ACG OD and angle-closure OS. Perimetry showed superonasal visual field defects OD and no defects OS. Ocular coherence tomography (OCT) revealed thinning of the inferior pole of the optic nerve OD. Medical management proved ineffective. A laser peripheral iridotomy (LPI) OD was performed, without resolution of the angle-closure, and a diagnosis of plateau iris syndrome (PIS) was made. She was then treated with an argon laser peripheral iridoplasty (ALPI) and clear lens extraction with a posterior chamber intraocular lens (PCIOL) and goniosynechialysis OD, but her IOP remained elevated OU. She was referred to New York Eye and Ear Infirmary of Mount Sinai, where an LPI OS was performed, but angle-closure persisted, consistent with PIS. An ALPI OS with touch-up was performed, and her IOP normalized with dark-room gonioscopy revealing open angles OU. Conclusions And importance: NPS has been associated with ocular hypertension (OHTN) and open-angle glaucoma (OAG); however, to our knowledge, no association between NPS and angle-closure has previously been reported. The case described here, of a patient with a rare de novo mutation and ocular findings of PIS with associated ACG, represents a novel genetic and clinical presentation of NPS. AD - M.A. Gardin, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th St, South Building, 5th Floor, New York, NY, United States AU - Gardin, M. A. AU - Khor, C. C. AU - Silva, L. AU - Krefting, E. A. AU - Ritch, R. DB - Embase DO - 10.1016/j.ajoc.2020.100886 KW - argon laser posterior chamber lens YAG laser brimonidine brinzolamide chloramphenicol dexamethasone dorzolamide plus timolol mirtazapine pilocarpine prednisolone accommodation adult article best corrected visual acuity blurred vision body weight gain breast development case report clinical article closed angle glaucoma cornea thickness cup-to-disc ratio decreased appetite depression dislocation elbow eye examination eye pain female finger malformation foot malformation gene mutation genetic screening gonioscopy headache human hypermetropia hypoplasia intraocular hypertension intraocular pressure iridotomy iris disease low level laser therapy middle phalanx muscle mass musculoskeletal pain nail hypoplasia nail patella syndrome Norway ocular pruritus open angle glaucoma optic nerve optical coherence tomography patient compliance perimetry plateau iris syndrome pronation radial head supination tarsometatarsal joint treatment failure ulnar styloid process visual field defect visual impairment LA - English M3 - Article N1 - L2007697373 2020-09-09 2020-09-16 PY - 2020 SN - 2451-9936 ST - Plateau iris syndrome and angle-closure glaucoma in a patient with nail-patella syndrome T2 - American Journal of Ophthalmology Case Reports TI - Plateau iris syndrome and angle-closure glaucoma in a patient with nail-patella syndrome UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2007697373&from=export http://dx.doi.org/10.1016/j.ajoc.2020.100886 VL - 20 ID - 2359 ER - TY - JOUR AB - PURPOSE: To compare different tests used in the clinical management of glaucoma, with respect to the testing experience for patients undergoing each test., DESIGN: Evaluation of diagnostic tests., PARTICIPANTS: A total of 101 subjects with high-risk ocular hypertension or early glaucoma., METHODS: Subjects were asked to give their opinion on 7 tests used clinically in glaucoma management by assigning each a score between 0 (absolute dislike) and 10 (perfect satisfaction)., MAIN OUTCOME MEASURE: Tests were ranked for each subject from 1 (favorite test) to 7 (least favorite test) on the basis of patient-assigned scores., RESULTS: Goldmann applanation tonometry for measurement of intraocular pressure was ranked significantly better than any other test (median rank 2.5, P